FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU He, HB
   Shi, MQ
   Zeng, XW
   Yang, XZ
   Yang, J
   Wu, LM
   Li, LD
AF He, Haibo
   Shi, Mengqiong
   Zeng, Xiaowei
   Yang, Xianzhe
   Yang, Jun
   Wu, Limao
   Li, Lianda
TI RETRACTED: Decreased FKBP12.6 expression and enhanced endothelin
   receptor signaling associated with arrhymogenesis in myocardial
   infarction rats (Retracted Article. See vol 22, pg 1698, 2008)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE ryanodine receptor 2 (RyR2); FKBP12.6; endothelin-1; calcium transients;
   salvianolic acid B; propranolol
ID POLYMORPHIC VENTRICULAR-TACHYCARDIA; CHANNEL RYANODINE RECEPTOR; SUDDEN
   CARDIAC DEATH; LONG-QT SYNDROME; HEART-FAILURE; SEPTIC SHOCK; CA2+ LEAK;
   CARDIOMYOPATHY; PHOSPHORYLATION; FIBRILLATION
AB An increased propensity towards cardiac arrhythmias and aggravated heart function is observed in myocardial infarction (MI), the development of which is associated with the calcium handling system in the myocardium. It was hypothesized that the abnormal changes in the MI model may be a consequence of the abnormal expression and function of the RyR2-FKBP12.6 channel complex and that these abnormalities may be related to an over-activated endothelin (ET) system. Salvianolic acid B is expected to suppress life-threatening arrhythmias and to restore the abnormality of the RyR2-FKBP12.6 complex in rats. MI was produced by ligating the coronary artery for 4 weeks. Salvianolic acid B (100 mg/kg/day, p.o. for 4 weeks) was administered to rats 0.5 h before surgery. Measurements of cardiac arrhythmias, cardiac function, calcium transient, cardiac calcium release channel handling proteins and the endothelin system were conducted. The aggravated arrhythmia and compromised cardiac function in MI rats was accompanied by elevated diastolic Ca2+ levels in the cytosol and a significant down-regulation of expression of RyR2-FKBP12.6. These were closely linked with an over-activated ET pathway in the myocardium. After a 4-week treatment with salvianolic acid B, all abnormalities were reversed significantly. Salvianolic acid B was capable of normalizing FKBP12.6 expression levels and decreasing the propensity towards arrhythmias by attenuating the tip-regulated ET pathway. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [He, Haibo; Zeng, Xiaowei; Yang, Xianzhe; Yang, Jun; Wu, Limao; Li, Lianda] Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herb Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Shi, Mengqiong] Ctr Med Sci Anal, Hangzhou 310053, Zhejiang, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herb Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM wulimao@zju.edu.cn
FU National Natural Science Foundation of China [30500661]; National
   Important Basic Development Plan of China [2005CB523405]; Zhejiang
   Provincial Science and Technology [200403022, 2005C13027]; Zhejiang
   Department of Education [20061328]; Zhejiang Bureau of Traditional
   Chinese Medicine [2006Z015]
FX The study was supported by a common project from National Natural
   Science Foundation of China (No: 30500661), a grant from National
   Important Basic Development Plan of China (also called 973 project, No:
   2005CB523405) and grants from Mega-projects of Zhejiang Provincial
   Science and Technology, (No. 200403022, 2005C13027), a grant from
   Zhejiang Department of Education (No. 20061328), a grant from Zhejiang
   Bureau of Traditional Chinese Medicine (No, 2006Z015). Dr Yuling Ma,
   University of Reading, UK a visiting Professor in our Department,
   provided assistance with the composition and English styling of the
   paper.
CR Ahmad F, 2003, CLIN INVEST MED, V26, P167
   Ai X, 2005, CIRC RES, V97, P1314, DOI 10.1161/01.RES.0000194329.41863.89
   Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003
   Clozel M, 2000, J CARDIOVASC PHARM, V35, pS65, DOI 10.1097/00005344-200000002-00015
   COLATSKY TJ, 1995, PHARM NEWS, V2, P17
   Dai De-Zai, 2005, Curr Opin Investig Drugs, V6, P289
   Dai DZ, 2000, ACTA PHARMACOL SIN, V21, P289
   Dumaine R, 2002, CURR OPIN CARDIOL, V17, P36, DOI 10.1097/00001573-200201000-00006
   Ferreira F, 2004, J NUTR, V134, P63
   He HB, 2007, J PHARM PHARMACOL, V59, P977, DOI 10.1211/jpp.59.7.0010
   Huang M, 2002, DRUG DEVELOP RES, V55, P262
   JOHNSTON KM, 1983, CAN J PHYSIOL PHARM, V61, P1340, DOI 10.1139/y83-193
   Kanoh S, 1999, AM J PHYSIOL-LUNG C, V276, pL891, DOI 10.1152/ajplung.1999.276.6.L891
   Katra RP, 2007, AM J PHYSIOL-HEART C, V292, pH2144, DOI 10.1152/ajpheart.00924.2006
   Kontula K, 2005, CARDIOVASC RES, V67, P379, DOI 10.1016/j.cardiores.2005.04.027
   Lahat H, 2003, CIRCULATION, V107, pE29, DOI 10.1161/01.CIR.0000050555.40735.ED
   Laitinen PJ, 2004, ANN MED, V36, P81, DOI 10.1080/17431380410032599
   Lehnart SE, 2004, BIOCHEM BIOPH RES CO, V322, P1267, DOI 10.1016/j.bbrc.2004.08.032
   Lehnart SE, 2004, CIRCULATION, V109, P3208, DOI 10.1161/01.CIR.0000132472.98675.EC
   Luqman N, 2007, INT J CARDIOL, V119, P283, DOI 10.1016/j.ijcard.2006.09.016
   Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a
   Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1
   Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8
   Na T, 2007, ACTA PHARMACOL SIN, V28, P773, DOI 10.1111/j.1745-7254.2007.00580.x
   Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467
   Priori SG, 2001, CIRCULATION, V103, P196
   Reiken S, 2001, CIRCULATION, V104, P2843, DOI 10.1161/hc4701.099578
   Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49
   Ren AJ, 2006, EXP BIOL MED, V231, P937
   Roden DM, 2002, ANNU REV PHYSIOL, V64, P431, DOI 10.1146/annurev.physiol.64.083101.145105
   Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996
   Scoote M, 2002, CARDIOVASC RES, V56, P359, DOI 10.1016/S0008-6363(02)00574-6
   Song Y, 2006, J PHARMACOL EXP THER, V318, P214, DOI 10.1124/jpet.106.101832
   Tajima M, 1999, CIRCULATION, V99, P127, DOI 10.1161/01.CIR.99.1.127
   Tilly N, 2003, EXP CLIN ENDOCR DIAB, V111, P80, DOI 10.1055/s-2003-39234
   VOERMAN HJ, 1992, CRIT CARE MED, V20, P1097, DOI 10.1097/00003246-199208000-00005
   WALKER MJA, 1988, CARDIOVASC RES, V22, P447, DOI 10.1093/cvr/22.7.447
   Wang HI, 2004, ACTA PHARMACOL SIN, V25, P738
   Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301
   Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3
   WU XD, 2004, ACTA PHARMACOL SIN, V25, P738
   Yamauchi-Kohno R, 1999, CIRCULATION, V99, P2171, DOI 10.1161/01.CIR.99.16.2171
   Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131
   ZHANG GO, 2001, CHINESE PHARMACOL B, V2, P1
NR 44
TC 2
Z9 2
U1 4
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD AUG
PY 2008
VL 22
IS 8
BP 1115
EP 1124
DI 10.1002/ptr.2470
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 345IH
UT WOS:000258989300021
PM 18570278
DA 2018-12-27
ER

PT J
AU Chen, FL
   Lu, SM
   Chi-Chuan, W
   Chang, YL
AF Chen, Falin
   Lu, Shyl-Min
   Chi-Chuan, Wang
   Chang, Yi-Lln
TI RETRACTED: Promotion strategies for renewable energy in Taiwan
   (Retracted article. See vol. 51, pg. 1796, 2015)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE renewable energy; promotion strategy; Taiwan
AB To promote the development and application of renewable energy, under the planning and execution of Bureau of Energy of Ministry of Economical Affairs (BOEMOEA), Taiwan has implemented many measures for subsidizing the installation of RE apparatus since 2000. Besides subsidizing the installing expenses, Taiwanese government also provides incentive measures of finance/tax, Such as investment deduction and accelerating depreciation. The successive growth of the amount of installing cases has apparently constructed the base of promotion and application of renewable energy; oil the other hand, many barriers to be overcome were continuously discovered during the executing processes. To effectively remove these promoting barriers, the Energy Commission (the pre-BOE) issued "Renewable Energy Development Plan" through the endorsement of Executive Yuan in January 2002. The purpose of this plan is to establish an inter-ministerial coordinating mechanism of a higher administrative level, which may focus all resources to be functioned as a working team. In the meantime, to further establish a systematically promoting mechanism, the Bureau of Energy then pushes the legislation of "Renewable Energy Development Bill", According to the drafted plan of this law, the power capacity of renewable energies will be 12% share of the national power installation capacity by 2020. Furthermore, in the Nuclear-free Homeland National Conference held in June 2003, government planned that the power capacity of renewable energy must reach 10% of the total power capacity in the nation by 2010. However, the share of the power capacity of renewable energy to the national power installation capacity is only 6.17%, currently, so there is still a lot of growing space for the development of renewable energy in Taiwan. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Chen, Falin; Lu, Shyl-Min; Chi-Chuan, Wang; Chang, Yi-Lln] Ind Technol Res Inst, Energy & Environm Res Labs, Hsinchu 310, Taiwan.
RP Lu, SM (reprint author), Ind Technol Res Inst, Energy & Environm Res Labs, Hsinchu 310, Taiwan.
EM shyimin@itri.org.tw
RI Wang, Chi-Chuan/G-5556-2010
OI Wang, Chi-Chuan/0000-0002-4451-3401
CR Boyle Godfrey, RENEWABLE ENERGY POW
   *BP, 2006, BP STAT REV WORLD EN
   CHIANG W, 2005, ENGINEERING, V78, P97
   *EN INF ADM, OFF EN STAT US GOVT
   *ESTIF, 2003, SUN ACT 2 SOL THERM
   *EUR REN EN COUNC, 2004, REN EN EUR BUILD MAR
   FOSS B, 2006, YAHOO NEWS      0714
   YAN W, WIND SOLAR ENERGY LA
NR 8
TC 22
Z9 22
U1 3
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD AUG
PY 2008
VL 12
IS 6
BP 1681
EP 1691
DI 10.1016/j.rser.2007.01.02
PG 11
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 310TT
UT WOS:000256554000009
DA 2018-12-27
ER

PT J
AU Stepp, BR
   Gibbs-Davis, JM
   Koh, DLF
   Nguyen, ST
AF Stepp, Brian R.
   Gibbs-Davis, Julianne M.
   Koh, Dorothea L. F.
   Nguyen, SonBinh T.
TI RETRACTED: Cooperative melting in caged dimers of rigid small
   molecule-DNA hybrids (Retracted article. See vol. 135, pg. 9950, 2013)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID SINGLE-STRANDED-DNA; NANOSTRUCTURES; ASSEMBLIES; PROBES
AB Rigid small-molecule DNA hybrids (rSMDHs) have been synthesized with three DNA strands attached to a rigid tris (phenyl acetylene) core. When combined under dilute conditions, complementary rSMDHs form cage dimers that melt at >10 degrees C higher and much sharper than either unmodified DNA duplexes or rSMDH aggregates formed at higher concentrations. With a 2.97 average number of cooperative duplexes, these caged dimers constitute the first example of cooperative melting in well-defined DNA-small-molecule structures, demonstrating the important roles that local geometry and ion concentration play in the hybridization/dehybridization of DNA-based materials.
C1 Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.
   Northwestern Univ, Int Inst Nanotechnol, Evanston, IL 60208 USA.
RP Nguyen, ST (reprint author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM stn@northwestern.edu
RI Nguyen, SonBinh/C-1682-2014
OI Nguyen, SonBinh/0000-0002-6977-3445
FU NCI NIH HHS [1U54CA11934-01]
CR Aldaye FA, 2006, ANGEW CHEM INT EDIT, V45, P2204, DOI 10.1002/anie.200502481
   Becerril HA, 2005, J AM CHEM SOC, V127, P2828, DOI 10.1021/ja043314l
   DAUBENDIEK SL, 1995, J AM CHEM SOC, V117, P7818, DOI 10.1021/ja00134a032
   Eckardt LH, 2002, NATURE, V420, P286, DOI 10.1038/420286a
   Frutos AG, 1998, J AM CHEM SOC, V120, P10277, DOI 10.1021/ja982030w
   Gaylord BS, 2003, J AM CHEM SOC, V125, P896, DOI 10.1021/ja027152+
   Gibbs JM, 2005, J AM CHEM SOC, V127, P1170, DOI 10.1021/ja046931i
   Gibbs-Davis JM, 2007, J AM CHEM SOC, V129, P15535, DOI 10.1021/ja073034g
   Gothelf KV, 2004, J AM CHEM SOC, V126, P1044, DOI 10.1021/ja038333u
   Jin RC, 2003, J AM CHEM SOC, V125, P1643, DOI 10.1021/ja021096v
   Kudlay A, 2007, J PHYS CHEM B, V111, P1610, DOI 10.1021/jp0664667
   Li YG, 2004, NAT MATER, V3, P38, DOI 10.1038/nmat1045
   Long H, 2006, J PHYS CHEM B, V110, P2918, DOI 10.1021/jp0556815
   LUKATSKY DB, 2005, J CHEM PHYS, V122
   Mammen M, 1998, J ORG CHEM, V63, P3821, DOI 10.1021/jo970944f
   Marti AA, 2007, J AM CHEM SOC, V129, P8680, DOI 10.1021/ja0717257
   MUELLER JE, 1991, J AM CHEM SOC, V113, P6306, DOI 10.1021/ja00016a077
   Nielsen M, 2005, BIOCONJUGATE CHEM, V16, P981, DOI 10.1021/bc0500793
   PARK SY, 2003, PHYS REV B, V68
   Saghatelian A, 2003, J AM CHEM SOC, V125, P346, DOI 10.1021/ja029009m
   Shchepinov MS, 1999, NUCLEIC ACIDS RES, V27, P3035, DOI 10.1093/nar/27.15.3035
   Shih WM, 2004, NATURE, V427, P618, DOI 10.1038/nature02307
   Stewart KM, 2004, J AM CHEM SOC, V126, P2050, DOI 10.1021/ja037424o
   Summerer D, 2002, ANGEW CHEM INT EDIT, V41, P89, DOI 10.1002/1521-3773(20020104)41:1<89::AID-ANIE89>3.3.CO;2-7
   Taton TA, 2000, J AM CHEM SOC, V122, P6305, DOI 10.1021/ja0007962
   Wu Gang, 2006, Natural Computing, V5, P427, DOI 10.1007/s11047-006-9006-8
   Yu CJ, 2001, J AM CHEM SOC, V123, P11155, DOI 10.1021/ja010045f
NR 27
TC 21
Z9 22
U1 5
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUL 30
PY 2008
VL 130
IS 30
BP 9628
EP +
DI 10.1021/ja801572n
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 329WY
UT WOS:000257902500004
PM 18597465
DA 2018-12-27
ER

PT J
AU Mukherjee-Goswami, A
   Nath, B
   Jana, J
   Sahu, SJ
   Sarkar, MJ
   Jacks, G
   Bhattacharya, P
   Mukherjee, A
   Polya, DA
   Jean, JS
   Chatterjee, D
AF Mukherjee-Goswami, Aishwaya
   Nath, Bibhash
   Jana, Joydev
   Sahu, Sudip Jyoti
   Sarkar, Madhav Jyoti
   Jacks, Gunnar
   Bhattacharya, Prosun
   Mukherjee, Abhijit
   Polya, David A.
   Jean, Jiin-Shuh
   Chatterjee, Debashis
TI RETRACTED: Hydrogeochemical behavior of arsenic-enriched groundwater in
   the deltaic environment: Comparison between two study sites in West
   Bengal, India (Retracted article. See vol. 146, pg. 74, 2013)
SO JOURNAL OF CONTAMINANT HYDROLOGY
LA English
DT Article; Retracted Publication
DE Bengal Delta Plain; arsenic mobility; geochemistry; redox behavior;
   aquifer
ID AQUIFERS CONDUCTING LOW; REACTIVE TRANSPORT; ORGANIC-MATTER;
   DRINKING-WATER; GANGES DELTA; MOBILIZATION; PLAIN; BANGLADESH;
   REDUCTION; SEDIMENTS
AB Groundwaters have been collected from deltaic areas of West Bengal (Chakdaha and Baruipur blocks) to record their hydrogeochemical characteristics, and to verify the mechanism of arsenic (As) release. The data reveals that shallow (< 70 m) groundwaters in both areas are of Ca-Mg-HCO3 type; however deeper (> 70 m) groundwaters in Baruipur areas are slightly enriched with Na, Cl and 504, indicating possible saline water intrusion. The groundwater is anoxic (mean Eh: - 124 and - 131 mV) with high levels of As (mean: 116 and 293 mu g/L), Fe (mean: 4.74 and 3.83 mg/L), PO4 (mean: 3.73 and 3.21 mg/L) and Mn (mean: 0.37 and 0.49 mg/L), respectively for Chakdaha and Baruipur areas. The observed values of As and bicarbonate (mean: 409 and 499 mg/L) in the shallow aquifer are indicative of redox processes (e.g., oxidation of organic matter) favouring the release of As. Moreover, the presence of DOC in the shallow aquifer suggests that organic matter is young and reactive, and may actively engage in redox driven processes. Our study further confirms that both Fe- and Mn-reduction processes are the dominant mechanisms for As release in these groundwaters. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Mukherjee-Goswami, Aishwaya; Jana, Joydev; Sahu, Sudip Jyoti; Sarkar, Madhav Jyoti; Chatterjee, Debashis] Univ Kalyani, Dept Chem, Nadia 741235, W Bengal, India.
   [Nath, Bibhash; Jean, Jiin-Shuh] Natl Cheng Kung Univ, Dept Earth Sci, Tainan 701, Taiwan.
   [Jacks, Gunnar; Bhattacharya, Prosun] KTH, Groundwater Arsen Res Grp, Dept Land Air & Water Resources Engn, SE-10044 Stockholm, Sweden.
   [Mukherjee, Abhijit] Univ Texas Austin, Jackson Sch Geosci, Bur Econ Geol, Austin, TX 78712 USA.
   [Polya, David A.] Univ Manchester, Sch Earth Atmospher & Environm Sci, Manchester M13 9PL, Lancs, England.
   [Polya, David A.] Univ Manchester, Williamson Res Ctr Mol Environm Sci, Manchester M13 9PL, Lancs, England.
RP Chatterjee, D (reprint author), Univ Kalyani, Dept Chem, Nadia 741235, W Bengal, India.
EM dbchat2001@rediffmail.com
RI Nath, Bibhash/A-1813-2011; Jean, Jiin-Shuh/E-7509-2010
OI Jean, Jiin-Shuh/0000-0003-2587-1307
CR Acharyya SK, 2000, ENVIRON GEOL, V39, P1127, DOI 10.1007/s002540000107
   Acharyya SK, 1999, NATURE, V401, P545, DOI 10.1038/44052
   Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174
   Berg M, 2001, ENVIRON SCI TECHNOL, V35, P2621, DOI 10.1021/es010027y
   BHATTACHARYA P, 2002, MANAGEMENT ARSENIC C, P308
   BHATTACHARYA P, 2002, ARSENIC ENV GLOBAL P, P145
   BHATTACHARYA P, 1997, WATER RESOUR DEV, V13, P79, DOI DOI 10.1080/07900629749944
   Bhattacharyya R, 2003, APPL GEOCHEM, V18, P1435, DOI 10.1016/S0883-2927(03)00061-1
   Bhattacharyya R, 2003, MOL CELL BIOCHEM, V253, P347, DOI 10.1023/A:1026001024578
   CGWB, 1999, HIGH INC GROUNDW W B
   Chakraborti D, 2002, TALANTA, V58, P3, DOI 10.1016/S0039-9140(02)00270-9
   Chakraborty S, 2007, J COLLOID INTERF SCI, V309, P392, DOI 10.1016/j.jcis.2006.10.014
   Charlet L, 2006, ELEMENTS, V2, P91, DOI 10.2113/gselements.2.2.91
   Charlet L, 2007, APPL GEOCHEM, V22, P1273, DOI 10.1016/j.apgeochem.2006.12.022
   Chatterjee D, 2005, ENVIRON GEOL, V49, P188, DOI 10.1007/s00254-005-0011-5
   Chatterjee D, 2003, J PHYS IV, V107, P293, DOI 10.1051/jp4:20030299
   Chowdhury TR, 1999, NATURE, V401, P545
   CHOWDHURY UK, 2001, ENV SCI, V8, P393
   Coker VS, 2006, ENVIRON SCI TECHNOL, V40, P7745, DOI 10.1021/es060990+
   Das D, 1996, ENVIRON GEOCHEM HLTH, V18, P5, DOI 10.1007/BF01757214
   Davis J, 1986, STAT DATA ANAL GEOLO
   Gault AG, 2005, MINERAL MAG, V69, P855, DOI 10.1180/0026461056950293
   Gault AG, 2005, ANAL BIOANAL CHEM, V381, P347, DOI 10.1007/s00216-004-2861-1
   Islam FS, 2005, MINERAL MAG, V69, P865, DOI 10.1180/0026461056950294
   Islam FS, 2005, APPL ENVIRON MICROB, V71, P8642, DOI 10.1128/AEM.71.12.8642-8648.2005
   Islam FS, 2004, NATURE, V430, P68, DOI 10.1038/nature02638
   Kapaj S, 2006, J ENVIRON SCI HEAL A, V41, P2399, DOI 10.1080/10934520600873571
   Kinniburgh D. G., 2001, ARSENIC CONTAMINATIO
   Mallick S, 1996, CURR SCI INDIA, V70, P956
   Mandal BK, 1998, SCI TOTAL ENVIRON, V218, P185, DOI 10.1016/S0048-9697(98)00220-4
   MAZUMDER DNG, 1988, B WORLD HEALTH ORGAN, V66, P499
   McArthur JM, 2004, APPL GEOCHEM, V19, P1255, DOI 10.1016/j.apgeochem.2004.02.001
   McArthur JM, 2001, WATER RESOUR RES, V37, P109, DOI 10.1029/2000WR900270
   MOORE JN, 1988, ENVIRON SCI TECHNOL, V22, P432, DOI 10.1021/es00169a011
   Mukherjee A, 2007, J HYDROL, V334, P151, DOI 10.1016/j.jhydrol.2006.10.004
   Mukherjee Arun B., 2001, Environmental Reviews, V9, P189, DOI 10.1139/er-9-3-189
   Nath B, 2005, MINERAL MAG, V69, P841, DOI 10.1180/0026461056950292
   Nath B, 2008, J CONTAM HYDROL, V99, P85, DOI 10.1016/j.jconhyd.2008.04.005
   Nath B, 2008, APPL GEOCHEM, V23, P996, DOI 10.1016/j.apgeochem.2007.11.017
   Nath B, 2008, APPL GEOCHEM, V23, P977, DOI 10.1016/j.apgeochem.2007.11.016
   Nath B, 2008, WATER AIR SOIL POLL, V190, P95, DOI 10.1007/s11270-007-9583-x
   Nickson RT, 2005, APPL GEOCHEM, V20, P55, DOI 10.1016/j.apgeochem.2004.06.004
   Nickson RT, 2000, APPL GEOCHEM, V15, P403, DOI 10.1016/S0883-2927(99)00086-4
   Pal T, 2002, CURR SCI INDIA, V82, P554
   *PHED, 1993, NAT DRINK WAT MISS P
   *RGNDWM, 2002, MIN RUR WAT DEV FIN
   RITTLE KA, 1995, GEOMICROBIOL J, V13, P1, DOI 10.1080/01490459509378000
   Rock NMS, 1988, LECT NOTES EARTH SCI, V18
   Rowland HAL, 2006, ORG GEOCHEM, V37, P1101, DOI 10.1016/j.orggeochem.2006.04.011
   Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5
   *SOES, 2008, SCH ENV STUD
   Sracek O, 2005, NATURAL ARSENIC IN GROUNDWATER: OCCURRENCE, REMEDIATION AND MANAGEMENT, P133
   Stuben D, 2003, APPL GEOCHEM, V18, P1417, DOI 10.1016/S0883-2927(03)00060-X
   Vogel A. I., 1989, VOGELS TXB QUANTITAT
NR 54
TC 15
Z9 16
U1 4
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-7722
EI 1873-6009
J9 J CONTAM HYDROL
JI J. Contam. Hydrol.
PD JUL 29
PY 2008
VL 99
IS 1-4
BP 22
EP 30
DI 10.1016/j.jconhyd.2008.04.004
PG 9
WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources
SC Environmental Sciences & Ecology; Geology; Water Resources
GA 346FW
UT WOS:000259055100003
PM 18584911
DA 2018-12-27
ER

PT J
AU Raghavan, G
   Haridevi, CK
   Gopinathan, CP
AF Raghavan, Gireesh
   Haridevi, Chanjaplackal Kesavan
   Gopinathan, Cherukara Purushothaman
TI RETRACTED: Growth and proximate composition of the Chaetoceros
   calcitrans f. pumilus under different temperature, salinity and carbon
   dioxide levels (Retracted article. See vol. 43, pg. 639, 2012)
SO AQUACULTURE RESEARCH
LA English
DT Article; Retracted Publication
DE Chaetoceros calcitrans; growth; composition; temperature; salinity;
   carbon dioxide; live feed
ID FATTY-ACID-COMPOSITION; CLONE T-ISO; BIOCHEMICAL-COMPOSITION;
   CHEMICAL-COMPOSITION; PHAEODACTYLUM-TRICORNUTUM; ISOCHRYSIS-GALBANA;
   BATCH CULTURES; CHLOROPHYLL-A; MICROALGAE; PHYTOPLANKTON
AB The marine diatom Chaetoceros calcitrans f. pumilus has been examined for its potential source as live feed in aquaculture. The present study investigated effects of temperature (20, 25 and 30 degrees C), salinity (25 and 35) and carbon dioxide addition (air+CO2) on the growth and proximate composition of C. calcitrans under laboratory conditions. The growth and biomass of C. calcitrans were primarily affected by carbon dioxide addition, and to a lesser extent by temperature and salinity. In general, lipid and carbohydrate contents were higher at lower temperatures (20 and 25 degrees C), while the protein content was unaffected. Carbon dioxide addition increased protein, while lowering carbohydrates, but had no effect on lipid content. Carbohydrates were increased while lipids and protein decreased at the highest salinity (35 +/- 0.9). These results should be taken into consideration when evaluating the dietary value of this micro alga for aquaculture.
C1 [Raghavan, Gireesh; Gopinathan, Cherukara Purushothaman] Cent Marine Fisheries Res Inst, Kochi, Kerala, India.
   [Haridevi, Chanjaplackal Kesavan] RC, Natl Inst Oceanog, Kochi, Kerala, India.
RP Raghavan, G (reprint author), Cent Marine Fisheries Res Inst, Kochi, Kerala, India.
EM girmsr@gmail.com
CR BAUMGARTEN MGZ, 1996, MANUAL ANAL QUIMICAS
   BENAMOTZ A, 1987, MAR BIOL, V95, P31, DOI 10.1007/BF00447482
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Brown MR, 1997, AQUACULTURE, V151, P315, DOI 10.1016/S0044-8486(96)01501-3
   BROWN MR, 1989, NUTR ASPECTS MICRO A
   CHRISMADHA T, 1994, J APPL PHYCOL, V6, P67, DOI 10.1007/BF02185906
   Chu WL, 1996, J APPL PHYCOL, V8, P389, DOI 10.1007/BF02178582
   Coutteau P., 1992, Journal of Shellfish Research, V11, P467
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   ENRIGHT CT, 1986, J EXP MAR BIOL ECOL, V96, P15, DOI 10.1016/0022-0981(86)90010-9
   EPIFANIO CE, 1981, AQUACULTURE, V23, P347, DOI 10.1016/0044-8486(81)90027-2
   FABREGAS J, 1985, AQUACULTURE, V50, P1
   Fabregas J, 2001, MAR BIOTECHNOL, V3, P256, DOI 10.1007/s101260000074
   FERNANDEZREIRIZ MJ, 1989, AQUACULTURE, V83, P17, DOI 10.1016/0044-8486(89)90057-4
   Fogg G. E., 1987, ALGAL CULTURES PHYTO
   Guillard R. R. L., 1973, HDB PHYCOLOGICAL MET, P69
   JEFFREY SW, 1994, MICRO ALGAE MARICULT
   LIANG I, 1985, MAR BIOL, V5, P37
   MYKLESTAD S, 1972, Journal of Experimental Marine Biology and Ecology, V9, P125, DOI 10.1016/0022-0981(72)90041-X
   OLAIZOLA M, 1991, J APPL PHYCOL, V3, P363, DOI 10.1007/BF00026099
   Renaud SM, 2002, AQUACULTURE, V211, P195, DOI 10.1016/S0044-8486(01)00875-4
   Renaud SM, 1995, J APPL PHYCOL, V7, P595, DOI 10.1007/BF00003948
   Richmond A., 1986, P69
   ROESSLER PG, 1990, J PHYCOL, V26, P393, DOI 10.1111/j.0022-3646.1990.00393.x
   SONTAYA K, 2005, CHEM ENG, V105, P91
   THOMPSON PA, 1992, J PHYCOL, V28, P481, DOI 10.1111/j.0022-3646.1992.00481.x
   Tzovenis I, 1997, AQUACULT INT, V5, P489, DOI 10.1023/A:1018349131522
   Walne P.R., 1974, CULTURE BIVALVE MOLL
   WELSCHMEYER NA, 1994, LIMNOL OCEANOGR, V39, P1985, DOI 10.4319/lo.1994.39.8.1985
   WHYTE JNC, 1987, AQUACULTURE, V60, P231, DOI 10.1016/0044-8486(87)90290-0
   WHYTE JNC, 1989, AQUACULTURE, V78, P333, DOI 10.1016/0044-8486(89)90110-5
   YOSHIHIRO S, 1995, J PHYCOL, V31, P880
   Zhu CJ, 1997, J APPL PHYCOL, V9, P451, DOI 10.1023/A:1007973319348
NR 33
TC 14
Z9 19
U1 6
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-557X
EI 1365-2109
J9 AQUAC RES
JI Aquac. Res.
PD JUL 17
PY 2008
VL 39
IS 10
BP 1053
EP 1058
DI 10.1111/j.1365-2109.2008.01964.x
PG 6
WC Fisheries
SC Fisheries
GA 324WM
UT WOS:000257550100005
DA 2018-12-27
ER

PT J
AU Sant'Ana, CD
   Menaldo, DL
   Costa, TR
   Godoy, H
   Muller, VDM
   Aquino, VH
   Albuquerque, S
   Sampaio, SV
   Monteiro, MC
   Stabeli, RG
   Soares, AM
AF Sant'Ana, Carolina D.
   Menaldo, Danilo L.
   Costa, Tassia R.
   Godoy, Harryson
   Muller, Vanessa D. M.
   Aquino, Victor H.
   Albuquerque, Sergio
   Sampaio, Suely V.
   Monteiro, Marta C.
   Stabeli, Rodrigo G.
   Soares, Andreimar M.
TI RETRACTED: Antiviral and antiparasite properties of an L-amino acid
   oxidase from the Snake Bothrops jararaca: Cloning and identification of
   a complete cDNA sequence (Retracted article. See vol. 80, pg. 288, 2010)
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE L-amino acid oxidase; Snake venom; Bothrops jararaca; parasiticide;
   antiviral; cDNA sequence
ID FUNCTIONAL-CHARACTERIZATION; PLATELET-AGGREGATION; VENOM; APOPTOSIS;
   MOOJENI
AB L-Amino acid oxidases (LAAOs, EC 1.4.3.2) are flavoenzymes that catalyze the stereospecific oxidative deamination of an L-amino acid substrate to the corresponding a-ketoacid with hydrogen peroxide and ammonia production. The present work describes the first report on the antiviral (Dengue virus) and antiprotozoal (trypanocidal and leishmanicide) activities of a Bothrops jararaca L-amino acid oxidase (BjarLAAO-I) and identify its cDNA sequence. Antiparasite effects were inhibited by catalase, suggesting that they are mediated by H(2)O(2) production. Cells infected with DENV-3 virus previously treated with BjarLAAO-I, showed a decrease in viral titer (13-83-fold) when compared with cells infected with untreated viruses. Untreated and treated promastigotes (T. cruzi and L. amazonensis) were observed by transmission electron microscopy with different degrees of damage. Its complete cDNA sequence, with 1452 bp, encoded an open reading frame of 484 amino acid residues with a theoretical molecular weight and pl of 54,771.8 and 5.7, respectively. The cDNA-deduced amino acid sequence of BjarLAAO shows high identity to LAAOs from other snake venoms. Further investigations will be focused on the related molecular and functional correlation of these enzymes. Such a study should provide valuable information for the therapeutic development of new generations of microbicidal drugs. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Sant'Ana, Carolina D.; Menaldo, Danilo L.; Costa, Tassia R.; Godoy, Harryson; Muller, Vanessa D. M.; Aquino, Victor H.; Albuquerque, Sergio; Sampaio, Suely V.; Soares, Andreimar M.] Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Monteiro, Marta C.] Univ Estudual, Ctr Oeste UNICENTRO, Guarapuava, PR, Brazil.
   [Stabeli, Rodrigo G.] Univ Rondonia, Inst Pesquisa Patol, IPEPATRO, Rondonia, AC, Brazil.
RP Soares, AM (reprint author), Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, Avenida Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM andreims@fcfrp.usp.br
RI Vilela, Suely/D-7429-2012; Muller, Vanessa/J-8722-2013; Soares,
   Andreimar/K-5556-2014; VILELA SAMPAIO, SUELY/C-3433-2013; Monteiro,
   Marta Chagas/F-6575-2010; Aquino, Victor/C-1922-2012
OI Vilela, Suely/0000-0003-3274-180X; Monteiro, Marta
   Chagas/0000-0002-3328-5650; Aquino, Victor/0000-0003-1910-0776
CR Ali SA, 2000, ARCH BIOCHEM BIOPHYS, V384, P216, DOI 10.1006/abbi.2000.2130
   Aquino VH, 2006, AM J TROP MED HYG, V75, P710, DOI 10.4269/ajtmh.2006.75.710
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   de Lima DC, 2005, EVID-BASED COMPL ALT, V2, P39, DOI 10.1093/ecam/neh063
   Deolindo P, 2005, MEM I OSWALDO CRUZ, V100, P33, DOI 10.1590/S0074-02762005000100006
   Du XY, 2002, TOXICON, V40, P659, DOI 10.1016/S0041-0101(02)00102-2
   Franca SC, 2007, BIOCHEM BIOPH RES CO, V355, P302, DOI 10.1016/j.bbrc.2006.12.217
   Izidoro LFM, 2006, BIOORGAN MED CHEM, V14, P7034, DOI 10.1016/j.bmc.2006.06.025
   Krobitsch S, 1998, J BIOL CHEM, V273, P6488, DOI 10.1074/jbc.273.11.6488
   Braga MDM, 2008, TOXICON, V51, P199, DOI 10.1016/j.toxicon.2007.09.003
   MOLYNEUX DH, 1991, ANN SOC BELG MED TR, V71, P151
   Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204
   Samel M, 2006, BBA-PROTEINS PROTEOM, V1764, P707, DOI 10.1016/j.bbapap.2006.01.021
   Santos MMD, 2008, BASIC CLIN PHARMACOL, V102, P533, DOI 10.1111/j.1742-7843.2008.00229.x
   Stabeli RG, 2004, BIOORGAN MED CHEM, V12, P2881, DOI 10.1016/j.bmc.2004.03.049
   Stabeli RG, 2007, INT J BIOL MACROMOL, V41, P132, DOI 10.1016/j.ijbiomac.2007.01.006
   Suhr SM, 1996, BIOCHEM BIOPH RES CO, V224, P134, DOI 10.1006/bbrc.1996.0996
   Sun LK, 2003, TOXICOL IN VITRO, V17, P169, DOI 10.1016/S0887-2333(03)00010-9
   Tempone AG, 2001, BIOCHEM BIOPH RES CO, V280, P620, DOI 10.1006/bbrc.2000.4175
   Torii S, 2000, BIOCHEMISTRY-US, V39, P3197, DOI 10.1021/bi992416z
   Toyama MH, 2006, TOXICON, V47, P47, DOI 10.1016/j.toxicon.2005.09.008
   Zhang YJ, 2003, BIOCHEM BIOPH RES CO, V309, P598, DOI 10.1016/j.bbrc.2003.08.044
   Zieler H, 2001, J EXP BIOL, V204, P4157
NR 23
TC 19
Z9 20
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUL 15
PY 2008
VL 76
IS 2
BP 279
EP 288
DI 10.1016/j.bcp.2008.05.003
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 324YP
UT WOS:000257555600014
PM 18555977
DA 2018-12-27
ER

PT J
AU Donev, RM
   Gray, LC
   Sivasankar, B
   Hughes, TR
   van den Berg, CW
   Morgan, BP
AF Donev, Rossen M.
   Gray, Lisa C.
   Sivasankar, Baalasubramanian
   Hughes, Timothy R.
   van den Berg, Carmen W.
   Morgan, B. Paul
TI RETRACTED: Modulation of CD59 expression by restrictive silencer
   factor-derived peptides in cancer immunotherapy for
   neuroblastoma(Retracted article. See vol. 73, pg. 6839, 2013)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID COMPLEMENT-REGULATORY PROTEINS; CELL LUNG-CANCER; TRANSCRIPTION FACTOR;
   IN-VIVO; NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; DNA-BINDING; FACTOR
   NRSF; RITUXIMAB; REPRESSOR
AB Tumor cells escape clearance by complement by abundantly expressing CD59 and other membrane complement regulators. Existing strategies for blocking/knocking down these regulators can contribute to tumor immunoclearance in vitro; however, there are numerous difficulties restricting their use in vivo. Here, we report a new strategy for suppression of CD59 expression in neuroblastoma using peptides that target regulators of CD59 expression. We identified the neuralrestrictive silencer factor (REST) as a target for modulation of CD59 expression in neuroblastoma. We next designed plasmids that encoded peptides comprising different DNA-binding domains of REST and transfected them into neuroblastoma cell lines. These peptides suppressed CD59 expression, sensitizing neuroblastoma to complement-mediated killing triggered by anti-GD2 therapeutic monoclonal antibody. These CD59-modulating peptides might be effective therapeutic adjuvants to therapeutic monoclonal antibodies used for treatment of neuroblastoma and other cancer types sharing the same mechanism for regulation of CD59 expression.
C1 [Donev, Rossen M.; Sivasankar, Baalasubramanian; Hughes, Timothy R.; Morgan, B. Paul] Cardiff Univ, Dept Med Biochem & Immunol, Sch Med, Cardiff, S Glam, Wales.
   [Gray, Lisa C.; van den Berg, Carmen W.] Cardiff Univ, Dept Pharmacol Therapeut & Toxicol, Sch Med, Cardiff, S Glam, Wales.
RP Donev, RM (reprint author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.
EM donevrm@cardiff.ac.uk
RI Donev, Rossen/C-5105-2009
FU Medical Research Council [G0700102(81345), G0700102]; Wellcome Trust
   [068590]
CR Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684
   Bjorge L, 1997, INT J CANCER, V70, P14, DOI 10.1002/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9
   Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507
   Chen SH, 2000, CANCER RES, V60, P3013
   CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8
   Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032
   Coulson JM, 1999, BRIT J CANCER, V80, P1935, DOI 10.1038/sj.bjc.6690623
   Coulson JM, 2000, CANCER RES, V60, P1840
   Davies CS, 2005, IMMUNOLOGY, V114, P280, DOI 10.1111/j.1365-2567.2004.02086.x
   Donev R, 2003, J BIOL CHEM, V278, P5214, DOI 10.1074/jbc.M206621200
   Donev RM, 2006, CANCER RES, V66, P2451, DOI 10.1158/0008-5472.CAN-05-3191
   Donev RM, 2008, MOL IMMUNOL, V45, P534, DOI 10.1016/j.molimm.2007.05.011
   Eggert US, 2006, MOL BIOSYST, V2, P93, DOI 10.1039/b515335b
   Enukashvily N, 2005, J CELL SCI, V118, P611, DOI 10.1242/jcs.01605
   Gazouli M, 2002, ANTICANCER RES, V22, P4237
   Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383
   Gorter A, 1999, IMMUNOL TODAY, V20, P576, DOI 10.1016/S0167-5699(99)01537-6
   Holguin MH, 1996, J IMMUNOL, V157, P1659
   Imai M, 2005, CANCER RES, V65, P10562, DOI 10.1158/0008-5472.CAN-05-1894
   Imai M, 2007, CANCER RES, V67, P9535, DOI 10.1158/0008-5472.CAN-07-1690
   Johnson T, 2007, IET CIRC DEVICE SYST, V1, P21, DOI 10.1049/iet-cds:20060054
   Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274
   Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200
   Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019
   Kimura Y, 1997, GENOMICS, V41, P477, DOI 10.1006/geno.1997.4680
   Lucas SD, 1996, HUM PATHOL, V27, P1329, DOI 10.1016/S0046-8177(96)90346-9
   Macor P, 2007, CANCER RES, V67, P10556, DOI 10.1158/0008-5472.CAN-07-1811
   Magyarlaki T, 1996, TUMORI, V82, P473
   Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982
   Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/spnc.2002.30156
   Matsumoto M, 1997, NAT MED, V3, P1266, DOI 10.1038/nm1197-1266
   MUJOO K, 1987, CANCER RES, V47, P1098
   Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310
   ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N
   Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5
   Plaisance V, 2005, J BIOL CHEM, V280, P401, DOI 10.1074/jbc.M411825200
   Protopopova M, 2003, CELL CYCLE, V2, P592, DOI 10.4161/cc.2.6.501
   Rushmere NK, 2004, INT J CANCER, V108, P930, DOI 10.1002/ijc.11606
   SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435
   Shimojo M, 2003, MOL CELL BIOL, V23, P9025, DOI 10.1128/MCB.23.24.9025-9031.2003
   Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200
   Spix C, 2001, EUR J CANCER, V37, P722, DOI 10.1016/S0959-8049(01)00003-X
   Takei K, 2006, LEUKEMIA RES, V30, P625, DOI 10.1016/j.leukres.2005.09.008
   van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033
NR 46
TC 23
Z9 29
U1 2
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2008
VL 68
IS 14
BP 5979
EP 5987
DI 10.1158/0008-5472.CAN-07-6828
PG 9
WC Oncology
SC Oncology
GA 327ZZ
UT WOS:000257768300058
PM 18632654
OA Green Accepted, Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zeoli, N
   Gu, S
   Kamnis, S
AF Zeoli, N.
   Gu, S.
   Kamnis, S.
TI RETRACTED: Numerical modelling of metal droplet cooling and
   solidification (Retracted article. See vol. 118, pg. 1374, 2018)
SO INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER
LA English
DT Article; Retracted Publication
DE gas atomisation; cooling; solidification; heat transfer; metal powder;
   break-up
ID SPRAY ATOMIZATION; BEHAVIOR
AB In an atomisation process for power production, metal droplets go through undercooling, recalescence, peritectic and segregated solidification before fully solidified. The cooling process is further complicated by droplet break-up during the atomisation. This paper describes a numerical model which combines both cooling and break-up in a single computation. The dynamic history of droplets is solved as discrete phase in an Eulerian gas flow. The coupling between droplet and gas flows are two-way, in which the heat and momentum exchanges affecting the gas flow are treated as source/sink terms in the fluid equations. The droplet model is employed to a gas atomisation process for metal powder production and good agreement is achieved with the results in open literature. The model results further confirm that thermal history of particles is strongly dependent on initial droplet size. Large droplets will not go through undercooling while small droplets-have identifiable stages of undercooling, unclearation and recalescence. The predictions demonstrate that droplets have very similar profiles during gas atomization and the major factor influencing the atomization and solidification process of droplets are in-flight distance. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Zeoli, N.; Gu, S.; Kamnis, S.] Aston Univ, Sch Engn & Appl Sci, Birmingham B4 7ET, W Midlands, England.
RP Gu, S (reprint author), Aston Univ, Sch Engn & Appl Sci, Birmingham B4 7ET, W Midlands, England.
EM zeolin@aston.ac.uk; s.gu@aston.ac.uk
CR Anderson JD, 2003, MODERN COMPRESSIBLE
   Bergmann D, 2000, INT J THERM SCI, V39, P53, DOI 10.1016/S1290-0729(00)00195-1
   CANTOR B, 2001, P 22 RIS INT S MAT S, P483
   Delplanque JP, 2000, J HEAT TRANS-T ASME, V122, P126, DOI 10.1115/1.521443
   *FLUENT EUR, FLUENT 6 2
   Hattel JH, 1999, MODEL SIMUL MATER SC, V7, P413, DOI 10.1088/0965-0393/7/3/309
   HIRTH JP, 1978, METALL TRANS A, V9, P401, DOI 10.1007/BF02646391
   Li B, 1996, ACTA MATER, V44, P2409, DOI 10.1016/1359-6454(95)00335-5
   LIU HM, 1995, MAT SCI ENG A-STRUCT, V191, P171, DOI 10.1016/0921-5093(94)09631-6
   Mates SP, 2005, ATOMIZATION SPRAY, V15, P19, DOI 10.1615/AtomizSpr.v15.i1.20
   MATHUR P, 1989, ACTA METALL MATER, V37, P429, DOI 10.1016/0001-6160(89)90227-7
   ORIYRJE PJ, 1987, 872089 SAE
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Reitz R.D., 1987, ATOMISATION SPRAY TE, V3, P309
   Scheil E., 1942, Z METALLKD, V34, P70
   Shukla P, 2001, B MATER SCI, V24, P547, DOI 10.1007/BF02706729
   Su YQ, 2005, INTERMETALLICS, V13, P267, DOI 10.1016/j.intermet.2004.07.010
   Underhill RP, 1997, INT J NON-EQUILIB PR, V10, P201
   Zeoli N, 2006, COMP MATER SCI, V38, P282, DOI 10.1016/j.commatsci.2006.02.012
NR 19
TC 27
Z9 27
U1 3
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0017-9310
EI 1879-2189
J9 INT J HEAT MASS TRAN
JI Int. J. Heat Mass Transf.
PD JUL 15
PY 2008
VL 51
IS 15-16
BP 4121
EP 4131
DI 10.1016/j.ijheatmasstransfer.2007.11.044
PG 11
WC Thermodynamics; Engineering, Mechanical; Mechanics
SC Thermodynamics; Engineering; Mechanics
GA 328TI
UT WOS:000257820300037
DA 2018-12-27
ER

PT J
AU Cannata, F
   Brunet, E
   Perrouault, L
   Roig, V
   Ait-Si-Ali, S
   Asseline, U
   Concorclet, JP
   Giovannangeli, C
AF Cannata, Fabio
   Brunet, Erika
   Perrouault, Loic
   Roig, Victoria
   Ait-Si-Ali, Slimane
   Asseline, Ulysse
   Concorclet, Jean-Paul
   Giovannangeli, Carine
TI RETRACTED: Triplex-forming oligonucleotide-orthophenanthroline
   conjugates for efficient targeted genome modification (Retracted
   article. See vol. 107, pg. 5261, 2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE synthetic nucleases; double strand break; gene targeting; homologous
   recombination
ID ZINC-FINGER NUCLEASES; DOUBLE-STRAND BREAK; SITE-SPECIFIC ENDONUCLEASE;
   HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; DNA-BINDING; GENE; CLEAVAGE;
   SPECIFICITY; MUTAGENESIS
AB The inefficiency of gene modification by homologous recombination can be overcome by the introduction of a double-strand break (DSB) in the target. Engineering the endonucleases needed, however, remains a challenging task that limits widespread application of nuclease-driven gene modification. We report here that conjugates of orthophenanthroline (OP), a DNA cleaving molecule, and triplex-forming oligonucleotides (TFOs), known to bind specific DNA sequences, are synthetic nucleases efficient at stimulating targeted genome modification. We show that in cultured cells, OP-TFO conjugates induce targeted DSBs. An OP-TFO with a unique target was highly efficient, and mutations at the target site were found in approximate to 10% of treated cells, including small deletions most likely introduced during DSB repair by nonhomologous end joining. Importantly, we found that when homologous donor DNA was cotransfected, targeted gene modification took place in >1.5% of treated cells. Because triplex-forming sequences are frequent in human and mouse genes, OP-TFO conjugates therefore constitute an important class of site-specific nucleases for targeted gene modification. Harnessing DNA-damaging molecules to predetermined genomic sites, as achieved here, should also provide inroads into mechanisms of DNA repair and cancer.
C1 Univ Paris 05, Inst Cochin, CNRS, UMR 8104, F-75014 Paris, France.
   Museum Natl Hist Nat, Biophys Lab, F-75005 Paris, France.
   Museum Natl Hist Nat, CNRS, UMR 5153, USM 503, F-75005 Paris, France.
   Museum Natl Hist Nat, Inst Natl Sante & Rech Med, U565, F-75005 Paris, France.
   CNRS, UPR 4301, Ctr Biophys Mol, F-45071 Orleans 02, France.
   CNRS, FRE 2944, Inst Andre Lwoff, F-94800 Villejuif, France.
   INSERM, U567, F-75014 Paris, France.
RP Concorclet, JP (reprint author), Univ Paris 05, Inst Cochin, CNRS, UMR 8104, F-75014 Paris, France.
EM giovanna@mnhn.fr; concordet@cochin.inserm.fr
OI Concordet, Jean-Paul/0000-0001-8924-4316
CR Alwin S, 2005, MOL THER, V12, P610, DOI 10.1016/j.ymthe.2005.06.094
   Andrieu-Soler C, 2005, NUCLEIC ACIDS RES, V33, P3733, DOI 10.1093/nar/gki686
   Ashworth J, 2006, NATURE, V441, P656, DOI 10.1038/nature04818
   Besch R, 2004, CURR DRUG TARGETS, V5, P691, DOI 10.2174/1389450043345100
   Bibikova M, 2002, GENETICS, V161, P1169
   Brunet E, 2005, NUCLEIC ACIDS RES, V33, P4223, DOI 10.1093/nar/gki726
   Brunet E, 2005, J BIOL CHEM, V280, P20076, DOI 10.1074/jbc.M500021200
   Brunet E, 2006, NUCLEIC ACIDS RES, V34, P4546, DOI 10.1093/nar/gkl630
   CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968
   Dervan Peter B., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P373, DOI 10.2174/1568011054222346
   Doyon JB, 2006, J AM CHEM SOC, V128, P2477, DOI 10.1021/ja0575191
   Francois JC, 2004, NUCL ACID M, V13, P223
   Gouble A, 2006, J GENE MED, V8, P616, DOI 10.1002/jgm.879
   Kim KH, 2007, NUCLEIC ACIDS RES, V35, P7604, DOI 10.1093/nar/gkm666
   Knauert MP, 2006, MOL THER, V14, P392, DOI 10.1016/j.ymthe.2006.03.020
   Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172
   Lloyd A, 2005, P NATL ACAD SCI USA, V102, P2232, DOI 10.1073/pnas.0409339102
   Miller JC, 2007, NAT BIOTECHNOL, V25, P778, DOI 10.1038/nbt1319
   Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9
   Pingoud A, 2007, NAT BIOTECHNOL, V25, P743, DOI 10.1038/nbt0707-743
   Porteus MH, 2006, MOL THER, V13, P438, DOI 10.1016/j.ymthe.2005.08.003
   Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125
   POVIRK LF, 1994, J MOL BIOL, V243, P216
   PUCHTA H, 1993, NUCLEIC ACIDS RES, V21, P5034, DOI 10.1093/nar/21.22.5034
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Rogers Faye A., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P319, DOI 10.2174/1568011054222300
   ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064
   SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414
   Smith J, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl720
   Szczepek M, 2007, NAT BIOTECHNOL, V25, P786, DOI 10.1038/nbt1317
   Treand C, 2006, EMBO J, V25, P1690, DOI 10.1038/sj.emboj.7601074
   Urnov FD, 2005, NATURE, V435, P646, DOI 10.1038/nature03556
   Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498
   Wu Q, 2007, MOL CARCINOGEN, V46, P15, DOI 10.1002/mc.20261
   Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451
NR 35
TC 16
Z9 17
U1 2
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 15
PY 2008
VL 105
IS 28
BP 9576
EP 9581
DI 10.1073/pnas.0710433105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 328FV
UT WOS:000257784700024
PM 18599454
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ma, X
   Zubcevic, L
   Ashcroft, FM
AF Ma, Xiaosong
   Zubcevic, Lejla
   Ashcroft, Frances M.
TI RETRACTED: Glucose regulates the effects of leptin on hypothalamic POMC
   neurons (Retracted article. See vol. 106, pg 7263, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE excitatory postsynaptic currents; glucose sensing; inhibitory
   postsynaptic currents; K-ATP channel; appetite
ID CENTRAL-NERVOUS-SYSTEM; ARCUATE NUCLEUS; PROOPIOMELANOCORTIN NEURONS;
   NEUROPEPTIDE-Y; BODY-WEIGHT; FOOD-INTAKE; RECEPTOR; HOMEOSTASIS;
   OBESITY; RAT
AB Leptin is believed to exert its potent appetite-suppressing effects via stimulation of hypothalamic anorexigenic proopiomelanocortin (POMC)-containing neurons and inhibition of orexigenic agouti-related protein (AgRP) neurons. We show here that at 11 mM glucose leptin excites POMC cells. At 5 mM glucose, however, leptin hyperpolarizes POMC neurons and suppresses action potential firing, by producing a greater decrease in excitatory synaptic tone than inhibitory tone. These results argue that when glucose is low (5 mM or less) AgRP neurons will be more important for mediating the anorectic effects of leptin than POMC cells. However, at high glucose concentrations (11 mM), activation of POMC cells may contribute to the appetite-suppressing effects of leptin. Our data also suggest the regulation of neuropeptide efficacy as a novel function of hypothalamic glucose sensing.
C1 [Ma, Xiaosong; Zubcevic, Lejla; Ashcroft, Frances M.] Univ Oxford, Henry Wellcome Ctr Gene Funct, Dept Physiol Anat & Genet, Oxford OX1 3PT, England.
RP Ashcroft, FM (reprint author), Univ Oxford, Henry Wellcome Ctr Gene Funct, Dept Physiol Anat & Genet, Parks Rd, Oxford OX1 3PT, England.
EM frances.ashcroft@dpag.ox.ac.uk
FU Wellcome Trust
CR Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004
   Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828
   Bates SH, 2003, TRENDS ENDOCRIN MET, V14, P447, DOI 10.1016/j.tem.2003.10.003
   Burdakov D, 2006, NEURON, V50, P711, DOI 10.1016/j.neuron.2006.04.032
   Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489
   Choudhury AI, 2005, J CLIN INVEST, V115, P940
   Claret M, 2007, J CLIN INVEST, V117, P2325, DOI 10.1172/JCI31516
   Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914
   Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455
   Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085
   Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0
   Elmquist JK, 2005, J COMP NEUROL, V493, P63, DOI 10.1002/cne.20786
   Elmquist JK, 1998, J COMP NEUROL, V395, P535
   Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204
   Fioramonti X, 2007, DIABETES, V56, P1219, DOI 10.2337/db06-0567
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548
   Ibrahim N, 2003, ENDOCRINOLOGY, V144, P1331, DOI 10.1210/en.2002-221033
   Kiss J, 2005, EUR J NEUROSCI, V21, P2111, DOI 10.1111/j.1460-9568.2005.04012.x
   Ma XS, 2007, J NEUROSCI, V27, P7125, DOI 10.1523/JNEUROSCI.1025-07.2007
   Ma XS, 2007, J NEUROSCI, V27, P1529, DOI 10.1523/JNEUROSCI.3583-06.2007
   MERCHENTHALER I, 1991, NEUROSCIENCE, V44, P655, DOI 10.1016/0306-4522(91)90085-3
   Parton LE, 2007, NATURE, V449, P228, DOI 10.1038/nature06098
   Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459
   Plum L, 2006, J CLIN INVEST, V116, P1886, DOI 10.1172/JCI27123
   Powis JE, 1998, AM J PHYSIOL-REG I, V274, pR1468, DOI 10.1152/ajpregu.1998.274.5.R1468
   Routh VH, 2002, PHYSIOL BEHAV, V76, P403, DOI 10.1016/S0031-9384(02)00761-8
   Schwartz MW, 2000, NATURE, V404, P661
   SILVER IA, 1994, J NEUROSCI, V14, P5068
   Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379
   STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0
   Takahashi KA, 2005, ENDOCRINOLOGY, V146, P1043, DOI 10.1210/en.2004-1397
   van den Pol AN, 1998, J NEUROSCI, V18, P7962
   van den Top M, 2004, NAT NEUROSCI, V7, P493, DOI 10.1038/nn1226
   Wu Q, 2008, P NATL ACAD SCI USA, V105, P2687, DOI 10.1073/pnas.0712062105
   Xu AW, 2007, ENDOCRINOLOGY, V148, P72, DOI 10.1210/en.2006-1119
   Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI24301
NR 37
TC 8
Z9 8
U1 3
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 15
PY 2008
VL 105
IS 28
BP 9811
EP 9816
DI 10.1073/pnas.0800952105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 328FV
UT WOS:000257784700064
PM 18599453
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Anandatheerthavarada, HK
   Sepuri, NBV
   Biswas, G
   Avadhani, NG
AF Anandatheerthavarada, Hindupur K.
   Sepuri, Naresh Babu V.
   Biswas, Gopa
   Avadhani, Narayan G.
TI RETRACTED: An unusual TOM20/TOM22 bypass mechanism for the mitochondrial
   targeting of cytochrome P450 proteins containing N-terminal chimeric
   signals (Retracted Article. See vol 283, pg 36060, 2008)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID IMPORT RECEPTORS TOM20; ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE; MOLECULAR
   CHAPERONES; SACCHAROMYCES-CEREVISIAE; TRANSLOCATION; BIOGENESIS;
   PREPROTEINS; ACTIVATION; PATHWAY
AB Previously we showed that xenobiotic-inducible cytochrome P450 (CYP) proteins are bimodally targeted to the endoplasmic reticulum and mitochondria. In the present study, we investigated the mechanism of delivery of chimeric signal-containing CYP proteins to the peripheral and channel-forming mitochondrial outer membrane translocases (TOMs). CYP + 33/1A1 and CYP2B1 did not require peripheral TOM70, TOM20, or TOM22 for translocation through the channel-forming TOM40 protein. In contrast, CYP + 5/1A1 and CYP2E1 were able to bypass TOM20 and TOM22 but required TOM70. CYP27, which contains a canonical cleavable mitochondrial signal, required all of the peripheral TOMs for its mitochondrial translocation. We investigated the underlying mechanisms of bypass of peripheral TOMs by CYPs with chimeric signals. The results suggested that interaction of CYPs with Hsp70, a cytosolic chaperone involved in the mitochondrial import, alone was sufficient for the recognition of chimeric signals by peripheral TOMs. However, sequential interaction of chimeric signal-containing CYPs with Hsp70 and Hsp90 resulted in the bypass of peripheral TOMs, whereas CYP27 interacted only with Hsp70 and was not able to bypass peripheral TOMs. Our results also show that delivery of chimeric signal-containing client proteins by Hsp90 required the cytosol-exposed N-terminal 143 amino acids of TOM40. TOM40 devoid of this domain was unable to bind CYP proteins. These results suggest that, compared with the unimodal mitochondria-targeting signals, the chimeric mitochondria-targeting signals are highly evolved and dynamic in nature.
C1 [Avadhani, Narayan G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA.
RP Avadhani, NG (reprint author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.
EM narayan@vet.upenn.edu
FU NIGMS NIH HHS [GM-34883, R01 GM034883]
CR Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589
   Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494
   Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030
   Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855
   BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965
   Beddoe T, 2002, BBA-MOL CELL RES, V1592, P35, DOI 10.1016/S0167-4889(02)00262-8
   Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014
   Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730
   Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522
   Brunner M, 1995, COLD SPRING HARB SYM, V60, P619, DOI 10.1101/SQB.1995.060.01.066
   Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3
   DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6
   Diekert K, 2001, EMBO J, V20, P5626, DOI 10.1093/emboj/20.20.5626
   Dolezal P, 2006, SCIENCE, V313, P314, DOI 10.1126/science.1127895
   Ellis RJ, 2003, NATURE, V421, P801, DOI 10.1038/421801a
   Fan ACY, 2006, J BIOL CHEM, V281, P33313, DOI 10.1074/jbc.M605250200
   Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x
   Gabaldon T, 2004, BBA-BIOENERGETICS, V1659, P212, DOI 10.1016/j.bbabio.2004.07.011
   GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470
   GLICK B, 1991, ANNU REV GENET, V25, P21
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   Hill K, 1998, NATURE, V395, P516
   Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649
   JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.0551m.x
   Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394
   Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084
   Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587
   Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LITHGOW T, 1994, J BIOL CHEM, V269, P15325
   Ma YL, 2008, J BIOL CHEM, V283, P11743, DOI 10.1074/jbc.M710494200
   Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001
   Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767
   MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051
   Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409
   NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495
   NOTHWEHR SF, 1990, BIOESSAYS, V12, P479, DOI 10.1002/bies.950121005
   Otera H, 2007, J CELL BIOL, V179, P1355, DOI 10.1083/jcb.200702143
   PFALLER R, 1989, J BIOL CHEM, V264, P34
   PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9
   Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012
   Robin MA, 2003, J BIOL CHEM, V278, P18960, DOI 10.1074/jbc.M301807200
   Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200
   ROSE MD, 1987, METHOD ENZYMOL, V152, P481
   RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6
   Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519
   SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0
   Sepuri NBV, 2007, FEBS J, V274, P4615, DOI 10.1111/j.1742-4658.2007.05990.x
   Sepuri NBV, 1998, J BIOL CHEM, V273, P1420, DOI 10.1074/jbc.273.3.1420
   Stan T, 2003, MOL CELL BIOL, V23, P2239, DOI 10.1128/MCB.23.7.2239-2250.2003
   STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353
   SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657
   Subramani S, 1998, PHYSIOL REV, V78, P171
   SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327
   Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793
   VAN AE, 2006, BIOCHIM BIOPHYS ACTA, V1763, P1629
   VAN WS, 1999, NATURE, V401, P485
   VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4
   Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1
   Voos W, 2003, MOL CELL, V11, P1, DOI 10.1016/S1097-2765(03)00002-9
   Wickner W, 2005, SCIENCE, V310, P1452, DOI 10.1126/science.1113752
   WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938
   Wilkinson BM, 1997, J MEMBRANE BIOL, V155, P189, DOI 10.1007/s002329900171
   Yamano K, 2008, J BIOL CHEM, V283, P3799, DOI 10.1074/jbc.M708339200
   Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3
   ZALMAN LS, 1980, J BIOL CHEM, V255, P1771
NR 68
TC 4
Z9 4
U1 2
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 11
PY 2008
VL 283
IS 28
BP 19769
EP 19780
DI 10.1074/jbc.M801464200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 322PK
UT WOS:000257387600061
PM 18480056
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Barlogie, B
   Shaughnessy, JD
   Crowley, J
AF Barlogie, Bart
   Shaughnessy, John D., Jr.
   Crowley, John
TI RETRACTED: Duration of survival in patients with myeloma treated with
   thalidomide (Retracted article. See vol 359, pg. 1410, 2008)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter; Retracted Publication
ID MULTIPLE-MYELOMA
C1 [Barlogie, Bart; Shaughnessy, John D., Jr.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
   [Crowley, John] Canc Res & Biostat, Seattle, WA 98101 USA.
RP Barlogie, B (reprint author), Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
EM barlogiebart@uams.edu
CR Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583
   BARLOGIE B, IN PRESS LEUKEMIA
   Shaughnessy J, 2003, BLOOD, V101, P3849, DOI 10.1182/blood-2002-09-2873
NR 3
TC 8
Z9 8
U1 4
U2 11
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 10
PY 2008
VL 359
IS 2
BP 210
EP 212
DI 10.1056/NEJMc0801352
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 323PJ
UT WOS:000257459000034
PM 18614793
DA 2018-12-27
ER

PT J
AU Zhang, XT
   Wei, PH
   Li, B
AF Zhang, Xiutang
   Wei, Peihai
   Li, Bin
TI RETRACTED: Diaqua-1 kappa O,3 kappa O-di-mu-cyanido-1 : 2 kappa N-2 :
   C;2 : 3 kappa C-2 : N-dicyanido-2 kappa C-2-bis{4,4 '-dibromo-2,2
   '-[propane-1,2-diyl-bis(nitrilomethylidine)]diphenolato}-1 kappa O-4,N,N
   ',O ';3 kappa O-4,N,N ',O '-1,3-di-iron(III)-2-nickel(II) (Retracted
   article. See vol. 67, pg. E16, 2011)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Fe2Ni(C17H14Br2N2O2)(2)(CN)(4)(H2O)(2)] or [{Fe(C17H14Br2N2O2)(H2O)}(2)(mu-CN)(2){Ni(CN)(2)}], is iso-structural with its Mn-III-containing analogue. Each Fe-III atom is chelated by a Schiff base ligand via two N and two O atoms and is additionally coordinated by a water molecule, forming a slightly distorted octahedral geometry. The two Fe-III centres are bridged by a square-planar Ni(CN)(4) unit, which lies on an inversion centre. A two-dimensional network is formed via O-H center dot center dot center dot O and O-H center dot center dot center dot N hydrogen bonds.
C1 [Zhang, Xiutang; Wei, Peihai; Li, Bin] ShanDong Inst Educ, Dept Chem & Chem Engn, Jinan 250013, Peoples R China.
RP Wei, PH (reprint author), ShanDong Inst Educ, Dept Chem & Chem Engn, Jinan 250013, Peoples R China.
EM weipeihai@yahoo.com.cn
CR *BRUK AXS INC, 2004, APEX2
   Bruker, 2001, SAINT PLUS SADABS
   Kuang SM, 2002, INORG CHEM, V41, P147, DOI 10.1021/ic0110070
   KUCHAR J, 2003, MONOGR SER INT C COO, V6, P127
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sun ZH, 2008, ACTA CRYSTALLOGR E, V64, pM783, DOI 10.1107/S1600536808012749
   Yang JY, 2003, INORG CHEM, V42, P1403, DOI 10.1021/ic026065f
NR 7
TC 1
Z9 1
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUL
PY 2008
VL 64
BP M926
EP U622
DI 10.1107/S1600536808017893
PN 7
PG 11
WC Crystallography
SC Crystallography
GA 319ML
UT WOS:000257167600054
PM 21202781
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Das, M
   Pal, S
   Ghosh, A
AF Das, Mithun
   Pal, Susil
   Ghosh, Arnab
TI RETRACTED: Rural urban differences of cardiovascular disease risk
   factors in adult Asian Indians (Retracted article. See vol. 21, pg. 861,
   2009)
SO AMERICAN JOURNAL OF HUMAN BIOLOGY
LA English
DT Article; Retracted Publication
ID CORONARY-HEART-DISEASE; FATTY-ACIDS PROFILES; BENGALI-HINDU MEN;
   METABOLIC SYNDROME; CENTRAL OBESITY; GLUCOSE-INTOLERANCE;
   INSULIN-RESISTANCE; ARTERY-DISEASE; BLOOD-PRESSURE; PREVALENCE
AB The prevalence of cardiovascular disease (CVD) risk factors in "People of Indian Origin" (PIO) is exceedingly high and strong relationships among elevated blood pressure, increased levels of lipoproteins, visceral obesity, physical inactivity and subsequent high occurrence of coronary heart disease, type 2 diabetes mellitus etc., were evident in many studies. Increasing urbanization with effective changes in lifestyles could be attributed to explain this exaggerated rate. The present community based cross-sectional investigation was aimed to identify rural-urban differences in prevalence of risk factors of CVD in the adult Asian Indians. A total of 350 adult (30 years and above) individuals (184 males and 166 females) belong to urban (n = 193, males = 104, and females = 89) and rural (n = 157, males = 80, and females = 77) areas participated in the study. Anthropometric measures, lipids profiles, fasting blood glucose and blood pressure measures were obtained from participants. The mean body mass index (kg/m(2)) for male and female was 22.37 +/- 4.09 and 23.20 +/- 4.37, respectively. There existed significant differences for anthropometric, metabolic, and blood pressure variables between rural and urban areas. Habitat (rural vs. urban) had significant impact on central adiposity, lipids, lipoproteins, and blood pressure measures even after adjusted for age and sex. Overall, 84.3% of females had lower HDL level compared with only 20.1% in males. It was also observed that the prevalence of metabolic syndrome was 56.2% in urban females compared with 36.4% in rural females. Effective urbanization and or modernization seem to influence CVD risk factors and warrants intervention as early as adulthood to check this menace.
C1 [Ghosh, Arnab] Visva Bharati Univ, Dept Anthropol, Sriniketan 731236, W Bengal, India.
   [Pal, Susil] Human Genet Engn Res Ctr, Kolkata, W Bengal, India.
   [Das, Mithun] Sree Chaitanya Coll, Dept Anthropol, Habra, W Bengal, India.
RP Ghosh, A (reprint author), Visva Bharati Univ, Dept Anthropol, Sriniketan 731236, W Bengal, India.
EM arnab_cu@rediffmail.com
CR *AM DIAB ASS, 1997, DIABETES CARE, V20, P1183
   Anjana M, 2004, DIABETES CARE, V27, P2948, DOI 10.2337/diacare.27.12.2948
   Chadha SL, 1998, CURR SCI INDIA, V74, P1069
   CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424
   Deepa R, 2002, INDIAN J MED RES, V115, P118
   Deurenberg-Yap M, 2001, INT J OBESITY, V25, P1554, DOI 10.1038/sj.ijo.0801739
   Dudeja V, 2001, BRIT J NUTR, V86, P105, DOI 10.1079/BJN2001382
   Enas E A, 2000, J Indian Med Assoc, V98, P694
   ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J
   Ghosh A, 2007, EUR J CLIN NUTR, V61, P412, DOI 10.1038/sj.ejcn.1602534
   Ghosh A, 2006, ASIA PAC J CLIN NUTR, V15, P189
   Ghosh A, 2005, DIABETES-METAB RES, V21, P58, DOI 10.1002/dmrr.481
   Ghosh A, 2004, NUTR METAB CARDIOVAS, V14, P170, DOI 10.1016/S0939-4753(04)80038-3
   Ghosh A, 2003, ASIA PAC J CLIN NUTR, V12, P166
   GHOSH A, CARDIOVAC J IN PRESS
   Ghosh A, 2007, AM J HUM BIOL, V19, P34, DOI 10.1002/ajhb.20570
   Gopinath N, 1994, J Assoc Physicians India, V42, P212
   Guha Santanu, 2005, Indian Heart J, V57, P738
   Gupta R, 1994, Indian Heart J, V46, P145
   Gupta R, 1995, Indian Heart J, V47, P331
   Ho SC, 2001, INT J OBESITY, V25, P1689, DOI 10.1038/sj.ijo.0801784
   *JNC V, 1993, ARCH INTERN MED, V153, P154
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   MAJUMDER PP, 1994, AM J HUM BIOL, V6, P183, DOI 10.1002/ajhb.1310060206
   MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P
   Misra A, 2005, DIABETES CARE, V28, P398, DOI 10.2337/diacare.28.2.398
   Misra A, 2002, NATL MED J INDIA, V15, P242
   Mohan V, 2005, DIABETIC MED, V22, P863, DOI 10.1111/j.1464-5491.2005.01541.x
   Mohan V, 2003, J Assoc Physicians India, V51, P771
   Mohan V, 2005, METABOLISM, V54, P476, DOI 10.1016/j.metabol.2004.10.016
   *NCEP, 2001, JAMA-J AM MED ASSOC, V285, P2479
   *NIH NCEP ATP 2, 1993, NIH PUBL
   Premalatha G, 2000, DIABETES CARE, V23, P1295, DOI 10.2337/diacare.23.9.1295
   Ramachandran A, 1997, DIABETES RES CLIN PR, V36, P121, DOI 10.1016/S0168-8227(97)00040-5
   Ramachandran A, 1998, DIABETES CARE, V21, P967, DOI 10.2337/diacare.21.6.967
   RAMACHANDRAN A, 1992, DIABETES CARE, V15, P1348, DOI 10.2337/diacare.15.10.1348
   Reddy K. S., 1993, World Health Statistics Quarterly, V46, P101
   Shanthirani C S, 2003, J Assoc Physicians India, V51, P20
   SNEHALATHA C, 1994, DIABETIC MED, V11, P445, DOI 10.1111/j.1464-5491.1994.tb00304.x
   Venkatramana P, 2002, ASIA PAC J CLIN NUTR, V11, P66, DOI 10.1046/j.1440-6047.2002.00250.x
   *WHO, 1995, TECH REP SER WHO, V158
   WHO/IASO/IOTF, 2000, AS PAC PERSP RED OB
   Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9
NR 43
TC 30
Z9 30
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-0533
EI 1520-6300
J9 AM J HUM BIOL
JI Am. J. Hum. Biol.
PD JUL-AUG
PY 2008
VL 20
IS 4
BP 440
EP 445
DI 10.1002/ajhb.20757
PG 6
WC Anthropology; Biology
SC Anthropology; Life Sciences & Biomedicine - Other Topics
GA 318NV
UT WOS:000257099700008
PM 18348170
DA 2018-12-27
ER

PT J
AU Yuling, H
   Ruijing, X
   Xiang, J
   Luokun, X
   Wenjun, Y
   Feng, C
   Baojun, H
   Hui, Y
   Guang, Y
   Chunlei, Y
   Jixin, Z
   Lang, C
   Li, Q
   Chang, A
   Zhuan, B
   Youxin, J
   Feili, G
   Jinquan, T
AF Yuling, H.
   Ruijing, X.
   Xiang, J.
   Luokun, X.
   Wenjun, Y.
   Feng, C.
   Baojun, H.
   Hui, Y.
   Guang, Y.
   Chunlei, Y.
   Jixin, Z.
   Lang, C.
   Li, Q.
   Chang, A.
   Zhuan, B.
   Youxin, J.
   Feili, G.
   Jinquan, T.
TI RETRACTED: Essential role of sphingosine-1-phosphate receptor 1-bearing
   CD8(+)CD44(+)CCR7(+) T cells in acute skin allograft rejection
   (Retracted article. See vol. 11, pg. 1343, 2011)
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article; Retracted Publication
DE acute allograft rejection; chemokine receptor; cytotoxicity; memory T
   cells; siRNA
ID HETEROLOGOUS ANTIVIRAL IMMUNITY; DENDRITIC CELLS; TRANSPLANTATION
   TOLERANCE; SPHINGOSINE 1-PHOSPHATE; LYMPHOCYTE EGRESS; BLOOD
   LYMPHOCYTES; CUTTING EDGE; MEMORY CELLS; DIFFERENTIATION; EXPRESSION
AB A subset of naturally formed sphingosine-1-phosphate receptor 1 (S1P1)-bearing CD8(+)CD44(+)CCR7(+) memory T cells has been identified in transplant recipient BALB/c (H-2(d)) mice. The frequency of this subset of memory T cells is significantly increased in the spleen, lymph nodes and skin grafts in the recipient BALB/c mice during acute skin allograft rejections. The immune-reconstitution with CD8(+)CD44(+)CCR7(+)S1P1(+) memory T cells facilitates acute skin allograft rejection in SCID mice. Being Th1-polarized and cytotoxic, CD8(+)CD44(+)CCR7(+)S1P1(+) memory T cells proliferate and differentiate immediately into effectors upon encountering allo-antigens. A siRNA against S1P1 inhibits CD8(+)CD44(+)CCR7(+)S1P1(+) memory T cell-mediated acute skin allograft rejection in SCID mice by means of knocking-down S1P1-expression. CCL21 mutant (CCL21-Delta CT) has been used to compete with wild-type CCL21 in the course of binding to CCR7. Combined administration of siRNA S1P1 and CCL21-Delta CT significantly prolongs the survival of skin allograft in the recipient BALB/c mice by means of inhibiting accumulation of CD8(+)CD44(+)CCR7(+)S1P1(+) memory T cells in the spleen and the skin grafts. Our data provide direct evidence that S1P1 and CCR7 are involved in the proliferation and trafficking of CD8(+)CD44(+)CCR7(+)S1P1(+) memory T cells. S1P1 may serve as a functional marker for CD8(+)CD44(+)CCR7(+) memory T cells. Targeting CD8(+)CD44(+)CCR7(+)S1P1(+) T cells may be a useful strategy to prolong the survival of allograft transplant.
C1 [Luokun, X.; Baojun, H.; Hui, Y.; Guang, Y.; Chunlei, Y.; Jixin, Z.; Lang, C.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430074, Peoples R China.
   [Yuling, H.; Ruijing, X.; Xiang, J.; Luokun, X.; Feng, C.; Lang, C.; Li, Q.; Chang, A.; Jinquan, T.] Wuhan Univ, Sch Med, Dept Immunol, Wuhan 430072, Peoples R China.
   [Yuling, H.; Ruijing, X.; Xiang, J.; Luokun, X.; Feng, C.; Lang, C.; Li, Q.; Chang, A.; Jinquan, T.] Wuhan Univ, Sch Med, Lab Allergy & Clin Immunol, Inst Allergy & Immunerelated Dis, Wuhan 430072, Peoples R China.
   [Yuling, H.; Ruijing, X.; Xiang, J.; Luokun, X.; Feng, C.; Lang, C.; Li, Q.; Chang, A.; Jinquan, T.] Wuhan Univ, Sch Med, Med Res Ctr, Wuhan 430072, Peoples R China.
   [Wenjun, Y.; Zhuan, B.] Wuhan Univ, Sch Med, Dept Orthodont, Wuhan 430072, Peoples R China.
   [Baojun, H.] Anhui Med Univ, Sch Basic Med Sci, Dept Immunol, Hefei, Peoples R China.
   [Youxin, J.] Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai, Peoples R China.
RP Feili, G (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430074, Peoples R China.
EM flgong@tjmu.edu.cn; jinquan_tan@whu.edu.cn
OI Zhong, Jixin/0000-0002-3534-7480
CR Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477
   Bjorkman PJ, 1997, CELL, V89, P167, DOI 10.1016/S0092-8674(00)80195-6
   Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882
   Chalmers IMH, 1998, BLOOD, V92, P11
   Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727
   Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2
   Czeloth N, 2007, J IMMUNOL, V179, P5855, DOI 10.4049/jimmunol.179.9.5855
   Garrod KR, 2006, J IMMUNOL, V177, P863, DOI 10.4049/jimmunol.177.2.863
   Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084
   Guillet M, 2001, CURR OPIN IMMUNOL, V13, P566, DOI 10.1016/S0952-7915(00)00260-0
   Hartig CV, 2000, J IMMUNOL, V164, P2790, DOI 10.4049/jimmunol.164.5.2790
   Jang MH, 2006, J IMMUNOL, V176, P803, DOI 10.4049/jimmunol.176.2.803
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854
   Lewis DL, 2005, METHOD ENZYMOL, V392, P336, DOI 10.1016/S0076-6879(04)92020-4
   Lin CY, 2002, NAT IMMUNOL, V3, P1208, DOI 10.1038/ni853
   Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509
   Marsland BJ, 2005, IMMUNITY, V22, P493, DOI 10.1016/j.immuni.2005.02.010
   Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867
   Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Ming JK, 2003, J IMMUNOL, V170, P1556, DOI 10.4049/jimmunol.170.3.1556
   Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705
   Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606
   Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969
   Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722
   Tanabe S, 1997, J IMMUNOL, V159, P5671
   Unsoeld H, 2002, J IMMUNOL, V169, P638, DOI 10.4049/jimmunol.169.2.638
   Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820
   Zhang QP, 2004, CANCER RES, V64, P7579, DOI 10.1158/0008-5472.CAN-04-0641
NR 35
TC 2
Z9 2
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2008
VL 8
IS 7
BP 1401
EP 1412
DI 10.1111/j.1600-6143.2008.02275.x
PG 12
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 324WJ
UT WOS:000257549800011
PM 18510631
OA Bronze
DA 2018-12-27
ER

PT J
AU Mishra, R
   Jain, SR
   Kumar, A
AF Mishra, Ruchi
   Jain, Seema Rani
   Kumar, Ashok
TI RETRACTED: Microbial production of dihydroxyacetone (Retracted article.
   See vol. 28, pg. 938, 2010)
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review; Retracted Publication
DE dihydroxyacetone production; gluconobacter oxydans; batch mode;
   fed-batch mode; substrate inhibition; product inhibition
ID GLUCONOBACTER-OXYDANS CELLS; GLYCEROL DEHYDROGENASE; KINETIC ASPECTS;
   CULTURE-MEDIUM; OXIDATION; GROWTH; CONVERSION; SKIN; OPTIMIZATION;
   BIOTRANSFORMATION
AB Dihydroxyacetone is extensively used in cosmetic industry as an artificial suntan besides having clinical and biological applications. Thus, it is important to meet the commercial demand of dihydroxyacetone at an economical and qualitative level. Microbial route of production is found to be more favorable for di. hydroxyacetone as compared to chemical methods. This review gives detailed information about the microbial route of clihydroxyacetone production. Till date the microorganism which is most utilized for dihydroxyacetone production is Gluconobacter oxydans. Some limitations associated with dihydroxyacetone production by G. oxydans like substrate inhibition, product inhibition and oxygen limitation are discussed here. Various fermentation modes and culture conditions have been tried for their ability to overcome these limitations. It has been found that fed-batch mode of fermentation provides a better yield as compared to batch mode for dihydroxyacetone production. Two-stage repeated fed-batch mode of fermentation has been found to be the most optimized mode. Immobilization has also been recognized as a much better alternative for fermentation since it avoids the problem of substrate and product inhibition to a greater extent. Although these methods have increased the dihydroxyacetone production to a prominent level yet the production has not reached the level required to meet the commercial demand. One looks for future prospects of developing recombinant microbial method for dihydoxyacetone production. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Mishra, Ruchi; Jain, Seema Rani; Kumar, Ashok] Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
RP Kumar, A (reprint author), Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
EM ashokkum@iitk.ac.in
RI Kumar, Ashok/G-8515-2015
CR ADLERCREUTZ P, 1985, APPL MICROBIOL BIOT, V22, P1
   ADLERCREUTZ P, 1984, APPL MICROBIOL BIOT, V20, P296, DOI 10.1007/BF00270589
   Ahmed I, 2002, MAYO CLIN PROC, V77, P825, DOI 10.4065/77.8.825
   Albin A, 2007, J BIOTECHNOL, V131, pS160, DOI 10.1016/j.jbiotec.2007.07.884
   AMEYAMA M, 1985, AGR BIOL CHEM TOKYO, V49, P1001, DOI 10.1080/00021369.1985.10866858
   Asawanonda P, 1999, INT J DERMATOL, V38, P916, DOI 10.1046/j.1365-4362.1999.00779.x
   ASNIS RE, 1953, J BIOL CHEM, V203, P153
   BALTZING BL, 1971, J BACTERIOL, V108, P592
   Bauer R, 2006, BIOTECHNOL PROGR, V22, P278, DOI 10.1021/bp050342e
   Bauer R, 2005, BIOPROC BIOSYST ENG, V28, P37, DOI 10.1007/s00449-005-0009-0
   Bianchi CL, 2005, CATAL TODAY, V102, P203, DOI 10.1016/j.cattod.2005.02.003
   Bicker M, 2005, J MOL CATAL A-CHEM, V239, P151, DOI 10.1016/j.molcata.2005.06.017
   Biondi PA, 2007, CHROMATOGRAPHIA, V65, P65, DOI 10.1365/s10337-006-0118-1
   BORIES A, 1991, PROCESS BIOCHEM, V26, P243, DOI 10.1016/0032-9592(91)85006-A
   Brown DA, 2001, J PHOTOCH PHOTOBIO B, V63, P148, DOI 10.1016/S1011-1344(01)00212-3
   Campbell WR, 1926, J BIOL CHEM, V67, P59
   CARR JG, 1961, NATURE, V192, P683, DOI 10.1038/192683b0
   Cassidy MB, 1996, J IND MICROBIOL, V16, P79, DOI 10.1007/BF01570068
   CASTELLS J, 1980, TETRAHEDRON LETT, V21, P4517, DOI 10.1016/S0040-4039(00)74538-2
   Chen HW, 2007, CHROMATOGRAPHIA, V65, P629, DOI 10.1365/s10337-007-0193-y
   Ciriminna R, 2006, TETRAHEDRON LETT, V47, P6993, DOI 10.1016/j.tetlet.2006.07.123
   CLARET C, 1993, J IND MICROBIOL, V11, P105, DOI 10.1007/BF01583682
   CLARET C, 1994, APPL MICROBIOL BIOT, V41, P359
   CLARET C, 1992, CURR MICROBIOL, V25, P149, DOI 10.1007/BF01571023
   CLAUS GW, 1975, J BACTERIOL, V123, P1169
   Deppenmeier U, 2002, APPL MICROBIOL BIOT, V60, P233, DOI 10.1007/s00253-002-1114-5
   Dimitratos N, 2005, APPL CATAL A-GEN, V291, P210, DOI 10.1016/j.apcata.2005.01.044
   DJURANOVIC SP, 2006, BIOCHIM BIOPHYS ACTA, V1758, P1012
   DRYSDALE GS, 1988, AM J ENOL VITICULT, V39, P143
   Erni B, 2006, CELL MOL LIFE SCI, V63, P890, DOI 10.1007/s00018-005-5518-0
   FERIOLI V, 1995, CHROMATOGRAPHIA, V41, P61, DOI 10.1007/BF02688001
   Fesq H, 2001, DERMATOLOGY, V203, P241, DOI 10.1159/000051757
   FLICKINGER MC, 1977, APPL ENVIRON MICROB, V33, P706
   Forest SE, 2003, PHOTOCHEM PHOTOBIOL, V77, P524, DOI 10.1562/0031-8655(2003)077<0524:FSIODO>2.0.CO;2
   Fusaro RM, 2005, ANN NY ACAD SCI, V1043, P174, DOI 10.1196/annals.1333.022
   Gatgens C, 2007, APPL MICROBIOL BIOT, V76, P553, DOI 10.1007/s00253-007-1003-z
   GARCIA R, 1995, APPL CATAL A-GEN, V127, P165, DOI 10.1016/0926-860X(95)00048-8
   Gupta A, 2001, J MOL MICROB BIOTECH, V3, P445
   Hekmat D, 2003, BIOPROC BIOSYST ENG, V26, P109, DOI 10.1007/s00449-003-0338-9
   HOIST O, 1982, EUR J APPL MICROBIOL, V14, P64
   Ivy JL, 1998, MED SCI SPORT EXER, V30, P837, DOI 10.1097/00005768-199806000-00010
   JONES JG, 1991, BIOCHEM J, V280, P475, DOI 10.1042/bj2800475
   KATO N, 1986, APPL MICROBIOL BIOT, V23, P180
   Koeller KM, 2001, NATURE, V409, P232, DOI 10.1038/35051706
   Lapenaite I, 2005, ANAL CHIM ACTA, V549, P140, DOI 10.1016/j.aca.2005.06.025
   LEVY SB, 2001, DERMATOL THER, V14, P215
   LILI W, 2006, ANAL CHIM ACTA, V557, P262
   Liu ZQ, 2008, BIOCHEM ENG J, V38, P285, DOI 10.1016/j.bej.2007.07.015
   Macauley S, 2001, CRIT REV BIOTECHNOL, V21, P1, DOI 10.1080/07388550490465817
   NABE K, 1979, APPL ENVIRON MICROB, V38, P1056
   NAGASAWA T, 1995, PURE APPL CHEM, V67, P1241, DOI 10.1351/pac199567071241
   NEIJSSEL OM, 1975, ARCH MICROBIOL, V104, P83, DOI 10.1007/BF00447304
   Nguyen BC, 2003, BRIT J DERMATOL, V149, P332, DOI 10.1046/j.1365-2133.2003.05434.x
   Niknahad H, 2002, TOXICOL LETT, V132, P95, DOI 10.1016/S0378-4274(02)00016-4
   Niknahad H, 1996, TOXICOL APPL PHARM, V138, P186, DOI 10.1006/taap.1996.0112
   Oh CH, 2007, NUCLEOS NUCLEOT NUCL, V26, P403, DOI 10.1080/15257770701297018
   Ohrem HL, 1996, PROCESS BIOCHEM, V31, P295, DOI 10.1016/0032-9592(95)00068-2
   Ohrem HL, 1996, BIOTECHNOL LETT, V18, P245, DOI 10.1007/BF00142939
   OHREM HL, 1995, BIOTECHNOL LETT, V17, P1195, DOI 10.1007/BF00128385
   Petersen AB, 2003, MUTAT RES-GEN TOX EN, V542, P129, DOI 10.1016/j.mrgentox.2003.09.003
   PINTER JK, 1967, ARCH BIOCHEM BIOPHYS, V121, P404, DOI 10.1016/0003-9861(67)90094-X
   Prust C, 2005, NAT BIOTECHNOL, V23, P195, DOI 10.1038/nbt1062
   Raska J, 2007, COLLECT CZECH CHEM C, V72, P1269, DOI 10.1135/cccc20071269
   Ruzheinikov SN, 2001, STRUCTURE, V9, P789, DOI 10.1016/S0969-2126(01)00645-1
   Schleyer U, 2008, INT J FOOD MICROBIOL, V125, P91, DOI 10.1016/j.ijfoodmicro.2007.04.016
   SCHLIFKE AC, 1999, NUTR BYTES, V5, P1
   SHINJOH M, 1995, J FERMENT BIOENG, V79, P95, DOI 10.1016/0922-338X(95)94074-2
   Shipar AH, 2006, FOOD CHEM, V97, P231, DOI 10.1016/j.foodchem.2005.03.041
   STANKO RT, 1990, J APPL PHYSIOL, V68, P119
   STREEKSTRA H, 1987, ARCH MICROBIOL, V147, P268, DOI 10.1007/BF00463487
   Tkac J, 2001, ENZYME MICROB TECH, V28, P383, DOI 10.1016/S0141-0229(00)00328-8
   TOIT WJD, 2002, ANAL MICROBIOL, V52, P155
   TRAMPER J, 1983, EUR J APPL MICROBIOL, V17, P13, DOI 10.1007/BF00510565
   TSAO MU, 1962, ANAL BIOCHEM, V3, P448, DOI 10.1016/0003-2697(62)90075-1
   TSUURA Y, 1994, DIABETOLOGIA, V37, P1082, DOI 10.1007/BF00418371
   Underkofler LA, 1943, J BACTERIOL, V45, P183
   Uzcategui NL, 2007, ANTIMICROB AGENTS CH, V51, P3960, DOI 10.1128/AAC.00423-07
   Virtanen AI, 1933, BIOCHEM J, V27, P442
   Vostiar I, 2004, ELECTROCHEM COMMUN, V6, P621, DOI 10.1016/j.elecom.2004.04.017
   Wei SH, 2007, PREP BIOCHEM BIOTECH, V37, P113, DOI 10.1080/10826060701199049
   Wei SH, 2007, PREP BIOCHEM BIOTECH, V37, P67, DOI 10.1080/10826060601040954
   Wethmar M, 1999, BIOTECHNOL TECH, V13, P283, DOI 10.1023/A:1008978903231
   WHITE SA, 1982, J BACTERIOL, V150, P934
   WITTGENSTEIN E, 1960, SCIENCE, V132, P894, DOI 10.1126/science.132.3431.894
   YOUNG T, 1997, J BACTERIOL, V179, P6041
NR 85
TC 35
Z9 44
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD JUL-AUG
PY 2008
VL 26
IS 4
BP 293
EP 303
DI 10.1016/j.biotechadv.2008.02.001
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 323YG
UT WOS:000257483800001
PM 18387770
DA 2018-12-27
ER

PT J
AU Yamamoto, N
   Suyama, H
   Nakazato, H
   Yamamoto, N
   Koga, Y
AF Yamamoto, Nobuto
   Suyama, Hirofumi
   Nakazato, Hiroaki
   Yamamoto, Nobuyuki
   Koga, Yoshihiko
TI RETRACTED: Immunotherapy of metastatic colorectal cancer with vitamin
   D-binding protein-derived macrophage-activating factor, GcMAF (Retracted
   article. See vol. 63, pg. 1349, 2014)
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article; Retracted Publication
DE colorectal cancer; macrophages; macrophage-activating factor;
   immunotherapy; deglycosylation; alpha-N-acetylgalactosaminidase;
   immunosuppression
ID GROUP-SPECIFIC COMPONENT; ALPHA-N-ACETYLGALACTOSAMINIDASE;
   INFLAMMATION-PRIMED ACTIVATION; MOUSE PERITONEAL-MACROPHAGES; EHRLICH
   ASCITES TUMOR; D-3-BINDING PROTEIN; VITAMIN-D-3-BINDING PROTEIN;
   BETA-GALACTOSIDASE; ADJUVANT ACTIVITY; SERUM
AB Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein of colorectal cancer patients was lost or reduced because Gc protein is deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Deglycosylated Gc protein cannot be converted to MAF, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase generated the most potent macrophage-activating factor (GcMAF) ever discovered, but it produces no side effect in humans. Macrophages treated with GcMAF (100 pg/ml) develop an enormous variation of receptors and are highly tumoricidal to a variety of cancers indiscriminately. Administration of 100 nanogram (ng)/human maximally activates systemic macrophages that can kill cancerous cells. Since the half-life of the activated macrophages is approximately 6 days, 100 ng GcMAF was administered weekly to eight nonanemic colorectal cancer patients who had previously received tumor-resection but still carried significant amounts of metastatic tumor cells. As GcMAF therapy progressed, the MAF precursor activities of all patients increased and conversely their serum Nagalase activities decreased. Since serum Nagalase is proportional to tumor burden, serum Nagalase activity was used as a prognostic index for time course analysis of GcMAF therapy. After 32-50 weekly administrations of 100 ng GcMAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells. During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.
C1 [Yamamoto, Nobuto; Yamamoto, Nobuyuki] Socrates Inst Therapeut Immunol, Div Canc Immunol & Mol Biol, Philadelphia, PA 19126 USA.
   [Suyama, Hirofumi] Nagasaki Immunotherapy Res Grp, Nagasaki, Japan.
   [Nakazato, Hiroaki] Yokoyama Gastroenterol Hosp, Nagoya, Aichi, Japan.
   [Koga, Yoshihiko] Nakagawa Hosp, Fukuoka 8111345, Japan.
RP Yamamoto, N (reprint author), Socrates Inst Therapeut Immunol, Div Canc Immunol & Mol Biol, 1040,66th Ave, Philadelphia, PA 19126 USA.
EM nobutoyama@verizon.net
FU NIAID NIH HHS [AI 32140]
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Braun S, 1999, MED ONCOL, V16, P154, DOI 10.1007/BF02906127
   COHEN AM, 1989, CANCER PRINCIPLES PR, P895
   DECOSSE JJ, 1994, CA-CANCER J CLIN, V44, P27, DOI 10.3322/canjclin.44.1.27
   Gleason D., 1977, UROLOGIC PATHOLOGY P, P171
   GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439
   HOMMA S, 1990, CLIN EXP IMMUNOL, V79, P307
   HOMMA S, 1993, IMMUNOL CELL BIOL, V71, P249, DOI 10.1038/icb.1993.29
   Kanda S, 2002, J NATL CANCER I, V94, P1311
   Kisker O, 2003, NEOPLASIA, V5, P32, DOI 10.1016/S1476-5586(03)80015-5
   Koga Y, 1999, P SOC EXP BIOL MED, V220, P20, DOI 10.1046/j.1525-1373.1999.d01-3.x
   KOPROWSKI H, 1981, SCIENCE, V212, P53, DOI 10.1126/science.6163212
   LINK RP, 1986, ANAL BIOCHEM, V157, P262, DOI 10.1016/0003-2697(86)90624-X
   MAEHARA Y, 1990, SEMIN SURG ONCOL, V6, P42, DOI 10.1002/ssu.2980060109
   MORTON DL, 1970, SURGERY, V68, P158
   NARAPARAJU VR, 1994, IMMUNOL LETT, V43, P143, DOI 10.1016/0165-2478(94)90214-3
   NGWENYA BZ, 1985, BIOCHIM BIOPHYS ACTA, V839, P9, DOI 10.1016/0304-4165(85)90175-8
   NGWENYA BZ, 1990, P SOC EXP BIOL MED, V193, P118
   NGWENYA BZ, 1986, CANCER IMMUNOL IMMUN, V21, P174
   OLSON RM, 1980, CANCER-AM CANCER SOC, V45, P2969, DOI 10.1002/1097-0142(19800615)45:12<2969::AID-CNCR2820451214>3.0.CO;2-7
   RICH T, 1983, CANCER, V52, P1317, DOI 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6
   YAMAMOTO N, 1991, IMMUNOLOGY, V74, P420
   YAMAMOTO N, 1987, CANCER IMMUNOL IMMUN, V25, P185
   YAMAMOTO N, 1991, P NATL ACAD SCI USA, V88, P8539, DOI 10.1073/pnas.88.19.8539
   Yamamoto N, 2006, AIDS RES HUM RETROV, V22, P262, DOI 10.1089/aid.2006.22.262
   Yamamoto N, 2004, IMMUNOLOGY 2004: CYTOKINE NETWORK, REGULATORY CELLS, SIGNALING, AND APOPTOSIS, APPENDIX, P197
   Yamamoto N, 2005, MICROBES INFECT, V7, P674, DOI 10.1016/j.micinf.2005.01.015
   YAMAMOTO N, 1993, INFECT IMMUN, V61, P5388
   Yamamoto N, 1996, CANCER RES, V56, P2827
   Yamamoto N, 1997, CANCER RES, V57, P2187
   YAMAMOTO N, 1993, J IMMUNOL, V151, P2794
   Yamamoto N, 1996, MOL IMMUNOL, V33, P1157, DOI 10.1016/S0161-5890(96)00081-8
   YAMAMOTO N, 1987, CANCER RES, V47, P2008
   Yamamoto N, 1998, IMMUNOL CELL BIOL, V76, P237, DOI 10.1046/j.1440-1711.1998.00748.x
   YAMAMOTO N, 1991, J IMMUNOL, V147, P273
   YAMAMOTO N, 1995, AIDS RES HUM RETROV, V11, P1373, DOI 10.1089/aid.1995.11.1373
   Yamamoto N, 1997, CANCER RES, V57, P295
   YAMAMOTO N, 1988, CANCER RES, V48, P6044
   YAMAMOTO N, 2004, IMMUNOLOGY 2000, P210
   Yamamoto N., 1994, US Patent, Patent No. [5,326,749, 5326749]
   YAMAMOTO N, 1998, Patent No. 5712104
   YAMAMOTO N, 2002, Patent No. 64100269
   YAMAMOTO N, 1997, Patent No. 5620846
   YAMAMOTO N, 1993, Patent No. 5177002
   YAMAMOTO N, 1998, ENCY IMMUNOLOGY, P2494
   Yamamoto N, 2008, INT J CANCER, V122, P461, DOI 10.1002/ijc.23107
   ZBAR B, 1971, SCIENCE, V172, P271, DOI 10.1126/science.172.3980.271
   Zhang SL, 1998, CLIN CANCER RES, V4, P2669
NR 48
TC 37
Z9 39
U1 3
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD JUL
PY 2008
VL 57
IS 7
BP 1007
EP 1016
DI 10.1007/s00262-007-0431-z
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA 294HR
UT WOS:000255397600007
PM 18058096
DA 2018-12-27
ER

PT J
AU Liu, JC
   Zhang, JZ
   Yang, J
   Zuo, J
   Zhang, JB
   Yu, SQ
   Chen, T
   Xu, XZ
   Wei, XF
   Yi, DH
AF Liu, Jin-Cheng
   Zhang, Jin-Zhou
   Yang, Jian
   Zuo, Jian
   Zhang, Jin-Bao
   Yu, Shi-Qiang
   Chen, Tao
   Xu, Xue-Zeng
   Wei, Xu-Feng
   Yi, Dinghua
TI RETRACTED: Combined interventional and surgical treatment for acute
   aortic type a dissection (Retracted Article. See vol 34, pg 220, 2011)
SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article; Retracted Publication
DE interventional radiology; type A dissection; endovascular
   stent-grafting; total arch replacement
ID ENDOVASCULAR STENT-GRAFT; HOSPITAL MORTALITY; RISK-FACTORS; REPAIR;
   ANGIOGRAPHY; PLACEMENT; ANEURYSMS; THERAPY
AB Surgical repair and endovascular stent-graft placement are both therapies for thoracic aortic dissection. A combination of these two approaches may be effective in patients with type A dissection. In this study, we evaluated the prognosis of this combined technique. From December 2003 to December 2006, 15 patients with type A dissection were admitted to our institute; clinical data were retrospectively reviewed. Follow-up was performed at discharge and approximately 12 months after operation. Endovascular stent-graft placement by interventional radiology and surgical repair for reconstruction of aortic arch was performed in all patients. Total arch replacement for distal arch aneurysm was carried out under deep hypothermia with circulatory arrest; antegrade-selected cerebral perfusion was used for brain protection. Four patients concomitantly received a coronary artery bypass graft. Hospital mortality rate was 6.7%; the patient died of cerebral infarction. Neurological complications developed in two patients. Multi-detector-row computed tomography scans performed before discharge revealed complete thrombosis of the false lumen in six patients and partial thrombosis in eight patients. At the follow-up examination, complete thrombosis was found in another three patients, aortic rupture, endoleaks, or migration of the stent-graft was not observed and injuries of peripheral organs or anastomotic endoleaks did not occur. For patients with aortic type A dissection, combining intervention and surgical procedures is feasible, and complete or at least partial thrombosis of the false lumen in the descending aorta can be achieved. This combined approach simplified the surgical procedures and shortened the circulatory arrest time, minimizing the necessity for further aortic operation.
C1 [Liu, Jin-Cheng; Zhang, Jin-Zhou; Yang, Jian; Zuo, Jian; Zhang, Jin-Bao; Yu, Shi-Qiang; Chen, Tao; Xu, Xue-Zeng; Wei, Xu-Feng; Yi, Dinghua] Fourth Mil Med Univ, Dept Cardiovasc Surg, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
RP Zhang, JZ (reprint author), Fourth Mil Med Univ, Dept Cardiovasc Surg, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
EM jinzhouzhang2006@yahoo.com; Yidh@fmmu.edu.cn
OI Yu, Shiqiang/0000-0003-3519-0943
CR BORST HG, 1983, THORAC CARDIOV SURG, V31, P37, DOI 10.1055/s-2007-1020290
   Bortone AS, 2001, EUR J CARDIO-THORAC, V20, P514, DOI 10.1016/S1010-7940(01)00829-6
   CRESWELL LL, 1995, ANN THORAC SURG, V59, P585, DOI 10.1016/0003-4975(94)00880-9
   Dake MD, 1999, NEW ENGL J MED, V340, P1546, DOI 10.1056/NEJM199905203402004
   Dake MD, 1998, J THORAC CARDIOV SUR, V116, P689, DOI 10.1016/S0022-5223(98)00455-3
   FANN JI, 1995, CIRCULATION, V92, P113, DOI 10.1161/01.CIR.92.9.113
   Fleck T, 2002, ANN THORAC SURG, V74, P761, DOI 10.1016/S0003-4975(02)03745-1
   Genoni M, 2001, EUR J CARDIO-THORAC, V19, P606, DOI 10.1016/S1010-7940(01)00662-5
   Genoni M, 1997, SCHWEIZ MED WSCHR, V127, P208
   GLOWER DD, 1990, CIRCULATION, V82, P39
   Ince H, 2001, Z KARDIOL, V90, P67, DOI 10.1007/s003920170215
   Juvonen T, 1999, J THORAC CARDIOV SUR, V117, P776, DOI 10.1016/S0022-5223(99)70299-0
   Juvonen T, 1997, ANN THORAC SURG, V63, P1533, DOI 10.1016/S0003-4975(97)00414-1
   Kawahito K, 2001, ANN THORAC SURG, V71, P1239, DOI 10.1016/S0003-4975(00)02654-0
   Kawamura SK, 2004, J VASC SURG, V39, P668, DOI 10.1016/j.jvs.2003.08.015
   Mitchell RS, 1999, ANN THORAC SURG, V67, P1971, DOI 10.1016/S0003-4975(99)00436-1
   Miyamoto S, 2001, ANN THORAC SURG, V71, P705, DOI 10.1016/S0003-4975(00)01943-3
   Nienaber CA, 1999, NEW ENGL J MED, V340, P1539, DOI 10.1056/NEJM199905203402003
   Penn MS, 2000, J AM COLL CARDIOL, V35, P889, DOI 10.1016/S0735-1097(99)00638-5
   RIZZO RJ, 1994, J THORAC CARDIOV SUR, V108, P567
   SEREF AK, 2005, EUR J CARDIO-THORAC, V27, P638
   Sorokin VA, 2007, ANN THORAC SURG, V83, P666, DOI 10.1016/j.athoracsur.2006.07.057
NR 22
TC 5
Z9 6
U1 4
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0174-1551
EI 1432-086X
J9 CARDIOVASC INTER RAD
JI Cardiovasc. Interv. Radiol.
PD JUL
PY 2008
VL 31
IS 4
BP 745
EP 750
DI 10.1007/s00270-008-9326-4
PG 6
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 335TV
UT WOS:000258314700010
PM 18389185
DA 2018-12-27
ER

PT J
AU Pokojski, S
   Busch, C
   Grgic, I
   Kacik, M
   Salman, W
   Preisig-Muller, R
   Heyken, WT
   Daut, J
   Hoyer, J
   Kohler, R
AF Pokojski, Sebastian
   Busch, Christoph
   Grgic, Ivica
   Kacik, Michael
   Salman, Waleed
   Preisig-Mueller, Regina
   Heyken, Willm-Thomas
   Daut, Juergen
   Hoyer, Joachim
   Koehler, Ralf
TI RETRACTED: TWIK-related two-pore domain potassium channel TREK-1 in
   carotid endothelium of normotensive and hypertensive mice (Retracted
   Article. See vol 80, pg 320, 2008)
SO CARDIOVASCULAR RESEARCH
LA English
DT Article; Retracted Publication
DE carotid artery; endothelium-dependent vasodilation; endothelium-derived
   hyperpolarizing factor; hypertension; mice; two-pore domain potassium
   channel; K(Ca)3.1; TREK-1; TREK-2; TRAAK
ID POLYUNSATURATED FATTY-ACIDS; CA2+-ACTIVATED K+ CHANNEL; HYPERPOLARIZING
   FACTOR; FUNCTIONAL EXPRESSION; ARACHIDONIC-ACID; SMOOTH-MUSCLE; TRAAK;
   ARTERIES; CLONING; CONDUCTANCE
AB Aims Potassium channels are essential elements of endothelial function. Recently, evidence emerged that the TWIK (tandem of P domains in a weak inwardly rectifying K+ channel)-related K+ channel (TREK-1) of the two-pore domain potassium channel gene family (K-2P) may be involved in the regulation of vascular tone. However, the functional and molecular characterization of vascular TREK-1 is incomplete. In this study, we therefore analysed the functional expression of TREK-1 in the endothelium. Moreover, we hypothesized that changes in channel expression may contribute to altered endothelial vasodilator response under conditions of elevated blood pressure.
   Methods and results Gene expression and function of endothelial TREK-1 were analysed by single-cell RT-PCR, the patch-clamp technique and pressure myography in murine carotid arteries (CA). K+ outward currents displaying the characteristics of TREK-1 were observed following various TREK-1-activating stimuli such as membrane stretch, intracellular acidosis, polyunsaturated fatty acids, isoflurane (ISOFL), riluzole, and acetylcholine (ACh). In K(Ca)3.1(-/-) mice exhibiting elevated blood pressure, endothelial TREK-1 currents and TREK-1 mRNA expression were enhanced as compared with normotensive control mice. TREK-1-mediated vasodilator responses to alpha-linolenic acid, ISOFL, or ACh were increased. A similar up-regulation of endothelial TREK-1 was observed in spontaneously hypertensive rats.
   Conclusion We have found that TREK-1 is an endothelial K+ channel capable of producing hyperpolarization and vasodilation. A correlation between hypertension and up-regulation of TREK-1 was observed in two different animal models of elevated blood pressure. Thus, TREK-1 may play a protective role in the cardiovascular system by providing a novel type of endothelial hyperpolarization-mediated vasodilator response.
C1 [Pokojski, Sebastian; Busch, Christoph; Grgic, Ivica; Kacik, Michael; Salman, Waleed; Heyken, Willm-Thomas; Hoyer, Joachim; Koehler, Ralf] Univ Marburg, Dept Internal Med Nephrol, D-35033 Marburg, Hessen, Germany.
   [Preisig-Mueller, Regina; Daut, Juergen] Univ Marburg, Inst Physiol & Pathophysiol, D-35033 Marburg, Hessen, Germany.
RP Kohler, R (reprint author), Univ Marburg, Dept Internal Med Nephrol, D-35033 Marburg, Hessen, Germany.
EM rkoehler@med.uni-marburg.de
CR Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200
   Blondeau N, 2007, CIRC RES, V101, P176, DOI 10.1161/CIRCRESAHA.107.154443
   Bryan RM, 2006, AM J PHYSIOL-HEART C, V291, pH770, DOI 10.1152/ajpheart.01377.2005
   Duprat F, 2000, MOL PHARMACOL, V57, P906
   Edwards G, 1998, NATURE, V396, P269
   Eichler I, 2003, BRIT J PHARMACOL, V138, P594, DOI 10.1038/sj.bjp.0705075
   Feletou M, 2006, ARTERIOSCL THROM VAS, V26, P1215, DOI 10.1161/01.ATV.0000217611.81085.c5
   Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297
   Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   Gardener MJ, 2004, BRIT J PHARMACOL, V142, P192, DOI 10.1038/sj.bjp.0705691
   Garry A, 2007, EMBO REP, V8, P354, DOI 10.1038/sj.embor.7400916
   Goldstein SAN, 2005, PHARMACOL REV, V57, P527, DOI 10.1124/pr.57.4.12
   Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256
   Griffith TM, 2004, BRIT J PHARMACOL, V141, P881, DOI 10.1038/sj.bjp.0705698
   Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234
   Kang DW, 2006, AM J PHYSIOL-CELL PH, V291, pC649, DOI 10.1152/ajpcell.00047.2006
   Khurana S, 2004, EUR J PHARMACOL, V493, P127, DOI 10.1016/j.ejphar.2004.04.012
   Kim D, 2005, CURR PHARM DESIGN, V11, P2717, DOI 10.2174/1381612054546824
   Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008
   Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P64, DOI 10.1007/s004240000496
   Kohler R, 2007, KIDNEY INT, V72, P145, DOI 10.1038/sj.ki.5002303
   Kohler R, 2000, CIRC RES, V87, P496
   Kohler R, 2001, CIRC RES, V89, P174, DOI 10.1161/hh1401.093460
   Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200
   Lesage F, 2000, FEBS LETT, V471, P137, DOI 10.1016/S0014-5793(00)01388-0
   Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x
   Li XT, 2006, CARDIOVASC RES, V69, P86, DOI 10.1016/j.cardiores.2005.08.018
   LONGNECKER DE, 1984, MICROCIRC ENDOTH LYM, V1, P129
   Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128
   Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691
   Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381
   Meadows HJ, 2000, PFLUG ARCH EUR J PHY, V439, P714, DOI 10.1007/s004240050997
   MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Patel AJ, 1999, NAT NEUROSCI, V2, P422
   Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283
   Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5
   Reyes R, 2000, NEUROSCIENCE, V95, P893
   Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863
   Rosa JC, 1998, J MED CHEM, V41, P2, DOI 10.1021/jm970571a
   Si H, 2006, CIRC RES, V99, P537, DOI 10.1161/01.RES.0000238377.08219.0c
   Talley EM, 2001, J NEUROSCI, V21, P7491
   Thummler S, 2007, BIOCHEM BIOPH RES CO, V354, P284, DOI 10.1016/j.bbrc.2006.12.199
   Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151
NR 45
TC 4
Z9 5
U1 2
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD JUL 1
PY 2008
VL 79
IS 1
BP 80
EP 88
DI 10.1093/cvr/cvn069
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 319BJ
UT WOS:000257136500012
PM 18339646
OA Bronze
DA 2018-12-27
ER

PT J
AU Qi, SH
   Zhang, S
   Gao, CH
   Li, QX
AF Qi, Shu-Hua
   Zhang, Si
   Gao, Cheng-Hai
   Li, Qin-Xing
TI RETRACTED: Purine and pyrimidine derivatives from the South China Sea
   gorgonian Subergorgia suberosa (Retracted article. See vol. 58, pg. 884,
   2010)
SO CHEMICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE Subergorgia suberosa; gorgonian; purine derivative
ID INDIAN-OCEAN; BROMOPYRROLE ALKALOIDS; SESQUITERPENES; CARDIOTOXIN;
   PALLAS; ACID
AB Three new purine derivatives, namely, 4-caryboxy-5,6-dihydro-4H,8H-pyrimido[1,2,3-cd]purine-8,10(9H)dione (1), 7,9-dihydro-1-(3-oxobtityl)-1H-purine-6,8-dione (2), and 7-hydro-9-(3-oxobutyl)-1H-purine-6,8-dione (3) together with six known purine and pyrimidine derivatives were isolated from the EtOH/CH2Cl2 extracts of the South China Sea gorgonian Subergorgia suberosa. The structures of 1-3 were determined on the bases of extensive spectroscopic analysis, including 1D and 2D NMR data.
C1 [Qi, Shu-Hua; Zhang, Si; Gao, Cheng-Hai; Li, Qin-Xing] Chinese Acad Sci, S China Sea Inst Oceanol, Key Lab Marine Bioresourses Sustainable Utilizat, Guangdong Key Lab Marine Mat Med, Guangzhou 510301, Guangdong, Peoples R China.
RP Qi, SH (reprint author), Chinese Acad Sci, S China Sea Inst Oceanol, Key Lab Marine Bioresourses Sustainable Utilizat, Guangdong Key Lab Marine Mat Med, 164 W Xingang Rd, Guangzhou 510301, Guangdong, Peoples R China.
EM shuhuaqi2001@yahoo.com
CR Aiello A, 2006, BIOORGAN MED CHEM, V14, P17, DOI 10.1016/j.bmc.2005.07.057
   Aknin M, 1998, STEROIDS, V63, P575, DOI 10.1016/S0039-128X(98)00065-8
   Anjaneyulu ASR, 1997, INDIAN J CHEM B, V36, P418
   Bokesch HR, 1996, TETRAHEDRON LETT, V37, P3259, DOI 10.1016/0040-4039(96)00528-X
   Cafieri F, 1996, TETRAHEDRON LETT, V37, P3587, DOI 10.1016/0040-4039(96)00629-6
   Capon RJ, 2005, J NAT PROD, V68, P1689, DOI 10.1021/np0502692
   Capon RJ, 2000, J NAT PROD, V63, P261, DOI 10.1021/np990378e
   GROWEISS A, 1985, TETRAHEDRON LETT, V26, P2379, DOI 10.1016/S0040-4039(00)94832-9
   Parameswaran PS, 1998, J NAT PROD, V61, P832, DOI 10.1021/np9705423
   Qi SH, 2005, J NAT PROD, V68, P1288, DOI 10.1021/np050105l
   SU JY, 1984, ACTA SCI NAT U SUNYA, V1, P97
   Subrahmanyam C, 2003, INDIAN J CHEM B, V42, P219
   Uemoto H, 1999, J NAT PROD, V62, P1581, DOI 10.1021/np9902542
   Wang GH, 2002, J NAT PROD, V65, P887, DOI 10.1021/np010586i
   Wang GH, 2002, J NAT PROD, V65, P1033, DOI 10.1021/np0106586
   YU DQ, 1999, ANAL CHEM BOOK, V7, P908
NR 16
TC 10
Z9 12
U1 5
U2 21
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0009-2363
J9 CHEM PHARM BULL
JI Chem. Pharm. Bull.
PD JUL
PY 2008
VL 56
IS 7
BP 993
EP 994
DI 10.1248/cpb.56.993
PG 2
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 333VE
UT WOS:000258180000023
PM 18591817
OA Bronze
DA 2018-12-27
ER

PT J
AU Piper, SN
   Rohm, KD
   Boldt, J
   Odermatt, B
   Maleck, WH
   Suttner, SW
AF Piper, S. N.
   Roehm, K. D.
   Boldt, J.
   Odermatt, B.
   Maleck, W. H.
   Suttner, S. W.
TI RETRACTED: Hepatocellular integrity in patients requiring parenteral
   nutrition: comparison of structured MCT/LCT vs. a standard MCT/LCT
   emulsion and a LCT emulsion (Retracted article. See vol. 28, pg. 468,
   2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 8th German Interdisciplinary Congress on Intensive Care
CY NOV 08-11, 2006
CL Hamburg, GERMANY
DE triglycerides; long chain; medium chain; fat emulsions intravenous;
   parenteral nutrition; glutathione S-transferase alpha; liver
ID LONG-CHAIN TRIGLYCERIDES; GLUTATHIONE S-TRANSFERASES; LIPID EMULSIONS;
   POSTOPERATIVE-PATIENTS; SURGICAL-PATIENTS; HEALTHY-SUBJECTS;
   CRITICALLY-ILL; FATTY-ACID; METABOLISM; MIXTURES
AB Background and objective: The aetiology of parenteral nutrition-associated hepatic Injury remains unresolved. The aim of the study was to evaluate the effects of structured triglycerides in parenteral nutrition compared either to a physical medium-chain triglycerides (MCT)/long-chain triglcerides (LCT) mixture or to a LCT emulsion on hepatic integrity. Methods: In a randomized, double-blinded trial, we studied 45 patients undergoing abdominal surgery, who were expected to receive parenteral nutrition for 5 days. Patients were allocated to one of three nutrition regimens: Group A (n = 15) received structured triglycerides, Group B (n = 15) a MCT/LCT and Group C (n = 15) a LCT lipid emulsion. Before the start of parenteral nutrition (T0), 24 h (T1), 48 h (T2), 72 h (T3) and 120 h (T4) after start of infusion the following parameters were measured: Alpha-glutathione S-transferase (alpha-GST), alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose and serum triglycerides. Results: At T3 and T4, alpha-GST levels were significantly higher in Group B (T3: 9.4 +/- 9.9; T4: 14.6 +/- 19.5 mu g L-1) and Group C (T3: 14.2 +/- 2 0.8; T4: 22.4 +/- 39.3 mu g L-1) compared with the patients receiving structured triglycerides (T3: 1.9 +/- 1.8; T4: 3.2 +/- 2.7 mu g L-1). Whereas the mean alpha-GST-levels in structured triglycerides group always remained in the normal range, this was not the case in both other groups at T3 and T4. There were no significant differences concerning ALT, AST and glucose levels. At T3 and T4, triglyceride levels were significantly lower in Group A than in Groups B and C. Conclusions: Hepatic integrity was well retained with the administration of structured triglycerides, whereas both MCT/LCT emulsion and LCT emulsion caused subclinical hepatic Injury.
C1 [Piper, S. N.; Roehm, K. D.; Boldt, J.; Odermatt, B.; Suttner, S. W.] Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Ludwigshafen, Germany.
   [Maleck, W. H.] Dept Anaesthesia, Menziken, Switzerland.
RP Piper, SN (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Crit Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM swen.n.piper@t-online.de
CR Adolph M, 1999, ANN NUTR METAB, V43, P1, DOI 10.1159/000012761
   Antebi H, 2004, JPEN J Parenter Enteral Nutr, V28, P142, DOI 10.1177/0148607104028003142
   BALL MJ, 1993, INTENS CARE MED, V19, P89, DOI 10.1007/BF01708368
   BECKETT GJ, 1987, J CLIN BIOCHEM NUTR, V2, P1
   BECKETT GJ, 1993, ADV CLIN CHEM, V30, P281, DOI 10.1016/S0065-2423(08)60198-5
   Buchman AL, 2001, JPEN-PARENTER ENTER, V25, P260, DOI 10.1177/0148607101025005260
   Chambrier C, 1999, NUTRITION, V15, P274, DOI 10.1016/S0899-9007(99)00006-4
   Grimm H, 2006, EUR J NUTR, V45, P55, DOI 10.1007/s00394-005-0573-8
   Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013
   Holt LE, 1935, J PEDIATR-US, V6, P151, DOI 10.1016/S0022-3476(35)80176-5
   HULTIN M, 1994, J LIPID RES, V35, P1850
   Jarstrand C, 1978, JPEN J Parenter Enteral Nutr, V2, P663, DOI 10.1177/0148607178002005663
   JEEVANANDAM M, 1995, NUTRITION, V11, P275
   JIANG ZM, 1993, ANN SURG, V217, P175, DOI 10.1097/00000658-199302000-00012
   Kim H, 2003, AM J HEALTH-SYST PH, V60, P1760
   Kruimel JW, 2001, JPEN-PARENTER ENTER, V25, P237, DOI 10.1177/0148607101025005237
   Lin MT, 2002, CLIN NUTR, V21, P39, DOI 10.1054/clnu.2001.0501
   MAIZ A, 1984, METABOLISM, V33, P901, DOI 10.1016/0026-0495(84)90243-9
   Martin-Pena G, 2002, JPEN-PARENTER ENTER, V26, P30, DOI 10.1177/014860710202600130
   Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011
   MOK KT, 1984, METABOLISM, V33, P910, DOI 10.1016/0026-0495(84)90244-0
   NORDENSTROM J, 1995, NUTRITION, V11, P269
   Nordenstrom J, 2006, METABOLISM, V55, P1443, DOI 10.1016/j.metabol.2006.05.004
   PALMBLAD J, 1991, CLIN NUTR, V10, P303, DOI 10.1016/0261-5614(91)90058-K
   Piper SN, 2003, ANASTH INTENSIV NOTF, V38, P781
   Porayko M K, 1998, Clin Liver Dis, V2, P133, DOI 10.1016/S1089-3261(05)70368-8
   Rohm KD, 2005, EUR J ANAESTH, V22, P209, DOI 10.1017/S0265021505000360
   Rubin M, 2000, NUTRITION, V16, P95, DOI 10.1016/S0899-9007(99)00249-X
   SANDSTROM R, 1995, JPEN-PARENTER ENTER, V19, P381, DOI 10.1177/0148607195019005381
   SEIDNER DL, 1989, JPEN-PARENTER ENTER, V13, P614, DOI 10.1177/0148607189013006614
   Simoens C, 2004, CLIN NUTR, V23, P665, DOI 10.1016/j.clnu.2003.11.004
   YOO JSH, 1990, J NUTR, V120, P1718
   Zhou Y, 2006, ASIA PAC J CLIN NUTR, V15, P406
NR 33
TC 10
Z9 11
U1 3
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD JUL
PY 2008
VL 25
IS 7
BP 557
EP 565
DI 10.1017/S0265021508004055
PG 9
WC Anesthesiology
SC Anesthesiology
GA 320FX
UT WOS:000257220200007
PM 18413006
DA 2018-12-27
ER

PT J
AU Kobayashi, S
   Soda, Y
   Bai, Y
   Tojo, A
AF Kobayashi, Seiichiro
   Soda, Yasushi
   Bai, Yuansong
   Tojo, Arinobu
TI RETRACTED: Heterogeneous promoter activity of the telomerase reverse
   transcriptase gene in individual acute myeloid leukemia cells defined by
   lentiviral reporter assay (Retracted Article. See vol 93, pg 1280, 2008)
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Letter; Retracted Publication
ID TRANSDUCTION; EXPRESSION; VECTORS; PROTEIN
C1 [Tojo, Arinobu] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku,Adv Clin Res Ctr, Tokyo 1088639, Japan.
RP Tojo, A (reprint author), Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku,Adv Clin Res Ctr, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
EM a-tojo@ims.u-tokyo.ac.jp
CR Ali ASM, 2000, LEUKEMIA, V14, P2176, DOI 10.1038/sj.leu.2401950
   Bai Y, 2003, GENE THER, V10, P1446, DOI 10.1038/sj.gt.3302026
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   COUNTER CM, 1995, BLOOD, V85, P2315
   Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085
   Horikawa I, 1999, CANCER RES, V59, P826
   Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682
   Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87
   Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100
   Roth A, 2003, LEUKEMIA, V17, P2410, DOI 10.1038/sj.leu.2403177
   Vigna E, 2000, J GENE MED, V2, P308
   Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x
NR 12
TC 3
Z9 3
U1 3
U2 12
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD JUL
PY 2008
VL 93
IS 7
BP 1103
EP 1105
DI 10.3324/haematol.12123
PG 3
WC Hematology
SC Hematology
GA 323CI
UT WOS:000257421200028
PM 18508798
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Reynolds, LP
AF Reynolds, Lawrence P.
TI RETRACTED: Application of cellular mechanisms to growth and development
   of food producing animals (Retracted Article)
SO JOURNAL OF ANIMAL SCIENCE
LA English
DT Correction; Retracted Publication
C1 N Dakota State Univ, Dept Anim & Range Sci, Fargo, ND 58105 USA.
RP Reynolds, LP (reprint author), N Dakota State Univ, Dept Anim & Range Sci, Hultz Hall, Fargo, ND 58105 USA.
RI Reynolds, Lawrence/I-5267-2015
OI Reynolds, Lawrence/0000-0002-6838-7809
CR Chung K Y, 2008, J Anim Sci, V86, pE226
   REYNOLDS LP, 2007, J ANIM SCI, V23, P321
NR 2
TC 0
Z9 0
U1 2
U2 9
PU AMER SOC ANIMAL SCIENCE
PI CHAMPAIGN
PA 2441 VILLAGE GREEN PLACE, CHAMPAIGN, IL 61822 USA
SN 0021-8812
J9 J ANIM SCI
JI J. Anim. Sci.
PD JUL
PY 2008
VL 86
IS 7
BP 1724
EP 1724
DI 10.2527/jas.2008-86-7-1724
PG 1
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 319DK
UT WOS:000257144100028
PM 18586754
OA Bronze
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
AF Lichtenthaler, Ulrich
TI RETRACTED: Externally commercializing technology assets: An examination
   of different process stages (Retracted article. See vol. 28, pg. 581,
   2013)
SO JOURNAL OF BUSINESS VENTURING
LA English
DT Article; Retracted Publication
DE external technology commercialization; open innovation; licensing;
   technology exploitation; technology transfer
ID PRODUCT DEVELOPMENT; DYNAMIC CAPABILITIES; UNITED-STATES; INNOVATION
   PERFORMANCE; ABSORPTIVE-CAPACITY; ALLIANCE CAPABILITY; MANUFACTURING
   FIRMS; SUCCESS FACTORS; JOINT VENTURES; MANAGEMENT
AB Besides applying technological knowledge in products and services, firms may externally leverage their technology assets, e.g., by means of technology licensing. Despite its increasing managerial and theoretical importance, outward technology transfer has been relatively neglected in prior research. We use data from 152 industrial companies to analyze how different levels of proficiency in managing different stages of the external technology exploitation process influence a firm's out-licensing performance. With the trend towards open innovation strategies, this research represents an important complement to the large number of success factor studies into new product development. (c) 2007 Elsevier Inc. All rights reserved.
C1 WHU Otto Beisheim Sch Management, D-56179 Vallendar, Germany.
RP Lichtenthaler, U (reprint author), WHU Otto Beisheim Sch Management, Burgpl 2, D-56179 Vallendar, Germany.
EM lichtenthaler@whu.edu
CR Amesse F, 2001, RES POLICY, V30, P1459, DOI 10.1016/S0048-7333(01)00162-7
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   Avadikyan A, 2001, RES POLICY, V30, P1443, DOI 10.1016/S0048-7333(01)00161-5
   BAGOZZI RP, 1991, ADMIN SCI QUART, V36, P421, DOI 10.2307/2393203
   Branzei O, 2006, J BUS VENTURING, V21, P75, DOI 10.1016/j.jbusvent.2004.10.002
   BROCKHOFF K, 1991, IND MARKET MANAG, V20, P91, DOI 10.1016/0019-8501(91)90027-D
   BROWN SL, 1995, ACAD MANAGE REV, V20, P343, DOI 10.2307/258850
   Chesbrough H, 2003, CALIF MANAGE REV, V45, P33, DOI 10.2307/41166175
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   CONTRACTOR FJ, 1985, J INT BUS STUD, V16, P23, DOI 10.1057/palgrave.jibs.8490449
   COOPER RG, 1995, J PROD INNOVAT MANAG, V12, P374, DOI 10.1016/0737-6782(95)00059-3
   DAVIS JL, 2001, EDISON BOARDROOM LEA
   Deeds DL, 2000, J BUS VENTURING, V15, P211, DOI 10.1016/S0883-9026(98)00013-5
   DENISON DR, 1995, ORGAN SCI, V6, P204, DOI 10.1287/orsc.6.2.204
   Doz Y. L., 1998, ALLIANCE ADVANTAGE A
   Draulans J, 2003, LONG RANGE PLANN, V36, P151, DOI 10.1016/S0024-6301(02)00173-5
   Dyer JH, 2001, MIT SLOAN MANAGE REV, V42, P37
   Eisenhardt KM, 2000, STRATEGIC MANAGE J, V21, P1105, DOI 10.1002/1097-0266(200010/11)21:10/11<1105::AID-SMJ133>3.0.CO;2-E
   EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557
   Ernst H, 2002, INT J MANAG REV, V4, P1, DOI 10.1111/1468-2370.00075
   Escher JP, 2003, TECHNOLOGY INNOVATIO, P215
   Forrest J.E., 1992, R&D MANAGE, V22, P55
   Fosfuri A, 2006, STRATEGIC MANAGE J, V27, P1141, DOI 10.1002/smj.562
   Fricke SE, 2000, IEEE T ENG MANAGE, V47, P258, DOI 10.1109/17.846792
   Frishammar J, 2005, J PROD INNOVAT MANAG, V22, P251, DOI 10.1111/j.0737-6782.2005.00121.x
   Gambardella A, 2001, MARKETS TECHNOLOGY E
   George VP, 1999, R&D MANAGE, V29, P379, DOI 10.1111/1467-9310.00148
   GERBING DW, 1988, J MARKETING RES, V25, P186, DOI 10.2307/3172650
   GERYBADZE A, 1994, R&D MANAGE, V24, P131, DOI 10.1111/j.1467-9310.1994.tb00865.x
   GHOSHAL S, 1986, SLOAN MANAGE REV, V28, P49
   Griffin A, 1996, J PROD INNOVAT MANAG, V13, P191, DOI 10.1016/0737-6782(96)00025-2
   Grindley PC, 1997, CALIF MANAGE REV, V39, P8, DOI 10.2307/41165885
   Hair J., 2006, MULTIVARIATE DATA AN
   HAKANSON L, 1993, R&D MANAGE, V23, P273, DOI 10.1111/j.1467-9310.1993.tb00834.x
   Harmon B, 1997, J BUS VENTURING, V12, P423, DOI 10.1016/S0883-9026(96)00064-X
   Hoegl M, 2005, J MANAGE, V31, P530, DOI 10.1177/0149206304272291
   Hoffmann WH, 2005, LONG RANGE PLANN, V38, P121, DOI 10.1016/j.lrp.2005.03.001
   Jayachandran S, 2005, J MARKETING, V69, P177, DOI 10.1509/jmkg.2005.69.4.177
   Jones GK, 2001, J BUS VENTURING, V16, P255, DOI 10.1016/S0883-9026(99)00048-8
   Kale P, 2002, STRATEGIC MANAGE J, V23, P747, DOI 10.1002/smj.248
   Kline D, 2003, MIT SLOAN MANAGE REV, V44, P89
   Kostoff RN, 2001, IEEE T ENG MANAGE, V48, P132, DOI 10.1109/17.922473
   Lane PJ, 2006, ACAD MANAGE REV, V31, P833, DOI 10.5465/AMR.2006.22527456
   Laursen K, 2006, STRATEGIC MANAGE J, V27, P131, DOI 10.1002/smj.507
   Lichtenthaler E, 2003, R&D MANAGE, V33, P361, DOI 10.1111/1467-9310.00304
   Lichtenthaler U, 2006, R&D MANAGE, V36, P367, DOI 10.1111/j.1467-9310.2006.00443.x
   Lindell MK, 2001, J APPL PSYCHOL, V86, P114, DOI 10.1037//0021-9010.86.1.114
   LONG JS, 2002, REGRESSION MODELS CA
   LORANGE P, 1993, STRATEGIC ALLIANCES
   Makadok R, 2001, MANAGE SCI, V47, P1621, DOI 10.1287/mnsc.47.12.1621.10245
   Makhija MV, 1997, ORGAN SCI, V8, P508, DOI 10.1287/orsc.8.5.508
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   Markman GD, 2005, J BUS VENTURING, V20, P241, DOI 10.1016/j.jbusvent.2003.12.003
   Martin X, 2003, J INT BUS STUD, V34, P356, DOI 10.1057/palgrave.jibs.8400037
   McEvily B, 2005, STRATEGIC MANAGE J, V26, P1033, DOI 10.1002/smj.484
   Miles M B., 1994, QUALITATIVE DATA ANA
   Phan PH, 2005, J BUS VENTURING, V20, P165, DOI 10.1016/j.jbusvent.2003.12.001
   Powers JB, 2005, J BUS VENTURING, V20, P291, DOI 10.1016/j.jbusvent.2003.12.008
   Reid D, 2001, INT J MANAG REV, V3, P79, DOI 10.1111/1468-2370.00055
   Rivette K, 2000, REMBRANDTS ATTIC UNL
   Rothaermel FT, 2006, J BUS VENTURING, V21, P429, DOI 10.1016/j.jbusvent.2005.02.006
   Santos FA, 2005, ORGAN SCI, V16, P491, DOI 10.1287/orsc.1050.0152
   Shane S, 2004, J BUS VENTURING, V19, P127, DOI 10.1016/S0883-9026(02)00114-3
   Sherry EF, 2004, RES POLICY, V33, P179, DOI 10.1016/jS0048-7333(03)00088-X
   Song XM, 1997, J MARKETING, V61, P1, DOI 10.2307/1251827
   Teece DJ, 1998, CALIF MANAGE REV, V40, P55, DOI 10.2307/41165943
   Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z
   Walter A, 2006, J BUS VENTURING, V21, P541, DOI 10.1016/j.jbusvent.2005.02.005
   WEISS SE, 1987, COLUMBIA J WORLD BUS, V22, P23
   West J., 2006, OPEN INNOVATION RES, P285
   YAN AM, 1994, ACAD MANAGE J, V37, P1478, DOI 10.2307/256796
   Yin R. K., 2003, CASE STUDY RES DESIG
   Zaheer A, 1998, ORGAN SCI, V9, P141, DOI 10.1287/orsc.9.2.141
NR 73
TC 36
Z9 37
U1 2
U2 62
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0883-9026
J9 J BUS VENTURING
JI J. Bus. Ventur.
PD JUL
PY 2008
VL 23
IS 4
BP 445
EP 464
DI 10.1016/j.jbusvent.2007.06.002
PG 20
WC Business
SC Business & Economics
GA 302UD
UT WOS:000255994300004
DA 2018-12-27
ER

PT J
AU Shirai, T
   Yasuoka, M
   Hotta, Y
   Kinemuchi, Y
   Watari, K
AF Shirai, Takashi
   Yasuoka, Masaki
   Hotta, Yuji
   Kinemuchi, Yoshiaki
   Watari, Koji
TI RETRACTED: Drying behavior of a slip cast body using a microwave heating
   (Retracted article. See vol. 93, pg. 2107, 2010)
SO JOURNAL OF THE AMERICAN CERAMIC SOCIETY
LA English
DT Article; Retracted Publication
ID ALUMINA SLURRY; KINETICS
AB To reduce the drying period a significant enhancement of manufacturing speed and improvement of productivity of ceramic fabrication were needed. The evaporation and transport of water were the keys to drying and controlling the kinetics of drying, which subsequently affects the properties of green bodies. This research was conducted to investigate the effects of rapid drying of ZnO slip cast bodies by microwave drying and compared with those dried by conventional drying techniques. From these results, the extent of warpage of a dried body was smaller in microwave drying than in other conventional drying methods. Furthermore, the number and size of pores were smaller for this drying technique than for other drying methods after sintering. Microwave heating was tentatively considered as a small difference in the water content between the inside and the outside of the green body, because the free and bound waters with NH(4)(+) salt of polyacrylic acid in a green body were selectively heated compared with ZnO powder, and evaporation and diffusion of water was done efficiently from the inside of the green body under microwave drying. Microwave drying has merits in terms of both the rapid drying and structural uniformity of dried bodies. It not only reduces drying period, but also improves the characteristics of green and sintered bodies.
C1 [Shirai, Takashi; Yasuoka, Masaki; Hotta, Yuji; Kinemuchi, Yoshiaki; Watari, Koji] Natl Inst Adv Ind Sci & Technol, Nagoya, Aichi 4638560, Japan.
RP Shirai, T (reprint author), Natl Inst Adv Ind Sci & Technol, Nagoya, Aichi 4638560, Japan.
EM t-shirai@aist.go.jp
RI Kinemuchi, Yoshiaki/M-4352-2018; Hotta, Yuji/M-2129-2018; Yasuoka,
   Masaki/C-6331-2018
OI Kinemuchi, Yoshiaki/0000-0002-8808-0409; Yasuoka,
   Masaki/0000-0001-8264-5547
CR Basma A. A., 1994, Applied Clay Science, V9, P151, DOI 10.1016/0169-1317(94)90017-5
   CHOU KS, 1989, J AM CERAM SOC, V72, P1622, DOI 10.1111/j.1151-2916.1989.tb06293.x
   Garrido LB, 2001, J EUR CERAM SOC, V21, P2259, DOI 10.1016/S0955-2219(00)00311-3
   Hotta Y, 2003, J AM CERAM SOC, V86, P755, DOI 10.1111/j.1151-2916.2003.tb03370.x
   JOLLY P, 1990, J MICROWAVE POWER EE, V25, P3
   JOLLY P, 1986, J MICROWAVE POWDER, V23, P65
   OFOLI RY, 1988, J FOOD PROCESS PRES, V12, P219, DOI 10.1111/j.1745-4549.1988.tb00081.x
   Omura N, 2005, J CERAM SOC JPN, V113, P495, DOI 10.2109/jcersj.113.495
   PARODI F, 1998, CHIM IND, V80, P55
   SCHERER GW, 1990, J AM CERAM SOC, V73, P3, DOI 10.1111/j.1151-2916.1990.tb05082.x
   Shirai T, 2006, J CERAM SOC JPN, V114, P217, DOI 10.2109/jcersj.114.217
   SHIRAKI Y, 1980, GIHODO SHUPPAN, P39
   SKANSI D, 1995, CERAM INT, V21, P207, DOI 10.1016/0272-8842(95)90911-2
   SUTTON WH, 1989, AM CERAM SOC BULL, V68, P376
   TURNER IW, 1991, DRY TECHNOL, V9, P1209, DOI 10.1080/07373939108916749
   Wei WCJ, 1999, J CERAM SOC JPN, V107, P313, DOI 10.2109/jcersj.107.313
NR 16
TC 4
Z9 4
U1 4
U2 16
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-7820
J9 J AM CERAM SOC
JI J. Am. Ceram. Soc.
PD JUL
PY 2008
VL 91
IS 7
BP 2367
EP 2370
DI 10.1111/j.1551-2916.2008.02398.x
PG 4
WC Materials Science, Ceramics
SC Materials Science
GA 327DF
UT WOS:000257709100046
DA 2018-12-27
ER

PT J
AU Shokeir, T
   Badawy, A
   Abo-Hashem, H
AF Shokeir, Tarek
   Badawy, Ahmed
   Abo-Hashem, Hatem
TI RETRACTED: Preoperative risk factors for intraabdominal adhesions should
   not contraindicate surgical laparoscopy for infertility (Retracted
   article. See vol. 16, pg. 189, 2012)
SO JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS
LA English
DT Article; Retracted Publication
DE infertility; laparoscopy; adhesions
ID PREVIOUS ABDOMINAL-SURGERY; WALL ADHESIONS; ENTRY; CHOLECYSTECTOMY;
   PERITONEAL; LAPAROTOMY; INSERTION
AB Objective: Abdominal wall adhesions at laparoscopy may predispose infertile patients to access-related injuries and increase the complexity of the procedure. We have observed concern from referring physicians regarding the safety of surgical laparoscopy in infertile patients who previously underwent surgery because of the risk of abdominal adhesions. To assess the risk of intraabdominal adhesions at laparoscopy, a retrospective cohort study was performed.
   Methods: All infertile patients who underwent a reproductive laparoscopic procedure in a 6-year period at our institution were included in this study. A chart review was performed to obtain demographic/surgical data and identify preoperative risk factors for intraabdominal adhesions. Preoperative videotapes were reviewed to determine the presence and location of adhesions. Standard statistical analyses were performed.
   Results: During the study period, 254 infertile patients underwent reproductive surgical laparoscopy, and videotapes on 164 (65%) were available for review. A total of 88 patients (54%) were identified with preoperative risk factors for intraabdominal adhesions (group 1), while 76 (46%) had no risk factors (group 2). The relative risk of adhesions was 1.34 (95% CI, range 0.89 to 2.01, P=0.18) when risk factors were identified. There were no differences in the groups regarding patient age, operative time, access techniques, conversion to open surgery, or complications. Estimated blood loss was significantly higher in group 2, likely due to the predominance of laparoscopic surgery for ovarian endometriomata and complexicity of the cases rather than the presence or absence of intraabdominal adhesion risk factors.
   Conclusions: No difference existed in the risk of intra-abdominal adhesions in infertile patients with and without identifiable preoperative risk factors. Preoperative risk factors for intraabdominal adhesions should not contraindicate the surgical laparoscopic approach for reproductive procedures.
C1 [Shokeir, Tarek; Badawy, Ahmed; Abo-Hashem, Hatem] Mansoura Univ Hosp, Dept Obstet & Gynecol, Fertil Care Unit, Mansoura Fac Med, Mansoura, Egypt.
RP Shokeir, T (reprint author), Mansoura Univ Hosp, Dept Obstet & Gynecol, Fertil Care Unit, Mansoura Fac Med, Mansoura, Egypt.
EM tarekshokeir@hotmail.com
CR AUDEBERT AJ, 2000, FERTIL STERIL, V12
   Audebert AJM, 2000, FERTIL STERIL, V73, P631, DOI 10.1016/S0015-0282(99)00555-5
   Baakdah Hanadi, 2005, Surg Technol Int, V14, P185
   Barwijuk Andrzej Jan, 2004, Ginekol Pol, V75, P35
   BHOGRUL S, 2001, J AM COLL SURGEONS, V192, P677
   Borzellino G, 1998, SURG LAPAROSC ENDOSC, V8, P273, DOI 10.1097/00019509-199808000-00006
   BRILL AI, 1995, OBSTET GYNECOL, V85, P269, DOI 10.1016/0029-7844(94)00352-E
   CAPRINI JA, 1995, SURG ENDOSC-ULTRAS, V9, P283
   Champault G, 1996, SURG LAPAROSC ENDOSC, V6, P367, DOI 10.1097/00019509-199610000-00006
   Chandler JG, 2001, J AM COLL SURGEONS, V192, P478, DOI 10.1016/S1072-7515(01)00820-1
   Chandler JG, 2001, J AM COLL SURGEONS, V192, P491, DOI 10.1016/S1072-7515(01)00825-0
   CHANG FH, 1995, J AM ASSOC GYN LAP, V2, P335, DOI 10.1016/S1074-3804(05)80119-7
   Davey AK, 2007, J MINIM INVAS GYN, V14, P15, DOI 10.1016/j.jmig.2006.07.013
   DIAMOND MP, 1991, FERTIL STERIL, V55, P700
   Gersin KS, 1998, J LAPAROENDOSC ADV A, V8, P125, DOI 10.1089/lap.1998.8.125
   Hasson HM, 2000, OBSTET GYNECOL, V96, P763, DOI 10.1016/S0029-7844(00)01026-7
   HASSON HM, 1974, J REPROD MED, V12, P234
   HEDGE A, 2005, J MINIM INVAS GYN, V12, P463
   Kaminski P, 2006, NEUROENDOCRINOL LETT, V27, P813
   Kothari SN, 2006, AM J SURG, V192, P843, DOI 10.1016/j.amjsurg.2006.08.055
   McKernan J B, 1995, Endosc Surg Allied Technol, V3, P35
   MILLER K, 1993, SURG ENDOSC-ULTRAS, V7, P400, DOI 10.1007/BF00311729
   ORLANDO R, 1987, ENDOSCOPY, V19, P150, DOI 10.1055/s-2007-1018266
   Parker J, 1999, AUST NZ J OBSTET GYN, V39, P88, DOI 10.1111/j.1479-828X.1999.tb03452.x
   Pelosi MA, 1995, J AM ASSOC GYN LAP, V3, P91, DOI 10.1016/S1074-3804(05)80142-2
   PENFIELD AJ, 1985, J REPROD MED, V30, P660
   Schaller G, 1995, Endosc Surg Allied Technol, V3, P55
   Scharl A, 2005, Zentralbl Gynakol, V127, P380, DOI 10.1055/s-2005-836905
   SCHIRMER BD, 1995, SURG ENDOSC-ULTRAS, V9, P1085
   SIGEL B, 1991, SURG ENDOSC-ULTRAS, V5, P161, DOI 10.1007/BF02653253
   Sokol AI, 2003, J AM ASSOC GYN LAP, V10, P469, DOI 10.1016/S1074-3804(05)60146-6
   SZIGETVARI I, 1989, J REPROD MED, V34, P465
   WEIBEL MA, 1973, AM J SURG, V126, P345, DOI 10.1016/S0002-9610(73)80123-0
   YU SC, 1994, J LAPAROENDOSC SURG, V4, P31, DOI 10.1089/lps.1994.4.31
NR 34
TC 3
Z9 3
U1 1
U2 11
PU SOC LAPAROENDOSCOPIC SURGEONS
PI MIAMI
PA 7330 SW 62 PL, STE 410, MIAMI, FL 33143-4825 USA
SN 1086-8089
J9 JSLS-J SOC LAPAROEND
JI JSLS-J. Soc. Laparoendosc. Surg.
PD JUL-SEP
PY 2008
VL 12
IS 3
BP 267
EP 272
PG 6
WC Surgery
SC Surgery
GA 343DN
UT WOS:000258833000009
PM 18765050
DA 2018-12-27
ER

PT J
AU He, HB
   Shi, MQ
   Yang, J
   Zeng, XW
   Qiao, HX
   Wu, LM
   Li, LD
AF He, Haibo
   Shi, Mengqiong
   Yang, Jun
   Zeng, Xiaowei
   Qiao, Hongxiang
   Wu, Limao
   Li, Lianda
TI RETRACTED: The correlation between angiogenesis and abnormal expression
   of SERCA2a, phospholamban and the endothelin pathway in heart failure,
   and improvement by puerarin (Retracted article. See vol. 23, pg. 745,
   2009)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE angiogenesis pathway; heart failure; ET-ROS pathway; SERCA2a; PLB;
   puerarin
ID LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; RECEPTOR
   ANTAGONIST; GROWTH-FACTOR; ETB-RECEPTOR; RATS; THERAPY; REPOLARIZATION;
   STIMULATION; ISCHEMIA
AB Emerging evidence indicates that angiogenesis may be a potential new target in treating heart failure (HF). It was hypothesized that a lack of angiogenesis would correlate with an abnormal expression of sarco/endoplasmic reticulum ATPase 2a (SERCA2a) and phospholamban (PLB), and the activated endothelin (ET) pathway and oxidative stress in HIT. If this is the case, such normal changes could be reversed by puerarin. HIF was produced by coronary artery ligation for 4 weeks in rats. The rats were divided into three groups: sham, HIF untreated and HIT + puerarin (120 mg/kg per day, i.p.). Hemodynamic and echocardiographic changes, angiogenesis, cardiac morphology, serum biochemistry, mRNA and proteins of the angiogenesis pathway, the ET pathway and redox were measured. In the HF rats, hemodynarnic and echocardiographic abnormalities, cardiac remodeling and histological changes with features of cardiac failure were associated with a lack of the angiogenesis pathway, accompanied by oxidative stress, an up-regulated ET pathway and abnormal SERCA2a and PLB expressions in HF rats. Puerarin significantly promoted angiogenesis and reversed the above changes. In conclusion, the absence of the angiogenesis pathway correlated with abnormal expression of SERCA2a and PLB and an activated ET-ROS (reactive oxygen species) system in the affected myocardium. Puerarin promoted the angiogenesis pathway, improved myocardial microcirculation and down-regulated the ET system, resulting in a reversal of the abnormalities of expression of SERCA2a and PLB, and the cardiac performance in HF. Copyright (c) 2008 John Wiley & Sons, Ltd.
C1 [He, Haibo; Yang, Jun; Zeng, Xiaowei; Qiao, Hongxiang; Wu, Limao; Li, Lianda] Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herbal Med, Hangzhou 310058, Peoples R China.
   [Shi, Mengqiong] Ctr Med Sci Anal, Dahe Clique, Hangzhou, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herbal Med, Zijiangang Campus, Hangzhou 310058, Peoples R China.
EM wulimao@zju.edu.cn
CR Adamson PB, 2001, J AM COLL CARDIOL, V37, P1741, DOI 10.1016/S0735-1097(01)01185-8
   del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564
   Fan TP, 2006, TRENDS PHARMACOL SCI, V27, P297, DOI 10.1016/j.tips.2006.04.006
   Francis B, 2004, J CARDIOVASC PHARM, V44, pS54, DOI 10.1097/01.fjc.0000166214.42791.f2
   Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329
   Gao Q, 2005, P ANN INT IEEE EMBS, P5591
   Gianni D, 2005, J BIOENERG BIOMEMBR, V37, P375, DOI 10.1007/s10863-005-9474-z
   Gotze S, 2006, CLIN RES CARDIOL, V95, P18, DOI 10.1007/s00392-006-2006-y
   Guo Xiao-gang, 2004, Zhongguo Zhong Yao Za Zhi, V29, P248
   He HB, 2007, J PHARM PHARMACOL, V59, P977, DOI 10.1211/jpp.59.7.0010
   He HB, 2006, ACTA PHARMACOL SIN, V27, P1213, DOI 10.1111/j.1745-7254.2006.00373.x
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Ji XY, 2003, LIFE SCI, V73, P1413, DOI 10.1016/S0024-3205(03)00432-6
   Kastrup J, 2005, J AM COLL CARDIOL, V45, P982, DOI 10.1016/j.jacc.2004.12.068
   Leite-Moreira AF, 2004, AM J PHYSIOL-HEART C, V287, pH1194, DOI 10.1152/ajpheart.00563.2003
   [Liu Qing 刘庆], 2004, [应用与环境生物学报, Chinese Journal of Applied and Environmental Biology], V10, P281
   MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151
   Morgan EE, 2004, AM J PHYSIOL-HEART C, V287, pH2049, DOI 10.1152/ajpheart.00393.2004
   Nagaya N, 2001, CIRCULATION, V104, P1430, DOI 10.1161/hc3601.095575
   NICOSIA RF, 1994, AM J PATHOL, V145, P1023
   Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467
   PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085
   Purdham DM, 2004, AM J PHYSIOL-HEART C, V287, pH2877, DOI 10.1152/ajpheart.00499.2004
   Qi MY, 2006, J CARDIOVASC PHARM, V47, P729, DOI 10.1097/01.fjc.0000211765.52012.aa
   Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6
   Sticherling C, 2006, SWISS MED WKLY, V136, P611
   Sumi M, 2007, LIFE SCI, V80, P559, DOI 10.1016/j.lfs.2006.10.020
   Thomsen MB, 2005, BASIC RES CARDIOL, V100, P279, DOI 10.1007/s00395-005-0519-6
   Tsuruda T, 2002, CIRC RES, V90, P128, DOI 10.1161/hh0202.103613
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Vandervelde S, 2005, J MOL CELL CARDIOL, V39, P363, DOI 10.1016/j.yjmcc.2005.05.012
   Wu LM, 2007, PHYTOTHER RES, V21, P751, DOI 10.1002/ptr.2157
   Xie Rui-qin, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P895
   Zhang Fu-rong, 2004, Zhongguo Zhongyao Zazhi, V29, P777
   Zhang Li, 2006, Wuhan Daxue Xuebao (Yixue Ban), V27, P249
   Zhang SY, 2006, BIOL PHARM BULL, V29, P945, DOI 10.1248/bpb.29.945
NR 36
TC 13
Z9 18
U1 5
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JUL
PY 2008
VL 22
IS 7
BP 948
EP 956
DI 10.1002/ptr.2437
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 332AO
UT WOS:000258054200016
PM 18389490
DA 2018-12-27
ER

PT J
AU Johnson, CS
   Norton, MI
   Nelson, LD
   Stapel, D
   Chartrand, TL
AF Johnson, Camille S.
   Norton, Michael I.
   Nelson, Leif D.
   Stapel, Diederik
   Chartrand, Tanya L.
TI RETRACTED: The downside of feeling better: Self-regard repair harms
   performance (Retracted article. See vol. 12, pg. 237, 2013)
SO SELF AND IDENTITY
LA English
DT Article; Retracted Publication
ID AFFIRMATION; ENHANCEMENT; DISSONANCE; FUTURE; ESTEEM
AB While threats to self-regard are unpleasant and aversive, such threats can also be motivating, leading people to change their views of themselves, and their behavior. The current studies show that when individuals experience a threat to self-regard through upward social comparison, learning about an opportunity to demonstrate competency can be affirming, leading to restored self-regard. However, self-regard is repaired only when the new task is in a domain different from? the threatened domain (Study 1), and only when that new task is diagnostic of an important ability (Study 2). Study 3 examines the behavioral outcomes associated with threat, demonstrating the positive impact of threat on performance on these new tasks; ironically, when threat-the motivating force behind improved performance-is reduced, performance suffers.
C1 [Johnson, Camille S.] Stanford Univ, Stanford, CA 94305 USA.
   [Norton, Michael I.] Harvard Univ, Sch Business, Cambridge, MA 02138 USA.
   [Nelson, Leif D.] Univ Calif San Diego, Rady Sch Management, San Diego, CA 92103 USA.
   [Stapel, Diederik] Tilburg Univ, NL-5000 LE Tilburg, Netherlands.
   [Chartrand, Tanya L.] Duke Univ, Durham, NC USA.
RP Johnson, CS (reprint author), San Jose State Univ, COB Org & Management, 1 Washington Sq, San Jose, CA 95192 USA.
EM johnson.1967@osu.edu
CR ARONSON J, 1995, J PERS SOC PSYCHOL, V68, P986, DOI 10.1037/0022-3514.68.6.986
   Carver C. S., 1998, SELF REGULATION BEHA
   HEATHERTON TF, 1991, J PERS SOC PSYCHOL, V60, P895, DOI 10.1037//0022-3514.60.6.895
   Johnson CS, 2007, J PERS SOC PSYCHOL, V92, P1051, DOI 10.1037/0022-3514.92.6.1051
   Johnson CS, 2007, EUR J SOC PSYCHOL, V37, P258, DOI 10.1002/ejsp.361
   JOHNSON CS, 2007, SOCIAL COMPARISON SE
   Jonas E, 2002, PERS SOC PSYCHOL B, V28, P1342, DOI 10.1177/014616702236834
   Kruglanski A. W., 1996, PSYCHOL ACTION LINKI, P599
   Lockwood P, 1997, J PERS SOC PSYCHOL, V73, P91, DOI 10.1037//0022-3514.73.1.91
   McQueen A, 2006, SELF IDENTITY, V5, P289, DOI 10.1080/15298860600805325
   MEDNICK SA, 1962, PSYCHOL REV, V69, P220, DOI 10.1037/h0048850
   Nelson LD, 2005, J EXP SOC PSYCHOL, V41, P423, DOI 10.1016/j.jesp.2004.08.003
   Oettingen G, 2002, J PERS SOC PSYCHOL, V83, P1198, DOI 10.1037//0022-3514.83.5.1198
   Pemberton M, 2001, J PERS SOC PSYCHOL, V81, P234, DOI 10.1037//0022-3514.81.2.234
   Schimel J, 2004, SOC COGNITION, V22, P75, DOI 10.1521/soco.22.1.75.30984
   Sedikides C, 2005, J PERS SOC PSYCHOL, V89, P539, DOI 10.1037/0022-3514.89.4.539
   SEDIKIDES C, 1993, J PERS SOC PSYCHOL, V65, P317, DOI 10.1037/0022-3514.65.2.317
   Sherman DK, 2006, ADV EXP SOC PSYCHOL, V38, P183, DOI 10.1016/S0065-2601(06)38004-5
   Smith JL, 2006, BASIC APPL SOC PSYCH, V28, P51, DOI 10.1207/s15324834basp2801_5
   Steele Claude, 1988, ADV EXPT SOCIAL PSYC, P261, DOI DOI 10.1016/S0065-2601(08)60229-4
   STEELE CM, 1983, J PERS SOC PSYCHOL, V45, P5, DOI 10.1037/0022-3514.45.1.5
   STEELE CM, 1975, J PERS SOC PSYCHOL, V31, P361, DOI 10.1037/h0076291
   Tesser A, 2000, PERS SOC PSYCHOL B, V26, P1476, DOI 10.1177/01461672002612003
   Tesser A., 2005, BUILDING DEFENDING R
   TESSER A, 1988, ADV EXPT SOCIAL PSYC, V2, P1
   TROPE Y, 1979, J PERS SOC PSYCHOL, V37, P1505, DOI 10.1037/0022-3514.37.9.1505
   WOOD JV, 1989, PSYCHOL BULL, V106, P231, DOI 10.1037//0033-2909.106.2.231
NR 27
TC 5
Z9 5
U1 3
U2 16
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1529-8868
EI 1529-8876
J9 SELF IDENTITY
JI Self Identity
PD JUL-SEP
PY 2008
VL 7
IS 3
BP 262
EP 277
DI 10.1080/15298860701438414
PG 16
WC Psychology, Social
SC Psychology
GA 323RL
UT WOS:000257466000003
DA 2018-12-27
ER

PT J
AU Guilleminault, C
   Quo, S
   Huynh, NT
   Li, K
AF Guilleminault, Christian
   Quo, Stacey
   Huynh, Nelly T.
   Li, Kasey
TI RETRACTED: Orthodontic expansion treatment and adenotonsillectomy in the
   treatment of obstructive sleep apnea in prepubertal children (Retracted
   article. See vol. 33, pg. 8, 2010)
SO SLEEP
LA English
DT Article; Retracted Publication
DE prepubertal children; pediatric obstructive sleep apnea; orthodontics;
   adenotonsillectomy; treatment
ID RAPID MAXILLARY EXPANSION; NASAL AIRWAY-RESISTANCE
AB Study objective: Rapid maxillary expansion and adenotonsillectomy are proven treatments of obstructive sleep apnea (OSA) in children. Our goal was to investigate whether rapid maxillary expansion should be offered as an alternative to surgery in select patients. In addition, if both therapies are required, the order in which to perform these interventions needs to be determined.
   Design: Prepubertal children with moderate OSA clinically judged to require both adenotonsillectomy and orthodontic treatment were randomized into 2 treatment groups. Group 1 underwent adenotonsillectomy followed by orthodontic expansion. Group 2 underwent therapies in the reverse sequence.
   Subjects: Thirty-two children (16 girls) in an academic sleep clinic.
   Method: Clinical evaluation and polysomnography were performed after each stage to assess efficacy of each treatment modality.
   Results: The 2 groups were similar in age, symptoms, apnea-hypopnea index, and lowest oxygen saturation. Two children with orthodontic treatment first did not require subsequent adenotonsillectomy. Thirty children underwent both treatments. Two of them were still symptomatic and presented with abnormal polysomogram results following both therapies. In the remaining 28 children, all results were significantly different from those at entry (P = 0.001) and from single therapy (P = 0.01), regardless of the order of treatment. Both therapies were necessary to obtain complete resolution of OSA.
   Conclusion: In our study, 87.5% of the children with sleep-disordered breathing had both treatments. In terms of treatment order, 2 of 16 children underwent orthodontic treatment alone, whereas no children underwent surgery alone to resolve OSA. Two children who underwent both treatments continued to have OSA.
C1 [Guilleminault, Christian; Huynh, Nelly T.; Li, Kasey] Stanford Univ, Sleep Disorders Clin, Sleep Med Program, Stanford, CA 94305 USA.
   [Quo, Stacey] Univ Calif San Francisco, Sch Dent, San Francisco, CA 94143 USA.
RP Guilleminault, C (reprint author), Stanford Univ, Sleep Disorders Clin, Sleep Med Program, 401 Quarry Rd,Suite 3301, Stanford, CA 94305 USA.
EM cguil@stanford.edu
CR [Anonymous], 1992, Sleep, V15, P173
   Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X
   Cistulli PA, 1998, SLEEP, V21, P831, DOI 10.1093/sleep/21.8.831
   Friedman M, 1999, LARYNGOSCOPE, V109, P1901, DOI 10.1097/00005537-199912000-00002
   Friedman M, 2002, OTOLARYNG HEAD NECK, V127, P13, DOI 10.1067/mhn.2002.126477
   GRAY LP, 1975, J LARYNGOL OTOL, V89, P601, DOI 10.1017/S0022215100080804
   GUILLEMINAULT C, 1989, J PEDIATR-US, V114, P997, DOI 10.1016/S0022-3476(89)80447-0
   Guilleminault C, 2004, LARYNGOSCOPE, V114, P132, DOI 10.1097/00005537-200401000-00024
   Guilleminault C, 2004, ARCH PEDIAT ADOL MED, V158, P153, DOI 10.1001/archpedi.158.2.153
   Guilleminault C, 2001, Semin Pediatr Neurol, V8, P207, DOI 10.1053/spen.2001.29045
   Guilleminault C, 2007, OTOLARYNG HEAD NECK, V136, P169, DOI 10.1016/j.otohns.2006.09.021
   HAAS AJ, 1961, ANGLE ORTHOD, V31, P73
   HERSHEY HG, 1976, AM J ORTHOD DENTOFAC, V69, P274, DOI 10.1016/0002-9416(76)90076-2
   MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357
   Mitchell RB, 2004, INT J PEDIATR OTORHI, V68, P1375, DOI 10.1016/j.ijporl.2004.04.026
   Pirelli P, 2004, SLEEP, V27, P761, DOI 10.1093/sleep/27.4.761
   Rechtschaffen A, 1968, MANUAL STANDARDIZED
   Tasker C, 2002, ARCH DIS CHILD, V86, P34, DOI 10.1136/adc.86.1.34
   Terzano MG, 2002, SLEEP MED, V3, P187, DOI 10.1016/S1389-9457(02)00003-5
   Timms D J, 1974, Br J Orthod, V1, P127
   TIMMS DJ, 1984, J LARYNGOL OTOL, V98, P357, DOI 10.1017/S0022215100146730
   Villa MP, 2007, SLEEP MED, V8, P128, DOI 10.1016/j.sleep.2006.06.009
   WERTZ RA, 1970, AMER J ORTHODONTICS, V58, P41, DOI 10.1016/0002-9416(70)90127-2
NR 23
TC 22
Z9 25
U1 2
U2 21
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUL 1
PY 2008
VL 31
IS 7
BP 953
EP 957
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 321GX
UT WOS:000257293800006
PM 18652090
DA 2018-12-27
ER

PT J
AU Johnston, CA
   Kimple, AJ
   Giguere, PM
   Siderovski, DP
AF Johnston, Christopher A.
   Kimple, Adam J.
   Giguere, Patrick M.
   Siderovski, David P.
TI RETRACTED: Structure of the parathyroid hormone receptor C terminus
   bound to the G-protein dimer G beta(1)gamma(2) (Retracted article. See
   vol. 19, pg. 1200, 2011)
SO STRUCTURE
LA English
DT Article; Retracted Publication
ID BETA-GAMMA-SUBUNITS; NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE;
   ADENYLYL-CYCLASE; ALPHA-SUBUNIT; ACTIVATION; TRANSDUCIN; SITES;
   RHODOPSIN; SPECIFICITY
AB A critical role of the G beta gamma dimer in heterotrimeric G-protein signaling is to facilitate the engagement and activation of the G alpha subunit by cell-surface G-protein-coupled receptors. However, high-resolution structural information of the connectivity between receptor and the G beta gamma dimer has not previously been available. Here, we describe the structural determinants of G beta(1)gamma(2) in complex with a C-terminal region of the parathyroid hormone receptor-1 (PTH1R) as obtained by X-ray crystallography. The structure reveals that several critical residues within PTH1R contact only G beta residues located within the outer edge of WD1- and WD7-repeat segments of the G beta toroid structure. These regions encompass a predicted membrane-facing region of G beta thought to be oriented in a fashion that is accessible to the membrane-spanning receptor. Mutation of key receptor contact residues on G beta(1) leads to a selective loss of function in receptor/heterotrimer coupling while preserving G beta(1)gamma(2) activation of the effector phospholipase-C beta.
C1 [Johnston, Christopher A.; Kimple, Adam J.; Giguere, Patrick M.; Siderovski, David P.] Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Johnston, Christopher A.; Kimple, Adam J.; Giguere, Patrick M.; Siderovski, David P.] Univ N Carolina, UNC Neurosci Ctr, Chapel Hill, NC 27599 USA.
RP Siderovski, DP (reprint author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, 1106 ME Jones Bldg,CB 7365, Chapel Hill, NC 27599 USA.
EM dsiderov@med.unc.edu
FU NIGMS NIH HHS [F32 GM076944-02, R01 GM074268, F32 GM076944, R01
   GM074268-02, F32 GM076944-01, R01 GM074268-01A1]
CR Agler HL, 2003, J GEN PHYSIOL, V121, P495, DOI 10.1085/jgp.200208770
   Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200
   Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Cheever ML, 2008, NAT STRUCT MOL BIOL, V15, P155, DOI 10.1038/nsmb.1377
   Davis TL, 2005, BIOCHEMISTRY-US, V44, P10593, DOI 10.1021/bi050655i
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ernst OP, 2007, P NATL ACAD SCI USA, V104, P10859, DOI 10.1073/pnas.0701967104
   Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271
   FUNG BKK, 1983, J BIOL CHEM, V258, P495
   Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8
   George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913
   Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921
   Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798
   Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200
   Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200
   Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200
   Johnston CA, 2005, STRUCTURE, V13, P1069, DOI 10.1016/j.str.2005.04.007
   Johnston CA, 2007, MOL PHARMACOL, V72, P219, DOI 10.1124/mol.107.034348
   Johnston CA, 2007, P NATL ACAD SCI USA, V104, P2001, DOI 10.1073/pnas.0608599104
   Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5
   Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265
   Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348
   Mahon MJ, 2006, MOL ENDOCRINOL, V20, P136, DOI 10.1210/me.2005-0169
   McCudden CR, 2005, CELL MOL LIFE SCI, V62, P551, DOI 10.1007/s00018-004-4462-3
   OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P56
   Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298
   Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1
   Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198
   Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103
   Snow BE, 2002, METHOD ENZYMOL, V344, P740
   Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489
   Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5
   Taylor JM, 1996, J BIOL CHEM, V271, P3336
   Van Eps N, 2006, P NATL ACAD SCI USA, V103, P16194, DOI 10.1073/pnas.0607972103
   Wall MA, 1998, STRUCT FOLD DES, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8
   Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005
   White JF, 2007, P NATL ACAD SCI USA, V104, P12199, DOI 10.1073/pnas.0705312104
   Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104
   Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026
   Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197
NR 41
TC 20
Z9 23
U1 3
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD JUL
PY 2008
VL 16
IS 7
BP 1086
EP 1094
DI 10.1016/j.str.2008.04.010
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 327MA
UT WOS:000257732000013
PM 18611381
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Raghavan, G
   Gopinathan, CP
AF Raghavan, Gireesh
   Gopinathan, Cherukara Purushothaman
TI RETRACTED: Effects of diet, stocking density and environmental factors
   on growth, survival and metamorphosis of clam, Paphia malabarica
   (Chemnitz) larvae (Retracted article. See vol. 39, pg. 928, 2012)
SO AQUACULTURE RESEARCH
LA English
DT Article; Retracted Publication
DE Paphia malabarica; diet; stocking density; illumination intensity;
   growth and metamorphosis; survival
AB A series of experiments were conducted to evaluate the effects of diet, stocking density and environmental factors on the growth, survival and metamorphosis of short neck clam Paphia malabarica larvae. These experiments examined the following factors: diet [Isochrysis galbana, Nannochloropsis salina and a mixture of I. galbana and N. salina (1:1 w/w)], stocking density (1, 3, 5 and 7 larvae mL(-1)), light intensity (unshaded, partially shaded and fully shaded) and water filtration (unfiltered and sand filtered). Results indicated that N. salina could replace 50% of I. galbana as a food source for the clam larvae with an increase in growth, survival (47.2%), metamorphosis (33.5%) and early settlement. Larval growth decreased significantly with increasing stocking density. A density of 1-3 larvae mL(-1) appeared to be optimal for normal growth of clam larvae. Neither diet nor stocking density used in the study had a significant effect on larval survival. Under partially shaded (light intensity=1000-5000 lx) and fully shaded (light intensity < 1000 lx) conditions, larval growth was significantly faster than under direct sunlight (unshaded). Larvae grew significantly faster in the unfiltered water than in the filtered water.
C1 [Raghavan, Gireesh; Gopinathan, Cherukara Purushothaman] Cent Marine Fisheries Res Inst, Kochi 682018, Kerala, India.
RP Raghavan, G (reprint author), Cent Marine Fisheries Res Inst, Ernakulam N PO, Kochi 682018, Kerala, India.
EM girmsr@gmail.com
CR Appukuttan K. R., 1996, SEA FOOD EXPORT J, V27, P17
   APPUKUTTAN KK, 1993, THESIS U KERALA
   APPUKUTTAN KK, 1999, 4 IND FISH FOR P, P31
   CENNI S, 1989, Journal of Shellfish Research, V8, P444
   Dong Bo, 2000, Oceanologia et Limnologia Sinica, V31, P636
   Duggan W. P., 1973, P NATL SHELLFISH ASS, V63, P68
   Gireesh R., 2004, Journal of the Marine Biological Association of India, V46, P146
   LIN B, 1983, J FISH CHINA, V7, P15
   LUCAS SJ, 1988, AUSTR CTR INT AGR RE, V98, P129
   MITCHELL D, 1992, WORKSH WAT QUAL ALT, V4, P29
   Morizane T., 1991, P79
   Muthiah P., 1992, Journal of the Marine Biological Association of India, V34, P138
   Muthiah P, 2002, AQUACULTURE, V211, P393, DOI 10.1016/S0044-8486(02)00027-3
   Narasimham K.A., 1988, Indian Journal of Fisheries, V35, P107
   NELSON JR, 1992, AQUACULTURE, V106, P357, DOI 10.1016/0044-8486(92)90267-O
   Numaguchi K, 1998, AQUACULT INT, V6, P77, DOI 10.1023/A:1009225921044
   Sun Hushan, 1999, Journal of Fishery Sciences of China, V6, P54
   WANG XY, 1985, T OCEANOLOGY LIMNOLO, V4, P66
   Wei L.P, 1996, SHANDONG FISH, V13, P15
NR 19
TC 10
Z9 10
U1 4
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1355-557X
EI 1365-2109
J9 AQUAC RES
JI Aquac. Res.
PD JUN 25
PY 2008
VL 39
IS 9
BP 928
EP 933
DI 10.1111/j.1365-2109.2008.01951.x
PG 6
WC Fisheries
SC Fisheries
GA 312QF
UT WOS:000256685200004
DA 2018-12-27
ER

PT J
AU Meijer, J
   Ogink, J
   Kreike, B
   Nuyten, D
   de Visser, KE
   Roos, E
AF Meijer, Joost
   Ogink, Janneke
   Kreike, Bas
   Nuyten, Dimitry
   de Visser, Karin E.
   Roos, Ed
TI RETRACTED: The chemokine receptor CXCR6 and its ligand CXCL16 are
   expressed in carcinomas and inhibit proliferation (Retracted article.
   See vol. 71, pg. 1196, 2011)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID COLORECTAL-CANCER; INFILTRATING LYMPHOCYTES; GROWTH-INHIBITION;
   COLON-CARCINOMA; ANGIOTENSIN-II; CELL-LINE; PROTEIN; DESENSITIZATION;
   INACTIVATION; INFLAMMATION
AB The chemokine receptor CXCR6 and its ligand CXCL16 are involved in inflammation. Thus far, they were known to be expressed mainly by T cells and macrophages, respectively. However, we detected both in all of 170 human primary mammary carcinomas and at similar levels in all 8 human mammary carcinoma cell lines tested by microarray analysis. Expression was confirmed by reverse transcription-PCR and for the cell lines also by fluorescence-activated cell sorting analysis. CXCR6 and CXCL16 were also detected in several mouse and human mammary, colon, and pancreatic carcinoma cell lines. CXCL16 is a transmembrane protein from which the soluble chemokine can be cleaved off. The transmembrane form is present on the surface of the carcinoma cells. Surprisingly, suppression of either CXCR6 or CXCL16 led to greatly enhanced proliferation in vitro as well as in vivo, indicating that their interaction inhibits proliferation. This notion was verified using inhibitory antibodies and by introduction of CXCL16 into a rare CXCL16-negative cell line. The effect was mediated by the G protein-coupled receptor CXCR6 because it was blocked by the G(i) protein inhibitor pertussis toxin. In contrast, the soluble CXCL16 chemokine enhanced proliferation, and this was also mediated by CXCR6 but not via G(i) protein. It is remarkable that both CXCR6 and CXCL16 are expressed by all mammary carcinomas because cells that lose either acquire a growth advantage and should be selected during tumor progression. This suggests an unknown important role in tumor formation. Proteases, possibly macrophage derived, might convert inhibitory transmembrane CXCL16 into the stimulatory chemokine.
C1 [Meijer, Joost; Ogink, Janneke; Roos, Ed] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands.
   [Kreike, Bas; Nuyten, Dimitry] Netherlands Canc Inst, Div Radiotherapy, NL-1066 CX Amsterdam, Netherlands.
   [Kreike, Bas] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands.
   [de Visser, Karin E.] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands.
RP Roos, E (reprint author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM e.roos@nki.nl
CR Alderton F, 2001, MOL PHARMACOL, V59, P1119
   Aslanian AM, 2006, CIRCULATION, V114, P583, DOI 10.1161/CIRCULATIONAHA.105.540583
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Burdon D, 2002, BIOCHEM J, V367, P549, DOI 10.1042/BJ20020446
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Geissmann F, 2005, PLOS BIOL, V3, P650, DOI 10.1371/journal.pbio.0030113
   Gough PJ, 2004, J IMMUNOL, V172, P3678, DOI 10.4049/jimmunol.172.6.3678
   Hase K, 2006, J IMMUNOL, V176, P43, DOI 10.4049/jimmunol.176.1.43
   Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266
   Heydtmann M, 2005, J IMMUNOL, V174, P1055, DOI 10.4049/jimmunol.174.2.1055
   Hojo S, 2007, CANCER RES, V67, P4725, DOI 10.1158/0008-5472.CAN-06-3424
   Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431
   Katayama A, 2005, CLIN CANCER RES, V11, P2937, DOI 10.1158/1078-0432.CCR-04-1470
   Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078
   Kimura A, 1999, CANCER RES, V59, P5133
   Krudewig R, 2000, J NEUROCHEM, V74, P1721, DOI 10.1046/j.1471-4159.2000.0741721.x
   Kulbe H, 2004, INT J DEV BIOL, V48, P489, DOI 10.1387/ijdb.041814hk
   Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Ludwig A, 2005, J NEUROCHEM, V93, P1293, DOI 10.1111/j.1471-4159.2005.03123.x
   Ludwig A, 2007, THROMB HAEMOSTASIS, V97, P694
   Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738
   McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001
   Meijer J, 2006, CANCER RES, V66, P9576, DOI 10.1158/0008-5472.CAN-06-1507
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663
   Nanki T, 2005, ARTHRITIS RHEUM, V52, P3004, DOI 10.1002/art.21301
   Ou DL, 2006, J PATHOL, V210, P363, DOI 10.1002/path.2053
   Patel DN, 2006, BIOCHEM BIOPH RES CO, V347, P1113, DOI 10.1016/j.bbre.2006.07.015
   Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   Scala S, 2005, CLIN CANCER RES, V11, P1835, DOI 10.1158/1078-0432.CCR-04-1887
   Schimanski CC, 2005, CLIN CANCER RES, V11, P1743, DOI 10.1158/1078-0432.CCR-04-1195
   Seidl H, 2007, HUM PATHOL, V38, P768, DOI 10.1016/j.humpath.2006.11.013
   Shimaoka T, 2003, J IMMUNOL, V171, P1647, DOI 10.4049/jimmunol.171.4.1647
   Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650
   Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5
   Tulipano G, 2004, J BIOL CHEM, V279, P21374, DOI 10.1074/jbc.M313522200
   van der Voort R, 2005, ARTHRITIS RHEUM, V52, P1381, DOI 10.1007/art.21004
   Wagsater D, 2004, ANTICANCER RES, V24, P3711
   Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
   Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI11330
   Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024
NR 47
TC 41
Z9 46
U1 3
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2008
VL 68
IS 12
BP 4701
EP 4708
DI 10.1158/0008-5472.CAN-08-0482
PG 8
WC Oncology
SC Oncology
GA 315CO
UT WOS:000256855700028
PM 18559516
OA Bronze
DA 2018-12-27
ER

PT J
AU Pankratov, EL
AF Pankratov, E. L.
TI RETRACTED: Optimization of laser annealing of radiation defects for
   production of an implanted-junction rectifier (Retracted article. See
   vol. 42, pg. Nil_413, 2009)
SO JOURNAL OF PHYSICS D-APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID P-N-JUNCTION; SILICON; DOPANT; REDISTRIBUTION; DIFFUSION
AB In this paper we optimized pulse laser annealing for increasing the recently described effect (see, for example, Pankratov and Spagnolo 2005 Eur. Phys. J. B 46 15, Pankratov 2005 Phys. Rev. B 72 075201, Pankratov 2008 Phys. Lett. A 372 1897) of increasing at one time the sharpness of the p-n junction and the homogeneity of the impurity distribution in a doped area. Some conditions on the correlation between the inhomogeneities of the multilayer structure and the temperature distribution, which was formed by laser pulses, have been considered.
C1 RAS, Inst Phys Microstruct, Nizhnii Novgorod 603950, Russia.
RP Pankratov, EL (reprint author), RAS, Inst Phys Microstruct, GSP-105, Nizhnii Novgorod 603950, Russia.
EM elp2004@mail.ru
CR Abdullaev NA, 2002, PHYS SOLID STATE+, V44, P1859, DOI 10.1134/1.1514773
   Ahlgren T, 1997, PHYS REV B, V56, P4597, DOI 10.1103/PhysRevB.56.4597
   FAHEY PM, 1989, REV MOD PHYS, V61, P289, DOI 10.1103/RevModPhys.61.289
   Golubkov AV, 2007, PHYS SOLID STATE+, V49, P1216, DOI 10.1134/S1063783407070025
   Grebene AB, 1983, BIPOLAR MOS ANALOGOU
   Gusev V. G., 1991, ELECTRONICS
   JELLISON GE, 1995, PHYS REV B, V52, P14607, DOI 10.1103/PhysRevB.52.14607
   Mazhukin V. I., 2000, MATH MODELLING, V12, P75
   Ong KK, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2364834
   Pankratov EL, 2008, PHYS LETT A, V372, P1897, DOI 10.1016/j.physleta.2007.10.058
   Pankratov EL, 2007, EUR PHYS J B, V57, P251, DOI [10.1140/epjb/e2007-00173-8, 10.1140/epjb/c2007-00173-8]
   Pankratov EL, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.075201
   Pankratov EL, 2005, EUR PHYS J B, V46, P15, DOI 10.1140/epjb/e2005-00233-1
   PANKRATOV EL, 2007, J APPL PHYS, V103
   Ryssel H, 1978, ION IMPLANTATION
   Sanchez AFC, 1999, PHYS REV B, V59, P10630, DOI 10.1103/PhysRevB.59.10630
   SHALIMOVA KV, 1985, PHYS SEMICONDUCTORS
   Sisianu ST, 2002, SEMICONDUCTORS+, V36, P581, DOI 10.1134/1.1478552
   Tsagarakis ED, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2387964
   YU D, 1955, APPL MECH, V1, P23
   YU GZ, 1991, TECHNOLOGY MICROELEC
   Zorin EI, 1975, ION DOPING SEMICONDU
NR 22
TC 4
Z9 4
U1 3
U2 10
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0022-3727
EI 1361-6463
J9 J PHYS D APPL PHYS
JI J. Phys. D-Appl. Phys.
PD JUN 7
PY 2008
VL 41
IS 11
AR 115105
DI 10.1088/0022-3727/41/11/115105
PG 6
WC Physics, Applied
SC Physics
GA 305IR
UT WOS:000256172200019
DA 2018-12-27
ER

PT J
AU Kuhn, DE
   Nuovo, GJ
   Martin, MM
   Malana, GE
   Pleister, AP
   Jiang, J
   Schmittgen, TD
   Terry, AV
   Gardiner, K
   Head, E
   Feldman, DS
   Elton, TS
AF Kuhn, Donald E.
   Nuovo, Gerard J.
   Martin, Mickey M.
   Malana, Geraldine E.
   Pleister, Adam P.
   Jiang, Jinmai
   Schmittgen, Thomas D.
   Terry, Alvin V., Jr.
   Gardiner, Katheleen
   Head, Elizabeth
   Feldman, David S.
   Elton, Terry S.
TI RETRACTED: Human chromosome 21-derived miRNAs are overexpressed in down
   syndrome brains and hearts (Retracted article. See vol. 436, pg. 564,
   2013)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE down syndrome; microRNA; microRNA profiling; RT-PCR; in situ
   hybridization; cardiac; brain
ID GENE-EXPRESSION; CRITICAL REGION; UP-REGULATION; IN-VIVO; MICRORNA;
   PHENOTYPES; MECHANISM; PROTEINS; BINDING; TARGET
AB Down syndrome (DS), or Trisomy 21, is the most common genetic cause of cognitive impairment and congenital heart defects in the human population. To date, the contribution of microRNAs (miRNAs) in DS has not been investigated. Bioinformatic analyses demonstrate that human chromosome 21 (Hsa21) harbors five miRNA genes; miR-99a, let-7c, miR-125b-2, miR-155, and miR-802. MiRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrate that these miRNAs are overexpressed in fetal brain and heart specimens from individuals with DS when compared with age- and sex-matched controls. We hypothesize that trisomic 21 gene dosage overexpression of Hsa21-derived miRNAs results in the decreased expression of specific target proteins and contribute, in part, to features of the neuronal and cardiac DS phenotype. Importantly, Hsa21-derived miRNAs may provide novel therapeutic targets in the treatment of individuals with DS. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Feldman, David S.] Ohio State Univ, Dept Med, Div Cardiol, Columbus, OH 43210 USA.
   [Kuhn, Donald E.; Nuovo, Gerard J.; Martin, Mickey M.; Malana, Geraldine E.; Pleister, Adam P.; Feldman, David S.; Elton, Terry S.] Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
   [Nuovo, Gerard J.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA.
   [Jiang, Jinmai; Schmittgen, Thomas D.] Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA.
   [Elton, Terry S.] Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA.
   [Terry, Alvin V., Jr.] Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA.
   [Elton, Terry S.] Ohio State Univ, Dept Med, Div Cardiovasc Med, Columbus, OH 43210 USA.
   [Gardiner, Katheleen] Univ Colorado Denver, Dept Pediat, Aurora, CO 80045 USA.
   [Gardiner, Katheleen] Hlth Sci Ctr, Aurora, CO 80045 USA.
   [Head, Elizabeth] Univ Calif Irvine, Inst Brain Aging & Dementia, Dept Neurol, Gillespie Neurosci Facil 1259, Irvine, CA 92697 USA.
RP Feldman, DS (reprint author), Ohio State Univ, Dept Med, Div Cardiol, DHLRI 515,473 W 12th Ave, Columbus, OH 43210 USA.
EM david.feldman@osumc.edu
FU NHLBI NIH HHS [R01 HL048848, R01 HL084498, HL48848, R29 HL048848,
   HL084498, R01 HL084498-01A2]; NIA NIH HHS [AG21912, R01 AG021912]; NIEHS
   NIH HHS [ES012241, R01 ES012241]
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Elmen J, 2008, NUCLEIC ACIDS RES, V36, P1153, DOI 10.1093/nar/gkm1113
   EPSTEIN CJ, 1986, CONSEQUENCES CHROMOS
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Gardiner K, 2006, AM J MED GENET C, V142C, P196, DOI 10.1002/ajmg.c.30098
   HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034
   HOOK EG, 1982, ADV BIOMEDICINE BEHA, P11
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   LEJEUNE J, 1959, CR HEBD ACAD SCI, V248, P1721
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao R, 2003, GENOMICS, V81, P457, DOI 10.1016/S0888-7543(03)00035-1
   Martin MM, 2007, J BIOL CHEM, V282, P24262, DOI 10.1074/jbc.M701050200
   Martin MM, 2006, J BIOL CHEM, V281, P18277, DOI 10.1074/jbc.M601496200
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Nuovo GJ, 2008, METHODS, V44, P39, DOI 10.1016/j.ymeth.2007.10.008
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Olson LE, 2004, SCIENCE, V306, P687, DOI 10.1126/science.1098992
   Olson LE, 2007, HUM MOL GENET, V16, P774, DOI 10.1093/hmg/ddm022
   Roizen NJ, 2003, LANCET, V361, P1281, DOI 10.1016/S0140-6736(03)12987-X
   Sethupathy P, 2007, AM J HUM GENET, V81, P405, DOI 10.1086/519979
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   TAM W, 2001, GENE, V274, P57
   Wang Y, 2007, FRONT BIOSCI-LANDMRK, V12, P2316, DOI 10.2741/2234
NR 26
TC 117
Z9 127
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 6
PY 2008
VL 370
IS 3
BP 473
EP 477
DI 10.1016/j.bbrc.2008.03.120
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 298CT
UT WOS:000255664700018
PM 18387358
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Xiao, YA
   Fu, XK
   Sui, Y
   Wu, Q
   Xiong, SH
AF Xiao, Yi-An
   Fu, Xiang-Kai
   Sui, Yan
   Wu, Qing
   Xiong, Shao-Hui
TI RETRACTED:
   {mu-6,6'-Diethoxy-2,2'-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenol
   ato}-trinitratoholmium(III) nickel(II) (Retracted article. See vol. 66,
   pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Ni-II-Ho-III complex (systematic name: {mu-6,6'-diethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethyl idyne)]diphenolato-1 kappa O-4(1),O-1',O-6,O-6':2 kappa O-4(1),N,N',O-1'}trinitrato-1 kappa O-6,O'-holmium(III)nickel(II)), [HoNi(C20H22N2O4)-(NO3)(3)], with the hexadentate Schiff base compartmental ligand N, N'-bis(3-ethoxysalicylidene)ethylenediamine (H2L), the Ho and Ni atoms are doubly bridged by two phenolate O atoms of the Schiff base ligand. The coordination of Ni is square-planar with the donor centers of two imine N atoms and two phenolate O atoms. The holmium( III) center has a tenfold coordination environment of O atoms, involving the phenolate O atoms, two ethoxy O atoms and two O atoms each from the three nitrates. Weak C - H center dot center dot center dot O and O center dot center dot center dot Ni [3.383 (4) angstrom] interactions generate a two-dimensional zigzag sheet.
C1 [Sui, Yan; Wu, Qing; Xiong, Shao-Hui] Jinggangshan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
   [Xiao, Yi-An] Jinggangshan Univ, Coll Life Sci, Jian 343009, Jiangxi, Peoples R China.
   [Fu, Xiang-Kai] Southwest Univ, Coll Chem & Chem Engn, Chongqing 400715, Peoples R China.
RP Sui, Y (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUK AXS INC, 2004, APEX2 SADABS
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2008, PUBLCIF UNPUB
NR 9
TC 2
Z9 2
U1 3
U2 14
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUN
PY 2008
VL 64
BP M806
EP U689
DI 10.1107/S1600536808013755
PN 6
PG 13
WC Crystallography
SC Crystallography
GA 309DP
UT WOS:000256441200062
PM 21202492
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xiao, YA
   Sui, Y
   Yi, XG
   Wu, JH
   Zhang, LP
AF Xiao, Yi-An
   Sui, Yan
   Yi, Xiu-Guang
   Wu, Jian-Hong
   Zhang, Li-Ping
TI RETRACTED: {mu-6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato}-mu-nitrato-dinit
   ratoholmium(III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn(II)-Ho(III) complex (systematic name: {mu-6,6'-dimethoxy-2,20-[ethane-1,2-diylbis(nitrilomethylidyne)] diphenolato-1 kappa(4)O(1),O(1)',O(6),O(6)':2 kappa(4) O(1), N, N', O(1)')-mu-nitrato- 1:2 kappa(2)O:O'-dinitrato-1 kappa(4)O,O'-holmium(III)zinc(II)), [HoZn(C(18)H(18)N(2)O(4))(NO(3))(3)], with the hexadentate Schiff base compartmental ligand N, N'-bis(3-methoxysalicylidene) ethylenediamine (H(2)L), the Ho and Zn atoms are triply bridged by two phenolate O atoms of the Schiff base ligand and one nitrate ion. The five-coordinate Zn atom is in a square-pyramidal geometry with the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Ho III center has a ninefold coordination environment of O atoms, involving the phenolate O atoms, two methoxy O atoms, two O atoms from two nitrate ions and one from the bridging nitrate ion. Weak intermolecular C-H center dot center dot center dot O interactions generate a two-dimensional double-layer structure.
C1 [Sui, Yan; Yi, Xiu-Guang; Wu, Jian-Hong; Zhang, Li-Ping] Jinggangshan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
   [Xiao, Yi-An] Jinggangshan Univ, Coll Life Sci, Jian 343009, Jiangxi, Peoples R China.
RP Sui, Y (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
FU NCCIH NIH HHS [R21 AT002567]
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUK AXS INC, 2004, APEX2 SADABS
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2008, PUBLCIF UNPUB
NR 9
TC 1
Z9 1
U1 3
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUN
PY 2008
VL 64
BP M804
EP U676
DI 10.1107/S1600536808013743
PN 6
PG 13
WC Crystallography
SC Crystallography
GA 309DP
UT WOS:000256441200061
PM 21202491
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Cai, LF
   Xu, CX
AF Cai, Longfei
   Xu, Chunxiu
TI RETRACTED: Simultaneous determination of trace iron and aluminum by
   catalytic spectrophotometry based on a novel oxidation reaction of
   xylene cyanol FF (Retracted article. See vol 25, pg 949, 2009)
SO ANALYTICAL SCIENCES
LA English
DT Article; Retracted Publication
ID HYDROGEN-PEROXIDE; VANADIUM; COPPER; NICKEL
AB A new, simple, sensitive and selective method for the simultaneous determination of trace iron and aluminum by catalytic spectrophotometry was presented, based on the catalytic effects of iron and aluminum on the discoloring reaction of xylene cyanol FF proceeded by hydrogen peroxide and potassium periodate in weak nitric acid medium. No catalytic effect was obtained in the presence of hydrogen peroxide or potassium periodate only. With the conditional rate constants determined in reaction systems catalyzed by Al or Fe only, the concentrations of Fe and Al in the samples can be calculated. The method was applied to the simultaneous determination of trace Fe and Al in tap water, lake water, river water and tea leaves without separation and preconcentration.
C1 [Cai, Longfei] Zhejiang Univ, Chem Expt Ctr, Inst Microanalyt Syst, Dept Chem, Hangzhou 310058, Peoples R China.
   [Xu, Chunxiu] Hanshan Normal Univ, Dept Chem, Chaozhou 521041, Peoples R China.
RP Cai, LF (reprint author), Zhejiang Univ, Chem Expt Ctr, Inst Microanalyt Syst, Dept Chem, Zijingang Campus, Hangzhou 310058, Peoples R China.
EM cif-123@tom.com
CR BLANCO M, 1993, TALANTA, V40, P261, DOI 10.1016/0039-9140(93)80332-L
   CAI LF, 2004, CHIN J ANAL LAB, V23, P50
   DENG LP, 2000, CHIN J ANAL LAB, V19, P67
   DONG DF, 1994, ROCK MIN ANAL, V13, P41
   Du B, 2007, J ANAL CHEM+, V62, P794, DOI 10.1134/S1061934807080175
   FU KJ, 1995, HUMAN VITAL ELEMENTS
   FUKASAWA T, 1986, MIKROCHIM ACTA, V3, P71
   Gong RM, 2003, MICROCHIM ACTA, V143, P53, DOI 10.1007/s00604-003-0036-y
   HOSSEIN T, 1998, TALANTA, V47, P479
   HU LF, 2001, METALL ANAL, V21, P57
   JIANG GB, 2004, PRETREATMENT ENV SAM
   Khuhawar MY, 1996, J CHROMATOGR A, V740, P296, DOI 10.1016/0021-9673(96)00227-0
   Kumar TNK, 2003, ANAL BIOANAL CHEM, V376, P1126, DOI 10.1007/s00216-003-2023-x
   LI HZ, 1994, SPECTROSC SPECT ANAL, V14, P79
   LIU HW, 1994, SPECTROSC SPEC ANAL, V14, P89
   Mohamed AA, 2001, ANAL SCI, V17, P769, DOI 10.2116/analsci.17.769
   Mutaftchiev KL, 2006, CHEM PAP-CHEM ZVESTI, V60, P279, DOI 10.2478/s11696-006-0048-2
   RUAN YP, 1995, J XIAMEN U NAT SCI E, V34, P582
   Sikalos TS, 2000, MIKROCHIM ACTA, V135, P197, DOI 10.1007/s006040070011
   TAKATSU A, 1995, CHROMATOGRAPHIA, V40, P125, DOI 10.1007/BF02272158
   WANG C, 1998, ENVIRON CHEM, V17, P508
   Wang KY, 2004, TREE PHYSIOL, V24, P19, DOI 10.1093/treephys/24.1.19
   Wrobel K, 2000, BIOL TRACE ELEM RES, V78, P271, DOI 10.1385/BTER:78:1-3:271
   YANG GY, 1994, SPECTROSC SPEC ANAL, V14, P91
   YU JH, 2000, CHIN J ANAL LAB, V19, P50
   Zhu WF, 2001, CHINESE J ORG CHEM, V21, P49
NR 26
TC 1
Z9 1
U1 5
U2 24
PU JAPAN SOC ANALYTICAL CHEMISTRY
PI TOKYO
PA 26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN
SN 0910-6340
EI 1348-2246
J9 ANAL SCI
JI Anal. Sci.
PD JUN
PY 2008
VL 24
IS 6
BP 775
EP 778
DI 10.2116/analsci.24.775
PG 4
WC Chemistry, Analytical
SC Chemistry
GA 313CY
UT WOS:000256719900015
PM 18544868
OA Bronze
DA 2018-12-27
ER

PT J
AU Ni, ZM
   Xing, FF
   Wang, P
   Cao, GT
AF Ni, Zheming
   Xing, Fangfang
   Wang, Ping
   Cao, Genting
TI RETRACTED: Synthesis, characterization and release of
   curcumin-intercalated Mg-Al-layered double hydroxides (Retracted
   article. See vol. 47, pg. 469, 2010)
SO APPLIED CLAY SCIENCE
LA English
DT Article; Retracted Publication
DE layered double hydroxides; curcumin; drug-inorganic composite;
   intercalation; release
ID IN-VITRO RELEASE; EXCHANGE INTERCALATION; LIPID-PEROXIDATION;
   INHIBITION; ANIONS; DRUG
AB A drug-inorganic clay composite involving a pharmaceutically active compound curcumin (Cur) intercalated Mg-Al layered double hydroxides (Cur-LDHs) with Mg/Al = 3 has been assembled by co-precipitation and ion-exchange methods. Powder X-ray diffraction (XRD) and Fourier transform infrared spectra (FT-IR) analysis indicate a successful intercalation of Cur between the layers with monolayer horizontal (parallel to the layer) and vertical (perpendicular to the layer) orientations of Cur anion. (TGDTA) analyses shows that the thermal stability of intercalated organic species is largely enhanced due to host-guest interaction involving the hydrogen bond compared to pure form before intercalation. The release studies show that release percentages decrease with increasing pH from 4.0 to 6.5 due to possible change of release mechanism during the release process. The kinetic simulation for the release data indicates that the dissolution mechanism is mainly responsible for the release behavior of Cur-LDHs at pH 4.0, while the ion-exchange one is responsible for that at pH 6.5. It suggests that layered double hydroxides may have application as the basis of a novel tunable drug delivery system. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Wang, Ping] Zhejiang Univ Technol, Coll Pharm, Hangzhou 310014, Peoples R China.
   [Cao, Genting] Zhejiang Ocean Univ, Marine Sci & Technol Coll, Zhoushan 316004, Peoples R China.
EM jchx@zjut.edu.cn
RI Wang, Ping/G-3502-2011; Ni, Zheming/H-3439-2011
CR AMBROGI V, 2002, AAPS PHARMSCITECH, V3
   ARCO M, 2004, J SOLID STATE CHEM, V177, P3954
   BALASUBRAMANIAN K, 1991, INDIAN J CHEM A, V30, P61
   BHASKAR R, 1986, INT J PHARM, V28, P59, DOI 10.1016/0378-5173(86)90147-X
   bin Hussein MZ, 2002, J CONTROL RELEASE, V82, P417, DOI 10.1016/S0168-3659(02)00172-4
   Cavani F, 1991, CATAL TODAY, V11, P173, DOI 10.1016/0920-5861(91)80068-K
   Choy JH, 2001, J MATER CHEM, V11, P1671, DOI 10.1039/b008680k
   Costantino U, 2001, LAYERED DOUBLE HYDRO, P383
   Del Arco M, 2004, J PHARM SCI-US, V93, P1649, DOI 10.1002/jps.20054
   Fogg AM, 1998, CHEM MATER, V10, P356, DOI 10.1021/cm970553h
   Fogg AM, 1998, CHEM MATER, V10, P351, DOI 10.1021/cm9705202
   HUANG MT, 1991, CANCER RES, V51, P813
   JANKUN ES, 2000, INT J MOL MED, V6, P521
   Khan AI, 2002, J MATER CHEM, V12, P3191, DOI 10.1039/b204076j
   Li BX, 2004, APPL CLAY SCI, V27, P199, DOI 10.1016/j.clay.2004.07.02
   Lopes WA, 2001, NATURE, V414, P735, DOI 10.1038/414735a
   MARGARITA BP, 2004, SPECTROCHIM ACTA A, V60, P1091
   Meng JH, 2005, CHINESE SCI BULL, V50, P745, DOI 10.1360/982004-212
   Nakayama H, 2004, INT J PHARM, V269, P469, DOI 10.1016/j.ijpharm.2003.09.043
   Newman SP, 1998, NEW J CHEM, V22, P105, DOI 10.1039/a708319j
   Nurfina AN, 1997, EUR J MED CHEM, V32, P321, DOI 10.1016/S0223-5234(97)89084-8
   Rives V, 1999, COORDIN CHEM REV, V181, P61, DOI 10.1016/S0010-8545(98)00216-1
   RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J
   Sreejayan N, 1997, INT J PHARM, V151, P127, DOI 10.1016/S0378-5173(97)04900-4
   Tang B, 2002, J AGR FOOD CHEM, V50, P1355, DOI 10.1021/jf0111965
   Tronto J, 2004, J PHYS CHEM SOLIDS, V65, P475, DOI 10.1016/j.jpcs.2003.09.019
   Tsonko M. K., 2005, INT J QUANTUM CHEM, V102, P1069
   Tyner KM, 2004, J CONTROL RELEASE, V95, P501, DOI 10.1016/j.jconrel.2003.12.027
   Venkatesan P, 2000, J PHARM PHARMACOL, V52, P1123, DOI 10.1211/0022357001774886
   Wei M, 2005, J MATER CHEM, V15, P1197, DOI 10.1039/b416068a
   Whilton NT, 1997, J MATER CHEM, V7, P1623, DOI 10.1039/a701237c
   Zhang H, 2005, J SOLID STATE CHEM, V178, P3485, DOI 10.1016/j.jssc.2005.09.008
NR 32
TC 15
Z9 16
U1 5
U2 49
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-1317
EI 1872-9053
J9 APPL CLAY SCI
JI Appl. Clay Sci.
PD JUN
PY 2008
VL 40
IS 1-4
BP 72
EP 80
DI 10.1016/j.clay.2007.07.008
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary; Mineralogy
SC Chemistry; Materials Science; Mineralogy
GA 326DA
UT WOS:000257637000010
DA 2018-12-27
ER

PT J
AU Zhu, SJ
   Hou, HB
   Xue, YJ
AF Zhu, Shujing
   Hou, Haobo
   Xue, Yongjie
TI RETRACTED: Kinetic and isothermal studies of lead ion adsorption onto
   bentonite (Retracted article. See vol. 47, pg. 468, 2010)
SO APPLIED CLAY SCIENCE
LA English
DT Article; Retracted Publication
DE bentonite; lead; isothermal; kinetic; adsorption
ID AQUEOUS-SOLUTIONS; WASTE-WATER; METAL REMOVAL; HEAVY-METALS; SORPTION;
   EQUILIBRIUM; ZEOLITE; PALYGORSKITE; MECHANISMS; SEPIOLITE
AB The use of bentonite for the removal of Pb(II) from aqueous solutions for different contact times, pH of suspension, and initial concentration of Pb and particle sizes of absorbent was investigated. Batch adsorption kinetic experiments revealed that the adsorption of Pb(II) onto bentonite involved fast and slow processes. The adsorption mechanisms in the lead/bentonite system followed pseudo-second-order kinetics with a significant contribution of film diffusion. The adsorption isotherms were described by means of the Langmuir and Freundlich isotherms and the Langmuir model represented the adsorption process better than the Freundlich model. The maximum adsorption capacity of Pb(II) onto natural bentonite was 78.82 mg g(-1). (C) 2007 Elsevier B.V. All fights reserved.
C1 [Zhu, Shujing; Hou, Haobo; Xue, Yongjie] Wuhan Univ, Wuhan, Peoples R China.
RP Zhu, SJ (reprint author), Wuhan Univ, Wuhan, Peoples R China.
EM tonnygoal@yahoo.com.cn
CR Alvarez-Ayuso E, 2003, ENVIRON POLLUT, V125, P337, DOI 10.1016/S0269-7491(03)00121-0
   Baskaralingam P, 2006, J HAZARD MATER, V128, P138, DOI 10.1016/j.jhazmat.2005.07.049
   Bektas N, 2004, J HAZARD MATER, V112, P115, DOI 10.1016/j.jhazmat.2004.04.015
   Brown PA, 2000, WATER RES, V34, P3907, DOI 10.1016/S0043-1354(00)00152-4
   BURBA P, 1983, TALANTA, V30, P381, DOI 10.1016/0039-9140(83)80087-3
   BURRIEL F, 1989, QUIMICA ANAL CUALITA
   ESMAILI A, 2003, P 8 C ENV SCI TECHN, pB193
   GILES CH, 1960, J CHEM SOC, P3973, DOI 10.1039/jr9600003973
   Guibal E, 1998, IND ENG CHEM RES, V37, P1454, DOI 10.1021/ie9703954
   GUPTA SS, 2006, J COLLOID INTERF SCI, V295, P71
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Ibrahim KM, 2002, ENVIRON GEOL, V41, P547, DOI 10.1007/s002540100430
   Karabulut S, 2000, SEP PURIF TECHNOL, V18, P177, DOI 10.1016/S1383-5866(99)00067-2
   Lagergren S, 1898, KUNGLIGA SVENSKA VET, V24, P1, DOI DOI 10.1007/BF01501332
   Lin SH, 2000, J HAZARD MATER, V76, P139, DOI 10.1016/S0304-3894(00)00207-7
   Mier MV, 2001, WATER RES, V35, P373, DOI 10.1016/S0043-1354(00)00270-0
   Monser L, 2002, SEP PURIF TECHNOL, V26, P137, DOI 10.1016/S1383-5866(01)00155-1
   MOORE JW, 1994, HEAVY METALS NATURAL
   NAIDU VM, 1988, THESIS SRI VENKATESW
   Naseem R, 2001, WATER RES, V35, P3982, DOI 10.1016/S0043-1354(01)00130-0
   Ouki SK, 1999, WATER SCI TECHNOL, V39, P115, DOI 10.1016/S0273-1223(99)00260-7
   Pehlivan E, 2006, J HAZARD MATER, V135, P193, DOI 10.1016/j.jhazmat.2005.11.049
   Potgieter JH, 2006, MINER ENG, V19, P463, DOI 10.1016/j.mineng.2005.07.004
   RATHERZOHAR Y, 1983, SOIL SCI SOC AM J, V47, P1056
   REICHENBERG D, 1953, J AM CHEM SOC, V75, P589, DOI 10.1021/ja01099a022
   Sheta AS, 2003, MICROPOR MESOPOR MAT, V61, P127, DOI 10.1016/S1387-1811(03)00360-3
   Strawn DG, 1998, ENVIRON SCI TECHNOL, V32, P2596, DOI 10.1021/es980152i
   Turan M, 2005, CHEMOSPHERE, V60, P1487, DOI 10.1016/j.chemosphere.2005.02.036
   Wang SB, 2006, J COLLOID INTERF SCI, V295, P71, DOI 10.1016/j.jcis.2005.08.006
   Weber W J, 1963, J SANITARY ENGINEERI, V89, P31, DOI DOI 10.1016/J.DESAL.2010.08.036
NR 30
TC 42
Z9 49
U1 5
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-1317
EI 1872-9053
J9 APPL CLAY SCI
JI Appl. Clay Sci.
PD JUN
PY 2008
VL 40
IS 1-4
BP 171
EP 178
DI 10.1016/j.clay.2007.08.001
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Mineralogy
SC Chemistry; Materials Science; Mineralogy
GA 326DA
UT WOS:000257637000019
DA 2018-12-27
ER

PT J
AU Okawa, Y
   Hideshima, T
   Ikeda, H
   Raje, N
   Vallet, S
   Kiziltepe, T
   Yasui, H
   Enatsu, S
   Pozzi, S
   Breitkreutz, I
   Cirstea, D
   Santo, L
   Richardson, P
   Anderson, KC
AF Okawa, Yutaka
   Hideshima, Teru
   Ikeda, Hiroshi
   Raje, Noopur
   Vallet, Sonia
   Kiziltepe, Tanyel
   Yasui, Hiroshi
   Enatsu, Sotaro
   Pozzi, Samantha
   Breitkreutz, Iris
   Cirstea, Diana
   Santo, Loredana
   Richardson, Paul
   Anderson, Kenneth C.
TI RETRACTED: Fatty acid synthase is a novel therapeutic target in multiple
   myeloma (Retracted Article)
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article; Retracted Publication
DE multiple myeloma; fatty acid synthase; apoptosis; JNK
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; INDEPENDENT
   CELL-DEATH; BREAST-CANCER CELLS; RESISTANCE CAM-DR; N-TERMINAL KINASE;
   PROSTATE-CANCER; DAP-KINASE; C-JUN; ANTIBIOTIC CERULENIN
AB This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin triggered growth inhibition in both MM cell lines and MM patient cells, and overcame the survival and growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells. It induced apoptosis in MM cell lines with only modest activation of caspase -8, -9, -3 and PARP; moreover, the pan-caspase inhibitor Z-VAD-FMK did not inhibit Cerulenin-induced apoptosis and cell death. In addition, treatment of MM cells with Cerulenin primarily up-regulated apoptosis-inducing factor/endonuclease G, mediators of caspase-independent apoptosis. Importantly, Cerulenin induced endoplasmic reticulum stress response via up-regulation of the Grp78/IRE1 alpha/JNK pathway. Although the C-Jun-NH2-terminal kinase (JNK) inhibitor SP600215 blocked Cerulenin-induced cytotoxicity, it did not inhibit apoptosis and caspase cleavage. Furthermore, Cerulenin showed synergistic cytotoxic effects with various agents including Bortezomib, Melphalan and Doxorubicin. Our results therefore indicate that inhibition of FAS by Cerulenin primarily triggered caspase-independent apoptosis and JNK-dependent cytotoxicity in MM cells. This report demonstrated that inhibition of FAS has anti-tumour activity against MM cells, suggesting that it represents a novel therapeutic target in MM.
C1 [Okawa, Yutaka; Hideshima, Teru; Ikeda, Hiroshi; Raje, Noopur; Vallet, Sonia; Kiziltepe, Tanyel; Yasui, Hiroshi; Enatsu, Sotaro; Pozzi, Samantha; Breitkreutz, Iris; Cirstea, Diana; Santo, Loredana; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma,Dept Med Oncol, Boston, MA 02115 USA.
   [Okawa, Yutaka; Hideshima, Teru; Ikeda, Hiroshi; Raje, Noopur; Vallet, Sonia; Kiziltepe, Tanyel; Yasui, Hiroshi; Enatsu, Sotaro; Pozzi, Samantha; Breitkreutz, Iris; Cirstea, Diana; Santo, Loredana; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Myloma Ctr, Boston, MA 02115 USA.
   [Okawa, Yutaka] Jikei Univ, Dept Internal Med, Div Hematol & Oncol, Tokyo, Japan.
RP Anderson, KC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma,Dept Med Oncol, Mayer 557,44 Binney St, Boston, MA 02115 USA.
EM yutaka_okawa@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu
RI Pozzi, Samantha/A-7617-2012
OI Pozzi, Samantha/0000-0001-7917-1774
FU NCI NIH HHS [R01 CA050947, P01 CA078378]
CR Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002
   Ahn EY, 2004, J BIOL CHEM, V279, P5661, DOI 10.1074/jbc.M311040200
   Asturias FJ, 2005, NAT STRUCT MOL BIOL, V12, P225, DOI 10.1038/nsmb899
   Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197
   Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708
   Bialik S, 2004, SEMIN CANCER BIOL, V14, P283, DOI 10.1016/j.semcancer.2004.04.008
   Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x
   BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695
   Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Cox JS, 1997, MOL BIOL CELL, V8, P1805
   Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Damiano JS, 1999, BLOOD, V93, P1658
   Daugas E, 2000, FASEB J, V14, P729
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   De Schrijver E, 2003, CANCER RES, V63, P3799
   Gabrielson EW, 2001, CLIN CANCER RES, V7, P153
   Hayashi T, 2002, MOL CANCER THER, V1, P851
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   Heiligtag SJ, 2002, CELL DEATH DIFFER, V9, P1017, DOI 10.1038/sj.cdd.4401055
   Hideshima T, 2000, BLOOD, V96, P2943
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Ishitsuka K, 2005, ONCOGENE, V24, P5888, DOI 10.1038/sj.onc.1208739
   Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416
   Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x
   Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389
   Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758
   Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004
   Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006
   Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.CAN-03-3645
   Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673
   Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897
   Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Little JL, 2007, CANCER RES, V67, P1262, DOI 10.1158/0008-5472.CAN-06-1794
   Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514
   McCafferty-Grad J, 2003, MOL CANCER THER, V2, P1155
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115
   Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9
   Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664
   Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031
   Nakamura M, 2006, LEUKEMIA LYMPHOMA, V47, P531, DOI 10.1080/10428190500312196
   OMURA S, 1976, BACTERIOL REV, V40, P681
   Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766
   Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200
   Pizer ES, 1996, CANCER RES, V56, P745
   Pizer ES, 1996, CANCER RES, V56, P2745
   Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052
   Podar K, 2007, CANCER RES, V67, P1680, DOI 10.1158/0008-5472.CAN-06-1863
   Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood-2004-06-2281
   Richardson Paul, 2004, Curr Treat Options Oncol, V5, P227, DOI 10.1007/s11864-004-0014-6
   Rossi S, 2003, MOL CANCER RES, V1, P707
   Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136
   Swinnen JV, 2003, BIOCHEM BIOPH RES CO, V302, P898, DOI 10.1016/S0006-291X(03)00265-1
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   van der Sanden MHM, 2004, J BIOL CHEM, V279, P52007, DOI 10.1074/jbc.M405577200
   VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443
   WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001
   Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JC126373
   Yamamoto M, 2002, EUR J BIOCHEM, V269, P139, DOI 10.1046/j.0014-2956.2002.00029.x
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.006
NR 73
TC 23
Z9 23
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUN
PY 2008
VL 141
IS 5
BP 659
EP 671
DI 10.1111/j.1365-2141.2008.07114.x
PG 13
WC Hematology
SC Hematology
GA 297UU
UT WOS:000255643700011
PM 18410446
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ghosh, A
   Das, PK
AF Ghosh, Arpita
   Das, P. K.
TI RETRACTED: Generation of a superposition of coherent states in a
   resonant cavity and its nonclassicality and decoherence (Retracted
   article. See vol. 92, pg. 1283, 2014)
SO CANADIAN JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
ID PHOTON STATISTICS; SQUEEZED STATES; QUANTUM; FIELD; PHASE; EVEN
AB We discuss nonclassicality of a superposition of coherent states in terms of sub-Poissonian photon statistics as well as the negativity of the Wigner function. We derive an analytic expression for the Wigner function from which we find that the function has some negative region in phase space. We obtain a compact form of the Wigner function when decoherence occurs and study the effect of decoherence on the state. We demonstrate the behavior of the nonclassicality indicator.
C1 [Ghosh, Arpita; Das, P. K.] Indian Stat Inst, Phys & Appl Math Unit, Kolkata 700108, India.
RP Das, PK (reprint author), Indian Stat Inst, Phys & Appl Math Unit, 203 BT Rd, Kolkata 700108, India.
EM daspk@isical.ac.in
CR Agarwal GS, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.053813
   Auffeves A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.230405
   Bartlett SD, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevB.65.042304
   Bouwmeester D., 2000, PHYS QUANTUM INFORM
   Browne DE, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.062320
   Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887
   BUZEK V, 1992, PHYS REV A, V45, P6570, DOI 10.1103/PhysRevA.45.6570
   Davidovich L, 1996, PHYS REV A, V53, P1295, DOI 10.1103/PhysRevA.53.1295
   DODONOV VV, 1974, PHYSICA, V72, P597, DOI 10.1016/0031-8914(74)90215-8
   EISELT J, 1989, OPT COMMUN, V72, P351, DOI 10.1016/0030-4018(89)90438-0
   Giedke G, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.032316
   Kenfack A, 2004, J OPT B-QUANTUM S O, V6, P396, DOI 10.1088/1464-4266/6/10/003
   LEE CT, 1990, PHYS REV A, V42, P1608, DOI 10.1103/PhysRevA.42.1608
   Li SB, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.045801
   Liu XM, 2003, PHYS LETT A, V317, P210, DOI 10.1016/j.physleta.2003.08.048
   MANDEL L, 1979, OPT LETT, V4, P205, DOI 10.1364/OL.4.000205
   MANDEL L, 1986, PHYS SCRIPTA, VT12, P34, DOI 10.1088/0031-8949/1986/T12/005
   MOYACESSA H, 1993, PHYS REV A, V48, P2479, DOI 10.1103/PhysRevA.48.2479
   Nha H, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.020401
   Ottaviani C, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.197902
   Pathak PK, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.043823
   Raimond JM, 1997, PHYS REV LETT, V79, P1964, DOI 10.1103/PhysRevLett.79.1964
   SCLEICH PW, 2001, QUANTUM OPTICS PHASE
   SLUSHER RE, 1985, PHYS REV LETT, V55, P2409, DOI 10.1103/PhysRevLett.55.2409
   TARA K, 1993, PHYS REV A, V47, P5024, DOI 10.1103/PhysRevA.47.5024
   TITULAER UM, 1965, PHYS REV, V140, pB676, DOI 10.1103/PhysRev.140.B676
   van Enk SJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.017902
   WITSCHEL W, 1981, INT J QUANTUM CHEM, V20, P1233, DOI 10.1002/qua.560200608
   YURKE B, 1986, PHYS REV LETT, V57, P13, DOI 10.1103/PhysRevLett.57.13
   Zeng R, 2007, OPT COMMUN, V271, P162, DOI 10.1016/j.optcom.2006.10.032
   Zurek WH, 2001, NATURE, V412, P712, DOI 10.1038/35089017
NR 31
TC 6
Z9 6
U1 3
U2 10
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4204
EI 1208-6045
J9 CAN J PHYS
JI Can. J. Phys.
PD JUN
PY 2008
VL 86
IS 6
BP 811
EP 818
DI 10.1139/P08-013
PG 8
WC Physics, Multidisciplinary
SC Physics
GA 330ZD
UT WOS:000257980500006
DA 2018-12-27
ER

PT J
AU Kanno, R
   Janakiraman, H
   Kanno, M
AF Kanno, Rieko
   Janakiraman, Harinarayanan
   Kanno, Masamoto
TI RETRACTED: Epigenetic regulator polycomb group protein complexes control
   cell fate and cancer (Retracted Article. See vol 99, pg 2547, 2008)
SO CANCER SCIENCE
LA English
DT Review; Retracted Publication
ID HISTONE METHYLTRANSFERASE ACTIVITY; AGGRESSIVE BREAST-CANCER; TRITHORAX
   GROUP PROTEINS; HOX GENE-EXPRESSION; INK4A-ARF LOCUS; X-INACTIVATION; H3
   LYSINE-27; TRANSCRIPTIONAL REPRESSOR; H2A UBIQUITINATION; H3K27
   DEMETHYLASES
AB The chromatin-associated Polycomb group (PcG) proteins were first identified in genetic screens for homeotic transformations in Drosophila melanogaster. Besides body patterning, members of the PcG are now known to regulate epigenetic cellular memory, stem cell self-renewal, and cancer development. Here, we discuss the multifarious functions of the PcG family, isoforms of protein complexes, and its enzymatic activities, for example histone methylation, links to DNA methylation, its phosphorylation status, H2A mono-ubiquitination, SUMOylation, and links to non-coding RNA. We also discuss the function of cytosolic PcG complexes as a regulator of receptor-induced actin polymerization and proliferation in a methylation-dependent manner. We propose that the functional versatility of PcG protein complexes contributed significantly to the complexity of heritable gene repression mechanisms, signal transduction, and cell proliferation in cancer development.
C1 [Kanno, Rieko; Janakiraman, Harinarayanan; Kanno, Masamoto] Hiroshima Univ, Dept Immunol, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan.
RP Kanno, M (reprint author), Hiroshima Univ, Dept Immunol, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM mkanno@hiroshima-u.ac.jp
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Akasaka T, 1996, DEVELOPMENT, V122, P1513
   Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6
   Akasaka T, 2001, DEVELOPMENT, V128, P1587
   Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bea S, 2001, CANCER RES, V61, P2409
   Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006
   Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chanvivattana Y, 2004, DEVELOPMENT, V131, P5263, DOI 10.1242/dev.01400
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632
   Eissenberg JC, 2001, GENE, V275, P19, DOI 10.1016/S0378-1119(01)00628-X
   Elderkin S, 2007, MOL CELL, V28, P107, DOI 10.1016/j.molcel.2007.08.009
   Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.110503
   Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576
   Fujisaki S, 2003, BIOCHEM BIOPH RES CO, V300, P135, DOI 10.1016/S0006-291X(02)02791-2
   Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Gunster MJ, 2001, J CELL BIOCHEM, P129, DOI 10.1002/jcb.1093
   Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447
   Hall TMT, 2005, CURR OPIN STRUC BIOL, V15, P367, DOI 10.1016/j.sbi.2005.04.004
   HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A
   Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kagey MH, 2005, EMBO J, V24, P108, DOI 10.1038/sj.emboj.7600506
   Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4
   KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x
   Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445
   Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802
   Kim SY, 2006, DEVELOPMENT, V133, P4957, DOI 10.1242/dev.02677
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kohler C, 2003, GENE DEV, V17, P1540, DOI 10.1101/gad.257403
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lee N, 2005, NATURE, V438, P234, DOI 10.1038/nature04120
   Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385
   Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007
   Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002
   Makarevich G, 2006, EMBO REP, V7, P947, DOI 10.1038/sj.embor.7400760
   Martinez AM, 2006, CELL CYCLE, V5, P1189, DOI 10.4161/cc.5.11.2781
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Mimori K, 2005, EJSO, V31, P376, DOI 10.1016/j.ejso.2004.11.001
   Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603
   Nekrasov M, 2005, EMBO REP, V6, P348, DOI 10.1038/sj.embor.7400376
   Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X
   Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004
   Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096
   Sawa M, 2005, INT J HEMATOL, V82, P42, DOI 10.1532/IJH97.05013
   Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187
   Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrcd1991
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883
   Sung SB, 2004, CURR OPIN PLANT BIOL, V7, P4, DOI 10.1016/j.pbi.2003.11.010
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5
   Tie F, 2007, MOL CELL BIOL, V27, P2014, DOI 10.1128/MCB.01822-06
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9
   VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x
   Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200
   Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100
   Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Weikert S, 2005, INT J MOL MED, V16, P349
   Wiederschain D, 2007, MOL CELL BIOL, V27, P4968, DOI 10.1128/MCB.02244-06
   Wutz A, 2007, TRENDS GENET, V23, P457, DOI 10.1016/j.tig.2007.07.004
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zhang H, 2004, MOL CELL, V14, P841, DOI 10.1016/j.molcel.2004.06.001
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 99
TC 19
Z9 20
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD JUN
PY 2008
VL 99
IS 6
BP 1077
EP 1084
DI 10.1111/j.1349-7006.2008.00797.x
PG 8
WC Oncology
SC Oncology
GA 301OT
UT WOS:000255906200002
PM 18422744
OA Bronze
DA 2018-12-27
ER

PT J
AU Okada, M
   Takezawa, SI
   Mezaki, Y
   Yamaoka, I
   Takada, I
   Kitagawa, H
   Kato, S
AF Okada, Maiko
   Takezawa, Shin-ichiro
   Mezaki, Yoshihiro
   Yamaoka, Ikuko
   Takada, Ichiro
   Kitagawa, Hirochika
   Kato, Shigeaki
TI RETRACTED: Switching of chromatin-remodelling complexes for oestrogen
   receptor-alpha (Retracted Article)
SO EMBO REPORTS
LA English
DT Article; Retracted Publication
DE oestrogen receptor; cell cycle; chromatin-remodelling complex
ID NUCLEAR RECEPTOR; TRANSCRIPTIONAL REPRESSION; HISTONE METHYLATION;
   DIOXIN RECEPTOR; DISPLACEMENT; ASSOCIATION; EXPRESSION; COMPONENTS;
   PROMOTERS
AB The female sex steroid hormone oestrogen stimulates both cell proliferation and cell differentiation in target tissues. These biological actions are mediated primarily through nuclear oestrogen receptors (ERs). The ligand-dependent transactivation of ERs requires several nuclear co-regulator complexes; however, the cell-cycle-dependent associations of these complexes are poorly understood. By using a synchronization system, we found that the transactivation function of ER alpha at G2/M was lowered. Biochemical approaches showed that ER alpha associated with two discrete classes of ATP-dependent chromatin-remodelling complex in a cell-cycle-dependent manner. The components of the NuRD-type complex were identified as G2/M-phase-specific ER alpha co-repressors. Thus, our results indicate that the transactivation function of ER alpha is cell-cycle dependent and is coupled with a cell-cycle-dependent association of chromatin-remodelling complexes.
C1 [Okada, Maiko; Takezawa, Shin-ichiro; Mezaki, Yoshihiro; Yamaoka, Ikuko; Takada, Ichiro; Kitagawa, Hirochika; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   [Takezawa, Shin-ichiro; Yamaoka, Ikuko; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Baumann C, 2007, CELL, V128, P101, DOI 10.1016/j.cell.2006.11.041
   Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3
   Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853
   Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030
   Hill Stephen J., 2001, Current Opinion in Pharmacology, V1, P526, DOI 10.1016/S1471-4892(01)00091-1
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   MANAVATHI M, 2007, NUCL RECEPT SIGNAL, V5, P1
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200
   MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30
   Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023
   Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418
   Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x
   Narayanan R, 2005, MOL CELL BIOL, V25, P2885, DOI 10.1128/MCB.25.8.2885-2898.2005
   Nuthall HN, 2002, J BIOL CHEM, V277, P51049, DOI 10.1074/jbc.M111660200
   Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005
   Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5
   Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548
   Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892
   Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
NR 36
TC 21
Z9 22
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD JUN
PY 2008
VL 9
IS 6
BP 563
EP 568
DI 10.1038/embor.2008.55
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 307GW
UT WOS:000256308400017
PM 18451880
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Rosenthal, J
AF Rosenthal, Josh
TI RETRACTED: Hangin' on the Bowery: Observations on the accomplishment of
   authenticity at CBGB' (vol 9, pg 139, 2008) (Retracted article. See vol.
   9, pg. 415, 2008)
SO ETHNOGRAPHY
LA English
DT Correction; Retracted Publication
CR ROSENTHAL J, 2008, ETHNOGRAPHY, V9, P139
NR 1
TC 0
Z9 0
U1 2
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1466-1381
EI 1741-2714
J9 ETHNOGRAPHY
JI Ethnography
PD JUN
PY 2008
VL 9
IS 2
DI 10.1177/1466138108089466
PG 1
WC Anthropology; Sociology
SC Anthropology; Sociology
GA 537MG
UT WOS:000273116400001
DA 2018-12-27
ER

PT J
AU Li, Z
   Xia, F
   Zhang, YQ
AF Li, Zhen
   Xia, Feng
   Zhang, Yuanqiang
TI RETRACTED: Polarized release of RANTES by cytotoxic T cells paints tumor
   targets and enhances apoptotic cell removal (Retracted Article. See vol
   22, pg 3409, 2008)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE chemokine; macrophage; phagocytosis
ID IN-VIVO; CHEMOKINE RECEPTORS; EFFECTOR-CELLS; OLIGOMERIZATION;
   EXPRESSION; GENE; ANTAGONISTS; DEATH
AB The release of regulated on activation normal T-cell expressed and secreted (RANTES) from CD8 + lymphocytes has been shown to be dependent on T-cell receptor triggering by major histocompatability complex class I/peptide complex engagement. We characterized the secretion of RANTES by human leukocyte antigen-A2-restricted tyrosinase-specific cytotoxic T lymphocyte (CTL) in the context of human melanoma cell killing. CTL contact with tumor cell targets elicited a vectorial release of the chemokine RANTES resulting in the selective deposition of RANTES on target cells but not on nontarget bystander cells or the CTL. RANTES on the surface of apoptotic cells enhanced their phagocytosis by murine macrophages. This effect appeared unique to RANTES as the related chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and monocyte chemoattractant protein-1 did not significantly affect uptake and were mediated through chemokine receptor CCR1. Oligomerization of RANTES, at least at the level of a tetramer, was required for the enhanced phagocytosis. These results suggest that the role of RANTES in inflammatory disorders might not be restricted to inducing leukocyte infiltration but could also extend to potent macrophage modulation, directly regulating inflammation.
C1 [Li, Zhen; Zhang, Yuanqiang] Fourth Mil Med Univ, Dept Histol & Embryol, Xian 710032, Shaanxi, Peoples R China.
   [Xia, Feng] Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
RP Zhang, YQ (reprint author), Fourth Mil Med Univ, Dept Histol & Embryol, 17 Changle W Rd, Xian 710032, Shaanxi, Peoples R China.
EM zhangyq@fmmu.edu.cn
CR Anders HJ, 2006, KIDNEY INT, V69, P29, DOI 10.1038/sj.ki.5000053
   Anders HJ, 2003, J IMMUNOL, V170, P5658, DOI 10.4049/jimmunol.170.11.5658
   BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902
   Baltus T, 2003, BLOOD, V102, P1985, DOI 10.1182/blood-2003-04-1175
   Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27
   Bouet-Toussaint F, 2003, CANCER IMMUNOL IMMUN, V52, P699, DOI 10.1007/s00262-003-0412-9
   Catalfamo M, 2004, IMMUNITY, V20, P219, DOI 10.1016/S1074-7613(04)00027-5
   Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077
   Fadok VA, 1999, J MAMMARY GLAND BIOL, V4, P203, DOI 10.1023/A:1011384009787
   Fessele S, 2002, TRENDS GENET, V18, P60, DOI 10.1016/S0168-9525(02)02591-X
   Henkart PA, 2004, ADV IMMUNOL, V83, P233
   Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s
   JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601
   Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X
   Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697
   Medof ME, 1996, FASEB J, V10, P574
   Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203
   Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227
   Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2
   Ortiz BD, 1997, IMMUNOL TODAY, V18, P468, DOI 10.1016/S0167-5699(97)01128-6
   Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   SCHALL TJ, 1988, J IMMUNOL, V141, P1018
   Swanson BJ, 2002, IMMUNITY, V17, P605, DOI 10.1016/S1074-7613(02)00456-9
   Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7
   vonLuettichau I, 1996, CYTOKINE, V8, P89, DOI 10.1006/cyto.1996.0012
   Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983
   Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129
   Weber C, 2001, BLOOD, V97, P1144, DOI 10.1182/blood.V97.4.1144
NR 30
TC 3
Z9 3
U1 4
U2 12
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2008
VL 22
IS 6
BP 1748
EP 1755
DI 10.1096/fj.07-101212RET
PG 8
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 307XK
UT WOS:000256352700015
PM 18198213
DA 2018-12-27
ER

PT J
AU Azizi, M
AF Azizi, Michel
TI RETRACTED: Direct renin inhibition: clinical pharmacology (Retracted
   article. See vol. 90, pg. 465, 2012)
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review; Retracted Publication
DE renin; inhibitor; pharmacology; hypertension
ID CONVERTING-ENZYME-INHIBITOR; ANGIOTENSIN RECEPTOR BLOCKER;
   ASPARTYL-LYSYL-PROLINE; BLOOD-PRESSURE; ANTIHYPERTENSIVE EFFICACY;
   ESSENTIAL-HYPERTENSION; DIABETES-MELLITUS; DOUBLE-BLIND; PHARMACOKINETIC
   INTERACTIONS; HEALTHY-VOLUNTEERS
AB Initial attempts to inhibit renin in humans have faced numerous difficulties. Molecular modeling and X-ray crystallography of the active site of renin have led to the development of new orally active renin inhibitors such as aliskiren. Aliskiren has a low bioavailality (2.6% to 5%) compensated by its high potency to inhibit renin and a long plasma half-life (24 to 40 h), which makes it suitable for once-daily dosing. The once-daily administration of aliskiren to hypertensive patients lowers blood pressure as strongly as standard doses of established AT1 receptor blockers (losartan, valsartan, and irbesartan), angiotensin-converting enzyme inhibitors (ramipril and lisnopril), hydrochlorothiazide, or long-acting calcium channel blockers (amlodipine). In combination therapy, aliskiren further decreases blood pressure when combined with either hydrochlorothiazide, amlodipine, valsartan, irbesartan, or ramipril. However, the biochemical consequences of renin inhibition differ from those of angiotensin I-converting enzyme inhibition and angiotensin II antagonism, particularly in terms of angiotensin profiles and interactions with the bradykinin-NO-cGMP pathway. Blockade of the renin-angiotensin system with angiotensin I-converting enzyme inhibitors, AT1 receptor blockers, or a combination of these drugs has become one of the most successful therapeutic approaches in medicine. However, it remains unclear how to optimize renin-angiotensin system blockade to maximize cardiovascular and renal benefits. In this context, renin inhibition to render the renin-angiotensin system fully quiescent is a new possibility requiring further study. Preliminary results show that short-term administration of aliskiren has beneficial antialbuminuric effects in diabetic patients with chronic nephropathy and favorable neurohormonal effects in patients with chronic heart failure.
C1 [Azizi, Michel] Univ Paris 05, Hop Europeen Georges Pompidou, Fac Med, AP HP,Clin Invest Ctr 9201, Paris, France.
RP Azizi, M (reprint author), Hop Europeen Georges Pompidou, Clin Invest Ctr 9201, 20-40 Rue Leblanc, F-75908 Paris, France.
EM michel.azizi@egp.aphp.fr
RI Azizi, Michel/L-3418-2013
CR Agodoa L, 2007, J HYPERTENS, V25, P951
   Aviv A, 2004, KIDNEY INT, V65, P361, DOI 10.1111/j.1523-1755.2004.00389.x
   Azizi M, 2006, J HYPERTENS, V24, P243, DOI 10.1097/01.hjh.0000202812.72341.99
   Azizi M, 2004, J AM SOC NEPHROL, V15, P3126, DOI 10.1097/01.ASN.0000146686.35541.29
   Azizi M, 2004, CIRCULATION, V109, P2492, DOI 10.1161/01.CIR.0000131449.94713.AD
   Azizi M, 1996, J CLIN INVEST, V97, P839, DOI 10.1172/JCI118484
   Azizi M, 2007, CLIN J AM SOC NEPHRO, V2, P947, DOI 10.2215/CJN.00360107
   Birkenhaeger WH, 2007, LANCET, V370, P195, DOI 10.1016/S0140-6736(07)61099-X
   CALHOUN D, 2006, J CLIN HYPERTENS SA, V8, pA77
   Campbell DJ, 2008, HYPERTENSION, V51, P15, DOI 10.1161/HYPERTENSIONAHA.107.101287
   Carey RM, 2003, ENDOCR REV, V24, P261, DOI 10.1210/er.2003-0001
   Danser AHJ, 2005, HYPERTENSION, V46, P1069, DOI 10.1161/01.HYP.0000186329.92187.2e
   DEGASPARO M, 1989, BRIT J CLIN PHARMACO, V27, P587
   Deinum J, 1999, DIABETOLOGIA, V42, P1006, DOI 10.1007/s001250051260
   DERKX FHM, 1992, J BIOL CHEM, V267, P22837
   Dieterle W, 2005, INT J CLIN PHARM TH, V43, P527
   Dieterle W, 2004, BRIT J CLIN PHARMACO, V58, P433, DOI 10.1111/j.1365-2125.2004.02160.x
   Doulton TWR, 2005, HYPERTENSION, V45, P880, DOI 10.1161/01.HYP.0000161880.59963.da
   Dzau VJ, 2001, HYPERTENSION, V37, P1047, DOI 10.1161/01.HYP.37.4.1047
   Ferrario CM, 2006, HYPERTENSION, V47, P515, DOI 10.1161/01.HYP.0000196268.08909.fb
   Fisher ND, 2007, CIRCULATION, V116, P556
   FISHER NDL, 1995, CLIN PHARMACOL THER, V57, P342, DOI 10.1016/0009-9236(95)90160-4
   Fisher NDL, 2005, J AM SOC NEPHROL, V16, P592, DOI 10.1681/ASN.2004100874
   Frampton JE, 2007, DRUGS, V67, P1767, DOI 10.2165/00003495-200767120-00008
   GAVRAS H, 1981, LANCET, V2, P543
   Gradman AH, 2005, CIRCULATION, V111, P1012, DOI 10.1161/01.CIR.0000156466.02908.ED
   GRADMAN AH, 2004, AM J HYPERTENS, V17, pS108
   Hollenberg NK, 2004, KIDNEY INT, V66, P1, DOI 10.1111/j.1523-1755.2004.00701.x
   Hollenberg NK, 2007, J HYPERTENS, V25, P1921, DOI 10.1097/HJH.0b013e328277596e
   Hollenberg NK, 2007, J RENIN-ANGIO-ALDO S, V8, P53, DOI 10.3317/jraas.2007.020
   Jordan J, 2007, HYPERTENSION, V49, P1047, DOI 10.1161/HYPERTENSIONAHA.106.084301
   Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135
   Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190
   LONDON GM, 1994, CIRCULATION, V90, P2786, DOI 10.1161/01.CIR.90.6.2786
   Lonn EM, 2001, CIRCULATION, V103, P919
   LUETSCHER JA, 1985, NEW ENGL J MED, V312, P1412, DOI 10.1056/NEJM198505303122202
   MACFADYEN RJ, 1995, J CARDIOVASC PHARM, V25, P347, DOI 10.1097/00005344-199503000-00001
   Marre M, 2004, BRIT MED J, V328, P495, DOI 10.1136/bmj.37970.629537.0D
   MENARD J, 1995, CIRCULATION, V91, P330, DOI 10.1161/01.CIR.91.2.330
   Menard J, 2006, J HYPERTENS, V24, P529, DOI 10.1097/01.hjh.0000209989.59230.2e
   Menard J, 2007, J HYPERTENS, V25, P1775
   Morgan T, 2002, AM J HYPERTENS, V15, P1003, DOI 10.1016/S0895-7061(02)03028-5
   Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276
   *NOV PHARM CORP, 2007, US PRESCR INF
   Nussberger J, 2002, HYPERTENSION, V39, pE1, DOI 10.1161/hy0102.102293
   O'Brien E, 2007, HYPERTENSION, V49, P276, DOI 10.1161/01.HYP.0000253780.36691.4f
   Oh BH, 2007, J AM COLL CARDIOL, V49, P1157, DOI 10.1016/j.jacc.2006.11.032
   Oparil S, 2007, LANCET, V370, P221, DOI 10.1016/S0140-6736(07)61124-6
   PARVING HH, 2007, ALISKIREN EVALUATION
   Peng HM, 2007, HYPERTENSION, V49, P695, DOI 10.1161/01.HYP.0000258406.66954.4f
   Pitt B, 2007, CIRCULATION, V116, P549
   Pool JL, 2007, AM J HYPERTENS, V20, P11, DOI 10.1016/j.amjhyper.2006.06.003
   Price DA, 1999, J AM SOC NEPHROL, V10, P2382
   Rahuel J, 2000, CHEM BIOL, V7, P493, DOI 10.1016/S1074-5521(00)00134-4
   Reudelhuber TL, 2006, HYPERTENSION, V47, P811, DOI 10.1161/01.HYP.0000209020.69734.73
   Rossing K, 2005, KIDNEY INT, V68, P1190, DOI 10.1111/j.1523-1755.2005.00511.x
   Schmieder RE, 2005, J AM SOC NEPHROL, V16, P3038, DOI 10.1681/ASN.2005020138
   Sealey JE, 2007, AM J HYPERTENS, V20, P587, DOI 10.1016/j.amjhyper.2007.04.001
   Staessen JA, 2006, LANCET, V368, P1449, DOI 10.1016/S0140-6736(06)69442-7
   Stanton A, 2003, HYPERTENSION, V42, P1137, DOI 10.1161/01.HYP.0000101688.17370.87
   Stergiou GS, 2005, J HYPERTENS, V23, P883, DOI 10.1097/01.hjh.0000163159.22116.ab
   Strasser RH, 2007, J HUM HYPERTENS, V21, P780, DOI 10.1038/sj.jhh.1002220
   Stubbs AJM, 2004, J RENIN-ANGIO-ALDO S, V5, P189, DOI 10.3317/jraas.2004.039
   Uresin Y, 2006, J HYPERTENS, V24, pS82
   Vaidyanathan S, 2006, INT J CLIN PRACT, V60, P1343, DOI 10.1111/j.1742-1241.2006.01164.x
   Vaidyanathan S, 2007, CLIN PHARMACOKINET, V46, P661, DOI 10.2165/00003088-200746080-00003
   Vaidyanathan S, 2007, J CLIN PHARMACOL, V47, P453, DOI 10.1177/0091270006297921
   Vaidyanathan S, 2007, J CLIN PHARMACOL, V47, P192, DOI 10.1177/009127006294404
   van Kesteren CAM, 1997, HYPERTENSION, V30, P1389, DOI 10.1161/01.HYP.30.6.1389
   Van Paassen P, 2000, J AM SOC NEPHROL, V11, P1813
   VANDENMEIRACKER AH, 1990, BRIT MED J, V301, P205, DOI 10.1136/bmj.301.6745.205
   Veniant M, 1996, J CLIN INVEST, V98, P1966, DOI 10.1172/JCI119000
   Villamil A, 2007, J HYPERTENS, V25, P217, DOI 10.1097/HJH.0b013e3280103a6b
   Waldmeier F, 2007, DRUG METAB DISPOS, V35, P1418, DOI 10.1124/dmd.106.013797
   Weir MR, 2007, J AM SOC HYPERTENS, V1, P264, DOI 10.1016/j.jash.2007.04.004
   Wood JM, 2003, BIOCHEM BIOPH RES CO, V308, P698, DOI 10.1016/S0006-291X(03)01451-7
   Yusuf S, 2002, AM J CARDIOL, V89, p18A
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
   Zhao Y, 2003, J NEUROCHEM, V85, P759, DOI 10.1046/j.1471-4159.2003.01719.x
NR 79
TC 18
Z9 18
U1 2
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-2716
J9 J MOL MED
JI J. Mol. Med.
PD JUN
PY 2008
VL 86
IS 6
BP 647
EP 654
DI 10.1007/s00109-008-0329-z
PG 8
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 299HO
UT WOS:000255746900008
PM 18368379
DA 2018-12-27
ER

PT J
AU Mohammadzadeh, A
   Heidari, M
   Soltanghoraee, H
   Jeddi-Tehrani, M
   Novin, MG
   Akhondi, MMA
   Zeraati, H
   Mohammadzadeh, F
AF Mohammadzadeh, Afsaneh
   Heidari, Mahnaz
   Soltanghoraee, Haleh
   Jeddi-Tehrani, Mahmood
   Novin, Marefat Ghaffari
   Akhondi, Mahammad Mahdi A.
   Zeraati, Hojjat
   Mohammadzadeh, Farzaneh
TI RETRACTED: Evaluation of the effect of pentoxifylline on white blood
   cell count in serum and peritoneal fluid in female rats with
   endometriosis (Retracted article. See vol. 38, pg. 1395, 2012)
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article; Retracted Publication
DE anti-tumor necrosis factor-alpha drugs; endometriosis; female rat;
   infertility; pentoxifylline; tumor necrosis factor-alpha
ID INFERTILE WOMEN; MODEL; IMMUNOMODULATION; INHIBITION; PLACEBO; DISEASE
AB Aim: Endometriosis is defined as the growth of endometrium outside of the uterus in ectopic places. Immune system disturbances have an important role in endometriosis which may lead to infertility. It seems that inflammatory cytokines, specially tumor necrosis factor-alpha (TNF-alpha), which are produced by activated macrophages, play an important role in the pathology of endometriosis. Based on this theory, anti-TNF-alpha drugs are suggested as new drugs for endometriosis. This experimental study has been performed on female rats to determine the effect of pentoxifylline on the white blood cell count in serum and peritoneal fluid.
   Methods: During the proestrous phase, one horn of the bicorn uterus of rats was removed surgically, and the endometrium implanted to different places as follows: subcutaneous, peritoneum and near the ovaries. After 2 months' observation, female rats were divided randomly into two groups. The treated group (n = 10) were given pentoxifylline (5 mg/kg twice a day), and the control group (n = 10) were given normal saline (the same dose), which was injected subcutaneously. Then via second laparotomy and in the same phase of the cycles, the size of implants and the white blood cell levels in the serum and peritoneum were measured.
   Results: In the treated group, the total implant mass (mm(2)) decreased significantly in the right subcutaneous (8.05 mm(2)vs 13.5 mm(2); P = 0.01), left subcutaneous (7.64 mm(2)vs 14.00 mm(2); P = 0.01), right ovary (6.64 mm(2)vs 15.22 mm(2); P = 0.001) and left ovary (7.18 mm(2)vs 14.56 mm(2); P = 0.005). The total white blood cell count (5254.5455 +/- 178.73 vs 15 833.33 +/- 259.27; P = 0.02) and neutrophils (297.34 +/- 57.34 vs 2736.00 +/- 346.75; P = < 0.001) in the serum were decreased and the total count of lymphocytes (4967.92 +/- 696.194 vs 13 048.33 +/- 178.73; P = 0.003) in serum was increased. There were not any significant changes in the total white blood cell count in the peritoneum in both groups. The number of estrous cycles in both groups was similar.
   Conclusion: Based on our study, pentoxifylline could decrease the size of endometrial implants, especially in the ovaries and subcutaneous areas, and total white blood cell count in serum. Pentoxifylline could increase the lymphocyte count and decrease the neutrophil count in serum, and because these changes it might alter the immune system. Pentoxifylline did not have any adverse effect on rats' cycles and a good aspect of treatment with pentoxifylline was achieved.
C1 [Mohammadzadeh, Afsaneh; Novin, Marefat Ghaffari; Akhondi, Mahammad Mahdi A.] Avesina Res Inst ACERCR, Reprod Biotechnol Res Ctr, Dept Reprod Endocrinol & Embryol, Tehran, Iran.
   [Heidari, Mahnaz] Avesina Res Inst ACERCR, Nanobiotechnol Res Ctr, Dept Nanotechnol, Tehran, Iran.
   [Soltanghoraee, Haleh] Avesina Res Inst ACERCR, Reprod Biotechnol Res Ctr, Dept Reprod & Biotechnol Genet, Tehran, Iran.
   [Jeddi-Tehrani, Mahmood] Avesina Res Inst ACERCR, Monoclonal Antibody Res Ctr, Dept Monoclonal Antibody, Tehran, Iran.
   [Zeraati, Hojjat] Univ Tehran, Dept Epidemiol & Biostat, Tehran, Iran.
   [Mohammadzadeh, Farzaneh] Iran Med Sci Univ, Dept Anat, Tehran, Iran.
RP Mohammadzadeh, A (reprint author), Avesina Infertil Ctr, Nyavaran St Next Shahrdari Clinc, Tehran, Iran.
EM af23mohammadzadeh@yahoo.com
OI Jeddi-Tehrani, Mahmood/0000-0002-8831-4711
CR Akande VA, 2004, HUM REPROD, V19, P96, DOI 10.1093/humrep/deh045
   Alborzi S, 2007, J MINIM INVAS GYN, V14, P54, DOI 10.1016/j.jmig.2006.06.024
   Balasch J, 1997, HUM REPROD, V12, P2046, DOI 10.1093/humrep/12.9.2046
   Berkkanoglu M, 2003, AM J REPROD IMMUNOL, V50, P48, DOI 10.1034/j.1600-0897.2003.00042.x
   Berkley KJ, 2001, NEUROSCI LETT, V306, P185, DOI 10.1016/S0304-3940(01)01906-1
   Bruner KL, 1997, J CLIN INVEST, V99, P2851, DOI 10.1172/JCI119478
   Denny E, 2006, J Obstet Gynaecol, V26, P501
   Gomez-Torres MJ, 2002, HUM REPROD, V17, P777, DOI 10.1093/humrep/17.3.777
   HANSEN AK, 2000, HDB LAB ANIMAL BACTE, P15
   Jerzak M, 2002, IMMUNOL LETT, V81, P65, DOI 10.1016/S0165-2478(01)00337-6
   Kyama Cleophas M, 2003, Reprod Biol Endocrinol, V1, P123, DOI 10.1186/1477-7827-1-123
   Maeda N, 2002, FERTIL STERIL, V77, P297, DOI 10.1016/S0015-0282(01)02964-8
   MAKSYMOWYCH WP, 1995, J RHEUMATOL, V22, P625
   Mohammadzadeh A., 2006, Iranian Journal of Reproductive Medicine, V4, P63
   NOTHNICK WB, 1994, AM J REPROD IMMUNOL, V31, P151, DOI 10.1111/j.1600-0897.1994.tb00860.x
   Nothnick WB, 2001, FERTIL STERIL, V76, P223, DOI 10.1016/S0015-0282(01)01878-7
   Reimund JM, 1997, GUT, V40, P475, DOI 10.1136/gut.40.4.475
   Richter O, 1998, Zentralbl Gynakol, V120, P332
   Sharpe-Timms KL, 2002, ANN NY ACAD SCI, V955, P318, DOI 10.1111/j.1749-6632.2002.tb02792.x
   STEINLEITNER A, 1991, FERTIL STERIL, V56, P975
   SULLIVAN GW, 1988, INFECT IMMUN, V56, P1722
   Tomassetti C, 2006, REPROD BIOMED ONLINE, V13, P58, DOI 10.1016/S1472-6483(10)62016-0
   VERNON MW, 1985, FERTIL STERIL, V44, P684
   WAGGIE K, 1996, MANUAL MICROBIOLOGIC, P59
   WARD A, 1987, DRUGS, V34, P50, DOI 10.2165/00003495-198734010-00003
NR 25
TC 4
Z9 6
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD JUN
PY 2008
VL 34
IS 3
BP 307
EP 313
DI 10.1111/j.1447-0756.2008.00745.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 312RC
UT WOS:000256687500003
PM 18686342
DA 2018-12-27
ER

PT J
AU Blanton, H
   Stapel, DA
AF Blanton, Hart
   Stapel, Diederik A.
TI RETRACTED: Unconscious and spontaneous and ... Complex: The three selves
   model of social comparison assimilation and contrast (Retracted article.
   See vol. 104, pg. 198, 2013)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE assimilation; contrast; possible selves; social comparison; social
   identity
ID IMPLICIT ASSOCIATION TEST; SELF-ESTEEM; IN-GROUP; PHYSICAL
   ATTRACTIVENESS; IMPRESSION-FORMATION; INFORMATION; JUDGMENTS;
   ACTIVATION; BEHAVIOR; TRAIT
AB Several theoretical perspectives predict that social comparisons lead to simple, default-driven effects when triggered outside of conscious awareness. These theoretical perspectives differ, however, in the default effects they predict. Some theories argue for self-evaluative contrast, whereas others argue for self-evaluative assimilation. The current studies tested the prediction that the default effect would vary as a function of the social context and the type of self-concept activated. When attention was focused on the personal self, contrast effects emerged. When attention was focused on collective or possible selves, assimilation effects emerged. These findings suggest that a wide range of comparison effects can be triggered spontaneously and outside of conscious awareness. However, some results also show ways in which social comparison processes simplify when deliberate reflection is lacking.
C1 [Blanton, Hart] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.
   [Stapel, Diederik A.] Tilburg Univ, TIBER, NL-5000 LE Tilburg, Netherlands.
RP Blanton, H (reprint author), Texas A&M Univ, Dept Psychol, 4235 TAMU, College Stn, TX 77843 USA.
EM hblanton@gmail.com; d.a.stapel@uvt.nl
CR ASPINWALL LG, 1993, J PERS SOC PSYCHOL, V64, P708, DOI 10.1037/0022-3514.64.5.708
   Baccus JR, 2004, PSYCHOL SCI, V15, P498, DOI 10.1111/j.0956-7976.2004.00708.x
   BARGH J A, 1989, P3
   Bargh JA, 1996, J PERS SOC PSYCHOL, V71, P230, DOI 10.1037/0022-3514.71.2.230
   BARGH JA, 1982, J PERS SOC PSYCHOL, V43, P437, DOI 10.1037/0022-3514.43.3.437
   BARGH JA, 1997, ADV SOC COG, V10, P1
   BIERNAT M, 1991, J PERS SOC PSYCHOL, V60, P485, DOI 10.1037/0022-3514.60.4.485
   Blanton H, 2006, J EXP SOC PSYCHOL, V42, P192, DOI 10.1016/j.jesp.2005.07.003
   Blanton H, 2002, J EXP SOC PSYCHOL, V38, P253, DOI 10.1006/jesp.2001.1510
   Blanton H, 2001, COGNITIVE SOCIAL PSYCHOLOGY, P75
   Blanton H, 2000, J EXP SOC PSYCHOL, V36, P519, DOI 10.1006/jesp.2000.1425
   BREWER MB, 1994, J PERS SOC PSYCHOL, V66, P268, DOI 10.1037/0022-3514.66.2.268
   Butler R, 2000, J PERS SOC PSYCHOL, V78, P965, DOI 10.1037//0022-3514.78.5.965
   Buunk B, 1997, HLTH COPING WELL BEI, P359
   CASH TF, 1983, PERS SOC PSYCHOL B, V9, P351, DOI 10.1177/0146167283093004
   Cheng RW, 2007, BRIT J EDUC PSYCHOL, V77, P197, DOI 10.1348/000709905X72795
   CROCKER J, 1990, J PERS SOC PSYCHOL, V58, P60, DOI 10.1037/0022-3514.58.1.60
   De Houwer J, 2006, HDB IMPLICIT COGNITI, P11, DOI DOI 10.4135/9781412976237.N2
   Deaux K, 1996, SOCIAL PSYCHOL HDB B
   DEVINE PG, 1989, J PERS SOC PSYCHOL, V56, P5, DOI 10.1037/0022-3514.56.5.680
   Dijksterhuis A, 2006, SCIENCE, V311, P1005, DOI 10.1126/science.1121629
   Dijksterhuis A, 2004, J PERS SOC PSYCHOL, V86, P345, DOI 10.1037/0022-3514.86.2.345
   DWECK CS, 1988, PSYCHOL REV, V95, P256, DOI 10.1037//0033-295X.95.2.256
   ERDLEY CA, 1993, CHILD DEV, V64, P863, DOI 10.2307/1131223
   Fazio RH, 2003, ANNU REV PSYCHOL, V54, P297, DOI 10.1146/annurev.psych.54.101601.145225
   Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202
   FOX R, 1992, PSYCHOL INQ, V3, P137
   Gardner WL, 2002, J PERS SOC PSYCHOL, V82, P239, DOI 10.1037//0022-3514.82.2.239
   Gawronski B, 2007, PERSPECT PSYCHOL SCI, V2, P181, DOI 10.1111/j.1745-6916.2007.00036.x
   Gawronski B, 2006, CONSCIOUS COGN, V15, P485, DOI 10.1016/j.concog.2005.11.007
   GILBERT DT, 1991, AM PSYCHOL, V46, P107, DOI 10.1037//0003-066X.46.2.107
   GILBERT DT, 1995, J PERS SOC PSYCHOL, V69, P227, DOI 10.1037/0022-3514.69.2.227
   Greenwald AG, 2000, J PERS SOC PSYCHOL, V79, P1022, DOI 10.1037//0022-3514.79.6.1022
   Gregg AP, 2006, J PERS SOC PSYCHOL, V90, P1, DOI 10.1037/0022-3514.90.1.1
   Gruder C. L., 1977, SOCIAL COMP PROCESSE, P21
   HERR PM, 1983, J EXP SOC PSYCHOL, V19, P323, DOI 10.1016/0022-1031(83)90026-4
   HIGGINS E T, 1989, P75
   Higgins ET, 1996, SOCIAL PSYCHOL HDB B, P133
   HONG Y, 1999, J INTERCULTURAL RELA, V23, P257
   KOOLE SL, 2000, POSITIVITY SELF EVAL
   LINDER DE, 1967, J PERS SOC PSYCHOL, V6, P245, DOI 10.1037/h0021220
   Lockwood P, 1997, J PERS SOC PSYCHOL, V73, P91, DOI 10.1037//0022-3514.73.1.91
   Lowery BS, 2001, J PERS SOC PSYCHOL, V81, P842, DOI 10.1037//0022-3514.81.5.842
   Macrae CN, 1998, SOC COGNITION, V16, P400, DOI 10.1521/soco.1998.16.4.400
   MAJOR B, 1993, PERS SOC PSYCHOL B, V19, P711, DOI 10.1177/0146167293196006
   Major B., 1991, SOCIAL COMP CONT THE, P237
   MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037//0003-066X.41.9.954
   MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037//0033-295X.98.2.224
   MARTIN LL, 1986, J PERS SOC PSYCHOL, V51, P493, DOI 10.1037/0022-3514.51.3.493
   MARTIN LL, 1990, J PERS SOC PSYCHOL, V59, P27, DOI 10.1037//0022-3514.59.1.27
   MARX DM, IN PRESS SOCIAL COGN
   MILLER DT, 1988, J PERS SOC PSYCHOL, V55, P908, DOI 10.1037/0022-3514.55.6.908
   MORSE S, 1970, J PERS SOC PSYCHOL, V16, P148, DOI 10.1037/h0029862
   Moskowitz GB, 1999, J PERS SOC PSYCHOL, V76, P911, DOI 10.1037/0022-3514.76.6.911
   MULLEN B, 1991, J EXP SOC PSYCHOL, V27, P297, DOI 10.1016/0022-1031(91)90028-5
   Mussweiler T, 2004, J EXP SOC PSYCHOL, V40, P689, DOI 10.1016/j.jesp.2004.01.004
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   Mussweiler T, 2002, J PERS SOC PSYCHOL, V82, P19, DOI 10.1037//0022-3514.82.1.19
   PARDUCCI A, 1990, PSYCHOL EXPLORATIONS, P94
   Pelham BW, 2002, J PERS SOC PSYCHOL, V82, P469, DOI 10.1037//0022-3514.82.4.469
   PELHAM BW, 1995, J PERS SOC PSYCHOL, V69, P825, DOI 10.1037//0022-3514.69.5.825
   Robins RW, 2001, PERS SOC PSYCHOL B, V27, P151, DOI 10.1177/0146167201272002
   Rosenberg M., 1965, SOC ADOLESCENT SELF
   SANDERS GS, 1982, SOCIAL PSYCHOL HLTH, P129
   SCHWARZ N, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P217
   Schwinghammer SA, 2006, PERS SOC PSYCHOL B, V32, P27, DOI 10.1177/0146167205277096
   SHERIF M, 1961, SOCIAL JUDGMENT
   SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037//0033-295X.84.2.127
   Srull T.K, 1989, MEMORY COGNITION ITS
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 2006, J PERS SOC PSYCHOL, V90, P258, DOI 10.1037/0022-3514.90.2.258
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P860, DOI 10.1037/0022-3514.87.6.860
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 1996, J PERS SOC PSYCHOL, V70, P437, DOI 10.1037/0022-3514.70.3.437
   Stapel DA, 1997, J EXP SOC PSYCHOL, V33, P47, DOI 10.1006/jesp.1996.1311
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Stapel DA, 2001, J PERS SOC PSYCHOL, V81, P742, DOI 10.1037//0022-3514.81.4.742
   STRACK F, 1988, EUR J SOC PSYCHOL, V18, P429, DOI 10.1002/ejsp.2420180505
   SWANN WB, 2007, IMPLICIT SELF ESTEEM
   Tajfel H., 1978, DIFFERENTIATION SOCI, P61
   Tesser A., 1988, ADV EXPT SOCIAL PSYC, P181, DOI DOI 10.1016/S0065-2601(08)60227-0
   THORNTON B, 1993, PERS SOC PSYCHOL B, V19, P474, DOI 10.1177/0146167293194012
   TRIANDIS HC, 1989, PSYCHOL REV, V96, P506, DOI 10.1037//0033-295X.96.3.506
   Trope Y., 1986, HDB MOTIVATION COGNI, V1, P350
   Turner J. C., 1987, REDISCOVERING SOCIAL
   Turner J. C, 1979, SOCIAL PSYCHOL INTER, P33, DOI DOI 10.1016/S0065-2601(05)37005-5
   WEGENER DT, 1995, J PERS SOC PSYCHOL, V68, P36, DOI 10.1037/0022-3514.68.1.36
   Wilson TD, 2004, ANNU REV PSYCHOL, V55, P493, DOI 10.1146/annurev.psych.55.090902.141954
   Winkielman P, 2005, PERS SOC PSYCHOL B, V31, P121, DOI 10.1177/0146167204271309
   Yzerbyt V. Y., 1997, PSYCHOL STEREOTYPING, P20
   ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151
NR 92
TC 26
Z9 26
U1 3
U2 25
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD JUN
PY 2008
VL 94
IS 6
BP 1018
EP 1032
DI 10.1037/0022-3514.94.6.1018
PG 15
WC Psychology, Social
SC Psychology
GA 304KM
UT WOS:000256108400007
PM 18505315
DA 2018-12-27
ER

PT J
AU Cilloni, D
   Messa, F
   Rosso, V
   Arruga, F
   Defilippi, I
   Carturan, S
   Catalano, R
   Pautasso, M
   Panuzzo, C
   Nicoli, P
   Messa, E
   Morotti, A
   Iacobucci, I
   Martinelli, G
   Bracco, E
   Saglio, G
AF Cilloni, D.
   Messa, F.
   Rosso, V.
   Arruga, F.
   Defilippi, I.
   Carturan, S.
   Catalano, R.
   Pautasso, M.
   Panuzzo, C.
   Nicoli, P.
   Messa, E.
   Morotti, A.
   Iacobucci, I.
   Martinelli, G.
   Bracco, E.
   Saglio, G.
TI RETRACTED: Increase sensitivity to chemotherapeutical agents and
   cytoplasmatic interaction between NPM leukemic mutant and NF-kappa B in
   AML carrying NPM1 mutations (Retracted article. See vol. 24, pg. 1103,
   2010)
SO LEUKEMIA
LA English
DT Article; Retracted Publication
DE NPM1; NF-kappa B; acute leukemia; chemosensitivity
ID ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ARF
   TUMOR-SUPPRESSOR; DRUG DEVELOPMENT; FAVORABLE PROGNOSIS; NUCLEOPHOSMIN
   NPM1; NORMAL KARYOTYPE; GENE-MUTATIONS; FUSION GENE; PROTEIN
AB Mutations in nucleophosmin (NPM) exon 12 and the resulting delocalization of NPM into the cytoplasm are the most specific and frequent cellular events in acute myeloid leukemia patients (AML) with normal karyotype. Cytoplasmatic NPM (NPMc+) is associated with responsiveness to chemotherapy and better prognosis. The activation of nuclear factor-kappa B (NF-kappa B) has been demonstrated to occur in a subset of AML patients and is thought to induce resistance to many chemotherapeutical agents. In this study, we demonstrate the increased in vitro sensitivity of NPMc+ cells to chemotherapeutical agents and their reduced NF-kappa B activity. Furthermore, we provide evidence of the interaction between NPMc+ and NF-kappa B in the cytoplasm, resulting in the sequestration and inactivation of NF-kappa B. The cytosolic localization and consequent inactivation of NF-kappa B justifies the reduced NF-kappa B DNA-binding activity observed in NPMc+ patients. These data, taken together, may provide a possible explanation for the increased rate of chemosensitivity observed among the NPMc+ patients.
C1 [Cilloni, D.] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Div Hematol & Internal Med, I-10043 Turin, Italy.
   [Iacobucci, I.; Martinelli, G.] Univ Bologna, Seragnoli Inst, Div Hematol, Dept Hematol & Oncol Sci, Bologna, Italy.
RP Cilloni, D (reprint author), Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Div Hematol & Internal Med, Gonzole 10, I-10043 Turin, Italy.
EM daniela.cilloni@unito.it
RI Morotti, Alessandro/J-7590-2018
OI Morotti, Alessandro/0000-0002-8407-2903; Arruga,
   Francesca/0000-0001-5298-9314; Panuzzo, Cristina/0000-0002-2814-6453;
   rosso, valentina/0000-0002-6061-5272; Saglio,
   Giuseppe/0000-0002-1046-3514
CR Adams J, 1999, CANCER RES, V59, P2615
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Brown P, 2007, BLOOD, V110, P979, DOI 10.1182/blood-2007-02-076604
   Cheng K, 2007, ONCOGENE, V26, P7391, DOI 10.1038/sj.onc.1210549
   Cilloni D, 2006, LEUKEMIA, V20, P61, DOI 10.1038/sj.leu.2403998
   Cilloni D, 2007, HAEMATOL-HEMATOL J, V92, P1224, DOI 10.3324/haematol.11199
   Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005
   COLOMBO E, CANC RES, V66, P3044
   den Besten W, 2005, CELL CYCLE, V4, P1593
   Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200
   Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164
   Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974
   Falini B, 2007, BLOOD, V109, P874, DOI 10.1182/blood-2006-07-012252
   Frelin C, 2005, BLOOD, V105, P804, DOI 10.1182/blood-2004-04-1463
   Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj/leu/2402482
   GHOSH S, 2002, CELL S, V109, P81
   Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112
   Quentmeier H, 2005, LEUKEMIA, V19, P1760, DOI 10.1038/sj.leu.2403899
   Redner RL, 1996, BLOOD, V87, P882
   Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248
   SENFTLEBEN U, 2002, CRIT CARE MED, V30, P18
   Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733
   Takebayashi T, 2003, J BIOL CHEM, V278, P14897, DOI 10.1074/jbc.M210849200
   TURCO MC, 2003, LEUKEMIA, V18, P1
   van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592
   Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168
   YonedaKato N, 1996, ONCOGENE, V12, P265
NR 30
TC 38
Z9 43
U1 3
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD JUN
PY 2008
VL 22
IS 6
BP 1234
EP 1240
DI 10.1038/leu.2008.68
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 311SC
UT WOS:000256618900019
PM 18401421
OA Bronze
DA 2018-12-27
ER

PT J
AU Han, CS
AF Han, Chang Suk
TI RETRACTED: Microstructure and strength of B2-ordered (Ni,Co)Al
   (Retracted article. See vol. 21, pg. 610, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE age hardening; precipitates; orientation relationship; B2-(Ni,Co)Al;
   (Ni,CO)(2)Al
ID ALLOYS
AB A transmission electron microscopy (TEM) investigation of the morphologies and crystal structures of precipitates in supersaturated B2-ordered (Ni,Co)Al has revealed that rod-like precipitates of the (Ni,CO)(2)Al phase with a hexagonal structure form parallel to the < 111 > direction of the B2 matrix. By aging at temperatures below 973 K, a long period superlattice structure of hexagonal (Ni,CO)(2)Al was formed. The (Ni,Co)Al hardens appreciably by the precipitation of these phases. An energy dispersive spectroscopy (EDS) was used to analyze the compositions of each phase formed in the B2-(Ni,Co)Al. The effects of the dispersion of the (Ni,Co)(2)Al phase on the temperature dependence of the strength of the B2-(Ni,Co)Al have been investigated over a temperature range from 298 K to 1173 K.
C1 Hoseo Univ, Dept Def Sci & Technol, Asan 336795, Chungnam, South Korea.
RP Han, CS (reprint author), Hoseo Univ, Dept Def Sci & Technol, 165 Sechul Ri, Asan 336795, Chungnam, South Korea.
EM hancs@hoseo.edu
CR HUBERTPROTOPOTE.M, 1991, TERNARY ALLOYS, P263
   ISHIDA K, 1991, METALL TRANS A, V22, P441, DOI 10.1007/BF02656811
   KHADKIKAR PS, 1993, METALL TRANS A, V24, P83, DOI 10.1007/BF02669606
   KHAN TI, 2001, MAT T, V42, P263
   PASCOE RT, 1968, METAL SCI J, V2, P138
   REYNAUD F, 1976, J APPL CRYSTALLOGR, V9, P263, DOI 10.1107/S0021889876011333
   Ur SC, 2002, MET MATER INT, V8, P333, DOI 10.1007/BF03186104
NR 7
TC 3
Z9 4
U1 4
U2 16
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD JUN
PY 2008
VL 14
IS 3
BP 291
EP 295
DI 10.3365/met.mat.2008.06.291
PG 5
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 319NM
UT WOS:000257170700003
DA 2018-12-27
ER

PT J
AU Ireland, BS
   Brockmeier, U
   Howe, CM
   Elliott, T
   Williams, DB
AF Ireland, Breanna S.
   Brockmeier, Ulf
   Howe, Christopher M.
   Elliott, Tim
   Williams, David B.
TI RETRACTED: Lectin-deficient calreticulin retains full functionality as a
   chaperone for class I histocompatibility molecules (Retracted article.
   See vol. 27, pg. 2517, 2016)
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article; Retracted Publication
ID MHC CLASS-I; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM;
   MONOCLONAL-ANTIBODIES; CROSS-PRESENTATION; LOADING COMPLEX; CALNEXIN;
   PEPTIDE; BINDING; PROTEIN
AB Calreticulin is a molecular chaperone of the endoplasmic reticulum that uses both a lectin site specific for Glc(1)Man(5-9)GlcNAc(2) oligosaccharides and a polypeptide binding site to interact with nascent glycoproteins. The latter mode of substrate recognition is controversial. To examine the relevance of polypeptide binding to protein folding in living cells, we prepared lectin-deficient mutants of calreticulin and examined their abilities to support the assembly and quality control of mouse class I histocompatibility molecules. In cells lacking calreticulin, class I molecules exhibit inefficient loading of peptide ligands, reduced cell surface expression and aberrantly rapid export from the endoplasmic reticulum. Remarkably, expression of calreticulin mutants that are completely devoid of lectin function fully complemented all of the class I biosynthetic defects. We conclude that calreticulin can use nonlectin-based modes of substrate interaction to effect its chaperone and quality control functions on class I molecules in living cells. Furthermore, pulse-chase coimmunoisolation experiments revealed that lectin-deficient calreticulin bound to a similar spectrum of client proteins as wild-type calreticulin and dissociated with similar kinetics, suggesting that lectin-independent interactions are commonplace in cells and that they seem to be regulated during client protein maturation.
C1 [Ireland, Breanna S.; Brockmeier, Ulf; Williams, David B.] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.
   [Ireland, Breanna S.; Brockmeier, Ulf; Williams, David B.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada.
   [Howe, Christopher M.; Elliott, Tim] Univ Southampton, Sch Med, Canc Sci Div, Southampton SO16 6YD, Hants, England.
   [Howe, Christopher M.; Elliott, Tim] Univ Southampton, Sch Med, CRC Med Oncol Unit, Southampton SO16 6YD, Hants, England.
RP Williams, DB (reprint author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.
EM david.williams@utoronto.ca
OI Elliott, Tim/0000-0003-1097-0222
FU Canadian Cancer Society; Canadian Institutes for Health Research; Cancer
   Research UK; Canadian Institutes of Health Research Strategic Training
   Program; Cancer Research UK [10601]
FX We gratefully acknowledge Brian Barber, Ron Germain, Jennifer Gommerman,
   Marek Michalak, Jacques Neefjes, and Young Yang and for gifts of cells
   and reagents and to Emmanuelle Cordat for help with the Moloney virus
   expression system. This work was supported by grants from the Canadian
   Cancer Society and the Canadian Institutes for Health Research (to D. B.
   W.) and from Cancer Research UK (to T. E.). U. B. is a postdoctoral
   trainee of the Canadian Institutes of Health Research Strategic Training
   Program in the Structural Biology of Membrane Proteins Linked to
   Disease.
CR BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4
   Brockmeier A, 2006, BIOCHEMISTRY-US, V45, P12906, DOI 10.1021/bi0614378
   Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199
   Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x
   Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200
   DAVID V, 1993, J BIOL CHEM, V268, P9585
   DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653
   Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703
   Elliott T, 2005, IMMUNOL REV, V207, P89, DOI 10.1111/j.0105-2896.2005.00311.x
   Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099
   Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6
   Gopalakrishnapai J, 2006, BIOCHEM BIOPH RES CO, V351, P14, DOI 10.1016/j.bbrc.2006.09.164
   Harris MR, 1998, J IMMUNOL, V160, P5404
   HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X
   Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752
   HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0
   Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4
   JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0
   Kapoor M, 2004, BIOCHEMISTRY-US, V43, P97, DOI 10.1021/bi0355286
   Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200
   Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200
   LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x
   Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311
   Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073
   Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290
   OZATO K, 1980, J IMMUNOL, V125, P2473
   Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001
   PETERSON JR, 1995, MOL BIOL CELL, V6, P1173
   Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1
   Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200
   Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001
   Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x
   Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2
   Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718
   Sandhu N, 2007, BBA-PROTEINS PROTEOM, V1774, P701, DOI 10.1016/j.bbapap.2007.03.019
   SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4
   Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944
   Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588
   Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200
   SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286
   Suh WK, 1999, J IMMUNOL, V162, P1530
   Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555
   TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638
   Thammavongsa V, 2005, J BIOL CHEM, V280, P33497, DOI 10.1074/jbc.M503648200
   Thomson SP, 2005, CELL STRESS CHAPERON, V10, P242, DOI 10.1379/CSC-126.1
   TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0
   VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997
   Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x
   WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697
   Wearsch PA, 2004, J BIOL CHEM, V279, P25112, DOI 10.1074/jbc.M401721200
   Wearsch PA, 2007, NAT IMMUNOL, V8, P873, DOI 10.1038/ni1485
   Williams DB, 2006, J CELL SCI, V119, P615, DOI 10.1242/jcs.02856
   Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3
   ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944
NR 54
TC 48
Z9 49
U1 3
U2 10
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD JUN
PY 2008
VL 19
IS 6
BP 2413
EP 2423
DI 10.1091/mbc.E07-10-1055
PG 11
WC Cell Biology
SC Cell Biology
GA 347QD
UT WOS:000259155200007
PM 18337472
OA Green Published
DA 2018-12-27
ER

PT J
AU Varthakavi, V
   Heimann-Nichols, E
   Smith, RM
   Sun, Y
   Bram, RJ
   Ali, S
   Rose, J
   Ding, L
   Spearman, P
AF Varthakavi, Vasundhara
   Heimann-Nichols, Ellen
   Smith, Rita M.
   Sun, Yuehui
   Bram, Richard J.
   Ali, Showkat
   Rose, Jeremy
   Ding, Lingmei
   Spearman, Paul
TI RETRACTED: Identification of calcium-modulating cyclophilin ligand as a
   human host restriction to HIV-1 release overcome by Vpu (Retracted
   article. See vol. 16, pg. 238, 2010)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID VIRUS TYPE-1 VPU; PARTICLE RELEASE; ENVELOPE PROTEIN; F-BOX; CD4;
   RETROVIRUSES; DEGRADATION; LYMPHOCYTES; MACHINERY; PATHWAY
AB The HIV-1 Vpu protein is required for efficient viral release from human cells. For HIV-2, the envelope (Env) protein replaces the role of Vpu. Both Vpu and HIV-2 Env enhance virus release by counteracting an innate host-cell block within human cells that is absent in African green monkey (AGM) cells. Here we identify calcium-modulating cyclophilin ligand (CAML) as a Vpu-interacting host factor that restricts HIV-1 release. Expression of human CAML (encoded by CAMLG) in AGM cells conferred a strong restriction of virus release that was reversed by Vpu and HIV-2 Env, suggesting that CAML is the mechanistic link between these two viral regulators. Depletion of CAML in human cells eliminated the need for Vpu in enhancing HIV-1 and murine leukemia virus release. These results point to CAML as a Vpu-sensitive host restriction factor that inhibits HIV release from human cells. The ability of CAML to inhibit virus release should illuminate new therapeutic strategies against HIV.
C1 [Varthakavi, Vasundhara; Heimann-Nichols, Ellen; Smith, Rita M.; Sun, Yuehui] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Pediat, Nashville, TN 37232 USA.
   [Bram, Richard J.] Mayo Clin, Mayo Med Sch, Div Pediat, Dept Pediat & Adolescent Med,Res Labs, Rochester, MN 55905 USA.
   [Ali, Showkat; Rose, Jeremy; Ding, Lingmei; Spearman, Paul] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA.
RP Varthakavi, V (reprint author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Pediat, 1161 21st Ave S,D-7235 MCN, Nashville, TN 37232 USA.
EM vasundhara.varthakavi@vanderbilt.edu; paul.spearman@emory.edu
FU NCI NIH HHS [R01 CA112414-02, R01 CA112414, 5R01CA112414]; NIAID NIH HHS
   [R01 AI058828, AI058828, P30 AI054999, P30 AI054999-03, R01 AI058828-05]
CR Abada P, 2005, J VIROL, V79, P3627, DOI 10.1128/JVI.79.6.3627.3638.2005
   Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7
   Bartee E, 2006, PLOS PATHOG, V2, P975, DOI 10.1371/journal.ppat.0020107
   Bour S, 1996, J VIROL, V70, P8285
   BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0
   Callahan MA, 1998, J VIROL, V72, P5189
   Cervantes-Acosta G, 2001, J VIROL METHODS, V92, P207, DOI 10.1016/S0166-0934(00)00289-5
   Feng PH, 2002, J VIROL, V76, P11491, DOI 10.1128/JVI.76.22.11491-11504.2002
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2
   Gomez TS, 2006, IMMUNITY, V24, P741, DOI 10.1016/j.immuni.2006.03.022
   GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381
   KLIMKAIT T, 1990, J VIROL, V64, P621
   MALDARELLI F, 1993, J VIROL, V67, P5056
   Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8
   Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003
   Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553
   Neil SJD, 2006, PLOS PATHOG, V2, P354, DOI 10.1371/journal.ppat.0020039
   SCHUBERT U, 1995, J VIROL, V69, P7699
   Schwartz MD, 1996, VIROLOGY, V224, P302, DOI 10.1006/viro.1996.0532
   SMITH AJ, 1990, J VIROL, V64, P2743
   Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6
   STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888
   Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003
   TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163
   Tovey SC, 2000, BIOCHEM BIOPH RES CO, V276, P97, DOI 10.1006/bbrc.2000.3442
   Tram DD, 2005, IMMUNITY, V23, P139, DOI 10.1016/j.immuni.2005.06.006
   Tran DD, 2003, DEV CELL, V5, P245, DOI 10.1016/S1534-5807(03)00207-7
   Varthakavi V, 2006, TRAFFIC, V7, P298, DOI 10.1111/j.1600-0854.2005.00380.x
   Varthakavi V, 2003, P NATL ACAD SCI USA, V100, P15154, DOI 10.1073/pnas.2433165100
   Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481
   WILLEY RL, 1992, J VIROL, V66, P7193
   YAO XJ, 1992, J VIROL, V66, P5119
NR 32
TC 32
Z9 32
U1 3
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2008
VL 14
IS 6
BP 641
EP 647
DI 10.1038/nm1778
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 309NY
UT WOS:000256468700030
PM 18500349
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Sticklen, MB
AF Sticklen, Mariam B.
TI RETRACTED: Plant genetic engineering for biofuel production: towards
   affordable cellulosic ethanol (Retracted article. See vol 11, pg 308,
   2010)
SO NATURE REVIEWS GENETICS
LA English
DT Review; Retracted Publication
ID ACIDOTHERMUS-CELLULOLYTICUS ENDOGLUCANASE; CARBOHYDRATE-BINDING MODULES;
   MEDICAGO-SATIVA L.; CINNAMYL ALCOHOL-DEHYDROGENASE; LIGNIN-MODIFYING
   ENZYMES; SOLANUM-TUBEROSUM L.; DOWN-REGULATION; CELL-WALL; TRANSGENIC
   TOBACCO; CLOSTRIDIUM-THERMOCELLUM
AB Biofuels provide a potential route to avoiding the global political instability and environmental issues that arise from reliance on petroleum. Currently, most biofuel is in the form of ethanol generated from starch or sugar, but this can meet only a limited fraction of global fuel requirements. Conversion of cellulosic biomass, which is both abundant and renewable, is a promising alternative. However, the cellulases and pretreatment processes involved are very expensive. Genetically engineering plants to produce cellulases and hemicellulases, and to reduce the need for pretreatment processes through lignin modification, are promising paths to solving this problem, together with other strategies, such as increasing plant polysaccharide content and overall biomass.
C1 Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA.
RP Sticklen, MB (reprint author), Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA.
EM stickle1@msu.edu
CR Andersson-Gunneras S, 2006, PLANT J, V45, P144, DOI 10.1111/j.1365-313X.2005.02584.x
   Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717
   AYERS AR, 1978, EUR J BIOCHEM, V90, P171, DOI 10.1111/j.1432-1033.1978.tb12588.x
   BAO WJ, 1992, FEBS LETT, V302, P77, DOI 10.1016/0014-5793(92)80289-S
   Baucher M, 1999, PLANT MOL BIOL, V39, P437, DOI 10.1023/A:1006182925584
   Biswas GCG, 2006, PLANT SCI, V171, P617, DOI 10.1016/j.plantsci.2006.06.004
   Blaschke L, 2004, PHYSIOL PLANTARUM, V121, P75, DOI 10.1111/j.0031-9317.2004.00297.x
   Bolwell GP, 2000, TRENDS GLYCOSCI GLYC, V12, P143, DOI 10.4052/tigg.12.143
   BOOMINATHAN K, 1992, HDB APPLIED MYCOLOGY, V4, P763
   Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892
   BORDETSKY A, 2005, SECURING AM SOLVING
   Bothast RJ, 2005, APPL MICROBIOL BIOT, V67, P19, DOI 10.1007/s00253-004-1819-8
   Boudet AM, 2000, PLANT PHYSIOL BIOCH, V38, P81, DOI 10.1016/S0981-9428(00)00166-2
   BREUIL C, 1992, BIORESOURCE TECHNOL, V39, P139, DOI 10.1016/0960-8524(92)90132-H
   CARPITA N, 2002, BIOCH MOL BIOL PLANT, pCH2
   Chabannes M, 2001, PLANT J, V28, P257, DOI 10.1046/j.1365-313X.2001.01140.x
   Chapple C, 2007, NAT BIOTECHNOL, V25, P746, DOI 10.1038/nbt0707-746
   Chen F, 2007, NAT BIOTECHNOL, V25, P759, DOI 10.1038/nbt1316
   Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000
   COSGROVE DJ, 2007, Patent No. 20070166805
   D'Souza TM, 1999, APPL ENVIRON MICROB, V65, P5307
   Dai ZY, 2005, TRANSGENIC RES, V14, P627, DOI 10.1007/s11248-005-5695-5
   Dai ZY, 2000, TRANSGENIC RES, V9, P43, DOI 10.1023/A:1008922404834
   Dai ZY, 1999, APPL BIOCHEM BIOTECH, V77-9, P689, DOI 10.1385/ABAB:79:1-3:689
   Dai ZY, 2000, MOL BREEDING, V6, P277, DOI 10.1023/A:1009653011948
   DEAN JFD, 2004, BIOTECHNOLOGY BIOPOL, P4
   *DEP EN, 2007, DOE SEL 6 CELL ETH P
   Ding SY, 2006, J AGR FOOD CHEM, V54, P597, DOI 10.1021/jf051851z
   Dodd AN, 2005, SCIENCE, V309, P630, DOI 10.1126/science.1115581
   Eriksson ME, 2000, NAT BIOTECHNOL, V18, P784
   Festucci-Buselli Reginaldo A., 2007, Braz. J. Plant Physiol., V19, P1, DOI 10.1590/S1677-04202007000100001
   Fischer R, 2004, CURR OPIN PLANT BIOL, V7, P152, DOI 10.1016/j.pbi.2004.01.007
   Graves MV, 1999, VIROLOGY, V257, P15, DOI 10.1006/viro.1999.9628
   HAIGLER CH, 2006, SCI LORE PLANT CELL
   Han Y W, 1990, Adv Appl Microbiol, V35, P171, DOI 10.1016/S0065-2164(08)70244-2
   Han YJ, 2007, ENZYME MICROB TECH, V41, P638, DOI 10.1016/j.enzmictec.2007.05.012
   HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0
   Henriksson G, 2000, J BIOTECHNOL, V78, P93, DOI 10.1016/S0168-1656(00)00206-6
   Herbers K., 1995, NAT BIOTECHNOL, V13, P63, DOI DOI 10.1038/NBT0195-63
   Himmel ME, 2007, SCIENCE, V315, P804, DOI 10.1126/science.1137016
   Horn ME, 2004, PLANT CELL REP, V22, P711, DOI 10.1007/s00299-004-0767-1
   Howard JA, 2005, ADV AGRON, V85, P91, DOI 10.1016/S0065-2113(04)85002-8
   Hu WJ, 1999, NAT BIOTECHNOL, V17, P808
   Hyunjong B, 2006, J EXP BOT, V57, P161, DOI 10.1093/jxb/erj019
   Jeoh T, 2007, BIOTECHNOL BIOENG, V98, P112, DOI 10.1002/bit.21408
   Kawagoe Y, 1997, Genet Eng (N Y), V19, P63
   Kawasaki T, 2002, VIROLOGY, V302, P123, DOI 10.1006/viro.2002.1572
   Kimura T, 2003, APPL MICROBIOL BIOT, V62, P374, DOI 10.1007/s00253-003-1301-z
   Kimura T, 2003, J BIOSCI BIOENG, V95, P397
   KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341
   Knauf M, 2004, INT SUGAR J, V106, P147
   Levy I, 2002, BIOMOL ENG, V19, P17, DOI 10.1016/S1389-0344(02)00007-2
   Li YC, 2007, APPL ENVIRON MICROB, V73, P3165, DOI 10.1128/AEM.02960-06
   Luo Y, 1997, FUNCT ECOL, V11, P696, DOI 10.1046/j.1365-2435.1997.00142.x
   McCartney L, 2006, P NATL ACAD SCI USA, V103, P4765, DOI 10.1073/pnas.0508887103
   Montalvo-Rodriguez R, 2000, BIOTECHNOL BIOENG, V70, P151, DOI 10.1002/1097-0290(20001020)70:2<151::AID-BIT4>3.0.CO;2-D
   Mosier N, 2005, BIORESOURCE TECHNOL, V96, P673, DOI 10.1016/j.biortech.2004.06.025
   *NAT CORN GROW ASS, 2007, WORLD CORN
   *NAT RES COUNC, 2004, BIOC GEN ENG ORG NAT
   O'Neill MA, 2004, ANNU REV PLANT BIOL, V55, P109, DOI 10.1146/annurev.arplant.55.031903.141750
   OBEMBE O, 2007, J PLANT RES, V120, P607
   Okumura S, 2006, TRANSGENIC RES, V15, P637, DOI 10.1007/s11248-006-9009-3
   Oraby H, 2007, TRANSGENIC RES, V16, P739, DOI 10.1007/s11248-006-9064-9
   Patel M, 2000, MOL BREEDING, V6, P113, DOI 10.1023/A:1009640427515
   Persson S, 2005, P NATL ACAD SCI USA, V102, P8633, DOI 10.1073/pnas.0503392102
   Pilate G, 2002, NAT BIOTECHNOL, V20, P607, DOI 10.1038/nbt0602-607
   Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736
   Ralph J, 2006, J BIOL CHEM, V281, P8843, DOI 10.1074/jbc.M511598200
   RANSOM CB, 2007, APPL BIOCHEM BIOTECH, V36, P207
   Reddy MSS, 2005, P NATL ACAD SCI USA, V102, P16573, DOI 10.1073/pnas.0505749102
   Reggi S, 2005, PLANT MOL BIOL, V57, P101, DOI 10.1007/s11103-004-6832-x
   Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3
   Saloheimo M, 2002, EUR J BIOCHEM, V269, P4202, DOI 10.1046/j.1432-1033.2002.03095.x
   Schillberg S, 1999, TRANSGENIC RES, V8, P255, DOI 10.1023/A:1008937011213
   Schillberg S, 2003, CELL MOL LIFE SCI, V60, P433, DOI 10.1007/s000180300037
   Schlamadinger B, 1997, BIOMASS BIOENERG, V13, P359, DOI 10.1016/S0961-9534(97)10032-0
   Shoseyov O, 2006, MICROBIOL MOL BIOL R, V70, P283, DOI 10.1128/MMBR.00028-05
   Smidansky ED, 2003, PLANTA, V216, P656, DOI 10.1007/s00425-002-0897-z
   Somerville C, 2006, SCIENCE, V312, P1277, DOI 10.1126/science.1130034
   Somleva MN, 2002, CROP SCI, V42, P2080, DOI 10.2135/cropsci2002.2080
   STICKLEN M, 2006, Patent No. 7049485
   Sticklen M, 2006, CURR OPIN BIOTECH, V17, P315, DOI 10.1016/j.copbio.2006.05.003
   Sticklen MB, 2007, CROP SCI, V47, P2238, DOI 10.2135/cropsci2007.04.0212
   Sticklen MB, 2005, IN VITRO CELL DEV-PL, V41, P187, DOI 10.1079/IVP2004616
   STICKLEN MB, 2004, P 2 INT UKR C BIOM E, P133
   Sticklen MB, 2007, US Patent, Patent No. [2007 0192900, 20070192900]
   Teymouri F., 2004, Applied Biochemistry and Biotechnology, V116, P1183, DOI 10.1385/ABAB:116:1-3:1183
   Vaaje-Kolstad G, 2005, J BIOL CHEM, V280, P11313, DOI 10.1074/jbc.M407175200
   Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183
   Xiao ZZ, 2001, BIOTECHNOL LETT, V23, P711, DOI 10.1023/A:1010325122851
   Yang PL, 2007, BIOTECHNOL LETT, V29, P659, DOI 10.1007/s10529-006-9280-7
   Yennawar NH, 2006, P NATL ACAD SCI USA, V103, P14664, DOI 10.1073/pnas.0605979103
   Ziegelhoffer T, 2001, MOL BREEDING, V8, P147, DOI 10.1023/A:1013338312948
   Ziegelhoffer T, 1999, MOL BREEDING, V5, P309, DOI 10.1023/A:1009646830403
   Ziegler MT, 2000, MOL BREEDING, V6, P37, DOI 10.1023/A:1009667524690
NR 95
TC 262
Z9 272
U1 5
U2 143
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-0056
J9 NAT REV GENET
JI Nat. Rev. Genet.
PD JUN
PY 2008
VL 9
IS 6
BP 433
EP 443
DI 10.1038/nrg2336
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 302FF
UT WOS:000255953500011
PM 18487988
DA 2018-12-27
ER

PT J
AU Barnett, RLE
AF Barnett, R. -L. Etienne
TI RETRACTED: On the chaotic fragmentation of meaning - An essay of
   retrospection (Retracted article. See vol. 42, pg. 359, 2015)
SO NEOHELICON
LA French
DT Article; Retracted Publication
C1 Univ Atlanta, Off Univ Provost & Execut Vice President Operat, Atlanta, GA 30360 USA.
RP Barnett, RLE (reprint author), Univ Atlanta, Off Univ Provost & Execut Vice President Operat, Atlanta, GA 30360 USA.
EM RLEBarnett@UofA.edu
CR ARIES P, 1997, MANGEURS METAMORPHOS
   ARON JP, 1973, MANGEUR 29 SIECLE
   BAETENS Jan, 1995, ETHIQUE CONTRAINTE
   BARNETT RLE, 1999, LITTERATURES, V24, P111
   BARTHES R, 1953, GOMMES, P160
   BARTHES R, 1987, OBVIE OBTUS
   BARTHES R, 1975, R BARTHES R BARTHES, P182
   BARTHES R, 1970, EMPIRE DES SIGNES, P21
   BARTHES R, 1970, TEXTE PLEIN SENS MUL, P90
   BENS J, 1996, CUSINE JEUX
   BRILLATSAVARIN, 1828, PHYSL GOUT, V1, P152
   CHATELET, 1988, CORPS CORPS CULINAIR
   DALLENBACH L, 1987, CLAUDE SIMON, P124
   DALLENBACH L, 1996, CANNE BALZAC
   DEMAUPASSANT G, 1957, CONTES NOUVELLES, V2, P904
   DURAS M, 1974, PARLEUSES, P86
   FENSARMELAGOS J, 1985, ANTHR COUTUMES ALIME
   FERRETFLEURY C, 1996, GOUT MOTS
   Flandrin J.-L., 1996, HIST ALIMENTATION
   Guillemard C., 1990, MOTS CUISINE TABLE
   JENNY L, 1983, POETIQUE, V79, P181
   JOST P, 1998, GOURMANDISE
   LACOUELABARTHE P, 1978, ABSOLU LITTERAIRE, P88
   MALLARME, 1945, OEUVRES COMPLETES, P1576
   OFFRE LD, 1980, POETIQUE, V42, P207
   OPPOSE GG, 1966, SILENCES FLAUBERT FO, P223
   PEREC G, 1965, CHOSES, P57
   REVEL JF, 1985, SENSIBILITE GASTRONO
   ROGER J, 1998, MAGAZINE LIT, V364, P48
   SIMON C, 1957, VENT TENTATIVE RESTI, P174
   SOLLERS P, 2000, GUERRE GOUT
   STAROBINSKI J, 1998, MAGAZINE LIT, V364, P52
   2008, POETIQUE MARGES LECT
   1974, PROUST MONDE SENSIBL
   2001, DEGRE 2, V37, P88
   2003, NEOPHILOLOGUS, P107
   1982, OEUVRES COMPLETES GE
   1969, BATAILLE PHARSALE, P238
NR 38
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD JUN
PY 2008
VL 35
IS 1
BP 97
EP 105
DI 10.1007/s11059-008-3007-9
PG 9
WC Literature
SC Literature
GA 318OU
UT WOS:000257102300007
DA 2018-12-27
ER

PT J
AU Ruys, KI
   Stapel, DA
AF Ruys, Kirsten I.
   Stapel, Diederik A.
TI RETRACTED: Emotion elicitor or emotion messenger? Subliminal priming
   reveals two faces of facial expressions (Retracted article. See vol. 23,
   pg. 828, 2012)
SO PSYCHOLOGICAL SCIENCE
LA English
DT Article; Retracted Publication
ID IMPRESSION-FORMATION; PERCEPTION; EXPERIENCE; RESPONSES; MICROGENESIS;
   AWARENESS; COGNITION; BEHAVIOR; MOOD
AB Facial emotional expressions can serve both as emotional stimuli and as communicative signals. The research reported here was conducted to illustrate how responses to both roles of facial emotional expressions unfold over time. As an emotion elicitor, a facial emotional expression (e.g., a disgusted face) activates a response that is similar to responses to other emotional stimuli of the same valence (e.g., a dirty, nonflushed toilet). As an emotion messenger, the same facial expression (e.g., a disgusted face) serves as a communicative signal by also activating the knowledge that the sender is experiencing a specific emotion (e.g., the sender feels disgusted). By varying the duration of exposure to disgusted, fearful, angry, and neutral faces in two subliminal-priming studies, we demonstrated that responses to faces as emotion elicitors occur prior to responses to faces as emotion messengers, and that both types of responses may unfold unconsciously.
C1 [Ruys, Kirsten I.; Stapel, Diederik A.] Tilburg Univ, TIBER, NL-5000 LE Tilburg, Netherlands.
RP Ruys, KI (reprint author), Tilburg Univ, TIBER, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM k.i.ruys@uvt.nl
CR ADELMANN PK, 1989, ANNU REV PSYCHOL, V40, P249, DOI 10.1146/annurev.ps.40.020189.001341
   Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056
   Adolphs R, 2006, CURR DIR PSYCHOL SCI, V15, P222, DOI 10.1111/j.1467-8721.2006.00440.x
   Atkinson A. P., 2005, EMOTION CONSCIOUSNES, P150
   BARGH JA, 1982, J PERS SOC PSYCHOL, V43, P437, DOI 10.1037/0022-3514.43.3.437
   Cacioppo JT, 1999, ANNU REV PSYCHOL, V50, P191, DOI 10.1146/annurev.psych.50.1.191
   Chartrand TL, 1996, J PERS SOC PSYCHOL, V71, P464, DOI 10.1037/0022-3514.71.3.464
   DEGELDER B, 2005, EMOTION CONSCIOUSNES, P123
   Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221
   DIMBERG U, 1996, MOTIV EMOTION, P20
   EKMAN P, 1992, PSYCHOL REV, V99, P550, DOI 10.1037/0033-295X.99.3.550
   EKMAN P, 1983, SCIENCE, V221, P1208, DOI 10.1126/science.6612338
   Ekman P, 1976, PICTURES FACIAL AFFE
   ERDLEY CA, 1988, J PERS SOC PSYCHOL, V54, P741, DOI 10.1037//0022-3514.54.5.741
   FERNANDEZDOLS JM, 1997, PSYCHOL FACIAL EXPRE, P275
   Fridlund A. J., 1994, HUMAN FACIAL EXPRESS
   HATFIELD E, 1992, EMOTION SOCIAL BEHAV, P151
   Hess U, 1998, COGNITION EMOTION, V12, P509, DOI 10.1080/026999398379547
   IZARD CE, 1994, PSYCHOL BULL, V115, P288, DOI 10.1037//0033-2909.115.2.288
   Jakobs E, 1997, J NONVERBAL BEHAV, V21, P103, DOI 10.1023/A:1024904019590
   Keltner D, 1999, COGNITION EMOTION, V13, P505, DOI 10.1080/026999399379168
   LANZETTA JT, 1989, J PERS SOC PSYCHOL, V56, P543, DOI 10.1037/0022-3514.56.4.543
   Ledoux J., 1989, COGNITION EMOTION, V3, P267, DOI DOI 10.1080/02699938908412709
   MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723
   Neumann R, 2000, J PERS SOC PSYCHOL, V79, P211, DOI 10.1037//0022-3514.79.2.211
   Palermo R, 2007, NEUROPSYCHOLOGIA, V45, P75, DOI 10.1016/j.neuropsychologia.2006.04.025
   Phillips ML, 2004, NEUROIMAGE, V21, P1484, DOI 10.1016/j.neuroimage.2003.12.013
   Rosenthal V, 2004, THEORY DECIS LIB A, V38, P221
   Russell J.A., 1997, PSYCHOL FACIAL EXPRE, P3, DOI DOI 10.1017/CBO9780511659911.003
   RUSSELL JA, 1994, PSYCHOL BULL, V115, P102, DOI 10.1037//0033-2909.115.1.102
   Ruys KI, 2008, J PERS SOC PSYCHOL, V94, P777, DOI 10.1037/0022-3514.94.5.777
   Ruys KI, 2007, BRIT J PSYCHOL, V98, P361, DOI 10.1348/000712606X132949
   Smith C. A., 1997, PSYCHOL FACIAL EXPRE, P229, DOI DOI 10.1017/CBO9780511659911.012
   Stapel DA, 2006, J EXP SOC PSYCHOL, V42, P112, DOI 10.1016/j.jesp.2005.02.002
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   STAPEL DA, 2003, SOCIAL JUDGMENTS IMP, P227
   STAPEL DA, 2005, PERSONALITY SOCIAL P, V9, P1286
   WERNER H, 1956, J ABNORM SOC PSYCH, V52, P347, DOI 10.1037/h0048896
   Winkielman P, 2005, PERS SOC PSYCHOL B, V31, P121, DOI 10.1177/0146167204271309
   ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151
NR 40
TC 34
Z9 34
U1 2
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0956-7976
EI 1467-9280
J9 PSYCHOL SCI
JI Psychol. Sci.
PD JUN
PY 2008
VL 19
IS 6
BP 593
EP 600
DI 10.1111/j.1467-9280.2008.02128.x
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA 311YR
UT WOS:000256636800011
PM 18578850
DA 2018-12-27
ER

PT J
AU Kanwar, R
   Fortini, ME
AF Kanwar, Ritu
   Fortini, Mark E.
TI RETRACTED: The big brain aquaporin is required for endosome maturation
   and notch receptor trafficking (Retracted article. See vol. 142, pg.
   170, 2010)
SO CELL
LA English
DT Article; Retracted Publication
ID AMYLOID PRECURSOR PROTEIN; DROSOPHILA-MELANOGASTER; LYSOSOMAL MEMBRANE;
   ALZHEIMERS-DISEASE; MOSAIC ANALYSIS; ENDOCYTOSIS; GENE; HRS; DOMAIN;
   COMPARTMENT
AB Activity of the big brain (bib) gene influences Notch signaling during Drosophila nervous system development. We demonstrate that Bib, which belongs to the aquaporin family of channel proteins, is required for endosome maturation in Drosophila epithelial cells. In the absence of Bib, early endosomes arrest and form abnormal clusters, and cells exhibit reduced acidification of endocytic trafficking organelles. Bib acts downstream of Hrs in early endosome morphogenesis and regulates biogenesis of endocytic compartments prior to the formation of Rab7-containing late endosomes. Abnormal endosome morphology caused by loss of Bib is accompanied by overaccumulation of Notch, Delta, and other signaling molecules as well as reduced intracellular trafficking of Notch to nuclei. Analysis of several endosomal trafficking mutants reveals a correlation between endosomal acidification and levels of Notch signaling. Our findings reveal an unprecedented role for an aquaporin in endosome maturation, trafficking, and acidification.
C1 [Kanwar, Ritu; Fortini, Mark E.] NCI, Canc & Dev Biol Lab, Frederick, MD 21701 USA.
RP Fortini, ME (reprint author), NCI, Canc & Dev Biol Lab, 1050 Boyles St,Bldg 560,Room 22-12, Frederick, MD 21701 USA.
EM fortini@ncifcrf.gov
FU PHS HHS [NIH0011405438]; Intramural NIH HHS [NIH0011405438]
CR Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815
   Childress JL, 2006, CURR BIOL, V16, P2228, DOI 10.1016/j.cub.2006.09.031
   CLAGUE MJ, 1994, J BIOL CHEM, V269, P21
   Doherty D, 1997, DEVELOPMENT, V124, P3881
   FAUNDEZ V, 2004, SCI STKE, V233, pRE8
   FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S
   Gallagher CM, 2006, DEV CELL, V11, P641, DOI 10.1016/j.devcel.2006.09.014
   Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360
   Hoepfner S, 2005, CELL, V121, P437, DOI 10.1016/j.cell.2005.02.017
   Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014
   Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508
   Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348
   Jaekel R, 2006, DEV CELL, V11, P655, DOI 10.1016/j.devcel.2006.09.019
   Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019
   King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469
   KOENIG JH, 1990, CELL TISSUE RES, V262, P233, DOI 10.1007/BF00309878
   Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538
   Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900
   Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789
   Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4
   LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482
   LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949
   Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6
   Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425
   MELLMAN I, 1992, J EXP BIOL, V172, P39
   Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018
   Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200
   PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603
   Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597
   Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791
   RAO Y, 1992, DEVELOPMENT, V116, P31
   RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0
   REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N
   Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043
   Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756
   Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4
   Seto ES, 2006, J CELL BIOL, V173, P95, DOI 10.1083/jcb.200510123
   STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O
   Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020
   Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019
   Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127
   Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519
   Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9
   XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1
   Yanochko GM, 2002, J NEUROSCI, V22, P2530, DOI 10.1523/JNEUROSCI.22-07-02530.2002
NR 47
TC 31
Z9 31
U1 2
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 30
PY 2008
VL 133
IS 5
BP 852
EP 863
DI 10.1016/j.cell.2008.04.038
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 306UY
UT WOS:000256274500017
PM 18510929
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Guo, YP
AF Guo, Yueping
TI RETRACTED: A component-based model for aircraft landing gear noise
   prediction (Retracted article. See vol. 333, pg. 4402, 2014)
SO JOURNAL OF SOUND AND VIBRATION
LA English
DT Article; Retracted Publication
AB This paper follows the general formulation of aircraft landing gear noise prediction to develop a component-based model, incorporating scaling laws of the theory of aerodynamic noise generation and correlations of these scaling laws with Currently available test data. The method decomposes the landing gear noise into three spectral components, respectively, for the low, the mid and the high frequencies, which corresponds to cataloging the parts in the landing gear assembly into three groups, namely, the wheels, the main struts, and the small details. For all three spectral components, models are presented for their spectra, far-field directivities and amplitudes. The spectral characteristics of the three components are defined by normalized spectra, as functions of the Strouhal numbers based on the respective length scales of the three groups of parts in the landing gear assembly. Individual directivity factors are also presented for the three spectral components, with the low-frequency component having the smallest variations with emission angle and the high-frequency component having the largest variations. The amplitudes of the three spectral components are correlated to parameters unique to each group of landing gear parts, with the low- and mid-frequency noise essentially characterized by the physical dimensions of the wheels and the main struts, respectively, and the high-frequency noise, whose generation is associated with a large number of small details in practical landing gears, defined by a complexity factor. Quantities that affect this complexity factor,ire discussed and,in empirical model is proposed for practical applications. The prediction model is validated by wing tunnel test data for in isolated Boeing 737 landing gear. In this case, the predictions agree well with data, both in parametric trends and in absolute noise levels. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Boeing Co, Huntington Beach, CA 92647 USA.
RP Guo, YP (reprint author), Boeing Co, Mail Code H013-B308,5301 Bolsa Ave, Huntington Beach, CA 92647 USA.
EM yueping.guo@boeing.com
CR CHOW LC, 2002, 20022408 AIAA
   Crighton D. G., 1991, RP1258 NASA, V1, P391
   CRIGHTON DG, 1992, MODERN METHODS ANAL
   CRIGHTON DG, 1975, PROG AEROSPACE SCI, V16, P31, DOI DOI 10.1016/0376-0421(75)90010-X
   DOBRYNSKI W, 2002, 20022409 AIAA
   DOBRZYNSKI W, 1997, 971597 AIAA
   FINK MR, 1979, J AIRCRAFT, V16, P659, DOI 10.2514/3.58586
   Guo YP, 2006, J AIRCRAFT, V43, P306, DOI 10.2514/1.11085
   Guo YP, 2005, J SOUND VIB, V282, P61, DOI 10.1016/j.jsv.2004.02.021
   GUO YP, 2006, NASINNL04AA11B NASA
   GUO YP, 2006, 20062627 AIAA
   Hedges LS, 2002, J FLUID ENG-T ASME, V124, P413, DOI 10.1115/1.1471532
   HELLER HH, 1977, J AIRCRAFT, V14, P768, DOI DOI 10.2514/3.5885I
   HORNE WC, 2002, 20022407 AIAA
   JAEGER SM, 2002, 20022410 AIAA
   Li F., 2002, 20022411 AIAA
   LIGHTHILL MJ, 1952, PROC R SOC LON SER-A, V211, P564, DOI 10.1098/rspa.1952.0060
   LOCKHARD D, 2004, 20042887 AIAA
   LOCKHARD D, 2003, 20033111 AIAA
   LOPES L, 2005, 20051202 AIAA
   MICHEL U, 1999, 991956 AIAA
   SEN R, 2000, NASI97040 NASA
   SMITH MG, 2002, 20022581 AIAA
   SMITH MG, 1998, 982228 AIAA
   SOULIEZ FJ, 2002, 20020799 AIAA
   STOKER RW, 1997, NASI97040 NASA
   WILLIAMS JE, 1969, PHILOS TR R SOC S-A, V264, P321, DOI 10.1098/rsta.1969.0031
NR 27
TC 11
Z9 17
U1 2
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-460X
EI 1095-8568
J9 J SOUND VIB
JI J. Sound Vibr.
PD MAY 20
PY 2008
VL 312
IS 4-5
BP 801
EP 820
DI 10.1016/j.jsv.2007.11.013
PG 20
WC Acoustics; Engineering, Mechanical; Mechanics
SC Acoustics; Engineering; Mechanics
GA 290QJ
UT WOS:000255137000017
DA 2018-12-27
ER

PT J
AU Trapasso, F
   Pichiorri, F
   Gaspari, M
   Palumbo, T
   Aqeilan, RI
   Gaudio, E
   Okumura, H
   Iuliano, R
   Di Leva, G
   Fabbri, M
   Birk, DE
   Raso, C
   Green-Church, K
   Spagnoli, LG
   Venuta, S
   Huebner, K
   Croce, CM
AF Trapasso, Francesco
   Pichiorri, Flavia
   Gaspari, Marco
   Palumbo, Tiziana
   Aqeilan, Rami I.
   Gaudio, Eugenio
   Okumura, Hiroshi
   Iuliano, Rodolfo
   Di Leva, Giampiero
   Fabbri, Muller
   Birk, David E.
   Raso, Cinzia
   Green-Church, Kari
   Spagnoli, Luigi G.
   Venuta, Salvatore
   Huebner, Kay
   Croce, Carlo M.
TI RETRACTED: Fhit interaction with ferredoxin reductase triggers
   generation of reactive oxygen species and apoptosis of cancer cells
   (Retracted article. See vol. 292, pg. 14279, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID FRAGILE HISTIDINE TRIAD; DNA-DAMAGE CHECKPOINT; DEFICIENT MICE;
   SUPPRESSES TUMORIGENICITY; FORMER SMOKERS; LUNG-CANCER; GENE; PROTEIN;
   EXPRESSION; ADRENODOXIN
AB Fhit protein is lost in most cancers, its restoration suppresses tumorigenicity, and virus-mediated FHIT gene therapy induces apoptosis and suppresses tumors in preclinical models. We have used protein cross-linking and proteomics methods to characterize a Fhit protein complex involved in triggering Fhit-mediated apoptosis. The complex includes Hsp60 and Hsp10 that mediate Fhit stability and may affect import into mitochondria, where it interacts with ferredoxin reductase, responsible for transferring electrons from NADPH to cytochrome P450 via ferredoxin. Viral-mediated Fhit restoration increases production of intracellular reactive oxygen species, followed by increased apoptosis of lung cancer cells under oxidative stress conditions; conversely, Fhit-negative cells escape apoptosis, carrying serious oxidative DNA damage that may contribute to an increased mutation rate. Characterization of Fhit interacting proteins has identified direct effectors of the Fhit- mediated apoptotic pathway that is lost in most cancers through loss of Fhit.
C1 [Trapasso, Francesco; Pichiorri, Flavia; Palumbo, Tiziana; Aqeilan, Rami I.; Gaudio, Eugenio; Okumura, Hiroshi; Iuliano, Rodolfo; Di Leva, Giampiero; Fabbri, Muller; Green-Church, Kari; Huebner, Kay] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Trapasso, Francesco; Gaspari, Marco; Gaudio, Eugenio; Iuliano, Rodolfo; Raso, Cinzia; Venuta, Salvatore] Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy.
   [Pichiorri, Flavia; Spagnoli, Luigi G.] Univ Roma Tor Vergata, Inst Anat Patol, I-00173 Rome, Italy.
   [Palumbo, Tiziana] Univ Catania, Dipartimento Farmacol Spreimentale Preclin & Clin, I-95123 Catania, Italy.
   [Birk, David E.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.
RP Croce, CM (reprint author), BRT Rm 1082,460 W 12th Ave, Columbus, OH 43210 USA.
EM Carlo.Croce@osumc.edu
RI Aqeilan, Rami/R-4443-2016; Birk, David/I-4072-2012; Green,
   Kari/H-3541-2011; Gaspari, Marco/C-2756-2009
OI Aqeilan, Rami/0000-0002-6034-023X; Birk, David/0000-0002-4865-9088;
   Gaspari, Marco/0000-0002-5411-8800; Spagnoli, Luigi
   Giusto/0000-0002-0684-5501
FU Associazione Italiana per la Ricerca sul Cancro; NCI NIH HHS [CA78890,
   CA77738, P01 CA078890, P01 CA077738]; NCRR NIH HHS [S10 RR023647]
CR Alexandre J, 2006, INT J CANCER, V119, P41, DOI 10.1002/ijc.21685
   Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378
   Daheron L, 2001, NUCLEIC ACIDS RES, V29, P1308, DOI 10.1093/nar/29.6.1308
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098
   Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497
   FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97
   Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485
   Gupta S, 2005, J CELL MOL MED, V9, P51, DOI 10.1111/j.1582-4934.2005.tb00336.x
   HANUKOGLU I, 1993, ARCH BIOCHEM BIOPHYS, V305, P489, DOI 10.1006/abbi.1993.1452
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025
   Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058
   Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111
   Ichikawa W, 2006, CANCER CHEMOTH PHARM, V58, P794, DOI 10.1007/s00280-006-0217-6
   Ishii H, 2003, FASEB J, V17, P1768, DOI 10.1096/fj.03-0241fje
   Ishii H, 2001, CANCER RES, V61, P1578
   Ishii H, 2006, CANCER RES, V66, P11287, DOI 10.1158/0008-5472.CAN-06-2503
   Ji L, 1999, CANCER RES, V59, P3333
   Kerley-Hamilton JS, 2005, ONCOGENE, V24, P6090, DOI 10.1038/sj.onc.1208755
   KIMURA T, 1967, J BIOL CHEM, V242, P485
   Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862
   Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857
   Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100
   Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195
   Ohashi M, 1999, GUT, V44, P366, DOI 10.1136/gut.44.3.366
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Ottey M, 2004, BRIT J CANCER, V91, P1669, DOI 10.1038/sj.bjc.6602058
   Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799
   Shi YF, 2000, BIOCHEM J, V352, P443, DOI 10.1042/0264-6021:3520443
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   Sozzi G, 1998, CANCER RES, V58, P5032
   Thavathiru E, 2005, MOL CARCINOGEN, V44, P174, DOI 10.1002/mc.20122
   Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100
   Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366
   Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898
NR 37
TC 55
Z9 58
U1 3
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 16
PY 2008
VL 283
IS 20
BP 13736
EP 13744
DI 10.1074/jbc.M709062200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 299AM
UT WOS:000255728200025
PM 18319262
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ni, QH
   Reid, KR
   Burant, CF
   Kennedy, RT
AF Ni, Qihui
   Reid, Kendra R.
   Burant, Charles F.
   Kennedy, Robert T.
TI RETRACTED: Capillary LC-MS for high sensitivity metabolomic analysis of
   single islets of Langerhans (Retracted Article. See vol 81, pg 9201,
   2009)
SO ANALYTICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID STIMULATED INSULIN-SECRETION; PANCREATIC BETA-CELLS; MASS-SPECTROMETRY;
   CELLULAR METABOLITES; ATP/ADP RATIO; GLUCOSE; CHROMATOGRAPHY;
   EXTRACTION; PRODUCTS; TECHNOLOGIES
AB Reversed-phase, packed capillary liquid chromatography interfaced by electrospray ionization to mass spectrometry was explored as an analytical method for determination of metabolites in microscale tissue samples using single islets of Langerhans as a model system. With the use of a 75 mu m inner diameter column coupled to a quadrupole ion trap mass spectrometer in full scan mode, detection limits of 0.1-33 fmol were achieved for glycoloytic and tricarboxylic acid cycle metabolites. Reproducible processing of islets for analysis with little loss of metabolites was performed by rapid freezing followed by methanol-water extraction. The method yielded 20 mu L of extract of which just 15 nL was injected suggesting the potential for performing multiple assays on the same islet. Approximately 200 presumed metabolites could be detected, of which 22 were identified by matching retention times and MS/MS spectra to standards. Relative standard deviations for peak detection was from 7 to 18% and was unaffected by storage for up to 11 days. The method was used to detect changes in metabolism associated with increasing extracellular islet glucose concentration from 3 to 20 mM yielding results largely consistent with known metabolism of islets. Because most previous studies of islet metabolism have only observed a few compounds at once and require far more tissue, this measurement method represents a significant advance for studies of metabolism of islets and other microscale samples.
C1 [Ni, Qihui; Reid, Kendra R.; Kennedy, Robert T.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
   [Burant, Charles F.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Kennedy, Robert T.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.
RP Kennedy, RT (reprint author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.
EM rtkenn@umich.edu
RI Kennedy, Robert/G-9095-2016
OI Kennedy, Robert/0000-0003-2447-7471; Burant, Charles/0000-0001-9189-5003
FU NIDDK NIH HHS [R01 DK046960, R37 DK046960, DK046960, R37 DK046960-16]
CR Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496
   Bajad SU, 2006, J CHROMATOGR A, V1125, P76, DOI 10.1016/j.chroma.2006.05.019
   Bolten CJ, 2007, ANAL CHEM, V79, P3843, DOI 10.1021/ac0623888
   Bundy JG, 2002, FEBS LETT, V521, P115, DOI 10.1016/S0014-5793(02)02854-5
   Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175
   DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2
   Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559
   Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905
   Dunn WB, 2005, ANALYST, V130, P606, DOI 10.1039/b418288j
   Edwards JL, 2007, J CHROMATOGR A, V1172, P127, DOI 10.1016/j.chroma.2007.09.075
   Edwards JL, 2005, ANAL CHEM, V77, P2201, DOI 10.1021/ac048323r
   Fernandez C, 2008, J PROTEOME RES, V7, P400, DOI 10.1021/pr070547d
   Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833
   FRIDLYAND LE, 2006, DIABETES REV, V2, P241
   Giroix MH, 2006, BBA-BIOENERGETICS, V1757, P773, DOI 10.1016/j.bbabio.2006.05.003
   Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O
   Griffin JL, 2004, CURR DRUG METAB, V5, P389, DOI 10.2174/1389200043335432
   Haskins WE, 2001, ANAL CHEM, V73, P5005, DOI 10.1021/ac010774d
   Hollywood K, 2006, PROTEOMICS, V6, P4716, DOI 10.1002/pmic.200600106
   Ishihara H, 2000, IUBMB LIFE, V49, P391
   Jiang N, 2007, MAMM GENOME, V18, P508, DOI 10.1007/s00335-007-9011-y
   Karas M, 2000, FRESEN J ANAL CHEM, V366, P669, DOI 10.1007/s002160051561
   KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016
   Kimball E, 2006, ANAL BIOCHEM, V358, P273, DOI 10.1016/j.ab.2006.07.038
   Lenz EM, 2007, J PROTEOME RES, V6, P443, DOI 10.1021/pr0605217
   MACDONALD M, 2007, J BIOL CHEM, V282
   MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004
   MacDonald MJ, 2003, BBA-GEN SUBJECTS, V1619, P77, DOI 10.1016/S0304-4165(02)00443-9
   Maharjan RP, 2003, ANAL BIOCHEM, V313, P145
   Mashego MR, 2004, BIOTECHNOL BIOENG, V85, P620, DOI 10.1002/bit.10907
   MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3
   Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091
   Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272
   Rochfort S, 2005, J NAT PROD, V68, P1813, DOI 10.1021/np050255w
   Ronnebaum SM, 2006, J BIOL CHEM, V281, P30593, DOI 10.1074/jbc.M511908200
   Roper MG, 2003, ANAL CHEM, V75, P4711, DOI 10.1021/ac0346813
   Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572
   Villas-Boas SG, 2005, MASS SPECTROM REV, V24, P613, DOI 10.1002/mas.20032
   Want EJ, 2005, CHEMBIOCHEM, V6, P1941, DOI 10.1002/cbic.200500151
   Want EJ, 2007, J PROTEOME RES, V6, P459, DOI 10.1021/pr060505+
NR 40
TC 16
Z9 16
U1 5
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD MAY 15
PY 2008
VL 80
IS 10
BP 3539
EP 3546
DI 10.1021/ac800406f
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 301BN
UT WOS:000255871500004
PM 18399659
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Lee, HJ
   Choi, HS
   Ju, JS
   Bae, YC
   Kim, SK
   Yoon, YW
   Aln, DK
AF Lee, Ho Jeong
   Choi, Hyo Soon
   Ju, Jin Sook
   Bae, Yong Chul
   Kim, Sung Kyo
   Yoon, Young Wook
   Aln, Dong Kuk
TI RETRACTED: Peripheral mGluR5 antagonist attenuated craniofacial muscle
   pain and inflammation but not mGluR1 antagonist in lightly anesthetized
   rats (Retracted Article. See vol 77, pg 70, 2008)
SO BRAIN RESEARCH BULLETIN
LA English
DT Article; Retracted Publication
DE antinociception; muscle inflammation; muscle pain; nociceptive
   behaviour; peripheral mGluR
ID METABOTROPIC GLUTAMATE RECEPTORS; OROFACIAL FORMALIN TEST;
   TEMPOROMANDIBULAR-JOINT; MUSTARD-OIL; NEUROGENIC INFLAMMATION;
   BEHAVIORAL-ASSESSMENT; MECHANICAL ALLODYNIA; IRRITANT APPLICATION;
   INFRAORBITAL NERVE; HYPERTONIC SALINE
AB The present study investigated the role of peripheral group I metabotropic glutamate receptors (mGluRs) in MO-induced nociceptive behaviour and inflammation in the masseter muscles of lightly anesthetized rats. Experiments were carried out on male Sprague-Dawley rats weighing 300-400 g. After initial anesthesia with sodium pentobarbital (40 mg/kg, i.p.), one femoral vein was cannulated and connected to an infusion pump for intravenous infusion of sodium pentobarbital. The rate of infusion was adjusted to provide a constant level of anesthesia. Mustard oil (MO, 30 mu l) was injected into the mid-region of the left masseter muscle via a 30-gauge needle over 10 s. After 30 mu l injection of 5, 10, 15, or 20% MO into the masseter muscle, the total number of hindpaw shaking behaviour and extravasated Evans' blue dye concentration in the masseter muscle were significantly higher in the MO-treated group in a dose-dependent manner compared with the vehicle (mineral oil)-treated group. Intramuscular pretreatment with 3 or 5% lidocaine reduced MO-induced hindpaw shaking behaviour and increases in extravasated Evans' blue dye concentration. Intramuscular pretreatment with 5 mM MCPG, non-selective group I/II mGluR antagonist, or MPEP, a selective group I mGluR5 antagonist, produced a significant attenuation of MO-induced hindpaw shaking behaviour and increases in extravasated Evans' blue dye concentration in the masseter muscle while LY367385, a selective group I mGluR1 antagonist, did not affect MO-induced nociceptive behaviour and inflammation in the masseter muscle. These results indicate that peripheral mGluR5 plays important role in mediating MO-induced nociceptive behaviour and inflammation in the craniofacial muscle. (C) 2005 Elsevier Inc. All rights reserved.
C1 [Lee, Ho Jeong; Choi, Hyo Soon; Ju, Jin Sook; Aln, Dong Kuk] Kyungpook Natl Univ, Dept Oral Physiol, Sch Dent, Taegu 700412, South Korea.
   [Bae, Yong Chul; Kim, Sung Kyo; Aln, Dong Kuk] Kyungpook Natl Univ, Dept Neurobiol, Sch Dent, Taegu 700412, South Korea.
   [Yoon, Young Wook] Korea Univ, Coll Med, Dept Physiol, Seoul 136705, South Korea.
RP Aln, DK (reprint author), Kyungpook Natl Univ, Dept Oral Physiol, Sch Dent, 188-1 Sam Deok 2Ga, Taegu 700412, South Korea.
EM dkahn@knu.ac.kr
OI Yoon, Young Wook/0000-0001-5701-6204
CR Ahn DK, 2004, NEUROSCI LETT, V357, P203, DOI 10.1016/j.neulet.2003.12.097
   ArendtNielsen L, 1996, PAIN, V64, P231, DOI 10.1016/0304-3959(95)00115-8
   ASHTONMILLER JA, 1990, SPINE, V15, P1006, DOI 10.1097/00007632-199015100-00005
   Bester H, 1998, EXP NEUROL, V154, P628, DOI 10.1006/exnr.1998.6953
   Bhave G, 2001, NAT NEUROSCI, V4, P417, DOI 10.1038/86075
   Cairns BE, 2002, NEUROSCIENCE, V109, P389, DOI 10.1016/S0306-4522(01)00489-4
   CARLSSON, 1995, TEMPOROMANDIBULAR DI, P211
   CARLTON SM, 1995, NEUROSCI LETT, V197, P25, DOI 10.1016/0304-3940(95)11889-5
   CHOI, 2005, KOREAN J PHYSIOL PHA, V9, P23
   Choi HS, 2003, NEUROSCI LETT, V352, P187, DOI 10.1016/S0304-3940(03)01074-7
   Choi HS, 2003, BRAIN RES BULL, V59, P365, DOI 10.1016/S0361-9230(02)00931-0
   CLAVELOU P, 1995, PAIN, V62, P295, DOI 10.1016/0304-3959(94)00273-H
   CLAVELOU P, 1989, NEUROSCI LETT, V103, P349, DOI 10.1016/0304-3940(89)90125-0
   Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0
   Coggeshall RE, 1998, J COMP NEUROL, V391, P78
   de Groot J, 2000, NEUROREPORT, V11, P497, DOI 10.1097/00001756-200002280-00014
   Du J, 2003, NEUROSCIENCE, V118, P547, DOI 10.1016/S0306-4522(03)00009-5
   Dux M, 1996, INFLAMM RES, V45, P10, DOI 10.1007/BF02263498
   Fiorentino PM, 1999, ARCH ORAL BIOL, V44, P27, DOI 10.1016/S0003-9969(98)00095-8
   Fisher K, 1998, NEUROREPORT, V9, P1169, DOI 10.1097/00001756-199804200-00038
   Graven-Nielsen T, 2002, EXP BRAIN RES, V146, P213, DOI 10.1007/s00221-002-1169-7
   GravenNielsen T, 1997, PAIN, V69, P111, DOI 10.1016/S0304-3959(96)03243-5
   GravenNielsen T, 1997, BRAIN RES, V744, P121, DOI 10.1016/S0006-8993(96)01077-3
   HAAS DA, 1992, ARCH ORAL BIOL, V37, P417, DOI 10.1016/0003-9969(92)90026-5
   HARADA M, 1971, J PHARM PHARMACOL, V23, P218, DOI 10.1111/j.2042-7158.1971.tb08647.x
   Hu HJ, 2002, J NEUROSCI, V22, P7444
   Inoue H, 1997, EUR J PHARMACOL, V333, P231, DOI 10.1016/S0014-2999(97)01040-6
   JENSEN K, 1992, CEPHALALGIA, V12, P101, DOI 10.1046/j.1468-2982.1992.1202101.x
   Kellgren JH, 1938, CLIN SCI, V3, P175
   Lawand NB, 2000, PAIN, V86, P69, DOI 10.1016/S0304-3959(99)00311-5
   Lawand NB, 1997, EUR J PHARMACOL, V324, P169, DOI 10.1016/S0014-2999(97)00072-1
   Liang YC, 2005, PAIN, V114, P417, DOI 10.1016/j.pain.2005.01.008.
   LYNN B, 1988, NEUROSCIENCE, V24, P769, DOI 10.1016/0306-4522(88)90065-6
   Nielsen AN, 2004, EUR J PHARMACOL, V487, P93, DOI 10.1016/j.ejphar.2004.01.017
   OCHOA J, 1989, J PHYSIOL-LONDON, V415, P583, DOI 10.1113/jphysiol.1989.sp017737
   Omote K, 1998, BRAIN RES, V787, P161, DOI 10.1016/S0006-8993(97)01568-0
   Pelissier T, 2002, PAIN, V96, P81, DOI 10.1016/S0304-3959(01)00432-8
   REEH PW, 1986, BRAIN RES, V384, P42, DOI 10.1016/0006-8993(86)91217-5
   REES H, 1994, NEUROREPORT, V5, P821, DOI 10.1097/00001756-199403000-00021
   Ro JY, 2005, BRAIN RES, V1047, P38, DOI 10.1016/j.brainres.2005.04.021
   Ro JY, 2003, BRAIN RES, V979, P78, DOI 10.1016/S0006-8993(03)02873-7
   Ro JY, 2003, PAIN, V104, P179, DOI 10.1016/S0304-3959(03)00005-8
   Sessle BJ, 1999, J OROFAC PAIN, V13, P238
   SIMONE DA, 1994, J NEUROPHYSIOL, V72, P883
   Sluka KA, 2001, MUSCLE NERVE, V24, P37, DOI 10.1002/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8
   Svensson P, 2005, J OROFAC PAIN, V19, P109
   Svensson P, 1996, PAIN, V64, P241, DOI 10.1016/0304-3959(95)00133-6
   Svensson P, 2003, PAIN, V101, P221, DOI 10.1016/S0304-3959(02)00079-9
   Svensson P, 2001, J OROFAC PAIN, V15, P117
   Svensson P, 2004, PAIN, V109, P225, DOI 10.1016/j.pain.2003.12.031
   Vos BP, 1998, PAIN, V76, P173, DOI 10.1016/S0304-3959(98)00039-6
   VOS BP, 1994, J NEUROSCI, V14, P2708
   Walker K, 2001, NEUROPHARMACOLOGY, V40, P10, DOI 10.1016/S0028-3908(00)00114-3
   Walker K, 2001, NEUROPHARMACOLOGY, V40, P1, DOI 10.1016/S0028-3908(00)00113-1
   Wong JK, 2001, ANESTH ANALG, V92, P1035
   YOUNG MR, 1994, NEUROPHARMACOLOGY, V33, P141, DOI 10.1016/0028-3908(94)90109-0
   Yu XM, 1996, PAIN, V68, P169, DOI 10.1016/S0304-3959(96)03181-8
   YU XM, 1995, PAIN, V60, P143, DOI 10.1016/0304-3959(94)00104-M
   Zhou ST, 2001, BRAIN RES, V913, P18, DOI 10.1016/S0006-8993(01)02747-0
   Zhu CZ, 2005, PAIN, V114, P195, DOI 10.1016/j.pain.2004.12.016
NR 60
TC 5
Z9 5
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD MAY 15
PY 2008
VL 76
IS 1-2
BP 8
EP 15
DI 10.1016/j.brainresbull.2005.09.002
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 296WU
UT WOS:000255577300002
PM 18395605
DA 2018-12-27
ER

PT J
AU Zhang, PY
   Yang, YW
   Zweidler-McKay, PA
   Hughes, DPM
AF Zhang, Pingyu
   Yang, Yanwen
   Zweidler-McKay, Patrick A.
   Hughes, Dennis P. M.
TI RETRACTED: Critical role of Notch signaling in osteosarcoma invasion and
   metastasis (Retracted article. See vol. 19, pg. 5256, 2013)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NONMETASTATIC OSTEOSARCOMA; TUMOR-SUPPRESSOR; DELTA HOMOLOG;
   GROWTH-FACTOR; CANCER; CELLS; EXPRESSION; MICE; TUMORIGENESIS;
   INHIBITION
AB Purpose: Notch signaling is an important mediator of growth and survival in several cancer types, with Notch pathway genes functioning as oncogenes or tumor suppressors in different cancers. However, the role of Notch in osteosarcoma is unknown.
   Experimental Design: We assessed the expression of Notch pathway genes in human osteosarcoma cell lines and patient samples. We then used pharmacologic and retroviral manipulation of the Notch pathway and studied the effect on osteosarcoma cell proliferation, survival, anchorage-independent growth, invasion, and metastasis in vitro and in vivo.
   Results: Notch pathway genes, including Notch ligand DLL1 Notch1 and Notch2, and the Notch target gene HES1, were expressed in osteosarcoma cells, and expression of HES1 was associated with invasive and metastatic potential. Blockade of Notch pathway signaling with a small molecule inhibitor of gamma secretase eliminated invasion in Matrigel without affecting cell proliferation, survival, or anchorage-independent growth. Manipulation of Notch and HES1 signaling showed a crucial role for HES1 in osteosarcoma invasiveness and metastasis in vivo.
   Conclusion: These studies identify a new invasion and metastasis-regulating pathway in osteosarcoma and define a novel function for the Notch pathway: regulation of metastasis. Because the Notch pathway can be inhibited pharmacologically, these findings point toward possible new treatments to reduce invasion and metastasis in osteosarcoma.
C1 [Zhang, Pingyu; Yang, Yanwen; Zweidler-McKay, Patrick A.; Hughes, Dennis P. M.] Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Childrens Canc Hosp, Houston, TX 77030 USA.
RP Hughes, DPM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Childrens Canc Hosp, Unit 853,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM dphughes@mdanderson.org
OI Zweidler-McKay, Patrick/0000-0001-6621-523X
FU NCI NIH HHS [K08 CA118730, 5P30CA016672-32, P30 CA016672,
   5K08CA118730-02, K08 CA118730-03]
CR Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bacci G, 2000, J CLIN ONCOL, V18, P4016, DOI 10.1200/JCO.2000.18.24.4016
   BERLIN O, 1993, CANCER RES, V53, P4890
   Bulman MP, 2000, NAT GENET, V24, P438
   CONLON RA, 1995, DEVELOPMENT, V121, P1533
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557
   Gorlick R, 1999, J CLIN ONCOL, V17, P2781, DOI 10.1200/JCO.1999.17.9.2781
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hughes DPM, 2006, PEDIATR BLOOD CANCER, V46, P614, DOI 10.1002/pbc.20454
   Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002
   Jia SF, 2003, CLIN CANCER RES, V9, P3462
   Kawakami T, 2004, EUR J MED RES, V9, P533
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094
   Kunnimalaiyaan M, 2007, ONCOLOGIST, V12, P535, DOI 10.1634/theoncologist.12-5-535
   Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961
   Lafleur EA, 2004, CLIN CANCER RES, V10, P8114, DOI 10.1158/1078-0432.CCR-04-0353
   Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Matsuno K, 2002, DEVELOPMENT, V129, P1049
   Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758
   Pollack Scott J, 2005, Curr Opin Investig Drugs, V6, P35
   Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76
   Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Rytting M, 2000, CLIN ORTHOP RELAT R, P39
   Schnabel M, 2002, INT J MOL MED, V9, P229
   Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463
   Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200
   Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5
   Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6
   Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9
   SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
   Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003
   WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6
   Yamada T, 2003, BLOOD, V101, P2227, DOI 10.1182/blood-2002-06-1740
   Zhang PY, 2004, PLANT J, V37, P566, DOI 10.1046/j.1365-313X.2003.01983.x
   Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355
NR 42
TC 115
Z9 122
U1 3
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2008
VL 14
IS 10
BP 2962
EP 2969
DI 10.1158/1078-0432.CCR-07-1992
PG 8
WC Oncology
SC Oncology
GA 303AW
UT WOS:000256012700009
PM 18483362
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Machado, FS
   Esper, L
   Dias, A
   Madan, R
   Gu, Y
   Hildeman, D
   Serhan, CN
   Karp, CL
   Aliberti, J
AF Machado, Fabiana S.
   Esper, Lisia
   Dias, Alexandra
   Madan, Rajat
   Gu, YuanYuan
   Hildeman, David
   Serhan, Charles N.
   Karp, Christopher L.
   Aliberti, Julio
TI RETRACTED: Native and aspirin-triggered lipoxins control innate immunity
   by inducing proteasomal degradation of TRAF6 (Retracted Article. See vol
   206, pg 2573, 2009)
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; TOXOPLASMA-GONDII; IL-12 PRODUCTION; DENDRITIC CELLS; KINASE
   ACTIVATION; INFLAMMATION; RECEPTOR; INTERLEUKIN-12; RESOLUTION;
   INFECTION
AB Innate immune signaling is critical for the development of protective immunity. Such signaling is, perforce, tightly controlled. Lipoxins (LXs) are eicosanoid mediators that play key counterregulatory roles during infection. The molecular mechanisms underlying LX-mediated control of innate immune signaling are of interest. In this study, we show that LX and aspirin (ASA)-triggered LX (ATL) inhibit innate immune signaling by inducing suppressor of cytokine signaling (SOCS) 2-dependent ubiquitinylation and proteasome-mediated degradation of TNF receptor-associated factor (TRAF) 2 and TRAF6, which are adaptor molecules that couple TNF and interleukin-1 receptor/Toll-like receptor family members to intracellular signaling events. LX-mediated degradation of TRAF6 inhibits proinflammatory cytokine production by dendritic cells. This restraint of innate immune signaling can be ablated by inhibition of proteasome function. In vivo, this leads to dysregulated immune responses, accompanied by increased mortality during infection. Proteasomal degradation of TRAF6 is a central mechanism underlying LX-driven immune counterregulation, and a hitherto unappreciated mechanism of action of ASA. These findings suggest a new molecular target for drug development for diseases marked by dysregulated inflammatory responses.
C1 [Machado, Fabiana S.; Esper, Lisia; Dias, Alexandra; Madan, Rajat; Gu, YuanYuan; Karp, Christopher L.; Aliberti, Julio] Cincinnati Childrens Hosp Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA.
   [Hildeman, David] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA.
   [Aliberti, Julio] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, Cincinnati, OH 45229 USA.
   [Aliberti, Julio] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA.
   [Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA.
   [Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Machado, FS (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA.
EM fabiana.machado@cchmc.org; julio.aliberti@cchmc.org
RI Aliberti, Julio/I-7354-2013; Hildeman, David/I-4884-2015; Aliberti,
   Julio/G-4565-2012
OI Aliberti, Julio/0000-0003-3420-8478; Hildeman,
   David/0000-0002-0421-8483; Madan, Rajat/0000-0002-9821-1257
FU NIAID NIH HHS [R01 AI075038, AI075038]; NIGMS NIH HHS [GM38765, R37
   GM038765, R01 GM038765]; PHS HHS [P50-DED16191]; NHLBI NIH HHS [R01
   HL079312, HL079312]
CR ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227
   Alberti J, 2003, NAT IMMUNOL, V4, P485, DOI 10.1038/ni915
   Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745
   Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957
   Aliberti J, 2005, NAT REV IMMUNOL, V5, P162, DOI 10.1038/nri1547
   Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183
   Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Bao JL, 2001, AM J PHYSIOL-HEART C, V281, pH2612
   Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788
   Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128
   Celik GE, 2007, CLIN EXP ALLERGY, V37, P1494, DOI 10.1111/j.1365-2222.2007.02806.x
   Chung JY, 2002, J CELL SCI, V115, P679
   CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475
   EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0
   Floto RA, 2006, SCIENCE, V314, P454, DOI 10.1126/science.1133515
   Grunvald E, 1996, INFECT IMMUN, V64, P2010
   Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056
   Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x
   Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414
   Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147
   Machado FS, 2006, IMMUNOL RES, V35, P209, DOI 10.1385/IR:35:3:209
   Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355
   Mackowiak PA, 2000, CLIN INFECT DIS, V31, pS154, DOI 10.1086/317510
   Mason NJ, 2004, INFECT IMMUN, V72, P5662, DOI 10.1128/IAI.72.10.5662-5667.2004
   Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661
   Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X
   Orr SJ, 2007, J BIOL CHEM, V282, P3418, DOI 10.1074/jbc.C600216200
   Paul-Clark MJ, 2004, J EXP MED, V200, P69, DOI 10.1084/jem.20040566
   Rico-Bautista E, 2006, CYTOKINE GROWTH F R, V17, P431, DOI 10.1016/j.cytogfr.2006.09.008
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   SAMUELSSON B, 1991, Z RHEUMATOL, V50, P3
   Santiago HC, 2005, J IMMUNOL, V175, P8165, DOI 10.4049/jimmunol.175.12.8165
   Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819
   Sousa CRE, 1999, IMMUNITY, V11, P637, DOI 10.1016/S1074-7613(00)80138-7
   Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202
   Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200
   Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093
NR 42
TC 40
Z9 42
U1 4
U2 10
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD MAY 12
PY 2008
VL 205
IS 5
BP 1077
EP 1086
DI 10.1084/jem.20072416
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 317EE
UT WOS:000257001800010
PM 18411340
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sell, A
   Tein, T
   Pitkanen, M
AF Sell, A.
   Tein, T.
   Pitkanen, M.
TI RETRACTED: Spinal 2-chloroprocaine: effective dose for ambulatory
   surgery (Retracted article. See vol. 56, pg. 667, 2012)
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
DE spinal anaesthesia; ambulatory; chloroprocaine
ID TRANSIENT NEUROLOGIC SYMPTOMS; INTRATHECAL 2-CHLOROPROCAINE;
   DOUBLE-BLIND; ANESTHESIA; BUPIVACAINE; LIDOCAINE; VOLUNTEERS;
   CHLOROPROCAINE; ARTHROSCOPY; TOXICITY
AB Background: There is an interest in finding a safe, short-acting spinal anaesthetic, suitable for ambulatory surgery. In this prospective study, we evaluated the effective dose of plain 2-chloroprocaine (2-CP) for lower limb surgery, including knee arthroscopy and saphenectomy.
   Methods: Sixty-four ASA physical status I-III patients undergoing elective lower limb surgery were randomly allocated to one of the four local anaesthetic groups for spinal anaesthesia in a double-blind manner. The patients (n=16 patients in each group) received 35, 40, 45 or 50 mg of 10 mg/ml isobaric 2-CP.
   Results: In all patients, anaesthesia was sufficient for the planned surgery. The median peak block height (T9) was similar in all four groups (P=0.66). Time to complete sensory block regression was faster in the 35 mg group (111 min, mean) and in the 40 mg group (108 min) than in the 50 mg group (134 min, P=0.005). No differences in time to complete motor block regression were observed (P=0.3). Home discharge time was faster in the 35 mg group (123 min) and in the 40 mg group (122 min) than in the 50 mg group (165 min, P=0.001). No complications related to spinal anaesthesia were observed and no transient neurologic symptoms (TNS) were reported at the 3-day follow-up.
   Conclusion: Spinal 2-CP, 10 mg/ml 35, 40, 45 and 50 mg provide reliable sensory and motor block for ambulatory surgery, while reducing the dose of 2-CP to 35 and 40 mg resulted in a spinal block of faster ambulation.
C1 [Sell, A.] Tartu Univ Hosp, Dept Anaesthesia, EE-51014 Tartu, Estonia.
   [Sell, A.; Tein, T.] Outpatient Clin Medex, Tartu, Estonia.
   [Tein, T.] Tartu Univ Hosp, Dept Traumatol & Orthopaed, EE-51014 Tartu, Estonia.
   [Pitkanen, M.] Orton Orthopaed Hosp, Helsinki, Finland.
RP Sell, A (reprint author), Tartu Univ Hosp, Dept Anaesthesia, L Puusepp 8, EE-51014 Tartu, Estonia.
EM andres.sell@kliinikum.ee
CR BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014
   Breebaart MB, 2003, BRIT J ANAESTH, V90, P309, DOI 10.1093/bja/aeg078
   Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8
   Casati A, 2006, ANESTH ANALG, V103, P234, DOI 10.1213/01.ane.0000221441.44387.82
   DEAN AM, 1998, DESIGN ANAL EXPT, P49
   Drasner K, 2005, ANESTH ANALG, V100, P549, DOI 10.1213/01.ANE.0000143382.89888.C3
   FOLDES FF, 1952, ANESTHESIOLOGY, V13, P287, DOI 10.1097/00000542-195205000-00009
   Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012
   GISSEN AJ, 1986, CLIN ANAESTHESIOL, V4, P101
   Gonter AF, 2005, ANESTH ANALG, V100, P573, DOI 10.1213/01.ANE.0000143380.36298.4A
   Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x
   Hampl KF, 1998, ANESTHESIOLOGY, V88, P629, DOI 10.1097/00000542-199803000-00012
   Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222
   Kopacz DJ, 2005, REGION ANESTH PAIN M, V30, P36, DOI 10.1016/j.rapm.2004.09.008
   Kouri ME, 2004, ANESTH ANALG, V98, P75, DOI 10.1213/01.ANE.0000093228.61443.EE
   Kuusniemi KS, 2000, REGION ANESTH PAIN M, V25, P605, DOI 10.1053/rapm.2000.8500
   Liu SS, 1996, ANESTHESIOLOGY, V85, P729, DOI 10.1097/00000542-199610000-00007
   Na KB, 2004, ANESTH ANALG, V98, P70, DOI 10.1213/01.ANE.0000093244.01831.D7
   RAVINDRAN RS, 1980, ANESTH ANALG, V59, P447
   REISNER LS, 1980, ANESTH ANALG, V59, P452
   SCHNEIDER M, 1993, ANESTH ANALG, V76, P1154
   Smith KN, 2004, ANESTH ANALG, V98, P81, DOI 10.1213/01.ANE.0000093361.48458.6E
   WANG BC, 1984, ANESTH ANALG, V63, P445
   Yoos JR, 2005, ANESTH ANALG, V100, P566, DOI 10.1213/01.ANE.0000143356.17013.A1
NR 24
TC 16
Z9 20
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD MAY
PY 2008
VL 52
IS 5
BP 695
EP 699
DI 10.1111/j.1399-6576.2008.01639.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 289FL
UT WOS:000255040300019
PM 18419724
DA 2018-12-27
ER

PT J
AU Emsen, IM
AF Emsen, I. M.
TI RETRACTED: Additional and different application of the bilobed flap:
   Bilobed in bilobed flap for reconstruction of the lower-upper lid and
   lateral canthal defects (Retracted Article. See vol 33, pg 675, 2009)
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article; Retracted Publication
DE ala; canthal; bilobed; flap; incision; landmark
ID SUPERFICIAL TEMPORAL ARTERY; ISLAND FLAP; EYELIDS
AB Background The rich blood supply to the skin of the face provides the reconstructive surgeon much variability with local flap planning. However, in the design of local flaps, incisions should be placed where the tension of the suture lines will not distort landmarks such as the lip, the ala, and especially the eyelid.
   Methods A case is presented with a different and further application of the bilobed flap in reconstruction of upper lower and lateral canthal region defects.
   Results With the described approach, the early postoperative and 18-month follow-up periods were seen as uneventful.
   Conclusion With regard to these local flap options, although the bilobed flap is an extremely useful flap whose usefulness in coverage of facial defects has been well described, no report has described its usage for eyelids and the lateral canthal region of this bilobed (bilobed in bilobed) flap variation.
C1 Numune State Hosp, Dept Plast Reconstruct & Aesthet Surg, Erzurum, Turkey.
RP Emsen, IM (reprint author), Numune State Hosp, Dept Plast Reconstruct & Aesthet Surg, Erzurum, Turkey.
EM ilterisemsen@hotmail.com
CR Acikel C, 2004, ANN PLAS SURG, V52, P97, DOI 10.1097/01.SAP.0000070432.99658.DB
   CARRAWAY JH, 1997, PLASTIC MAXILLOFACIA, P481
   Cologlu H, 2007, PLAST RECONSTR SURG, V119, P2080, DOI 10.1097/01.prs.0000260602.32664.ba
   ESER JFS, 1917, N Y MED J, V106, P264
   HUGHES WL, 1945, AM J OPHTHALMOL, V28, P1203, DOI 10.1016/0002-9394(45)91184-6
   Monks GH, 1898, BOSTON MED SURG J, V139, P385
   NAKAJIMA H, 1995, BRIT J PLAST SURG, V48, P439, DOI 10.1016/0007-1226(95)90118-3
   OHTSUKA H, 1982, BRIT J PLAST SURG, V35, P300, DOI 10.1016/0007-1226(82)90117-5
   Ozdemir R, 2002, PLAST RECONSTR SURG, V109, P1528
   SMALL JO, 1985, BRIT J PLAST SURG, V38, P488, DOI 10.1016/0007-1226(85)90005-0
   SPINELLI HM, 1993, PLAST RECONSTR SURG, V91, P1017, DOI 10.1097/00006534-199305000-00007
   UCHINUMA E, 1989, ANN PLAS SURG, V23, P433, DOI 10.1097/00000637-198911000-00010
NR 12
TC 1
Z9 1
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-216X
EI 1432-5241
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD MAY
PY 2008
VL 32
IS 3
BP 542
EP 545
DI 10.1007/s00266-008-9118-x
PG 4
WC Surgery
SC Surgery
GA 317LE
UT WOS:000257020900023
PM 18351416
DA 2018-12-27
ER

PT J
AU Sun, ZH
   Hu, CQ
   Wang, JY
AF Sun Zhi-Hua
   Hu Chang-Qi
   Wang Jin-Yi
TI RETRACTED: A new sesquiterpene from Caragana intermediia and its
   anti-Pyricularia oryzae P-2b activity (Retracted article. See vol. 30,
   pg. 2881, 2012)
SO CHINESE JOURNAL OF CHEMISTRY
LA English
DT Article; Retracted Publication
DE Caragana intermediia; leguminosae; sesquiterpene;
   (-)-alloaromadendrane-4 beta,10 beta-diol
AB A new aromadendrane-type sesquiterpene, ( - )-alloaromadendrane-4 beta,10 beta-diol (1), has been isolated from the aerial part of Caragana intermediia, the structure of which was established by spectroscopic methods, including X-ray analysis that provided its relative stereochemistry. Bioassay showed that 1 possessed anti-Pyricularia oryzae P-2b activity with an MIC (minimum inhibitory concentration) value of 10 mu g/mL.
C1 [Sun Zhi-Hua; Hu Chang-Qi] Fudan Univ, Sch Pharm, Dept Chem & Nat Product, Shanghai 200032, Peoples R China.
   [Wang Jin-Yi] NW A&F Univ, Coll Sci, Yangling 712100, Shaanxi, Peoples R China.
RP Hu, CQ (reprint author), Fudan Univ, Sch Pharm, Dept Chem & Nat Product, Shanghai 200032, Peoples R China.
EM cqhu@shmu.edu.cn; jinyiwangpharm@gmail.com
CR Adio AM, 2005, PHYTOCHEMISTRY, V66, P599, DOI 10.1016/j.phytochem.2005.01.015
   BEECHAN CM, 1978, TETRAHEDRON, V34, P2503, DOI 10.1016/0040-4020(78)88378-1
   GIJSEN HJM, 1992, TETRAHEDRON, V48, P2465, DOI 10.1016/S0040-4020(01)88765-2
   GOLDSBY G, 1987, PHYTOCHEMISTRY, V26, P1059, DOI 10.1016/S0031-9422(00)82350-X
   *JIANG SU NEW MED, 1985, DICT CHIN TRAD MED, P1019
   Kobayashi H, 1996, J ANTIBIOT, V49, P873, DOI 10.7164/antibiotics.49.873
   SHELRICK GM, 1997, SHELXL97 PROGRAM CRY
   Shi Jiao, 2003, Yaoxue Xuebao, V38, P599
   Sun ZH, 2004, J NAT PROD, V67, P1975, DOI 10.1021/np049866z
   Sun ZH, 2004, CHINESE J ORG CHEM, V24, P806
   Yang S, 2006, CHINESE J CHEM, V24, P1581, DOI 10.1002/cjoc.200690296
   [赵一之 ZHAO YiZhi], 2005, [生态学报, Acta Ecologica Sinica], V25, P3411
NR 12
TC 4
Z9 4
U1 4
U2 16
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1001-604X
EI 1614-7065
J9 CHINESE J CHEM
JI Chin. J. Chem.
PD MAY
PY 2008
VL 26
IS 5
BP 831
EP 834
DI 10.1002/cjoc.200890154
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 308AV
UT WOS:000256361600004
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Matsumoto, H
   Takeda, T
AF Iwamoto, Jun
   Matsumoto, Hideo
   Takeda, Tsuyoshi
TI RETRACTED: Efficacy of risedronate against hip fracture in patients with
   neurological diseases: a meta-analysis of randomized controlled trials
   (Retracted article. See vol. 33, pg. 1179, 2017)
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; hip fracture; Parkinson's disease; risedronate;
   stroke
ID POSTMENOPAUSAL OSTEOPOROSIS; CONTROLLED-TRIAL; ELDERLY-WOMEN; VITAMIN-D;
   INVOLUTIONAL OSTEOPOROSIS; NONVERTEBRAL FRACTURES; ANTIRESORPTIVE
   AGENTS; JAPANESE PATIENTS; PREVENTION; ALENDRONATE
AB Objective: Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures. The purpose of the present study was to clarify the efficacy of risedronate against hip fracture in patients with neurological diseases.
   Methods: The literature was searched with PubMed from 1995 to the present, with respect to strictly conducted randomized controlled trials (RCTs) with narrow confidence intervals (CIs), and a meta-analysis was conducted.
   Results: Four RCTs met the criteria; one RCT for Alzheimer's disease (n = 461, mean age = 78 years), two RCTs for stroke (n = 267, mean age = 76 years for men; n = 345, mean age = 71 years for women), and one RCT for Parkinson's disease (n = 223, mean age = 71 years). According to the results of RCTs, the relative risks (95% CI) for hip fracture with risedronate treatment compared with placebo treatment were 0.26 (0.10, 0.69) for Alzheimer's disease, 0.20 (0.04, 0.89) for stroke in men, 0.14 (0.02, 1.16) for stroke in women, and 0.34 (0.09, 1.21) for Parkinson's disease. Overall, the relative risk (95% Cl) for hip fracture with risedronate treatment was 0.25 (0.13, 0.48), suggesting 75% of risk reduction rate with risedronate treatment in patients with one of the three neurological diseases (heterogeneity: 0.58, p = 0.9016 and overall effect: 17.36, p < 0.0001). No severe adverse events were reported in the risedronate and placebo groups.
   Conclusion: The results of a meta-analysis of strictly conducted RCTs suggest that there is efficacy against hip fracture and safety with risedronate treatment in patients with neurological diseases including Alzheimer's disease, stroke, and Parkinson's disease.
C1 [Iwamoto, Jun; Matsumoto, Hideo; Takeda, Tsuyoshi] Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM jiwamoto@sc.itc.keio.ac.jp
RI Matsumoto, Hideo/A-2304-2014
CR Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Centre for Evidence-Based Medicine, OXF CTR EV BAS MED L
   Emkey Ronald, 2004, MedGenMed, V6, P6
   Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379
   Epstein S, 2007, BONE, V41, pS3, DOI 10.1016/j.bone.2007.03.006
   Fujita T, 2007, J BONE MINER METAB, V25, P130, DOI 10.1007/s00774-006-0738-4
   Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Iwamoto J, 2007, EXPERT OPIN PHARMACO, V8, P2743, DOI 10.1517/14656566.8.16.2743
   Iwamoto J, 2006, CURR MED RES OPIN, V22, P919, DOI 10.1185/030079906X100276
   Kendler D, 2004, MATURITAS, V48, P243, DOI 10.1016/j.maturitas.2003.12.012
   Kishimoto H, 2006, J BONE MINER METAB, V24, P405, DOI 10.1007/s00774-006-0706-z
   Kushida K, 2004, J BONE MINER METAB, V22, P469, DOI 10.1007/s00774-004-0509-z
   Liberman UA, 2006, INT J CLIN PRACT, V60, P1394, DOI 10.1111/j.1742-1241.2006.01148.x
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mellstrom DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223-004-0286-7
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8
   Sato Y, 2005, ARCH INTERN MED, V165, P1737, DOI 10.1001/archinte.165.15.1737
   Sato Y, 2005, NEUROLOGY, V64, P811, DOI 10.1212/01.WNL.0000152871.65027.76
   Sato Y, 2005, ARCH INTERN MED, V165, P1743, DOI 10.1001/archinte.165.15.1743
   Sato Y, 2002, BONE, V30, P325, DOI 10.1016/S8756-3282(01)00645-7
   Sato Y, 2007, NEUROLOGY, V68, P911, DOI 10.1212/01.wnl.0000257089.50476.92
   Sato Y, 2006, BONE, V39, P1080, DOI 10.1016/j.bone.2006.04.025
   Sato Y, 2006, MOVEMENT DISORD, V21, P924, DOI 10.1002/mds.20825
NR 26
TC 8
Z9 8
U1 5
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD MAY
PY 2008
VL 24
IS 5
BP 1379
EP 1384
DI 10.1185/030079908X297321
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 305PD
UT WOS:000256189400016
PM 18384711
OA Bronze
DA 2018-12-27
ER

PT J
AU Inokuchi, T
   Ka, T
   Yamamoto, A
   Moriwaki, Y
   Takahashi, S
   Tsutsumi, Z
   Tamada, D
   Yamamoto, T
AF Inokuchi, Taku
   Ka, Tuneyoshi
   Yamamoto, Asako
   Moriwaki, Yuji
   Takahashi, Sumio
   Tsutsumi, Zenta
   Tamada, Daisuke
   Yamamoto, Tetsuya
TI RETRACTED: Effects of ethanol on monosodium urate crystal-induced
   inflammation (Retracted article. See vol. 110, pg. 484, 2018)
SO CYTOKINE
LA English
DT Article; Retracted Publication
DE monosodium urate crystal; MAPK; p38; NF-kappa B; cytokine
ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; ACUTE ALCOHOL; PURINE-BASES;
   URIC-ACID; IN-VIVO; ACTIVATION; INTERLEUKIN-8; MONOCYTES; ARTHRITIS
AB To investigate whether ethanol is able to decrease monosodium urate (MSU) crystal-induced inflammation, differentiated THP1 cells from a human monocyte cell line were cultured in the presence or absence of MSU crystals with and without ethanol. In an in vivo experiment, MSU crystals were administered into subcutaneous air pouches created in mice, following peritoneal injection of ethanol diluted with PBS. MSU crystals (0.75 mg/ml) stimulated the secretion of TNF-alpha, IL-8, and IL- 1 beta from THP1 cells, while ethanol at a concentration of 0.8% reduced those increases by 1.79-, 1.63-, and 1.75-fold, respectively. In vitro, MSU crystals (0.75 mg/ml) significantly increased the expression of phosphorylated JNK, ERK1/2, and p38 proteins in THP1 cells, while ethanol at a concentration of 0.8% reduced those increased expressions by 1.28-, 1.14-, and 1.68-fold, respectively. In addition, MSU crystals (0.75 mg/ml) significantly increased the expression of phosphorylated NF-kappa B protein in the nuclear and cytosolic fractions and decreased the expression of I kappa B alpha in the cytosolic fraction. Ethanol at a concentration of 0.8% reduced the MSU-increased expression of phosphorylated NF-kappa B in the nuclear and cytosolic fractions by 1.25- and 1.27-fold, respectively, while it also reduced the MSU-decreased expression Of I kappa B alpha in the cytosolic fraction by 1.12-fold. In vivo, MSU crystals increased the number of leukocytes, as well as the concentrations of KC, MIP1 alpha, and IL-6 in pouch fluids, while ethanol (5 g/kg body weight) considerably inhibited the MSU crystal-induced inflammation. These results strongly suggest that ethanol suppresses the secretion of inflammatory cytokines induced by MSU crystals via a pathway including MAPK (p38, JNK, and ERK1/2, especially p38) and NF-kappa B. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Inokuchi, Taku; Ka, Tuneyoshi; Yamamoto, Asako; Moriwaki, Yuji; Takahashi, Sumio; Tsutsumi, Zenta; Tamada, Daisuke; Yamamoto, Tetsuya] Hyogo Coll Med, Dept Internal Med, Div Endocrinol & Metab, Nishinomiya, Hyogo 6638501, Japan.
RP Yamamoto, T (reprint author), Hyogo Coll Med, Dept Internal Med, Div Endocrinol & Metab, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan.
EM tetsuya@hyo-med.ac.jp
CR Arbabi S, 1999, J IMMUNOL, V162, P7441
   CHANG MP, 1990, ALCOHOL CLIN EXP RES, V14, P210, DOI 10.1111/j.1530-0277.1990.tb00474.x
   Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075
   DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213
   Goral J, 2004, J LEUKOCYTE BIOL, V75, P553, DOI 10.1189/jlb.0703350
   Goral J, 2005, J IMMUNOL, V174, P456, DOI 10.4049/jimmunol.174.1.456
   GUERNE PA, 1989, ARTHRITIS RHEUM-US, V32, P1443, DOI 10.1002/anr.1780321114
   Inokuchi T, 2006, CYTOKINE, V33, P21, DOI 10.1016/j.cyto.2005.11.010
   Jaramillo M, 2004, J BIOL CHEM, V279, P52797, DOI 10.1074/jbc.M403823200
   KAPLAN DR, 1986, CELL IMMUNOL, V102, P1, DOI 10.1016/0008-8749(86)90320-5
   LIEBER CHARLES S., 1965, ARTHRITIS RHEUM, V8, P786, DOI 10.1002/art.1780080442
   Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Matsukawa A, 1998, LAB INVEST, V78, P973
   NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422
   Oak S, 2006, J IMMUNOL, V176, P7628, DOI 10.4049/jimmunol.176.12.7628
   PUIG JG, 1984, J CLIN INVEST, V74, P936, DOI 10.1172/JCI111512
   ROBERGE CJ, 1993, J CLIN INVEST, V92, P1722, DOI 10.1172/JCI116759
   Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238
   Saeed RW, 2004, J IMMUNOL, V173, P6376, DOI 10.4049/jimmunol.173.10.6376
   Szabo G, 1999, J CLIN IMMUNOL, V19, P67, DOI 10.1023/A:1020518703050
   Szabo G, 1997, ALCOHOL HEALTH RES W, V21, P30
   Szabo G, 1996, ALCOHOL CLIN EXP RES, V20, P900, DOI 10.1111/j.1530-0277.1996.tb05269.x
   Tamura DY, 1998, J TRAUMA, V44, P320, DOI 10.1097/00005373-199802000-00015
   Terkeltaub R, 1998, ARTHRITIS RHEUM, V41, P900, DOI 10.1002/1529-0131(199805)41:5<900::AID-ART18>3.0.CO;2-K
   VERMA BK, 1993, J CLIN IMMUNOL, V13, P8, DOI 10.1007/BF00920631
   WATSON RR, 1988, LIFE SCI, V43, P865
   YAMAMOTO T, 1993, METABOLISM, V42, P1212, DOI 10.1016/0026-0495(93)90283-T
   Yamamoto T, 2005, CLIN CHIM ACTA, V356, P35, DOI 10.1016/j.cccn.2005.01.021
   Yamamoto T, 2003, METABOLISM, V52, P1501, DOI 10.1016/S0026-0495(03)00272-5
NR 30
TC 10
Z9 10
U1 1
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD MAY
PY 2008
VL 42
IS 2
BP 198
EP 204
DI 10.1016/j.cyto.2008.01.001
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 310NG
UT WOS:000256535700008
PM 18282764
DA 2018-12-27
ER

PT J
AU Hahn, S
AF Hahn, Sunku
TI RETRACTED: The convergence of fictitious play in games with strategic
   complementarities (Retracted article. See vol. 108, pg. 104, 2010)
SO ECONOMICS LETTERS
LA English
DT Article; Retracted Publication
DE fictitious play; convergence; strategic complementarities
AB This paper proved that a fictitious play always converges in I x J games with strategic complementarities. (C) 2007 Elsevier B.V. All rights reserved.
C1 Yonsei Univ, Dept Econ, Seoul 120749, South Korea.
RP Hahn, S (reprint author), Yonsei Univ, Dept Econ, Seoul 120749, South Korea.
EM hahn@yonsei.ac.kr
CR Hahn S, 1999, ECON LETT, V64, P57, DOI 10.1016/S0165-1765(99)00058-0
   Hofbauer J, 2002, ECONOMETRICA, V70, P2265, DOI 10.1111/1468-0262.00376
   KRISHNA V, 1992, 92073 HARV BUS SCH
   Miyasawa K., 1961, 33 PRINC U EC RES PR
NR 4
TC 2
Z9 2
U1 2
U2 10
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0165-1765
EI 1873-7374
J9 ECON LETT
JI Econ. Lett.
PD MAY
PY 2008
VL 99
IS 2
BP 304
EP 306
DI 10.1016/j.econlet.2007.07.018
PG 3
WC Economics
SC Business & Economics
GA 306FX
UT WOS:000256234800024
DA 2018-12-27
ER

PT J
AU Geymen, A
   Baz, I
AF Geymen, Abdurrahman
   Baz, Ibrahim
TI RETRACTED: The potential of remote sensing for monitoring land cover
   changes and effects on physical geography in the area of Kayisdagi
   Mountain and its surroundings (Istanbul) (Retracted Article. See vol
   162, pg 477, 2010)
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Retracted Publication
DE land degradation; geographic information system; physical geography;
   remote sensing; land cover; Istanbul; geomorphology; monitoring
ID INFORMATION-SYSTEM; CLASSIFICATION; INTEGRATION; SATELLITE; ACCURACY
AB The effect of land cover change, from natural to anthropogenic, on physical geography conditions has been studied in Kayisdagi Mountain. Land degradation is the most important environmental issue involved in this study. Most forms of land degradation are natural processes accelerated by human activity. Land degradation is a human induced or natural process that negatively affects the ability of land to function effectively within an ecosystem. Environmental degradation from human pressure and land use has become a major problem in the study area because of high population growth, urbanization rate, and the associated rapid depletion of natural resources. When studying the cost of land degradation, it is not possible to ignore the role of urbanization. In particular, a major cause of deforestation is conversion to urban land. The paper reviews the principles of current remote sensing techniques considered particularly suitable for monitoring Kayisdagi Mountain and its surrounding land cover changes and their effects on physical geography conditions. In addition, this paper addresses the problem of how spatially explicit information about degradation processes in the study area rangelands can be derived from different time series of satellite data. The monitoring approach comprises the time period between 1990 and 2005. Satellite remote sensing techniques have proven to be cost effective in widespread land cover changes. Physical geography and particularly natural geomorphologic processes like erosion, mass movement, physical weathering, and chemical weathering features etc. have faced significant unnatural variation.
C1 [Geymen, Abdurrahman] Erciyes Univ, Dept Geodesy & Photogrammetry Engn, Fac Engn, TR-38039 Kayseri, Turkey.
   [Baz, Ibrahim] Istanbul Metropolitan Municipal, Istanbul, Turkey.
RP Geymen, A (reprint author), Erciyes Univ, Dept Geodesy & Photogrammetry Engn, Fac Engn, TR-38039 Kayseri, Turkey.
EM ageymen@erciyes.edu.tr
CR CONGALTON RG, 1991, REMOTE SENS ENVIRON, V37, P35, DOI 10.1016/0034-4257(91)90048-B
   Devlet Istatistik Enstitusu (DIE), 2000, NUF SAYIM SON
   EHLERS M, 1990, PHOTOGRAMM ENG REM S, V56, P175
   Foody GM, 2002, REMOTE SENS ENVIRON, V80, P185, DOI 10.1016/S0034-4257(01)00295-4
   Geymen A, 2008, ENVIRON MONIT ASSESS, V136, P449, DOI 10.1007/s10661-007-9699-x
   Haack BN, 2000, PHOTOGRAMM ENG REM S, V66, P709
   HARRIS PM, 1995, PHOTOGRAMM ENG REM S, V61, P993
   Helmschrot J, 2002, PHYS CHEM EARTH, V27, P711, DOI 10.1016/S1474-7065(02)00055-4
   IRISH R, 1990, GIS WORLD        AUG, P59
   Jensen J. R., 1996, INTRO DIGITAL IMAGE
   KUCUKMEHMETOGLU M, 2006, 46 C EUR REG SCI VOL
   Maktav D, 2005, INT J REMOTE SENS, V26, P797, DOI 10.1080/01431160512331316784
   Mendoza JE, 2002, LANDSCAPE URBAN PLAN, V59, P147, DOI 10.1016/S0169-2046(02)00012-9
   Pal M, 2003, REMOTE SENS ENVIRON, V86, P554, DOI 10.1016/S0034-4257(03)00132-9
   RITTER DF, 1995, PROCESS GEOMORPHOLOG
   Steele BM, 2000, REMOTE SENS ENVIRON, V74, P545, DOI 10.1016/S0034-4257(00)00145-0
   TREITZ PM, 1992, PHOTOGRAMM ENG REM S, V58, P439
   Weber RM, 2001, PHOTOGRAMM ENG REM S, V67, P179
   WELCH R, 1988, PHOTOGRAMM ENG REM S, V54, P177
   WESTMORELAND S, 1992, PHOTOGRAMM ENG REM S, V58, P1593
NR 20
TC 6
Z9 8
U1 3
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6369
EI 1573-2959
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD MAY
PY 2008
VL 140
IS 1-3
BP 33
EP 42
DI 10.1007/s10661-007-9844-6
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 280NV
UT WOS:000254434400003
PM 17624804
DA 2018-12-27
ER

PT J
AU Faghri, J
AF Faghri, Jamshid
TI RETRACTED: Isolation of coagulase-negative staphylococci from
   extended-wear soft contact lenses in asymptomatic patients (Retracted
   article. See vol. 35, pg. 113, 2009)
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Article; Retracted Publication
DE soft contact lenses; coagulase Negative staphylococci; Pseudomonas
   aeruginosa; Serratia marcescens; extended-wear contact lenses
ID SERRATIA-MARCESCENS; KERATITIS; EYE
AB Background. Coagulase-negative staphylococci and diphtheroids are normal inhabitants of the outer Surface of the human eye. These microorganisms serve as part of the defense mechanism of the Ocular anatomy in preventing colonization and infection by pathogenic bacteria. Nevertheless. infections associated with contaminated solutions and cases became serious problems for people who wear soft contact lenses. The aim of this study is to isolate and identify aerobic bacteria, particularly, gram-negative species associated with the use of extended-wear soft contact lenses. Methods. Extended-wear contact lenses were collected, using aseptic technique, from the eyes of individuals after 30 days of extended wear (5-7 day intermittent periods) and were examined for adhered aerobic bacteria. Result. coagulase-negative staphylococci were isolated from 74% of the lenses. Serratia marcescens was found at air incidence of 10% and Pseudomonas aeruginosa at all incidence of 6%. Conclusions. The presence of species of bacteria. including P. aeruginosa and S. marcescens, which have been associated with daily wear soft contact lenses, Solutions. and cases also seem to be associated with extended-wear lenses.
C1 Isfahan Univ Med Sci, Dept Microbiol, Esfahan, Iran.
RP Faghri, J (reprint author), Isfahan Univ Med Sci, Dept Microbiol, Esfahan, Iran.
EM faghri@med.mui.ac.ir
RI faghri, jamshid/V-8503-2017
OI faghri, jamshid/0000-0001-7500-168X
CR Balows A, 1991, MANUAL CLIN MICROBIO
   CHANDLER JW, 1983, OPHTHALMOLOGY, V90, P585
   Cheng KH, 1999, LANCET, V354, P181, DOI 10.1016/S0140-6736(98)09385-4
   COKINGTIN CD, 1996, INFECTIONS EYE, P323
   FLEISZIG SMJ, 1992, J CLIN MICROBIOL, V30, P1156
   GHANDI PA, 1993, APPL ENVIRON MICROB, V59, P183
   Holden Brien A., 1996, CLAO Journal, V22, P47
   Keay Lisa, 2001, CLAO Journal, V27, P30
   Laibson Peter R., 1993, CLAO (Contact Lens Association of Ophthalmologists) Journal, V19, P73
   LARKIN DFP, 1991, EYE, V5, P70, DOI 10.1038/eye.1991.14
   Leitch EC, 1998, OPTOMETRY VISION SCI, V75, P258, DOI 10.1097/00006324-199804000-00022
   MAYO MS, 1987, J CLIN MICROBIOL, V25, P1398
   MILLER MJ, 2001, CLAO J, P2716
   PARMENT PA, 1981, ACTA OPHTHALMOL, V59, P560
   PARMENT PA, 1986, ACTA OPHTHALMOL, V64, P456
   STEPLETON F, 1995, EPIDEMIOL INFECT, V114, P395, DOI 10.1017/S0950268800052109
   Willcox MDP, 1997, OPTOMETRY VISION SCI, V74, P1030, DOI 10.1097/00006324-199712000-00025
   WILSON LA, 1991, ARCH OPHTHALMOL-CHIC, V109, P1155, DOI 10.1001/archopht.1991.01080080115043
   WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0
NR 19
TC 2
Z9 2
U1 4
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1542-2321
EI 1542-233X
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD MAY
PY 2008
VL 34
IS 3
BP 182
EP 184
DI 10.1097/ICL.0b013e318159aff6
PG 3
WC Ophthalmology
SC Ophthalmology
GA 343EK
UT WOS:000258835400010
PM 18463486
DA 2018-12-27
ER

PT J
AU Gethin, GT
   Cowman, S
   Conroy, RM
AF Gethin, Georgina T.
   Cowman, Seamus
   Conroy, Ronan M.
TI RETRACTED: The impact of Manuka honey dressings on the surface pH of
   chronic wounds (Retracted article. See vol. 11, pg. 342, 2014)
SO INTERNATIONAL WOUND JOURNAL
LA English
DT Article; Retracted Publication
DE Honey; pH; Wound healing
AB Chronic non healing wounds have an elevated alkaline environment. The acidic pH of Manuka honey makes it a potential treatment for lowering wound pH, but the duration of effect is unknown. Lowering wound pH can potentially reduce protease activity, increase fibroblast activity and increase oxygen release consequently aiding wound healing. The aim of this study was to analyse the changes in surface pH and size of non healing ulcers following application of Manuka honey dressing after 2 weeks. The study was an open label, non randomised prospective study. Patients presenting consecutively with non healing chronic superficial ulcers, determined by aetiology and no reduction in wound size in previous 3 weeks. Single pH measurements recorded using Blueline 27 glass surface electrode and R 315 pH meter set (Reagecon/Alkem, Co. Clare Ireland). Area determined using Visitrak (Smith & Nephew, Mull, UK) digital planimetry. Apinate (R) (Manuka honey) (Comvita, Slough, UK) applied to wounds for 2 weeks after which wounds re-evaluated. Eight males and nine females with 20 ulcers (3 bilateral) were included: venous, 50% (n = 10); mixed aetiology, 35% (n = 7); arterial, 10% (n = 2) and pressure ulcer, 5% (n = 1). Reduction in wound pH after 2 weeks was statistically significant (P < 0.001). Wounds with pH >= 8.0 did not decrease in size and wounds with pH <= 7.6 had a 30% decrease in size. A reduction in 0.1 pH unit was associated with an 8.1% reduction in wound size (P < 0.012). The use of Manuka honey dressings was associated with a statistically significant decrease in wound pH and a reduction in wound size. Elevated pH readings at the start were associated with minimal reduction in size. Surface wound pH measurements may contribute to objective wound assessments, but further research is necessary to determine its exact contribution.
C1 [Gethin, Georgina T.] Royal Coll Surgeons Ireland, Fac Nursing & Midwifery, Res Ctr, Dublin 2, Ireland.
RP Gethin, GT (reprint author), Royal Coll Surgeons Ireland, Fac Nursing & Midwifery, Res Ctr, Dublin 2, Ireland.
EM ggethin@eircom.net
OI Gethin, Georgina/0000-0001-5859-8357; Conroy, Ronan/0000-0001-5983-8682
FU Research and Education Foundation Sligo General Hospital; European Wound
   Management Association; Health Research Board of Ireland
FX This study formed part of other research studies, which is grant aided
   by Research and Education Foundation Sligo General Hospital, European
   Wound Management Association and Health Research Board of Ireland.
   Thanks to tissue viability nurses, Sligo General Hospital, for their
   assistance.
CR BRETT D, 2003, PH HISTORIC REV TOPI
   CHIRIFE J, 1983, ANTIMICROB AGENTS CH, V23, P766, DOI 10.1128/AAC.23.5.766
   Colin D, 1996, J Wound Care, V5, P444
   Cooper R, 1999, J Wound Care, V8, P161
   Cooper RA, 2002, J APPL MICROBIOL, V93, P857, DOI 10.1046/j.1365-2672.2002.01761.x
   Cooper RA, 1999, J ROY SOC MED, V92, P283, DOI 10.1177/014107689909200604
   DUNFORD C, 2000, NURS TIMES, V9, P7
   EFEM SEE, 1988, BRIT J SURG, V75, P679, DOI 10.1002/bjs.1800750718
   Flanagan M, 2003, J Wound Care, V12, P189
   GANONG WF, 2001, REV MED PHYSL
   Gethin G, 2006, J CLIN NURS, V15, P422, DOI 10.1111/j.1365-2702.2006.01364.x
   Gethin Georgina, 2005, Int Wound J, V2, P10, DOI 10.1111/j.1742-4801.2005.00078.x
   Green J.H., 1978, BASIC CLIN PHYSL
   Greener B, 2005, J Wound Care, V14, P59
   HIMEL HN, 1995, WOUNDS, V7, pA70
   HOFFMAN R, 1999, J WOUND CARE, V8, P272
   Hunt TK, 1997, SURG CLIN N AM, V77, P587, DOI 10.1016/S0039-6109(05)70570-3
   HUNT TK, 2005, WOUND MANAGEMENT MAN
   Johnson DW, 2005, J AM SOC NEPHROL, V16, P1456, DOI 10.1681/ASN.2004110997
   JULL AB, 2006, 16 C EUR WOUND MAN A, P48
   Kantor J, 2000, BRIT J DERMATOL, V142, P960, DOI 10.1046/j.1365-2133.2000.03478.x
   KAUFMAN T, 1985, BURNS, V12, P84, DOI 10.1016/0305-4179(85)90032-4
   Konig M, 2005, J Wound Care, V14, P320
   LEUNG D, 2001, HONG KONG J NEPHROL, V3, P38
   LEVEEN HH, 1973, ANN SURG, V178, P745, DOI 10.1097/00000658-197312000-00011
   Liu YW, 2002, WOUND REPAIR REGEN, V10, P336, DOI 10.1046/j.1524-475X.2002.10510.x
   MANI R, 2000, CHRONIC WOUND HEALIN, P136
   Margolis DJ, 2000, AM J MED, V109, P15, DOI 10.1016/S0002-9343(00)00379-X
   MELHUISH J, 1993, P 3 EUR C ADV WOUND, P41
   MILNER SM, 1992, LANCET, V340, P61, DOI 10.1016/0140-6736(92)92483-V
   MOLAN P, 2002, OSTOMY WOUND MANAG, V48, P228
   Molan P C, 2004, J Wound Care, V13, P353
   Molan PC, 1999, BEE WORLD, V80, P80, DOI 10.1080/0005772X.1999.11099430
   MOLAN PC, 2006, LOWER EXTREMITY WOUN, V5, P40
   MOLAN PC, 1998, PRIMARY INTENTION, V6, P148
   Morykwas M J, 1997, J South Orthop Assoc, V6, P279
   Okeniyi JAO, 2005, J ALTERN COMPLEM MED, V11, P511, DOI 10.1089/acm.2005.11.511
   PERCIVAL B, 2004, UNDERSTANDING EFFECT
   PHILLIPS I, 1968, LANCET, V1, P11
   Plassmann P, 1995, J Wound Care, V4, P269
   ROBERTS G, 1997, P 7 EUR C ADV WOUND, P104
   Romanelli M, 1997, WOUNDS, V9, P122
   Romanelli M, 2002, WOUNDS, V14, P58
   Romanelli M, 1997, EVALUATION SURFACE P
   Schultz G, 2005, WOUND REPAIR REGEN, V13, pS1, DOI 10.1111/j.1067-1927.2005.1304S1.x
   SHEFFIELD P, 1988, PROBLEM WOUNDS ROLE
   SOLOMON E, 1990, HUMAN ANATOMY PHYSL
   STACY M, 2000, CHRONIC WOUND HEALIN, P99
   Steed David L, 2006, Int Wound J, V3, P40, DOI 10.1111/j.1742-4801.2006.00178.x
   Subrahmanyam M, 1998, BURNS, V24, P157, DOI 10.1016/S0305-4179(97)00113-7
   Tallman P, 1997, ARCH DERMATOL, V133, P1231, DOI 10.1001/archderm.133.10.1231
   Thomas S, 1990, WOUND MANAGEMENT DRE
   TIMOTHY J, 2000, WOUND REPAIR REGEN, V8, P264
   Trengove N J, 1996, J Wound Care, V5, P277
   Trengove NJ, 1999, WOUND REPAIR REGEN, V7, P442, DOI 10.1046/j.1524-475X.1999.00442.x
   Tsukada K, 1992, WOUNDS, V4, P16
   Wayman J, 2000, J Tissue Viability, V10, P91
   WILSON IAI, 1979, VASA-J VASCULAR DIS, V8, P339
NR 58
TC 69
Z9 71
U1 3
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-4801
EI 1742-481X
J9 INT WOUND J
JI Int. Wound J.
PD MAY
PY 2008
VL 5
IS 2
BP 185
EP 194
DI 10.1111/j.1742-481X.2007.00424.x
PG 10
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V16AW
UT WOS:000207843500007
PM 18494624
DA 2018-12-27
ER

PT J
AU Yao, K
   Wu, W
   Yu, YB
   Zeng, QL
   He, JL
   Lu, DQ
   Wang, KJ
AF Yao, Ke
   Wu, Wei
   Yu, Yibo
   Zeng, Qunli
   He, Jiliang
   Lu, Deqiang
   Wang, Kaijun
TI RETRACTED: Effect of superposed electromagnetic noise on DNA damage of
   lens epithelial cells induced by microwave radiation (Retracted article.
   See vol. 50, pg. 4530, 2009)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article; Retracted Publication
ID PHOSPHORYLATED HISTONE H2AX; DOUBLE-STRAND BREAKS; RAT-BRAIN CELLS;
   IN-VITRO EXPOSURE; IONIZING-RADIATION; OXIDATIVE STRESS; RADIOFREQUENCY
   RADIATION; MAGNETIC-FIELDS; 1800 MHZ; EXPRESSION
AB PURPOSE. To investigate the influence of the 1.8-GHz radiofrequency fields (RFs) of the Global System for Mobile Communications on DNA damage, intracellular reactive oxygen species (ROS) formation, cell cycle, and apoptosis in human lens epithelial cells (hLECs) and whether the effects induced by RF could be blocked by superposing of electromagnetic noise.
   METHODS. After 24-hour intermittent exposure at the specific absorption rate of 1 W/kg, 2 W/kg, 3 W/kg, and 4 W/kg, the DNA damage of hLECs was examined by alkaline comet assay and immunofluorescence microscope detection of the phosphorylated form of histone variant H2AX (gamma H2AX) foci, respectively. ROS production was quantified by the fluorescent probe 2', 7'-dichlorodihydrofluorescein diacetate (DCFH-DA). Cell cycle and cell apoptosis were determined by flow cytometry.
   RESULTS. DNA damage examined by alkaline comet assay was significantly increased after 3 W/kg and 4 W/kg radiation (P < 0.05), whereas the double-strand breaks (DSBs) evaluated by gamma H2AX foci were significantly increased only after 4 W/kg radiation (P < 0.05). Significantly elevated intracellular ROS levels were also detected in the 3-W/kg and 4-W/kg groups (P < 0.05). After exposure to 4 W/kg for 24 hours, hLECs exhibited significant G(0)/G(1) arrest (P < 0.05). There was no detectable difference in cell apoptosis between the microwave radiation and sham exposure groups (P > 0.05). All the effects mentioned were blocked when the RF was superposed with 2 mu T electromagnetic noise.
   CONCLUSIONS. Microwave radiation induced hLEC DNA damage after G(0)/G(1) arrest does not lead to cell apoptosis. The increased ROS observed may be associated with DNA damage. Superposed electromagnetic noise blocks microwave radiation-induced DNA damage, ROS formation, and cell cycle arrest.
C1 [Yao, Ke; Wu, Wei; Yu, Yibo; Wang, Kaijun] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310009, Peoples R China.
   [Zeng, Qunli; Lu, Deqiang] Zhejiang Univ, Coll Med, Bioelectromagnet Lab, Hangzhou 310009, Peoples R China.
   [He, Jiliang] Zhejiang Univ, Coll Med, Inst Occupat Environm Hlth, Hangzhou 310009, Peoples R China.
RP Yao, K (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Ctr Eye, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
EM xlren@zju.edu.cn
CR Albino AP, 2004, CELL CYCLE, V3, P1062
   ARITA T, 1993, INVEST OPHTH VIS SCI, V34, P355
   ARITA T, 1990, INVEST OPHTH VIS SCI, V31, P2395
   Balci M, 2007, CURR EYE RES, V32, P21, DOI 10.1080/02713680601114948
   Banath JP, 2003, CANCER RES, V63, P4347
   Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002
   Belyaev IY, 2006, BIOELECTROMAGNETICS, V27, P295, DOI 10.1002/bem.20216
   Brusick D, 1998, ENVIRON MOL MUTAGEN, V32, P1
   Diem E, 2005, MUTAT RES-GEN TOX EN, V583, P178, DOI 10.1016/j.mrgentox.2005.03.006
   Dizdaroglu M, 1998, DNA AND FREE RADICALS: TECHNIQUES, MECHANISMS & APPLICATIONS, P3
   FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3
   Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024
   Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884
   Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509
   Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200
   Gallmeier E, 2005, CARCINOGENESIS, V26, P1811, DOI 10.1093/carcin/bgi132
   GARAJVRHOVAC V, 1991, MUTAT RES, V263, P143, DOI 10.1016/0165-7992(91)90054-8
   Hook GJ, 2004, RADIAT RES, V161, P193, DOI 10.1667/RR3127
   Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551
   *IEEE, 1999, C951 STD
   International Commission on Non-Ionizing Radiation Protection, 1998, HEALTH PHYS, V74, P494
   KLEIMAN NJ, 1993, CURR EYE RES, V12, P423, DOI 10.3109/02713689309024624
   Lai H, 1996, INT J RADIAT BIOL, V69, P513, DOI 10.1080/095530096145814
   Lai H, 2004, PHYSIOL BEHAV, V82, P785, DOI 10.1016/j.physbeh.2004.06.020
   LAI H, 1995, BIOELECTROMAGNETICS, V16, P207, DOI 10.1002/bem.2250160309
   Lawler JM, 2003, FREE RADICAL BIO MED, V35, P9, DOI 10.1016/S0891-5849(03)00186-2
   LIPMAN RM, 1988, SURV OPHTHALMOL, V33, P200, DOI 10.1016/0039-6257(88)90088-4
   Litovitz TA, 1997, BIOELECTROMAGNETICS, V18, P422, DOI 10.1002/(SICI)1521-186X(1997)18:6<422::AID-BEM4>3.0.CO;2-4
   LITOVITZ TA, 1994, BIOELECTROMAGNETICS, V15, P105, DOI 10.1002/bem.2250150203
   LITOVITZ TA, 1994, BIOELECTROMAGNETICS, V15, P399, DOI 10.1002/bem.2250150504
   LITOVITZ TA, 1991, BIOCHEM BIOPH RES CO, V178, P862, DOI 10.1016/0006-291X(91)90970-I
   MacPhail SH, 2003, INT J RADIAT BIOL, V79, P351, DOI 10.1080/0955300032000093128
   Malyapa RS, 1998, RADIAT RES, V149, P637, DOI 10.2307/3579911
   Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361
   Moneda AP, 2003, IEEE T BIO-MED ENG, V50, P667, DOI 10.1109/TBME.2003.812222
   Moustafa YM, 2001, J PHARMACEUT BIOMED, V26, P605, DOI 10.1016/S0731-7085(01)00492-7
   Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2
   Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/003-042
   Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100
   Schonborn F, 2001, BIOELECTROMAGNETICS, V22, P547, DOI 10.1002/bem.83
   Singh Narendra P., 1996, P3
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   SPECTOR A, 1995, FASEB J, V9, P1173
   Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207
   Stopczyk Dariusz, 2005, Ann Acad Med Stetin, V51 Suppl 1, P125
   Sun LX, 2006, MUTAT RES-FUND MOL M, V602, P135, DOI 10.1016/j.mrfmmm.2006.08.010
   Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   Wang BH, 2005, MUTAT RES-FUND MOL M, V578, P149, DOI 10.1016/j.mrfmmm.2005.05.001
   Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141
   Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200
   Xie Liang, 2006, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V24, P461
   Ye J, 2001, CHINESE MED J-PEKING, V114, P1290
   Zeng QL, 2006, BIOELECTROMAGNETICS, V27, P274, DOI 10.1002/bem.20207
   Zhang Dan-ying, 2006, Zhonghua Yufang Yixue Zazhi, V40, P149
NR 57
TC 23
Z9 23
U1 4
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2008
VL 49
IS 5
BP 2009
EP 2015
DI 10.1167/iovs.07-1333
PG 7
WC Ophthalmology
SC Ophthalmology
GA 292UH
UT WOS:000255291100036
PM 18436834
OA Bronze
DA 2018-12-27
ER

PT J
AU Gopikrishna, V
   Baweja, PS
   Venkateshbabu, N
   Thomas, T
   Kandaswamy, D
AF Gopikrishna, Velayutham
   Baweja, Parvinder Singh
   Venkateshbabu, Nagendrababu
   Thomas, Toby
   Kandaswamy, Deivanayagam
TI RETRACTED: Comparison of coconut water, propolis, HBSS, and milk on PDL
   cell survival (Retracted article. See vol. 40, pg. 290, 2014)
SO JOURNAL OF ENDODONTICS
LA English
DT Article; Retracted Publication
DE avulsed teeth; coconut water; collagenase dispase assay; propolis;
   transport media
ID PERIODONTAL-LIGAMENT CELLS; MATURE PERMANENT INCISORS; STORAGE MEDIA;
   AVULSED TEETH; REPLANTATION; VIABILITY; FIBROBLASTS; MONKEYS
AB Coconut water is biologically pure and sterile, with a rich presence of amino acids, proteins, vitamins, and minerals. The purpose of this study was to use a collagenase-dispase assay to investigate the potential of a new storage medium, coconut water, in comparison with propolis, Hank's balanced salt solution (HBSS), and milk in maintaining viable periodontal ligament (PDL) cells on simulated avulsed teeth. Seventy freshly extracted human teeth were divided into 4 experimental groups and 2 control groups, The positive and negative controls corresponded to 0-minute and 8-hour dry times, respectively. The experimental teeth were stored dry for 30 minutes and then immersed in 1 of the 4 media (coconut water, propolis, HBSS, and milk). The teeth were then treated with dispase grade II and collagenase for 30 minutes. The number of viable PDL cells was counted with a hemocytometer and analyzed. Statistical analysis showed that coconut water kept significantly more PDL cells viable compared with propolis, HBSS, or milk. Coconut water can be used as a superior transport medium for avulsed teeth.
C1 [Gopikrishna, Velayutham; Baweja, Parvinder Singh; Venkateshbabu, Nagendrababu; Thomas, Toby; Kandaswamy, Deivanayagam] Meenakshi Ammal Dent Coll, Dept Conservat Dent & Endodont, Madras 600095, Tamil Nadu, India.
RP Gopikrishna, V (reprint author), Meenakshi Ammal Dent Coll, Dept Conservat Dent & Endodont, Alapakkam Main Rd, Madras 600095, Tamil Nadu, India.
EM hi_gopikrishna@hotmail.com
RI gopikrishna, velayutham/P-8072-2015
OI gopikrishna, velayutham/0000-0002-1864-7254
CR American Association of Endodontists, 1995, REC GUID TREATM AV P
   ANDREASEN JO, 1981, ACTA ODONTOL SCAND, V39, P1
   ANDREASEN JO, 1981, INT J ORAL MAXILLOF, V10, P43, DOI 10.1016/S0300-9785(81)80007-5
   ANDREASEN JO, 1981, EXARTICULATION TRAUM
   Anzaldo FE, 1975, PHILIPP J PEDIAT, V24, P143
   BANKOVA VS, 1983, J NAT PROD, V46, P471, DOI 10.1021/np50028a007
   Barrett EJ, 1997, ENDOD DENT TRAUMATOL, V13, P153
   Blomlof L, 1981, Swed Dent J Suppl, V8, P1
   Campbell-Falck D, 2000, AM J EMERG MED, V18, P108, DOI 10.1016/S0735-6757(00)90062-7
   Cheng PC, 1996, BEE WORLD, V77, P8, DOI 10.1080/0005772X.1996.11099278
   DUMSHA T C, 1992, Dental Clinics of North America, V36, P425
   FOUNTAIN SB, 1998, PATHWAYS PULP
   Gopikrishna V, 2008, ORAL SURG ORAL MED O, V105, pE61, DOI 10.1016/j.tripleo.2007.08.003
   Hammer H, 1955, INT DENT J, V5, P439
   HILTZ J, 1991, ENDOD DENT TRAUMATOL, V7, P69
   KRASNER P, 1992, J AM DENT ASSOC, V123, P80, DOI 10.14219/jada.archive.1992.0300
   LINDSKOG S, 1982, ACTA ODONTOL SCAND, V40, P435, DOI 10.3109/00016358209025118
   Markham KR, 1996, PHYTOCHEMISTRY, V42, P205, DOI 10.1016/0031-9422(96)83286-9
   Martin MP, 2004, DENT TRAUMATOL, V20, P85, DOI 10.1111/j.1600-4469.2004.00233.x
   Matsson L, 1982, PEDIATR DENT, V4, P327
   Olson BD, 1997, J ENDODONT, V23, P676, DOI 10.1016/S0099-2399(97)80399-8
   Oncag Ozant, 2006, Gen Dent, V54, P319
   Ozan F, 2007, J ENDODONT, V33, P570, DOI 10.1016/j.joen.2006.12.021
   PATIL S, 1992, J ENDODONT, V18, P189
   Pileggi R, 2002, DENT TRAUMATOL, V18, P186, DOI 10.1034/j.1600-9657.2002.00092.x
   POLVERINI PJ, 1984, LAB INVEST, V51, P635
   REINHOLDT J, 1977, INT J ORAL MAXILLOF, V6, P215, DOI 10.1016/S0300-9785(77)80012-4
   Rethinam P., 2006, COCONUT WATER NATURE
   SODER PO, 1977, SCAND J DENT RES, V85, P164
   TRONSTAD L, 1988, ENDOD DENT TRAUMATOL, V4, P241
   Trope M, 1995, Dent Clin North Am, V39, P93
NR 31
TC 50
Z9 59
U1 4
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-2399
EI 1878-3554
J9 J ENDODONT
JI J. Endod.
PD MAY
PY 2008
VL 34
IS 5
BP 587
EP 589
DI 10.1016/j.joen.2008.01.018
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 294AB
UT WOS:000255375400018
PM 18436040
DA 2018-12-27
ER

PT J
AU Ahimastos, AA
   Dart, AM
   Lawler, A
   Blombery, PA
   Kingwell, BA
AF Ahimastos, Anna A.
   Dart, Anthony M.
   Lawler, Adam
   Blombery, Peter A.
   Kingwell, Bronwyn A.
TI RETRACTED: Reduced arterial stiffness may contribute to
   angiotensin-converting enzyme inhibitor induced improvements in walking
   time in peripheral arterial disease patients (Retracted article. See
   vol. 33, pg. 2552, 2015)
SO JOURNAL OF HYPERTENSION
LA English
DT Article; Retracted Publication
DE angiotensin-converting enzyme; arteries; blood flow; exercise;
   peripheral arterial disease
ID INCREASED PULSE PRESSURE; STAGE RENAL-DISEASE; AORTIC STIFFNESS;
   INDEPENDENT PREDICTOR; HYPERTENSIVE PATIENTS; CEREBRAL ARTERIOLES;
   VASCULAR-DISEASE; ALL-CAUSE; INCREASES; ASSOCIATION
AB Objective Claudication is a debilitating consequence of peripheral arterial disease. Evidence is accumulating to suggest that large artery stiffness may influence peripheral perfusion and walking time through effects on peripheral hemodynamics as well as microvascular structure and function. We have previously shown that the angiotensin-converting enzyme inhibitor ramipril increased systemic arterial compliance by 64%, and increased maximum walking time by over 200% in patients with peripheral arterial disease. In the current analysis in the same patient cohort, we hypothesized that this relationship may, in part, be causal.
   Methods Forty patients with peripheral arterial disease [66 +/- 4 years (mean +/- SD); n=20 per group] were randomized to ramipril, 10 mg once daily, or placebo for 24 weeks in a double-blind study. Maximum walking time was recorded during a standard treadmill test. Indices of arterial stiffness were assessed globally by systemic arterial compliance and augmentation index and regionally via central pulse wave velocity.
   Results Ramipril increased maximum walking time by 243% and improved arterial stiffness parameters by between 17 and 64% (all P<0.001 compared with placebo). There were moderately strong correlations between the pre/post intervention change in maximum walking time and the change in indices of arterial stiffness (systemic arterial compliance, r=0.65, P<0.001; central pulse wave velocity, r=-0.57, P<0.001; augmentation index, r=-0.79, P<0.001; time to pressure augmentation, r=0.52, P=0.001).
   Conclusion The present data support the hypothesis that the beneficial effects of ramipril on maximum walking time observed in our peripheral arterial disease population are, at least partly, a consequence of reduced arterial stiffness.
C1 [Ahimastos, Anna A.; Dart, Anthony M.; Lawler, Adam; Blombery, Peter A.; Kingwell, Bronwyn A.] Baker Med Res Inst, Alfred & Baker Med Unit, Melbourne, Vic 8008, Australia.
RP Blombery, PA (reprint author), Baker Med Res Inst, Alfred & Baker Med Unit, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.
EM bronwyn.kingwell@baker.edu.au
OI Dart, Anthony/0000-0003-1360-3778
CR Ahimastos AA, 2006, ANN INTERN MED, V144, P660, DOI 10.7326/0003-4819-144-9-200605020-00009
   Ahimastos AA, 2005, HYPERTENSION, V45, P1194, DOI 10.1161/01.HYP.0000168945.44069.aa
   BAUMBACH GL, 1991, CIRC RES, V68, P338, DOI 10.1161/01.RES.68.2.338
   Baumbach GL, 1996, HYPERTENSION, V27, P159, DOI 10.1161/01.HYP.27.2.159
   Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434
   Blacher J, 1998, HYPERTENSION, V32, P570, DOI 10.1161/01.HYP.32.3.570
   Boutouyrie P, 2002, HYPERTENSION, V39, P10, DOI 10.1161/hy0102.099031
   Brewer LC, 2007, ATHEROSCLEROSIS, V191, P384, DOI 10.1016/j.atherosclerosis.2006.03.038
   CAMERON JD, 1994, AM J PHYSIOL, V266, pH693
   Cheng KS, 2002, ATHEROSCLEROSIS, V164, P113, DOI 10.1016/S0021-9150(02)00042-4
   CHRISTENSEN KL, 1991, HYPERTENSION, V18, P722, DOI 10.1161/01.HYP.18.6.722
   FOLKOW B, 1987, AM HEART J, V114, P938, DOI 10.1016/0002-8703(87)90591-6
   Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526
   JAMES MA, 1995, HYPERTENSION, V26, P301, DOI 10.1161/01.HYP.26.2.301
   KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490
   Kingwell BA, 1997, AM J PHYSIOL-HEART C, V273, pH2186
   Kingwell BA, 2002, J AM COLL CARDIOL, V40, P773, DOI 10.1016/S0735-1097(02)02009-0
   Laurent S, 2003, STROKE, V34, P1203, DOI 10.1161/01.STR.0000065428.03209.64
   Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236
   Lehmann KG, 1998, AM J CARDIOL, V81, P1004, DOI 10.1016/S0002-9149(98)00080-0
   LIU ZR, 1986, AM J PHYSIOL, V251, pH588
   Mitchell GF, 2005, CIRCULATION, V112, P3722, DOI 10.1161/CIRCULATIONAHA.105.551168
   Mitchell GF, 2002, CIRCULATION, V105, P2955, DOI 10.1161/01.CIR.0000020500.77568.3C
   MURGO JP, 1980, CIRCULATION, V62, P105, DOI 10.1161/01.CIR.62.1.105
   RYAN SM, 1995, AM J PHYSIOL-HEART C, V268, pH359
   SAFAR ME, 1987, ARTERIOSCLEROSIS, V7, P232, DOI 10.1161/01.ATV.7.3.232
   Safar ME, 2007, ADV CARDIOL, V44, P199
   SUMMER DS, 1969, SURGERY, V65, P763
   Suzuki E, 2001, DIABETES CARE, V24, P2107, DOI 10.2337/diacare.24.12.2107
   Tai NRM, 1999, J VASC SURG, V30, P936, DOI 10.1016/S0741-5214(99)70020-0
   van Popele NM, 2001, STROKE, V32, P454, DOI 10.1161/01.STR.32.2.454
   WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4
NR 32
TC 37
Z9 37
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0263-6352
EI 1473-5598
J9 J HYPERTENS
JI J. Hypertens.
PD MAY
PY 2008
VL 26
IS 5
BP 1037
EP 1042
DI 10.1097/HJH.0b013e3282f8e3b6
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 293QU
UT WOS:000255350600028
PM 18398348
DA 2018-12-27
ER

PT J
AU Sethu, S
   Mendez-Corao, G
   Melendez, AJ
AF Sethu, Swaminathan
   Mendez-Corao, Grecia
   Melendez, Alirio J.
TI RETRACTED: Phospholipase D1 plays a key role in TNF-alpha signaling
   (Retracted article. See vol. 190, pg. 3006, 2013)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; ACTIVATED PROTEIN-KINASE;
   PHOSPHATIDIC-ACID; THERAPEUTIC TARGET; ANTI-TNF; RHEUMATOID-ARTHRITIS;
   CELLS; CACHECTIN; PATHWAY
AB The primary characteristic features of any inflammatory or infectious lesions are immune cell infiltration, cellular proliferation, and the generation of proinflammatory mediators. TNF-alpha is a potent proinflammatory and immuno-regulatory cytokine. Decades of research have been focused on the physiological/pathophysiological events triggered by TNF-a. However, the signaling network initiated by TNF-a in human leukocytes is still poorly understood. In this study, we report that TNF-a activates phospholipase D1 (PLD1), in a dose-dependent manner, and PLD1 is required for the activation of sphingosine kinase and cytosolic calcium signals. PLD1 is also required for NF kappa B and ERK1/2 activation in human monocytic cells. Using antisense oligonucleotides to reduce specifically the expression of PLD isozymes showed PLD1, but not PLD2, to be coupled to TNF-alpha signaling and that PLD1 is required to mediate receptor activation of sphingosine kinase and calcium transients. In addition, the coupling of TNF-a to activation of the phosphorylation of ERK1/2 and the activation of NFKB were inhibited by pretreating cells with antisense to PLD1, but not to PLD2; thus, demonstrating a specific requirement for PLD1. Furthermore, use of antisense oligonucleotides to reduce expression of PLDI or PLD2 demonstrated that PLD1 is required for TNF-alpha-induced production of several important cytokines, such as IL-1 beta, IL-5, IL-6, and IL-13, in human monocytes. These studies demonstrate the critical role of PLDI in the intracellular signaling cascades initiated by TNF-alpha and its functional role for coordinating the signals to inflammatory responses.
C1 [Sethu, Swaminathan; Mendez-Corao, Grecia; Melendez, Alirio J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore.
RP Melendez, AJ (reprint author), Univ Glasgow, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.
EM A.Melendez-Romero@clinmed.gla.ac.uk
FU Medical Research Council [G0700794]
CR ADERKA D, 1985, LANCET, V2, P1190
   Aoki Y, 1997, BIOCHEM BIOPH RES CO, V234, P424, DOI 10.1006/bbrc.1997.6658
   Bechoua S, 2001, J BIOL CHEM, V276, P31752, DOI 10.1074/jbc.M101265200
   BOLLING SF, 1992, TRANSPLANTATION, V53, P283, DOI 10.1097/00007890-199202010-00006
   Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p
   Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3
   Dana RR, 2000, J BIOL CHEM, V275, P32566, DOI 10.1074/jbc.M005406200
   DEVALCK D, 1993, EUR J BIOCHEM, V212, P491
   DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165
   DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3
   Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0
   Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x
   Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472
   HAMMOND SM, 1995, J BIOL CHEM, V270, P29640
   HANAHAN DJ, 1947, J BIOL CHEM, V168, P233
   Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z
   Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200
   Kang JH, 1998, EXP MOL MED, V30, P21, DOI 10.1038/emm.1998.3
   Kusner DJ, 1999, J IMMUNOL, V162, P2266
   LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1
   LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43
   Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5
   Matsumoto K, 1999, CLIN EXP IMMUNOL, V117, P361, DOI 10.1046/j.1365-2249.1999.00975.x
   MAURY CPJ, 1987, J EXP MED, V166, P1132, DOI 10.1084/jem.166.4.1132
   McDermott M, 2004, BIOCHEM CELL BIOL, V82, P225, DOI 10.1139/003-079
   Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421
   Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299
   OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6
   Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175
   Paruch S, 2005, FASEB J, V19, P142, DOI 10.1096/fj.05-3881fje
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Plo I, 2000, BIOCHEM J, V351, P459, DOI 10.1042/0264-6021:3510459
   REMICK DG, 1987, LAB INVEST, V56, P583
   Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   ROUXLOMBARD P, 1989, CLIN IMMUNOL IMMUNOP, V50, P374, DOI 10.1016/0090-1229(89)90144-X
   Sciorra VA, 1999, MOL BIOL CELL, V10, P3863, DOI 10.1091/mbc.10.11.3863
   SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102
   Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7
   Shatrov VA, 1997, BIOCHEM BIOPH RES CO, V234, P121, DOI 10.1006/bbrc.1997.6598
   Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995
   Steed P. M., 2001, Current Pharmaceutical Biotechnology, V2, P241, DOI 10.2174/1389201013378644
   STEPHENS JM, 1991, J BIOL CHEM, V266, P21839
   Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023
   TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421
   TRACEY KJ, 1994, ANNU REV MED, V45, P491
   TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0
   TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533
   TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211
   ULICH TR, 1991, AM J PATHOL, V138, P521
   VILCEK J, 1991, J BIOL CHEM, V266, P7313
   WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106
   Zhi L, 2006, J CELL PHYSIOL, V208, P109, DOI 10.1002/jcp.20646
NR 57
TC 18
Z9 19
U1 3
U2 14
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2008
VL 180
IS 9
BP 6027
EP 6034
DI 10.4049/jimmunol.180.9.6027
PG 8
WC Immunology
SC Immunology
GA 324GV
UT WOS:000257507000035
PM 18424723
OA Bronze
DA 2018-12-27
ER

PT J
AU Baritaki, S
   Suzuki, E
   Umezawa, K
   Spandidos, DA
   Berenson, J
   Daniels, TR
   Penichet, ML
   Jazirehi, AR
   Palladino, M
   Bonavida, B
AF Baritaki, Stavroula
   Suzuki, Eriko
   Umezawa, Kazuo
   Spandidos, Demetrios A.
   Berenson, James
   Daniels, Tracy R.
   Penichet, Manuel L.
   Jazirehi, Ali R.
   Palladino, Michael
   Bonavida, Benjamin
TI RETRACTED: Inhibition of Yin Yang 1-dependent repressor activity of DR5
   transcription and expression by the novel proteasome inhibitor NPI-0052
   contributes to its TRAIL-enhanced apoptosis in cancer cells (Retracted
   Article. See vol 197, pg 4860, 2016)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; MULTIPLE-MYELOMA CELLS; CCAAT/ENHANCER-BINDING-PROTEIN;
   CHRONIC LYMPHOCYTIC-LEUKEMIA; LIGAND-INDUCED APOPTOSIS; MEDIATED
   APOPTOSIS; SALINOSPORAMIDE-A; PROSTATE-CANCER; DOWN-REGULATION;
   UP-REGULATION
AB TRAIL promotes apoptotic tumor cell death; however, TRAIL-resistant tumors need to be sensitized to reverse resistance. Proteasome inhibitors potentiate TRAIL apoptosis in vitro and in vivo and correlate with up-regulation of death receptor 5 (DR5) via an unknown mechanism. We hypothesized that the proteasome inhibitor NPI-0052 inhibits the transcription repressor Yin Yang 1 (YY1) which regulates TRAIL resistance and negatively regulates DR5 transcription. Treatment of PC-3 and Ramos cells with NPI-0052 (<= 2.5 nM) and TRAIL sensitizes the tumor cells to TRAIL-induced apoptosis. By comparison to bortezomib, a 400-fold less concentration of NPI-0052 was used. NPI-0052 up-regulated DR5 reporter activity and both surface and total DR5 protein expression. NPI-0052-induced inhibition of NF-kappa B activity was involved in TRAIL sensitization as corroborated by the use of the NF-kappa B inhibitor dehydroxymethylepoxyquinomicin. NPI-0052 inhibited YY1 promoter activity as well as both YY1 mRNA and protein expression. The direct role of NPI-0052-induced inhibition of YY1 and up-regulation of DR5 in the regulation of TRAIL sensitivity was demonstrated by the use of YY1 small interfering RNA. The NPI-0052-induced sensitization to TRAIL involved activation of the intrinsic apoptotic pathway and dysregulation of genes that regulate apoptosis. The NPI-0052 concentrations used for TRAIL sensitization were not toxic to human hematopoetic stem cells. The present findings demonstrate, for the first time, the potential mechanism by which a proteasome inhibitor, like NPI-0052, inhibits the transcription repressor YY1 involved in TRAIL resistance and DR5 regulation. The findings also suggest the therapeutic application of subtoxic NPI-0052 concentrations in combination with TRAIL/agonist DR4/DR5 mAbs in the treatment of TRAIL-resistant tumors.
C1 [Baritaki, Stavroula; Suzuki, Eriko; Penichet, Manuel L.; Jazirehi, Ali R.; Bonavida, Benjamin] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, David Geffen Sch Med, Div Surg Oncol,Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Daniels, Tracy R.; Penichet, Manuel L.] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Div Surg Oncol,Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Suzuki, Eriko; Umezawa, Kazuo] Keio Univ, Dept Appl Chem, Yokohama, Kanagawa 223, Japan.
   [Spandidos, Demetrios A.] Univ Crete, Fac Med, Dept Clin Virol, Iraklion, Greece.
   [Berenson, James] Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA.
   [Palladino, Michael] Nereus Pharmaceut Inc, San Diego, CA 92121 USA.
RP Bonavida, B (reprint author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, David Geffen Sch Med, Div Surg Oncol,Johnson Comprehens Canc Ctr, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.
EM bbonavida@mednet.ucla.edu
RI Penichet, Manuel/L-4944-2018; SUZUKI, Eriko/G-1082-2013
FU NCI NIH HHS [R01 CA107023, CA 107023-02S1, CA 107023]
CR Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Aggarwal BB, 2004, VITAM HORM, V67, P453
   Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
   Ahn KS, 2007, BLOOD, V110, P2286, DOI 10.1182/blood-2007-04-084996
   An JB, 2003, CLIN CANCER RES, V9, P4537
   Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709
   Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521
   BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4
   Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013
   Chen SZ, 2007, MOL PHARMACOL, V72, P1269, DOI 10.1124/mol.107.037465
   Conticello C, 2007, J CLIN ENDOCR METAB, V92, P1938, DOI 10.1210/jc.2006-2157
   Cusack JC, 2006, CLIN CANCER RES, V12, P6758, DOI 10.1158/1078-0432.CCR-06-1151
   Cusack JC, 2001, CANCER RES, V61, P3535
   Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115
   Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080
   He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351
   Hideshima T, 2001, CANCER RES, V61, P3071
   Higuchi H, 2004, J BIOL CHEM, V279, P51, DOI 10.1074/jbc.M309476200
   Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655
   Jagannath S, 2005, BRIT J HAEMATOL, V129, P776, DOI 10.1111/j.1365-2141.2005.05540.x
   Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500
   Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9
   Keane MM, 1999, CANCER RES, V59, P734
   Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006
   Khanbolooki S, 2006, MOL CANCER THER, V5, P2251, DOI 10.1158/1535-7163.MCT-06-0075
   Kurbanov BM, 2007, ONCOGENE, V26, P3364, DOI 10.1038/sj.onc.1210134
   La Ferla-Bruhl K, 2007, ONCOGENE, V26, P571, DOI 10.1038/sj.onc.1209841
   Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003
   Liabakk NB, 2004, VITAM HORM, V67, P65
   Liu XG, 2004, J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322
   Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274
   Macherla VR, 2005, J MED CHEM, V48, P3684, DOI 10.1021/jm048995+
   Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128
   Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162
   Nagy K, 2006, PATHOL ONCOL RES, V12, P133, DOI 10.1007/BF02893359
   Nencioni A, 2007, LEUKEMIA, V21, P30, DOI 10.1038/sj.leu.2404444
   Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496
   Ng CP, 2002, MOL CANCER THER, V1, P1051
   Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290
   Papandreou CN, 2004, CANCER RES, V64, P5036, DOI 10.1158/0008-5472.CAN-03-2707
   Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Ruiz S, 2006, MOL CANCER THER, V5, P1836, DOI 10.1158/1535-7163.MCT-06-0065
   Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8
   Saulle E, 2007, APOPTOSIS, V12, P635, DOI 10.1007/s10495-006-0025-9
   Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975
   Scagliotti G, 2006, CRIT REV ONCOL HEMAT, V58, P177, DOI 10.1016/j.critrevonc.2005.12.001
   Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865
   Suzuki E, 2007, ONCOGENE, V26, P6184, DOI 10.1038/sj.onc.1210448
   Vega MI, 2005, J IMMUNOL, V175, P2174, DOI 10.4049/jimmunol.175.4.2174
   Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06
   Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232
   Williamson MJ, 2006, MOL CANCER THER, V5, P3052, DOI 10.1158/1535-7163.MCT-06-0185
   Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x
   Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200
   Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693
   Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7
NR 59
TC 54
Z9 62
U1 3
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2008
VL 180
IS 9
BP 6199
EP 6210
DI 10.4049/jimmunol.180.9.6199
PG 12
WC Immunology
SC Immunology
GA 324GV
UT WOS:000257507000054
PM 18424742
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Ruys, KI
   Stapel, DA
AF Ruys, Kirsten I.
   Stapel, Diederik A.
TI RETRACTED: How to heat up from the cold: Examining the preconditions for
   (unconscious) mood effects (Retracted article. See vol. 103, pg. 451,
   2012)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE subliminal perception; priming; mood; affect; need for cognition
ID SOCIAL-BEHAVIOR; IMPRESSION-FORMATION; EMOTIONAL STATES; FACE
   PERCEPTION; INFORMATION; COGNITION; JUDGMENT; RESPONSES; IMPACT; NEED
AB What are the necessary preconditions to make people feel good or bad? In this research, the authors aimed to uncover the bare essentials of mood induction. Several induction techniques exist, and most of these techniques demand a relatively high amount of cognitive capacity. Moreover, to be effective, most techniques require conscious awareness. The authors proposed that the common and defining element in all effective mood induction techniques is the dominating salience of evaluative tone over descriptive meaning. This evaluative-tone hypothesis was tested in two paradigms in which the evaluative meaning of the "primed" concept was more salient than its descriptive meaning (i.e., when subliminal stimulus exposure was so short that mainly the evaluative meaning was activated [see D. A. Stapel, W. Koomen, & K. I. Ruys, 2002] and when the primed concepts were sufficiently extreme such that evaluative meaning always dominated descriptive meaning). Explicit and implicit mood measures showed that the activation of a dominating evaluative tone affected people's mood states. Implications of these findings for theories on unconscious mood induction are discussed.
C1 [Ruys, Kirsten I.; Stapel, Diederik A.] Tilburg Univ, Tilburg Inst Behav Econ Res, Dept Social Psycol, NL-5000 LE Tilburg, Netherlands.
RP Ruys, KI (reprint author), Tilburg Univ, Tilburg Inst Behav Econ Res, Dept Social Psycol, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM k.i.ruys@uvt.nl
CR Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056
   Banse R, 2001, COGNITION EMOTION, V15, P501, DOI 10.1080/0269993004200213
   Bargh J. A., 1989, COGNITION INDIVIDUAL, P357
   Bargh JA, 2006, EUR J SOC PSYCHOL, V36, P147, DOI 10.1002/ejsp.336
   BARGH JA, 1997, ADV SOC COG, V10, P1
   BLESS H, 1990, PERS SOC PSYCHOL B, V16, P331, DOI 10.1177/0146167290162013
   Bless H, 1996, J PERS SOC PSYCHOL, V71, P665, DOI 10.1037//0022-3514.71.4.665
   CACIOPPO JT, 1982, J PERS SOC PSYCHOL, V42, P116, DOI 10.1037//0022-3514.42.1.116
   Cacioppo JT, 1996, PSYCHOL BULL, V119, P197, DOI 10.1037/0033-2909.119.2.197
   CHAIKEN S, 1980, J PERS SOC PSYCHOL, V39, P752, DOI 10.1037/0022-3514.39.5.752
   Chartrand TL, 2006, J EXP PSYCHOL GEN, V135, P70, DOI 10.1037/0096-3445.135.1.70
   Chartrand TL, 1996, J PERS SOC PSYCHOL, V71, P464, DOI 10.1037/0022-3514.71.3.464
   CLORE G, 2003, PSYCHOL EVALUATION, P169
   Clore G. L., 2005, EMOTION CONSCIOUSNES, P384
   EDWARDS K, 1990, J PERS SOC PSYCHOL, V59, P202, DOI 10.1037/0022-3514.59.2.202
   ERDLEY CA, 1988, J PERS SOC PSYCHOL, V54, P741, DOI 10.1037//0022-3514.54.5.741
   Farah MJ, 1998, PSYCHOL REV, V105, P482, DOI 10.1037/0033-295X.105.3.482
   Ferguson MJ, 2003, PSYCHOLOGY OF EVALUATION, P169
   FIEDLER K, 1986, MEM COGNITION, V14, P181, DOI 10.3758/BF03198378
   FIEDLER K, 2001, HDB AFFECT SOCIAL CO
   Fiedler K., 1990, EUROPEAN REV SOCIAL, V1, P1, DOI DOI 10.1080/14792779108401855.FIEDLER
   Fiedler K., 1991, EMOTION SOCIAL JUDGM, P83
   FORGAS JP, 1992, ADV EXP SOC PSYCHOL, V25, P227, DOI 10.1016/S0065-2601(08)60285-3
   FORGAS JP, 1995, PSYCHOL BULL, V117, P39, DOI 10.1037//0033-2909.117.1.39
   Gasper K, 2002, PSYCHOL SCI, V13, P34, DOI 10.1111/1467-9280.00406
   Gervey B, 2005, MOTIV EMOTION, V29, P269, DOI 10.1007/s11031-006-9011-3
   HAMPSON SE, 1986, J PERS SOC PSYCHOL, V51, P37, DOI 10.1037/0022-3514.51.1.37
   Hugenberg K, 2005, EMOTION, V5, P267, DOI 10.1037/1528-3542.5.3.267
   Innes-Ker A, 2002, J PERS SOC PSYCHOL, V83, P804, DOI 10.1037//0022-3514.83.4.804
   ISEN AM, 1987, ADV EXP SOC PSYCHOL, V20, P203, DOI 10.1016/S0065-2601(08)60415-3
   KELLNER D, 1993, PERSONALITY SOCIAL P, V19, P21
   KIHISTROM JF, 2000, COGNITION EMOTION
   KROSNICK JA, 1992, PERS SOC PSYCHOL B, V18, P152, DOI 10.1177/0146167292182006
   Ledoux J., 1989, COGNITION EMOTION, V3, P267, DOI DOI 10.1080/02699938908412709
   Maringer M, 2007, J EXP SOC PSYCHOL, V43, P712, DOI 10.1016/j.jesp.2006.07.007
   MAYER JD, 1988, J PERS SOC PSYCHOL, V55, P102, DOI 10.1037//0022-3514.55.1.102
   MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723
   Niedenthal PM, 2003, PSYCHOLOGY OF EVALUATION, P307
   NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037//0033-295X.84.3.231
   OHMAN A, 1994, J ABNORM PSYCHOL, V103, P231, DOI 10.1037/0021-843X.103.2.231
   Palermo R, 2007, NEUROPSYCHOLOGIA, V45, P75, DOI 10.1016/j.neuropsychologia.2006.04.025
   PETTY RE, 2001, HDB AFFECT SOCIAL CO
   Petty Richard E, 1986, ADV EXPT SOCIAL PSYC, V19, P123, DOI DOI 10.1016/S0065-2601(08)60214-2
   ROBLES R, 1987, PERS SOC PSYCHOL B, V13, P399, DOI 10.1177/0146167287133008
   RUYS KI, IN PRESS PSYCHOL SCI
   Ruys KI, 2007, BRIT J PSYCHOL, V98, P361, DOI 10.1348/000712606X132949
   Schwarz N., 1996, SOCIAL PSYCHOL HDB B, P433
   Schwarz N., 1990, HDB MOTIVATION COGNI, V2, P527, DOI DOI 10.1016/J.NEUBIOREV.2008.01.001
   Stapel DA, 2000, J PERS SOC PSYCHOL, V78, P19, DOI 10.1037//0022-3514.78.1.19
   Stapel DA, 2006, J EXP SOC PSYCHOL, V42, P112, DOI 10.1016/j.jesp.2005.02.002
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   STAPEL DA, 2003, SOCIAL JUDGMENTS IMP, P227
   STAPEL DA, 2005, PERSONALITY SOCIAL P, V9, P1286
   Storbeck J, 2004, PERS SOC PSYCHOL B, V30, P81, DOI 10.1177/0146167203258855
   Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5
   WEGENER DT, 1994, J PERS SOC PSYCHOL, V66, P1034, DOI 10.1037/0022-3514.66.6.1034
   Wentura D, 2000, J EXP PSYCHOL LEARN, V26, P456, DOI 10.1037/0278-7393.26.2.456
   Winkielman P, 2005, PERS SOC PSYCHOL B, V31, P121, DOI 10.1177/0146167204271309
   Winkielman P, 2004, CURR DIR PSYCHOL SCI, V13, P120, DOI 10.1111/j.0963-7214.2004.00288.x
   Winkielman P, 1997, COGNITION EMOTION, V11, P433, DOI 10.1080/026999397379872
   Winkielman P., 2005, EMOTION CONSCIOUSNES, P335
   Zajonc R., 2000, FEELING THINKING ROL, P31
   ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151
NR 63
TC 16
Z9 16
U1 3
U2 17
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD MAY
PY 2008
VL 94
IS 5
BP 777
EP 791
DI 10.1037/0022-3514.94.5.777
PG 15
WC Psychology, Social
SC Psychology
GA 292VH
UT WOS:000255293700003
PM 18444738
DA 2018-12-27
ER

PT J
AU Xie, CX
   Warburton, M
   Li, MS
   Li, XH
   Xiao, MJ
   Hao, ZF
   Zhao, Q
   Zhang, SH
AF Xie, Chuanxiao
   Warburton, Marilyn
   Li, Mingshun
   Li, Xinhai
   Xiao, Muji
   Hao, Zhuanfang
   Zhao, Qi
   Zhang, Shihuang
TI RETRACTED: An analysis of population structure and linkage
   disequilibrium using multilocus data in 187 maize inbred lines
   (Retracted article. See vol. 28, pg. 135, 2011)
SO MOLECULAR BREEDING
LA English
DT Article; Retracted Publication
DE association mapping; linkage disequilibrium; maize (Zea mays L .);
   population structure
ID GENETIC DIVERSITY; SSR MARKERS; FLOWERING TIME; CIMMYT MAIZE; MAYS L.;
   ASSOCIATION; GENOME; POLYMORPHISMS; PATTERNS; US
AB This study analyzes population structure and linkage disequilibrium (LD) among 187 commonly used Chinese maize inbred lines, representing the genetic diversity among public, commercial and historically important lines for corn breeding. Seventy SSR loci, evenly distributed over 10 chromosomes, were assayed for polymorphism. The identified 290 alleles served to estimate population structure and analyze the genome-wide LD. The population of lines was highly structured, showing 6 subpopulations: BSSS (American BSSS including Reid), PA (group A germplasm derived from modern U.S. hybrids in China), PB (group B germplasm derived from modern U.S. hybrid in China), Lan (Lancaster Surecrop), LRC (derivative lines from Lvda Reb Cob, a Chinese landrace) and SPT (derivative lines from Si-ping-tou, a Chinese landrace). Forty lines, which formerly had an unknown and/or miscellaneous origin and pedigree record, were assigned to the appropriate group. Relationship estimates based on SSR marker data were quantified in a Q matrix, and this information will inform breeder's decisions regarding crosses. Extensive inter- and intra-chromosomal LD was detected between 70 microsatellite loci for the investigated maize lines (2109 loci pairs in LD with D' > 0.1 and 93 out of them at P < 0.01).This suggests that rapidly evolving microsatellites may track recent population structure. Interlocus LD decay among the diverse maize germplasm indicated that association studies in QTLs and/or candidate genes might avoid nonfunctional and spurious associations since most of the LD blocks were broken between diverse germplasm. The defined population structure and the LD analysis present the basis for future association mapping.
C1 [Xie, Chuanxiao; Li, Mingshun; Li, Xinhai; Xiao, Muji; Hao, Zhuanfang; Zhang, Shihuang] Chinese Acad Agr Sci, Inst Crop Sci, Natl Key Facil Crop Gene Resources & Genet Improv, Beijing 100081, Peoples R China.
   [Warburton, Marilyn] CIMMYT Apdo, Appl Biotechnol Ctr, Mexico City 06600, DF, Mexico.
   [Zhao, Qi] Beijing Capital Normal Univ, Life Sch, Beijing, Peoples R China.
RP Zhang, SH (reprint author), Chinese Acad Agr Sci, Inst Crop Sci, Natl Key Facil Crop Gene Resources & Genet Improv, 12 Zhong Guan Cun S St, Beijing 100081, Peoples R China.
EM cxxie@caas.net.cn; cshzhang2000@yahoo.com.cn
CR Andersen JR, 2005, THEOR APPL GENET, V111, P206, DOI 10.1007/s00122-005-1996-6
   Camus-Kulandaivelu L, 2006, GENETICS, V172, P2449, DOI 10.1534/genetics.105.048603
   Chao SM, 2007, CROP SCI, V47, P1018, DOI 10.2135/cropsci2006.06.0434
   CHARCOSSET A, 1994, THEOR APPL GENET, V89, P336, DOI 10.1007/BF00225164
   DOEBLEY J, 1988, ECON BOT, V42, P120, DOI 10.1007/BF02859042
   EXCOFFIER L, 2001, HDB STAT GENETICS, P271
   Flint-Garcia SA, 2005, PLANT J, V44, P1054, DOI 10.1111/j.1365-313X.2005.02591.x
   Flint-Garcia SA, 2003, ANNU REV PLANT BIOL, V54, P357, DOI 10.1146/annurev.arplant.54.031902.134907
   Garris AJ, 2005, GENETICS, V169, P1631, DOI 10.1534/genetics.104.035642
   Kraakman ATW, 2004, GENETICS, V168, P435, DOI 10.1534/genetics.104.026831
   Li X, 2000, ROCK MECH ROCK ENG, V33, P1, DOI 10.1007/s006030050001
   Li Y, 2002, MAYDICA, V47, P93
   Li Y, 1998, MAYDICA, V43, P259
   Liu KJ, 2003, GENETICS, V165, P2117
   Lu H, 2005, CROP SCI, V45, P66, DOI 10.2135/cropsci2005.0066
   Lu H, 2001, THEOR APPL GENET, V103, P613, DOI 10.1007/PL00002917
   MALYSHEVAOTTO L, 2006, GENETICS, V7, P6
   Nordborg M, 2002, NAT GENET, V30, P190, DOI 10.1038/ng813
   Palaisa K, 2004, P NATL ACAD SCI USA, V101, P9885, DOI 10.1073/pnas.0307839101
   Pejic I, 1998, THEOR APPL GENET, V97, P1248, DOI 10.1007/s001220051017
   Pritchard JK, 2000, GENETICS, V155, P945
   PRITCHARD JK, 2001, NAT GENET, V28, P286
   Rafalski J. Antoni, 1996, P75, DOI 10.1016/B978-012101285-4/50005-9
   Reif J, 2006, THEOR APPL GENET, V113, P177, DOI 10.1007/s00122-006-0283-5
   Remington DL, 2001, P NATL ACAD SCI USA, V98, P11479, DOI 10.1073/pnas.201394398
   SAGHAIMAROOF MA, 1984, P NATL ACAD SCI-BIOL, V81, P8014, DOI 10.1073/pnas.81.24.8014
   Senior ML, 1998, CROP SCI, V38, P1088, DOI 10.2135/cropsci1998.0011183X003800040034x
   Smith JSC, 1997, THEOR APPL GENET, V95, P163, DOI 10.1007/s001220050544
   SMITH OS, 1992, MAYDICA, V37, P53
   Stich B, 2005, THEOR APPL GENET, V111, P723, DOI 10.1007/s00122-005-2057-x
   Szalma SJ, 2005, THEOR APPL GENET, V110, P1324, DOI 10.1007/s00122-005-1973-0
   Tenaillon MI, 2001, P NATL ACAD SCI USA, V98, P9161, DOI 10.1073/pnas.151244298
   Thornsberry JM, 2001, NAT GENET, V28, P286, DOI 10.1038/90135
   Vigouroux Y, 2005, GENETICS, V169, P1617, DOI 10.1534/genetics.104.032086
   Warburton ML, 2005, EUPHYTICA, V142, P97, DOI 10.1007/s10681-005-0817-y
   Wilson LM, 2004, PLANT CELL, V16, P2719, DOI 10.1105/tpc.104.025700
   WRIGHT S, 1951, ANN EUGENIC, V15, P323
   Xia XC, 2005, CROP SCI, V45, P2573, DOI 10.2135/cropsci2005.0246
   Yu JM, 2006, CURR OPIN BIOTECH, V17, P155, DOI 10.1016/j.copbio.2006.02.003
   Yu JM, 2006, NAT GENET, V38, P203, DOI 10.1038/ng1702
   Yuan Li-Xing, 2000, Acta Genetica Sinica, V27, P725
NR 41
TC 36
Z9 51
U1 3
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-3743
J9 MOL BREEDING
JI Mol. Breed.
PD MAY
PY 2008
VL 21
IS 4
BP 407
EP 418
DI 10.1007/s11032-007-9140-8
PG 12
WC Agronomy; Plant Sciences; Genetics & Heredity; Horticulture
SC Agriculture; Plant Sciences; Genetics & Heredity
GA 283GP
UT WOS:000254625000001
DA 2018-12-27
ER

PT J
AU Watt, MJ
   van Denderen, BJW
   Castelli, LA
   Bruce, CR
   Hoy, AJ
   Kraegen, EW
   Macaulay, L
   Kemp, BE
AF Watt, Matthew J.
   van Denderen, Bryce J. W.
   Castelli, Laura A.
   Bruce, Clinton R.
   Hoy, Andrew J.
   Kraegen, Edward W.
   Macaulay, Lance
   Kemp, Bruce E.
TI RETRACTED: Adipose triglyceride lipase regulation of skeletal muscle
   lipid metabolism and insulin responsiveness (Retracted article. See vol.
   24, pg. 1308, 2010)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID HORMONE-SENSITIVE LIPASE; 3T3-L1 ADIPOCYTES; FAMILY-MEMBERS;
   GLUCOSE-UPTAKE; FATTY-ACIDS; TNF-ALPHA; RESISTANCE; EXPRESSION;
   EXERCISE; TISSUE
AB Adipose triglyceride lipase ( ATGL) is important for triglyceride ( TG) metabolism in adipose tissue, and ATGL-null mice show increased adiposity. Given the apparent importance of ATGL in TG metabolism and the association of lipid deposition with insulin resistance, we examined the role of ATGL in regulating skeletal muscle lipid metabolism and insulin-stimulated glucose disposal. ATGL expression in myotubes was reduced by small interfering RNA and increased with a retrovirus encoding GFP-HA-ATGL. ATGL was also overexpressed in rats by in vivo electrotransfer. ATGL was down-regulated in skeletal muscle of obese, insulin-resistant mice and negatively correlated with intramyocellular TG levels. ATGL small interfering RNA in myotubes reduced TG hydrolase activity and increased TG content, whereas ATGL overexpression induced the reciprocal response, indicating that ATGL is an essential TG lipase in skeletal muscle. ATGL overexpression in myotubes increased the oxidation of fatty acid liberated from TG and diglyceride and ceramide contents. These responses in cells were largely recapitulated in rats overexpressing ATGL. When ATGL protein expression and TG hydrolase activity in obese, insulin-resistant rats were restored to levels observed in lean rats, TG content was reduced; however, the insulin resistance induced by the high-fat diet persisted. In conclusion, ATGL TG hydrolysis in skeletal muscle is a critical determinant of lipid metabolism and storage. Although ATGL content and TG hydrolase activity are decreased in obese, insulin-resistant phenotypes, overexpression does not rescue the condition, indicating reduced ATGL is unlikely to be a primary cause of obesity-associated insulin resistance.
C1 [Watt, Matthew J.; van Denderen, Bryce J. W.; Kemp, Bruce E.] Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
   [Watt, Matthew J.; van Denderen, Bryce J. W.; Kemp, Bruce E.] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia.
   [Castelli, Laura A.; Macaulay, Lance; Kemp, Bruce E.] Commonwealth Sci & Ind Res Org Mol & Hlth Technol, Parkville, Vic 3052, Australia.
   [Bruce, Clinton R.] Baker Heart Res Inst, Cellular & Mol Metab Lab, Prahran, Vic 8008, Australia.
   [Hoy, Andrew J.; Kraegen, Edward W.] St Vincents Hosp, Garvan Inst Med Res, Diabet & Obes Res Program, Darlinghurst, NSW 2010, Australia.
RP Watt, MJ (reprint author), Monash Univ, Dept Physiol, Clayton, Vic 3065, Australia.
EM matthew.watt@med.monash.edu.au
RI Kemp, Bruce/L-2633-2014; Macaulay, Stuart Lance/A-6086-2008; castelli,
   laura/C-5400-2013; Watt, Matthew/B-2089-2014; Hoy, Andrew/J-2289-2017
OI Kemp, Bruce/0000-0001-6735-5082; Macaulay, Stuart
   Lance/0000-0001-5069-9516; Hoy, Andrew/0000-0003-3922-1137; Bruce,
   Clinton/0000-0002-0515-3343
CR Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25
   AMIRNOVA E, 2006, EMBO REP, V7, P106
   BARON AD, 1988, AM J PHYSIOL, V255, pE769
   Bastie CC, 2004, DIABETES, V53, P2209, DOI 10.2337/diabetes.53.9.2209
   Bergmeyer HU, 1974, METHODS ENZYMATIC AN
   Bruce CR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1231, DOI 10.1152/ajpendo.00561.2006
   CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553
   CLARK PW, 1990, AM J PHYSIOL, V258, pE701
   Cleasby ME, 2005, DIABETES, V54, P2702, DOI 10.2337/diabetes.54.9.2702
   Granneman JG, 2007, J BIOL CHEM, V282, P5726, DOI 10.1074/jbc.M610580200
   GREENBERG AS, 1991, J BIOL CHEM, V266, P11341
   Gronke S, 2005, CELL METAB, V1, P323, DOI 10.1016/j.cmet.2005.04.003
   Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200
   Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965
   Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002
   JAMES DE, 1985, J CLIN INVEST, V76, P657, DOI 10.1172/JCI112019
   Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200
   Jocken JWE, 2007, J CLIN ENDOCR METAB, V92, P2292, DOI 10.1210/jc.2006-1318
   Kershaw EE, 2006, DIABETES, V55, P148, DOI 10.2337/diabetes.55.01.06.db05-0982
   Kim JY, 2006, AM J PHYSIOL-ENDOC M, V291, pE115, DOI 10.1152/ajpendo.00317.2005
   Kralisch S, 2005, MOL CELL ENDOCRINOL, V240, P43, DOI 10.1016/j.mce.2005.06.002
   Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123
   Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200
   Langfort J, 2000, BIOCHEM J, V351, P207, DOI 10.1042/0264-6021:3510207
   Langfort J, 1999, BIOCHEM J, V340, P459, DOI 10.1042/0264-6021:3400459
   Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005
   Miyoshi H, 2007, J BIOL CHEM, V282, P996, DOI 10.1074/jbc.M605770200
   MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206
   Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983
   Pinnamaneni SK, 2006, DIABETOLOGIA, V49, P3027, DOI 10.1007/s00125-006-0427-9
   Prats C, 2006, J LIPID RES, V47, P2392, DOI 10.1194/jlr.M600247-JLR200
   PREISS J, 1986, J BIOL CHEM, V261, P8597
   Roepstorff C, 2004, J PHYSIOL-LONDON, V560, P551, DOI 10.1113/jphysiol.2004.066480
   Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006
   Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202
   Steinberg GR, 2007, AM J PHYSIOL-ENDOC M, V293, pE958, DOI 10.1152/ajpendo.00235.2007
   Straczkowski M, 2004, DIABETES, V53, P1215, DOI 10.2337/diabetes.53.5.1215
   Turpin SM, 2006, AM J PHYSIOL-ENDOC M, V291, pE1341, DOI 10.1152/ajpendo.00095.2006
   Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200
   Watt MJ, 2006, ENDOCRINOLOGY, V147, P2077, DOI 10.1210/en.2005-1074
   Watt MJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE500, DOI 10.1152/ajpendo.00361.2005
   Watt MJ, 2004, FASEB J, V18, P1445, DOI 10.1096/fj.03-1067fje
   Watt MJ, 2006, NAT MED, V12, P541, DOI 10.1038/nm1383
   Watt MJ, 2003, J PHYSIOL-LONDON, V547, P301, DOI 10.1113/jphysiol.2002.034595
   Watt MJ, 2002, J APPL PHYSIOL, V93, P1185, DOI 10.1152/japplphysiol.00197.2002
   Watt MJ, 2003, J PHYSIOL-LONDON, V550, P325, DOI 10.1113/jphysiol.2003.043133
   Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200
   Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747
   ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857
NR 50
TC 31
Z9 41
U1 3
U2 12
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD MAY
PY 2008
VL 22
IS 5
BP 1200
EP 1212
DI 10.1210/me.2007-0485
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 293HW
UT WOS:000255327400016
PM 18202145
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Takada, Y
   Sethi, G
   Sung, B
   Aggarwal, BB
AF Takada, Yasunari
   Sethi, Gautam
   Sung, Bokyung
   Aggarwal, Bharat B.
TI RETRACTED: Flavopiridol suppresses tumor necrosis factor-induced
   activation of activator protein-1, c-jun N-terminal kinase, p38
   mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and akt, inhibits
   expression of antiapoptotic gene products, and enhances apoptosis
   through cytochrome c release and caspase activation in human myeloid
   cells(Retracted article. See vol. 90, pg. 63, 2016)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID BREAST-CARCINOMA CELLS; KAPPA-B ACTIVATION; FACTOR-ALPHA; LEUKEMIA
   CELLS; CYCLIN D1; INDUCTION; DEATH; PHOSPHORYLATION; L86-8275; CANCER
AB Although flavopiridol, a semisynthetic flavone, was initially thought to be a specific inhibitor of cyclin-dependent kinases, it has now been shown that flavopiridol mediates antitumor responses through mechanism(s) yet to be defined. We have shown previously that flavopiridol abrogates tumor necrosis factor (TNF)-induced nuclear factor-kappa B (NF-kappa B) activation. In this report, we examined whether this flavone affects other cellular responses activated by TNF. TNF is a potent inducer of activator protein-1 (AP-1), and flavopiridol abrogated this activation in a dose- and time-dependent manner. Flavopiridol also suppressed AP-1 activation induced by various carcinogens and inflammatory stimuli. When examined for its effect on other signaling pathways, flavopiridol inhibited TNF-induced activation of various mitogen-activated protein kinases, including c-Jun NH2-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), and p44/p42 MAPK. It is noteworthy that this flavone also suppressed TNF-induced activation of Akt, a cell survival kinase, and expression of various antiapoptotic proteins, such as IAP-1, IAP-2, XIAP, Bcl-2, Bcl-xL, and TRAF-1. Flavopiridol also inhibited the TNF-induced induction of intercellular adhesion molecule-1, c-Myc, and c-Fos, all known to mediate tumorigenesis. Moreover, TNF-induced apoptosis was enhanced by flavopiridol through activation of the bid-cytochrome-caspase-9-caspase-3 pathway. Overall, our results clearly suggest that flavopiridol interferes with the TNF cell-signaling pathway, leading to suppression of antiapoptotic mechanisms and enhancement of apoptosis.
C1 [Takada, Yasunari; Sethi, Gautam; Sung, Bokyung; Aggarwal, Bharat B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
RP Aggarwal, BB (reprint author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Sethi, Gautam/F-2372-2011; Aggarwal, Bharat/G-3388-2013
OI Sethi, Gautam/0000-0002-8677-8475; 
FU NCI NIH HHS [CA16672]
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Arguello F, 1998, BLOOD, V91, P2482
   Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056
   Bible KC, 1996, CANCER RES, V56, P4856
   Bible KC, 1997, CANCER RES, V57, P3375
   Carlson BA, 1996, CANCER RES, V56, P2973
   Cartee L, 2003, MOL CANCER THER, V2, P83
   Cartee L, 2002, MOL PHARMACOL, V61, P1313, DOI 10.1124/mol.61.6.1313
   Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926
   deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735
   DUYAO MP, 1992, J BIOL CHEM, V267, P16288
   Fornier MN, 2007, CLIN CANCER RES, V13, P5841, DOI 10.1158/1078-0432.CCR-07-1218
   Gojo I, 2002, CLIN CANCER RES, V8, P3527
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3
   Karp JE, 2003, CLIN CANCER RES, V9, P307
   Kim DM, 2003, CANCER RES, V63, P621
   Konig A, 1997, BLOOD, V90, P4307
   Kumar A, 2004, J MOL MED-JMM, V82, P434, DOI 10.1007/s00109-004-0555-y
   Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004
   LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742
   Morris Don G., 2006, Sarcoma, P1, DOI 10.1155/SRCM/2006/64374
   NAIK RG, 1988, TETRAHEDRON, V44, P2081, DOI 10.1016/S0040-4020(01)90352-7
   Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969
   Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661
   Rapella A, 2002, INT J CANCER, V99, P658, DOI 10.1002/ijc.10392
   Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229
   RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4
   Senderowicz AM, 2002, ONCOLOGIST, V7, P12
   Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211
   SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111
   Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1
   Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200
   Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531
   Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2
   VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
NR 40
TC 28
Z9 32
U1 3
U2 10
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAY
PY 2008
VL 73
IS 5
BP 1549
EP 1557
DI 10.1124/mol107.041350
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 288VP
UT WOS:000255014200024
PM 18287248
DA 2018-12-27
ER

PT J
AU He, HB
   Yang, XZ
   Shi, MQ
   Zeng, XW
   Wu, LM
   Li, LD
AF He, Hai-Bo
   Yang, Xian-Zhe
   Shi, Meng-Qiong
   Zeng, Xiao-Wei
   Wu, Li-Mao
   Li, Lian-Da
TI RETRACTED: Comparison of cardioprotective effects of salvianolic acid B
   and benazepril on large myocardial infarction in rats (Retracted
   Article. See vol 60, pg 750, 2008)
SO PHARMACOLOGICAL REPORTS
LA English
DT Article; Retracted Publication
DE salvianolic acid B; benazepril; large myocardial infarction; heart
   function; blood viscosity; angiogenesis; infarct size; ventricular
   remodeling
ID LEFT-VENTRICULAR DYSFUNCTION; ENDOTHELIAL GROWTH-FACTOR; HEART-FAILURE;
   IN-VITRO; NAD(P)H OXIDASE; NADPH OXIDASE; UP-REGULATION; ANGIOGENESIS;
   MILTIORRHIZA; EXPRESSION
AB In the present study, we compared cardioprotective effects of salvianolic acid B (Sal B) and the angiotension-converting enzyme inhibitor, benazepril, in rats with large myocardial infarction (MI). The large MI was produced by coronary artery ligation for 4 weeks in rats. The rats were divided into the following groups: sham operation; MI; MI + Sal B (100 mg/kg by a gavage, once a day for 4 weeks) and MI + benazepril (I mg/kg by a gavage, once a day for 4 weeks). Echocardiogram, hemodynamic and hemorheological changes, angiogenesis, infarct size and cardiac remodeling, as well as messenger ribonucleic acid (mRNA) of vascular endothelium growth factor (VEGF) were measured. The following similar effects were observed in MI rats treated with Sal B and benazepril: (1) a marked improvement of echocardiographic, hemodynamic and hemorheological parameters, (2) significant reduction of infarct size, (3) significantly attenuated heart hypertrophy, left ventricular (LV) dilatation and fibrosis. The unique effects of Sal B were: angiogenesis and augmented VEGF expression in the border and remote noninfarcted LV area. These results suggest that Sal B and benazepril exerted beneficial cardioprotective effects. However, Sal B enforced some different modality than benazepril, which might improve myocardial microcirculation by augmenting VEGF expression and promoting angiogenesis besides similar effects to benazepril.
C1 [He, Hai-Bo; Yang, Xian-Zhe; Zeng, Xiao-Wei; Wu, Li-Mao; Li, Lian-Da] Zhejiang Univ, Inst Chinese Herbal Med, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Shi, Meng-Qiong] Ctr Med Sci Anal, Hangzhou 310053, Zhejiang, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Inst Chinese Herbal Med, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM wulimao@zju.edu.cn
FU National Postdoctor Science Foundation of China [20070411201]; National
   Natural Science Foundation of China [30500661]; National Important Basic
   Development Plan of China [2005CB523405]
FX This study was supported by a project from National Postdoctor Science
   Foundation of China (No. 20070411201), a common project from National
   Natural Science Foundation of China (No. 30500661) and a grant of
   National Important Basic Development Plan of China (also called 973
   project, No Professor Dr Yu-Iing Ma (Research Fellow, School of
   Pharmacy, University of Reading, GB) provided assistance with the
   composition and English styling of the paper.
CR FENG Y, 2007, PHARM REP, V59, P1734
   FISHBEIN MC, 1978, AM J PATHOL, V90, P57
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   He HB, 2007, J PHARM PHARMACOL, V59, P977, DOI 10.1211/jpp.59.7.0010
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16
   Ji XY, 2003, LIFE SCI, V73, P1413, DOI 10.1016/S0024-3205(03)00432-6
   Kastrup J, 2005, J AM COLL CARDIOL, V45, P982, DOI 10.1016/j.jacc.2004.12.068
   Lay IS, 2003, PLANTA MED, V69, P26, DOI 10.1055/s-2003-37034
   Lin YL, 2006, J ETHNOPHARMACOL, V105, P215, DOI 10.1016/j.jep.2005.10.021
   Liu Jian-xun, 2006, Chin J Integr Med, V12, P199
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   Morgan EE, 2004, AM J PHYSIOL-HEART C, V287, pH2049, DOI 10.1152/ajpheart.00393.2004
   Na T, 2007, N-S ARCH PHARMACOL, V375, P39, DOI 10.1007/s00210-007-0134-1
   Nagaya N, 2001, CIRCULATION, V104, P1430, DOI 10.1161/hc3601.095575
   NICOSIA RF, 1994, AM J PATHOL, V145, P1023
   PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085
   PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001
   Sasaki H, 2002, J MOL CELL CARDIOL, V34, P335, DOI 10.1006/jmcc.2001.1516
   Soeki T, 2005, J AM COLL CARDIOL, V45, p420A
   Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939
   Stauss H M, 1994, J Cardiovasc Risk, V1, P255
   Sun J, 2005, LIFE SCI, V76, P2849, DOI 10.1016/lfs.2004.11.016
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077
   Wang YQ, 2004, DRUG DEVELOP RES, V63, P22, DOI 10.1002/ddr.10383
   Wu GF, 2006, AM J PHYSIOL-HEART C, V290, pH248, DOI 10.1152/ajpheart.01225.2004
   Zhang HS, 2006, J MOL CELL CARDIOL, V41, P138, DOI 10.1016/j.yjmcc.2006.03.007
   Zhang SY, 2006, BIOL PHARM BULL, V29, P945, DOI 10.1248/bpb.29.945
   Zhao BL, 1996, BIOCHEM MOL BIOL INT, V38, P1171
   Zhou LM, 2006, J PHARMACEUT BIOMED, V41, P744, DOI 10.1016/j.jpba.2005.12.032
   Zhu YC, 1997, AM J CARDIOL, V80, pA110, DOI 10.1016/S0002-9149(97)00465-7
   ZHU YZ, 1998, ACE INHIBITION TARGE, P1
NR 36
TC 19
Z9 24
U1 2
U2 12
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31-343 KRAKOW, POLAND
SN 1734-1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD MAY-JUN
PY 2008
VL 60
IS 3
BP 369
EP 381
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 353AB
UT WOS:000259537400009
PM 18622062
DA 2018-12-27
ER

PT J
AU Sajid, MS
AF Sajid, M. S.
TI RETRACTED: Bioethics and medical education (Retracted article. See vol.
   63, pg. 38, 2018)
SO SCOTTISH MEDICAL JOURNAL
LA English
DT Editorial Material; Retracted Publication
ID ETHICS EDUCATION; UNETHICAL CONDUCT; FUTURE
EM surgeon1wrh@hotmail.com
CR CHRISTAKIS DA, 1993, ACAD MED, V68, P249, DOI 10.1097/00001888-199304000-00003
   DuBois JM, 2002, ACAD MED, V77, P432, DOI 10.1097/00001888-200205000-00019
   FEUDTNER C, 1994, ACAD MED, V69, P670, DOI 10.1097/00001888-199408000-00017
   FOX E, 1995, ACAD MED, V70, P761, DOI 10.1097/00001888-199509000-00011
   *GEN MED COUNC, 1979, PROF COND DISC FITN
   KAY J, 1991, JAMA-J AM MED ASSOC, V263, P572
   LAMY O, 2006, REV MED SUISSE, V86, P2550
   MILES SH, 1989, ACAD MED, V64, P705, DOI 10.1097/00001888-198912000-00004
   Satterwhite RC, 2000, J MED ETHICS, V26, P462, DOI 10.1136/jme.26.6.462
   Yamey G, 2001, WESTERN J MED, V174, P355, DOI 10.1136/ewjm.174.5.355-a
   ZUCKER A, 2006, MED HUMANIT, V1, P48
NR 11
TC 1
Z9 1
U1 1
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0036-9330
EI 2045-6441
J9 SCOT MED J
JI Scott. Med. J.
PD MAY
PY 2008
VL 53
IS 2
BP 62
EP 63
DI 10.1258/rsmsmj.53.2.62
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 358KD
UT WOS:000259914800050
PM 18549072
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Nakayama, M
AF Fujii, Y.
   Nakayama, M.
TI RETRACTED: Prevention of postoperative nausea and vomiting with a small
   dose of propofol alone and combined with dexamethasone in patients
   undergoing laparoscopic cholecystectomy: A prospective, randomized,
   double-blind study (Retracted article. See vol. 27, pg. 2551, 2013)
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 3rd International Symposium on Natural Orifice Translumenal Endoscopic
   Surgery
CY JUL 10, 2008
CL San Francisco, CA
DE complications; vomiting; antieemetics; propofol; dexamethasone;
   laparoscopic cholecystectomy
ID NITROUS-OXIDE; ANESTHESIA; ONDANSETRON; PLACEBO; EMESIS
AB Background A small dose of propofol is directly antiemetic, and is effective for the prevention of postoperative nausea and vomiting ( PONV) in patients undergoing laparoscopic cholecystectomy (LC). However, this regimen cannot entirely control PONV after LC.
   Methods In a prospective, randomized, double-blind study, patients received intravenously either placebo (Intralipid (R)), propofol 0.5 mg/kg, or propofol 0.5 mg/kg plus dexamethasone 8 mg at the end of surgical procedure. A standard anesthetic technique, including sevoflurane and air in oxygen, was used. Emetic symptoms (nausea, retching, and vomiting) were recorded during the first 24 hours after anesthesia.
   Results A total of 120 patients (59 men and 61 nonpregnant women) were enrolled, and each treatment group consisted of 40 patients. The incidence of patients experiencing PONV during the first 24 hours after anesthesia was 33% with propofol (P = 0.003), 15% with propofol plus dexamethasone (P = 0.001), when compared to 65% with placebo. The efficacy of propofol combined with dexamethasone was superior to that of propofol alone (P = 0.029). No clinically important adverse events due to the study drugs were observed in any of the groups.
   Conclusions Propofol 0.5 mg/kg combined with dexamethasone 8 mg is more effective than propofol alone for the prevention of PONV during the first 24 hours after anesthesia in patients undergoing LC.
C1 [Fujii, Y.; Nakayama, M.] Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anaesthesiol 1, Ohta Ku, 6-11-1 Ohmori Nishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR BORGEAT A, 1992, ANESTH ANALG, V74, P539
   Cechetto DF, 2001, ANESTH ANALG, V92, P934
   Fisher DM, 1996, ANESTH ANALG, V83, P4, DOI 10.1097/00000539-199607000-00002
   Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95
   Hammas B, 1998, ACTA ANAESTH SCAND, V42, P447, DOI 10.1111/j.1399-6576.1998.tb05140.x
   Hartung J, 1996, ANESTH ANALG, V83, P114, DOI 10.1097/00000539-199607000-00020
   Helmy SAK, 1999, ANAESTHESIA, V54, P266, DOI 10.1046/j.1365-2044.1999.00335.x
   IITOMI T, 1995, MASUI, V44, P1727
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739
   OSMAN PL, 1990, ANESTH ANALG, V71, P536
   RAMSAY TM, 1994, CAN J ANAESTH, V41, P798, DOI 10.1007/BF03011586
   SANCHEZ LA, 1995, J RES PHARM EC, V6, P35
   SCHIMMER BP, 2001, GOODMAN GILMANS PHAR, P1649
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   Song DJ, 1998, ANESTHESIOLOGY, V89, P838, DOI 10.1097/00000542-199810000-00007
   TAYLOR E, 1992, ANESTHESIOLOGY, V76, P541, DOI 10.1097/00000542-199204000-00009
   Tramer M, 1996, BRIT J ANAESTH, V76, P186
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 21
TC 6
Z9 8
U1 3
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
EI 1432-2218
J9 SURG ENDOSC
JI Surg. Endosc.
PD MAY
PY 2008
VL 22
IS 5
BP 1268
EP 1271
DI 10.1007/s00464-007-9647-4
PG 4
WC Surgery
SC Surgery
GA 302WD
UT WOS:000255999700023
PM 18000709
DA 2018-12-27
ER

PT J
AU Kuzmin, A
   Stenback, T
   Lijequist, S
AF Kuzmin, Alexander
   Stenback, Tove
   Lijequist, Sture
TI RETRACTED: Memantine enhances the inhibitory effects of naltrexone on
   ethanol consumption (Retracted article. See vol. 761, pg. 424, 2015)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE ethanol; reward; naltrexone; memantine; self-administration
ID NMDA RECEPTOR ANTAGONIST; ALCOHOL DEPRIVATION; DRUG DISCRIMINATION;
   RATS; ACAMPROSATE; NALOXONE; DEPENDENCE; PHARMACOTHERAPY; COMBINATION;
   THERAPY
AB Effects of the opioid receptor antagonist naltrexone (0.1; 0.3; 1.0 mg/kg i.p.) on operant ethanol self-administration alone and in combination with the non-competitive NMDA antagonist memantine (0.5 and 1 mg/kg, i.p.) were studied in rats. Acute administration of naltrexone (0.1; 0.3; 1.0 mg/kg i.p.) inhibited ethanol self-administration in a dose-dependent manner. Nlemantine (1.0 mg/kg) significantly enhanced the effects of naltrexone at 0.1 mg/kg, failing per se to inhibit ethanol consumption. Thus, low, sub-effective dose of memantine in combination with low doses of naltrexone blocked the reinforcing properties of ethanol in rats. It is suggested that the combination of sub-effective doses of memantine and naltrexone may have therapeutic value in the treatment of alcoholism particularly in a subgroup of alcoholic patients who have high sensitivity to the adverse side effects of naltrexone. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Kuzmin, Alexander; Stenback, Tove; Lijequist, Sture] Karolinska Univ Hosp L4 00, Div Drug Dependence Res, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden.
RP Kuzmin, A (reprint author), Karolinska Univ Hosp L4 00, Div Drug Dependence Res, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden.
EM alexander.kuzmin@neuro.ki.se
CR Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003
   Bienkowski P, 1996, EUR J PHARMACOL, V314, P277, DOI 10.1016/S0014-2999(96)00658-9
   Bisaga A, 2004, PSYCHOPHARMACOLOGY, V172, P16, DOI 10.1007/s00213-003-1617-5
   Danysz W, 1997, NEUROSCI BIOBEHAV R, V21, P455, DOI 10.1016/S0149-7634(96)00037-1
   Davidson D, 1996, ALCOHOL CLIN EXP RES, V20, P664, DOI 10.1111/j.1530-0277.1996.tb01669.x
   DIMPFEL W, 1987, NEUROPSYCHOBIOLOGY, V18, P212, DOI 10.1159/000118420
   Feeney GFX, 2006, ALCOHOL ALCOHOLISM, V41, P321, DOI 10.1093/alcalc/ag1007
   FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G
   Heyser CJ, 2003, NEUROPSYCHOPHARMACOL, V28, P1463, DOI 10.1038/sj.npp.1300175
   Holter SM, 1996, EUR J PHARMACOL, V314, pR1, DOI 10.1016/S0014-2999(96)00670-X
   HUBBELL CL, 1986, ALCOHOL, V3, P39, DOI 10.1016/0741-8329(86)90070-4
   Hundt W, 1998, PSYCHOPHARMACOLOGY, V135, P44, DOI 10.1007/s002130050484
   Kiefer F, 2003, ARCH GEN PSYCHIAT, V60, P92, DOI 10.1001/archpsyc.60.1.92
   KORNHUBER J, 1995, NEUROSCI LETT, V195, P137, DOI 10.1016/0304-3940(95)11785-U
   Kotlinska J, 1997, EUR J PHARMACOL, V332, P1, DOI 10.1016/S0014-2999(97)01069-8
   Kranzler HR, 2000, ALCOHOL ALCOHOLISM, V35, P537, DOI 10.1093/alcalc/35.6.537
   Krupitsky EM, 2007, AM J PSYCHIAT, V164, P519, DOI 10.1176/appi.ajp.164.3.519
   Krystal JH, 2003, PHARMACOL THERAPEUT, V99, P79, DOI 10.1016/S0163-7258(03)00054-8
   Krystal JH, 1998, ARCH GEN PSYCHIAT, V55, P354, DOI 10.1001/archpsyc.55.4.354
   Kuzmin A, 2007, NEUROPSYCHOPHARMACOL, V32, P902, DOI 10.1038/sj.npp.1301169
   O'Malley SS, 2002, PSYCHOPHARMACOLOGY, V160, P19, DOI 10.1007/s002130100919
   Pant S. C., 1993, Biomedical and Environmental Sciences, V6, P103
   Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2
   Pickering C, 2003, PSYCHOPHARMACOLOGY, V168, P307, DOI 10.1007/s00213-003-1454-6
   Quack G, 1995, J NEURAL TRANSM-SUPP, P97
   SAMSON HH, 1985, PHARMACOL BIOCHEM BE, V22, P91, DOI 10.1016/0091-3057(85)90491-5
   SCHMIDT W J, 1991, Amino Acids (Vienna), V1, P225, DOI 10.1007/BF00806920
   SHELTON KL, 1994, BEHAV PHARMACOL, V5, P441
   Spanagel R, 1996, EUR J PHARMACOL, V305, P39, DOI 10.1016/0014-2999(96)00174-4
   Spanagel R, 1997, TRENDS PHARMACOL SCI, V18, P54, DOI 10.1016/S0165-6147(96)01026-7
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   WENK GL, 1995, EUR J PHARM-ENVIRON, V293, P267, DOI 10.1016/S0922-4106(05)80053-7
   WOLFFGRAMM J, 1995, BEHAV BRAIN RES, V70, P77, DOI 10.1016/0166-4328(95)00131-C
NR 33
TC 11
Z9 11
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 28
PY 2008
VL 584
IS 2-3
BP 352
EP 356
DI 10.1016/j.ejphar.2008.02.015
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 300KC
UT WOS:000255821700019
PM 18339371
DA 2018-12-27
ER

PT J
AU Chuderland, D
   Marmor, G
   Shainskaya, A
   Seger, R
AF Chuderland, Dana
   Marmor, Goldie
   Shainskaya, Alla
   Seger, Rony
TI RETRACTED: Calcium-mediated interactions regulate the subcellular
   localization of extracellular signal-regulated kinases (Retracted
   article. See vol. 292, pg. 8850, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; GONADOTROPIN-RELEASING-HORMONE; NUCLEAR EXPORT
   SIGNAL; MAP KINASE; GROWTH-FACTOR; ERK; TRANSLOCATION; MECHANISM;
   CASCADE; PHOSPHORYLATION
AB The subcellular localization of ERKs in cells, which is important for proper signaling, may be regulated through protein-protein interactions. We found that inactive ERK2 interacts with a large number of proteins through its cytosolic retention sequence/common docking domain, whereas the phospho-ERK2 interacts with only few substrates. Varying calcium concentrations significantly modified the repertoire of ERK2-interacting proteins, of which many were identified. The effect of calcium on ERK interactions also influenced the localization of ERKs, as calcium chelators enhanced nuclear translocation, whereas elevated calcium levels prevented it. This effect of calcium was apparent upon lysophosphatidic acid stimulation, where ERKs translocation was delayed compared with that induced by EGF in a calcium-dependent manner. In vitro translocation assay revealed that high calcium concentrations affect ERK translocation by preventing the shuttling machinery through the nuclear envelope, probably due to higher binding to nuclear pore proteins. These results are consistent with a model in which ERKs in quiescent cells are bound to several cytoplasmic proteins. Upon stimulation, ERKs are phosphorylated and released from cytoplasmic anchors to allow shuttling toward the nucleus. This translocation is delayed when calcium levels are increased, and this modifies the localization of ERKs and, therefore, also their spatiotemporal regulation. Thus, calcium regulates ERK localization, which is important for the compartmentalization of ERKs with their proper substrates and thereby their signaling specificity.
C1 [Chuderland, Dana; Marmor, Goldie; Seger, Rony] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
   [Shainskaya, Alla] Weizmann Inst Sci, Mass Spectroscopy Unit, IL-76100 Rehovot, Israel.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
EM rony.seger@weizmann.ac.il
CR Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575
   Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347
   Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849
   Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4
   Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006
   Bardwell L, 2006, BIOCHEM SOC T, V34, P837, DOI 10.1042/BST0340837
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129
   Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6
   Chuderland D, 2005, MOL BIOTECHNOL, V29, P57, DOI 10.1385/MB:29:1:57
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Cook SJ, 1999, MOL CELL BIOL, V19, P330
   Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237
   Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808
   Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082
   Erickson ES, 2006, CAN J PHYSIOL PHARM, V84, P309, DOI 10.1139/Y05-109
   Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024
   Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642
   Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901
   Ginnan R, 2002, AM J PHYSIOL-CELL PH, V282, pC754, DOI 10.1152/ajpcell.00335.2001
   Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131
   Harris D, 2003, ENDOCRINOLOGY, V144, P612, DOI 10.1210/en.2002-220690
   Imajo M, 2006, IUBMB LIFE, V58, P312, DOI 10.1080/15216540600746393
   Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742
   Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7
   Lee MA, 1998, CELL CALCIUM, V23, P91, DOI 10.1016/S0143-4160(98)90107-5
   Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3
   Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117
   Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625
   Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200
   Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942
   Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796
   Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668
   Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822
   Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5
   Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023
   Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Ranganathan A, 2006, J BIOL CHEM, V281, P15645, DOI 10.1074/jbc.M513866200
   RAO VN, 1994, ONCOGENE, V9, P1855
   Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673
   RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881
   Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003
   Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349
   SEGER R, 1995, FASEB J, V9, P726
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2
   Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2
   Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999
   Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200
   Xia ZG, 1996, J NEUROSCI, V16, P5425
   Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218
   Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X
   Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0
   Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200
NR 55
TC 28
Z9 29
U1 2
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 25
PY 2008
VL 283
IS 17
BP 11176
EP 11188
DI 10.1074/jbc.M709030200
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 289PW
UT WOS:000255067400013
PM 18268018
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU van Bueren, JJL
   Bleeker, WK
   Brannstrom, A
   von Euler, A
   Jansson, M
   Peipp, M
   Schneider-Merck, T
   Valerius, T
   van de Winkel, JGJ
   Parren, PWHI
AF van Bueren, Jeroen J. Larnmerts
   Bleeker, Wim K.
   Brannstrom, Annika
   von Euler, Anne
   Jansson, Magnus
   Peipp, Matthias
   Schneider-Merck, Tanja
   Valerius, Thomas
   van de Winkel, Jan G. J.
   Parren, Paul W. H. I.
TI RETRACTED: The antibody zalutumumab inhibits epidermal growth factor
   receptor signaling by limiting intra- and intermolecular flexibility
   (Retracted article. See vol. 109, pg. 5548, 2012)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE EGFR; mechanism of action; protein tomography
ID SQUAMOUS CARCINOMA-CELLS; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODY;
   DIMERIZATION; ACTIVATION; DYNAMICS; DOMAIN; IGG
AB The epidermal growth factor receptor (EGFR) activates cellular pathways controlling cell proliferation, differentiation, migration, and survival. It thus represents a valid therapeutic target for treating solid cancers. Here, we used an electron microscopy-based technique (Protein Tomography) to study the structural rearrangement accompanying activation and inhibition of native, individual, EGFR molecules. Reconstructed tomograms (311) density maps) showed a level of detail that allowed individual domains to be discerned. Monomeric, resting EGFR ectodomains demonstrated large flexibility, and a number of distinct conformations were observed. In contrast, ligand-activated EGFR complexes were detected only as receptor dimers with ring-like conformations. Zalutumumab, a therapeutic inhibitory EGFR antibody directed against domain III, locked EGFR molecules into a very compact, inactive conformation. Biochemical analyses showed bivalent binding of zalutumumab to provide potent inhibition of EGFR signaling. The structure of EGFR-zalutumumab complexes on the cell surface visualized by Protein Tomography indicates that the cross-linking spatially separates the EGFR molecules' intracellular kinase domains to an extent that appears incompatible with the induction of signaling. These insights into the mechanisms of action of receptor inhibition may also apply to other cell-surface tyrosine kinase receptors of the ErbB family.
C1 [van Bueren, Jeroen J. Larnmerts; Bleeker, Wim K.; van de Winkel, Jan G. J.; Parren, Paul W. H. I.] Genmab, NL-3508 AD Utrecht, Netherlands.
   [Brannstrom, Annika; von Euler, Anne; Jansson, Magnus] Sidec, S-16440 Kista, Sweden.
   [Peipp, Matthias; Schneider-Merck, Tanja; Valerius, Thomas] Univ Kiel, Div Nephrol & Hypertens, D-24105 Kiel, Germany.
   [van de Winkel, Jan G. J.] Univ Med Ctr Utrecht, Dept Immunol, Immunotherapy Lab, NL-3584 EA Utrecht, Netherlands.
RP Parren, PWHI (reprint author), Genmab, NL-3508 AD Utrecht, Netherlands.
EM ppa@genmab.com
RI Valerius, Thomas/A-3086-2011
CR Bleeker WK, 2004, J IMMUNOL, V173, P4699, DOI 10.4049/jimmunol.173.7.4699
   Bongini L, 2004, P NATL ACAD SCI USA, V101, P6466, DOI 10.1073/pnas.0400119101
   Bongini L, 2007, PHYS BIOL, V4, P172, DOI 10.1088/1478-3975/4/3/004
   Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2
   Chao G, 2004, J MOL BIOL, V342, P539, DOI 10.1016/j.jmb.2004.07.053
   FAN Z, 1994, J BIOL CHEM, V269, P27595
   FANELLI D, 2008, IN PRESS INVERSE PRO, V24
   Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9
   Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6
   GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464
   Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209
   KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286
   Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003
   Luhder F, 2003, J EXP MED, V197, P955, DOI 10.1084/jem.20021024
   Martin-Fernandez M, 2002, BIOPHYS J, V82, P2415, DOI 10.1016/S0006-3495(02)75585-9
   Miralles F, 2000, J CELL BIOL, V148, P271, DOI 10.1083/jcb.148.2.271
   Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7
   Prat M, 1998, J CELL SCI, V111, P237
   RAPOSO G, 1997, HDB EXPT IMMUNOLOGY, V4, P1
   RULLGARD H, 2007, INVERSE PROBL, V23, P1
   Sandin S, 2004, STRUCTURE, V12, P409, DOI 10.1016/j.str.2004.02.011
   Saphire EO, 2002, J MOL BIOL, V319, P9, DOI 10.1016/S0022-2836(02)00244-9
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Skoglund U, 1996, J STRUCT BIOL, V117, P173, DOI 10.1006/jsbi.1996.0081
   TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551
   van Bueren JJL, 2006, CANCER RES, V66, P7630, DOI 10.1158/0008-5472.CAN-05-4010
   Wu SL, 2006, MOL CELL PROTEOMICS, V5, P1610, DOI 10.1074/mcp.M600105-MCP200
   YARDEN Y, 2001, CELL BIOL, V2, P127
   Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411
   Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013
   Zhen YJ, 2003, BIOCHEMISTRY-US, V42, P5478, DOI 10.1021/bi027101p
NR 34
TC 41
Z9 42
U1 5
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 22
PY 2008
VL 105
IS 16
BP 6109
EP 6114
DI 10.1073/pnas.0709477105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 293SW
UT WOS:000255356000030
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Xiao, N
   Li, SZ
   Zhang, XP
   Chen, SY
AF Xiao, Nong
   Li, Shizhi
   Zhang, Xiaoping
   Chen, Siyuan
TI RETRACTED: Effect of ephedrine on neuronal plasticity of
   hypoxic-ischemic brain damage in neonatal rats (Retracted article. See
   vol. 528, pg. 90, 2012)
SO NEUROSCIENCE LETTERS
LA English
DT Article; Retracted Publication
DE ephedrine; anoxia and ischemia; neural plasticity
AB Objective: Study the effect of ephedrine on neural plasticity of hypoxic ischemic brain damaged (HIBD) in neonatal rats, and explore the underlying molecular mechanism. Methods: 60 Sprats suffered from HIBD (7 days old) were randomly divided into ephedrine group, D-amphetarmne (D-AMPH) group, cytidine triphosphate (CTP) group, ganglioside (GMI) group, and spontaneous recovery group. Using immunohistochemical method to test the expression of growth-associated protein-43(GAP-43) and synaptophysin (SYP) on one side of hippocampal CA3 area, then, 4 weeks later, Morris Water Maze test was performed for five days. Results: (1) The expression levels of GAP-43 and SYP on hippocampal CA3 area in ephedrine group were higher than that in spontaneous recovery group (P<0.05). However, there was no statistical difference in ephedrine groups, CTP group, and D-AMPH group. (2) The average time of escape latency was significantly shorter in treating groups than that in spontaneous recovery group (P<0.05), and the frequency of original platform passing was higher than that in spontaneous recovery group (P < 0.01). The average time of escape latency was longer in ephedrine group than that in GM I group. The frequency of original platform passing was significantly less in ephedrine group than that in GMI group, No statistical difference found in ephedrine groups, CTP group, and D-AMPH group. Conclusions: Ephedrine may enhance memory, the abilities of spatial orientation and learning in HIBD rats. This protective effect may be associated with increasing synaptic connectivity, as assessed by increased expression of GAP-43 and SYP after HIBD. Ephedrine triggered similar protection against HIBD as treatment Of D-AMPH and CTR However, the amelioration of ability of spatial orientation, learning and memory by ephedrine on HIBD rats in later stage is slightly weaker than that by GM L which may be related with ephedrine dosage. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Xiao, Nong; Li, Shizhi; Chen, Siyuan] Chongqing Med Univ, Childrens Hosp, Dept Neurol, Chongqing 400014, Peoples R China.
   [Zhang, Xiaoping] Chongqing Med Univ, Childrens Hosp, Pediat Res Inst, Chongqing 400014, Peoples R China.
RP Xiao, N (reprint author), Chongqing Med Univ, Childrens Hosp, Dept Neurol, Chongqing 400014, Peoples R China.
EM xiaonongwl@163.com
CR Carulli D, 2004, PROG NEUROBIOL, V72, P373, DOI 10.1016/j.pneurobio.2004.03.007
   D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4
   FENG Y, 2001, J HENAN MED U, V36, P494
   JIANG Y, 2003, J NEONANTOL, V18, P163
   RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206
   Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999
   [赵晓科 Zhao Xiaoke], 2005, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V20, P172
   ZHU CG, 2002, NEUROANATOMY, P202
NR 8
TC 10
Z9 14
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD APR 18
PY 2008
VL 435
IS 2
BP 99
EP 102
DI 10.1016/j.neulet.2008.02.058
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 294UK
UT WOS:000255431500004
PM 18358610
DA 2018-12-27
ER

PT J
AU Cheng, BQ
   Jia, CQ
   Liu, CT
   Fan, W
   Wang, QL
   Zhang, ZL
   Yi, CH
AF Cheng, Bao-Quan
   Jia, Chong-Qi
   Liu, Chun-Tao
   Fan, Wei
   Wang, Qing-Liang
   Zhang, Zong-Li
   Yi, Cui-Hua
TI RETRACTED: Chemoembolization combined with radiofrequency ablation for
   patients with hepatocellular carcinoma larger than 3 cm - A randomized
   controlled trial (Retracted article. See vol. 301, pg. 1931, 2009)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article; Retracted Publication
ID ETHANOL INJECTION; THERMAL ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION;
   LIPIODOL CHEMOEMBOLIZATION; ARTERIAL EMBOLIZATION; CLIP SCORE; THERAPY;
   HCC; VALIDATION; MANAGEMENT
AB Context Transarterial chemoembolization ( TACE) combined with radiofrequency ablation ( RFA) therapy has been used for patients with large hepatocellular carcinoma tumors, but the survival benefits of combined treatment are not known.
   Objective To compare rates of survival of patients with large hepatocellular carcinoma tumors who received treatment with TACE combined with RFA therapy ( TACE- RFA), TACE alone, and RFA alone.
   Design, Setting, and Patients Randomized controlled trial conducted from January 2001 to May 2004 among 291 consecutive patients with hepatocellular carcinoma larger than 3 cm at a single center in China.
   Intervention Patients were randomly assigned to treatment with combined TACE- RFA ( n= 96), TACE alone ( n= 95), or RFA alone ( n= 100).
   Main Outcome Measures The primary end point was survival and the secondary end point was objective response rate.
   Results During a median 28.5 months of follow- up, median survival times were 24 months in the TACE group ( 3.4 courses), 22 months in the RFA group ( 3.6 courses), and 37 months in the TACE- RFA group ( 4.4 courses). Patients treated with TACE-RFA had better overall survival than those treated with TACE alone ( hazard ratio [ HR], 1.87; 95% confidence interval [ CI], 1.33- 2.63; P <. 001) or RFA ( HR, 1.88; 95% CI, 1.34- 2.65; P <. 001). In a preplanned substratification analysis, survival was also better in the TACE- RFA group than in the RFA group for patients with uninodular hepatocellular carcinoma ( HR, 2.50; 95% CI, 1.42- 4.42; P=. 001) and in the TACE- RFA group than the TACE group for patients with multinodular hepatocellular carcinoma ( HR, 1.99; 95% CI, 1.31- 3.00; P <. 001). The rate of objective response sustained for at least 6 months was higher in the TACE- RFA group ( 54%) than with either TACE ( 35%; rate difference, 0.19; 95% CI, 0.06- 0.33; P=. 009) or RFA ( 36%; rate difference, 0.18; 95% CI, 0.05- 0.32; P=. 01) treatment alone.
   Conclusion In this patient group, TACE- RFA was superior to TACE alone or RFA alone in improving survival for patients with hepatocellular carcinoma larger than 3 cm.
   Trial Registration clinicaltrials. gov Identifier: NCT00479050.
C1 [Cheng, Bao-Quan; Liu, Chun-Tao; Fan, Wei] Shandong Univ, Qilu Hosp, Dept Gastroenterol, Sch Med, Jinan 250012, Peoples R China.
   [Wang, Qing-Liang] Qilu Hosp, Sch Med, Dept Radiol, Jinan 250012, Peoples R China.
   [Zhang, Zong-Li] Qilu Hosp, Sch Med, Dept Surg, Jinan 250012, Peoples R China.
   [Yi, Cui-Hua] Qilu Hosp, Sch Med, Dept Oncol, Jinan 250012, Peoples R China.
   [Jia, Chong-Qi] Shandong Univ, Dept Epidemiol & Hlth Stat, Jinan 250100, Peoples R China.
RP Cheng, BQ (reprint author), Shandong Univ, Qilu Hosp, Dept Gastroenterol, Sch Med, Jinan 250012, Peoples R China.
EM dcbq@sohu.com
CR Bloomston M, 2002, AM SURGEON, V68, P827
   Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617
   Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.23004.09.032
   Bruix J, 2003, HEPATOLOGY, V37, P507, DOI 10.1053/jhep.2003.50142
   Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
   Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089
   Cai ZH, 2001, CHIN J ULTRASONOGR, V10, P408
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Head HW, 2004, GASTROENTEROLOGY, V127, pS167, DOI 10.1053/j.gastro.2004.09.031
   HIGUCHI T, 1994, CANCER, V73, P2259, DOI 10.1002/1097-0142(19940501)73:9<2259::AID-CNCR2820730905>3.0.CO;2-P
   KASUGAI H, 1989, GASTROENTEROLOGY, V97, P965, DOI 10.1016/0016-5085(89)91505-9
   Kudo M, 2004, HEPATOLOGY, V40, P1396, DOI 10.1002/hep.20486
   Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003
   Livraghi T, 2000, RADIOLOGY, V214, P761, DOI 10.1148/radiology.214.3.r00mr02761
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047
   Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156
   Lu DSK, 2005, HEPATOLOGY, V41, P1130, DOI 10.1002/hep.20688
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   OBERTI F, 1995, NEW ENGL J MED, V332, P1256
   OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
   Omata M, 2004, GASTROENTEROLOGY, V127, pS159, DOI 10.1053/j.gastro.2004.09.030
   Perrone F, 2000, HEPATOLOGY, V31, P840
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Rossi S, 2000, RADIOLOGY, V217, P119, DOI 10.1148/radiology.217.1.r00se02119
   Rossi S, 1999, TUMORI, V85, P128
   SAKURAI M, 1984, CANCER, V54, P387, DOI 10.1002/1097-0142(19840801)54:3<387::AID-CNCR2820540303>3.0.CO;2-W
   Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009
   SORENSEN JB, 1993, BRIT J CANCER, V67, P773, DOI 10.1038/bjc.1993.140
   Sturm JW, 2004, ONKOLOGIE, V27, P294, DOI 10.1159/000077982
   Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021
   Veltri A, 2006, EUR RADIOL, V16, P661, DOI 10.1007/s00330-005-0029-9
   Yamakado K, 2004, ONCOL REP, V11, P105
NR 33
TC 130
Z9 146
U1 6
U2 35
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 9
PY 2008
VL 299
IS 14
BP 1669
EP 1677
DI 10.1001/jama.299.14.1669
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 285AL
UT WOS:000254749600023
PM 18398079
OA Bronze
DA 2018-12-27
ER

PT J
AU Marshall, L
   Kenneth, NS
   White, RJ
AF Marshall, Lynne
   Kenneth, Niall S.
   White, Robert J.
TI RETRACTED: Elevated tRNA(i)(Met) synthesis can drive cell proliferation
   and oncogenic transformation (Retracted article. See vol. 151, pg. 455,
   2012)
SO CELL
LA English
DT Article; Retracted Publication
ID RNA-POLYMERASE-III; YEAST SACCHAROMYCES-CEREVISIAE; ELONGATION-FACTOR
   EEF1A2; RETINOBLASTOMA PROTEIN; MALIGNANT-TRANSFORMATION; IN-VIVO;
   TRANSCRIPTION; CANCER; TRANSLATION; TFIIIB
AB Characteristics of transformed and tumor cells include increased levels of protein synthesis and elevated expression of RNA polymerase (pol) III products, such as tRNAs and 5S rRNA. However, whether deregulated pol III transcription contributes to transformation has been unclear. Generating cell lines expressing an inducible pol III-specific transcription factor, Brf1, allowed us to raise tRNA and 5S rRNA levels specifically. Brf1 induction caused an increase in cell proliferation and oncogenic transformation, whereas depletion of Brf1 impeded transformation. Among the gene products induced by Brf1 is the tRNA(i)(Met) that initiates polypeptide synthesis. Overexpression of tRNA(i)(Met) is sufficient to stimulate cell proliferation and allow immortalized fibroblasts to form foci in culture and tumors in mice. The data indicate that elevated tRNA synthesis can promote cellular transformation.
C1 [Marshall, Lynne; Kenneth, Niall S.; White, Robert J.] Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
   [Marshall, Lynne; White, Robert J.] Garscube Estate, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
RP White, RJ (reprint author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
EM white@beatson.gla.ac.uk
CR Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904
   Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027
   BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112
   Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755
   Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265
   Daly NL, 2005, ONCOGENE, V24, P880, DOI 10.1038/sj.onc.1208031
   DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0
   DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Fairley JA, 2005, P NATL ACAD SCI USA, V102, P18350, DOI 10.1073/pnas.0506415102
   Fairley JA, 2003, EMBO J, V22, P5841, DOI 10.1093/emboj/cdg544
   Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240
   Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200
   Felton-Edkins ZA, 2006, J BIOL CHEM, V281, P33871, DOI 10.1074/jbc.M600468200
   Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375
   FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486
   Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027
   Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327
   Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004
   Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447
   JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9
   Jones E, 2000, EXP CELL RES, V254, P163, DOI 10.1006/excr.1999.4739
   KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x
   Larminie CGC, 1999, MOL CELL BIOL, V19, P4927
   Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196
   Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061
   LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0
   Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549
   Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4
   Morton JP, 2007, NUCLEIC ACIDS RES, V35, P3046, DOI 10.1093/nar/gkm208
   Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0
   Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1
   Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400
   Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902
   Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200
   Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj/onc/1205372
   Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4
   Sudbery P, 2002, SCIENCE, V297, P351, DOI 10.1126/science.1073042
   Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255
   TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0
   Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113
   White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551
   White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547
   White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0
   WHITE RJ, 1995, MOL CELL BIOL, V15, P1983
   Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097
   ZETTERBE.A, 1965, EXP CELL RES, V40, P1, DOI 10.1016/0014-4827(65)90284-3
NR 57
TC 112
Z9 115
U1 3
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 4
PY 2008
VL 133
IS 1
BP 78
EP 89
DI 10.1016/j.cell.2008.02.035
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 283MW
UT WOS:000254641300010
PM 18394991
OA Bronze
DA 2018-12-27
ER

PT J
AU Nishiyama, T
AF Nishiyama, T.
TI RETRACTED: Interaction between a NMDA receptor antagonist, AP-5 and an
   AMPA receptor antagonist, YM 872 in antinociception in the spinal cord
   (Retracted article. See vol. 53, pg. 268, 2009)
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
DE antinociception; spinal cord; MNDA receptor; AMPA receptor; synergism
ID AMINO-ACID RECEPTORS; NOCICEPTIVE RESPONSE; INDUCED PAIN; FORMALIN; RAT;
   NEURONS; MICE; PLASTICITY; MORPHINE; YM872
AB Background: The intrathecal N-methyl-D-aspartate (NMDA) receptor antagonist, AP-5 and the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, YM 872 showed inhibition on both acute and facilitated nociception in our previous study. The present study was performed to investigate the interaction between intrathecal AP-5 and YM 872 in antinociception for acute and chronic nociception.
   Methods: Sprague-Dawley rats with lumbar intrathecal catheters were tested for their thermal tail withdrawal response and for their paw flinches by formalin injection after intrathecal administration of AP-5 or YM 872. The effects of the combination were tested by an isobolographic analysis using 50% effective dose (ED50). Total fractional dose was calculated as (ED50 dose of AP-5 in combination)/(ED50 dose of AP-5 alone)+(ED50 dose of YM 872 in combination)/(ED50 dose of YM 872 alone).
   Results: Intrathecally administered AP-5, YM 872, and their combination produced dose-dependent increases of the tail-flick latency and decreases in the number of flinches in both phase 1 and 2 of the formalin test. The ED50 values of the combination were significantly lower than the calculated additive values (P < 0.01). Total fractional dose value was 0.22 in the tail flick test, 0.12 in the phase 1 and 0.14 in the phase 2 of the formalin test.
   Conclusion: An NMDA receptor antagonist, AP-5 and an AMPA receptor antagonist, YM 872 had synergistic antinociceptive effects on both acute thermal and inflammatory induced acute and facilitated nociception.
C1 [Nishiyama, T.] Univ Tokyo, Dept Anesthesiol, Bunkyo Ku, Tokyo, Japan.
RP Nishiyama, T (reprint author), 3-2-6-603 Kawaguchi, Kawaguchi, Saitama 3320015, Japan.
EM nishit-tky@umin.ac.jp
CR BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0
   BUCHANAN JT, 1987, BRAIN RES, V408, P321, DOI 10.1016/0006-8993(87)90397-0
   DICKENSON AH, 1990, BRAIN RES, V506, P31, DOI 10.1016/0006-8993(90)91195-M
   HUNTER JC, 1994, NEUROSCI LETT, V174, P217, DOI 10.1016/0304-3940(94)90025-6
   Kawasaki-Yatsugi S, 1998, BRAIN RES, V793, P39, DOI 10.1016/S0006-8993(98)00108-5
   KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7
   Kullmann DM, 2000, CELL MOL LIFE SCI, V57, P1551, DOI 10.1007/PL00000640
   Lutfy K, 1997, PAIN, V70, P31, DOI 10.1016/S0304-3959(96)03290-3
   MURPHY SN, 1989, J PHARMACOL EXP THER, V249, P184
   NASSTROM J, 1992, EUR J PHARMACOL, V212, P21, DOI 10.1016/0014-2999(92)90067-E
   Nishiyama T, 2000, CAN J ANAESTH, V47, P693, DOI 10.1007/BF03019004
   Nishiyama T, 1999, ANESTHESIOLOGY, V91, P531, DOI 10.1097/00000542-199908000-00028
   Nishiyama T, 2000, EUR J PHARMACOL, V395, P203, DOI 10.1016/S0014-2999(00)00268-5
   Nishiyama T, 1999, ANESTH ANALG, V89, P143, DOI 10.1097/00000539-199907000-00024
   ROERIG SC, 1988, J PHARMACOL EXP THER, V247, P603
   Simmons RMA, 1998, NEUROPHARMACOLOGY, V37, P25, DOI 10.1016/S0028-3908(97)00188-3
   Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723
NR 17
TC 1
Z9 1
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD APR
PY 2008
VL 52
IS 4
BP 493
EP 498
DI 10.1111/j.1399-6576.2008.01593.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 274DV
UT WOS:000253982900006
PM 18339155
DA 2018-12-27
ER

PT J
AU Chen, JR
   Sui, Y
   Chen, L
   Wen, JW
   Yin, LY
AF Chen, Jing-Rong
   Sui, Yan
   Chen, Li
   Wen, Ji-Wu
   Yin, Li-Yang
TI RETRACTED: {mu-6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato}-mu-nitrato-dinitr
   atoterbium(III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn-II-Tb-III complex (systematic name: {6,6'-dimethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)] diphenolato-1k(4)O(6),O-1,O-1',O-6'}:2k O-4(1),N,N',O-1'-mu-nitrato- 1:2k(2)O:O'-dinitrato-1k(4)O,O'-terbium(III)zinc(II)), [TbZn(C18H18N2O4)(NO3)(3)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-methoxysalicylidene) ethylenediamine (H2L), the Tb and Zn atoms are triply bridged by two phenolate O atoms of the Schiff base ligand and one nitrate ion. The five-coordinate Zn atom is in a square-pyramidal geometry with the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Tb III center has a ninefold coordination environment of O atoms, involving the phenolate O atoms, two methoxy O atoms, two O atoms from two nitrate ions and one from the bridging nitrate ion. Weak intermolecular C-H center dot center dot center dot O interactions generate a two-dimensional layer structure.
C1 [Sui, Yan; Wen, Ji-Wu; Yin, Li-Yang] JingGangShan Univ, JiangXi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
   [Chen, Jing-Rong] Southwest Univ, Coll Chem & Chem Engn, Chongqing 400715, Peoples R China.
   [Chen, Li] JingGangShan Univ, Coll Educ, Jian 343009, Jiangxi, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, JiangXi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUX AXS INC, 2004, APEX2 SADABS
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2008, UNPUB  PUBICIF
NR 9
TC 2
Z9 2
U1 4
U2 14
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD APR
PY 2008
VL 64
BP M562
EP U457
DI 10.1107/S1600536808006958
PN 4
PG 13
WC Crystallography
SC Crystallography
GA 281VZ
UT WOS:000254528300040
PM 21202018
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Han, ZQ
AF Han, Zhen-Quan
TI RETRACTED: Bis(2-ethoxy-6-formylphenolato-kappa O-2(1),O-6)nickel(II)
   (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID ACTIVE-SITE; COMPLEXES; UREASE; MODELS
AB The title compound, [Ni(C9H9O3)(2)], was synthesized by the reaction of 3-ethoxysalicylaldehyde with nickel(II) nitrate in methanol solution. The asymmetric unit onsists of two half-molecules; each Ni atom lies on a centre of symmetry. The Ni II ions are coordinated by four O atoms from two deprotonated 3-ethoxysalicylaldehyde ligands in a slightly distorted square-planar coordination environment.
C1 Qiqihar Univ, Appl Techn Coll, Qiqihar 161006, Peoples R China.
RP Han, ZQ (reprint author), Qiqihar Univ, Appl Techn Coll, Qiqihar 161006, Peoples R China.
EM zhenquan_han@126.com
CR *BRUK AXS INC, 1998, SMART VERS 5 628 SAI
   Carlsson H, 2004, INORG CHEM, V43, P8252, DOI 10.1021/ic049048u
   Li YG, 2006, ACTA CRYSTALLOGR E, V62, pM1038, DOI 10.1107/S1600536806012391
   MOUNTS RD, 1974, ACTA CRYSTALLOGR B, V30, P542, DOI 10.1107/S0567740874003189
   Sheldrick G.M, 1996, SADABS
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Volkmer D, 1996, INORG CHEM, V35, P3792, DOI 10.1021/ic951567x
NR 7
TC 5
Z9 5
U1 1
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD APR
PY 2008
VL 64
BP M592
EP U707
DI 10.1107/S160053680800809X
PN 4
PG 9
WC Crystallography
SC Crystallography
GA 281VZ
UT WOS:000254528300061
PM 21202039
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Dubey, A
   Mishra, BG
   Sachdev, D
AF Dubey, Amit
   Mishra, Braj Gopal
   Sachdev, Divya
TI RETRACTED: Catalytic applications of ordered mesoporous magnesium oxide
   synthesized by mesoporous carbon (Retracted article. See vol. 366, pg.
   1, 2009)
SO APPLIED CATALYSIS A-GENERAL
LA English
DT Article; Retracted Publication
DE mesoporous materials; catalysts; ordered mesoporous MgO
ID CLAISEN-SCHMIDT CONDENSATION; BASE CATALYSTS; FINE CHEMICALS;
   HYDROTALCITES; ZEOLITES; SILICA; MGO
AB In an attempt to introduce the intrinsic basicity properties, we synthesized ordered mesoporous magnesium oxide (MgO) using mesoporous carbon (CMK-8) as the host material for more effective use for base catalysis. The catalytic activity studies for various base catalyzed condensation reactions showed very high activity and selectivity. The knowledge obtained was extended for the aldol condensation reaction between glyceraldehydes acetonide and acetone. Very high activity and selectivity of the desired product was observed compared to the values for other mixed oxides reported in the literature. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Dubey, Amit; Mishra, Braj Gopal; Sachdev, Divya] Birla Inst Technol & Sci, Chem Grp, Pilani 333031, Rajasthan, India.
RP Dubey, A (reprint author), Birla Inst Technol & Sci, Chem Grp, Pilani 333031, Rajasthan, India.
EM amitdubey@bits-pilani.ac.in
CR Aramendia MA, 1996, J CATAL, V161, P829, DOI 10.1006/jcat.1996.0246
   Cauvel A, 1997, J ORG CHEM, V62, P749, DOI 10.1021/jo9614001
   CLIMENT MJ, 1995, J CATAL, V151, P60, DOI 10.1006/jcat.1995.1008
   Climent MJ, 1999, CATAL LETT, V59, P33, DOI 10.1023/A:1019075227734
   CORMA A, 1995, CHEM REV, V95, P559, DOI 10.1021/cr00035a006
   Guida A, 1997, APPL CATAL A-GEN, V164, P251, DOI 10.1016/S0926-860X(97)00175-0
   HATHAWAY PE, 1989, J CATAL, V116, P263, DOI 10.1016/0021-9517(89)90091-2
   Hoelderich WF, 2000, CATAL TODAY, V62, P115, DOI 10.1016/S0920-5861(00)00413-2
   Jun S, 2000, J AM CHEM SOC, V122, P10712, DOI 10.1021/ja002261e
   JURCZAK J, 1986, TETRAHEDRON, V42, P447, DOI 10.1016/S0040-4020(01)87445-7
   Kleitz F, 2003, CHEM COMMUN, P2136, DOI 10.1039/b306504a
   LESPERAS M, 1997, STUD SURF SCI CATAL, V108, P75
   Macquarrie DJ, 1997, CHEM COMMUN, P1781, DOI 10.1039/a704156j
   MULZER J, 1990, ORGANIC SYNTHESIS HI, P221
   Ono Y, 1997, CATAL TODAY, V38, P321, DOI 10.1016/S0920-5861(97)81502-5
   Ono Y., 2000, CATALYSIS, V15, P1
   Roggenbuck J, 2005, J AM CHEM SOC, V127, P1096, DOI 10.1021/ja043605u
   RYOO R, 2001, ADV MATER, V9, P13
   SARKAR A, 1986, INDIAN J CHEM B, V25, P656
   Sheldon RA, 1996, J MOL CATAL A-CHEM, V107, P75, DOI 10.1016/1381-1169(95)00229-4
   SHELDON RA, 1991, CHEMTECH, V21, P566
   TICHIT D, 1995, J CATAL, V151, P50, DOI 10.1006/jcat.1995.1007
   TROST BM, 1991, SCIENCE, V254, P1471, DOI 10.1126/science.1962206
   TSUJI H, 1991, CHEM LETT, P1881, DOI 10.1246/cl.1991.1881
   Veloso CO, 2005, CATAL TODAY, V107-08, P294, DOI 10.1016/j.cattod.2005.07.085
   Wang Y, 1998, MICROPOR MESOPOR MAT, V26, P175, DOI 10.1016/S1387-1811(98)00231-5
   Wei YL, 2003, ADV MATER, V15, P1943, DOI 10.1002/adma.200305803
   Yu JI, 2001, CATAL LETT, V77, P165, DOI 10.1023/A:1012735011521
NR 28
TC 12
Z9 13
U1 5
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0926-860X
EI 1873-3875
J9 APPL CATAL A-GEN
JI Appl. Catal. A-Gen.
PD APR 1
PY 2008
VL 338
IS 1-2
BP 20
EP 26
DI 10.1016/j.apcata.2007.12.015
PG 7
WC Chemistry, Physical; Environmental Sciences
SC Chemistry; Environmental Sciences & Ecology
GA 287GM
UT WOS:000254905200004
DA 2018-12-27
ER

PT J
AU Rao, JS
   Kim, HW
   Rapoport, SI
AF Rao, Jagadeesh S.
   Kim, Hyung-Wook
   Rapoport, Stanley I.
TI RETRACTED: Decreased expression of GRK3 but not GRK2 in frontal cortex
   of bipolar disorder patients(Retracted article.See vol.19,pg.851, 2009)
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract; Retracted Publication
CT 63rd Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 01-03, 2008
CL Washington, DC
SP Soc Biol Psychiat
C1 [Rao, Jagadeesh S.; Kim, Hyung-Wook; Rapoport, Stanley I.] NIA, NIH, Brain Physiol & Metab Sect, Bethesda, MD 20892 USA.
RI Kim, Hyung-Wook/B-6308-2009; Rao, Jagadeesh/C-1250-2009
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD APR 1
PY 2008
VL 63
IS 7
SU S
MA 175
BP 60S
EP 60S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 276SV
UT WOS:000254163700192
DA 2018-12-27
ER

PT J
AU Zhang, S
   Yue, JX
   Yang, JH
   Cai, PC
   Kong, WJ
AF Zhang, Song
   Yue, Jian Xin
   Yang, Ju Hong
   Cai, Peng Cheng
   Kong, Wei Jia
TI RETRACTED: Overexpression of transketolase protein TKTL1 is associated
   with occurrence and progression in nasopharyngeal carcinoma (Retracted
   Article. See vol 10, pg 110, 2010)
SO CANCER BIOLOGY & THERAPY
LA English
DT Article; Retracted Publication
DE nasopharyngeal carcinoma; CNE cell line; pentose phosphate pathway;
   transketolase; transketolase-like-1; glycometabolism; metastasis
ID POSITRON EMISSION TOMOGRAPHY; CELL-PROLIFERATION; GENE; CANCER;
   CARCINOGENESIS; METABOLISM; EXPRESSION; SURVIVAL; TUMORS; COLON
AB Over 80 years ago, Warburg identified a particular metabolic pathway in carcinomas characterised by the anaerobic degradation of glucose even in the presence of oxygen that leads to the production of large amounts of lactate (known as the Warburg effect). Now, widespread clinical use of positron-emission tomography (PET) has confirmed that there exists enhanced glucose degradation in tumors. Recent research demonstrated that pentose phosphate pathway (PPP) was augmented in some tumors, especially non-oxidative part of PPP. The non-oxidative part of PPP is controlled by transketolase enzyme reactions. The present study designed to evaluate the effect of transketolase activity on nasopharyngeal carcinoma. It was found that the transketolase activity was significantly stronger in human nasopharyngeal carcinoma tissues than those in human chronic nasopharyngitis tissues. There is a strong upregulation of the transketolase-like-1 (TKTL1) in human nasopharyngeal carcinoma tissues and cell line (CNE), whereas transketolase (TKT) and transketolase-like-2 (TKTL2) were not upregulated. After inhibited the expression of TKTL1 by RNAi, we found that total transketolase activity was dramatically downregulated and the proliferation of cancer cells was significantly inhibited in CNE cells. These results indicate that TKTL1 gene influences total transketolase activity and cell proliferation in human nasopharyngeal carcinoma cells, suggesting that TKTL1 gene plays an important role on glycometabolism in tumors and it might become a novel target for tumor gene therapy.
C1 [Zhang, Song; Yue, Jian Xin; Kong, Wei Jia] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Otolaryngol, Wuhan 430022, Hubei, Peoples R China.
   [Yang, Ju Hong; Cai, Peng Cheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Lab, Wuhan 430022, Hubei, Peoples R China.
RP Kong, WJ (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Otolaryngol, 1277 Jiefang Dadao Ave, Wuhan 430022, Hubei, Peoples R China.
EM wjkong666@yahoo.cn
CR Boros LG, 1997, CANCER RES, V57, P4242
   CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220
   Comin-Anduix B, 2001, EUR J BIOCHEM, V268, P4177, DOI 10.1046/j.1432-1327.2001.02329.x
   Coy JF, 2005, CLIN LAB, V51, P257
   DICHIRO G, 1987, RADIOLOGY, V164, P521, DOI 10.1148/radiology.164.2.3496626
   Downey RJ, 2004, J CLIN ONCOL, V22, P3255, DOI 10.1200/JCO.2004.11.109
   Du MX, 2004, J BIOMOL SCREEN, V9, P427, DOI 10.1177/1087057104263913
   Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158
   Gatenby RA, 2003, CANCER RES, V63, P3847
   HABERKORN U, 1991, J NUCL MED, V32, P1548
   Hu LH, 2007, ANTI-CANCER DRUG, V18, P427, DOI 10.1097/CAD.0b013e328013d99e
   Kong WJ, 2006, ANTI-CANCER DRUG, V17, P251, DOI 10.1097/00001813-200603000-00003
   Langbein S, 2006, BRIT J CANCER, V94, P578, DOI 10.1038/sj.bjc.6602962
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MARTIN GR, 1994, CANCER RES, V54, P5670
   Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100
   Warburg O, 1924, BIOCHEM Z, V152, P309
   Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660
   Zhang S, 2007, CANCER LETT, V253, P108, DOI 10.1016/j.canlet.2007.01.010
NR 19
TC 23
Z9 24
U1 6
U2 22
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD APR
PY 2008
VL 7
IS 4
BP 517
EP 522
DI 10.4161/cbt.7.4.5479
PG 6
WC Oncology
SC Oncology
GA 312HC
UT WOS:000256658800006
PM 18296915
DA 2018-12-27
ER

PT J
AU Pavelko, KD
   Heckman, KL
   Hansen, MJ
   Pease, LR
AF Pavelko, Kevin D.
   Heckman, Karin L.
   Hansen, Michael J.
   Pease, Larry R.
TI RETRACTED: An effective vaccine strategy protective against
   antigenically distinct tumor variants (Retracted article. See vol. 70,
   pg. 9528, 2010)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID CROSS-LINKING ANTIBODY; T-CELL EPITOPES; DENDRITIC CELLS; METASTATIC
   MELANOMA; B7-DC; CANCER; IDENTIFICATION; IMMUNOTHERAPY; GENERATION;
   IMMUNITY
AB Antigenically distinct tumor variants can emerge in response to selective pressures inherent to. host-tumor interactions. The development of successful immunotherapeutic strategies can be limited by these disparate antigenic profiles. Using the immunomodulator B7-DC XAb to activate cytolytic T cells specific for tumor-associated antigens, we found that the specificity of immune responses elicited by live tumors are distinct from the specificity of the responses elicited by soluble proteins derived from the same tumors. Remarkably, whereas the induced antitumor immunity generated against live variants of the B16 melanoma and EL4 thymic lymphoma tumors were highly specific for the original tumor variant used in the challenge, immunity generated using soluble proteins derived from tumor lysates was broadly reactive, recognizing the challenge tumor, as well as antigenically distinct variants. The antigens detected using live tumor and tumor lysate vaccines could be distinguished biochemically, demonstrating that they are structurally distinct. We show that vaccines using antigens present in tumor cell lysates induce protective immunity with strong memory against distantly related tumor variants. The existence of a class of antigens shared among tumor variants provides an attractive target for vaccine development.
C1 [Pavelko, Kevin D.; Heckman, Karin L.; Hansen, Michael J.; Pease, Larry R.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
OI Pavelko, Kevin/0000-0001-7555-1315
FU NCI NIH HHS [R01CA104996-04, R01 CA104996]
CR Ahmad M, 2004, CANCER IMMUNOL IMMUN, V53, P844, DOI 10.1007/s00262-004-0540-x
   Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134
   Buteau C, 2002, MAYO CLIN PROC, V77, P339, DOI 10.4065/77.4.339
   Guevara-Patino JA, 2006, J CLIN INVEST, V116, P1382, DOI 10.1172/JCI25591
   Hao S., 2006, Experimental Oncology, V28, P126
   Heckman KL, 2007, EUR J IMMUNOL, V37, P1827, DOI 10.1002/eji.200637002
   Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100
   Hoffmann TK, 2000, J IMMUNOL, V165, P5938, DOI 10.4049/jimmunol.165.10.5938
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Kessler JH, 2007, LEUKEMIA, V21, P1859, DOI 10.1038/sj.leu.2404787
   Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064
   Mitchell MS, 2004, CLIN CANCER RES, V10, P76, DOI 10.1158/1078-0432.CCR-0689-3
   Mitchell MS, 2002, CANCER INVEST, V20, P759, DOI 10.1081/CNV-120002493
   Nanni P, 1998, CANCER RES, V58, P1225
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Paschen A, 2004, CANCER IMMUNOL IMMUN, V53, P196, DOI 10.1007/s00262-003-0479-3
   Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Reynolds SR, 2003, CLIN CANCER RES, V9, P657
   Sanchez-Perez L, 2005, CANCER RES, V65, P2009, DOI 10.1158/0008-5472.CAN-04-3216
   Schreiber K, 2001, CLIN CANCER RES, V7, p871S
   Seliger B, 2001, CANCER RES, V61, P1095
   Sosman Jeffrey A, 2003, Expert Rev Vaccines, V2, P353, DOI 10.1586/14760584.2.3.353
   Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008-5472.CAN-04-4125
   Van Keulen VP, 2006, CLIN EXP IMMUNOL, V143, P314, DOI 10.1111/j.1365-2249.2005.02992.x
   Viatte S, 2006, IMMUNOL CELL BIOL, V84, P318, DOI 10.1111/j.1440-1711.2006.01447.x
   Xda E. Dong, 2007, J IMMUNOTHER, V30, P596
   Xu YQ, 1997, J INVEST DERMATOL, V109, P788, DOI 10.1111/1523-1747.ep12340971
   Yoshikawa T, 2006, BIOL PHARM BULL, V29, P100, DOI 10.1248/bpb.29.100
NR 30
TC 11
Z9 11
U1 2
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2008
VL 68
IS 7
BP 2471
EP 2478
DI 10.1158/0008-5472.CAN-07-5937
PG 8
WC Oncology
SC Oncology
GA 284WU
UT WOS:000254738500051
PM 18381456
OA Bronze
DA 2018-12-27
ER

PT J
AU Sowmeyan, R
   Swaminathan, G
AF Sowmeyan, R.
   Swaminathan, G.
TI RETRACTED: Effluent treatment process in molasses-based distillery
   industries: A review (Retracted Article. See vol 170, pg 507, 2009)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Review; Retracted Publication
DE molasses; spentwash; treatment methods; anaerobic fluidized-bed reactor;
   Perlite; inverse anaerobic fluidized-bed reactor
ID FLUIDIZED-BED REACTOR; FIXED-FILM BIOMETHANATION; FERMENTATION
   WASTE-WATER; INVERSE TURBULENT BED; ANAEROBIC TREATMENT; BEET MOLASSES;
   BIOLOGICAL TREATMENT; COLOR REMOVAL; SPENT WASH; DIGESTION
AB Distillery effluent is a contaminated stream with high chemical oxygen demand (COD) varying from 45,000 to 75,000 mg/l and low pH values of between 4.3 and 5.3. Different processes covering aerobic, anaerobic as well as physico-chemical methods which have been employed to this effluent has been given in this review paper. Among the different methods available, it was found that "An Inverse Anaerobic Fluidization" to be a better choice for treating effluent from molasses-based distillery industries using an inverse anaerobic fluidized-bed reactor (IAFBR). This technology has been widely applied as an effective step in removing 80-85% of the COD in the effluent stream. Therefore, in this review, attention has been paid to highlight in respect of fluidization phenomena, process performance, stability of the system, operating parameters, configuration of inverse anaerobic fluidization and suitable carrier material employed in an inverse anaerobic fluidized-bed reactor especially for treating this effluent. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Sowmeyan, R.] Periyar Maniammai Univ, Civil Engn, Thanjavur 613403, Tamil Nadu, India.
   [Swaminathan, G.] Natl Inst Technol, Tiruchchirappalli 15, Tamil Nadu, India.
RP Sowmeyan, R (reprint author), Periyar Maniammai Univ, Civil Engn, Thanjavur 613403, Tamil Nadu, India.
EM sowmeyanr@yahoo.co.uk
CR Akunna JC, 2000, BIORESOURCE TECHNOL, V74, P257, DOI 10.1016/S0960-8524(00)00017-1
   ALAPPAT BJ, 1995, INT J ENERG RES, V19, P329, DOI 10.1002/er.4440190406
   Alfafara CG, 2000, WATER SCI TECHNOL, V42, P193
   Arnaiz C, 2005, WATER SCI TECHNOL, V51, P153
   ATHANASOPOULOS N, 1987, RESOUR CONSERV, V15, P147, DOI 10.1016/0166-3097(87)90044-7
   Beltran FJ, 1997, WATER RES, V31, P2415, DOI 10.1016/S0043-1354(97)00078-X
   Bernardo EC, 1997, CARBON, V35, P1217, DOI 10.1016/S0008-6223(97)00105-X
   BHANDARI HC, 2004, LIQUID ASSET, P167
   Billore SK, 2001, WATER SCI TECHNOL, V44, P441
   BORIES A, 1988, BIOL WASTE, V23, P251, DOI 10.1016/0269-7483(88)90014-6
   BORJA R, 1993, BIORESOURCE TECHNOL, V45, P99, DOI 10.1016/0960-8524(93)90097-U
   Buffiere P, 2000, WATER RES, V34, P673, DOI 10.1016/S0043-1354(99)00166-9
   Chandra R., 2000, INDIAN J ENV PROT, V21, P134
   Chandra R., 1999, IND J ENV PROT, V19, P833
   CHANG IS, 1994, J MEMBRANE SCI, V90, P131, DOI 10.1016/0376-7388(94)80040-5
   CHEREMISINOFF PN, 1994, BIOMANAGEMENT WASTE, P162
   CORTEZ LAB, 1997, BRAZ J CHEM ENG
   DEWILDE FGN, 1987, DESALINATION, V67, P481
   Dhale AD, 2000, INDIAN J CHEM TECHN, V7, P11
   DHAR GM, 1998, INDIAN CHEM ENG A, V40, P232
   Diez Blanco V., 1995, Water Research, V29, P1649, DOI 10.1016/0043-1354(95)00001-2
   DRIESSEN WJBM, 1994, WATER SCI TECHNOL, V30, P193
   FitzGibbon F, 1998, PROCESS BIOCHEM, V33, P799, DOI 10.1016/S0032-9592(98)00050-8
   FITZGIBBON FJ, 1995, J BASIC MICROB, V35, P293, DOI 10.1002/jobm.3620350504
   GAIKWAD RW, 2000, INDIAN J ENV PROTECT, V20, P106
   GarciaCalderon D, 1998, BIOTECHNOL BIOENG, V57, P136, DOI 10.1002/(SICI)1097-0290(19980120)57:2<136::AID-BIT2>3.0.CO;2-O
   GODSHALL MA, 1999, P 6 INT S ORG ASS AN, P28
   Gonzalez T, 2000, RAPID COMMUN MASS SP, V14, P1417, DOI 10.1002/1097-0231(20000815)14:15<1417::AID-RCM41>3.0.CO;2-I
   Goyal SK, 1996, BIORESOURCE TECHNOL, V56, P239, DOI 10.1016/0960-8524(96)00033-8
   GULATI N, 2004, LIQUID ASSET, P163
   Inanc B, 1999, WATER SCI TECHNOL, V40, P331, DOI 10.1016/S0273-1223(99)00370-4
   JAIN N, 2002, INDIAN J EXP BIOL, V10, pT105
   JAIN S, 2004, EUROMEMBRANE 2004
   JAYANTHA KS, 1995, BIOPROCESS ENG, V13, P307
   Jimenez AM, 2004, BIOCHEM ENG J, V18, P121, DOI 10.1016/S1369-703X(03)00198-0
   Jimenez AM, 2003, PROCESS BIOCHEM, V38, P1275, DOI 10.1016/S0032-9592(02)00325-4
   Joshi H. C, 1999, BIO ENERGY NEWS, V3, P10
   Kalavathi DF, 2001, ENZYME MICROB TECH, V29, P246, DOI 10.1016/S0141-0229(01)00383-0
   Karamanev DG, 1996, ENVIRON PROG, V15, P194, DOI 10.1002/ep.670150319
   KIDA K, 1995, PROCESS BIOCHEM, V30, P125, DOI 10.1016/0032-9592(95)95710-Z
   Kulkarni A.K., 1998, INDIAN CHEM ENG, V40, P169
   Kumaresan T, 2003, CHEM ENG J, V95, P199, DOI 10.1016/S1385-8947(03)00105-0
   Lalov IG, 2000, WATER RES, V34, P1503, DOI 10.1016/S0043-1354(99)00291-2
   Lata K, 2002, RESOUR CONSERV RECY, V35, P147, DOI 10.1016/S0921-3449(01)00112-4
   Mahimairaja S., 2004, 3 AUSTR NZ SOIL SCI
   MALL ID, 1997, CHEM ENG WORLD, V32, P89
   Mandal A, 2003, INDIAN CHEM ENG B, V45, P264
   Mane JD, 2006, BIORESOURCE TECHNOL, V97, P1752, DOI 10.1016/j.biortech.2005.10.016
   Metcalf & Eddy Inc, 2003, WAST ENG TREATM DISP
   MIGO VP, 1993, J FERMENT BIOENG, V75, P438, DOI 10.1016/0922-338X(93)90092-M
   Nandy T, 2002, J ENVIRON MANAGE, V65, P25, DOI 10.1006/jema.2001.0505
   Nataraj SK, 2006, WATER RES, V40, P2349, DOI 10.1016/j.watres.2006.04.022
   Pandey R.A., 2003, INT J ENVIRON STUD, V60, P263
   PATHADE GR, 1999, REV CURRENT TECHNOLO, P180
   PATIL RU, 2003, DECOLORIZATION SYNTH, P53
   Pena M, 2003, CHEMOSPHERE, V51, P893, DOI 10.1016/S0045-6535(03)00159-0
   Perez M, 1999, CHEMOSPHERE, V38, P3443, DOI 10.1016/S0045-6535(98)00556-6
   Pikaev AK, 2001, RADIAT PHYS CHEM, V61, P81, DOI 10.1016/S0969-806X(00)00377-7
   RAJOR R, 2000, INDIAN J ENV PROT, V22, P1241
   RAMTEKE D S, 1989, Indian Journal of Environmental Health, V31, P17
   Rao AG, 2005, BIORESOURCE TECHNOL, V96, P87, DOI 10.1016/j.biortech.2003.05.007
   Rivero-Perez MD, 2002, ANAL CHIM ACTA, V458, P169, DOI 10.1016/S0003-2670(01)01591-4
   Rodriguez-Trelles F, 2000, MOL BIOL EVOL, V17, P1710, DOI 10.1093/oxfordjournals.molbev.a026269
   Sekar D., 1998, INDIAN CHEM ENG A, V40, P176
   SENNITT T, 2005, 68 ANN WAT IND ENG O
   SETH R, 1995, RESOUR CONSERV RECY, V14, P79, DOI 10.1016/S0921-3449(95)80002-6
   SHEEHAN GJ, 1980, WATER RES, V14, P257, DOI 10.1016/0043-1354(80)90097-4
   Shieh WK, 1996, WATER RES, V30, P1253, DOI 10.1016/0043-1354(95)00285-5
   Sirianuntapiboon S, 2004, PROCESS BIOCHEM, V39, P917, DOI 10.1016/S0032-9592(03)00199-7
   Sowmeyan R, 2008, BIORESOURCE TECHNOL, V99, P3877, DOI 10.1016/j.biortech.2007.08.021
   Subramanian KA, 2005, BIOMASS BIOENERG, V29, P65, DOI 10.1016/j.biombioe.2005.02.001
   Tokuda M, 1999, PROCESS BIOCHEM, V35, P267, DOI 10.1016/S0032-9592(99)00063-1
   Torrijos M, 1997, WATER SCI TECHNOL, V35, P249, DOI 10.1016/S0273-1223(96)00903-1
   Uppal J., 2004, LIQUID ASSETS, P13
   Vijayaraghavan K, 2000, BIOPROCESS ENG, V22, P109, DOI 10.1007/s004490050019
   VLISSIDIS A, 1993, BIORESOURCE TECHNOL, V43, P131, DOI 10.1016/0960-8524(93)90172-8
   Vlyssides AG, 1997, WATER SCI TECHNOL, V36, P271, DOI 10.1016/S0273-1223(97)00398-3
   Wilkie AC, 2000, BIOMASS BIOENERG, V19, P63, DOI 10.1016/S0961-9534(00)00017-9
   Yeoh BG, 1997, WATER SCI TECHNOL, V36, P441, DOI 10.1016/S0273-1223(97)00553-2
NR 79
TC 15
Z9 15
U1 3
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD APR 1
PY 2008
VL 152
IS 2
BP 453
EP 462
DI 10.1016/j.jhazmat.2007.11.033
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 285GK
UT WOS:000254765100001
PM 18178308
DA 2018-12-27
ER

PT J
AU Dai, YP
AF Dai Youping
TI RETRACTED: Expression of extracellular signal-regulated kinase and
   angiotension-converting enzyme in human atria during atrial fibrilation.
   (Retracted Article)
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL
   SCIENCES
LA English
DT Correction; Retracted Publication
CR Dai Youping, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P32
NR 1
TC 0
Z9 0
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672-0733
EI 1993-1352
J9 J HUAZHONG U SCI-MED
JI J. Huazhong Univ. Sci. Tech.-Med.
PD APR
PY 2008
VL 28
IS 2
BP 234
EP 234
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 304EO
UT WOS:000256093000031
DA 2018-12-27
ER

PT J
AU Han, CS
AF Han, Chang Suk
TI RETRACTED: Microstructure of carbide precipitates in L1(2)-Ni3Al and
   L1(0)-TiAl (Retracted article. See vol. 21, pg. 609, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE M23C6; carbide; precipitation; perovskite
ID TIAL ALLOYS; NITROGEN; PHASE
AB The crystallographic structures of carbide formed in Ni3Al- and TiAl-based intermetallics containing carbon are investigated in this study using transmission electron microscopy. In an Ll(2)-ordered Ni3Al alloy with 4 mol.% of chromium and 0.2 mol.% to 3.0 mol.% of carbon, fine octahedral precipitates Of M23C6 type carbide were formed in the matrix by aging at temperatures around 973 K after solution annealing at 1423 K. TEM examination revealed that the M23C6 phase and the matrix lattices have a cube-cube orientation relationship and maintain partial atomic matching at the {111} interface. After prolonged aging or by aging at higher temperatures, the M23C6 precipitates adopt a rod-like morphology elongated parallel to the < 100 > directions. In L1(0)-ordered TiAl containing from 0.1 mol.% to 2.0 mol.% carbon, TEM observations reveal that needle-like precipitates, which lie only in one direction parallel to the [001] axis of the L1(0) matrix, appear in the matrix mainly at dislocations. Selected-area electron diffraction (SAED) patterns analyses showed that the needle-shaped precipitate is perovskite-type Ti3AlC. The orientation relationship between the Ti3AlC and the L1(0) matrix was found to be (001)(Ti3AlC)//(001)(L10) (matrix) and [010](Ti3AlC)//[010](L10) (mwix). By aging at higher temperatures or for a longer period at 1073 K, plate-like precipitates of TiAIC with a hexagonal structure form on the {111} planes of the L1(0) matrix. The orientation relationship between the Ti2AlC and the L1(0) matrix is (0001)(Ti2AlC)//(111)(L10) (matrix) and (Ti2AlC/L10 matrix).
C1 Hoseo Univ, Dept Def Sci & Technol, Asan 336795, Chungnam, South Korea.
RP Han, CS (reprint author), Hoseo Univ, Dept Def Sci & Technol, 165 Sechul Ri,Baebang Myeon, Asan 336795, Chungnam, South Korea.
EM hancs@hoseo.edu
CR BECKITT FR, 1967, ACTA METALL MATER, V15, P113, DOI 10.1016/0001-6160(67)90159-9
   CAM G, 1989, MATER RES SOC SYMP P, V133, P663
   GOLDSCHMIDT HJ, 1967, INTERSTITIAL ALLOYS, P187
   GUO JT, 1984, METALL TRANS A, V15, P1331
   Han CS, 2007, MET MATER INT, V13, P31, DOI 10.1007/BF03027820
   Han CS, 2006, MET MATER INT, V12, P467, DOI 10.1007/BF03027746
   Hayes F. H., 1992, TERNARY ALLOYS, V7, P557
   KAWABATA T, 1991, ISIJ INT, V31, P1161, DOI 10.2355/isijinternational.31.1161
   Khan T., 1990, HIGH TEMPERATURE ALU, P219
   Lewis M.H., 1965, Acta Metallurgica, V13, P1159, DOI 10.1016/0001-6160(65)90053-2
   NATHAL MV, 1992, NATO ADV SCI I E-APP, V213, P541
   OBLAK JM, 1974, METALL TRANS, V5, P1252, DOI 10.1007/BF02644342
   Radavick J. F., 1984, REV HIGH TEMP MAT, V1, P55
   SCHUSTER JC, 1984, J SOLID STATE CHEM, V53, P260, DOI 10.1016/0022-4596(84)90100-2
   SINGHAL LK, 1968, ACTA METALL MATER, V16, P1159, DOI 10.1016/0001-6160(68)90050-3
   Song SH, 2004, MET MATER-INT, V10, P307, DOI 10.1007/BF03185978
   VUJIC D, 1988, METALL TRANS A, V19, P2445, DOI 10.1007/BF02645472
NR 17
TC 3
Z9 3
U1 3
U2 14
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD APR
PY 2008
VL 14
IS 2
BP 151
EP 157
DI 10.3365/met.mat.2008.04.151
PG 7
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 295PA
UT WOS:000255485200004
DA 2018-12-27
ER

PT J
AU Horvath, EM
   Tackett, L
   McCarthy, AM
   Raman, P
   Brozinick, JT
   Elmendorf, JS
AF Horvath, Emily M.
   Tackett, Lixuan
   McCarthy, Alicia M.
   Raman, Priya
   Brozinick, Joseph T.
   Elmendorf, Jeffrey S.
TI RETRACTED: Antidiabetogenic effects of chromium mitigate
   Hyperinsulinemia-induced cellular insulin resistance via correction of
   plasma membrane cholesterol imbalance (Retracted article. See vol. 24,
   pg. 1308, 2010)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; GLUCOSE-TRANSPORTER TRANSLOCATION;
   SKELETAL-MUSCLE CELLS; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; IN-VIVO;
   PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PEROXISOME-PROLIFERATOR;
   DEPENDENT MECHANISM; METFORMIN TREATMENT
AB Previously, we found that a loss of plasma membrane ( PM) phosphatidylinositol 4,5-bisphosphate (PIP(2))-regulated filamentous actin (F-actin) structure contributes to insulin-induced insulin resistance. Interestingly, we also demonstrated that chromium picolinate (CrPic), a dietary supplement thought to improve glycemic status in insulin-resistant individuals, augments insulin-regulated glucose transport in insulin-sensitive 3T3-L1 adipocytes by lowering PM cholesterol. Here, to gain mechanistic understanding of these separate observations, we tested the prediction that CrPic would protect against insulin-induced insulin resistance by improving PM features important in cytoskeletal structure and insulin sensitivity. We found that insulin-induced insulin-resistant adipocytes display elevated PM cholesterol with a reciprocal decrease in PM PIP(2). This lipid imbalance and insulin resistance was corrected by the cholesterol-lowering action of CrPic. The PM lipid imbalance did not impair insulin signaling, nor did CrPic amplify insulin signal transduction. In contrast, PM analyses corroborated cholesterol and PIP 2 interactions influencing cytoskeletal structure. Because extensive in vitro study documents an essential role for cytoskeletal capacity in insulin-regulated glucose transport, we next evaluated intact skeletal muscle from obese, insulin-resistant Zucker (fa/fa) rats. Because insulin resistance in these animals likely involves multiple mechanisms, findings that cholesterol-lowering restored F-actin cytoskeletal structure and insulin sensitivity to that witnessed in lean control muscle were striking. Also, experiments using methyl-beta-cyclodextrin to shuttle cholesterol into or out of membranes respectively recapitulated the insulin-induced insulin-resistance and protective effects of CrPic on membrane/cytoskeletal interactions and insulin sensitivity. These data predict a PM cholesterol basis for hyperinsulinemia-associated insulin resistance and importantly highlight the reversible nature of this abnormality.
C1 [Horvath, Emily M.; Tackett, Lixuan; McCarthy, Alicia M.; Elmendorf, Jeffrey S.] Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Diabet Res Ctr, Indianapolis, IN 46202 USA.
   [Brozinick, Joseph T.; Elmendorf, Jeffrey S.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Diabet Res Ctr, Indianapolis, IN 46202 USA.
   [Raman, Priya] Cleveland Clin, Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA.
   [Brozinick, Joseph T.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
RP Elmendorf, JS (reprint author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Diabet Res Ctr, VanNuys Med Sci Bldg Rm 308A, Indianapolis, IN 46202 USA.
EM jelmendo@iupui.edu
FU NCCIH NIH HHS [F31-AT003977, R01 AT001846-04, R01 AT001846, F31
   AT003977]
CR Brautigan DL, 2006, BIOCHEM BIOPH RES CO, V347, P769, DOI 10.1016/j.bbrc.2006.06.154
   Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200
   Cefalu WT, 2002, J NUTR, V132, P1107
   Chen GL, 2006, MOL ENDOCRINOL, V20, P857, DOI 10.1210/me.2005-0255
   Chen GL, 2004, J BIOL CHEM, V279, P39705, DOI 10.1074/jbc.C400171200
   Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200
   Christian AE, 1997, J LIPID RES, V38, P2264
   Ciaraldi TP, 2002, DIABETES, V51, P30, DOI 10.2337/diabetes.51.1.30
   CZECH MP, 1980, DIABETES, V29, P399, DOI 10.2337/diab.29.5.399
   David TS, 1998, AM J PHYSIOL-REG I, V274, pR1446, DOI 10.1152/ajpregu.1998.274.5.R1446
   DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938
   Du XM, 2006, MOL BIOL CELL, V17, P2735, DOI 10.1091/mbc.E05-11-1094
   FERRANNINI E, 1985, J CLIN INVEST, V76, P357, DOI 10.1172/JCI111969
   Ferre P, 2004, DIABETES, V53, pS43, DOI 10.2337/diabetes.53.2007.S43
   FISCHER Y, 1995, ENDOCRINOLOGY, V136, P412, DOI 10.1210/en.136.2.412
   Foti M, 2007, P NATL ACAD SCI USA, V104, P1242, DOI 10.1073/pnas.0610523104
   GOTO Y, 1995, JPN J PHARMACOL, V67, P365, DOI 10.1254/jjp.67.365
   Han SH, 2005, HYPERTENSION, V46, P1086, DOI 10.1161/01.HYP.0000187900.36455.4c
   HANDBERG A, 1993, DIABETOLOGIA, V36, P481, DOI 10.1007/BF02743261
   Holloszy JO, 2005, J APPL PHYSIOL, V99, P338, DOI [10.1152/japplphysiol.00123.2005, 10.1152/japplphysiol.00123.2005.]
   Huang P, 2005, MOL BIOL CELL, V16, P2614, DOI 10.1091/mbc.E04-12-1124
   HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165
   Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C20029220
   Kim EJ, 2007, MOL PHARMACOL, V72, P62, DOI 10.1124/mol.107.034447
   KLIP A, 1992, ENDOCRINOLOGY, V130, P2535, DOI 10.1210/en.130.5.2535
   KOZKA IJ, 1993, DIABETES, V42, P1159, DOI 10.2337/diabetes.42.8.1159
   Leng SH, 2004, ACTA PHARMACOL SIN, V25, P496
   Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003
   MATTHAEI S, 1993, ENDOCRINOLOGY, V133, P304, DOI 10.1210/en.133.1.304
   McCarthy AM, 2006, AM J PHYSIOL-CELL PH, V291, pC860, DOI 10.1182/ajpcell.00107.2006
   MORRIS B, 1995, J ENDOCRINOL, V144, P135, DOI 10.1677/joe.0.1440135
   Muller S, 1997, EUR J PHARMACOL, V337, P103, DOI 10.1016/S0014-2999(97)01287-9
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981
   Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200
   Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Pattar GR, 2006, MUTAT RES-GEN TOX EN, V610, P93, DOI 10.1016/j.mrgentox.2006.06.018
   Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453
   PILCH PF, 1980, P NATL ACAD SCI-BIOL, V77, P915, DOI 10.1073/pnas.77.2.915
   Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802
   Pryor PR, 2000, BIOCHEM J, V348, P83, DOI 10.1042/0264-6021:3480083
   Razidlo GL, 2004, J BIOL CHEM, V279, P47808, DOI 10.1074/jbc.M406395200
   Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082
   ROURU J, 1995, BRIT J PHARMACOL, V115, P1182, DOI 10.1111/j.1476-5381.1995.tb15022.x
   Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565
   SARABIA V, 1992, J CLIN INVEST, V90, P1386, DOI 10.1172/JCI116005
   Tang LQ, 2006, J ETHNOPHARMACOL, V108, P109, DOI 10.1016/j.jep.2006.04.019
   Thomas CR, 1998, BIOCHEM PHARMACOL, V56, P1145, DOI 10.1016/S0006-2952(98)00151-8
   Turinsky J, 1996, BIOCHEM J, V313, P215, DOI 10.1042/bj3130215
   Vicogne J, 2006, P NATL ACAD SCI USA, V103, P14761, DOI 10.1073/pnas.0606881103
   Wang H, 2005, BIOCHEMISTRY-US, V44, P8167, DOI 10.1021/bi0473152
   Wang ZQ, 2006, J NUTR, V136, P415
   Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078
   WHITESELL RR, 1989, BIOCHEMISTRY-US, V28, P5618, DOI 10.1021/bi00439a042
   Wiernsperger NF, 1999, DIABETES METAB, V25, P110
   Wong SKF, 2004, ANAL BIOCHEM, V333, P265, DOI 10.1016/j.ab.2004.05.011
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 58
TC 29
Z9 32
U1 4
U2 13
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD APR 1
PY 2008
VL 22
IS 4
BP 937
EP 950
DI 10.1210/me.2007-0410
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 280JC
UT WOS:000254421500013
PM 18165437
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Renkema, LJ
   Stapel, DA
   Maringer, M
   van Yperen, NW
AF Renkema, Lennart J.
   Stapel, Diederik A.
   Maringer, Marcus
   van Yperen, Nico W.
TI RETRACTED: Terror management and stereotyping: Why do people stereotype
   when mortality is salient? (Retracted article. See vol. 39, pg. 264,
   2013)
SO PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN
LA English
DT Article; Retracted Publication
DE death; existentialism; stereotypes; comprehension; enhancement; goals
ID SELF-ESTEEM; NEGATIVE REACTIONS; WORLDVIEW; ACTIVATION; OTHERS;
   ACCESSIBILITY; THREATEN; VALUES; NEED
AB Three studies examine two routes by which mortality threats may lead to stereotyping. Mortality salience may activate both a comprehension goal and an enhancement goal. Enhancement goals are likely to be more active in situations where intergroup competition or conflict is salient. If this is not the case, then a comprehension goal will predominate. In line with a why-determines-how logic, when mortality salience activates a comprehension goal, both positive and negative stereotyping occur. In contrast, the activation of an enhancement goal only increases negative stereotyping.
C1 [Renkema, Lennart J.; van Yperen, Nico W.] Univ Groningen, Dept Social & Organ Psychol, NL-9712 TS Groningen, Netherlands.
   [Stapel, Diederik A.; Maringer, Marcus] Tilburg Univ, Tilburg, Netherlands.
RP Renkema, LJ (reprint author), Univ Groningen, Dept Social & Organ Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
EM l.j.renkema@rug.nl
RI Van Yperen, Nico W./C-2341-2012
OI Van Yperen, Nico W./0000-0003-2116-8841
CR Arndt J, 1999, PERS SOC PSYCHOL B, V25, P1331, DOI 10.1177/0146167299259001
   Arndt J, 2002, J PERS SOC PSYCHOL, V83, P26, DOI 10.1037//0022-3514.83.1.26
   BROWN JD, 1988, J PERS SOC PSYCHOL, V55, P445, DOI 10.1037//0022-3514.55.3.445
   Dechesne M., 2004, HDB EXPT EXISTENTIAL, P247
   DECHESNE M, 2001, UNPUB TERROR MANAGEM
   Fein S, 1997, J PERS SOC PSYCHOL, V73, P31, DOI 10.1037/0022-3514.73.1.31
   Forster J, 2005, J EXP SOC PSYCHOL, V41, P220, DOI 10.1016/j.jesp.2004.06.009
   GREENBERG J, 1992, J PERS SOC PSYCHOL, V63, P212, DOI 10.1037//0022-3514.63.2.212
   GREENBERG J, 1995, PERS SOC PSYCHOL B, V21, P1221, DOI 10.1177/01461672952111010
   GREENBERG J, 1990, J PERS SOC PSYCHOL, V58, P308, DOI 10.1037//0022-3514.58.2.308
   Jost JT, 2004, POLIT PSYCHOL, V25, P881, DOI 10.1111/j.1467-9221.2004.00402.x
   Jost JT, 2003, PSYCHOL BULL, V129, P339, DOI 10.1037/0033-2909.129.3.339
   Kaiser CR, 2004, PSYCHOL SCI, V15, P503, DOI 10.1111/j.0956-7976.2004.00709.x
   KRUGLANSKI AW, 2006, J TERRORISM POLITICA, V18, P192
   Kunda Z, 2003, PSYCHOL BULL, V129, P522, DOI 10.1037/0033-2909.129.4.522
   Landau MJ, 2006, J PERS SOC PSYCHOL, V90, P879, DOI 10.1037/0022-3514.90.6.879
   Landau MJ, 2004, J PERS SOC PSYCHOL, V87, P190, DOI 10.1037/0022-3514.87.2.190
   MCFARLIN DB, 1984, BASIC APPL SOC PSYCH, V5, P223, DOI 10.1207/s15324834basp0503_5
   McGregor HA, 1998, J PERS SOC PSYCHOL, V74, P590, DOI 10.1037/0022-3514.74.3.590
   Mikulincer M, 2002, BASIC APPL SOC PSYCH, V24, P261, DOI 10.1207/S15324834BASP2404_2
   OCHSMANN R, 1996, UNPUB DEPRECIATING D
   PENDRY LF, 1996, PERSONALITY SOCIAL P, V3, P250
   Pyszczynski T, 2004, PSYCHOL BULL, V130, P435, DOI 10.1037/0033-2909.130.3.435
   Pyszczynski T, 1997, PSYCHOL INQ, V8, P1, DOI 10.1207/s15327965pli0801_1
   Pyszczynski T., 2003, WAKE 9 11 PSYCHOL TE
   RENKEMA LJ, 2007, UNPUB TERROR POLITIC
   RENKEMA LJ, IN PRESS EUROPEAN J
   ROSENBLATT A, 1989, J PERS SOC PSYCHOL, V57, P681, DOI 10.1037/0022-3514.57.4.681
   Schimel J, 1999, J PERS SOC PSYCHOL, V77, P905, DOI 10.1037/0022-3514.77.5.905
   Schwinghammer SA, 2006, PERS SOC PSYCHOL B, V32, P27, DOI 10.1177/0146167205277096
   Schwinghammer SA, 2006, SOC COGNITION, V24, P703, DOI 10.1521/soco.2006.24.6.703
   SOLOMON S, 1991, ADV EXP SOC PSYCHOL, V24, P93
   Solomon S., 2004, HDB EXPT EXPERIENTIA, P111
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   STAPEL DA, 2001, PERSONALITY SOCIAL P, V8, P915, DOI DOI 10.1177/0146167201278001
   Steele Claude, 1988, ADV EXPT SOCIAL PSYC, P261, DOI DOI 10.1016/S0065-2601(08)60229-4
   Tesser A., 1988, ADV EXPT SOCIAL PSYC, P181, DOI DOI 10.1016/S0065-2601(08)60227-0
   van den Bos K, 2005, J EXP SOC PSYCHOL, V41, P91, DOI 10.1016/j.jesp.2004.06.001
   VANDENBOS A, 2007, UNPUB WHY WE STEREOT
NR 39
TC 16
Z9 16
U1 2
U2 23
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0146-1672
EI 1552-7433
J9 PERS SOC PSYCHOL B
JI Pers. Soc. Psychol. Bull.
PD APR
PY 2008
VL 34
IS 4
BP 553
EP 564
DI 10.1177/0146167207312465
PG 12
WC Psychology, Social
SC Psychology
GA 280BR
UT WOS:000254400400009
PM 18252834
DA 2018-12-27
ER

PT J
AU Dabrowska, E
   Pietka-Ottlik, M
   Palus, J
AF Dabrowska, Ewa
   Pietka-Ottlik, Magdalena
   Palus, Jerzy
TI RETRACTED: Bis(2-aminophenyl) diselenide derivatives with amino acids
   moieties as potential antivirals and antimicrobials (Retracted article.
   see vol 183, pg 1799, 2008)
SO PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 10th International Conference on the Chemistry of Selenium and Tellurium
CY JUN 22-27, 2007
CL Lodz, POLAND
DE antimicrobial activity; bis(2-aminophenyl) diselenide derivatives;
   seleno-amino acids; seleno-dipeptides; antivirals
ID ORGANOSELENIUM COMPOUNDS
AB The seleno-organic compounds based on bis(2-aminophenyl) diselenide-1 are potential antiviral, antibacterial and antifungal agents.(1) In this work, we reported synthesis of bis(2-aminophenyl) diselenide derivatives 2, 3 having amino acid and dipeptide moieties. This process was realized by acylation of amine groups in 1 with N-blocked amino acids, using the active esters method (with DCC and HOBT). After removing protective groups successive N-blocked amino acids were added the same way as previously.
   All compounds have been tested against broad spectrum of pathogenic microorganisms (Staphylococcus aureus, Staphylococcus simulans, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Candida albicans, Aspergillus niger) and viruses (HSV-1, EMCV, VSV), in vitro. Most of them exhibited high activity against EMCV. Some of tested compounds were active against gram-positive bacteria species (Staphylococcus aureus, Staphylococcus simulans) and yeast Candida albicans.
C1 [Dabrowska, Ewa; Pietka-Ottlik, Magdalena; Palus, Jerzy] Wroclaw Univ Technol, Fac Chem, Dept Bioorgan Chem, PL-50370 Wroclaw, Poland.
RP Dabrowska, E (reprint author), Wroclaw Univ Technol, Fac Chem, Dept Bioorgan Chem, Wybrzeze Wyspianskiego 27, PL-50370 Wroclaw, Poland.
EM ewa.dabrowska@pwr.wroc.p
CR HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561
   HWANG IY, 1989, EXP THER, V251, P448
   Mlochowski J, 1996, LIEBIGS ANN, P1751
   Mugesh G, 2001, CHEM REV, V101, P2125, DOI 10.1021/cr000426w
   WLOCHOWSKI J, 2007, ARCHIVOC, V6, P14
   WOJTOWICZ H, 2003, IL FARMACO, V58, P1235
NR 6
TC 3
Z9 3
U1 3
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-6507
EI 1563-5325
J9 PHOSPHORUS SULFUR
JI Phosphorus Sulfur Silicon Relat. Elem.
PD APR
PY 2008
VL 183
IS 4
BP 1082
EP 1086
DI 10.1080/10426500801901194
PG 5
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
SC Chemistry
GA 294WC
UT WOS:000255436000033
DA 2018-12-27
ER

PT J
AU Nunez, E
   Kwon, YS
   Hutt, KR
   Hu, Q
   Cardamone, MD
   Ohgi, KA
   Garcia-Bassets, I
   Rose, DW
   Glass, CK
   Rosenfeld, MG
   Fu, XD
AF Nunez, Esperanza
   Kwon, Young-Soo
   Hutt, Kasey R.
   Hu, Qidong
   Cardamone, Maria Dafne
   Ohgi, Kenneth A.
   Garcia-Bassets, Ivan
   Rose, David W.
   Glass, Christopher K.
   Rosenfeld, Michael G.
   Fu, Xiang-Dong
TI RETRACTED: Nuclear receptor-enhanced transcription requires motor- and
   LSD1-dependent gene networking in interchromatin granules (Retracted
   Article. See vol 134, pg 189, 2008)
SO CELL
LA English
DT Article; Retracted Publication
ID BETA-GLOBIN LOCUS; BINDING-SITES; DEPENDENT TRANSCRIPTION; ESTROGEN
   RESPONSE; MYOSIN-I; ACTIN; ACTIVATION; DYNAMICS; COMPLEX; GENOME
AB While the transcriptional machinery has been extensively dissected at the molecular level, little is known about regulation of chromosomal organization in the three-dimensional space of the nucleus to achieve integrated transcriptional responses to diverse signaling events. Here, we report that ligand induces rapid interchromosomal interactions among subsets of estrogen receptor alpha-bound transcription units, with a dramatic reorganization of nuclear territories requiring nuclear actin/myosin-I transport machinery, dynein light chain 1 (DLC1), and a specific subset of transcriptional coactivators and chromatin remodeling complexes. We establish a requirement for the histone lysine demethylase, LSD1, in directing specific interchromosomal interaction loci to distinct interchromatin granules, long thought to be "storage'' sites for splicing machinery, and demonstrate that these three-dimensional motor-dependent interactions are required to achieve enhanced transcription of specific estrogen-receptor target genes. These findings reveal roles for the modulation of nuclear architecture in orchestrating regulated gene-expression programs in the mammalian nucleus.
C1 [Nunez, Esperanza; Hutt, Kasey R.; Hu, Qidong; Cardamone, Maria Dafne; Ohgi, Kenneth A.; Garcia-Bassets, Ivan; Rosenfeld, Michael G.] Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA.
   [Nunez, Esperanza] Univ Calif San Diego, Biomed Sci Grad Program, Sch Med, La Jolla, CA 92093 USA.
   [Rose, David W.; Fu, Xiang-Dong] Univ Calif San Diego, Dept Med, Sch Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.
   [Kwon, Young-Soo; Glass, Christopher K.] Univ Calif San Diego, Dept Cellular & Mol Med, Sch Med, La Jolla, CA 92093 USA.
   [Hutt, Kasey R.] Univ Calif San Diego, Bioinformat Grad Program, Sch Med, La Jolla, CA 92093 USA.
   [Cardamone, Maria Dafne] Univ Turin, Dept Oncol Sci, Turin, Italy.
RP Rosenfeld, MG (reprint author), Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM mrosenfeld@ucsd.edu; xdfu@ucsd.edu
FU Howard Hughes Medical Institute; NCI NIH HHS [CA97134, CA52599,
   CA114184]; NHLBI NIH HHS [HL088129]; NIDDK NIH HHS [DK39949]; NIGMS NIH
   HHS [GM049369]; NINDS NIH HHS [NS34934]
CR Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370
   Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441
   Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138
   Bubb MR, 1998, METHOD ENZYMOL, V298, P26, DOI 10.1016/S0076-6879(98)98005-3
   Cai ST, 1999, METHODS, V19, P394, DOI 10.1006/meth.1999.0875
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051
   Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8
   Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104
   Chuang CH, 2006, CURR BIOL, V16, P825, DOI 10.1016/j.cub.2006.03.059
   Cook P, 1998, SCIENCE, V281, P1466, DOI 10.1126/science.281.5382.1466
   Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Dennis AP, 2005, J STEROID BIOCHEM, V93, P139, DOI 10.1016/j.jsbmb.2004.12.015
   Dillon N, 2006, CHROMOSOME RES, V14, P117, DOI 10.1007/s10577-006-1027-8
   FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703
   Ghosh MG, 2000, CANCER RES, V60, P6367
   Gonsior SM, 1999, J CELL SCI, V112, P797
   Gunawardena S, 2000, CURR BIOL, V10, P285, DOI 10.1016/S0960-9822(00)00360-2
   Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005
   Hewitt SL, 2004, EUR J IMMUNOL, V34, P3604, DOI 10.1002/eji.200425469
   Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649
   Hofmann WA, 2006, J CELL BIOL, V172, P495, DOI 10.1083/jcb.200601095
   Hofmann WA, 2006, BIOCHEM CELL BIOL, V84, P418, DOI 10.1139/O06-069
   Holzinger A, 2001, METH MOL B, V161, P109
   Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003
   Kahle M, 2007, HISTOCHEM CELL BIOL, V127, P139, DOI 10.1007/s00418-006-0231-0
   Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768
   Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104
   Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172
   Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191
   Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0
   Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402
   Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507
   Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423
   Paixao T, 2007, IMMUNOL CELL BIOL, V85, P315, DOI 10.1038/sj.icb.7100057
   Percipalle P, 2006, CURR OPIN CELL BIOL, V18, P267, DOI 10.1016/j.ceb.2006.03.001
   Percipalle P, 2006, J CELL BIOL, V172, P967, DOI 10.1083/jcb.200512083
   Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3
   Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337
   Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417
   Rizk RS, 2005, CURR BIOL, V15, pR841, DOI 10.1016/j.cub.2005.10.004
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0
   SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265
   Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574
   Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5
   Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028
   Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084
   Vega VB, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r82
   Wang Q, 2003, J CELL SCI, V116, P4227, DOI 10.1242/jcs.00709
   Williams RRE, 2006, J CELL SCI, V119, P132, DOI 10.1242/jcs.02727
   Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891
   Zink D, 2004, J CELL BIOL, V166, P815, DOI 10.1083/jcb.200404107
NR 62
TC 48
Z9 49
U1 2
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAR 21
PY 2008
VL 132
IS 6
BP 996
EP 1010
DI 10.1016/j.cell.2008.01.051
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 278GR
UT WOS:000254273600018
PM 18358812
OA Bronze
DA 2018-12-27
ER

PT J
AU Knight, RA
   Chen-Scarabelli, C
   Yuan, Z
   McCauley, RB
   Di Rezze, J
   Scarabelli, GM
   Townsend, PA
   Latchman, D
   Saravolatz, L
   Faggian, G
   Mazzueco, A
   Chowdrey, HS
   Stephanou, A
   Scarabelli, TM
AF Knight, Richard A.
   Chen-Scarabelli, Carol
   Yuan, Zhaokan
   McCauley, Roy B.
   Di Rezze, J.
   Scarabelli, Gabriele M.
   Townsend, Paul A.
   Latchman, David
   Saravolatz, Louis
   Faggian, Giuseppe
   Mazzueco, Alessandro
   Chowdrey, Hardial S.
   Stephanou, Anastasis
   Scarabelli, Tiziano M.
TI RETRACTED: Cardiac release of urocortin precedes the occurrence of
   irreversible myocardial damage in the rat heart exposed to
   ischemia/reperfusion injury (Retracted article. See vol. 592, pg. 657,
   2018)
SO FEBS LETTERS
LA English
DT Article; Retracted Publication
DE sublethal ischemia; biomarker; apoptosis; urocortin
ID GENE-EXPRESSION; APOPTOSIS; MYOCYTES; PROTECTS; PATHWAY; CELLS; CRH
AB This study evaluates whether cardiac ischemia induces release of urocortin, before and independently from myocyte cell death. Urocortin levels rose after 5-min ischemia and peaked after 10-min ischemia, when cell death was not detected. However, myocyte apoptosis and/or necrosis occurred following 20- and 30-min ischemia, which paralleled a fall in urocortin levels, suggesting that urocortin expression and release are mainly sustained by metabolically challenged, though still viable myocytes. Hence, since cardiac release of urocortin, unlike that of conventional biomarkers, occurs before and apart from cell death, urocortin levels may be clinically useful in the diagnosis of sublethal myocardial ischemia. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Knight, Richard A.; Townsend, Paul A.; Latchman, David; Stephanou, Anastasis] UCL, Med Mol Biol Unit, Inst Child Hlth, London WC1N 1EH, England.
   [Chen-Scarabelli, Carol] Univ Michigan, Div Cardiol Veteran Affairs Ann Arbor, Ann Arbor, MI 48109 USA.
   [Yuan, Zhaokan; McCauley, Roy B.; Di Rezze, J.; Scarabelli, Gabriele M.; Saravolatz, Louis; Scarabelli, Tiziano M.] Wayne State Univ, Sch Med, Div Cardiovasc Dis, Dept Internal Med, Detroit, MI USA.
   [Faggian, Giuseppe; Mazzueco, Alessandro] Univ Verona, Div Cardiochirurg, I-37100 Verona, Italy.
   [Chowdrey, Hardial S.] Univ Westminster, Dept Biomed Sci, London W1W 6UW, England.
RP Knight, RA (reprint author), UCL, Med Mol Biol Unit, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.
EM r.knight@ich.ucl.ac.uk
RI Faggian, Giuseppe/J-4590-2018
OI Faggian, Giuseppe/0000-0001-5371-5761
CR Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385
   Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508
   Brar BK, 2002, J MOL CELL CARDIOL, V34, P483, DOI 10.1006/jmcc.2002.1529
   Brar BK, 1999, MOL CELL ENDOCRINOL, V158, P55, DOI 10.1016/S0303-7207(99)00183-5
   DONALD RA, 1993, CLIN ENDOCRINOL, V38, P609, DOI 10.1111/j.1365-2265.1993.tb02142.x
   Gottlieb RA, 2003, BASIC RES CARDIOL, V98, P242, DOI 10.1007/s00395-003-0404-0
   Jaffe AS, 2004, CIRCULATION, V110, P104, DOI 10.1161/01.CIR.0000135581.79161.35
   Lawrence KM, 2004, BIOCHEM BIOPH RES CO, V321, P479, DOI 10.1016/j.bbrc.2004.06.170
   Lawrence KM, 2003, FASEB J, V17, P2313, DOI 10.1096/fj.02-0832fje
   Lawrence KM, 2002, CIRCULATION, V106, P1556, DOI 10.1161/01.CIR.0000028424.02525.AE
   Lim MM, 2006, BRAIN BEHAV EVOLUT, V68, P229, DOI 10.1159/000094360
   Ng LL, 2004, CLIN SCI, V106, P383, DOI 10.1042/CS20030311
   Okumura H, 2004, CIRCULATION, V109, P242, DOI 10.1161/01.CIR.0000109214.30211.7C
   PATRONO C, 1987, RADIOIMMUNOASSAY BAS
   Scarabelli Tiziano, 2004, Curr Med Chem Cardiovasc Hematol Agents, V2, P335, DOI 10.2174/1568016043356174
   Scarabelli TM, 2004, J THORAC CARDIOV SUR, V128, P364, DOI 10.1016/j.jtcvs.2003.11.028
   Scarabelli TM, 2002, J AM COLL CARDIOL, V40, P155, DOI 10.1016/S0735-1097(02)01930-7
   Scarabelli TM, 1999, J IMMUNOL METHODS, V228, P23, DOI 10.1016/S0022-1759(99)00090-3
NR 18
TC 24
Z9 26
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD MAR 19
PY 2008
VL 582
IS 6
BP 984
EP 990
DI 10.1016/j.febslet.2008.02.035
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 321UG
UT WOS:000257331400025
PM 18295601
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhong, JB
   Ma, D
   Zhao, H
   Li, MJ
   Xie, B
   Li, JZ
AF Zhong Junbo
   Ma Di
   Zhao Hong
   Li Minjiao
   Xie Bin
   Li Jianzhang
TI RETRACTED: Kinetic study on photocatalytic degradation of reactive
   orange 5 solution with phosphotungstic acid (Retracted article. See vol.
   298, pg. 125, 2009)
SO JOURNAL OF MOLECULAR CATALYSIS A-CHEMICAL
LA English
DT Article; Retracted Publication
DE phosphotungstic acid; photocatalytic degradation; reactive orange;
   kinetic; wastewater treatment
ID METHYL-ORANGE; AZO-DYES; OXIDATION; TIO2; WATER; DECOLORIZATION;
   DECOMPOSITION; MECHANISM; H3PW12O40; CO2
AB Increasing environmental pollution caused by toxic dyes due to their hazardous nature is a matter of great concern. It has been generally agreed that reactive orange 5 (KGN) can be effectively degraded in aerated phosphotungstic acid (HPA) homogeneous reaction system using near-UV irradiation. The knowledge on the kinetics of the system possesses both practical and theoretical values. The results reveal that the photocatalytic degradation reaction of KGN with HPA in a homogenous solution can be described by Langmuir-Hinshelwood equation; the results manifest the reaction is first-order with lower concentration and is zero-order with higher concentration. As the initial concentration goes up, the order of the reaction is reduced from 1 to 0, the limiting rate constant and the adsorption constant in this case are0.8098 mg L-1 min(-1) and 4.359 x 10(-2) L mg(-1), respectively. The paper reveals that the optimal amount of photocatalyst in our experimental conditions for the degradation of KGN is 0.6 g L-1. The effects of irradiation intensity and pH value on the degradation rate constant were also demonstrated, where special attention was paid on the nature of the photocatalyst itself. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Zhong Junbo; Ma Di; Li Minjiao; Xie Bin; Li Jianzhang] Sichuan Univ Sci & Engn, Dept Chem, Zigong 643000, Peoples R China.
   [Zhao Hong] Dalian Jiaotong Univ, Coll Environm & Chem Engn, Dalian 116026, Peoples R China.
RP Zhong, JB (reprint author), Sichuan Univ Sci & Engn, Dept Chem, Zigong 643000, Peoples R China.
EM junbozhong@sohu.com
CR Alberici RM, 1997, APPL CATAL B-ENVIRON, V14, P55, DOI 10.1016/S0926-3373(97)00012-X
   Anandan S, 2007, SOL ENERG MAT SOL C, V91, P143, DOI 10.1016/j.solmat.2006.07.009
   Augugliaro V, 2002, CHEMOSPHERE, V49, P1223, DOI 10.1016/S0045-6535(02)00489-7
   Behnajady MA, 2007, J HAZARD MATER, V148, P98, DOI 10.1016/j.jhazmat.2007.02.003
   Chagas EP, 2001, ENZYME MICROB TECH, V29, P473, DOI 10.1016/S0141-0229(01)00405-7
   Chai F, 2008, DYES PIGMENTS, V76, P113, DOI 10.1016/j.dyepig.2006.08.025
   Dimitratos N, 2007, CATAL TODAY, V122, P307, DOI 10.1016/j.cattod.2007.01.037
   Einaga H, 1996, B CHEM SOC JPN, V69, P3435, DOI 10.1246/bcsj.69.3435
   Farhadi S, 2005, TETRAHEDRON LETT, V46, P8483, DOI 10.1016/j.tetlet.2005.10.019
   Friesen DA, 2000, J PHOTOCH PHOTOBIO A, V133, P213, DOI 10.1016/S1010-6030(00)00237-9
   Guo YH, 2002, APPL CATAL B-ENVIRON, V36, P9, DOI 10.1016/S0926-3373(01)00260-0
   Guo YH, 2007, J MOL CATAL A-CHEM, V262, P136, DOI 10.1016/j.molcata.2006.08.039
   Hong CS, 1998, CHEMOSPHERE, V36, P1653, DOI 10.1016/S0045-6535(97)10040-6
   Hori H, 2004, J MOL CATAL A-CHEM, V211, P35, DOI 10.1016/j.molcata.2003.09.029
   Hu CW, 2000, APPL CATAL A-GEN, V194, P99, DOI 10.1016/S0926-860X(99)00358-0
   Hu MQ, 2004, CHEMOSPHERE, V54, P431, DOI 10.1016/S0045-6535(03)00712-4
   Jiang SJ, 2007, J COLLOID INTERF SCI, V308, P208, DOI 10.1016/j.jcis.2006.12.009
   Kim SB, 2002, APPL CATAL B-ENVIRON, V35, P305, DOI 10.1016/S0926-3373(01)00274-0
   Malik PK, 2003, SEP PURIF TECHNOL, V31, P241, DOI 10.1016/S1383-5866(02)00200-9
   Mittal A, 2007, J HAZARD MATER, V148, P229, DOI 10.1016/j.jhazmat.2007.02.028
   Mylonas A, 1996, J PHOTOCH PHOTOBIO A, V94, P77, DOI 10.1016/1010-6030(95)04207-5
   Neamtu M, 2004, DYES PIGMENTS, V60, P61, DOI 10.1016/S0143-7208(03)00129-3
   NGUYEN T, 1984, J PHYS CHEM-US, V88, P3386, DOI 10.1021/j150660a002
   Ozer RR, 2000, J PHYS CHEM B, V104, P9444, DOI 10.1021/jp000783a
   Qu XS, 2007, J MOL CATAL A-CHEM, V262, P128, DOI 10.1016/j.molcata.2006.08.026
   SHENG DN, 2003, ENV PHOTOCHEMISTRY, P384
   Sloboda Rozner D, 2007, J MOL CATAL A-CHEM, V262, P109
   TURCHI CS, 1990, J CATAL, V122, P178, DOI 10.1016/0021-9517(90)90269-P
   [王敏 WANG Min], 2006, [化学试剂, Chemical Reagents], V28, P515
   Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516
   ZHU XH, 2001, J DALIAN RAILWAY I, V22, P101
NR 31
TC 1
Z9 3
U1 2
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1381-1169
EI 1873-314X
J9 J MOL CATAL A-CHEM
JI J. Mol. Catal. A-Chem.
PD MAR 18
PY 2008
VL 283
IS 1-2
BP 93
EP 98
DI 10.1016/j.molcata.2007.12.010
PG 6
WC Chemistry, Physical
SC Chemistry
GA 284ZW
UT WOS:000254748100013
DA 2018-12-27
ER

PT J
AU Jiang, Y
   Jiang, J
   Xiong, J
   Cao, J
   Li, N
   Li, G
   Wang, S
AF Jiang, Yideng
   Jiang, Jianzhong
   Xiong, Jiantuan
   Cao, Jun
   Li, Nan
   Li, Guizhong
   Wang, Shuren
TI RETRACTED: Homocysteine-induced extracellular superoxide dismutase and
   its epigenetic mechanisms in monocytes (Retracted article. See vol. 211,
   pg. 3764, 2008)
SO JOURNAL OF EXPERIMENTAL BIOLOGY
LA English
DT Article; Retracted Publication
DE EC-SOD; H2O2; ox-LDL; DNA methylation
ID SMOOTH-MUSCLE-CELLS; DNA METHYLATION; RISK-FACTOR; VASCULAR-DISEASE;
   ATHEROSCLEROSIS; COPPER; HYPERHOMOCYSTEINEMIA; HYPOMETHYLATION;
   ACCUMULATION; INJURY
AB Although a modest homocysteine ( Hcy) elevation is associated with an increased cardiovascular risk, the underlying mechanisms whereby Hcy triggers the accumulation of cholesterol and the roles of the extracellular superoxide dismutase ( EC-SOD) in the development of foam cells have not yet been elucidated. In this study, we found both increased numbers of foam cells and an accumulation of cholesterol, and the H2O2 and oxidized low-density lipoprotein content also increased. Levels of EC-SOD were significantly suppressed by Hcy, however, while 5-azacytidine ( AZC), a potent DNA methyltransferase ( DNMT) inhibitor, increased the expression of EC-SOD. A quantitative real-time PCR of EC-SOD revealed that Hcy ( 100 mu mol l(-1)) accelerates DNA methylation of EC-SOD, but selectively increases the activity of DNA methyl transferase 1 ( DNMT1). It showed that Hcy can reduce binding of methyl CpG and binding protein 2 ( MeCP2) but has no effect on the activity of DNMT3. Moreover, chromatin immunoprecipitation assays demonstrated that Hcy increased the binding of acetylated histone H3 and H4 in monocytes. Based on the fact that the binding of MeCP2 with the EC-SOD was completely suppressed by AZC and trichostatin A [ TSA, a histone deacetylase ( HDAC) inhibitor], it is indicated that DNA methylation and HDAC mediate the binding of MeCP2 with EC-SOD gene. In conclusion, the study found that Hcy accelerates the development of foam cells by repressing EC-SOD transcription, and that Hcy exerts this function by upregulating DNA methylation via suppression of HDAC activity and increased DNMT1 activity.
C1 [Jiang, Yideng; Xiong, Jiantuan; Cao, Jun; Li, Nan] Ningxia Med Coll, Dept Pathophysiol, Ningxia 750004, Peoples R China.
   [Jiang, Jianzhong] Ningxia Med Coll, Dept Pathol, Ningxia 750004, Peoples R China.
   [Wang, Shuren] Sichuan Univ, W China Coll Preclin & Forens Med Sci, Dept Pathophysiol, Chengdu 610041, Peoples R China.
RP Jiang, Y (reprint author), Ningxia Med Coll, Dept Pathophysiol, Ningxia 750004, Peoples R China.
EM jwcjyd@163.com
CR Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753
   Bonaldi T, 2004, PROTEOMICS, V4, P1382, DOI 10.1002/pmic.200300743
   CAMPBELL GR, 1981, PATHOLOGY, V13, P423, DOI 10.3109/00313028109059061
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405
   Dong CM, 2002, J NUTR, V132, p2406S, DOI 10.1093/jn/132.8.2406S
   HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6
   Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588
   Iwama Y, 1998, J Cardiol, V32, P357
   Jiang YD, 2007, DNA CELL BIOL, V26, P737, DOI 10.1089/dna.2007.0619
   Jiang YD, 2007, ACTA BIOCH BIOPH SIN, V39, P657, DOI 10.1111/j.1745-7270.2007.00327.x
   Jiang YD, 2007, DNA CELL BIOL, V26, P603, DOI 10.1089/dna.2007.0584
   Jiang YD, 2007, ACTA BIOCH BIOPH SIN, V39, P366, DOI 10.1111/j.1745-7270.2007.00291.x
   Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171
   Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366
   Liu SX, 1996, ATHEROSCLEROSIS, V121, P55, DOI 10.1016/0021-9150(95)05683-1
   Maatouk DM, 2006, DEVELOPMENT, V133, P3411, DOI 10.1242/dev.02500
   Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074
   MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634
   PANG ZJ, 2000, FREE RADICAL MED STU
   Peng Ke Jun, 2006, Fen Zi Xi Bao Sheng Wu Xue Bao, V39, P509
   Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a
   Rong JX, 1999, ARTERIOSCL THROM VAS, V19, P2179, DOI 10.1161/01.ATV.19.9.2179
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445
   STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877
   STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442
   TURHAN H, 2005, LUPUS, V14, P878
   Umlauf David, 2004, Methods Mol Biol, V287, P99
   Vilar Lucio, 2007, Endocr Pract, V13, P363
   Wada Y, 2002, ARTERIOSCL THROM VAS, V22, P1712, DOI 10.1161/01.ATV.0000033834.57737.9B
   Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525
   WILLEMS J, 1993, J BIOL CHEM, V268, P24614
   Woo KS, 2000, CIRCULATION, V101, pE116
   ZELKO IN, 2003, GENE EXPR ENDOCRINOL, V146, P332
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
   Zhang KL, 2003, J CHROMATOGR B, V783, P173, DOI 10.1016/S1570-0232(02)00631-1
NR 39
TC 11
Z9 14
U1 3
U2 14
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0022-0949
EI 1477-9145
J9 J EXP BIOL
JI J. Exp. Biol.
PD MAR 15
PY 2008
VL 211
IS 6
BP 911
EP 920
DI 10.1242/jeb.012914
PG 10
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 280YM
UT WOS:000254462700014
PM 18310117
OA Bronze
DA 2018-12-27
ER

PT J
AU Istrate, FM
   Gagosz, FL
AF Istrate, Florin M.
   Gagosz, Fabien L.
TI RETRACTED: Synthesis of functionalized furans via gold(I)-catalyzed
   claisen-type rearrangement (Retracted Article)
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Correction; Retracted Publication
CR THEBASIS F, 2005, J ORG CHEM, V44, P850
NR 1
TC 0
Z9 0
U1 2
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD MAR 7
PY 2008
VL 73
IS 5
BP 2032
EP 2032
DI 10.1021/jo800265n
PG 1
WC Chemistry, Organic
SC Chemistry
GA 268QU
UT WOS:000253595100051
OA Bronze
DA 2018-12-27
ER

PT J
AU Jia, B
   Zhou, TQ
   Huang, AL
   Huang, WX
AF Jia Bei
   Zhou Ting-quan
   Huang Ai-long
   Huang Wen-xiang
TI RETRACTED: Role of TMS5: staphylococcal multidrug-efflux protein QacA
   (Retracted article. See vol. 124, pg. 4104, 2011)
SO CHINESE MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE multidrug-resistant; staphylococcus aureus; exporter; QacA; TMS5
ID SUBSTRATE-SPECIFICITY; TETRACYCLINE/H+ ANTIPORTER; DISINFECTANT
   RESISTANCE; ESCHERICHIA-COLI; P-GLYCOPROTEIN; TRANSPORTER; AUREUS;
   IDENTIFICATION
AB Background QacA, a main exporter mediating the multidrug-resistance of Staphylococcus aureus to a variety of antiseptics and disinfectants, possesses a topology of 14 a-helical transmembrane segments (TMS). Our study aimed to determine the importance and topology of amino acid residues in and flanking the cytoplasmic end of TMS5.
   Methods Site-directed mutagenesis was used to mutate 5 residues, including L146, A147, V148, W149 and S150, into cysteine. A minimum inhibitory concentration (MIC) and transport assay with or without N-ethylmaleimide (NEM) were performed to analyse the function of these mutants.
   Results All of the mutants showed comparable protein expression levels. MIC analysis suggested that mutant W149C showed low resistance levels to the drugs, but the mutations at L146, Al 47, V148, and S150C had little or no effect on the resistance level. And the results of the fluorimetric transport assay were in agreement with those of MIC analysis, that is to say, W149C did not allow transport to the substrates to be tested, while the other mutants retained significant transport ability. The reaction of the different mutant proteins with Fluorescein-NEM revealed that the mutant L146C was highly reactive with NEM; the W149C and S150C mutants were moderately reactive; A147C was barely reactive and V148C showed no reactivity.
   Conclusions The study identified that residues W149 and S150 situated at the interface of the aqueous: lipid junction as functionally important residues, probably involved in the substrate binding and translocation of QacA.
C1 [Jia Bei; Zhou Ting-quan; Huang Wen-xiang] First Affiliated Hosp Chongqing Med Univ, Dept Infect Dis, Key Lab Infect & Parasit Dis, Chongqing 400016, Peoples R China.
   First Affiliated Hosp Chongqing Med Univ, Dept Infect Dis, Chongqing 400010, Peoples R China.
RP Jia, B (reprint author), First Affiliated Hosp Chongqing Med Univ, Dept Infect Dis, Chongqing 400016, Peoples R China.
EM beijia123@sina.com
CR DHIR R, 1993, BIOCHEMISTRY-US, V32, P9492, DOI 10.1021/bi00087a030
   Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163
   Hassan KA, 2006, FEMS MICROBIOL LETT, V263, P76, DOI 10.1111/j.1574-6968.2006.00411.x
   Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821
   LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027
   LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259
   MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798
   Mitchell BA, 1999, J BIOL CHEM, V274, P3541, DOI 10.1074/jbc.274.6.3541
   Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1
   PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995
   Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630
   PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013
   ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x
   Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257
   Sharom FJ, 2001, SEMIN CELL DEV BIOL, V12, P257, DOI 10.1006/scdb.2000.0251
   Shi W, 2005, CHINESE MED J-PEKING, V118, P141
   Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200
   TENNENT JM, 1989, J GEN MICROBIOL, V135, P1
   Xu ZQ, 2006, J BIOL CHEM, V281, P792, DOI 10.1074/jbc.M508676200
   YAMAGUCHI A, 1992, FEBS LETT, V307, P229, DOI 10.1016/0014-5793(92)80773-A
   Zhou ZH, 2003, CHINESE MED J-PEKING, V116, P1244
NR 21
TC 3
Z9 3
U1 3
U2 15
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAR 5
PY 2008
VL 121
IS 5
BP 409
EP 413
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 279ME
UT WOS:000254358500005
PM 18364112
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Emsen, IM
AF Emsen, I. M.
TI RETRACTED: A different approach to the reconstruction of the stubborn
   crooked nose with a different spreader graft: Nasal bone grafts
   harvested from the removed nasal hump (Retracted Article. See vol 33, pg
   674, 2009)
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article; Retracted Publication
DE analog scale; cartilage; contracture; graft; rhinoplasty; scar
ID PRACTICAL CLASSIFICATION; SEPTONASAL DEVIATION; EFFECTIVE GUIDE; SEPTAL
   SURGERY; MIDDLE 3RD
AB Background Correction of a crooked or deviated nose is a complex cosmetic and functional problem as well as a big challenge for the rhinoplasty surgeon. Although corrections using a wide range of surgical techniques to straighten the nose and maximize nasal function have been proposed, recurrence is very common because of cartilage memory and scar contracture. Therefore, to prevent recurrence and maintain the correction of the septum, a permanent support that is stable and strong with the ability to maintain its given shape after placement on one or both sides of the septum is needed.
   Methods The author used a nasal bone graft. In this study, the concept and technique for correction of the crooked nose and the author's experience using it are presented.
   Results This graft material was used for 12 patients with crooked noses (8 with C-type and 4 with S-type noses). During a mean follow-up period of 20 months (range, 12-36 months), there were no complications, recurrences, or extrusions. Functional evaluations were performed using a visual analog scale before surgery and 6 months after surgery. Patients were asked to score their nasal breathing on a scale ranging from 0 to 100. The mean preoperative value was 17.67% +/- 1.22% (range, 15-25%), and the postoperative value was 89.88% +/- 1.24% (range, 85-95%).
   Use of nasal bone grafts as the spreader graft is a safe, effective, reliable, and permanent method for correction of the crooked nose. The author advises using this technique with nasal bone grafts for functional recovery and increased strength against further trauma or forces of scar contracture. This technique may prevent recurrence attributable to cartilage memory.
C1 Numune State Hosp, Dept Plast & Reconstruct Surg, TR-25240 Erzurum, Turkey.
RP Emsen, IM (reprint author), Numune State Hosp, Dept Plast & Reconstruct Surg, Numune Hastanesi, TR-25240 Erzurum, Turkey.
EM ilterisemsen@hotmail.com
CR BREITBART AS, 1997, GRABB SMITHS PLASTIC, P39
   Byrd HS, 1998, PLAST RECONSTR SURG, V102, P2148, DOI 10.1097/00006534-199811000-00055
   CONSTANTIAN MB, 1989, PLAST RECONSTR SURG, V83, P801, DOI 10.1097/00006534-198905000-00006
   Courtiss E H, 1978, Ann Plast Surg, V1, P443, DOI 10.1097/00000637-197809000-00002
   DANIEL RK, 1997, GRABB SMITHS PLASTIC, P651
   FRY H. J. H., 1966, BRIT J PLAST SURG, V19, P276, DOI 10.1016/S0007-1226(66)80055-3
   Gilbert SE, 1998, OTOLARYNG HEAD NECK, V119, P385, DOI 10.1016/S0194-5998(98)70084-1
   GUBISCH W, 1995, PLAST RECONSTR SURG, V95, P672, DOI 10.1097/00006534-199504000-00008
   GUNTER JP, 1988, CLIN PLAST SURG, V15, P43
   Gurlek A, 2005, ARCH FACIAL PLAST S, V7, P420, DOI 10.1001/archfaci.7.6.420-a
   Guyuron B, 1999, PLAST RECONSTR SURG, V104, P2202, DOI 10.1097/00006534-199912000-00039
   Mendelsohn M, 2005, ARCH FACIAL PLAST S, V7, P74, DOI 10.1001/archfaci.7.2.74
   Metzenbaum M, 1929, ARCHIV OTOLARYNGOL, V9, P282
   Okur E, 2004, AESTHET PLAST SURG, V28, P203, DOI 10.1007/s00266-004-0001-0
   Pontius Allison T, 2004, Arch Facial Plast Surg, V6, P263, DOI 10.1001/archfaci.6.4.263
   PORTER JP, 2002, AESTH PLAST SURG S1, V26, P18
   Rohrich RJ, 1999, PLAST RECONSTR SURG, V104, P2210, DOI 10.1097/00006534-199912000-00040
   Rohrich RJ, 2002, PLAST RECONSTR SURG, V110, P1509, DOI 10.1097/01.PRS.0000029975.08760.25
   ROHRICH RJ, 1987, AESTHETIC RHINOPLAST
   Seltzer AP, 1944, ARCHIV OTOLARYNGOL, V40, P433
   SHEEN JH, 1984, PLAST RECONSTR SURG, V73, P230, DOI 10.1097/00006534-198402000-00013
   TARDY ME, 1999, RINOPLASTICA STATO A, V2
   Toriumi DM, 1993, FACIAL PLAST SURG CL, V1, P63
NR 23
TC 10
Z9 11
U1 3
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-216X
EI 1432-5241
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD MAR
PY 2008
VL 32
IS 2
BP 266
EP 273
DI 10.1007/s00266-007-9108-4
PG 8
WC Surgery
SC Surgery
GA 269WA
UT WOS:000253680200013
PM 18231701
DA 2018-12-27
ER

PT J
AU Emsen, IM
AF Emsen, Ilteris Murat
TI RETRACTED: New and detailed classification of saddle nose deformities:
   Step-by-step surgical approach using the current techniques for each
   group (Retracted Article. See vol 33, pg 676, 2009)
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article; Retracted Publication
DE deformity; reconstruction; rhinoplasty; saddle; septal; septorhinoplasty
ID GRAFTS; RHINOPLASTY
AB Background Currently, saddle nose deformity is one of the most challenging deformities in all of rhinoplasty surgery. Recent advances in aesthetic reconstructive surgical techniques warrant discussion of this subject.
   Methods A review of saddle nose cases from January 2003 to February 2007 showed that the existence of an important subgroup exists, designated as septal saddle nose deformity. The pathophysiology was weakening or loss of septal support, bone, or both, but not the classic dorsal overresection. A prospective study of 33 consecutive cases was completed, with emphasis on analysis, classification, and treatment.
   Results Prior attempts at classification have emphasized cause. The author's study indicated that the majority of cases had multiple causes, the most common being trauma followed by septorhinoplasty (immediately or later), as opposed to simple fracture reduction. In addition, 23 of 33 cases were true secondary saddle nose deformities. Classification was divided into types. Different methods of composite reconstruction were devised according to each case and grade, which allows construction of a deep structural foundation layer that then is superimposed with an aesthetic layer.
   Conclusions Septal saddle nose still is an important entity that must be recognized and treated, especially when it is progressive. Composite reconstruction offers a unique solution to saddle nose deformity because it is a flexible method of restoring structural support and aesthetic contour.
C1 Numune State Hosp, Dept Plast & Reconstruct Surg, Erzurum, Turkey.
RP Emsen, IM (reprint author), Numune State Hosp, Dept Plast & Reconstruct Surg, Erzurum, Turkey.
EM ilterisemsen@hotmail.com
CR ALSARRAF P, 1999, FACIAL PLAST CLIN, V7, P303
   BYRD HS, 1993, PLAST RECONSTR SURG, V91, P15, DOI 10.1097/00006534-199301000-00003
   Converse JM, 1977, RECONSTRUCTIVE PLAST
   Daniel RK, 2004, PLAST RECONSTR SURG, V113, P2156, DOI 10.1097/01.PRS.0000122544.87086.B9
   DANIEL RK, 1994, PLAST RECONSTR SURG, V94, P597, DOI 10.1097/00006534-199410000-00005
   DANIEL RK, 2006, AESTHET PLAST SURG, V6, P209
   Daniel RK, 1993, AESTHETIC PLASTIC SU
   Daniel RK, 2002, RHINOPLASTY ATLAS SU
   Emsen IM, 2006, AESTHET PLAST SURG, V30, P705, DOI 10.1007/s00266-006-0062-3
   Graper C, 1996, J Craniomaxillofac Trauma, V2, P37
   Gunter JP, 2002, DALLAS RHINOPLASTY: NASAL SURGERY BY THE MASTERS, VOLS I AND II, P513
   JUGO SB, 1995, SURG ATLAS EXTERNAL
   MEYER R, 2002, SECONDARY RHINOPLAST
   Sheen JH, 1987, AESTHETIC RHINOPLAST
   TARDY M E JR, 1989, Facial Plastic Surgery, V6, P121, DOI 10.1055/s-2008-1064719
   Tardy ME, 1997, RHINOPLASTY ART SCI
   Toriumi DM, 1993, FACIAL PLAST SURG CL, V1, P63
   VARTANIAN AJ, EMEDICINE WEBMD
NR 18
TC 6
Z9 6
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-216X
EI 1432-5241
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD MAR
PY 2008
VL 32
IS 2
BP 274
EP 285
DI 10.1007/s00266-007-9033-6
PG 12
WC Surgery
SC Surgery
GA 269WA
UT WOS:000253680200014
PM 17885785
DA 2018-12-27
ER

PT J
AU Garcia-Barcelo, MM
   Lau, DK
   Ngan, ES
   Leon, TY
   Liu, T
   So, M
   Miao, X
   Lui, VC
   Wong, KK
   Ganster, RW
   Cass, DT
   Croaker, GDH
   Tam, PK
AF Garcia-Barcelo, M. -M.
   Lau, D. K.
   Ngan, E. S.
   Leon, T. Y.
   Liu, T.
   So, M.
   Miao, X.
   Lui, V. C.
   Wong, K. K.
   Ganster, R. W.
   Cass, D. T.
   Croaker, G. D. H.
   Tam, P. K.
TI RETRACTED: Evaluation of the NK2 homeobox 1 gene (NKX2-1) as a
   Hirschsprung's disease locus (Retracted Article. See vol 73, pg 131,
   2009)
SO ANNALS OF HUMAN GENETICS
LA English
DT Article; Retracted Publication
DE Hirschsprung's disease; NK2 homeobox 1; RET
ID RET PROTOONCOGENE; CONGENITAL HYPOTHYROIDISM; MODEL; EXPRESSION;
   MUTATIONS; RISK; TRANSCRIPTION; ASSOCIATION; PROMOTER; CHILDREN
AB Hirschsprung's disease (HSCR, colonic aganglionosis) is an oligogenic entity that usually requires mutations in RET and other interacting loci. Decreased levels of RET expression may lead to the manifestation of HSCR. We previously showed that RET transcription was decreased due to alteration of the NKX2-1 binding site by two HSCR-associated RET promoter single nucleotide polymorphisms (SNPs). This prompted us to investigate whether DNA alterations in NKX2-1 could play a role in HSCR by affecting the RET-regulatory properties of the NKX2-1 protein. Our initial study on 86 Chinese HSCR patients revealed a Gly322Ser amino acid substitution in the NKX2-1 protein. In this study, we have examined 102 additional Chinese and 70 Caucasian patients and 194 Chinese and 60 Caucasian unselected, unrelated, subjects as controls. The relevance of the DNA changes detected in NKX2-1 by direct sequencing were evaluated using bioinformatics, reporter and binding-assays, mouse neurosphere culture, immunohistochemistry and immunofluorescence techniques. Met3Leu and Pro48Pro were identified in 2 Caucasian and 1 Chinese patients respectively. In vitro analysis showed that Met3Leu reduced the activity of the RET promoter by 100% in the presence of the wild-type or HSCR-associated RET promoter SNP alleles. The apparent binding affinity of the NKX2-1 mutated protein was not decreased. The Met3Leu mutation may affect the interaction of NKX2-1 with its protein partners. The absence of NKX2-1 expression in mouse but not in human gut suggests that the role of NKX2-1 in gut development differs between the two species. NKX2-1 mutations could contribute to HSCR by affecting RET expression through defective interactions with other transcription factors.
C1 [Garcia-Barcelo, M. -M.; Lau, D. K.; Ngan, E. S.; Leon, T. Y.; Liu, T.; So, M.; Miao, X.; Lui, V. C.; Wong, K. K.; Ganster, R. W.; Tam, P. K.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Div Paediat Surg, Hong Kong, Peoples R China.
   [Tam, P. K.] Univ Hong Kong, Genome Res Ctr, Hong Kong, Peoples R China.
   [Cass, D. T.] Childrens Hosp, Sydney, NSW, Australia.
   [Croaker, G. D. H.] Canberra Hosp, Dept Paediat & Child Hlth, Canberra, ACT, Australia.
RP Garcia-Barcelo, MM (reprint author), Univ Hong Kong, Queen Mary Hosp, Med Ctr, Div Paediat Surg,Dept Surg, Hong Kong, Peoples R China.
EM mmgarcia@hkucc.hku.hk; paultam@hkucc.hku.hk
CR Amiel J, 2001, J MED GENET, V38, P729, DOI 10.1136/jmg.38.11.729
   Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268
   CANTRELL VA, 2004, HUM MOL GENET
   Carrasquillo MM, 2002, NAT GENET, V32, P237, DOI 10.1038/ng998
   Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321
   Croaker GDH, 1997, J PEDIATR SURG, V32, P1368, DOI 10.1016/S0022-3468(97)90325-0
   CUTLER AT, 1986, AM J DIS CHILD, V140, P479, DOI 10.1001/archpedi.1986.02140190089034
   DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649
   EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0
   Emison ES, 2005, NATURE, V434, P857, DOI 10.1038/nature03467
   Etensel B, 2005, J PEDIATR SURG, V40, P1258, DOI 10.1016/j.jpedsurg.2005.05.008
   Fitze G, 2003, HUM MOL GENET, V12, P3207, DOI 10.1093/hmg/ddg354
   Fougerousse F, 2000, HUM MOL GENET, V9, P165, DOI 10.1093/hmg/9.2.165
   FU M, 2004, J CELL BIOL
   Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868
   Garcia-Barcelo M, 2005, HUM MOL GENET, V14, P191, DOI 10.1093/hmg/ddi015
   Hamdan H, 1998, BBA-GENE STRUCT EXPR, V1396, P336, DOI 10.1016/S0167-4781(97)00210-8
   Jaruratanasirikul S, 1998, J PEDIATR ENDOCR MET, V11, P241
   Kimura S, 1999, BIOCHIMIE, V81, P321, DOI 10.1016/S0300-9084(99)80077-7
   Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828
   Li CG, 2000, BIOCHEM BIOPH RES CO, V270, P462, DOI 10.1006/bbrc.2000.2443
   McCallion AS, 2003, P NATL ACAD SCI USA, V100, P1826, DOI 10.1073/pnas.0337540100
   MUSTAFIN AA, 1985, VESTN KHIR IM GREKOV, V134, P89
   Newgreen D, 2002, PEDIATR DEVEL PATHOL, V5, P329, DOI 10.1007/s10024-002-0002-4
   NG PC, 2005, ANN REV GENOMICS HUM
   NGAN ES, 2007, BIOCH BIOPHYS ACTA
   Parisi MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017
   Park SM, 2005, J MED GENET, V42, P379, DOI 10.1136/jmg.2004.024158
   ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0
   Sancandi M, 2003, J MED GENET, V40, P714, DOI 10.1136/jmg.40.9.714
   SCHUCHARDT A, 1995, J INTERN MED, V238, P327, DOI 10.1111/j.1365-2796.1995.tb01206.x
   Torfs CP, 1998, 3 INT M HIRSCHSPR DI
   WynshawBoris A, 1996, NAT GENET, V13, P259, DOI 10.1038/ng0796-259
NR 33
TC 10
Z9 10
U1 7
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
EI 1469-1809
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD MAR
PY 2008
VL 72
BP 170
EP 177
DI 10.1111/j.1469-1809.2007.00403.x
PN 2
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 259GO
UT WOS:000252928000003
PM 18081917
DA 2018-12-27
ER

PT J
AU Behera, BC
   Verma, N
   Sonone, A
   Makhija, U
AF Behera, B. C.
   Verma, Neeraj
   Sonone, Anjah
   Makhija, Urmila
TI RETRACTED: Antioxidant and antibacterial properties of some cultured
   lichens (Retracted article. See vol. 99, pg. 7424, 2008)
SO BIORESOURCE TECHNOLOGY
LA English
DT Article; Retracted Publication
DE lichen; antioxidant; antibacterial
ID GHATTENSIS IN-VITRO; BULBOTHRIX-SETSCHWANENSIS; BIOLOGICAL-ACTIVITIES;
   TISSUE-CULTURES; USNIC ACID; EXTRACTS; INHIBITION; SUBSTANCES;
   TYROSINASE; GROWTH
AB The lichen species namely Usnea ghattensis, Heterodermia podocarpa, Arthothelium awasthii and Parmotrema tinctorum have been cultured in vitro and were screened for their antioxidant and antibacterial potential using different assay systems. The methanol extract of lichens showed antioxidant and antibacterial activities according to the order U ghattensis > A. awasthii > H. podocarpa > P. tinctorum. The IC50 values for the antioxidant activities of U. ghattensis and A. awasthii are less or equivalent to that of standard antioxidants. The methanolic extracts of the mycobiont and photobiont cultures of lichen U. ghattensis and A. awasthii were effective against Bacillus licheniformis, Bacillus megaterium, Bacillus subtilis and Staphylococcus aureus. The minimum inhibitory concentration (MIC) of the extract was found between 5 and 10 mu g extract/ml. The results suggested that the extract of mycobiont and photobiont cultures of lichen U. ghattensis and A. awasthii could be of use as an easily accessible source of natural antioxidants and antibacterial properties for the possible food supplement or in the pharmaceutical industry. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Behera, B. C.; Verma, Neeraj; Sonone, Anjah; Makhija, Urmila] Agharkar Res Inst, Plant Sci Div, Pune 411004, Maharashtra, India.
RP Behera, BC (reprint author), Agharkar Res Inst, Plant Sci Div, GG Agarkar Rd, Pune 411004, Maharashtra, India.
EM bcbehera2002@yahoo.co.in
CR Ahmadjian V., 1993, LICHEN SYMBIOSIS, P250
   Behera BC, 2006, MICROBIOL RES, V161, P232, DOI 10.1016/j.micres.2005.08.006
   Behera BC, 2006, FITOTERAPIA, V77, P208, DOI 10.1016/j.fitote.2006.02.002
   Behera BC, 2006, LWT-FOOD SCI TECHNOL, V39, P80, DOI 10.1016/j.lwt.2004.11.007
   Behera BC, 2005, BIOTECHNOL LETT, V27, P991, DOI 10.1007/s10529-005-7847-3
   Behera BC, 2000, CURR SCI INDIA, V78, P781
   Behera BC, 2002, CURR SCI INDIA, V82, P61
   Bischoff H. W., 1963, U TEXAS PUBL, V6318, P1
   BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0
   Boustie Joel, 2005, Plant Genetic Resources Characterization and Utilization, V3, P273, DOI 10.1079/PGR200572
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   DEASON TR, 1960, U TEXAS PUBL, V6022, P70
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   FEIGE GB, 1993, J CHROMATOGR, V646, P417, DOI 10.1016/0021-9673(93)83356-W
   Hettiarachchy NS, 1996, J FOOD SCI, V61, P516, DOI 10.1111/j.1365-2621.1996.tb13146.x
   HIGUCHI M, 1993, PLANTA MED, V59, P253, DOI 10.1055/s-2006-959662
   Jayaprakasha GK, 2000, Z NATURFORSCH C, V55, P1018
   Liegeois C, 2000, J AGR FOOD CHEM, V48, P1129, DOI 10.1021/jf9911242
   Lilly V.G., 1951, PHYSL FUNGI
   Liu F, 1997, LIFE SCI, V60, P763, DOI 10.1016/S0024-3205(97)00004-0
   Maksimovic Z, 2005, BIORESOURCE TECHNOL, V96, P873, DOI 10.1016/j.biortech.2004.09.006
   Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361
   Miao V, 2001, TRENDS BIOTECHNOL, V19, P349, DOI 10.1016/S0167-7799(01)01700-0
   MILLER NJ, 1995, J AGR FOOD CHEM, V43, P1794, DOI 10.1021/jf00055a009
   Muller K, 2001, APPL MICROBIOL BIOT, V56, P9, DOI 10.1007/s002530100684
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   NISHIKIMI M, 1972, BIOCHEM BIOPH RES CO, V46, P849, DOI 10.1016/S0006-291X(72)80218-3
   Rauha JP, 2000, INT J FOOD MICROBIOL, V56, P3, DOI 10.1016/S0168-1605(00)00218-X
   Sherwin E. R., 1990, FOOD ADDITIVES, P139
   SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49
   TEPE B, BIORESOURCE TECHNOL, DOI DOI 10.1016/J.BIOTECH.2006.10.019
   Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4
   YAMAMOTO Y, 1985, AGR BIOL CHEM TOKYO, V49, P3347, DOI 10.1080/00021369.1985.10867270
   Yamamoto Y., 1998, Recent Research Developments in Phytochemistry, V2, P23
   YEN GC, 1994, J AGR FOOD CHEM, V42, P629, DOI 10.1021/jf00039a005
NR 36
TC 17
Z9 18
U1 4
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD MAR
PY 2008
VL 99
IS 4
BP 776
EP 784
DI 10.1016/j.biortech.2007.01.031
PG 9
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 242VO
UT WOS:000251754500012
PM 17363243
DA 2018-12-27
ER

PT J
AU Chen, Y
   Li, XX
   Yin, H
   Gilbert, C
   Liang, JH
   Jiang, YR
   Zhao, MW
AF Chen, Y.
   Li, X-x
   Yin, H.
   Gilbert, C.
   Liang, J-h
   Jiang, Y-r
   Zhao, M-w
CA Beijing Rop Survey Grp
TI RETRACTED: Risk factors for retinopathy of prematurity in six neonatal
   intensive care units in Beijing, China (Retracted Article. See vol 92,
   pg 1159, 2008)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
ID BIRTH-WEIGHT INFANTS; COUNTRIES; SEVERITY
AB Objective: Guidelines on oxygenation policies and on the prevention and treatment of retinopathy of prematurity (ROP) were issued by the Chinese Medical Association in 2004. This study was undertaken to determine the incidence of and risk factors for ROP among preterm infants in Beijing, the capital of China, after implementation of the guidelines.
   Methods: Neonates with birth weights (BW) <= 2000 g or gestational age (GA) <= 34 weeks admitted to the six largest neonatal intensive care units in Beijing during 2005 were enrolled. Ophthalmological examinations started 3-4 weeks after birth, and ROP was classified using the revised International Classification. Maternal and perinatal risk factors for type 1 ROP were analysed.
   Results: Retinopathy of prematurity was detected in 10.8% of 639 neonates who had complete eye examinations, 23 of whom (3.6%) developed type 1 ROP and were treated. The rate of ROP needing treatment has not declined since 2002. Logistic regression analysis indicated that low BW, apnoea >20 s, anaemia, hypoxic-ischaemic encephalopathy and placenta abruption were significantly associated with type 1 ROP.
   Conclusion: In Beijing, rates of ROP needing treatment are high, and affected babies are more mature than in NICUs in high-income countries. More needs to be done to prevent ROP through improved neonatal care.
C1 [Chen, Y.; Li, X-x; Yin, H.; Liang, J-h; Jiang, Y-r; Zhao, M-w] Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China.
   [Gilbert, C.] London Sch Hyg & Trop Med, London WC1, England.
RP Li, XX (reprint author), Peking Univ, Peoples Hosp, 11 Xi Zhi Men S St, Beijing 100044, Peoples R China.
EM drlixiaoxin@yahoo.com.cn
CR Allegaert K, 2003, J AAPOS, V7, P34, DOI 10.1016/S1091-8531(02)42015-0
   Attar Mohammad A, 2005, J Perinatol, V25, P36, DOI 10.1038/sj.jp.7211203
   Bouzas L, 2007, An Pediatr (Barc), V66, P551, DOI 10.1157/13107388
   Bull MJ, 2001, PEDIATRICS, V107, P1480
   Chen Y, 2006, BRIT J OPHTHALMOL, V90, P268, DOI 10.1136/bjo.2005.078063
   Chinese Medical Association, 2005, ZHONGHUA YAN KE ZA Z, V41, P375
   Darlow BA, 2005, PEDIATRICS, V115, P990, DOI 10.1542/peds.2004-1309
   Delport SD, 2002, SAMJ S AFR MED J, V92, P986
   Early Treatment for Retinopathy of Prematurity Cooperative Group, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684, DOI DOI 10.1001/ARCHOPHT.121.12.1684
   FLYNN JT, IN PRESS INVEST OPHT
   Gaynon MW, 2006, RETINA-J RET VIT DIS, V26, pS18, DOI 10.1097/01.iae.0000244292.86627.1e
   GILBERT C, 1993, INT OPHTHALMOL, V17, P229, DOI 10.1007/BF01007745
   Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991
   Grunauer N, 2003, An Pediatr (Barc), V58, P471
   HUNGERFORD J, 1986, BRIT J OPHTHALMOL, V70, P463, DOI 10.1136/bjo.70.6.463
   Jiang Y R, 1994, Zhonghua Yan Ke Za Zhi, V30, P427
   Kim T, 2004, PAEDIATR PERINAT EP, V18, P130, DOI 10.1111/j.1365-3016.2003.00545.x
   Kopylov U, 2002, Harefuah, V141, P1066
   Phan MH, 2003, J PEDIAT OPHTH STRAB, V40, P208
   Rekha S, 1996, Indian Pediatr, V33, P999
   Shah VA, 2005, ANN ACAD MED SINGAP, V34, P169
   Sluncheva B, 2002, Akush Ginekol (Sofiia), V42, P10
   *SUBSP GROUP NEON, 2005, CHIN J CONT PEDIAT, V7, P25
   VanderVeen DK, 2006, J AAPOS, V10, P445, DOI 10.1016/j.jaapos.2006.04.010
   Vinekar Anand, 2007, Indian Journal of Ophthalmology, V55, P331
   Wheatley CM, 2002, BRIT J OPHTHALMOL, V86, P696, DOI 10.1136/bjo.86.6.696
   Wilkinson AR, 1996, EARLY HUM DEV, V46, P239
   Yang C S, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P706
   [尹虹 Yin Hong], 2005, [中华眼科杂志, Chinese Journal of Ophthalmology], V41, P295
NR 31
TC 48
Z9 54
U1 6
U2 20
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2008
VL 92
IS 3
BP 326
EP 330
DI 10.1136/bjo.2007.131813
PG 5
WC Ophthalmology
SC Ophthalmology
GA 274HG
UT WOS:000253991800006
PM 18303154
DA 2018-12-27
ER

PT J
AU Ramji, H
AF Ramji, Hasmita
TI RETRACTED: Exploring commonality and difference in in-depth
   interviewing: a case-study of researching British Asian women (Retracted
   article. See vol. 60, pg. 661, 2009)
SO BRITISH JOURNAL OF SOCIOLOGY
LA English
DT Article; Retracted Publication
DE cultural identity; in-depth interviews; commonality; difference; British
   Asians
ID RACE; ETHNICITY
AB This paper draws on the experience of researching British South Asian women's lives in London as a female British Asian researcher to explore how cultural commonality and difference is shaped by agency and interaction in the research process. It examines these issues through a discussion of how the shared cultural identity of the researcher and the interviewees emerged as both a point of commonality and difference in the research process; with the researcher being 'positioned' in terms of both as a result of the interviewees' agency in interpreting their cultural commonality. In particular, issues of 'Indianness' and religion emerged as points on which interviewees exercised agency and interpreted the researcher's cultural identity. This was the basis on which they claimed commonality or difference and this assessment consequently impacted on their interaction with the researcher. The article suggests that more attention needs to be given to how assumptions made by interviewees regarding the cultural identity of the researcher through their agency and interaction in the research process shapes interview dynamics.
C1 City Univ, Dept Sociol, Bangor, Gwynedd, Wales.
RP Ramji, H (reprint author), City Univ, Dept Sociol, Bangor, Gwynedd, Wales.
EM h.ramji@city.ac.uk
CR AHMAD F, 2003, S ASIAN WOMEN DIASPO
   Alexander C., 2000, ASIAN GANG
   Ali S, 2006, ETHNIC RACIAL STUD, V29, P471, DOI 10.1080/01419870600597891
   Anderson M., 1993, RACE ETHNICITY RES M
   Baumann G., 1996, CONTESTED CULTURES D
   Bhabha H., 1990, IDENTITY COMMUNITY C
   Bhachu P., 2003, DANGEROUS DESIGNS AS
   Bhachu P., 1991, NEW COMMUNITY, V17, P401
   Bhopal K, 2001, J GENDER STUD, V10, P279, DOI 10.1080/09589230120086485
   Brah Avtar, 1996, CARTOGRAPHIES DIASPO
   Bulmer M., 2004, RES RACE RACISM
   Dunbar C. J., 2002, HDB INTERVIEW RES CO
   EDWARDS R, 1990, WOMEN STUD INT FORUM, V13, P477, DOI 10.1016/0277-5395(90)90100-C
   Edwards R., 1993, RES SENSITIVE TOPICS
   Fenton S, 2000, SOCIOLOGICAL RES ONL, V5
   Fine M., 1998, LANDSCAPE QUALITATIV
   Frankenberg R., 1993, WHITE WOMEN RACE MAT
   Gunaratnam Y, 2003, RES RACE ETHNICITY
   Hall S., 1992, RACE CULTURE DIFFERE
   Knowles C, 2003, RACE SOCIAL ANAL
   MAND K, 2006, BRIT ANT ID POL C U
   OAKLEY A, 1981, DOING FEMINIST RES
   Papadopoulos I, 2002, J ADV NURS, V37, P258, DOI 10.1046/j.1365-2648.2002.02092.x
   Puwar N, 2000, FEMINIST REV, V66, P131
   RAM M, 1996, METHODOLOGICAL IMAGI
   Ramji H., 2003, S ASIAN WOMEN DIASPO
   RAMJI H, 2005, SOCIOLOGICAL RES ONL, V10
   Reed K., 2000, SOCIOLOGICAL RES ONL, V4
   Reissman C.K., 1987, GENDER SOC, V1, P172, DOI DOI 10.1177/0891243287001002004
   RHODES PJ, 1994, SOCIOLOGY, V28, P547, DOI 10.1177/0038038594028002011
   Smaje C, 1997, SOCIOLOGY, V31, P307, DOI 10.1177/0038038597031002007
   SONG M, 1995, SOCIOLOGY, V29, P241, DOI 10.1177/0038038595029002004
   Tang N, 2002, SOCIOLOGY, V36, P703, DOI 10.1177/0038038502036003011
   Thapar-Bjorkert S, 1999, J GENDER STUD, V8, P57, DOI 10.1080/095892399102823
   Twine F, 2000, RACING RES RES RACE
   WALLMAN S, 1978, MAN, V13, P200, DOI 10.2307/2800245
NR 36
TC 8
Z9 8
U1 2
U2 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007-1315
J9 BRIT J SOCIOL
JI Br. J. Sociol.
PD MAR
PY 2008
VL 59
IS 1
BP 99
EP 116
DI 10.1111/j.1468-4446.2007.00184.x
PG 18
WC Sociology
SC Sociology
GA 270ZA
UT WOS:000253757500009
PM 18321333
DA 2018-12-27
ER

PT J
AU Safriel, Y
   Ang, R
   Ali, M
AF Safriel, Yair
   Ang, Roberto
   Ali, Muhammed
TI RETRACTED: Gadolinium use in spine pain management procedures for
   patients with contrast allergies: Results in 527 procedures (Retracted
   Article. See vol 32, pg 847, 2009)
SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article; Retracted Publication
DE contrast; contrast allergies; discography; epidural injection; facet
   injections; gadolinium; nerve root blocks; pain management
ID EPIDURAL STEROID INJECTIONS; LOW-BACK-PAIN; GADOPENTETATE DIMEGLUMINE;
   MULTIPLE-SCLEROSIS; SUBARACHNOID SPACE; ADVERSE-REACTIONS;
   CLINICAL-TRIALS; SAFETY; DTPA; MEDIA
AB Introduction To review the safety and efficacy of gadolinium in spine pain management procedures in patients at high risk for a contrast reaction and who are not suitable candidates for the use of standard non-ionic contrast.
   Methods We reviewed records over a 61-month period of all image-guided spinal pain management procedures where patients had allergies making them unsuitable candidates for standard non-ionic contrast and where gadolinium was used to confirm needle tip placement prior to injection of medication.
   Results Three hundred and four outpatients underwent 527 procedures. A spinal needle was used in all but 41 procedures. Gadolinium was visualized using portable C-arm fluoroscopy in vivo allowing for confirmation of needle tip location. The gadolinium dose ranged from 0.2 to 10 ml per level. The highest dose received by one patient was 15.83 ml intradiscally during a three-level discogram. Three hundred and one patients were discharged without complication or known delayed complications. One patient had documented intrathecal injection but without sequelae and 2 patients who underwent cervical procedures experienced seizures requiring admission to the intensive care unit. Both the latter patients were discharged without any further complications.
   Conclusion Based on our experience we recommend using gadolinium judiciously for needle tip confirmation. We feel more confident using gadolinium in the lumbar spine and in cervical nerve blocks. Gadolinium should probably not be used as an injectate volume expander. The indications for gadolinium use in cervical needle-guided spine procedures are less clear and use of a blunt-tipped needle should be considered.
C1 [Safriel, Yair] Yale Univ, Sch Med, Dept Radiol, Neuroradiol Sect, New Haven, CT 06520 USA.
   [Safriel, Yair] Radiol Associates Clearwater, Clearwater, FL USA.
   [Safriel, Yair] Phamascan Clin Trials, New York, NY USA.
   [Ang, Roberto] Ctr Diagnost Imaging, St Cloud, MN USA.
   [Ali, Muhammed] Kaiser Permanente, Woodland Hills Med Ctr, Woodland Hills, CA USA.
RP Safriel, Y (reprint author), Yale Univ, Sch Med, Dept Radiol, Neuroradiol Sect, 333 Cedar St, New Haven, CT 06520 USA.
EM safriel@yale.edu
CR Abram SE, 1996, REGION ANESTH, V21, P149
   Bartynski WS, 2005, AM J NEURORADIOL, V26, P502
   Botwin KP, 2002, AM J PHYS MED REHAB, V81, P898, DOI 10.1097/01.PHM.0000034953.43372.72
   Evans W, 1930, LANCET, V2, P1225
   Falco Frank J E, 2003, Spine (Phila Pa 1976), V28, pE1, DOI 10.1097/00007632-200301010-00024
   Filippi M, 1998, BRAIN, V121, P2011, DOI 10.1093/brain/121.10.2011
   GOLDSTEIN HA, 1990, RADIOLOGY, V174, P17, DOI 10.1148/radiology.174.1.2403679
   HARBURY OL, 1991, AM J NEURORADIOL, V12, P666
   Henson JW, 2004, AM J NEURORADIOL, V25, P969
   Johnson BA, 1999, AM J NEURORADIOL, V20, P697
   Johnson DW, 1999, AM J NEURORADIOL, V20, P537
   Kaplan M, 1998, SPINE, V23, P1847, DOI 10.1097/00007632-199809010-00008
   KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107
   LYNCH MC, 1986, J BONE JOINT SURG BR, V68, P138
   Murphy KPJ, 1999, ACAD RADIOL, V6, P656, DOI 10.1016/S1076-6332(99)80114-7
   NELSON DA, 1993, SPINE, V18, P278, DOI 10.1097/00007632-199302000-00018
   NIENDORF HP, 1991, MAGNET RESON MED, V22, P222, DOI 10.1002/mrm.1910220212
   NIENDORF HP, 1991, INVEST RADIOL, V26, pS221, DOI 10.1097/00004424-199111001-00075
   Okada S, 2001, ACTA RADIOL, V42, P339, DOI 10.1034/j.1600-0455.2001.042003339.x
   RENFREW DL, 1991, AM J NEURORADIOL, V12, P1003
   Riew KD, 2000, J BONE JOINT SURG AM, V82A, P1589, DOI 10.2106/00004623-200011000-00012
   Sadowski EA, 2007, RADIOLOGY, V243, P148, DOI 10.1148/radiol.2431062144
   Scanlon GC, 2007, SPINE, V32, P1249, DOI 10.1097/BRS.0b013e318053ec50
   SELCUK HA, 2004, AM SOC NEUR ANN M SE
   Siebner HR, 1997, NEURORADIOLOGY, V39, P418, DOI 10.1007/s002340050436
   Skalpe IO, 1998, EUR RADIOL, V8, P427
   Skalpe IO, 1997, INVEST RADIOL, V32, P140, DOI 10.1097/00004424-199703000-00002
   Slipman CW, 2002, PAIN MED, V3, P23, DOI 10.1046/j.1526-4637.2002.02001.x
   Tali ET, 2002, INVEST RADIOL, V37, P152
   TARDY B, 1992, LANCET, V339, P494, DOI 10.1016/0140-6736(92)91102-E
   TISHLER S, 1990, AM J NEURORADIOL, V11, P1167
   Wagner AL, 2004, AM J NEURORADIOL, V25, P1824
   WHITE AH, 1980, SPINE, V5, P78, DOI 10.1097/00007632-198001000-00014
   Yousry I, 2000, MAGN RESON IMAGING, V18, P1183, DOI 10.1016/S0730-725X(00)00191-0
NR 34
TC 4
Z9 4
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0174-1551
EI 1432-086X
J9 CARDIOVASC INTER RAD
JI Cardiovasc. Interv. Radiol.
PD MAR
PY 2008
VL 31
IS 2
BP 325
EP 331
DI 10.1007/s00270-007-9192-5
PG 7
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 275QT
UT WOS:000254087400012
PM 17939000
DA 2018-12-27
ER

PT J
AU Junbo, Z
   Hong, Z
   Di, M
   An, L
   Minjiao, L
   Bin, X
   Jianzhang, L
AF Junbo, Zhong
   Hong, Zhao
   Di, Ma
   An, Lian
   Minjiao, Li
   Bin, Xie
   Jianzhang, Li
TI RETRACTED: Kinetic and anion degradation products study on
   photocatalytic degradation of reactive orange 5 solution with
   phosphotungstic acid (Retracted article. See vol. 6, pg. 657, 2008)
SO CENTRAL EUROPEAN JOURNAL OF CHEMISTRY
LA English
DT Article; Retracted Publication
DE phosphotungstic acid; photocatalytic degradation; reactive orange;
   kinetics; anion products
ID AQUEOUS-SOLUTIONS; AZO-DYES; WATER; TIO2; DECOLORIZATION; OXIDATION;
   CO2; PHENOLS; HCL
AB Increasing environmental pollution caused by toxic dyes is a matter of great concern due to their hazardous nature. So it is crucial to develop processes which can destroy these dyes effectively. It has been generally agreed that reactive orange 5 (KGN) can be effectively degraded in aerated phosphotungstic acid (HPA) in a homogeneous reaction system using near-UV irradiation. In this paper, photocatalytic degradation of reactive orange 5 solutions with phosphotungstic acid was investigated, especially more attention was paid to the kinetic model and the anion degradation products. The results revealed that the photocatalytic degradation reaction of KGN with HPA in a homogenous solution can be described by Langmuir-Hinshelwood equation and Langmuir-Hinshewood kinetic model described it well. The reaction manifested the first order with lower concentration(<= 30 mg L-1) with the limiting rate constant and the adsorption constant in this case being 0.8098 mg L-1 min(-1) and 4.359 10(-2) L mg(-1), respectively. The degradation mechanism of KGN with HPA is different from that with TiO2, the anion products of the two reaction systems are the same. The difference in degradation mechanism of KGN with HPA from that with TiO2 is caused by the nature of the photocatalyst.
C1 [Junbo, Zhong; Di, Ma; An, Lian; Minjiao, Li; Bin, Xie; Jianzhang, Li] Sichuan Univ Sci & Engn, Dept Chem, Zigong 643000, Peoples R China.
   [Hong, Zhao] Dalian Jiaotong Univ, Coll Environm & Chem Engn, Dalian 116026, Peoples R China.
RP Junbo, Z (reprint author), Sichuan Univ Sci & Engn, Dept Chem, Zigong 643000, Peoples R China.
EM junbozhong@163.com
CR Alberici RM, 1997, APPL CATAL B-ENVIRON, V14, P55, DOI 10.1016/S0926-3373(97)00012-X
   Anandan S, 2007, SOL ENERG MAT SOL C, V91, P143, DOI 10.1016/j.solmat.2006.07.009
   Androulaki E, 2000, ENVIRON SCI TECHNOL, V34, P2024, DOI 10.1021/es990802y
   Augugliaro V, 2002, CHEMOSPHERE, V49, P1223, DOI 10.1016/S0045-6535(02)00489-7
   Barltrop J. A., 1978, PRINCIPLES PHOTOCHEM
   Behnajady MA, 2007, J HAZARD MATER, V148, P98, DOI 10.1016/j.jhazmat.2007.02.003
   Chagas EP, 2001, ENZYME MICROB TECH, V29, P473, DOI 10.1016/S0141-0229(01)00405-7
   Chai F, 2008, DYES PIGMENTS, V76, P113, DOI 10.1016/j.dyepig.2006.08.025
   Crano NJ, 1996, J MOL CATAL A-CHEM, V114, P65, DOI 10.1016/S1381-1169(96)00304-4
   Dimitratos N, 2007, CATAL TODAY, V122, P307, DOI 10.1016/j.cattod.2007.01.037
   Ermolenko L, 1996, J MOL CATAL A-CHEM, V114, P87, DOI 10.1016/S1381-1169(96)00306-8
   Friesen DA, 2000, J PHOTOCH PHOTOBIO A, V133, P213, DOI 10.1016/S1010-6030(00)00237-9
   Guo YH, 2002, APPL CATAL B-ENVIRON, V36, P9, DOI 10.1016/S0926-3373(01)00260-0
   Guo YH, 2007, J MOL CATAL A-CHEM, V262, P136, DOI 10.1016/j.molcata.2006.08.039
   Hong CS, 1998, CHEMOSPHERE, V36, P1653, DOI 10.1016/S0045-6535(97)10040-6
   Hori H, 2004, J MOL CATAL A-CHEM, V211, P35, DOI 10.1016/j.molcata.2003.09.029
   Hu CW, 2000, APPL CATAL A-GEN, V194, P99, DOI 10.1016/S0926-860X(99)00358-0
   JIANG SJ, 2007, COLLOID INTERF SCI, V308, P208
   Kim SB, 2002, APPL CATAL B-ENVIRON, V35, P305, DOI 10.1016/S0926-3373(01)00274-0
   Maldotti A, 1996, J MOL CATAL A-CHEM, V114, P141, DOI 10.1016/S1381-1169(96)00312-3
   Malik PK, 2003, SEP PURIF TECHNOL, V31, P241, DOI 10.1016/S1383-5866(02)00200-9
   MITTAL A, 2007, J HAZARD MATER, V148, P127
   MYLONAS A, 1994, J MOL CATAL, V92, P261, DOI 10.1016/0304-5102(94)00083-2
   Mylonas A, 1996, J MOL CATAL A-CHEM, V114, P191, DOI 10.1016/S1381-1169(96)00317-2
   Mylonas A, 1996, J PHOTOCH PHOTOBIO A, V94, P77, DOI 10.1016/1010-6030(95)04207-5
   Neamtu M, 2004, DYES PIGMENTS, V60, P61, DOI 10.1016/S0143-7208(03)00129-3
   NGUYEN T, 1984, J PHYS CHEM-US, V88, P3386, DOI 10.1021/j150660a002
   Qu XS, 2007, J MOL CATAL A-CHEM, V262, P128, DOI 10.1016/j.molcata.2006.08.026
   Ruya R. O., 2000, J PHYS CHEM B, V104, P9444
   SHENG DN, 2003, ENV PHOTOCHEMISTRY
   Sloboda Rozner D, 2007, J MOL CATAL A-CHEM, V262, P109
   Tanielian C, 1998, COORDIN CHEM REV, V178, P1165, DOI 10.1016/S0010-8545(98)00160-X
   TURCHI CS, 1990, J CATAL, V122, P178, DOI 10.1016/0021-9517(90)90269-P
NR 33
TC 0
Z9 0
U1 5
U2 24
PU DE GRUYTER OPEN LTD
PI WARSAW
PA BOGUMILA ZUGA 32A ST, 01-811 WARSAW, POLAND
SN 1895-1066
EI 1644-3624
J9 CENT EUR J CHEM
JI Cent. Eur. J. Chem
PD MAR
PY 2008
VL 6
IS 1
BP 99
EP 105
DI 10.2478/s11532-007-0064-2
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 252SQ
UT WOS:000252467300014
OA Other Gold
DA 2018-12-27
ER

PT J
AU Leman, ES
   Schoen, RE
   Magheli, A
   Sokoll, LJ
   Chan, DW
   Getzenberg, RH
AF Leman, Eddy S.
   Schoen, Robert E.
   Magheli, Ahmed
   Sokoll, Lori J.
   Chan, Daniel W.
   Getzenberg, Robert H.
TI RETRACTED: Evaluation of colon cancer-specific antigen 2 as a potential
   serum marker for colorectal cancer (Retracted article. See vol. 19, pg.
   508, 2013)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID MATRIX PROTEIN ALTERATIONS
AB Purpose: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics.
   Experimental Design: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study.
   Results: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 mu g/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95).
   Conclusion: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.
C1 [Leman, Eddy S.; Magheli, Ahmed; Sokoll, Lori J.; Chan, Daniel W.; Getzenberg, Robert H.] Johns Hopkins Univ, Sch Med, Brady Urol Inst, Baltimore, MD USA.
   [Sokoll, Lori J.; Chan, Daniel W.; Getzenberg, Robert H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Schoen, Robert E.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
   [Schoen, Robert E.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
RP Getzenberg, RH (reprint author), Johns Hopkins Univ Hosp, Brady Urol Inst, Marburg 121,600 N Wolfe St, Baltimore, MD 21287 USA.
EM rgetzen1@jhmi.edu
FU NCI NIH HHS [U01 CA084968, U01 CA084968-01, CA084968]
CR ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002
   Bond J H, 2000, Semin Gastrointest Dis, V11, P176
   Brunagel G, 2004, J CELL BIOCHEM, V91, P365, DOI 10.1002/jcb.10695
   Brunagel G, 2002, CANCER RES, V62, P2437
   Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Konety BR, 1999, J CELL BIOCHEM, P183
   Leman ES, 2007, CANCER RES, V67, P5600, DOI 10.1158/0008-5472.CAN-07-0649
   LEMAN ES, 2007, J CELL BIOCH    0423
   Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x
   Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434
   MILLER TE, 1992, CANCER RES, V52, P422
   Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8
NR 13
TC 26
Z9 30
U1 2
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 1
PY 2008
VL 14
IS 5
BP 1349
EP 1354
DI 10.1158/1078-0432.CCR-07-4110
PG 6
WC Oncology
SC Oncology
GA 268FR
UT WOS:000253565000012
PM 18316554
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Lozano, SC
   Hard, BM
   Tversky, B
AF Lozano, Sandra C.
   Hard, Bridgette Martin
   Tversky, Barbara
TI RETRACTED: Putting motor resonance in perspective (Retracted article.
   See vol. 110, pg. 123, 2009)
SO COGNITION
LA English
DT Article; Retracted Publication
DE perspective taking; embodied cognition; action understanding; language;
   motor resonance
ID LANGUAGE COMPREHENSION; MENTAL MODELS; SOCIAL-INTERACTION; FMRI;
   REPRESENTATIONS; PERCEPTION; SYSTEMS; MOTION; WORDS; RECOGNITION
AB Perceiving another person's actions changes the spatial perspective people use to describe objects in a scene, possibly because seeing human action induces people to map the actions, including their spatial context, to their own body and motor representations [Lozano, S. C., Hard, B. M., & Tversky, B. (2007). Putting action in perspective. Cognition 103, 480-490]. If so, then the effect of perceived action on perspective should be modulated by action experience. The present studies tested this prediction by showing participants a photograph and asking them to describe the location of one object relative to another. Across studies, adoption of the actor's perspective increased when participants saw actions that were more familiar or were performed with a limb (hand or foot) that observers had more experience performing actions with themselves. The present findings indicate that observers' experience performing observed actions influences their tendency to engage in self-other mapping, and consequently, their interpretations and descriptions of spatial scenes. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Lozano, Sandra C.; Hard, Bridgette Martin; Tversky, Barbara] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.
RP Lozano, SC (reprint author), Stanford Univ, Dept Psychol, Bldg 01-420,Jordan Hall, Stanford, CA 94305 USA.
EM scl@psych.stanford.edu
CR Baldwin J. M., 1895, MENTAL DEV CHILD RAC
   Barsalou LW, 1999, BEHAV BRAIN SCI, V22, P577
   Binkofski F, 2000, HUM BRAIN MAPP, V11, P273, DOI 10.1002/1097-0193(200012)11:4<273::AID-HBM40>3.0.CO;2-0
   Blakemore SJ, 2005, NEUROPSYCHOLOGIA, V43, P260, DOI 10.1016/j.neuropsychologia.2004.11.012
   Borghi AM, 2004, MEM COGNITION, V32, P863, DOI 10.3758/BF03196865
   BOWER GH, 1990, SCIENCE, V247, P44, DOI 10.1126/science.2403694
   Buccino G, 2005, COGNITIVE BRAIN RES, V24, P355, DOI 10.1016/j.cogbrainres.2005.02.020
   Buccino G, 2004, J COGNITIVE NEUROSCI, V16, P114, DOI 10.1162/089892904322755601
   Calvo-Merino B, 2005, CEREB CORTEX, V15, P1243, DOI 10.1093/cercor/bhi007
   Calvo-Merino B, 2006, CURR BIOL, V16, P1905, DOI 10.1016/j.cub.2006.07.065
   CARLSON LA, 2005, GROUNDING COGNITION, P35
   CARPENTER WB, 1974, PRINCIPLES MENTAL PH
   Chartrand TL, 1999, J PERS SOC PSYCHOL, V76, P893, DOI 10.1037/0022-3514.76.6.893
   Clark A, 2006, TRENDS COGN SCI, V10, P370, DOI 10.1016/j.tics.2006.06.012
   Connell L, 2007, COGNITION, V102, P476, DOI 10.1016/j.cognition.2006.02.009
   Costantini M, 2005, CEREB CORTEX, V15, P1761, DOI 10.1093/cercor/bhi053
   Cross ES, 2006, NEUROIMAGE, V31, P1257, DOI 10.1016/j.neuroimage.2006.01.033
   Darwin C, 1872, EXPRESSION EMOTIONS
   Dijkstra K, 2007, COGNITION, V102, P139, DOI 10.1016/j.cognition.2005.12.009
   Fadiga L, 2002, EUR J NEUROSCI, V15, P399, DOI 10.1046/j.0953-816x.2001.01874.x
   Flanagan JR, 2003, NATURE, V424, P769, DOI 10.1038/nature01861
   FRANKLIN N, 1990, J EXP PSYCHOL GEN, V119, P63, DOI 10.1037/0096-3445.119.1.63
   Gallese V, 2005, COGN NEUROPSYCHOL, V22, P455, DOI 10.1080/02643290442000310
   Glenberg AM, 2002, PSYCHON B REV, V9, P558, DOI 10.3758/BF03196313
   Glenberg AM, 1997, BEHAV BRAIN SCI, V20, P1
   GLENBERG AM, 1987, J MEM LANG, V26, P69, DOI 10.1016/0749-596X(87)90063-5
   GOLDMAN AI, 2002, SIMULATION KNOWLEDGE, P1
   Gordon R., 1986, MIND LANG, V1, P158, DOI DOI 10.1111/J.1468-0017.1986.TB00324.X
   Grafton ST, 1996, EXP BRAIN RES, V112, P103
   GREENWALD AG, 1970, PSYCHOL REV, V77, P73, DOI 10.1037/h0028689
   Grezes J, 2003, NEUROIMAGE, V18, P928, DOI 10.1016/S1053-8119(03)00042-9
   Harris PL, 1989, CHILDREN EMOTION DEV
   Hauk O, 2004, NEURON, V41, P301, DOI 10.1016/S0896-6273(03)00838-9
   JAMES W, 1990, PRINCIPLES PSYCHOLOG
   Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832
   Kaschak MP, 2005, COGNITION, V94, pB79, DOI 10.1016/j.cognition.2004.06.005
   KLATZKY RL, 1989, J MEM LANG, V28, P56, DOI 10.1016/0749-596X(89)90028-4
   LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279
   Lozano SC, 2007, COGNITION, V103, P480, DOI 10.1016/j.cognition.2006.04.010
   Martin M, 1998, MEM COGNITION, V26, P193, DOI 10.3758/BF03201132
   Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913
   Prinz W, 2006, CORTEX, V42, P515, DOI 10.1016/S0010-9452(08)70389-7
   Pulvermuller F, 2005, EUR J NEUROSCI, V21, P793, DOI 10.1111/j.1460-9568.2005.03900.x
   RIBOT TH, 1897, PSYCHOL EMOTIONS
   Richardson DC, 2003, COGNITIVE SCI, V27, P767, DOI 10.1016/S0364-0213(03)00064-8
   Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060
   Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230
   Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0
   RUBIN DC, 1983, MEM COGNITION, V11, P335, DOI 10.3758/BF03202446
   Smith A, 1759, THEORY MORAL SENTIME
   Sommerville JA, 2006, PSYCHON B REV, V13, P179, DOI 10.3758/BF03193831
   Stanfield RA, 2001, PSYCHOL SCI, V12, P153, DOI 10.1111/1467-9280.00326
   Stevens JA, 2000, NEUROREPORT, V11, P109, DOI 10.1097/00001756-200001170-00022
   TAYLOR HA, 1992, J MEM LANG, V31, P261, DOI 10.1016/0749-596X(92)90014-O
   Tettamanti M, 2005, J COGNITIVE NEUROSCI, V17, P273, DOI 10.1162/0898929053124965
   Tversky B., 2000, HDB MEMORY, P363
   Tversky B, 2005, HDB HIGHER LEVEL VIS, P1, DOI DOI 10.1017/CBO9780511610448.002
   Varela Francisco J, 1991, EMBODIED MIND COGNIT
   Wilson M, 2002, PSYCHON B REV, V9, P625, DOI 10.3758/BF03196322
   Wilson M, 2005, PSYCHOL BULL, V131, P460, DOI 10.1037/0033-2909.131.3.460
   Zwaan RA, 2002, PSYCHOL SCI, V13, P168, DOI 10.1111/1467-9280.00430
   Zwaan RA, 2006, J EXP PSYCHOL GEN, V135, P1, DOI 10.1037/0096-3445.135.1.1
   Zwaan RA, 2004, COGNITIVE SCI, V28, P611, DOI 10.1016/j.cogsci.2004.03.004
NR 63
TC 7
Z9 7
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0010-0277
EI 1873-7838
J9 COGNITION
JI Cognition
PD MAR
PY 2008
VL 106
IS 3
BP 1195
EP 1220
DI 10.1016/j.cognition.2007.05.014
PG 26
WC Psychology, Experimental
SC Psychology
GA 272GB
UT WOS:000253846800005
PM 17662266
DA 2018-12-27
ER

PT J
AU Shu, L
   Sauter, NS
   Schulthess, FT
   Matveyenko, AV
   Oberholzer, J
   Maedler, K
AF Shu, Luan
   Sauter, Nadine S.
   Schulthess, Fabienne T.
   Matveyenko, Aleksey V.
   Oberholzer, Jose
   Maedler, Kathrin
TI RETRACTED: Transcription factor 7-like 2 regulates beta-cell survival
   and function in human pancreatic islets(Retracted article. See vol. 66,
   pg. 1729, 2017)
SO DIABETES
LA English
DT Article; Retracted Publication
ID HUMAN PANCREATIC-ISLETS; INSULIN-SECRETION; INDUCED APOPTOSIS;
   GENE-EXPRESSION; TCF7L2; GLUCOSE; SUSCEPTIBILITY; POLYMORPHISMS; RISK;
   ASSOCIATION
AB OBJECTIVE-Type 2 diabetes is characterized by impaired insulin secretion in response to increased metabolic demand. This defect in beta-cell compensation seems to result from the interplay between environmental factors and genetic predisposition. Genome-wide association studies reveal that common variants in transcription factor 7-like 2 (TCF7L2) are associated with increased risk of type 2 diabetes. The aim of the present study was to establish whether TCF7L2 plays a role in P-cell function and/or survival.
   RESEARCH DESIGN AND METHODS-To investigate the effects of TCFL7L2 depletion, isolated islets were exposed to TCF7L2 small interfering RNA (siRNA) versus scrambled siRNA, and beta-cell survival and function were examined. For TCF7L2 overexpression, islets were cultured in glucose concentrations of 5.5-33.3 mmol/l and the cytokine mix interleukin-1 beta/gamma-interferon with or without overexpression of TCF7L2. Subsequently, glucose-stimulated insulin secretion (GSIS), P-cell apoptosis [by transferase-mediated dUTP nick-end labeling assay and Western blotting for poly(ADP-ribose) polymerase and Caspase-3 cleavage], and P-cell proliferation (by Ki67 immunostaining) were analyzed.
   RESULTS-Depleting TCF7L2 by siRNA resulted in a 5.1-fold increase in P-cell apoptosis, 2.2-fold decrease in beta-cell proliferation (P < 0.001), and 2.6-fold decrease in GSIS (P < 0.01) in human islets. Similarly, loss of TCF7L2 resulted in impaired P-cell function in mouse islets. In contrast, overexpression of TCF7L2 protected islets from glucose and cytokine-induced apoptosis and impaired function.
   CONCLUSIONS-TCF7L2 is required for maintaining GSIS and beta-cell survival. Changes in the level of active TCF7L2 in beta-cells from carriers of, at-risk allele may be the reason for defective insulin secretion and progression of type 2 diabetes.
C1 [Shu, Luan; Sauter, Nadine S.; Schulthess, Fabienne T.; Matveyenko, Aleksey V.; Maedler, Kathrin] Univ Calif Los Angeles, Larry L Hillblom Islet Res Ctr, Dept Med, Los Angeles, CA USA.
   [Oberholzer, Jose] Univ Calif Los Angeles, Div Transplantat, Los Angeles, CA USA.
RP Maedler, K (reprint author), Univ Bremen, Ctr Biomol Interact Bremen, NW2,Box 33 04 40, D-28334 Bremen, Germany.
EM kmaedler@uni-bremen.de
CR Aikin R, 2006, DIABETOLOGIA, V49, P2900, DOI 10.1007/s00125-006-0476-0
   Bernal-Mizrachi E, 2004, J CLIN INVEST, V114, P928, DOI 10.1172/JCI200420016
   Buchanan TA, 2003, CLIN THER, V25, pB32, DOI 10.1016/S0149-2918(03)80241-2
   Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102
   Cauchi S, 2006, DIABETES, V55, P2903, DOI 10.2337/db06-0474
   D'Alessandris C, 2004, FASEB J, V18, P959, DOI 10.1096/fj.03-0725fje
   Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501
   Elbein SC, 2007, DIABETOLOGIA, V50, P1621, DOI 10.1007/s00125-007-0717-x
   Florez JC, 2007, CURR OPIN CLIN NUTR, V10, P391, DOI 10.1097/MCO.0b013e3281e2c9be
   Florez JC, 2006, NEW ENGL J MED, V355, P241, DOI 10.1056/NEJMoa062418
   Freathy RM, 2007, AM J HUM GENET, V80, P1150, DOI 10.1086/518517
   G CN, 2006, DIABETES, V55, P2645
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Groves CJ, 2006, DIABETES, V55, P2640, DOI 10.2337/db06-0355
   KAISER N, 1991, ENDOCRINOLOGY, V129, P2067, DOI 10.1210/endo-129-4-2067
   Kaiser N, 2003, J PEDIATR ENDOCR MET, V16, P5, DOI 10.1515/JPEM.2003.16.1.5
   Katoh M, 2005, INT J MOL MED, V16, P1103
   Kwan EP, 2005, DIABETES, V54, P2734, DOI 10.2337/diabetes.54.9.2734
   Li L, 2005, DIABETOLOGIA, V48, P1339, DOI 10.1007/s00125-005-1787-2
   Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774
   Lyssenko V, 2007, J CLIN INVEST, V117, P2155, DOI 10.1172/JC130706
   Maedler K, 2004, DIABETES, V53, P1706, DOI 10.2337/diabetes.53.7.1706
   MAEDLER K, 2007, IN PRESS DIABETES OB
   Maedler K, 2006, DIABETES, V55, P2713, DOI 10.2337/db05-1430
   Maedler K, 2006, DIABETES, V55, P2455, DOI 10.2337/db05-1586
   MONTROSERAFIZADEH C, 1994, ENDOCRINOLOGY, V135, P589, DOI 10.1210/en.135.2.589
   Oberholzer J, 2000, TRANSPLANTATION, V69, P1115, DOI 10.1097/00007890-200003270-00016
   PARTON IE, 2006, AM J PHYSIOL-ENDOC M, V291, pE982
   Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345
   ROBERTSON RP, 1989, DIABETES, V38, P1501, DOI 10.2337/diabetes.38.12.1501
   Saxena R, 2006, DIABETES, V55, P2890, DOI 10.2337/db06-0381
   Schafer SA, 2007, DIABETOLOGIA, V50, P2443, DOI 10.1007/s00125-007-0753-6
   Schumann DM, 2007, P NATL ACAD SCI USA, V104, P2861, DOI 10.1073/pnas.0611487104
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Smith U, 2007, DIABETOLOGIA, V50, P5, DOI 10.1007/s00125-006-0521-z
   Song SH, 2002, J CLIN ENDOCR METAB, V87, P213, DOI 10.1210/jc.87.1.213
   Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968
   Topp B, 2000, J THEOR BIOL, V206, P605, DOI 10.1006/jtbi.2000.2150
   Yi FH, 2005, J BIOL CHEM, V280, P1457, DOI 10.1074/jbc.M411487200
NR 39
TC 188
Z9 204
U1 5
U2 17
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD MAR
PY 2008
VL 57
IS 3
BP 645
EP 653
DI 10.2337/db07-0847
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 271PJ
UT WOS:000253800900019
PM 18071026
OA Bronze
DA 2018-12-27
ER

PT J
AU Csoma, H
   Sipiczki, M
AF Csoma, Hajnalka
   Sipiczki, Matthias
TI RETRACTED: Taxonomic reclassification of Candida stellata strains
   reveals frequent occurrence of Candida zemplinina in wine fermentation
   (Retracted article. See vol 8, pg. 509, 2008)
SO FEMS YEAST RESEARCH
LA English
DT Article; Retracted Publication
DE Candida taxonomy; wine yeast; LSU rRNA gene; ITS; chromosome
   polymorphism
ID YEAST POPULATION-DYNAMICS; BOTRYTIS-AFFECTED WINE;
   SACCHAROMYCES-CEREVISIAE; ENOLOGICAL PROPERTIES; GRAPE; CELLS;
   DIVERSITY; EVOLUTION; GROWTH; REGION
AB Yeasts identified as Candida stellata are frequently associated with overripe and botrytized grapes and can survive in the fermenting must until the completion of vinification. The molecular taxonomic examination of 41 strains deposited in six culture collections or described in the literature as C. stellata revealed that most of those isolated from grapes or wines belonged to Candida zemplinina and related species. This confusion around the taxonomic position of the strains may account for the rather controversial descriptions of the oenological properties of C. stellata in the literature. Because the authors did not find it among strains newly isolated from botrytized grapes and wines, it was proposed that it is usually C. zemplinina rather than C. stellata that occurs on grapes and in wine fermentation.
C1 [Csoma, Hajnalka; Sipiczki, Matthias] Univ Debrecen, Dept Genet & Appl Microbiol, H-4010 Debrecen, Hungary.
RP Sipiczki, M (reprint author), Univ Debrecen, Dept Genet & Appl Microbiol, POB 56, H-4010 Debrecen, Hungary.
EM lipovy@tigris.unideb.hu
CR Antunovics Z., 2003, Bulletin de l'O.I.V., V76, P380
   Barbe JC, 2001, J APPL MICROBIOL, V90, P34, DOI 10.1046/j.1365-2672.2001.01200.x
   Ciani M, 1996, APPL ENVIRON MICROB, V62, P128
   Ciani M, 1998, WORLD J MICROB BIOT, V14, P199, DOI 10.1023/A:1008825928354
   Ciani M, 1998, J APPL MICROBIOL, V85, P247, DOI 10.1046/j.1365-2672.1998.00485.x
   Ciani M, 2000, ENZYME MICROB TECH, V27, P698, DOI 10.1016/S0141-0229(00)00269-6
   Clemente-Jimenez JM, 2004, FOOD MICROBIOL, V21, P149, DOI 10.1016/S0740-0020(03)00063-7
   Combina M, 2005, INT J FOOD MICROBIOL, V99, P237, DOI 10.1016/j.iifoodmicro.2004.08.017
   Constanti M, 1997, AM J ENOL VITICULT, V48, P339
   Coton E, 2006, INT J FOOD MICROBIOL, V108, P130, DOI 10.1016/j.ijfoodmicro.2005.10.016
   CUOTO MMB, 2005, INT J FOOD MICROBIOL, V102, P49
   Divol B, 2005, J APPL MICROBIOL, V99, P85, DOI 10.1111/j.1365-2672.2005.02578.x
   Fernandez MT, 1999, FEMS MICROBIOL LETT, V173, P223, DOI 10.1016/S0378-1097(99)00078-6
   Ferraro L, 2000, PROCESS BIOCHEM, V35, P1125, DOI 10.1016/S0032-9592(00)00148-5
   FLEET GH, 1984, APPL ENVIRON MICROB, V48, P1034
   Hierro N, 2006, FEMS YEAST RES, V6, P102, DOI 10.1111/j.1567-1364.2005.00014.x
   HOLLOWAY P, 1990, CAN I FOOD SC TECH J, V23, P212, DOI 10.1016/S0315-5463(90)70245-3
   HOLLOWAY P, 1992, FOOD RES INT, V25, P147, DOI 10.1016/0963-9969(92)90157-Z
   Kurtzman C. P., 1998, YEASTS TAXONOMIC STU
   LACHANCE MA, 1995, J IND MICROBIOL, V14, P484, DOI 10.1007/BF01573963
   Lachance MA, 2001, FEMS YEAST RES, V1, P1
   LODDER J, 1952, YEASTS TAXONOMIC STU
   Loureiro V, 2003, INT J FOOD MICROBIOL, V86, P23, DOI 10.1016/S0168-1605(03)00246-0
   Mills DA, 2002, APPL ENVIRON MICROB, V68, P4884, DOI 10.1128/AEM.68.10.4884-4893.2002
   Minarik E., 1982, WEIN WISSEN, V3, P187
   MORA J, 1990, AM J ENOL VITICULT, V41, P156
   Nielsen DS, 2007, INT J FOOD MICROBIOL, V114, P168, DOI 10.1016/j.ijfoodmicro.2006.09.010
   Nielsen DS, 2005, YEAST, V22, P271, DOI 10.1002/yea.1207
   PARDO I, 1989, APPL ENVIRON MICROB, V55, P539
   PHAFF H. J., 1956, ANTONIE VAN LEEUWENHOEK JOUR MICROBIOL AND SEROL, V22, P145, DOI 10.1007/BF02538322
   POVHE JK, 2005, FOOD MICROBIOL, V22, P293
   Puig S, 2000, APPL ENVIRON MICROB, V66, P2057, DOI 10.1128/AEM.66.5.2057-2061.2000
   RIJ NJW, 1984, YEASTS TAXONOMIC STU
   Rosa CA, 1998, INT J SYST BACTERIOL, V48, P1413, DOI 10.1099/00207713-48-4-1413
   ROSINI G, 1982, MICROBIAL ECOL, V8, P83, DOI 10.1007/BF02011464
   Sipiczki M, 2005, FOLIA MICROBIOL, V50, P494, DOI 10.1007/BF02931436
   Sipiczki M, 2004, J BASIC MICROB, V44, P471, DOI 10.1002/jobm.200410449
   Sipiczki M, 2001, METH BIOTEC, V14, P273
   Sipiczki M, 2003, INT J SYST EVOL MICR, V53, P2079, DOI 10.1099/ijs.0.02649-0
   Soden A., 2000, Australian Journal of Grape and Wine Research, V6, P21, DOI 10.1111/j.1755-0238.2000.tb00158.x
   SOLES RM, 1982, AM J ENOL VITICULT, V33, P94
   Solieri L, 2006, J APPL MICROBIOL, V101, P63, DOI 10.1111/j.1365-2672.2006.02906.x
   Torija MJ, 2001, ANTON LEEUW INT J G, V79, P345, DOI 10.1023/A:1012027718701
   VANDERWALT JP, 1984, METHODS ISOLATION MA, P45
   Xufre A, 2006, INT J FOOD MICROBIOL, V108, P376, DOI 10.1016/j.ijfoodmicro.2006.01.025
NR 45
TC 58
Z9 60
U1 4
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1567-1356
EI 1567-1364
J9 FEMS YEAST RES
JI FEMS Yeast Res.
PD MAR
PY 2008
VL 8
IS 2
BP 328
EP 336
DI 10.1111/j.1567-1364.2007.00339.x
PG 9
WC Biotechnology & Applied Microbiology; Microbiology; Mycology
SC Biotechnology & Applied Microbiology; Microbiology; Mycology
GA 259UK
UT WOS:000252966200015
PM 18179579
OA Bronze
DA 2018-12-27
ER

PT J
AU Boran, MS
   Baltrons, MA
   Garcia, A
AF Boran, Mariela Susana
   Baltrons, Maria Antonia
   Garcia, Agustina
TI RETRACTED: The ANP-cGMP-protein kinase G pathway induces a phagocytic
   phenotype but decreases inflammatory gene expression in microglial cells
   (Retracted article. See vol. 56, pg. NIL_0001, 2008)
SO GLIA
LA English
DT Article; Retracted Publication
DE actin; Rho GTPases; NOS-2; TNF-alpha; glia
ID ATRIAL-NATRIURETIC-PEPTIDE; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE
   SYNTHASE; RHO-GTPASES; CYCLIC-GMP; ASTROCYTE COCULTURES; ACTIN
   CYTOSKELETON; RAMIFIED MICROGLIA; RAT HIPPOCAMPUS; NO/CGMP PATHWAY
AB Reactive gliosis is a prominent feature of CNS injury that involves dramatic changes in glial cell morphology together with increased motility, phagocytic activity, and release of inflammatory mediators. We have recently demonstrated that stimulation of the cGMP-protein kinase G (PKG) pathway by NO or atrial natriuretic peptide (ANP) regulates cytoskeleton dynamics and motility in rat astrocytes in culture. In this work, we show that the cGMP-PKG pathway stimulated by ANP, but not by NO, regulates microglial cell morphology by inducing a dramatic reorganization in the actin cytoskeleton. Both ANP (0.01-1.0 mu M) and the permeable cGMP analog, dibutyryl-cGMP (1-100 mu M), promote a rapid (maximal at 30 min) and concentration-dependent increase in size, rounding, and lamellipodia and filopodia formation in rat brain cultured microglia. These morphological changes involve an augment and redistribution of Factin and result in increased phagocytic activity. ANP-induced rearrangements in actin cytoskeleton and inert particle phagocytosis are prevented by the PKG inhibitor, Rp-8-Br-PET-cGMPS (0.5 mu M), and involve inhibition of RhoA GTPase and activation of Rac1 and Cdc42. However, ANP does not induce NO synthase Type 2 (NOS-2) or tumor necrosis factor-a expression and is able to decrease lipopolysaccharide (LPS)-elicited induction of these inflammatory genes. The morphological changes and the decrease of LPS-induced NOS-2 expression produced by ANP in cultured microglia are also observed by immunostaining in organotypic cultures from rat hippocampus. These results suggest that stimulation of the ANP-cGMP-PKG pathway in microglia could play a beneficial role in the resolution of neuroinflammation by removing dead cells and decreasing levels of proinflammatory mediators. (c) 2008 Wiley-Liss, Inc.
C1 [Boran, Mariela Susana; Baltrons, Maria Antonia; Garcia, Agustina] Univ Autonoma Barcelona, Inst Biotechnol & Bio Med, E-08193 Barcelona, Spain.
   [Baltrons, Maria Antonia; Garcia, Agustina] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain.
RP Garcia, A (reprint author), Univ Autonoma Barcelona, Inst Biotechnol & Bio Med, E-08193 Barcelona, Spain.
EM agustina.garcia@uab.es
OI Garcia, Agustina/0000-0001-7359-264X
CR ABDELBASSET E, 1995, J NEUROSCI RES, V41, P222, DOI 10.1002/jnr.490410210
   Abraham H, 2001, BRAIN RES, V906, P115, DOI 10.1016/S0006-8993(01)02569-0
   Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593
   AGULLO L, 1995, BRAIN RES, V686, P160, DOI 10.1016/0006-8993(95)00486-A
   Allen WE, 1997, J CELL SCI, V110, P707
   Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106
   Baltrons MA, 1997, J NEUROSCI RES, V49, P333
   Baltrons MA, 1999, J NEUROCHEM, V73, P2149
   Begum N, 2002, DIABETES, V51, P2256, DOI 10.2337/diabetes.51.7.2256
   Bohatschek M, 2001, J NEUROSCI RES, V64, P508, DOI 10.1002/jnr.1103
   Boran MS, 2007, J NEUROCHEM, V102, P216, DOI 10.1111/j.1471-4159.2007.04464.x
   Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717
   Choi SH, 2002, J NEUROSCI RES, V67, P411, DOI 10.1002/jnr.10102
   Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487
   Dello Russo C, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-9
   DEVENTE J, 1989, BRAIN RES, V504, P332, DOI 10.1016/0006-8993(89)91380-2
   DEVENTE J, 2000, HAND CHEM N, V17, P355
   Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943
   ERWIG LP, 2007, IN PRESS CELL DEATH, DOI DOI 10.1038/SJ.CCD.4402184
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Feinstein DL, 2002, NEUROCHEM INT, V41, P357, DOI 10.1016/S0197-0186(02)00049-9
   Fryer BH, 2006, J BIOL CHEM, V281, P11487, DOI 10.1074/jbc.M600279200
   Furst R, 2005, CIRC RES, V96, P43, DOI 10.1161/01.RES.0000151983.01148.06
   GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945
   Ghafouri M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-28
   Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219
   Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200
   Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609
   Kalla R, 2003, GLIA, V41, P50, DOI 10.1002/glia.10176
   Ke XC, 2001, BBA-MOL CELL RES, V1539, P101, DOI 10.1016/S0167-4889(01)00090-8
   Kiemer AK, 1998, J BIOL CHEM, V273, P13444, DOI 10.1074/jbc.273.22.13444
   Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562
   Kim YS, 2006, EXP MOL MED, V38, P333, DOI 10.1038/emm.2006.40
   Kloss CUA, 2001, EXP NEUROL, V168, P32, DOI 10.1006/exnr.2000.7575
   Krepinsky JC, 2003, J AM SOC NEPHROL, V14, P2790, DOI 10.1097/01.ASN.0000094085.04161.A7
   Krzan M, 2003, J NEUROSCI, V23, P1580
   Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1
   Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685
   Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219
   Minghetti L, 2005, BRAIN RES REV, V48, P251, DOI 10.1016/j.brainresrev.2004.12.015
   Moriyama N, 2006, BIOCHEM BIOPH RES CO, V350, P322, DOI 10.1016/j.bbrc.2006.09.034
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Nogami M, 2001, HISTOCHEM J, V33, P87, DOI 10.1023/A:1017996113871
   Paris D, 1999, EXP NEUROL, V157, P211, DOI 10.1006/exnr.1999.7055
   Paris D, 2000, NEUROSCI LETT, V278, P5, DOI 10.1016/S0304-3940(99)00901-5
   Perez-Sala D, 2001, AM J PHYSIOL-RENAL, V280, pF466
   Pilz RB, 2005, FRONT BIOSCI, V10, P1239, DOI 10.2741/1616
   Potucek YD, 2006, NEUROCHEM INT, V49, P204, DOI 10.1016/j.neuint.2006.04.005
   Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21
   Roy A, 2006, J BIOL CHEM, V281, P14971, DOI 10.1074/jbc.M600236200
   Sandu OA, 2001, J APPL PHYSIOL, V91, P1475
   Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274
   Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200
   Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200
   Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194
   Sola C, 2002, EUR J NEUROSCI, V16, P1275, DOI 10.1046/j.1460-9568.2002.02199.x
   STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M
   Streit WJ, 2005, BRAIN RES REV, V48, P234, DOI 10.1016/j.brainresrev.2004.12.013
   STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209
   Teunissen CE, 2000, DEV BRAIN RES, V125, P99, DOI 10.1016/S0165-3806(00)00128-0
   Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200
   Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24
   Townsend KP, 2005, EUR J IMMUNOL, V35, P901, DOI 10.1002/eji.200425585
   van Staveren WCG, 2004, EUR J NEUROSCI, V19, P2155, DOI 10.1111/j.1460-9568.2004.03327.x
   Vollmar AM, 2005, PEPTIDES, V26, P1086, DOI 10.1016/j.peptides.2004.08.034
   Vollmar AM, 1997, EUR J PHARMACOL, V319, P279, DOI 10.1016/S0014-2999(96)00859-X
   Wiggins AK, 2003, NEUROSCIENCE, V118, P715, DOI 10.1016/S0306-4522(03)00006-X
   Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484
   ZAMIR N, 1986, BRAIN RES, V365, P105, DOI 10.1016/0006-8993(86)90727-4
NR 71
TC 19
Z9 19
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-1491
EI 1098-1136
J9 GLIA
JI Glia
PD MAR
PY 2008
VL 56
IS 4
BP 394
EP 411
DI 10.1002/glia.20618
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 264GZ
UT WOS:000253277100004
PM 18186083
DA 2018-12-27
ER

PT J
AU Osonnaya, C
   Osonnaya, K
   Swain, P
AF Osonnaya, C.
   Osonnaya, K.
   Swain, P.
TI RETRACTED: Effect of Helicobacter pylori eradication on dyspepsia,
   quality of life and utilisation of health care resources in the Eastern
   England Helicobacter Pylori project: randomised control trial (Retracted
   Article)
SO GUT
LA English
DT Correction; Retracted Publication
CR Osonnaya C, 2005, GUT, V54, pA85
NR 1
TC 0
Z9 0
U1 6
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAR
PY 2008
VL 57
IS 3
BP 427
EP 427
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 261OV
UT WOS:000253090800029
DA 2018-12-27
ER

PT J
AU Osonnaya, C
   Osonnaya, K
   Abdi, M
AF Osonnaya, C.
   Osonnaya, K.
   Abdi, M.
TI RETRACTED: Effect of Helicobacter pylori eradication on dyspepsia,
   quality of life and utilisation of health care resources in the Eastern
   England Helicobacter Pylori project: randomised control trial (Retracted
   Article)
SO GUT
LA English
DT Correction; Retracted Publication
CR MURRAY JA, 2006, BMJ-BRIT MED J, V332, P199
   Osonnaya C, 2007, GUT, V56, pA16
NR 2
TC 0
Z9 0
U1 6
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAR
PY 2008
VL 57
IS 3
BP 427
EP 427
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 261OV
UT WOS:000253090800028
DA 2018-12-27
ER

PT J
AU Libby, R
   Hunton, JE
   Tan, HT
   Seybert, N
AF Libby, Robert
   Hunton, James E.
   Tan, Hun-Tong
   Seybert, Nicholas
TI RETRACTED: Relationship incentives and the optimistic/pessimistic
   pattern in analysts' forecasts (Retracted article. See vol. 53, pg. 911,
   2015)
SO JOURNAL OF ACCOUNTING RESEARCH
LA English
DT Article; Retracted Publication
ID EARNINGS FORECASTS; SECURITY ANALYSTS; RECOMMENDATIONS; EXPECTATIONS;
   ACCURACY; PERFORMANCE; MANAGEMENT; GUIDANCE; BIAS
AB We examine whether analysts' incentives to maintain good relationships with management contribute to the optimistic/pessimistic within-period time trend in analysts' forecasts. In our experiments, 81 experienced sell-side analysts from two brokerage firms predict earnings based on historical information and management guidance. Analysts' forecasts exhibit an optimistic/pessimistic pattern across the two timing conditions (early and late in the quarter), and the effect is significantly stronger when the analysts have a good relationship with management than when their only incentive is to be accurate. Debriefing results indicate that analysts are aware of this pattern of forecasts, and believe that this benefits their future relationships with management and with brokerage clients. The analysts most frequently cite favored conference call participation and information access when describing benefits from maintaining good relationships with management. Our results suggest the following: The optimistic/pessimistic pattern in forecasts is in part a conscious response to relationship incentives, information access is perceived to be a major benefit of management relationships, and recent regulatory changes may have lessened but have not eliminated this conflict of interest source.
C1 [Libby, Robert; Seybert, Nicholas] Cornell Univ, Ithaca, NY 14853 USA.
   [Hunton, James E.] Univ Maastricht, Maastricht, Netherlands.
   [Hunton, James E.] Bentley Coll, Waltham, MA 02154 USA.
   [Tan, Hun-Tong] Nanyang Technol Univ, Singapore 639798, Singapore.
RP Libby, R (reprint author), Cornell Univ, Ithaca, NY 14853 USA.
CR Affleck-Graves John, 1990, CONTEMP ACCOUNT RES, V6, P501
   Baik B., 2006, J ACCOUNTING PUBLIC, V25, P531, DOI DOI 10.1016/J.JACCPUBPOL.2006.07.006
   Bartov E, 2002, J ACCOUNT ECON, V33, P173, DOI 10.1016/S0165-4101(02)00045-9
   BROWN L, 1997, FINANCIAL ANAL J, V53, P81, DOI DOI 10.2469/FAJ.V53.N6.2133
   BROWN LD, 1987, J ACCOUNT ECON, V9, P61, DOI 10.1016/0165-4101(87)90017-6
   Brown LD, 2001, FINANC ANAL J, V57, P44, DOI 10.2469/faj.v57.n6.2492
   Brown LD, 2001, J ACCOUNTING RES, V39, P221, DOI 10.1111/1475-679X.00010
   Chen SP, 2006, J ACCOUNTING RES, V44, P657, DOI 10.1111/j.1475-679X.2006.00217.x
   Clement MB, 1999, J ACCOUNT ECON, V27, P285, DOI 10.1016/S0165-4101(99)00013-0
   Cotter J, 2006, CONTEMP ACCOUNT RES, V23, P593, DOI 10.1506/FJ4D-04UN-68T7-R8CA
   Cowen A, 2006, J ACCOUNT ECON, V41, P119, DOI 10.1016/j.jacceco.2005.09.001
   COX C, 2005, RESPONSE LETT SENATO
   Eames M, 2002, J ACCOUNTING RES, V40, P85, DOI 10.1111/1475-679X.00040
   Eames MJ, 2006, BEHAV RES ACCOUNT, V18, P37, DOI 10.2308/bria.2006.18.1.37
   Easterwood JC, 1999, J FINANC, V54, P1777, DOI 10.1111/0022-1082.00166
   Gefen D., 2005, J ACCOUNTING LIT, V16, P91
   Hunton JE, 1997, ACCOUNT REV, V72, P497
   Hutton AP, 2005, CONTEMP ACCOUNT RES, V22, P867, DOI 10.1506/6QUR-CR5M-AQQX-KX1A
   Jacob J, 1999, J ACCOUNT ECON, V28, P51, DOI 10.1016/S0165-4101(99)00016-6
   Ke B, 2006, J ACCOUNTING RES, V44, P965, DOI 10.1111/j.1475.679X.2006.00221.x
   Koonce L., 2005, J ACCOUNTING LIT, V24, P175
   Libby R, 2002, ACCOUNT ORG SOC, V27, P777
   Lin HW, 1998, J ACCOUNT ECON, V25, P101, DOI 10.1016/S0165-4101(98)00016-0
   MAYEW WJ, IN PRESS J ACCOUNTIN
   Michaely R, 1999, REV FINANC STUD, V12, P653, DOI 10.1093/rfs/12.4.653
   Mikhail MB, 1997, J ACCOUNTING RES, V35, P131, DOI 10.2307/2491458
   Mohanram PS, 2006, CONTEMP ACCOUNT RES, V23, P491, DOI 10.1506/7H81-8J8X-C6RT-UVJP
   O'Brien PC, 2005, J ACCOUNTING RES, V43, P623, DOI 10.1111/j.1475-679X.2005.00184.x
   OBRIEN PC, 1988, J ACCOUNT ECON, V10, P53, DOI 10.1016/0165-4101(88)90023-7
   Richardson S, 2004, CONTEMP ACCOUNT RES, V21, P885, DOI 10.1506/KHNW-PJYL-ADUB-0RP6
   Schipper K., 1991, ACCOUNT HORIZ, V5, P105
   Tan HT, 2002, J ACCOUNT RES, V40, P223, DOI 10.1111/1475-679X.00045
NR 32
TC 39
Z9 39
U1 3
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8456
EI 1475-679X
J9 J ACCOUNT RES
JI J. Account. Res.
PD MAR
PY 2008
VL 46
IS 1
BP 173
EP 198
DI 10.1111/j.1475-679X.2007.00265.x
PG 26
WC Business, Finance
SC Business & Economics
GA 252GB
UT WOS:000252433900006
DA 2018-12-27
ER

PT J
AU Li, HL
   Liu, C
   de Couto, G
   Ouzounian, M
   Sun, M
   Wang, AB
   Huang, Y
   He, CW
   Shi, Y
   Chen, X
   Nghiem, MP
   Liu, YA
   Chen, MY
   Dawood, F
   Fukuoka, M
   Maekawa, Y
   Zhang, LY
   Leask, A
   Ghosh, AK
   Kirshenbaum, LA
   Liu, PP
AF Li, Hong-Liang
   Liu, Chen
   de Couto, Geoffrey
   Ouzounian, Maral
   Sun, Mei
   Wang, Ai-Bing
   Huang, Yue
   He, Cheng-Wei
   Shi, Yu
   Chen, Xin
   Nghiem, Mai P.
   Liu, Youan
   Chen, Manyin
   Dawood, Fayez
   Fukuoka, Masahiro
   Maekawa, Yuichiro
   Zhang, Liyong
   Leask, Andrew
   Ghosh, Asish K.
   Kirshenbaum, Lorrie A.
   Liu, Peter P.
TI RETRACTED: Curcumin prevents and reverses murine cardiac hypertrophy
   (Retracted article. See vol 119, pg 2113, 2009)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID HISTONE ACETYLTRANSFERASE ACTIVITY; PRESSURE-OVERLOAD;
   MYOCARDIAL-INFARCTION; GENE-EXPRESSION; ANGIOTENSIN-II; HEART-FAILURE;
   IN-VIVO; KAPPA-B; P300; ACETYLATION
AB Chromatin remodeling, particularly histone acetylation, plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. We hypothesized that curcumin, a natural polyphenolic compound abundant in the spice turmeric and a known suppressor of histone acetylation, would suppress cardiac hypertrophy through the disruption of p300 histone acetyltransferase-dependent (p300-HAT-dependent) transcriptional activation. We tested this hypothesis using primary cultured rat cardiac myocytes and fibroblasts as wen as two well-established mouse models of cardiac hypertrophy. Curcumin blocked phenylephrin-induced (PE-induced) cardiac hypertrophy in vitro in a dose-dependent manner. Furthermore, curcumin both prevented and reversed mouse cardiac hypertrophy induced by aortic banding (AB) and PE infusion, as assessed by heart weight/BW and lung weight/BW ratios, echocardiographic parameters, and gene expression of hypertrophic markers. Further investigation demonstrated that curcumin abrogated histone acetylation, GATA4 acetylation, and DNA-binding activity through blocking p300-HAT activity. Curcumin also blocked AB-induced inflammation and fibrosis through disrupting p300-HAT-dependent signaling pathways. Our results indicate that curcumin has the potential to protect against cardiac hypertrophy, inflammation, and fibrosis through suppression of p300-HAT activity and downstream GATA4, NF-kappa B, and TGF-beta-Smad signaling pathways.
C1 [Li, Hong-Liang; Liu, Chen; de Couto, Geoffrey; Ouzounian, Maral; Sun, Mei; Shi, Yu; Chen, Xin; Nghiem, Mai P.; Liu, Youan; Chen, Manyin; Dawood, Fayez; Fukuoka, Masahiro; Maekawa, Yuichiro; Zhang, Liyong; Liu, Peter P.] Univ Toronto, Univ Hlth Network, Heart & Stroke Richard Lewar Ctr Excellence, Div Cardiol, Toronto, ON, Canada.
   [Wang, Ai-Bing] NHLBI, NIH, Mol Cardiol Lab, Bethesda, MD 20892 USA.
   [Huang, Yue] Wellcome Trust Genome Campus, Cambridge, England.
   [Huang, Yue] Sanger Inst, Cambridge, England.
   [He, Cheng-Wei] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [He, Cheng-Wei] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Leask, Andrew] Univ Western Ontario, Schulich Sch Med & Dent, CIHR Grp Skeletal Dev & Remodeling, Div Oral Biol, London, ON, Canada.
   [Leask, Andrew] Univ Western Ontario, Schulich Sch Med & Dent, CIHR Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON, Canada.
   [Ghosh, Asish K.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA.
   [Kirshenbaum, Lorrie A.] St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada.
   [Liu, Peter P.] Canadian Inst Hlth Res, Inst Circulatory & Resp Hlth, Ottawa, ON, Canada.
RP Liu, PP (reprint author), Toronto Gen Hosp, CIHR, NCSB 11-1266,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
EM peter.liu@utoronto.ca
CR Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Berk BC, 2007, J CLIN INVEST, V117, P568, DOI 10.1172/JCI31044
   Bhattacharyya S, 2005, ARTHRITIS RHEUM, V52, P1248, DOI 10.1002/art.20996
   Bisping E, 2006, P NATL ACAD SCI USA, V103, P14471, DOI 10.1073/pnas.0602543103
   Chan HM, 2001, J CELL SCI, V114, P2363
   Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7
   Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017
   Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200
   Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200
   Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178
   Dubey RK, 1998, HYPERTENSION, V31, P943, DOI 10.1161/01.HYP.31.4.943
   Epstein JA, 2005, CIRCULATION, V112, P592, DOI 10.1161/CIRCULATIONAHA.104.479857
   Fedak PWM, 2004, CIRCULATION, V110, P2401, DOI 10.1161/01.CIR.0000134959.83967.2D
   Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200
   Gong J, 2006, ONCOGENE, V25, P2011, DOI 10.1038/sj.onc.1209231
   Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200
   Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983
   Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006
   Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200
   Kawamura T, 2005, J BIOL CHEM, V280, P19682, DOI 10.1074/jbc.M41248200
   Kook H, 2003, TRENDS CARDIOVAS MED, V13, P261, DOI 10.1016/S1050-1738(03)00107-5
   Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137
   Kuster GM, 2005, CIRCULATION, V111, P420, DOI 10.1161/01.CIR.0000153800.09920.40
   Lebeche D, 2004, CIRCULATION, V110, P3435, DOI 10.1161/01.CIR.0000148176.33730.3F
   Li HL, 2005, FREE RADICAL BIO MED, V38, P243, DOI 10.1016/j.freeradbiomed.2004.10.020
   Li HL, 2007, HYPERTENSION, V49, P1399, DOI 10.1161/HYPERTENSIONAHA.106.085399
   Li HL, 2007, CIRCULATION, V115, P1885, DOI 10.1161/CIRCULATIONAHA.106.656835
   Li HL, 2007, J CELL BIOCHEM, V100, P1086, DOI 10.1002/jcb.21197
   Li HL, 2006, FREE RADICAL BIO MED, V40, P1756, DOI 10.1016/j.freeradbiomed.2006.01.005
   MacPartlin M, 2005, J BIOL CHEM, V280, P30604, DOI 10.1074/jbc.M503352200
   Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007
   Mai A, 2006, J MED CHEM, V49, P6897, DOI 10.1021/jm060601m
   Miquel J, 2002, ARCH GERONTOL GERIAT, V34, P37, DOI 10.1016/S0167-4943(01)00194-7
   Miyamoto S, 2006, CIRCULATION, V113, P679, DOI 10.1161/CIRCULATIONAHA.105.585182
   Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa
   Perkins S, 2002, CANCER EPIDEM BIOMAR, V11, P535
   SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Sun M, 2007, CIRCULATION, V115, P1398, DOI 10.1161/CIRCULATIONAHA.106.643585
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552
   Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003
   Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4
   Zeisberg EM, 2005, J CLIN INVEST, V115, P1522, DOI 10.1172/JCI23769
NR 45
TC 93
Z9 103
U1 5
U2 24
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2008
VL 118
IS 3
BP 879
EP 893
DI 10.1172/JCI32865
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 269JX
UT WOS:000253646400013
PM 18292803
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, ZH
   Zhang, T
   Dai, HY
   Liu, GH
   Wang, HB
   Sun, YY
   Zhang, Y
   Ge, ZM
AF Li, Zhenhua
   Zhang, Tao
   Dai, Hongyan
   Liu, Guanghui
   Wang, Haibin
   Sun, Yingying
   Zhang, Yun
   Ge, Zhiming
TI RETRACTED: Endoplasmic reticulum stress is involved in myocardial
   apoptosis of streptozocin-induced diabetic rats (Retracted Article. See
   vol 207, pg 123, 2010)
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID UNFOLDED PROTEIN RESPONSE; ATRIAL-NATRIURETIC-PEPTIDE; INDUCED OXIDATIVE
   STRESS; CELL-DEATH; VENTRICULAR MYOCYTES; INTRACELLULAR CA2+; INTRINSIC
   PATHWAY; BETA-CELLS; CARDIOMYOPATHY; DYSFUNCTION
AB Apoptosis plays a critical role in the diabetic cardiomyopathy, and endoplasmic reticulum stress (ERS) is one of the intrinsic apoptosis pathways. Previous studies have shown that the endoplasmic reticulum becomes swollen and dilated in diabetic myocardium, and ERS is involved in heart failure and diabetic kidney. This study is aimed to demonstrate whether ERS is induced in myocardium of streptozotocin (STZ)-induced diabetic rats. We established a type 1 diabetic rat model, used echocardiographic evaluation, hematoxylin-eosin staining, and the terminal deoxynucleotidyl transferase-mediated DNA nick-end labeling staining to identity the existence of diabetic cardiomyopathy and enhanced apoptosis in the diabetic heart. We performed immunohistochemistry, western blot, and real-time PCR to analyze the hallmarks of ERS that include glucose-regulated protein 78, CCAAT/enhancer-binding protein homologous protein (CHOP) and caspase12. We found these hallmarks to have enhanced expression in protein and mRNA levels in diabetic myocardium. Also, another pathway that can lead to cell death of EKS, c-jun NH2-terminal kinase-dependent pathway, was also activated in diabetic heart. Those results suggested that ERS was induced in STZ-induced diabetic rats' myocardium, and ERS-associated apoptosis occurred in the pathophysiology of diabetic cardiomyopathy.
C1 [Li, Zhenhua; Liu, Guanghui; Wang, Haibin; Sun, Yingying; Zhang, Yun; Ge, Zhiming] Qilu Hosp Shandong Univ, Dept Cardiol, Key Lab Cardiovasc Remodeling & Funct Res, Minist Educ, Jinan 250012, Peoples R China.
   [Li, Zhenhua; Liu, Guanghui; Wang, Haibin; Sun, Yingying; Zhang, Yun; Ge, Zhiming] Minist Hlth, Jinan 250012, Peoples R China.
   [Zhang, Tao] Shandong Univ, Sch Med, Jinan Ctr Hosp, Dept Orthoped, Jinan 250012, Shandong, Peoples R China.
   [Dai, Hongyan] Qingdao Muncipal Hosp, Dept Cardiol, Qingdao 266021, Shandong, Peoples R China.
RP Ge, ZM (reprint author), Qilu Hosp Shandong Univ, Dept Cardiol, Key Lab Cardiovasc Remodeling & Funct Res, Minist Educ, Jinan 250012, Peoples R China.
EM gezhiming@sdu.edu.cn
CR Adeghate E, 2004, MOL CELL BIOCHEM, V261, P187, DOI 10.1023/B:MCBI.0000028755.86521.11
   Avogaro A, 2004, AM J CARDIOL, V93, p13A, DOI 10.1016/j.amjcard.2003.11.003
   Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200
   BHIMJI S, 1986, ACTA ANAT, V125, P195
   Borradaile NM, 2006, J LIPID RES, V47, P2726, DOI 10.1194/jlr.M600299-JLR200
   Cai Lu, 2003, Cardiovasc Toxicol, V3, P219, DOI 10.1385/CT:3:3:219
   Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452
   Choi KM, 2002, AM J PHYSIOL-HEART C, V283, pH1398, DOI 10.1152/ajpheart.00313.2002
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Detaille D, 2005, DIABETES, V54, P2179, DOI 10.2337/diabetes.54.7.2179
   Dyntar D, 2006, J CLIN ENDOCR METAB, V91, P1961, DOI 10.1210/jc.2005-1904
   Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255
   Feuvray D, 2004, ARCH MAL COEUR VAISS, V97, P261
   Galderisi M, 2006, J AM COLL CARDIOL, V48, P1548, DOI 10.1016/j.jacc.2006.07.033
   GANGULY PK, 1991, CAN J CARDIOL, V7, P275
   Ghosh S, 2006, BBA-MOL CELL BIOL L, V1761, P1148, DOI 10.1016/j.bbalip.2006.08.010
   Hayden MR, 2005, J PANCREAS, V6, P287
   Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537
   Hotamisligil GS, 2005, DIABETES, V54, pS73, DOI 10.2337/diabetes.54.suppl_2.S73
   Howarth FC, 2006, ANN NY ACAD SCI, V1084, P155, DOI 10.1196/annals.1372.007
   JACKSON CV, 1985, DIABETES, V34, P876, DOI 10.2337/diabetes.34.9.876
   King GL, 2004, HISTOCHEM CELL BIOL, V122, P333, DOI 10.1007/s00418-004-0678-9
   Ligeti L, 2006, INT J MOL MED, V17, P1035
   Malhotra A, 2005, MOL CELL BIOCHEM, V268, P169, DOI 10.1007/s11010-005-3858-6
   Mao WK, 2006, AM J PHYSIOL-CELL PH, V290, pC1373, DOI 10.1152/ajpcell.00369.2005
   Mulhern ML, 2006, INVEST OPHTH VIS SCI, V47, P3951, DOI 10.1167/iovs.06-0193
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200
   Obineche E, 2006, ANN NY ACAD SCI, V1084, P223, DOI 10.1196/annals.1372.025
   Okada K, 2004, CIRCULATION, V110, P705, DOI 10.1161/01.CIR.0000137836.95625.D4
   Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JC1200214550
   Pang Y, 2002, DIABETES, V51, P3461, DOI 10.2337/diabetes.51.12.3461
   Pereira L, 2006, DIABETES, V55, P608, DOI 10.2337/diabetes.55.03.06.db05-1284
   Picano E, 2003, J AM COLL CARDIOL, V42, P454, DOI 10.1016/S0735-1097(03)00647-8
   Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200
   Riggs AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Siebenhofer A, 2003, DIABETIC MED, V20, P535, DOI 10.1046/j.1464-5491.2003.00948.x
   Tappia PS, 2004, MOL CELL BIOCHEM, V261, P193, DOI 10.1023/B:MCBI.0000028756.31782.46
   Tiwari M, 2006, CARCINOGENESIS, V27, P2047, DOI 10.1093/carcin/bgl051
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708
   Wang XZ, 1996, MOL CELL BIOL, V16, P4273
   Werstruck GH, 2006, DIABETES, V55, P93, DOI 10.2337/diabetes.55.1.93
   Wijekoon EP, 2007, BIOCHEM SOC T, V35, P1175, DOI 10.1042/BST0351175
   Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 47
TC 44
Z9 64
U1 4
U2 20
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022-0795
EI 1479-6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD MAR
PY 2008
VL 196
IS 3
BP 565
EP 572
DI 10.1677/JOE-07-0230
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 278PC
UT WOS:000254297800013
PM 18310452
OA Bronze
DA 2018-12-27
ER

PT J
AU Zamani, N
AF Zamani, N.
TI RETRACTED: On graded distributive modules (Retracted article. See vol.
   102, pg. 133, 2017)
SO MATHEMATICAL NOTES
LA English
DT Article; Retracted Publication
DE graded distributive module; commutative ring; Krull associated primes;
   distributive lattice; prime ideal; quasilocal ring
AB Let R be a Z-graded commutative ringwith identity. Several characterizations of graded distributive modules will be investigated.
EM naserzak@yahoo.com
CR Bruns W., 1998, CAMBRIDGE STUDIES AD, V39
   DAVISON TMK, 1974, J REINE ANGEW MATH, V271, P28
   ERDOGDU V, 1990, J ALGEBRA, V132, P263, DOI 10.1016/0021-8693(90)90129-C
   Erdogdu V, 1997, COMMUN ALGEBRA, V25, P1635, DOI 10.1080/00927879708825941
   ERDOGDU V, 1987, CAN MATH BULL, V30, P248, DOI 10.4153/CMB-1987-035-x
   Escoriza J, 1998, COMMUN ALGEBRA, V26, P1867, DOI 10.1080/00927879808826244
   Goto S., 1978, J MATH SOC JAPAN, V30, P179, DOI 10.2969/jmsj/03020179
   KUNTZ RA, 1972, CAN J MATH, V24, P808, DOI 10.4153/CJM-1972-079-0
   McCarthy P. J., 1971, PURE APPL MATH, V43
   NAGHIPOUR R, 2005, SE ASIAN B MATH, V29, P1095
   NASTASESCU C, 1982, GRADED RING THEORY N, V28
   STEPHENSON W, 1974, P LOND MATH SOC, V28, P291
   Tuganbaev A. A., 1998, MATH ITS APPL, V449
   TUGANBAEV AA, 1999, ALGEBRA LOGIC APPL, V12
   Underwood D.H., 1969, J MATH KYOTO U, V35, P69
NR 15
TC 1
Z9 1
U1 3
U2 5
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0001-4346
EI 1573-8876
J9 MATH NOTES+
JI Math. Notes
PD MAR-APR
PY 2008
VL 83
IS 3-4
BP 485
EP 491
DI 10.1134/S0001434608030218
PG 7
WC Mathematics
SC Mathematics
GA 302VT
UT WOS:000255998600021
DA 2018-12-27
ER

PT J
AU Urdaneta, F
   Lobato, EB
   Beaver, T
   Muehlschlegel, JD
   Kirby, DS
   Klodell, C
   Sidi, A
AF Urdaneta, F.
   Lobato, E. B.
   Beaver, T.
   Muehlschlegel, J. D.
   Kirby, D. S.
   Klodell, C.
   Sidi, A.
TI RETRACTED: Treating pulmonary hypertension post cardiopulmonary bypass
   in pigs: milrinone vs. sildenafil analog (Retracted article. See vol.
   23, pg. 117, 2011)
SO PERFUSION-UK
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 25th Annual Meeting of the Society-of-Cardiovascular-Anesthesiologists
CY APR 26-30, 2003
CL Miami, FL
SP Soc Cardiovascular Anesthesiologists
DE pulmonary hypertension; milrinone; cardiopulmonary bypass; sildenafil
ID INHALED NITRIC-OXIDE; CARDIAC-SURGERY; HEART-TRANSPLANTATION;
   ARTERIAL-HYPERTENSION; PROSTACYCLIN; VASODILATOR; INHIBITORS; LUNG;
   VASCULATURE; COMBINATION
AB Procedures using cardiopulmonary bypass (CPB) and aortic cross-clamping are associated with a variable degree of ischemia/reperfusion of the lungs, leading to acute pulmonary hypertension (PHT). The purpose of this study was to compare the effects of the sildenafil analog (UK343-664), a phosphodiesterase type V(PDEV) inhibitor, with milrinone, a PDE type III inhibitor, in a porcine model of acute PHT following CPB. After the pigs were anesthetized, pressure-tipped catheters were placed in the right ventricle and carotid and pulmonary arteries. Cardiac output was measured with an ultrasound probe on the ascending aorta. After heparinization and placement of aortic and right atrial cannulae, non-pulsatile CPB was instituted and cardioplegia administered following aortic cross-clamping. After 30 minutes, the clamp was removed and the animals re-warmed and separated from CPB in sinus rhythm. The animals were randomized to 3 groups, and 16 animals were studied to completion: milrinone (n=5) 50 mu g/kg; sildenafil-analog (n=5) 500 mu g/kg; and normal saline (NS) (n=6). Hemodynamic data were collected at baseline pre-CPB and, following termination of CPB, at baseline, 5, 10 and 30 minutes after administration of the drug. Pulmonary hypertension was present in all groups following CPB. After administration of the drugs, mean pulmonary artery pressure decreased in all 3 groups; however, only in the sildenafil-analog group did pulmonary vascular resistance(PVR) decrease by 35%, from 820 to 433 dynes . cm . sec(-5) at 5 minutes (p<0.05), and continued to be decreased at 10 minutes by 26% (P<0.05). Pulmonary selectivity was demonstrated with sildenafil-analog, because there were no similar changes in systemic vascular resistance(SVR) and no significant changes in systemic hemodynamics. Sildenafil-analog, a PDEV inhibitor, shows a promising role for managing the PVR increases that occur following CPB.
C1 [Urdaneta, F.; Lobato, E. B.; Muehlschlegel, J. D.; Sidi, A.] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA.
   [Urdaneta, F.; Lobato, E. B.; Beaver, T.; Muehlschlegel, J. D.; Klodell, C.; Sidi, A.] Anesthesia Serv, Gainesville, FL USA.
   [Beaver, T.; Klodell, C.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL USA.
   [Urdaneta, F.; Lobato, E. B.; Kirby, D. S.] Malcom Randall Vet Adm Med Ctr, Gainesville, FL USA.
RP Sidi, A (reprint author), Univ Florida, Coll Med, Dept Anesthesiol, Box 100254,JHMHSC,1600 SW Archer Rd, Gainesville, FL USA.
EM Asidi@anest.ufl.edu
OI Muehlschlegel, Jochen/0000-0002-6209-7253
CR Atz AM, 1999, ANESTHESIOLOGY, V91, P307, DOI 10.1097/00000542-199907000-00041
   Bhatia S, 2003, MAYO CLIN PROC, V78, P1207, DOI 10.4065/78.10.1207
   Bonnell MR, 2004, ANN THORAC SURG, V77, P238, DOI 10.1016/S0003-4975(03)01489-9
   Bradford KK, 2000, J CARDIOVASC PHARM, V36, P146, DOI 10.1097/00005344-200008000-00002
   Carteaux JP, 1999, EUR J CARDIO-THORAC, V15, P346, DOI 10.1016/S1010-7940(99)00017-2
   Chen EP, 1998, J HEART LUNG TRANSPL, V17, P669
   DENT G, 1994, LUNG, V172, P129
   Fattouch K, 2006, J CARDIOVASC MED, V7, P119, DOI 10.2459/01.JCM.0000203850.97890.fe
   Fullerton DA, 1996, ANN THORAC SURG, V61, P1856, DOI 10.1016/0003-4975(96)00046-X
   Ghofrani HA, 2004, J AM COLL CARDIOL, V44, P1488, DOI 10.1016/j.jacc.2004.06.060
   HOPKINS RA, 1991, EUR J CARDIO-THORAC, V5, P628, DOI 10.1016/1010-7940(91)90118-4
   Ibrahim M, 2007, CAN J CARDIOL, V23, P363, DOI 10.1016/S0828-282X(07)70769-9
   Ichinose F, 2004, CIRCULATION, V109, P3106, DOI 10.1161/01.CIR.0000134595.80170.62
   KAYE MP, 1993, J HEART LUNG TRANSPL, V12, P541
   KIELERJENSEN N, 1993, J HEART LUNG TRANSPL, V12, P179
   Lobato EB, 2006, BRIT J ANAESTH, V96, P317, DOI 10.1093/bja/ael009
   Lowson SM, 2002, CRIT CARE MED, V30, P2762, DOI 10.1097/00003246-200212000-00023
   Lowson SM, 2002, ANESTHESIOLOGY, V96, P1504, DOI 10.1097/00000542-200206000-00034
   Madden BP, 2004, BRIT J ANAESTH, V93, DOI 10.1093/bja/aeh571
   Matot I, 2004, CHEST, V125, P644, DOI 10.1378/chest.125.2.644
   McMullan DM, 2001, AM J PHYSIOL-HEART C, V280, pH777
   Mikhail GW, 2004, EUR HEART J, V25, P431, DOI 10.1016/j.ehj.2004.01.013
   Mychaskiw G, 2001, J CLIN ANESTH, V13, P218, DOI 10.1016/S0952-8180(01)00252-5
   Ocal A, 2005, TOHOKU J EXP MED, V207, P51, DOI 10.1620/tjem.207.51
   Ockaili R, 2002, AM J PHYSIOL-HEART C, V283, pH1263, DOI 10.1152/ajpheart.00324.2002
   Oztekin I, 2007, YAKUGAKU ZASSHI, V127, P375, DOI 10.1248/yakushi.127.375
   PASCUAL JMS, 1990, J HEART TRANSPLANT, V9, P644
   Reich DL, 1999, ANESTH ANALG, V89, P814, DOI 10.1097/00000539-199910000-00002
   RUSSELL PC, 1990, EUR RESPIR J, V3, P779
   Rybalkin SD, 2003, CIRC RES, V93, P280, DOI 10.1161/01.RES.0000087541.15600.2B
   Schermuly RT, 2001, AM J RESP CRIT CARE, V164, P1694, DOI 10.1164/ajrccm.164.9.2105060
   Schmid ER, 1999, ANESTH ANALG, V89, P1108
   Schulze-Neick I, 2003, CIRCULATION, V108, P167, DOI 10.1161/01.cir.0000087384.76615.60
   Steiner MK, 2005, CURR OPIN PHARMACOL, V5, P245, DOI 10.1016/j.coph.2004.12.008
   TANAKA H, 1990, CLIN EXP PHARMACOL P, V17, P681, DOI 10.1111/j.1440-1681.1990.tb01267.x
   TANAKA H, 1991, CRIT CARE MED, V19, P68, DOI 10.1097/00003246-199101000-00017
   TILNEY NL, 1967, ANN SURG, V166, P759, DOI 10.1097/00000658-196711000-00004
   TONZ M, 1994, ANN THORAC SURG, V58, P1031
   Trachte AL, 2005, ANN THORAC SURG, V79, P194, DOI 10.1016/j.athoracsur.2004.06.086
   Tsai BM, 2005, SHOCK, V24, P417, DOI 10.1097/01.shk.0000183390.9851905
   VanObbergh LJ, 1996, BRIT J ANAESTH, V77, P227, DOI 10.1093/bja/77.2.227
   WAHLERS T, 1988, CLIN TRANSPLANT, V2, P252
   Weimann J, 2000, ANESTHESIOLOGY, V92, P1702, DOI 10.1097/00000542-200006000-00030
   WESSEL DL, 1993, CIRCULATION, V88, P447
NR 44
TC 6
Z9 7
U1 2
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0267-6591
EI 1477-111X
J9 PERFUSION-UK
JI Perfusion-UK
PD MAR
PY 2008
VL 23
IS 2
BP 117
EP 125
DI 10.1177/0267659108094739
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 354DW
UT WOS:000259620100008
PM 18840581
DA 2018-12-27
ER

PT J
AU Spence, RJ
AF Spence, Robert J.
TI RETRACTED: An algorithm for total and subtotal facial reconstruction
   using an expanded transposition flap: A 20 year experience (Retracted
   article. See vol. 122, pg. 997, 2008)
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 85th Annual Meeting of the American-Association-of-Plastic-Surgeons
CY MAY 06-09, 2006
CL Hilton Head Isl, SC
SP Amer Assoc Plast Surg
AB Background: Reconstruction of major facial soft-tissue deformities and deficits is a continuing challenge for surgeons who wish to reliably restore facial function and appearance. A primary problem is deficiency of well-matched donor skin. Others include the unique characteristics of facial skin, the fine anatomical nuances, and the unique functional demands placed on the face making reconstruction difficult. The author presents an algorithm developed for total and subtotal reconstruction of the face using an expanded shoulder transposition flap as a key element.
   Methods: Expanded shoulder transposition flaps have been used since 1986 for head and neck resurfacing. An algorithm using the expanded shoulder transposition flap as a key element was developed for total and subtotal resurfacing of the face. The validity of this approach was evaluated by clinical results over 20 years. During that time, expanded shoulder transposition flaps were used 58 times in 41 patients ranging in age from 2 to 62 years.
   Results: With the expanded shoulder transposition flap as its central component, the algorithm proved remarkably reliable and reproducible in resurfacing the peripheral facial aesthetic units with the main flap, and the pedicle skin often used for grafting the central face with its finer features. The donor site of the flap is closed primarily.
   Conclusions: This study examines the experience using an algorithm developed with the expanded shoulder transposition flap for major facial reconstruction. The experience suggests that the algorithm provides versatility and reliability; minimizes the donor-site defect; and is well within the skill, patience, and courage of most reconstructive surgeons.
C1 [Spence, Robert J.] Johns Hopkins Sch Med, Baltimore, MD USA.
RP Spence, RJ (reprint author), Good Samaritan Hosp, Natl Burn Reconstruct Ctr, 5601 Loch Raven Blvd, Baltimore, MD 21239 USA.
EM robert.spence@medstar.net
CR EDGERTON M T, 1960, Plast Reconstr Surg Transplant Bull, V25, P455, DOI 10.1097/00006534-196005000-00001
   FELDMAN JJ, 1987, PERSPECTIVES PLASTIC, V1, P110
   FELDMAN JJ, 1987, ARTISTRY RECONSTRUCT, V1, P327
   Gillies HD, 1957, PRINCIPLES ART PLAST
   GONZALEZ-ULLOA M, 1956, Br J Plast Surg, V9, P212, DOI 10.1016/S0007-1226(56)80036-2
   Rennekampff Hans O., 1996, Journal of Burn Care and Rehabilitation, V17, P522, DOI 10.1097/00004630-199611000-00008
   SPENCE RJ, 1988, ANN PLAS SURG, V21, P58, DOI 10.1097/00000637-198807000-00012
   SPENCE RJ, 1997, PLAST SURG FORUM, V20, P181
   SPENCE RJ, 2007, J BURNS WOUNDS, V6, P100
NR 9
TC 15
Z9 17
U1 3
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0032-1052
EI 1529-4242
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD MAR
PY 2008
VL 121
IS 3
BP 795
EP 805
DI 10.1097/01.prs.0000299911.54966.13
PG 11
WC Surgery
SC Surgery
GA 268GA
UT WOS:000253566000010
PM 18317129
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Sato, Y
   Uzawa, M
   Takeda, T
   Matsumoto, H
AF Iwamoto, Jun
   Sato, Yoshihiro
   Uzawa, Mitsuyoshi
   Takeda, Tsuyoshi
   Matsumoto, Hideo
TI RETRACTED: Comparison of effects of alendronate and raloxifene on lumbar
   bone mineral density, bone turnover, and lipid metabolism in elderly
   women with osteoporosis (Retracted article. See vol. 59, pg. 167, 2018)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE alendronate; raloxifene; osteoporosis; postmenopausal women; lipid
   metabolism
ID CONTINUING OUTCOMES RELEVANT; RANDOMIZED CLINICAL-TRIAL; POSTMENOPAUSAL
   WOMEN; BIOCHEMICAL MARKERS; VERTEBRAL FRACTURES; ANTIRESORPTIVE AGENTS;
   DIAGNOSTIC-CRITERIA; JAPANESE PATIENTS; BREAST-CANCER; ASIAN WOMEN
AB Purpose: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BNID), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. Results: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both alendronate and raloxifene increased lumbar BNID (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. Conclusion: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BNID through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.
C1 [Iwamoto, Jun; Takeda, Tsuyoshi; Matsumoto, Hideo] Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Sato, Yoshihiro] Mitate Hosp, Dept Neurol, Fukuoka, Japan.
   [Uzawa, Mitsuyoshi] Keiyu Orthopaed Hosp, Dept Orthopaed Surg, Gunma, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM jiwamoto@sc.itc.keio.ac.jp
RI Matsumoto, Hideo/A-2304-2014
CR Barrett-Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002
   Cryer B, 2002, MAYO CLIN PROC, V77, P1031, DOI 10.4065/77.10.1031
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X
   Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532-5415.2000.tb02641.x
   Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379
   Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Iwamoto J, 2005, J BONE MINER METAB, V23, P238, DOI 10.1007/s00774-004-0590-3
   Kanis JA, 2003, BONE, V32, P468, DOI 10.1016/S8756-3282(03)00061-9
   Kung AWC, 2003, J CLIN ENDOCR METAB, V88, P3130, DOI 10.1210/jc.2002-021855
   Kushida K, 2002, CURR THER RES CLIN E, V63, P606, DOI 10.1016/S0011-393X(02)80065-0
   Liberman UA, 2006, INT J CLIN PRACT, V60, P1394, DOI 10.1111/j.1742-1241.2006.01148.x
   Lufkin EG, 2004, CURR MED RES OPIN, V20, P351, DOI 10.1185/030079904125003071
   Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319
   Morii H, 2003, OSTEOPOROSIS INT, V14, P793, DOI 10.1007/s00198-003-1424-1
   Nakamura T, 2006, J BONE MINER METAB, V24, P414, DOI 10.1007/s00774-006-0702-3
   Nishizawa Y, 2005, J BONE MINER METAB, V23, P97, DOI 10.1007/s00774-004-0547-6
   Orimo H, 1998, J BONE MINER METAB, V16, P139, DOI 10.1007/s007740050038
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198-004-1725-z
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8
   Sambrook PN, 2004, J INTERN MED, V255, P503, DOI 10.1111/j.1365-2796.2004.01317.x
   Shiraki M, 1999, OSTEOPOROSIS INT, V10, P183, DOI 10.1007/s001980050214
   Siris ES, 2005, J BONE MINER RES, V20, P1514, DOI 10.1359/JBMR.050509
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
NR 32
TC 18
Z9 19
U1 2
U2 7
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD FEB 29
PY 2008
VL 49
IS 1
BP 119
EP 128
DI 10.3349/ymj.2008.49.1.119
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 270NJ
UT WOS:000253727200015
PM 18306478
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Dede, A
   Isaacs, D
   Torzillo, PJ
   Wakerman, J
   Roseby, R
   Fahy, R
   Clothier, G
   White, A
AF Dede, Apakasimaka
   Isaacs, David
   Torzillo, Paul J.
   Wakerman, John
   Roseby, Rob
   Fahy, Rose
   Clothier, George
   White, Andrew
TI RETRACTED: Respiratory syncytial virus infections in children in Alice
   Springs Hospital (Retracted article. See vol. 188, pg. 431, 2008)
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Letter; Retracted Publication
C1 [Dede, Apakasimaka] Hervey Bay Hosp, Hervey Bay, Qld, Australia.
   [Isaacs, David] Childrens Hosp Westmead, Dept Immunol & Infect Dis, Sydney, NSW, Australia.
   [Torzillo, Paul J.] Royal Prince Alfred Hosp, Sydney, NSW, Australia.
   [Wakerman, John; White, Andrew] Ctr Remote Hlth, Alice Springs, NT, Australia.
   [Roseby, Rob; Fahy, Rose; Clothier, George] Alice Springs Hosp, Alice Springs, NT, Australia.
RP Dede, A (reprint author), Hervey Bay Hosp, Hervey Bay, Qld, Australia.
EM davidi@chw.edu.au
CR *AUSTR BUR STAT, 2005, 13627 ABS
   Chang AB, 2002, MED J AUSTRALIA, V177, P200
   Gregson D, 2005, J CLIN MICROBIOL, V43, P5782, DOI 10.1128/JCM.43.11.5782-5783.2005
   Roche Paul, 2003, Commun Dis Intell Q Rep, V27, P117
   TORZILLO PJ, 1995, MED J AUSTRALIA, V162, P182
   Zhao Y, 2007, POPULATION ESTIMATES
NR 6
TC 3
Z9 3
U1 3
U2 7
PU AUSTRALASIAN MED PUBL CO LTD
PI PYRMONT
PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD FEB 18
PY 2008
VL 188
IS 4
BP 261
EP 261
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 301SB
UT WOS:000255914800024
PM 18279143
DA 2018-12-27
ER

PT J
AU Abdelkefi, A
   Ladeb, S
   Torjman, L
   Ben Othman, T
   Lakhal, A
   Ben Romdhane, N
   El Omri, H
   Elloumi, M
   Belaaj, H
   Jeddi, R
   Aissaoui, L
   Ksouri, H
   Ben Hassen, A
   Msadek, F
   Saad, A
   Hsairi, M
   Boukef, K
   Amouri, A
   Louzir, H
   Dellagi, K
   Ben Abdeladhim, A
AF Abdelkefi, Abderrahman
   Ladeb, Saloua
   Torjman, Lamia
   Ben Othman, Tarek
   Lakhal, Amel
   Ben Romdhane, Neila
   El Omri, Halima
   Elloumi, Moez
   Belaaj, Hatem
   Jeddi, Ramzi
   Aissaoui, Lamia
   Ksouri, Habib
   Ben Hassen, Assia
   Msadek, Fahmi
   Saad, Ali
   Hsaieri, Mohamed
   Boukef, Kamel
   Amouri, Ahlem
   Louzir, Hechmi
   Dellagi, Koussay
   Ben Abdeladhim, Abdeladhim
CA Tunisian Multiple Myeloma Study Gr
TI RETRACTED: Single autologous stem-cell transplantation followed by
   maintenance therapy with thalidomide is superior to double autologous
   transplantation in multiple myeloma: results of a multicenter randomized
   clinical trial (Retracted article. See vol. 113, pg. 6265, 2009)
SO BLOOD
LA English
DT Article; Retracted Publication
ID HIGH-DOSE CHEMOTHERAPY; ALLOGENEIC TRANSPLANTATION; MARROW
   TRANSPLANTATION; DEXAMETHASONE; SURVIVAL; METAANALYSIS; COMBINATION;
   PREDNISONE; MANAGEMENT; AUTOGRAFT
AB From April 2003 to December 2006, 195 patients with de novo symptomatic myeloma and younger than 60 years of age were randomly assigned to receive either tandem transplantation up front (arm A, n = 97) or one autologous stem-cell transplantation followed by a maintenance therapy with thalidomide (day + 90, 100 mg per day during 6 months) (arm B, n = 98). Patients included in arm B received a second transplant at disease progression. In both arms, autologous stem-cell transplantation was preceded by first-line therapy with thalidomide-dexamethasone and subsequent collection of peripheral blood stem cells with high-dose cyclophosphamide (4 g/m(2)) and granulocyte colony stimulating factor. Data were analyzed on an intent-to-treat basis. With a median follow-up of 33 months (range, 6-46 months), the 3-year overall survival was 65% in arm A and 85% in arm B (P = .04). The 3-year progression-free survival was 57% in arm A and 85% in arm B (P = .02). Up-front single autologous transplantation followed by 6 months of maintenance therapy with thalidomide (with second transplant in reserve for relapse or progression) is an effective therapeutic strategy to treat multiple myeloma patients and appears superior to tandem transplant in this setting. This study was registered at www.ClinicalTrials.gov as (NCT 00207805).
C1 [Abdelkefi, Abderrahman; Ladeb, Saloua; Torjman, Lamia; Ben Othman, Tarek; Lakhal, Amel; Ksouri, Habib; Ben Hassen, Assia; Ben Abdeladhim, Abdeladhim] Ctr Natl Greffe Moelle Osseue, Tunis, Tunisia.
   [Ben Romdhane, Neila] Hop La Rabta, Tunis, Tunisia.
   Hop Farhat Hachet, Sousse, Tunisia.
   [Elloumi, Moez; Belaaj, Hatem] Hop Hedi Chaker, Afax, Tunisia.
   [Saad, Ali] Hop Farhat Hached, Lab Cytogenet, Sousse, Tunisia.
   [Boukef, Kamel] Ctr Natl Transfus Sanguine, Sanguine, Tunisia.
   [Amouri, Ahlem; Louzir, Hechmi; Dellagi, Koussay] Inst Pasteur Tunis, Tunis, Tunisia.
RP Abdelkefi, A (reprint author), Ctr Natl Greffe Moelle Osseue, Tunis, Tunisia.
CR Abdelkefi A, 2005, BONE MARROW TRANSPL, V36, P193, DOI 10.1038/sj.bmt.1705050
   Alexanian R, 2002, ANN ONCOL, V13, P1116, DOI 10.1093/annonc/mdf188
   ALVARES CL, 2003, HAEMATOLOGICA, V91, P141
   Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290
   Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204
   Attal M, 2006, BLOOD, V108, P3289, DOI 10.1182/bloos-2006-05-022962
   Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583
   Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
   Cavo M, 2005, BLOOD, V106, P35, DOI 10.1182/blood-2005-02-0522
   Cavo M, 2007, J CLIN ONCOL, V25, P2434, DOI 10.1200/JCO.2006.10.2509
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284
   Durie BGM, 2001, BLOOD, V98, p163A
   El Accaoui RN, 2007, THROMB HAEMOSTASIS, V97, P1031, DOI 10.1160/TH06-09-0494
   Elice F, 2006, AM J HEMATOL, V81, P426, DOI 10.1002/ajh.20641
   Fermand JP, 1998, BLOOD, V92, P3131
   Gertz MA, 2000, BONE MARROW TRANSPL, V26, P45, DOI 10.1038/sj.bmt.1702445
   Koreth J, 2007, BIOL BLOOD MARROW TR, V13, P183, DOI 10.1016/j.bbmt.2006.09.010
   Kulkarni S, 1998, BLOOD, V92, p344B
   Mehta J, 1998, BONE MARROW TRANSPL, V21, P887, DOI 10.1038/sj.bmt.1701208
   Mileshkin L, 2006, J CLIN ONCOL, V24, P4507, DOI 10.1200/JCO.2006.05.6689
   Morris C, 2004, J CLIN ONCOL, V22, P1674, DOI 10.1200/JCO.2004.06.144
   MUNSHI NC, 2007, NAT CLIN PRACT ONCOL
   Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4
   Qazilbash MH, 2006, CANCER, V106, P1084, DOI 10.1002/cncr.21700
   Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116
   Richardson P, 2004, MAYO CLIN PROC, V79, P875, DOI 10.4065/79.7.875
   Richardson P, 2007, BLOOD, V2007
   Richardson PG, 2007, ONCOLOGIST, V12, P664, DOI 10.1634/theoncologist.12-6-664
   Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood-2006-04-015909
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Sirohi B, 2002, BONE MARROW TRANSPL, V29, pS12
   Smith A, 2001, BRIT J HAEMATOL, V115, P522
   SPENCER A, 2006, BLOOD, V108, pA58
   Stewart AK, 2004, CLIN CANCER RES, V10, P8170, DOI 10.1158/1078-0432.CCR-04-1106
   TRICOT G, 1995, BONE MARROW TRANSPL, V16, P7
   Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139
NR 37
TC 86
Z9 90
U1 2
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 15
PY 2008
VL 111
IS 4
BP 1805
EP 1810
DI 10.1182/blood-2007-07-101212
PG 6
WC Hematology
SC Hematology
GA 263XZ
UT WOS:000253251100021
PM 17875806
OA Bronze
DA 2018-12-27
ER

PT J
AU Kim, HS
   Hwang, JT
   Yun, H
   Chi, SG
   Lee, SJ
   Kang, I
   Yoon, KS
   Choe, WJ
   Kim, SS
   Ha, J
AF Kim, Hak-Su
   Hwang, Jin-Taek
   Yun, Hee
   Chi, Sung-Gil
   Lee, Su-Jae
   Kang, Insug
   Yoon, Kyung-Sik
   Choe, Won-Jae
   Kim, Sung-Soo
   Ha, Joohun
TI RETRACTED: Inhibition of AMP-activated protein kinase sensitizes cancer
   cells to cisplatin-induced apoptosis via Hyper-induction of p53
   (Retracted article. See vol. 293, pg. 18015, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SIGNAL-REGULATED KINASE; DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE;
   GENE-EXPRESSION; GROWTH-FACTOR; CHECKPOINT; PATHWAYS; HYPOXIA; LKB1;
   STIMULATION
AB Cisplatin is one of the most effective and widely used chemotherapeutic agents. However, one of the most salient limitations to the clinical application of cisplatin is the acquired or intrinsic drug resistance exhibited by some tumors. In the present study, we have assessed the potential of an intracellular energy balancing system as a target for augmentation of cisplatin sensitivity in tumors. AMP-activated protein kinase (AMPK) regulates the energy balance system by monitoring intracellular energy status. Here we demonstrate that AMPK is rapidly activated by cisplatin in AGS and HCT116 cancer cells. The inhibition of AMPK in those cells and in xenografts of HCT116 resulted in a remarkable increase in cisplatin-induced apoptosis, which was associated with hyper-induction of the tumor suppressor p53. We further showed that ERK, but not ATM (ataxia telangiectasia mutated) and ATR (ATM- and Rad3-related) kinases, was involved in the hyper-induction of p53 by the inhibition of cisplatin-induced AMPK. By way of contrast, cisplatin did not induce AMPK activation in HeLa cells, which appear to have a relatively high sensitivity to cisplatin-induced cytotoxicity, but expression of the constitutive active form of AMPK in HeLa cells resulted in a significant increase of cell viability after cisplatin treatment. Collectively, our data suggest that AMPK performs a pivotal function for protection against the cytotoxic effect of cisplatin, thereby implying that AMPK is one of the cellular factors determining the cellular sensitivity to cisplatin. On the basis of these observations, we propose that a strategy combining cisplatin and AMPK inhibition could be developed into a novel chemotherapeutic modality.
C1 [Kim, Hak-Su; Yun, Hee; Yoon, Kyung-Sik; Choe, Won-Jae; Kim, Sung-Soo; Ha, Joohun] Kyung Hee Univ, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Dept Biochem & Mol Biol, Seoul 130701, South Korea.
   [Hwang, Jin-Taek] Korea Food Res Inst, Songnam 463746, South Korea.
   [Chi, Sung-Gil] Korea Univ, Sch Life Sci, Seoul 136701, South Korea.
   [Lee, Su-Jae] Hanyang Univ, Dept Chem, Seoul 133791, South Korea.
RP Ha, J (reprint author), Kyung Hee Univ, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Dept Biochem & Mol Biol, Tongdaemun-gu,Hoegi-dong 1, Seoul 130701, South Korea.
EM hajh@khu.ac.kr
CR Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702
   Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674
   Boulay JL, 2000, CANCER GENE THER, V7, P1215, DOI 10.1038/sj.cgt.7700227
   Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x
   Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677
   Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200
   Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544
   Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122
   Dyck JRB, 2006, J PHYSIOL-LONDON, V574, P95, DOI 10.1113/jphysiol.2006.109389
   El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949
   Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951
   Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003
   HA J, 1994, J BIOL CHEM, V269, P22162
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231
   Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28
   Hwang JT, 2006, CANCER RES, V66, P10057, DOI 10.1158/0008-5472.CAN-06-1814
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737
   Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200
   Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200
   Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011
   Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200
   Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324
   Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597
   Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200
   PRESTAYKO AW, 1979, CANCER TREAT REV, V6, P17, DOI 10.1016/S0305-7372(79)80057-2
   Rosenberg B, 1977, Adv Exp Med Biol, V91, P129
   Schipper DL, 1996, ANTI-CANCER DRUG, V7, P137, DOI 10.1097/00001813-199602000-00001
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437
   Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248
   Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152
   Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189
   Yun H, 2005, J BIOL CHEM, V280, P9963, DOI 10.1074/jbc.M412994200
   Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200
NR 47
TC 59
Z9 61
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 15
PY 2008
VL 283
IS 7
BP 3731
EP 3742
DI 10.1074/jbc.M704432200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 261MO
UT WOS:000253083500006
PM 18079115
OA Bronze
DA 2018-12-27
ER

PT J
AU Ulianich, L
   Garbi, C
   Treglia, AS
   Punzi, D
   Miele, C
   Raciti, GA
   Beguinot, F
   Consiglio, E
   Di Jeso, B
AF Ulianich, Luca
   Garbi, Corrado
   Treglia, Antonella Sonia
   Punzi, Dario
   Miele, Claudia
   Raciti, Gregory Alexander
   Beguinot, Francesco
   Consiglio, Eduardo
   Di Jeso, Bruno
TI RETRACTED: ER stress is associated with dedifferentiation and an
   epithelial-to-mesenchymal transition-like phenotype in PCCl3 thyroid
   cells (Retracted Article. See vol. 129, pg 3518, 2016)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE ER stress; thyroid cells; dedifferentiation; epithelial-mesenchymal
   transition
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION
   FACTOR SNAIL; EPIDERMAL-GROWTH-FACTOR; E-CADHERIN; MESSENGER-RNAS;
   BREAST-CANCER; TUMOR-CELLS; THYROGLOBULIN; DIFFERENTIATION
AB Conditions perturbing the homeostasis of the endoplasmic reticulum (ER) cause accumulation of unfolded proteins and trigger ER stress. In PC Cl3 thyroid cells, thapsigargin and tunicamycin interfered with the folding of thyroglobulin, causing accumulation of this very large secretory glycoprotein in the ER. Consequently, mRNAs encoding BiP and XBP-1 were induced and spliced, respectively. In the absence of apoptosis, differentiation of PC Cl3 cells was inhibited. mRNA and protein levels of the thyroid-specific genes encoding thyroglobulin, thyroperoxidase and the sodium/iodide symporter and of the genes encoding the thyroid transcription factors TTF-1, TTF-2 and Pax-8 were dramatically downregulated. These effects were, at least in part, transcriptional. Moreover, they were selective and temporally distinct from the general and transient PERK-dependent translational inhibition. Thyroid dedifferentiation was accompanied by changes in the organization of the polarized epithelial monolayer. Downregulation of the mRNA encoding E-cadherin, and upregulation of the mRNAs encoding vimentin, alpha-smooth muscle actin, alpha(1)(I) collagen and SNAI1/SIP1, together with formation of actin stress fibers and loss of trans-epithelial resistance were found, confirming an epithelial-mesenchymal transition (EMT). The thyroid-specific and epithelial dedifferentiation by thapsigargin or tunicamycin were completely prevented by the PP2 inhibitor of Src-family kinases and by stable expression of a dominant-negative Src. Together, these data indicate that ER stress induces dedifferentiation and an EMT-like phenotype in thyroid cells through a Src-mediated signaling pathway.
C1 [Treglia, Antonella Sonia; Di Jeso, Bruno] Univ Lecce, Dipartimento Sci & Tecnol Biol & Ambientali, Fac Sci Matemat Fis & Nat, I-73100 Lecce, Italy.
   [Ulianich, Luca; Miele, Claudia; Raciti, Gregory Alexander; Beguinot, Francesco; Consiglio, Eduardo] Ist Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy.
   [Garbi, Corrado; Punzi, Dario; Raciti, Gregory Alexander; Beguinot, Francesco; Consiglio, Eduardo] Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy.
RP Di Jeso, B (reprint author), Univ Lecce, Dipartimento Sci & Tecnol Biol & Ambientali, Fac Sci Matemat Fis & Nat, I-73100 Lecce, Italy.
EM bdijeso@ilenic.unile.it
OI di jeso, bruno/0000-0001-8713-5984
FU Associazione Italiana per la Ricerca sul Cancro
CR Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511
   Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200
   Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Damante G, 2001, PROG NUCLEIC ACID RE, V66, P307
   De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545
   Di Jeso B, 2005, MOL CELL BIOL, V25, P9793, DOI 10.1128/MCB.25.22.9793-9805.2005
   Di Jeso B, 2003, BIOCHEM J, V370, P449, DOI 10.1042/BJ20021257
   Di Jeso B, 1998, EUR J BIOCHEM, V252, P583, DOI 10.1046/j.1432-1327.1998.2520583.x
   di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144
   DIJESO B, 1992, J BIOL CHEM, V267, P1938
   DIJESO B, 2004, THYROID, P77
   Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052
   FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365
   Gass JN, 2004, TRENDS IMMUNOL, V25, P17, DOI 10.1016/j.it.2003.11.004
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hernandez MV, 2006, J CELL SCI, V119, P1233, DOI 10.1242/jcs.02846
   Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Kaimori A, 2007, J BIOL CHEM, V282, P22089, DOI 10.1074/jbc.M700998200
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kawai T, 2004, MOL CELL BIOL, V24, P6773, DOI 10.1128/MCB.24.15.6773-6787.2004
   KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29
   Leonardi A, 2002, ENDOCRINOLOGY, V143, P2169, DOI 10.1210/en.143.6.2169
   Lievens PMJ, 2006, J MOL BIOL, V357, P783, DOI 10.1016/j.jmb.2006.01.058
   Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0
   Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837
   Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912
   MIYAMOTO M, 1988, CANCER RES, V48, P3652
   Okladnova O, 1997, GENOMICS, V42, P452, DOI 10.1006/geno.1997.4735
   Oyadomari S, 2006, CELL, V126, P727, DOI 10.1016/j.cell.2006.06.051
   Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200
   Pirot P, 2007, DIABETOLOGIA, V50, P1006, DOI 10.1007/s00125-007-0609-0
   Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Seki K, 2003, J BIOL CHEM, V278, P41862, DOI 10.1074/jbc.M308336200
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tsang KY, 2007, PLOS BIOL, V5, P568, DOI 10.1371/journal.pbio.0050044
   Ulianich L, 2004, EUR J ENDOCRINOL, V150, P851, DOI 10.1530/eje.0.1500851
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965
   Westermark K, 1996, HISTOPATHOLOGY, V28, P221, DOI 10.1046/j.1365-2559.1996.d01-427.x
   Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5471CAN-05-3086
   Yang L, 2005, J BIOL CHEM, V280, P31156, DOI 10.1074/jbc.M501069200
NR 47
TC 92
Z9 94
U1 4
U2 14
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD FEB 15
PY 2008
VL 121
IS 4
BP 477
EP 486
DI 10.1242/jcs.017202
PG 10
WC Cell Biology
SC Cell Biology
GA 266HT
UT WOS:000253425800009
PM 18211961
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X. -M.
   Luo, Q. -Y.
   Xu, Y. -P.
TI RETRACTED: catena-Poly[[(1,10-phenanthroline-kappa N-2,N
   ')praseodymium(III)]-di-mu-phenoxyacetato-kappa O-4 : O
   '-[(1,10-phenanthroline-kappa N-2,N
   ')praseodymium(III)]-di-mu-phenoxyacetato-kappa O-4 : O
   '-di-mu-phenoxyacetato-kappa O-3,O ': O;kappa O-3 : O,O '] (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID LANTHANIDE(III) COMPLEXES; HEXAHYDRATE; ACID
C1 [Zhong, H.; Luo, Q. -Y.; Xu, Y. -P.] Jingganshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   [Yang, X. -M.] Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jingganshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Daiguebonne C, 2000, INORG CHIM ACTA, V304, P161, DOI 10.1016/S0020-1693(00)00079-7
   Farrugia LJ, 2000, ACTA CRYSTALLOGR C, V56, pE435, DOI 10.1107/S0108270100012087
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G.M, 1996, SADABS
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   *SIEM AN XR INSTR, 1996, SMART SAINT SHELXTL
   STARYNOWICZ P, 1993, ACTA CRYSTALLOGR C, V49, P1895, DOI 10.1107/S0108270193004603
   STARYNOWICZ P, 1991, ACTA CRYSTALLOGR C, V47, P294, DOI 10.1107/S0108270190007892
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zeng XR, 2000, ACTA CRYSTALLOGR C, V56, pE325, DOI 10.1107/S0108270100009604
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2508, DOI 10.1107/S1600536807043528
NR 15
TC 0
Z9 0
U1 5
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2008
VL 64
BP M317
EP U458
DI 10.1107/S1600536807068614
PN 2
PG 16
WC Crystallography
SC Crystallography
GA 271HO
UT WOS:000253779700048
PM 21201288
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Suzuki, N
   Kozuma, K
   Ueno, Y
   Nagaoka, K
   Kyono, H
   Ishikawa, S
   Watanabe, H
   Yokoyama, N
   Takeshita, S
   Isshiki, T
AF Suzuki, Nobuaki
   Kozuma, Ken
   Ueno, Yasunari
   Nagaoka, Kensuke
   Kyono, Hiroyuki
   Ishikawa, Shuichi
   Watanabe, Hidenori
   Yokoyama, Naoyuki
   Takeshita, Satoshi
   Isshiki, Takaaki
TI RETRACTED: Serial quantitative coronary analyses for the evaluation of
   one-year change in saphenous vein grafts (Retracted Article. See vol.
   86, pg 1726, 2008)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID INTERNAL MAMMARY ARTERY; BYPASS GRAFTS; AORTOCORONARY BYPASS;
   ANGIOGRAPHIC CHANGES; BALLOON ANGIOPLASTY; RISK-FACTORS;
   ATHEROSCLEROSIS; SURGERY; TERM; PROGRESSION
AB Background. A paucity of data exists with respect to changes in whole saphenous vein grafts (SVGs) despite accelerated atherosclerosis within grafted saphenous vein conduits. In the present study, we evaluated the one-year change in SVGs by means of quantitative coronary analysis.
   Methods. This study enrolled consecutive 52 patients with 109 SVGs, who underwent coronary artery bypass graft surgery successfully. A follow-up study was performed in 33 patients with 65 SVGs after one year because 16 SVGs were obstructed (baseline, 8; follow-up period, 8), and 15 patients with 28 SVGs dropped out within one year.
   Results. Both minimal and mean lumen diameters decreased significantly (3.17 +/- 0.64 mm vs 2.41 +/- 0.57 mm, p < 0.001; 3.70 +/- 0.69 mm vs 2.92 +/- 0.70 mm, p < 0.001; respectively). Graft length also decreased significantly (107.1 +/- 25.8 vs 100.6 +/- 25.2 mm, p < 0.001). The graft shortening rate (graft shortening length/baseline graft length x 100) was greater than 5% in 33 vessels (51%) and greater than 10% in 23 vessels (35%). Coronary risk factors (smoking, diabetes mellitus, hypertension, dyslipidemia) did not reveal significant relationship with late loss of minimal and mean lumen diameters.
   Conclusions. The present study showed a considerable and uniform lumen loss of SVGs after one year, irrespective of coronary risk factors. Graft length shortening was seen more than elongation.
C1 [Suzuki, Nobuaki] Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, Tokyo 1738605, Japan.
   Natl Cardiovasc Ctr, Dept Med, Osaka, Japan.
RP Suzuki, N (reprint author), Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.
EM nsuzu@bronze.ocn.ne.jp
CR ANGELINI GD, 1989, EUR HEART J, V10, P273, DOI 10.1093/oxfordjournals.eurheartj.a059476
   BARBORIAK JJ, 1976, ANN THORAC SURG, V21, P524, DOI 10.1016/S0003-4975(10)63922-7
   BATAYIAS GE, 1977, CIRCULATION, V56, P18
   BJORK VO, 1981, SCAND J THORAC CARD, V15, P23, DOI 10.3109/14017438109101021
   BOURASSA MG, 1991, J AM COLL CARDIOL, V17, P1081, DOI 10.1016/0735-1097(91)90835-W
   CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101
   de Groot P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000091
   DEFEYTER PIMJ, 1993, J AM COLL CARDIOL, V21, P1539, DOI 10.1016/0735-1097(93)90366-9
   Durrani A, 1998, ANN THORAC SURG, V66, P966, DOI 10.1016/S0003-4975(98)00630-4
   FitzGibbon GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9
   FREY RR, 1984, J THORAC CARDIOV SUR, V87, P167
   Hausleiter J, 1997, CORONARY ARTERY DIS, V8, P83, DOI 10.1097/00019501-199702000-00003
   Kleemann A, 1999, EUR HEART J, V20, P1393, DOI 10.1053/euhj.1999.1483
   Korpilahti K, 1998, SCAND CARDIOVASC J, V32, P343, DOI 10.1080/14017439850139799
   Lau GT, 2006, CIRCULATION, V114, pI435, DOI 10.1161/CIRCULATIONAHA.105.001008
   LAWRIE GM, 1976, AM J CARDIOL, V38, P856, DOI 10.1016/0002-9149(76)90798-0
   Lesperance J, 1996, INT J CARDIAC IMAG, V12, P299, DOI 10.1007/BF01797743
   LIE JT, 1977, AM J CARDIOL, V40, P906, DOI 10.1016/0002-9149(77)90041-8
   Mochida M, 2006, ANGIOLOGY, V57, P85, DOI 10.1177/000331970605700112
   Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916
   REIBER JHC, 1993, CATHETER CARDIO DIAG, V28, P187, DOI 10.1002/ccd.1810280301
   SILVER KH, 1987, CATHETER CARDIO DIAG, V13, P291, DOI 10.1002/ccd.1810130502
   SINGH RN, 1983, J THORAC CARDIOV SUR, V86, P359
   SMITH SH, 1983, ARCH PATHOL LAB MED, V107, P13
   SPRAY TL, 1976, J THORAC CARDIOV SUR, V72, P282
   VLODAVER Z, 1971, Circulation, V44, P719
   WALLER BF, 1984, J AM COLL CARDIOL, V4, P784, DOI 10.1016/S0735-1097(84)80407-6
NR 27
TC 1
Z9 2
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 2008
VL 85
IS 2
BP 525
EP 529
DI 10.1016/j.athoracsur.2007.09.040
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 255NO
UT WOS:000252664900028
PM 18222257
DA 2018-12-27
ER

PT J
AU Volf, V
   Marx, D
   Pliskova, L
   Sumegh, L
   Celko, A
AF Volf, Vladimir
   Marx, David
   Pliskova, Ludmila
   Sumegh, Laszlo
   Celko, Alexander
TI RETRACTED: A survey of hepatitis B and C prevalence amongst the homeless
   community of Prague (Retracted article. See vol 19, pg 443, 2009)
SO EUROPEAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article; Retracted Publication
DE hepatitis B; hepatitis C infection; homelessness; intravenous drug use
ID VIRUS-INFECTION; RISK BEHAVIORS; HOMOSEXUAL MEN; TRANSMISSION; SERUM;
   HIV; DNA
AB Background: Viral hepatitis B (VHB) and C (VHC) are a major health concern worldwide, with 170 million people chronically infected and at risk of liver cancer, cirrhosis or liver failure. Since no vaccination is available against VHC it is important to understand how to prevent future infection. The modes of transmission include intravenous drug use (IDU), blood products, tattooing and, to a lesser extent, sexual intercourse. Homelessness is a risk factor of VHB and VHC because of the environments and behaviours associated with homeless communities such as poor hygiene, nutrition and high levels of IDU. The aim of this project was to determine the prevalence of VHB and VHC and its risk factors amongst homeless community of Prague, Czech Republic. Patients and methods: Ninety-eight individuals of the Prague homeless community were interviewed and tested for VHB and VHC infection markers. Results: The prevalence of both VHB and VHC was 26.5%. The major risk factors in this population were past and present IDU, young age and sharing the paraphernalia used by intravenous drug users (e.g. spoons, foils and filters). Conclusion: With the exception of age, all these risk factors could all be targeted in order to combat the major public health concern that VHB and VHC poses to the homeless community of Prague.
C1 [Volf, Vladimir; Marx, David] Charles Univ Prague, Dept Paediat & Adolescent Med, Fac Med 3, Prague 10089, Czech Republic.
   [Pliskova, Ludmila] Univ Hosp, Dept Biochem & Diagnost, Hradec Kralove, Czech Republic.
   [Sumegh, Laszlo] Social Worker Chance Ctr, Prague, Czech Republic.
   [Celko, Alexander] Charles Univ Prague, Dept Epidemiol, Fac Med 3, Ctr Prevent Med, Prague 10089, Czech Republic.
RP Volf, V (reprint author), Charles Univ Prague, Dept Paediat & Adolescent Med, Fac Med 3, Srobarova 50, Prague 10089, Czech Republic.
EM volf@fnkv.cz
CR ALTER MJ, 2005, SEMIN LIVER DIS, P15
   [Anonymous], 1999, J HEPATOL, V30, P956
   Cheung RC, 2002, J CLIN GASTROENTEROL, V34, P476, DOI 10.1097/00004836-200204000-00021
   Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5
   DESJARLAIS DC, 2007, BMC HEALTH SERV RES, P8
   Gyarmathy VA, 2006, DRUG ALCOHOL DEPEN, V82, pS65, DOI 10.1016/S0376-8716(06)80011-6
   KELLY JA, 2006, BMJ-BRIT MED J, V25, P1098
   KINGSLEY L, 1990, JAMA-J AM MED ASSOC, V2, P230
   KINGSLEY LA, 1990, JAMA-J AM MED ASSOC, V264, P230
   Kramvis A, 1996, J CLIN MICROBIOL, V34, P2731
   Mravcik V., 2000, Epidemiologie Mikrobiologie Imunologie, V49, P19
   MRAVCIK V, 2003, CZECH HLTH STAT YB
   NEMEECEK V, 2003, CEM, V12, P12
   OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385
   POLANECKY V, 2004, CZECH HLTH STAT YB
   Raoult D, 2001, Lancet Infect Dis, V1, P77, DOI 10.1016/S1473-3099(01)00062-7
   ROSENBLUM L, 1992, JAMA-J AM MED ASSOC, V267, P2477, DOI 10.1001/jama.267.18.2477
   Roy E, 2001, CAN MED ASSOC J, V165, P557
   SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7
   SCULLY LJ, 1994, J MED VIROL, V44, P293, DOI 10.1002/jmv.1890440314
   Shapatava E, 2006, DRUG ALCOHOL DEPEN, V82, pS35, DOI 10.1016/S0376-8716(06)80006-2
   Stroffolini T, 1997, MICROBIOLOGICA, V20, P333
   STUDNICKOVA B, 2004, INCIDENCE PREVALENCE
   Trmal J., 1999, Epidemiologie Mikrobiologie Imunologie, V48, P171
   *WHO, 1999, J VIRAL HEPATITUS, V6, P35, DOI DOI 10.1046/J.1365-2893.1999.6120139.X.PUBMED:10847128
NR 25
TC 13
Z9 13
U1 4
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1101-1262
EI 1464-360X
J9 EUR J PUBLIC HEALTH
JI Eur. J. Public Health
PD FEB
PY 2008
VL 18
IS 1
BP 44
EP 47
DI 10.1093/eurpub/ckm072
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 256HB
UT WOS:000252717600010
PM 17613558
OA Bronze
DA 2018-12-27
ER

PT J
AU Hurlstone, DP
   Kiesslich, R
   Thomson, M
   Atkinson, R
   Cross, SS
AF Hurlstone, D. P.
   Kiesslich, R.
   Thomson, M.
   Atkinson, R.
   Cross, S. S.
TI RETRACTED: Confocal chromoscopic endomicroscopy is superior to
   chromoscopy alone for the detection and characterisation of
   intraepithelial neoplasia in chronic ulcerative colitis (Retracted
   Article. See vol 57, pg 1634, 2008)
SO GUT
LA English
DT Article; Retracted Publication
ID INFLAMMATORY-BOWEL-DISEASE; COLON-CANCER; IN-VIVO; COLONOSCOPY;
   DYSPLASIA; CHROMOENDOSCOPY; MANAGEMENT
AB Background: The diagnosis of intraepithelial neoplasia is pivotal for ongoing clinical management decisions in ulcerative colitis. Previous studies have compared the diagnostic yield of endomicroscopy with conventional "white light'' endoscopy and hence the overall objective increase of endomicroscopy targeted biopsies as compared to chromoscopy guided alone is not apparent.
   Aims: We performed a prospective randomised controlled study to compare the diagnostic yield of intraepithelial neoplasia and cancer in patients undergoing ulcerative colitis screening using chromoscopy assisted endomicroscopy (group A) versus pan-colonic chromoscopy assisted colonoscopy (group B).
   Methods: Patients were randomised in a 1:1 ratio to undergo screening colonoscopy using either chromoscopic endomicroscopy or chromoscopy alone with targeted biopsies. Circumscribed lesions were characterised using endomicroscopy and chromoscopy with pit pattern analysis. Targeted biopsies in addition to conventional 10 cm quadrantic biopsies were taken. Primary outcome addressed the number of intraepithelial neoplasias detected in each group.
   Results: Endomicroscopy targeted biopsies significantly increased the yield of intraepithelial neoplasia as compared to pan-chromoscopy and biopsy alone (p<0.001) and also increased the yield of high-grade dysplastic lesions (p<0.001). Endomicroscopy targeted biopsies increased the diagnostic yield of intraepithelial neoplasia as compared to chromoscopy guided biopsies alone by 2.5-fold.
   Conclusions: This is the first randomised controlled study to show the true clinical benefit of endomicroscopy for the in vivo detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis surveillance colonoscopy. Endomicroscopy with targeted biopsy may potentially be the "gold standard'' for the detection of intraepithelial neoplasia in ulcerative colitis.
C1 [Hurlstone, D. P.; Atkinson, R.] Sheffield Hallam Univ, Gastroenterol & Liver Unit, Royal Hallamshire Hosp, Acad Endomicroscopy, Sheffield S1 1WB, S Yorkshire, England.
   [Kiesslich, R.] Johannes Gutenberg Univ Mainz, Med Clin, D-6500 Mainz, Germany.
   [Thomson, M.] Sheffield Childrens Hosp, Dept Endoscopy, Sheffield, S Yorkshire, England.
   [Cross, S. S.] Univ Sheffield, Sch Med, Div Gen Med, Sect Oncol & Pathol,Acad Unit Pathol, Sheffield S10 2TN, S Yorkshire, England.
RP Hurlstone, DP (reprint author), 40 Alexandra Gardens,Lyndhurst Rd,Nether Edge, Sheffield S11 9DQ, S Yorkshire, England.
EM p.hurlstone@shef.ac.uk
CR Carter MJ, 2004, GUT, V53, DOI 10.1136/gut.2004.043372
   Dekker E, 2007, ENDOSCOPY, V39, P216, DOI 10.1055/s-2007-966214
   Hurlstone DP, 2006, ENDOSCOPY, V38, P1213, DOI 10.1055/s-2006-944732
   Hurlstone DP, 2007, GUT, V56, P838, DOI 10.1136/gut.2006.106294
   Hurlstone DP, 2005, J GASTROEN HEPATOL, V20, P173, DOI 10.1111/j.1400-1746.2004.03433.x
   Hurlstone DP, 2005, ENDOSCOPY, V37, P1186, DOI 10.1055/s-921032
   Hurlstone DP, 2004, GASTROENTEROLOGY, V126, P376, DOI 10.1053/j.gastro.2003.05.021
   HURLSTONE DP, 2007, IN PRESS BR J SURG
   Kiesslich R, 2006, ENDOSCOPY, V38, P5, DOI 10.1055/s-2005-921122
   Kiesslich R, 2004, INFLAMM BOWEL DIS, V10, P695, DOI 10.1097/00054725-200409000-00031
   Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050
   Kiesslich R, 2003, GASTROENTEROLOGY, V124, P880, DOI 10.1053/gast.2003.50146
   Kiesslich R, 2007, GASTROENTEROLOGY, V132, P874, DOI 10.1053/j.gastro.2007.01.048
   Kiesslich Ralf, 2005, Gastrointest Endosc Clin N Am, V15, P715, DOI 10.1016/j.giec.2005.08.010
   Kudo S, 2001, ENDOSCOPY, V33, P367
   Paris Workshop Participants, 2003, GASTROINTEST ENDOSC, V58, pS3
   RUBIN CE, 1992, GASTROENTEROLOGY, V103, P1611, DOI 10.1016/0016-5085(92)91185-7
   Rutter MD, 2004, GUT, V53, P256, DOI 10.1136/gut.2003.016386
   Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251
NR 19
TC 54
Z9 56
U1 2
U2 11
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD FEB
PY 2008
VL 57
IS 2
BP 196
EP 204
DI 10.1136/gut.2007.131359
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 250LM
UT WOS:000252301600014
PM 18192453
DA 2018-12-27
ER

PT J
AU Chen, L
   Woo, SLC
AF Chen, Li
   Woo, Savio L. C.
TI RETRACTED: Site-specific transgene integration in the human genome
   catalyzed by phi BT1 phage integrase (Retracted Article. See vol 21, pg
   1036, 2010)
SO HUMAN GENE THERAPY
LA English
DT Article; Retracted Publication
ID PHI-C31 INTEGRASE; MAMMALIAN-CELLS; GENE; RECOMBINATION; EXPRESSION;
   CONSTRUCTION; DELIVERY; SYSTEM
AB The Streptomyces phage phi BT1 integrase catalyzes recombination between phage attP and bacterial attB sites (att, attachment), resulting in phage DNA integration into the bacterial host genome in a unidirectional manner. Multiple pseudo-attB and -attP sites are present serendipitously in mammalian genomes and can recombine with wild-type attP and attB sequences. The phi BT1 system has been used previously to achieve site-specific integration of murine phenylalanine hydroxylase cDNA into hepatocytes of mice with phenylketonuria, which led to the complete and permanent correction of the disease phenotypes without apparent toxicities. Here we report the identification of three pseudo-attP and two pseudo-attB sites in human cells, which are located in intergenic regions of five different chromosomes. There are no microdeletions of human genomic sequences at the insertional junctions and the integrated transgenes are expressed. Human cells expressing phi BT1 integrase showed normal karyotypes without chromosomal translocations between the pseudo-attB and -attP sites. Polymerase chain reaction analyses were performed on genomic DNA isolated from various human cell types expressing phi BT1 integrase, using primers flanking the pseudo-attB and -attP sites from mismatched human chromosomes. No chromosomal translocation events were detected in normal human hepatocytes, peripheral blood mononuclear cells, vascular microendothelial cells, and two other transformed human cell lines, although one such event was observed in a human melanoma cell line. The results suggest that the occurrence of chromosomal translocations is human cell type dependent, and that the phi BT1 system for site-specific integration of transgenes into the human genome can be used in selected applications.
C1 [Chen, Li; Woo, Savio L. C.] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA.
RP Woo, SLC (reprint author), Mt Sinai Sch Med, Dept Gene & Cell Med, 1 Gustave L Levy Pl,POB 1496, New York, NY 10029 USA.
EM savio.woo@mssm.edu
FU NIGMS NIH HHS [GM-075018]
CR Allen BG, 2005, NAT METHODS, V2, P975, DOI 10.1038/NMETH814
   Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787
   Calos MP, 2006, CURR GENE THER, V6, P633, DOI 10.2174/156652306779010642
   Chalberg TW, 2005, INVEST OPHTH VIS SCI, V46, P2140, DOI 10.1167/iovs.04-1252
   Chalberg TW, 2006, J MOL BIOL, V357, P28, DOI 10.1016/j.jmb.2005.11.098
   Chen L, 2005, P NATL ACAD SCI USA, V102, P15581, DOI 10.1073/pnas.0503877102
   Ehrhardt A, 2006, HUM GENE THER, V17, P1077, DOI 10.1089/hum.2006.17.1077
   Ginsburg DS, 2005, ADV GENET, V54, P179, DOI 10.1016/S0065-2660(05)54008-2
   Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775
   Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097
   Held PK, 2005, MOL THER, V11, P399, DOI 10.1016/j.ymthe.2004.11.001
   Hollis Roger P, 2003, Reprod Biol Endocrinol, V1, P79, DOI 10.1186/1477-7827-1-79
   Ishikawa Y, 2006, J GENE MED, V8, P646, DOI 10.1002/jgm.891
   KERAVALA A, 2006, MOL GENET GENOMICS, V276, P136
   KITAJIMA K, 2006, THROMB VASC BIOL, V26, P1852
   Liu J, 2006, GENE THER, V13, P1188, DOI 10.1038/sj.gt.3302789
   Lutz KA, 2004, PLANT J, V37, P906, DOI 10.1111/j.1365-313X.2004.02015.x
   Malla S, 2005, NUCLEIC ACIDS RES, V33, P6101, DOI 10.1093/nar/gki922
   OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642
   Olivares EC, 2001, GENE, V278, P167, DOI 10.1016/S0378-1119(01)00711-9
   Ortiz-Urda S, 2003, HUM GENE THER, V14, P923, DOI 10.1089/104303403765701204
   Portlock JL, 2006, HUM GENE THER, V17, P871, DOI 10.1089/hum.2006.17.871
   Quenneville SP, 2004, MOL THER, V10, P679, DOI 10.1016/j.ymthe.2004.05.034
   Sauer Brian, 1994, Current Opinion in Biotechnology, V5, P521, DOI 10.1016/0958-1669(94)90068-X
   Smith MCM, 2002, MOL MICROBIOL, V44, P299, DOI 10.1046/j.1365-2958.2002.02891.x
   Stoll SM, 2002, J BACTERIOL, V184, P3657, DOI 10.1128/JB.184.13.3657-3663.2002
   Thomason LC, 2001, MOL GENET GENOMICS, V265, P1031, DOI 10.1007/s004380100498
   Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001
   VONDERWEGEN P, 2006, MOL THER, V13, P374
   Yang HY, 2002, J BACTERIOL, V184, P1859, DOI 10.1128/JB.184.7.1859-1864.2002
NR 30
TC 8
Z9 8
U1 2
U2 14
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB
PY 2008
VL 19
IS 2
BP 143
EP 151
DI 10.1089/hum.2007.110
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 266SB
UT WOS:000253456200004
PM 18067406
DA 2018-12-27
ER

PT J
AU Alinvi, O
   Bohlin, J
   Ball, JP
AF Alinvi, O.
   Bohlin, J.
   Ball, J. P.
TI RETRACTED: Interspecific competition among ants in the boreal forest:
   Testing predictions from a linear hierarchical competition model
   (Retracted article)
SO INSECTES SOCIAUX
LA English
DT Article; Retracted Publication
DE competition; wood ants; nest density; community composition; transitive
   hierarchy
ID SANGUINEA LATR. HYMENOPTERA; FORMICA-FUSCA; WOOD ANTS; COMMUNITIES;
   INTERFERENCE; ASSEMBLAGES; TERRITORIES; POLYCTENA; MYRMICA; TAIGA
AB Competitive interactions often play an important role in local community structure, and particularly so in ant communities. We test predictions derived from a competition model proposed for Scandinavian ant communities by comparing ant nest densities inside and outside fifty randomly-selected territories of competitively dominant wood ants within 30 km of Umea, northern Sweden. As predicted by the model, competitively-intermediate encounter species, as well as other territorial species, showed complementary occurrences with both studied wood ants, Formica aquilonia Yarrow and F. lugubris Zett.. In contrast, complementary abundances, i.e. lower density of competitively-inferior submissive species in the presence of wood ants, as predicted by the model, was not supported for all submissive species. Of the two studied wood ant species, the nest density of submissive species was negatively correlated only with F. aquilonia. Submissives as a group, as well as Myrmica-species, showed complementary abundances with F. aquilonia, but one Leptothorax and two Serviformica species had higher nest densities in the presence of this competitively-dominant species. We propose that, for Leptothorax, these deviations from the model predictions may be because of limited niche overlap with dominant wood ants, a small worker force and a timid behaviour which does not elicit aggression in wood ants. For the two Serviformica species, we propose a combination of protection against social parasites, inter-specific social control performed by F. aquilonia, and dominance relationships between competitively-inferior submissive species as reasons for the higher nest density inside F. aquilonia territories. Monogyny, and thereby smaller nests, lower worker force, smaller territory (as shown by this study) in F. lugubris, as compared to the polygyny in F. aquilonia, may also help explain the differences in their effects on subordinate species. Our analyses indicate that the linear competition hierarchy model proposed for Scandinavian ants accurately predicts the outcome of interaction between and community composition for dominant territorial and encounter species, but that it needs refinement with respect to the relationship between territorial and submissive species and the resulting community composition. Further studies are needed, especially addressing the complex relationships between these latter groups, and the effects of different competitively-dominant wood ants, to determine the mechanisms determining the outcome of these relationships and to more accurately predict community composition.
C1 [Alinvi, O.; Bohlin, J.; Ball, J. P.] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden.
RP Alinvi, O (reprint author), Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, SE-90183 Umea, Sweden.
EM Ola.Alinvi@vfm.slu.se
CR Ahti T., 1968, ANN BOT FENN, V5, P169
   ANDERSEN AN, 1991, ANT - PLANT INTERACTIONS, P539
   ANDERSEN AN, 1997, CONSERV ECOL, V1
   BRIAN MV, 1956, J ANIM ECOL, V25, P319, DOI 10.2307/1929
   BRIAN MV, 1952, J ANIM ECOL, V21, P12, DOI 10.2307/1907
   BRIAN MV, 1965, J ANIM ECOL, V34, P545, DOI 10.2307/2448
   BRIAN MV, 1976, J ANIM ECOL, V45, P115, DOI 10.2307/3771
   BUSS LW, 1980, P NATL ACAD SCI-BIOL, V77, P5355, DOI 10.1073/pnas.77.9.5355
   BUSS LW, 1979, AM NAT, V113, P223, DOI 10.1086/283381
   Cerda X, 1997, J ANIM ECOL, V66, P363, DOI 10.2307/5982
   Collingwood C.A., 1979, Fauna Entomologica Scandinavica, V8, P1
   Czechowski W, 2005, POL J ECOL, V53, P467
   Czechowski W, 2000, ANN ZOOL, V50, P35
   CZECHOWSKI W, 1985, Annales Zoologici (Warsaw), V39, P153
   CZECHOWSKI W, 1988, Annales Zoologici (Warsaw), V41, P355
   Czechowski W., 1979, Annales Zoologici (Warsaw), V34, P437
   Czechowski W., 1990, Memorabilia Zoologica, V44, P83
   Czechowski W, 2001, ANN ZOOL, V51, P267
   Czechowski W, 2002, ANTS HYMENOPTERA FOR
   Czechowski Wojciech, 1997, Annales Zoologici (Warsaw), V47, P469
   Czechowski Wojciech, 1999, Annales Zoologici (Warsaw), V49, P117
   Czechowski W, 2006, ANN ZOOL, V56, P539
   Czechowski Wojciech, 1999, Annales Zoologici (Warsaw), V49, P125
   DOBRZANSKI JAN, 1966, ACTA BIOL EXP, V26, P71
   Douwes Per, 1995, Entomologisk Tidskrift, V116, P83
   GREENSLA.PJ, 1973, INSECT SOC, V20, P343, DOI 10.1007/BF02226087
   GUREVITCH J, 1992, AM NAT, V140, P539, DOI 10.1086/285428
   LeBrun EG, 2005, OECOLOGIA, V142, P643, DOI 10.1007/s00442-004-1763-4
   MABELIS AA, 1984, NETH J ZOOL, V34, P1
   Majer Jonathan D., 1993, P115
   MARIKOVSKY PI, 1962, ENTOMOL REV, V41, P47
   Marko B, 2004, ANN ZOOL, V54, P365
   Novgorodova T.A., 1996, Sibirskii Ekologicheskii Zhurnal, V3, P239
   OINONEN EA, 1957, ACTA ENTOMOL FENNICA, V12, P1
   Oliveras J, 2005, SOCIOBIOLOGY, V45, P643
   Parr CL, 2005, AM NAT, V165, P481, DOI 10.1086/428292
   Pickles W, 1936, J ANIM ECOL, V5, P262, DOI 10.2307/1032
   PISARSKI B, 1989, Annales Zoologici (Warsaw), V42, P321
   PISARSKI B, 1980, INSECT SOC, V27, P284
   PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989
   Punttila P, 1996, ECOGRAPHY, V19, P16, DOI 10.1111/j.1600-0587.1996.tb00151.x
   PUNTTILA P, 1991, OIKOS, V61, P250, DOI 10.2307/3545343
   Punttila P, 1996, OIKOS, V75, P291, DOI 10.2307/3546252
   Punttila Pekka, 1996, Silva Fennica, V30, P421
   Retana J, 2000, OECOLOGIA, V123, P436, DOI 10.1007/s004420051031
   REZNIKOVA JI, 1982, BEHAVIOUR, V80, P84, DOI 10.1163/156853982X00454
   REZNIKOVA Z, 1994, P 6 INT C EC MANCH U, P27
   Reznikova Zh I, 2005, Dokl Biol Sci, V401, P110, DOI 10.1007/s10630-005-0058-1
   Reznikova ZI, 1999, RUSS J ECOL+, V30, P187
   REZNIKOVA ZI, 2001, DOKL AKAD NAUK, V380, P367
   Ribas CR, 2002, OECOLOGIA, V131, P606, DOI 10.1007/s00442-002-0912-x
   ROSENGREN R, 1986, ANN ZOOL FENN, V23, P297
   Sanders NJ, 2003, ECOLOGY, V84, P1024, DOI 10.1890/0012-9658(2003)084[1024:RIATOO]2.0.CO;2
   SAVOLAINEN R, 1988, OIKOS, V51, P135, DOI 10.2307/3565636
   SAVOLAINEN R, 1989, OECOLOGIA, V81, P481, DOI 10.1007/BF00378955
   SAVOLAINEN R, 1991, BEHAV ECOL SOCIOBIOL, V28, P1
   SAVOLAINEN R, 1989, OIKOS, V56, P3, DOI 10.2307/3566082
   SAVOLAINEN R, 1990, ECOL ENTOMOL, V15, P79, DOI 10.1111/j.1365-2311.1990.tb00786.x
   Schlick-Steiner BC, 2006, INSECT SOC, V53, P274, DOI 10.1007/s00040-006-0869-6
   Seifert Bernhard, 1992, Abhandlungen und Berichte des Naturkundemuseums Goerlitz, V66, P1
   Siegel S, 1956, NONPARAMETRIC STAT B
   SMITRIENKO VK, 1976, MURAVI TAEZHNYK BIOS
   STEBAEV I V, 1972, Ekologia polska, V20, P103
   STRONG DR, 1984, ECOLOGICAL COMMUNITI
   Vepsalainen K, 2000, ANN ZOOL FENN, V37, P135
   VEPSALAINEN K, 1990, J ANIM ECOL, V59, P643, DOI 10.2307/4886
   VEPSALAINEN K, 1982, ANN ZOOL FENN, V19, P327
   VEPSALAINEN K, 1980, INSECT SOC, V27, P281
   Weiher E, 1999, OIKOS, V87, P355, DOI 10.2307/3546751
   Wiens J.A., 1989, ECOLOGY BIRD COMMUNI, VI
NR 70
TC 2
Z9 3
U1 2
U2 19
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0020-1812
EI 1420-9098
J9 INSECT SOC
JI Insect. Soc.
PD FEB
PY 2008
VL 55
IS 1
BP 1
EP 11
DI 10.1007/s00040-007-0964-3
PG 11
WC Entomology
SC Entomology
GA 267RU
UT WOS:000253527700001
DA 2018-12-27
ER

PT J
AU Unal, GS
   Yapar, A
   Akduman, I
AF Uenal, Guel Seda
   Yapar, Ali
   Akduman, Ibrahim
TI RETRACTED: Surface impedance determination of an object located over a
   planar PEC surface and its use in shape reconstruction (Retracted
   article. See vol. 25, pg. NIL_0246, 2009)
SO INVERSE PROBLEMS
LA English
DT Article; Retracted Publication
ID PERFECTLY CONDUCTING OBJECTS; INVERSE SCATTERING; BOUNDARY-CONDITIONS
AB A method is presented for the reconstruction of inhomogeneous surface impedance of a two-dimensional (2D) cylindrical object of slightly varying arbitrary shape located over a perfectly electric conducting (PEC) plane. The method is an extension of the one given previously (Akduman I and Kress R 2003 Radio Sci. 38 1055). By the use of a single layer potential representation of the scattered field the problem is first reduced to the solution of an ill-posed integral equation which can be treated by truncated singular value decomposition (TSVD). Then the field itself and its normal derivative on the boundary of the object, which are required for the evaluation of the surface impedance, are obtained by the use of jump relations through the Nystrom method. Since the reconstruction of the surface impedance from the field and its normal derivative is ill-posed, a regularized solution in the sense of least squares is applied. By considering the relation between the shape of a PEC object and its equivalent one in terms of surface impedance, it is shown that the method can also be used in the shape reconstruction. The numerical implementation shows that the method is capable of reconstructing the surface impedance as well as shape even with aspect limited data. This is due to the fact that the PEC plane has a mirror effect on the measured data which corresponds to full view configuration as in the case of objects located in an infinite medium.
C1 [Uenal, Guel Seda; Yapar, Ali; Akduman, Ibrahim] Istanbul Tech Univ, Elect & Elect Engn Fac, TR-34469 Istanbul, Turkey.
RP Unal, GS (reprint author), Istanbul Tech Univ, Elect & Elect Engn Fac, TR-34469 Istanbul, Turkey.
CR Akduman I, 2003, RADIO SCI, V38, DOI 10.1029/2002RS002631
   Akduman I, 2001, IEEE T ANTENN PROPAG, V49, P304, DOI 10.1109/8.914298
   Belkebir K, 1997, IEEE T MICROW THEORY, V45, P469, DOI 10.1109/22.566625
   BOJARSKI NN, 1982, IEEE T ANTENN PROPAG, V30, P980, DOI 10.1109/TAP.1982.1142890
   Cakoni F, 2003, SIAM J APPL MATH, V64, P709, DOI 10.1137/S0036139903424254
   Colton D, 2003, INVERSE PROBL, V19, pS105, DOI 10.1088/0266-5611/19/6/057
   COLTON D, 1999, INVERSE ACOUSTIC ELE
   Colton D, 2006, INVERSE PROBL, V22, pR49, DOI 10.1088/0266-5611/22/3/R01
   Hoppe D J, 1995, IMPEDANCE BOUNDARY C
   IMBRIALE WA, 1970, IEEE T ANTENN PROPAG, VAP18, P633, DOI 10.1109/TAP.1970.1139769
   KIRSCH A., 1987, BOUNDARY ELEMENTS 9, V3, P3
   Kress R, 2003, INVERSE PROBL, V19, pS91, DOI 10.1088/0266-5611/19/6/056
   Kress R, 2001, INVERSE PROBL, V17, P1075, DOI 10.1088/0266-5611/17/4/334
   LIU CY, 1996, IEEE T ANTENN PROPAG, V44, P310
   Marceaux O, 2000, IEEE T ANTENN PROPAG, V48, P429, DOI 10.1109/8.841904
   Ozdemir O, 2007, IEEE T GEOSCI REMOTE, V45, P1291, DOI 10.1109/TGRS.2007.893564
   Pierri R, 2001, IEEE T ANTENN PROPAG, V49, P1333, DOI 10.1109/8.947025
   Qing A, 2001, IEEE T GEOSCI REMOTE, V39, P665, DOI 10.1109/36.911123
   Sabatier P.C., 1987, BASIC METHODS TOMOGR, P127
   Sahinturk H, 2004, IEEE T MAGN, V40, P1152, DOI 10.1109/TMAG.2004.824610
   Senior T.B.A., 1995, APPROXIMATE BOUNDARY
   Senior TBA, 1997, IEEE T ANTENN PROPAG, V45, P107, DOI 10.1109/8.554247
   Yapar A, 2001, RADIO SCI, V36, P539, DOI 10.1029/2000RS002529
NR 23
TC 1
Z9 1
U1 2
U2 9
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0266-5611
EI 1361-6420
J9 INVERSE PROBL
JI Inverse Probl.
PD FEB
PY 2008
VL 24
IS 1
AR 015020
DI 10.1088/0266-5611/24/1/015020
PG 12
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA 276OC
UT WOS:000254150900022
DA 2018-12-27
ER

PT J
AU Mengistu, AM
   Wolf, MW
   Boldt, J
   Rohm, KD
   Lang, J
   Piper, SN
AF Mengistu, Andinet M.
   Wolf, Michael W.
   Boldt, Joachim
   Roehm, Kerstin D.
   Lang, Johannes
   Piper, Swen N.
TI RETRACTED: Evaluation of a new platelet function analyzer in cardiac
   surgery: A comparison of modified thromboelastography and whole-blood
   aggregometry (Retracted article. See vol. 25, pg. 756, 2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE platelets; aggregometry; point of care; cardiopulmonary bypass;
   thromboelastography
ID ARTERY-BYPASS-SURGERY; CARDIOPULMONARY BYPASS; RECEPTORS; AGGREGATION
AB Objectives: Impaired hemostasis of multiple etiologies are often present in patients undergoing cardiopulmonary bypass (CPB) surgery. Platelet dysfunction is considered to be important in the early postoperative period. Therefore, a new whole-blood platelet function analyzer was compared with thromboelastography in predicting postoperative hemostatic outcomes as measured by blood loss and blood product use. Design: Prospective study. Setting: Teaching hospital. Participants: The study enrolled 54 patients scheduled for coronary artery bypass surgery with CPB. Interventions: Coagulation and platelet function were assessed preoperatively, after CPB, at 3 hours, and at 24 hours after surgery by using thromboelastography and impedance aggregometry. Patients were divided into a transfused, and nontransfused group on the basis of postoperative transfusion requirements. Postoperative blood loss and requirements of blood transfusions were documented until 24 hours postoperatively. Measurements and Main Results: Twenty-five patients (46%) received postoperative blood transfusions. Impaired hemostasis occurred after CPB detected by thromboelastography (p < 0.01) and impedance aggregometry (p < 0.01). In contrast to thromboelastography, preoperative adenosine diphosphate-mediated aggregometry correlated with postoperative requirements for blood transfusion (Spearman r = -0.302, p < 0.05) and was significantly lower in patients receiving allogeneic blood transfusion compared with nontransfused patients (p < 0.05). Neither aggregometry nor thromboelastography was correlated with postoperative blood loss. Conclusion: Impedance aggregometry as well as thromboelastography are able to detect impaired hemostasis after CPB. In contrast to thromboelastography, aggregometry using a new whole-blood aggregometer identified patients with a reduced risk for postoperative transfusion requirements. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Mengistu, Andinet M.; Wolf, Michael W.; Boldt, Joachim; Roehm, Kerstin D.; Lang, Johannes; Piper, Swen N.] Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Mengistu, AM (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM a.mengistu@gmx.de
CR AuBuchon J P, 1996, Am J Med, V101, p38S, DOI 10.1016/S0002-9343(96)00163-5
   Breddin HK, 2005, PLATELETS, V16, P151, DOI 10.1080/09537100400020161
   Cammerer U, 2003, ANESTH ANALG, V96, P51, DOI 10.1213/01.ANE.0000039800.43911.C0
   Cattaneo M, 1999, ARTERIOSCL THROM VAS, V19, P2281, DOI 10.1161/01.ATV.19.10.2281
   Chandler WL, 1995, SEMIN THROMB HEMOST, V21, P1
   Dietrich GV, 1998, THROMB RES, V89, P295, DOI 10.1016/S0049-3848(98)00020-6
   Dietrich W, 2006, ANAESTHESIST, V55, P753, DOI 10.1007/s00101-006-1035-2
   DORMAN BH, 1993, ANESTH ANALG, V76, P694
   Dyszkiewicz-Korpanty AM, 2005, CLIN APPL THROMB-HEM, V11, P25, DOI 10.1177/107602960501100103
   Ereth MH, 1997, ANESTH ANALG, V85, P259, DOI 10.1097/00000539-199708000-00004
   Essell J H, 1993, J Cardiothorac Vasc Anesth, V7, P410, DOI 10.1016/1053-0770(93)90161-D
   Fattorutto M, 2003, BRIT J ANAESTH, V90, P692, DOI 10.1093/bja/aeg110
   Forestier F, 2002, BRIT J ANAESTH, V89, P715, DOI 10.1093/bja/aef250
   Holada K, 1996, PERFUSION-UK, V11, P401, DOI 10.1177/026765919601100508
   KESTIN AS, 1993, BLOOD, V82, P107
   Khurana S, 1997, J LAB CLIN MED, V130, P401, DOI 10.1016/S0022-2143(97)90040-8
   Michelson AD, 2004, CIRCULATION, V110, pE489, DOI 10.1161/01.CIR.0000147228.29325.F9
   PRISCO D, 2003, THROMB J, V1, P1, DOI DOI 10.1186/1477-9560-1-1
   RAY MJ, 1994, BLOOD COAGUL FIBRIN, V5, P679, DOI 10.1097/00001721-199410000-00002
   Ray MJ, 1997, ANN THORAC SURG, V63, P57
   RINDER CS, 1991, ANESTHESIOLOGY, V75, P388, DOI 10.1097/00000542-199109000-00002
   RINDER CS, 1991, ANESTHESIOLOGY, V75, P563, DOI 10.1097/00000542-199110000-00004
   Shore-Lesserson L, 1999, ANESTH ANALG, V88, P312, DOI 10.1097/00000539-199902000-00016
   SPIESS BD, 1995, J CARDIOTHOR VASC AN, V9, P168, DOI 10.1016/S1053-0770(05)80189-2
   Stehling LC, 1996, ANESTHESIOLOGY, V84, P732
   Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009
   VALLES J, 1991, BLOOD, V78, P154
   WOODMAN RC, 1990, BLOOD, V76, P1680
NR 28
TC 45
Z9 45
U1 3
U2 20
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD FEB
PY 2008
VL 22
IS 1
BP 40
EP 46
DI 10.1053/j.jvca.2007.02.015
PG 7
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 265VH
UT WOS:000253389200009
PM 18249329
DA 2018-12-27
ER

PT J
AU Liu, HH
   Liu, J
   Fan, SL
   Song, MZ
   Han, XL
   Liu, F
   Shen, FF
AF Liu, H. H.
   Liu, J.
   Fan, S. L.
   Song, M. Z.
   Han, X. L.
   Liu, F.
   Shen, F. F.
TI RETRACTED: Molecular cloning and characterization of a salinity
   stress-induced gene encoding DEAD-box helicase from the halophyte
   Apocynum venetum (Retracted article. See vol. 69, pg. 4145, 2018)
SO JOURNAL OF EXPERIMENTAL BOTANY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Annual Meeting of the Society-for-Experimental-Biology
CY MAR 31-APR 04, 2007
CL Glasgow, SCOTLAND
SP Soc Expt Biol
DE Apocynum venetum; ATPase; ATP-dependent DNA helicase; ATP-independent
   RNA helicase; AvDH1; DEAD-box family; salt stress
ID TRANSLATION INITIATION-FACTOR; DOUBLE-STRANDED-RNA; DNA HELICASE;
   PROTEIN FAMILY; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ABIOTIC
   STRESS; PISUM-SATIVUM; FACTOR EIF-4A; SALT STRESS
AB The genes encoding DEAD-box helicases play a key role in various abiotic stresses, including temperature, light, oxygen, and salt stress. A salt-responsive gene, designated AvDH1, was isolated from the halophyte dogbane (Apocynum venetum) by using suppression subtractive hybridization and RACE (rapid amplification of cDNA ends) PCR. The deduced amino acid sequence has nine conserved helicase motifs of the DEAD-box protein family. The AvDH1 gene is present as a single copy in the dogbane genome. This gene is expressed in response to NaCl and not polyethlene glycol (PEG) nor abscisic acid, and its expression increases with time. The transcription of AvDH1 is also induced by low temperature (4 degrees C), but its accumulation first increases then decreases with time. The purified recombinant protein contains ATP-dependent DNA helicase activity, ATP-independent RNA helicase activity, and DNA- or RNA-dependent ATPase activity. The ATPase activity of AvDH1 is stimulated more by single-stranded DNA than by double-stranded DNA or RNA. These results suggested that AvDH1 belonging to the DEAD-box helicase family is induced by salinity, functions as a typical helicase to unwind DNA and RNA, and may play an important role in salinity tolerance.
C1 [Liu, H. H.; Liu, J.; Han, X. L.; Liu, F.; Shen, F. F.] Shandong Agr Univ, Coll Agron, State Key Lab Crop Biol, Tai An 271018, Shandong, Peoples R China.
   [Fan, S. L.; Song, M. Z.] Chinese Acad Agr Sci, Cotton Res Inst, Anyang 455100, Henan, Peoples R China.
RP Shen, FF (reprint author), Shandong Agr Univ, Coll Agron, State Key Lab Crop Biol, Tai An 271018, Shandong, Peoples R China.
EM ffshen@sdau.edu.cn
CR Aubourg S, 1999, NUCLEIC ACIDS RES, V27, P628, DOI 10.1093/nar/27.2.628
   BAGLIONI C, 1978, EUR J BIOCHEM, V92, P155, DOI 10.1111/j.1432-1033.1978.tb12733.x
   BRANDER KA, 1995, BBA-GENE STRUCT EXPR, V1261, P442, DOI 10.1016/0167-4781(95)00052-I
   CANNON GC, 1990, PLANT MOL BIOL, V15, P457, DOI 10.1007/BF00019162
   Chao DY, 2005, CELL RES, V15, P796, DOI 10.1038/sj.cr.7290349
   Chen Y. Y., 2007, CHINESE WILD PLANT R, V26, P49
   Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045
   Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019
   Diges CM, 2001, EMBO J, V20, P5503, DOI 10.1093/emboj/20.19.5503
   EDY VG, 1976, EUR J BIOCHEM, V61, P563, DOI 10.1111/j.1432-1033.1976.tb10051.x
   Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0
   Gong ZZ, 2005, PLANT CELL, V17, P256, DOI 10.1105/tpc.104.027557
   Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677
   JACOBSON AB, 1976, P NATL ACAD SCI USA, V73, P307, DOI 10.1073/pnas.73.2.307
   Jankowsky E, 2007, CURR OPIN STRUC BIOL, V17, P316, DOI 10.1016/j.sbi.2007.05.007
   Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76
   Kawasaki S, 2001, PLANT CELL, V13, P889, DOI 10.1105/tpc.13.4.889
   Kikuma T, 2004, J BIOL CHEM, V279, P20692, DOI 10.1074/jbc.M400231200
   KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x
   Kim DW, 2007, MOL CELLS, V24, P45
   KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0
   Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532
   Liu HY, 2002, J BIOL CHEM, V277, P2637, DOI 10.1074/jbc.M109016200
   Lorkovic ZJ, 1997, MOL CELL BIOL, V17, P2257, DOI 10.1128/MCB.17.4.2257
   Mahajan S, 2005, ARCH BIOCHEM BIOPHYS, V444, P139, DOI 10.1016/j.abb.2005.10.018
   Montero-Lomeli M, 2002, J BIOL CHEM, V277, P21542, DOI 10.1074/jbc.M201977200
   Mukhopadhyay A, 2006, J BACTERIOL, V188, P4068, DOI 10.1128/JB.01921-05
   Munns R, 2005, NEW PHYTOL, V167, P645, DOI 10.1111/j.1469-8137.2005.01487.x
   Nakamura T, 2004, PLANT SCI, V167, P63, DOI 10.1016/j.plantsci.2004.03.001
   Owttrim GW, 2006, NUCLEIC ACIDS RES, V34, P3220, DOI 10.1093/nar/gkl408
   Ozturk ZN, 2002, PLANT MOL BIOL, V48, P551, DOI 10.1023/A:1014875215580
   PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789
   PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x
   Pham XH, 2000, PLANT J, V24, P219, DOI 10.1046/j.1365-313x.2000.00869.x
   Phan TN, 2003, EUR J BIOCHEM, V270, P1735, DOI 10.1046/j.1432-1033.2003.03532.x
   Rausell A, 2003, PLANT J, V34, P257, DOI 10.1046/j.1365-313X.2003.01719.x
   Rensink Willem Albert, 2005, Functional & Integrative Genomics, V5, P201, DOI 10.1007/s10142-005-0141-6
   RODRIGUEZ PL, 1993, J BIOL CHEM, V268, P8105
   Sanan-Mishra N, 2005, P NATL ACAD SCI USA, V102, P509, DOI 10.1073/pnas.0406485102
   SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x
   Steiner P, 2003, APPL MICROBIOL BIOT, V63, P293, DOI 10.1007/s00253-003-1405-5
   Tuteja N, 1996, EUR J BIOCHEM, V238, P54, DOI 10.1111/j.1432-1033.1996.0054q.x
   Tuteja N, 1998, PLANT PHYSIOL, V118, P1029, DOI 10.1104/pp.118.3.1029
   Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x
   Tuteja N, 2004, EUR J BIOCHEM, V271, P1835, DOI 10.1111/j.1432-1033.2004.04093.x
   Tuteja N, 2003, J EXP BOT, V54, P2201, DOI 10.1093/jxb/erg246
   Tuteja N, 2001, PLANT J, V25, P9, DOI 10.1046/j.1365-313x.2001.00918.x
   Vashisht AA, 2005, PLANT J, V44, P76, DOI 10.1111/j.1365-313X.2005.02511.x
   Vashisht AA, 2005, ARCH BIOCHEM BIOPHYS, V440, P79, DOI 10.1016/j.abb.2005.05.025
   Vashisht AA, 2006, J PHOTOCH PHOTOBIO B, V84, P150, DOI 10.1016/j.jphotobiol.2006.02.010
   WAIDTEE R, 2007, J BIOL CHEM, V282, P34185
   Wang H, 2003, PLANT MOL BIOL, V52, P873, DOI 10.1023/A:1025029026375
   Wong CE, 2006, PLANT PHYSIOL, V140, P1437, DOI 10.1104/pp.105.070508
   Yamaguchi T, 2005, TRENDS PLANT SCI, V10, P615, DOI 10.1016/j.tplants.2005.10.002
   Yang QS, 2005, BIOCHEMISTRY-US, V44, P13591, DOI 10.1021/bi0508946
   Yu E, 2000, NUCLEIC ACIDS RES, V28, P3926, DOI 10.1093/nar/28.20.3926
NR 56
TC 31
Z9 37
U1 2
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-0957
EI 1460-2431
J9 J EXP BOT
JI J. Exp. Bot.
PD FEB
PY 2008
VL 59
IS 3
BP 633
EP 644
DI 10.1093/jxb/erm355
PG 12
WC Plant Sciences
SC Plant Sciences
GA 278NN
UT WOS:000254293700018
PM 18272921
OA Bronze
DA 2018-12-27
ER

PT J
AU Nagy, N
   Malik, G
   Tosaki, A
   Ho, YS
   Maulik, N
   Das, DK
AF Nagy, Norbert
   Malik, Gautam
   Tosaki, Arpad
   Ho, Ye-Shih
   Maulik, Nilanjana
   Das, Dipak K.
TI RETRACTED: Overexpression of glutaredoxin-2 reduces myocardial cell
   death by preventing both apoptosis and necrosis (Retracted article. See
   vol. 53, pg. 744, 2012)
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article; Retracted Publication
DE heart; glutaredoxin-2; redox signaling; reactive oxygen species;
   transgenic mice
ID CARDIOMYOCYTE APOPTOSIS; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; REDOX
   REGULATION; TRANSGENIC MICE; CYTOCHROME-C; THIOREDOXIN; MITOCHONDRIA;
   HEART; SURVIVAL
AB Mitochondrial glutaredoxin-2 (Glrx2) has been recognized as an important redox regulator in mammalian organs including heart. To date no investigations have addressed the potential role of Glrx2 in cardiac disorders. The present study examined if myocardial overexpression of Glrx2 in the heart could rescue the cardiac cells from apoptosis and necrosis induced by ischemia and reperfasion. The human Glrx2 transgene was created by placing a full-length cDNA fragment encoding human mitochondrial Glrx2 downstream to the 5' flanking sequence and promoter of the mouse a-myosin heavy chain gene. The isolated hearts from Glrx2 transgenic mice and non-transgenic (wild type) littermates [on c57BL/6xC3H hybrid background] were subjected to 30 min of global ischemia followed by 2 h of reperfasion via working mode. The hearts from Glrx2 transgenic mice displayed significantly improved contractile performance and reduced myocardial infarct size and cardiomyocyte apoptosis. There was a reduction in cytochrome c release and activation of caspase 3 and caspase 9. Glrx2 overexpression also reduced the ischemia/reperfusion-mediated loss of mitochondrial cardiolipin, decreased the activities of reactive oxygen species (ROS) and preserved GSH/GSSG ratio. Glrx2 mediated survival signal appeared to be stemmed from PI-3-kinase-Akt survival signaling pathway and involved the activation of redox sensitive transcription factor NF kappa B and antiapoptotic protein Bcl-2. The results indicated a crucial role of mitochondrial Glrx2 in cardioprotection. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Nagy, Norbert; Maulik, Nilanjana; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   [Nagy, Norbert; Malik, Gautam; Tosaki, Arpad] Univ Debrecen, Dept Pharmacol, Fac Pharm, Hlth Sci Ctr, H-4012 Debrecen, Hungary.
   [Ho, Ye-Shih] Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI USA.
RP Das, DK (reprint author), Univ Debrecen, Dept Pharmacol, Fac Pharm, Hlth Sci Ctr, H-4012 Debrecen, Hungary.
EM DDAS@NEURON.UCHC.EDU
FU NHLBI NIH HHS [HL 22559, HL 56803, HL 33889]; NIEHS NIH HHS [P30
   ES06639]
CR Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780
   Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200
   Berndt C, 2007, AM J PHYSIOL-HEART C, V292, pH1227, DOI 10.1152/ajpheart.01162.2006
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Capano M, 2006, BIOCHEM J, V395, P57, DOI 10.1042/BJ20051654
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313
   CORDIS GA, 1995, J MOL CELL CARDIOL, V27, P1645, DOI 10.1016/S0022-2828(95)90656-8
   Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Del Re DP, 2007, J BIOL CHEM, V282, P8069, DOI 10.1074/jbc.M604298200
   Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067
   Fariss MW, 2005, MOL INTERV, V5, P94, DOI 10.1124/mi.5.2.7
   Fernando MR, 2006, FASEB J, V20, P2645, DOI 10.1096/fj.06-5919fje
   Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9
   HOGAN R, 1994, MANIPULATING MOUSE E
   HOLMGREN A, 1989, J BIOL CHEM, V264, P13963
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102
   Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101
   Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea
   Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0
   Metrailler-Ruchonnet I, 2007, FREE RADICAL BIO MED, V42, P1062, DOI 10.1016/j.freeradbiomed.2007.01.008
   MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002
   Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183
   PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275
   SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613
   Turoczi T, 2003, J MOL CELL CARDIOL, V35, P695, DOI 10.1016/S0022-2828(03)00117-2
   Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90
   Xiong Y, 2006, FREE RADICAL BIO MED, V41, P46, DOI 10.1016/j.freeradbiomed.2006.02.024
   Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019
NR 37
TC 43
Z9 46
U1 2
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD FEB
PY 2008
VL 44
IS 2
BP 252
EP 260
DI 10.1016/j.yjmcc.2007.08.021
PG 9
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA 275AC
UT WOS:000254043300005
PM 18076901
DA 2018-12-27
ER

PT J
AU Malik, G
   Nagy, N
   Ho, YS
   Maulik, N
   Das, DK
AF Malik, Gautam
   Nagy, Norbert
   Ho, Ye-Shih
   Maulik, Nilanjana
   Das, Dipak K.
TI RETRACTED: Role of glutaredoxin-1 in cardioprotection: An insight with
   Glrx1 transgenic and knockout animals (Retracted article. See vol. 53,
   pg. 745, 2012)
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article; Retracted Publication
DE glutaredoxin; reactive oxygen species; transgenic and knockout mice;
   adapted heart; ischemia/reperfusion; redox signaling
ID S-GLUTATHIOLATION; OXIDATIVE STRESS; THIOREDOXIN; HEART;
   THIOLTRANSFERASE; EXPRESSION; PROTECTION; APOPTOSIS; SIGNAL;
   MITOCHONDRIAL
AB This study examined if glutaredoxin-1 (Glrx1), a redox-regulator of thioredoxin superfamily, plays any role in the redox signaling of ischemic myocardium. The hearts were subjected to 30 min of coronary occlusion followed by 24 h of reperfusion. Another group of hearts was rendered tolerant to ischemia (preconditioned, PC) by four cyclic episodes of 5 min ischemia each followed by another 10 min of reperfusion, which was then subjected to 30 min ischemia, and 24 It of coronary occlusion. While ischemia/reperfusion had no effect on Glrx1 expression, adaptation to ischemia resulted in the upregulation of Glrx1 expression, which was inhibited by cadmium, a known inhibitor of Glrx1. CdCl2 also abolished cardioprotection afforded by PC as evidenced by its ability to partially increase myocardial infarct size without affecting cardiomyocyte apoptosis. The amount of ROS was significantly decreased in the PC heart, which was abolished by CdCl2. The cardioprotective role of Glrx1 was further confirmed with Glrx1 transgenic and knockout mice. The mouse hearts overexpressing Glrx1 exhibited significantly improved post-ischemic ventricular recovery and reduced myocardial infarct size while hearts deficient in Glrx1 exhibited depressed functional recovery and increased infarct size as compared to the wild-type hearts. Furthermore, Glrx1-overexpressing hearts exhibited reduced and Glrx1-deficient hearts exhibited increased ROS production during ischemia and reperfusion. Adapted hearts showed increased Akt phosphorylation that was inhibited by CdCl2. The amount of Bcl-2 protein expression was not affected by the inhibition of Glrx1. Taken together, the results of this study implicate a role of Glrx1 in cardioprotection and redox signaling of the ischemic myocardium. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM DDAS@NEURON.UCHC.EDU
FU NIEHS NIH HHS [P30 ES06639]; NHLBI NIH HHS [HL 85804, HL63317, HL33889,
   HL22559, HL 34360]
CR Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119
   Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200
   Chung WH, 2004, BIOCHEM BIOPH RES CO, V321, P922, DOI 10.1016/j.bbrc.2004.07.042
   CORDIS GA, 1995, J MOL CELL CARDIOL, V27, P1645, DOI 10.1016/S0022-2828(95)90656-8
   Das M, 2007, J MOL CELL CARDIOL, V42, P206, DOI 10.1016/j.yjmcc.2006.08.118
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x
   GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831
   Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959
   HOGAN R, 1994, MANIPULATING MOUSE E
   HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237
   HOLMGREN A, 1989, J BIOL CHEM, V264, P13963
   Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x
   Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200
   Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9
   MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002
   Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   RODTIGUEZMANZAN.MT, 2002, MOL BIOL CELL, V13, P1109
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206856200
   Starke DW, 2003, J BIOL CHEM, V278, P14607, DOI 10.1074/jbc.M210434200
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   Turoczi T, 2003, J MOL CELL CARDIOL, V35, P695, DOI 10.1016/S0022-2828(03)00117-2
   Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90
   Wang YM, 2006, FREE RADICAL BIO MED, V41, P775, DOI 10.1016/j.freeradbiomed.2006.05.029
NR 28
TC 29
Z9 32
U1 3
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD FEB
PY 2008
VL 44
IS 2
BP 261
EP 269
DI 10.1016/j.yjmcc.2007.08.022
PG 9
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA 275AC
UT WOS:000254043300006
PM 17976641
DA 2018-12-27
ER

PT J
AU Quinonez, R
   Stearns, SC
AF Quinonez, Rocio
   Stearns, Sally C.
TI RETRACTED: Issues and early evidence for the economic evaluation of the
   effects of periodontal therapy on pregnancy outcomes (Retracted Article.
   See vol 79, pg 773, 2008)
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Editorial Material; Retracted Publication
DE cost analysis; periodontal disease; pregnancy complications
ID LOW-BIRTH-WEIGHT; PRETERM BIRTH; GESTATIONAL-AGE; DISEASE; WOMEN;
   PREMATURE; REDUCE; COST; RISK
C1 [Quinonez, Rocio] Univ N Carolina, Sch Dent, Dept Pediat Dent & Pediat, Chapel Hill, NC USA.
   [Quinonez, Rocio] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Stearns, Sally C.] Univ N Carolina, Sch Publ Hlth, Dept Hlth Policy & Adm, Chapel Hill, NC USA.
RP Quinonez, R (reprint author), Univ N Carolina, Sch Dent, Dept Pediat Dent, CB 7450, Chapel Hill, NC 27599 USA.
EM quinoner@dentistry.unc.edu
CR *AM DENT ASS, 2002, ORIG NAT DENT ADV SE, P6
   Boggess KA, 2006, MATERN CHILD HLTH J, V10, pS169, DOI 10.1007/s10995-006-0095-x
   Bureau of labor statistics, CONS PRIC IND
   Dasanayake Ananda P, 2003, Dent Clin North Am, V47, P115, DOI 10.1016/S0011-8532(02)00056-3
   Gilbert WM, 2003, OBSTET GYNECOL, V102, P488, DOI 10.1016/S0029-7844(03)00617-3
   Goldenberg RL, 2006, NEW ENGL J MED, V355, P1925, DOI 10.1056/NEJMe068210
   Lopez NJ, 2005, J PERIODONTOL, V76, P2144, DOI 10.1902/jop.2005.76.11-S.2144
   Lopez NJ, 2002, J PERIODONTOL, V73, P911, DOI 10.1902/jop.2002.73.8.911
   Michalowicz BS, 2006, NEW ENGL J MED, V355, P1885, DOI 10.1056/NEJMoa062249
   Offenbacher S, 2007, J PERIODONTOL, V78, P195, DOI 10.1902/jop.2007.060506
   Petrou S, 2003, PEDIATRICS, V112, P1290, DOI 10.1542/peds.112.6.1290
   Phibbs CS, 2006, EARLY HUM DEV, V82, P85, DOI 10.1016/j.earlhumdev.2006.01.001
NR 12
TC 2
Z9 2
U1 3
U2 9
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA
SN 0022-3492
EI 1943-3670
J9 J PERIODONTOL
JI J. Periodont.
PD FEB
PY 2008
VL 79
IS 2
BP 203
EP 206
DI 10.1902/jop.2008.070286
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 262YW
UT WOS:000253185800003
PM 18251634
DA 2018-12-27
ER

PT J
AU Godge, MR
   Purkayastha, A
   Dasgupta, I
   Kumar, PP
AF Godge, Mandar R.
   Purkayastha, Arunima
   Dasgupta, Indranil
   Kumar, Prakash P.
TI RETRACTED: Virus-induced gene silencing for functional analysis of
   selected genes (Retracted Article. See vol 28, pg 335, 2009)
SO PLANT CELL REPORTS
LA English
DT Review; Retracted Publication
DE VIGS; viral vectors; gene silencing; functional genomics
ID TOBACCO RATTLE VIRUS; PROGRAMMED CELL-DEATH; NICOTIANA-BENTHAMIANA;
   MOSAIC-VIRUS; DISEASE RESISTANCE; CHALCONE SYNTHASE; PLANTS;
   ARABIDOPSIS; EXPRESSION; SYSTEM
AB Virus-induced gene silencing (VIGS) is a technology that exploits an RNA-mediated antiviral defense mechanism and has been shown to be of great potential in plant reverse genetics. Circumvention of plant transformation, methodological simplicity, robustness, and speedy results makes VIGS an attractive alternative instrument in functional genomics, even in a high throughput fashion. The system is well established in Nicotiana benthamiana, and efforts are being made to improve VIGS in other species, including monocots. Here, we discuss the issues specific to the application of VIGS technology to determine gene function, which has revealed the roles of a variety of genes in disease resistance, abiotic stress, cellular signaling and secondary metabolite biosynthesis.
C1 [Godge, Mandar R.; Kumar, Prakash P.] Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117543, Singapore.
   [Purkayastha, Arunima; Dasgupta, Indranil] Univ Delhi, Dept Plant Mol Biol, New Delhi 110021, India.
RP Kumar, PP (reprint author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117543, Singapore.
EM dbskumar@nus.edu.sg
CR Abbott JC, 2002, PLANT PHYSIOL, V128, P844, DOI 10.1104/pp.010698
   Ahn CS, 2005, MOL CELLS, V20, P112
   Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113
   Baulcombe DC, 1999, CURR OPIN PLANT BIOL, V2, P109, DOI 10.1016/S1369-5266(99)80022-3
   Brigneti G, 2004, PLANT J, V39, P264, DOI 10.1111/j.1365-313X.2004.02122.x
   Brunt A. A., 1996, PLANT VIRUSES ONLINE
   Burch-Smith TM, 2006, PLANT PHYSIOL, V142, P21, DOI [10.1104/pp.106.084624, 10.1104/pp.084624]
   Burch-Smith TM, 2004, PLANT J, V39, P734, DOI 10.1111/j.1365-313X.2004.02158.x
   Cai XZ, 2006, PLANT MOL BIOL, V62, P223, DOI 10.1007/s11103-006-9016-z
   Chen JC, 2005, PLANT J, V44, P16, DOI 10.1111/j.1365-313X.2005.02505.x
   Chen JC, 2004, PLANT MOL BIOL, V55, P521, DOI 10.1007/s11103-004-0590-7
   Chung E, 2004, MOL CELLS, V17, P377
   Constantin GD, 2004, PLANT J, V40, P622, DOI 10.1111/j.1365-313X.2004.02233.x
   Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0
   Ding XS, 2006, MOL PLANT MICROBE IN, V19, P1229, DOI 10.1094/MPMI-19-1229
   Ekengren SK, 2003, PLANT J, V36, P905, DOI 10.1046/j.1365-313X.2003.01944.x
   Faivre-Rampant O, 2004, PLANT PHYSIOL, V134, P1308, DOI 10.1104/pp.103.037507
   Fitzmaurice Wayne P., 2002, OMICS A Journal of Integrative Biology, V6, P137, DOI 10.1089/153623102760092742
   FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423
   Fofana IBF, 2004, PLANT MOL BIOL, V56, P613, DOI 10.1007/s11103-004-0161-y
   Fu DQ, 2006, MOL CELLS, V21, P153
   Fu DQ, 2005, PLANT J, V43, P299, DOI 10.1111/j.1365-313X.2005.02441.x
   Gossele V, 2002, PLANT J, V32, P859, DOI 10.1046/j.1365-313X.2002.01471.x
   GOULD B, 2007, BMC PLANT METHODS, V12, P6
   He XH, 2004, PLANT J, V38, P563, DOI 10.1111/j.1365-313X.2004.02073.x
   Hein I, 2005, PLANT PHYSIOL, V138, P2155, DOI 10.1104/pp.105.062810
   HERNANDEZ C, 1995, J GEN VIROL, V76, P2847, DOI 10.1099/0022-1317-76-11-2847
   Hileman LC, 2005, PLANT J, V44, P334, DOI 10.1111/j.1365-313X.2005.02520.x
   Holzberg S, 2002, PLANT J, V30, P315, DOI 10.1046/j.1365-313X.2002.01291.x
   Hou HS, 2003, J VIROL METHODS, V111, P37, DOI 10.1016/S0166-0934(03)00149-6
   Hull R., 2002, MATTHEWS PLANT VIROL
   Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284
   Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
   Kim M, 2006, PLANT CELL, V18, P2341, DOI 10.1105/tpc.106.041509
   Kim YK, 2005, J BIOL CHEM, V280, P37098, DOI 10.1074/jbc.M504805200
   Kjemtrup S, 1998, PLANT J, V14, P91, DOI 10.1046/j.1365-313X.1998.00101.x
   Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283
   KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679
   Lacomme C, 2003, PLANT J, V34, P543, DOI 10.1046/j.1365-313X.2003.01733.x
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007
   Liu YL, 2002, PLANT J, V31, P777, DOI 10.1046/j.1365-313X.2002.01394.x
   Liu YL, 2002, PLANT J, V30, P415, DOI 10.1046/j.1365-313X.2002.01297.x
   Lu R, 2003, METHODS, V30, P296, DOI 10.1016/S1046-2023(03)00037-9
   Lu R, 2003, EMBO J, V22, P5690, DOI 10.1093/emboj/cdg546
   MacFarlane SA, 2000, VIROLOGY, V267, P29, DOI 10.1006/viro.1999.0098
   Moeder W, 2007, PLANT MOL BIOL, V63, P273, DOI 10.1007/s11103-006-9087-x
   Muangsan Nooduan, 2004, Methods Mol Biol, V265, P101
   NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279
   Nasir KHB, 2005, PLANT J, V43, P491, DOI 10.1111/j.1365-313X.2005.02472.x
   Naylor M, 2005, J VIROL METHODS, V124, P27, DOI 10.1016/j.jviromet.2004.10.007
   Orzaez D, 2006, PLANT PHYSIOL, V140, P3, DOI 10.1104/pp.105.068221
   Page JE, 2004, PLANT PHYSIOL, V134, P1401, DOI 10.1104/pp.103.038133
   Parinov S, 1999, PLANT CELL, V11, P2263, DOI 10.1105/tpc.11.12.2263
   Peele C, 2001, PLANT J, V27, P357, DOI 10.1046/j.1365-313x.2001.01080.x
   Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558
   Ratcliff F, 2001, PLANT J, V25, P237, DOI 10.1046/j.0960-7412.2000.00942.x
   ROTHSTEIN SJ, 1987, P NATL ACAD SCI USA, V84, P8439, DOI 10.1073/pnas.84.23.8439
   Ruiz MT, 1998, PLANT CELL, V10, P937
   Ryu CM, 2004, PLANT J, V40, P322, DOI 10.1111/j.1365-313X.2004.02211.x
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Scofield SR, 2005, PLANT PHYSIOL, V138, P2165, DOI 10.1104/pp.105.061861
   Senthil-Kumar M, 2007, PLANTA, V225, P523, DOI 10.1007/s00425-006-0367-0
   Slaymaker DH, 2002, P NATL ACAD SCI USA, V99, P11640, DOI 10.1073/pnas.182427699
   Smith NA, 2000, NATURE, V407, P319, DOI 10.1038/35030305
   Speulman E, 1999, PLANT CELL, V11, P1853, DOI 10.1105/tpc.11.10.1853
   Tao XR, 2004, PLANT J, V38, P850, DOI 10.1111/j.1365-313X.2004.02087.x
   Thomas CL, 2001, PLANT J, V25, P417, DOI 10.1046/j.1365-313x.2001.00976.x
   Turnage MA, 2002, PLANT J, V30, P107, DOI 10.1046/j.1365-313X.2002.01261.x
   Valentine T, 2004, PLANT PHYSIOL, V136, P3999, DOI 10.1104/pp.104.051466
   VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291
   vanKammen A, 1997, TRENDS PLANT SCI, V2, P409, DOI 10.1016/S1360-1385(97)01128-X
   Wang CC, 2006, FUNCT PLANT BIOL, V33, P347, DOI 10.1071/FP05096
   Wang EM, 2003, PLANTA, V216, P686, DOI 10.1007/s00425-002-0904-4
   Watson JM, 2005, FEBS LETT, V579, P5982, DOI 10.1016/j.febslet.2005.08.014
   Yoshioka H, 2003, PLANT CELL, V15, P706, DOI 10.1105/tpc.008680
   Zhang CQ, 2006, VIROLOGY, V344, P401, DOI 10.1016/j.virol.2005.08.046
NR 77
TC 15
Z9 30
U1 3
U2 25
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-7714
J9 PLANT CELL REP
JI Plant Cell Reports
PD FEB
PY 2008
VL 27
IS 2
BP 209
EP 219
DI 10.1007/s00299-007-0460-2
PG 11
WC Plant Sciences
SC Plant Sciences
GA 252VY
UT WOS:000252476100001
PM 17938933
DA 2018-12-27
ER

PT J
AU Avvannavar, SM
   Mani, M
AF Avvannavar, Santosh M.
   Mani, Monto
TI RETRACTED: A conceptual model of people's approach to sanitation
   (Retracted article. See vol. 447, pg. 525, 2013)
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Review; Retracted Publication
DE sanitation approach; society; attitude
AB Sanitation is a term primarily used to characterize the safe and sound handling (and disposal) of human excreta - or simply, people's approach to take-care of their (unavoidable) primal urge. According to the recent Human Development Report 2006 Global access to proper sanitation stands at approximately 58% with 37% being a conservative estimate both for South Asia and Sub-Saharan Africa. Various multi-million dollar sanitation programmes the world over have had little success, often due to inadequate understanding of people's sanitation approach. Sanitation approach includes the perception, feel and practices involved in satisficing the primal need to defecate and urinate (and their disposal). This paper presents a structure to understand the nature of psycho-socio-economic influences that determine societal approach to sanitation.
   Societies across the globe have evolved imbibing diverse influences attributed to the local environment, religion, cultural practices, war, etc. While a civilization's living environment reflects these influences in their built-environment characteristics, the influences are often deep-rooted and can be traced to the way the community members satisfice their need to defecate and urinate (sanitation approach).
   The objective of this paper is to trace the various approaches that diverse societies/civilizations, over time, across the world have had towards sanitation, and present a structure to articulate and understand determining factors. Sanitation also involves other domestic (solid and liquid) waste disposal but in the context of this paper the scope of sanitation has been restricted to human excreta alone. The structure presented and discussed in this paper would be useful in understanding a community better in terms of providing appropriate sanitation. It is hoped that this structure be considered as a basis for further refinement and detailed research into each of the factors determining people's sanitation approach. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Avvannavar, Santosh M.; Mani, Monto] Indian Inst Sci, Ctr Sustainable Technol, Bangalore 560012, Karnataka, India.
RP Avvannavar, SM (reprint author), Indian Inst Sci, Ctr Sustainable Technol, Bangalore 560012, Karnataka, India.
EM santosh@astra.iisc.emet.in
CR *BIS, 1966, 2488 BIS
   CURTIS V, 2003, BIOL LETT S4, P131
   Douglas M., 1982, RISK CULTURE ESSAY S
   Drangert JO, 1998, WATER SA, V24, P157
   DRANGERT JO, 2004, ECOSANRES PUBLICATIO
   FARUQUI NI, 1998, ISLAM WATER MANAGEME
   Geest S. V. D, 1998, ANTHR TODAY, V14, P8, DOI DOI 10.2307/2783049
   HANNAN C, 2001, 97 ANN M ASS AM GEOG
   HOGLUND, 2001, THESIS ROYAL I TECHN
   Horan Julie L., 1996, PORCELAIN GOD SOCIAL
   Hoy Suellen, 1995, CHASING DIRT AM PURS
   Human Development Report (HDR), 2006, SCARC POW POV GLOB W
   Jenkins MW, 2005, SOC SCI MED, V61, P2446, DOI 10.1016/j.socscimed.2005.04.036
   Jenssen P. D., 2004, ECOLOGICAL SANITATIO
   JHA PK, 2004, SUSTAINABLE TECHNOLO
   Krech D., 1962, INDIVIDUAL SOC TXB S
   LAMBTON L, 1998, TEMPLES CONVENIENCE
   MAJBRITT Q, 1996, CHANGING IDEAS BODIL
   MANI M, 2005, SUSTAINABILITY HUMAN
   Maslow A., 1954, MOTIVATION PERSONALI
   NAWAB B, 2006, CULTURAL PREFERENCES
   NIDDK, 1994, DIG DIS US EP IMP, P94
   Nussbaum MC, 2004, HIDING FROM HUMANITY: DISGUST, SHAME, AND THE LAW, P1
   PATHAK B, 1986, SULABH SHAUCHALAYA H
   PATHAK B, 2001, 1 WORLD TOIL SUMM 20
   Paul Rozin, 1999, HDB COGNITION EMOTIO
   Peasey A., 2000, HLTH ASPECTS DRY SAN
   PENN C, 2005, TECHNOLOGY NOTES
   Rosenquist LED, 2005, J ENVIRON PSYCHOL, V25, P335, DOI 10.1016/j.jenvp.2005.07.003
   SAWYER R, 2003, SANITATION IT REALLY
   TANNER RES, 1995, J PREVENTATIVE MED H, V36, P85
   UN- Habitat, 2003, CHALL SLUMS GLOB REP
   WARNER W, 2000, WATER           0811, P21
   Waterkeyn J, 2005, SOC SCI MED, V61, P1958, DOI [10.1016/j.socscimed.2005.04.012, 10.1016/j.socsimed.2005.04.012]
NR 34
TC 21
Z9 21
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD FEB 1
PY 2008
VL 390
IS 1
BP 1
EP 12
DI 10.1016/j.scitotenv.2007.09.018
PG 12
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 255ZF
UT WOS:000252696500001
PM 17964633
DA 2018-12-27
ER

PT J
AU Fu, XY
   Parks, WC
   Heinecke, JW
AF Fu, Xiaoyun
   Parks, William C.
   Heinecke, Jay W.
TI RETRACTED: Activation and silencing of matrix metalloproteinases
   (Retracted article. See vol. 20, pg. 375, 2009)
SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
LA English
DT Review; Retracted Publication
DE cysteine-switch; zymogen; hypochlorous acid; compartmentalization;
   substrate
ID NECROSIS-FACTOR-ALPHA; BRONCHIOLE BRANCHING MORPHOGENESIS; HUMAN
   ATHEROSCLEROTIC INTIMA; HUMAN FIBROSARCOMA CELLS; ACUTE LUNG INJURY;
   A-DEFICIENT MICE; TISSUE-INHIBITOR; EXTRACELLULAR-MATRIX; HYPOCHLOROUS
   ACID; CYSTEINE SWITCH
AB Matrix metalloproteinases (MMPs) were first described as proteases that act on protein components of the extracellular matrix. However, subsequent studies of MMP function in vivo have revealed that these proteinases also cleave numerous non-ECM protein substrates. Because their substrates are diverse in functions, MMPs are involved in variety of homeostatic functions, such as tissue repair and immunity, as well as pathological processes, including cancer, fibroses and inflammation. Essential steps in regulating MMP proteolysis are conversion of the zymogen into an active proteinase and subsequent inactivation. A number of mechanisms including proteolysis, allosteric interactions, oxidative modification, pericellular compartmentalization, interaction with tissue inhibitor of metalloproteinases (TIMPs), endocytosis, and more have been proposed to control the activation and inactivation of MMPs. In this paper, we discuss these and other mechanisms, and their relevance to in vivo control of MMP-mediated functions. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Fu, Xiaoyun; Parks, William C.; Heinecke, Jay W.] Univ Washington, Dept Med, Seattle, WA USA.
RP Parks, WC (reprint author), Ctr Lung Biol, 815 Mercer St, Seattle, WA 98109 USA.
EM parksw@u.washington.edu
FU NHLBI NIH HHS [R01 HL075381]
CR Ahonen M, 1998, CANCER RES, V58, P2310
   Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M007674200
   Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200
   Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bode W, 2003, BIOCHEM SOC SYMP, V70, P1
   Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0
   CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801
   Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174
   Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439
   Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0
   Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200
   Chen P, 2006, AM J RESP CELL MOL, V34, P464, DOI 10.1165/rcmb.2005-03440C
   Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC
   Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773
   Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382
   Creemers E, 2000, AM J PATHOL, V156, P1865, DOI 10.1016/S0002-9440(10)65060-2
   DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342
   Deschamps AM, 2005, CIRCULATION, V111, P1166, DOI 10.1161/01.CIR.0000157149.71297.3A
   Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200
   Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516
   Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200
   English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046
   Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628
   Fang KC, 1999, J IMMUNOL, V162, P5528
   Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171
   Fedak PWM, 2004, CIRCULATION, V110, P2401, DOI 10.1161/01.CIR.0000134959.83967.2D
   Filippov S, 2003, J EXP MED, V198, P925, DOI 10.1084/jem.20030626
   Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200
   Fu XY, 2004, J BIOL CHEM, V279, P6209, DOI 10.1074/jbc.C300506200
   Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200
   Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516
   Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X
   Gill SE, 2006, DEV BIOL, V298, P540, DOI 10.1016/j.ydbio.2006.07.004
   Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157
   Grinnell F, 1998, J INVEST DERMATOL, V110, P771, DOI 10.1046/j.1523-1747.1998.00192.x
   Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634
   Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200
   Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748
   Han YP, 2002, J BIOL CHEM, V277, P27319, DOI 10.1074/jbc.M202842200
   Han YP, 2007, J BIOL CHEM, V282, P12928, DOI 10.1074/jbc.M700554200
   Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091
   HARRISON JE, 1976, J BIOL CHEM, V251, P1371
   Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002
   Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379
   Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080
   Holmbeck K, 2003, J CELL BIOL, V163, P661, DOI 10.1083/jcb.200307061
   Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1
   Illman SA, 2003, BIOCHEM J, V375, P191, DOI 10.1042/BJ20030497
   IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691
   Imai K, 1996, CANCER RES, V56, P2707
   ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2
   Itoh T, 1998, CANCER RES, V58, P1048
   Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643
   Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782
   Janssens S, 2006, CARDIOVASC RES, V69, P585, DOI 10.1016/j.cardiores.2005.12.010
   Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698
   Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281
   Kang TB, 2002, CANCER RES, V62, P675
   Kassim SY, 2005, J BIOL CHEM, V280, P30201, DOI 10.1074/jbc.M503292200
   Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6
   Kim KH, 2005, AM J RESP CELL MOL, V33, P271, DOI 10.1165/rcmb.2005-0111OC
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Lafleur MA, 2006, J BIOL CHEM, V281, P6826, DOI 10.1074/jbc.M513084200
   Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433
   Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520
   Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6
   Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035
   Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106
   MACKAY AR, 1990, J BIOL CHEM, V265, P21929
   Massova I, 1998, FASEB J, V12, P1075
   MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z
   Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413
   Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132
   Monea S, 2002, J CELL PHYSIOL, V192, P160, DOI 10.1002/jcp.10126
   Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384
   MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265
   Nagase H, 1997, BIOL CHEM, V378, P151
   Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9
   Ohno-Matsui K, 2003, INVEST OPHTH VIS SCI, V44, P5370, DOI 10.1167/iovs.03-0249
   OKADA Y, 1992, J BIOL CHEM, V267, P21712
   Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127
   Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2
   Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064
   Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x
   PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0
   PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322
   Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2
   Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066
   Ruangpanit N, 2002, EXP CELL RES, V272, P109, DOI 10.1006/excr.2001.5403
   RudolphOwen LA, 1997, ENDOCRINOLOGY, V138, P4902, DOI 10.1210/en.138.11.4902
   SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351
   Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7
   Saunders WB, 2005, J CELL SCI, V118, P2325, DOI 10.1242/jcs.02360
   Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8
   Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5
   Shiomi T, 2005, LAB INVEST, V85, P1489, DOI 10.1038/labinvest.3700351
   SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200
   STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331
   STRONGIN AY, 1993, J BIOL CHEM, V268, P14033
   Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200
   Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934
   Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200
   Van den Steen PE, 2006, J BIOL CHEM, V281, P18626, DOI 10.1074/jbc.M512308200
   VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578
   Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200
   Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200
   WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263
   WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211
   Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573
   Yamamoto K, 2006, J BIOL CHEM, V281, P9170, DOI 10.1074/jbc.M510377200
   Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200
   Yu Q, 2000, GENE DEV, V14, P163
   Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183
   Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702
   Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197
NR 129
TC 61
Z9 65
U1 3
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1084-9521
J9 SEMIN CELL DEV BIOL
JI Semin. Cell Dev. Biol.
PD FEB
PY 2008
VL 19
IS 1
BP 2
EP 13
DI 10.1016/j.semcdb.2007.06.005
PG 12
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 299BE
UT WOS:000255730000002
PM 17689277
DA 2018-12-27
ER

PT J
AU Mukherjee, S
   Gangopadhyay, H
   Das, DK
AF Mukherjee, Subhendu
   Gangopadhyay, Hiranmoy
   Das, Dipak K.
TI RETRACTED: Broccoli: A unique vegetable that protects mammalian hearts
   through the redox cycling of the thioredoxin superfamily (Retracted
   article. See vol. 60, pg. 2768, 2012)
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article; Retracted Publication
DE broccoli; heart; cardioprotection; ischemia/reperfusion; thioredoxin;
   glutaredoxin; peroxiredoxin; Nrf2; redox signaling; survival signaling
ID CHEMOPREVENTIVE AGENT SULFORAPHANE; ISCHEMIA-REPERFUSION INJURY;
   MYOCARDIAL-ISCHEMIA; OXIDATIVE STRESS; SURVIVAL SIGNAL; CELL-SURVIVAL;
   REDUCTASE; GLUTAREDOXIN; EXPRESSION; APOPTOSIS
AB Epidemiological evidence indicates several health benefits of the consumption of broccoli, especially related to chemoprevention. Because broccoli contains high amounts of selenium and glucosinolates (particularly glucoraphanin and isothiocyanate sulforaphane), which can produce redox-regulated cardioprotective protein thioredoxin (Trx), it was reasoned that consumption of broccoli could be beneficial to the heart. To test this hypothesis, a group of rats were fed broccoli (slurry made with water) through gavaging; control animals were gavaged water only. After 30 days, the rats were sacrificed; isolated hearts perfused via working mode were made ischemic for 30 min followed by 2 h of reperfusion. The results demonstrated significant cardioprotection with broccoli as evidenced by improved postischemic ventricular function, reduced myocardial infarct size, and decreased cardiomyocyte apoptosis accompanied by reduced cytochrome c release and increased pro-caspase 3 activities. Ischemia/reperfusion reduced both RNA transcripts and protein levels of the thioredoxin superfamily including Trx1, Trx2, glutaredoxin Grx1, Grx2, and peroxiredoxin (Prdx), which were either restored or enhanced with broccoli. Broccoli enhanced the expression of Nrf2, a cytosolic suppressor of Keapl, suggesting a role of antioxidant response element (ARE) in the induction of Trx. Additionally, broccoli induced the expression of another cardioprotective protein, heme oxygenase (HO)-1, which could be transactivated during the activation of Trx. Examination of the survival signal revealed that broccoli caused the phosphorylation of Akt and the induction of Bcl2 in concert with the activation of redox-sensitive transcription factor NF kappa B and Src kinase, indicating a role of Akt, Bcl2, and cSrc in the generation of survival signal. Taken together, the results of the present study indicate that the consumption of broccoli triggers cardioprotection by generating a survival signal through the activation of several survival proteins and by redox cycling of thioredoxins.
C1 [Mukherjee, Subhendu; Gangopadhyay, Hiranmoy; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM ddas@neuron.uchc.edu
FU NHLBI NIH HHS [HL 34360, HL33889, HL22559]
CR Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780
   Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200
   Bjornstedt M, 1996, BIOCHEMISTRY-US, V35, P8511, DOI 10.1021/bi9528762
   DANIELS LA, 1996, BIOL TRACE ELEM RES, V54, P165
   Das DK, 2004, BIOCHEMISTRY-MOSCOW+, V69, P10, DOI 10.1023/B:BIRY.0000016345.19027.54
   Das DK, 2004, ANTIOXID REDOX SIGN, V6, P405, DOI 10.1089/152308604322899477
   Ejima K, 2002, ANTIOXID REDOX SIGN, V4, P569, DOI 10.1089/15230860260220067
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   Finley John W., 2003, Journal of Medicinal Food, V6, P19, DOI 10.1089/109662003765184714
   Finley JW, 2005, J NUTR, V135, P1236
   Finley JW, 1996, NUTR RES, V16, P723, DOI 10.1016/0271-5317(96)00062-0
   GAUTAM M, 2007, IN PRESS J MOL CELL
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gurusamy N, 2007, FREE RADICAL BIO MED, V43, P397, DOI 10.1016/j.freeradbiomed.2007.04.025
   Hattori R, 2001, AM J PHYSIOL-HEART C, V281, pH1066
   HAYASHI T, 1993, J BIOL CHEM, V268, P11380
   HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199
   HOLMGREN A, 1989, J BIOL CHEM, V264, P13963
   Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138
   Jekell A, 2004, EUR J HEART FAIL, V6, P883, DOI 10.1016/j.ejheart.2004.03.003
   Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200
   Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012
   Liang H, 2006, J FOOD COMPOS ANAL, V19, P473, DOI 10.1016/j.jfca.2005.11.005
   Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102
   Malik G, 2006, ANTIOXID REDOX SIGN, V8, P2101, DOI 10.1089/ars.2006.8.2101
   Matusheski NV, 2006, J AGR FOOD CHEM, V54, P2069, DOI 10.1021/jf0525277
   Miller S, 2001, CLIN SCI, V100, P543, DOI 10.1042/CS20000299
   Miyamoto M, 2003, CIRC J, V67, P116, DOI 10.1253/circj.67.116
   Murashima M, 2004, BIOFACTORS, V22, P271, DOI 10.1002/biof.5520220154
   Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001
   Nagy N, 2006, AM J PHYSIOL-HEART C, V291, pH2636, DOI 10.1152/ajpheart.00399.2006
   Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2
   Nestle M, 1997, P NATL ACAD SCI USA, V94, P11149, DOI 10.1073/pnas.94.21.11149
   Nimata M, 2003, MOL CELL BIOCHEM, V248, P193, DOI 10.1023/A:1024156923322
   Perocco P, 2006, MUTAT RES-FUND MOL M, V595, P125, DOI 10.1016/j.mrfmmm.2005.11.007
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   Sato M, 2000, AM J PHYSIOL-HEART C, V279, pH901
   Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   TUROCZI T, J MOL CELL CARDIOL
   Yochum L, 1999, AM J EPIDEMIOL, V149, P943
   Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
NR 43
TC 88
Z9 89
U1 5
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JAN 23
PY 2008
VL 56
IS 2
BP 609
EP 617
DI 10.1021/jf0728146
PG 9
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 252GK
UT WOS:000252434800047
PM 18163565
OA Bronze
DA 2018-12-27
ER

PT J
AU Erin, EM
   Jenkins, GR
   Kong, OM
   Zacharasiewicz, AS
   Nicholson, GC
   Neighbour, H
   Tennant, RC
   Tan, AJ
   Leaker, BR
   Bush, A
   Jose, PJ
   Barnes, PJ
   Hansel, TT
AF Erin, Edward M.
   Jenkins, Gavin R.
   Kong, Onn Min
   Zacharasiewicz, Angela S.
   Nicholson, Grant C.
   Neighbour, Helen
   Tennant, Rachel C.
   Tan, Andrew J.
   Leaker, Brian R.
   Bush, Andrew
   Jose, Peter J.
   Barnes, Peter J.
   Hansel, Trevor T.
TI RETRACTED: Optimized dialysis and protease inhibition of sputum
   dithiothreitol supernatants (Retracted article. See vol. 183, pg. 418,
   2011)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
DE sputum cytokines; dithiothreitol; dialysis; protease inhibitors
ID NECROSIS-FACTOR-ALPHA; OBSTRUCTIVE PULMONARY-DISEASE; BRONCHOALVEOLAR
   LAVAGE FLUID; SEVERE PERSISTENT ASTHMA; INFLAMMATORY MEDIATORS; CELL
   COUNTS; NEUTROPHILIC INFLAMMATION; EOSINOPHILIC BRONCHITIS;
   EXACERBATIONS; INTERLEUKIN-5
AB Rationale: Dithiothreitol (DTT) is commonly used to liquefy induced sputum samples before assessment of cytology, but causes reduction of disulfide bonds and denaturation of proteins.
   Objectives: To process sputum supernatants containing DTT to enable quantification of cytokines and chemokines. Methods: A standard solution of 22 pooled chemokines and cytokines was incubated with DTT at the concentrations used during sputum liquefaction and then dialyzed under 20 different denaturant and redox conditions.
   Measurements and Main Results: After incubation of the standard solution with DTT there was loss of detectable protein mediators on immunoassay, but optimized dialysis permitted recovery of chemokines to 96 +/- 4% and cytokines to 91 +/- 6%. Optimized dialysis of DTT supernatants from subjects with asthma covering a range of severities (n = 35) was performed in the presence of a cocktail of protease inhibitors and demonstrated significantly elevated levels of the chemokine CXCL10 (IFN-gamma-inducible protein-10), CXCL8 (IL-8), and CCL3 (macrophage inflammatory protein-1 alpha); with lower but significantly elevated levels of CCL2 (monocyte chemotactic protein-1), CCL11 (eotaxin), and CCL5 (regulated on activation, normal T-cell expressed and secreted) in severe asthma. In sputum from subjects with severe asthma there were also significantly elevated levels of IL-4, IL-5, IL-13, tumor necrosis factor-alpha, IL-6, granulocyte-macrophage colony-stimulating factor, and IL-12(p40). Conclusions: The technique of optimized dialysis and protease inhibition of sputum DTT supernatants aids the detection of chemokines and cytokines. The detection of elevated levels of particular sputum chemokines and cytokines in individual patients may provide a rationale for specific therapies.
C1 [Hansel, Trevor T.] Royal Brompton Hosp, NHLI Clin Studies Unit, London SW3 6HP, England.
   [Erin, Edward M.; Jenkins, Gavin R.; Nicholson, Grant C.; Neighbour, Helen; Tennant, Rachel C.; Tan, Andrew J.; Hansel, Trevor T.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Clin Studies Unit, London, England.
   [Kong, Onn Min] St Marys Hosp, Dept Resp Med, London, England.
   [Zacharasiewicz, Angela S.; Bush, Andrew] Royal Free Hosp, Dept Resp Paediat, London NW3 2QG, England.
   [Leaker, Brian R.] Royal Free Hosp, Dept Nephrol, London NW3 2QG, England.
   [Jose, Peter J.] Univ London Imperial Coll Sci Technol & Med, Dept Leukocyte Biol, London, England.
   [Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, London, England.
RP Hansel, TT (reprint author), Royal Brompton Hosp, NHLI Clin Studies Unit, Fulham Rd, London SW3 6HP, England.
EM t.hansel@imperial.ac.uk
OI Kon, Onn Min/0000-0003-2647-4688
FU Medical Research Council [G0400503B]
CR Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524
   Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580
   Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032
   Brightling CE, 2001, RESP MED, V95, P999, DOI 10.1053/rmed.2001.1195
   Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723
   Christen U, 2003, J IMMUNOL, V171, P6838, DOI 10.4049/jimmunol.171.12.6838
   Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x
   Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102
   Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC
   Erin EM, 2005, CLIN EXP ALLERGY, V35, P1608, DOI 10.1111/j.1365-2222.2005.02381.x
   Erin EM, 2005, ALLERGY, V60, P1524, DOI 10.1111/j.1398-9995.2005.00928.x
   Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105
   Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329
   Grebski E, 2001, CHEST, V119, P1521, DOI 10.1378/chest.119.5.1521
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5
   Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875
   Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1046/j.1365-2222.1997.890900.x
   Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053
   Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260
   Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170
   Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704
   Jenkins GR, 2001, THORAX, V56, P79
   Keatings VM, 1997, THORAX, V52, P372, DOI 10.1136/thx.52.4.372
   Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092
   Kelly MM, 2000, J ALLERGY CLIN IMMUN, V105, P1162, DOI 10.1067/mai.2000.106375
   Kelly MM, 2002, EUR RESPIR J, V20, p24S, DOI 10.1183/09031936.02.00002402
   Kelly MM, 2001, EUR RESPIR J, V18, P685, DOI 10.1183/09031936.01.00098501
   Kim JS, 2001, PEDIATR PULM, V32, P152, DOI 10.1002/ppul.1101
   Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC
   Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234
   Louis R, 1999, EUR RESPIR J, V13, P660, DOI 10.1183/09031936.99.13366099
   Middelberg APJ, 2002, TRENDS BIOTECHNOL, V20, P437, DOI 10.1016/S0167-7799(02)02047-4
   Moodley YP, 2000, THORAX, V55, P696, DOI 10.1136/thorax.55.8.696
   *NAT HEART BLOOD I, 2005, GLOB IN ASTH GLOB ST
   Park SW, 2005, CHEST, V128, P1921, DOI 10.1016/S0012-3692(15)52584-1
   Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174
   Simpson JL, 2004, EUR RESPIR J, V23, P759, DOI 10.1183/09031936.04.00043104a
   Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13
   Stockley RA, 2000, EUR RESPIR J, V15, P778, DOI 10.1034/j.1399-3003.2000.15d24.x
   Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590
   Vignola AM, 2005, ALLERGY, V60, P1511, DOI 10.1111/j.1398-9995.2005.00827.x
   Vignola AM, 2002, EUR RESPIR J, V20, p51S
   Wells TNC, 2006, TRENDS PHARMACOL SCI, V27, P41, DOI 10.1016/j.tips.2005.11.001
   Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110
   Woolhouse IS, 2002, THORAX, V57, P667, DOI 10.1136/thorax.57.8.667
   Yamamoto K, 2003, RESPIRATION, V70, P600, DOI 10.1159/000075205
NR 46
TC 20
Z9 21
U1 3
U2 13
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JAN 15
PY 2008
VL 177
IS 2
BP 132
EP 141
DI 10.1164/rccm.200603-311OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 251BJ
UT WOS:000252345300003
PM 17962642
DA 2018-12-27
ER

PT J
AU Schavinsky-Khrapunsky, Y
   Priel, E
   Aboud, M
AF Schavinsky-Khrapunsky, Yana
   Priel, Esther
   Aboud, Mordechai
TI RETRACTED: Dose-dependent dual effect of HTLV-1 Tax oncoprotein on
   p53-dependent nucleotide excision repair in human T-cells (Retracted
   article. See vol. 140, pg. 2833, 2017)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE HTLV-1; Tax; nucleotide excision repair (NER); host cell reactivation
   (HCR); p53
ID LEUKEMIA-VIRUS TYPE-1; NF-KAPPA-B; MITOTIC SPINDLE CHECKPOINT;
   DNA-DAMAGE RECOGNITION; P53 TUMOR-SUPPRESSOR; LONG TERMINAL REPEAT;
   PROTEIN-KINASE-C; WILD-TYPE P53; I TAX; TRANSCRIPTIONAL ACTIVITY
AB In this study we investigated the effect of Tax on nucleotide excision repair (NER) in human T-cell lines by using the host cell repair analysis of UVC-irradiated reporter plasmid. This analysis revealed a p53-dpendent NER activity in wild type (w.t.) p53-containing T-cells and p53-independent NER in w.t. p53-lacking T-cells. Notably, in the w.t. p53-containing cells Tax exerted a dose-dependent dual effect on NER. While low Tax doses markedly stimulated this repair, high Tax doses strongly reduced it. Further experiments demonstrated that the low Tax doses enhanced, in these cells, the level and the transcriptional function of their w.t. p53 protein. On the other hand, although the high Tax doses further increased the level of p53, they functionally inactivated its accumulating molecules. Both of these Tax effects on p53 proved to be mediated by Tax-induced NF-kappa B-related mechanisms. Together, these data suggest that by NF-kappa B activation Tax elevates the level of the cellular w.t. p53. However, while at low Tax doses the elevating w.t. p53 molecules are functionally active and capable of stimulating NER, intensifying further the NF-kappa B activation by the high Tax doses concomitantly evokes certain mechanism(s) which functionally inactivates the accumulating p53 protein. In contrast to this dual effect on the p53-dependent NER, Tax displayed only an inhibitory effect on the p53-independent NER by its high doses, whereas its low doses had no effect on this repair. The mechanisms of the NF-kappa B-associated effects on the level and function of the cellular w.t.p53 and of the p53-independent NER noted in our experimental systems are further investigated in our laboratory. (C) 2007 Wiley-Liss, Inc.
C1 [Schavinsky-Khrapunsky, Yana; Priel, Esther; Aboud, Mordechai] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.
   [Schavinsky-Khrapunsky, Yana; Priel, Esther; Aboud, Mordechai] Ben Gurion Univ Negev, Ctr Canc Res, IL-84105 Beer Sheva, Israel.
RP Aboud, M (reprint author), Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.
EM aboud@bgu.ac.il
CR Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S4568-7864(03)0087-9
   Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952
   Azran Inbal, 2004, Retrovirology, V1, P20
   Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1
   Bree RT, 2004, DNA REPAIR, V3, P989, DOI 10.1016/j.dnarep.2004.03.016
   CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502
   Ching YP, 2006, NAT CELL BIOL, V8, P717, DOI 10.1038/ncb1432
   de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099
   Essers J, 2006, CURR OPIN CELL BIOL, V18, P240, DOI 10.1016/j.ceb.2006.03.004
   Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073
   Ford JM, 2005, MUTAT RES-FUND MOL M, V577, P195, DOI 10.1016/j.mrfmmm.2005.04.005
   Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000
   Furukawa Y, 2006, INT J CANCER, V118, P381, DOI 10.1002/ijc.21328
   Giam CZ, 2007, FRONT BIOSCI, V12, P1496, DOI 10.2741/2163
   Gomez-Lazaro M, 2004, J PHYSIOL BIOCHEM, V60, P287, DOI 10.1007/BF03167075
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200
   Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642
   Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308
   Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019
   Hussain S. Perwez, 2006, Journal of Nippon Medical School, V73, P54
   Iwanaga Y, 2002, CANCER RES, V62, P2618
   Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200
   Jefford CE, 2006, CRIT REV ONCOL HEMAT, V59, P1, DOI 10.1016/j.critrevonc.2006.02.005
   Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825
   Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200
   Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174
   Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200
   KAO SY, 2000, RES ADV VIROL, V1, P1
   Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200
   Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Lairmore MD, 2005, ONCOGENE, V24, P6005, DOI 10.1038/sj.onc.1208974
   Lemoine FJ, 2002, ONCOGENE, V21, P7230, DOI 10.1038/sj.onc.1205898
   Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Li G, 1998, BRIT J DERMATOL, V139, P3
   Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379
   Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008
   Low KG, 1997, J VIROL, V71, P1956
   Manel N, 2005, ONCOGENE, V24, P6016, DOI 10.1038/sj.onc.1208972
   Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976
   Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1007/BF02256583
   MATSUOKA M, 2007, T CELL LEUKAEMIA VIR, V7, P270
   Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500
   Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005
   Mogilner M, 2006, TRENDS CELL BIOL, V16, P88, DOI 10.1016/j.tcb.2005.12.007
   MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566
   Mulloy JC, 1998, J VIROL, V72, P8852
   Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830
   Oh HM, 2004, FREE RADICAL BIO MED, V37, P463, DOI 10.1016/j.freerbiomed.2004.04.042
   Pauls E, 2006, J LEUKOCYTE BIOL, V80, P659, DOI 10.1189/jlb.0306189
   Pise-Masison CA, 2005, ARCH IMMUNOL THER EX, V53, P283
   Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000
   Pise-Masison CA, 1998, J VIROL, V72, P1165
   Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   Pumfery A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-50
   Ressler S, 1997, J VIROL, V71, P1181
   RICHARDSON JH, 1990, J VIROL, V64, P5682
   Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082
   SANADA I, 1985, BLOOD, V65, P649
   Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343
   Sasaki M, 2006, ONCOGENE, V25, P3621, DOI 10.1038/sj.onc.1209404
   Schavinsky-Khrapunsky Y, 2003, ONCOGENE, V22, P5315, DOI 10.1038/sj.onc.1206782
   Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64
   Shuh M, 2005, MICROSC RES TECHNIQ, V68, P176, DOI 10.1002/jemt.20231
   SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875
   Tabakin-Fix, 2006, CURR CANC THER REV, V2, P101
   Tabakin-Fix Y, 2006, CARCINOGENESIS, V27, P673, DOI 10.1093/carcin/bgi274
   Taylor GP, 2005, ONCOGENE, V24, P6047, DOI 10.1038/sj.onc.1208979
   Tergaonkar V, 2007, MOL CELL, V26, P158, DOI 10.1016/j.molcel.2007.04.006
   Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779
   Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363
   UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503
   Wani MA, 2002, MUTAT RES-FUND MOL M, V505, P13, DOI 10.1016/S0027-5107(02)00107-0
   WU HY, 1994, J BIOL CHEM, V269, P20067
   Xie L, 2005, J VIROL, V79, P14536, DOI 10.1128/JVI.79.23.14536-14545.2005
   Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981
NR 79
TC 8
Z9 8
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 15
PY 2008
VL 122
IS 2
BP 305
EP 316
DI 10.1002/ijc.23091
PG 12
WC Oncology
SC Oncology
GA 242DJ
UT WOS:000251704400008
PM 17918160
OA Bronze
DA 2018-12-27
ER

PT J
AU Yamamoto, N
   Suyama, H
   Yamamoto, N
   Ushijima, N
AF Yamamoto, Nobuto
   Suyama, Hirofumi
   Yamamoto, Nobuyuki
   Ushijima, Naofumi
TI RETRACTED: Immunotherapy of metastatic breast cancer patients with
   vitamin D-binding protein-derived macrophage activating factor (GcMAF)
   (Retracted article. See vol. 135, pg. 1509, 2014)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE macrophage activating factor; tumoricidal; immunotherapy;
   deglycosylation; alpha-N-acetylgalactosaminidase
ID ALPHA-N-ACETYLGALACTOSAMINIDASE; INFLAMMATION-PRIMED ACTIVATION;
   GROUP-SPECIFIC COMPONENT; MOUSE PERITONEAL-MACROPHAGES; EHRLICH ASCITES
   TUMOR; D-3-BINDING PROTEIN; ADJUVANT ACTIVITY; GC PROTEIN; CELLS;
   LYSOPHOSPHATIDYLCHOLINE
AB Serum vitamin D-3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized P-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years. (c) 2007 Wiley-Liss, Inc.
C1 [Yamamoto, Nobuto; Yamamoto, Nobuyuki; Ushijima, Naofumi] Socrates Inst Therapeut Immunol, Div Canc Immunol & Mol Biol, Philadelphia, PA 19126 USA.
   [Suyama, Hirofumi] Nagasaki Immunotherapy Res Grp, Nagasaki 850806, Japan.
RP Yamamoto, N (reprint author), Socrates Inst Therapeut Immunol, Div Canc Immunol & Mol Biol, 1040 66th Ave, Philadelphia, PA 19126 USA.
EM nobutoyama@verizon.net
FU NIAID NIH HHS [AI-32140]
CR Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678
   BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   FIDLER IJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P151, DOI 10.1016/0304-419X(88)90009-1
   Gion M, 1999, CLIN CHEM, V45, P630
   HOLLAND R, 1990, J CLIN ONCOL, V8, P1451, DOI 10.1200/JCO.1990.8.9.1451
   HOMMA S, 1990, CLIN EXP IMMUNOL, V79, P307
   HOMMA S, 1993, IMMUNOL CELL BIOL, V71, P249, DOI 10.1038/icb.1993.29
   KELLER R, 1993, RES IMMUNOL, V144, P271, DOI 10.1016/0923-2494(93)80105-8
   KLOSTERGAARD J, 1993, RES IMMUNOL, V144, P274, DOI 10.1016/0923-2494(93)80106-9
   Koga Y, 1999, P SOC EXP BIOL MED, V220, P20, DOI 10.1046/j.1525-1373.1999.d01-3.x
   Korbelik M, 1998, BRIT J CANCER, V77, P1009, DOI 10.1038/bjc.1998.166
   LICHENSTEIN HS, 1994, J BIOL CHEM, V269, P18149
   LINK RP, 1986, ANAL BIOCHEM, V157, P262, DOI 10.1016/0003-2697(86)90624-X
   MORTON DL, 1970, SURGERY, V68, P158
   Musselli C, 2002, INT J CANCER, V97, P660, DOI 10.1002/ijc.10081
   NARAPARAJU VR, 1994, IMMUNOL LETT, V43, P143, DOI 10.1016/0165-2478(94)90214-3
   NGWENYA BZ, 1985, BIOCHIM BIOPHYS ACTA, V839, P9, DOI 10.1016/0304-4165(85)90175-8
   NGWENYA BZ, 1990, P SOC EXP BIOL MED, V193, P118
   NGWENYA BZ, 1986, CANCER IMMUNOL IMMUN, V21, P174
   Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI13903
   SILLIMAN RA, 1993, JNCI-J NATL CANCER I, V85, P190, DOI 10.1093/jnci/85.3.190
   SPIELMANN M, 1994, J CLIN ONCOL, V12, P1764, DOI 10.1200/JCO.1994.12.9.1764
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   TONDINI C, 1988, CANCER RES, V48, P4107
   YAMAGISAWA K, 1993, HEAD NECK-J SCI SPEC, V15, P1
   YAMAMOTO N, 1991, IMMUNOLOGY, V74, P420
   YAMAMOTO N, 1987, CANCER IMMUNOL IMMUN, V25, P185
   YAMAMOTO N, 1991, P NATL ACAD SCI USA, V88, P8539, DOI 10.1073/pnas.88.19.8539
   Yamamoto N, 2006, AIDS RES HUM RETROV, V22, P262, DOI 10.1089/aid.2006.22.262
   Yamamoto N, 2004, IMMUNOLOGY 2004: CYTOKINE NETWORK, REGULATORY CELLS, SIGNALING, AND APOPTOSIS, APPENDIX, P201
   Yamamoto N, 2005, J IMMUNOTHER, V28, P642, DOI 10.1097/01.cji.0000191043.76190.2b
   YAMAMOTO N, 1994, INFLAMMATION, V18, P311, DOI 10.1007/BF01534272
   Yamamoto N, 2005, MICROBES INFECT, V7, P674, DOI 10.1016/j.micinf.2005.01.015
   YAMAMOTO N, 1992, PHOTOCHEM PHOTOBIOL, V56, P245, DOI 10.1111/j.1751-1097.1992.tb02153.x
   YAMAMOTO N, 1993, INFECT IMMUN, V61, P5388
   Yamamoto N, 1996, CANCER RES, V56, P2827
   Yamamoto N, 1997, CANCER RES, V57, P2187
   Yamamoto N, 1996, MOL IMMUNOL, V33, P1157, DOI 10.1016/S0161-5890(96)00081-8
   YAMAMOTO N, 1987, CANCER RES, V47, P2008
   Yamamoto N, 1998, IMMUNOL CELL BIOL, V76, P237, DOI 10.1046/j.1440-1711.1998.00748.x
   YAMAMOTO N, 1991, J IMMUNOL, V147, P273
   YAMAMOTO N, 1995, AIDS RES HUM RETROV, V11, P1373, DOI 10.1089/aid.1995.11.1373
   Yamamoto N, 1997, CANCER RES, V57, P295
   YAMAMOTO N, 1988, CANCER RES, V48, P6044
   YAMAMOTO N, 1998, Patent No. 5712104
   YAMAMOTO N, 1997, Patent No. 5620846
   YAMAMOTO N, 1993, Patent No. 5177002
   YAMAMOTO N, 1998, ENCY IMMUNOLOGY, P2494
   YAMAMOTO N, 2002, Patent No. 6410269
   YAMAMOTO N, 2004, P INT C IMM, P197
   Yamamoto N, 2006, J IMMUNOTHER, V29, P677
   YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A
   ZBAR B, 1971, SCIENCE, V172, P271, DOI 10.1126/science.172.3980.271
   Zhang SL, 1997, INT J CANCER, V73, P42, DOI 10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1
   Zhang SL, 1997, INT J CANCER, V73, P50, DOI 10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.3.CO;2-O
   Zhang SL, 1998, CLIN CANCER RES, V4, P2669
NR 57
TC 45
Z9 48
U1 3
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 15
PY 2008
VL 122
IS 2
BP 461
EP 467
DI 10.1002/ijc.23107
PG 7
WC Oncology
SC Oncology
GA 242DJ
UT WOS:000251704400028
PM 17935130
DA 2018-12-27
ER

PT J
AU Said, YH
   Wegman, EJ
   Sharabati, WK
   Rigsby, JT
AF Said, Yasmin H.
   Wegman, Edward J.
   Sharabati, Walid K.
   Rigsby, John T.
TI RETRACTED: Social networks of author-coauthor relationships (Retracted
   article. See vol. 55, pg. 3386, 2011)
SO COMPUTATIONAL STATISTICS & DATA ANALYSIS
LA English
DT Article; Retracted Publication
DE clustering; network science; allegiance; entrepreneurial model; mentor
   model; solo model; laboratory model; co-occurence matrix
AB Social network analysis has proven to be a useful too] in analysis of many situations. We begin by giving an overview of social network analysis. We then illustrate the concepts by examining the social networks of co-authors of scholarly publications. Scholarly publication is in many ways the lifeblood of academic institutions and there are strong incentives, both in terms of prestige and financial compensation, for faculty members to publish. Different disciplines and individuals have evolved distinguishable mechanisms for coping with the publication pressures. We examine the co-authorship networks of a number of prominent scholars. Based on the clustering within the co-author social network, we distinguish several styles of co-authorship including solo models (no co-authors), mentor models, entrepreneurial models, and team models. We conjecture that certain styles of co-authorship lead to the possibility of group-think, reduced creativity, and the possibility of less rigorous reviewing processes. Published by Elsevier B.V.
C1 [Said, Yasmin H.; Wegman, Edward J.; Sharabati, Walid K.; Rigsby, John T.] George Mason Univ, Dept Computat & Data Sci, Fairfax, VA 22030 USA.
RP Wegman, EJ (reprint author), George Mason Univ, Dept Computat & Data Sci, Fairfax, VA 22030 USA.
EM ewegman@gmail.com
CR GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469
   RIGSBY JT, 2005, BLOCK MODELS ALLEGIA
   Wasserman S, 1994, SOCIAL NETWORK ANAL
   WEGMAN EJ, 2006, ADHOC COMMITTEE REPO
NR 4
TC 28
Z9 29
U1 4
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-9473
EI 1872-7352
J9 COMPUT STAT DATA AN
JI Comput. Stat. Data Anal.
PD JAN 10
PY 2008
VL 52
IS 4
BP 2177
EP 2184
DI 10.1016/j.csda.2007.07.021
PG 8
WC Computer Science, Interdisciplinary Applications; Statistics &
   Probability
SC Computer Science; Mathematics
GA 264JL
UT WOS:000253283500027
DA 2018-12-27
ER

PT J
AU Hu, RH
   Sui, Y
   Chen, L
   He, CM
AF Hu, Rong-Hua
   Sui, Yan
   Chen, Li
   He, Chun-Mei
TI RETRACTED: {mu-6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato}-mu-nitrato-dinitr
   atoeuropium(III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
C1 [Hu, Rong-Hua; Sui, Yan; He, Chun-Mei] JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
   [Chen, Li] JingGangShan Univ, Coll Educ, Jian 343009, Jiangxi, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUK AXS INC, 2004, APEX2 VERS 1 22 SADA
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G M., 1997, SHELXLS97 SHELXL97
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 1
Z9 1
U1 4
U2 11
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JAN
PY 2008
VL 64
BP M8
EP U143
DI 10.1107/S160053680706151X
PN 1
PG 13
WC Crystallography
SC Crystallography
GA 247AK
UT WOS:000252049300013
PM 21200648
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, ZX
   Zhang, XL
   Pu, XH
AF Li, Zongxiao
   Zhang, Xinli
   Pu, Xiaohua
TI RETRACTED: Bis(4-chloro-2-formylphenolato)-nickel(II) (Retracted
   article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID COMPLEXES; LIGANDS
AB The asymmetric unit of the title compound, [Ni(C7H4ClO2)(2)], contains one half-molecule. The Ni-II ion, lying on an inversion centre, is four-coordinated by O atoms of 5-chloro-salicylaldehydate ligands in a square-planar geometry.
C1 [Li, Zongxiao; Zhang, Xinli; Pu, Xiaohua] Baoji Univ Arts & Sci, Dept Chem, Baoji 721007, Shaanxi, Peoples R China.
RP Li, ZX (reprint author), Baoji Univ Arts & Sci, Dept Chem, Baoji 721007, Shaanxi, Peoples R China.
EM mingtian8001@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Boudalis AK, 2004, INORG CHEM, V43, P1574, DOI 10.1021/ic0351904
   *BRUK AXS INC, 1997, SMART SAINT
   Erxleben A, 2001, EUR J INORG CHEM, P3039
   Gavrilova AL, 2004, CHEM REV, V104, P349, DOI 10.1021/cr020604g
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1995, SHELXTL VERSION 5 0
   Veauthier JM, 2004, INORG CHEM, V43, P1220, DOI 10.1021/ic0352001
NR 9
TC 1
Z9 1
U1 4
U2 13
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JAN
PY 2008
VL 64
BP M215
EP U2072
DI 10.1107/S1600536807056309
PN 1
PG 8
WC Crystallography
SC Crystallography
GA 247AK
UT WOS:000252049300179
PM 21200562
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: catena-Poly[[(nitrato-kappa O)(1,10-phen-anthroline-kappa
   N-2,N ')manganese(II)]-mu-nitrato-kappa O-2 : O '] (Retracted article.
   See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 [Liu, T.] Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   [Zhu, J. Y.] Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   *BRUK AXS INC, 2005, APEX2, V34, P231
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELXS97 SHELX97
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 10
TC 0
Z9 0
U1 4
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JAN
PY 2008
VL 64
BP M28
EP U328
DI 10.1107/S160053680706254X
PN 1
PG 10
WC Crystallography
SC Crystallography
GA 247AK
UT WOS:000252049300029
PM 21200602
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hwang, HS
   Maeng, YS
   Kim, YH
   Kwon, YG
   Park, YW
   Kim, IK
AF Hwang, Han-Sung
   Maeng, Yong-Sun
   Kim, Young-Han
   Kwon, Young-Guen
   Park, Yong-Won
   Kim, In-Kyu
TI RETRACTED: Nestin expression during differentiation of fetal endothelial
   progenitor cells and hypoxic culture of human umbilical vein endothelial
   cells (Retracted Article. See vol 88, pg 495, 2009)
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
DE nestin; endothelial progenitor cell; human umbilical vein endothelial
   cell
ID STEM-CELLS; PROLIFERATIVE ENDOTHELIUM; BLOOD-VESSELS;
   NEOVASCULARIZATION; ANGIOGENESIS; MOBILIZATION; RECRUITMENT; PRECURSORS;
   MARKER; GROWTH
AB Objective. The aim of this study was to assess whether nestin is expressed during differentiation of endothelial progenitor cells (EPCs) obtained from human umbilical cord blood (HUCB), and nestin expression is changed in hypoxia-conditioned culture of human umbilical vein endothelial cells (HUVECs). Methods. Among deliveries at our institute, 20 normal pregnant women who delivered by cesarean section at 37-40 weeks' gestation were selected. HUCB mononuclear cells (MNCs) from HUCB were isolated and cultivated. After characterization of CXCR4/KDR/CD34 positive cells (EPCs) by flow cytometry and fluorescent chemical staining, EPC culture was continued through day 10 for differentiation to outgrowth endothelial cell (OEC). For identification of EPC and OEC, RT-PCR was performed for each specific cell markers, such as AC133, CD45, CXCR4, CDH5, vWF, eNOs, CD34, and Flt 1. HUVECs were isolated from human umbilical cord veins by collagenase treatment. Culture of HUVEC in hypoxic and normoxic conditions was performed for 24 h. Nestin expression in EPCs, OECs and HUVECs was detected by RT-PCR and Western blotting. Results. Western blot analysis and RT-PCR revealed that nestin was not expressed in EPC, but well expressed in OECs and HUVECs. During 24 h of HUVEC culture, time course gene expression of VEGF was significantly increased, but nestin was not changed. Conclusions. Our results showed that nestin could be used as a new differentiation marker of EPCs, and hypoxic stimuli did not directly affect nestin gene expression.
C1 [Hwang, Han-Sung; Kim, Young-Han; Park, Yong-Won; Kim, In-Kyu] Yonsei Univ Hlth Syst, Dept Obstet & Gynecol, Div Maternal & Fetal Med, Seoul, South Korea.
   [Maeng, Yong-Sun; Kwon, Young-Guen] Yonsei Univ, Dept Biochem, Seoul 120749, South Korea.
RP Kim, IK (reprint author), Yonsei Univ Hlth Syst, Dept Obstet & Gynecol, Div Maternal & Fetal Med, 250 Seongsanno, Seoul, South Korea.
EM ikkim@yuhs.ac
OI Kim, Young-Han/0000-0003-0645-6028
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Carmeliet P, 2001, THROMB HAEMOSTASIS, V86, P289
   CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   DAHLSTRAND J, 1992, CANCER RES, V52, P5334
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Eggermann J, 2003, CARDIOVASC RES, V58, P478, DOI 10.1016/S0008-6363(03)00252-9
   Harry Lorraine E., 2003, Birth Defects Research, V69, P363, DOI 10.1002/bdrc.10024
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Hwang HS, 2007, ACTA OBSTET GYN SCAN, V86, P909, DOI 10.1080/00016340701417018
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Keelan JA, 2003, PLACENTA, V24, pS33, DOI 10.1053/plac.2002.0948
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Lardon J, 2002, HISTOCHEM CELL BIOL, V117, P535, DOI 10.1007/s00418-002-0412-4
   LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Mokry J, 2004, STEM CELLS DEV, V13, P658, DOI 10.1089/scd.2004.13.658
   Mokry J, 1998, FOLIA BIOL-PRAGUE, V44, P155
   Mokry J, 1999, Gen Physiol Biophys, V18 Suppl 1, P25
   Peichev M, 2000, BLOOD, V95, P952
   Shimizu T, 2006, NEUROL MED-CHIR, V46, P111, DOI 10.2176/nmc.46.111
   SJOBERG G, 1994, EXP CELL RES, V214, P447, DOI 10.1006/excr.1994.1281
   Sugawara K, 2002, LAB INVEST, V82, P345, DOI 10.1038/labinvest.3780428
   Takahashi T, 1999, NAT MED, V5, P434
   TOHYAMA T, 1992, LAB INVEST, V66, P303
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55
   Wroblewski J, 1997, DIFFERENTIATION, V61, P151, DOI 10.1046/j.1432-0436.1997.6130151.x
   Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22
   ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1
NR 31
TC 8
Z9 12
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6349
EI 1600-0412
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PY 2008
VL 87
IS 6
BP 643
EP 651
DI 10.1080/00016340802085326
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 330AC
UT WOS:000257910700009
PM 18568464
DA 2018-12-27
ER

PT J
AU Olley, BO
AF Olley, Benjamin O.
TI RETRACTED: Higher-risk sexual behaviour among HIV patients receiving
   antiretroviral treatment in Ibadan, Nigeria (Retracted article. See vol.
   13, pg. 99, 2014)
SO AJAR-AFRICAN JOURNAL OF AIDS RESEARCH
LA English
DT Article; Retracted Publication
DE Africa; coping; models; negative life events; psychosocial aspects; self
   reporting; stress
ID SOUTH-AFRICA; PSYCHOLOGICAL DISTRESS; BISEXUAL MEN; POSITIVE GAY;
   INFECTION; DEPRESSION; TRANSMISSION; HIV/AIDS; WOMEN; ASSOCIATION
AB A stress-coping model was tested to examine the role that negative life events, coping methods, and depression might play in moderating the associations between HIV-related factors (ARV drug regimen, HIV staging and CD4 count) and higher-risk sexual behaviours of people living with HIV/AIDS. The model depicted hypothesised relationships among several characteristics of HIV-related variables, negative life events, coping behaviours and depression. One hundred and fifty-four HIV patients who were receiving antiretroviral therapy through the PEPFAR programme in Ibadan, Nigeria, responded to a questionnaire. In a hierarchical multiple regression analysis, variables were entered into the equation in the order specified a priori by the model. The results show that: (a) patients on the combined 3-drug ARV regimen were more likely to have engaged in higher-risk sexual behaviours as compared to those on a regimen of two or one ARV drugs; (b) negative life events and (c) a coping method characterised by HIV-status denial both predicted increased higher-risk-sexual-behaviour practice among the patients. The study underscores the need for continuous evaluation of the level of higher-risk-sexual-behaviour practice and associated factors, particularly among HIV/AIDS patients receiving ARV treatment.
C1 Univ Ibadan, Dept Psychol, Fac Social Sci, Secretariat HO, Ibadan, Oyo State, Nigeria.
RP Olley, BO (reprint author), Univ Ibadan, Dept Psychol, Fac Social Sci, Secretariat HO, POB 29530, Ibadan, Oyo State, Nigeria.
EM olley28@yahoo.com
CR Bouhnik AD, 2002, J EPIDEMIOL COMMUN H, V56, P349, DOI 10.1136/jech.56.5.349
   Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6
   Catz SL, 2001, AIDS EDUC PREV, V13, P239, DOI 10.1521/aeap.13.3.239.19746
   CLEARY PD, 1991, AM J PUBLIC HEALTH, V81, P1586, DOI 10.2105/AJPH.81.12.1586
   Comulada WS, 2003, AM J HEALTH BEHAV, V27, P389, DOI 10.5993/AJHB.27.4.11
   Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224
   DICLEMENTE RJ, 2002, GENITAL TRACT DIS, V6, P62
   EICHHOCHLI D, 1998, AM J HEALTH BEHAV, V27, P389
   Evans DL, 2002, AM J PSYCHIAT, V159, P1752, DOI 10.1176/appi.ajp.159.10.1752
   FOLKMAN S, 1992, HEALTH PSYCHOL, V11, P218, DOI 10.1037/0278-6133.11.4.218
   Hutton HE, 2004, AM J PSYCHIAT, V161, P912, DOI 10.1176/appi.ajp.161.5.912
   Hutton HE, 2001, PSYCHIATR SERV, V52, P508, DOI 10.1176/appi.ps.52.4.508
   Ibanez GE, 2005, AIDS, V19, pS49, DOI 10.1097/01.aids.0000167351.00503.92
   Kalichman SC, 1997, HEALTH PSYCHOL, V16, P369, DOI 10.1037//0278-6133.16.4.369
   Kalichman SC, 1999, AIDS CARE, V11, P415, DOI 10.1080/09540129947794
   Kalichman SC, 1997, AIDS CARE, V9, P441, DOI 10.1080/09540129750124984
   Kaminer D, 2001, BRIT J PSYCHIAT, V178, P373, DOI 10.1192/bjp.178.4.373
   KELLY JA, 1992, AM J PSYCHIAT, V149, P886
   KELLY JA, 1993, HEALTH PSYCHOL, V12, P215, DOI 10.1037//0278-6133.12.3.215
   KENNEDY CA, 1993, AIDS, V7, P1493, DOI 10.1097/00002030-199311000-00014
   Marks G, 1999, AIDS, V13, P297, DOI 10.1097/00002030-199902250-00001
   MCKINNON K, 1993, AM J PSYCHIAT, V150, P972
   *NAT AIDS STD CONT, 2006, FACT SHEET
   NEUGEBAUER R, 1992, AM J PSYCHIAT, V149, P1374
   Olley BO, 2005, AIDS CARE, V17, P1, DOI 10.1080/095401204123315089
   Olley BO, 2004, AIDS PATIENT CARE ST, V18, P481, DOI 10.1089/1087291041703700
   OLLEY BO, 2008, INT J STD A IN PRESS
   Petrak J, 2000, SEX TRANSM INFECT, V76, P457, DOI 10.1136/sti.76.6.457
   Semple SJ, 2000, AIDS EDUC PREV, V12, P340
   Skydsbjerg M, 2001, SCAND J PSYCHOL, V42, P327, DOI 10.1111/1467-9450.00244
   Stephenson JM, 2003, SEX TRANSM INFECT, V79, P7, DOI 10.1136/sti.79.1.7
   SWARTZ L, 1983, J PSYCHOSOM RES, V27, P223, DOI 10.1016/0022-3999(83)90026-0
   *UNAIDS, 2007, AIDS EP UPD
   Varga CA, 2001, AIDS CARE, V13, P351, DOI 10.1080/09540120120044008
NR 34
TC 9
Z9 9
U1 3
U2 15
PU NATL INQUIRY SERVICES CENTRE PTY LTD
PI GRAHAMSTOWN
PA 19 WORCESTER STREET, PO BOX 377, GRAHAMSTOWN 6140, SOUTH AFRICA
SN 1608-5906
EI 1727-9445
J9 AJAR-AFR J AIDS RES
JI AJAR-Afr. J. Aids Res.
PY 2008
VL 7
IS 1
BP 71
EP 78
DI 10.2989/AJAR.2008.7.1.8.436
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 351UQ
UT WOS:000259451800008
PM 25871273
DA 2018-12-27
ER

PT J
AU White, J
   Guerin, T
   Swanson, H
   Post, S
   Zhu, HN
   Gong, M
   Liu, J
   Everson, WV
   Li, XA
   Graf, GA
   Ballard, HO
   Ross, SA
   Smart, EJ
AF White, James
   Guerin, Theresa
   Swanson, Hollie
   Post, Steven
   Zhu, Haining
   Gong, Ming
   Liu, Jun
   Everson, William V.
   Li, Xiang-An
   Graf, Gregory A.
   Ballard, Hubert O.
   Ross, Stuart A.
   Smart, Eric J.
TI RETRACTED: Diabetic HDL-associated myristic acid inhibits
   acetylcholine-induced nitric oxide generation by preventing the
   association of endothelial nitric oxide synthase with calmodulin
   (Retracted article. See vol. 304, pg. C812, 2013)
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE fatty acid; lipoprotein; diabetes; signaling
ID HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; SCAVENGER
   RECEPTOR; DEPENDENT MANNER; CLASS-B; SR-BI; INSULIN-RESISTANCE;
   METABOLIC SYNDROME; FATTY-ACIDS; ATHEROSCLEROSIS
AB In the current study, we examined whether diabetes affected the ability of HDL to stimulate nitric oxide (NO) production. Using HDL isolated from both diabetic humans and diabetic mouse models, we found that female HDL no longer induced NO synthesis, despite containing equivalent amounts of estrogen as nondiabetic controls. Furthermore, HDL isolated from diabetic females and males prevented acetylcholine-induced stimulation of NO generation. Analyses of both the human and mouse diabetic HDL particles showed that the HDLs contained increased levels of myristic acid. To determine whether myristic acid associated with HDL particles was responsible for the decrease in NO generation, myristic acid was added to HDL isolated from nondiabetic humans and mice. Myristic acid-associated HDL inhibited the generation of NO in a dose-dependent manner. Importantly, diabetic HDL did not alter the levels of endothelial NO synthase or acetylcholine receptors associated with the cells. Surprisingly, diabetic HDL inhibited ionomycin-induced stimulation of NO production without affecting ionomycin-induced increases in intracellular calcium. Further analysis indicated that diabetic HDL prevented calmodulin from interacting with endothelial NO synthase (eNOS) but did not affect the activation of calmodulin kinase or calcium-independent mechanisms for stimulating eNOS. These studies are the first to show that a specific fatty acid associated with HDL inhibits the stimulation of NO generation. These findings have important implications regarding cardiovascular disease in diabetic patients.
C1 [White, James; Guerin, Theresa; Liu, Jun; Everson, William V.; Li, Xiang-An; Ballard, Hubert O.; Ross, Stuart A.; Smart, Eric J.] Univ Kentucky, Kentucky Pediat Res Inst, Lexington, KY 40536 USA.
   [White, James; Guerin, Theresa; Liu, Jun; Everson, William V.; Li, Xiang-An; Ballard, Hubert O.; Ross, Stuart A.; Smart, Eric J.] Univ Kentucky, Dept Pediat, Lexington, KY 40536 USA.
   [Swanson, Hollie; Post, Steven] Univ Kentucky, Dept Pharmacol, Lexington, KY 40536 USA.
   [Zhu, Haining] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
   [Gong, Ming; Smart, Eric J.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
   [Graf, Gregory A.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
RP Smart, EJ (reprint author), Univ Kentucky, Kentucky Pediat Res Inst, 423 Sanders Brown,800 S Limestone St, Lexington, KY 40536 USA.
EM ejsmart@email.uky.edu
FU NCRR NIH HHS [P20-RR-105592]; NHLBI NIH HHS [HL-68509]; NIDDK NIH HHS
   [DK-63025]
CR ACTON SL, 1994, J BIOL CHEM, V269, P21003
   Akamine EH, 2006, J VASC RES, V43, P309, DOI 10.1159/000093196
   Albertini R., 2002, Current Molecular Medicine (Hilversum), V2, P579, DOI 10.2174/1566524023362177
   Assanasen C, 2005, J CLIN INVEST, V115, P969, DOI 10.1172/JCI23858
   Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512
   Boo YC, 2006, FREE RADICAL BIO MED, V41, P144, DOI 10.1016/j.freeradbiomed.2006.03.024
   Braith RW, 2006, CIRCULATION, V113, P2642, DOI 10.1161/CIRCULATIONAHA.105.584060
   Carpentier YA, 2006, AM J CLIN NUTR, V83, p1499S, DOI 10.1093/ajcn/83.6.1499S
   CHAPMAN MJ, 1986, PLASMA LIPOPROTEINS, P70
   Chetiveaux M, 2002, J LIPID RES, V43, P1986, DOI 10.1197/jlrD200024-JLR200
   Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0
   Duckworth William C, 2006, Endocr Pract, V12 Suppl 1, P85
   Duffy D, 2006, CIRCULATION, V113, P1140, DOI 10.1161/CIRCULATIONAHA.105.593855
   Fu T, 2006, BIOCHEM BIOPH RES CO, V341, P1172, DOI 10.1016/j.bbrc.2006.01.071
   Gharavi NM, 2006, CIRC RES, V98, P768, DOI 10.1161/01.RES.0000215343.89308.93
   Gong M, 2003, J CLIN INVEST, V111, P1579, DOI 10.1172/JCI200316777
   Grundy SM, 2006, J AM COLL CARDIOL, V47, P1093, DOI 10.1016/j.jacc.2005.11.046
   GWYNNE JT, 1989, J BIOL CHEM, V264, P8141
   Harris William S, 2005, Curr Atheroscler Rep, V7, P375, DOI 10.1007/s11883-005-0050-0
   Kim JA, 2006, CIRCULATION, V113, P1888, DOI 10.1161/CIRCULATIONAHA.105.563213
   Komers R, 2006, DIABETES, V55, P1651, DOI 10.2337/db05-1595
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEROY A, 1993, J BIOL CHEM, V268, P4798
   Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200
   Libby P, 2000, BBA-MOL CELL BIOL L, V1529, P299, DOI 10.1016/S1388-1981(00)00161-X
   Libby P, 2001, AM J CARDIOL, V88, p3N
   Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200
   Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061
   Schnell Oliver, 2006, Endocr Pract, V12 Suppl 1, P16
   SCHUMAKER VN, 1986, PLASMA LIPOPROTEIN A, P155
   Stender S, 2004, ANN NUTR METAB, V48, P61, DOI 10.1159/000075591
   Tooke J, 1999, DIABETES OBES METAB, V1, pS17
   Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278
   van Berkel TJC, 2005, CURR OPIN LIPIDOL, V16, P525, DOI 10.1097/01.mol.0000183943.20277.26
   Verges B, 2005, DIABETES METAB, V31, P429, DOI 10.1016/S1262-3636(07)70213-6
   Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986
   Zhang YZ, 2005, J CLIN INVEST, V115, P2870, DOI 10.1172/JCI25327
   Zhu WF, 2005, J BIOL CHEM, V280, P29543, DOI 10.1074/jbc.M501238200
NR 38
TC 8
Z9 8
U1 3
U2 12
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JAN
PY 2008
VL 294
IS 1
BP C295
EP C305
DI 10.1152/ajpcell.00042.2007
PG 11
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 253GV
UT WOS:000252507600033
PM 17977947
DA 2018-12-27
ER

PT J
AU Das, B
   Sengupta, S
AF Das, Bhaskar
   Sengupta, Sarthak
TI RETRACTED: HbE genotypes and fertility: A study on a Tibeto-Burmese
   population in Upper Assam, India (Retracted Article. See vol 38, pg 382,
   2011)
SO ANNALS OF HUMAN BIOLOGY
LA English
DT Article; Retracted Publication
DE HbE genotypes; fertility; Mishing; restriction digestion; iron
   deficiency
ID HEMOGLOBIN E TRAIT; PLASMODIUM-FALCIPARUM; MALARIA; THALASSEMIA;
   THAILAND
AB Background: The north-eastern states of India in general and the state of Assam in particular appear to be areas with a very high incidence of HbE, with the highest frequency of the allele observed among the Kachari population.
   Aim: In the present study a Tibeto-Burmese speaking population of Assam, India has been studied with regard to haemoglobin E (HbE) and to examine the role of different HbE genotypes on fertility.
   Subjects and methods: Detailed reproductive histories and socio-economic data were collected from 159 unrelated Mishing (a Tibeto-Burmese population) couples initially. Haemoglobin typing was done by restriction digestion to detect wild type (HbA/HbA), heterozygotes (HbA/HbE) and homozygotes (HbE/HbE).
   Results and conclusion: The HbE gene frequency for the total 318 individuals was 0.4623. The results suggest that HbE homozygosity is associated with a higher pregnancy rate. Mothers homozygous for HbE also have more live births in spite of having more spontaneous abortions. The study shows that HbE homozygous women may be getting an advantage up to the point of conception but beyond that various factors come into play to increase miscarriage and infant mortality and that the socio-economic factor is one important reason behind this.
C1 [Das, Bhaskar; Sengupta, Sarthak] Dibrugarh Univ, Dept Anthropol, Dibrugarh 786004, Assam, India.
RP Das, B (reprint author), Dibrugarh Univ, Dept Anthropol, Dibrugarh 786004, Assam, India.
EM bd_das2002@yahoo.co.in
CR BALGIR R S, 1992, Indian Journal of Pediatrics, V59, P449, DOI 10.1007/BF02751560
   Barkakaty B. N., 1992, Indian Journal of Malariology, V29, P173
   BARUA N, 1974, THESIS DIBRUGARH U I
   Bhuyan M., 1997, Journal of Communicable Diseases, V29, P243
   BUNYARATVEJ A, 1986, ACTA HAEMATOL-BASEL, V76, P155
   CHAKRAVARTY K, 1997, HLTH STUDIES ANTHR, V25, P137
   Chotivanich K, 2002, BLOOD, V100, P1172
   DAS B M, 1980, Journal of the Indian Anthropological Society, V15, P153
   DAS BM, 1971, HUMANGENETIK, V12, P264, DOI 10.1007/BF00702780
   DAS BM, 1985, INDIAN ANTHR, V15, P21
   Das N. G., 2004, Journal of Vector Borne Diseases, V41, P5
   Das N. G., 1997, Indian Journal of Malariology, V34, P164
   de Silva S, 2000, LANCET, V355, P786, DOI 10.1016/S0140-6736(99)08246-X
   DEKA R, 1981, HUM GENET, V59, P172, DOI 10.1007/BF00293071
   DEKA R, 1988, HUM HERED, V38, P261, DOI 10.1159/000153796
   DEKA R, 1975, THESIS DIBRUGARH U I
   Dev V., 1993, Community participation in malaria control., P247
   DUTTA P, 1989, Indian Journal of Malariology, V26, P149
   EATON JW, 1971, NATURE, V231, P456, DOI 10.1038/231456a0
   FLATZ G, 1965, ANN HUM GENET, V29, P151, DOI 10.1111/j.1469-1809.1965.tb00511.x
   FLATZ G, 1967, HUMANGENETIK, V3, P189, DOI 10.1007/BF00273124
   Gogoi S. C., 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P228
   HOFLIGER H, 1971, FORTPFLANZUNG FRAUEN
   Hutagalung R, 1999, J INFECT DIS, V179, P283, DOI 10.1086/314561
   Hutagalung R, 2000, J INFECT DIS, V181, P1513, DOI 10.1086/315373
   Jamsai D, 2006, GENOMICS, V88, P309, DOI 10.1016/j.ygeno.2006.03.009
   KAR RK, 1994, B DEPT ANTHR DIBRUGA, V22, P29
   KRUATRACHUE M, 1969, B WORLD HEALTH ORGAN, V40, P459
   LIVINGSTONE FB, 1971, ANNU REV GENET, V5, P33, DOI 10.1146/annurev.ge.05.120171.000341
   Nandi J., 1993, Journal of Communicable Diseases, V25, P18
   Ohashi J, 2004, AM J HUM GENET, V74, P1198, DOI 10.1086/421330
   ORKIN SH, 1982, NATURE, V300, P768, DOI 10.1038/300768a0
   PAMEGAM T, 1997, ASOMOR JANAJATI, V3, P155
   Prakash A, 1996, INDIAN J MED RES, V103, P146
   VERNES AJM, 1986, T ROY SOC TROP MED H, V80, P642, DOI 10.1016/0035-9203(86)90163-X
   Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704
NR 36
TC 6
Z9 6
U1 4
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0301-4460
EI 1464-5033
J9 ANN HUM BIOL
JI Ann. Hum. Biol.
PY 2008
VL 35
IS 4
BP 422
EP 431
DI 10.1080/03014460802221121
PG 10
WC Anthropology; Biology; Public, Environmental & Occupational Health
SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public,
   Environmental & Occupational Health
GA 329TW
UT WOS:000257894500007
PM 18654872
DA 2018-12-27
ER

PT J
AU Bener, A
   Alsaied, A
   Al-Ali, M
   Hassan, AS
   Basha, B
   Al-Kubaisi, A
   Abraham, A
   Mian, M
   Guiter, G
   Tewfik, I
AF Bener, Abdulbari
   Alsaied, Amer
   Al-Ali, Mariam
   Hassan, Abdelmonem S.
   Basha, Basma
   Al-Kubaisi, Aisha
   Abraham, Amit
   Mian, Marcellina
   Guiter, Gerardo
   Tewfik, Ihab
TI RETRACTED: Impact of Lifestyle and Dietary Habits on Hypovitaminosis D
   in Type 1 Diabetes Mellitus and Healthy Children from Qatar, a Sun-Rich
   Country (Retracted article. See vol. 67, pg. 133, 2015)
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Article; Retracted Publication
DE Hypovitaminosis D; Dietary habits; Type 1 diabetes mellitus
ID VITAMIN-D-DEFICIENCY; D METABOLISM; RISK; ADOLESCENTS
AB Background: There are no population-based studies that have examined the association between vitamin D and type 1 diabetes mellitus (T1DM) and the role of lifestyle habits and dietary factors in young children in the Arabian Gulf and Middle East region. Little data on the intake of these nutrients in Mediterranean countries exist, and predictors of their suboptimal intake are not well defined. Objective: The objective of this study was to determine the association between vitamin D status and T1DM and assess the impact of lifestyle and dietary habits on hypovitaminosis D in the young population of the State of Qatar. A matched case-control study was carried out among T1DM children and healthy subjects < 16 years of age at the pediatric endocrinology outpatient clinics of the Hamad General Hospital and the primary health care clinics center. The survey was conducted over a period from 6 August to 25 December 2007. The sample included 170 cases and 170 controls matched by age, gender and ethnicity. Methods: Face to face interviews were based on a questionnaire that included variables such as sociodemographic information, assessment of non-dietary covariates, assessment of dietary intake including vitamin D, type of feeding, clinical manifestations and laboratory investigations. Their health status was assessed by medical conditions, family history, body mass index, past or present clinical manifestations, serum 25(OH) vitamin D, calcium, alkaline phosphates, phosphorus, hemoglobin A1C, parathyroid hormone, magnesium and creatinine analysis. Results: The study revealed that the incidence of severe vitamin D deficiency was considerably higher in T1DM (28.8%) compared with healthy children (17.1%). Although the mean serum level of vitamin D was significantly lower in T1DM children (15.80 +/- 9.23 ng/ml), compared with nondiabetic children (18.45 +/- 9.56 ng/ml), both groups belonged to the mild-moderate vitamin D deficiency category. A family history of vitamin D deficiency (35.3%; p = 0.012) and diabetes mellitus (56.5%; p < 0.001) was significantly higher in diabetic children. More than half of the diabetic (67.1%) and healthy children (51.2%) had no physical activity in their daily life. Both groups (65.9 vs. 62.9%) had very limited exposure to sunlight. Vitamin D supplement intake was very poor in diabetic children compared with healthy children; 60% of diabetic and 40.6% of healthy children never had any vitamin D supplement. The study revealed that vitamin D serum concentration, phosphorus, hemoglobin A1C, magnesium and creatinine show statistically significant differences between T1DM and healthy control subjects. A significant difference was noted between diabetic and healthy children for fractures (p = 0.005), weakness (p = 0.001) and gastroenteritis (p = 0.025). Conclusions: The present study revealed that vitamin D deficiency is a common problem in Qatari children, but the incidence of vitamin D deficiency becomes very severe in T1DM children, compared with healthy children. This suggests that there is an association between vitamin D deficiency and T1DM. The data show that vitamin D status is dependent on sunshine exposure and dietary vitamin D intake. The results suggest the necessity of nutrition education to promote healthy eating habits among adolescents and their parents. Copyright (C) 2008 S. Karger AG, Basel
C1 [Bener, Abdulbari] Hamad Gen Hosp, Hamad Med Corp, Dept Med Stat & Epidemiol, Doha, Qatar.
   [Al-Ali, Mariam] Hamad Gen Hosp, Hamad Med Corp, Dept Paediat, Doha, Qatar.
   [Bener, Abdulbari; Alsaied, Amer; Basha, Basma; Al-Kubaisi, Aisha; Abraham, Amit; Mian, Marcellina; Guiter, Gerardo] Univ Qatar, Weill Cornell Med Coll Qatar, Doha, Qatar.
   [Hassan, Abdelmonem S.] Univ Qatar, Coll Arts & Sci, Doha, Qatar.
   [Bener, Abdulbari] Univ Manchester, Sch Epidemiol & Hlth Sci, Dept Evidence Populat Hlth Unit, Manchester, Lancs, England.
   [Tewfik, Ihab] Univ Westminster, Dept Human & Hlth Sci, London W1R 8AL, England.
RP Bener, A (reprint author), Hamad Gen Hosp, Hamad Med Corp, Dept Med Stat & Epidemiol, POB 3050, Doha, Qatar.
EM abener@hmc.org.qa
CR Bailey R, 2007, DIABETES, V56, P2616, DOI 10.2337/db07-0652
   Bajpai A, 2005, INDIAN PEDIATR, V42, P23
   Bhattacharyya A K, 1992, World Rev Nutr Diet, V67, P140
   Bouillon R, 1998, OSTEOPOROSIS INT, V8, pS13, DOI 10.1007/PL00022727
   Dahlquist G, 1999, DIABETOLOGIA, V42, P51
   Das G, 2006, ARCH DIS CHILD, V91, P569, DOI 10.1136/adc.2005.077974
   Dawodu A, 2002, MIDDLE E PAEDIAT, V7, P12
   Di Cesar DJ, 2006, DIABETES CARE, V29, P174, DOI 10.2337/diacare.29.1.174
   Fraser DR, 2004, J STEROID BIOCHEM, V89-90, P491, DOI 10.1016/j.jsbmb.2004.03.057
   Gannage-Yared MH, 2000, J BONE MINER RES, V15, P1856, DOI 10.1359/jbmr.2000.15.9.1856
   Glerup H, 2000, J INTERN MED, V247, P260, DOI 10.1046/j.1365-2796.2000.00595.x
   Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338
   Holick MF, 2005, SOUTH MED J, V98, P1024, DOI 10.1097/01.SMJ.0000140865.32054.DB
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1
   Kamal M, 2006, ACTA PHARMACOL SIN, V27, P724, DOI 10.1111/j.1745-7254.2006.00313.x
   Lapatsanis D, 2005, CALCIFIED TISSUE INT, V77, P348, DOI 10.1007/s00223-004-0096-y
   Littorin B, 2006, DIABETOLOGIA, V49, P2847, DOI 10.1007/s00125-006-0426-x
   Luong KVQ, 2005, DIABETES-METAB RES, V21, P338, DOI 10.1002/dmrr.557
   MAJID MA, 2000, PEDIATR INT, V42, P280
   MATHIEU C, 2005, TRENDS ENDOCRIN MET, V16, P6
   Mishal AA, 2001, OSTEOPOROSIS INT, V12, P931, DOI 10.1007/s001980170021
   Mrena S, 2003, J CLIN ENDOCR METAB, V88, P2682, DOI 10.1210/jc.2002-020644
   Ovesen L, 2003, P NUTR SOC, V62, P813, DOI 10.1079/PNS2003297
   Plotnikoff GA, 2003, MAYO CLIN PROC, V78, P1463, DOI 10.4065/78.12.1463
   Stang J, 2000, J AM DIET ASSOC, V100, P905, DOI 10.1016/S0002-8223(00)00262-5
   Stene LC, 2003, AM J CLIN NUTR, V78, P1128
   Thacher TD, 2006, ANN TROP PAEDIATR, V26, P1, DOI 10.1179/146532806X90556
   *US EPA, 1989, 400189001 EPA
NR 29
TC 27
Z9 28
U1 4
U2 14
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 1421-9697
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PY 2008
VL 53
IS 3-4
BP 215
EP 222
DI 10.1159/000184439
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 412TE
UT WOS:000263746300010
PM 19077420
DA 2018-12-27
ER

PT J
AU Radenovic, L
AF Radenovic, Lidija
TI RETRACTED: Effect of 7-nitroindazole on superoxide production and MnSOD
   activity in the rat brain following kainate-induced neurotoxicity
   (Retracted article. See vol. 67, pg. 749, 2015)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE kainate; glutamate neurotoxicity; 7-nitroindazole; brain; mitochondria;
   MnSOD; oxidative stress; superoxide
ID METHYL-D-ASPARTATE; NITRIC-OXIDE; OXIDATIVE STRESS; INDUCED SEIZURE;
   RECEPTORS; DISMUTASES; AUTORADIOGRAPHY; GLUTAMATE
AB We investigated the effect of 7-nitroindazole (7-NI), a selective neuronal nitric oxide synthase inhibitor in vivo, on superoxide concentration as well its influence on mitochondrial MnSOD activity since this activity is associated with the production of reactive oxygen species after kainate-induced neurotoxicity. The time course of in vivo oxidative damage in different brain regions was investigated. Measurements were performed at different times (5 min, 15 min, 2 h, 48 h, and 7 days) in the ipsi- and contralateral hippocampus, forebrain cortex, striatum, and cerebellum homogenates. Our results indicated that 7-NI had no statistically significant influence on superoxide concentrations in the tested brain structures compared to the control values. However, superoxide concentrations after kainate-induced neurotoxicity returned to the control values after pretreatment with 7-NI in all tested brain structures. Regarding the activity of MnSOD, our results demonstrated statistically significant increase 7 days after intrahippocampal KA treatment in all tested brain structures after pretreatment with 7-NI. The obtained results suggest that neuronal NO synthase inhibitors may be useful in the treatment of neurological diseases in which excitotoxic mechanisms play a role.
C1 Univ Belgrade, Fac Biol, Inst Physiol & Biochem, Belgrade 11000, Serbia.
RP Radenovic, L (reprint author), Univ Belgrade, Fac Biol, Inst Physiol & Biochem, Belgrade 11000, Serbia.
CR Alabadi JA, 1999, BRAIN RES, V839, P305, DOI 10.1016/S0006-8993(99)01749-7
   Bailey A, 2001, EUR J PHARMACOL, V431, P305, DOI 10.1016/S0014-2999(01)01463-7
   Bidmon HJ, 1999, ANN ANAT, V181, P345, DOI 10.1016/S0940-9602(99)80125-3
   Budd SL, 1996, J NEUROCHEM, V67, P2282
   Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0
   Carroll FY, 1998, NEUROSCI LETT, V255, P71, DOI 10.1016/S0304-3940(98)00720-4
   Ciriolo MR, 2001, J NEUROCHEM, V77, P1433, DOI 10.1046/j.1471-4159.2001.00383.x
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   DUGAN LL, 1995, J NEUROSCI, V15, P6377
   FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525
   Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040
   Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6
   Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x
   Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x
   Lindenau J, 2000, GLIA, V29, P25, DOI 10.1002/(SICI)1098-1136(20000101)29:1<25::AID-GLIA3>3.0.CO;2-G
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Montecot C, 1997, J CEREBR BLOOD F MET, V17, P94, DOI 10.1097/00004647-199701000-00012
   Nakaki T, 2000, NEUROSCI LETT, V290, P209, DOI 10.1016/S0304-3940(00)01363-X
   Radenovic L, 2004, NEUROSCI RES COMMUN, V34, P92, DOI 10.1002/nrc.20003
   Radenovic L, 2003, COMP BIOCHEM PHYS C, V135, P443, DOI 10.1016/S1532-0456(03)00150-9
   RADENOVIC L, 2005, ARCH BIOL SCI BELGRA, V57, P75, DOI DOI 10.2298/ABS0502075R
   RADENOVIC L, 2005, ARCH BIOL SCI, V57, P259, DOI DOI 10.2298/ABS0504259R
   SPITZ DR, 1989, METHOD ENZYMOL, V105, P457
NR 23
TC 1
Z9 1
U1 4
U2 6
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2008
VL 60
IS 1
BP 25
EP 32
DI 10.2298/ABS0801025R
PG 8
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 285ZC
UT WOS:000254813700005
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Cipollone, F
AF Cipollone, Francesco
TI RETRACTED: The balance between PGD synthase and PGE synthase is a major
   determinant of atherosclerotic plaque instability in humans (Retracted
   Article)
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Correction; Retracted Publication
C1 Univ Chieti G D Annunzio, Atherosclerosis Prevent Ctr, Chieti, Italy.
RP Cipollone, F (reprint author), Univ Chieti G D Annunzio, Atherosclerosis Prevent Ctr, Chieti, Italy.
CR Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be
NR 1
TC 0
Z9 0
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JAN 1
PY 2008
VL 28
IS 1
BP E1
EP E1
DI 10.1161/ATVBAHA.107.158881
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 248NE
UT WOS:000252159500030
PM 18094391
OA Bronze
DA 2018-12-27
ER

PT J
AU Sulkowska, JI
   Cieplak, M
AF Sulkowska, Joanna I.
   Cieplak, Marek
TI RETRACTED: Stretching to understand proteins - A survey of the protein
   data bank (Retracted Article. See vol 95, pg 5487, 2008)
SO BIOPHYSICAL JOURNAL
LA English
DT Article; Retracted Publication
ID MOLECULE FORCE SPECTROSCOPY; MECHANICAL RESISTANCE; DYNAMICS SIMULATION;
   GLOBULAR-PROTEINS; PULLING GEOMETRY; SPECTRIN REPEATS; ANKYRIN REPEATS;
   TITIN; TRANSITION; MICROSCOPY
AB We make a survey of resistance of 7510 proteins to mechanical stretching at constant speed as studied within a coarse-grained molecular dynamics model. We correlate the maximum force of resistance with the native structure, predict proteins which should be especially strong, and identify the nature of their force clamps.
C1 [Sulkowska, Joanna I.; Cieplak, Marek] Polish Acad Sci, Inst Phys, Warsaw, Poland.
RP Cieplak, M (reprint author), Polish Acad Sci, Inst Phys, Warsaw, Poland.
EM mc@ifpan.edu.pl
CR ABE H, 1981, BIOPOLYMERS, V20, P1013, DOI 10.1002/bip.1981.360200512
   Baumann CG, 2000, BIOPHYS J, V78, P1965, DOI 10.1016/S0006-3495(00)76744-0
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Best RB, 2001, BIOPHYS J, V81, P2344, DOI 10.1016/S0006-3495(01)75881-X
   Brockwell DJ, 2005, BIOPHYS J, V89, P506, DOI 10.1529/biophysj.105.061465
   Brockwell DJ, 2003, NAT STRUCT BIOL, V10, P731, DOI 10.1038/nsb968
   Carl P, 2001, P NATL ACAD SCI USA, V98, P1565, DOI 10.1073/pnas.031409698
   Carrion-Vazquez M, 2003, NAT STRUCT BIOL, V10, P738, DOI 10.1038/nsb965
   Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1
   Cecconi C, 2005, SCIENCE, V309, P2057, DOI 10.1126/science.1116702
   Chyan CL, 2004, BIOPHYS J, V87, P3995, DOI 10.1529/biophysj.104.042754
   Cieplak M, 2006, BBA-BIOMEMBRANES, V1758, P537, DOI 10.1016/j.bbamem.2006.03.028
   Cieplak M, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1839572
   Cieplak M, 2004, PROTEINS, V56, P285, DOI 10.1002/prot.20081
   Cieplak M, 2003, BIOPHYS J, V84, P475, DOI 10.1016/S0006-3495(03)74867-X
   Clementi C, 2000, J MOL BIOL, V298, P937, DOI 10.1006/jmbi.2000.3693
   Janovjak H, 2003, EMBO J, V22, P5220, DOI 10.1093/emboj/cdg509
   Karanicolas J, 2002, PROTEIN SCI, V11, P2351, DOI 10.1110/ps.0205402
   Kwiecinska JI, 2005, J PHYS-CONDENS MAT, V17, pS1565, DOI 10.1088/0953-8984/17/18/013
   Law R, 2004, J BIOL CHEM, V279, P16410, DOI 10.1074/jbc.M313107200
   Law R, 2003, BIOPHYS J, V84, P533, DOI 10.1016/S0006-3495(03)74872-3
   LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805
   Lee G, 2006, NATURE, V440, P246, DOI 10.1038/nature04437
   Lenne PF, 2000, FEBS LETT, V476, P124, DOI 10.1016/S0014-5793(00)01704-X
   Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697
   Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00398
   Li LW, 2006, BIOPHYS J, V90, pL30, DOI 10.1529/biophysj.105.078436
   Li LW, 2005, J MOL BIOL, V345, P817, DOI 10.1016/j.jmb.2004.11.021
   Li PC, 2004, J CHEM PHYS, V121, P4826, DOI 10.1063/1.1778152
   Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3
   Oberschall A, 2002, CONTEMP SOCIOL, V31, P447, DOI 10.2307/3089104
   Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8
   Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466
   Schlierf M, 2006, BIOPHYS J, V90, pL33, DOI 10.1529/biophysj.105.077982
   Schlierf M, 2005, J MOL BIOL, V354, P497, DOI 10.1016/j.jmb.2005.09.070
   Schwaiger I, 2005, EMBO REP, V6, P46, DOI 10.1038/sj.embor.7400317
   Schwaiger I, 2004, NAT STRUCT MOL BIOL, V11, P81, DOI 10.1038/nsmb705
   Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327
   Szymczak P, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2358346
   Tsai J, 1999, J MOL BIOL, V290, P253, DOI 10.1006/jmbi.1999.2829
   Veitshans T, 1997, FOLD DES, V2, P1, DOI 10.1016/S1359-0278(97)00002-3
   Watanabe K, 2002, J STRUCT BIOL, V137, P248, DOI 10.1006/jsbi.2002.4458
   Watanabe K, 2002, J BIOL CHEM, V277, P11549, DOI 10.1074/jbc.M200356200
   West DK, 2006, BIOPHYS J, V90, P287, DOI 10.1529/biophysj.105.071035
   Yang GL, 2000, P NATL ACAD SCI USA, V97, P139, DOI 10.1073/pnas.97.1.139
NR 45
TC 27
Z9 28
U1 3
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD JAN 1
PY 2008
VL 94
IS 1
BP 6
EP 13
DI 10.1529/iophysj.107.105973
PG 8
WC Biophysics
SC Biophysics
GA 240VH
UT WOS:000251615800004
PM 17704142
DA 2018-12-27
ER

PT J
AU Guo, YJ
   Li, WH
   Wu, R
   Xie, Q
   Zhang, ZH
   Cui, LQ
AF Guo, Y. J.
   Li, W. H.
   Wu, R.
   Xie, Q.
   Zhang, Z. H.
   Cui, L. Q.
TI RETRACTED: Niemann-Pick type C1 protein influences the delivery of
   cholesterol to the SREBP : SCAP complex (Retracted article. See vol 41,
   pg. 437, 2008)
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Niemann-Pick type C1 protein; low-density lipoprotein cholesterol;
   fluorescence microscopy; sterol regulatory element binding protein
   complex; cholesterol homeostasis
ID LOW-DENSITY-LIPOPROTEIN; STEROL REGULATORY ELEMENT;
   ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; SENSING DOMAIN; DISEASE;
   BINDING; MICE; HOMEOSTASIS; TRANSPORT
AB The proposed role of Niemann-Pick type C1 protein (NPC1) in the delivery of low-density lipoprotein (LDL) cholesterol to the sterol regulatory element binding protein (SREBP): SREBP cleavage activation protein (SCAP) complex in the endoplasmic reticulum has been largely based on indirect studies and remains contentious. The major aim of the present study was to assess whether NPC1 is involved in the delivery of LDL cholesterol to the SREBP: SCAP complex. A cell line stably expressing green fluorescence protein-SCAP was cultured in the presence of U18666A, which can induce a Niemann-Pick type C disease phenotype, in order to locate the SREBP: SCAP complex by fluorescence microscopy. Our major finding was that defective NPC1 caused a delay in the ability of LDL cholesterol to suppress SREBP processing. This was shown in a time-course experiment by the effect of LDL on green fluorescence protein-SCAP movement when cells were treated with pharmacological agents to induce a Niemann-Pick type C disease phenotype. We demonstrated directly by fluorescence microscopy that defective NPC1 causes a delay in LDL cholesterol delivery to the endoplasmic reticulum where SCAP senses cholesterol.
C1 [Guo, Y. J.; Zhang, Z. H.; Cui, L. Q.] Shandong Univ, Shandong Prov Hosp, Dept Cardiol, Jinan 250021, Peoples R China.
   [Guo, Y. J.; Li, W. H.; Wu, R.; Xie, Q.] Fujian Med Univ, Hosp Xiamen 1, Dept Cardiol, Xiamen, Peoples R China.
RP Cui, LQ (reprint author), Shandong Univ, Shandong Prov Hosp, Dept Cardiol, 324 Jingwuweiqi Rd, Jinan 250021, Peoples R China.
EM lianqun_cui@hotmail.com
CR AIKAWA K, 1994, BBA-LIPID LIPID MET, V1213, P127
   Amigo L, 2002, HEPATOLOGY, V36, P819, DOI 10.1053/jhep.2002.35617
   BALASUBRAMANIAM S, 1978, EUR J BIOCHEM, V90, P377, DOI 10.1111/j.1432-1033.1978.tb12614.x
   BITTMAN R, 1972, P NATL ACAD SCI USA, V69, P3795, DOI 10.1073/pnas.69.12.3795
   BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022
   BRIGGS MR, 1993, J BIOL CHEM, V268, P14490
   Brown AJ, 1996, J LIPID RES, V37, P320
   Butler A, 2002, AM J PATHOL, V161, P1061, DOI 10.1016/S0002-9440(10)64267-8
   DRABIKOWSKI W, 1973, BIOCHIM BIOPHYS ACTA, V291, P61, DOI 10.1016/0005-2736(73)90060-6
   Du XM, 2004, J BIOL CHEM, V279, P47010, DOI 10.1074/jbc.M408690200
   Erickson RP, 2001, BIOCHEM BIOPH RES CO, V284, P326, DOI 10.1006/bbrc.2001.4971
   Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200
   Garver WS, 2002, J LIPID RES, V43, P579
   GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241
   Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8
   Ikonen E, 2004, SEMIN CELL DEV BIOL, V15, P445, DOI 10.1016/j.semedb.2004.03.001
   Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200
   Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915
   Loewen CJR, 2002, CURR BIOL, V12, pR779, DOI 10.1016/S0960-9822(02)01292-7
   Millard EE, 2005, J BIOL CHEM, V280, P28581, DOI 10.1074/jbc.M414024200
   Mukhejee S, 2004, BBA-MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009
   Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4
   Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101
   Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x
   PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775
   Sakai J, 2001, CURR OPIN LIPIDOL, V12, P261, DOI 10.1097/00041433-200106000-00004
   Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5
   SCRIVER CR, 1995, METABOLIC MOL BASES, V2
   Sugii S, 2006, J BIOL CHEM, V281, P23191, DOI 10.1074/jbc.M603215200
   Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x
   Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336
NR 31
TC 5
Z9 5
U1 4
U2 13
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JAN
PY 2008
VL 41
IS 1
BP 26
EP 33
DI 10.1590/S0100-879X2006005000005
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 265CV
UT WOS:000253337600005
PM 18060319
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Prantl, L
   Schmitt, S
   Gais, S
   Tsui, TY
   Lamby, P
   Babilas, P
   Nerlich, M
   Kubale, R
   Zorger, N
   Herold, T
   Feuerbach, S
   Jung, EM
AF Prantl, L.
   Schmitt, St.
   Gais, S.
   Tsui, T. Y.
   Lamby, P.
   Babilas, P.
   Nerlich, M.
   Kubale, R.
   Zorger, N.
   Herold, T.
   Feuerbach, S.
   Jung, E. M.
TI RETRACTED: Contrast harmonic ultrasound and indocyanine-green
   fluorescence video angiography for evaluation of dermal and subdermal
   microcirculation in free parascapular flaps(Retracted article. See vol.
   55, pg. 283, 2013)
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article; Retracted Publication
ID RECONSTRUCTIVE SURGERY; ENHANCED ULTRASOUND; TISSUE PERFUSION; FLAP
   VIABILITY; RAT MODEL; QUANTIFICATION; DOPPLER; FLOW; VASCULARIZATION;
   METASTASES
AB Purpose: Contrast harmonic ultrasound (CHI) with a linear transducer is a new diagnostic approach that allows dynamic and quantitative flow detection of tissue perfusion in microsurgery. The aim of the study was the evaluation of perfusion of the dermal and subdermal layers of microvascular tissue transplants with CHI in comparison to ICG-fluorescence angiography. Material and method: In a prospective clinical study indocyanine-green fluorescence video angiography and contrast enhanced high resolution ultrasound (5-10 MHz; linear transducer; Logiq 9; GE) were used for evaluation of the microcirculation in 10 transplanted free parascapular flaps. Two regions were analysed, the centre of the flap and the region of the anastomosis. The perfusion patterns of both methods were compared. Results: The perfusion indexes measured by ICG-fluorescence angiography correlated very precisely in all patients with the quantitative perfusion curves of contrast-enhanced US with CHI. Two flaps with slow filling and low dye intensity showed low contrast enhancement in CHI with modified perfusion curves with slow increase. In two cases a reduced perfusion and filling were found. There were no statistical differences between the two diagnostic methods (p > 0.01). Conclusion: CHI improves US detections of dermal and subdermal microcirculation in comparison to ICG fluorescence angiography. CHI is a new diagnostic method for postoperative monitoring of free flaps.
C1 [Prantl, L.; Schmitt, St.; Gais, S.; Tsui, T. Y.; Lamby, P.; Babilas, P.; Nerlich, M.] Univ Hosp Regensburg, Inst Trauma Plast & Reconstruct Surg, Regensburg, Germany.
   [Zorger, N.; Herold, T.; Feuerbach, S.; Jung, E. M.] Univ Hosp Regensburg, Inst Diag Radiol, Regensburg, Germany.
   [Kubale, R.] Hosp Pirmasens, Inst Radiol Nucl Med & Sonog, Pirmasens, Germany.
RP Prantl, L (reprint author), Univ Regensburg, Dept Plast Surg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM lukas.prantl@klinik.uniregensburg.de
CR Bruce M, 2004, ULTRASOUND MED BIOL, V30, P735, DOI 10.1016/j.ultrasmedbio.2004.03.016
   Christiansen JP, 2002, ULTRASOUND MED BIOL, V28, P315, DOI 10.1016/S0301-5629(01)00523-3
   Disa JJ, 1999, PLAST RECONSTR SURG, V104, P97, DOI 10.1097/00006534-199907000-00013
   Forsberg F, 2004, ULTRASONICS, V43, P79, DOI 10.1016/j.ultras.2004.04.005
   FOX IJ, 1956, AM J PHYSIOL, V187, P599
   FOX IJ, 1960, P STAFF M MAYO CLIN, V35, P732
   Giunta RE, 2005, BRIT J PLAST SURG, V58, P695, DOI 10.1016/j.bjps.2005.02.018
   Gori T, 2006, CLIN HEMORHEOL MICRO, V35, P169
   HALLER M, 1993, LIFE SCI, V53, P1597, DOI 10.1016/0024-3205(93)90183-4
   Holm C, 2002, BRIT J PLAST SURG, V55, P635, DOI 10.1054/bjps.2002.3969
   Jung EM, 2006, CLIN HEMORHEOL MICRO, V34, P483
   Jung EM, 2005, CLIN HEMORHEOL MICRO, V33, P109
   Jung EM, 2005, CLIN HEMORHEOL MICRO, V33, P63
   KHALID AN, 2006, HEAD NECK SURG, V134, P635
   Kharin N, 2003, PHYS MED BIOL, V48, P3239, DOI 10.1088/0031-9155/48/19/010
   Kind GM, 1998, PLAST RECONSTR SURG, V101, P1268, DOI 10.1097/00006534-199804050-00016
   Krishnan KG, 2005, BRIT J PLAST SURG, V58, P330, DOI 10.1016/j.bjps.2004.10.003
   Krix M, 2005, RADIOLOGE, V45, P552, DOI 10.1007/s00117-005-1186-1
   Krix M, 2005, J ULTRAS MED, V24, P431, DOI 10.7863/jum.2005.24.4.431
   Krix M, 2004, ULTRASOUND MED BIOL, V30, P1355, DOI 10.1016/j.ultrasmedbio.2004.08.011
   Krix M, 2004, INVEST RADIOL, V39, P216, DOI 10.1097/01.rli.0000116361.62063.b5
   Krix M, 2003, RADIOLOGE, V43, P823, DOI 10.1007/s00117-003-0958-8
   Lin DC, 2002, AM J ROENTGENOL, V179, P1629, DOI 10.2214/ajr.179.6.1791629
   Lucidarme O, 2003, RADIOLOGY, V228, P473, DOI 10.1148/radiol.2282020699
   LUNDJOHANSEN P, 1990, EUR HEART J, V11, P6, DOI 10.1093/eurheartj/11.suppl_I.6
   Mothes H, 2004, J TRAUMA, V57, P1018, DOI 10.1097/01.TA.0000123041.47008.70
   PAUMGARTNER G, 1975, SCHWEIZ MED WSCHR, V105, P5
   Pollard RE, 2002, TECHNOL CANCER RES T, V1, P459, DOI 10.1177/153303460200100606
   Prantl L, 2007, CLIN HEMORHEOL MICRO, V36, P203
   SERAFIN D, 1981, Journal of Microsurgery, V2, P165
   Thorniley MS, 1998, BRIT J PLAST SURG, V51, P218, DOI 10.1054/bjps.1997.0145
   Top H, 2006, NUCL MED COMMUN, V27, P91, DOI 10.1097/00006231-200601000-00013
   Yvonne-Tee GB, 2006, CLIN HEMORHEOL MICRO, V34, P457
NR 33
TC 11
Z9 12
U1 2
U2 8
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2008
VL 38
IS 1
BP 31
EP 44
PG 14
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 242JM
UT WOS:000251721400004
PM 18094456
DA 2018-12-27
ER

PT J
AU Swaminathan, G
   Shivakumar, KN
   Sharpe, M
AF Swaminathan, Gowthaman
   Shivakumar, Kunigal N.
   Sharpe, Mathew
TI RETRACTED: Evaluation of specific properties of glass and carbon/vinyl
   ester composites (Retracted article. See vol.39, pg. 1287, 2008)
SO COMPOSITES PART B-ENGINEERING
LA English
DT Article; Retracted Publication
DE carbon fibre; glass fibres; mechanical properties; stitch bonded fabric
ID STRENGTH
AB The paper describes the processing and mechanical characterization of two different fibers (glass and carbon) and two different fabric architectures (woven roving and stitch bonded) made into composites with Dow Chemical's Derakane 510A-40, a brominated vinyl ester resin. Both E-glass and T700 carbon fibers were coated with vinyl ester compatible sizing. Composite panels were fabricated by vacuum assisted resin transfer molding (VARTM), specimens were machined, and mechanical tests were conducted as per the accepted test standards. Tension, compression, in-plane shear and inter-laminar shear properties were measured and their associated failure modes were compared with each other. The specific properties of the composites were compared with that of steel. (C) 2007 Published by Elsevier Ltd.
C1 N Carolina Agr & Tech State Univ, Ctr Composite Mat Res, Greensboro, NC 27411 USA.
RP Swaminathan, G (reprint author), N Carolina Agr & Tech State Univ, Ctr Composite Mat Res, Fort IRC Rm 205,1601 E Market St, Greensboro, NC 27411 USA.
EM gswamina@neat.edu
CR Abali F, 2003, J COMPOS MATER, V37, P453, DOI 10.1106/002199803031053
   *AMT AS, 650C12 LT AMT AS
   *ASTM INT, 2002, ANN BOOK ASTM STAND, P126
   BUDIANSKY B, 1983, MICROMECHANICS COMPU, V16
   CHALLA P, 2001, 42 AIAA ASME ASCE AH
   CHANDRA S, 2004, CMES COMPUTER MAT EN, V6, P1
   *COPC MAX 3 CNC, 2004, EX NONCR REINF COMP
   COX B, 1995, 4686 NASA
   Dow M. B, 1997, NASATP97206234
   Emehel TC, 1997, J REINF PLAST COMP, V16, P86, DOI 10.1177/073168449701600107
   *FIB GLASS IND, 1854, DAT SHEET ROVCL
   *FIB GLASS IND, 1800, DAT SHEET KNITM
   FLECK NA, 1990, P IUTAM S IN DEF COM, P235
   HSU K, 2000, PROG QUANTITATIVE ND, V19, P2053
   Isaac MD, 1994, ENG MECH COMPOSITE M
   *K MAY TEXT MACH C, 1999, DIR OR STRUCT
   SADLER R, 2003, 18 ANN TECHN C ASC U, P19
   Shivakumar K, 2004, CMC-COMPUT MATER CON, V1, P173
   SMITH S, 2005, EVALUATION COMPOSITE
   SWAMINATHAN G, 2004, SECTAM, V22, P227
NR 20
TC 3
Z9 3
U1 5
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-8368
EI 1879-1069
J9 COMPOS PART B-ENG
JI Compos. Pt. B-Eng.
PY 2008
VL 39
IS 1
BP 27
EP 35
DI 10.1016/j.compositesb.2007.02.012
PG 9
WC Engineering, Multidisciplinary; Materials Science, Composites
SC Engineering; Materials Science
GA 238YC
UT WOS:000251483400005
DA 2018-12-27
ER

PT J
AU Rajam, G
   Anderton, JM
   Carlone, GM
   Sampson, JS
   Ades, EW
AF Rajam, Gowrisankar
   Anderton, Julie M.
   Carlone, George M.
   Sampson, Jacquelyn S.
   Ades, Edwin W.
TI RETRACTED: Pneumococcal Surface Adhesin A (PsaA): A Review (Retracted
   article. See vol. 35, pg. Nil_0002, 2009)
SO CRITICAL REVIEWS IN MICROBIOLOGY
LA English
DT Review; Retracted Publication
DE Streptococcus pneumoniae; PsaA; Vaccine
ID ACUTE OTITIS-MEDIA; NASOPHARYNGEAL EPITHELIAL-CELLS; MATURATION
   PROTEIN-A; EXPRESSED IN-VIVO; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE
   VACCINE; IMMUNE-RESPONSES; PENICILLIN TOLERANCE; PHASE VARIATION;
   ANTI-PSAA
AB Pneumococcal surface adhesin A (PsaA) is a surface-exposed common 37-kilodalton multi-functional lipoprotein detected on all known serotypes of Streptococcus pneumoniae. This lipoprotein belongs to the ABC-type transport protein complex that transports Mn2+; it is also an adhesin that plays a major role in pneumococcal attachment to the host cell and virulence. PsaA is immunogenic and natural nasopharyngeal colonization of pneumococci elicits an increase in antibody towards PsaA. Hence, PsaA is being actively evaluated as a component of a vaccine in formulations composed of pneumococcal common proteins. PsaA has been expressed as an E. coli recombinant protein, purified, and evaluated in a phase one clinical trial. This article reviews PsaA, its structure and role in pneumococcal virulence, immunogenicity, and potential to reduce nasopharyngeal colonization (a major prerequisite for pneumococcal pathogenesis) as a component of a common pneumococcal protein vaccine.
C1 [Ades, Edwin W.] Ctr Dis Control & Prevent, Immunol Sect, Div Bacterial Dis, Atlanta, GA 30333 USA.
RP Ades, EW (reprint author), Ctr Dis Control & Prevent, Immunol Sect, Div Bacterial Dis, Bldg 18,Room B-104,MS G-05,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM EAdes@cdc.gov
RI Ades, Edwin/A-9931-2009
CR Adrian PV, 2004, VACCINE, V22, P2737, DOI 10.1016/j.vaccine.2004.01.042
   Anderton JM, 2007, MICROB PATHOGENESIS, V42, P225, DOI 10.1016/j.micpath.2007.02.003
   Audouy SAL, 2007, VACCINE, V25, P2497, DOI 10.1016/j.vaccine.2006.09.026
   AVERY OSWALD T., 1931, JOUR EXP MED, V54, P73, DOI 10.1084/jem.54.1.73
   BALTIMORE RS, 1991, BACTERIAL INFECTIONS, P525
   Baril L, 2006, CLIN EXP IMMUNOL, V145, P277, DOI 10.1111/j.1365-2249.2006.03148.x
   Barocchi MA, 2007, VACCINE, V25, P2963, DOI 10.1016/j.vaccine.2007.01.065
   Berry AM, 1996, INFECT IMMUN, V64, P5255
   Blau K, 2007, J INFECT DIS, V195, P1828, DOI 10.1086/518038
   Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5
   Briles DE, 2000, VACCINE, V18, P1707, DOI 10.1016/S0264-410X(99)00511-3
   Briles DE, 2000, INFECT IMMUN, V68, P796, DOI 10.1128/IAI.68.2.796-800.2000
   Briles DE, 2005, INFECT IMMUN, V73, P6945, DOI 10.1128/IAI.73.10.6945-6951.2005
   Briles DE, 2003, J INFECT DIS, V188, P339, DOI 10.1086/376571
   Bronsdon MA, 2004, J CLIN MICROBIOL, V42, P1596, DOI 10.1128/JCM.42.4.1596-1600.2004
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Castaneda-Roldan EI, 2006, CELL MICROBIOL, V8, P1877, DOI 10.1111/j.1462-5822.2006.00754.x
   CHEONG YM, 1988, J TROP PEDIATRICS, V34, P182, DOI 10.1093/tropej/34.4.182
   Claverys JP, 1999, MOL MICROBIOL, V32, P881, DOI 10.1046/j.1365-2958.1999.01369.x
   Crook J, 1998, CLIN DIAGN LAB IMMUN, V5, P205
   CUNDELL DR, 1995, INFECT IMMUN, V63, P757
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   De BK, 1999, PATHOBIOLOGY, V67, P115, DOI 10.1159/000028060
   De BK, 2000, VACCINE, V18, P1811, DOI 10.1016/S0264-410X(99)00481-8
   Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x
   Faden H, 1997, J INFECT DIS, V175, P1440, DOI 10.1086/516477
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x
   Gor DO, 2002, INFECT IMMUN, V70, P5589, DOI 10.1128/IAI.70.10.5589-5595.2002
   GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923
   Greenwood B, 1999, PHILOS T R SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005
   Hausdorff WP, 2001, LANCET, V357, P950, DOI 10.1016/S0140-6736(00)04222-7
   HEIDELBERGER M, 1960, J BACTERIOL, V80, P145
   Holmlund E, 2006, VACCINE, V24, P57, DOI 10.1016/j.vaccine.2005.07.055
   Jakubovics NS, 2001, MICROBIOL-SGM, V147, P1709, DOI 10.1099/00221287-147-7-1709
   Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001
   JENKINSON HF, 1994, FEMS MICROBIOL LETT, V121, P133, DOI 10.1016/0378-1097(94)90117-1
   Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566
   Johnson SE, 2002, J INFECT DIS, V185, P489, DOI 10.1086/338928
   Johnston JW, 2006, INFECT IMMUN, V74, P1171, DOI 10.1128/IAI.74.2.1171-1180.2006
   Johnston JW, 2004, INFECT IMMUN, V72, P5858, DOI 10.1128/IAI.72.10.5858-5867.2004
   KAMERLING JP, 2000, STREPTOCOCCUS PNEUMO, P81
   Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443
   Kim JO, 1998, J INFECT DIS, V177, P368, DOI 10.1086/514205
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171
   Kolenbrander PE, 1998, J BACTERIOL, V180, P290
   Lawrence MC, 1998, STRUCT FOLD DES, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1
   Lee CJ, 1997, CRIT REV MICROBIOL, V23, P121, DOI 10.3109/10408419709115133
   Leowski J, 1986, World Health Stat Q, V39, P138
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   McAllister LJ, 2004, MOL MICROBIOL, V53, P889, DOI 10.1111/j.1365-2958.2004.04164.x
   McCluskey J, 2004, MOL MICROBIOL, V51, P1661, DOI 10.1046/j.1365-2958.2003.03917.x
   Messina AF, 2007, PEDIATR INFECT DIS J, V26, P461, DOI 10.1097/INF.0b013e31805cdbeb
   Messmer TO, 2004, DIAGN MICR INFEC DIS, V49, P249, DOI 10.1016/j.diagmicrobio.2004.04.013
   Miyaji EN, 2001, VACCINE, V20, P805, DOI 10.1016/S0264-410X(01)00395-4
   Morrison KE, 2000, J CLIN MICROBIOL, V38, P434
   Nelson AL, 2007, INFECT IMMUN, V75, P83, DOI 10.1128/IAI.01475-06
   Novak R, 2000, MOL MICROBIOL, V36, P1504, DOI 10.1046/j.1365-2958.2000.01959.x
   Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x
   O'Brien KL, 2004, AM J EPIDEMIOL, V159, P634, DOI 10.1093/aje/kwh082
   Obaro SK, 2000, ACTA TROP, V75, P141, DOI 10.1016/S0001-706X(99)00094-7
   Ogunniyi AD, 2000, INFECT IMMUN, V68, P3028, DOI 10.1128/IAI.68.5.3028-3033.2000
   Ogunniyi AD, 2002, MICROBIOL-SGM, V148, P2045, DOI 10.1099/00221287-148-7-2045
   Orihuela CJ, 2004, J INFECT DIS, V190, P1661, DOI 10.1086/424596
   Orihuela CJ, 2004, INFECT IMMUN, V72, P5582, DOI 10.1128/IAI.72.10.5582-5596.2004
   Overweg K, 2000, INFECT IMMUN, V68, P4180, DOI 10.1128/IAI.68.7.4180-4188.2000
   Pai R, 2005, J INFECT DIS, V192, P1988, DOI 10.1086/498043
   Palaniappan R, 2005, INFECT IMMUN, V73, P1006, DOI 10.1128/IAI.73.2.1006-1013.2005
   Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06
   Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088
   Pelton SI, 1999, PEDIATR INFECT DIS J, V18, P926, DOI 10.1097/00006454-199910000-00018
   Pilling PA, 1998, ACTA CRYSTALLOGR D, V54, P1464, DOI 10.1107/S0907444998005812
   Pimenta FC, 2006, INFECT IMMUN, V74, P4939, DOI 10.1128/IAI.00134-06
   Pracht D, 2005, INFECT IMMUN, V73, P2680, DOI 10.1128/IAI.73.5.2680-2689.2005
   RAJAM G, 2005, 105 GEN M ASM ASM AT
   Rajam G, 2007, J MICROBIOL METH, V70, P219, DOI 10.1016/j.mimet.2007.04.008
   Rajam G, 2008, MICROB PATHOGENESIS, V44, P186, DOI 10.1016/j.micpath.2007.09.003
   Rapola S, 2003, VACCINE, V21, P3608, DOI 10.1016/S0264-410X(03)00409-2
   Rapola S, 2001, PEDIATR INFECT DIS J, V20, P482, DOI 10.1097/00006454-200105000-00003
   Rapola S, 2000, J INFECT DIS, V182, P1146, DOI 10.1086/315822
   Read TD, 2002, SCIENCE, V296, P2028, DOI 10.1126/science.1071837
   Reglier-Poupet H, 2003, INFECT IMMUN, V71, P474, DOI 10.1128/IAI.71.1.474-482.2003
   Rigden DJ, 2003, CRIT REV BIOCHEM MOL, V38, P143, DOI 10.1080/713609215
   Romero-Steiner S, 2006, VACCINE, V24, P3224, DOI 10.1016/j.vaccine.2006.01.042
   Romero-Steiner S, 2003, CLIN DIAGN LAB IMMUN, V10, P246, DOI 10.1128/CDLI.10.2.246-251.2003
   Rosinha GMS, 2002, INFECT IMMUN, V70, P5036, DOI 10.1128/IAI.70.9.5036-5044.2002
   RUSSELL H, 1990, J CLIN MICROBIOL, V28, P2191
   Sa-Leao R, 2006, MICROBIOL-SGM, V152, P367, DOI 10.1099/mic.0.28596-0
   SAMPSON JS, 1994, INFECT IMMUN, V62, P319
   Sampson JS, 1997, INFECT IMMUN, V65, P1967
   Scott JAG, 2005, CLIN DIAGN LAB IMMUN, V12, P1195, DOI 10.1128/CDLI.12.10.1195-1201.2005
   Seo JY, 2002, INFECT IMMUN, V70, P1143, DOI 10.1128/IAI.70.3.1143-1149.2002
   Simell B, 2001, J INFECT DIS, V183, P887, DOI 10.1086/319246
   Singh KV, 1998, FEMS IMMUNOL MED MIC, V21, P323, DOI 10.1016/S0928-8244(98)00087-X
   Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784
   Srivastava N, 2000, HYBRIDOMA, V19, P23, DOI 10.1089/027245700315761
   Standish AJ, 2007, J BACTERIOL, V189, P5591, DOI 10.1128/JB.00335-07
   Swiatlo E, 2003, INFECT IMMUN, V71, P7149, DOI 10.1128/IAI.71.12.7149-7153.2003
   Swiatlo E, 2003, FEMS IMMUNOL MED MIC, V38, P1, DOI 10.1016/S0928-8244(03)00146-9
   Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942
   TAM R, 1993, MICROBIOL REV, V57, P320
   Tharpe JA, 1998, PATHOBIOLOGY, V66, P77, DOI 10.1159/000028000
   Tharpe JA, 1996, CLIN DIAGN LAB IMMUN, V3, P227
   Tseng HJ, 2002, INFECT IMMUN, V70, P1635, DOI 10.1128/IAI.70.3.1635-1639.2002
   Verhelst R, 2003, J CLIN MICROBIOL, V41, P3521, DOI 10.1128/JCM.41.8.3521-3525.2003
   Weiser JN, 1996, INFECT IMMUN, V64, P2240
   WEISER JN, 1994, INFECT IMMUN, V62, P2582
   Weiser JN, 2003, P NATL ACAD SCI USA, V100, P4215, DOI 10.1073/pnas.0637469100
   Weiser JN, 2001, INFECT IMMUN, V69, P5430, DOI 10.1128/IAI.69.9.5430-5439.2001
   WHALEY MJ, 2006, INT C EM INF DIS AM
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   *WHO, 1997, ACH PLAN ACT MEN PNE
   Yu XH, 1999, J INFECT DIS, V180, P1569, DOI 10.1086/315096
   ZENNI MK, 1995, J PEDIATR-US, V127, P533, DOI 10.1016/S0022-3476(95)70108-7
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
   Zhang QB, 2002, INFECT IMMUN, V70, P5363, DOI 10.1128/IAI.70.10.5363-5369.2002
NR 118
TC 24
Z9 26
U1 3
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-841X
EI 1549-7828
J9 CRIT REV MICROBIOL
JI Crit. Rev. Microbiol.
PY 2008
VL 34
IS 3-4
BP 163
EP 173
AR PII 903023267
DI 10.1080/10408410802383610
PG 11
WC Microbiology
SC Microbiology
GA 370YB
UT WOS:000260797900004
PM 18819028
DA 2018-12-27
ER

PT J
AU Abou-Elela, A
AF Abou-Elela, A.
TI RETRACTED: Outcome of anterior vaginal wall sparing during female
   radical cystectomy with orthotopic urinary diversion (Retracted article.
   See vol. 35, pg. 448, 2009)
SO EJSO
LA English
DT Article; Retracted Publication
DE urinary diversion; vagina; bladder; cystectomy; bladder neoplasms
ID BLADDER SUBSTITUTION; GYNECOLOGIC ORGANS; ILEAL NEOBLADDER; WOMEN;
   EXPERIENCE; CANCER; PRESERVATION; INVOLVEMENT; SPECIMENS
AB Purpose: Orthotopic urinary reconstruction has been shown to be a viable option in women undergoing radical cystectomy and is currently the diversion of choice in many institutions. We evaluated the technique of vaginal wall preservation during female radical cystectomy and orthotopic neobladder construction.
   Materials and methods: Thirty female patients underwent radical cystectomy with bilateral pelvic lymphadenectomy and orthotopic urinary diversion from January 2001 to December 2006. We reviewed perioperative early and late complications, postoperative care, follow-up, pathological and functional results.
   Results: Early complications included prolonged ileus in 4 patients, urinary tract infection in 2, deep venous thrombosis in 2, wound infection in 2 and prolonged urine leak in 1. Late complications requiring rehospitalization or reoperation included small bowel obstruction, requiring surgical exploration in I patient, an ileal pouch calculus requiring endoscopic removal in another patient and a unilateral ureter-oileal stenosis treated by antegrade dilatation and stenting in the third patient. Pathological specimens revealed a negative posterior bladder wall and urethral margins in all cases. At a median follow-up of 18 months daytime and nighttime continence was 100% and 93%, respectively. All but 2 patients voided spontaneously. One patient had local recurrence of bladder carcinoma.
   Conclusions: With strict selection criteria, anterior vaginal wall preservation in female radical cystectomy with orthotopic neobladder substitution is technically feasible, maintains vaginal length and support, has excellent functional results, acceptable complication rate and can achieve negative margins. Long-term evaluation is needed for better assessment of the impact on functional outcomes and cancer control. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Cairo Univ, Dept Urol, Cairo 35290, Egypt.
RP Abou-Elela, A (reprint author), Cairo Univ, Dept Urol, Cairo 35290, Egypt.
EM ashrafaboelela@yahoo.co.uk
CR Ali-El-Dein B, 1999, J UROLOGY, V161, P1875, DOI 10.1016/S0022-5347(05)68832-5
   Ali-El-Dein B, 2004, J UROLOGY, V172, P885, DOI 10.1097/01.ju.0000133986.29257.bf
   Blute ML, 1998, MAYO CLIN PROC, V73, P501, DOI 10.4065/73.6.501
   CANCRINI A, 1995, J UROLOGY, V153, P956, DOI 10.1016/S0022-5347(01)67612-2
   Chang SS, 2002, J UROLOGY, V168, P147, DOI 10.1016/S0022-5347(05)64849-5
   Chang SS, 2002, J UROLOGY, V168, P1442, DOI 10.1097/01.ju.000030700.53228.aa
   COLOBY PJ, 1994, J UROLOGY, V152, P1438, DOI 10.1016/S0022-5347(17)32440-0
   Ghoneim MA, 1997, UROL CLIN N AM, V24, P225, DOI 10.1016/S0094-0143(05)70365-7
   Hautmann RE, 1996, J UROLOGY, V155, P76, DOI 10.1016/S0022-5347(01)66546-7
   HAUTMANN RE, 1998, EUR UROL, V33, P512
   MARSHALL FF, 1991, UROL CLIN N AM, V18, P765
   Mills RD, 2000, J UROLOGY, V163, P1501, DOI 10.1016/S0022-5347(05)67651-3
   Nandipati KC, 2006, UROLOGY, V67, P185, DOI 10.1016/j.urology.2005.07.024
   Shimogaki H, 1999, J UROLOGY, V161, P573, DOI 10.1016/S0022-5347(01)61954-2
   Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666
   Stenzl A, 1997, WORLD J UROL, V15, P134, DOI 10.1007/BF02201985
   Stenzl A, 1996, WORLD J UROL, V14, P15, DOI 10.1007/BF01836339
   Studer UE, 1997, UROL CLIN N AM, V24, P781, DOI 10.1016/S0094-0143(05)70420-1
   TURNER WH, 1998, CONT UROL, V33
   Westney OL, 1998, J UROLOGY, V159, P792, DOI 10.1016/S0022-5347(01)63733-9
NR 20
TC 8
Z9 9
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD JAN
PY 2008
VL 34
IS 1
BP 115
EP 121
DI 10.1016/j.ejso.2007.09.005
PG 7
WC Oncology; Surgery
SC Oncology; Surgery
GA 257AO
UT WOS:000252771200020
PM 17951022
DA 2018-12-27
ER

PT J
AU Das, S
   Khan, N
   Mukherjee, S
   Bagchi, D
   Gurusamy, N
   Swartz, H
   Das, DK
AF Das, Samarjit
   Khan, Nadeem
   Mukherjee, Subhendu
   Bagchi, Debasis
   Gurusamy, Narasimman
   Swartz, Harold
   Das, Dipak K.
TI RETRACTED: Redox regulation of resveratrol-mediated switching of death
   signal into survival signal (Retracted article. See vol. 53, pg. 642,
   2012)
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE heart; ischemia; resveratrol; redox; redox switch; redox environment;
   death signal; survival signal; thioredoxin; free radicals
ID ELEMENT-BINDING PROTEIN; ADENOSINE-A(3) RECEPTOR; OXIDATIVE STRESS;
   ISCHEMIC-HEART; RAT-HEART; THIOREDOXIN; CANCER; INHIBITION; MYOCARDIUM;
   ACTIVATION
AB In this study, we determined the changes in the intracellular redox environment of the heart during ischemia and reperfusion and the effects of resveratrol on such changes. Because redox regulation by thioredoxin (Trx) plays a crucial role in signal transduction and cytoprotection against ROS, the effects of resveratrol on the changes in the amounts of thioredoxin were monitored in an attempt to determine the role of intracellular thioredoxin in resveratrol-mediated changes in intracellular redox environment and its role in resveratrol-mediated cardioprotection. Rats were randomly divided into four groups: group I, control (rats were gavaged with vehicle only); group II, rats were gavaged with 2.5 mg/kg body wt resveatrol per day for 10 days; group III, rats were given resveratrol for 10 days, but on the 7th day, they were treated with shRNA against Trx-1 group IV, rats were given resveratrol for 10 days, but were injected (iv) with cisplatin (1 mg/kg body wt) on days 1, 3, 5, 7, and 9. In concert, two groups of mice (Dn-Trx-1) and a corresponding wild-type group were also gavaged with 2.5 mg/kg body wt resveratrol for 10 days. After 10 days, isolated rat and mouse hearts perfused via working mode were made globally ischemic for 30 min followed by 2 h of reperfusion. Ischemia/ reperfusion developed an infarct size of about 40% and resulted in about 25% apoptotic cardiomyocytes, which were reduced by resveratrol. Cisplatin, but not shRNA-Trx-1, abolished the cardioprotective abilities of resveratrol. In the experiments with mouse hearts, similar to rat hearts, resveratrol significantly reduced the ischemia/reperfusion-mediated increase in infarct size and apoptosis in both groups. MDA formation, a presumptive marker for lipid peroxidation, was increased in the I/R group and reduced in the resveratrol group, and resveratrol-mediated reduction in NIDA formation was abolished with cisplatin, but not with shRNA-Trx-1. I/R-induced reduction in GSH/GSSH ratio was prevented by resveratrol, and resveratrol-mediated preservation of GSH/GSSG ratio was reduced by cisplatin, but not by sh-RNA-Trx-1. RT-PCR revealed an increase in both Trx-1 and Trx-2 transcripts; but only Trx-2 protein, not Trx-1 protein, was enhanced with resveratrol by Western blot analysis. Electron paramagnetic resonance spectroscopic study revealed that resveratrol treatment significantly increased the decay rates of nitroxide radicals compared to control hearts, suggesting that resveratrol can switch into the reduction state more compared to control heart. Finally, resveratrol generated a survival signal by phosphorylation of Akt and increase in induction of Bcl-2 expression, which was inhibited by cisplatin, but not by shRNA-Trx-1. Taken together, the results of this study indicate that resveratrol provides cardioprotection by maintaining intracellular redox environments, and Trx-2 is likely to play a role in switching I/R-induced death signal into survival signal. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Das, Samarjit; Mukherjee, Subhendu; Gurusamy, Narasimman; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   [Khan, Nadeem; Swartz, Harold] Dartmouth Med Sch, Study Viable Syst, EPR Ctr, Hanover, NH 03755 USA.
   [Bagchi, Debasis] Creighton Univ, Sch Pharm, Omaha, NE 68178 USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM ddas@neuron.uchc.edu
FU NHLBI NIH HHS [R01 HL056322, HL34360, R01 HL034360, R37 HL056322,
   HL22599, HL 56322, R01 HL022559]; NIBIB NIH HHS [P41 EB002032]
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Biaglow JE, 2005, CANCER BIOL THER, V4, P6
   CORDIS GA, 1995, J MOL CELL CARDIOL, V27, P1645, DOI 10.1016/S0022-2828(95)90656-8
   Das DK, 2004, ANTIOXID REDOX SIGN, V6, P405, DOI 10.1089/152308604322899477
   DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2
   DAS DK, 1993, PATHOPHYSIOLOGY REPE, P149
   Das S, 2005, VASC PHARMACOL, V42, P281, DOI 10.1016/j.vph.2005.02.013
   Das S, 2005, AM J PHYSIOL-HEART C, V288, pH328, DOI 10.1152/ajpheart.00453.2004
   Das S, 2005, J PHARMACOL EXP THER, V314, P762, DOI 10.1124/jpet.105.084285
   DAS S, 2006, S AFR J ENOL VITIC, V27, P127
   Das S, 2006, FREE RADICAL RES, V40, P1066, DOI 10.1080/10715760600833085
   Das S, 2006, J PHARMACOL EXP THER, V317, P980, DOI 10.1124/jpet.105.095133
   Grinberg OY, 1997, ADV EXP MED BIOL, V411, P171
   Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008-6363(00)00102-4
   Hyodo F, 2006, CANCER RES, V66, P9921, DOI 10.1158/0008-5472.CAN-06-0879
   Isowa N, 2000, J CELL PHYSIOL, V182, P33, DOI 10.1002/(SICI)1097-4652(200001)182:1<33::AID-JCP4>3.0.CO;2-5
   KIHLSTROM M, 1990, J APPL PHYSIOL, V68, P1672
   Mikuni T, 2004, CANCER RES, V64, P6495, DOI 10.1158/0008-5472.CAN-04-0319
   Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2
   Ray PS, 1999, FREE RADICAL BIO MED, V27, P160, DOI 10.1016/S0891-5849(99)00063-5
   RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F
   Turoczi T, 2003, J MOL CELL CARDIOL, V35, P695, DOI 10.1016/S0022-2828(03)00117-2
   Wilson T, 1996, LIFE SCI, V59, pPL15, DOI 10.1016/0024-3205(96)00260-3
   YAGI K, 1994, J THORAC CARDIOV SUR, V108, P913
   Yamamoto M, 2003, J CLIN INVEST, V112, P1395, DOI 10.1172/JCI200317700
   Yokoyama H, 2006, J MAGN RESON IMAGING, V23, P637, DOI 10.1002/jmri.20560
   Zhu XH, 2007, ANTIOXID REDOX SIGN, V9, P447, DOI 10.1089/ars.2006.1389
NR 27
TC 43
Z9 44
U1 3
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN 1
PY 2008
VL 44
IS 1
BP 82
EP 90
DI 10.1016/j.freeradbiomed.2007.09.008
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 245JR
UT WOS:000251931400009
PM 18045550
DA 2018-12-27
ER

PT J
AU Wood, SA
   Beringer, J
   Hutley, LB
   Mcguire, AD
   Van Dijk, A
   Kilinc, M
AF Wood, Stephen A.
   Beringer, Jason
   Hutley, Lindsay B.
   Mcguire, A. David
   Van Dijk, Albert
   Kilinc, Musa
TI RETRACTED: Impacts of fire on forest age and runoff in mountain ash
   forests (Retracted article. See vol. 37, pg. 1192, 2010)
SO FUNCTIONAL PLANT BIOLOGY
LA English
DT Article; Retracted Publication
DE eddy covariance; Eucalyptus regnans; sap flow; transpiration
ID REGNANS F MUELL; EUCALYPTUS-REGNANS; WATER YIELD; SAP FLOW; SAPWOOD
   AREA; TRANSPIRATION; TREES; CATCHMENT; NIGHT; PRODUCTIVITY
AB Runoff from mountain ash ( Eucalyptus regnans F. Muell.) forested catchments has been shown to decline significantly in the few decades following fire-returning to pre-fire levels in the following centuries-owing to changes in ecosystem water use with stand age in a relationship known as Kuczera's model. We examined this relationship between catchment runoff and stand age by measuring whole-ecosystem exchanges of water using an eddy covariance system measuring forest evapotranspiration (ET) combined with sap-flow measurements of tree water use, with measurements made across a chronosequence of three sites (24, 80 and 296 years since. re). At the 296-year old site eddy covariance systems were installed above the E. regnans overstorey and above the distinct rainforest understorey. Contrary to predictions from the Kuczera curve, we found that measurements of whole-forest ET decreased by far less across stand age between 24 and 296 years. Although the overstorey tree water use declined by 1.8 mm day(-1) with increasing forest age (an annual decrease of 657 mm) the understorey ET contributed between 1.2 and 1.5 mm day(-1), 45% of the total ET (3 mm day(-1)) at the old growth forest.
C1 [Wood, Stephen A.; Beringer, Jason; Kilinc, Musa] Monash Univ, Sch Geog & Environm Sci, Clayton, Vic 3800, Australia.
   [Hutley, Lindsay B.] Charles Darwin Univ, Fac Educ Hlth & Sci, Sch Sci & Primary Ind, Darwin, NT 0909, Australia.
   [Mcguire, A. David] Univ Alaska Fairbanks, US Geol Survey, Alaska Cooperat Fish & Wildlife Res Unit, Fairbanks, AK 99775 USA.
   [Van Dijk, Albert] Black Mt Lab, CSIRO Land & Water, Canberra, ACT 2601, Australia.
RP Wood, SA (reprint author), Monash Univ, Sch Geog & Environm Sci, Clayton, Vic 3800, Australia.
EM stephen.wood@arts.monash.edu.au
RI Beringer, Jason/B-8528-2008; Hutley, Lindsay/A-7925-2011; Van Dijk,
   Albert/B-3106-2011
OI Beringer, Jason/0000-0002-4619-8361; Hutley,
   Lindsay/0000-0001-5533-9886; Van Dijk, Albert/0000-0002-6508-7480
CR Andreassian V, 2004, J HYDROL, V291, P1, DOI 10.1016/j.jhydrol.2003.12.015
   Ashton DH, 2000, AUST J BOT, V48, P1, DOI 10.1071/BT98045
   ASHTON DH, 1976, AUST J BOT, V24, P397, DOI 10.1071/BT9760397
   Ashton DH, 2000, P ROYAL SOC VICTORIA, V11, P185
   Aubinet M, 2005, BOUND-LAY METEOROL, V116, P63, DOI 10.1007/s10546-004-7091-8
   Baldocchi D, 1998, AGR FOREST METEOROL, V90, P1, DOI 10.1016/S0168-1923(97)00072-5
   Becker P, 1998, TREE PHYSIOL, V18, P177
   Benyon RG, 1999, TREE PHYSIOL, V19, P853
   Beringer J, 2005, AGR FOREST METEOROL, V131, P143, DOI 10.1016/j.agrformet.2005.05.006
   Beringer J, 2007, GLOBAL CHANGE BIOL, V13, P990, DOI 10.1111/j.1365-2486.2007.01334.x
   Cherry M., 1998, Tasforests, V10, P75
   COHEN Y, 1985, CAN J FOREST RES, V15, P422, DOI 10.1139/x85-068
   Cornish PM, 2001, J HYDROL, V242, P43, DOI 10.1016/S0022-1694(00)00384-X
   Dawson TE, 2007, TREE PHYSIOL, V27, P561, DOI 10.1093/treephys/27.4.561
   *DEP SUST ENV, 1998, FOR MAN PLAN CENTR H
   DUNN GM, 1993, TREE PHYSIOL, V13, P321, DOI 10.1093/treephys/13.4.321
   England JR, 2006, TREES-STRUCT FUNCT, V20, P79, DOI 10.1007/s00468-005-0015-5
   Goldstein G, 1998, PLANT CELL ENVIRON, V21, P397, DOI 10.1046/j.1365-3040.1998.00273.x
   Goodwin A. N., 2004, Tasforests, V15, P85
   HATTON TJ, 1990, TREE PHYSIOL, V6, P201, DOI 10.1093/treephys/6.2.201
   Haydon SR, 1997, J HYDROL, V187, P351, DOI 10.1016/S0022-1694(96)03016-8
   Hibbert AR, 1967, INT S FOR HYDR, P527
   HORNBECK JW, 1993, J HYDROL, V150, P323, DOI 10.1016/0022-1694(93)90115-P
   Hutley LB, 2005, AUST J BOT, V53, P663, DOI 10.1071/BT04147
   JAYASURIYA MDA, 1993, J HYDROL, V150, P345, DOI 10.1016/0022-1694(93)90116-Q
   KUCZERA G, 1987, J HYDROL, V94, P215, DOI 10.1016/0022-1694(87)90054-0
   LANGFORD KJ, 1976, J HYDROL, V29, P87, DOI 10.1016/0022-1694(76)90007-X
   Ma ZM, 2008, J HYDROL, V352, P239, DOI 10.1016/j.jhydrol.2007.12.022
   Marks CO, 2007, TREE PHYSIOL, V27, P577, DOI 10.1093/treephys/27.4.577
   Martin D, 2007, AGR FOREST METEOROL, V147, P58, DOI 10.1016/j.agrformet.2007.06.008
   *MELB WAT, 2006, PROT MELB WAT CATCHM
   *MUS VICT, 2002, FIR FOR
   Papale D, 2006, BIOGEOSCIENCES, V3, P571, DOI 10.5194/bg-3-571-2006
   Papale D, 2003, GLOBAL CHANGE BIOL, V9, P525, DOI 10.1046/j.1365-2486.2003.00609.x
   Phillips NG, 2003, TREE PHYSIOL, V23, P237, DOI 10.1093/treephys/23.4.237
   Roberts S, 2001, FOREST ECOL MANAG, V143, P153, DOI 10.1016/S0378-1127(00)00514-4
   Snyder KA, 2003, J EXP BOT, V54, P861, DOI 10.1093/jxb/erg082
   Swank WT, 2001, FOREST ECOL MANAG, V143, P163, DOI 10.1016/S0378-1127(00)00515-6
   Van Pelt R., 2004, FOREST CANOPIES, P49
   VERTESSY RA, 1995, TREE PHYSIOL, V15, P559, DOI 10.1093/treephys/15.9.559
   Vertessy RA, 1997, TREE PHYSIOL, V17, P747
   Vertessy RA, 1996, TREE PHYSIOL, V16, P221
   Vertessy RA, 2001, FOREST ECOL MANAG, V143, P13, DOI 10.1016/S0378-1127(00)00501-6
   Watson FGR, 1999, HYDROL PROCESS, V13, P689, DOI 10.1002/(SICI)1099-1085(19990415)13:5<689::AID-HYP773>3.3.CO;2-4
   Whetton P. H, 2002, CLIMATE CHANGE VICTO
   Whitehead D, 2004, FOREST ECOL MANAG, V193, P113, DOI 10.1016/j.foreco.2004.01.026
   Williams J., 1983, SOILS AUSTR VIEWPOIN, P507
NR 47
TC 18
Z9 18
U1 3
U2 18
PU CSIRO PUBLISHING
PI COLLINGWOOD
PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA
SN 1445-4408
J9 FUNCT PLANT BIOL
JI Funct. Plant Biol.
PY 2008
VL 35
IS 6
BP 483
EP 492
DI 10.1071/FP08120
PG 10
WC Plant Sciences
SC Plant Sciences
GA 333EI
UT WOS:000258134900006
DA 2018-12-27
ER

PT J
AU Jegen, DA
AF Jegen, Dominika A.
TI RETRACTED: Compressing "The sandwiched": An examination of reductionist
   health policies on women in Canada (Retracted article. See vol. 30, pg.
   1, 2009)
SO HEALTH CARE FOR WOMEN INTERNATIONAL
LA English
DT Article; Retracted Publication
ID DETERMINANTS; WORK; TIME; CARE
AB Worldwide, policymakers are critically examining the escalating costs of health care. One proposed solution has been to move away from a centralized general hospital-type of treatment in favor of a family-based model emphasizing health as well as treatment. While I agree that such approaches constitute an innovative outlook on health care, I draw on a social ecological approach in order to attract attention to and lay out the argument for future research examining the unacknowledged and unstudied impact that such proposed policies will have on women. Undoubtedly, it is they who will bear the brunt of the proposed health-related responsibilities offloaded by governments. I examine the implications of such proposed policies on Canadians, particularly Canadian women, although the Canadian system is but an exemplar of the changing dynamics of caregiving in a broader world situation.
C1 Univ Calgary, Dept Sociol, Calgary, AB T2N 1N4, Canada.
RP Jegen, DA (reprint author), Univ Calgary, Dept Sociol, RM 943,Social Sci Bldg,2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.
EM jegen@ucalgary.edu
OI Gahagan, Jacqueline/0000-0001-6483-7916
CR ANGUS DE, 1995, SUSTAINABLE HLTH CAR
   Basu A M, 1991, Health Transit Rev, V1, P83
   Beach SR, 2005, J AM GERIATR SOC, V53, P255, DOI 10.1111/j.1532-5415.2005.53111.x
   BERMAN P, 1994, SOC SCI MED, V38, P205, DOI 10.1016/0277-9536(94)90390-5
   Bittman M, 1999, FEM ECON, V5, P27, DOI 10.1080/135457099337798
   BLOCH H, 1983, PERCEPTION, V12, pA29
   Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX
   BRONFENBRENNER U, 1975, IFLUENCES HUMAN DEV
   *CLAIR COMM, 2001, EM SOL REP REC
   Cooper SM, 2007, FAM COMMUNITY HEALTH, V30, P29, DOI 10.1097/00003727-200701000-00005
   DOWNS B, 2002, CURRENT POPULATION R, pP20
   DUMAS J, 1994, REPORT DEMOGRAPHIC S
   Earls F, 2001, ANNU REV PUBL HEALTH, V22, P143, DOI 10.1146/annurev.publhealth.22.1.143
   Evans R, 1994, WHY ARE SOME PEOPLE
   Fast J, 2004, CAN J AGING, V23, P5, DOI 10.1353/cja.2004.0003
   FAST J, 2001, EC IMPACT HLTH INCOM
   Frederick J., 1999, CAN SOC TRENDS   AUT, P26
   FRUIN D, 1998, MATTER CHANCE CARERS
   Fyke KJ, 2001, CARING MEDICARE SUST
   GAUTHIER AH, 2001, ANN M POP ASS AM WAS
   *GEN SOC SURV, 1992, 12M0007XDB GEN SOC S
   *GEN SOC SURV, 2002, 1270016GPE GEN SOC S
   *GEN SOC SURV, 1998, 12F0080XIE GEN SOC S
   Glouberman S, 2003, AM J PUBLIC HEALTH, V93, P388, DOI 10.2105/AJPH.93.3.388
   Gori C, 2000, INT J SOC WELF, V9, P261, DOI 10.1111/1468-2397.00138
   Haas L., 2002, COMMUNITY WORK FAMIL, V5, P319, DOI DOI 10.1080/1366880022000041801
   HAVENS B, 2001, INT ASS GER VANC BC
   Kipp Walter, 2007, Health Care Women Int, V28, P856, DOI 10.1080/07399330701615275
   Koerner SS, 2007, FAM RELAT, V56, P1, DOI 10.1111/j.1741-3729.2007.00435.x
   Lalonde M., 1974, NEW PERSPECTIVE HLTH
   LANGTON N, 1998, WORK ORG, V5, P83
   Lasser KE, 2006, AM J PUBLIC HEALTH, V96, P1300, DOI 10.2105/AJPH.2004.059402
   LAST M, 1992, SOC SCI MED, V35, P799, DOI 10.1016/0277-9536(92)90080-A
   MAZANKOWSKI D, 2002, PREMIERS ADVISORY CO
   MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401
   Mendelson C, 2003, PUBLIC HEALTH NURS, V20, P95, DOI 10.1046/j.1525-1446.2003.20203.x
   Mendelson Cindy, 2005, Health Care Women Int, V26, P355, DOI 10.1080/07399330590925871
   MOORE AR, 2006, J SOCIOLOGY SOCIAL P, V26, P63
   *NAT ADV COUNC AG, 1999, 1999 CHALL AG CAN SO
   Palese A., 2004, DIVERSITY HLTH SOCIA, V1, P31
   Park K, 2005, SOCIOL INQ, V75, P372, DOI 10.1111/j.1475-682X.2005.00127.x
   Romanow R, 2002, BUILDING VALUES FUTU
   Sampselle CM, 2007, FAM COMMUNITY HEALTH, V30, pS4, DOI 10.1097/00003727-200701001-00003
   Sayer LC, 2004, AM J SOCIOL, V110, P1, DOI 10.1086/386270
   Silver C., 2000, CAN SOC TRENDS, P26
   Smedley BD, 2002, UNEQUAL TREATMENT CO
   *STAND SEN COMM SO, 2001, HLTH CAN FED ROL
   *STAT CAN, 1999, 1999 WORKPL EMPL SUR
   TEO P, 2004, J AGING SOCIAL POLIC, V46, P43
   THOMPSON L, 1991, J FAM ISSUES, V12, P181, DOI 10.1177/019251391012002003
   Tsuji I, 2002, J WOMEN AGING, V14, P135, DOI 10.1300/J074v14n01_09
   Upchurch DM, 1999, J MARRIAGE FAM, V61, P920, DOI 10.2307/354013
   WAGNER DL, 2003, MONOGRAPH NATL CTR C
   White JM, 2002, FAMILY THEORIES
   Williams C., 2005, CANADIAN SOCIAL TREN, V5, P16
   Wootton J C, 1998, J Womens Health, V7, P597, DOI 10.1089/jwh.1998.7.597
NR 56
TC 1
Z9 1
U1 2
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0739-9332
J9 HEALTH CARE WOMEN IN
JI Health Care Women Int.
PY 2008
VL 29
IS 10
BP 980
EP 996
DI 10.1080/07399330802269667
PG 17
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA 354HF
UT WOS:000259628900003
PM 18821210
DA 2018-12-27
ER

PT J
AU Knobloch, K
   Wagner, S
   Haasper, C
   Probst, C
   Krettek, C
   Vogt, PM
   Otte, D
   Richter, M
AF Knobloch, K.
   Wagner, S.
   Haasper, C.
   Probst, C.
   Krettek, C.
   Vogt, P. M.
   Otte, D.
   Richter, M.
TI RETRACTED: Sternal fractures are frequent among polytraumatised patients
   following high deceleration velocities in a severe vehicle crash
   (Retracted article. See vol 40, pg 571, 2009)
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article; Retracted Publication
DE sternal fracture; injury; crash; ISS; polytrauma
ID RETROSPECTIVE ANALYSIS; THORACIC SPINE; INJURIES; PATTERN; CAGE
AB Introduction: Sternal fractures are a rare entity. We hypothesised that a sternal fracture is an indicator of injury severity following traffic accidents.
   Methods: Analysis of technical indicators of the collision, preclinical and clinical data of patients with sternal fractures from 1985 to 2004 among 42,055 injured patients assessed by an Accident Research Unit.
   Results: Only 267/42,055 patients (0.64%) suffered a sternal fracture within the 20-year period. Soft tissue bruises are most often concomitant injuries (55%), followed by cervical spine injuries (23%), multiple rib fractures (14%) and lung injuries (12%). Eighteen percent of patients were polytraumatised, with 11.2% dying at the scene, 2.3% in hospital. Deceleration velocity (AV) was significantly correlated with injury severity score (ISS, r(2) = 0.92, y = 0.408x - 4.1573) as with maximal abbreviated injury scale (MAIS, r(2) = 0.81). Patients suffering a sternal fracture being polytraumatised had significantly higher deceleration velocity (60 +/- 17 km/h versus 37 +/- 16 km/h [37.3 +/- 10.6 mph versus 23 +/- 9.9 mph], p = 0.0001). Patients dying with a sternal fracture had a significant higher deceleration velocity (61 km/h, 37.9 mph) versus those surviving (38 km/h, 23.6 mph, p = 0.0001). Regarding the vehicle type, the majority occurred after car accidents in 0.81% (251/31,183 patients), followed by 0.19% (5/2633 patients) driving motorbikes, and 0.11% (4/3258 patients) driving a truck. Only 13% of all passengers suffering a sternal fracture had an airbag on board (33/255 car/trucks), with an airbag malfunction in 18%. 22% were not admitted to hospital, 28% were admitted to a trauma ICU with a sternal, fracture.
   Conclusion: In 1/5 of cases sternal fractures encountered in polytraumatised patients following significantly higher deceleration velocities during the crash. Typically car drivers without a functioning airbag suffer a sternal fracture. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Knobloch, K.; Vogt, P. M.] Hannover Med Sch, Plast Hand & Reconstruct Surg, D-30625 Hannover, Germany.
   [Knobloch, K.; Wagner, S.; Haasper, C.; Probst, C.; Krettek, C.; Richter, M.] Hannover Med Sch, Hannover, Germany.
   [Otte, D.] Hannover Med Sch, Accident Res Unit, Hannover, Germany.
RP Knobloch, K (reprint author), Hannover Med Sch, Plast Hand & Reconstruct Surg, Carl-Neuberg-Str 1, D-30625 Hannover, Germany.
EM kknobi@yahoo.com
RI Haasper, Carl/F-3804-2010
CR Alkadhi H, 2004, J COMPUT ASSIST TOMO, V28, P378, DOI 10.1097/00004728-200405000-00013
   ARAJARVI E, 1989, J TRAUMA, V29, P37
   Athanassiadi K, 2002, WORLD J SURG, V26, P1243, DOI 10.1007/s00268-002-6511-5
   BROOKES JG, 1993, J TRAUMA, V35, P46, DOI 10.1097/00005373-199307000-00008
   DEWAELE JJ, 2002, EUR J TRAUMA, V3, P178
   Hendrickson SC, 1996, ANN THORAC SURG, V62, P512, DOI 10.1016/0003-4975(96)00318-9
   Loo GT, 1996, J TRAUMA, V41, P935, DOI 10.1097/00005373-199612000-00001
   Lund JM, 2001, INJURY, V32, P254, DOI 10.1016/S0020-1383(00)00235-7
   Mahlfeld A, 2001, ZBL CHIR, V126, P62, DOI 10.1055/s-2001-11727
   Ozaki W, 1998, ANN THORAC SURG, V65, P1660, DOI 10.1016/S0003-4975(98)00231-8
   Richter M, 2001, J TRAUMA, V51, P10, DOI 10.1097/00005373-200107000-00002
   Richter M, 2001, J ORTHOP TRAUMA, V15, P287, DOI 10.1097/00005131-200105000-00009
   STURM JT, 1989, ANN THORAC SURG, V48, P697, DOI 10.1016/0003-4975(89)90795-9
   Turk EE, 2004, J TRAUMA, V57, P301, DOI 10.1097/01.TA.0000074554.86172.0E
   von Garrel T, 2004, J TRAUMA, V57, P837, DOI 10.1097/01.TA.000091112.02703.D8
   Watkins R, 2005, SPINE, V30, P1283, DOI 10.1097/01.brs.0000164257.69354.bb
NR 16
TC 12
Z9 14
U1 3
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD JAN
PY 2008
VL 39
IS 1
BP 36
EP 43
DI 10.1016/j.injury.2007.07.007
PG 8
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 264GE
UT WOS:000253274700005
PM 18001736
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Airoldi, C
   Viana, RR
AF Guerra, Denis L.
   Airoldi, Claudio
   Viana, Rubia Ribeiro
TI RETRACTED: Performance of modified montmorillonite clay in mercury
   adsorption process and thermodynamic studies (Retracted article. See
   vol. 14, pg. 1988, 2011)
SO INORGANIC CHEMISTRY COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE montmorillonite; adsorption isotherms; mercury; calorimetry
ID KAOLINITE; NMR
AB The montmorillonite clay sample from amazon region, Par State, Brazil, was used for intercalation process with pyridine (P) and organofunctionalization with 3-aminopropyltriethoxysilane (APS). The montmorillonite-P/APS shows variation of d(001) values, by changing d(001) from 1.15 to 2.10 mm. The original and modified samples were used for mercury cation adsorption from aqueous solution at room temperature and pH 6.0. The energetic effect caused by mercury cation adsorption was deter-mined though calorimetric titration at the solid-liquid interface and gave a net thermal effect that enabled the calculation of the exothermic values and the equilibrium constant. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Guerra, Denis L.; Airoldi, Claudio] Univ Estadual Campinas, Inst Quim, BR-13084971 Campinas, SP, Brazil.
   [Viana, Rubia Ribeiro] Univ Fed Matogrosso, Ctr Recursos Minerais, Cuiaba, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Quim, Caixa Postal 6154, BR-13084971 Campinas, SP, Brazil.
EM diguerra@iqm.unicamp.br
CR Bhattacharyya KG, 2006, COLLOID SURFACE A, V277, P191, DOI 10.1016/j.colsurfa.2005.11.060
   Carrado KA, 2000, CHEM MATER, V12, P3052, DOI 10.1021/cm000366a
   Fonseca M.G., 2000, J MATER CHEM, V10, P1457
   Frost RL, 1997, CLAY MINER, V32, P587, DOI 10.1180/claymin.1997.032.4.09
   Gonzalez F, 1999, APPL CATAL A-GEN, V181, P71, DOI 10.1016/S0926-860X(98)00391-3
   GUERRA DL, 2006, POLYHEDRON, V25, P1880
   KOYUNCU H, 2007, MATER, V40, P489
   Ledoux RL, 1967, SILICATES IND, V32, P269
   Machado MO, 2006, J CHEM THERMODYN, V38, P130, DOI 10.1016/j.jct.2005.04.008
   Moore D. E, 1997, XRAY DIFFRACTION IDE
   Park KW, 2004, B KOR CHEM SOC, V25, P965
   Thompson AR, 2001, ENERG FUEL, V15, P176, DOI 10.1021/ef000195w
   WADA K, 1965, AM MINERAL, V50, P921
   WEBER WJ, 1991, WATER RES, V25, P499, DOI 10.1016/0043-1354(91)90125-A
   Yildiz N, 2004, ADSORPT SCI TECHNOL, V22, P145, DOI 10.1260/026361704323150926
NR 15
TC 42
Z9 49
U1 2
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-7003
J9 INORG CHEM COMMUN
JI Inorg. Chem. Commun.
PD JAN
PY 2008
VL 11
IS 1
BP 20
EP 23
DI 10.1016/j.inoche.2007.09.029
PG 4
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 261UJ
UT WOS:000253105200006
DA 2018-12-27
ER

PT J
AU Liu, K
   Xu, Q
AF Liu, Kang
   Xu, Qiang
TI RETRACTED: Roxithromycin inhibits the effector phase of delayed-type
   hypersensitivity (Retracted article. See vol. 10, pg. 1477, 2010)
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE roxithromycin; delayed-type hypersensitivity; contact hypersensitivity;
   effector phase; MMP-9; Th1
ID T-LYMPHOCYTES; CONTACT SENSITIVITY; DIFFUSE PANBRONCHIOLITIS;
   CELL-MIGRATION; TH2 CELLS; IN-VITRO; ERYTHROMYCIN; MICE; MECHANISM;
   ADHESION
AB In the present paper, the effect of roxithromycin on delayed-type hypersensitivity (DTH) was evaluated. Roxithromycin had no effect on sheep red blood cells (SRBC)-induced food pad swelling when orally administered in induction phase, whereas it suppressed the SRBC-induced DTH reaction and 2,4,6-Trinitrochlorobenzene (TNCB)-induced contact hypersensitivity (CHS) significantly when administered to mice in effector phase. For the sustained-CHS model induced by multi-challenge with TNCB, roxithromycin also inhibited the ear swelling when exposed to mice in three effector phases while showed no inhibitory effect on CHS by continuous treatment. Administration of this antibiotic in effector phase also down-regulated the MMP-9 activity and the higher in vitro survival of splenocytes from SRBC-challenged mice. Furthermore, this drug inhibited the gene expression of T-helper type 1 (Th1) cytokines such as IL-2 and IFN-gamma of Lymph node cells from mice immuned by TNCB or of Con A-stimulated spleen cells. In addition, roxithromycin administered in vivo decreased the concanavalin A (Con A)-induced splenocyte proliferation without affecting the cell survival in vitro. These results suggest that roxithromycin might alleviate DTH reaction at least by suppressing the function and survival of effector T cells. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Liu, Kang] China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, Nanjing 210038, Peoples R China.
   [Xu, Qiang] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China.
RP Liu, K (reprint author), China Pharmaceut Univ, Dept Pharmacol Chinese Mat Med, 1 Shen Nong Rd, Nanjing 210038, Peoples R China.
EM liukangcpu@yahoo.com.cn
CR Abraham M, 2005, J NEUROIMMUNOL, V163, P157, DOI 10.1016/j.jneuroim.2005.02.001
   Arnold R, 2006, EUR J IMMUNOL, V36, P1654, DOI 10.1002/eji.200636197
   Asano K, 2001, INT IMMUNOPHARMACOL, V1, P1913, DOI 10.1016/S1567-5769(01)00116-3
   Baumer W, 2003, EUR J PHARMACOL, V481, P271, DOI 10.1016/j.ejphar.2003.09.031
   Goetzl EJ, 1996, J IMMUNOL, V156, P1
   ISSEKUTZ TB, 1988, J IMMUNOL, V140, P2989
   Jun YT, 2003, ANTIMICROB AGENTS CH, V47, P1161, DOI 10.1128/AAC.47.3.1161-1164.2003
   KADOTA J, 1993, AM REV RESPIR DIS, V147, P153, DOI 10.1164/ajrccm/147.1.153
   Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6
   Kermani F, 2000, TOXICOL APPL PHARM, V169, P231, DOI 10.1006/taap.2000.9058
   Kobayashi H, 1995, AM J MED, V99, pS26, DOI 10.1016/S0002-9343(99)80282-4
   Kobayashi M, 2004, CELL IMMUNOL, V228, P27, DOI 10.1016/j.cellimm.2004.03.011
   Kobayashi Y, 1999, J IMMUNOL, V163, P5989
   Kudoh S, 1998, AM J RESP CRIT CARE, V157, P1829, DOI 10.1164/ajrccm.157.6.9710075
   Labro M. T., 1998, Journal of Antimicrobial Chemotherapy, V41, P37, DOI 10.1093/jac/41.suppl_2.37
   Mitsui G, 2004, INT IMMUNOPHARMACOL, V4, P57, DOI 10.1016/j.intimp.2003.10.005
   NELSON S, 1987, AM REV RESPIR DIS, V136, P1207, DOI 10.1164/ajrccm/136.5.1207
   Rubin BK, 2004, CHEST, V125, p70S, DOI 10.1378/chest.125.2_suppl.70S
   Saint-Mezard P, 2004, EUR J DERMATOL, V14, P131
   Scaglione F., 1998, Journal of Antimicrobial Chemotherapy, V41, P47, DOI 10.1093/jac/41.suppl_2.47
   Shoji T, 1999, CLIN EXP ALLERGY, V29, P950
   Sun Y, 2003, J PHARM PHARMACOL, V55, P839, DOI [10.1211/002235703765951465, 10.1211/0022357021035]
   Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3
   Wang JL, 2005, INT IMMUNOPHARMACOL, V5, P407, DOI 10.1016/j.intimp.2004.10.007
NR 24
TC 7
Z9 7
U1 4
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JAN
PY 2008
VL 8
IS 1
BP 126
EP 131
DI 10.1016/j.intimp.2007.10.002
PG 6
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 248ZK
UT WOS:000252195700015
PM 18068108
DA 2018-12-27
ER

PT J
AU Lorenzi, M
   Gimona, M
AF Lorenzi, Maria
   Gimona, Mario
TI RETRACTED: Synthetic actin-binding domains reveal compositional
   constraints for function (Retracted article. See vol. 45, pg. 512, 2013)
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE synthetic biology; thin filament association; actin-binding; FRAP;
   alpha-actinin; filamin; calponin homology domain
ID ALPHA-ACTININ; CRYSTAL-STRUCTURE; CROSS-LINKING; F-ACTIN; CRYOELECTRON
   MICROSCOPY; DYSTROPHIN; FILAMENTS; CALPONIN; HOMOLOGY; MUSCLE
AB The actin-binding domains of many proteins consist of a canonical type 1/type 2 arrangement of the structurally conserved calponin homology domain. Using the actin-binding domain of alpha-actinin-1 as a scaffold we have generated synthetic actin-binding domains by altering position and composition of the calponin homology domains. We show that the presence of two calponin homology domains alone and in the context of an actin-binding domain is not sufficient for actin-binding, and that both single and homotypic type 2 calponin homology domain tandems fail to bind to actin in vitro and in transfected cells. In contrast, single and tandem type 1 calponin homology domain arrays bind actin directly but result in defective turnover rates on actin filaments, and in aberrant actin bundling when introduced into the full-length alpha-actinin molecule. An actin-binding domain harboring the calponin homology domains in an inverted position, however, functions both in isolation and in the context of the dimeric alpha-actinin molecule. Our data demonstrate that the dynamics and specificity of actin-binding via actin-binding domains requires both the filament binding properties of the type 1, and regulation by type 2 calponin homology domains, and appear independent of their position. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Gimona, Mario] Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Unit Actin Cytoskeleton Regulat, I-66030 Santa Maria Imbaro, Italy.
RP Gimona, M (reprint author), Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Unit Actin Cytoskeleton Regulat, Via Nazl 8A, I-66030 Santa Maria Imbaro, Italy.
EM gimona@negrisud.it
CR Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5
   BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424
   Borrego-Diaz E, 2006, J STRUCT BIOL, V155, P230, DOI 10.1016/j.jsb.2006.01.013
   Burgstaller G, 2004, J CELL SCI, V117, P223, DOI 10.1242/jcs.00839
   CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y
   CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1
   Dixson JD, 2003, J MOL EVOL, V56, P1, DOI 10.1007/s00239-002-2374-5
   Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9
   Fontao L, 2001, J CELL SCI, V114, P2065
   Franzot G, 2005, J MOL BIOL, V348, P151, DOI 10.1016/j.jmb.2005.01.002
   GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P
   Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9
   HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369
   ISOBE Y, 1988, P NATL ACAD SCI USA, V85, P6758, DOI 10.1073/pnas.85.18.6758
   KARINCH AM, 1990, J BIOL CHEM, V265, P11833
   Keep NH, 1999, J MOL BIOL, V285, P1257, DOI 10.1006/jmbi.1998.2406
   KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R
   LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D
   Liu J, 2004, J MOL BIOL, V338, P115, DOI 10.1016/j.jmb.2004.02.034
   MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433
   MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013
   Nakamura F, 2007, J CELL BIOL, V179, P1011, DOI 10.1083/jcb.200707073
   Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007
   PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065
   Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8
   STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x
   Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789
   WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835
   Weins A, 2007, P NATL ACAD SCI USA, V104, P16080, DOI 10.1073/pnas.0702451104
   WINDER SJ, 1995, J CELL SCI, V108, P63
   Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570
   Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0
   Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614
NR 33
TC 6
Z9 6
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PY 2008
VL 40
IS 9
BP 1806
EP 1816
DI 10.1016/j.biocel.2008.01.011
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 331ZU
UT WOS:000258052000018
PM 18296101
DA 2018-12-27
ER

PT J
AU Pushparaj, PN
   H'ng, SC
   Melendez, AJ
AF Pushparaj, Peter N.
   H'ng, Shiau Chen
   Melendez, Alirio J.
TI RETRACTED: Refining siRNA in vivo transfection: Silencing SPHK1 reveals
   its key role in C5a-induced inflammation in vivo (Retracted article. See
   vol. 45, pg. 1154, 2013)
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE siRNA; delivery; inflammation; anaphylatoxin; C5a
ID TUMOR-NECROSIS-FACTOR; SPHINGOSINE KINASE; GENE-EXPRESSION;
   SIGNAL-TRANSDUCTION; CYTOKINE PRODUCTION; RNA INTERFERENCE; CA2+
   SIGNALS; ADULT MICE; CELLS; DELIVERY
AB The transfection of siRNA in vivo is essential for the study of gene functions, target validation, and for gene therapy. However, the successful delivery of siRNA in whole organisms is still very difficult to achieve. A high-pressure delivery technique, called the "hydrodynamics" method, has been used for siRNA transfection in mice. However, it is a method based on a high-speed and high-volume of i.v. injection, which makes it very difficult to implement in vivo, due to vascular breakage. Here, we systematically investigated ways to optimize the siRNA delivery, in order to avoid strong side effects, while achieving a high-efficiency siRNA-gene knockdown. We show here that the amount of siRNA delivered is crucial, as using too little or too much siRNA minimizes the knockdown effect. We demonstrate that by carefully identifying an optimal-minimal volume, and an optimal amount of siRNA, we achieve a high knockdown effect, with a 100% survival rate. We have previously shown that SphK1 plays a key role in anaphylatoxin (C5a) signaling in neutrophils and macrophages. Our approach, optimizing the dosage of siRNA, allowed us to successfully silence our target gene-product (SphK1) in vivo, and enabled us to validate SphK1 as a key player in our in vivo model of C5a-induced acute peritonitis and systemic inflammation including multi-organ damage, demonstrating that this improved siRNA-silencing method not only allowed us to identify SphK1 as a key therapeutic target, but brings us a step closer to the usage of siRNA for therapeutic intervention. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Pushparaj, Peter N.; H'ng, Shiau Chen; Melendez, Alirio J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore.
RP Melendez, AJ (reprint author), Univ Glasgow, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.
EM a.melendez-romero@clinmed.gla.ac.uk
FU Medical Research Council [G0700794]
CR Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994
   BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193
   Choi OH, 1996, NATURE, V380, P634
   Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512
   Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855
   HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5
   Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983
   Hong J, 2005, BIOCHEM J, V390, P675, DOI 10.1042/BJ20050647
   Ibrahim FBM, 2004, J BIOL CHEM, V279, P44802, DOI 10.1074/jbc.M403977200
   KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3
   Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393
   Melendez AJ, 2008, BBA-PROTEINS PROTEOM, V1784, P66, DOI 10.1016/j.bbapap.2007.07.013
   Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5
   Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596
   Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200
   Mohr M, 1998, EUR J CLIN INVEST, V28, P227
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153
   Pellas TC, 1998, J IMMUNOL, V160, P5616
   Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5
   SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225
   Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456
   Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100
   ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34
NR 30
TC 25
Z9 25
U1 2
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PY 2008
VL 40
IS 9
BP 1817
EP 1825
DI 10.1016/j.biocel.2008.01.015
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 331ZU
UT WOS:000258052000019
PM 18308614
DA 2018-12-27
ER

PT J
AU Pyun, YD
   Kim, YJ
AF Pyun, Young Don
   Kim, Yun Joo
TI RETRACTED: Norms for the Korean Version of the Harvard Group Scale of
   Hypnotic Susceptibility, Form A (Retracted article. See vol. 60, pg. R1,
   2012)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL HYPNOSIS
LA English
DT Article; Retracted Publication
AB The Korean Version of the Harvard Group Scale of Hypnotic Susceptibility, Form A (HGSHS:K) was adapted and studied in order to determine Korean norms. In total, 271 subjects (175 males and 96 females) participated in the study. Comparisons are made between the Korean samples and previously published international samples. The normative data from the Korean sample on the HGSHS:K are generally congruent, including means and standard deviations, with data from international reference samples. However, the pass rate on the hallucination item on the Harvard Group Scale of Hypnotic Susceptibility, Form A, was significantly different from that of the American sample. Females showed higher overall scores than males.
C1 [Pyun, Young Don] Pyun Neuropsychiat Clin, Seoul 135080, South Korea.
   [Kim, Yun Joo] Hanyang Cyber Univ, Seoul, South Korea.
RP Pyun, YD (reprint author), Pyun Neuropsychiat Clin, 628-10 Yoksamdong, Seoul 135080, South Korea.
EM pyunyd@naver.com
CR Benham G, 2002, INT J CLIN EXP HYP, V50, P5, DOI 10.1080/00207140208410087
   Bergman M, 2003, INT J CLIN EXP HYP, V51, P348, DOI 10.1076/iceh.51.4.348.16414
   BONGARTZ W, 1985, INT J CLIN EXP HYP, V33, P131, DOI 10.1080/00207148508406643
   David D, 2003, INT J CLIN EXP HYP, V51, P66
   De Pascalis V, 2000, INT J CLIN EXP HYP, V48, P44, DOI 10.1080/00207140008410360
   Hilgard E. R, 1965, HYPNOTIC SUSCEPTIBIL
   Kallio SPI, 1999, INT J CLIN EXP HYP, V47, P227, DOI 10.1080/00207149908410034
   LAMAS JR, 1989, INT J CLIN EXP HYP, V37, P264, DOI 10.1080/00207148908414477
   Rudski JM, 2004, INT J CLIN EXP HYP, V52, P39, DOI 10.1076/iceh.52.1.39.23924
   SHEEHAN PW, 1979, INT J CLIN EXP HYP, V27, P294, DOI 10.1080/00207147908407568
   Shor R, 1962, HARVARD GROUP SCALE
   SHOR RONALD E., 1963, INTERNATL JOUR CLIN AND EXPTL HYPNOSIS, V11, P39
   Spiegel H., 2004, TRANCE TREATMENT
   Zachariae R, 1996, INT J CLIN EXP HYP, V44, P140, DOI 10.1080/00207149608416076
NR 14
TC 9
Z9 9
U1 2
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0020-7144
EI 1744-5183
J9 INT J CLIN EXP HYP
JI Int. J. Clin. Exp. Hypn.
PY 2008
VL 57
IS 1
BP 117
EP 126
AR PII 905942034
DI 10.1080/00207140802463799
PG 10
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 376HN
UT WOS:000261174800006
PM 19031236
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Nakayama, M
AF Fujii, Y.
   Nakayama, M.
TI RETRACTED: Dexamethasone for reduction of nausea, vomiting and analgesic
   use after gynecological laparoscopic surgery (Retracted article. See
   vol. 121, pg. 97, 2013)
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article; Retracted Publication
DE vomiting; pain; nausea; dexamethasone; gynecological laparoscopic
   surgery
ID HIGH-DOSE DEXAMETHASONE; POSTOPERATIVE NAUSEA; DOUBLE-BLIND; ANTIEMETIC
   EFFICACY; CONTROLLED TRIAL; PREVENTION; CHOLECYSTECTOMY; ONDANSETRON;
   EXTRACTION; CISPLATIN
AB Objective: To evaluate the prophylactic use of dexamethasone for reducing postoperative nausea and vomiting (PONV) and analgesic use after gynecological laparoscopic surgery. Methods: In a prospective randomized, double-blind, placebo-controlled trial, 90 women received either intravenous placebo, 4 mg dexamethasone or 8 mg dexamethasone at the end of surgery. PONV and analgesic requirements were evaluated. Results: The rate of patients experiencing PONV within 24 h after anesthesia was 53% in the 4 mg dexamethasone group (P=0.3) and 20% in the 8 mg dexamethasone group (P=0.001), compared with the placebo group (63%). Requests for indomethacin to relieve intolerable pain were less in patients in the 8 mg dexamethasone group compared with the 4 mg dexamethasone (P=0.047) or placebo (P=0.029) groups. Conclusion: Prophylactic use of 8 mg dexamethasone is effective for reducing PONV and analgesic requirements after gynecological laparoscopic surgery. (c) 2007 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics.
C1 [Fujii, Y.; Nakayama, M.] Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, 6-11-1 Ohmori Nishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR AAPRO MS, 1981, NEW ENGL J MED, V305, P520
   AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   BAXENDALE BR, 1993, ANAESTHESIA, V48, P961
   Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030
   BODNER M, 1991, ANESTH ANALG, V73, P250
   Bradshaw WA, 2002, SURG ENDOSC, V16, P777, DOI 10.1007/s00464-001-8342-0
   FREDRIKSON M, 1992, BRIT J CANCER, V65, P779, DOI 10.1038/bjc.1992.165
   Fujii Y, 2005, CLIN THER, V27, P740, DOI 10.1016/j.clinthera.2005.05.011
   Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95
   Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038
   Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6
   *JAP PHARM INF CTR, 2006, DRUG JAP ETH DRUGS
   Koivuranta M, 1997, ACTA ANAESTH SCAND, V41, P1273, DOI 10.1111/j.1399-6576.1997.tb04644.x
   Laiq Nasreen, 2005, J Coll Physicians Surg Pak, V15, P778
   Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046
   LIVREA P, 1985, J NEUROL, V231, P336, DOI 10.1007/BF00313712
   RAMSAY TM, 1994, CAN J ANAESTH, V41, P798, DOI 10.1007/BF03011586
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   SCHIMMER BP, 2001, GOODMAN GILMANS PHAR, P1649
   Sekine I, 1997, BRIT J CANCER, V76, P90, DOI 10.1038/bjc.1997.341
   Splinter WM, 1996, ANESTH ANALG, V83, P913, DOI 10.1097/00000539-199611000-00004
   Tramer MR, 1999, BRIT J ANAESTH, V82, P379, DOI 10.1093/bja/82.3.379
   Wang JJ, 2000, ANESTH ANALG, V91, P1404, DOI 10.1097/00000539-200012000-00019
   Wang JJ, 1999, BRIT J ANAESTH, V83, P772
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 25
TC 13
Z9 16
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JAN
PY 2008
VL 100
IS 1
BP 27
EP 30
DI 10.1016/j.ijgo.2007.07.017
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 260QT
UT WOS:000253025900007
PM 17900579
DA 2018-12-27
ER

PT J
AU Ogban, IU
   Ogbobe, O
AF Ogban, I. U.
   Ogbobe, O.
TI RETRACTED: The Effect of Agro-Wastes and Crustacean Fillers on Poly
   (Vinyl-Acetate) Emulsion Wood Adhesives (Retracted article. See vol. 58,
   pg. 1, 2009)
SO INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS
LA English
DT Article; Retracted Publication
DE agro-wastes; emulsion; wood adhesives
AB Cellulosic and crustacean filler materials were used to study their effects on poly(vinyl-acetate) (PVAC) emulsion wood adhesives. The elastoplastic behavior of the filler-treated PVAC emulsion was studied using differential scanning calorimetry and dynamic mechanical thermal analysis. The result revealed that the glass transition temperature (Tg) of the filler-treated polymer is not significantly changed by the addition of the filler materials, whereas the tensile modulus, adhesive hardness, and the stiffness were markedly changed. The viscosity of the emulsions and their performance on wood surfaces were greatly affected by fillers. The cellulosic fillers have high oil-absorption capacity, hence increased viscosity to a greater extent than the case with crustacean-based filler materials, which have faster coalescence but yield mechanically weaker films. The acidity of the fillers influenced the setting time for wood adhesive bonding.
C1 [Ogban, I. U.] CRUTECH, Dept Chem Sci, Calabar, Nigeria.
   [Ogbobe, O.] Fed Univ Technol Owerri, Sch Engn & Engn Technol, Dept Polymer & Textile Technol, Owerri, Imo State, Nigeria.
RP Ogban, IU (reprint author), CRUTECH, Dept Chem Sci, PMB 1123, Calabar, Nigeria.
EM Ogbanina505@yahoo.com
CR BRIMSON HF, 1990, ENG MAT HDB, V3
   Brydson J.A., 1989, PLASTIC MAT
   COLLETT BM, 1972, WOOD SCI TECHNOL, V6, P1, DOI 10.1007/BF00351806
   GILLESPIE BH, 1975, H FOREST PRODUCT J, V25, P26
   MILEWSKI JJ, 1985, HDB FILLER REINFORCE, V2
   MOHSEN RM, 1992, PIGM RESIN TECHNOL, P10
   OGBAN IU, 1989, B ELECTROCHEM, V5, P60
   SELLER J, 1985, PLYWOOD ADHESIVE TEC
NR 8
TC 2
Z9 2
U1 3
U2 12
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0091-4037
EI 1563-535X
J9 INT J POLYM MATER
JI Int. J. Polym. Mater.
PY 2008
VL 57
IS 3
BP 266
EP 274
DI 10.1080/00914030701476915
PG 9
WC Polymer Science
SC Polymer Science
GA 370LB
UT WOS:000260762600007
DA 2018-12-27
ER

PT J
AU Robbins, WA
   Wei, FS
   Elashoff, DA
   Wu, GP
   Xun, L
   Jia, J
AF Robbins, Wendie A.
   Wei, Fusheng
   Elashoff, David A.
   Wu, Guoping
   Xun, Lin
   Jia, Juan
TI RETRACTED: Y : X sperm ratio in boron-exposed men (Retracted article.
   See vol. 32, pg. 550, 2011)
SO JOURNAL OF ANDROLOGY
LA English
DT Article; Retracted Publication
DE sperm; spermatogenesis; sex ratio at birth
ID IN-SITU HYBRIDIZATION; BORIC-ACID; REPRODUCTIVE TOXICITY; HEALTHY-MEN;
   BLOOD-BORON; ANEUPLOIDY; WORKERS; BIRTH; MICE
AB Several epidemiologic investigations have shown shifts in sex ratios at birth toward females in populations with relatively high boron exposure. To investigate the paternal origin of these shifts, we assayed sperm Y:X ratio in men exposed to a range of environmental and workplace boron. Participants included 63 workers in boron industry: 39 men living in an area of high environmental boron but not employed in boron industry, and 44 controls living in an area of low environmental boron. Total daily boron exposure was calculated as the sum of boron in 24-hour duplicate food and fluid intakes plus personal air sampling for workplace inhalable dust. Internal dose was measured in blood, urine, and semen. Sperm were analyzed by fluorescence in situ hybridization for Y- versus X-bearing cells. Potential confounders were identified using a questionnaire. Total exposure was correlated with internal dose (Pearson correlation for total exposure and boron in blood = 0.63, P <.0001; semen = 0.80, P <.001; and urine=0.79, P <.0001). Linear regression of logged boron in biologic fluids on Y:X ratio was significant for blood P =.02, semen P =.0003, and urine P=.005. Additionally, when subjects were categorized by exposure group, decreased Y:X sperm ratio was found for boron workers compared with men in a high boron environment and controls (P <.0001). Exogenous environmental or workplace boron exposures were associated with decreases in Y- versus X-bearing sperm. This may explain earlier findings from us and others showing changes in offspring sex ratios at birth for men exposed to boron.
C1 [Robbins, Wendie A.] Univ Calif Los Angeles, Ctr Environm & Occupat Hlth, Los Angeles, CA 90095 USA.
   [Wei, Fusheng; Wu, Guoping] China Natl Environm Monitoring Stn, Beijing, Peoples R China.
   [Elashoff, David A.; Jia, Juan] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
   [Xun, Lin] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
RP Robbins, WA (reprint author), Univ Calif Los Angeles, Ctr Environm & Occupat Hlth, Room 5-254 Factor Bldg,Mailcode 956919, Los Angeles, CA 90095 USA.
EM wrobbins@sonnet.ucla.edu
CR Bay K, 2006, BEST PRACT RES CL EN, V20, P77, DOI 10.1016/j.beem.2005.09.004
   Catalano R, 2006, P NATL ACAD SCI USA, V103, P1639, DOI 10.1073/pnas.0510567103
   Chang Betty L, 2006, AAOHN J, V54, P435
   CHAPIN RE, 1994, ENVIRON HEALTH PERSP, V102, P87, DOI 10.2307/3431969
   CULVER BD, 1994, ENVIRON HEALTH PERSP, V102, P133, DOI 10.2307/3431976
   Davis DL, 1998, JAMA-J AM MED ASSOC, V279, P1018, DOI 10.1001/jama.279.13.1018
   FAIL PA, 1991, FUND APPL TOXICOL, V17, P225, DOI 10.1016/0272-0590(91)90215-P
   Gomez LD, 2002, LANCET, V360, P143, DOI 10.1016/S0140-6736(02)09386-8
   Howe PD, 1998, BIOL TRACE ELEM RES, V66, P153, DOI 10.1007/BF02783135
   James WH, 2006, J THEOR BIOL, V238, P383, DOI 10.1016/j.jtbi.2005.05.022
   KU WW, 1993, REPROD TOXICOL, V7, P305, DOI 10.1016/0890-6238(93)90020-8
   Mathews T J, 2005, Natl Vital Stat Rep, V53, P1
   Mocarelli P, 2000, LANCET, V355, P1858, DOI 10.1016/S0140-6736(00)02290-X
   Moorman WJ, 2000, REPROD TOXICOL, V14, P293, DOI 10.1016/S0890-6238(00)00089-7
   Namekawa SH, 2006, CURR BIOL, V16, P660, DOI 10.1016/j.cub.2006.01.066
   Ong TD, 2002, J ANDROL, V23, P270
   Park M, 2004, MOL CELL, V16, P331, DOI 10.1016/j.molcel.2004.09.030
   Price CJ, 1998, BIOL TRACE ELEM RES, V66, P359, DOI 10.1007/BF02783148
   Richold M, 1998, BIOL TRACE ELEM RES, V66, P121, DOI 10.1007/BF02783132
   Robbins WA, 1995, REPROD FERT DEVELOP, V7, P799, DOI 10.1071/RD9950799
   Rubes J, 2002, AM J HUM GENET, V70, P1507, DOI 10.1086/340791
   Sayli BS, 2003, BIOL TRACE ELEM RES, V93, P19, DOI 10.1385/BTER:93:1-3:19
   Sayli BS, 1998, BIOL TRACE ELEM RES, V66, P409, DOI 10.1007/BF02783152
   Shi Q, 2000, CYTOGENET CELL GENET, V90, P79, DOI 10.1159/000015668
   Tarasenko N Iu, 1972, Gig Tr Prof Zabol, V16, P13
   Tiido T, 2005, HUM REPROD, V20, P1903, DOI 10.1093/humrep/deh855
   Wang PJ, 2005, HUM MOL GENET, V14, P2911, DOI 10.1093/hmg/ddi322
   WHORTON MD, 1994, OCCUP ENVIRON MED, V51, P761, DOI 10.1136/oem.51.11.761
   WHORTON MD, 1983, MUTAT RES, V123, P13, DOI 10.1016/0165-1110(83)90044-1
   WOODS WG, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3431956
   XING XR, 2006, ENV SCI, V27, P1208
   Yazbeck C, 2005, ENVIRON GEOCHEM HLTH, V27, P419, DOI 10.1007/s10653-005-1796-6
NR 32
TC 26
Z9 26
U1 4
U2 12
PU AMER SOC ANDROLOGY, INC
PI LAWRENCE
PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA
SN 0196-3635
EI 1939-4640
J9 J ANDROL
JI J. Androl.
PD JAN-FEB
PY 2008
VL 29
IS 1
BP 115
EP 121
DI 10.2164/jandrol.107.003541
PG 7
WC Andrology
SC Endocrinology & Metabolism
GA 246YQ
UT WOS:000252044700018
PM 17881766
DA 2018-12-27
ER

PT J
AU Khan, MA
   Xu, W
   Khizar-ul-Haq
   Bai, Y
   Jiang, XY
   Zhang, ZL
   Zhu, WQ
   Zhang, ZL
   Zhu, WQ
AF Khan, M. A.
   Xu, Wei
   Khizar-ul-Haq
   Bai, Yu
   Jiang, X. Y.
   Zhang, Z. L.
   Zhu, W. Q.
   Zhang, Z. L.
   Zhu, W. Q.
TI RETRACTED: Electron mobility of 4,7-diphyenyl-1,10-phenanthroline
   estimated by using space-charge-limited currents (Retracted article. See
   vol. 109, artn no. 109904, 2011)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID LIGHT-EMITTING-DIODES; TRANSPORT; DEVICES; ELECTROLUMINESCENCE; LAYER;
   TIME
AB The electron mobility of 4,7-diphyenyl-1,10-phenanthroline (BPhen) at various thicknesses (50-300nm) has been estimated by using space-charge-limited current measurements. The measured bulk mobility is in excellent agreement with results from time-of-flight method. It has been observed that the electron mobility of, BPhen approaches its true value when the thickness is more than 150 nm. The estimated electron mobility of BPhen at 300 nm is found to be 3.4 X 10(-4) cm(2)/V s (at 0.3 MV/cm) with weak dependence on electric field. For thickness typical of organic light-emitting devices, the electron mobility of BPhen is also investigated. (c) 2008 American Institute of Physics.
C1 [Khan, M. A.; Xu, Wei; Khizar-ul-Haq; Bai, Yu; Jiang, X. Y.; Zhang, Z. L.; Zhu, W. Q.] Shanghai Univ, Dept Mat Sci, Shanghai 201800, Peoples R China.
   [Zhang, Z. L.; Zhu, W. Q.] Shanghai Univ, Key Lab Adv Display & Syst Applicat, Minist Educ, Shanghai 200072, Peoples R China.
RP Khan, MA (reprint author), Shanghai Univ, Dept Mat Sci, Shanghai 201800, Peoples R China.
EM rauf_ak@yahoo.com
CR Baldo MA, 1998, NATURE, V395, P151
   Blom PWM, 1996, APPL PHYS LETT, V68, P3308, DOI 10.1063/1.116583
   Bozano L, 1999, APPL PHYS LETT, V74, P1132, DOI 10.1063/1.123959
   Buttenhausen J., 1997, J APPL PHYS, V82, P4957
   Chen ZJ, 2001, J APPL PHYS, V89, P7895, DOI 10.1063/1.1371939
   Choong VE, 1999, APPL PHYS LETT, V75, P172, DOI 10.1063/1.124309
   Chu TY, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2741055
   Di CA, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2718274
   GILL WD, 1972, J APPL PHYS, V43, P5033, DOI 10.1063/1.1661065
   Kim SH, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2410224
   Lin LB, 1996, APPL PHYS LETT, V69, P3495, DOI 10.1063/1.117223
   Malliaras GG, 1998, PHYS REV B, V58, P13411, DOI 10.1103/PhysRevB.58.R13411
   Malliaras GG, 2001, APPL PHYS LETT, V79, P2582, DOI 10.1063/1.1410343
   Naka S, 2000, APPL PHYS LETT, V76, P197, DOI 10.1063/1.125701
   Pal AJ, 1997, APPL PHYS LETT, V71, P228, DOI 10.1063/1.119917
   Redecker M, 1999, APPL PHYS LETT, V75, P109, DOI 10.1063/1.124291
   SLYKE SAV, 1996, APPL PHYS LETT, V69, P2160, DOI DOI 10.1063/1.117151
   Stossel M, 2000, APPL PHYS LETT, V76, P115, DOI 10.1063/1.125674
   TANG CW, 1987, APPL PHYS LETT, V51, P913, DOI 10.1063/1.98799
   TOKUHISA H, 1995, APPL PHYS LETT, V66, P3433, DOI 10.1063/1.113378
   Tse SC, 2003, J APPL PHYS, V94, P2033, DOI 10.1063/1.1589175
   Wang XJ, 2004, J APPL PHYS, V95, P3828, DOI 10.1063/1.1655676
   Yasuda T, 2002, JPN J APPL PHYS 1, V41, P5626, DOI 10.1143/JJAP.41.5626
NR 23
TC 58
Z9 60
U1 4
U2 34
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-8979
J9 J APPL PHYS
JI J. Appl. Phys.
PD JAN 1
PY 2008
VL 103
IS 1
AR 014509
DI 10.1063/1.2829805
PG 4
WC Physics, Applied
SC Physics
GA 258SV
UT WOS:000252890700100
DA 2018-12-27
ER

PT J
AU Pan, Q
   Luo, XP
   Chegini, N
AF Pan, Qun
   Luo, Xiaoping
   Chegini, Nasser
TI RETRACTED: Differential expression of microRNAs in myometrium and
   leiomyomas and regulation by ovarian steroids (Retracted article. See
   vol. 19, pg. 2512, 2015)
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 54th Annual Meeting of the Society-for-Gynecologic-Investigation
CY MAR 14-17, 2007
CL Reno, NV
SP Soc Gynecol Invest
DE leiomyoma; miRNA; expression; smooth muscle cells; leiomyosarcoma;
   regulation; ovarian steroids
ID ESTROGEN-RECEPTOR-ALPHA; CATECHOL-O-METHYLTRANSFERASE; HORMONE ANALOG
   THERAPY; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; GENE-EXPRESSION;
   UTERINE LEIOMYOMATA; RNA EXPRESSION; MESSENGER-RNA; CANCER
AB Given the emerging roles of microRNAs (miRNAs) as key regulator of mRNA stability we assessed their expression profile in paired myometrium and leiomyoma, their isolated smooth muscle cells (MSMC and LSMC), a spontaneously transformed leiomyoma smooth muscle cells (T-LSMC) and SK-LMS-1, a leiomyosarcoma cell line using microarray and real time PCR.Based on global normalization of expression values of 385 miRNAs and statistical analysis (ANOVA), 91 miRNAs were expressed above the threshold levels in myometrium, with a progressive decline in numbers in leiomyomas, MSMC, LSMC, T-LSMC and SK-LMS-1 (P < 0.05).We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P < 0.05).Treatments of MSMC and LSMC with 17 beta estradiol and medroxyprogesterone acetate (10(-8)M), or ICI-182780 and RU-486 (10(-6)M) resulted in differential regulation of these miRNAs (P < 0.05).In conclusion, the expression of a number of miRNAs in myometrium and leiomyoma with their progressive aberrant from normal MSMC into LSMC, transformed and cancerous stage, suggests that miRNAs and their regulation by ovarian steroids play a key role in pathogenesis of leiomyoma through gene expression stability.
C1 [Pan, Qun; Luo, Xiaoping; Chegini, Nasser] Univ Florida, Dept Obstet & Gynecol, Gainesville, FL 32611 USA.
RP Chegini, N (reprint author), Univ Florida, Dept Obstet & Gynecol, Box 100294, Gainesville, FL 32611 USA.
EM cheginin@obgyn.ufl.edu
FU NICHD NIH HHS [R01 HD037432-07, HD37432, R01 HD037432]
CR Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Al-Hendy A, 2006, J SOC GYNECOL INVEST, V13, P136, DOI 10.1016/j.jsgi.2005.10.007
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chegini N, 2003, J SOC GYNECOL INVEST, V10, P161, DOI 10.1016/S1071-5576(03)00004-2
   Chegini N, 2002, MOL HUM REPROD, V8, P1071, DOI 10.1093/molehr/8.12.1071
   CHEGINI N, 2005, UTERINE LEIOMYOMATA, P41
   CHEGINI N, 2000, CYTOKINES HUMAN REPR, P133
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Davison TS, 2006, METHOD ENZYMOL, V411, P14, DOI 10.1016/S0076-6879(06)11002-2
   DeManno D, 2003, STEROIDS, V68, P1019, DOI 10.1016/j.steroids.2003.09.008
   Denschlag D, 2006, FERTIL STERIL, V85, P462, DOI 10.1016/j.fertnstert.2005.07.1308
   Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537
   Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96
   Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912
   Ligon AH, 2001, HUM REPROD UPDATE, V7, P8, DOI 10.1093/humupd/7.1.8
   Luo XP, 2005, ENDOCRINOLOGY, V146, P1074, DOI 10.1210/en.2004-1384
   Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377
   Matsuzaki S, 2000, FERTIL STERIL, V73, P1219, DOI 10.1016/S0015-0282(00)00527-6
   Matsuzaki S, 2001, FERTIL STERIL, V75, P1198, DOI 10.1016/S0015-0282(01)01783-6
   Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373
   Palomba S, 2002, HUM REPROD, V17, P3213, DOI 10.1093/humrep/17.12.3213
   Pan Q, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-34
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Quade BJ, 2004, GENE CHROMOSOME CANC, V40, P97, DOI 10.1002/gcc.20018
   Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Steinauer J, 2004, OBSTET GYNECOL, V103, P1331, DOI 10.1097/01.AOG.0000127622.63269.8b
   Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200
   Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228
   Tsibris JCM, 2002, FERTIL STERIL, V78, P114, DOI 10.1016/S0015-0282(02)03191-6
   Varol N, 2001, AUST NZ J OBSTET GYN, V41, P295, DOI 10.1111/j.1479-828X.2001.tb01231.x
   Villanova FE, 2006, STEROIDS, V71, P960, DOI 10.1016/j.steroids.2006.07.005
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang HB, 2003, FERTIL STERIL, V80, P266, DOI 10.1016/S0015-0282(03)00730-1
   Wang TS, 2007, GENE CHROMOSOME CANC, V46, P336, DOI 10.1002/gcc.20415
   Wise LA, 2005, OBSTET GYNECOL, V105, P563, DOI 10.1097/01.AOG.0000154161.03418.e3
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Yu J, 2006, BIOCHEM BIOPH RES CO, V349, P59, DOI 10.1016/j.bbrc.2006.07.207
   Zaitseva M, 2006, MOL HUM REPROD, V12, P187, DOI 10.1093/molehr/gal018
   Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908
   Zhao JJ, 2006, CHILD NERV SYST, V22, P1419, DOI 10.1007/s00381-006-0173-9
NR 49
TC 91
Z9 96
U1 4
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN-FEB
PY 2008
VL 12
IS 1
BP 227
EP 240
DI 10.1111/j.1582-4934.2007.00207.x
PG 14
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 278HJ
UT WOS:000254275500016
PM 18182067
OA Green Accepted, Green Published
DA 2018-12-27
ER

PT J
AU Metz, R
   Machado, C
   Houabes, M
   Elkhatib, M
   Hassanzadeh, M
AF Metz, Renaud
   Machado, Celine
   Houabes, Mourad
   Elkhatib, Mazen
   Hassanzadeh, Mehrdad
TI RETRACTED: Nitrogen spray atomization of molten tin metal: Powder
   morphology characteristics (Retracted article. See vol. 212, pg. 1988,
   2012)
SO JOURNAL OF MATERIALS PROCESSING TECHNOLOGY
LA English
DT Article; Retracted Publication
DE melt atomization; tin powder
ID GAS ATOMIZATION; SIZE; BISMUTH
AB The gas atomization process used for metal powder production has been studied using a low melting point metal: tin. The influence of two experimental atomization parameters (gas flow rate and gas pressure) and the possibility to preview the particle mean diameter with the Lubanska equation are investigated. The ability of spray processing to control and produce well defined metal powders with both the desired particle size range and shape is discussed. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Metz, Renaud; Machado, Celine; Houabes, Mourad; Elkhatib, Mazen] UCB Lyon 1, SNPE Hydrazines Procedes, CNRS, UMR 5179,Lab Commun Lyon 1, F-69622 Villeurbanne, France.
   [Hassanzadeh, Mehrdad] AREVA, F-34965 Montpellier 2, France.
RP Metz, R (reprint author), UCB Lyon 1, SNPE Hydrazines Procedes, CNRS, UMR 5179,Lab Commun Lyon 1, Batiment Berhollet 731 3eme Etage,22 Ave Gaston B, F-69622 Villeurbanne, France.
EM metz@univ-lyon.fr
OI Houabes, Mourad/0000-0003-0258-0750
CR BEDDOW JK, 1977, POWDER MONOGRAPHS SC
   DATE UR, 1967, INT J POWDER METALL, V3, P49
   GOLDAEV IP, 1971, POROSHKOV METALL, V11, P9
   GUMMESON PU, 1972, POWDER METALL, V15, P67, DOI 10.1179/pom.1972.15.29.006
   Helmersson G, 1997, SCAND J METALL, V26, P93
   JUAREZISLAS J, 1999, J MATER SCI, V34, P1222
   KIM KY, 1971, AICHE J, V17, P575, DOI 10.1002/aic.690170318
   Lagutkin S, 2004, MAT SCI ENG A-STRUCT, V383, P1, DOI 10.1016/j.msea.2004.02.059
   Lawley A., 1978, POWDER METALLURGY PR
   LUBANSKA H, 1970, JOM-J MIN MET MAT S, V22, P45
   Metz R, 2004, J ELECTROCERAM, V13, P825, DOI 10.1007/s10832-004-5199-3
   Metz R, 2000, MATER CHEM PHYS, V63, P157, DOI 10.1016/S0254-0584(99)00227-8
   OZBILEN S, 2000, MET POWDER REP, V55, P36
   RAO KP, 1981, MODERN DEV POWDER ME, V12, P113
   TAMURA K, 1963, T NATL RES I MET, V5, P252
   UNAL A, 1987, MATER SCI TECH SER, V3, P1029
   VERHEIJEN PJT, 2001, STAT DISTRIBUTIONS P
   WIGG LD, 1964, J I FUEL, V11, P46
NR 18
TC 5
Z9 5
U1 2
U2 12
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0924-0136
J9 J MATER PROCESS TECH
JI J. Mater. Process. Technol.
PD JAN 1
PY 2008
VL 195
IS 1-3
BP 248
EP 254
DI 10.1016/j.jmatprotec.2007.05.006
PG 7
WC Engineering, Industrial; Engineering, Manufacturing; Materials Science,
   Multidisciplinary
SC Engineering; Materials Science
GA 249LW
UT WOS:000252230900032
DA 2018-12-27
ER

PT J
AU He, HB
   Yang, XZ
   Shi, MQ
   Zeng, XW
   Yang, J
   Wu, LM
   Li, LD
AF He, Haibo
   Yang, Xianzhe
   Shi, Mengqiong
   Zeng, Xiaowei
   Yang, Jun
   Wu, Limao
   Li, Lianda
TI RETRACTED: Protective effects of hydroxysafflor yellow A on acute and
   chronic congestive cardiac failure mediated by reducing ET-1, NOS and
   oxidative stress in rats (Retracted article. See vol. 61, pg. 685, 2009)
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID NITRIC-OXIDE SYNTHASE; LEFT-VENTRICULAR DYSFUNCTION; CHRONIC
   HEART-FAILURE; MYOCARDIAL-INFARCTION; GENE-EXPRESSION; PROBUCOL
AB The present study was conducted to investigate whether hydroxysafflor yellow A (HSYA) has a protective effect on acute and chronic heart failure (AHF/CHF) induced by ligation of the left anterior descending coronary artery for 3 h and 8 weeks, respectively. The rats were divided into the following groups: sham operation, coronary artery ligation (CAL), CAL+HSYA (100mg kg(-1) by gavage) and CAL+diltiazem (20mg kg(-1) by gavage). In the AHF model, heart function, as determined by haemodynamic studies and echocardiography, was improved significantly by pretreatment with HSYA or diltiazem. Significant reductions in elevated serum creatine phosphokinase, lactate dehydrogenase, malondialdehyde (MDA), glutamic oxalacetic transaminase, glutamic pyruvic transaminase and blood viscosity were observed, and the activity of serum superoxide dismutase (SOD) was enhanced (all P<0.01). In the CHF model, HSYA and diltiazem restored abnormal heart function, and completely suppressed the elevated plasma atrial natriuretic polypeptide (ANP) and endothelin-1 (ET-1), serum and left-ventricular tissue inducible nitric oxide (NO) synthase (iNOS), NO and MDA, and improved the decrease in SOD. HSYA and diltiazem improved cardiac performance in AHF and reduced cardiac remodelling in CHF by reducing tissue weight indices: left ventricular weight/body weight (BW), right ventricular weight/BW, kidney weight/BW and lung weight/BW, and attenuating increases in infarct size, inner diameter of the left ventricle and collagen volume fraction in non-infarcted areas, and the decrease in mean wall thickness of infarcted myocardium. These results suggest that HSYA exerted beneficial actions in cardiac performance in models of both AHF and CHF, mainly by suppressing ET-1, iNOS and oxidative stress in infarcted tissue.
C1 [He, Haibo; Yang, Xianzhe; Zeng, Xiaowei; Yang, Jun; Wu, Limao; Li, Lianda] Zhejiang Univ, Inst Chinese Herb Med, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Shi, Mengqiong] Ctr Med Sci Anal, Hangzhou 310053, Zhejiang, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Inst Chinese Herb Med, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM wulimao@zju.edu.cn
CR AN XQ, 1990, CHIN TRADIT HERB DRU, V21, P188
   CHEN DB, 2005, LISHIZHEN MED MAT ME, V16, P828
   CHEN DB, 2006, RES PRACT CHIN MED, V19, P24
   CHRIS MT, 2001, ANN PHARMACOTHER, V35, P1066
   DAI DZ, 1995, J CHIN PHARM U, V26, P291
   Ding SS, 2002, CARDIOVASC RES, V53, P963, DOI 10.1016/S0008-6363(01)00558-2
   Fukuchi M, 1998, CIRCULATION, V98, P132, DOI 10.1161/01.CIR.98.2.132
   GAO GM, 1990, CHIN TRDIT HERB DRUG, V21, P188
   Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161
   He HB, 2007, J PHARM PHARMACOL, V59, P977, DOI 10.1211/jpp.59.7.0010
   JAY NC, 2000, J AM COLL CARDIOL, V35, P569
   JIN M, 2006, CHIN TRAD HERBAL DRU, V16, P665
   Jin Ming, 2004, Zhongguo Zhong Yao Za Zhi, V29, P447
   JOHN MM, 2002, CIRCULATION, V105, P2099
   Kinugawa S, 2000, CIRC RES, V87, P392
   KOBAYASHI N, 2002, J HYPERTENS, V20, P2355
   KOU QA, 2006, TRAD CHIN DRUG RES C, V17, P294
   LI XZ, 2006, CHINESE PHARMACOL B, V22, P537
   LIANG XT, 2004, SCIENCE 2, P102
   Liu F., 1992, Acta Pharmaceutica Sinica, V27, P785
   Maki T, 2001, CARDIOVASC RES, V51, P608, DOI 10.1016/S0008-6363(01)00258-9
   Mason RB, 2000, J NEUROSURG, V93, P99, DOI 10.3171/jns.2000.93.1.0099
   MESELHY MR, 1993, CHEM PHARM BULL, V41, P1796
   Miller Alan B., 2001, Cardiology Clinics, V19, P195, DOI 10.1016/S0733-8651(05)70207-1
   Morgan EE, 2004, AM J PHYSIOL-HEART C, V287, pH2049, DOI 10.1152/ajpheart.00393.2004
   Nakamura R, 2002, CIRCULATION, V106, P362, DOI 10.1161/01.CIR.0000021430.04195.51
   Okere IC, 2006, HYPERTENSION, V48, P1116, DOI 10.1161/01.HYP.0000248430.26229.0f
   PU Y, 2005, CHIN HERBAL MED, V35, P374
   Saavedra WF, 2002, CIRC RES, V90, P297, DOI 10.1161/hh0302.104531
   Sandmann S, 1998, CARDIOVASC RES, V39, P339, DOI 10.1016/S0008-6363(98)00087-X
   SHAN HL, 2004, CHIN J CLIN REHABIL, V25, P243
   Sia YT, 2002, CIRCULATION, V105, P2549, DOI 10.1161/01.CIR.0000016721.84535.00
   Soeki T, 2005, J AM COLL CARDIOL, V45, p420A
   SONG Y, 2005, J CHIN PHARM SCI, V14, P181
   Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939
   Takimoto Y, 2000, INT J CARDIOL, V76, P135, DOI 10.1016/S0167-5273(00)00394-6
   [田京伟 Tian Jingwei], 2003, [中草药, Chinese Traditional and Herbal Drugs], V34, P741
   WANG YP, 1995, CHIN J THORAC CARDIO, V11, P176
   Wei XB, 2005, NEUROSCI LETT, V386, P58, DOI 10.1016/j.neulet.2005.05.069
   XIAO WY, 2006, P CLIN MED J, V15, P646
   XU CH, 2005, CHIN J CLIN REHABIL, V43, P93
   Zang Bao-xia, 2002, Yaoxue Xuebao, V37, P696
   ZHENG WC, 2005, CHINA TRAD CHIN MED, V12, P36
   [郑为超 Zheng Weichao], 2005, [中国药理学通报, Chinese Pharmacological Bulletin], V21, P978
   ZHENG ZB, 2003, CHINA TRAD CHIN MED, V10, P290
   ZHENG ZB, 2000, CHINA PHARM REPORT, V16, P290
NR 46
TC 25
Z9 29
U1 4
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JAN
PY 2008
VL 60
IS 1
BP 115
EP 123
DI 10.1211/jpp.60.1.0015
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 262ML
UT WOS:000253152500015
PM 18088512
DA 2018-12-27
ER

PT J
AU Niu, YP
   Li, LD
   Wu, LM
AF Niu, Yang-Ping
   Li, Lian-Da
   Wu, Li-Mao
TI RETRACTED: Beta-aescin: A potent natural inhibitor of proliferation and
   inducer of apoptosis in human chronic myeloid leukemia K562 cells in
   vitro (Retracted Article. See vol 50, pg 1061, 2009)
SO LEUKEMIA & LYMPHOMA
LA English
DT Article; Retracted Publication
DE Chinese horse chestnut (Aesculus chinensis); beta-aescin; human chronic
   myeloid leukemia K562 cells; cell proliferation; cell apoptosis
ID VENOUS INSUFFICIENCY; TRITERPENOID SAPONINS; PRODUCTS; EXTRACT; GROWTH;
   MICE
AB Beta-aescin, a natural triterpenoid saponin isolated from the seed of Chinese horse chestnut (Aesculus chinensis), is known to generate a wide variety of biochemical and pharmacological effects. In the present study, the authors investigated the anti-proliferative and apoptotic effects of beta-aescin in human chronic myeloid leukemia K562 cell line invitro. The anti-proliferative effects were detected by CFU-K562 colony formation and cell viability assay. The apoptotic effects were analysed by morphological analysis, annexin V assay, DNA fragmentation assay and flow cytometry DNA content analysis. The results showed that beta-aescin exhibited potent dose- and time-dependent anti-proliferative effects in K562 cells. Morphological evidence of apoptosis, a significant increase of annexin V+ and PI- cells (early apoptotic) and apoptotic DNA fragmentation, were observed in cells treated with beta-aescin. Flow cytometry analysis revealed that beta-aescin could lead to an accumulation of sub G1 population in K562 cells, and suggesting a potential G1 phase accumulation in cell cycle profile of K562 cells. Our findings revealed that beta-aescin is a potent natural inhibitor of proliferation and inducer of apoptosis in K562 cells, and beta-aescin may be a candidate lead compound to explore potential antileukemia drugs.
C1 [Niu, Yang-Ping] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310032, Zhejiang, Peoples R China.
   [Niu, Yang-Ping; Li, Lian-Da; Wu, Li-Mao] Zhejiang Univ, Coll Pharmaceut Sci, Inst Tradit Chinese Med, Hangzhou 310058, Zhejiang, Peoples R China.
RP Niu, YP (reprint author), Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310032, Zhejiang, Peoples R China.
EM niuyangping@hotmail.com; wulimao@zju.edu.cn
CR ARENDS MJ, 1990, AM J PATHOL, V136, P593
   BERTI F, 1977, PROSTAG OTH LIPID M, V14, P241, DOI 10.1016/0090-6980(77)90169-1
   Diehm C, 1996, LANCET, V347, P292, DOI 10.1016/S0140-6736(96)90467-5
   FACINO RM, 1995, ARCH PHARM, V328, P720, DOI 10.1002/ardp.19953281006
   Gaidi G, 2002, J NAT PROD, V65, P1568, DOI 10.1021/np020105a
   Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098
   HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506
   KIKUCHI Y, 1991, ANTI-CANCER DRUG, V2, P63, DOI 10.1097/00001813-199102000-00009
   Lacaille-Dubois MA, 2000, STUD NAT PROD CHEM, V21, P633
   Lee YN, 1996, EUR J CANCER, V32A, P1420, DOI 10.1016/0959-8049(96)00102-5
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Matsuda H, 2000, LIFE SCI, V66, P2233, DOI 10.1016/S0024-3205(00)00551-8
   Mujoo K, 2001, CANCER RES, V61, P5486
   MURAKI K, 1992, PFLUG ARCH EUR J PHY, V420, P461, DOI 10.1007/BF00374620
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Niu Yang-Ping, 2001, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V9, P178
   Niu Yang-ping, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P450
   Niu Yang-ping, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P127
   Park JA, 1997, CANCER LETT, V121, P73, DOI 10.1016/S0304-3835(97)00333-9
   Patiolla JMR, 2006, MOL CANCER THER, V5, P1459, DOI 10.1158/1535-7163.MCT-05-0495
   Pearson P J, 1993, Rev Physiol Biochem Pharmacol, V122, P1, DOI 10.1007/BFb0035273
   Pittler MH, 1998, ARCH DERMATOL, V134, P1356, DOI 10.1001/archderm.134.11.1356
   Reddy L, 2003, PHARMACOL THERAPEUT, V99, P1, DOI 10.1016/S0163-7258(03)00042-1
   Sirtori CR, 2001, PHARMACOL RES, V44, P183, DOI 10.1006/phrs.2001.0847
   Suter A, 2006, ADV THER, V23, P179, DOI 10.1007/BF02850359
   TODE T, 1993, J CANCER RES CLIN, V120, P24, DOI 10.1007/BF01200720
   TUTTON PJM, 1980, BRIT J CANCER, V41, P47, DOI 10.1038/bjc.1980.6
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Yang Xiu-Wei, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P31
   Yui S, 2001, INT IMMUNOPHARMACOL, V1, P1989, DOI 10.1016/S1567-5769(01)00126-6
NR 30
TC 21
Z9 28
U1 4
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PY 2008
VL 49
IS 7
BP 1384
EP 1391
DI 10.1080/10428190802090151
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA 322AS
UT WOS:000257348200025
PM 18452082
DA 2018-12-27
ER

PT J
AU Zhang, XG
   Zhou, LG
   Chen, B
   Hu, SY
   Wachtel, MS
   Frezza, EE
AF Zhang, Xiuguo
   Zhou, Liguang
   Chen, Bo
   Hu, Sanyuan
   Wachtel, Mitchell S.
   Frezza, Eldo E.
TI RETRACTED: Microwave ablation with cooled-tip electrode for liver
   cancer: An analysis of 160 cases (Retracted article. See vol. 18, pg.
   373, 2009)
SO MINIMALLY INVASIVE THERAPY & ALLIED TECHNOLOGIES
LA English
DT Article; Retracted Publication
DE Microwave; ablation; catheter; liver cancer; ultrasonography
ID HEPATOCELLULAR-CARCINOMA; COAGULATION THERAPY
AB A novel microwave electrode with a cooled tip (FORSEA MTC-3 type, China) was devised to better enable microwave ablation of liver cancers. The efficacy of this technology was evaluated. The records of 160 patients (97 with hepatoma, 63 with metastatic cancer of the liver) who had undergone microwave ablation with this new device were reviewed. One-year survival in 86 patients whose follow-up had been more than one year was determined. Pre-operative and post-operative contrast-enhanced CT scans were performed to assess completion of therapy and the presence or absence of recurrent tumor. For patients with hepatoma, serum alpha-fetoprotein (AFP) levels were evaluated pre-operatively and, if elevated, post-operatively. A median two (range one to five) applications were required per session. All patients exhibited initial radiographic resolution of their lesions after therapy. The ablated areas were not enhanced in any phases of contrast CT scan. Eight patients required a second microwave therapy for recurrent tumor, two patients required a third treatment. Twenty-five patients with hepatoma had elevated AFP (104.2 +/- 22.5 ng/ml), which, after microwave ablation, recovered to normal or almost normal (24.6 +/- 3.6 ng/ml) (t = 2.1, p < 0.05). There were no post-operative deaths. Complications included fever in three of four patients, successfully treated with indomethacin, elevated transaminases in four of five patients, requiring no treatment except for those with pre-operative ascites (who were dialyzed), pleural effusions in fourteen patients, only one of whom required drainage, and obstructive jaundice requiring drainage in two patients. The one-year survival rate was 91.9%. Microwave ablation with this novel cooled-tip electrode is safe, minimally invasive and effective. The tool may greatly expand the fraction of patients with liver cancer who might be candidates for microwave ablation.
C1 [Zhang, Xiuguo] Shandong Univ, Qilu Hosp, Dept Gen Surg, E Ward 5, Jinan 250012, Peoples R China.
   [Zhou, Liguang] Shandong Prov Hosp, Dept Ultrasonog, Jinan, Peoples R China.
   [Wachtel, Mitchell S.] Texas Tech Univ Hlth Sci Ctr, Dept Pathol, Lubbock, TX USA.
   [Frezza, Eldo E.] Texas Tech Univ Hlth Sci Ctr, Dept Gen Surg, Lubbock, TX USA.
RP Chen, B (reprint author), Shandong Univ, Qilu Hosp, Dept Gen Surg, E Ward 5, 107 Wenhua W Rd, Jinan 250012, Peoples R China.
EM chenbo_780721@hotmail.com
CR Dong BW, 1998, AM J ROENTGENOL, V171, P449, DOI 10.2214/ajr.171.2.9694473
   Kuang M, 2007, RADIOLOGY, V242, P914, DOI 10.1142/radiol.2423052028
   Liu YJ, 2006, INT J HYPERTHER, V22, P491, DOI 10.1080/02656730600905686
   Lu MD, 2001, RADIOLOGY, V221, P167, DOI 10.1148/radiol.2211001783
   Ng KKC, 2003, J GASTROEN HEPATOL, V18, P616, DOI 10.1046/j.1440-1746.2003.02991.x
   Rossi P, 2007, MINIM INVASIV THER, V16, P66, DOI 10.1080/13645700701191511
   SEKI T, 1994, CANCER, V74, P817, DOI 10.1002/1097-0142(19940801)74:3<817::AID-CNCR2820740306>3.0.CO;2-8
   Tateishi R, 2005, CANCER, V103, P1201, DOI 10.1002/cncr.20892
   Xu HX, 2005, CLIN RADIOL, V60, P1018, DOI 10.1016/j.crad.2005.04.009
   Yang D, 2007, IEEE T BIO-MED ENG, V54, P150, DOI 10.1109/TBME.2006.884647
NR 10
TC 4
Z9 8
U1 3
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1364-5706
EI 1365-2931
J9 MINIM INVASIV THER
JI Minim. Invasive Ther. Allied Technol.
PY 2008
VL 17
IS 5
BP 303
EP 307
DI 10.1080/13645700802383926
PG 5
WC Surgery
SC Surgery
GA 362WJ
UT WOS:000260227600006
PM 18942003
DA 2018-12-27
ER

PT J
AU Donev, RM
   Sivasankar, B
   Mizuno, M
   Morgan, BP
AF Donev, Rossen M.
   Sivasankar, Baalasubrarnanian
   Mizuno, Masashi
   Morgan, B. Paul
TI RETRACTED: The mouse complement regulator CD59b is significantly
   expressed only in testis and plays roles in sperm acrosome activation
   and motility (Retracted article. See vol. 58, pg. 150, 2014)
SO MOLECULAR IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE mouse; CD59a; CD59b; complement; reproductive immunology; acrosome
ID PRIMER-TEMPLATE MISMATCHES; FUNCTIONAL-CHARACTERIZATION; TISSUE
   DISTRIBUTION; DISEASE SEVERITY; DEFICIENCY; MICE; INJURY; MODEL;
   LOCALIZATION; SPERMATOZOA
AB \In mouse, genes encoding complement regulators CD55 and CD59 have been duplicated. The first described form of CD59, CD59a, is broadly distributed in mouse tissues, while the later identified CD59b was originally described as testis specific. Subsequent studies have been contradictory, some reporting widespread and abundant expression of CD59b. Resolution of the distribution patterns of the CD59 isoforms is important for interpretation of disease studies utilising CD59 knockout mice. Here we have performed a comprehensive distribution study of the CD59 isoforms at the mRNA and protein levels. These data confirm that expression of CD59b is essentially restricted to adult testis; trace expression in other tissues is a consequence of contamination with blood cells, shown previously to express CD59b at low level. In testis, onset of expression of CD59b coincided with puberty and was predominant on the spermatozoal acrosome. Ligation of CD59b, but not CD59a, markedly reduced spermatozoal motility, suggesting a specific role in reproductive function. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales.
RP Donev, RM (reprint author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales.
EM donevrm@cardiff.ac.uk; morganbp@cardiff.ac.uk
RI Donev, Rossen/C-5105-2009
FU Medical Research Council [G0700102]; Wellcome Trust [068590]
CR Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684
   Christopherson C, 1997, NUCLEIC ACIDS RES, V25, P654, DOI 10.1093/nar/25.3.654
   Harris CL, 2003, IMMUNOLOGY, V109, P117, DOI 10.1046/j.1365-2567.2003.01628.x
   Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442
   KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999
   Lin F, 2004, J IMMUNOL, V172, P2636, DOI 10.4049/jimmunol.172.4.2636
   LOFFERT D, 1998, QIAGEN NEWS, V2, P3
   Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015
   MERI S, 1990, IMMUNOLOGY, V71, P1
   Mizuno M, 2005, BIOL REPROD, V72, P908, DOI 10.1095/biolreprod.104.035485
   Mizuno M, 2004, BIOL REPROD, V71, P1374, DOI 10.1095/biolreprod.104.030114
   Powell MB, 1997, J IMMUNOL, V158, P1692
   Qian YM, 2000, J IMMUNOL, V165, P2528, DOI 10.4049/jimmunol.165.5.2528
   Qin X, 2006, GENES IMMUN, V7, P287, DOI 10.1038/sj.gene.6364296
   Qin XB, 2005, J IMMUNOL, V175, P6294, DOI 10.4049/jimmunol.175.10.6294
   Qin XB, 2004, DIABETES, V53, P2653, DOI 10.2337/diabetes.53.10.2653
   Qin XB, 2003, IMMUNITY, V18, P217, DOI 10.1016/S1074-7613(03)00022-0
   Qin XB, 2001, MAMM GENOME, V12, P582, DOI 10.1007/s00335-001-2060-8
   SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749
   Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7
   Turnberg D, 2003, J AM SOC NEPHROL, V14, P2271, DOI 10.1097/01.ASN.0000083901.47783.2E
   Williams AS, 2004, ARTHRITIS RHEUM-US, V50, P3035, DOI 10.1002/art.20478
NR 22
TC 24
Z9 27
U1 3
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JAN
PY 2008
VL 45
IS 2
BP 534
EP 542
DI 10.1016/j.molimm.2007.05.011
PG 9
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 221TE
UT WOS:000250249400023
PM 17597212
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Azebaze, AGB
   Ouahouo, BMW
   Vardamides, JC
   Valentin, A
   Kuete, V
   Acebey, L
   Beng, VP
   Nkengfack, AE
   Meyer, M
AF Azebaze, A. G. B.
   Ouahouo, B. M. W.
   Vardamides, J. C.
   Valentin, A.
   Kuete, V.
   Acebey, L.
   Beng, V. P.
   Nkengfack, A. E.
   Meyer, M.
TI RETRACTED: Antimicrobial and antileishmanial xanthones from the stem
   bark of Allanblackia gabonensis (Guttiferae) (Retracted article. See
   vol. 22, pg. 333, 2008)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE guttiferae; allanblackia; Allanxanthone D; xanthones; antileishmania
   and; antimicrobial activities
ID NATURAL-PRODUCTS; PRENYLATED XANTHONE; EXTRACTIVES
AB The phytochemical study of stem bark of Allanblackia gabonensis has resulted in the isolation and characterisation of one new xanthone derivative, named allanxanthone D, together with 10 known compounds, including 6 xanthones derivatives, allanxanthone A, 1,5-dihydroxyxanthone, 1,7-dihydroxyxanthone and 1,3,6,7-tetrahydroxy-2-(3-methylbut-2-enyl)xanthone, forbexanthone, 6-deoxyisojacareubin, one polyisoprenylated benzophenone, guttiferone F, one flavanol, epicathechin, two phytosterols, -sitosterol and campesterol. The structures of these compounds were established on the basis of one- and two-dimensional NMR homo- and hetero-nuclear evidence. These compounds were evaluated for their activity against Leishmania amazonensis in vitro and antimicrobial activities against a range of Gram negative and Gram positive bacteria.
C1 [Azebaze, A. G. B.; Vardamides, J. C.] Univ Douala, Fac Sci, Dept Chem, Douala, Cameroon.
   [Ouahouo, B. M. W.; Nkengfack, A. E.] Univ Yaounde I, Dept Organ Chem, Fac Sci, Yaounde, Cameroon.
   [Valentin, A.; Acebey, L.] Univ Toulouse 3, Fac Pharm, UMR 152, IRD UPS, F-31062 Toulouse, France.
   [Kuete, V.; Beng, V. P.] Univ Yaounde I, Fac Sci, Dept Biochem, Yaounde, Cameroon.
   [Meyer, M.] CNRS, UMR 5154, USM 0502,MNHN, Lab Chim & Biochim Subst Nat, F-75005 Paris, France.
RP Azebaze, AGB (reprint author), Univ Douala, Fac Sci, Dept Chem, POB 24157, Douala, Cameroon.
EM azebaze@yahoo.com
RI Valentin, Alexis/I-6821-2015
OI Valentin, Alexis/0000-0002-2133-112X; Kuete, Victor/0000-0002-1070-1236
CR Azebaze AGB, 2006, CHEM PHARM BULL, V54, P111, DOI 10.1248/cpb.54.111
   Azebaze AGB, 2004, PHYTOCHEMISTRY, V65, P2561, DOI 10.1016/j.phytochem.2004.07.027
   BAMPS P, 1969, B JARDIN BOT NATL BE, V1030, P347
   BAMPS P, 1970, SPERMAPHITES GUTTIFE, V1
   Fuller RW, 1999, J NAT PROD, V62, P130, DOI 10.1021/np9801514
   Fuller RW, 1999, J NAT PROD, V62, P67, DOI 10.1021/np980152w
   Hay AE, 2004, J NAT PROD, V67, P707, DOI 10.1021/np0304971
   JACKSON B, 1967, J CHEM SOC C, P785, DOI 10.1039/j39670000785
   Jullian V, 2005, BIOORG MED CHEM LETT, V15, P5065, DOI 10.1016/j.bmcl.2005.07.090
   KHOON HL, 1989, PHYTOCHEMISTRY, V28, P1099
   KIJJOQ A, 2002, PHYTOCHEMISTRY, V53, P1021
   LOCKSLEY HD, 1966, J CHEM SOC C, P430, DOI 10.1039/j39660000430
   Nkengfack AE, 2002, PHYTOCHEMISTRY, V60, P381, DOI 10.1016/S0031-9422(02)00036-5
   RAPONDAWALKER A, 1976, PLANTES UTILES GABON, V216
   Salem MM, 2006, CURR MED CHEM, V13, P2571, DOI 10.2174/092986706778201611
   SEN AK, 1981, PHYTOCHEMISTRY, V20, P183, DOI 10.1016/0031-9422(81)85250-8
   Sereno D, 1997, ANTIMICROB AGENTS CH, V41, P972, DOI 10.1128/AAC.41.5.972
   Stern JL, 1996, J CHEM ECOL, V22, P1877, DOI 10.1007/BF02028510
   TAO WF, 2004, TIANRAN CHANWU YANJI, V16, P26
   VIVIEN J, 1995, ESPECES CAMEROUN, V119
   Zgoda JR, 2001, PHARM BIOL, V39, P221, DOI 10.1076/phbi.39.3.221.5934
NR 21
TC 10
Z9 10
U1 3
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PY 2008
VL 22
IS 4
BP 333
EP 341
DI 10.1080/14786410701855811
PG 9
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 270PW
UT WOS:000253733700006
PM 18322848
DA 2018-12-27
ER

PT J
AU Kan, CW
AF Kan, C. W.
TI RETRACTED: Interaction of laser on some textile properties of
   poly(ethylene terephthalate) (Retracted article. See vol. 267, pg. 3491,
   2009)
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM
   INTERACTIONS WITH MATERIALS AND ATOMS
LA English
DT Article; Retracted Publication
DE poly(ethylene terephthalate); surface; laser; textile
ID EXCIMER-LASER; SYNTHETIC-FIBERS; SURFACE-PROPERTIES; IRRADIATION;
   TEREPHTHALATE; POLYMERS; PLASMA
AB In this paper, effects on some textile properties of poly(ethylene terephthalate) (PET) due to laser irradiation were studied. Properties included fibre weight and diameter, tensile strength and elongation, yarn abrasion, bending, surface lustre, wetting, air permeability as well as crystallinity. Properties such as wettability and air permeability were positively affected but some properties such as fibre weight and diameter, tensile strength, yarn abrasion and bending properties were adversely affected. In this paper, the laser irradiation used could not affect the bulk property of polymer due to its low penetration depth, and hence, the effect of the laser irradiation on the bulk and structural properties was limited. However, the performance and comfort properties of the laser irradiated PET could be largely affected by laser irradiation as these properties could have been changed considerably if the surface was modified. (C) 2007 Elsevier B.V. All rights reserved.
C1 Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China.
RP Kan, CW (reprint author), Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China.
EM tccwk@inet.polyu.edu.hk
OI Kan, Chi-wai/0000-0002-7668-2410
CR ANDREW JE, 1983, APPL PHYS LETT, V43, P717, DOI 10.1063/1.94488
   BAHNERS T, 1990, J APPL PHYS, V68, P1854, DOI 10.1063/1.346623
   BAHNERS T, 1989, J APPL PHYS, V66, P1884, DOI 10.1063/1.344371
   BAHNERS T, 1993, APPL SURF SCI, V69, P12, DOI 10.1016/0169-4332(93)90474-P
   Csete M, 1998, APPL SURF SCI, V133, P5, DOI 10.1016/S0169-4332(98)00192-5
   DYER PE, 1986, APPL PHYS LETT, V48, P445, DOI 10.1063/1.96526
   Kan CW, 2006, J APPL POLYM SCI, V102, P5958, DOI 10.1002/app.25165
   Knittel D, 1997, POLYM INT, V43, P231, DOI 10.1002/(SICI)1097-0126(199707)43:3<231::AID-PI797>3.0.CO;2-E
   Knittel D, 1998, POLYM INT, V45, P103, DOI 10.1002/(SICI)1097-0126(199801)45:1<103::AID-PI917>3.0.CO;2-2
   Knittel D, 1997, POLYM INT, V43, P240, DOI 10.1002/(SICI)1097-0126(199707)43:3<240::AID-PI798>3.0.CO;2-9
   Lau KS, 1997, J MATER PROCESS TECH, V63, P524, DOI 10.1016/S0924-0136(96)02677-5
   Lippert T, 1997, APPL SURF SCI, V109, P227, DOI 10.1016/S0169-4332(96)00663-0
   TODA T, 1995, POLYMER, V36, P699, DOI 10.1016/0032-3861(95)93097-6
   Wong W, 2000, J MATER PROCESS TECH, V103, P225, DOI 10.1016/S0924-0136(00)00470-2
   Wong W, 2001, MATER RES INNOV, V4, P344, DOI 10.1007/s100190000116
   Wong W, 2001, TEXT RES J, V71, P117, DOI 10.1177/004051750107100205
   WONG W, 1999, RES J TEXT APPAREL, V3, P1
NR 17
TC 5
Z9 5
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-583X
EI 1872-9584
J9 NUCL INSTRUM METH B
JI Nucl. Instrum. Methods Phys. Res. Sect. B-Beam Interact. Mater. Atoms
PD JAN
PY 2008
VL 266
IS 1
BP 79
EP 85
DI 10.1016/j.nimb.2007.10.014
PG 7
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Atomic, Molecular & Chemical; Physics, Nuclear
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA 261LN
UT WOS:000253080300014
DA 2018-12-27
ER

PT J
AU Knapp, W
   Schmitt, P
AF Knapp, Wolfgang
   Schmitt, Peter
TI RETRACTED: Discourse on 'metropolitan driving forces' and 'uneven
   development': Germany and the RhineRuhr conurbation (Retracted article.
   See vol. 43, pg. 156, 2009)
SO REGIONAL STUDIES
LA English
DT Article; Retracted Publication
DE uneven development; re-scaling; metropolitan regions; polycentricity;
   metropolitan governance; strategic planning
ID WESTERN-EUROPE; SCALE; GLOBALIZATION; POLITICS; REGIONS; URBAN
AB This paper provides a contribution to the debate on re-scaling and uneven development from the point of view of the governance of spatial development. Its main purpose is not to advance new theoretical perspectives on 're-scaling' and 'uneven development', but rather to reflect on those notions in the context of the actual reworking of territorial space in Germany, and the attempts to establish a regime of metropolitan regions as 'driving forces' of growth and international competitiveness. The paper examines Germany's inherited and newly emerging polycentric landscape of metropolitan regions, and the distinct division of metropolitan functions that have developed among them. More specifically, it discusses the re-scaling process within Germany's biggest conurbation, RhineRuhr, and the obvious difficulties faced in creating metropolitan governance structures. It is argued that this can (also) be ascribed to the uneven socio-economic development within RhineRuhr, which has so far impeded a more synergetic, multi-scalar approach to making better use of urban complementarities at the regional scale.
C1 [Knapp, Wolfgang] ILS Res Inst Reg & Urban Dev GmbH, D-44339 Dortmund, Germany.
   [Schmitt, Peter] Nordregio Nord Ctr Spatial Dev, SE-11186 Stockholm, Sweden.
RP Knapp, W (reprint author), ILS Res Inst Reg & Urban Dev GmbH, Deutsch Str 5, D-44339 Dortmund, Germany.
EM wolfgang.knapp@ils.nrw.de; peter.schmitt@nordregio.se
CR AMIN A, 1992, INT J URBAN REGIONAL, V16, P571, DOI 10.1111/j.1468-2427.1992.tb00197.x
   Aring J., 2005, AUSGLEICH VERSUS WAC, P39
   BBR-Bundesamt fur Bauwesen und Raumordnung, 2005, RAUM 2005, V21
   Beaverstock JV, 1999, CITIES, V16, P445, DOI 10.1016/S0264-2751(99)00042-6
   *BFAG BBR BMVBW, 2005, LEITB HANDL RAUM DEU
   Blotevogel H.H., 2005, HANDWORTERBUCH RAUMO, V4, P642
   Blotevogel H. H., 2000, METROPOLEN LAB MODER, P139
   BLOTEVOGEL HH, 2006, LEITLINIEN NIEDERSAC
   BLOTEVOGEL HH, 2006, AGGLOMERATIONEN SITU, V325, P5
   BLOTEVOGEL HH, 2006, GEOGRAPHISCHE RUNDSC, V58, P28
   *BMBAU, 1995, RAUM HANDL 1995
   *BMBAU, 1993, RAUM OR LEITB RAUML
   *BMBAU, 1995, GRUNDL EUR RAUM
   *BMVBS, 2006, LEITB HANDL RAUM DTS
   *BMVBW, 2005, STOLP WEICH MOB WACH
   *BMVBW, 2005, WEIT RAUM LEITB HAND
   Brenner N, 2000, EUR URBAN REG STUD, V7, P319, DOI 10.1177/096977640000700403
   Brenner N, 1997, PUBLIC CULTURE, V10, P135, DOI 10.1215/08992363-10-1-135
   Brenner N, 2004, REV INT POLIT ECON, V11, P447, DOI 10.1080/0969229042000282864
   Brenner N, 2003, EUR URBAN REG STUD, V10, P297, DOI 10.1177/09697764030104002
   Brenner N, 1997, POLIT GEOGR, V16, P273, DOI 10.1016/S0962-6298(96)00003-0
   Brenner N., 2004, NEW STATE SPACES URB
   Castells M., 1989, INFORM CITY INFORM T
   Castells Manuel, 2000, INFORM AGE EC SOC CU, V1
   Collinge C, 1999, ENVIRON PLANN D, V17, P557, DOI 10.1068/d170557
   *DTSCH BUND, 1994, RAUM 1993
   *EUR COMM, 1999, EUR SPAT DEV PERSP B
   Frey R.L., 2005, DISP, V161, P5
   FRIEDMANN J, 1986, DEV CHANGE, V17, P69, DOI 10.1111/j.1467-7660.1986.tb00231.x
   FRIEDMANN J, 1995, WORLD CITIES WORLD S, P21, DOI DOI 10.1017/CBO9780511522192
   FROMMER H, 2004, STAT NACHRICHTEN STA, V2, P4
   Hahn Seokyung, 2005, BMC Med Res Methodol, V5, P10, DOI 10.1186/1471-2288-5-10
   Hahne U, 2005, RAUMFORSCH RAUMORDN, V63, P257, DOI 10.1007/BF03183812
   Hall P., 2006, POLYCENTRIC METROPOL
   Harvey D, 1985, SOCIAL RELATIONS SPA, P128
   Harvey David, 1982, LIMITS CAPITAL
   HOYLER M, 2002, TAGUNGSBERICHT WISSE, V53, P76
   Hubler KH, 2005, RAUMFORSCH RAUMORDN, V63, P55
   *IKM, 2005, STELL IN EUR METR DE
   *IKM, 2003, STRAT 31
   *IKM, 2006, STELL IN EUR METR DE
   IKM-Initiativkreis Europaische Metropolregionen in Deutschland, 2006, REG MON 2006 DAT KAR
   Jessop B, 2000, INT J URBAN REGIONAL, V24, P323, DOI 10.1111/1468-2427.00251
   Jessop B, 1999, WARW ST GLOBAL, P19
   JESSOP B, 1999, RETHINKING STATE MIL, P185
   Knapp W, 2004, EUR PLAN STUD, V12, P323, DOI 10.1080/0965431042000195047
   Knapp W., 2006, BUILT ENV, V32, P137
   Knapp W., 2006, POLYCENTRIC METROPOL, P154
   KRATKE S, 2004, Z WIRTSCHAFTSGEOGR, V48, P145
   Lefebvre H., 1991, PRODUCTION SPACE
   Massey Do-reen, 1985, SPATIAL DIVISIONS LA
   *METREX, 2004, POS PAP FUT STRUCT F
   Priebs Axel, 2004, NEUES ARCH NIEDERSAC, V2, P101
   *REG NRW BUND ARB, 2004, DAT FAKT
   Sassen S., 1991, GLOBAL CITY
   SASSEN S, 1993, CITIES WORLD EC
   SCHMITT P, 2001, OTB HOUSING URBAN PO, V18, P78
   SCHMITT P, 2003, OTB HOUSING URBAN PO, V25, P154
   Schmitt P., 2007, RAUMPOLITISCHE DISKU
   Schmitz G, 2005, RAUMFORSCH RAUMORDN, V63, P360, DOI 10.1007/BF03183096
   Scott A, 2001, GLOBAL CITY REGIONS, P11
   Scott AJ, 2001, EUR PLAN STUD, V9, P813, DOI 10.1080/09654310120079788
   Scott AJ, 1996, FUTURES, V28, P391, DOI 10.1016/0016-3287(96)00016-X
   SMITH N, 1995, COMPETITIVE EUROPEAN, P169
   Smith Neil, 1984, UNEVEN DEV
   Stiens G., 2000, INFORM RAUMENTWICKLU, V9, P517
   Storper M, 1989, CAPITALIST IMPERATIV
   SWYNGEDOUW E, 1997, PERSPECT ECON CHANGE, P137
   Swyngedouw E, 1992, CITIES REGIONS NEW E, P39
   Taylor P. J., 2004, WORLD CITY NETWORK G
   TAYLOR PJ, 2005, 11 C SPAT PLANN N RH
   ZIMMERMANN H, 2005, AUSGLEICH VERSUS WAC, V10, P12
NR 72
TC 6
Z9 6
U1 2
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0034-3404
EI 1360-0591
J9 REG STUD
JI Reg. Stud.
PY 2008
VL 42
IS 8
BP 1187
EP 1204
DI 10.1080/00343400801932292
PG 18
WC Economics; Environmental Studies; Geography
SC Business & Economics; Environmental Sciences & Ecology; Geography
GA 353WN
UT WOS:000259599800010
DA 2018-12-27
ER

PT J
AU Auler, JOC
   Galas, FRBG
   Sundin, MR
   Hajjar, LA
AF Auler, Jose Otavio C., Jr.
   Galas, Filomena R. B. G.
   Sundin, Marcia R.
   Hajjar, Ludhmila A.
TI RETRACTED: Arterial pulse pressure variation predicting fluid
   responsiveness in critically ill patients (Retracted article. See vol.
   31, pg. 542, 2009)
SO SHOCK
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 4th International Sepsis Symposium
CY MAY, 2007
CL Sao Paulo, BRAZIL
SP Brazilian Shock Soc, Latin Amer Sepsis Inst
DE dynamic; parameters; stroke volume variation; fluid responsiveness
ID PLETHYSMOGRAPHIC DYNAMIC INDEXES; SEPTIC VENTILATED PATIENTS;
   GOAL-DIRECTED THERAPY; MECHANICAL VENTILATION; CARDIAC-SURGERY;
   CLINICAL-TRIAL; TIDAL VOLUME; RESTRICTION; MANAGEMENT; CHALLENGE
AB In critically ill patients, it is important to predict which patients will have their systemic blood flow increased in response to volume expansion to avoid undesired hypovolemia and fluid overloading. Static parameters such as the central venous pressure, the pulmonary arterial occlusion pressure, and the left ventricular end-diastolic dimension cannot accurately discriminate between responders and nonresponders to a fluid challenge. In this regard, respiratory-induced changes in arterial pulse pressure have been demonstrated to accurately predict preload responsiveness in mechanically ventilated patients. Some experimental and clinical studies confirm the usefulness of arterial pulse pressure as a useful tool to guide fluid therapy in critically ill patients.
C1 [Auler, Jose Otavio C., Jr.; Galas, Filomena R. B. G.; Sundin, Marcia R.; Hajjar, Ludhmila A.] Univ Sao Paulo, Fac Med, Hosp Clin, Inst Heart,Dept Anesthesia & Surg Intens Care, Sao Paulo, Brazil.
RP Auler, JOC (reprint author), Univ Sao Paulo, Fac Med, Hosp Clin, Inst Heart,Dept Anesthesia & Surg Intens Care, Sao Paulo, Brazil.
EM auler@incor.usp.br
RI Auler Junior, Jose Otavio Costa/C-4492-2017; Hajjar,
   Ludhmila/K-3512-2017
OI Auler Junior, Jose Otavio Costa/0000-0002-3919-1743; 
CR Auler JO, 2008, ANESTH ANALG, V106, P1201, DOI 10.1213/01.ane.0000287664.03547.c6
   Bendjelid K, 2003, INTENS CARE MED, V29, P352, DOI 10.1007/s00134-002-1615-9
   Bliacheriene F, 2007, ACTA ANAESTH SCAND, V51, P1268, DOI 10.1111/j.1399-6576.2007.01432.x
   Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23
   Bundgaard-Nielsen M, 2007, ACTA ANAESTH SCAND, V51, P331, DOI 10.1111/j.1399-6576.2006.01221.x
   CANNESSON M, 2007, CRIT CARE MED, V11, P105
   Cannesson M, 2007, ANESTHESIOLOGY, V106, P1105, DOI 10.1097/01.anes.0000267593.72744.20
   Charron C, 2006, ANESTH ANALG, V102, P1511, DOI 10.1213/01.ane.0000209015.21418.f4
   Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2
   De Backer D, 2005, INTENS CARE MED, V31, P517, DOI 10.1007/s00134-005-2586-4
   Feissel M, 2005, CRIT CARE MED, V33, P2534, DOI 10.1097/01.CCM.0000186415.43713.2F
   Feissel M, 2007, INTENS CARE MED, V33, P993, DOI 10.1007/s00134-007-0602-6
   Hadian M, 2007, CURR OPIN CRIT CARE, V13, P318, DOI 10.1097/MCC.0b013e32811e14dd
   Hofer CK, 2005, CHEST, V128, P848, DOI 10.1378/chest.128.2.848
   Jardin F, 2004, INTENS CARE MED, V30, P1047, DOI 10.1007/s00134-004-2254-0
   Kramer A, 2004, CHEST, V126, P1563, DOI 10.1378/chest.126.5.1563
   Kumar A, 2004, CRIT CARE MED, V32, P691, DOI 10.1097/01.CCM.0000114996.681110.C9
   Lafanechere A, 2006, CRIT CARE, V10, DOI 10.1186/cc5044
   Lopes MR, 2007, CRIT CARE, V11, DOI 10.1186/cc6117
   Lopes Marcel Rezende, 2006, Clinics, V61, P345, DOI 10.1590/S1807-59322006000400012
   MacKay G, 2006, BRIT J SURG, V93, P1469, DOI 10.1002/bjs.5593
   Michard F, 2002, CHEST, V121, P2000, DOI 10.1378/chest.121.6.2000
   Michard F, 2000, AM J RESP CRIT CARE, V162, P134, DOI 10.1164/ajrccm.162.1.9903035
   Michard F, 2005, ANESTHESIOLOGY, V103, P419, DOI 10.1097/00000542-200508000-00026
   Monnet X, 2006, CRIT CARE MED, V34, P1402, DOI 10.1097/01.CCM.0000215453.11735.06
   Monnet X, 2007, CURR OPIN CRIT CARE, V13, P549, DOI 10.1097/MCC.0b013e3282ec68b2
   Monnet X, 2006, CURR OPIN CRIT CARE, V12, P235, DOI 10.1097/01.ccx.0000224868.86205.53
   Natalini G, 2006, ANESTH ANALG, V103, P1478, DOI 10.1213/01.ane.0000246811.88524.75
   Nisanevich V, 2005, ANESTHESIOLOGY, V103, P25, DOI 10.1097/00000542-200507000-00008
   Osman D, 2007, CRIT CARE MED, V35, P64, DOI 10.1097/01.CCM.0000249851.94101.4F
   Preisman S, 2005, BRIT J ANAESTH, V95, P746, DOI 10.1093/bja/aei262
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Solus-Biguenet H, 2006, BRIT J ANAESTH, V97, P808, DOI 10.1093/bja/ael250
   Tyberg JV, 2000, RESP PHYSIOL, V119, P171, DOI 10.1016/S0034-5687(99)00112-7
   Vieillard-Baron A, 2004, INTENS CARE MED, V30, P1734, DOI 10.1007/s00134-004-2361-y
   Vincent JL, 2006, CRIT CARE MED, V34, P1333, DOI 10.1097/01.CCM.0000214677.76535.A5
   Westphal GA, 2006, SHOCK, V26, P140, DOI 10.1097/01.shk.0000227439.76418.7d
NR 37
TC 14
Z9 16
U1 3
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PY 2008
VL 30
SU 1
BP 18
EP 22
DI 10.1097/SHK.0b013e3181818708
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 351JM
UT WOS:000259420600005
PM 18704014
DA 2018-12-27
ER

PT J
AU Aguilera-Manzano, JM
AF Aguilera-Manzano, Jose Maria
TI RETRACTED: Slavery and medicine in the Caribbean at the end of the
   Ancien Regime (Retracted article. See vol. 35, pg. 251, 2010)
SO SOCIAL HISTORY
LA English
DT Article; Retracted Publication
ID PHILOSOPHY
AB .
C1 Florida Int Univ, Miami, FL 33199 USA.
RP Aguilera-Manzano, JM (reprint author), Florida Int Univ, Miami, FL 33199 USA.
CR ARAVAMUDAN S, 1993, DIACRITICS, V23, P48, DOI 10.2307/465400
   Benitez-Rojo Antonio, 1996, REPEATING ISLAND CAR, P33
   Bernasconi Robert, 2001, CONCEPTS RACE 18 CEN
   BEWELL A, 1999, SLAVERY ABOLITION EM
   Buchan W, 1769, DOMESTIC MED FAMILY
   BUFFON GLL, 1781, NATURAL HIST GEN PAR, V3, P151
   Canizares-Esguerra Jorge, 2001, WRITE HIST NEW WORLD
   Chaplin JE, 1997, WILLIAM MARY QUART, V54, P229, DOI 10.2307/2953318
   CHARLEVOIX PFX, 1731, HIST ISLE ESPAGNOLE
   CHATEAUSALINS HB, 1831, VADEMECUM HACENDADOS
   Collins David, 1803, PRACTICAL RULES MANA
   Dain Bruce, 2002, HIDEOUS MONSTER MIND
   DAZILLE JB, 1776, OBSERVATIONS MALADIE
   DOMINGO FBY, 1953, REFLEXIONES HIST FIS, V11, P64
   Esguerra JC, 1999, AM HIST REV, V104, P33, DOI 10.2307/2650180
   Flouret Michele, 1985, PRATIQUES CORPS MED, P141
   Gerbi A., 1973, DISPUTE NEW WORLD HI
   GONZALEZRIPOLL MD, 1999, CUBA ISLA ENSAYOS CU, P196
   GRAINGER J, 1764, ESSAY MORE COMMON W
   HUNT LA, 1996, FRENCH REVOLUTION HU, P52
   Jackson Stanley W., 1986, MELANCHOLIA DEPRESSI, P373
   Jacques TC, 1997, HIST THEORY, V36, P190, DOI 10.1111/0018-2656.00010
   JOHNSON S, 2001, SOCIAL TRANSFORMATIO, P181
   KAEMPFER E, 1712, AMOENITATUM EXOTICAR, P524
   KIPLE K., 1984, CARIBBEAN SLAVE BIOL
   Kitson Peter, 1999, SLAVERY ABOLITION EM, V8
   ROSEN G, 1975, CLIO MED, V10, P32
   Saakwa-Mante N., 1999, RACE SCI MED 1700 19, P29
   SANCHEZ JL, 1974, ANALES ACAD CIENCIAS, pR3
   SCHEUCHZER JJ, 1731, NOSTALGIA BONONIENSI, P307
   SHERIDAN Richard B, 1985, DOCTORS SLAVES MED D
   STOLER L, 1995, RACE ED DESIRE FOUCA, P15
   TEJERO VM, 2000, CONDE ARANDA TIEMPO, V1, P374
   Weaver K. K., 2004, FRENCH COLONIAL HIST, V5, P93
   Weaver KK, 2002, B HIST MED, V76, P429, DOI 10.1353/bhm.2002.0149
NR 35
TC 1
Z9 1
U1 1
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0307-1022
EI 1470-1200
J9 SOC HIST
JI Soc. Hist.
PY 2008
VL 33
IS 4
BP 383
EP +
AR PII 905235261
DI 10.1080/03071020802410312
PG 20
WC History
SC History
GA 370MX
UT WOS:000260767400001
DA 2018-12-27
ER

PT J
AU Kim, JH
   Lee, MR
   Kim, JH
   Jee, MK
   Kang, SK
AF Kim, Jeong Hwan
   Lee, Mi Ran
   Kim, Jee Hun
   Jee, Min Ki
   Kang, Soo Kyung
TI RETRACTED: IFATS Collection: Selenium Induces Improvement of Stem Cell
   Behaviors in Human Adipose-Tissue Stromal Cells via SAPK/JNK and
   Stemness Acting Signals (Retracted article. See vol. 31, pg. 2848, 2013)
SO STEM CELLS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 5th Annual Scientific Meeting of the
   International-Federation-of-Adipose-Therapeutics-and-Science
CY OCT 18-20, 2007
CL Indianapolis, IN
SP Int Federat Adipose Therapet & Sci
DE Dedifferentiation; Selenium; Adipose tissue stromal cells
ID SPINAL-CORD-INJURY; RADIAL-GLIA; PLANT-CELLS; ADULT-RATS; ASTROCYTES;
   DIFFERENTIATION; DEDIFFERENTIATION; TRANSFORMATION; PROLIFERATION;
   PROTOPLASTS
AB In the present study, the potential of selenium to enhance stem cell behavior through improvement of human adipose tissue-derived stromal cells (ATSCs) and the associated molecular mechanism was evaluated. Selenium-induced improvement in stem cell behavior of human ATSCs caused expression of several genes, indicating downregulated mature cell marker proteins coupled with increased cell growth and telomerase activities after the overexpression of Rex1, Nanog, OCT4, SOX2, KLF4, and c-Myc. Also, selenium-treated ATSCs significantly downregulated p53 and p21 tumor suppressor gene products. Selenium induced active growth and growth enhanced by the activation of signal proteins in ATSCs via the inhibition of reactive oxygen species-mediated phospho-stress-activated protein kinase/c-Jun N-terminal protein kinase activation. The selenium-induced activation of extracellular regulated kinases 1/2 and Akt in ATSCs resulted in a subsequent induction of the expression of stemness transcription factors, particularly Rex1, Nanog, and Oct4, along with definitive demethylation on regulatory regions of Rex-1, Nanog, and Oct4. The results of our small interfering RNA knockdown experiment showed that Rex1 plays a major role in the proliferation of selenium-induced ATSCs. Selenium-treated ATSCs also exhibited more profound differentiation into mesodermal and neural lineages. We performed a direct comparison of gene expression profiles in control ATSCs and selenium-treated ATSCs and delineated specific members of important growth factor, signaling, cell adhesion, and transcription factor families. The observations of improved life span and multipotency of selenium-treated ATSCs clearly indicate that selenium-treated ATSCs represent an extraordinarily useful candidate cell source for tissue regeneration. STEM CELLS 2008; 26: 2724-2734
C1 [Kim, Jeong Hwan; Lee, Mi Ran; Jee, Min Ki; Kang, Soo Kyung] Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea.
   [Kim, Jee Hun] Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea.
RP Kang, SK (reprint author), Pusan Natl Univ, Coll Med, Dept Physiol, 1-10 Ami Dong, Pusan 602739, South Korea.
EM skkang@pusan.ac.kr
CR Alves JAJ, 2002, J NEUROBIOL, V52, P251, DOI 10.1002/neu.10087
   Avivi Y, 2004, DEV DYNAM, V230, P12, DOI 10.1002/dvdy.20006
   BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5
   CASTROMALASPINA H, 1980, BLOOD, V56, P289
   Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k
   CRIQUI MC, 1992, MECH DEVELOP, V38, P121, DOI 10.1016/0925-4773(92)90004-4
   GIULIAN D, 1993, J NEUROSCI, V13, P29
   Grafi G, 2004, DEV BIOL, V268, P1, DOI 10.1016/j.ydbio.2003.12.027
   Grafi G, 2007, DEV BIOL, V306, P838, DOI 10.1016/j.ydbio.2007.03.023
   HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y
   Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962
   HATTEN ME, 1984, DEV BRAIN RES, V13, P309, DOI 10.1016/0165-3806(84)90166-4
   Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828
   HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061
   Huttmann K, 2003, EUR J NEUROSCI, V18, P2769, DOI 10.1046/j.1460-9568.2003.03002.x
   Imam SZ, 1999, BRAIN RES, V818, P575, DOI 10.1016/S0006-8993(98)01311-0
   JAMET E, 1990, CELL DIFFER DEV, V29, P37, DOI 10.1016/0922-3371(90)90022-O
   Kang SK, 2006, STEM CELLS DEV, V15, P583, DOI 10.1089/scd.2006.15.583
   Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982
   Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211
   Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3
   Patten BA, 2003, J NEUROSCI, V23, P6132
   PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X
   RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O
   ROSEN GD, 1994, DEV BRAIN RES, V82, P127, DOI 10.1016/0165-3806(94)90155-4
   ROSEN GD, 1992, J NEUROPATH EXP NEUR, V51, P601, DOI 10.1097/00005072-199211000-00005
   Schmid RS, 2003, P NATL ACAD SCI USA, V100, P4251, DOI 10.1073/pnas.0630496100
   SHEPARD JF, 1977, PLANT PHYSIOL, V60, P313, DOI 10.1104/pp.60.2.313
   Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8
   Soriano E, 1997, NEURON, V18, P563, DOI 10.1016/S0896-6273(00)80298-6
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TSAI CK, 1977, SCI SINICA, V20, P458
   Yeo JE, 2008, CELL PHYSIOL BIOCHEM, V21, P225, DOI 10.1159/000113764
   Zhao J, 2001, J BIOL CHEM, V276, P22772, DOI 10.1074/jbc.M101756200
   Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3
NR 38
TC 29
Z9 30
U1 10
U2 52
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PY 2008
VL 26
IS 10
BP 2724
EP 2734
DI 10.1634/stemcells.2008-0184
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 362DH
UT WOS:000260177900030
PM 18583539
OA Bronze
DA 2018-12-27
ER

PT J
AU Gadgeel, SM
   Ali, S
   Philip, PA
   Ahmed, F
   Wozniak, A
   Sarkar, FH
AF Gadgeel, Shirish M.
   Ali, Shadan
   Philip, Philip A.
   Ahmed, Fakhara
   Wozniak, Antoinette
   Sarkar, Fazlul H.
TI RETRACTED: Response to dual blockade of epidermal growth factor receptor
   (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent
   on the EGFR mutational status of the tumor (Retracted article. See vol.
   122, pg. 3248, 2016)
SO CANCER
LA English
DT Article; Retracted Publication
DE celecoxib; erlotinib; gefitinib; epidermal growth factor receptor
   mutations; nonsmall cell lung cancer
ID PHASE-II TRIAL; PROSTAGLANDIN E-2; TYROSINE KINASE; ERLOTINIB
   SENSITIVITY; GEFITINIB; CYCLOOXYGENASE-2; EXPRESSION; INHIBITOR;
   CARCINOMA; PATHWAYS
AB BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR-TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)-2 pathways are known to enhance the procarcinogenic effects of each other in different tumor types. Therefore, it was hypothesized that tumor EGFR mutation status may influence the effectiveness of simultaneous EGFR and COX-2 inhibition in patients with NSCLC.
   METHODS. Three NSCLC cell lines with varying EGFR mutation status and sensitivities to EGFR-TKIs were selected: H3255 (L858R), H1650 (del E746-A750), and H1781 (wild-type EGFR). Cells were treated with erlotinib, gefitinib, or celecoxib alone, and the combination of both EGFR-TKI inhibitors with celecoxib. Cell survival and apoptosis was assessed and correlated with the expression of COX-2, EGFR, pEGFR, Akt, pAkt, expression, and derived prostaglandin E2 (PGE(2)).
   RESULTS. Celecoxib by itself was found to have no effects on cell growth or apoptosis in any of the cell lines. Erlotinib and gefitinib inhibited cell growth and induced apoptosis in both mutant cell lines and did so in H1781 cells at 10-fold higher concentrations. Celecoxib when added to erlotinib or gefitinib significantly enhanced the antiproliferative and proapoptotic effects in both mutant cell lines but had no additional effects in H1781 cells. Greater down-regulation of COX-2, EGFR, pEGFR, Akt, pAkt, and PGE(2) was found when H3255 cells were treated with the combination compared with any of the single agents alone.
   CONCLUSIONS. The results of the current study demonstrate that the effectiveness of the addition of celecoxib to an EGFR-TKI is significantly greater in NSCLC cells with EGFR mutations, which is likely due to more complete inhibition of both pathways.
C1 [Gadgeel, Shirish M.; Ali, Shadan; Philip, Philip A.; Wozniak, Antoinette] Wayne State Univ, Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI USA.
   [Ahmed, Fakhara; Sarkar, Fazlul H.] Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Detroit, MI USA.
RP Gadgeel, SM (reprint author), Wayne State Univ, Karmanos Canc Ctr, Div Hematol Oncol, 4100 John R St,4 HWCRC, Detroit, MI 48201 USA.
EM gadgeels@karmanos.org
CR Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0
   Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200
   Cappuzzo F, 2005, J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112
   Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6
   DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D
   Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635
   Dowlati A, 2004, MOL CANCER THER, V3, P459
   Edwards BK, 2005, J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289
   Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038
   Gadgeel SM, 2007, J THORAC ONCOL, V2, P299, DOI 10.1097/01.JTO.0000263712.61697.69
   Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008
   GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791
   Griffin Graeme, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P543
   Hida T, 1998, CANCER RES, V58, P3761
   Hida T, 2000, CLIN CANCER RES, V6, P2006
   Janne PA, 2006, CLIN CANCER RES, V12, p4416S, DOI 10.1158/1078-0432.CCR-06-0555
   Kris MG, 2004, J CLIN ONCOL, V22, p631S
   Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149
   Lippman SM, 2005, CLIN CANCER RES, V11, P6097, DOI 10.1158/1078-0432.CCR-05-1217
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289
   PAZARES L, 2006, J CLIN ONCOL, V24, pS18
   Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057
   Peyton Michael J., 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P799
   Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078-0432.CCR-06-0112
   Sheng HM, 1998, CANCER RES, V58, P362
   Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637
   Subbaramaiah K, 1996, CANCER RES, V56, P4424
   Taketo MM, 1998, J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609
   Torrance CJ, 2000, NAT MED, V6, P1024
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   Wolff H, 1998, CANCER RES, V58, P4997
NR 37
TC 24
Z9 28
U1 3
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 15
PY 2007
VL 110
IS 12
BP 2775
EP 2784
DI 10.1002/cncr.23100
PG 10
WC Oncology
SC Oncology
GA 240FW
UT WOS:000251573600023
PM 17948911
OA Bronze
DA 2018-12-27
ER

PT J
AU Biris, AS
   Schmitt, TC
   Little, RB
   Li, Z
   Xu, Y
   Biris, AR
   Lupu, D
   Dervishi, E
   Trigwell, S
   Miller, DW
   Rahman, Z
AF Biris, Alexandru S.
   Schmitt, Thomas C.
   Little, Reginald B.
   Li, Zhongrui
   Xu, Yang
   Biris, Alexandru R.
   Lupu, Dan
   Dervishi, Enkeleda
   Trigwell, Steve
   Miller, Dwight W.
   Rahman, Zia
TI RETRACTED: Influence of the RF excitation of the catalyst system on the
   morphology of multiwalled carbon nanotubes (Retracted article. See vol.
   116, pg. 18571, 2012)
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article; Retracted Publication
ID GROWTH; CCVD; ACETYLENE; DECOMPOSITION; HYDROGEN; SUPPORT
AB Multiwalled carbon nanotubes were synthesized by catalytic chemical vapor deposition using two different methods of heating. By one method, an external resistive tube furnace was used, whereas the other method involved heating with radio frequency excitation by induction coil. A comprehensive comparison was made between these two methods with regards to feed gas utilization, nanotube growth efficiency, nanotube product characterization and morphology, and the formation of amorphous carbon and gaseous byproducts. The carbon nanotubes synthesized using radio frequency excitation exhibited smaller outer diameters, fewer carbon layers, less amorphous carbon, and superior crystalline properties than those produced by external tube furnace. The radio frequency process resulted in more rapid and sustained growth rates of the nanotubes and more efficient use of the carbon source. The reason for these enhanced effects by inductive heating may be due not only to the internally produced thermodynamic heat flow characteristics but perhaps also to induced electron currents generated within the magnetic and metallic catalytic clusters due to RF.
C1 Univ Arkansas, Nanotechnol Ctr, Little Rock, AR 72204 USA.
   Univ Arkansas, Dept Appl Sci, Little Rock, AR 72204 USA.
   US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
   Elizabeth City State Univ, Dept Chem, Elizabeth City, NC 27909 USA.
   Natl Inst Res & Dev Isotop & Mol Technol, R-400293 Cluj Napoca, Romania.
   NASA, Electrostat & Surface Phys Lab, Kennedy Space Ctr, Kennedy Space Ctr, FL 32899 USA.
   Univ Cent Florida, Adv Mat Proc & Anal Ctr, Orlando, FL 32826 USA.
RP Biris, AS (reprint author), Univ Arkansas, Nanotechnol Ctr, Little Rock, AR 72204 USA.
EM asbiris@ualr.edu
RI Dervishi, Enkeleda/B-2239-2010; Biris, Alexandru/A-8507-2010; Biris,
   Alexandru/C-4517-2011; Li, Zhongrui/D-6343-2018; Li,
   Zhongrui/I-4872-2017; Lupu, Dan/C-3346-2009
CR Ando Y, 2004, MATER TODAY, V7, P22, DOI 10.1016/S1369-7021(04)00446-8
   BACH RD, 1985, J AM CHEM SOC, V107, P2837, DOI 10.1021/ja00296a002
   Colomer JF, 1999, CHEM COMMUN, P1343, DOI 10.1039/a903142a
   Couteau E, 2003, CHEM PHYS LETT, V378, P9, DOI 10.1016/S0009-2614(03)01218-1
   Dal HJ, 1996, CHEM PHYS LETT, V260, P471, DOI 10.1016/0009-2614(96)00862-7
   Dresselhaus MS, 2002, CARBON, V40, P2043, DOI 10.1016/S0008-6223(02)00066-0
   GREGG GSB, 2006, J PHYS CHEM B, V110, P1179
   Hernadi K, 2003, MATER CHEM PHYS, V77, P536, DOI 10.1016/S0254-0584(02)00105-0
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   KITIAMA B, 2000, CHEM PHYS LETT, V17, P497
   Kwok K, 2006, DIAM RELAT MATER, V15, P1438, DOI 10.1016/j.diamond.2005.10.056
   Liang Q, 2001, CARBON, V39, P897, DOI 10.1016/S0008-6223(00)00193-7
   Little RB, 2003, J CLUST SCI, V14, P135, DOI 10.1023/A:1024841621054
   LITTLE RB, 2001, Patent No. 6761871
   Lupu D, 2004, CARBON, V42, P503, DOI 10.1016/j.carbon.2003.12.034
   Lupu D, 2002, PARTICUL SCI TECHNOL, V20, P225, DOI 10.1080/02726350290058056
   Okamoto A, 2005, CARBON, V43, P431, DOI 10.1016/j.carbon.2004.10.006
   Piao LY, 2002, CATAL TODAY, V74, P145, DOI 10.1016/S0920-5861(01)00540-5
   Sato S, 2003, CHEM PHYS LETT, V382, P361, DOI 10.1016/j.cplett.2003.10.076
   Schmitt TC, 2006, CARBON, V44, P2032, DOI 10.1016/j.carbon.2006.01.008
   Soneda Y, 2002, CARBON, V40, P965, DOI 10.1016/S0008-6223(02)00086-6
   Zaikovskii VI, 2001, KINET CATAL+, V42, P813, DOI 10.1023/A:1013235300777
NR 22
TC 18
Z9 18
U1 4
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD DEC 6
PY 2007
VL 111
IS 48
BP 17970
EP 17975
DI 10.1021/jp0740346
PG 6
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 236GV
UT WOS:000251291900046
DA 2018-12-27
ER

PT J
AU Liu, D
   Lin, J
   Xu, Y
   Huang, C
   Li, X
AF Liu, Dongsheng
   Lin, Junyue
   Xu, Yaping
   Huang, Changcang
   Li, Xinfa
TI RETRACTED:
   mu-Acetato-tri-mu-ferrocenecarboxylato-bis[(N,N-dimethylformamide)copper
   (II)] (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID MOLECULAR-STRUCTURE; CRYSTAL; COMPLEXES
AB The title compound, [Cu2Fe3(C5H5)(3)(C2H3O2)(C6H4O2)(3)-(C3H7NO)(2)], contains a dinuclear copper(II) paddlewheel unit, where the metal ions are bridged by the O atoms of three ferrocenecarboxylate groups and one acetate group. The crystal packing is mainly determined by van der Waals interactions.
C1 Fuzhou Univ, Dept Chem, Fujian 350002, Peoples R China.
   JingGangShan Univ, Dept Chem, Jian 343009, Peoples R China.
RP Huang, C (reprint author), Fuzhou Univ, Dept Chem, Fujian 350002, Peoples R China.
EM changcanghuang@hotmail.com
CR Chen BL, 2006, CRYST GROWTH DES, V6, P825, DOI 10.1021/cg050585e
   Chung YH, 1999, INORG CHEM COMMUN, V2, P269, DOI 10.1016/S1387-7003(99)00064-7
   CHURCHILL MR, 1985, INORG CHEM, V24, P2684, DOI 10.1021/ic00211a020
   ERRE LS, 1985, INORG CHEM, V24, P2297
   Maspoch D, 2002, CHEM COMMUN, P2958, DOI 10.1039/b208759f
   PORTER LC, 1984, INORG CHEM, V23, P997, DOI 10.1021/ic00176a002
   *RIG CORP, 1998, RAPID AUTO PC VERS
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   SHELDRICK GM, 1993, SHELXTL PC
   Viossat B, 2005, J INORG BIOCHEM, V99, P355, DOI 10.1016/j.jinorgbio.2004.10.001
NR 10
TC 1
Z9 1
U1 2
U2 17
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD DEC
PY 2007
VL 63
BP M3094
EP U2125
DI 10.1107/S1600536807059041
PN 12
PG 16
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300189
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: catena-Poly[[(nitrato-kappa O)(1,10-phenanthroline-kappa
   N-2,N ')cobalt(II)]-mu-acetamidato-kappa O-2 : N] (Retracted article.
   See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the crystal structure of the title compound, [Co(C2H4NO)( NO3)(C12H8N2)](n), the Co-II atoms are linked by acetamidate ligands to form a chain. Each Co-II atom is five-coordinated by two N atoms of a 1,10-phenanthroline ligand, one nitrate O atom, and one N atom and one O atom of an acetamidate ligand within a trigonal-bipyramidal coordination geometry. In the crystal structure, the chains are linked by hydrogen bonds into a polymeric ribbon structure.
C1 Jinggangshan Univ, Coll Engn, Jinggangshan 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jinggangshan 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2977, DOI 10.1107/S1600536807056504
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
NR 6
TC 0
Z9 0
U1 3
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M3144
EP U2558
DI 10.1107/S1600536807060631
PN 12
PG 10
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300227
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: catena-Poly[[(nitrato-kappa O)(1,10-phenanthroline-kappa
   N-2,N ')copper(II)]-mu-acetamido-kappa O-2 : N] (Retracted article. See
   vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the crystal structure of the title compound, [Cu(NO3)-(C2H4NO)(C12H8N2)](n), the Cu-II atoms are linked by acetamidate ligands, forming a chain. Each Cu II atom is fivecoordinated by two N atoms of the 1,10-phenanthroline ligand, one nitrate O atom, and one N and one O atoms of acetamidate in a trigonal-bipyramidal geometry. In the crystal structure, the chains are linked by hydrogen bonds into a polymeric ribbon structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2977, DOI 10.1107/S1600536807056504
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
NR 6
TC 0
Z9 0
U1 4
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M3108
EP U2239
DI 10.1107/S1600536807059077
PN 12
PG 10
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300199
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. -Y.
TI RETRACTED: catena-poly[[(nitrato-kappa O)(1,10-phenanthroline-kappa
   N-2,N ')nickel(II)]-mu-acetamido-kappa O-2 : N] (Retracted article. See
   vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID BENZAMIDES; DIOXYGEN; COMPLEX
AB In the crystal structure of the title compound, [Ni(C2H4NO)- (NO3)(C12H8N2)](n), the Ni-II atoms are linked by acetamidate ligands to form a chain. Each Ni-II atom is five-coordinated by two N atoms of a 1,10-phenanthroline ligand, one nitrate O atom, and one N and one O atom of acetamide within a bipyramidal coordination geometry. In the crystal structure, the chains are linked by hydrogen bonds into a polymeric ribbon structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Foster JE, 1999, BIOORGAN MED CHEM, V7, P2415, DOI 10.1016/S0968-0896(99)00185-6
   Harrop TC, 2003, CHEM COMMUN, P410, DOI 10.1039/b211395n
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Qi JY, 2003, CHEM COMMUN, P1294, DOI 10.1039/b301963b
   Qi JY, 2003, CHEM COMMUN, P1058, DOI 10.1039/b212899c
   Rauko P, 2001, EUR J PHARM SCI, V12, P387, DOI 10.1016/S0928-0987(00)00180-9
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
   Zhou YX, 1999, CHEMOMETR INTELL LAB, V45, P95, DOI 10.1016/S0169-7439(98)00092-6
NR 18
TC 2
Z9 2
U1 2
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2977
EP U1071
DI 10.1107/S1600536807056504
PN 12
PG 11
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300096
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: Tetrakis(pyridine-kappa N)bis(thiocyanato-kappa
   N)vanadium(II) (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title complex, [ V(NCS)(2)(C(5)H(5)N)(4)], the V(II) atom, located on a centre of inversion, is coordinated in a distorted octahedral arrangement by two N atoms of two SCN-and four N atoms of four pyridine ligands. In the crystal structure, C-H center dot center dot center dot N hydrogen bonds result in the formation of a supramolecular network.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2809, DOI 10.1107/S1600536807051756
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
NR 6
TC 0
Z9 0
U1 1
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2912
EP U510
DI 10.1107/S1600536807054529
PN 12
PG 9
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300046
DA 2018-12-27
ER

PT J
AU Liu, YQ
   Wen, HR
AF Liu, Yin-Qiu
   Wen, He-Rui
TI RETRACTED: Aqua(dimethylglyoxime-kappa N-2,N
   ')-(3,5-dinitro-2-oxidobenzoato-kappa O-2(1),O-2)copper(II) (Retracted
   article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title complex, [Cu( C7H2N2O7)(C4H8N2O2)(H2O)], is a mononuclear copper(II) compound. The Cu II ion is five-coordinated in a distorted pyramidal geometry by two N atoms from one dimethylglyoxime molecule, two O atoms from one 3,5-dinitro-2-oxidobenzoate ligand and one O atom from a water molecule. Strong hydrogen bonds connect adjacent molecules into a three-dimensional network.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Province Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   GanNan Teachers Coll, Dept Chem, GanZhou 343009, Peoples R China.
RP Liu, YQ (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Province Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM liuyiqja@163.com
CR *BRUK AXS INC, 1997, SMART VERS 2 10
   *BRUK AXS INC, 2003, SAINT VERS 7 06A
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Sui AX, 2006, ACTA CRYSTALLOGR E, V62, pM1592, DOI 10.1107/S1600536806022203
NR 5
TC 2
Z9 2
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2928
EP U648
DI 10.1107/S1600536807054244
PN 12
PG 10
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300059
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, CJ
   Li, ML
AF Zhong, H.
   Yang, X. -M.
   Luo, C. -J.
   Li, M. -L.
TI RETRACTED: (Dimethylglyoxime-kappa N-2,N ')bis(1,10-phenanthroline-kappa
   N-2,N ')copper(II) dinitrate dihydrate (Retracted article. See vol. 66,
   pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the cation of the title compound, [Cu(C12H8N2)(2)(C4H8N2O2)](NO3)(2)center dot 2H(2)O, the Cu atom has a distorted octahedral coordination formed by six N atoms from one dimethylglyoxime and two 1,10-phenanthroline ligands. In the crystal structure, components are linked into a three-dimensional framework by O - H center dot center dot center dot O and C - H center dot center dot center dot O hydrogen bonds and pi - pi stacking interactions [centroid - centroid distance 3.592 (4) angstrom].
C1 Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jinggangshan 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jinggangshan 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM639, DOI 10.1107/S1600536807004102
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM642, DOI 10.1107/S1600536807004096
NR 6
TC 1
Z9 1
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M3160
EP U2712
DI 10.1107/S1600536807061193
PN 12
PG 13
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300241
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Duan, SH
   Hong, YP
AF Zhong, H.
   Yang, X. -M.
   Duan, S. -H.
   Hong, Y. -P.
TI RETRACTED: catena-Poly[[tetra-mu-anilinoacetato-bis(1,10-phenanthroline)
   dieuropium(III)]di-mu- anilinoacetato] (Retracted article. See vol. 66,
   pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the crystal structure of the title compound, [Eu(2)(C(8)H(8)NO(2))(6)(C(12)H(8)N(2))(2)](n), the Eu(III) atoms are bridged by two tridentate, two bidentate and four mondentate carboxylate groups with an inversion centre between the two EuIII ions of this dinuclear structural unit. Each Eu atom is nine-coordinated by two 1,10-phenanthroline N atoms and seven O atoms of four anilinoacetate ligands. In the crystal structure, the chains are linked by C - H center dot center dot center dot N and C - H center dot center dot center dot O hydrogen bonds into a polymeric ribbon structure.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jinggangshan 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jinggangshan 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2772, DOI 10.1107/S1600536807051240
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2680, DOI 10.1107/S1600536807048489
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2508, DOI 10.1107/S1600536807043528
NR 8
TC 0
Z9 0
U1 5
U2 16
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M3142
EP U2548
DI 10.1107/S1600536807060643
PN 12
PG 14
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300226
DA 2018-12-27
ER

PT J
AU Zhong, H
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: Hexaaquacobalt(II) bis(4-aminobenzene-sulfonate) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The asymmetric unit of the title compound, [Co(H(2)O)(6)]-(C(6)H(6)NO(3)S)(2), contains one half-cation and one anion; the Co atom lies on an inversion centre. In the crystal structure, intermolecular O-H center dot center dot center dot O and O-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network. The conformation of the anion is stabilized by an intramolecular C-H center dot center dot center dot O hydrogen-bonding interaction.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM, 1996, SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2913, DOI 10.1107/S1600536807054372
NR 6
TC 0
Z9 0
U1 2
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M3054
EP U1766
DI 10.1107/S1600536807058527
PN 12
PG 9
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300157
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: catena-Poly[[(acetato-kappa O)(1,10-phenanthroline-kappa
   N-2,N ')nickel(II)]-mu-acetato-kappa O-2 : O '] (Retracted article. See
   vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the polymeric title complex, [Ni(C2H3O2)(2)(C12H8N2)](n), Ni-II ions are bridged by single syn-anti acetate ligands. Each Ni atom is five-coordinated by two 1,10-phenanthroline N atoms and three O atoms of acetate ligands in a distorted square-pyramidal coordination geometry. In the crystal structure, C-H center dot center dot center dot O hydrogen bonds result in the formation of a polymeric ribbon structure.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jianxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2895, DOI 10.1107/S1600536807053494
NR 5
TC 0
Z9 0
U1 6
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M3053
EP U1757
DI 10.1107/S1600536807058540
PN 12
PG 10
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300156
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zhong, QY
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Zhong, Q. -Y.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: Hexaaquazinc(II) bis(4-aminobenzenesulfonate) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The asymmetric unit of the title compound, [Zn(H(2)O)(6)](C(6)H(6)NO(3)S)(2), contains one half-cation and one anion; the Zn atom lies on an inversion centre. In the crystal structure, intermolecular O-H center dot center dot center dot O and O-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network; an intramolecular C-H center dot center dot center dot O hydrogen bond is also present.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jian Training Sch, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   SHELDRICK GM, 1997, SHELX97 SHELXL97
   *SIEM AN XR INSTR, 1996, SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2913, DOI 10.1107/S1600536807054372
NR 5
TC 0
Z9 0
U1 4
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2990
EP U1170
DI 10.1107/S1600536807056498
PN 12
PG 9
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300105
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: catena-poly[[(acetato-kappa O)(1,10-phenanthroline-kappa
   N-2,N ')copper(II)]-mu-acetato-kappa O-2 : O '] (Retracted article. See
   vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Cu(C2H3O2)(2)(C12H8N2)](n), is a polymeric complex involving bridging of Cu-II ions by single syn-anti acetate ligands. Each Cu atom is five-coordinated by two 1,10-phenanthroline N atoms and three O atoms of acetate ligands in a distorted square-pyramidal geometry. In the crystal structure, C-H center dot center dot center dot O hydrogen bonds result in the formation of a polymeric ribbon structure.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2895, DOI 10.1107/S1600536807053494
NR 5
TC 0
Z9 0
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2979
EP U1081
DI 10.1107/S160053680705622X
PN 12
PG 10
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300097
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zhong, QY
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Zhong, Q. Y.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: Hexaaquanickel(II) bis(4-aminobenzenesulfonate) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB The asymmetric unit of the title compound, [Ni(H(2)O)(6)]( C(6)H(6)NO(3)S)(2), contains one half-cation and one anion; the Ni atom lies on an inversion centre. In the crystal structure, intermolecular O-H center dot center dot center dot O and O-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network. The conformation of the anion is stabilized by an intramolecular C-H center dot center dot center dot O hydrogen-bonding interaction.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jian Training Sch, Jian 343000, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELXS97 SHELXL973
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 14
TC 2
Z9 2
U1 4
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2913
EP U520
DI 10.1107/S1600536807054372
PN 12
PG 10
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300047
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: catena-Poly[[(acetato-kappa O)(1,10-phenanthroline-kappa
   N-2,N ')cobalt(II)]-mu-acetato-kappa O-2 : O '] (Retracted article. See
   vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY; ACID
AB The title compound, [Co(C2H3O2)(2)(C12H8N2)](n), is a polymeric complex involving bridging of Co-II ions by single syn-anti acetate ligands. Each Co atom is five-coordinated by two 1,10-phenanthroline N atoms and three O atoms of acetate ligands within a bipyramidal coordination geometry. In the crystal structure, C-H center dot center dot center dot O hydrogen bonds result in the formation of a polymeric ribbon structure.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3167
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 17
TC 2
Z9 2
U1 2
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP M2895
EP U386
DI 10.1107/S1600536807053494
PN 12
PG 11
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300035
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: Ethylenediammonium perchlorate (Retracted article. See vol.
   66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB The the crystal structure of the title compound, C(2)H(9)N(2)(+)center dot ClO(4)(-), C - H center dot center dot center dot O, N - H center dot center dot center dot O and N - H center dot center dot center dot Cl hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XR INSTR, 1996, SMART SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 13
TC 0
Z9 0
U1 4
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP O4874
EP U6610
DI 10.1107/S1600536807059909
PN 12
PG 8
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300617
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. -Y.
TI RETRACTED: Ethylenediammonium sulfate (Retracted article. See vol. 66,
   pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB In the crystal structure of the title complex, C(2)H(10)N(2)(2+)center dot SO(4)(2-), C-H center dot center dot center dot O, N-H center dot center dot center dot O and N-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 13
TC 0
Z9 0
U1 2
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP O4660
EP U4600
DI 10.1107/S1600536807056280
PN 12
PG 9
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300419
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: N '-(3-nitro-4-pyridylcarbonyl)pyridine-4-carbohydrazide
   (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, C(12)H(9)N(5)O(4), the rings are oriented at a dihedral angle of 8.00 (2)center dot. In the crystal structure, intermolecular N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   I H, 2005, ACTA CRYSTALLOGR C, V61, pM19
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 11
TC 0
Z9 0
U1 2
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP O4574
EP U3821
DI 10.1107/S1600536807054876
PN 12
PG 9
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300340
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: N '-Benzoyl-4-nitronicotinohydrazide (Retracted article. See
   vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the crystal structure of the title compound, C(13)H(10)N(4)O(4), all bond lengths and angles are within normal ranges and the benzene and pyridine rings are oriented at a dihedral angle of 7.988 (4)degrees. N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Unic Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   *BRUK AXS INC, 2005, APEXW
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 12
TC 0
Z9 0
U1 2
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2007
VL 63
BP O4527
EP U3362
DI 10.1107/S1600536807053068
PN 12
PG 9
WC Crystallography
SC Crystallography
GA 236DD
UT WOS:000251282300298
DA 2018-12-27
ER

PT J
AU Yao, J
   Tang, HB
   Wang, HX
   Liu, C
   Liu, Y
AF Yao Jie
   Tang Hai-Bin
   Wang Hai-Xing
   Liu Chang
   Liu Yu
TI RETRACTED: Simulation of high energy plasma injecting effect on magnetic
   field inflation (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE particle in cell method; magnetic field inflation; dipole magnetic field
ID NUMERICAL-SIMULATION; EXPANSION; STABILITY
AB Using three-dimentional model, the hybrid particle in cell method is used to simulate the inflation of magnetic field by injecting plasma into dipole magnetic field. Two different types of magnetic field expansions are considered: the high density plasma is injected into a dipole magnetic field with or without a background magnetic field. It is found that the existence of background magnetic field not only changes the particle distribution, but also significantly changes the extent of magnetic field inflation. The effects of plasma injection velocity on the magnetic field inflation are also studied. It is shown that the higher the injection velocity, the larger is the size of the inflated magnetic bubble. For the lower injection velocity, the gyroradius of the injected particle is small compared with the dipole field scale length, so that the particles are trapped in the dipole field and the effect on dipole magnetic field can be ignored.
C1 [Yao Jie; Tang Hai-Bin; Wang Hai-Xing; Liu Chang; Liu Yu] Beijing Univ Aeronaut & Astronaut, Sch Astronaut, Beijing 100083, Peoples R China.
RP Yao, J (reprint author), Beijing Univ Aeronaut & Astronaut, Sch Astronaut, Beijing 100083, Peoples R China.
CR Chen M, 2006, ACTA PHYS SIN-CH ED, V55, P2381
   GALVEZ M, 1988, PHYS FLUIDS, V31, P1554, DOI 10.1063/1.866695
   HUBA JD, 1990, PHYS FLUIDS B-PLASMA, V2, P1676, DOI 10.1063/1.859441
   Jin XL, 2006, ACTA PHYS SIN-CH ED, V55, P5935
   SAHA S, 2003, THESIS U ALBAMA HUNS
   Tonge J, 2003, PHYS PLASMAS, V10, P3475, DOI 10.1063/1.1594188
   WINGLEE R, 2003, 36 JOINT PROP C EXH, P1
   Winglee RM, 2000, J GEOPHYS RES-SPACE, V105, P21067, DOI 10.1029/1999JA000334
   Winglee RM, 1998, GEOPHYS RES LETT, V25, P4441, DOI 10.1029/1998GL900217
   Winske D, 2005, PHYS PLASMAS, V12, DOI 10.1063/1.1947487
   WINSKE D, 1989, PHYS FLUIDS B-PLASMA, V1, P1900, DOI 10.1063/1.858922
   Xiong JG, 2000, ACTA PHYS SIN-CH ED, V49, P2420
NR 12
TC 0
Z9 0
U1 2
U2 10
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD DEC
PY 2007
VL 56
IS 12
BP 6899
EP 6904
PG 6
WC Physics, Multidisciplinary
SC Physics
GA 246PI
UT WOS:000252018900019
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Kong, DJ
   Banerjee, S
   Li, YW
   Adsay, NV
   Abbruzzese, J
   Sarkar, FH
AF Wang, Zhiwei
   Kong, Dejuan
   Banerjee, Sanjeev
   Li, Yiwei
   Adsay, N. Volkan
   Abbruzzese, James
   Sarkar, Fazlul H.
TI RETRACTED: Down-regulation of platelet-derived growth factor-D inhibits
   cell growth and angiogenesis through inactivation of notch-1 and nuclear
   factor kappa B signaling (Retracted article. See vol. 78, pg. 5469,
   2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID PANCREATIC-CANCER CELLS; RECEPTOR-RELATED PROTEIN; PDGF-D; MOUSE MODEL;
   EXPRESSION; INVASION; CARCINOMA; PHOSPHORYLATION; PROGRESSION;
   METASTASIS
AB Platelet-derived growth factor-D (PDGF-D) signaling plays critical roles in the pathogenesis and progression of human malignancies; however, the precise mechanism by which PDGF-D causes tumor cell invasion and angiogenesis remain unclear. Because Notch-1, nuclear factor-kappa B (NF-kappa B), vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMP) are critically involved in the processes of tumor cell invasion and metastasis, we investigated whether PDGF-D down-regulation could be mechanistically associated with the down-regulation of Notch-1, NF-kappa B, VEGF, and MMP-9, resulting in the inhibition of tumor cell invasion and angiogenesis. Our data showed that down-regulation of PDGF-D leads to the inactivation of Notch-1 and NF-kappa B DNA-binding activity and, in turn, down regulates the expression of its target genes, such as VEGF and MMP-9. We also found that the down-regulation of PDGF-D by small interfering RNA (siRNA) decreased tumor cell invasion, whereas PDGF-D overexpression by cDNA transfection led to increased cell invasion. Consistent with these results, we also found that the down-regulation of PDGF-D not only decreased MMP-9 mRNA and its protein expression but also inhibited the processing of pro-MMP-9 protein to its active form. Moreover, conditioned medium from PDGF-D siRNA-transfected cells showed reduced levels of VEGF and, in turn, inhibited the tube formation of human umbilical vascular endothelial cells, suggesting that down-regulation of PDGF-D leads to the inhibition of angiogenesis. Taken together, we conclude that the down-regulation of PDGF-D by novel approaches could lead to the down-regulation of Notch-1 and, in turn, inactivate NF-kappa B and its target genes (i.e., MMP-9 and VEGF), resulting in the inhibition of invasion and angiogenesis.
C1 Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.
   Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.
EM sarkarf@karmanos.org
RI Adsay, Volkan/N-7130-2017; Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [1P20-CA010193-01, 5R01CA101870-05]
CR Baker CH, 2006, INT J ONCOL, V29, P125
   Bongarzone ER, 2000, J NEUROSCI RES, V62, P319, DOI 10.1002/1097-4547(20001101)62:3<319::AID-JNR1>3.0.CO;2-G
   Cheon H, 2004, SCAND J IMMUNOL, V60, P455, DOI 10.1111/j.0300-9475.2004.01505.x
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   EBERT M, 1995, INT J CANCER, V62, P529, DOI 10.1002/ijc.2910620507
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323
   Hwang RF, 2003, CLIN CANCER RES, V9, P6534
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   LaRochelle WJ, 2002, CANCER RES, V62, P2468
   LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593
   Li H, 2003, ONCOGENE, V22, P1501, DOI 10.1038/sj.onc.1206223
   Li XR, 2003, CYTOKINE GROWTH F R, V14, P91, DOI 10.1016/S1359-6101(02)00090-4
   Lokker NA, 2002, CANCER RES, V62, P3729
   Miele L, 2006, CURR CANCER DRUG TAR, V6, P313, DOI 10.2174/156800906777441771
   Nagakawa Y, 2002, PANCREAS, V24, P169, DOI 10.1097/00006676-200203000-00008
   Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036
   Pohlers D, 2006, ARTHRITIS RHEUM-US, V54, P788, DOI 10.1002/art.21670
   Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742-4658.2005.04989.x
   Romashkova JA, 1999, NATURE, V401, P86
   Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902
   Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647
   Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005
   Ustach CV, 2004, CANCER RES, V64, P1722, DOI 10.1158/0008-5472.CAN-03-3047
   Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485
   Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265
   Wang ZW, 2006, CANCER RES, V66, P7653, DOI 10.1158/0008-5472.CAN-06-1019
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
   Wang ZW, 2006, MOL CANCER THER, V5, P483, DOI 10.1158/1535-7163.MCT-05-0299
   Wey JS, 2005, CANCER, V104, P427, DOI 10.1002/cncr.21145
   Xiong HQ, 2004, INT J CANCER, V108, P181, DOI 10.1002/ijc.11562
   Xu L, 2005, CANCER RES, V65, P5711, DOI 10.1158/0008-5472.CAN-04-4313
   Zhang YX, 2006, CANCER RES, V66, P1025, DOI 10.1158/0008-5472.CAN-05-2968
NR 34
TC 90
Z9 109
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2007
VL 67
IS 23
BP 11377
EP 11385
DI 10.1158/0008-5472.CAN-07-2803
PG 9
WC Oncology
SC Oncology
GA 238JQ
UT WOS:000251444100037
PM 18056465
OA Bronze
DA 2018-12-27
ER

PT J
AU Parthasarathy, S
   Manikandakumar, K
AF Parthasarathy, S.
   Manikandakumar, K.
TI RETRACTED: Multiple period-doubling bifurcation route to chaos in
   periodically pulsed Murali-Lakshmanan-Chua circuit-controlling and
   synchronization of chaos (Retracted Article. See vol 20, ARTN 039901,
   2010)
SO CHAOS
LA English
DT Article; Retracted Publication
ID DISSIPATIVE NONAUTONOMOUS CIRCUIT; STRANGE NONCHAOTIC ATTRACTORS;
   STOCHASTIC RESONANCE; UNIDIMENSIONAL MAPS; SYSTEM; PERTURBATIONS;
   FEEDBACK
AB We consider a simple nonautonomous dissipative nonlinear electronic circuit consisting of Chua's diode as the only nonlinear element, which exhibit a typical period doubling bifurcation route to chaotic oscillations. In this paper, we show that the effect of additional periodic pulses in this Murali-Lakshmanan-Chua (MLC) circuit results in novel multiple-period-doubling bifurcation behavior, prior to the onset of chaos, by using both numerical and some experimental simulations. In the chaotic regime, this circuit exhibits a rich variety of dynamical behavior including enlarged periodic windows, attractor crises, distinctly modified bifurcation structures, and so on. For certain types of periodic pulses, this circuit also admits transcritical bifurcations preceding the onset of multiple-period-doubling bifurcations. We have characterized our numerical simulation results by using Lyapunov exponents, correlation dimension, and power spectrum, which are found to be in good agreement with the experimental observations. Further controlling and synchronization of chaos in this periodically pulsed MLC circuit have been achieved by using suitable methods. We have also shown that the chaotic attractor becomes more complicated and their corresponding return maps are no longer simple for large n-periodic pulses. The above study also indicates that one can generate any desired n-period-doubling bifurcation behavior by applying n-periodic pulses to a chaotic system. (c) 2007 American Institute of Physics.
C1 [Parthasarathy, S.; Manikandakumar, K.] Bharathidasan Univ, Sch Life Sci, Dept Bioinformat, Tiruchchirappalli 620024, Tamil Nadu, India.
RP Parthasarathy, S (reprint author), Bharathidasan Univ, Sch Life Sci, Dept Bioinformat, Tiruchchirappalli 620024, Tamil Nadu, India.
EM bdupartha@gmail.com
CR BRAIMAN Y, 1991, PHYS REV LETT, V66, P2545, DOI 10.1103/PhysRevLett.66.2545
   CHUA LO, 1990, IEEE T CIRCUITS SYST, V37, P885, DOI 10.1109/31.55064
   Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223
   GRASSBERGER P, 1985, PHYSICA D, V17, P99
   GREBOGI C, 1984, PHYSICA D, V13, P261, DOI 10.1016/0167-2789(84)90282-3
   Guckenheimer J., 1983, NONLINEAR OSCILLATIO
   GUEMEZ J, 1993, PHYS LETT A, V181, P29, DOI 10.1016/0375-9601(93)91119-P
   HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953
   Lakshmanan M, 1996, CHAOS NONLINEAR OSCI
   LAKSHMANAN M, 2003, NONLINEAR DYNAMICS I
   LICHTENBERG AJ, 1983, REGULAR STOCHASTIC M
   LIMA R, 1990, PHYS REV A, V41, P726, DOI 10.1103/PhysRevA.41.726
   MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854
   MURALI K, 1993, PHYS REV E, V48, pR1624, DOI 10.1103/PhysRevE.48.R1624
   MURALI K, 1994, INT J BIFURCAT CHAOS, V4, P1511, DOI 10.1142/S0218127494001179
   MURALI K, 1995, INT J BIFURCAT CHAOS, V5, P563, DOI 10.1142/S0218127495000466
   MURALI K, 1992, IEEE T CIRCUITS SYST, V39, P263
   OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196
   Ott E., 1993, CHAOS DYNAMICAL SYST
   PARTHASARATHY S, 1995, PHYS REV E, V51, P6239, DOI 10.1103/PhysRevE.51.6239
   PARTHASARATHY S, 2004, DYN SYST, V4, P80
   PECORA LM, 1990, PHYS REV LETT, V64, P821, DOI 10.1103/PhysRevLett.64.821
   PECORA LM, 1991, PHYS REV A, V44, P2374, DOI 10.1103/PhysRevA.44.2374
   PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0
   Press William H., 1993, NUMERICAL RECIPES FO
   PYRAGAS K, 1992, PHYS LETT A, V170, P421, DOI 10.1016/0375-9601(92)90745-8
   RAJASEKAR S, 1993, PHYSICA D, V67, P282, DOI 10.1016/0167-2789(93)90211-I
   Rajasekar S, 1997, CHAOS SOLITON FRACT, V8, P1545, DOI 10.1016/S0960-0779(96)00154-3
   Summers D, 2000, CHAOS SOLITON FRACT, V11, P2331, DOI 10.1016/S0960-0779(99)00154-X
   Venkatesan A, 1999, PHYS LETT A, V259, P246, DOI 10.1016/S0375-9601(99)00456-9
   Venkatesan A, 1998, PHYS REV E, V58, P3008, DOI 10.1103/PhysRevE.58.3008
   VENKATESAN A, 2003, SOLITONS FRACTALS, V13, P261
   WOLF A, 1996, PHYSICA D, V77, P1751
NR 33
TC 2
Z9 2
U1 3
U2 14
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 1054-1500
J9 CHAOS
JI Chaos
PD DEC
PY 2007
VL 17
IS 4
AR 043120
DI 10.1063/1.2813010
PG 9
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA 246DK
UT WOS:000251987500029
PM 18163784
DA 2018-12-27
ER

PT J
AU Rudner, M
   Foo, C
   Ronnberg, J
   Lunner, T
AF Rudner, Mary
   Foo, Catharina
   Ronnberg, Jerker
   Lunner, Thomas
TI RETRACTED: Phonological mismatch makes aided speech recognition in noise
   cognitively taxing (Retracted Article. See vol 29, pg 814, 2008)
SO EAR AND HEARING
LA English
DT Article; Retracted Publication
ID HEARING-AID; AUDITORY ACCLIMATIZATION; PERFORMANCE; THRESHOLD; BENEFIT;
   PERIOD; SIGNAL; USERS; QUIET
AB Objectives: The working memory framework for Ease of Language Understanding predicts that speech processing becomes more effortful, thus requiring more explicit cognitive resources, when there is mismatch between speech input and phonological representations in long-term memory. To test this prediction, we changed the compression release settings in the hearing instruments of experienced users and allowed them to train for 9 weeks with the new settings. After training, aided speech recognition in noise, was tested with both the trained settings and orthogonal settings. We postulated that training would,lead to acclimatization to the trained setting, which in turn would involve establishment of new phonological representations in long-term memory. Further, we postulated that after training, testing with orthogonal settings would give rise to phonological mismatch, associated with more explicit cognitive processing.
   Design: Thirty-two participants (mean = 70.3 years, SD = 7.7) with bilateral sensorineural hearing loss (pure-tone average = 46.0 dB HL, SD = 6.5), bilaterally fitted for more than 1 year with digital, two-channel, nonlinear signal processing hearing instruments and chosen from the patient population at the Linkoping University Hospital were randomly assigned to 9 weeks training with new, fast (40 ms) or slow (640 ms), compression release settings in both channels. Aided speech recognition in noise performance was tested according to a design with three within-group factors: test occasion (T1, T2), test setting (fast, slow), and type of noise (un-modulated, modulated) and one between-group factor: experience setting (fast, slow) for two types of speech materials-the highly constrained Hagerman sentences and the less-predictable Hearing in Noise Test (HINT). Complex cognitive capacity was measured using the reading span and letter monitoring tests. Prediction: We predicted that speech recognition in noise at T2 with mismatched experience and test settings would be associated with more explicit cognitive processing and thus stronger correlations with complex cognitive measures, as well as poorer performance if complex cognitive capacity was exceeded.
   Results: Under mismatch conditions, stronger correlations were found between performance on speech recognition with the Hagerman sentences and reading span, along with poorer speech recognition for participants with low reading span scores. No consistent mismatch effect was found with HINT.
   Conclusions. The mismatch prediction generated by the working memory framework for Ease of Language Understanding is supported for speech recognition in noise with the highly constrained Hagerman sentences but not the less-predictable HINT.
C1 Linkoping Univ, Dept Behav Sci & Learning, Swedish Inst Disabil Res, SE-58183 Linkoping, Sweden.
   Linkoping Univ, Dept Tech Audiol, SE-58183 Linkoping, Sweden.
   Oticon AS, Res Ctr Eriksholm, Snekkersten, Denmark.
RP Rudner, M (reprint author), Linkoping Univ, Dept Behav Sci & Learning, Swedish Inst Disabil Res, SE-58183 Linkoping, Sweden.
EM mary.rudner@liu.se
OI Ronnberg, Jerker/0000-0001-7311-9959
CR Arlinger S, 1996, EAR HEARING, V17, pS87, DOI 10.1097/00003446-199617031-00009
   BLALOCK HM, 1972, SOCIAL STAT
   Brand T., 2000, ANAL OPTIMIZATION PS
   DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561
   Dillon H., 2001, HEARING AIDS
   Dreschler WA, 2001, AUDIOLOGY, V40, P148
   ELBERLING C, 1996, HEAR REV, V3, P38
   FOO C, 2007, J AM ACAD AUDIOL, V18, P553
   FOSTER J R, 1987, British Journal of Audiology, V21, P165, DOI 10.3109/03005368709076402
   Gatehouse S, 2006, INT J AUDIOL, V45, P153, DOI 10.1080/14992020500429484
   Gatehouse S, 2003, INT J AUDIOL, V42, pS77
   GATEHOUSE S, 1992, J ACOUST SOC AM, V92, P1258, DOI 10.1121/1.403921
   Gathercole SE, 2004, APPL COGNITIVE PSYCH, V18, P1, DOI 10.1002/acp.934
   HAGERMAN B, 1995, SCAND AUDIOL, V24, P71, DOI 10.3109/01050399509042213
   Hagerman B, 2002, INT J AUDIOL, V41, P321, DOI 10.3109/14992020209090406
   Hallgren M, 2006, INT J AUDIOL, V45, P227, DOI 10.1080/14992020500429583
   Humes LE, 2003, J SPEECH LANG HEAR R, V46, P137, DOI 10.1044/1092-4388(2003/011)
   Humes LE, 2002, J ACOUST SOC AM, V112, P1112, DOI 10.1121/1.1499132
   *IEC, 1997, IEC STAND 118 HEAR 2
   KNUTSON JF, 1991, ANN OTO RHINOL LARYN, V100, P877, DOI 10.1177/000348949110001103
   Kuk Francis K, 2003, J Am Acad Audiol, V14, P84, DOI 10.3766/jaaa.14.2.4
   Lunner T, 2003, INT J AUDIOL, V42, pS49
   Lunner T, 1997, EAR HEARING, V18, P373, DOI 10.1097/00003446-199710000-00003
   LUNNER T, 2007, J AM ACAD AUDIOL, V18, P539
   Lyxell B, 1998, SCAND J PSYCHOL, V39, P175, DOI 10.1111/1467-9450.393075
   LYXELL B, 1996, J DEAF STUD DEAF EDU, V1, P190, DOI DOI 10.1093/OXFORDJOURNALS.DEAFED.A014294
   Munro KJ, 2004, INT J AUDIOL, V43, P555, DOI 10.1080/14992020400050071
   Munro KJ, 2003, J ACOUST SOC AM, V114, P484, DOI 10.1121/1.1577556
   Naatanen R, 2004, CLIN NEUROPHYSIOL, V115, P140, DOI 10.1016/j.clinph.2003.04.001
   Nilsson LG, 2003, ACTA NEUROL SCAND, V107, P7, DOI 10.1034/j.1600-0404.107.s179.5.x
   NILSSON M, 1994, J ACOUST SOC AM, V95, P1085, DOI 10.1121/1.408469
   Philibert B, 2005, HEARING RES, V205, P131, DOI 10.1016/j.heares.2005.03.013
   Reber MB, 2005, AURIS NASUS LARYNX, V32, P345, DOI 10.1016/j.anl.2005.05.008
   RONNBERG J, 1989, J SPEECH HEAR RES, V32, P725
   RONNBERG J, 1993, EUR J COGN PSYCHOL, V5, P19, DOI 10.1080/09541449308406512
   Ronnberg J, 2003, INT J AUDIOL, V42, pS68
   Ronnberg J., 1990, EUROPEAN J COGNITIVE, V2, P253, DOI DOI 10.1080/09541449008406207
   RONNBERG JERKER, 2003, HDB DEAF STUDIES LAN, P478
   SCHUM D, 1996, HEAR J, V49, P28
   van Toor T, 2002, INT J AUDIOL, V41, P379, DOI 10.3109/14992020209090415
   WASS M, 2006, ASHA CONV MIAM BEACH
NR 41
TC 8
Z9 8
U1 3
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD DEC
PY 2007
VL 28
IS 6
BP 879
EP 892
DI 10.1097/AUD.0b013e3181576c9c
PG 14
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 228ZA
UT WOS:000250769900015
PM 17982373
DA 2018-12-27
ER

PT J
AU Liu, GD
   Lin, YY
   Wu, H
   Lin, Y
AF Liu, Guodong
   Lin, Ying-Ying
   Wu, Hong
   Lin, Yuehe
TI RETRACTED: Voltammetric detection of Cr(VI) with disposable
   screen-printed electrode modified with gold nanoparticles (Retracted
   Article. See vol 42, pg 3117, 2008)
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article; Retracted Publication
ID ADSORPTIVE STRIPPING VOLTAMMETRY; ATOMIC-ABSORPTION-SPECTROMETRY;
   INDUCTIVELY-COUPLED PLASMA; CARBON-PASTE ELECTRODE; HEXAVALENT CHROMIUM;
   INJECTION-ANALYSIS; FLOW SYSTEM; REDUCTION; WATER; SPECIATION
AB Gold nanoparticle (Au-NP) enhanced voltammetric detection of Cr(VI) is developed for determination of trace amounts of Cr(VI) in an acetate buffer media (pH 4.6). The Au-NPs were electrode posited onto a disposable screen printed electrode (SPE) via an electrode position step. It was found that the electrode posited Au-NP has strong adsorption on Cr(VI) species, which results in an enhanced reduction current of Cr(VI). Compared with the bulk gold electrode, the reduction current of COO was enhanced 10 times with the Au-NP-modified SPE electrode. Square wave voltammetric (SWV) measurement with the disposable Au-NP-modified SPE provides a fast, simple and sensitive detection of trace amounts of Cr(VI). The adsorption of Cr(VI) on Au-NP was characterized with voltammetry, X-ray photoelectron spectroscopy and ultraviolet spectra. The different parameters including the electrodepositing time, supporting electrolyte, and pH that govern the analytical performance of the electrode have been studied in detail and optimized. The detection limit of 5 mu g L(-1) Cr (VI) was obtained under optimum experimental conditions. The performance of the sensor was successfully evaluated with river water samples spiked with Cr(VI), indicating this convenient and sensitive technique offers great promise for onsite environmental monitoring and biomonitoring of Cr(VI).
C1 Pacific NW Natl Lab, Richland, WA 99352 USA.
RP Lin, Y (reprint author), Pacific NW Natl Lab, Richland, WA 99352 USA.
EM yuehe.lin@pnl.gov
FU NIEHS NIH HHS [1R01 ES010976-01A2]
CR AHERN F, 1985, ANAL CHIM ACTA, V175, P147, DOI 10.1016/S0003-2670(00)82726-9
   Balasubramanian S, 1999, TALANTA, V50, P457, DOI 10.1016/S0039-9140(99)00135-6
   BOUSSEMART M, 1992, ANAL CHIM ACTA, V262, P103, DOI 10.1016/0003-2670(92)80014-X
   Brett CMA, 2003, ANAL LETT, V36, P955, DOI 10.1081/AL-120019255
   Burke LD, 1997, ELECTROCHIM ACTA, V42, P399, DOI 10.1016/S0013-4686(96)00234-4
   Cathum S, 2002, ANAL BIOANAL CHEM, V373, P103, DOI 10.1007/s00216-002-1292-0
   CROSMUN ST, 1975, ANAL CHIM ACTA, V75, P199, DOI 10.1016/S0003-2670(01)81967-X
   Dai X, 2004, ANAL CHEM, V76, P5924, DOI 10.1021/ac049232x
   Danilov FI, 1998, RUSS J ELECTROCHEM+, V34, P276
   Dominguez O, 2002, ANAL CHIM ACTA, V470, P241, DOI 10.1016/S0003-2670(02)00757-2
   Donais MK, 1999, TALANTA, V49, P1045, DOI 10.1016/S0039-9140(99)00136-8
   El-Deab MS, 2003, J ELECTROCHEM SOC, V150, pA851, DOI 10.1149/1.1574806
   Grabarczyk M, 2004, ELECTROANAL, V16, P1503, DOI 10.1002/elan..200402977
   Jin YD, 2004, J PHYS CHEM B, V108, P8142, DOI 10.1021/jp0375517
   Korolczuk M, 1999, MICROCHEM J, V62, P311, DOI 10.1006/mchj.1999.1740
   Korolczuk M, 1999, TALANTA, V49, P703, DOI 10.1016/S0039-9140(99)00066-1
   Li QY, 2003, ANAL CHIM ACTA, V479, P151, DOI 10.1016/S0003-2670(02)01531-3
   Liu SQ, 2003, ANALYST, V128, P1420, DOI 10.1039/b310100b
   Ndung'u K, 1999, ANALYST, V124, P1367, DOI 10.1039/a902519g
   Nielsen SC, 1999, TALANTA, V49, P1027, DOI 10.1016/S0039-9140(99)00044-2
   Palrecha MM, 1997, TALANTA, V45, P433, DOI 10.1016/S0039-9140(97)00150-1
   PANELI M, 1993, MIKROCHIM ACTA, V110, P205, DOI 10.1007/BF01245105
   Pereira MC, 1997, ELECTROANAL, V9, P941, DOI 10.1002/elan.1140091215
   Raj CR, 2005, ELECTROCHEM COMMUN, V7, P888, DOI 10.1016/j.elecom.2005.06.005
   Svancara I, 2004, TALANTA, V64, P844, DOI 10.1016/j.talanta.2004.03.062
   Tudorache M., 2006, ANAL BIOANAL CHEM, V384, P601
   Vukomanovic DV, 1997, MICROCHEM J, V57, P86, DOI 10.1006/mchj.1997.1495
   Wang J, 1999, ANALYST, V124, P349, DOI 10.1039/a807639a
   Welch CM, 2006, ANAL BIOANAL CHEM, V384, P601, DOI 10.1007/s00216-005-0230-3
   Welch CM, 2005, TALANTA, V65, P74, DOI 10.1016/j.talanta.2004.05.017
   Welch CM, 2004, CHEMPHYSCHEM, V5, P1405, DOI 10.1002/cphc.200400263
   Yu AM, 2003, NANO LETT, V3, P1203, DOI 10.1021/nl034363j
NR 32
TC 53
Z9 54
U1 5
U2 52
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD DEC 1
PY 2007
VL 41
IS 23
BP 8129
EP 8134
DI 10.1021/es071726z
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 236LW
UT WOS:000251305500032
PM 18186348
DA 2018-12-27
ER

PT J
AU Ramji, H
AF Ramji, Hasmita
TI RETRACTED: Race in professional spaces - Exploring the experience of
   British Hindu women accountants (Retracted article. See vol. 9, pg. 575,
   2009)
SO ETHNICITIES
LA English
DT Article; Retracted Publication
DE accountancy; class mobility; professional employment; 'race'
ID SERVICE; GENDER
AB The sustained policy focus on combating institutional racism at all levels of British society has given new impetus to discovering how racialized groups experience a variety of institutional settings. This article draws on research conducted amongst British Hindu women working as professional accountants to further understand how privileged institutional spaces are racialized. The narratives of the women discussed in this article demonstrate how professional occupations are important in understanding articulations of racial identity in privileged institutional spaces as not only empirically and historically contingent, but also complex, contradictory and ambivalent. The article suggests that although their professional work spaces were racialized, the experiences of the research sample did not seem to indicate that race was an all-determining influence in their career progression. Its influence did not appear to close all avenues for potential change and progression against discriminative employment cultures.
C1 City Univ London, Dept Sociol, London EC1V 0HB, England.
RP Ramji, H (reprint author), City Univ London, Dept Sociol, Northampton Sq, London EC1V 0HB, England.
EM h.ramji@city.ac.uk
CR Abbott A., 1988, SYSTEM PROFESSIONS
   Ahmad F., 2003, S ASIAN WOMEN EMPLOY
   Alexander C, 2002, ETHNIC RACIAL STUD, V25, P552, DOI 10.1080/01419870220136637
   Anderson-Gough F, 1998, MAKING ACCOUNTANTS O
   Anderson-Gough F., 2002, ACCOUNTING BUSINESS, V32, P41, DOI DOI 10.1080/00014788.2002.9728953
   Barker PC, 1998, ACCOUNT ORG SOC, V23, P813, DOI 10.1016/S0361-3682(98)00009-9
   Bhachu P., 1991, NEW COMMUNITY, V17, P401
   Bhavnani R., 1994, BLACK WOMEN LABOUR M
   Bhopal K., 1997, GENDER RACE PATRIARC
   Bourdieu P., 1992, LANGUAGE SYMBOLIC PO
   Bourdieu P., 1996, STATE NOBILITY ELITE
   Bourdieu P, 1984, DISTINCTION SOCIAL C
   Brah Avtar, 1996, CARTOGRAPHIES DIASPO
   Brown MS, 2000, ETHNIC RACIAL STUD, V23, P1035, DOI 10.1080/014198700750018405
   BURGHART R, 1987, HINDUISM GREAT BRIT
   COFFEY AJ, 1994, SOCIOLOGY, V28, P943, DOI 10.1177/0038038594028004009
   Collins M., 1991, ACCOUNTING AUDITING, V4, P23
   Collinson D., 1994, RESISTANCE POWER ORG, P25
   Crompton R, 1999, RESTRUCTURING GENDER
   CROMWELL J, 1987, J HEALTH POLIT POLIC, V12, P1, DOI 10.1215/03616878-12-1-1
   Dale A, 2002, ETHNIC RACIAL STUD, V25, P942, DOI 10.1080/0141987022000009386
   Devine F, 2000, WORK EMPLOY SOC, V14, P521, DOI 10.1177/09500170022118554
   DEX S, 1984, WOMENS WORK HIST ANA
   Dyer R., 1997, WHITENESS
   Fanon F., 1986, BLACK SKINS WHITE MA
   Foucault Michel, 1977, DISCIPLINE PUNISH BI
   Frankenberg R., 1993, WHITE WOMEN RACE MAT
   Gatens M., 1996, IMAGINARY BODIES ETH
   Gilman Sander L., 1985, DIFFERENCE PATHOLOGY
   Goldberg David Theo, 1997, RACIAL SUBJECTS WRIT
   Grey C, 1998, ACCOUNT ORG SOC, V23, P569, DOI 10.1016/S0361-3682(97)00003-2
   Hammond T., 1996, ACCOUNTING AUDITING, V9, P79, DOI DOI 10.1108/09513579610122018
   Hanlon G, 1998, SOCIOLOGY, V32, P43, DOI 10.1177/0038038598032001004
   HANTRAIS L, 1995, EUROPEAN ACCOUNTING, V4, P197
   HAYNES K, 2006, 16 U YORK DEP MAN ST
   HOOD R, 1992, RACE SENTENCING
   Johnson T, 1972, PROFESSIONS POWER
   JONES S, 1985, APPL QUALITATIVE RES, P86
   Kim HK, 2004, CORONARY ARTERY DIS, V15, P1, DOI 10.1097/01.mca.0000100286.73402.b0
   Knowles C, 2003, RACE SOCIAL ANAL
   LEMERT C, 1997, SOCIAL THINGS
   MACPHERSON CLUNY, 1999, S LAWRENCE INQUIRY R
   May T., 1997, SOCIAL RES ISSUES ME
   Maynard M., 1994, RES WOMENS LIVES FEM, P10
   McClintock Anne, 1995, IMPERIAL LEATHER
   McNicholas P., 2004, CRIT PERSPECT, V15, P57, DOI DOI 10.1016/S1045-2354(03)00007-8
   Mercer K., 1994, WELCOME JUNGLE NEW P
   Miliband R., 1973, STATE CAPITALIST SOC
   Mills C., 1997, RACIAL CONTRACT
   Modood T., 1997, ETHNIC MINORITIES BR
   Modood T, 2005, MULTICULTURAL POLITI
   Mumford M., 1991, ACCOUNTING BUSINESS, V1, P123
   Napier C. J., 1996, ACCOUNTING AUDITING, V9, P7, DOI DOI 10.1108/09513579610121956
   Nealon J.T., 1998, ALTERITY POLITICS ET
   Office of National Statistics, 2001, CENS 2001
   Pateman C., 1989, DISORDER WOMEN DEMOC
   Performance Innovation Unit, 2002, ETHN MIN LAB MARK IN
   Puwar N, 2001, SOCIOLOGY, V35, P651, DOI 10.1017/S0038038501000335
   RAMJI H, 2002, THESIS CITY U LONDON
   RAMJI H, 2003, CRITICAL REFLECTIONS, P227
   Reinharz S., 1992, FEMINIST METHODS SOC
   Sayer A, 2000, SOCIOLOGY, V34, P707, DOI 10.1177/S0038038500000432
   SIKKA PH, 1989, ACCOUNTING AUDITING, V2, P25
   Smithson J, 2004, WORK EMPLOY SOC, V18, P115, DOI 10.1177/0950017004040765
   Solomon E. I., 1999, INORGANIC ELECT STRU, V1, P161
   SONGG M, 2003, ETHNIC CHOICE
   Thompson Paul Richard, 1988, VOICE PAST ORAL HIST
   WARE V, 1992, PALE
   Wetherell M, 1998, DISCOURSE SOC, V9, P387, DOI 10.1177/0957926598009003005
   Williams P. J., 1997, SEEING COLOUR BLIND
   Yow Valerie, 1994, RECORDING ORAL HIST
NR 71
TC 2
Z9 2
U1 2
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1468-7968
EI 1741-2706
J9 ETHNICITIES
JI Ethnicities
PD DEC
PY 2007
VL 7
IS 4
BP 590
EP 613
DI 10.1177/1468796807084018
PG 24
WC Ethnic Studies
SC Ethnic Studies
GA 245NH
UT WOS:000251941600005
DA 2018-12-27
ER

PT J
AU Izquierdo, I
   Plaza, MT
   Tamayo, JA
   Sanchez-Cantalejo, F
AF Izquierdo, Isidoro
   Plaza, Maria T.
   Tamayo, Juan A.
   Sanchez-Cantalejo, Fernando
TI RETRACTED: A new synthetic approach to (+)-hyacinthacine A(1) and the
   first total synthesis and absolute configuration assignment of naturally
   occurring (+)-hyacinthacine A(6) (Retracted article. See pg 3809, 2009)
SO EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article; Retracted Publication
DE alkaloids; azasugars; hyacinthacines; enantioselectivity; synthetic
   methods; enzyme inhibitors
ID POLYHYDROXYLATED PYRROLIZIDINES; STEREOSELECTIVE-SYNTHESIS; D-FRUCTOSE;
   ENANTIOSPECIFIC SYNTHESIS; BIOLOGICAL-ACTIVITY; PART 4; ALKALOIDS;
   HYACINTHACINES; PYRROLIDINES; A(2)
AB Naturally occurring (1S,2R,3R,7aR)-1,2-dihydroxy-3-hydroxymethylpyrrolizidine [(+)-hyacinthacine A(1) (1)] and (1S,2R,3R,5R,7aR)-1,2-dihydroxy-3-hydroxymethyl-5-methylpyrrolizidine [(+)-hyacinthacine A(6) (2)] have been synthesized by Wittig's methodology using aldehyde 7, prepared from (2R,3S,4R,5R)-3,4-bis(benzyloxy)-2'-O-(tert-butyldiphenylsilyl)-2,5-bis(hydroxymethyl)pyrrolidine (3, partially protected DALDP), as the homochiral starting material and the appropriated ylide to afford either the corresponding alpha,beta-unsaturated ester 8 or ketone 9, which were submitted to internal lactamization and reductive amination, respectively, to give the corresponding intermediate pyrrolizidin-5-one 11 and the totally protected pyrrolizidine 14. Compounds and 14 were easily transformed into the above hyacinthacines 1 and 2, respectively. (C) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007.
C1 [Izquierdo, Isidoro; Plaza, Maria T.; Tamayo, Juan A.; Sanchez-Cantalejo, Fernando] Univ Granada, Fac Pharm, Dept Med Organic Chem, Granada 18071, Spain.
RP Izquierdo, I (reprint author), Univ Granada, Fac Pharm, Dept Med Organic Chem, Granada 18071, Spain.
EM isidoro@ugr.es
CR Asano N, 2004, J NAT PROD, V67, P846, DOI 10.1021/np0499721
   Asano N, 2003, CURR TOP MED CHEM, V3, P471, DOI 10.2174/1568026033452438
   Asano N, 2000, TETRAHEDRON-ASYMMETR, V11, P1, DOI 10.1016/S0957-4166(99)00508-X
   Calveras J, 2007, ADV SYNTH CATAL, V349, P1661, DOI 10.1002/adsc.200700168
   Chabaud L, 2005, ORG LETT, V7, P2587, DOI 10.1021/ol050713s
   FELLOWS LE, 1987, CHEM BRIT, V23, P842
   Goss PE, 1995, CLIN CANCER RES, V1, P935
   Izquierdo I, 2006, TETRAHEDRON, V62, P2693, DOI 10.1016/j.tet.2005.12.023
   Izquierdo I, 2005, TETRAHEDRON, V61, P6527, DOI 10.1016/j.tet.2005.05.004
   Izquierdo I, 2004, TETRAHEDRON-ASYMMETR, V15, P1465, DOI 10.1016/j.tetasy.2004.03.013
   Izquierdo I, 2003, TETRAHEDRON-ASYMMETR, V14, P3933, DOI 10.1016/j.tetasy.2003.09.042
   Izquierdo I, 2002, TETRAHEDRON-ASYMMETR, V13, P1581, DOI 10.1016/S0957-4166(02)00408-1
   Izquierdo I, 2002, TETRAHEDRON-ASYMMETR, V13, P1503, DOI 10.1016/S0957-4166(02)00369-5
   Izquierdo I, 2001, TETRAHEDRON-ASYMMETR, V12, P2481, DOI 10.1016/S0957-4166(01)00440-2
   Izquierdo I., 2000, CARBOHYD RES, V330, P401
   Izquierdo I, 2007, TETRAHEDRON, V63, P1440, DOI 10.1016/j.tet.2006.11.070
   Izquierdo I, 2006, J CARBOHYD CHEM, V25, P281, DOI 10.1080/07328300600735181
   Izquierdo I, 2006, TETRAHEDRON, V62, P6006, DOI 10.1016/j.tet.2006.04.003
   Kato A, 1999, CARBOHYD RES, V316, P95, DOI 10.1016/S0008-6215(99)00043-9
   Kato A, 2007, J NAT PROD, V70, P993, DOI 10.1021/np0700826
   MENG QC, 1991, HELV CHIM ACTA, V74, P445, DOI 10.1002/hlca.19910740222
   MOLYNEUX RJ, 1988, J NAT PROD, V51, P1198, DOI 10.1021/np50060a024
   NASH RJ, 1988, TETRAHEDRON LETT, V29, P2487, DOI 10.1016/S0040-4039(00)87914-9
   Pyne SG, 2005, CURR ORG CHEM, V9, P1393, DOI 10.2174/1385272054880188
   Toyao A, 2003, SYNLETT, P35
   WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199
   Wormald MR, 1998, TETRAHEDRON-ASYMMETR, V9, P2549, DOI 10.1016/S0957-4166(98)00254-7
   Yamashita T, 2002, J NAT PROD, V65, P1875, DOI 10.1021/np020296h
NR 28
TC 20
Z9 20
U1 3
U2 17
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1434-193X
EI 1099-0690
J9 EUR J ORG CHEM
JI Eur. J. Org. Chem.
PD DEC
PY 2007
IS 36
BP 6078
EP 6083
DI 10.1002/ejoc.200700820
PG 6
WC Chemistry, Organic
SC Chemistry
GA 245EI
UT WOS:000251917400011
DA 2018-12-27
ER

PT J
AU Mavridis, G
   Livaditi, E
   Christopoulos-Geroulanos, G
AF Mavridis, G.
   Livaditi, E.
   Christopoulos-Geroulanos, G.
TI RETRACTED: Management of hydatidosis in children. Twenty-one year
   experience (Retracted Article. See vol 19, pg 89, 2009)
SO EUROPEAN JOURNAL OF PEDIATRIC SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Annual Congress of the European-Paediatric-Surgeons-Association
CY MAY, 2007
CL Turin, ITALY
SP European Paediat Surg Assoc
DE hydatidosis; abdominal; pulmonary; treatment; children
ID CYSTIC ECHINOCOCCOSIS; SURGICAL-TREATMENT; PULMONARY HYDATIDOSIS;
   DISEASE; MEBENDAZOLE; LIVER; CHEMOTHERAPY; ALBENDAZOLE; SURGERY; LUNG
AB Purpose: Hydatidosis is a serious problem in non-endemic countries due to the influx of immigrants from nations where preventive measures are inadequate. The aim of this retrospective study is to present our experience in the management of hydatidosis in children and to define the criteria for the most effective model of treatment.
   Material and Methods: Over a 21-year period (1985-2006), 150 children with pulmonary and abdominal hydatidosis (Echinococcus cysticus) were treated at our department. The anatomical location of the parasite was as follows: liver 82, lungs 59, spleen 4, mesentery 2, kidneys 2 and pelvic floor I case. Medical treatment with oral antihelminthic agents was given to 37 patients (45.1%), with liver hydatidosis, 36 patients (61%) with pulmonary hydatidosis and one patient with hydatid cyst of the spleen. The remaining 76 patients were submitted primarily to excision of the cyst or partial capsectomy.
   Results: Medical treatment was ineffective in 16 patients (43.2%) with liver hydatidosis, 11 patients (30.6%) with pulmonary hydatidosis and one patient with hydatidosis of the spleen. All patients with pulmonary hydatidosis who failed to respond to medical treatment developed complications requiring surgical intervention. Of the 76 patients who were submitted to surgery initially, only 4 (5.3%) presented with postoperative complications requiring reoperation. In all cases who responded inadequately to medical treatment or developed complications the cyst diameter exceeded 6 cm. The overall long-term results were good.
   Conclusions: a) Hydatid cysts with sizes exceeding 6 cm in diameter should not be treated medically; b) medical treatment seems to be more effective for pulmonary hydatidosis but failed medical treatment in these patients leads to complications with increased morbidity; c) large hydatid cysts should be treated surgically from the start.
C1 [Mavridis, G.; Livaditi, E.; Christopoulos-Geroulanos, G.] Aghia Sophia Childrens Hosp, Dept Pediat Surg 2, Athens, Greece.
RP Mavridis, G (reprint author), Aghia Sophia Childrens Hosp, Dept Pediat Surg 2, 79 Alevizatou Str,15669 Papagou, Athens, Greece.
EM mavridig@yahoo.gr
CR Akhan O, 1998, ABDOM IMAGING, V23, P209, DOI 10.1007/s002619900325
   Baykal K, 1996, Int J Urol, V3, P497, DOI 10.1111/j.1442-2042.1996.tb00584.x
   Besim H, 1998, HPB Surg, V10, P347, DOI 10.1155/1998/78170
   CELIC M, 2000, J PEDIATR SURG, V12, P1710
   Dogru D, 2005, PARASITOL INT, V54, P135, DOI 10.1016/j.parint.2005.02.003
   ELBURJO M, 1995, THORAX, V50, P396, DOI 10.1136/thx.50.4.396
   Franchi C, 1999, CLIN INFECT DIS, V29, P304, DOI 10.1086/520205
   Galanakis E, 1997, SCAND J INFECT DIS, V29, P638, DOI 10.3109/00365549709035913
   HALEZEROGLU S, 1991, J THORAC CARDIOVASC, V102, P427
   Kabaalioglu A, 1996, EUR RADIOL, V6, P872, DOI 10.1007/BF00240694
   KAMMERER WS, 1976, AM J TROP MED HYG, V25, P714, DOI 10.4269/ajtmh.1976.25.714
   KARPATHIOS T, 1984, ARCH DIS CHILD, V59, P894, DOI 10.1136/adc.59.9.894
   Khoury G, 1998, SURG ENDOSC-ULTRAS, V12, P452, DOI 10.1007/s004649900703
   Koseoglu B, 2002, SURG TODAY, V32, P779, DOI 10.1007/s005950200149
   Liu YH, 2000, CHINESE MED J-PEKING, V113, P827
   Marks J, 1998, SURG ENDOSC-ULTRAS, V12, P331, DOI 10.1007/s004649900664
   MESSARITAKIS J, 1991, ARCH DIS CHILD, V66, P532, DOI 10.1136/adc.66.4.532
   MORRIS DL, 1985, JAMA-J AM MED ASSOC, V253, P2053, DOI 10.1001/jama.253.14.2053
   MUTAF O, 1994, EUR J PEDIATR SURG, V4, P70, DOI 10.1055/s-2008-1066071
   NAHMIAS J, 1994, ANN TROP MED PARASIT, V88, P295, DOI 10.1080/00034983.1994.11812870
   OZCELIK C, 1994, J PEDIATR SURG, V29, P392, DOI 10.1016/0022-3468(94)90575-4
   Rebhandl W, 1999, PEDIATR PULM, V27, P336, DOI 10.1002/(SICI)1099-0496(199905)27:5<336::AID-PPUL7>3.0.CO;2-1
   Reuter S, 1998, MED KLIN, V93, P463, DOI 10.1007/BF03042595
   RUIZCASTRO M, 1997, REV ESP ANESTESIOL R, V44, P124
   Salih OK, 1998, CAN J SURG, V41, P131
   SOLAK H, 1988, SCAND J THORAC CARD, V22, P101, DOI 10.3109/14017438809105937
   TODOROV T, 1992, B WORLD HEALTH ORGAN, V70, P347
   Todorov T, 2005, ANN TROP MED PARASIT, V99, P649, DOI 10.1179/136485905X65125
   Turkyilmaz Z, 2004, WORLD J SURG, V28, P597, DOI 10.1007/s00268-004-7029-9
   Yucel O, 1996, SURG ENDOSC-ULTRAS, V10, P434, DOI 10.1007/s004649910084
NR 30
TC 4
Z9 4
U1 3
U2 13
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0939-7248
EI 1439-359X
J9 EUR J PEDIATR SURG
JI Eur. J. Pediatr. Surg.
PD DEC
PY 2007
VL 17
IS 6
BP 400
EP 403
DI 10.1055/s-2007-989269
PG 4
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA 251GK
UT WOS:000252360400007
PM 18072024
DA 2018-12-27
ER

PT J
AU Tripathi, P
   Tripathi, P
   Kashyap, L
   Singh, V
AF Tripathi, Parul
   Tripathi, Prashant
   Kashyap, Luv
   Singh, Vinod
TI RETRACTED: The role of nitric oxide in inflammatory reactions (Retracted
   article. See vol. 66, pg. 449, 2012)
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Review; Retracted Publication
DE nitric oxide; iNOS; Th1; Th2 cytokines; immune response; macrophage
ID SYNTHASE MESSENGER-RNA; L-ARGININE; RELAXING FACTOR; CHROMOSOMAL
   LOCALIZATION; PHYSIOLOGICAL MESSENGER; ANTIMICROBIAL ACTIVITY;
   AUTOIMMUNE-DISEASE; TRYPANOSOMA-CRUZI; MOLECULAR-CLONING;
   INTERFERON-GAMMA
AB Nitric oxide (NO) was initially described as a physiological mediator of endothelial cell relaxation, an important role in hypotension. NO is an intercellular messenger that has been recognized as one of the most versatile players in the immune system. Cells of the innate immune system - macrophages, neutrophils and natural killer cells - use pattern recognition receptors to recognize the molecular patterns associated with pathogens. Activated macrophages then inhibit pathogen replication by releasing a variety of effector molecules, including NO. In addition to macrophages, a large number of other immune-system cells produce and respond to NO. Thus, NO is important as a toxic defense molecule against infectious organisms. It also regulates the functional activity, growth and death of many immune and inflammatory cell types including macrophages, T lymphocytes, antigen-presenting cells, mast cells, neutrophils and natural killer cells. However, the role of NO in nonspecific and specific immunity in vivo and in immunologically mediated diseases and inflammation is poorly understood. This Minireview will discuss the role of NO in immune response and inflammation, and its mechanisms of action in these processes.
C1 Canc Hosp & Res Inst, Dept Microbiol, Gwalior, India.
   ICGEB, Immunol Grp, New Delhi, India.
   JNU Med Coll, Dept Biochem, Aligarh, Uttar Pradesh, India.
   AMU, Fac Life Sci, Dept Biochem, Aligarh, Uttar Pradesh, India.
RP Singh, V (reprint author), Canc Hosp & Res Inst, Dept Microbiol, Gwalior, India.
EM vsingh3@rediff.com
CR Adams MR, 1997, CIRCULATION, V95, P662, DOI 10.1161/01.CIR.95.3.662
   Albina J E, 1995, New Horiz, V3, P46
   Appleton I, 1996, Adv Pharmacol, V35, P27, DOI 10.1016/S1054-3589(08)60274-4
   BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592
   BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6
   Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218
   Barnes PJ, 1995, RES IMMUNOL, V146, P698, DOI 10.1016/0923-2494(96)84921-2
   Bauer H, 1997, IMMUNOLOGY, V90, P205, DOI 10.1046/j.1365-2567.1997.00161.x
   Billiar TR, 1997, GASTROENTEROLOGY, V113, P1405, DOI 10.1053/gast.1997.v113.agast971131405
   BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003
   Bogdan C, 1997, Behring Inst Mitt, P58
   Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7
   Bogdan C., 2000, V143, P443
   Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361
   Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582
   CATTELL V, 1995, HISTOCHEM J, V27, P777
   Chang RH, 1997, IMMUNOLOGY, V90, P364, DOI 10.1111/j.1365-2567.1997.00364.x
   CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765
   Chiwakata CB, 2000, INFECT IMMUN, V68, P394, DOI 10.1128/IAI.68.1.394-399.2000
   CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599
   Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783
   Cifone MG, 1995, ADV NEUROIMMUNOL, V5, P443, DOI 10.1016/0960-5428(95)00028-3
   Di Virgilio F, 2004, CURR PHARM DESIGN, V10, P1647
   DING AH, 1988, J IMMUNOL, V141, P2407
   Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126
   Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184
   EVANS CH, 1995, AGENT ACTION SUPPL, V47, P107
   Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473
   FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351
   Fushiya S, 1999, PLANTA MED, V65, P404, DOI 10.1055/s-1999-14084
   GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323
   Gaston B., 1999, NITRIC OXIDE INFECT, P37
   GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491
   Gnanapandithen K, 1996, BBA-GENE STRUCT EXPR, V1308, P103, DOI 10.1016/0167-4781(96)00098-X
   Gobert AP, 2000, INFECT IMMUN, V68, P4653, DOI 10.1128/IAI.68.8.4653-4657.2000
   Granger DN, 1996, METHOD ENZYMOL, V269, P434
   GREEN SJ, 1994, IMMUNOL LETT, V43, P87, DOI 10.1016/0165-2478(94)00158-8
   GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423
   GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809
   HALL AV, 1994, J BIOL CHEM, V269, P33082
   HALL LR, 1995, J IMMUNOL, V155, P3501
   Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528
   Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K
   Huang Yiping, 1998, ASIAN-PAC ECON LIT, V12, P19
   IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265
   Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777
   JANSSENS SP, 1992, J BIOL CHEM, V267, P14519
   JORENS PG, 1995, MEDIAT INFLAMM, V4, P75, DOI 10.1155/S0962935195000135
   Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8
   KOSHLAND DE, 1992, SCIENCE, V258, P1861, DOI 10.1126/science.1470903
   Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147
   Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X
   LASKIN JD, 1994, TRENDS ENDOCRIN MET, V5, P377, DOI 10.1016/1043-2760(94)90105-8
   Li JR, 2000, SEMIN PERINATOL, V24, P46, DOI 10.1016/S0146-0005(00)80055-5
   LIEW FY, 1994, IMMUNOL LETT, V43, P95, DOI 10.1016/0165-2478(94)00157-X
   LIEW FY, 1995, ADV NEUROIMMUNOL, V5, P201, DOI 10.1016/0960-5428(95)00009-Q
   Liew FY, 1997, PHILOS T R SOC B, V352, P1311, DOI 10.1098/rstb.1997.0115
   Lirk Philipp, 2002, Current Drug Targets - Inflammation and Allergy, V1, P89, DOI 10.2174/1568010023344913
   LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009
   MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   Madan G, 1996, Indian J Med Sci, V50, P318
   Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854
   MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001
   MARLETTA MA, 1993, J BIOL CHEM, V268, P12231
   MARSDEN PA, 1994, GENOMICS, V19, P183, DOI 10.1006/geno.1994.1039
   McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266
   MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293
   Mehta S, 1997, AM J PHYSIOL-LUNG C, V272, pL124
   MERRITT WT, 1993, TRANSPL P, V25, P2014
   Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750
   MIYAHARA K, 1994, EUR J BIOCHEM, V223, P719, DOI 10.1111/j.1432-1033.1994.tb19045.x
   MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   MONCADA S, 2002, NEW ENGL J MED, V329, P2012
   MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841
   NATHAN C, 1994, J BIOL CHEM, V269, P13725
   NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G
   Niedbala W, 1999, EUR J IMMUNOL, V29, P2498, DOI 10.1002/(SICI)1521-4141(199908)29:08<2498::AID-IMMU2498>3.0.CO;2-M
   OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726
   Okuda Y, 1996, IMMUNOL LETT, V52, P135, DOI 10.1016/0165-2478(96)02597-7
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Park CS, 1997, NITRIC OXIDE-BIOL CH, V1, P294, DOI 10.1006/niox.1997.0138
   Piacenza L, 2001, P NATL ACAD SCI USA, V98, P7301, DOI 10.1073/pnas.121520398
   REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836
   Reiss CS, 1998, J VIROL, V72, P4547
   ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068
   Rothe H, 1999, J MOL MED-JMM, V77, P40, DOI 10.1007/s001090050298
   Saeftel M, 2001, INFECT IMMUN, V69, P2252, DOI 10.1128/IAI.69.4.2252-2259.2001
   Schindler H, 2001, INT IMMUNOPHARMACOL, V1, P1443, DOI 10.1016/S1567-5769(01)00089-3
   STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928
   Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X
   Tarrant TK, 1999, J EXP MED, V189, P219, DOI 10.1084/jem.189.2.219
   TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430
   VALLANCE P, 1994, J ROY COLL PHYS LOND, V28, P209
   van der Veen RC, 2001, INT IMMUNOPHARMACOL, V1, P1491, DOI 10.1016/S1567-5769(01)00093-5
   VLADUTIU AO, 1995, CLIN IMMUNOL IMMUNOP, V76, P1, DOI 10.1006/clin.1995.1081
   Wong J M, 1995, Adv Pharmacol, V34, P155
   WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0
   XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522
   YUI Y, 1991, J BIOL CHEM, V266, P3369
NR 105
TC 127
Z9 136
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0928-8244
EI 1574-695X
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD DEC
PY 2007
VL 51
IS 3
BP 443
EP 452
DI 10.1111/j.1574-695X.2007.00329.x
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 228VU
UT WOS:000250761500001
PM 17903207
OA Bronze
DA 2018-12-27
ER

PT J
AU Henary, B
   Sherwood, CP
   Crandall, JR
   Kent, RW
   Vaca, FE
   Arbogast, KB
   Bull, MJ
AF Henary, B.
   Sherwood, C. P.
   Crandall, J. R.
   Kent, R. W.
   Vaca, F. E.
   Arbogast, K. B.
   Bull, M. J.
TI RETRACTED: Car safety seats for children: rear facing for best
   protection (Retracted article. See vol. 24, 2018)
SO INJURY PREVENTION
LA English
DT Article; Retracted Publication
AB Objective: To compare the injury risk between rear-facing (RFCS) and forward-facing (FFCS) car seats for children less than 2 years of age in the USA.
   Methods: Data were extracted from a US National Highway Traffic Safety Administration vehicle crash database for the years 1988-2003. Children 0-23 months of age restrained in an RFCS or FFCS when riding in passenger cars, sport utility vehicles, or light trucks were included in the study. Logistic regression models and restraint effectiveness calculations were used to compare the risk of injury between children restrained in RFCSs and FFCSs.
   Results: Children in FFCSs were significantly more likely to be seriously injured than children restrained in RFCSs in all crash types (OR = 1.76, 95% CI 1.40 to 2.20). When considering frontal crashes alone, children in FFCSs were more likely to be seriously injured (OR = 1.23), although this finding was not statistically significant (95% CI 0.95 to 1.59). In side crashes, however, children in FFCSs were much more likely to be injured (OR = 5.53, 95% CI 3.74 to 8.18). When 1 year olds were analyzed separately, these children were also more likely to be seriously injured when restrained in FFCSs (OR = 5.32, 95% CI 3.43 to 8.24). Effectiveness estimates for RFCSs (93%) were found to be 15% higher than those for FFCSs (78%).
   Conclusions: RFCSs are more effective than FFCSs in protecting restrained children aged 0-23 months. The same findings apply when 1 year olds are analyzed separately. Use of an RFCS, in accordance with restraint recommendations for child size and weight, is an excellent choice for optimum protection up to a child's second birthday.
C1 Univ Virginia, Ctr Appl Biomech, Charlottesville, VA 22902 USA.
   Univ Calif Irvine, Ctr Trauma & Injury Prevent Res, Irvine, CA USA.
   Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA.
   Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
RP Crandall, JR (reprint author), Univ Virginia, Ctr Appl Biomech, 1011 Linden Ave, Charlottesville, VA 22902 USA.
EM jrc2h@virginia.edu
RI Crandall, Jeff/N-2210-2014
CR *AAP, 2007, CAR SAF SEATS GUID F
   Arbogast Kristy B, 2005, Traffic Inj Prev, V6, P351, DOI 10.1080/15389580500255831
   BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001
   Beattie T F, 1998, Inj Prev, V4, P228
   BURDI AR, 1969, BIOMECHANICS, V2, P267
   Evans L., 1991, TRAFFIC SAFETY DRIVE
   HOYERT DL, 2006, DEATHS FINAL DATA 20, V54
   *IIHS, 2005, INS I HIGHW SAF FAT
   ISAKSSONHELLMAN I, 1997, P CHILD OCC PROT 2 S, P316
   Jakobsson L, 2005, P 19 INT TECHN C ENH
   *NAT HIGHW TRAFF S, 2001, NAT AUT SAMPL SYST N
   *NAT HIGHW TRAFF S, 2006, GEN CHILD SEAT US IN
   *PART CHILD PASS S, 2000 INT REP
   SHERWOOD C, 2003, P 47 ASS ADV AUT MED
   Weber K, 2000, UMTRI RES REV, V31, P1
NR 15
TC 61
Z9 63
U1 1
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1353-8047
EI 1475-5785
J9 INJURY PREV
JI Inj. Prev.
PD DEC
PY 2007
VL 13
IS 6
BP 398
EP 402
DI 10.1136/ip.2006.015115
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 237GI
UT WOS:000251361800010
PM 18056317
OA Green Published
DA 2018-12-27
ER

PT J
AU Nigg, HN
   Schumann, RA
   Stuart, RJ
   Etxeberria, E
   Yang, JJ
   Fraser, S
AF Nigg, H. N.
   Schumann, R. A.
   Stuart, R. J.
   Etxeberria, E.
   Yang, J. J.
   Fraser, S.
TI RETRACTED: Consumption of sugars by Anastrepha suspensa (Diptera :
   Tephritidae) (Retracted article. See vol. 111, pg. 2504, 2018)
SO JOURNAL OF ECONOMIC ENTOMOLOGY
LA English
DT Article; Retracted Publication
DE bait design; bait station; Caribbean fruit fly
ID CARIBBEAN FRUIT-FLY; INSECT NUTRITION; TEPHRITIDAE; DIPTERA; SUCROSE;
   PROTEIN; BEHAVIOR; DIETS; RATES; FLIES
AB We were interested in determining the feeding response of the Caribbean fruit fly, Anastrepha suspensa Loew (Diptera: Tephritidae), to various sugar concentrations to develop an improved bait for adults. We compared the consumption of 0.01-1.00 M concentrations of glucose, fructose, raffinose, and sucrose in no-choice tests for 24-h- and 6-d-old male and female flies. Sucrose was the most consumed sugar or within the most consumed group of sugars at 0.02-0.20 M concentrations. There were no differences in consumption among sugars at 0.01, 0.40, and 1.00 M. Consumption generally increased with increasing sugar concentration except that sucrose consumption peaked at 0.20 M. Twenty-four-hour females consumed less fructose than other sugars; 24-h males consumed more sucrose than fructose or raffinose, with an intermediate response to glucose. Females in the 6-d group consumed more sucrose than the other three sugars, whereas 6-d males exhibited no difference in consumption among sugars. In choice tests, flies consumed more sugar solution than water, but the difference between 0.20 M fructose and water was not significant for 24-h males or 24-h females. In choice tests between 0.20 M fructose and 0.20 M sucrose, both 24-h and 6-d females showed a preference for fructose. Males of both age classes showed no preference. These results indicate that the responses of flies to different sugars can vary by sugar, gender, and age.
C1 [Nigg, H. N.; Schumann, R. A.; Stuart, R. J.; Yang, J. J.] Univ Florida, Dept Entomol & Nematol, Ctr Citrus Res & Educ, Inst Food & Agr Sci, Lake Alfred, FL 33850 USA.
   [Nigg, H. N.] Univ Florida, Dept Hort Sci, Ctr Citrus Res & Educ, Inst Food & Agr Sci, Lake Alfred, FL 33850 USA.
   [Fraser, S.] Florida Dept Agr & Consumer Serv, Div Plant Ind, Gainesville, FL 32608 USA.
RP Nigg, HN (reprint author), Univ Florida, Dept Entomol & Nematol, Ctr Citrus Res & Educ, Inst Food & Agr Sci, 700 Expt Stn Rd, Lake Alfred, FL 33850 USA.
EM hnn@ufl.edu
CR ALUJA M, 1994, ANNU REV ENTOMOL, V39, P155, DOI 10.1146/annurev.en.39.010194.001103
   Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23
   DETHIER VG, 1961, BIOL BULL, V121, P456, DOI 10.2307/1539446
   ETXEBERRIA EJ, 2004, SUCROSE ENCY PLANT
   FRIEND WG, 1958, ANNU REV ENTOMOL, V3, P57, DOI 10.1146/annurev.en.03.010158.000421
   GALUN R, 1985, ENVIRON ENTOMOL, V14, P726, DOI 10.1093/ee/14.6.726
   GELPERIN A, 1967, PHYSIOL ZOOL, V40, P218, DOI 10.1086/physzool.40.3.30152859
   GRANT N, 2001, ROLE NUTR INSECT BEH
   Hallem EA, 2006, ANNU REV ENTOMOL, V51, P113, DOI 10.1146/annurev.ento.51.051705.113646
   HENDRICHS J, 1996, FRUIT FLY PESTS WORL
   HOUSE HL, 1962, ANNU REV BIOCHEM, V31, P653, DOI 10.1146/annurev.bi.31.070162.003253
   LANDOLT PJ, 1993, ANN ENTOMOL SOC AM, V86, P749, DOI 10.1093/aesa/86.6.749
   LAWRENCE PO, 1989, INSECT SCI APPL, V10, P353, DOI 10.1017/S174275840000360X
   LEPPLA N C, 1976, Entomophaga, V21, P353, DOI 10.1007/BF02371633
   LIPKE H, 1956, ANNU REV ENTOMOL, V1, P17, DOI 10.1146/annurev.en.01.010156.000313
   MAY PG, 1985, OECOLOGIA, V66, P381, DOI 10.1007/BF00378303
   MUMFORD JD, 1998, AREA WIDE CONTROL FR, P39
   Nigg H. N., 2004, Proceedings of the 6th International Symposium on fruit flies of economic importance, Stellenbosch, South Africa, 6-10 May 2002, P335
   Nigg H. N., 2004, Proceedings of the 6th International Symposium on fruit flies of economic importance, Stellenbosch, South Africa, 6-10 May 2002, P179
   NIGG HN, 1995, J ECON ENTOMOL, V88, P669, DOI 10.1093/jee/88.3.669
   Nigg HN, 2004, J ECON ENTOMOL, V97, P1850
   NIGG HN, 1994, J ECON ENTOMOL, V87, P589, DOI 10.1093/jee/87.3.589
   Nylin S, 1998, ANNU REV ENTOMOL, V43, P63, DOI 10.1146/annurev.ento.43.1.63
   PIVNICK KA, 1985, OECOLOGIA, V66, P226, DOI 10.1007/BF00379859
   PONTIS HG, 1977, PLANT BIOCH, P80
   *SAS I, 2001, SAS REL 8 2
   SCRIBER JM, 1981, ANNU REV ENTOMOL, V26, P183, DOI 10.1146/annurev.en.26.010181.001151
   SHARP JL, 1984, ENVIRON ENTOMOL, V13, P768, DOI 10.1093/ee/13.3.768
   SHARP JL, 1984, J GEORGIA ENTOMOL SO, V19, P176
   SIMPSON SE, 1993, FLA ENTOMOL, V76, P228, DOI 10.2307/3495719
   SLANSKY F, 1982, FLA ENTOMOL, V65, P45
   SWANSON RW, 1972, P FLA STATE HORTIC S, V85, P271
   Tsiropoulos George J., 1992, P93
   Waldbauer G. P., 1968, P229, DOI 10.1016/S0065-2806(08)60230-1
   WALDBAUER GP, 1991, ANNU REV ENTOMOL, V36, P43, DOI 10.1146/annurev.en.36.010191.000355
   WEBSTER RP, 1979, ANN ENTOMOL SOC AM, V72, P41, DOI 10.1093/aesa/72.1.41
   WEEMS HOWARD V., 1966, PROC FLA STATE HORT SOC, V79, P401
   WEEMS HV, 1965, ANASTREPHA SUSPENSA, V38, P1
   Yee WL, 2003, PHYSIOL ENTOMOL, V28, P122, DOI 10.1046/j.1365-3032.2003.00326.x
NR 39
TC 3
Z9 3
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-0493
EI 1938-291X
J9 J ECON ENTOMOL
JI J. Econ. Entomol.
PD DEC
PY 2007
VL 100
IS 6
BP 1938
EP 1944
DI 10.1603/0022-0493(2007)100[1938:COSBAS]2.0.CO;2
PG 7
WC Entomology
SC Entomology
GA 242BV
UT WOS:000251700400027
PM 18232414
DA 2018-12-27
ER

PT J
AU Miao, Z
AF Miao, Zewei
TI RETRACTED: Modeling responses of leafy Spurge dispersal to control
   strategies (Retracted Article. See vol 50, pg 638, 2008)
SO JOURNAL OF INTEGRATIVE PLANT BIOLOGY
LA English
DT Article; Retracted Publication
DE Allee effects; dispersal curve; invasive species; non-indigenous;
   propagule pressure; stochastic process-based model
ID NORTHERN GREAT-PLAINS; EUPHORBIA-ESULA; UNITED-STATES; POPULATIONS;
   INVASIONS; DENSITY; SPREAD; DISTANCE
AB Leafy spurge (Euphorbia esula L.) has substantial negative effects on grassland biodiversity, productivity, and economic benefit in North America. To predict these negative impacts, we need an appropriate plant-spread model which can simulate the response of an invading population to different control strategies. In this study, using a stochastic map lattice approach we generated a spatially explicitly stochastic process-based model to simulate dispersal trajectories of leafy spurge under various control scenarios. The model integrated dispersal curve, propagule pressure, and population growth of leafy spurge at local and short-temporal scales to capture spread features of leafy spurge at large spatial and long-temporal scales. Our results suggested that narrow-, medium-, and fat-tailed kernels did not differ in their ability to predict spread, in contrast to previous works. For all kernels, Allee effects were significantly present and could explain the lag phase (three decades) before leafy spurge spread accelerated. When simulating from the initial stage of introduction, Allee effects were critical in predicting spread rate of leafy spurge, because the prediction could be seriously affected by the low density period of leafy spurge community. No Allee effects models were not able to simulate spread rate well in this circumstance. When applying control strategies to the current distribution, Allee effects could stop the spread of leafy spurge; no Allee effects models, however, were able to slow but not stop the spread. The presence of Allee effects had significant ramifications on the efficiencies of control strategies. For both Allee and no Allee effects models, the later that control strategies were implemented, the more effort had to be input to achieve similar control results.
C1 Rutgers State Univ, Cook Coll, Grant F Walton Ctr Remote Sensing & Spatial Anal, New Brunswick, NJ 08901 USA.
RP Miao, Z (reprint author), Rutgers State Univ, Cook Coll, Grant F Walton Ctr Remote Sensing & Spatial Anal, New Brunswick, NJ 08901 USA.
EM zmiao@crssa.rutgers.edu
CR Bangsund DA, 1999, J ENVIRON MANAGE, V56, P35, DOI 10.1006/jema.1999.0269
   BANGSUND DA, 1997, 382 NDSU N DAK AGR E, P1
   BELCHER JW, 1989, J RANGE MANAGE, V42, P172, DOI 10.2307/3899318
   Belisle M, 2002, CONSERV ECOL, V5
   Bixby R. E., 1992, ORSA Journal on Computing, V4, P267
   Cain ML, 2000, AM J BOT, V87, P1217, DOI 10.2307/2656714
   Clark JS, 2003, ECOLOGY, V84, P1979, DOI 10.1890/01-0618
   Dennis B, 2002, OIKOS, V96, P389, DOI 10.1034/j.1600-0706.2002.960301.x
   DUNN PH, 1979, WEED SCI, V27, P509
   Engen S, 2003, ECOLOGY, V84, P2378, DOI 10.1890/02-0123
   EVERITT JH, 1995, WEED TECHNOL, V9, P599
   Getz WM, 1996, ECOLOGY, V77, P2014, DOI 10.2307/2265697
   GOFFE WL, 1994, J ECONOMETRICS, V60, P65, DOI 10.1016/0304-4076(94)90038-8
   Grevstad Fritzi S., 1999, Biological Invasions, V1, P313, DOI 10.1023/A:1010037912369
   HENGEVELD R, 1994, TRENDS ECOL EVOL, V9, P339, DOI 10.1016/0169-5347(94)90155-4
   HERBERT CH, 1933, N DAKOTA AGR EXPT ST, V266
   Higgins SI, 1996, ECOLOGY, V77, P2043, DOI 10.2307/2265699
   HOBBS RJ, 1995, CONSERV BIOL, V9, P761, DOI 10.1046/j.1523-1739.1995.09040761.x
   HOBBS RJ, 1995, MEDITERRANEAN TYPE E, P1
   Kot M, 1996, ECOLOGY, V77, P2027, DOI 10.2307/2265698
   LEISTRITZ FL, 1992, WEED SCI, V40, P275
   LEITCH JA, 1994, 316 N DOK STAT U, P1
   Leung B, 2004, ECOLOGY, V85, P1651, DOI 10.1890/02-0571
   Leung B, 2002, P ROY SOC B-BIOL SCI, V269, P2407, DOI 10.1098/rspb.2002.2179
   Liebhold A, 2003, ECOL LETT, V6, P133, DOI 10.1046/j.1461-0248.2003.00405.x
   LYM RG, 1997, HIST LEAFY SPURGE CO
   LYM RG, 1993, LEAFY SPURGE IDENTIF, P1
   MacIsaac HJ, 2004, ECOL APPL, V14, P773, DOI 10.1890/02-5377
   MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522
   Padbury G, 2002, AGRON J, V94, P251, DOI 10.2134/agronj2002.0251
   Rouget M, 2003, BIOL CONSERV, V112, P63, DOI 10.1016/S0006-3207(02)00395-6
   Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037
   Seaman DE, 1996, ECOLOGY, V77, P2075, DOI 10.2307/2265701
   SELLECK GW, 1962, ECOL MONOGR, V32, P1, DOI 10.2307/1942359
   STROH RK, 1990, LEAFY SPURGE PATCH E, P15
   TAYLOR RAJ, 1978, ECOL ENTOMOL, V3, P63, DOI 10.1111/j.1365-2311.1978.tb00903.x
   *USDA ARS TEAM LEA, 2002, MULT SPEC GRAZ LEAF
   *USDA ARS TEAM LEA, 2002, BIOL CONTR LEAF SPUR
   *USDA ARS TEAM LEA, 2002, HERB CONTR LEAF SPUR
   WALLACE B, 1966, AM NAT, V100, P551, DOI 10.1086/282449
   WALLACE N M, 1992, North Dakota Farm Research, V49, P9
   Watson A. K., 1985, LEAFY SPURGE, P93
NR 42
TC 1
Z9 1
U1 4
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1672-9072
EI 1744-7909
J9 J INTEGR PLANT BIOL
JI J. Integr. Plant Biol.
PD DEC
PY 2007
VL 49
IS 12
BP 1681
EP 1692
DI 10.1111/j.1744-7909.2007.00601.x
PG 12
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 234WL
UT WOS:000251194800003
DA 2018-12-27
ER

PT J
AU Zi, XH
   Abuhamed, M
   Wang, YQ
AF Zi Xiaohong
   Abuhamed, Mutasem
   Wang Ya-Qin
TI RETRACTED: Mutation analysis of WASF2 and GALE genes in one chinese
   family with benign familial infantile convulsions with a novel locus
   (Retracted Article. See vol 56, pg 726, 2008)
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Article; Retracted Publication
DE benign familial infantile convulsions; epilepsy; linkage analysis;
   candidate genes
ID EPIMERASE-DEFICIENCY GALACTOSEMIA; SEIZURES; EPILEPSY; LINKAGE; CHANNEL
AB Benign familial infantile convulsions (BFIC) are an autosomal dominant form of idiopathic epilepsy in which partial and generalized seizures commence in the first 3 months of life and spontaneously remit by age 1 year. As it is still unknown whether WASF2 and GALE genes are responsible for pure BFIC syndromes, in this article, mutations of the WASF2 and GALE genes in the proband of one Chinese family with pure BFICs were studied. Mutation analysis was carried out by polymerse chain reaction and deoxyribonucleic acid direct sequencing. One exonic variant (1047A -> G) and one intronic variant (lVS10+13A -> G), neither causing a modification of the physiologic messenger ribonucleic acid maturation, were found. The WASF2 and GALE genes do not appear to be involved in the ethiopathogenesis of pure BFIC syndromes, at least in the Chinese family we studied.
C1 [Zi Xiaohong; Abuhamed, Mutasem; Wang Ya-Qin] Cent S Univ, Affiliated Xiangya Hosp 3, Dept Neurol, Changsha 410013, Hunan, Peoples R China.
RP Zi, XH (reprint author), Cent S Univ, Affiliated Xiangya Hosp 3, Dept Neurol, Changsha 410013, Hunan, Peoples R China.
CR Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080
   Berkovic SF, 2004, ANN NEUROL, V55, P550, DOI 10.1002/ana.20029
   BERQUIN P, 1992, MED HYG, V50, P425
   Callenbach Petra M C, 2002, Eur J Paediatr Neurol, V6, P269, DOI 10.1053/ejpn.2002.0609
   Caraballo R, 2001, AM J HUM GENET, V68, P788, DOI 10.1086/318805
   DORDI B, 1992, REV ESP EPILEPSIA, V7, P10
   ECHENNE B, 1994, BRAIN DEV-JPN, V16, P108, DOI 10.1016/0387-7604(94)90044-2
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   FRIEDMAN JH, 1989, NEUROLOGY, V39, P741, DOI 10.1212/WNL.39.5.741
   Guipponi M, 1997, HUM MOL GENET, V6, P473, DOI 10.1093/hmg/6.3.473
   Heron SE, 2002, LANCET, V360, P851, DOI 10.1016/S0140-6736(02)09968-3
   International League Against Epilepsy, 1989, EPILEPSIA, V30, P389, DOI DOI 10.1111/J.1528-1157.1989.TB05316.X
   LEE WL, 1993, J PEDIATR-US, V123, P588, DOI 10.1016/S0022-3476(05)80958-8
   Malacarne M, 2001, AM J HUM GENET, V68, P1521, DOI 10.1086/320596
   Miki H, 2000, NATURE, V408, P732
   Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125
   Pereira S, 2004, EPILEPSIA, V45, P384, DOI 10.1111/j.0013-9580.2004.47703.x
   Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517
   Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200
   Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1
   VIGEVANO F, 1992, EUR J PEDIATR, V151, P608, DOI 10.1007/BF01957732
   WANG JQ, 2002, ZHONGHUA ER KE ZA ZH, V40, P513
   Xiao B, 2005, EUR J NEUROL, V12, P344, DOI 10.1111/j.1468-1331.2004.00989.x
NR 23
TC 0
Z9 0
U1 3
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD DEC
PY 2007
VL 55
IS 8
BP 439
EP 443
DI 10.2310/6650.2007.00027
PG 5
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 263LL
UT WOS:000253218500015
DA 2018-12-27
ER

PT J
AU Wijnhoven, TJM
   Lensen, JFM
   Wismans, RGP
   Lefeber, DJ
   Rops, ALWMM
   van der Vlag, J
   Berden, JHM
   van den Heuvel, LPWJ
   van Kuppevelt, TH
AF Wijnhoven, Tessa J. M.
   Lensen, Joost F. M.
   Wismans, Ronnie G. P.
   Lefeber, Dirk J.
   Rops, Angelique L. W. M. M.
   van der Vlag, Johan
   Berden, Jo H. M.
   van den Heuvel, Lambert P. W. J.
   van Kuppevelt, Toin H.
TI RETRACTED: Removal of heparan sulfate from the glomerular basement
   membrane blocks protein passage (Retracted Article. See vol 19, pg 647,
   2008)
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article; Retracted Publication
ID CONGENITAL NEPHROTIC SYNDROME; DIABETIC-NEPHROPATHY; SIALIC-ACID;
   SELECTIVE PROTEINURIA; MONOCLONAL-ANTIBODY; FILTRATION BARRIER; ANIONIC
   SITES; FINNISH TYPE; EXPRESSION; KIDNEY
AB Heparan sulfate (HIS) within the glomerular basement membrane (GBM) is thought to play a major role in the charge-selective properties of the glomerular capillary wall. Recent data, however, raise questions regarding the direct role of HIS in glomerular filtration. For example, in situ studies suggest that HS may prevent plasma macromolecules from clogging the GBM, keeping it in an "open" state. We evaluated this potential role of HIS in vivo by studying the passage of protein through the glomerular capillary wall in the presence and absence of HS. Intravenous administration of neuraminidase removed neuraminic acid-but not HS-from the GBM, and this led to albuminuria. Concomitant removal of HIS with heparinase 111, confirmed by ultrastructural imaging, prevented the development of albuminuria in response to neuraminidase treatment. Taken together, these results suggest that HIS keeps the GBM in an open state, facilitating passage of proteins through the glomerular capillary wall.
C1 [Wijnhoven, Tessa J. M.; Lensen, Joost F. M.; Wismans, Ronnie G. P.; van Kuppevelt, Toin H.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Matrix Biochem, Nijmegen, Netherlands.
   [Rops, Angelique L. W. M. M.; van der Vlag, Johan; Berden, Jo H. M.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Nephrol Res Lab, Nijmegen, Netherlands.
   [Wijnhoven, Tessa J. M.; van den Heuvel, Lambert P. W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Nephrol, Nijmegen, Netherlands.
   [Lefeber, Dirk J.] Radboud Univ Nijmegen, Med Ctr, Lab Pediat & Neurol, Nijmegen, Netherlands.
   [Rops, Angelique L. W. M. M.; van der Vlag, Johan; Berden, Jo H. M.] Radboud Univ Nijmegen, Med Ctr, Div Nephrol, Nijmegen, Netherlands.
RP van Kuppevelt, TH (reprint author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Matrix Biochem 280, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM a.vankuppevelt@ncmls.ru.nl
RI Van der Vlag, Johan/E-4636-2010; Heuvel, L.P.W.J./H-8044-2014; Berden,
   J.H.M./H-8009-2014; Lefeber, Dirk/A-2146-2014
OI Van der Vlag, Johan/0000-0001-7843-5918; Heuvel,
   L.P.W.J./0000-0003-3917-6727; 
CR Bowry SK, 2002, INT J ARTIF ORGANS, V25, P447
   Chahine NO, 2005, BIOPHYS J, V89, P1543, DOI 10.1529/biophysj.104.057315
   CHAREST PM, 1985, P NATL ACAD SCI USA, V82, P8508, DOI 10.1073/pnas.82.24.8508
   CHEN S, 2006, J AM SOC NEPHROL, V17
   D'Amico G, 2003, KIDNEY INT, V63, P809, DOI 10.1046/j.1523-1755.2003.00840.x
   DANIELS BS, 1994, J LAB CLIN MED, V124, P224
   DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961
   Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Gelberg H, 1996, LAB INVEST, V74, P907
   GREGOR HP, 1978, SCI AM, V239, P88
   Groffen AJ, 1998, J HISTOCHEM CYTOCHEM, V46, P19, DOI 10.1177/002215549804600104
   Groffen AJA, 1999, NEPHROL DIAL TRANSPL, V14, P2119, DOI 10.1093/ndt/14.9.2119
   HARVEY S, 2005, J AM SOC NEPHROL, V16
   Inoue S, 1996, ULTRASTRUCT PATHOL, V20, P409, DOI 10.3109/01913129609016343
   KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688
   KANWAR YS, 1991, SEMIN NEPHROL, V11, P390
   KANWAR YS, 1982, KIDNEY INT, V21, P565, DOI 10.1038/ki.1982.63
   KANWAR YS, 1982, J CELL BIOL, V93, P489, DOI 10.1083/jcb.93.2.489
   KLINKMANN H, 1995, NEPHROL DIAL TRANSPL, V10, P39, DOI 10.1093/ndt/10.supp3.39
   Kramer A, 2006, J AM SOC NEPHROL, V17, P2513, DOI 10.1681/ASN.2006020184
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979
   LJUNGBERG P, 1995, HISTOCHEM J, V27, P536
   MAKINO H, 1992, NEPHRON, V61, P415, DOI 10.1159/000186959
   MITSUHASHI H, 1993, CLIN NEPHROL, V39, P231
   MORIYA T, 1993, NEPHRON, V65, P444, DOI 10.1159/000187527
   Raats CJI, 2000, KIDNEY INT, V57, P385, DOI 10.1046/j.1523-1755.2000.00858.x
   Raats CJI, 1998, J BIOL CHEM, V273, P17832, DOI 10.1074/jbc.273.28.17832
   REEVES WH, 1980, J CELL BIOL, V85, P735, DOI 10.1083/jcb.85.3.735
   ROGERIEUX F, 1993, ANAL BIOCHEM, V211, P200, DOI 10.1006/abio.1993.1257
   Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019
   SHEMESH O, 1986, KIDNEY INT, V29, P916, DOI 10.1038/ki.1986.86
   SHEMESH O, 1986, J CLIN INVEST, V77, P868, DOI 10.1172/JCI112384
   Smit MF, 1996, BIOPHYS CHEM, V62, P73, DOI 10.1016/S0301-4622(96)02214-4
   SUZUKI M, 1984, CLIN CHIM ACTA, V143, P147
   TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060
   TOMLANOVICH S, 1987, DIABETES, V36, P556, DOI 10.2337/diabetes.36.5.556
   Tryggvason K, 2005, PHYSIOLOGY, V20, P96, DOI 10.1152/physiol.00045.2004
   van de Westerlo EMA, 2002, BLOOD, V99, P2427, DOI 10.1182/blood.V99.7.2427
   van den Hoven MJ, 2006, KIDNEY INT, V70, P2100, DOI 10.1038/sj.ki.5001985
   van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960
   VANDELEST CHA, 1994, ANAL BIOCHEM, V221, P356, DOI 10.1006/abio.1994.1425
   vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303
   VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15
   VANDENBORN J, 1995, DIABETOLOGIA, V38, P161, DOI 10.1007/s001250050266
   VANDENBORN J, 1993, KIDNEY INT, V43, P453
   VANDENHEUVEL LPWJ, 1992, PEDIATR NEPHROL, V6, P10, DOI 10.1007/BF00856820
   VANKUPPEVELT THMSM, 1994, MICROSC RES TECHNIQ, V28, P125, DOI 10.1002/jemt.1070280204
   Wijnhoven TJM, 2007, J AM SOC NEPHROL, V18, P823, DOI 10.1681/ASN.2006070692
   Zcharia E, 2004, FASEB J, V18, P252, DOI 10.1096/fj.03-0572com
NR 51
TC 16
Z9 17
U1 3
U2 8
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD DEC
PY 2007
VL 18
IS 12
BP 3119
EP 3127
DI 10.1681/ASN.2007020198
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 241AG
UT WOS:000251628700015
PM 18003778
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Koay, LB
   Sun, CS
   Tsai, SL
   Lin, CY
AF Koay, Lok-Beng
   Sun, Chi-Shu
   Tsai, Sun-Lung
   Lin, Ching-Yih
TI RETRACTED: Significant association of HLA-DQ5 with autoimmune hepatitis
   in Taiwan (Retracted Article. See vol 107, pg 275, 2008)
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article; Retracted Publication
DE autoimmune hepatitis; HLA antigens; HLA-DQ5; PCR
ID JAPANESE PATIENTS; TYPE-1; SUSCEPTIBILITY
AB Genetic predisposition is known to be an important etiopathogenic factor of autoimmune hepatitis (AIH). HLA antigens associated with AIH have been well studied in Western countries and Japan, but there is no HLA typing data of AIH patients in Taiwan. We therefore investigated HLA phenotypes and their association with AIH patients and compared the results with those of normal subjects and patients with chronic liver disease. Group I consisted of 22 AIH patients. All were born in Taiwan with no history of blood transfusion. Group 2 consisted of 19 chronic liver disease patients. Group 3 consisted of 81 unrelated healthy subjects who were normal blood donors. All three groups were tested for HLA phenotypes (HLA-A, B, C, DR, DQ) using the polymerase chain reaction-sequence specific probe method. The statistical method used was Fisher's exact test. We found that HLA-DQ5 was significantly more frequent in the AIH group compared to the control group (RR, 2.03; p = 0.034). Low frequency of A1 (n = 2/22), 138 (n = 1/22) and DR3 (n = 0/22) were noted compared to results from the West; only HLA-DR4 showed a higher rate in our AIH patients (n = 8/22). This is a preliminary report of our study of HLA antigens in AIH patients. Further investigation to characterize AIH patients into HLA allelic subgroups is being done.
C1 [Koay, Lok-Beng; Sun, Chi-Shu; Tsai, Sun-Lung; Lin, Ching-Yih] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan 710, Taiwan.
RP Koay, LB (reprint author), Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, 901 Chung Hwa Rd, Tainan 710, Taiwan.
EM 860316@mail.chimei.org.tw
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   BOBERG KM, 2002, CLIN LIVER DIS, V6, P347
   BODMER JG, 1992, HUM IMMUNOL, V34, P4, DOI 10.1016/0198-8859(92)90079-3
   Czaja AJ, 1997, HEPATOLOGY, V25, P317
   CZAJA AJ, 1995, MAYO CLIN PROC, V70, P1154, DOI 10.4065/70.12.1154
   CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1502, DOI 10.1016/0016-5085(93)90157-8
   Czaja AJ, 2002, DIGEST DIS SCI, V47, P2139, DOI 10.1023/A:1020166605016
   Czaja Albert J, 2005, Ann Hepatol, V4, P6
   Donachie SP, 2002, EXTREMOPHILES, V6, P419, DOI 10.1007/s00792-002-0274-7
   DONALDSON PT, 1991, HEPATOLOGY, V13, P701, DOI 10.1002/hep.1840130415
   Fainboim L, 2001, HEPATOLOGY, V33, P1512, DOI 10.1053/jhep.2001.24562
   Goldberg AC, 2001, HUM IMMUNOL, V62, P165, DOI 10.1016/S0198-8859(00)00234-2
   Gough A, 1996, BRIT MED J, V312, P169
   KOAY LB, 2005, J INTERN MED TAIWAN, V16, P18
   Koay LB, 2006, DIGEST DIS SCI, V51, P1978, DOI 10.1007/s10620-005-9068-y
   McFarlane IG, 1999, BIOMED PHARMACOTHER, V53, P255, DOI 10.1016/S0753-3322(99)80096-1
   Pando M, 1999, HEPATOLOGY, V30, P1374, DOI 10.1002/hep.510300611
   Qiu DK, 2003, J GASTROEN HEPATOL, V18, P63, DOI 10.1046/j.1440-1746.2003.02918.x
   SANDRO V, 1995, LANCET, V346, P608
   SEKI T, 1992, GASTROENTEROLOGY, V103, P1041, DOI 10.1016/0016-5085(92)90041-V
   Vazquez-Garcia MN, 1998, J HEPATOL, V28, P985, DOI 10.1016/S0168-8278(98)80347-4
   Yoshizawa K, 2005, J HEPATOL, V42, P578, DOI 10.1016/j.jhep.2004.12.019
NR 22
TC 4
Z9 5
U1 3
U2 13
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD DEC
PY 2007
VL 106
IS 12
BP 1063
EP 1068
DI 10.1016/S0929-6646(08)60085-6
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 246YG
UT WOS:000252043700014
PM 18194915
OA Bronze
DA 2018-12-27
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI RETRACTED: Validation of gene signatures that predict the response of
   breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC
   10994/BIG 00-01 clinical trial (Retracted Article. See vol 12, pg 116,
   2011)
SO LANCET ONCOLOGY
LA English
DT Article; Retracted Publication
ID PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; PREOPERATIVE
   CHEMOTHERAPY; RECEPTOR STATUS; DOCETAXEL; CYCLOPHOSPHAMIDE; DOXORUBICIN;
   TUMORS; WOMEN
AB Background We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial.
   Methods This trial compares a non-taxane regimen (fluorouracil, epirubicin, and cyclophosphamide [FEC] for six cycles) with a taxane regimen (docetaxel for three cycles followed by epirubicin plus docetaxel [TET] for three cycles) in women with oestrogen-receptor-negative breast cancer. The primary endpoint of the study is the difference in progression-free survival based on TP53 status and will be reported later. Predicting response with gene signatures was a planned secondary endpoint of the trial and is reported here. Pathological complete response, defined as complete disappearance of the tumour with no more than a few scattered tumour cells detected by the pathologist in the resection specimen, was used to assess chemosensitivity. RNA was prepared from sections of frozen biopsies taken at diagnosis and hybridised to Affymetrix X3P microarrays. in-vitro single-agent drug sensitivity signatures were combined to obtain FEC and TET regimen-specific signatures. This study is registered on the clinical trials site of the US National Cancer Institute website http://www.clinicaltrials.gov/ct/show/NCT00017095.
   Findings Of 212 patients with oestrogen-receptor-negative tumours assessed, 87 patients were excluded. 125 oestrogen-receptor-negative turnours (55 that showed pathological complete responses) were tested: 66 in the FEC group (28 that showed pathological complete responses) and 59 in the TET group (27 that showed pathological complete responses). The regimen-specific signatures significantly predicted pathological complete response in patients treated with the appropriate regimen (p<0.0001). The FEC predictor had a sensitivity of 96% (27 of 28 patients [95% CI 82-99]), specificity of 66% (25 of 38 patients [50-79]), positive predictive value (PPV) of 68% (27 of 40 patients [52-80]), and negative predictive value (NPV) of 96% (25 of 26 patients [81-99]). The TET predictor had a sensitivity of 93% (25 of 27 patients [77-98]), specificity 69% (22 of 32 patients [51-82]), PPV of 71% (25 of 35 patients (55-84]), and NPV of 92% (22 of 24 patients [74-98]). Analysis of tumour size, grade, nodal status, age, and regimen-specific signatures showed that the genomic signatures were the only independent variables predicting pathological complete response at p<0.01. Selection of patients with these signatures would increase the proportion of patients with pathological complete responses from 44% to around 70% in the patients studied here.
   Interpretation We have validated the use of regimen-specific drug sensitivity signatures in the context of a multicentre randomised trial. The high NPV of both signatures may allow early selection of patients with breast cancer who should be considered for trials with new drugs.
CR Abe O, 2005, LANCET, V365, P1687
   Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007
   Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005
   Bonadonna G, 1998, J CLIN ONCOL, V16, P93, DOI 10.1200/JCO.1998.16.1.93
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672
   Fisher ER, 2002, CANCER, V95, P681, DOI 10.1002/cncr.10740
   Gianni L, 2005, J CLIN ONCOL, V23, P7265, DOI 10.1200/JCO.2005.02.0818
   Guarneri V, 2006, J CLIN ONCOL, V24, P1037, DOI 10.1200/JCO.2005.02.6914
   Hannemann J, 2005, J CLIN ONCOL, V23, P3331, DOI 10.1200/JCO.2005.09.077
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078
   PEPE M, 2003, STAT EVALUTATION MED
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Ring AE, 2004, BRIT J CANCER, V91, P2012, DOI 10.1038/sj.bjc.6602235
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019
   Trudeau M, 2005, LANCET ONCOL, V6, P886, DOI 10.1016/S1470-2045(05)70424-1
   *UICC, 1997, TNM CLASS MAL TUM
NR 22
TC 0
Z9 0
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD DEC
PY 2007
VL 8
IS 12
BP 1071
EP 1078
DI 10.1016/S1470-2045(07)70345-5
PG 8
WC Oncology
SC Oncology
GA 242YR
UT WOS:000251762600024
DA 2018-12-27
ER

PT J
AU Behera, BC
   Verma, N
   Sonone, A
   Makhija, U
AF Behera, B. C.
   Verma, Neeraj
   Sonone, Anjali
   Makhija, Urmila
TI RETRACTED: Tissue culture of some lichens and screening of their
   antioxidant, antityrosinase and antibacterial properties (Retracted
   article. See vol 22, pg 708, 2008)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE lichens; antioxidant; antityrosinase; antibacterial
ID GHATTENSIS IN-VITRO; USNEA-GHATTENSIS; XANTHINE-OXIDASE;
   BULBOTHRIX-SETSCHWANENSIS; BIOLOGICAL-ACTIVITIES; USNIC ACID;
   TYROSINASE; INHIBITION; CONSTITUENTS; SUPEROXIDE
AB Lichen species Usnea ghattensis, Heterodermia podocarpa, Arthothelium awasthii and Parmotrema tinctorum have been cultured in vitro and screened for their antioxidant, antimicrobial and antityrosinase potential using different assay systems. The methanol extract of lichens showed antioxidant, antimicrobial and antityrosinase activities according to the order Usnea ghattensis > Arthothelium awasthii > Heterodermia podocarpa > Parmotrema tinctorum. The IC50 values for the antioxidant and antityrosinase activities of U. ghattensis and A. awasthii were less than or equivalent to that of standard antioxidants and tyrosinase inhibitors. The methanol extracts of the lichen cultures Usnea ghattensis and Arthothelium awasthii were effective against Bacillus licheniformis, Bacillus megaterium, Bacillus subtilis and Staphylococcus aureus. The minimum inhibitory concentration (MIC) of the extract was found to be between 5 and 10 mu g extract/mL. The results suggested that the extract of lichen cultures, U. ghattensis and A. awasthii, could be of use as an easily accessible source of natural antioxidants, tyrosinase inhibitory and antimicrobial properties as possible food supplements or in the pharmaceutical industry. Copyright (C) 2007 John Wiley & Sons, Ltd.
C1 [Behera, B. C.; Verma, Neeraj; Sonone, Anjali; Makhija, Urmila] Agharkar Res Inst, Plant Sci Div, Pune 411004, Maharashtra, India.
RP Behera, BC (reprint author), Agharkar Res Inst, Plant Sci Div, GG Agarkar Rd, Pune 411004, Maharashtra, India.
EM bcbehera2002@yahoo.co.in
CR Ahmadjian V, 1961, BRYOLOGIST, V64, P168
   AIKEN MG, 1977, BENTLEYS TXB PHARM, P498
   Arnao MB, 2000, TRENDS FOOD SCI TECH, V11, P419, DOI 10.1016/S0924-2244(01)00027-9
   Behera BC, 2006, MICROBIOL RES, V161, P232, DOI 10.1016/j.micres.2005.08.006
   Behera BC, 2006, FITOTERAPIA, V77, P208, DOI 10.1016/j.fitote.2006.02.002
   Behera BC, 2006, LWT-FOOD SCI TECHNOL, V39, P80, DOI 10.1016/j.lwt.2004.11.007
   Behera BC, 2005, BIOTECHNOL LETT, V27, P991, DOI 10.1007/s10529-005-7847-3
   Behera BC, 2005, PHYTOTHER RES, V19, P58, DOI 10.1002/ptr.1607
   Behera BC, 2004, CURR SCI INDIA, V87, P83
   Behera BC, 2000, CURR SCI INDIA, V78, P781
   Behera BC, 2003, PHYTOMEDICINE, V10, P536, DOI 10.1078/094471103322331511
   Behera BC, 2002, CURR SCI INDIA, V82, P61
   BEHERA BC, 2005, BIOTECHNOLOGICAL APP, P94
   Bischoff H. W., 1963, U TEXAS PUBL, V6318, P1
   BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0
   Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cano A, 1998, PHYTOCHEM ANALYSIS, V9, P196, DOI 10.1002/(SICI)1099-1565(199807/08)9:4<196::AID-PCA395>3.0.CO;2-W
   Cervellati R, 2002, J AGR FOOD CHEM, V50, P7504, DOI 10.1021/jf020578n
   CRITTENDEN PD, 1991, TRENDS BIOTECHNOL, V9, P409, DOI 10.1016/0167-7799(91)90141-4
   DEASON TR, 1960, U TEXAS PUBL, V6022, P70
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Duh Pin-Der, 1999, Lebensmittel-Wissenschaft and Technologie, V32, P269, DOI 10.1006/fstl.1999.0548
   *EUR PHARM, 1971, EUR PHARM, V2, P49
   FEIGE GB, 1993, J CHROMATOGR, V646, P417, DOI 10.1016/0021-9673(93)83356-W
   Funasaka Y, 2000, PIGM CELL RES, V13, P170, DOI 10.1111/j.0893-5785.2000.130830.x
   Gardner PT, 2000, FOOD CHEM, V68, P471, DOI 10.1016/S0308-8146(99)00225-3
   Gorinstein S, 2002, J SCI FOOD AGR, V82, P1166, DOI 10.1002/jsfa.1178
   GRICE HC, 1986, FOOD CHEM TOXICOL, V24, P1235
   HALLIWELL B, 1984, BIOCHEM J, V219, P1
   HATANO T, 1989, CHEM PHARM BULL, V37, P2016
   HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x
   Hettiarachchy NS, 1996, J FOOD SCI, V61, P516, DOI 10.1111/j.1365-2621.1996.tb13146.x
   HIDALGO ME, 1994, PHYTOCHEMISTRY, V37, P1585, DOI 10.1016/S0031-9422(00)89571-0
   HIGUCHI M, 1993, PLANTA MED, V59, P253, DOI 10.1055/s-2006-959662
   Honda NK, 1999, QUIM NOVA, V22, P110, DOI 10.1590/S0100-40421999000100018
   Huneck S, 1999, NATURWISSENSCHAFTEN, V86, P559, DOI 10.1007/s001140050676
   Jayaprakasha GK, 2000, Z NATURFORSCH C, V55, P1018
   KUBO I, 1995, J NAT PRODUCTS, V58, P739, DOI 10.1021/np50119a013
   Liegeois C, 2000, J AGR FOOD CHEM, V48, P1129, DOI 10.1021/jf9911242
   Lilly VG, 1951, PHYSL FUNGI, P464
   Liu F, 1997, LIFE SCI, V60, P763, DOI 10.1016/S0024-3205(97)00004-0
   Marin A, 2004, J AGR FOOD CHEM, V52, P3861, DOI [10.1021/jf0497915, 10.1021/f0497915]
   MILLER NJ, 1995, J AGR FOOD CHEM, V43, P1794, DOI 10.1021/jf00055a009
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Nash III T. H., 1996, LICHEN BIOL, P1
   NISHIKIMI M, 1972, BIOCHEM BIOPH RES CO, V46, P849, DOI 10.1016/S0006-291X(72)80218-3
   OKAMOTO G, 1992, BIOSCI BIOTECH BIOCH, V56, P928, DOI 10.1271/bbb.56.928
   Rauha JP, 2000, INT J FOOD MICROBIOL, V56, P3, DOI 10.1016/S0168-1605(00)00218-X
   Sanchez-Moreno C, 1999, FOOD RES INT, V32, P407, DOI 10.1016/S0963-9969(99)00097-6
   Sasaki K, 2002, BIOL PHARM BULL, V25, P806, DOI 10.1248/bpb.25.806
   SHAHIDI F, 1992, CRIT REV FOOD SCI, V32, P67, DOI 10.1080/10408399209527581
   Sherwin E. R., 1990, FOOD ADDITIVES, P139
   SIMIC MG, 1988, MUTAT RES, V202, P377, DOI 10.1016/0027-5107(88)90199-6
   SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49
   SUZUKI S, 1992, BIOSCI BIOTECH BIOCH, V56, P84, DOI 10.1271/bbb.56.84
   TOMA N, 2001, ROUM BIOTECHNOL LETT, V6, P1
   Wichi HP, 1988, FOOD CHEM TOXICOL, V26, P717
   YAMAMOTO Y, 1985, AGR BIOL CHEM TOKYO, V49, P3347, DOI 10.1080/00021369.1985.10867270
   YAMAMOTO Y, 1993, BRYOLOGIST, V96, P384, DOI 10.2307/3243868
   Yamamoto Y., 1998, Recent Research Developments in Phytochemistry, V2, P23
   YANAKI T, 1986, AGR BIOL CHEM TOKYO, V50, P2415, DOI 10.1080/00021369.1986.10867761
   YEN GC, 1994, J AGR FOOD CHEM, V42, P629, DOI 10.1021/jf00039a005
NR 63
TC 7
Z9 7
U1 3
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD DEC
PY 2007
VL 21
IS 12
BP 1159
EP 1170
DI 10.1002/ptr.2228
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 253XL
UT WOS:000252550800010
PM 17628467
DA 2018-12-27
ER

PT J
AU Yao, W
   Lisha, D
   YangBo, H
   Yong, Z
   BaoYu, Y
   ShiYun, C
AF Yao, Wang
   Lisha, Ding
   YangBo, Hu
   Yong, Zhang
   BaoYu, Yang
   ShiYun, Chen
TI RETRACTED: The flhDC gene affects motility and biofilm formation in
   Yersinia pseudotuberculosis (Retracted article. See vol. 52, pg. 796,
   2009)
SO SCIENCE IN CHINA SERIES C-LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE Yersinia pseudotuberculosis; flhDC; motility; biofilm
ID FLAGELLAR MASTER OPERON; QUORUM-SENSING SYSTEM; PSEUDOMONAS-AERUGINOSA;
   ESCHERICHIA-COLI; CAENORHABDITIS-ELEGANS; SWARMING MOTILITY; VIRULENCE;
   EXPRESSION; PHOSPHOLIPASE; REGULATOR
AB The flagella master regulatory gene flhDC of Yersinia pseudotuberculosis serotype III (YPIII) was mutated by deleting the middle region and replaced by a tetracycline resistant gene, and the subsequent mutant strain named YPIII. flhDC was obtained. Swimming assay showed that the swimming motility of the mutant strain was completely abolished. The promoter region of the flagella second-class regulatory gene fliA was fused with the lux box, and was conjugated with the mutant and the parent strains respectively for the first cross. LUCY assay result demonstrated that flhDC regulated the expression of fliA in YPIII as reported in E. coli. Biofilm formation of the mutant strain on abiotic and biotic surfaces was observed and quantified. The results showed that mutation of flhDC decreased biofilm formation on both abiotic and biotic surfaces, and abated the infection on Caenorhabdtis elegans. Our results suggest that mutation of the flagella master regulatory gene flhDC not only abolished the swimming motility, but also affected biofilm formation of YPIII on different surfaces. The new function of flhDC identified in this study provides a novel viewpoint for the control of bacterial biofilm formation.
C1 Chinese Acad Sci, Wuhan Inst Virol, Wuhan 430071, Peoples R China.
   Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China.
RP ShiYun, C (reprint author), Chinese Acad Sci, Wuhan Inst Virol, Wuhan 430071, Peoples R China.
EM ychen@wh.iov.cn
CR Atkinson S, 2006, J BACTERIOL, V188, P1451, DOI 10.1128/JB.188.4.1451-1641.2006
   Atkinson S, 1999, MOL MICROBIOL, V33, P1267, DOI 10.1046/j.1365-2958.1999.01578.x
   Bleves S, 2002, J BACTERIOL, V184, P3214, DOI 10.1128/JB.184.12.3214-3223.2002
   Clutterbuck AL, 2007, VET MICROBIOL, V121, P1, DOI 10.1016/j.vetmic.2006.12.029
   Garbom S, 2004, INFECT IMMUN, V72, P1333, DOI 10.1128/IAI.72.3.1333-1340.2004
   Givaudan A, 2000, J BACTERIOL, V182, P107, DOI 10.1128/JB.182.1.107-115.2000
   GIVSKOV M, 1995, MOL MICROBIOL, V15, P445, DOI 10.1111/j.1365-2958.1995.tb02258.x
   Harris SJ, 1998, MOL MICROBIOL, V28, P705, DOI 10.1046/j.1365-2958.1998.00825.x
   Huber B, 2001, MICROBIOL-SGM, V147, P2517, DOI 10.1099/00221287-147-9-2517
   Jefferson KK, 2004, FEMS MICROBIOL LETT, V236, P163, DOI 10.1016/j.femsle.2004.06.005
   Joshua GWP, 2003, MICROBIOL-SGM, V149, P3221, DOI 10.1099/mic.0.26475-0
   Kalmokoff M, 2006, J BACTERIOL, V188, P4312, DOI 10.1128/JB.01975-05
   Klausen M, 2003, MOL MICROBIOL, V48, P1511, DOI 10.1046/j.1365-2958.2003.03525.x
   Lauriano CM, 2004, J BACTERIOL, V186, P4864, DOI 10.1128/JB.186.15.4864-4874.2004
   MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023
   McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703
   O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x
   Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x
   Pruss BM, 2001, FEMS MICROBIOL LETT, V197, P91
   PRUSS BM, 2003, AER J BACTERIOL, V185, P534
   Schmiel DH, 2000, J BACTERIOL, V182, P2314, DOI 10.1128/JB.182.8.2314-2320.2000
   Simmons WL, 2007, J BACTERIOL, V189, P1905, DOI 10.1128/JB.01512-06
   Sperandio V, 2002, MOL MICROBIOL, V43, P809, DOI 10.1046/j.1365-2958.2002.02803.x
   Spoering AL, 2006, CURR OPIN MICROBIOL, V9, P133, DOI 10.1016/j.mib.2006.02.004
   Suntharalingam P, 2005, TRENDS MICROBIOL, V13, P3, DOI 10.1016/j.tim.2004.11.009
   Tan L, 2004, J BACTERIOL, V186, P5087, DOI 10.1128/jb.186.15.5087-5092.2004
   Wang SY, 2006, J MOL BIOL, V355, P798, DOI 10.1016/j.jmb.2005.11.020
   Wang Y, 2007, SCI CHINA SER C, V50, P385, DOI 10.1007/s11427-007-0044-y
NR 28
TC 2
Z9 2
U1 4
U2 17
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9305
J9 SCI CHINA SER C
JI Sci. China Ser. C-Life Sci.
PD DEC
PY 2007
VL 50
IS 6
BP 814
EP 821
DI 10.1007/s11427-007-0101-6
PG 8
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 232LB
UT WOS:000251020100014
DA 2018-12-27
ER

PT J
AU Yamamoto, H
   Teramoto, S
   Yamaguchi, Y
   Hanaoka, Y
   Ishii, M
   Hibi, S
   Ouchi, Y
AF Yamamoto, Hiroshi
   Teramoto, Shinji
   Yamaguchi, Yasuhiro
   Hanaoka, Yoko
   Ishii, Masaki
   Hibi, Shinichiro
   Ouchi, Yasuyoshi
TI RETRACTED: Long-term oxygen administration reduces plasma adrenomedullin
   levels in patients with obstructive sleep apnea syndrome (Retracted
   article. See vol. 10, pg. 152, 2009)
SO SLEEP MEDICINE
LA English
DT Article; Retracted Publication
DE adrenomedullin; sleep apnea; hypertension; cardiovascular disorders;
   oxyhemoglobin desaturation intensity; hypoxic stress
ID ENDOTHELIAL GROWTH-FACTOR; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASES;
   CIRCULATING ICAM-1; CELLS; EXPRESSION; ATHEROSCLEROSIS; INTERLEUKIN-6;
   RISK
AB Background and purpose: Obstructive sleep apnea syndrome (OSAS) is recognized as one of the risk factors of hypertension and cardiovascular disorders. In the current study, we hypothesized that the hypoxic stress caused by obstructive sleep apnea would increase circulating adrenomedullin (ADM) levels in untreated OSAS patients compared to an age-matched control group. We further hypothesized that oxygen administration treatment may decrease OSAS-induced hypoxic stress and ADM levels.
   Methods: We examined short-term and long-term oxygen administration effects on circulating ADM in 41 OSAS patients.
   Results: The circulating levels of ADM in untreated OSAS patients were significantly greater than those in the controls. We did not observe a significant effect inU:/AP/DTD501/SLEEP/896 2 weeks of oxygen administration on the circulating ADM in the patients, but we observed a significant effect in long-term oxygen administration for more than 3 months on plasma ADM levels. Long-term oxygen therapy decreased both the magnitude of arterial oxygen desaturation and plasma ADM levels in patients but did not decrease blood pressure.
   Conclusions: These observations suggest that long-term oxygen therapy could reduce OSAS-induced nocturnal hypoxemia and plasma ADM levels in patients with OSAS. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Yamamoto, Hiroshi; Teramoto, Shinji; Yamaguchi, Yasuhiro; Hanaoka, Yoko; Ishii, Masaki; Hibi, Shinichiro; Ouchi, Yasuyoshi] Univ Tokyo, Bunkyo Ku, Grad Sch Med, Fac Med,Dept Geriatr Med, Tokyo 1138655, Japan.
RP Teramoto, S (reprint author), Univ Tokyo, Bunkyo Ku, Grad Sch Med, Fac Med,Dept Geriatr Med, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM shinjit-tky@umin.ac.jp
CR Can M, 2006, CHEST, V129, P233, DOI 10.1378/chest.129.2.233
   Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010
   Chhajed PN, 2006, NEW ENGL J MED, V354, P1087
   Ferrario CM, 2006, AM J CARDIOL, V98, P121, DOI 10.1016/j.amjcard.2006.01.059
   Hagi-Pavli E, 2004, AM J PHYSIOL-CELL PH, V286, pC239, DOI 10.1152/ajpcell.00036.2003
   HAGIPAVLI E, 2003, ARTERIOSCLER THROMB, V23, P1377
   Ip MSM, 2004, AM J RESP CRIT CARE, V169, P348, DOI 10.1164/rccm.200306.767OC
   Kato M, 2000, CIRCULATION, V102, P2607
   Lavie L, 2002, AM J RESP CRIT CARE, V165, P1624, DOI 10.1164/rccm.20110-040OC
   Ohga E, 1999, J APPL PHYSIOL, V87, P10
   Ohga E, 2003, J APPL PHYSIOL, V94, P179, DOI 10.1152/japplphysiol.00177.2002
   Saito T, 2001, AM J PHYSIOL-HEART C, V281, pH1364
   Schulz R, 2006, J SLEEP RES, V15, P89, DOI 10.1111/j.1365-2869.2006.00498.x
   SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827
   Suzuki YJ, 2006, FREE RADICAL BIO MED, V40, P1683, DOI 10.1016/j.freerabiomed.2006.01.008
   Teramoto S, 2003, CIRCULATION, V107, pE40, DOI 10.1161/01.CIR.0000053956.46188.5F
   Teramoto S, 2005, CHEST, V127, P1074, DOI 10.1378/chest.127.3.1074
   Teramoto S, 2004, CHEST, V125, P1964, DOI 10.1378/chest.125.5.1964
   Teramoto S, 1999, CHEST, V116, P17, DOI 10.1378/chest.116.1.17
   Teramoto S, 2003, SLEEP MED, V4, P403, DOI 10.1016/S1389-9457(03)00102-3
   Teramoto S, 2003, INTERNAL MED, V42, P681, DOI 10.2169/internalmedicine.42.681
   Teramoto S, 1999, LANCET, V354, P1213, DOI 10.1016/S0140-6736(05)75426-X
   Teramoto S, 2002, LANCET, V360, P341, DOI 10.1016/S0140-6736(02)09530-2
   Teramoto S, 2001, EUR RESPIR J, V17, P573, DOI 10.1183/09031936.01.17305730
   Toba H, 2006, HYPERTENS RES, V29, P105, DOI 10.1291/hypres.29.105
   Wolk R, 2003, CIRCULATION, V108, P9, DOI 10.1161/01.CIR.0000072346.56728.E4
   Wolk R, 2004, AM J HYPERTENS, V17, P74, DOI 10.1016/j.amjpher.2003.09.004
   Yoshii T, 2006, HYPERTENS RES, V29, P457, DOI 10.1291/hypres.29.457
   Yoshimoto T, 2005, HYPERTENS RES, V28, P165, DOI 10.1291/hypres.28.165
NR 29
TC 2
Z9 2
U1 3
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
EI 1878-5506
J9 SLEEP MED
JI Sleep Med.
PD DEC
PY 2007
VL 9
IS 1
BP 80
EP 87
DI 10.1016/j.sleep.2007.02.002
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 255ZD
UT WOS:000252696300013
PM 17512795
DA 2018-12-27
ER

PT J
AU Kuhle, M
AF Kuhle, Matthias
TI RETRACTED: The past valley glacier network in the Himalayas and the
   Tibetan ice sheet during the last glacial period and its
   glacial-isostatic, eustatic and climatic consequences (Retracted
   article. See vol. 485, pg. 333, 2010)
SO TECTONOPHYSICS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 17th Biennial Workshop on Electromagnetic Induction in the Earth
CY OCT 18-23, 2004
CL Hyderabad, INDIA
DE glacial geomorphology; ice ages; Tibetan ice sheet; former glaciation of
   central Asia; glacio-isostatic uplift; lowering of sea level; Quaternary
   climate
ID TARIM-BASIN; PLATEAU; IMPACT
AB Since 1973 new data were obtained on the maximum extent of glaciation in High Asia. Evidence for an ice sheet covering Tibet during the Last Glacial Period means a radical rethinking about glaciation in the Northern Hemisphere. The ice sheet's subtropical latitude, vast size (2.4 million km(2)) and high elevation (6000 m asl) are supposed to have resulted in a substantial, albedo-induced cooling of the Earth's atmosphere and the disruption of summer monsoon circulation. Moraines were found to reach down to 460 m asl on the southern flank of the Himalayas and to 2300 m asl on the northern slope of the Tibetan Plateau, in the Qilian Shan region. On the northern slopes of the Karakoram, Aghil and Kuen-Lun mountains, moraines occur as far down as 1900 m asl. In southern Tibet radiographic analyses of erratics suggest a former ice thickness of at least 1200 m. Glacial polish and roches moutonnees in the Himalayas and Karakoram suggest former glaciers as thick as 1200-2700 m. On the basis of this evidence, a 1100-1600 m lower equilibrium line (ELA) has been reconstructed, resulting in an ice sheet of 2.4 million km(2), covering almost all of Tibet. Radiometric ages, obtained by different methods, classify this glaciation as isotope stage 3-2 in age (Wurmian = last glacial period). With the help of 13 climate measuring stations, radiation- and radiation balance measurements have been carried out between 3800 and 6650 m asl in Tibet. They indicate that the subtropical global radiation reaches its highest energies on the High Plateau, thus making Tibet today's most important heating surface of the atmosphere. At glacial times 70% of those energies were reflected into space by the snow and firn of the 2.4 million km(2) extended glacier area covering the upland. As a result, 32% of the entire global cooling during the ice ages, determined by the albedo, were brought about by this area-now the most significant cooling surface. The uplift of Tibet to a high altitude about 2.75 Ma ago, coincides with the commencement of the Quaternary Ice Ages. When the Plateau was lifted above the snowline (= ELA) and glaciated, this cooling effect gave rise to the global depression of the snowline and to the first Ice Age. The interglacial periods are explained by the glacial-isostatic lowering of Tibet by 650 m, having the effect that the initial Tibet ice-which had evoked the build-up of the much more extended lowland ices-could completely melt away in a period of positive radiation anomalies. The next ice age begins, when-because of the glacial-isostatic reverse uplift-the surface of the Plateau has again reached the snowline. This explains, why the orbital variations (Milankovic-theory) could only have a modifying effect on the Quaternary climate dynamic, but were not primarily time-giving: as long as Tibet does not glaciate automatically by rising above the snowline, the depression in temperature is not sufficient for initiating a worldwide ice age; if Tibet is glaciated, but not yet lowered isostatically, a warming-up by 4 degrees C might be able to cause an important loss in surface but no deglaciation, so that its cooling effect remains in a maximum intensity. Only a glaciation of the Plateau lowered by isostasy, can be removed through a sufficiently strong warming phase, so that interglacial climate conditions are prevailing until a renewed uplift of Tibet sets in up to the altitude of glaciation.
   An average ice thickness for all of Tibet of approximately 1000 m would imply that 2.2 million km(3) of water were stored in the Tibetan ice sheet. This would correspond to a lowering in sea level of about 5.4 m. (C) 2007 Elsevier B.V All rights reserved.
C1 [Kuhle, Matthias] Univ Gottingen, Geog & High Mt Geomorphol, Inst Geog, D-37077 Gottingen, Germany.
RP Kuhle, M (reprint author), Univ Gottingen, Geog & High Mt Geomorphol, Inst Geog, Goldschmidtstr 5, D-37077 Gottingen, Germany.
EM mkuhle@gwdg.de
CR ANDREWS JT, 1970, CAN J EARTH SCI, V7, P703
   BERNHARDT F, 1958, EINSTRAHLUND ABHANDL, P1
   BROECKER WS, 1990, SCI AM, V262, P48, DOI 10.1038/scientificamerican0190-48
   CLIMAP Climate: Long-Range Investigation Mapping and Prediction Project Members, 1981, GEOL SOC AM MAP CHAR, V36, P1
   DERBYSHIRE E, 1991, QUATERNARY SCI REV, V10, P485, DOI 10.1016/0277-3791(91)90042-S
   DETERRA H, 1932, GEOLOGISCHE FORSCHUN, V2
   GANSSER A, 1983, KONGELIGE DANSKE VID, V40, P3
   Grosswald KG., 1994, GEOJOURNAL, P273, DOI [10.1007/BF00812878, DOI 10.1007/BF00812878]
   Grosswald M. G., 1994, INT PROJECT PALEOLIM, V8, P48
   GROSSWALD MG, 1987, LAST GLACIATION SAYA, P152
   HASERODT K, 1989, BEITRAGE MAT REGIONA, V2, P181
   Heuberger H., 1986, GOTTINGER GEOGR ABH, V81, P29
   HSU H, 1998, INT S QINGH TIB PLAT, V4
   IWATA S, 1982, J NEPAL GEOLOGICAL S, V2, P81
   Kamp U, 1999, BERLINER GEOGRAPHISC, P50
   Kaufmann G, 1997, QUATERNARY RES, V48, P267, DOI 10.1006/qres.1997.1924
   KUHLE M, 1988, GEOGR Z, V76, P135
   Kuhle M, 1998, QUATERN INT, V47-8, P173
   Kuhle M., 1997, GeoJournal, V42, P87, DOI 10.1023/A:1006865305667
   Kuhle M, 1998, QUATERN INT, V45-6, P71, DOI 10.1016/S1040-6182(97)00008-6
   Kuhle M., 1990, GeoJournal, V20, P415
   Kuhle M., 1999, GeoJournal, V47, P3, DOI 10.1023/A:1007039510460
   Kuhle M., 1987, GeoJournal, V14, P393
   Kuhle M., 1988, GeoJournal, V17, P581
   Kuhle M., 1988, GeoJournal, V17, P545
   Kuhle M., 1988, GeoJournal, V17, P457
   Kuhle M., 1974, Z GEOMORPHOL, V18, P472
   Kuhle M., 1976, GOTTINGER GEOGRAPHIS, VI, P1
   KUHLE M, 1987, REPORTS NE PART QUIN, P176
   KUHLE M., 1994, GEOJOURNAL, V33, P133
   KUHLE M, 1996, NEUE ERGEBNISSE EI S
   KUHLE M, 1998, KARAKORUM HINDUKUSH, P29
   Kuhle M., 2004, EISZEITALTER GEGENWA, V54, P95
   Kuhle M., 1986, NEPAL HIMALAYA GEOEC, P437
   KUHLE M, 1996, FORSCHUNG NANGA PARB, V8, P135
   KUHLE M, 1985, SUBTROPISCHES INLAND
   KUHLE M, 1991, KLIMAGESCHICHTLICHE, V1, P293
   KUHLE M, 2006, KARAKORAM TRANSITION
   KUHLE M, 1988, DTSCH GEOGRAPHENTAG, V46, P606
   KUHLE M, 1995, NEW RESULTS CONCERNI
   KUHLE M, 1982, ERSTE DTSCH CHINESIS, V43, P63
   KUHLE M, 1993, PETERMANNS GEOGRAPHI, V137, P133
   Kuhle M., 1976, GOTTINGER GEOGRAPHIS, VII, P1
   Kuhle M., 1982, SITZUNGSBER MITT BRA, V6, P68
   Kuhle M., 2001, GEOJOURNAL, V54, P109
   Kuhle M, 1991, GEOJOURNAL, V25, P133
   Kuhle M., 1982, Z GEOMORPHOLOGIE S, V41
   KUHLE M, 1980, KLIMAGEOMORPHOLOGISC, V42, P244
   KUHLE M, 2003, Z GEOMORPHOL, V130, P75
   Kuhle M., 1987, REPORTS QINGHAI XIZA, P250
   Kuhle M., 2004, EXTENT CHRONOLOGY GL, V3, P175
   KUHLE M, 1987, ABSOLUTE DATIERUNGEN, V45, P200
   Kuhle M., 1983, Z GEOMORPHOLOGIE S, V41, P1
   KUHLE M, 1988, GEOMORPHOLOGIE NIVAL, V46, P413
   Kuhle M, 2005, GEOJOURNAL, V62, P193, DOI 10.1007/s10708-005-2338-6
   Kutzbach J, 1998, QUATERNARY SCI REV, V17, P473, DOI 10.1016/S0277-3791(98)00009-2
   LANGTYPE D, 1928, CONDIZIONIFISICHE 2, V4
   LAUSCHER F, 1956, BER DT WETTERDIENST, V4, P21
   LAUTENSCHLAGER M, 1987, 11 MPG I MET, P1
   LICHTENECKER N, 1936, GEGENWARTIGE EISZEIT, V3, P141
   Louis H., 1955, GEOGRAPHISCHES TASCH, P414
   Marsiat I, 1994, PALAEOCLIMATES, V1, P59
   MILANKOVIC M, 1941, KANON ERDBESTRAHULUN
   MORNER NA, 1978, GEOLOGY, V6, P41, DOI 10.1130/0091-7613(1978)6<41:FFASAF>2.0.CO;2
   NORIN E, 1982, SINOSWEDISH EXPEDITI, V541
   Norin E, 1932, GEOGR REV, V22, P591, DOI 10.2307/208816
   PORTER SC, 1970, GEOL SOC AM BULL, V81, P1421, DOI 10.1130/0016-7606(1970)81[1421:QGRISK]2.0.CO;2
   PRINZ G, 1927, JB KONIGLICH UNGARIS, V25
   Schneider H. J., 1959, MITT GEOGR GES MUNCH, V44, P201
   SCHNEIDER HJ, 1957, GEOL RUNDSCH, V46, P426, DOI DOI 10.1007/BF01803034
   SCHWARZBACH M, 1974, KLIMA VORZEIT, V3, P1
   SHIY, 1979, P CANB S 1979
   Tafel A., 1914, MEINE TIBETREISE STU, V2
   TIANCHI L, 1988, GEOJOURNAL, V17, P649
   TRINKLER E, 1932, GEOGRAPHISCHE FORSCH, P1
   VERBITSKY MY, 1992, J GEOPHYS RES-ATMOS, V97, P5895, DOI 10.1029/92JD00223
   von Heimhalt Hofer, 1879, SITZUNGSBERICHT A MP, V79, P331
   von Wissmann H, 1959, AKAD WISS LIT AB MNW, V14, P1103
   VONLOCZY L, 1990, WISSENSCHAFTLICHEN E, V3, P307
   Ward FK, 1926, GEOGR J, V67, P97, DOI 10.2307/1783136
   Yamanaka H, 1982, SCI REPORT TOHOKU U, V32, P46
   Zabirov RD, 1955, OLEDENENIE PAMIRA
   1987, SEISMOGRAPHIC MAP CH
NR 83
TC 8
Z9 8
U1 3
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0040-1951
J9 TECTONOPHYSICS
JI Tectonophysics
PD DEC 1
PY 2007
VL 445
IS 1-2
BP 116
EP 144
DI 10.1016/j.tecto.2007.06.007
PG 29
WC Geochemistry & Geophysics
SC Geochemistry & Geophysics
GA 244CU
UT WOS:000251844400008
DA 2018-12-27
ER

PT J
AU Tsagias, N
   Kouzi-Koliakos, K
   Hamidi-Alamdari, D
   Karagiannis, V
   Kostidou, E
   Koliakos, G
AF Tsagias, N.
   Kouzi-Koliakos, K.
   Hamidi-Alamdari, D.
   Karagiannis, V.
   Kostidou, E.
   Koliakos, G.
TI RETRACTED: Cell recovery sufficient for adult transplantation by
   additional cord blood collection from placenta (Retracted Article)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Retracted Publication
ID UNRELATED DONORS; ENGRAFTMENT; RECIPIENTS; SURVIVAL; LEUKEMIA
AB The amount of newborn blood that can be collected from a single cord donor is limited, but a significant amount remains in the placenta. We used a simplified perfusion method to collect this additional blood. Umbilical cord blood from 15 newborns was collected before placental delivery by umbilical vein puncture. After delivery, the placenta was placed on sterile gauze and 63 mL of citrate-phosphate-dextrose-adenine anticoagulant were injected into the umbilical vein that was then clamped near the placenta. The placenta was gently massaged, hung over a sterile vessel, and the umbilical cord cut sterilely near the embryonic surface. Additional blood was collected into the sterile vessel by pressuring a gauze bag around the placenta. We assessed the contribution of this second fraction to the total volume, total nucleated cell (NC), CD34(+), hernatopoietic progenitors cell, and colony forming unit count and bacterial contamination risk.
   The total collected volume was 127.3 mL (range 92-170) and the NC content was 1.6 +/- 0.73 x 10(9). The mean second fraction contribution from 15 units to the total nucleated and mononuclear cell content was 54 +/- 9.87% and 54 +/- 9.52%, respectively. The added percentage of CD34(+) and hematopoietic progenitor cells was 54.3 +/- 10.35% and 46.7 +/- 11.5%, respectively, while the additional percentages of colony forming-granulocyte macrophage and colony forming-erythroid in the second fraction were 43.2 +/- 5.5% and 39.8 +/- 4.3%, respectively, indicating that the cells collected after placental perfusion (second fraction) had similar HPC content and in vitro hematopoietic potential. The method did not increase the risk of bacterial contamination.
C1 [Hamidi-Alamdari, D.; Kostidou, E.; Koliakos, G.] Aristotle Univ Thessaloniki, Sch Med, Dept Biol Chem, Thessaloniki 54124, Greece.
   [Tsagias, N.; Karagiannis, V.] Aristotle Univ Thessaloniki, Sch Med, Univ Obstet & Gynaecol Clin, Ippokrat Gen Hosp, Thessaloniki 54124, Greece.
   [Kouzi-Koliakos, K.] Aristotle Univ Thessaloniki, Sch Med, Dept Histol, Thessaloniki 54124, Greece.
RP Koliakos, G (reprint author), Aristotle Univ Thessaloniki, Sch Med, Dept Biol Chem, Thessaloniki 54124, Greece.
EM koliakos@yahoo.gr
CR Barker JN, 2003, NAT REV CANCER, V3, P526, DOI 10.1038/nrc1125
   Barker JN, 2001, NEW ENGL J MED, V344, P1870, DOI 10.1056/NEJM200106143442417
   Bornstein R, 2005, STEM CELLS, V23, P324, DOI 10.1634/stemcells.2004-0047
   Elchalal U, 2000, AM J OBSTET GYNECOL, V182, P227, DOI 10.1016/S0002-9378(00)70517-5
   Gluckman E, 2001, NEW ENGL J MED, V344, P1860, DOI 10.1056/NEJM200106143442410
   Jaroscak J, 2003, BLOOD, V101, P5061, DOI 10.1182/blood-2001-12-0290
   Keeney M, 2000, CYTOTHERAPY, V2, P395, DOI 10.1080/146532400539242
   Kogler G, 1998, BONE MARROW TRANSPL, V22, pS14
   Kogler G, 1999, KLIN PADIATR, V211, P224, DOI 10.1055/s-2008-1043793
   Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303
   Long GD, 2003, BIOL BLOOD MARROW TR, V9, P772, DOI 10.1016/j.bbmt.2003.08.007
   Michel G, 2003, BLOOD, V102, P4290, DOI 10.1182/blood-2003-04-1288
   Migliaccio AR, 2000, BLOOD, V96, P2717
   Pecora AL, 2000, BONE MARROW TRANSPL, V25, P797, DOI 10.1038/sj.bmt.1702222
   Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201
   Rubinstein P, 2000, BLOOD, V96, p588A
   Shpall EJ, 2002, BIOL BLOOD MARROW TR, V8, P368, DOI 10.1053/bbmt.2002.v8.pm12171483
   TSAGIAS N, TRANSPLANT P, V43, P1365
   Wagner JE, 2002, BLOOD, V100, P1611, DOI 10.1182/blood-2002-01-0294
NR 19
TC 4
Z9 4
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2007
VL 39
IS 10
BP 3380
EP 3384
DI 10.1016/j.transproceed.2007.06.087
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 246WG
UT WOS:000252037900092
PM 18089389
DA 2018-12-27
ER

PT J
AU Villares, GJ
   Zigler, M
   Blehm, K
   Bogdan, C
   McConkey, D
   Colin, D
   Bar-Eli, M
AF Villares, G. J.
   Zigler, M.
   Blehm, K.
   Bogdan, C.
   McConkey, D.
   Colin, D.
   Bar-Eli, Menashe
TI RETRACTED: Targeting EGFR in bladder cancer (Retracted article. See vol.
   30, pg. 723, 2012)
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE bladder cancer; EGFR; mutations; tyrosine kinase
ID EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; FACTOR RECEPTOR COMMON;
   MONOCLONAL-ANTIBODIES; MUTANT EGFRVIII; NUDE-MICE; GEFITINIB;
   EXPRESSION; RESISTANCE; MUTATIONS
AB Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers. In addition to gene amplification, point mutations within the kinase domain also occur. Previous reports indicate that the patient's response to gefitinib depends on either the presence of mutations within the kinase domain of EGFR or the expression of the most frequent alteration, the truncated EGFR variant III (EGFRvIII). Therefore, it is important to determine if these EGFR alterations are present in urothelial carcinoma. The kinase domain of EGFR (exons 18-21) from 11 bladder cancer cell lines as well as from 75 patient tumors was analyzed by automated sequencing. No mutations were detected in all samples tested. Furthermore, analysis of EGFRvIII by immunohistochemistry revealed that almost half of all the patient samples expressed this truncation in a urothelial carcinoma tissue microarray. However, there have been previous reports of inconsistencies in detecting EGFRvIII by immunohistochemistry owing to the specificity of the antibodies and the methodologies utilized. Therefore, these results were validated by reverse transcription PCR, real-time PCR and western blot analysis. In these assays, none of the samples tested positive for EGFRvIII. Taken together, these results indicate that mutations within the tyrosine kinase domain of EGFR and expression of EGFRvIII are rare events in bladder cancer and therefore do not contribute to the malignant phenotype of this tumor. These results have clinical implications in selecting tyrosine kinase inhibitors for the therapy of urothelial carcinoma.
C1 Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA.
RP Bar-Eli, M (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA.
EM mbareli@mdanderson.org
CR Araujo A, 2007, ONCOLOGIST, V12, P201, DOI 10.1634/theoncologist.12-2-201
   BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251
   Bellmunt J, 2003, CRIT REV ONCOL HEMAT, V46, pS85, DOI 10.1016/S1040-8428(03)00067-2
   BIGNER SH, 1990, CANCER RES, V50, P8017
   Blehm KN, 2006, CLIN CANCER RES, V12, P4671, DOI 10.1158/1078-0432.CCR-06-0407
   Cappuzzo F, 2005, J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112
   CARPENTER G, 1990, J BIOL CHEM, V265, P7709
   Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855
   DINNEY CPN, 1995, J UROLOGY, V154, P1532, DOI 10.1016/S0022-5347(01)66923-4
   GARCIA DP, 1993, CANCER RES, V53, P3217
   Highshaw RA, 2004, CURR OPIN UROL, V14, P295, DOI 10.1097/00042307-200409000-00008
   Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927
   Kassouf W, 2005, CANCER RES, V65, P10524, DOI 10.1158/0008-5472.CAN-05-1536
   Kim JH, 2005, LAB INVEST, V85, P532, DOI 10.1038/labinvest.3700250
   Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521
   Liukkonen T, 1999, EUR UROL, V36, P393, DOI 10.1159/000020039
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   MELLON K, 1995, J UROLOGY, V153, P919, DOI 10.1016/S0022-5347(01)67604-3
   Montgomery RB, 2002, INT J CANCER, V101, P111, DOI 10.1002/ijc.10560
   MOSCATELLO DK, 1995, CANCER RES, V55, P5536
   Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200
   Moscatello DK, 1996, ONCOGENE, V13, P85
   NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727
   Pedersen MW, 2005, BRIT J CANCER, V93, P915, DOI 10.1038/sj.bjc.6602793
   Perrotte P, 1999, CLIN CANCER RES, V5, P257
   Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639
   Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9
   REIST CJ, 1995, CANCER RES, V55, P4375
   Schmidt MHH, 2005, J BIOL CHEM, V280, P3414, DOI 10.1074/jbc.M409839200
   Shrader M, 2007, CANCER RES, V67, P1430, DOI 10.1158/0008-5472.CAN-06-1224
   Sriplakich S, 1999, BJU INT, V83, P498
   SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602
   Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526
   WIKSTRAND CJ, 1995, CANCER RES, V55, P3140
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
NR 35
TC 38
Z9 40
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
PD DEC
PY 2007
VL 25
IS 6
BP 573
EP 579
DI 10.1007/s00345-007-0202-7
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 236QU
UT WOS:000251319300004
PM 17690890
DA 2018-12-27
ER

PT J
AU Shih, HC
   Chou, P
   Liu, CM
   Tung, TH
AF Shih, Hui-Chuan
   Chou, Pesus
   Liu, Chi-Ming
   Tung, Tao-Hsin
TI RETRACTED: Estimation of progression of multi-state chronic disease
   using the Markov model and prevalence pool concept (Retracted article.
   See vol. 9, art. no. 45, 2009)
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article; Retracted Publication
ID SOJOURN TIME; CANCER; RATES; TAIWAN
AB Background: We propose a simple new method for estimating progression of a chronic disease with multi-state properties by unifying the prevalence pool concept with the Markov process model.
   Methods: Estimation of progression rates in the multi-state model is performed using the E-M algorithm. This approach is applied to data on Type 2 diabetes screening.
   Results: Good convergence of estimations is demonstrated. In contrast to previous Markov models, the major advantage of our proposed method is that integrating the prevalence pool equation ( that the numbers entering the prevalence pool is equal to the number leaving it) into the likelihood function not only simplifies the likelihood function but makes estimation of parameters stable.
   Conclusion: This approach may be useful in quantifying the progression of a variety of chronic diseases.
C1 [Shih, Hui-Chuan] Kaohsiung Armed Forces Gen Hosp, Dept Nursing, Kaohsiung, Taiwan.
   [Chou, Pesus; Liu, Chi-Ming; Tung, Tao-Hsin] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan.
   [Chou, Pesus; Liu, Chi-Ming; Tung, Tao-Hsin] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan.
   [Liu, Chi-Ming; Tung, Tao-Hsin] Cheng Hsin Rehabil Med Ctr, Dept Med Res & Educ, Taipei, Taiwan.
   [Tung, Tao-Hsin] Fu Jen Catholic Univ, Sch Med, Fac Publ Hlth, Taipei, Taiwan.
RP Shih, HC (reprint author), Kaohsiung Armed Forces Gen Hosp, Dept Nursing, Kaohsiung, Taiwan.
EM arden.shih@msa.hinet.net; pschou@ym.edu.tw; ch2783@chgh.org.tw;
   ch2876@chgh.org.tw
CR BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404
   Chen HH, 1997, J EPIDEMIOL BIOSTAT, V2, P9
   CHEN HH, 1996, STATISTICIAN, V45, P307
   Chen KT, 1999, DIABETES RES CLIN PR, V43, P101, DOI 10.1016/S0168-8227(98)00126-0
   CHOU P, 1992, DIABETES CARE, V15, P81, DOI 10.2337/diacare.15.1.81
   Cox D, 1965, THEORY STOCHASTIC PR
   DAY NE, 1984, BIOMETRICS, V40, P1, DOI 10.2307/2530739
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1
   DUFFY SW, 1995, STAT MED, V14, P1531, DOI 10.1002/sim.4780141404
   EMILI M, 1996, MATH 3 0 STANDARD AD
   KALBFLEISCH JD, 1985, J AM STAT ASSOC, V80, P863, DOI 10.2307/2288545
   Longford NT, 2000, J R STAT SOC A STAT, V163, P381, DOI 10.1111/1467-985X.00174
   Prevost TC, 1998, AM J EPIDEMIOL, V148, P609
   ROTHMAN K, 1998, MODERN EPIDEMIOLOGY
   SHARPLES LD, 1993, STAT MED, V12, P1155
   Tabar L, 1999, CANCER, V86, P449, DOI 10.1002/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.3.CO;2-H
   Tanner MA., 1996, TOOLS STAT INFERENCE
   van Oortmarssen G J, 1995, Stat Methods Med Res, V4, P33
   VANOORTMARSSEN GJ, 1990, INT J CANCER, V46, P207, DOI 10.1002/ijc.2910460211
   Welton NJ, 2005, MED DECIS MAKING, V25, P633, DOI 10.1177/0272989X05282637
NR 20
TC 4
Z9 4
U1 3
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD NOV 9
PY 2007
VL 7
AR 34
DI 10.1186/1472-6947-7-34
PG 12
WC Medical Informatics
SC Medical Informatics
GA 261XW
UT WOS:000253114300001
PM 17996074
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: 2-(benzoylhydrazinocarbonyl)benzoic acid(Retracted article.
   See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID X-RAY; ACID
AB In the molecule of the title compound, C15H12N2O4, the benzene rings are oriented at a dihedral angle of 8.01 ( 3) degrees. In the crystal structure, intermolecular N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3167
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 13
TC 0
Z9 0
U1 2
U2 9
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD NOV
PY 2007
VL 63
BP O4441
EP U4582
DI 10.1107/S160053680705204X
PN 11
PG 10
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800416
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED:
   catena-poly[[tetra-mu-anilinoacetamidato-is(1,10-phenanthroline)dicerium
   (III)]di-mu-anilinoacetamidato] (Retracted article. See vol. 66, pg.
   E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Ce7(C(8)H(8)N(2)O)(6)(C(12)H(8)N(2))(2)](n), is a polymeric complex based on a binuclear unit with an inversion centre midway between the two Ce(III) ions, which are bridged by two tridentate, two bidentate and four monodentate ( within the binuclear unit) acetamide groups. Each Ce atom is nine-coordinated by two 1,10-phenanthroline N atoms, four O and three N atoms of anilinoacetamide ligands. In the crystal structure, C-H center dot center dot center dot O, C-H center dot center dot center dot N, N-H center dot center dot center dot N and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supra-olecular network structure; an N-H center dot center dot center dot O hydrogen bond is also present within one ligand.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2659, DOI 10.1107/S1600536807047733
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2592, DOI 10.1107/S1600536807045485
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
NR 6
TC 0
Z9 0
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2775
EP U1337
DI 10.1107/S1600536807050969
PN 11
PG 15
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800121
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED:
   catena-Poly[hexakis(mu(2)-anilinoacetamide)bis(1,10-phenanthroline)-dipr
   aseodymium(III)] (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Pr-2(C8H9N2O)(6)C12H8N2)(2)](n), is a polymeric complex based on a binuclear unit with an inversion centre mid-way between the two Pr-III ions, which are bridged by two tridentate, two bidentate and four monodentate (within the binuclear unit) acetamide groups. Each Pr atom is nine-coordinated by two 1,10-phenanthroline N atoms and four O and three N atoms of anilinoacetamide ligands. In the crystal structure, C-H center dot center dot center dot O, C-H center dot center dot center dot N, N-H center dot center dot center dot N and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure; an N-H center dot center dot center dot O hydrogen bond is also present within one ligand.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2592, DOI 10.1107/S1600536807045485
   Shledrick G.M., 1997, SHELXS97 SHELXL97
   SHLEDRICK GM, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
NR 5
TC 1
Z9 1
U1 3
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2659
EP U310
DI 10.1107/S1600536807047733
PN 11
PG 15
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800029
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: Tetrakis(pyridine-kappa N)bis(thiocyanato-kappa
   N)chromium(II) (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title complex, [Cr(NCS)(2)(C(5)H(5)N)(4)], the Cr(II) atom is bonded in a distorted octahedral arrangement to two N atoms of two SCN(-) ligands and four N atoms of four pyridine ligands. The Cr atom is located on a centre of inversion. In the crystal structure, C-H center dot center dot center dot N hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   POPE MT, 2001, POLYOXOMETALATE CHEM, P319
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM1445, DOI 10.1107/S160053680701879X
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM1379, DOI 10.1107/S1600536807017461
NR 12
TC 1
Z9 1
U1 3
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2809
EP U1660
DI 10.1107/S1600536807051756
PN 11
PG 9
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800145
DA 2018-12-27
ER

PT J
AU Liu, YQ
   Zeng, XR
   Luo, QY
   Xu, YP
AF Liu, Yin-Qiu
   Zeng, Xi-Rui
   Luo, Qiu-Yan
   Xu, Ya-Ping
TI RETRACTED: {2,2
   '-[o-phenylenebis(nitrilomethylidyne)]diphenolato}manganese(II)
   (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title complex, [Mn(C(20)H(14)N(2)O(2))], is a mononuclear manganese(II) compound. The manganese( II) ion is four-coordinated in a square-planar geometry by two imine N and two phenolate O atoms from one 2,2 '-[o-phenylenebis(nitrilo-methylidyne)] diphenolate Schiff base ligand. No strong hydrogen bonds were found in the crystal structure.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jianxi Province Key Lab Coordinat Chem, Jianxi 343009, Peoples R China.
RP Liu, YQ (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jianxi Province Key Lab Coordinat Chem, Jianxi 343009, Peoples R China.
EM liuyiqja@163.com
CR *BRUK AXS INC, 1997, SMART VERS 7 06A SAI
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   Liu YQ, 2007, ACTA CRYSTALLOGR E, V63, pM2396, DOI 10.1107/S1600536807040640
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   *SIEM AN XRAY INST, 1996, SHELXTL
NR 5
TC 1
Z9 1
U1 3
U2 14
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2854
EP U2058
DI 10.1107/S1600536807052993
PN 11
PG 9
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800180
DA 2018-12-27
ER

PT J
AU Liu, YQ
   Zeng, XR
AF Liu, Yin-Qiu
   Zeng, Xi-Rui
TI RETRACTED: N,N '-(o-Phenylene)dipicolinamide-kappa N-4]-nickel(II)
   (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Ni(C18H12N4O2)], which was synthesized by reaction of N-[2-(picolinamido) phenyl] picolinamide with Ni(NO3)(2)center dot 6H(2)O in ethanol, is a mononuclear complex in which the nickel(II) ion is coordinated by four N atoms and displays a distorted square-planar coordination geometry.
C1 JingGangShan Univ, JiangXi Province Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
RP Liu, YQ (reprint author), JingGangShan Univ, JiangXi Province Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
EM liuyiqja@163.com
CR BRUKER, 1997, SMART SAINT SADABS
   Liu YQ, 2007, ACTA CRYSTALLOGR E, V63, pM2396, DOI 10.1107/S1600536807040640
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   SIEMENS, 1996, SAINT SHELXTL
NR 4
TC 3
Z9 3
U1 4
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2684
EP U511
DI 10.1107/S1600536807048386
PN 11
PG 9
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800047
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. M.
   Xie, H. L.
   Luo, C. J.
TI RETRACTED: Hexaaquamanganese(II) bis(4-methyl-benzenesulfonate)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The asymmetric unit of the title compound, [Mn(H(2)O)(6)](C(7)H(7)O(3)S)(2), contains one half-cation and one anion; the Mn atom lies on an inversion centre. In the crystal structure, intermolecular O-H center dot center dot center dot O and O-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network structure; an intramolecular C-H center dot center dot center dot O hydrogen bond is also present.
C1 Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Math, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2724, DOI 10.1107/S1600536807049525
NR 5
TC 1
Z9 1
U1 3
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2825
EP U1817
DI 10.1107/S1600536807052051
PN 11
PG 9
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800158
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: Hexaaquachromium(II)bis(4-methyl-benzenesulfonate) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The asymmetric unit of the title compound, [Cr(H(2)O)(6)]-( C(7)H(7)O(3)S)(2), contains one half-cation and one anion; the Cr atom lies on an inversion centre. In the crystal structure, intermolecular O-H center dot center dot center dot O and O-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network; an intramolecular C-H center dot center dot center dot O hydrogen bond is also present.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR Allen FH, 1987, J CHEM SOC P2
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2724, DOI 10.1107/S1600536807049525
NR 5
TC 0
Z9 0
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2774
EP U1322
DI 10.1107/S1600536807051227
PN 11
PG 10
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800120
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED: Hexaaquacopper(II) bis(4-methylbenzenesulfonate) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB The asymmetric unit of the title compound, [Cu(H(2)O)(6)]( C(7)H(7)O(3)S)(2), contains one half- cation and one anion; the Cu atom lies on an inversion centre. In the crystal structure, intermolecular O-H center dot center dot center dot O and O-H center dot center dot center dot S hydrogen bonds result in the formation of a supramolecular network structure; an intramolecular C-H center dot center dot center dot O hydrogen bond is also present.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 13
TC 2
Z9 2
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2724
EP U857
DI 10.1107/S1600536807049525
PN 11
PG 10
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800079
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED:
   catena-poly[[tetra-mu-anilinoacetato-bis(1,10-phenanthroline)dilanthanum
   (III)]-di-mu-anilinoacetato] (Retracted article. See vol. 66, pg. E11,
   2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the crystal structure of the title compound, [La(2)(C(8)H(8)NO(2))(6)(C(12)H(8)N(2))(2)](n), the La(III) atoms are bridged by two tridentate, two bidentate and four mondentate carboxylate groups with an inversion centre between the two La(III) ions. Each La atom is nine-coordinated by two 1,10-phenanthroline N atoms and seven O atoms of four anilinoacetate ligands. In the crystal structure, the chains are linked by hydrogen bonds into a polymeric sheet structure.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2680, DOI 10.1107/S1600536807048489
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2508, DOI 10.1107/S1600536807043528
NR 7
TC 1
Z9 1
U1 4
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2772
EP U1312
DI 10.1107/S1600536807051240
PN 11
PG 14
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800119
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X. -M.
   Xie, H. -L.
   Luo, C. -J.
TI RETRACTED:
   catena-Poly[[tetra-mu-anilinoacetatobis(1,10-phenanthroline)dineodymium(
   III)]-di-mu-anilinoacetato] (Retracted article. See vol. 66, pg. E11,
   2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the crystal structure of the title compound, [Nd(2)(C(8)H(8)NO(2))(6)(C(12)H(8)N(2))(2)](n), the Nd(III) atoms are bridged by two tridentate, two bidentate and four mondentate carboxylate groups with an inversion centre between the two Nd(III) ions. Each Nd atom is nine-coordinated by two 1,10-phenanthroline N atoms and seven O atoms of four anilinoacetate ligands. In the crystal structure, the chains are linked by hydrogen bonds into a polymeric ribbon structure.
C1 Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BRUKER, 2005, APEX2
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2508, DOI 10.1107/S1600536807043528
NR 6
TC 2
Z9 2
U1 2
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP M2680
EP U484
DI 10.1107/S1600536807048489
PN 11
PG 14
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800045
DA 2018-12-27
ER

PT J
AU Li, NG
   Tao, RM
   Fu, BF
AF Li, Nai-Gen
   Tao, Rui-Min
   Fu, Bang-Feng
TI RETRACTED: N-(2-Amino-3-pyridyl) urea monohydrate (Retracted article.
   See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
DE single-crystal X-ray study; T=273 K; mean sigma(C-C)=0.006 angstrom;
   H-atom completeness 91%; R factor=0.058; wR factor=0.177;
   data-to-parameter ratio=11.9
ID CRYSTAL; ZN; CO; NI
AB In the crystal structure of the title compound, C(6)H(9)N(4)O center dot H(2)O, intermolecular O-H center dot center dot center dot N and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure; intramolecular O-H center dot center dot center dot N hydrogen bonds are also present.
C1 Xinyu Coll, Dept Mech & Elect Engn, Xinyu 338000, Peoples R China.
RP Li, NG (reprint author), Xinyu Coll, Dept Mech & Elect Engn, Xinyu 338000, Peoples R China.
EM naigenli07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 13
TC 1
Z9 1
U1 3
U2 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP O4228
EP U2561
DI 10.1107/S1600536807047526
PN 11
PG 9
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800226
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: 2-ammonio-3-carboxy-5-nitrobenzoate monohydrate (Retracted
   article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY; BENZENE-1,2-DIOXYACETIC ACID; COMPLEXES; BDOAH(2)
AB In the crystal structure of the title compound, C8H6N2O6 center dot H2O, intramolecular N-H center dot center dot center dot O and intermolecular O-H center dot center dot center dot O, O-H center dot center dot center dot N, N-H center dot center dot center dot N and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jingganshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jingganshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3617, DOI 10.1016/0277-5387(95)00161-K
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 14
TC 0
Z9 0
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP O4267
EP U2905
DI 10.1107/S1600536807048477
PN 11
PG 9
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800259
DA 2018-12-27
ER

PT J
AU Yang, XM
AF Yang, Xiao-Mao
TI RETRACTED: N-(2-Fluorophenyl) carbamic acid monohydrate (Retracted
   article. See vol. 66, pg. E21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY
AB In the crystal structure of the title complex, C(7)H(6)FNO(2)center dot H(2)O, intramolecular O-H center dot center dot center dot O hydrogen bonds are present; intermolecular N-H center dot center dot center dot O and O-H center dot center dot center dot F hydrogen bonds result in the formation of a supramolecular network.
C1 Jiangxi Univ Finance & Econ, Coll Resource & Environm Management, Inst Appl Mat, Nanchang 330013, Peoples R China.
RP Yang, XM (reprint author), Jiangxi Univ Finance & Econ, Coll Resource & Environm Management, Inst Appl Mat, Nanchang 330013, Peoples R China.
EM xiaomaoyang07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   BRUKER, 2005, APEX2
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3167
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 14
TC 2
Z9 2
U1 3
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2007
VL 63
BP O4453
EP U4691
DI 10.1107/S1600536807052464
PN 11
PG 8
WC Crystallography
SC Crystallography
GA 236CY
UT WOS:000251281800427
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Uemura, A
AF Fujii, Yoshitaka
   Uemura, Aki
TI RETRACTED: The effects of different dobutamine infusion rates on
   hypercapnic depression of diaphragmatic contractility in
   pentobarbital-anesthetized dogs (Retracted article. See vol. 116, pg.
   747, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RESPIRATORY MUSCLES; CARBON-DIOXIDE; FAILURE; RESPONSES; VOLUNTARY;
   RECOVERY; FATIGUE
AB Previously, we demonstrated that dobutamine was more effective than dopamine for the improvement of diaphragmatic contractility during hypercapnia. Here, we studied the effects of different dobutamine infusion rates on hypercapnic depression of diaphragmatic contractility in pentobarbitalanesthetized dogs. METHODS:Animals were divided into four groups of six each. In each group, hypercapnia (80-90 mm Hg) was produced by adding 10%, CO2 to inspired gas. When hypercapnia was established, group Dob 0 received no study drug; group Dob 5 was induced with dobutamine 5 mu g center dot kg(-1) center dot min(-1); group Dob 10 was induced with dobutamine 10 mu g center dot kg(-1) center dot min (-1); group Dob 15 was induced with dobutamine 15 mu g center dot kg(-1) center dot min(-1). Study drugs were - g min administered IV for 60 min. Diaphragmatic contractility was assessed by measurement of transcliaphragmatic pressure (Pdi). RESULTS: In the presence of hypercapnia, in each group, Pdi at low-frequency (20 Hz) and high-frequency (100 Hz) stimulation decreased from baseline (P < 0.05). In group Dob 0, Pdi to each Stimulus did not change from hypercapnia-induced values. In groups Dob 5, Dob 10 and Dob 15, during the study drug administration, Pdi at both stimuli increased from hypercapnia-induced values (P < 0.05). There was a significant positive correlation between dobutamine infusion rates and Pdi at both Stimuli (P = 0.0001). CONCLUSION: Dobutamine effectively improves hypercapnic depression of diaphragmatic contractility in an infusion rate-dependent manner in pentobarbitalanesthetized dogs. (Anesth Analg 2007;105:1379-84)
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, 6-11-1 Ohmori Nishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR EBATA T, 1992, CAN J ANAESTH, V39, P375, DOI 10.1007/BF03009049
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   FITZGERALD RS, 1984, J APPL PHYSIOL, V57, P1202
   Fujii Y, 2004, PULM PHARMACOL THER, V17, P289, DOI 10.1016/j.pupt.2004.07.001
   Fujii Y, 2004, ANESTH ANALG, V99, P113, DOI 10.1213/01.ANE.0000116927.80080.1E
   Fujii Y, 2003, ANESTH ANALG, V97, P755, DOI 10.1213/01.ANE.0000076142.42255.BF
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   Hermansen L, 1981, Ciba Found Symp, V82, P75
   HOFFMAN BB, 2001, GOODMAN GILMANS PHAR, P215
   HOWELL S, 1985, AM REV RESPIR DIS, V132, P241
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   JUAN G, 1984, NEW ENGL J MED, V310, P874, DOI 10.1056/NEJM198404053101402
   KATZ AM, 1969, AM J MED, V47, P497, DOI 10.1016/0002-9343(69)90180-6
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Mas A, 2000, CRIT CARE MED, V28, P360, DOI 10.1097/00003246-200002000-00012
   MATTHEWS AW, 1976, CLIN SCI MOL MED, V50, P199, DOI 10.1042/cs0500199
   Moxham J, 1981, Ciba Found Symp, V82, P197
   NAKAMARU Y, 1972, J GEN PHYSIOL, V59, P22, DOI 10.1085/jgp.59.1.22
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROCHESTER DF, 1982, AM REV RESPIR DIS, V126, P46
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   YANOS J, 1993, AM REV RESPIR DIS, V147, P616, DOI 10.1164/ajrccm/147.3.616
NR 23
TC 2
Z9 2
U1 2
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD NOV
PY 2007
VL 105
IS 5
BP 1379
EP 1384
DI 10.1213/01.ane.0000282835.10607.b8
PG 6
WC Anesthesiology
SC Anesthesiology
GA 222SN
UT WOS:000250317500033
PM 17959969
DA 2018-12-27
ER

PT J
AU Sahoo, NK
   Thakur, S
   Tokas, RB
   Kamble, NM
AF Sahoo, N. K.
   Thakur, S.
   Tokas, R. B.
   Kamble, N. M.
TI RETRACTED: Refractive-index tailoring and morphological evolutions in
   Gd2O3-SiO2 and ZrO2-SiO2 composite thin films (Retracted article. See
   vol. 123, 2017)
SO APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING
LA English
DT Article; Retracted Publication
ID ELECTRON-BEAM EVAPORATION; ATOMIC-FORCE MICROSCOPY; ION-ASSISTED
   DEPOSITION; TIO2-SIO2 MIXED FILMS; THIN-FILMS; OPTICAL-PROPERTIES;
   SPECTROSCOPIC ELLIPSOMETRY; MECHANICAL-PROPERTIES;
   STRUCTURAL-PROPERTIES; DIELECTRIC-CONSTANT
AB Refractive-index tailoring and morphological evolutions in two different thin film composite systems of gadolinia-silica (Gd2O3:SiO2) and zirconia-silica (ZrO2:SiO2) deposited through reactive electron-beam codeposition processes are discussed in this research paper. For Gd2O3:SiO2 the refractive-index tuning has been achieved from 1.45 to 2.18, whereas in the case of ZrO2:SiO2 the achieved tunable range is from 1.45 to 2.45 in the ultraviolet region. Under certain compositional mixings with lower silica fractions both the systems demonstrated relative microstructural and morphological densifications. Such evolutions were very successfully derived through phase-modulated ellipsometry and atomic force microscopy. The composition-dependent refractive-index tailoring and microstructural densifications have been investigated by adopting Tauc-Lorentz and single-effective-oscillator models. The morphological correlation functions have also very aptly supported such evolutions in these composite films. These experimental results indicate their favourable properties and applicability down to the extreme ultraviolet wavelength region of the electromagnetic spectrum.
C1 Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
RP Sahoo, NK (reprint author), Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
EM nksahoo@barc.gov.in
CR BELKIND A, 1991, SURF COAT TECH, V49, P155, DOI 10.1016/0257-8972(91)90048-2
   BELKIND A, 1991, J VAC SCI TECHNOL A, V9, P530, DOI 10.1116/1.577403
   CEVRO M, 1995, THIN SOLID FILMS, V258, P91, DOI 10.1016/0040-6090(94)06356-7
   Chao S, 1999, J OPT SOC AM A, V16, P1477, DOI 10.1364/JOSAA.16.001477
   CHAO S, 1991, APPL OPTICS, V30, P3233, DOI 10.1364/AO.30.003233
   Chen JS, 1996, APPL OPTICS, V35, P90, DOI 10.1364/AO.35.000090
   Chen YH, 2004, MEAS SCI TECHNOL, V15, P2005, DOI 10.1088/0957-0233/15/10/010
   CHERON JP, 1992, J VAC SCI TECHNOL A, V10, P3207, DOI 10.1116/1.577844
   CLUCK NS, 1991, J APPL PHYS, V69, P3037
   DEMIRYONT H, 1985, APPL OPTICS, V24, P2647, DOI 10.1364/AO.24.002647
   FARABAUGH EN, 1987, J VAC SCI TECHNOL A, V5, P1671, DOI 10.1116/1.574544
   FELDMAN A, 1989, APPL OPTICS, V28, P5229, DOI 10.1364/AO.28.005229
   FELDMAN A, 1986, J VAC SCI TECHNOL A, V4, P2969, DOI 10.1116/1.573610
   Feldman A., 1987, SOC PHOTOOPT INSTRUM, V821, P129
   FELDMAN A, 1988, NBS SPEC PUBL, V746, P299
   FELDMAN A, 1985, NBS SPEC PUBL, V697, P122
   FINKENRATH H, 1988, INFRARED PHYS, V28, P363, DOI 10.1016/0020-0891(88)90061-9
   Gaffar MA, 2003, CRYST RES TECHNOL, V38, P798, DOI 10.1002/crat.200310098
   He HB, 2005, APPL SURF SCI, V241, P442, DOI 10.1016/j.apsusc.2004.07.045
   Jensen TR, 2002, APPL OPTICS, V41, P3205, DOI 10.1364/AO.41.003205
   Kaiser N, 2002, APPL OPTICS, V41, P3053, DOI 10.1364/AO.41.003053
   KOBAYASHI M, 1983, APPL OPTICS, V22, P3121, DOI 10.1364/AO.22.003121
   Koo WH, 2004, J VAC SCI TECHNOL A, V22, P2048, DOI 10.1116/1.1782638
   LAIRD R, 1992, J VAC SCI TECHNOL A, V10, P1908, DOI 10.1116/1.578114
   Lee CC, 2005, APPL OPTICS, V44, P2996, DOI 10.1364/AO.44.002996
   Lee CC, 2002, APPL OPTICS, V41, P2043, DOI 10.1364/AO.41.002043
   Lee H, 2001, J APPL PHYS, V90, P813, DOI 10.1063/1.1378337
   Liu ZJ, 2002, J APPL PHYS, V92, P3559, DOI 10.1063/1.1504497
   Luo RJ, 1997, APPL OPTICS, V36, P8153, DOI 10.1364/AO.36.008153
   Mannelquist A, 1998, APPL PHYS A-MATER, V66, pS891, DOI 10.1007/s003390051262
   Mohamed SH, 2004, PHYS STATUS SOLIDI A, V201, P90, DOI 10.1002/pssa.200306707
   Osipov AV, 2005, THIN SOLID FILMS, V472, P31, DOI 10.1016/j.tsf.2004.06.102
   Park YB, 2003, J MATER SCI LETT, V22, P1325, DOI 10.1023/A:1025775025358
   POND BJ, 1989, APPL OPTICS, V28, P2800, DOI 10.1364/AO.28.002800
   Poznyak SK, 2002, THIN SOLID FILMS, V405, P35, DOI 10.1016/S0040-6090(01)01761-8
   RAVINDRA NM, 1979, INFRARED PHYS, V19, P605, DOI 10.1016/0020-0891(79)90082-4
   Sahoo NK, 1998, APPL OPTICS, V37, P8043, DOI 10.1364/AO.37.008043
   Sahoo NK, 2003, THIN SOLID FILMS, V440, P155, DOI 10.1016/S0040-6090(03)00678-3
   Sahoo NK, 1998, APPL OPTICS, V37, P698, DOI 10.1364/AO.37.000698
   SANKUR H, 1989, J APPL PHYS, V66, P4747, DOI 10.1063/1.343784
   SANKUR HO, 1991, APPL OPTICS, V30, P495, DOI 10.1364/AO.30.000495
   SEELEY JS, 1981, APPL OPTICS, V20, P31, DOI 10.1364/AO.20.000031
   Stadler BJH, 1998, J APPL PHYS, V84, P93, DOI 10.1063/1.368005
   TCHELIEBOU F, 1994, THIN SOLID FILMS, V249, P86, DOI 10.1016/0040-6090(94)90090-6
   Thielsch R, 2002, APPL OPTICS, V41, P3211, DOI 10.1364/AO.41.003211
   Tsai RY, 1996, APPL OPTICS, V35, P5073, DOI 10.1364/AO.35.005073
   Tsou Y, 1996, APPL OPTICS, V35, P5091, DOI 10.1364/AO.35.005091
   Utsugi Y, 1999, PHYS STATUS SOLIDI B, V212, pR9, DOI 10.1002/(SICI)1521-3951(199903)212:1<R9::AID-PSSB99999>3.0.CO;2-Z
   von Blanckenhagen B, 2002, APPL OPTICS, V41, P3137, DOI 10.1364/AO.41.003137
   Wang XR, 1999, THIN SOLID FILMS, V338, P105, DOI 10.1016/S0040-6090(98)01007-4
   WEMPLE SH, 1971, PHYS REV B, V3, P1338, DOI 10.1103/PhysRevB.3.1338
   YANG HN, 1993, J APPL PHYS, V74, P101, DOI 10.1063/1.354139
   Yoon JG, 1998, J KOREAN PHYS SOC, V33, P699
   Zhang CH, 2004, J APPL PHYS, V95, P1460, DOI 10.1063/1.1638611
   Zhang DW, 2005, APPL SURF SCI, V243, P232, DOI 10.1016/j.apsusc.2004.09.083
   ZHANG HW, 1992, THIN SOLID FILMS, V209, P148, DOI 10.1016/0040-6090(92)90665-X
   Zhao YP, 1996, APPL PHYS LETT, V68, P3063, DOI 10.1063/1.116423
NR 57
TC 6
Z9 6
U1 3
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0947-8396
EI 1432-0630
J9 APPL PHYS A-MATER
JI Appl. Phys. A-Mater. Sci. Process.
PD NOV
PY 2007
VL 89
IS 3
BP 711
EP 719
DI 10.1007/s00339-007-4148-9
PG 9
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 213JQ
UT WOS:000249663500022
DA 2018-12-27
ER

PT J
AU Si, JT
   Mueller, L
   Schuler, A
   Simon, J
   Collins, SJ
AF Si, Jutong
   Mueller, LeMoyne
   Schuler, Aaron
   Simon, Julian
   Collins, Steven J.
TI RETRACTED: The retinoic acid receptor/CaMKII interaction: Pharmacologic
   inhibition of CaMKII enhances the differentiation of myeloid leukemia
   cells (Retracted article. See vol. 42, pg. 300, 2009)
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 7th International Workshop on Molecular Aspects of Myeloid Stem Cell
   Development and Leukemia
CY MAY 13-16, 2007
CL Annapolis, MD
DE retinoic acid receptors; Ca++/calmodulin-dependent protein kinases;
   myeloid leukemia cell differentiation; KN-62; HL-60 cell line
ID ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN-KINASE-II; BINDING; ACTIVATION
AB Certain myeloid leukemia cells, particularly the acute promyelocytic leukemia (APL) subset, undergo terminal granulocytic differentiation in response to retinoic acid (RA). RA mediates its biologic effects through specific retinoic acid receptors (RARs) which serve as ligand-activated nuclear transcription factors. The Ca++/calmodulin-dependent protein kinases (CaMKs) are multifunctional serine/threonine kinases that are regulated by Ca++ signaling. We have observed significant cross-talk between these Ca++ and RA signaling pathways that regulates the differentiation of myeloid leukemia cells. We observe that CaMKII gamma is the CaMK that is predominantly expressed in myeloid cells. This enzyme localizes to the promoter of RAR target genes, physically interacts with and phospborylates RAR alpha and inhibits RAR transcriptional activity. KN-62, a pharmacological inhibitor of the CaMKs, enhances both retinoic acid receptor transcriptional activity as well as the terminal in vitro differentiation of certain myeloid leukemia cell lines including HL-60. However, this compound, as well as related synthetic analogs that enhance HL-60 terminal differentiation, fails to inhibit the growth of HL-60 xenografts in NOD-SCID mice likely because of the unfavorable pharmacokinetics displayed by these compounds. Nevertheless, our observations suggest that CaMKII gamma may provide a new therapeutic target for the treatment of the RA-responsive human myeloid leukemias. (C) 2007 Elsevier Inc. All rights reserved.
C1 Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.
RP Collins, SJ (reprint author), Fred Hutchinson Canc Res Ctr, Human Biol Div, 1100 Fairview Ave N, Seattle, WA 98109 USA.
EM scollins@fhcre.org
FU NCI NIH HHS [R01 CA118971, R01 CA118971-02]; NHLBI NIH HHS [HL54881]
CR Andersen PB, 2002, INFO ORG DESIGN SER, V2, P23
   Brown P, 2004, BLOOD, V104, P1841, DOI 10.1182/blood-2004-03-1034
   COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154
   Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9
   Glass CK, 2000, GENE DEV, V14, P121
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471
   Johnson BS, 1999, MOL CELL BIOL, V19, P3372
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   LANOTTE M, 1991, BLOOD, V77, P1080
   Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753
   NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0
   Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887
   PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x
   ROBERTSON KA, 1992, BLOOD, V80, P1885
   Schuler AD, 2007, LEUKEMIA RES, V31, P683, DOI 10.1016/j.leukres.2006.07.022
   Si JT, 2002, BLOOD, V100, P4401, DOI 10.1182/blood-2001-12-0374
   Si JT, 2007, J CLIN INVEST, V117, P1412, DOI 10.1172/JCI30779
   SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E
   Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759
   TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315
   White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166
NR 22
TC 6
Z9 6
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD NOV-DEC
PY 2007
VL 39
IS 3
BP 307
EP 315
DI 10.1016/j.bcmd.2007.05.009
PG 9
WC Hematology
SC Hematology
GA 220WE
UT WOS:000250187200012
PM 17644368
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Nakayama, M
AF Fujii, Yoshitaka
   Nakayama, Masahiro
TI RETRACTED: Reduction of postoperative nausea and vomiting and analgesic
   requirement with dexamethasone in women undergoing general anesthesia
   for mastectomy(Retracted article. See vol. 23, pg. 120, 2017)
SO BREAST JOURNAL
LA English
DT Article; Retracted Publication
DE breast surgery; complications; dexamethasone; pain; vomiting
ID HIGH-DOSE DEXAMETHASONE; BREAST SURGERY; PREVENTION; ONDANSETRON;
   EXTRACTION; CISPLATIN; EFFICACY; TEETH
AB Dexamethasone has antiemetic and analgesic effects in various types of surgery. In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of dexamethasone for reducing postoperative nausea and vomiting (PONV) and analgesic requirement in women undergoing general anesthesia for mastectomy. Patient were allocated randomly to one of three groups (n = 30 of each) to receive intravenously either placebo or dexamethasone at two different doses (4 mg, 8 mg) at the end of surgery. Postoperatively, emetic episodes and analgesic requirement were evaluated by an investigator. Patient demographics and types of surgery were not different among the treatment groups. The rate of patients experiencing PONV during 024 hours after anesthesia was 33% with dexamethasone 4 mg (p = 0.01) and 27% with dexamethasone 8 mg (p = 0.002), compared with placebo (67%). The need of indomethacin for intolerable pain was less in patients who had received dexamethasone 8 mg than in those who had received placebo (p = 0.001) or dexamethasone 4 mg (p = 0.034). No difference in analgesic requirement was found between the dexamethasone 4 mg and placebo groups (p = 0.18). No clinically serious adverse events attributed to the study drug were observed in any of the groups. We conclude that dexamethasone 8 mg effectively decreases PONV and analgesic requirement in women undergoing general anesthesia for mastectomy.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, 6-11-1 Ohmori Nishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR AAPRO MS, 1981, NEW ENGL J MED, V305, P520
   AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   BAXENDALE BR, 1993, ANAESTHESIA, V48, P961
   FREDRIKSON M, 1992, BRIT J CANCER, V65, P779, DOI 10.1038/bjc.1992.165
   Hammas B, 2002, ACTA ANAESTH SCAND, V46, P232, DOI 10.1034/j.1399-6576.2002.460302.x
   Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6
   Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046
   LIVREA P, 1985, J NEUROL, V231, P336, DOI 10.1007/BF00313712
   ODDBYMUHRBECK E, 1994, ACTA ANAESTH SCAND, V38, P52, DOI 10.1111/j.1399-6576.1994.tb03837.x
   RAMSAY TM, 1994, CAN J ANAESTH, V41, P798, DOI 10.1007/BF03011586
   Sadhasivam S, 1999, ANESTH ANALG, V89, P1340, DOI 10.1097/00000539-199912000-00002
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   SCHIMMER BP, 2001, GOODMAN GILMANS PHAR, P1649
   Sekine I, 1997, BRIT J CANCER, V76, P90, DOI 10.1038/bjc.1997.341
   SPLINTER WM, 2000, ANESTH ANALG, V90, P186
   Wang JJ, 1999, BRIT J ANAESTH, V83, P772
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Wattwil M, 2003, ACTA ANAESTH SCAND, V47, P823, DOI 10.1034/j.1399-6576.2003.00172.x
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 21
TC 17
Z9 17
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1075-122X
EI 1524-4741
J9 BREAST J
JI Breast J.
PD NOV-DEC
PY 2007
VL 13
IS 6
BP 564
EP 567
DI 10.1111/j.1524-4741.2007.00497.x
PG 4
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 226KP
UT WOS:000250588200005
PM 17983396
DA 2018-12-27
ER

PT J
AU Bahar, I
   Kaiserman, I
   Rootman, D
AF Bahar, Irit
   Kaiserman, Igor
   Rootman, David
TI RETRACTED: Cionni endocapsular ring implantation in Marfan's syndrome
   (Retracted Article. See vol 94, pg 1695, 2010)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
ID INTRAOCULAR-LENS IMPLANTATION; CAPSULAR TENSION RING; SUBLUXATED
   CRYSTALLINE LENSES; PARS-PLANA LENSECTOMY; SCLERAL FIXATION; ZONULAR
   DIALYSIS; ECTOPIA LENTIS; COMPLICATIONS; MANAGEMENT; CHILDREN
AB Objectives: To evaluate the visual outcomes, intraoperative and postoperative complications of Cionni ring implantation in eyes with a subluxated lens associated with Marfan Syndrome.
   Methods: This case series included 15 eyes of 12 patients aged 19-56 years with a subluxated lens secondary to Marfan's syndrome operataed at the Departament of Ophtalmology, Toronto Western Hospital between 2003 and 2007. A 2-eyelet Cionni ring and an AcrySof (R) (Alcon) foldable intraocular lens (IOL) were implanted in 13 eyes. Two eyes had trans-scleral IOL fixation in the ciliary sulcus. Best-corrected visual acuity, wavefront evaluation of eye aberration and complication rates were analysed.
   Results: In all eyes, capsular bag centration was excellent. Preoperative visual acuity ranged from 20/50 to counting fingers, and improved to better than 20/40 in all eyes. The mean follow-up duration was 14 +/- 9.49 months. The most frequent postoperative complication was posterior capsule opacification, which occurred in 3 eyes (18.7%), 2 of which required a neodymium:YAG posterior capsulotomy. No eye developed retinal detachment. Total eye aberration, tilt and high-order aberrations with a 6-mm pupil diameter decreased significantly after surgery (n=5): Total eye aberration decreased from a mean of 14.8 +/- 5.5 preoperatively to 2.1 +/- 4.3 microns after the operation. Tilt was decreased from 4.1 +/- 2.5 to 0.12 +/- 2.1 microns, and high-order aberrations decreased from 4.37 +/- 3.8 microns, before the operation, to 1.47 +/- 3.5 after the operation.
   Conclusion: Cionni ring implantation is an effective procedure to correct partial lens subluxation and has few complications (during 14 months of follow-up) in patients with Marfan's Syndrome.
C1 Univ Toronto, Toronto Western Hosp, Dept Ophthalmol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada.
RP Bahar, I (reprint author), Toronto Western Hosp, Toronto, ON M5T 2S8, Canada.
EM iritbahar@yahoo.com
CR Aspiotis M, 2006, J REFRACT SURG, V22, P99, DOI 10.3928/1081-597X-20060101-18
   CHANDLER PA, 1964, ARCH OPHTHALMOL-CHIC, V71, P765, DOI 10.1001/archopht.1964.00970010781002
   CIONNI RJ, 1995, J CATARACT REFR SURG, V21, P245, DOI 10.1016/S0886-3350(13)80126-5
   Cionni RJ, 1998, J CATARACT REFR SURG, V24, P1299, DOI 10.1016/S0886-3350(98)80218-6
   Cionni RJ, 2003, J CATARACT REFR SURG, V29, P1668, DOI 10.1016/S0886-3350(03)00238-4
   CROSS HE, 1973, AM J OPHTHALMOL, V75, P405, DOI 10.1016/0002-9394(73)91149-5
   Dietlein TS, 2000, J CATARACT REFR SURG, V26, P937, DOI 10.1016/S0886-3350(00)00318-7
   Dureau P, 2006, J CATARACT REFR SURG, V32, P1109, DOI 10.1016/j.jcrs.2006.01.096
   Gimbel HV, 1997, OPHTHALMIC SURG LAS, V28, P273
   JARRETT WH, 1967, ARCH OPHTHALMOL-CHIC, V78, P289, DOI 10.1001/archopht.1967.00980030291006
   JENSEN AD, 1974, AM J OPHTHALMOL, V77, P261, DOI 10.1016/0002-9394(74)90685-0
   Kazemi S, 2000, Trans Am Ophthalmol Soc, V98, P247
   Kugelberg U, 1997, J CATARACT REFR SURG, V23, P635, DOI 10.1016/S0886-3350(97)80046-6
   Lam DSC, 2000, J CATARACT REFR SURG, V26, P609, DOI 10.1016/S0886-3350(99)00403-4
   Lifshitz T, 2004, J CATARACT REFR SURG, V30, P1977, DOI 10.1016/j.jcrs.2004.01.022
   Maumenee I H, 1981, Trans Am Ophthalmol Soc, V79, P684
   Moreno-Montanes J, 1999, J CATARACT REFR SURG, V25, P959, DOI 10.1016/S0886-3350(99)00045-0
   Moreno-Montanes J, 2003, J CATARACT REFR SURG, V29, P492, DOI 10.1016/S0886-3350(02)01604-8
   Morrison D, 2005, J AAPOS, V9, P240, DOI 10.1016/j.jaapus.2005.02.004
   Nishi O, 2001, J CATARACT REFR SURG, V27, P1359, DOI 10.1016/S0886-3350(01)00892-6
   Omulecki W, 1998, OPHTHALMIC SURG LAS, V29, P375
   Siganos DS, 2000, J CATARACT REFR SURG, V26, P781, DOI 10.1016/S0886-3350(00)00302-3
   Tsai YY, 1999, J CATARACT REFR SURG, V25, P722, DOI 10.1016/S0886-3350(99)00019-X
   Vadala P, 2000, J PEDIAT OPHTH STRAB, V37, P206
   Wagoner MD, 2003, OPHTHALMOLOGY, V110, P840, DOI 10.1016/S0161-6420(02)02000-6
   Zetterstrom C, 1999, J CATARACT REFR SURG, V25, P776, DOI 10.1016/S0886-3350(99)00043-7
NR 26
TC 17
Z9 20
U1 3
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2007
VL 91
IS 11
BP 1477
EP 1480
DI 10.1136/bjo.2007.131169
PG 4
WC Ophthalmology
SC Ophthalmology
GA 221LN
UT WOS:000250229300019
PM 17947268
OA Green Published
DA 2018-12-27
ER

PT J
AU Barre, B
   Perkins, ND
AF Barre, Benjamin
   Perkins, Neil D.
TI RETRACTED: A cell cycle regulatory network controlling NF-kappa B
   subunit activity and function (Retracted article. See vol. 33, pg. 1978,
   2014)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE cell cycle; IKK; NF-kappa B; transcription
ID ARF TUMOR-SUPPRESSOR; C-MYC EXPRESSION; SYNCHRONY TECHNIQUES;
   NF-KAPPA-B2 P100; GENE-EXPRESSION; MESSENGER-RNA; D1 EXPRESSION;
   BREAST-CANCER; S-PHASE; ACTIVATION
AB Aberrantly active NF-kappa B complexes can contribute to tumorigenesis by regulating genes that promote the growth and survival of cancer cells. We have investigated NF-kappa B during the cell cycle and find that its ability to regulate the G1-phase expression of key proto-oncogenes is subject to regulation by the integrated activity of I kappa B kinase (IKK) alpha, IKK beta, Akt and Chk1. The coordinated binding of NF- kappa B subunits to the Cyclin D1, c-Myc and Skp2 promoters is dynamic with distinct changes in promoter occupancy and RelA(p65) phosphorylation occurring through G1, S and G2 phases, concomitant with a switch from coactivator to corepressor recruitment. Akt activity is required for IKK-dependent phosphorylation of NF-kappa B subunits in G1 and G2 phases, where Chk1 is inactive. However, in S-phase, Akt is inactivated, while Chk1 phosphorylates RelA and associates with IKK alpha, inhibiting the processing of the p100 (NF-kappa B2) subunit, which also plays a critical role in the regulation of these genes. These data reveal a complex regulatory network integrating NF-kappa B with the DNA-replication checkpoint and the expression of critical regulators of cell proliferation.
C1 Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, MSI WTB JBC Complex, Dundee DD1 5EH, Scotland.
RP Perkins, ND (reprint author), Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, MSI WTB JBC Complex, Dow Str, Dundee DD1 5EH, Scotland.
EM n.d.perkins@dundee.ac.uk
CR Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186
   BAIN J, 2007, BIOCH J         0913
   Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505
   Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234
   Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5
   Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015
   Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412
   Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005
   Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602
   GRDINA DJ, 1984, CELL TISSUE KINET, V17, P223, DOI 10.1111/j.1365-2184.1984.tb00583.x
   Grumont R, 2004, IMMUNITY, V21, P19, DOI 10.1016/j.immuni.2004.06.004
   Gustin JA, 2006, J BIOL CHEM, V281, P16473, DOI 10.1074/jbc.M507373200
   Guttridge DC, 1999, MOL CELL BIOL, V19, P5785
   HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0
   Hinz M, 1999, MOL CELL BIOL, V19, P2690
   Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010
   Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999
   Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6
   Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200
   Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877
   LA RF, 1994, MOL CELL BIOL, V14, P1039
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.06.041
   Ouyang WM, 2005, CANCER RES, V65, P9287, DOI 10.1158/0008-5472.CAN-05-0469
   Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006
   Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256
   Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009
   RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x
   Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221
   Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003
   Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608
   Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217
   Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2
   Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259
   Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343
   Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x
   THAKUR S, 1994, ONCOGENE, V9, P2335
   THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0
   Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996
   Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212
   WEST R, 2001, CHEM ORGANIC SILICON, V3, P1
   WHITE RA, 1984, CELL TISSUE KINET, V17, P237, DOI 10.1111/j.1365-2184.1984.tb00584.x
   Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3
   Zhang JP, 2007, ENDOCRINOLOGY, V148, P268, DOI 10.1210/en.2006-0500
NR 46
TC 90
Z9 92
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD NOV
PY 2007
VL 26
IS 23
BP 4841
EP 4855
DI 10.1038/sj.emboj.7601899
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 236DE
UT WOS:000251282400005
PM 17962807
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Tomimori, K
   Uema, E
   Teruya, H
   Ishikawa, C
   Okudaira, T
   Senba, M
   Yamamoto, K
   Matsuyama, T
   Kinjo, F
   Fujita, J
   Mori, N
AF Tomimori, Koh
   Uema, Eriko
   Teruya, Hiromitsu
   Ishikawa, Chie
   Okudaira, Taeko
   Senba, Masachika
   Yamamoto, Kazuo
   Matsuyama, Toshifumi
   Kinjo, Fukunori
   Fujita, Jiro
   Mori, Naoki
TI RETRACTED: Helicobacter pylori induces CCL20 expression (Retracted
   article. See vol. 79, pg. 545, 2011)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; GASTRIC EPITHELIAL-CELLS; INFLAMMATORY PROTEIN 3-ALPHA;
   LEUKEMIA-VIRUS TYPE-1; HUMAN DENDRITIC CELLS; MEMORY T-CELLS; VIRULENCE
   FACTORS; PATHOGENICITY ISLAND; IMMUNE-RESPONSE; FLOW CONDITIONS
AB CCL20 attracts immature dendritic cells and memory T cells and plays a role on mucosal surfaces in inflammation. However, whether Helicobacter pylori infection induces CCL20 in human gastric epithelial cells remains to be determined. The aim of this study was to analyze the molecular mechanism of H. pylori-induced CCL20 expression. Expression of CCL20 mRNA was assessed by reverse transcription-PCR. Five normal and five H. pylori-infected gastric tissue samples were stained immunohistochemically for CCL20. A luciferase assay was used to monitor activation of the CCL20 gene promoter, and an electrophoretic mobility shift assay was used to explore the binding of transcription factors to this promoter. The CCL20 expression in epithelial cells of H. pylori-positive tissues was higher than that in H. pylori-negative tissues. H. pylori induced CCL20 expression in gastric epithelial cell lines, and the induction was dependent on an intact cag pathogenicity island. Activation of the CCL20 promoter by H. pylori occurred through the action of NF-kappa B. Transfection of I kappa B kinase and NF-kappa B-inducing kinase dominant negative mutants inhibited H. pylori-mediated activation of CCL20. Treatment with an inhibitor of Hsp90 suppressed H. pylori-induced CCL20 mRNA due to deactivation of NF-kappa B. Collectively, these results suggest that H. pylori activates NF-kappa B through an intracellular signaling pathway that involves I kappa B kinase and NF-kappa B-inducing kinase, leading to CCL20 gene transcription, and that Hsp90 is a crucial regulator of H. pylori-induced CCL20 expression, presumably contributing to the immune response in H. pylori.
C1 Univ Ryukyus, Grad Sch Med, Univ Hosp, Div Control & Prevent Infect Dis, Okinawa 9030215, Japan.
   Univ Ryukyus, Univ Hosp, Div Child Hlth & Welfare, Fac Med, Okinawa 9030215, Japan.
   Univ Ryukyus, Univ Hosp, Div Endocrinol & Metab, Fac Med, Okinawa 9030215, Japan.
   Univ Ryukyus, Univ Hosp, Dept Endoscopy, Okinawa 9030215, Japan.
   Nagasaki Univ, Inst Trop Med, Dept Pathol, Nagasaki 8528523, Japan.
   Nagasaki Univ, Grad Sch Biomed Sci, Div Cytokine Signaling, Nagasaki 8528523, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Aihara M, 1997, INFECT IMMUN, V65, P3218
   Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   BLASER MJ, 1995, CANCER RES, V55, P2111
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645
   Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495
   Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0
   Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328
   CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7
   DElios MM, 1997, J IMMUNOL, V158, P962
   Dieu-Nosjean MC, 1999, J LEUKOCYTE BIOL, V66, P252
   Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705
   Fitzhugh DJ, 2000, J IMMUNOL, V165, P6677, DOI 10.4049/jimmunol.165.12.6677
   Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Hafsi N, 2004, J IMMUNOL, V173, P1249, DOI 10.4049/jimmunol.173.2.1249
   Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846
   Hocker M, 2003, LANCET, V362, P1231, DOI 10.1016/S0140-6736(03)14547-3
   Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037
   Hromas R, 1997, BLOOD, V89, P3315
   Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058
   Imaizumi Y, 2002, INT IMMUNOL, V14, P147, DOI 10.1093/intimm/14.2.147
   Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381
   Jeremias I, 1998, BLOOD, V91, P4624
   Johansson-Lindbom B, 2007, IMMUNOL REV, V215, P226, DOI 10.1111/j.1600-065X.2006.00482.x
   KAO JY, 2006, LIVER PHYSL, V291, pG73
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   KARTTUNEN R, 1995, GUT, V36, P341, DOI 10.1136/gut.36.3.341
   Kranzer K, 2005, INFECT IMMUN, V73, P4180, DOI 10.1128/IAI.73.7.4180-4189.2005
   Liao F, 1999, J IMMUNOL, V162, P186
   Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540
   Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3
   Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   Mizushima T, 2002, HELICOBACTER, V7, P22, DOI 10.1046/j.1523-5378.2002.00052.x
   Mori N, 1999, BLOOD, V93, P2360
   Moss SF, 2003, CURR OPIN INFECT DIS, V16, P445, DOI 10.1097/01.qco.0000092816.64370.e2
   Nishi T, 2003, INFECT IMMUN, V71, P2153, DOI 10.1128/IAI.71.4.2153-2162.2003
   Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131
   Robinson K, 2007, BEST PRACT RES CL GA, V21, P237, DOI 10.1016/j.bpg.2007.01.001
   Rossi DL, 1997, J IMMUNOL, V158, P1033
   Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2
   Sharma SA, 1998, J IMMUNOL, V160, P2401
   Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542
   Tanaka J, 2003, CELL MICROBIOL, V5, P395, DOI 10.1046/j.1462-5822.2003.00286.x
   Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x
   Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Wu YY, 2007, INFECT IMMUN, V75, P4357, DOI 10.1128/IAI.01660-06
   Yeo M, 2004, BIOCHEM BIOPH RES CO, V320, P816, DOI 10.1016/j.bbrc.2004.05.214
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
   Zhang ZW, 2002, J MED MICROBIOL, V51, P495, DOI 10.1099/0022-1317-51-6-495
   Zhu FG, 2001, INFECT IMMUN, V69, P5546, DOI 10.1128/IAI.69.9.5546-5552.2001
NR 59
TC 19
Z9 19
U1 2
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD NOV
PY 2007
VL 75
IS 11
BP 5223
EP 5232
DI 10.1128/IAT.00731-07
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 224MU
UT WOS:000250451900017
PM 17724069
DA 2018-12-27
ER

PT J
AU Weinman, EJ
   Biswas, RS
   Peng, Q
   Shen, L
   Turner, CL
   Xiaofei, E
   Steplock, D
   Shenolikar, S
   Cunningham, R
AF Weinman, Edward J.
   Biswas, Rajat S.
   Peng, Quihong
   Shen, Lily
   Turner, Christina L.
   Xiaofei, E.
   Steplock, Deborah
   Shenolikar, Shirish
   Cunningham, Rochelle
TI RETRACTED: Parathyroid hormone inhibits renal phosphate transport by
   phosphorylation of serine 77 of sodium-hydrogen exchanger regulatory
   factor-1 (Retracted article. See vol. 123, pg. 2752, 2013)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID PROXIMAL TUBULE CELLS; PDZ-DOMAIN INTERACTIONS; NHE3 ACTIVITY; IIA;
   COTRANSPORTER; KINASE; NHERF-1; TRAFFICKING; ADAPTATION; EXPRESSION
AB Parathyroid hormone (pTH), via activation of PKC and/or protein kinase A, inhibits renal proximal tubular phosphate reabsorption by facilitating the internalization of the major sodium-dependent phosphate transporter, Npt2a. Herein, we explore the hypothesis that the effect of PTH is mediated by phosphorylation of serine 77 (S77) of the first PDZ domain of the Npt2a-binding protein sodium-hydrogen exchanger regulatory factor-1 (NHERF-1). Using recombinant polypeptides representing PDZ 1, S77 of NHERF-1 is phosphorylated by PKC but not PKA. When expressed in primate kidney epithelial cells (BSC-1 cells), however, activation of either protein kinase phosphorylates S77, suggesting that the phosphorylation of PDZ I by PKC and PKA proceeds by different biochemical pathways. PTH and other activators of PKC and PKA dissociate NHERF-1/Npt2a complexes, as assayed using quantitative coimmunoprecipitation, confocal microscopy, and sucrose density gradient ultracentrifugation in mice. Murine NHERF-1(-/-) renal proximal tubule cells infected with adenovirus-GFP-NHERF-1 containing an S77A mutation showed significantly increased phosphate transport compared with a phosphomimetic S77D mutation and were resistant to the inhibitory effect of PTH compared with cells infected with wild-type NHERF-1. These results indicate that PTH-mediated inhibition of renal phosphate transport involves phosphorylation of S77 of the NHERF-1 PDZ I domain and the dissociation of NHERF-1/Npt2a complexes.
C1 Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
   Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.
   Vet Affairs Med Ctr, Med Serv, Baltimore, MD USA.
   Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA.
RP Weinman, EJ (reprint author), Univ Maryland, Sch Med, Dept Med, Room N3W143 UHM,22 S Greene St, Baltimore, MD 21201 USA.
FU NIDDK NIH HHS [R01 DK055881, DK55881]
CR Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617
   Cha B, 2006, MOL BIOL CELL, V17, P2661, DOI 10.1091/mbc.E05-09-0843
   CONNES A, 1999, J HIGH ENERGY PHYS, P3
   Cunningham R, 2005, AM J PHYSIOL-RENAL, V289, pF933, DOI 10.1152/ajprenal.00005.2005
   Cunningham R, 2007, J AM SOC NEPHROL, V18, P1419, DOI 10.1681/ASN.2006090980
   Cunningham R, 2006, AM J PHYSIOL-RENAL, V291, pF896, DOI 10.1152/ajpreanal.00036.2006
   Cunninghan R, 2004, J BIOL CHEM, V279, P37815, DOI 10.1074/jbc.M405893200
   Deliot N, 2005, AM J PHYSIOL-CELL PH, V289, pC159, DOI 10.1152/ajpcell.00456.2004
   Fouassier L, 2005, EXP CELL RES, V306, P264, DOI 10.1016/j.yexer.2005.02.011
   Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328
   HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1
   He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200
   Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699
   ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X
   Jankowski M, 2001, KIDNEY BLOOD PRESS R, V24, P1, DOI 10.1159/000054198
   KAHN AM, 1983, AM J PHYSIOL, V245, pF151
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Murer H, 2003, ANNU REV PHYSIOL, V65, P531, DOI 10.1146/annurev.physiol.65.042902.092424
   Murer H, 2002, KIDNEY INT, V62, P375, DOI 10.1046/j.1523-1755.2002.00461.x
   Murtazina R, 2006, J BIOL CHEM, V281, P17845, DOI 10.1074/jbc.M601740200
   Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100
   Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699
   VOLTZ JW, 2007, IN PRESS J BIOL CHEM
   Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m
   Weinman EJ, 2003, AM J PHYSIOL-RENAL, V285, pF1225, DOI 10.1152/ajprenal.00215.2003
   Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204
NR 26
TC 85
Z9 86
U1 3
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2007
VL 117
IS 11
BP 3412
EP 3420
DI 10.1172/JC132738
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 227RR
UT WOS:000250676000033
PM 17975671
DA 2018-12-27
ER

PT J
AU Pham, KN
   Fullston, D
   Sagoe-Crentsil, K
AF Pham, Khoa N.
   Fullston, Damian
   Sagoe-Crentsil, Kwesi
TI RETRACTED: Surface modification for stability of nano-sized silica
   colloids (Retracted article, see vol 342, pg 643, 2010)
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article; Retracted Publication
DE silica; colloids; zeta potential; surface charge; surface modification;
   alkoxysilane; stability; light scattering; nano-size
ID AMORPHOUS SILICA; PARTICLE-SIZE; NANOPARTICLES; DISPERSION;
   POLYMERIZATION; BEHAVIOR; LUDOX
AB The surfaces of commercial 30-nm colloidal silica particles were modified by reacting with functional silanes. The high specific surface area and reactivity of the particles due to the small size make the process susceptible to irreversible aggregation not found previously with larger particles. This study compares surface charge results from different reaction conditions and characterization methods. Measurements of the zeta potential as a function of pH and gelation kinetics shed light on the mechanism of instability in nano-sized silica suspensions. Experimental results showed that very stable particles can be suspended in a nonaqueous solvent after refluxing of the silica particles, while maintaining the original particles physical properties of size and electrochemical behavior. Extremely stable particles are obtained by ammosilane surface modification. Factors affecting susceptibility of small particles to irreversible aggregation caused by a nonaqueous solvent or a high concentration of a trialkoxysilane, including the large amount of reactive silanol groups on the surface gel layer of the particles, are discussed. (c) 2007 Elsevier Inc. All rights reserved.
C1 CSIRO, Highett, Vic 3190, Australia.
RP Pham, KN (reprint author), CSIRO, Graham Rd, Highett, Vic 3190, Australia.
EM khoa.pham@csiro.au
RI Pham, Khoa/B-8049-2008
OI Pham, Khoa/0000-0002-6234-0903
CR ALEXANDER GB, 1957, J PHYS CHEM-US, V61, P1563, DOI 10.1021/j150557a024
   Allison S, 2004, J COLLOID INTERF SCI, V277, P248, DOI 10.1016/j.jcis.2004.04.050
   ARKLES B, 1992, J ADHES SCI TECHNOL, V6, P193, DOI 10.1163/156856192X00133
   BOURGEAT-LAMI E, 1995, POLYMER, V36, P4385, DOI 10.1016/0032-3861(95)96843-W
   Bourgeat-Lami E, 1998, J COLLOID INTERF SCI, V197, P293, DOI 10.1006/jcis.1997.5265
   Corrie SR, 2006, LANGMUIR, V22, P2731, DOI 10.1021/la052433r
   Ho J, 2007, J COLLOID INTERF SCI, V308, P374, DOI 10.1016/j.jcis.2007.01.009
   Hunter RJ, 1993, INTRO MODERN COLLOID
   Iijima M, 2007, J COLLOID INTERF SCI, V307, P418, DOI 10.1016/j.jcis.2006.11.044
   Iler R.K., 1979, CHEM SILICA SOLUBILI
   ILER RK, 1980, J COLLOID INTERF SCI, V75, P138, DOI 10.1016/0021-9797(80)90357-4
   Jesionowski T, 2003, COLLOID SURFACE A, V222, P87, DOI 10.1016/S0927-7757(03)00237-1
   Jesionowski T, 2003, APPL SURF SCI, V205, P212, DOI 10.1016/S0169-4332(02)01090-5
   Jesionowski T, 2002, J MATER SCI, V37, P1621, DOI 10.1023/A:1014936428636
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6
   Kamiya H, 2000, J AM CERAM SOC, V83, P287
   Kim JW, 2007, BIOMACROMOLECULES, V8, P215, DOI 10.1021/bm060560b
   Kneuer C, 2000, INT J PHARM, V196, P257, DOI 10.1016/S0378-5173(99)00435-4
   Kuchibhatla SVNT, 2005, JOM-US, V57, P52, DOI 10.1007/s11837-005-0183-1
   Laven J, 2001, J COLLOID INTERF SCI, V238, P8, DOI 10.1006/jcis.2001.7452
   Leong YK, 2005, J COLLOID INTERF SCI, V292, P557, DOI 10.1016/j.jcis.2005.06.004
   LIU HC, 1993, COLLOID SURFACE A, V74, P7
   Markowitz MA, 1999, COLLOID SURFACE A, V150, P85, DOI 10.1016/S0927-7757(98)00715-8
   PARKS GA, 1965, CHEM REV, V65, P177, DOI 10.1021/cr60234a002
   PERRAM JW, 1974, AUST J CHEM, V27, P461, DOI 10.1071/CH9740461
   Posthumus W, 2004, J COLLOID INTERF SCI, V269, P109, DOI 10.1016/j.jcis.2003.07.008
   Sun YY, 2005, J COLLOID INTERF SCI, V292, P436, DOI 10.1016/j.jcis.2005.05.067
   VIGIL G, 1994, J COLLOID INTERF SCI, V165, P367, DOI 10.1006/jcis.1994.1242
   Zhang K, 2003, MACROMOL MATER ENG, V288, P380, DOI 10.1002/mame.200390031
NR 29
TC 61
Z9 64
U1 3
U2 56
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
EI 1095-7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD NOV 1
PY 2007
VL 315
IS 1
BP 123
EP 127
DI 10.1016/j.jcis.2007.06.064
PG 5
WC Chemistry, Physical
SC Chemistry
GA 218AX
UT WOS:000249989500017
PM 17686487
DA 2018-12-27
ER

PT J
AU Thakur, A
   Raman, R
   Malhotra, SN
AF Thakur, Ashish
   Raman, R.
   Malhotra, S. N.
TI RETRACTED: Effect of natural aging on the resistivity evolution during
   artificial aging of the Al-Zn-Mg-Zr alloy (Retracted article. See vol.
   210, pg. 824, 2010)
SO JOURNAL OF MATERIALS PROCESSING TECHNOLOGY
LA English
DT Article; Retracted Publication
DE aluminum; heat treatment; natural aging; precipitation; electrical
   resistivity
ID PRECIPITATION
AB The effect of natural aging on the aging response of the A1-Zn-Mg-Zr alloy AA7020 was studied using low-temperature electrical resistivity measurements. Two experimental conditions were examined: (i) natural aging for 2 weeks followed by artificial aging in the temperature range of 90-160 degrees C and (ii) natural aging for variable periods followed by aging at 160 degrees C. The resistivity variation during underaging and overaging periods was discussed in relation to the microstructural evolution. (C) 2007 Elsevier B.V. All rights reserved.
C1 Indian Inst Technol, Dept Met Engn & Mat Sci, Powai 400076, Maharashtra, India.
RP Thakur, A (reprint author), Indian Inst Technol, Dept Met Engn & Mat Sci, Powai 400076, Maharashtra, India.
EM ashish_sthakur@iitb.ac.in
CR DUBOST B, 1986, ALUMINIUM ALLOYS THE, V2, P1109
   Esmaeili S, 2003, ACTA MATER, V51, P2243, DOI 10.1016/S1359-6454(03)00028-4
   Hatch John E., 1984, ALUMINUM PROPERTIES
   Lloyd D. J., 1998, ADV IND MAT, P3
   Martin J. W., 1998, PRECIPITATION HARDEN
   Murayama M, 1998, MAT SCI ENG A-STRUCT, V250, P127, DOI 10.1016/S0921-5093(98)00548-6
   PANSERI C, 1966, J I MET, V94, P99
   Poole WJ, 1997, MAT SCI ENG A-STRUCT, V234, P306, DOI 10.1016/S0921-5093(97)00192-5
NR 8
TC 2
Z9 2
U1 4
U2 20
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0924-0136
J9 J MATER PROCESS TECH
JI J. Mater. Process. Technol.
PD NOV 1
PY 2007
VL 194
IS 1-3
BP 184
EP 186
DI 10.1016/j.matprotec.2007.04.104
PG 3
WC Engineering, Industrial; Engineering, Manufacturing; Materials Science,
   Multidisciplinary
SC Engineering; Materials Science
GA 222FL
UT WOS:000250281400024
DA 2018-12-27
ER

PT J
AU Kumar, PS
   Bhattacharjee, J
   Sahoo, T
AF Kumar, P. Suresh
   Bhattacharjee, J.
   Sahoo, T.
TI RETRACTED: Scattering of surface and internal waves by rectangular dikes
   (retracted article. see vol 130, art no 011005, 2008)
SO JOURNAL OF OFFSHORE MECHANICS AND ARCTIC ENGINEERING-TRANSACTIONS OF THE
   ASME
LA English
DT Article; Retracted Publication
ID 2-LAYER FLUID; POROUS BREAKWATER; OBLIQUE WAVES; DIFFRACTION; OBSTACLES
AB The scattering of surface and internal waves by a single dike or a pair of identical dikes in a two-layer fluid is analyzed in two dimensions within the context of linearized theory of water waves. The dikes are approximated as cylinders of rectangular geometry and are placed in a two-layer fluid of finite depth. In the study, both the cases of surface-piercing and bottom-standing dikes are considered. The solution of the associated boundary value problem is derived by a matched eigenfunction expansion method. Because of the flow discontinuity at the interface, the eigenfunctions involved have an integrable singularity at the interface and the orthonormal relation used in the present analysis is a generalization of the classical one corresponding to a single-layer fluid. The reflection coefficients and force amplitudes are computed and analyzed in various cases. The computed results in a two-layer fluid are compared with those existing in the literature for a single-layer fluid The results obtained by the matched eigenfunction expansion method are compared with that of wide-spacing approximation method, and it is observed that the results from both the methods are in good agreement when the dikes are widely spaced The general behavior of reflection coefficients for interface-piercing and non-interface-piercing obstacles is found to be different in both cases of surface-piercing and bottom-standing dikes. Moreover for surface-piercing dikes, the results show the Possibility of very large resonant motions between the dikes but with a very narrow bandwidth for the frequency of interest.
C1 Korean Ocean Res & Dev Inst, Coastal Engn Res Dept, Seoul 425600, South Korea.
   Indian Inst Technol, Dept Ocean Engn & Naval Architecture, Kharagpur 721302, W Bengal, India.
RP Kumar, PS (reprint author), Korean Ocean Res & Dev Inst, Coastal Engn Res Dept, Ansan PO Box 29, Seoul 425600, South Korea.
EM suresh_bbsr2000@yahoo.com
CR BAI KJ, 1975, J FLUID MECH, V68, P513, DOI 10.1017/S0022112075001802
   Barthelemy E, 2000, FLUID DYN RES, V26, P235, DOI 10.1016/S0169-5983(99)00025-8
   Cadby JR, 2000, J FLUID MECH, V423, P155, DOI 10.1017/S0022112000002007
   Kumar PS, 2007, J FLUID STRUCT, V23, P633, DOI 10.1016/j.jfluidstructs.2006.10.011
   Kumar PS, 2006, J ENG MECH-ASCE, V132, P1007, DOI 10.1061/(ASCE)0733-9399(2006)132:9(1007)
   KUMAR PS, 2004, P 3 IND NAT C HARB C, P451
   KUMAR PS, 2004, NAT WORKSH ADV FLUID
   KUMAR PS, 2007, THESIS INDIAN I TECH, P200
   KUMAR PS, 2005, P 15 INT OFFSH POL E, V3, P572
   Kundu P. K., 2002, FLUID MECH
   Lamb H., 1932, HYDRODYNAMICS
   Linton CM, 1995, J FLUID MECH, V304, P213, DOI 10.1017/S002211209500440X
   Manam SR, 2005, J ENG MATH, V52, P355, DOI 10.1007/s10665-005-0190-9
   MCIVER P, 1986, APPL OCEAN RES, V8, P67
   MEI CC, 1969, J FLUID MECH, V38, P499, DOI 10.1017/S0022112069000309
   MILES JW, 1967, J FLUID MECH, V28, P755, DOI 10.1017/S0022112067002423
   Milne-Thomson L. M., 1996, THEORETICAL HYDRODYN
   NEWMAN JN, 1965, J FLUID MECH, V23, P23, DOI 10.1017/S0022112065001210
   Sherief HH, 2003, CAN J PHYS, V81, P675, DOI 10.1139/P02-133
   Soylemez M, 2003, APPL OCEAN RES, V25, P345, DOI 10.1016/j.apor.2004.04.001
   SROKOSZ MA, 1979, J FLUID MECH, V90, P337, DOI 10.1017/S0022112079002251
   Stokes GG, 1847, T CAMBRIDGE PHIL SOC, V8, P441
   Wehausen J. V., 1960, HDB PHYSIK, P446
   Yang HTO, 1997, APPL OCEAN RES, V19, P263, DOI 10.1016/S0141-1187(97)00035-7
   Yeung R. W., 1999, P 22 S NAV HYDR, P875
NR 25
TC 8
Z9 8
U1 3
U2 13
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0892-7219
EI 1528-896X
J9 J OFFSHORE MECH ARCT
JI J. Offshore Mech. Arct. Eng. Trans. ASME
PD NOV
PY 2007
VL 129
IS 4
BP 306
EP 317
DI 10.1115/1.2786473
PG 12
WC Engineering, Ocean; Engineering, Mechanical
SC Engineering
GA 236KP
UT WOS:000251302200007
DA 2018-12-27
ER

PT J
AU Clayton, AH
AF Clayton, Anita H.
TI RETRACTED: Epidemiology and Neurobiology of female sexual dysfunction
   (Retracted Article. See vol 49, pg 421, 2008)
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article; Retracted Publication
DE feinole sexual dysfunction; epidemiology; neurobiology
ID DESIRE DISORDER; WOMEN; PREVALENCE; DIAGNOSIS; BEHAVIOR; THERAPY;
   LEPTIN; HEALTH; PREDICTORS; PHYSICIANS
AB Introduction. Although several conceptual frameworks for female sexual dysfunction (FSD) have been advanced, there still is considerable disagreement over what constitutes a normal vs. abnormal response. Sexual dysfunction is a disturbance in sexual functioning involving one or multiple phases of the sexual response cycle or pain Associated with sexual activity, while a sexual disorder includes both dysfunction And marked distress.
   Aim. Review the literature regarding the epidemiology., and neurobiology of FSD.
   Methods. Review of the literature.
   Results. While a wide range of epidemiologic studies has been published, it is still difficult to determine the scope of FSD and sexual disorders in the general population. It is becoming clear that good sexual health is associated with good physical and mental health as well as compatible relationships with one's sexual partner. Central nervous system, (CNS) control of the sexual response is a relatively new area of scientific exploration.
   Conclusions. We are improving our understanding of the contributions of the CNS neuroendocrine and neurotransmitter systems that modulate sexual behavior.
C1 Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22903 USA.
RP Clayton, AH (reprint author), Univ Virginia, Dept Psychiat & Neurobehav Sci, Northridge Bldg,Suite 210,2955 Ivy Rd, Charlottesville, VA 22903 USA.
EM ahc8v@virginia.edu
CR Addis IB, 2006, OBSTET GYNECOL, V107, P755, DOI 10.1097/01.AOG.0000202398.27428.e2
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Bachmann G, 2006, J SEX MED, V3, P639, DOI 10.1111/j.1743-6109.2006.00265.x
   Basson R, 2000, J UROLOGY, V163, P888, DOI 10.1016/S0022-5347(05)67828-7
   Basson R, 2005, J SEX MED, V2, P291, DOI 10.1111/j.1743-6109.2005.20346.x
   CASPER RC, 1985, ARCH GEN PSYCHIAT, V42, P1098
   Clayton AH, 2002, J CLIN PSYCHIAT, V63, P357, DOI 10.4088/JCP.v63n0414
   Clayton AH, 2003, PSYCHIAT CLIN N AM, V26, P673, DOI 10.1016/S0193-953X(03)00043-1
   CLAYTON AH, 2007, P ABSTR 1 WORLD C SE, pS25
   CLAYTON AH, 2006, DIRECTIONS PSYCHIAT, V26, P227
   Cushing BS, 1999, J NEUROENDOCRINOL, V11, P765
   Dunn KM, 1998, FAM PRACT, V15, P519, DOI 10.1093/fampra/15.6.519
   Enzlin P, 2002, DIABETES CARE, V25, P672, DOI 10.2337/diacare.25.4.672
   Giargiari TD, 2005, ARCH SEX BEHAV, V34, P547, DOI 10.1007/s10508-005-6280-y
   Halaris A, 2003, CNS SPECTRUMS, V8, P211, DOI 10.1017/S1092852900024445
   Hayes RD, 2006, J SEX MED, V3, P589, DOI 10.1111/j.1743-6109.2006.00241.x
   Heim LJ, 2001, AM FAM PHYSICIAN, V63, P1535
   Hull EM, 1999, BEHAV BRAIN RES, V105, P105, DOI 10.1016/S0166-4328(99)00086-8
   Imbimbo C, 2003, J Endocrinol Invest, V26, P102
   Kadri N, 2002, Arch Womens Ment Health, V5, P59, DOI 10.1007/s00737-002-0141-7
   Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537
   Leiblum SR, 2006, MENOPAUSE, V13, P46, DOI 10.1097/01.gme.0000172596.76272.06
   Masters W., 1966, HUMAN SEXUAL RESPONS
   Melis MR, 2003, CURR DRUG TARGETS, V4, P55, DOI 10.2174/1389450033347190
   Munarriz R, 2002, UROL CLIN N AM, V29, P685, DOI 10.1016/S0094-0143(02)00069-1
   OSBORN M, 1988, BRIT MED J, V296, P959, DOI 10.1136/bmj.296.6627.959
   Pauls RN, 2005, OBSTET GYNECOL SURV, V60, P196, DOI 10.1097/01.ogx.0000157978.91721.0f
   Rellini A, 2006, J SEX MED, V3, P283, DOI 10.1111/j.1743-6109.2005.00153.x
   Salonia A, 2006, DIABETES CARE, V29, P312, DOI 10.2337/diacare.29.02.06.dc05-1067
   Sand M, 2007, J SEX MED, V4, P708, DOI 10.1111/j.1743-6109.2007.00496.x
   Sand PK, 2006, AM J OBSTET GYNECOL, V195, P1730, DOI 10.1016/j.ajog.2006.08.013
   Schaffir J, 2006, J SEX MARITAL THER, V32, P305, DOI 10.1080/0092623060066311
   Schneider JE, 2000, HORM BEHAV, V37, P306, DOI 10.1006/hbeh.2000.1590
   Schneider JE, 1999, AM J PHYSIOL-REG I, V277, pR1020, DOI 10.1152/ajpregu.1999.277.4.R1020
   SMITH PJ, 1986, CLIN PHARMACY, V5, P373
   Tsimtsiou Z, 2006, J SEX MED, V3, P583, DOI 10.1111/j.1743-6109.2006.00271.x
   Van der Ploeg LHT, 2002, P NATL ACAD SCI USA, V99, P11381, DOI 10.1073/pnas.172378699
   Voisey J, 2003, CURR DRUG TARGETS, V4, P586
   Wade GN, 1997, AM J PHYSIOL-REG I, V272, pR1354
   Warnock JK, 2002, CNS DRUGS, V16, P745, DOI 10.2165/00023210-200216110-00003
   Wimberly YH, 2006, J NATL MED ASSOC, V98, P1924
NR 41
TC 64
Z9 65
U1 3
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD NOV
PY 2007
VL 4
SU 4
BP 260
EP 268
DI 10.1111/j.1743-6109.2007.00609.x
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 228TL
UT WOS:000250755400003
PM 17958618
DA 2018-12-27
ER

PT J
AU Weber, S
AF Weber, Scott
TI RETRACTED: Critical care nurse practitioners and clinical nurse
   specialists interface patterns with computer-based decision support
   systems (Retracted article. See vol. 23, pg. 331, 2011)
SO JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS
LA English
DT Review; Retracted Publication
DE clinical decision support systems; advanced practice nursing; critical
   care nursing; decision systems; predicting; forecasting; clinical
   decision making
ID SCORING SYSTEMS; COMPLEXITY; SEVERITY
AB Purpose: The purposes of this review are to examine the types of clinical decision support systems in use and to identify patterns of how critical care advanced practice nurses (APNs) have integrated these systems into their nursing care patient management practices. The decision-making process itself is analyzed with a focus on how automated systems attempt to capture and reflect human decisional processes in critical care nursing, including how systems actually organize and process information to create outcome estimations based on patient clinical indicators and prognosis logarithms. Characteristics of APN clinicians and implications of these characteristics on decision system use, based on the body of decision system user research, are introduced.
   Data sources: A review of the Medline, Ovid, CINAHL, and PubMed literature databases was conducted using "clinical decision support systems," "computerized clinical decision making," and "APNs"; an examination of components of several major clinical decision systems was also undertaken.
   Conclusions: Use patterns among APNs and other clinicians appear to vary; there is a need for original research to examine how APNs actually use these systems in their practices in critical care settings. Because APNs are increasingly responsible for admission to, and transfer from, critical care settings, more understanding is needed on how they interact with this technology and how they see automated decision systems impacting their practices.
   Implications for practice: APNs who practice in critical care settings vary significantly in how they use the clinical decision systems that are in operation in their practice settings. These APNs must have an understanding of their use patterns with these systems and should critically assess whether their patient care decision making is affected by the technology.
C1 Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA.
RP Weber, S (reprint author), Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, 415 Victoria Bldg, Pittsburgh, PA 15261 USA.
EM webersjm@pitt.edu
CR ABELSON RP, 2005, HDB SOCIAL PSYCHOL, P231
   ADAMS DA, 1992, MIS QUART, V16, P227, DOI 10.2307/249577
   ALAVI M, 2001, SCIENCE, V27, P1309
   ALAVI M, 2002, MIS Q, V22, P95
   ALBERT DA, 1988, REASONING MED INTRO, P181
   Baggs J G, 1997, Am J Crit Care, V6, P393
   BAGGS JG, 2005, RES NURSING HLTH, V18, P345
   BAKKER JO, 1991, SLEEP RES A, V20, P485
   BARIE PS, 2005, ARCH SURG-CHICAGO, V130, P77
   BARKI H, 2004, MIS Q, V24, P59
   BARKIN SR, 1997, INFORM MANAGE, V1, P35
   BEMBASAT L, 2002, J ACCOUNT RES, V20, P1
   BENBENISHTY R, 2002, SOC SERV REV, V66, P598
   Benner P, 1983, Image J Nurs Sch, V15, P36, DOI 10.1111/j.1547-5069.1983.tb01353.x
   Benner P., 1984, NOVICE EXPERT EXCELL
   BLOIS MS, 2000, NEW ENGL J MED, V303, P192
   BOWER FL, 2002, PROCESS PLANNING NUR
   BRANNEN GG, 1988, J SOC MED DECISION M, V12, P44
   BRENNEN PF, 1988, APPL NURS RES, V17, P89
   Burkes M, 1991, Comput Nurs, V9, P190
   BUTTERS S, 2002, J SYST MANAGE, V43, P28
   CARNVALE F, 2001, DO YOU KNOW WHAT YOU
   CARNVALE F, 1984, DIAGNOSTIC REASONING, P25
   CASTELLA X, 1995, CRIT CARE MED, V23, P1327, DOI 10.1097/00003246-199508000-00005
   COOPER HM, 2000, PSYCHOL BULL, V87, P442
   CORCORAN S, 1986, NURSING HLTH CARE, V7, P149
   CORCORAN SA, 1986, RES NURS HEALTH, V9, P155, DOI 10.1002/nur.4770090211
   CORCORAN SA, 1986, NURS RES, V35, P107
   Elstein AS, 2000, CLINICAL REASONING IN THE HEALTH PROFESSIONS, 2ND EDITION, P95
   Elstein AS, 1978, MED PROBLEM SOLVING
   FAGERHAUGH S, 2003, UNPUB DECISION MAKIN
   FIRBY CM, 2004, COMPUTERS NURSING, V6, P20
   GARDNER RM, 1994, J AM MED INFORM ASSN, V1, P428, DOI 10.1136/jamia.1994.95153432
   Gibson RF, 1996, J AM MED INFORM ASSN, V3, P349, DOI 10.1136/jamia.1996.97035026
   GINSBERG MJ, 1999, TIMIS STUDIES MANAGE, V13, P85
   GORE ML, 2004, P 5 IMIA INT C NURS
   GRIER MR, 2004, ANN REV NURSING RES, V2, P265
   GROEN GJ, 1985, MED EDUC, V19, P95, DOI 10.1111/j.1365-2923.1985.tb01148.x
   HADORN DC, 1994, ASSESSING PERFORMANC
   HENRY SB, 2005, CRITICAL CARE NURSIN, V7, P191
   HOLZEMER WL, 1986, NURS RES, V35, P231
   IVES B, 2004, MANAGE SCI, V30, P580
   KEEN PGW, 1999, DATAMATION, V25, P117
   KEEN PGW, 2001, COMMUN ACM, V24, P24
   KEEN PGW, 1998, DECISION SUPPORT SYS
   KING WR, 1981, MANAGE SCI, V27, P717, DOI 10.1287/mnsc.27.6.717
   KNAUS RR, 2005, J SOC MED DECISION M, V19, P29
   KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619
   KNAUS WA, 2006, ANN INTERN MED, V104, P410
   KNAUS WA, 2001, SCIENCE, V18, P345
   KNOEBEL SB, 1986, PERSPECTIVES CLIN DE
   KRUSE JA, 2006, JAMA-J AM MED ASSOC, V260, P1739
   LANCASTER W, 2002, J NURS ADMIN, V12, P23
   LOEWENBERG FM, 2002, INT SOCIAL WORK, V35, P429
   LUDWIGS U, 1995, CRIT CARE MED, V23, P854, DOI 10.1097/00003246-199505000-00013
   MALLACH EG, 1991, MANAGING END USER CO, V4, P5
   MALLACH EG, 2004, UNDERSTANDING DECISI
   MCCLISH PR, 2004, RES GUIDANCE QUALITA
   MOCK TJ, 2002, J ACCOUNT RES, V10, P129
   MURDACH AD, 2005, HLTH SOCIAL WORK, V20, P187
   NEWELL A, 2002, HUMAN PROBLEMS SOLVI
   NEWMAN M, 1992, MIS QUART, V16, P249, DOI 10.2307/249578
   Offredy M, 1998, J ADV NURS, V28, P988, DOI 10.1046/j.1365-2648.1998.00823.x
   Offredy M, 2002, J ADV NURS, V40, P532, DOI 10.1046/j.1365-2648.2002.02410.x
   Patel VL, 1999, TACIT KNOWLEDGE IN PROFESSIONAL PRACTICE, P75
   PATTON RAF, 2000, CRITICAL CARE DECISI
   PUTZIER DJ, 1985, HEART LUNG, V14, P430
   SCHEIN EH, 2002, PROFESSIONAL ED NEW
   SCHULTZ S, 2004, J NURS ADMIN, V14, P15
   SILVER LM, 1991, J MED DECISION MAKIN, V12, P14
   SILVER MS, 2000, INFORM SYST RES, V1, P47
   SULTANA N, 2006, J ADV NURS, V15, P696
   SWANSON EB, 2004, MANAGE SCI, V21, P178
   TAIT P, 1988, MIS QUART, V12, P91, DOI 10.2307/248809
   Tan J., 1998, HLTH DECISION SUPPOR
   TANNER CA, 1987, NURS RES, V36, P358
   TANNER GA, 1997, ANN REV NURSING RES, V5, P153
   TANNER GA, 2002, REV RES NURSING ED
   TAYLOR RN, 1975, ACAD MANAGE J, V18, P74, DOI 10.2307/255626
   TERES D, 1994, CRIT CARE CLIN, V10, P91
   TODD P, 2002, MIS Q, V16, P373
   VANDENBERG R, 1996, J HLTH INFORM MANAGE, V16, P60
   WATTS CM, 2004, CRITICAL CARE CLIN, V10, P73
   WHITE RT, 1992, J CURRICULUM STUD, V24, P153, DOI 10.1080/0022027920240204
   ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005
   ZINKHAN RR, 1997, RES METHODS NURSING
NR 86
TC 6
Z9 6
U1 4
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1041-2972
EI 1745-7599
J9 J AM ACAD NURSE PRAC
JI J. Am. Acad. Nurse Pract.
PD NOV
PY 2007
VL 19
IS 11
BP 580
EP 590
DI 10.1111/j.1745-7599.2007.00262.x
PG 11
WC Health Care Sciences & Services; Nursing
SC Health Care Sciences & Services; Nursing
GA 225EB
UT WOS:000250498800003
PM 17970858
DA 2018-12-27
ER

PT J
AU Rakovitsky, N
   Buganim, Y
   Swissa, T
   Kinel-Tahan, Y
   Brenner, S
   Cohen, MA
   Levine, A
   Wides, R
AF Rakovitsky, Nadya
   Buganim, Yosef
   Swissa, Torner
   Kinel-Tahan, Yael
   Brenner, Shirly
   Cohen, Malkiel A.
   Levine, Anna
   Wides, Ron
TI RETRACTED: Drosophila Ten-a is a maternal pair-rule and patterning gene
   (Retracted article. See vol. 129, pg. 73, 2012)
SO MECHANISMS OF DEVELOPMENT
LA English
DT Article; Retracted Publication
DE segmentation; Odz/Tenm genes; signal transduction; metamerism
ID ODD OZ ODZ; SEGMENTATION; EXPRESSION; PROTEINS; FAMILY; MELANOGASTER;
   IDENTIFICATION; TRANSCRIPTION; LOCALIZATION; CHROMOSOME
AB The Ten-a gene of Drosophila melanogaster encodes several alternative variants of a full length member of the Odz/Tenm protein family. A number of Ten-a mutants created by inexact excisions of a resident P-element insertion are embryonic lethal, but show no pair-rule phenotype. In contrast, these mutants, and deficiencies removing Ten-a, do enhance the segmentation phenotype of a weak allele of the paralog gene odz (or Ten-m) to the odz amorphic phenotype. Germ line clone derived Ten-a(-) embryos display a pair-rule phenotype which phenocopies that of odz. Post segmentation eye patterning phenotypes of Ten-a mutants establish it as a pleiotropic patterning co-partner of odz. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
C1 [Rakovitsky, Nadya; Buganim, Yosef; Swissa, Torner; Kinel-Tahan, Yael; Brenner, Shirly; Cohen, Malkiel A.; Levine, Anna; Wides, Ron] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.
RP Wides, R (reprint author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.
EM wides@mail.biu.ac.il
CR Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185
   Bagutti C, 2003, J CELL SCI, V116, P2957, DOI 10.1242/jcs.00603
   BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8
   BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x
   Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427
   Ben-Zur T, 2000, DEV BIOL, V217, P107, DOI 10.1006/dbio.1999.9532
   CHOU TB, 1992, GENETICS, V131, P643
   Chou TB, 1996, GENETICS, V144, P1673
   Daubresse G, 1999, DEVELOPMENT, V126, P1175
   Dgany O, 2002, BIOCHEM J, V363, P633, DOI 10.1042/0264-6021:3630633
   Drabikowski K, 2005, DEV BIOL, V282, P27, DOI 10.1016/j.ydbio.2005.02.017
   Fascetti N, 2002, MECH DEVELOP, V114, P197, DOI 10.1016/S0925-4773(02)00055-2
   Feng K, 2002, J BIOL CHEM, V277, P26128, DOI 10.1074/jbc.M203722200
   Gerlitz O, 2002, GENE DEV, V16, P1055, DOI 10.1102/gad.991802
   Hacker U, 1997, DEVELOPMENT, V124, P3565
   Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101
   Kinel-Tahan Y, 2007, DEV DYNAM, V236, P2541, DOI 10.1002/dvdy.21284
   Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1
   LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8
   Levine A, 1997, DEV DYNAM, V209, P1, DOI 10.1002/(SICI)1097-0177(199705)209:1<1::AID-AJA1>3.0.CO;2-M
   Levine A, 1997, GENE, V200, P59, DOI 10.1016/S0378-1119(97)00375-2
   Lossie AC, 2005, GENETICS, V169, P285, DOI 10.1534/genetics.104.034967
   Mieda M, 1999, MECH DEVELOP, V87, P223, DOI 10.1016/S0925-4773(99)00155-0
   Minet AD, 2000, GENE, V257, P87, DOI 10.1016/S0378-1119(00)00388-7
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Oohashi T, 1999, J CELL BIOL, V145, P563, DOI 10.1083/jcb.145.3.563
   Otaki JM, 1999, DEV BIOL, V212, P165, DOI 10.1006/dbio.1999.9310
   Peel A, 2004, BIOESSAYS, V26, P1108, DOI 10.1002/bies.20097
   Perrimon N, 1996, GENETICS, V144, P1681
   Peter A, 2002, EMBO REP, V3, P34, DOI 10.1093/embo-reports/kvf012
   ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0
   Rubin BP, 1999, DEV BIOL, V216, P195, DOI 10.1006/dbio.1999.9503
   Seaver EC, 2003, INT J DEV BIOL, V47, P583
   SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X
   Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109
   TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041
   Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619
   Wieschaus E., 1986, P199
   WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158
   WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0
NR 40
TC 10
Z9 10
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4773
EI 1872-6356
J9 MECH DEVELOP
JI Mech. Dev.
PD NOV-DEC
PY 2007
VL 124
IS 11-12
BP 911
EP 924
DI 10.1016/j.mod.2007.08.003
PG 14
WC Developmental Biology
SC Developmental Biology
GA 241GI
UT WOS:000251644500008
PM 17890064
OA Bronze
DA 2018-12-27
ER

PT J
AU Asea, A
AF Asea, Alexzander
TI RETRACTED: Hsp72 release: Mechanisms and methodologies (Retracted
   article. See vol. 47, pg. 223, 2009)
SO METHODS
LA English
DT Article; Retracted Publication
DE cancer; chaperokine; heat shock proteins; inflammation; protein
   transport; receptors; signal transduction
ID HEAT-SHOCK PROTEINS; ADAPTIVE IMMUNE-RESPONSES; GP96 INDUCES MATURATION;
   DENDRITIC CELLS; SERUM HEAT-SHOCK-PROTEIN-70; ESTABLISHED HYPERTENSION;
   INFLAMMATORY RESPONSE; STRESS-PROTEINS; B-LYMPHOCYTES; IN-VITRO
AB To date there are two mechanisms that are recognized by which heat shock proteins (HSP) are released from cells; a passive release mechanism, including necrotic cell death, severe blunt trauma, surgery and following infection with lytic viruses, and an active release mechanism which involves the non classical protein release pathway in which HSPs are released within highly immunologically potent exosomes and as free HSP. This chapter describes the experimental procedures that have been developed to study the mechanism by which stress induces the release of HSP72 into the circulation and addresses the biological significance of circulating HSP72 to host defense against disease. (C) 2007 Published by Elsevier Inc.
C1 Texas A&M Univ, Hlth Sci Ctr, Coll Med, Temple, TX 76504 USA.
   Scott & White Mem Hosp & Clin, Div Investigat Pathol, Temple, TX USA.
RP Asea, A (reprint author), Scott & White Mem Hosp & Clin, Div Investigat Pathol, 1901 S 1st St,Bldg 205, Temple, TX 76504 USA.
EM aasea@swmail.sw.org
RI Asea, Alexzander/I-4112-2013
OI Asea, Alexzander/0000-0003-3592-3481
FU NCI NIH HHS [R01CA91889]
CR Adewoye AH, 2005, AM J HEMATOL, V78, P240, DOI 10.1002/ajh.20292
   Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2
   Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Asea A, 2005, EXERC IMMUNOL REV, V11, P34
   Asea A, 2003, EXERC IMMUNOL REV, V9, P25
   Asea A, 2000, NAT MED, V6, P435
   Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1
   Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539
   Basu S, 2000, CELL STRESS CHAPERON, V5, P443, DOI 10.1379/1466-1268(2000)005<0443:HSPTFO>2.0.CO;2
   Bausero MA, 2005, J IMMUNOL, V175, P2900, DOI 10.4049/jimmunol.175.5.2900
   Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029
   Calderwood SK, 2005, TRENDS BIOTECHNOL, V23, P57, DOI 10.1016/j.tibtech.2004.12.011
   Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494
   de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871
   Dybdahl B, 2005, HEART, V91, P299, DOI 10.1136/hrt.2003.028092
   Dybdahl B, 2004, EUR J CARDIO-THORAC, V25, P985, DOI 10.1016/j.ejcts.2004.03.002
   Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121
   Fink AL, 1999, PHYSIOL REV, V79, P425
   Fleshner M, 2004, PSYCHONEUROENDOCRINO, V29, P1142, DOI 10.1016/j.psyneuen.2004.01.007
   Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X
   Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200
   Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6
   Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804
   Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3
   Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437
   Hunter-Lavin C, 2004, BIOCHEM BIOPH RES CO, V324, P511, DOI 10.1016/j.bbrc.2004.09.075
   Hut HMJ, 2005, MOL BIOL CELL, V16, P3776, DOI 10.1091/mbc.E05-01-0038
   Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124
   Lancaster GI, 2004, CELL STRESS CHAPERON, V9, P276, DOI 10.1379/CSC-18R.1
   Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200
   Lehner T, 2000, EUR J IMMUNOL, V30, P594, DOI 10.1002/1521-4141(200002)30:2<594::AID-IMMU594>3.0.CO;2-1
   LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215
   Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849
   Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143
   Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581
   Moehler MH, 2005, HUM GENE THER, V16, P996, DOI 10.1089/hum.2005.16.996
   Noessner E, 2002, J IMMUNOL, V169, P5424, DOI 10.4049/jimmunol.169.10.5424
   Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997
   Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001
   Pockley AG, 2002, J HYPERTENS, V20, P1815, DOI 10.1097/00004872-200209000-00027
   Pockley AG, 2003, HYPERTENSION, V42, P235, DOI 10.1161/01.HYP.0000086522.13672.23
   Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Roper K, 2000, NAT CELL BIOL, V2, P582
   Schneider EM, 2002, ANN NY ACAD SCI, V973, P8, DOI 10.1111/j.1749-6632.2002.tb04598.x
   Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0
   Sobo K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000391
   Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801
   Srivastava PK, 2001, VACCINE, V19, P2590, DOI 10.1016/S0264-410X(00)00492-8
   Srivastava PK, 2000, DRUG NEWS PERSPECT, V13, P517, DOI 10.1358/dnp.2000.13.9.858479
   SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93
   Srivastava Pramod K, 2005, Curr Oncol Rep, V7, P104, DOI 10.1007/s11912-005-0035-8
   Srivastava Pramod K, 2003, Cancer Immun, V3, P4
   Tang D, 2001, BIOCHEM BIOPH RES CO, V280, P280, DOI 10.1006/bbrc.2000.4118
   Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2
   Terry DF, 2004, ANN NY ACAD SCI, V1019, P502, DOI 10.1196/annals.1297.092
   Wright BH, 2000, HEART VESSELS, V15, P18, DOI 10.1007/s003800070043
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
   ZITVOGEL L, 1999, EUR J CANCER, V35, P36
NR 60
TC 19
Z9 19
U1 3
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
J9 METHODS
JI Methods
PD NOV
PY 2007
VL 43
IS 3
BP 194
EP 198
DI 10.1016/j.ymeth.2007.06.002
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 228NG
UT WOS:000250736000005
PM 17920515
DA 2018-12-27
ER

PT J
AU Kitagawa, H
   Ray, WJ
   Glantschnig, H
   Nantermet, PV
   Yu, YJ
   Leu, CT
   Harada, SI
   Kato, S
   Freedman, LP
AF Kitagawa, Hirochika
   Ray, William J.
   Glantschnig, Helmut
   Nantermet, Pascale V.
   Yu, Yuanjiang
   Leu, Chih-Tai
   Harada, Shun-Ichi
   Kato, Shigeaki
   Freedman, Leonard P.
TI RETRACTED: A regulatory circuit mediating convergence between Nurr1
   transcriptional regulation and Wnt signaling (Retracted article. See
   vol. 34, pg. 917, 2014)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID ORPHAN NUCLEAR RECEPTOR; MESENCEPHALIC DOPAMINERGIC-NEURONS;
   BETA-CATENIN ACTIVATION; LIGAND-BINDING DOMAIN; ANDROGEN RECEPTOR;
   COACTIVATOR RECRUITMENT; TYROSINE-HYDROXYLASE; INTERACTION SURFACE;
   TUMOR-SUPPRESSOR; VENTRAL MIDBRAIN
AB The orphan nuclear receptor Nurr1 is essential for the development and maintenance of midbrain dopaminergic neurons, the cells that degenerate during Parkinson's disease, by promoting the transcription of genes involved in dopaminergic neurotransmission. Since Nurr1 lacks a classical ligand-binding pocket, it is not clear which factors regulate its activity and how these factors are affected during disease pathogenesis. Since Wnt signaling via beta-catenin promotes the differentiation of Nurr1(+) dopaminergic precursors in vitro, we tested for functional interactions between these systems. We found that beta-catenin and Nurr1 functionally interact at multiple levels. In the absence of P-catenin, Nurr1 is associated with Lef-1 in corepressor complexes. P-Catenin binds Nurr1 and disrupts these corepressor complexes, leading: to coactivator recruitment and induction of Wnt- and Nurr1-responsive genes. We then identified KCNIP,4/calsenilin-like protein as being responsive to concurrent activation by Nurr1 and beta-catenin. Since KCNIP4 interacts with presenilins, the Alzheimer's disease-associated proteins that promote beta-catenin degradation, we tested the possibility that KCNIP4 induction regulates beta-catenin signaling. KCNIP4 induction limited beta-catenin activity in a presenilindependent manner, thereby serving as a negative feedback loop; furthermore, Nurr1 inhibition of beta-catenin activity was absent in PS1 (-/-) cells or in the presence of small interfering RNAs specific to KCNIP4. These data describe regulatory convergence between Nurr1 and beta-catenin, providing a mechanism by which Nurr1 could be regulated by Wnt signaling.
C1 Merck Res Labs, Dept Mol Endocrinol, West Point, PA 19486 USA.
   Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Freedman, LP (reprint author), Wyeth Res, 500 Arcola Rd N2283, Collegeville, PA 19426 USA.
EM freedlp@wyeth.com
OI Ray, William/0000-0002-4491-167X
CR Alimohamad H, 2005, J NEUROCHEM, V95, P513, DOI 10.1111/j.1471-4159.2005.03388.x
   Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036
   Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030
   Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826
   Castelo-Branco GA, 2006, MOL CELL NEUROSCI, V31, P251, DOI 10.1016/j.mcn.2005.09.014
   Castelo-Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100
   Castelo-Branco G, 2006, NEURODEGENER DIS, V3, P5, DOI 10.1159/000092086
   Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483
   Chan HM, 2001, J CELL SCI, V114, P2363
   Chu YP, 2006, J COMP NEUROL, V494, P495, DOI 10.1002/cne.20828
   Chu YP, 2002, J COMP NEUROL, V450, P203, DOI 10.1002/cne.10261
   Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200
   Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0
   Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912
   Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196
   Dean B, 2002, POSTGRAD MED J, V78, P142, DOI 10.1136/pmj.78.917.142
   FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6
   Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200
   Gould TD, 2002, NEUROSCIENTIST, V8, P497, DOI 10.1177/107385802237176
   Hermanson E, 2003, EXP CELL RES, V288, P324, DOI 10.1016/S0014-4827(03)00216-7
   Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200
   Jiang CT, 2005, EXP NEUROL, V191, P154, DOI 10.1016/j.expneurol.2004.08.035
   Joseph B, 2003, P NATL ACAD SCI USA, V100, P15619, DOI 10.1073/pnas.2635658100
   Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4
   Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200
   Kim KS, 2003, J NEUROCHEM, V85, P622, DOI 10.1046/j.1471-4159.2003.01671.x
   Kim SY, 2006, J NEUROSCI, V26, P4567, DOI 10.1523/JNEUROSCI.5236-05.2006
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200
   Kozlovsky N, 2006, INT J NEUROPSYCHOPH, V9, P337, DOI 10.1017/S1461145705006097
   Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066
   Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441-06
   Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003
   Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200
   Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034
   Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39
   Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310203200
   Nordzell M, 2004, BIOCHEM BIOPH RES CO, V313, P205, DOI 10.1016/j.bbrc.2003.11.079
   Palacino JJ, 2001, J BIOL CHEM, V276, P38563, DOI 10.1074/jbc.M105376200
   Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680
   Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462
   Powzaniuk M, 2004, MOL ENDOCRINOL, V18, P2011, DOI 10.1210/me.2004-0065
   Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x
   Sacchetti P, 2006, NUCLEIC ACIDS RES, V34, P5515, DOI 10.1093/nar/gkl712
   Sakurada K, 1999, DEVELOPMENT, V126, P4017
   Salthun-Lassalle B, 2004, J NEUROSCI, V24, P5922, DOI 10.1523/JNEUROSCI.5668-03.2004
   Satoh J, 2002, NEUROPATHOLOGY, V22, P219, DOI 10.1046/j.1440-1789.2002.00460.x
   Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013
   Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806
   Singh R, 2006, ENDOCRINOLOGY, V147, P141, DOI 10.1210/en.2005-1649
   Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785
   Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200
   Volakakis N, 2006, J MOL ENDOCRINOL, V37, P317, DOI 10.1677/jme.1.02106
   Volpicelli F, 2004, J NEUROCHEM, V88, P1283, DOI 10.1046/j.1471-4159.2003.02254.x
   Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645
   Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200
   Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248
NR 59
TC 42
Z9 43
U1 2
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2007
VL 27
IS 21
BP 7486
EP 7496
DI 10.1128/MCB.00409-07
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 223LK
UT WOS:000250371600012
PM 17709391
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Igarashi, M
   Yogiashi, Y
   Mihara, M
   Takada, I
   Kitagawa, H
   Kato, S
AF Igarashi, Mamoru
   Yogiashi, Yoshiko
   Mihara, Masatomo
   Takada, Ichiro
   Kitagawa, Hirochika
   Kato, Shigeaki
TI RETRACTED: Vitamin K induces osteoblast differentiation through pregnane
   X receptor-mediated transcriptional control of the Msx2 gene (Retracted
   article. See vol. 34, pg. 918, 2014)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID GAMMA-CARBOXYGLUTAMIC ACID; BONE-MINERAL DENSITY; NUCLEAR RECEPTOR;
   SIGNALING PATHWAY; HIP-FRACTURE; LIGAND; METABOLISM; PXR; PROTEIN; SXR
AB Vitamin K is a fat-soluble vitamin that serves as a coenzyme for vitamin K-dependent carboxylase. Besides its canonical action, vitamin K binds to the steroid and xenobiotic receptor (SXR)/pregnane X receptor (PXR) and modulates gene transcription. To determine if the osteoprotective action of vitamin K is the result of the PXR/SXR pathway, we screened by two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis the PXR/SXR target genes in an osteoblastic cell line (MC3T3-E1) treated with a vitamin K2 (menaquinone 4 [MK4]). Osteoblastic differentiation of MC3T3-E1 cells was induced by MK4. Msx2, an osteoblastogenic transcription factor, was identified as an MK4-induced gene. Functional analysis of the Msx2 gene promoter mapped a vitamin K-responsive element (PXR-responsive element [PXRE]) that was directly bound by a PXR/retinoid X receptor alpha heterodimer. In a chromatin immunoprecipitation analysis, PXR was recruited together with a coactivator, p300, to the PXRE in the Msx2 promoter. MK4-bound PXR cooperated with estrogen-bound estrogen receptor a to control transcription at the Msx2 promoter. Knockdown of either PXR or Msx2 attenuated the effect of MK4 on osteoblastic differentiation. Thus, the present study suggests that Msx2 is a target gene for PXR activated by vitamin K and suggests that the osteoprotective action of MK4 in the human mediates, at least in part, a genomic pathway of vitamin K signaling.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208
   Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195
   Booth SL, 2000, AM J CLIN NUTR, V71, P1201
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019
   Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853
   HAUSCHKA PV, 1978, J BIOL CHEM, V253, P9063
   Ichikawa T, 2006, J BIOL CHEM, V281, P16927, DOI 10.1074/jbc.M600896200
   Iwamoto I, 1999, MATURITAS, V31, P161, DOI 10.1016/S0378-5122(98)00114-5
   JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4506, DOI 10.1021/bi00852a047
   Kaneki M, 2001, NUTRITION, V17, P315, DOI 10.1016/S0899-9007(00)00554-2
   Kim M, 2007, MOL ENDOCRINOL, V21, P334, DOI 10.1210/me.2006-0231
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001.0038
   Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9
   Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Mani S, 2005, CLIN CANCER RES, V11, P6359, DOI 10.1158/1078-0432.CCR-05-0252
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447
   PRICE PA, 1985, J BIOL CHEM, V260, P4971
   Reschly EJ, 2006, CURR DRUG METAB, V7, P349, DOI 10.2174/138920006776873526
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Sato T, 2002, BRIT J NUTR, V87, P307, DOI [10.1079/BJN2001519, 10.1079/BJNBJN2001519]
   Satokata I, 2000, NAT GENET, V24, P391
   Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469
   Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942
   Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200
   Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548
   Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762
   Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753
   Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
NR 38
TC 62
Z9 63
U1 3
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2007
VL 27
IS 22
BP 7947
EP 7954
DI 10.1128/MCB.00813-07
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 229KD
UT WOS:000250800900018
PM 17875939
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Baritaki, S
   Katsman, A
   Chatterjee, D
   Yeung, KC
   Spandidos, DA
   Bonavida, B
AF Baritaki, Stavroula
   Katsman, Alina
   Chatterjee, Devasis
   Yeung, Kam C.
   Spandidos, Demetrios A.
   Bonavida, Benjamin
TI RETRACTED: Regulation of tumor cell sensitivity to TRAIL-induced
   apoptosis by the metastatic suppressor Raf kinase, inhibitor protein via
   Yin Yang 1 inhibition and death receptor 5 up-regulation (Retracted
   Article. See vol 197, pg 4859, 2016)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; PROSTATE-CANCER CELLS; ELEMENT-BINDING PROTEIN;
   TRANSCRIPTION FACTOR; MEDIATED APOPTOSIS; MAP KINASE; T-CELLS;
   CONSTITUTIVE ACTIVATION; SPINDLE CHECKPOINT; GENE-EXPRESSION
AB Raf-1 kinase inhibitor protein (RKIP) has been implicated in the regulation of cell survival pathways and metastases, and is poorly expressed in tumors. We have reported that the NF-kappa B pathway regulates tumor resistance to apoptosis by the TNF-alpha family via inactivation of the transcription repressor Yin Yang 1 (YY1). We hypothesized that RKIP overexpression may regulate tumor sensitivity to death ligands via inhibition of YY1 and up-regulation of death receptors (DRs). The TRAIL-resistant prostate carcinoma PC-3 and melanoma M202 cell lines were examined. Transfection with CMV-RKIP, but not with control CMV-EV, sensitized the cells to TRAIL-mediated apoptosis. Treatment with RKIP small interfering RNA (ARNA) inhibited TRAIL-induced apoptosis. RKIP overexpression was paralleled with up-regulation of DR5 transcription and expression; no change in DR4, decoy receptor 1, and decoy receptor 2 expression; and inhibition of YY1 transcription and expression. Inhibition of YY1 by YY1 ARNA sensitized the cells to TRAIL apoptosis concomitantly with DR5 up-regulation. RKIP overexpression inhibited several antiapoptotic gene products such as X-linked inhibitor of apoptosis (XIAP), c-FLIP long, and Bcl-X-L that were accompanied with mitochondrial membrane depolarization. RKIP overexpression in combination with TRAIL resulted in the potentiation of these above effects and activation of caspases 8, 9, and 3, resulting in apoptosis. These findings demonstrate that RKIP overexpression regulates tumor cell sensitivity to TRAIL via inhibition of YY1, up-regulation of DR5, and modulation of apoptotic pathways. We suggest that RKIP may serve as an immune surveillance cancer gene, and its low expression or absence in tumors allows the tumor to escape host immune cytotoxic effector cells.
C1 Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Davis Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   Brown Univ, Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA.
   Med Coll Ohio, Toledo, OH 43614 USA.
   Univ Crete, Fac Med, Dept Clin Virol, Iraklion, Greece.
RP Bonavida, B (reprint author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Davis Geffen Sch Med, Jonsson Comprehens Canc Ctr, 10833 Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.
EM bbonavida@mednet.ucla.edu
CR Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709
   Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521
   Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103
   Bodmer JL, 2000, NAT CELL BIOL, V2, P241
   Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395
   Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200
   Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200
   Chen XF, 2003, CANCER RES, V63, P1059
   Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.210015200
   Cory GOC, 2002, NATURE, V418, P732, DOI 10.1038/418732a
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015
   Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878
   Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75
   Gasparian AV, 2002, J CELL SCI, V115, P141
   Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080
   Hamai A, 2006, ONCOGENE, V25, P7618, DOI 10.1038/sj.onc.1209738
   Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655
   Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500
   JAZIREHI AR, 2006, CHEMO IMMUNOSENSITIZ, P63
   Keller ET, 2004, CANCER LETT, V207, P131, DOI 10.1016/j.canlet.2004.02.006
   Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200
   Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136
   LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145
   Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198
   Merchant MS, 2007, CANCER IMMUNOL IMMUN, V56, P1037, DOI 10.1007/s00262-006-0257-0
   MITAKE S, 1995, NEUROPATH APPL NEURO, V21, P35, DOI 10.1111/j.1365-2990.1995.tb01026.x
   Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749
   Nagane M, 2000, CANCER RES, V60, P847
   Ng CP, 2002, MOL CANCER THER, V1, P1051
   Nimmanapalli R, 2001, CANCER RES, V61, P759
   Ochsenbein AF, 2005, SPRINGER SEMIN IMMUN, V27, P19, DOI 10.1007/s00281-004-0192-0
   Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6
   Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160
   Pardoll D, 2001, NATURE, V411, P1010, DOI 10.1038/35082676
   Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435
   PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235
   Pitti RM, 1998, NATURE, V396, P699
   Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096
   Rosner MR, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-1
   Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595
   Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002
   Shankar S, 2005, PROSTATE, V62, P165, DOI 10.1002/pros.20126
   Sheikh MS, 1998, CANCER RES, V58, P1593
   Simister PC, 2002, ACTA CRYSTALLOGR D, V58, P1077, DOI 10.1107/S090744490200522X
   Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851
   Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3
   Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356
   Trakul N, 2005, CELL RES, V15, P19, DOI 10.1038/sj.cr.7290258
   Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200
   Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9
   Vega MI, 2005, J IMMUNOL, V175, P2174, DOI 10.4049/jimmunol.175.4.2174
   Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06
   Yang XH, 1997, CANCER LETT, V119, P149, DOI 10.1016/S0304-3835(97)00273-5
   Yeung K, 1999, NATURE, V401, P173
   Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001
   Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7
   Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792
   Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936
NR 60
TC 74
Z9 85
U1 3
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2007
VL 179
IS 8
BP 5441
EP 5453
DI 10.4049/jimmunol.179.8.5441
PG 13
WC Immunology
SC Immunology
GA 219QJ
UT WOS:000250099400053
PM 17911631
OA Bronze
DA 2018-12-27
ER

PT J
AU Sand, M
   Bechara, FG
AF Sand, Michael
   Bechara, Falk G.
TI RETRACTED: A growing, bleeding, violet mole (Retracted article. See vol.
   371, pg. 288, 2008)
SO LANCET
LA English
DT Editorial Material; Retracted Publication
ID ENDOMETRIOSIS
C1 Ruhr Univ Bochum, Acad Teaching Hosp, Augusta Krankenanstalt, Dept Gen & Visceral Surg, D-44791 Bochum, Germany.
   Ruhr Univ Bochum, Dept Dermatol & Allergol, D-44791 Bochum, Germany.
RP Sand, M (reprint author), Ruhr Univ Bochum, Acad Teaching Hosp, Augusta Krankenanstalt, Dept Gen & Visceral Surg, Bergstr 26, D-44791 Bochum, Germany.
EM michael.sand@ruhr-uni-bochum.de
CR BERGQVIST A, 1993, GYNECOL ENDOCRINOL, V7, P207, DOI 10.3109/09513599309152504
   FRANKLIN RR, 1990, PROG CLIN BIOL RES, V323, P289
   Kondi-Pafiti A, 2004, Clin Exp Obstet Gynecol, V31, P302
   PURVIS RS, 1994, J DERMATOL SURG ONC, V20, P693, DOI 10.1111/j.1524-4725.1994.tb00456.x
   von Stemm AMR, 1999, J EUR ACAD DERMATOL, V12, P30, DOI 10.1016/S0926-9959(98)00099-3
NR 5
TC 2
Z9 2
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD OCT 13
PY 2007
VL 370
IS 9595
BP 1392
EP 1392
DI 10.1016/S0140-6736(07)61582-7
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 220SC
UT WOS:000250176600034
PM 17933655
DA 2018-12-27
ER

PT J
AU Kim, SH
   Holway, AH
   Wolff, S
   Dillin, A
   Michael, WM
AF Kim, Seung-Hwan
   Holway, Antonia H.
   Wolff, Suzanne
   Dillin, Andrew
   Michael, W. Matthew
TI RETRACTED: SMK-1/PPH-4.1-mediated silencing of the CHK-1 response to DNA
   damage in early C. elegans embryos (Retracted Article. See vol 189, pg
   1187, 2010)
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID RADIATION-SENSITIVE MUTANTS; CAENORHABDITIS-ELEGANS; REPLICATION
   CHECKPOINT; MIDBLASTULA TRANSITION; PHOSPHATASE COMPLEX; CELL-DIVISION;
   GENE; IDENTIFICATION; MECHANISMS; CISPLATIN
AB During early embryogenesis in Caenorhabditis elegans, the ATL-1-CHK-1 ( ataxia telangiectasia mutated and Rad3 related-Chk1) checkpoint controls the timing of cell division in the future germ line, or P lineage, of the animal. Activation of the CHK-1 pathway by its canonical stimulus DNA damage is actively suppressed in early embryos so that P lineage cell divisions may occur on schedule. We recently found that the rad-2 mutation alleviates this checkpoint silent DNA damage response and, by doing so, causes damage-dependent delays in early embryonic cell cycle progression and subsequent lethality. In this study, we report that mutations in the smk-1 gene cause the rad-2 phenotype. SMK-1 is a regulatory subunit of the PPH-4.1 (protein phosphatase 4) protein phosphatase, and we show that SMK-1 recruits PPH-4.1 to replicating chromatin, where it silences the CHK-1 response to DNA damage. These results identify the SMK-1-PPH-4.1 complex as a critical regulator of the CHK-1 pathway in a developmentally relevant context.
C1 Harvard Univ, Dept Mol & Cellular Biol, Biol Lab, Cambridge, MA 02138 USA.
   Salk Inst Biol Studies, Mol Cell Biol Lab, La Jolla, CA 92037 USA.
RP Michael, WM (reprint author), Harvard Univ, Dept Mol & Cellular Biol, Biol Lab, Cambridge, MA 02138 USA.
EM mmichael@fas.harvard.edu
FU NIGMS NIH HHS [R01 GM067735, R01GM67735]
CR Aoki H, 2000, MOL GEN GENET, V264, P119, DOI 10.1007/s004380000291
   Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493
   Brauchle M, 2003, CURR BIOL, V13, P819, DOI 10.1016/S0960-9822(03)00295-1
   BRENNER S, 1974, GENETICS, V77, P71
   Conn CW, 2004, DEV CELL, V7, P275, DOI 10.1016/j.devcel.2004.07.003
   Crest J, 2007, GENETICS, V175, P567, DOI 10.1534/genetics.106.065219
   DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G
   den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105
   EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2
   Encalada SE, 2000, DEV BIOL, V228, P225, DOI 10.1006/dbio.2000.9965
   Gingras AC, 2005, MOL CELL PROTEOMICS, V4, P1725, DOI 10.1074/mcp.M500231-MCP200
   HARTMAN PS, 1989, GENETICS, V122, P379
   HARTMAN PS, 1985, GENETICS, V109, P81
   HARTMAN PS, 1984, PHOTOCHEM PHOTOBIOL, V39, P169, DOI 10.1111/j.1751-1097.1984.tb03424.x
   HARTMAN PS, 1982, GENETICS, V102, P159
   Holway AH, 2006, J CELL BIOL, V172, P999, DOI 10.1083/jcb.200512136
   Holway AH, 2005, GENETICS, V169, P1451, DOI 10.1534/genetics.104.036137
   Jones CA, 1996, PHOTOCHEM PHOTOBIOL, V63, P187, DOI 10.1111/j.1751-1097.1996.tb03012.x
   Kalogeropoulos N, 2004, CELL CYCLE, V3, P1196
   Kawasaki I, 1998, CELL, V94, P635, DOI 10.1016/S0092-8674(00)81605-0
   Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384
   Lambie EJ, 2002, BIOESSAYS, V24, P38, DOI 10.1002/bies.10019
   Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06
   Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305
   Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5
   O'Farrell PH, 2004, CURR BIOL, V14, pR35, DOI 10.1016/j.cub.2003.12.022
   Olsen A, 2006, SCIENCE, V312, P1381, DOI 10.1126/science.1124981
   Polanowska J, 2004, BIOTECHNIQUES, V36, P778, DOI 10.2144/04365BM05
   Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9
   Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439
   Spradling AC, 1999, GENETICS, V153, P135
   Su TT, 1999, CURR BIOL, V9, P919, DOI 10.1016/S0960-9822(99)80399-6
   Sumiyoshi E, 2002, J CELL SCI, V115, P1403
   Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579
   Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042
   Wu HI, 2004, CANCER RES, V64, P3940, DOI 10.1158/0008-5472.CAN-03-3113
   Yu KR, 2000, NAT CELL BIOL, V2, P609
   Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747
NR 40
TC 16
Z9 24
U1 2
U2 8
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD OCT 8
PY 2007
VL 179
IS 1
BP 41
EP 52
DI 10.1083/jcb.200705182
PG 12
WC Cell Biology
SC Cell Biology
GA 221LE
UT WOS:000250228000007
PM 17908915
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Oka, H
   Yoshioka, M
   Morita, M
   Onouchi, K
   Suzuki, M
   Ito, Y
   Hirai, T
   Mochio, S
   Inoue, K
AF Oka, H.
   Yoshioka, M.
   Morita, M.
   Onouchi, K.
   Suzuki, M.
   Ito, Y.
   Hirai, T.
   Mochio, S.
   Inoue, K.
TI RETRACTED: Reduced cardiac I-123-MIBG uptake reflects cardiac
   sympathetic dysfunction in Lewy body disease (Retracted article. See vol
   71, pg 63, 2008)
SO NEUROLOGY
LA English
DT Article; Retracted Publication
ID MULTIPLE SYSTEM ATROPHY; IDIOPATHIC PARKINSONS-DISEASE; VALSALVA
   MANEUVER; AUTONOMIC FAILURE; CARDIOVASCULAR DYSAUTONOMIA; MYOCARDIAL
   SCINTIGRAPHY; DENERVATION; DEMENTIA; BODIES; DIFFERENTIATION
AB Objective: To examine the relation between the results of cardiac (123)vertical bar- meta- iodobenzylguanidine ( MIBG) scintigraphy and cardiovascular autonomic function in Lewy body disease ( LBD).
   Methods: The subjects were 66 patients with LBD, 44 of whom had Parkinson disease ( PD), 10 PD with dementia ( PDD), and 12 dementia with Lewy bodies ( DLB); 20 age- matched healthy subjects were studied as controls. Cardiovascular autonomic function was evaluated on the basis of cardiac (123)vertical bar- MIBG uptake, cardiovascular autonomic response on the Valsalva maneuver ( VM), and systolic blood pressure ( SBP) response on head- up tilt table ( HUT) testing.
   Results: Patients with LBD had reduced cardiac (123)vertical bar- MIBG uptake, cardiovascular autonomic response on the VM, and SBP response on HUT testing as compared with controls. Cardiac (123)vertical bar MIBG uptake and cardiovascular autonomic function in PDD and DLB were severely impaired as compared with those in PD. Cardiac (123)vertical bar- MIBG uptake in LDB was not significantly related to vasomotor sympathetic function, baroreceptor reflex gain, cardiac parasympathetic function, or the changes in SBP on HUT testing. Cardiac (123)vertical bar- MIBG uptake was, however, significantly related to the blood pressure overshoot in phase IV of the VM.
   Conclusion: Cardiac (123)vertical bar- meta- iodobenzylguanidine uptake clinically reflects cardiac sympathetic dysfunction in Lewy body disease.
C1 Jikei Univ, Sch Med, Dept Neurol, Tokyo 1058461, Japan.
RP Oka, H (reprint author), Jikei Univ, Sch Med, Dept Neurol, Tokyo 1058461, Japan.
EM h.oka@jike.ac.jp
CR Amino T, 2005, BRAIN PATHOL, V15, P29, DOI 10.1111/j.1750-3639.2005.tb00097.x
   BENARROCH EE, 1991, MUSCLE NERVE, V14, P1165, DOI 10.1002/mus.880141204
   Braune S, 1998, ACTA NEUROL SCAND, V97, P307, DOI 10.1111/j.1600-0404.1998.tb05958.x
   Braune S, 1999, NEUROLOGY, V53, P1020, DOI 10.1212/WNL.53.5.1020
   CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721
   Courbon F, 2003, MOVEMENT DISORD, V18, P890, DOI 10.1002/mds.10461
   Denq JC, 1998, J CLIN NEUROPHYSIOL, V15, P535, DOI 10.1097/00004691-199811000-00013
   Druschky A, 2000, J NEUROL SCI, V175, P3, DOI 10.1016/S0022-510X(00)00279-3
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   GILMAN S, 1998, PARKINSONS DIS MOVEM, P245
   Hesse B, 2005, EUR J NUCL MED MOL I, V32, P855, DOI 10.1007/s00259-005-1779-y
   KIRCHHEIM HR, 1976, PHYSIOL REV, V56, P100
   KORNER PI, 1976, J APPL PHYSIOL, V40, P434
   MAGALHAES M, 1995, ACTA NEUROL SCAND, V91, P98
   McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1
   NAKAMURA T, 2005, AUTON NERV SYST TOKY, V42, P295
   Oka H, 2006, ACTA NEUROL SCAND, V113, P221, DOI 10.1111/j.1600-0404.2005.00526.x
   Oka H, 2006, J NEUROL SCI, V241, P59, DOI 10.1016/j.jns.2005.10.014
   Oka H, 2007, J NEUROL SCI, V254, P72, DOI 10.1016/j.jns.2007.01.002
   Oka Hisayoshi, 2003, Rinsho Shinkeigaku, V43, P465
   Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189
   Orimo S, 2002, J NEUROL NEUROSUR PS, V73, P776, DOI 10.1136/jnnp.73.6.776
   Orimo S, 2001, NEUROLOGY, V57, P1140, DOI 10.1212/WNL.57.6.1140
   Orimo S, 2007, ACTA NEUROPATHOL, V113, P81, DOI 10.1007/s00401-006-0160-y
   Sandroni P, 1991, Clin Auton Res, V1, P147, DOI 10.1007/BF01826212
   SANDRONI P, 1991, J APPL PHYSIOL, V71, P1563
   Satoh A, 1999, J NUCL MED, V40, P371
   Suzuki M, 2006, J NEUROL SCI, V240, P15, DOI 10.1016/j.jns.2005.08.011
   Taki J, 2000, EUR J NUCL MED, V27, P566, DOI 10.1007/s002590050544
   Thaisetthawatkul P, 2004, NEUROLOGY, V62, P1804, DOI 10.1212/01.WNL.0000125192.69777.6D
   Vogel ER, 2005, NEUROLOGY, V65, P1533, DOI 10.1212/01.wnl.0000184504.13173.ef
   Yoshita M, 1998, J NEUROL SCI, V155, P60, DOI 10.1016/S0022-510X(97)00278-5
NR 32
TC 29
Z9 30
U1 5
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 2
PY 2007
VL 69
IS 14
BP 1460
EP 1465
DI 10.1212/01.wnl.0000277450.49788.82
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 216KO
UT WOS:000249877100011
PM 17909159
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J.-Y.
TI RETRACTED:
   catena-poly[hexakis(mu(2)-anilinoacetamide)bis(1,10-phenanthroline)-disa
   marium(III] (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID LANTHANIDE(III) COMPLEXES; HEXAHYDRATE; ACID
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Daiguebonne C, 2000, INORG CHIM ACTA, V304, P161, DOI 10.1016/S0020-1693(00)00079-7
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XR INSTR, 1996, SMART SAINT SHELXTL
   STARYNOWICZ P, 1993, ACTA CRYSTALLOGR C, V49, P1895, DOI 10.1107/S0108270193004603
   STARYNOWICZ P, 1991, ACTA CRYSTALLOGR C, V47, P294, DOI 10.1107/S0108270190007892
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zeng XR, 2000, ACTA CRYSTALLOGR C, V56, pE325, DOI 10.1107/S0108270100009604
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
NR 14
TC 2
Z9 2
U1 1
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP M2592
EP U1447
DI 10.1107/S1600536807045485
PN 10
PG 15
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100128
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: Bis(2,2 '-bipyridine-kappa N,N ')bis(thiocyanato-kappa
   N)iron(II) (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   BANGLIN C, 2001, SCIENCE, V291, P102
   Ferey G, 2001, CHEM MATER, V13, P3084, DOI 10.1021/cm011070n
   Hill CL, 1998, CHEM REV, V98, P1, DOI 10.1021/cr960395y
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2062, DOI 10.1107/S1600536807031613
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2208, DOI 10.1107/S1600536807035337
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2141, DOI 10.1107/S1600536807033181
NR 15
TC 0
Z9 0
U1 3
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP M2506
EP U654
DI 10.1107/S1600536807043486
PN 10
PG 12
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100058
DA 2018-12-27
ER

PT J
AU Liu, YQ
   Zeng, XR
AF Liu, Yin-Qiu
   Zeng, Xi-Rui
TI RETRACTED: [N,N '-(o-Phenylene)bis(picolinamido)-kappa N-4,N ',N '',N
   ''']cobalt(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 Jinggangshan Univ, Jiangxi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
RP Liu, YQ (reprint author), Jinggangshan Univ, Jiangxi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
EM liuyiqja@163.com
CR [Anonymous], 2005, APEX2
   Bruker, 1997, SAINT
   Liu YQ, 2007, ACTA CRYSTALLOGR E, V63, pM2396, DOI 10.1107/S1600536807040640
   SHELDRICK GM, 2000, SHELXTL VERSION 6 10
   SHELDRICK GM, 2002, SADABS VERSION 2 03
NR 5
TC 3
Z9 3
U1 4
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP M2547
EP U1008
DI 10.1107/S1600536807044571
PN 10
PG 10
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100088
DA 2018-12-27
ER

PT J
AU Liu, YQ
   Zeng, XR
   Chen, WT
AF Liu, Yin-Qiu
   Zeng, Xi-Rui
   Chen, Wen-Tong
TI RETRACTED: trans-bis(ethylenediamine-kappa N-2,N ')bis(nitrato-kappa
   O)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL-STRUCTURE
C1 JingGangShan Univ, Jiangxi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
RP Liu, YQ (reprint author), JingGangShan Univ, Jiangxi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
EM liuyiqja@163.com
CR *BRUK AXS INC, 1997, SADABS SAINT SHELXTL
   Bruker-AXS, 2006, APEX2
   FRONCZEK FR, 1995, COMMUNICATION
   KOMIYAMA Y, 1964, ACTA CRYSTALLOGR, V17, P1145, DOI 10.1107/S0365110X64002961
   Manriquez V, 1996, J CHEM CRYSTALLOGR, V26, P15, DOI 10.1007/BF02018691
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
NR 6
TC 1
Z9 1
U1 4
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP M2462
EP U256
DI 10.1107/S1600536807042390
PN 10
PG 8
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100023
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X.-M.
   Xie, H.-L.
   Luo, C.-J.
TI RETRACTED: catena-poly[[bis(mu-anilinoacetato-kappa O-2 : O
   ')bis(mu-anilinoacetato-kappa O-3,O ': O)-bis[(1,10-phenanthroline-kappa
   N-2,N ')-samarium(III)]-mu-anilinoacetato-kappa O-2 : O '] (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID LANTHANIDE(III) COMPLEXES; HEXAHYDRATE; ACID
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Daiguebonne C, 2000, INORG CHIM ACTA, V304, P161, DOI 10.1016/S0020-1693(00)00079-7
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   STARYNOWICZ P, 1993, ACTA CRYSTALLOGR C, V49, P1895, DOI 10.1107/S0108270193004603
   STARYNOWICZ P, 1991, ACTA CRYSTALLOGR C, V47, P294, DOI 10.1107/S0108270190007892
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zeng XR, 2000, ACTA CRYSTALLOGR C, V56, pE325, DOI 10.1107/S0108270100009604
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
NR 15
TC 4
Z9 4
U1 3
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP M2508
EP U668
DI 10.1107/S1600536807043528
PN 10
PG 14
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100059
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: 3-hydroxy-2,4,6-trinitropyridine monohydrate (Retracted
   article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Carter PJ, 1998, J AM CHEM SOC, V120, P632, DOI 10.1021/ja9729589
   Lowe G, 1999, J MED CHEM, V42, P999, DOI 10.1021/jm981074c
   Pai CC, 2000, J AM CHEM SOC, V122, P11513, DOI 10.1021/ja000163n
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELX97 SHELXL97
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Swarnabala G, 1998, INORG CHEM, V37, P1483, DOI 10.1021/ic971261l
   Zhao ZJ, 2005, BIOORG MED CHEM LETT, V15, P905, DOI 10.1016/j.bmcl.2004.12.062
NR 9
TC 0
Z9 0
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP O4112
EP U3630
DI 10.1107/S1600536807045230
PN 10
PG 9
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100328
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X.-M.
   Xie, H.-L.
   Luo, C.-J.
TI RETRACTED: 2-Hydroxy-5-nitrobenzene-1,3-dicarboxylic acid monohydrate
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3167
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 13
TC 0
Z9 0
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2007
VL 63
BP O4191
EP U4349
DI 10.1107/S1600536807045199
PN 10
PG 9
WC Crystallography
SC Crystallography
GA 217KP
UT WOS:000249947100399
DA 2018-12-27
ER

PT J
AU Razem, FA
   Hill, RD
AF Razem, Fawzi A.
   Hill, Robert D.
TI RETRACTED: Hydrogen peroxide affects abscisic acid binding to ABAP1 in
   barley aleurones (Retracted article. See vol. 88, pg. 129, 2010)
SO BIOCHEMISTRY AND CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE abscisic acid; ABA-binding protein; protein unfolding; tryptophan
   fluorescence; hydrogen peroxide; H2O2
ID PROTEIN PHOSPHATASE 2C; PROGRAMMED CELL-DEATH; OXYGEN SPECIES
   PRODUCTION; STOMATAL GUARD-CELLS; REACTIVE OXYGEN; SIGNAL-TRANSDUCTION;
   OXIDATIVE STRESS; ACTIVE OXYGEN; POLY(PHENOLIC) DOMAIN; CEREAL ALEURONE
AB Dramatic increases in H2O2 levels have been observed following abscisic acid (ABA) treatment of plant tissues. Following ABA treatment in aleurone cells, H2O2 reached transient levels of approximately 115 mu mol/L H2O2. To determine whether ABA perception was modified by such changes, the effect of H2O2 on a recently characterized ABA-binding protein (ABAP1), cloned from barley aleurone layers, was examined. ABA binding to the protein was weakened by H2O2 in a concentration-dependent manner. A concentration of 75 mu mol/L H2O2 gave a 50% decline in ABA binding in a reaction following first-order kinetics, indicative of binding-site susceptibility to its microenvironment. We monitored the unfolding of ABAP1 using steady-state and time-resolved tryptophan fluorescence, while following the capacity of ABAP1 to bind ABA. ABA binding decreased by 50% following ABAP1 denaturation with 1 mol/L guanidine hydrochloride or 2 mol/L urea, while the maximum emission spectra (lambda(emi)) red shifted from 338 to 347 nm at 3.5 mol/L guanidine hydrochloride and 5 mol/L urea. However, only a slight blue shift of lambda(emi) was observed following either ABAP1 incubation with H2O2 or binding to (+)-ABA (physiologically active ABA). The equilibrium ABA dissociation rate accelerated in the presence of 250 mu mol/L H2O2, with the half-time dissociation reduced to 8 min. A comparison of inactivation kinetics and conformational changes shows that inactivation of ABAP1 occurs before any noticeable conformational change. This suggests that the ABA binding site is highly responsive to its microenvironment and is situated in a region that is more flexible than the protein molecule as a whole. The results demonstrate that H2O2, generated by ABA treatment of aleurone layers, is sufficient to affect the ABA-binding capacity of ABAP1, suggesting that this may be another level of control of ABA signal transduction.
C1 Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
RP Hill, RD (reprint author), Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
EM rob_hill@umanitoba.ca
CR Bernards MA, 2001, PHYTOCHEMISTRY, V57, P1115, DOI 10.1016/S0031-9422(01)00046-2
   Bernards Mark A., 2004, Phytochemistry Reviews, V3, P113, DOI 10.1023/B:PHYT.0000047810.10706.46
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRIGGS DE, 1978, BARLEY, P178
   Bueno P, 1998, PLANT SCI, V138, P27, DOI 10.1016/S0168-9452(98)00154-X
   Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7
   Creissen G, 1999, PLANT CELL, V11, P1277
   Desikan R, 1998, BIOCHEM J, V330, P115, DOI 10.1042/bj3300115
   Desikan R, 2004, J EXP BOT, V55, P205, DOI 10.1093/jxb/erh033
   Fath A, 2001, PLANT PHYSIOL, V126, P156, DOI 10.1104/pp.126.1.156
   Fath A, 2001, NEW PHYTOL, V151, P99, DOI 10.1046/j.1469-8137.2001.00153.x
   Fath A, 2002, J EXP BOT, V53, P1273, DOI 10.1093/jexbot/53.372.1273
   Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441
   Gilroy S, 1996, PLANT CELL, V8, P2193
   Guan LQM, 2000, PLANT J, V22, P87, DOI 10.1046/j.1365-313x.2000.00723.x
   HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234
   Hamilton DWA, 2000, P NATL ACAD SCI USA, V97, P4967, DOI 10.1073/pnas.080068897
   Hill R. D., 1992, Seed Science Research, V2, P207
   Himmelbach A, 2003, CURR OPIN PLANT BIOL, V6, P470, DOI 10.1016/S1369-5266(03)00090-6
   Jiang M, 2003, PLANT CELL ENVIRON, V26, P929, DOI 10.1046/j.1365-3040.2003.01025.x
   Jiang MY, 2001, PLANT CELL PHYSIOL, V42, P1265, DOI 10.1093/pcp/pce162
   Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277
   Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251
   Liu XG, 2007, SCIENCE, V315, P1712, DOI 10.1126/science.1135882
   MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467
   Meinhard M, 2002, PLANTA, V214, P775, DOI 10.1007/s00425-001-06745-3
   Meinhard M, 2001, FEBS LETT, V508, P443, DOI 10.1016/S0014-5793(01)03106-4
   MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457
   Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561
   Murata Y, 2001, PLANT CELL, V13, P2513, DOI 10.1105/tpc.13.11.2513
   Neill S, 2002, CURR OPIN PLANT BIOL, V5, P388, DOI 10.1016/S1369-5266(02)00282-0
   Orozco-Cardenas M, 1999, P NATL ACAD SCI USA, V96, P6553, DOI 10.1073/pnas.96.11.6553
   Pace C N, 1986, Methods Enzymol, V131, P266
   Palma K, 2003, FREE RADICAL BIO MED, V35, P1261, DOI 10.1016/S0891-5849(03)00511-2
   Pastori GM, 2002, PLANT PHYSIOL, V129, P460, DOI 10.1104/pp.011021
   Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067
   Razem FA, 2006, NATURE, V439, P290, DOI 10.1038/nature04373
   Razem FA, 2004, J BIOL CHEM, V279, P9922, DOI 10.1074/jbc.M311064200
   Razem FA, 2003, J EXP BOT, V54, P935, DOI 10.1093/jxb/erg094
   Razem FA, 2002, J AGR FOOD CHEM, V50, P1009, DOI 10.1021/jf0110248
   RAZEM FA, 2003, THESIS U W ONTARIO L
   Razem FA, 2006, CURR OPIN PLANT BIOL, V9, P454, DOI 10.1016/j.pbi.2006.07.007
   Shen YY, 2006, NATURE, V443, P823, DOI 10.1038/nature05176
   Sommer D, 2000, EUR J BIOCHEM, V267, P2312, DOI 10.1046/j.1432-1327.2000.01240.x
   TSOU CL, 1993, SCIENCE, V262, P380, DOI 10.1126/science.8211158
   Vranova E, 2002, J EXP BOT, V53, P1227, DOI 10.1093/jexbot/53.372.1227
   Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681
   Wu FB, 2004, CHEMOSPHERE, V57, P447, DOI 10.1016/j.chemosphere.2004.06.042
   Zhang X, 2001, PLANT PHYSIOL, V126, P1438, DOI 10.1104/pp.126.4.1438
NR 49
TC 9
Z9 9
U1 3
U2 13
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0829-8211
EI 1208-6002
J9 BIOCHEM CELL BIOL
JI Biochem. Cell Biol.
PD OCT
PY 2007
VL 85
IS 5
BP 628
EP 637
DI 10.1139/007-107
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 226YN
UT WOS:000250624500010
PM 17901904
DA 2018-12-27
ER

PT J
AU Iyamu, EW
   Ekekezie, C
   Woods, GM
AF Iyamu, Efemwonkiekie W.
   Ekekezie, Chiazotam
   Woods, Gerald M.
TI RETRACTED: In vitro evidence of the inhibitory capacity of chloroquine
   on arginase activity in sickle erythrocytes (Retracted article. See vol.
   155, pg. 133, 2011)
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article; Retracted Publication
DE sickle cell disease; chloroquine; inflammation; enzymes inhibition
ID CELL-DISEASE; PULMONARY-HYPERTENSION; PATHOGENESIS; THERAPY;
   HYDROXYUREA; EXPRESSION; CHILDREN; LIVER
AB Increased levels of erythrocyte arginase activity are believed to play a key role in the pathogenesis of sickle cell disease (SCD). Because increased arginase activity has been implicated in the exacerbation of pulmonary hypertension in SCD, this enzyme is considered an important therapeutic target for identifying new drugs to treat and manage SCD and other inflammatory disorders. Although chloroquine (CQ) is prescribed as an anti-malarial and anti-rheumatoid drug, the mechanism of its anti-inflammatory activity is largely unknown. The present study found that CQ inhibited arginase in a dose-dependent manner, and also displayed a linear competitive inhibition on sickle erythrocyte arginase. The apparent K-M values in the presence of inhibitor were considerably reduced at both physiological and slightly acidic pHs. Slope replots of the double reciprocal plots at pH 6.8 and 7.4 also indicated simple competitive inhibitory mechanism of CQ, and Ki values for CQ were within micromolar levels. To our knowledge, this is the first example of an anti-malarial and anti-inflammatory agent displaying competitive inhibition kinetics on arginase. The outcome of this study may provide a template for the rational design of specific agents either alone or in combination with CQ for the inhibition of arginase activity.
C1 Childrens Mercy Hosp, Pedoat Res Ctr, Div Hematol & Oncol, Kansas City, MO 64108 USA.
   Univ Missouri, Med Ctr, Dept Pediat, Kansas City, MO 64110 USA.
RP Iyamu, EW (reprint author), Childrens Mercy Hosp, Pedoat Res Ctr, Div Hematol & Oncol, 2401 Gillham Rd,3730 01, Kansas City, MO 64108 USA.
EM eiyamu@cmh.edu
FU NHLBI NIH HHS [K01 HL076695-01]
CR AZIZI E, 1970, CLIN CHIM ACTA, V28, P391, DOI 10.1016/0009-8981(70)90063-X
   BERUTER J, 1978, BIOCHEM J, V175, P449, DOI 10.1042/bj1750449
   BEUTLER E, 1975, RED CELL METABOLISM
   Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948
   CHINARD FP, 1952, J BIOL CHEM, V199, P91
   FREEDMAN A, 1976, ANN RHEUM DIS, V15, P251
   GRIFFIN TC, 1994, NEW ENGL J MED, V330, P733, DOI 10.1056/NEJM199403173301101
   Hillery CA, 2004, MICROCIRCULATION, V11, P195, DOI 10.1080/10739680490278600
   HIRSCHKOLB H, 1970, ANAL BIOCHEM, V35, P60, DOI 10.1016/0003-2697(70)90009-6
   HONG DD, 1976, ANAL PROFILES DRUG S, P61
   Iyamu EW, 2005, BRIT J HAEMATOL, V131, P389, DOI 10.1111/j.1365-2141.2005.05772.x
   Iyamu EW, 2003, EXP HEMATOL, V31, P592, DOI 10.1016/S0301-472X(03)00105-X
   Karres I, 1998, AM J PHYSIOL-REG I, V274, pR1058, DOI 10.1152/ajpregu.1998.274.4.R1058
   Kim PS, 2002, MOL GENET METAB, V76, P100, DOI 10.1016/S1096-7192(02)00034-3
   Kinney TR, 1999, PEDIATRICS, V103, P640, DOI 10.1542/peds.103.3.640
   Lavulo LT, 2001, J BIOL CHEM, V276, P14242, DOI 10.1074/jbc.M010575200
   McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458
   Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001/jama.294.1.81
   Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200308-967OC
   OU CN, 1993, CLIN CHEM, V39, P820
   Pathare A, 2004, AM J HEMATOL, V77, P323, DOI 10.1002/ajh.20196
   Romero JR, 2002, BLOOD, V99, P1103, DOI 10.1182/blood.V99.4.1103
   SALMERON G, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)91266-4
   Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4
   SIEGEL IH, 1975, ENZYME KINETICS, P929
   Stuart MJ, 1999, BLOOD, V94, P1555
   Tormanen CD, 1997, J INORG BIOCHEM, V66, P111, DOI 10.1016/S0162-0134(96)00191-2
   WALLACE DJ, 1994, RHEUM DIS CLIN N AM, V20, P243
   WEBER SM, 2002, J IMMUNOL, V165, P1534
   Wun T, 2001, HEMATOLOGY, V5, P403
   Zachlederova M, 2003, BLOOD CELL MOL DIS, V30, P70, DOI 10.1016/S1079-9796(03)00011-1
   ZHU X, 1993, IMMUNOLOGY, V80, P122
   Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912
NR 33
TC 11
Z9 11
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD OCT
PY 2007
VL 139
IS 2
BP 337
EP 343
DI 10.1111/j.1365-2141.2007.06798.x
PG 7
WC Hematology
SC Hematology
GA 214OG
UT WOS:000249747400022
PM 17897312
OA Bronze
DA 2018-12-27
ER

PT J
AU Augustin, G
   Antabak, A
   Davila, S
AF Augustin, Goran
   Antabak, Anko
   Davila, Slavko
TI RETRACTED: The periosteum Part 1: Anatomy, histology and molecular
   biology (Retracted Article. See vol 39, pg 824, 2008)
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Review; Retracted Publication
DE periosteum; fibrous layer; cambium layer; Sharpey's fibres; periosteal
   circulation; bone formation; bone resorption; perichondrial ossification
   groove
ID HUMAN FEMORAL-NECK; BONE STRENGTH; CORTICAL BONE; OSTEOPOROTIC
   FRACTURES; PARATHYROID-HORMONE; EXTRA-PERIOSTEAL; TIBIAL DIAPHYSIS;
   PROXIMAL FEMUR; GROWTH-FACTORS; HIP GEOMETRY
AB The periosteum is a thin layer of connective tissue that covers the outer surface of a bone in all places except at joints (which are protected by articular cartilage). As opposed to bone itself, it has nociceptive nerve endings, making it very sensitive to manipulation. It also provides nourishment in the form of blood supply to the bone. The periosteum is connected to the bone by strong collagenous fibres called Sharpey's fibres, which extend to the outer circumferential and interstitial lamellae of bone. The periosteum consists of an outer "fibrous layer" and inner "cambium layer". The fibrous layer contains fibroblasts white the cambium layer contains progenitor cells which develop into osteoblasts that are responsible for increasing bone width. After a bone fracture the progenitor cells develop into osteobtasts and chondrobtasts which are essential to the heating process. This review discusses the anatomy, histology and molecular biology of the periosteum in detail. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Zagreb, Clin Hosp Ctr, Zagreb 10000, Croatia.
RP Augustin, G (reprint author), Univ Zagreb, Clin Hosp Ctr, Kispaticeva 12, Zagreb 10000, Croatia.
EM augustin.goran@gmail.com; anko.antabak@zg.t-com.hr;
   stavko.davita@yahoo.com
OI Augustin, Goran/0000-0002-0202-3324
CR Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464
   Allen MR, 2005, BONE, V36, P311, DOI 10.1016/j.bone.2004.10.013
   Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   ANDERSON C, 1978, AM J VET RES, V39, P1763
   ANSEROFF NJ, 1934, Z ANAT ENTWICKLUNGS, V103, P793
   Aubin J. E., 2002, PRINCIPLES BONE BIOL, V1, P59
   August M, 1999, AGING SKELETON, P359
   Bagi CM, 1997, BONE, V21, P261, DOI 10.1016/S8756-3282(97)00121-X
   BALENA R, 1992, J BONE MINER RES, V7, P1475
   BANKS HH, 1964, P C ASEPTIC NECROSIS, P465
   Beck TJ, 2001, J BONE MINER RES, V16, P2103, DOI 10.1359/jbmr.2001.16.11.2103
   Beck TJ, 2001, J BONE MINER RES, V16, P1108, DOI 10.1359/jbmr.2001.16.6.1108
   BECK TJ, 1993, CALCIFIED TISSUE INT, V53, pS41, DOI 10.1007/BF01673401
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180
   Bikle D, 2001, J BONE MINER RES, V16, P2320, DOI 10.1359/jbmr.2001.16.12.2320
   BOER FC, 2002, OSTEO TRAUMA CARE, V10, P1
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Bradney M, 2000, J BONE MINER RES, V15, P1871, DOI 10.1359/jbmr.2000.15.10.1871
   BRIGHTON CT, 1978, CLIN ORTHOP RELAT R, V136, P22
   BRIGHTON CT, 1992, GROWTH DEV BONE GROW, P105
   BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, V275, P287
   BROOKES M, 1984, BLOOD SUPPLY BONE, P88
   BRUNS RR, 1968, J CELL BIOL, V37, P244, DOI 10.1083/jcb.37.2.244
   Buckwalter J A, 1996, Instr Course Lect, V45, P371
   BURSTEIN FD, 1989, PLAST RECONSTR SURG, V83, P500, DOI 10.1097/00006534-198903000-00019
   Cadet ER, 2003, J BONE JOINT SURG AM, V85A, P1739, DOI 10.2106/00004623-200309000-00013
   Chanavaz M, 1995, J Oral Implantol, V21, P214
   CHONG DA, 1982, ARCH ORAL BIOL, V27, P777, DOI 10.1016/0003-9969(82)90029-2
   COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014
   Crabtree N, 2000, BONE, V27, P151, DOI 10.1016/S8756-3282(00)00300-8
   CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5
   DIAZFLORES L, 1992, PERICYTES SUPPL SOUR, P280
   DIMITRIUO CG, 1988, CLIN ORTHOP RELAT R, V236, P265
   Dixon T, 2000, SKELETAL RADIOL, V29, P587, DOI 10.1007/s002560000260
   DUHAMEN D, 1757, REC PERIOD OBS MED C, V7, P153
   DUPUYTREN C, 1847, INJURIES DIS BONES B
   EINHORN TA, 1992, CALCIFIED TISSUE INT, V51, P333, DOI 10.1007/BF00316875
   ELLENDER G, 1988, J ANAT, V158, P173
   EPKER BN, 1966, ANAT REC, V154, P573, DOI 10.1002/ar.1091540307
   EPKER BN, 1965, ANAT REC, V152, P129, DOI 10.1002/ar.1091520203
   FERRETTI JL, 1995, CALCIFIED TISSUE INT, V57, P399, DOI 10.1007/BF00301939
   Forriol F, 2005, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000156001.78631.e9
   FREITAS RA, 1999, NANOMEDICINE, V1, P5
   Gallie WE, 1914, CAN MED ASSOC J, V4, P33
   Garn S. M, 1970, EARLIER GAIN LATER L
   Gross TS, 2002, J BONE MINER RES, V17, P493, DOI 10.1359/jbmr.2002.17.3.493
   HAASBEEK JF, 1995, J PEDIATR ORTHOPED, V15, P677, DOI 10.1097/01241398-199509000-00025
   HAYES WC, 1982, SCIENCE, V217, P945, DOI 10.1126/science.7112107
   HENLE J, 1868, HDB GERASSLEHRE MENS
   HERNANDEZ JA, 1995, CLIN ORTHOP RELAT R, P211
   HERT J, 1972, ACTA ANAT, V82, P420
   HERT J, 1972, PRAKTISCHE ANATOMIE, V14
   HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   HOLTROP M E, 1975, Annals of Clinical and Laboratory Science, V5, P264
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   HYRTL J, 1882, HDB TOPOGRAPHISCHEN, V2
   IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1
   IWAKU F, 1992, SCANNING ELECTRON MI, P72
   Jacobsen FS, 1997, J PEDIATR ORTHOP B, V6, P84, DOI 10.1097/01202412-199704000-00003
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E
   Kowalski MJ, 1996, CALCIFIED TISSUE INT, V59, P24, DOI 10.1007/s002239900080
   LaMothe JM, 2005, MED ENG PHYS, V27, P277, DOI 10.1016/j.medengphy.2004.04.012
   Lee KCL, 2002, BONE, V31, P407, DOI 10.1016/S8756-3282(02)00842-6
   Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115
   Looker AC, 2001, J BONE MINER RES, V16, P1291, DOI 10.1359/jbmr.2001.16.7.1291
   MACNAB I, 1974, CLIN ORTHOP RELAT R, V105, P27
   MARTIN RB, 1977, J BIOMECH, V10, P223, DOI 10.1016/0021-9290(77)90045-8
   MEADE JB, 1984, CALCIFIED TISSUE INT, V36, pS25, DOI 10.1007/BF02406130
   MENCK J, 1992, ACTA ANAT, V143, P67
   MEYRICK B, 1979, ANAT REC, V193, P71, DOI 10.1002/ar.1091930106
   Midura RJ, 2003, J BIOL CHEM, V278, P51462, DOI 10.1074/jbc.M307567200
   MILLER SC, 1991, BONE, V12, P439, DOI 10.1016/8756-3282(91)90033-F
   MULLER ME, 1963, TECHNIK OPERATIVEN F, P38
   NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402
   NAKAMURA T, 1994, J BONE MINER RES, V9, P1071
   Nelson DA, 2000, J BONE MINER RES, V15, P1992, DOI 10.1359/jbmr.2000.15.10.1992
   O'Driscoll SWM, 2001, J ORTHOPAED RES, V19, P95, DOI 10.1016/S0736-0266(00)00014-0
   Orwoll ES, 2001, CALCIFIED TISSUE INT, V69, P185, DOI 10.1007/s00223-001-1062-6
   Orwoll ES, 2003, J BONE MINER RES, V18, P949, DOI 10.1359/jbmr.2003.18.6.949
   Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272
   PANKOVICH AM, 1975, ARCH SURG-CHICAGO, V110, P20
   Parfitt AM, 2002, J BONE MINER RES, V17, P1741, DOI 10.1359/jbmr.2002.17.10.1741
   PEAD MJ, 1988, J BONE MINER RES, V3, P647
   PFEILSCHIFTER J, 1993, J BONE MINER RES, V8, P707
   Phemister D., 1939, J BONE JOINT SURG, V21, P681
   Power J, 2003, OSTEOPOROSIS INT, V14, P141, DOI 10.1007/s00198-002-1333-8
   PRESCHER A, 1991, VERSAMMLUNG ANAT ANZ, V170, P207
   Rauch F, 2001, J BONE MINER RES, V16, P1547, DOI 10.1359/jbmr.2001.16.8.1547
   Reilly TM, 1998, CLIN ORTHOP RELAT R, P95
   REINELANDER FW, 1972, BIOCH PHYSL BONE, V2, P38
   RHODIN JAG, 1974, HISTOLOGY TEXT ATLAS, P196
   RIGAL WM, 1962, RADIOISOTOPES BONE, P197
   Rucker M, 1998, MICROVASC RES, V56, P30, DOI 10.1006/mvre.1998.2077
   Seeman E, 1997, J BONE MINER RES, V12, P509, DOI 10.1359/jbmr.1997.12.4.509
   Seeman E, 2002, J BONE MINER RES, V17, P373, DOI 10.1359/jbmr.2002.17.3.373
   SHAPIRO F, 1977, J BONE JOINT SURG AM, V59, P703, DOI 10.2106/00004623-197759060-00001
   SHAPIRO F, 1981, ACTA ORTHOP SCAND, V52, P649, DOI 10.3109/17453678108992162
   Shapiro F, 2002, PEDIAT ORTHOPEDIC DE
   Shea JE, 2001, J ANAT, V198, P153, DOI 10.1046/j.1469-7580.2001.19820153.x
   Sheng MHC, 1999, BONE, V25, P421, DOI 10.1016/S8756-3282(99)00184-2
   Simon TM, 2003, J ORTHOP RES, V21, P470, DOI 10.1016/S0736-0266(02)00206-1
   SIMPSON AHRW, 1985, J ANAT, V140, P697
   SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1
   SMITH RW, 1964, SCIENCE, V145, P156, DOI 10.1126/science.145.3628.156
   Solomon L, 1966, J Bone Joint Surg Br, V48, P170
   SQUIER CA, 1990, J ANAT, V171, P233
   Srinivasan S, 2002, J BONE MINER RES, V17, P1613, DOI 10.1359/jbmr.2002.17.9.1613
   STEPHEN E, 2000, J NEUROSCI, V20, P1495
   Szechinski JW, 2002, ORTHOPEDICS, V25, P1365
   TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271
   TANG XM, 1986, CHINESE MED J-PEKING, V99, P950
   TAYLOR JF, 1992, BONE GROWTH, V6
   Tonna E A, 1963, Clin Orthop Relat Res, V30, P218
   TONNA EA, 1966, PERIODONTICS, V4, P105
   TONNA EA, 1974, LAB INVEST, V31, P609
   TONNA EA, 1961, J BIOPHYS BIOCHEM CY, V9, P813, DOI 10.1083/jcb.9.4.813
   TRIFFITT PD, 1993, J ORTHOPAED RES, V11, P49, DOI 10.1002/jor.1100110107
   TRUETA J, 1974, CLIN ORTHOP RELAT R, P11
   TURNER RT, 1990, J ORTHOPAED RES, V8, P612, DOI 10.1002/jor.1100080418
   URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986
   Vajda EG, 1999, ANAT RECORD, V255, P202, DOI 10.1002/(SICI)1097-0185(19990601)255:2<202::AID-AR10>3.0.CO;2-0
   vanderMeulen MCH, 1996, J ORTHOPAED RES, V14, P22, DOI 10.1002/jor.1100140106
   WHEATER PR, 1987, FUNCTIONAL HISTOLOGY, P149
   WHITESIDE LA, 1978, J BONE JOINT SURG AM, V60, P23, DOI 10.2106/00004623-197860010-00003
   WHITESIDE LA, 1978, J BONE JOINT SURG AM, V60, P26, DOI 10.2106/00004623-197860010-00004
   WILSON JW, 1986, BONE CLIN ORTHOPEDIC, P57
   ZAGBAMONGALIMA G, 1988, GERONTOLOGY, V34, P264, DOI 10.1159/000212965
   ZUCMAN J, 1960, BRIT J SURG, V48, P324, DOI 10.1002/bjs.18004820915
NR 129
TC 55
Z9 64
U1 3
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD OCT
PY 2007
VL 38
IS 10
BP 1115
EP 1130
DI 10.1016/j.injury.2007.05.017
PG 16
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 229GS
UT WOS:000250791900002
PM 17889870
DA 2018-12-27
ER

PT J
AU Hsu, DS
   Balakumaran, BS
   Acharya, CR
   Vlahovic, V
   Walters, KS
   Garman, K
   Anders, C
   Riedel, RF
   Lancaster, J
   Harpole, D
   Dressman, HK
   Nevins, JR
   Febbo, PG
   Potti, A
AF Hsu, David S.
   Balakumaran, Bala S.
   Acharya, Chaitanya R.
   Vlahovic, Vanja
   Walters, Kelli S.
   Garman, Katherine
   Anders, Carey
   Riedel, Richard F.
   Lancaster, Johnathan
   Harpole, David
   Dressman, Holly K.
   Nevins, Joseph R.
   Febbo, Phillip G.
   Potti, Anil
TI RETRACTED: Pharmacogenomic strategies provide a rational approach to the
   treatment of cisplatin-resistant patients with advanced cancer
   (Retracted article. See vol. 28, pg. 5229, 2010)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
ID CELL LUNG-CANCER; PHASE-III TRIAL; CHEMOTHERAPY REGIMENS;
   OVARIAN-CANCER; BREAST-CANCER; SOLID TUMORS; EXPRESSION; SURVIVAL;
   PREDICTION; VINORELBINE
AB Purpose Standard treatment for advanced non-small-cell lung cancer (NSCLC) includes the use of a platinum-based chemotherapy regimen. However, response rates are highly variable. Newer agents, such as pemetrexed, have shown significant activity as second-line therapy and are currently being evaluated in the front-line setting. We utilized a genomic strategy to develop signatures predictive of chemotherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective individualized medicine.
   Methods Using in vitro drug sensitivity data, coupled with microarray data, we developed gene expression signatures predicting sensitivity to cisplatin and pemetrexed. Signatures were validated with response data from 32 independent ovarian and lung cancer cell lines as well as 59 samples from patients previously treated with cisplatin.
   Results Genomic-derived signatures of cisplatin and pemetrexed sensitivity were shown to accurately predict sensitivity in vitro and, in the case of cisplatin, to predict treatment response in patients treated with cisplatin. The accuracy of the cisplatin predictor, based on available clinical data, was 83.1% (sensitivity, 100%; specificity 57%; positive predictive value, 78%; negative predictive value, 100%). Interestingly, an inverse correlation was seen between in vitro cisplatin and pemetrexed sensitivity, and importantly, between the likelihood of cisplatin and pemetrexed response in patients.
   Conclusion The use of genomic predictors of response to cisplatin and pemetrexed can be incorporated into strategies to optimize therapy for advanced solid tumors.
C1 Duke Univ, Dept Med, Med Ctr, Div Med Oncol, Durham, NC 27710 USA.
   Duke Univ, Inst Genome Sci & Policy, Durham, NC 27710 USA.
   Duke Univ, Dept Surg, Durham, NC 27710 USA.
   Univ S Florida, H Lee Moffitt Canc Ctr, Div Gynecol Oncol, Tampa, FL 33682 USA.
RP Potti, A (reprint author), Duke Univ, Dept Med, Med Ctr, Div Med Oncol, Box 3841, Durham, NC 27710 USA.
EM anil.potti@duke.edu
CR BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734
   Bunn PA, 1998, CLIN CANCER RES, V4, P1087
   Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Golub TR, 2001, NEW ENGL J MED, V344, P601, DOI 10.1056/NEJM200102223440809
   Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570
   Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163
   JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5
   Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Paz-Ares L, 2003, CANCER, V97, P2056, DOI 10.1002/cncr.11279
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914
   Rustin GJS, 2006, J CLIN ONCOL, V24, P45, DOI 10.1200/JCO.2005.01.2757
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954
   SHEPHERD FA, 1994, SEMIN ONCOL, V21, P7
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   YEN L, 1995, MUTAT RES-DNA REPAIR, V337, P179, DOI 10.1016/0921-8777(95)00022-C
NR 27
TC 76
Z9 78
U1 3
U2 17
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 1
PY 2007
VL 25
IS 28
BP 4350
EP 4357
DI 10.1200/JCO.2007.11.0593
PG 8
WC Oncology
SC Oncology
GA 233EN
UT WOS:000251073300007
PM 17906199
DA 2018-12-27
ER

PT J
AU Chu, SH
   Ma, YB
   Zhang, H
   Feng, DF
   Zhu, ZA
   Li, ZQ
   Yuan, XH
AF Chu, Sheng-hua
   Ma, Yan-bin
   Zhang, Hong
   Feng, Dong-fu
   Zhu, Zhi-an
   Li, Zhi-qiang
   Yuan, Xian-hou
TI RETRACTED: Hepatocyte growth factor production is stimulated by
   gangliosides and TGF-beta isoforms in human glioma cells (Retracted
   Article. See vol 97, pg 309, 2010)
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article; Retracted Publication
DE gangliosides; growth factors; hepatocyte growth factor; glioma
ID IN-VITRO; BRAIN-TUMOR; EXPRESSION; ANGIOGENESIS; MIGRATION; ASTROCYTES;
   GD3; GLIOBLASTOMA; ENDOTHELIUM; VASCULARITY
AB Hepatocyte growth factor (HGF) is a pleiotrophic cytokine that stimulates motility and invasion of several cancer cell types and induces angiogenesis, which is known to be expressed in several malignancies including glioma. The effect of transforming growth factor-beta (TGF-beta) isoforrns as well as gangliosides on HGF production was investigated in human glioma cell lines. TGF-beta isoforms and gangliosides were found to differentially stimulate HGF production by these cells. The ganglioside GD3 enhanced this release to the greatest extent and the stimulation was more marked in a glioblastoma cell line than in the two other anaplastic astrocytoma cell lines. These results suggest that both TGF-beta s and gangliosides may act as indirect angiogenic factors by stimulating HGF secretion.
C1 Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp Affilated 3, Dept Neurosurg, Shanghai 201900, Peoples R China.
   Wuhan Univ, Zhongnam Hosp, Dept Neurosurg, Wuhan 430071, Peoples R China.
RP Chu, SH (reprint author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp Affilated 3, Dept Neurosurg, Shanghai 201900, Peoples R China.
EM shenghuachu@126.com
CR Abate LE, 2006, J NEUROCHEM, V98, P1973, DOI 10.1111/j.1471-4159.2006.04097.x
   Abounader R, 2005, NEURO-ONCOLOGY, V7, P436, DOI 10.1215/S1152851705000050
   ALESSANDRI G, 1987, CANCER RES, V47, P4243
   Brockmann MA, 2003, NEUROSURGERY, V52, P1391, DOI 10.1227/01.NEU.0000064806.87785.AB
   BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154
   Chattopadhyay N, 2002, MOL BRAIN RES, V102, P73, DOI 10.1016/S0169-328X(02)00215-2
   Chattopadhyay N, 2001, MOL BRAIN RES, V87, P100, DOI 10.1016/S0165-3806(00)00154-1
   Chu SH, 2006, SURG NEUROL, V65, P533, DOI 10.1016/j.surneu.2005.11.024
   CHU SH, 2005, CHIN J NEUROMED, V4, P1093
   CHU SH, 2007, IN PRESS J SURG RES, V137
   CHU SH, 2005, CHIN J NEUROMED, V4, P1208
   CHU SH, 2005, TUMOR, V25, P173
   Chu SH, 2006, J NEURO-ONCOL, V80, P143, DOI 10.1007/s11060-006-9174-5
   Chu Sheng-Hua, 2005, Zhonghua Yi Xue Za Zhi, V85, P835
   CLARKE TM, 1992, BRIT J NEUROSURG, V6, P85
   CONSTAM DB, 1992, J IMMUNOL, V148, P1404
   DECRISTAN G, 1990, J CELL PHYSIOL, V144, P505
   Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205
   FREDMAN P, 1993, J NEUROCHEM, V60, P99, DOI 10.1111/j.1471-4159.1993.tb05827.x
   Gaini S M, 1988, Acta Neurochir Suppl (Wien), V43, P126
   Guerin C, 2000, BIOCHEM BIOPH RES CO, V273, P287, DOI 10.1006/bbrc.2000.2935
   [江普查 JIANG Pucha], 2006, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V23, P540
   Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648
   Kawai K, 1999, VIRCHOWS ARCH, V434, P201, DOI 10.1007/s004280050328
   KNOTT JCA, 1990, NEUROPATH APPL NEURO, V16, P489, DOI 10.1111/j.1365-2990.1990.tb01288.x
   Koochekpour S, 1996, CANCER LETT, V102, P209, DOI 10.1016/0304-3835(96)04161-4
   Koochekpour S, 1996, CANCER LETT, V104, P97, DOI 10.1016/0304-3835(96)04231-0
   KOOCHEKPOUR S, 1995, NEUROSCI LETT, V186, P53, DOI 10.1016/0304-3940(95)11280-A
   Lux Andreas, 2006, BMC Cardiovasc Disord, V6, P13, DOI 10.1186/1471-2261-6-13
   Maidment SL, 1996, EUR J CANCER, V32A, P868, DOI 10.1016/0959-8049(95)00659-1
   Manfredi MG, 1999, CANCER RES, V59, P5392
   Mennel HD, 2005, CLIN NEUROPATHOL, V24, P13
   MERZAK A, 1995, MOL CHEM NEUROPATHOL, V24, P121, DOI 10.1007/BF02962138
   Nabors LB, 2001, CANCER RES, V61, P2154
   Nakamura Y, 1996, J HYPERTENS, V14, P1067, DOI 10.1097/00004872-199609000-00004
   Nishimura K, 1999, PROSTATE, V41, P145
   Nishimura K, 2000, Hinyokika Kiyo, V46, P769
   Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603
   PACUSZKA T, 1991, BIOCHEMISTRY-US, V30, P2563, DOI 10.1021/bi00224a001
   Ren RF, 1999, NEUROSCIENCE, V93, P1041, DOI 10.1016/S0306-4522(99)00215-8
   SHIBAMOTO S, 1992, CELL STRUCT FUNCT, V17, P185, DOI 10.1247/csf.17.185
   Shimao Y, 1999, INT J CANCER, V82, P449, DOI 10.1002/(SICI)1097-0215(19990730)82:3<449::AID-IJC20>3.0.CO;2-H
   SHINOURA N, 1992, NEUROSURGERY, V31, P541, DOI 10.1227/00006123-199209000-00017
   Sinha M, 2003, EUR BIOPHYS J BIOPHY, V32, P381, DOI 10.1007/s00249-003-0281-3
   Stiles JD, 1997, J NEUROPATH EXP NEUR, V56, P435, DOI 10.1097/00005072-199704000-00012
   Urbanska-Rys H, 2003, EUR CYTOKINE NETW, V14, P40
   Vasir B, 2000, DIABETOLOGIA, V43, P763, DOI 10.1007/s001250051374
   Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843
   Xiong B, 2002, WORLD J GASTROENTERO, V8, P496, DOI 10.3748/wjg.v8.i3.496
   ZICHE M, 1989, LAB INVEST, V61, P629
   ZICHE M, 1992, LAB INVEST, V67, P711
NR 51
TC 14
Z9 15
U1 6
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD OCT
PY 2007
VL 85
IS 1
BP 33
EP 38
DI 10.1007/s11060-007-9387-2
PG 6
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 210LP
UT WOS:000249458000004
PM 17464449
DA 2018-12-27
ER

PT J
AU Karthikeyan, M
   Bhaskaran, R
   Radhika, K
   Mathiyazhagan, S
   Sandosskumar, R
   Samiyappan, R
   Velazhahan, R
AF Karthikeyan, M.
   Bhaskaran, R.
   Radhika, K.
   Mathiyazhagan, S.
   Sandosskumar, R.
   Samiyappan, R.
   Velazhahan, R.
TI RETRACTED: Random amplified polymorphic DNA analysis of genetic
   variability among isolates of Ganoderma species (Retracted article. See
   vol 116, pg 143, 2009)
SO JOURNAL OF PLANT DISEASES AND PROTECTION
LA English
DT Article; Retracted Publication
DE coconut; Ganoderma sp.; genetic variability; RAPD
ID SEQUENCE ANALYSES; RAPD; IDENTIFICATION; PRIMERS; MARKERS
AB Ganoderma wilt of coconut caused by Ganoderma lucidum (Leys) Karst. is the most serious disease constraint to coconut production throughout the world. The genus Ganoderma has a wide host range and shows morphological variability among the isolates from different hosts. Random amplified polymorphic DNA (RAPD) analyses were used to determine the genetic relatedness within and. between G. lucidum isolates from infected coconut palm and Ganoderma sp. from other hosts from different locations in India. RAPD analysis using ten random primers showed variations of banding patterns within and between the isolates from coconut and other hosts, indicating that they were genetically heterogeneous. There was no specific banding pattern that could differentiate between G. lucidum isolates from coconut palm and Ganoderma sp. from other hosts. Dendrograms from cluster analysis based on unweighted pair-group method using arithmetic means (UPGMA) of RAPD data showed that G. lucidum isolates from infected coconut palm and Ganoderma sp. from other hosts did not cluster separately into two distinct clusters, but were clustered together, which indicated that both groups of Ganoderma are closely related. The similarity values from RAPD analysis showed a broad range of values from 44 to 77 percent for G. lucidum isolates from infected coconut palm and Ganoderma sp. from other hosts. The finding that the Ganoderma isolates from coconut stumps are closely related to Ganoderma isolates from other hosts would have an important bearing in the formulation of disease control measures and planting procedures, especially in areas where the previous crop was infected with Ganoderma disease.
C1 Tamil Nadu Agr Univ, Dept Plant Pathol, Ctr Plant Protect Studies, Coimbatore 641003, Tamil Nadu, India.
   Coconut Res Stn, Veppankulam 614906, Tamil Nadu, India.
   Annamalai Univ, Fac Agr, Annamalainagar 608002, Tamil Nadu, India.
RP Karthikeyan, M (reprint author), Tamil Nadu Agr Univ, Dept Plant Pathol, Ctr Plant Protect Studies, Coimbatore 641003, Tamil Nadu, India.
EM karthipath@rediffmail.com
CR Abdullah F., 2000, Ganoderma diseases of perennial crops, P183, DOI 10.1079/9780851993881.0183
   BHASKARAN R, 1985, P NAT SEM INT PEST D, P183
   Bounou S, 1999, MYCOL RES, V103, P1, DOI 10.1017/S0953756298006522
   Bryan GT, 1999, MYCOL RES, V103, P319, DOI 10.1017/S0953756298007072
   DARMONO TW, 1998, 2 INT WORKSH GAN DIS
   de Oliveira Andreia M. R., 2002, Genetics and Molecular Research, V1, P350
   FREEMAN S, 2000, APPL ENVIRON MICROB, V66, P5627
   IDRIS AS, 1996, P 1996 PORIM INT PAL, P538
   Jaccard P., 1901, B SOC VAUD SCI NAT, V37, P547, DOI DOI 10.5169/SEALS-266450
   Kini KR, 2002, J PHYTOPATHOL, V150, P209, DOI 10.1046/j.1439-0434.2002.00739.x
   Koike M, 1996, PLANT DIS, V80, P1224, DOI 10.1094/PD-80-1224
   Latiffah Z., 2002, Malaysian Applied Biology, V31, P37
   Lyons GA, 2000, MYCOL RES, V104, P1431, DOI 10.1017/S0953756200002872
   Malvick DK, 1998, MYCOL RES, V102, P465, DOI 10.1017/S0953756297005029
   Martinez-Culebras PV, 2002, J PHYTOPATHOL, V150, P680, DOI 10.1046/j.1439-0434.2002.00823.x
   Miller RNG, 1999, PLANT PATHOL, V48, P595, DOI 10.1046/j.1365-3059.1999.00390.x
   MOLLER EM, 1992, NUCLEIC ACIDS RES, V20, P6115, DOI 10.1093/nar/20.22.6115
   Muraguchi H, 2003, FUNGAL GENET BIOL, V40, P93, DOI 10.1016/S1087-1845(03)00087-2
   Paavanen-Huhtala S, 1999, MYCOL RES, V103, P625, DOI 10.1017/S0953756298007485
   Pei MH, 1997, MYCOL RES, V101, P7, DOI 10.1017/S0953756296002006
   Pilotti C. A., 2000, Ganoderma diseases of perennial crops, P195, DOI 10.1079/9780851993881.0195
   PILOTTI CA, 1998, 2 INT WORKSH GAN DIS
   REDDY NPE, 1986, INDIAN PHYTOPATHOL, V38, P172
   Rohlf F. J, 1990, NTSYS PC NUMERICAL T
   SCHLICK A, 1994, CURR GENET, V26, P74, DOI 10.1007/BF00326307
   TURNER PD, 1981, OIL DIS DISORDERS
   Weiland JJ, 1999, PHYTOPATHOLOGY, V89, P176, DOI 10.1094/PHYTO.1999.89.2.176
   WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531
   Zakaria L, 2005, ASIA PAC J MOL BIOL, V13, P23
NR 29
TC 1
Z9 1
U1 1
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-3829
EI 1861-3837
J9 J PLANT DIS PROTECT
JI J. Plant Dis. Prot.
PD OCT
PY 2007
VL 114
IS 5
BP 205
EP 212
PG 8
WC Agriculture, Multidisciplinary; Plant Sciences
SC Agriculture; Plant Sciences
GA 233GQ
UT WOS:000251078900003
DA 2018-12-27
ER

PT J
AU Shin, SG
AF Shin, Soon-Gi
TI RETRACTED: Two-dimensional simulation of percolation structure, in
   two-phase composites (Retracted article. See vol. 24, pg. 439, 2018)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE simulation; composites; percolation structure; second phase; aspect
   ratio
ID PROPERTY
AB Two-dimensional simulations were conducted on a percolation structure in which second phases of various aspect ratios were arranged in a matrix phase. The second phases were randomly arranged in an array with two different computational programs, one prohibiting overlap among second phases and the other allowing overlap. From the simulation where overlap is prohibited, it was predicted that a continuous path was formed at lesser amounts of the second phase with higher aspect ratios. In the simulation allowing the overlap, a continuous path throughout the array was formed by arranging a second phase having an aspect ratio of 5, where this phase (complete path) accounts for less than 43 % of the array.
C1 Kangwon Natl Univ, Div Adv Mat & Chem Engn, Gangwon 245711, South Korea.
RP Shin, SG (reprint author), Kangwon Natl Univ, Div Adv Mat & Chem Engn, 1 Joongang Ro, Gangwon 245711, South Korea.
EM ssg@kangwon.ac.kr
CR BALBERG I, 1983, PHYS REV B, V28, P3799, DOI 10.1103/PhysRevB.28.3799
   DANG MC, 1994, J MATER SCI, V29, P2315, DOI 10.1007/BF00363420
   HOLM EA, 1989, J AM CERAM SOC, V72, P303, DOI 10.1111/j.1151-2916.1989.tb06119.x
   KIRKPATRICK S, 1973, REV MOD PHYS, V45, P574, DOI 10.1103/RevModPhys.45.574
   MCLACHLAN DS, 1990, J AM CERAM SOC, V73, P2187, DOI 10.1111/j.1151-2916.1990.tb07576.x
   MIYAYAMA M, 1993, J MATER SCI, V28, P6442, DOI 10.1007/BF01352210
   OKUHARA Y, 2000, T MRS J, V25, P581
   ROLLETT AD, 1989, ACTA METALL MATER, V37, P1227, DOI 10.1016/0001-6160(89)90117-X
   RUSCHAU GR, 1992, J APPL PHYS, V72, P953, DOI 10.1063/1.352350
   SERGO V, 1991, J MATER SCI LETT, V10, P855, DOI 10.1007/BF00724759
   Shin SG, 2006, MET MATER INT, V12, P137, DOI 10.1007/BF03027469
   Shin SG, 2001, MET MATER INT, V7, P605, DOI 10.1007/BF03179259
   ZHANG JS, 1992, J AM CERAM SOC, V75, P2286, DOI 10.1111/j.1151-2916.1992.tb04497.x
NR 13
TC 2
Z9 2
U1 2
U2 3
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD OCT
PY 2007
VL 13
IS 5
BP 385
EP 389
DI 10.1007/BF03027872
PG 5
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 237LD
UT WOS:000251374300005
DA 2018-12-27
ER

PT J
AU Tseng, JD
   Liu, WT
AF Tseng, Jan-Dong
   Liu, Wei-Ting
TI RETRACTED: Novel method for skirt response improvement of open-stub
   low-pass filter (Retracted article. See vol. 57, pg. 2229, 2015)
SO MICROWAVE AND OPTICAL TECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE direct circuit replacement; skirt response; open-stub; low-pass filter;
   interdigital
ID DEFECTED GROUND STRUCTURE; DESIGN
AB A direct circuit replacement method using interdigital low-pass structure directly replaced all open stubs of odd-order open-stub low-pass filter to achieve sharp skirt response. The Characteristics of the interdigital structure are analyzed by lumped element equivalent circuits and investigated by full-wave electromagnetic simulator, IE3D. These simulated results were then applied as a guideline for the replacement. Two open-stub low-pass filters were designed by this method to enhance the skirt response near 3-dB cutoff frequency. The measured results show very good improvement on skirt response and the rejection level in stop band. (c) 2007 Wiley Periodicals, Inc.
C1 Natl Chin Yi Univ Technol, Dept Elect Engn, Taiping City 411, Taichung County, Taiwan.
RP Tseng, JD (reprint author), Natl Chin Yi Univ Technol, Dept Elect Engn, 35 Lane 215,Sec 1 Chung Shan Rd, Taiping City 411, Taichung County, Taiwan.
EM jdtseng@chinyi.ncit.edu.tw
CR Ahn D, 2001, IEEE T MICROW THEORY, V49, P86, DOI 10.1109/22.899965
   ALLEY GD, 1970, IEEE T MICROW THEORY, VMT18, P1028, DOI 10.1109/TMTT.1970.1127407
   CHIOU YC, 2005, P IMP LOW PASS FILT, V3
   GUPTA KC, 1982, COMPUT AIDED DESIGN, P207
   Hsieh LH, 2003, IEEE T MICROW THEORY, V51, P193, DOI 10.1109/TMTT.2002.806901
   Karmakar NC, 2003, IEEE T MICROW THEORY, V51, P564, DOI 10.1109/TMTT.2002.807817
   Kim T, 2000, IEEE MICROW GUIDED W, V10, P13, DOI 10.1109/75.842072
   KUO JT, 2001, P AS PAC MICR C, V1, P330
   LEE MQ, 2002, IEEE MTTS INT MICROW, V3, P1797
   Lim JS, 2005, IEEE T MICROW THEORY, V53, P2539, DOI 10.1109/TMTT.2005.852765
   PARK JI, 1999, 1999 AS PAC MICR C D, V2, P331
   Pozar David M., 1998, MICROWAVE ENG
   SHE XY, 1986, P IEE, V133
   SMERKLO L, 2004, P INT C MOD PROBL RA, P154
   TSENG JD, 2006, ASIA PACIFIC MICROWA
   TSENG JD, 2004, 2004 CROSS STRAIT TR, P59
   Tu WH, 2005, IEEE MICROW WIREL CO, V15, P404, DOI 10.1109/LMWC.2005.850479
   WENZEL RJ, 1970, IEEE T MICROW THEORY, VMT18, P1150, DOI 10.1109/TMTT.1970.1127424
   Zverev A. I., 1967, HDB FILTER SYNTHESIS
NR 19
TC 2
Z9 3
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0895-2477
EI 1098-2760
J9 MICROW OPT TECHN LET
JI Microw. Opt. Technol. Lett.
PD OCT
PY 2007
VL 49
IS 10
BP 2434
EP 2438
DI 10.1002/mop.22764
PG 5
WC Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA 199RX
UT WOS:000248714000031
DA 2018-12-27
ER

PT J
AU Tseng, JD
   Chang, WG
AF Tseng, Jan-Dong
   Chang, Wei-Geo
TI RETRACTED: Planar rectangular split ring shape band-pass structures
   (Retracted article. See vol. 57, pg. 2464, 2015)
SO MICROWAVE AND OPTICAL TECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE planar; rectangular; split ring; band pass; coupled line
ID RESONATORS; FILTERS; DESIGN
AB A planar rectangular split ring shaped band-pass structure is proposed and analyzed by coupled line equivalent circuit instead of commonly used LC resonator circuit. The derived results were then used to design two- and three-cascaded rectangular split ring shape structures. Two Prototypes were both designed at center frequency at 2.45 GHz., simulated by microwave simulators: lE3D and microwave office and fabricated on FR-4 substrate. The simulated and experimental results show good agreement within 0-10 GHz.(c) 2007 Wiley Periodicals, Inc.
C1 Natl Chin Yi Univ Tehcnol, Dept Elect Engn, Taiping 411, Taichung, Taiwan.
RP Tseng, JD (reprint author), Natl Chin Yi Univ Tehcnol, Dept Elect Engn, 35 Lane 215,Sec 1 Chung Shan Rd, Taiping 411, Taichung, Taiwan.
EM jdtseng@chinyi.ncit.edu.tw
CR Bonache J, 2006, IEEE T MICROW THEORY, V54, P265, DOI 10.1109/TMTT.2005.861664
   Bonache J, 2005, ELECTRON LETT, V41, P810, DOI 10.1049/el:20050895
   FRICKEY DA, 1994, IEEE T MICROW THEORY, V42, P205, DOI 10.1109/22.275248
   Garcia-Garcia J, 2004, IEEE MICROW WIREL CO, V14, P416, DOI 10.1099/LMWC.2004.832066
   HONG JS, 2001, MICRSTRIP FILTERS RF
   Iza F, 2003, IEEE T PLASMA SCI, V31, P782, DOI 10.1109/TPS.2003.815470
   JUNG J, 2006, 36 EUR MICR C SEP 20, P95
   Kim J, 2005, ELECTRON LETT, V41, P1333, DOI 10.1049/el:20053306
   Li C, 2007, ELECTRON LETT, V43, P35, DOI 10.1049/el:20072945
   MARQUES R, 2003, IEEE MED, P222
   Martel J, 2004, IEEE MICROW WIREL CO, V14, P210, DOI 10.1109/LMWC.2004.827836
   Martel J, 2007, IEEE MICROW WIREL CO, V17, P28, DOI 10.1109/LMWC.2006.887246
   MATTHAEI G, 1980, MICROWAVES FILTERS I
   Pendry JB, 1998, J PHYS-CONDENS MAT, V10, P4785, DOI 10.1088/0953-8984/10/22/007
   Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002
   SHEPARD KW, 1983, IEEE T MAGN, V19, P1312, DOI 10.1109/TMAG.1983.1062559
   ZYSMAN GI, 1969, IEEE T MICROW THEORY, VMT17, P753, DOI 10.1109/TMTT.1969.1127055
NR 17
TC 3
Z9 4
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0895-2477
EI 1098-2760
J9 MICROW OPT TECHN LET
JI Microw. Opt. Technol. Lett.
PD OCT
PY 2007
VL 49
IS 10
BP 2520
EP 2523
DI 10.1002/mop.22794
PG 4
WC Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA 199RX
UT WOS:000248714000053
DA 2018-12-27
ER

PT J
AU Chen, L
   Woo, SLC
AF Chen, Li
   Woo, Savio L. C.
TI RETRACTED: Correction in female PKU mice by repeated administration of
   mPAH cDNA using phiBT1 integration system (Retracted article. See vol.
   18, pg. 2191, 2010)
SO MOLECULAR THERAPY
LA English
DT Article; Retracted Publication
ID SITE-SPECIFIC RECOMBINATION; MEDIATED GENE-TRANSFER; PHAGE PHI-C31
   INTEGRASE; GENOMIC INTEGRATION; MOUSE MODEL; PHENYLALANINE-HYDROXYLASE;
   PHENOTYPIC CORRECTION; HUMAN-CELLS; IN-VIVO; TRANSGENE EXPRESSION
AB Phenylketonuria (PKU) is a metabolic disorder secondary to a hepatic deficiency of phenylalanine hydroxylase (PAH) that predisposes affected children to develop severe and irreversible mental retardation. We have previously reported the complete and permanent correction of the hyperphenylalaninemic and hypopigmentation phenotypes in male, but not female, PKU mice after genome-targeted delivery of murine PAH (mPAH) complementary DNA (cDNA) in a phiBT1 bacteriophage integration system. Here we show that sequential administration of green fluorescent protein (GFP)- and red fluorescent protein (RFP)-expressing cassettes in the phiBT1 integration system led to distinct and non-overlapping populations of green and red fluorescent hepatocytes in vivo. The hyperphenylalaninemic and hypopigmentation phenotypes of female PKU mice were completely corrected after 10 weekly administrations of mPAH cDNA. Importantly, there was no apparent liver pathology in mice even after 10 consecutive administrations of the phiBT1 integration system. The results indicate that repeated administration of transgenes in the phiBT1 integration system can lead to their genome-targeted integration in a diverse population of hepatocytes and result in the elevation of transgene expression levels in a cumulative manner, which can be utilized to overcome insufficient transgene expression owing to low genome integration frequencies in a gene therapy paradigm for metabolic disorders.
C1 CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA.
RP Woo, SLC (reprint author), CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.
EM savio.woo@mssm.edu
FU NIDDK NIH HHS [DK-62972]
CR Allen BG, 2005, NAT METHODS, V2, P975, DOI 10.1038/NMETH814
   Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787
   Blau N, 2004, MOL GENET METAB, V82, P101, DOI 10.1016/j.ymgme.2004.03.006
   Calos MP, 2006, CURR GENE THER, V6, P633, DOI 10.2174/156652306779010642
   Chalberg TW, 2005, INVEST OPHTH VIS SCI, V46, P2140, DOI 10.1167/iovs.04-1252
   Chalberg TW, 2006, J MOL BIOL, V357, P28, DOI 10.1016/j.jmb.2005.11.098
   Chen L, 2005, P NATL ACAD SCI USA, V102, P15581, DOI 10.1073/pnas.0503877102
   Chen L, 2007, MOL THER, V15, P1079, DOI 10.1038/sj.mt.6300137
   Chen ZY, 2003, MOL THER, V8, P495, DOI 10.1016/S1525-0016(03)00168-0
   Dafhnis-Calas F, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni192
   Dale Y, 2003, J CHROMATOGR B, V788, P1, DOI 10.1016/S1570-0232(02)01005-X
   Ding Z, 2006, GENE THER, V13, P587, DOI 10.1038/sj.gt.3302684
   FANG B, 1994, GENE THER, V1, P247
   Ginsburg DS, 2005, ADV GENET, V54, P179, DOI 10.1016/S0065-2660(05)54008-2
   Gregory MA, 2003, J BACTERIOL, V185, P5320, DOI 10.1128/JB.185.17.5320-5323.2003
   Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775
   Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097
   Harding CO, 2006, GENE THER, V13, P457, DOI 10.1038/sj.gt.3302678
   Held PK, 2005, MOL THER, V11, P399, DOI 10.1016/j.ymthe.2004.11.001
   Hollis Roger P, 2003, Reprod Biol Endocrinol, V1, P79, DOI 10.1186/1477-7827-1-79
   Ishikawa Y, 2006, J GENE MED, V8, P646, DOI 10.1002/jgm.891
   Keravala A, 2006, MOL GENET GENOMICS, V276, P135, DOI 10.1007/s00438-006-0129-5
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Liu J, 2006, GENE THER, V13, P1188, DOI 10.1038/sj.gt.3302789
   Lutz KA, 2004, PLANT J, V37, P906, DOI 10.1111/j.1365-313X.2004.02015.x
   Malla S, 2005, NUCLEIC ACIDS RES, V33, P6101, DOI 10.1093/nar/gki922
   Mochizuki S, 2004, GENE THER, V11, P1081, DOI 10.1038/sj.gt.3302262
   Oh HJ, 2004, PEDIATR RES, V56, P278, DOI 10.1203/01.PDR.0000132873.29067.0E
   Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X
   Olivares EC, 2001, GENE, V278, P167, DOI 10.1016/S0378-1119(01)00711-9
   Olivares EC, 2002, NAT BIOTECHNOL, V20, P1124, DOI 10.1038/nbt753
   Ortiz-Urda S, 2003, HUM GENE THER, V14, P923, DOI 10.1089/104303403765701204
   PENG H, 1988, P NATL ACAD SCI USA, V85, P8146, DOI 10.1073/pnas.85.21.8146
   Portlock JL, 2006, HUM GENE THER, V17, P871, DOI 10.1089/hum.2006.17.871
   Quenneville SP, 2004, MOL THER, V10, P679, DOI 10.1016/j.ymthe.2004.05.034
   Sarkissian CN, 2000, MOL GENET METAB, V69, P188, DOI 10.1006/mgme.2000.2974
   SCRIVER CR, 1995, CLIN BIOCHEM, V28, P137, DOI 10.1016/0009-9120(94)00076-8
   SHEDLOVSKY A, 1993, GENETICS, V134, P1205
   Smith MCA, 2004, NUCLEIC ACIDS RES, V32, P2607, DOI 10.1093/nar/gkh538
   Smith MCM, 2002, MOL MICROBIOL, V44, P299, DOI 10.1046/j.1365-2958.2002.02891.x
   Stoll SM, 2002, J BACTERIOL, V184, P3657, DOI 10.1128/JB.184.13.3657-3663.2002
   Thomason LC, 2001, MOL GENET GENOMICS, V265, P1031, DOI 10.1007/s004380100498
   Thorpe HM, 1998, P NATL ACAD SCI USA, V95, P5505, DOI 10.1073/pnas.95.10.5505
   Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001
   WOO SLC, 1987, ENZYME, V38, P207, DOI 10.1159/000469206
   Yang HY, 2002, J BACTERIOL, V184, P1859, DOI 10.1128/JB.184.7.1859-1864.2002
NR 46
TC 5
Z9 5
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD OCT
PY 2007
VL 15
IS 10
BP 1789
EP 1795
DI 10.1038/sj.mt.6300257
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 214ZX
UT WOS:000249778000012
PM 17637719
OA Other Gold
DA 2018-12-27
ER

PT J
AU Kow, YW
   Imhoff, B
   Weiss, B
   Hung, DCI
   Hindoyan, AA
   Story, RM
   Goodman, SD
AF Kow, Yoke W.
   Imhoff, Barry
   Weiss, Bernard
   Hung, David C. I.
   Hindoyan, Antreas A.
   Story, Randall M.
   Goodman, Steven D.
TI RETRACTED: Escherichia coli HU protein has a role in the repair of
   abasic sites in DNA (Retracted Article. See vol 37, pg 3474, 2009)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article; Retracted Publication
ID BASE EXCISION-REPAIR; ENDONUCLEASE-III; CRUCIFORM DNA; MECHANISM;
   BINDING; IHF; RECOMBINATION; MUTAGENESIS; POLYMERASE; MUTANT
AB HU is one of the most abundant DNA binding proteins in Escherichia coli. We find that it binds strongly to DNA containing an abasic (AP) site or tetrahydrofuran (THF) (apparent K-d approximate to 50 nM). It also possesses an AP lyase activity that cleaves at a deoxyribose but not at a THF residue. The binding and cleavage of an AP site was observed only with the HU alpha beta heterodimer. Site-specific mutations at K3 and R61 residues led to a change in substrate binding and cleavage. Both K3A(alpha)K3A(beta) and R61A(alpha)R61A(beta) mutant HU showed significant reduction in binding to DNA containing AP site; however, only R61A(alpha)R61A(beta) mutant protein exhibited significant loss in AP lyase activity. Both K3A(alpha)K3A(beta) and R61K(alpha)R61K(beta) showed slight reduction in AP lyase activities. The function of HU protein as an AP lyase was confirmed by the ability of hupA or hupB mutations to further reduce the viability of an E. coli dut(Ts) xth mutant, which generates lethal AP sites at 37 degrees C; the hupA and hupB derivatives, respectively, had a 6-fold and a 150-fold lower survival at 37 degrees C than did the parental strain. These data suggest, therefore, that HU protein plays a significant role in the repair of AP sites in E. coli.
C1 Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   Univ So Calif, Div Diagnost Sci, Los Angeles, CA 90089 USA.
   Univ So Calif, Dept Mol & Computat Biol, Los Angeles, CA 90089 USA.
RP Kow, YW (reprint author), Emory Univ, Sch Med, Dept Radiat Oncol, Clifton Rd NE, Atlanta, GA 30322 USA.
EM ykow@emory.edu
RI Goodman, Steven/C-5732-2013
FU NCI NIH HHS [R56 CA090860, R01 CA090860, CA90860]; NIEHS NIH HHS [P01
   ES011163]; NIDCR NIH HHS [R01 DE13965, R01 DE013965]
CR BOCKRATH R, 1993, MUTAT RES, V288, P207, DOI 10.1016/0027-5107(93)90086-U
   BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563
   BOUBRIK F, 1995, P NATL ACAD SCI USA, V92, P3958, DOI 10.1073/pnas.92.9.3958
   CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291
   Claret L, 1997, J MOL BIOL, V273, P93, DOI 10.1006/jmbi.1997.1310
   CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986
   Friedberg E.C., 2006, DNA REPAIR MUTAGENES
   Grove A, 2002, BIOCHEMISTRY-US, V41, P7597, DOI 10.1021/bi016095e
   Hashimoto M, 2003, J BIOL CHEM, V278, P28501, DOI 10.1074/jbc.M303970200
   HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989
   Jaffe A, 1997, J BACTERIOL, V179, P3494, DOI 10.1128/jb.179.11.3494-3499.1997
   Kamashev D, 2000, EMBO J, V19, P6527, DOI 10.1093/emboj/19.23.6527
   Kamau E, 2005, BIOCHEM J, V390, P49, DOI 10.1042/BJ20050274
   KANO Y, 1991, GENE, V103, P25
   Kow Yoke Wah, 2006, P323
   Kow YW, 2000, METHODS, V22, P164, DOI 10.1006/meth.2000.1057
   Li SS, 1998, J BACTERIOL, V180, P3750
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221
   MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033
   MENGERITSKY G, J MOL BIOL, V231, P646
   Miller J. H., 1992, SHORT COURSE BACTERI
   Miyabe I, 2000, INT J RADIAT BIOL, V76, P43
   Pinson V, 1999, J MOL BIOL, V287, P485, DOI 10.1006/jmbi.1999.2631
   PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x
   Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200
   Purmal AA, 1996, MUTAT RES-DNA REPAIR, V364, P193, DOI 10.1016/S0921-8777(96)00032-8
   Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a
   Rice PA, 1997, CURR OPIN STRUC BIOL, V7, P86, DOI 10.1016/S0959-440X(97)80011-5
   Rouviere-Yaniv J, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 1, P439
   ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1
   STERNBERG NL, 1991, METHOD ENZYMOL, V204, P18
   Swinger KK, 2003, EMBO J, V22, P3749, DOI 10.1093/emboj/cdg351
   Swinger KK, 2004, CURR OPIN STRUC BIOL, V14, P28, DOI 10.1016/j.sbi.2003.12.003
   TAYLOR AF, 1982, J BACTERIOL, V151, P351
   Venkhataraman R, 2001, NUCLEIC ACIDS RES, V29, P407, DOI 10.1093/nar/29.2.407
   WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9
   WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002
   YAMAZAKI K, 1984, MOL GEN GENET, V196, P217, DOI 10.1007/BF00328053
   Yao M, 1997, J BIOL CHEM, V272, P30774, DOI 10.1074/jbc.272.49.30774
   ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579
NR 41
TC 6
Z9 7
U1 3
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD OCT
PY 2007
VL 35
IS 19
BP 6672
EP 6680
DI 10.1093/nar/gkm567
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 229TJ
UT WOS:000250827000029
PM 17916578
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Shin, DH
AF Shin, Dong Hee
TI RETRACTED: Potential user factors driving adoption of IPTV. What are
   customers expecting from IPTV? (Retracted article. See vol. 80, pg.
   1444, 2013)
SO TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE
LA English
DT Article; Retracted Publication
DE IPTV; user analysis; logistic model; south Korea
ID DEMAND
AB Internet Protocol Television (IPTV), the convergence services of television and Internet, is being rapidly developed around the world. The advent of digital technologies has changed the convergence market dramatically with the wide diffusion of the convergent services. Using the Technology Acceptance Model as a conceptual framework and method of logistic regression, this research analyzes the demand for IPTV by drawing data from 452 consumers. Individuals' responses to questions about whether they accept IPTV are collected and combined with observations of their socio-economic status and intrinsic/extrinsic factors modified from the Technology Acceptance Model. Results of logistic regression show two variables (intrinsic and extrinsic factors) that seem to explain what influences consumer behavior towards adopting IPTV Overall, the logistic regression model explains over 50% of the variance in the IPTV adoption. The variances shed light on the multi-open platform environment that IPTV will forge. (C) 2006 Elsevier Inc. All rights reserved.
C1 Penn State Univ, Reading, PA 19610 USA.
RP Shin, DH (reprint author), Penn State Univ, Tulpehocken Rd,POB 7009, Reading, PA 19610 USA.
EM dshin@psu.edu
CR *AM ASS PUBL OP RE, 2005, STAND DEF FIN DISP C
   Arnold M., 2003, Information and Organization, V13, P231, DOI 10.1016/S1471-7727(03)00013-7
   Aydin S, 2005, EUR J MARKETING, V39, P910, DOI 10.1108/03090560510601833
   BLUMLER J, 1974, USSES MASS COMMUNICA
   Burgoon J. K., 2000, J MANAGE INFORM SYST, V16, P33
   CHEONG Y, 2004 ANN C AM AC ADV
   CHEVERST K, 2003, P 5 ACM INT S HUM CO, P366
   Cox D.R., 1989, ANAL BINARY DATA
   DAY G, 2000, MANAGING EMERGING TE, P86
   Fadlalla A, 2005, INFORM MANAGE-AMSTER, V42, P695, DOI 10.1016/j.im.2004.04.005
   Gandal N, 2000, RAND J ECON, V31, P43, DOI 10.2307/2601028
   *GARTN GROUP, 2005, IPTV PRED
   GILL TG, 1996, MISQ, V20
   HARRIS A, 2005, IDC ANAL FUTURE SERI
   Hosmer D. W., 2000, APPL LOGISTIC REGRES
   IEEE Institute of Electrical and Electronics Engineers, 1990, IEE STAND COMP DICT
   IGBARIA M, 1993, OMEGA-INT J MANAGE S, V21, P73, DOI 10.1016/0305-0483(93)90040-R
   Kalwani M. U., 1982, MARKET SCI, V1, P243, DOI DOI 10.1287/MKSC.1.3.243
   KIM M, 2005, ETRI J, V2, P67
   Kim WC, 2004, HARVARD BUS REV, V82, P76
   Klein R, 1997, J ECONOMETRICS, V76, P53, DOI 10.1016/0304-4076(95)01782-8
   Kwon H. S., 2000, P HICSS 34 HAW JAN 3
   LIMI A, 2005, TELECOMMUNICATIONS P, V29, P3
   Moore GC, 1991, INFORM SYST RES, V2, P192, DOI 10.1287/isre.2.3.192
   NAKANISHI Y, 2002, C HUM FACT COMP SYST, P642
   Polit D. F., 1996, DATA ANAL STAT NURSI
   REKIMOTO J, 2003, P MOB HCI 2003, P104
   ROGERS EM, 1995, DIFFUSION INNOVATION, P124
   Sawng YW, 2005, ICMB 2005: INTERNATIONAL CONFERENCE ON MOBILE BUSINESS, P413, DOI 10.1109/ICMB.2005.57
   SCHERER FM, 1982, J IND ECON, V30, P225, DOI 10.2307/2098216
   SCHMIDT A, 1998, P INT WORKSH INT APP
   SCHNARS SP, J PROD INNOV MANAG, V10, P66
   SHOCKER AD, 1979, J MARKETING RES, V16, P159, DOI 10.2307/3150681
   Shurmer M, 1997, TELECOMMUN POLICY, V21, P611, DOI 10.1016/S0308-5961(97)00038-4
   SMITH SA, 1986, MARKET SCI, V5, P70, DOI DOI 10.1287/MKSC.5.1.70
   SONG K, 2005, PROSPECTUS IPTV ELEC
   Tang J., 2001, P SIGCHI C HUM FACT, P221
   TAPLIN J, 2005, C NETW SOC KNOWL EC
   VENKATESH V, 1999, MISQ, V23
   *YANK GROUP, 2005, IPTV OUTL CROSS COUN
   2002, MOBILE GROUNDBREAKIN
NR 41
TC 36
Z9 36
U1 4
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0040-1625
J9 TECHNOL FORECAST SOC
JI Technol. Forecast. Soc. Chang.
PD OCT
PY 2007
VL 74
IS 8
BP 1446
EP 1464
DI 10.1016/j.techfore.2006.05.007
PG 19
WC Business; Planning & Development
SC Business & Economics; Public Administration
GA 219YQ
UT WOS:000250124500019
DA 2018-12-27
ER

PT J
AU Nanjawade, BK
   Manvi, FV
   Manjappa, AS
AF Nanjawade, Basavaraj K.
   Manvi, F. V.
   Manjappa, A. S.
TI RETRACTED: In situ.-forming hydrogels for sustained ophthalmic drug
   delivery (Retracted article. See vol. 167, pg. 219, 2013)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review; Retracted Publication
DE in situ; gelation; ophthalmic drug delivery; hydrogels; nasolachrymal
   drainage
ID PLURONIC F-127 GELS; SYSTEMIC ABSORPTION; OCULAR DELIVERY; RABBIT EYES;
   GELLAN GUM; VISCOUS PHENYLEPHRINE; TOPICAL DELIVERY; HYALURONIC-ACID;
   ALBINO RABBITS; CORNEAL
AB Ophthalmic drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. The conventional ocular drug delivery systems like solutions, suspensions, and ointments show drawbacks such as increased precorneal elimination, high variability in efficiency, and blurred vision respectively. in situ-forming hydrogels are liquid upon instillation and undergo phase transition in the ocular cul-de-sac to form visco-elastic gel and this provides a response to environmental changes. In the past few years, an impressive number of novel temperature, pH, and ion induced in situ-forming systems have been reported for sustain ophthalmic drug delivery. Each system has its own advantages and drawbacks. The choice of a particular hydrogel depends on its intrinsic properties and envisaged therapeutic use. This review includes various temperature, pH, and ion induced in situ-forming polymeric systems used to achieve prolonged contact time of drugs with the cornea and increase their bioavailability. (C) 2007 Elsevier B.V All rights reserved.
C1 KLESs Coll Pharm, Dept Pharmaceut, Belgaum 590010, Karnataka, India.
RP Nanjawade, BK (reprint author), KLESs Coll Pharm, Dept Pharmaceut, JN Med Coll Campus, Belgaum 590010, Karnataka, India.
EM bknanjwade@yahoo.co.in; fvmanvi5@rediffmnail.com; manju_as82@yahoo.co.in
CR AHMED I, 1985, INVEST OPHTH VIS SCI, V26, P584
   AHMED I, 1987, INT J PHARM, V38, P9, DOI 10.1016/0378-5173(87)90092-5
   BHASKARAN S, 2005, INDIAN J PHARM SCI, V67, P404
   Bochot A, 1998, INT J PHARM, V162, P119, DOI 10.1016/S0378-5173(97)00419-5
   BORCHARDT RT, 1990, DRUG DEV IND PHARM, V16, P2595, DOI 10.3109/03639049009058549
   BOTHNER H, 1990, DRUG DEV IND PHARM, V16, P755, DOI 10.3109/03639049009114907
   BRON AJ, 1989, EYE, V3, P428
   Cabana A, 1997, J COLLOID INTERF SCI, V190, P307, DOI 10.1006/jcis.1997.4880
   CARLSSON A, 1988, COLLOID POLYM SCI, V266, P1031, DOI 10.1007/BF01428813
   CHANG SC, 1988, EXP EYE RES, V46, P59, DOI 10.1016/S0014-4835(88)80093-9
   CHANG SC, 1987, J OCUL PHARMACOL, V3, P159, DOI 10.1089/jop.1987.3.159
   CHIEN DS, 1990, CURR EYE RES, V9, P1051, DOI 10.3109/02713689008997579
   CHRAI SS, 1974, J PHARM SCI, V63, P1218, DOI 10.1002/jps.2600630810
   CHRAI SS, 1973, J PHARM SCI, V62, P1112, DOI 10.1002/jps.2600620712
   Cohen S, 1997, J CONTROL RELEASE, V44, P201, DOI 10.1016/S0168-3659(96)01523-4
   DAS SK, 1995, PHARMACEUT RES, V12, P534, DOI 10.1023/A:1016249812466
   DAVIES NM, 1991, PHARMACEUT RES, V8, P1039, DOI 10.1023/A:1015813225804
   Davies NM, 2000, CLIN EXP PHARMACOL P, V27, P558, DOI 10.1046/j.1440-1681.2000.03288.x
   DEASY PB, 1991, INT J PHARM, V73, P117, DOI 10.1016/0378-5173(91)90034-L
   Draize JH, 1944, J PHARMACOL EXP THER, V82, P377
   DUMORTIER G, 1992, STP PHARMA SCI, V2, P111
   DURRANI AM, 1992, INT J PHARM, V88, P409, DOI 10.1016/0378-5173(92)90340-8
   El-Kamel AH, 2002, INT J PHARMACEUT, V241, P47, DOI 10.1016/S0378-5173(02)00234-X
   FELT O, 1999, ENCY CONTROLLED DRUG, V2, P605
   FITZGERALD P, 1987, INT J PHARM, V40, P81, DOI 10.1016/0378-5173(87)90050-0
   FOLK JC, 1986, ARCH OPHTHALMOL-CHIC, V104, P1192, DOI 10.1001/archopht.1986.01050200098059
   FRANCOEUR M, 1983, INT J PHARM, V16, P203, DOI 10.1016/0378-5173(83)90057-1
   FRIEDRICH SW, 1993, J OCUL PHARMACOL, V9, P229, DOI 10.1089/jop.1993.9.229
   FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1
   Gangrade N.K., 1996, OCULAR THERAPEUTICS, P377
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   GILBERT JC, 1986, INT J PHARM, V32, P223, DOI 10.1016/0378-5173(86)90182-1
   GRASS GM, 1984, J PHARM SCI, V73, P1021, DOI 10.1002/jps.2600730803
   GRASS GM, 1988, J PHARM SCI, V77, P15, DOI 10.1002/jps.2600770104
   GREAVES JL, 1993, BRIT J CLIN PHARMACO, V35, P188
   GREAVES JL, 1990, CURR EYE RES, V9, P415, DOI 10.3109/02713689008999606
   GREAVES JL, 1992, STP PHARMA SCI, V2, P13
   GREEN K, 1987, J TOXICOL-CUTAN OCUL, V6, P89, DOI 10.3109/15569528709052168
   GROVE J, 1990, INT J PHARM, V66, P23, DOI 10.1016/0378-5173(90)90380-M
   GURNY R, 1987, Journal of Controlled Release, V6, P367, DOI 10.1016/0168-3659(87)90090-3
   GURNY R, 1985, Journal of Controlled Release, V2, P353, DOI 10.1016/0168-3659(85)90057-4
   GURNY R, 1987, ADV DRUG DELIVERY SY, V3, P367
   HARRINGTON WF, 1961, ADV PROTEIN CHEM, V16, P1
   HAUG A, 1966, ACTA CHEM SCAND, V20, P183, DOI 10.3891/acta.chem.scand.20-0183
   HAYAKAWA E, 1992, PHARMACEUT RES, V9, P769, DOI 10.1023/A:1015803605621
   HITZENBERGER CK, 1994, AM J OPHTHALMOL, V118, P468, DOI 10.1016/S0002-9394(14)75798-8
   HOFFMAN A, 1995, P INT S CONTR REL BI, V22
   HOFFMAN A S, 1986, Journal of Controlled Release, V4, P213
   HUANG AJW, 1989, INVEST OPHTH VIS SCI, V30, P684
   HUI HW, 1985, INT J PHARM, V26, P203, DOI 10.1016/0378-5173(85)90230-3
   JANSSON PE, 1983, CARBOHYD RES, V124, P135, DOI 10.1016/0008-6215(83)88361-X
   JARVINEN K, 1995, ADV DRUG DELIVER REV, V16, P3, DOI 10.1016/0169-409X(95)00010-5
   JARVINEN K, 1994, CURR EYE RES, V13, P897, DOI 10.3109/02713689409015093
   JARVINEN K, 1992, STP PHARMA SCI, V2, P105
   KANAI A, 1989, TRANSPLANT P, V21, P3150
   KANG KS, 1982, APPL ENVIRON MICROB, V43, P1086
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   KOGBE O, 1992, STP PHARMA SCI, V2, P39
   KOMAI Y, 1991, INVEST OPHTH VIS SCI, V32, P2244
   KREUTER J, 1990, BIOADHESIVE DRUG DEL, P203
   KUMAR S, 1994, J OCUL PHARMACOL, V10, P47, DOI 10.1089/jop.1994.10.47
   KUMAR S, 1995, J PHARM SCI, V84, P344, DOI 10.1002/jps.2600840315
   KUMAR V, 1986, ARCH OPHTHALMOL-CHIC, V104, P1189, DOI 10.1001/archopht.1986.01050200095058
   KUNOU N, 1995, J CONTROL RELEASE, V37, P143, DOI 10.1016/0168-3659(95)00074-I
   KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5
   LARSEN B, 1970, ACTA CHEM SCAND, V24, P726, DOI 10.3891/acta.chem.scand.24-0726
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   LEE VHL, 1979, J PHARM SCI, V68, P673, DOI 10.1002/jps.2600680606
   LEE VHL, 1993, OPHTHALMIC DRUG DELI, P59
   Leung S. H., 1988, J CONTROL RELEASE, V5, P223
   LIAW JH, 1992, INT J PHARM, V88, P111, DOI 10.1016/0378-5173(92)90308-O
   MARRIOTT C, 1988, PHARM SCI DOSAGE FOR, P17
   MARSHALL GE, 1993, CURR EYE RES, V12, P143, DOI 10.3109/02713689308999482
   Maurice D.M., 1984, PHARM EYE, P19
   MAURICE DM, 1992, J PHARM SCI, V81, P615, DOI 10.1002/jps.2600810704
   Maurice DM, 1984, HDB EXPT PHARM, P16
   MAZOR Z, 1979, BRIT J OPHTHALMOL, V63, P48, DOI 10.1136/bjo.63.1.48
   MCGINITY JW, 1986, HDB PHARM EXCIPIENTS, P41
   MEQI SA, 2002, CONTROLLED NOVEL DRU, P82
   MERKUS FWHM, 1993, J CONTROL RELEASE, V24, P201, DOI 10.1016/0168-3659(93)90179-9
   MESEGUER G, 1993, INT J PHARM, V95, P229, DOI 10.1016/0378-5173(93)90410-H
   MILLER SC, 1984, INT J PHARM, V18, P269, DOI 10.1016/0378-5173(84)90142-X
   MILLER SC, 1982, INT J PHARM, V12, P147, DOI 10.1016/0378-5173(82)90114-4
   Miyazaki S, 1998, J CONTROL RELEASE, V56, P75, DOI 10.1016/S0168-3659(98)00079-0
   Miyazaki S, 2001, INT J PHARM, V229, P29, DOI 10.1016/S0378-5173(01)00825-0
   MOORHOUSE R, 1981, ACS SYM SER, V150, P111
   Morris V. J., 1995, V67, P341
   NEWELL FW, 1986, OPHTHALMOLOGY
   NOMURA M, 1994, J PHARM PHARMACOL, V46, P768, DOI 10.1111/j.2042-7158.1994.tb03900.x
   Olejnik O., 1993, NOVEL CONTROL DRUG D, P117
   PAINTER T, 1968, ACTA CHEM SCAND, V22, P1637, DOI 10.3891/acta.chem.scand.22-1637
   PARK K, 1984, INT J PHARM, V19, P107, DOI 10.1016/0378-5173(84)90154-6
   PATTON TF, 1975, J PHARM SCI, V64, P1312, DOI 10.1002/jps.2600640811
   POLAND DE, 1988, J CATARACT REFR SURG, V14, P489, DOI 10.1016/S0886-3350(88)80003-8
   ROBINSON G, 1991, FOOD POLYM GELS COLL
   ROJANASAKUL Y, 1992, PHARMACEUT RES, V9, P1029, DOI 10.1023/A:1015802427428
   ROJANASAKUL YY, 1989, INT J PHARM, V55, P237, DOI 10.1016/0378-5173(89)90047-1
   ROZIER A, 1989, INT J PHARM, V57, P163, DOI 10.1016/0378-5173(89)90305-0
   Ruel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   SAETTONE MF, 1984, INT J PHARM, V20, P187, DOI 10.1016/0378-5173(84)90229-1
   SAETTONE MF, 1989, INT J PHARM, V51, P203, DOI 10.1016/0378-5173(89)90193-2
   SAETTONE MF, 1995, ADV DRUG DELIVER REV, V16, P95, DOI 10.1016/0169-409X(95)00014-X
   SAETTONE MF, 1986, INT J PHARM, V31, P261, DOI 10.1016/0378-5173(86)90160-2
   SAETTONE MF, 1982, J PHARM PHARMACOL, V34, P464, DOI 10.1111/j.2042-7158.1982.tb04762.x
   SALMINEN L, 1984, EXP EYE RES, V38, P203, DOI 10.1016/0014-4835(84)90104-0
   SANZGIRI YD, 1993, J CONTROL RELEASE, V26, P195, DOI 10.1016/0168-3659(93)90186-9
   Scherlund M, 2000, J COLLOID INTERF SCI, V229, P365, DOI 10.1006/jcis.2000.7006
   SCHMOLKA IR, 1972, J BIOMED MATER RES, V6, P571, DOI 10.1002/jbm.820060609
   SCHOENWALD RD, 1990, CLIN PHARMACOKINET, V18, P255, DOI 10.2165/00003088-199018040-00001
   SCHOENWALD RD, 1978, J PHARM SCI, V67, P1280, DOI 10.1002/jps.2600670923
   Schoenwald RD, 1993, OPHTHALMIC DRUG DELI, P83
   Shirakawa M, 1998, FOOD HYDROCOLLOID, V12, P25, DOI 10.1016/S0268-005X(98)00052-6
   STRATFORD RE, 1986, INT J PHARM, V30, P73, DOI 10.1016/0378-5173(86)90137-7
   URTTI A, 1990, INT J PHARM, V61, P241, DOI 10.1016/0378-5173(90)90215-P
   URTTI A, 1993, SURV OPHTHALMOL, V37, P435, DOI 10.1016/0039-6257(93)90141-S
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   VANOOTEGHEM MM, 1993, BIOPHARMACEUTICS OCU, P27
   WARING GO, 1979, S OCUL THER, P127
   WATSKY MA, 1988, CURR EYE RES, V7, P483, DOI 10.3109/02713688809031801
   Worakul N, 1997, EUR J PHARM BIOPHARM, V44, P71, DOI 10.1016/S0939-6411(97)00064-7
   ZIMMER A, 1991, J MICROENCAPSUL, V8, P497, DOI 10.3109/02652049109021873
NR 123
TC 149
Z9 162
U1 6
U2 64
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 26
PY 2007
VL 122
IS 2
BP 119
EP 134
DI 10.1016/j.jconrel.2007.07.009
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 219EY
UT WOS:000250068700001
PM 17719120
DA 2018-12-27
ER

PT J
AU Zhang, QR
   Wu, GH
   Richards, E
   Jia, SG
   Zeng, CQ
AF Zhang, Qingrun
   Wu, Guanghua
   Richards, Elliott
   Jia, Shan'gang
   Zeng, Changqing
TI RETRACTED: Universal primers for HBV genome DNA amplification across
   subtypes: a case study for designing more effective viral primers
   (Retracted article. See vol 4, pg Nil_1, 2007)
SO VIROLOGY JOURNAL
LA English
DT Article; Retracted Publication
ID HEPATITIS-B-VIRUS; GENOTYPE-C; EVOLUTION; PCR; HETEROGENEITY;
   TRANSMISSION; SEQUENCE; MUTANTS; USERS
AB Background: The highly heterogenic characteristic of viruses is the major obstacle to efficient DNA amplification. Taking advantage of the large number of virus DNA sequences in public databases to select conserved sites for primer design is an optimal way to tackle the difficulties in virus genome amplification.
   Results: Here we use hepatitis B virus as an example to introduce a simple and efficient way for virus primer design. Based on the alignment of HBV sequences in public databases and a program BxB in Perl script, our method selected several optimal sites for HBV primer design. Polymerase chain reaction showed that compared with the success rate of the most popular primers for whole genome amplification of HBV, one set of primers for full length genome amplification and four sets of walking primers showed significant improvement. These newly designed primers are suitable for most subtypes of HBV.
   Conclusion: Researchers can extend the method described here to design universal or subtype specific primers for various types of viruses. The BxB program based on multiple sequence alignment not only can be used as a separate tool but also can be integrated in any open source primer design software to select conserved regions for primer design.
C1 Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China.
   Brigham Young Univ, Coll Biol & Agr, Provo, UT 84602 USA.
RP Zeng, CQ (reprint author), Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China.
EM zhangqr@big.ac.cn; wugh@genomics.org.cn; elliott.richards@gmail.com;
   jsg200830@163.com; czeng@genomics.org.cn
CR Alexopoulou A., 2005, Current Drug Targets - Inflammation and Allergy, V4, P47, DOI 10.2174/1568010053622867
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   BLUM HE, 1993, INTERVIROLOGY, V35, P40, DOI 10.1159/000150294
   Chen BF, 2004, J MED VIROL, V73, P13, DOI 10.1002/jmv.20051
   Chen BF, 2006, J GEN VIROL, V87, P39, DOI 10.1099/vir.0.81357-0
   GUNTHER S, 1995, J VIROL, V69, P5437
   Gunther S, 1998, J CLIN MICROBIOL, V36, P531
   Ngui SL, 1997, J VIRAL HEPATITIS, V4, P309, DOI 10.1046/j.1365-2893.1997.00066.x
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   Ohishi W, 2003, INTERVIROLOGY, V46, P355, DOI 10.1159/000074992
   OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575
   OKAMOTO H, 1987, JPN J EXP MED, V57, P231
   ORITO E, 1989, P NATL ACAD SCI USA, V86, P7059, DOI 10.1073/pnas.86.18.7059
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Tellier R, 1996, J CLIN MICROBIOL, V34, P3085
   Tellier R, 1996, P NATL ACAD SCI USA, V93, P4370, DOI 10.1073/pnas.93.9.4370
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Wang ZH, 2005, J GEN VIROL, V86, P985, DOI 10.1099/vir.0.80771-0
   Yim HJ, 2006, HEPATOLOGY, V44, P703, DOI 10.1002/hep.21290
NR 19
TC 12
Z9 12
U1 3
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD SEP 24
PY 2007
VL 4
AR 92
DI 10.1186/1743-422X-4-92
PG 7
WC Virology
SC Virology
GA 238MF
UT WOS:000251451200001
PM 17892576
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Bai, S
   Datta, J
   Jacob, ST
   Ghoshal, K
AF Bai, Shoumei
   Datta, Jharna
   Jacob, Samson T.
   Ghoshal, Kalpana
TI RETRACTED: Treatment of PC12 cells with nerve growth factor induces
   proteasomal degradation of T-cadherin that requires tyrosine
   phosphorylation of its cadherin domain (Retracted article. See vol. 293,
   pg. 3590, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID DNA METHYLTRANSFERASE 3B; SMOOTH-MUSCLE-CELLS; UBIQUITIN LIGASE;
   PROTEIN-DEGRADATION; ADHESION MOLECULE; INTERFERON-ALPHA; CYCLE CONTROL;
   CBL-B; RECEPTOR; DESTRUCTION
AB T-cadherin (T-Cad), a unique member of the cadherin family of proteins, plays an important role in cell adhesion and cell signaling. Recently, we demonstrated that T-Cad is transcriptionally repressed by DNA methyltransferase 3b during nerve growth factor (NGF)-induced neuronal differentiation of PC12 cells. Here, we show that T-Cad expression is also regulated at the post-translational level by the proteasomal pathway in these cells, which is facilitated upon NGF treatment. Pulse-chase experiments demonstrated that NGF treatment significantly reduced the half-life of T-Cad. Degradation of T-Cad was blocked upon treatment of PC12 cells with the proteasomal inhibitor ZLLL or lactacystin. Ectopic expression of Cdh1 (CDC20 homolog 1), one of the substrate recognition components of anaphase promoting complex (E3 ligase), stimulated T-Cad degradation. Deletion of CD1, one of the five extracellular cadherin domains (CD), promoted degradation of T-Cad, especially in the presence of NGF. On the contrary, deletion of CD2 stabilized this protein maximally. Ubiquitination of different deletion mutants indicates that T-Cad harbors multiple ubiquitination signals. Furthermore, genistein, a protein-tyrosine kinase inhibitor, impeded T-Cad degradation in PC12 cells, implicating requirement of tyrosine phosphorylation in this process. Mutation at tyrosine 327 (Y327F) markedly increased the half-life of T-Cad, suggesting that phosphorylation of this tyrosine residue located within CD2 is critical for this process. These results show that T-cadherin is subject to dual regulation during NGF-induced differentiation of PC12 cells, namely transcriptional repression mediated by Dnmt3b and post-translational degradation through the proteasomal pathway. These data, together with the inhibitory role of T-Cad in neurite outgrowth of PC12 cells upon NGF treatment, underscore the significance of its stringent regulation during this differentiation process.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Jacob, ST (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
EM jacob.42@osu.edu
FU NCI NIH HHS [P01 CA101956-020003, R01 CA086978-02, R01 CA086978-03, P01
   CA101956-01A2, P01 CA101956-02, P01 CA101956-01A20003, R01 CA086978, R01
   CA086978-01A2, P01 CA101956, R01 CA086978-05, R01 CA086978-06A1, P01
   CA101956-01A25284, CA 86978, CA 10195, R01 CA086978-04]
CR Aguilar RC, 2005, P NATL ACAD SCI USA, V102, P2679, DOI 10.1073/pnas.0500213102
   Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614
   Angst BD, 2001, J CELL SCI, V114, P629
   Bai SM, 2006, J BIOL CHEM, V281, P13604, DOI 10.1074/jbc.M513278200
   Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005
   Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330
   Bloom J, 2004, CELL CYCLE, V3, P138
   Bromhead C, 2006, GENE, V374, P58, DOI 10.1016/j.gene.2006.01.013
   Buschhorn BA, 2006, NAT CELL BIOL, V8, P209, DOI 10.1038/ncb0306-209
   d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x
   Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952
   Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937
   Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499
   FREDETTE BJ, 1994, J NEUROSCI, V14, P7331
   Fredette BJ, 1996, DEVELOPMENT, V122, P3163
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Goubaeva F, 2005, BIOCHEM BIOPH RES CO, V329, P624, DOI 10.1016/j.bbrc.2005.02.020
   Hershko A, 2005, CELL DEATH DIFFER, V12, P1191, DOI 10.1038/sj.cdd.4401702
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexer.2003.09.030
   Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kumar KGS, 2003, EMBO J, V22, P5480
   Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010
   Niermann T, 2003, BIOCHEM BIOPH RES CO, V300, P943, DOI 10.1016/S0006-291X(02)02970-4
   Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414
   Patel SD, 2006, CELL, V124, P1255, DOI 10.1016/j.cell.2005.12.046
   Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500
   Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5
   RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7
   Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519
   Stegmuller J, 2005, TRENDS NEUROSCI, V28, P596, DOI 10.1016/j.tins.2005.09.003
   Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042
   Toyooka S, 2002, CANCER RES, V62, P3382
   Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796
NR 39
TC 16
Z9 16
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 14
PY 2007
VL 282
IS 37
BP 27171
EP 27180
DI 10.1074/jbc.M700691200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 208FJ
UT WOS:000249304900058
PM 17631504
OA Green Accepted, Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Liu, YQ
   Zeng, XR
   Luo, QY
   Xu, YP
AF Liu, Yin-Qiu
   Zeng, Xi-Rui
   Luo, Qiu-Yan
   Xu, Ya-Ping
TI RETRACTED: {2,2
   '-[o-Phenylenebis(nitrilomethylidyne)]diphenolato}zinc(II) (Retracted
   article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB The title complex, [Zn(C20H14N2O2)], is a mononuclear zinc(II)compound. The zinc( II) ion is four-coordinated in a square-planar geometry by two imine N and two phenolate O atoms from one 2,2 '-[o-phenylenebis(nitrilomethylidyne)]-diphenolate Schiff base ligand. No strong hydrogen bonds were found in the crystal.
C1 JingGangShan Univ, JiangXi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, JiangXi, Peoples R China.
RP Liu, YQ (reprint author), JingGangShan Univ, JiangXi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, JiangXi, Peoples R China.
EM liuyiqja@163.com
CR *BRUK AXS INC, 1997, SMART VERS 5 044 SAI
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   *SIEM AN XRAY INST, 1996, SHELXTL
NR 4
TC 6
Z9 6
U1 3
U2 13
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD SEP
PY 2007
VL 63
BP M2396
EP U1353
DI 10.1107/S1600536807040640
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900125
DA 2018-12-27
ER

PT J
AU Huang, CF
   Chen, HL
AF Huang, Chun-Fang
   Chen, Hua-Long
TI RETRACTED:
   Catena-poly[[chloridonickel(II)]-di-mu-chlorido[chloridonickel(II)]-mu-4
   ,4 '-methylenebis(3,5-dimethylpyrazole)-kappa(2) N-2 : N-2 '] (Retracted
   article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID COORDINATION POLYMERS; LIGANDS
AB The title compound, [NiCl2(C11H16N4)](n), is a one-dimensional polymer built up from alternating (NiCl2)(2) units and bridging 4,4 '-methylenebis(3,5-dimethylpyrazole) ligands. An unusual NiCl3N2 square-based pyramidal coordination arises for the metal atom. The packing is consolidated by N-H center dot center dot center dot Cl hydrogen bonds.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Huang, CF (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM jgschl@126.com
CR *BRUK AXS INC, 2004, APEX2
   *BRUK AXS INC, 1998, SHELXTL
   Bruker, 1999, SAINT
   CONSTABLE EC, 1992, J CHEM SOC DALTON, P3467, DOI 10.1039/dt9920003467
   Hennigar TL, 1997, ANGEW CHEM INT EDIT, V36, P972, DOI 10.1002/anie.199709721
   Kaes C, 1998, ANGEW CHEM INT EDIT, V37, P920, DOI 10.1002/(SICI)1521-3773(19980420)37:7<920::AID-ANIE920>3.0.CO;2-O
   Loi M, 1999, CHEM COMMUN, P603, DOI 10.1039/a900501c
   Neels A, 1997, INORG CHEM, V36, P3402, DOI 10.1021/ic970175i
   Neeraj S, 1999, ANGEW CHEM INT EDIT, V38, P3480, DOI 10.1002/(SICI)1521-3773(19991203)38:23<3480::AID-ANIE3480>3.0.CO;2-S
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   Velten U, 1996, CHEM COMMUN, P2639, DOI 10.1039/cc9960002639
   Yaghi OM, 1998, ACCOUNTS CHEM RES, V31, P474, DOI 10.1021/ar970151f
NR 13
TC 1
Z9 1
U1 4
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP M2356
EP U993
DI 10.1107/S1600536807039384
PN 9
PG 11
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900092
DA 2018-12-27
ER

PT J
AU Sui, Y
   Sui, YH
   Luo, QY
   Wang, YD
AF Sui, Yan
   Sui, Yu-Hua
   Luo, Qiu-Yan
   Wang, Ya-Dong
TI RETRACTED: {6,6 '-dimethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato}-methanol-mu-nitr
   ato-dinitratolutetium(III)-zinc(II) (Retracted article. See vol. 66, pg.
   e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn(II)-Lu(III) complex (systematic name: {6,6'-dimethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato-1 kappa(4)O(1),O(1'),O(6),O(6'):2 kappa(4)O(1),N,N',O(1')}(methanol-1 kappa O)-mu-nitrato-1:2 kappa(2)O:O'-dinitrato-1 kappa(4)O,O'-lutetium(III)zinc(II)), [LuZn(C(18)H(18)N(2)O(4))(NO(3))(3)(CH(4)O)], with the hexadentate Schiff base compartmental ligand N, N'-bis(3-methoxysalicylidene) ethylenediamine, the Lu and Zn atoms are triply bridged by two phenolate O atoms provided by the Schiff base ligand and one nitrate ion. The five-coordinated Zn is in a square-pyramidal geometry with the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Lu(III) center has a tenfold coordination environment of O atoms, involving the phenolate O atoms, two methoxy O atoms, one methanol O atom, and two O atoms from two nitrate ions and one from the bridging nitrate ion. Weak intermolecular C-H center dot center dot center dot O interactions generate a two-dimensional layer structure.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
   Jilin Oil Field Co, Vocat Educ Ctr, Songyuan 131200, Jilin, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUKER AXS INC, 2004, APEX2 VERS 1 2 SADAB
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 4
Z9 4
U1 2
U2 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP M2277
EP U296
DI 10.1107/S1600536807037737
PN 9
PG 13
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900027
DA 2018-12-27
ER

PT J
AU Sui, Y
   Fang, XN
   Yuan, MW
AF Sui, Yan
   Fang, Xiao-Niu
   Yuan, Ming-Wen
TI RETRACTED: {6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato}methanol-mu-nitra
   to-dinitrato-praseodymium(III)zinc(II) (Retracted article. See vol. 66,
   pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn(II)-Pr(III) complex (systematic name: {6,6'-dimethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)] diphenolato-1 kappa(4)O(1),O(1,),O(6),O(6'):2 kappa(4)O(1),N,N',O(1)}(methanol-1 kappa O)-mu-nitrato-1:2 kappa(2)O:O'-dinitrato-1 kappa(4)O,O'-praseodymium(III) zinc(II)), [PrZn(C(18)H(18)N(2)O(4))(NO(3))(3)(CH(4)O)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-methoxysalicylidene) ethylenediamine (H(2)L), the Pr and Zn atoms are triply bridged by two phenolate O atoms provided by the Schiff base ligand and one nitrate. The five-coordinate Zn atom is in a square-pyramidal geometry, with the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Pr III center has a tenfold coordination environment of O atoms, involving the phenolate O atoms, two methoxy O atoms, one methanol O atom, and two O atoms from two nitrates and one from the bridging nitrate. Strong intermolecular O-H center dot center dot center dot O and some weak C-H center dot center dot center dot O interactions generate a two-dimensional layer structure.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUK AXS INC, 2004, APEX2 VERS 1 22 SADA
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 1
Z9 1
U1 4
U2 13
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP M2275
EP U283
DI 10.1107/S1600536807037488
PN 9
PG 13
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900026
DA 2018-12-27
ER

PT J
AU Sui, Y
   Zhang, JH
   Hu, RH
   Jiang, RQ
AF Yan Sui
   Jin-Hai Zhang
   Rong-Hua Hu
   Run-Qing Jiang
TI RETRACTED: {6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato}-methanol-mu-nitr
   ato-dinitrato-samarium(III)nickel(II) (Retracted article. See vol. 66,
   pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Ni(II)-Sm(III) complex (systematic name: {6,6'-dimethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)] diphenolato-1 kappa(4)O(1),O(1'),O(6),O(6'): 2 kappa(4)O(1),N,N',O(1')}(methan-ol-1 kappa O)-mu-nitrato-1:2 kappa(2)O:O'-dinitrato-1 kappa(4)O,O'-nickel(II)samarium( III)), [NiSm(C(18)H(18)N(2)O(4))(NO(3))(3)(CH(4)O)], with the hexadentate Schiff base compartmental ligand N, N'-bis(3-methoxysalicylidene) ethylenediamine, the Ni and Sm atoms are triply bridged by two phenolate O atoms provided by the Schiff base ligand and one nitrate ion. The five-coordinate Ni atom is in a square-pyramidal geometry with the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Sm III center has a tenfold coordination environment of O atoms, involving the phenolate O atoms, two methoxy O atoms, one methanol O atom, and two O atoms from two nitrates and one from the bridging nitrate. Strong intermolecular O-H center dot center dot center dot O and some weak C-H center dot center dot center dot O interactions generate a two-dimensional layer structure.
C1 JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Province Key Lab Coordinat Chem, Jinan 343009, Peoples R China.
   Inst Food Durg Control, Jinan 343000, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Province Key Lab Coordinat Chem, Jinan 343009, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   *BRUK AXS INC, 2004, APEX 2 VERS 1 22 SAD
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G.M., 1997, SHELXS 97 SHELXL 97
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 3
Z9 3
U1 3
U2 12
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP M2256
EP U119
DI 10.1107/S1600536807037130
PN 9
PG 13
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900011
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J.-Y.
TI RETRACTED: 2-(1-hydroxy-2-pyridyl) acetamide monohydrate (Retracted
   article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB In the crystal structure of the title complex, C(7)H(7)N(2)O(2) center dot H(2)O, intermolecular O-H center dot center dot center dot O and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure; intramolecular O-H center dot center dot center dot O and O-H center dot center dot center dot N hydrogen bonds are also present.
C1 Jinggangshan Univ, Coll Engn, Jinan 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jinan 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 13
TC 0
Z9 0
U1 2
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3860
EP U3485
DI 10.1107/S1600536807040652
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900329
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J.-Y.
TI RETRACTED: 2-amino-3,5-dinitrobenzoic acid ammonia (1/1) (Retracted
   article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY; BENZENE-1,2-DIOXYACETIC ACID; COMPLEXES; BDOAH(2)
AB The title complex, C(7)H(5)N(3)O(6) center dot NH(3), contains one 2-amino-3,5-dinitrobenzoic acid molecule and one ammonia molecule. In the crystal structure, intermolecular N-H center dot center dot center dot N and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure; intramolecular N-H center dot center dot center dot O hydrogen bonds are also present.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3617, DOI 10.1016/0277-5387(95)00161-K
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G.M, 1996, SADABS
   Sheldrick G.M., 1997, SHELXS 97 SHELXL 97
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 13
TC 0
Z9 0
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3829
EP U3196
DI 10.1107/S1600536807040068
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900301
DA 2018-12-27
ER

PT J
AU Liu, T
   Zhu, JY
AF Liu, T.
   Zhu, J. Y.
TI RETRACTED: 2-hydroxy-3,5-dinitrobenzamide monohydrate (Retracted
   article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB In the crystal structure of the title compound, C(7)H(5)N(3)O(6) center dot H(2)O, O-H center dot center dot center dot O and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiagxi Univ Sci & Technol, Dept Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   *BRUCK AXS INC, 2005, APEX 2
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M., 1997, SHELXS 97 SHELXS 97
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 14
TC 1
Z9 1
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3830
EP U3205
DI 10.1107/S1600536807039712
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900302
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X.-M.
   Xie, H.-L.
   Luo, C.-J.
TI RETRACTED: N-(2-Hydroxyphenyl)carbamic acid-ammonia (1/1) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY; BENZENE-1,2-DIOXYACETIC ACID; COMPLEXES; BDOAH(2)
AB In the crystal structure of the title complex, C(7)H(7)NO(3) center dot NH(3), intermolecular N-H center dot center dot center dot O, N-H center dot center dot center dot N and O-H center dot center dot center dot N hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3617, DOI 10.1016/0277-5387(95)00161-K
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 14
TC 0
Z9 0
U1 4
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3882
EP U3694
DI 10.1107/S160053680704086X
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900350
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X.-M.
   Xie, H.-L.
   Luo, C.-J.
TI RETRACTED: 1-Hydroxy-4,6-dinitropyridine-2-carboxamide monohydrate
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID BENZAMIDES; DIOXYGEN; COMPLEX
AB In the crystal structure of the title compound, C(6)H(5)N(4)O(6) center dot H(2)O, intermolecular O-H center dot center dot center dot N and O-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure; intramolecular O-H center dot center dot center dot O and N-H center dot center dot center dot O hydrogen bonds are also present.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Foster JE, 1999, BIOORGAN MED CHEM, V7, P2415, DOI 10.1016/S0968-0896(99)00185-6
   Harrop TC, 2003, CHEM COMMUN, P410, DOI 10.1039/b211395n
   Qi JY, 2003, CHEM COMMUN, P1294, DOI 10.1039/b301963b
   Qi JY, 2003, CHEM COMMUN, P1058, DOI 10.1039/b212899c
   Rauko P, 2001, EUR J PHARM SCI, V12, P387, DOI 10.1016/S0928-0987(00)00180-9
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhou YX, 1999, CHEMOMETR INTELL LAB, V45, P95, DOI 10.1016/S0169-7439(98)00092-6
NR 13
TC 0
Z9 0
U1 2
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3881
EP U3685
DI 10.1107/S1600536807040779
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900349
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X.-M.
   Xie, H.-L.
   Luo, C.-J.
TI RETRACTED: 2-fluoro-3,5-dinitrobenzoic acid-ammonia (1/1) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID X-RAY; BENZENE-1,2-DIOXYACETIC ACID; COMPLEXES; BDOAH(2)
AB In the crystal structure of the title complex, C(7)H(3)FN(2)O(6) center dot NH(3), the uncoordinated ammonia molecule interacts with nearby nitro and carboxyl groups and the F atom of the 3,5-dinitro-2-fluorobenzoic acid by way of N-H center dot center dot center dot O, N-H center dot center dot center dot F and O H center dot center dot center dot N hydrogen bonds. These hydrogen bonds lead to a supramolecular network structure.
C1 Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   *BRUCK AXS INC, 2005, APEX 2
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030
   McCann M, 1996, POLYHEDRON, V15, P2117, DOI 10.1016/0277-5387(95)00492-0
   MCCANN M, 1995, POLYHEDRON, V14, P3617, DOI 10.1016/0277-5387(95)00161-K
   Min D, 2002, INORG CHEM COMMUN, V5, P978, DOI 10.1016/S1387-7003(02)00630-5
   Sheldrick G.M, 1996, SADABS
   Sheldrick G.M., 1997, SHELXS 97 SHELXL 97
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Wai H.Y., 1990, J CRYST SPECTROSC, V20, P307
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
NR 14
TC 0
Z9 0
U1 3
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3831
EP U3214
DI 10.1107/S1600536807039724
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900303
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Xie, HL
   Luo, CJ
AF Zhong, H.
   Yang, X.-M.
   Xie, H.-L.
   Luo, C.-J.
TI RETRACTED: 2-fluoro-3,5-dinitrobenzamide monohydrate (Retracted article.
   See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL; ZN; CO; NI
AB The title complex, C7H4FN3O5 center dot H2O, contains one 2-fluoro-3,5-dinitrobenzamide molecule and one water molecule. In the crystal structure, O-H center dot center dot center dot O, O-H center dot center dot center dot F and N-H center dot center dot center dot O hydrogen bonds result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111
   DESIRAJU GR, 1997, J CHEM SOC CHEM COMM, P1475
   Ma BQ, 2001, J CHEM SOC DALTON, P130, DOI 10.1039/b006142p
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Pan L, 2001, CHEM-EUR J, V7, P4431, DOI 10.1002/1521-3765(20011015)7:20<4431::AID-CHEM4431>3.0.CO;2-P
   Prior TJ, 2001, CHEM COMMUN, P1222, DOI 10.1039/b102809j
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM, 1996, SMART SAINT SHELXTL
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
NR 13
TC 0
Z9 0
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2007
VL 63
BP O3780
EP U2781
DI 10.1107/S1600536807038676
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 214TB
UT WOS:000249759900261
DA 2018-12-27
ER

PT J
AU Oka, H
   Yoshioka, M
   Onouchi, K
   Morita, M
   Mochio, S
   Suzuki, M
   Hirai, T
   Ito, Y
   Inoue, K
AF Oka, Hisayoshi
   Yoshioka, Masayuki
   Onouchi, Kenji
   Morita, Masayo
   Mochio, Soichiro
   Suzuki, Masahiko
   Hirai, Toshiaki
   Ito, Yasuhiko
   Inoue, Kiyoharu
TI RETRACTED: Characteristics of orthostatic hypotension in Parkinson's
   disease (Retracted Article. See vol 131, pg 1674, 2008)
SO BRAIN
LA English
DT Article; Retracted Publication
DE parkinson's disease; cardiovascular sympathetic dysautonomia; cardiac
   radioiodinated metaiodobenzylguanidine (I-123-MIBG) scintigraphy;
   Valsalva maneuver; baroreflex sensitivity
ID MULTIPLE SYSTEM ATROPHY; HEART-RATE-VARIABILITY; LEWY BODY DISEASE;
   AUTONOMIC DYSFUNCTION; VISUAL HALLUCINATIONS; BAROREFLEX SENSITIVITY;
   VALSALVA MANEUVER; CARDIOVASCULAR DYSAUTONOMIA; LEVODOPA TREATMENT;
   SEVERITY
AB Clinical symptoms of Parkinson's disease (PD) include not only motor distress but also autonomic dysfunction. Orthostatic hypotension ( OH) occurs in one-fifth to one-half of all patients with PD. We examined the relation of this type of hypotension to clinical features and cardiovascular parameters such as cardiac I-123-meta-iodobenzylguanidine ( MIBG) uptake, changes on the Valsalva maneuver, and plasma norepinephrine concentrations on head-up tilt-table testing ( HUT). We performed HUT in 55 patients with PD and divided them into two groups according to the presence or absence of OH, defined as a drop in systolic blood pressure (SBP mmHg) by 20 mmHg or more on standing. We evaluated cardiac sympathetic function by I-123-MIBG scintigraphy and assessed cardiovascular autonomic function by using the Valsalva maneuver in all subjects. We also performed HUT, I-123-MIBG scintigraphy and assessed cardiovascular autonomic function by using the Valsalva maneuver in 20 controls. The results of HUT showed that 20 patients had OH and 35 did not. The hypotension was associated with gender, older age, longer disease duration, posture and gait instability phenotype, low mini-mental state examination scores and visual hallucinations. Cardiac I-123-MIBG uptakes were lower in patients with OH. SBP fell further during early second phase in patients with OH than in patients without the condition and their increase in SBP during the late second phase and the overshoot of SBP during the fourth phase were lower. The blood pressure recovery time during the fourth phase on the Valsalva maneuver was longer in patients with OH than in those without OH. There was, however, no association between the fall in SBP on HUT and baroreflex sensitivity or the plasma norepinephrine concentrations, adjusted by age, disease duration, disease severity and dopaminergic medication using multiple regression analyses. Patients without OH already had impaired cardiac sympathetic and baroreceptor reflex functions as early abnormalities of cardiovascular autonomic control. Our results suggest that pronounced vasomotor and cardiac sympathetic dysfunction is the primary cause of OH in PD, although baroreceptor reflex failure may also make a minor contribution. It was unclear whether vasomotor and cardiac sympathetic dysfunction in patients with PD was caused primarily by the impairment of preganglionic or postganglionic lesions.
C1 Jikei Univ, Sch Med, Dept Neurol, Minato Ku, Tokyo 105, Japan.
RP Oka, H (reprint author), Jikei Univ, Sch Med, Dept Neurol, Minato Ku, 3-35-8 Nishishinbashi, Tokyo 105, Japan.
EM h.oka@jikei.ac.jp
CR Allcock LM, 2006, MOVEMENT DISORD, V21, P1851, DOI 10.1002/mds.20996
   Allcock LM, 2004, J NEUROL NEUROSUR PS, V75, P1470, DOI 10.1136/jnnp.2003.029413
   Amino T, 2005, BRAIN PATHOL, V15, P29, DOI 10.1111/j.1750-3639.2005.tb00097.x
   [Anonymous], 1996, CLIN AUTON RES, V6, P125
   Barbic F, 2007, HYPERTENSION, V49, P120, DOI 10.1161/01.HYP.0000250939.71343.7c
   CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721
   COLOSIMO C, 1995, ARCH NEUROL-CHICAGO, V52, P294, DOI 10.1001/archneur.1995.00540270090024
   *DEEP BRAIN STIM P, 2001, NEW ENGL J MED, V345, P956, DOI DOI 10.1056/NEJMOA000827
   Devos D, 2003, J NEURAL TRANSM, V110, P997, DOI 10.1007/s00702-003-0016-8
   Fahn S., 1987, RECENT DEV PARKINSON, P153
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   GALINIER M, 1994, CLIN EXP HYPERTENS, V16, P373, DOI 10.3109/10641969409072223
   Goldstein DS, 2005, HYPERTENSION, V46, P1333, DOI 10.1161/01.HYP.0000188052.69549.e4
   Goldstein DS, 2006, CLIN AUTON RES, V16, P46, DOI 10.1007/s10286-006-0317-8
   Goldstein DS, 2003, LANCET NEUROL, V2, P669, DOI 10.1016/S1474-4422(03)00555-6
   Goldstein DS, 2003, HYPERTENSION, V42, P136, DOI 10.1161/01.HYP.0000081216.11623.C3
   Haapaniemi TH, 2001, J NEUROL NEUROSUR PS, V70, P305, DOI 10.1136/jnnp.70.3.305
   Harding AJ, 2002, BRAIN, V125, P391, DOI 10.1093/brain/awf033
   Hesse B, 2005, EUR J NUCL MED MOL I, V32, P855, DOI 10.1007/s00259-005-1779-y
   Hillen ME, 1996, ARCH PHYS MED REHAB, V77, P710, DOI 10.1016/S0003-9993(96)90013-1
   Hobson DE, 1999, CAN J NEUROL SCI, V26, pS27, DOI 10.1017/S0317167100000068
   HOLROYD S, 1995, AM J GERIAT PSYCHIAT, V3, P198, DOI 10.1097/00019442-199522330-00003
   Hughes TA, 2000, NEUROLOGY, V54, P1596, DOI 10.1212/WNL.54.8.1596
   Idiaquez J, 2007, CLIN AUTON RES, V17, P93, DOI 10.1007/s10286-007-0410-7
   James MA, 1996, HYPERTENSION, V28, P953, DOI 10.1161/01.HYP.28.6.953
   Jankovic J, 2001, ARCH NEUROL-CHICAGO, V58, P1611, DOI 10.1001/archneur.58.10.1611
   Kautzner J, 1996, AM J CARDIOL, V78, P575, DOI 10.1016/S0002-9149(96)00370-0
   KORNER PI, 1976, J APPL PHYSIOL, V40, P434
   Levy G, 2002, ANN NEUROL, V51, P722, DOI 10.1002/ana.10219
   MAGALHAES M, 1995, ACTA NEUROL SCAND, V91, P98
   MAGALHAES MVM, 1998, MOV DISORD S2, V13, P273
   Marder K, 2002, PARKINSONS DIS DIAGN, P125
   MARTIN R, 1993, ITAL J NEUROL SCI, V14, P437, DOI 10.1007/BF02339173
   MATHIAS CJ, 1999, AUTONOMIC FAILURE TX
   Mesec A, 1993, Clin Auton Res, V3, P339, DOI 10.1007/BF01827336
   MICIELI G, 1987, NEUROLOGY, V37, P386, DOI 10.1212/WNL.37.3.386
   Niimi Y, 1999, CLIN AUTON RES, V9, P139, DOI 10.1007/BF02281627
   Oishi N, 2005, NEUROLOGY, V65, P1708, DOI 10.1212/01.wnl.0000187116.13370.e0
   Oka H, 2006, ACTA NEUROL SCAND, V113, P221, DOI 10.1111/j.1600-0404.2005.00526.x
   Oka H, 2006, J NEUROL SCI, V241, P59, DOI 10.1016/j.jns.2005.10.014
   Oka H, 2003, EUR NEUROL, V50, P230, DOI 10.1159/000073865
   OKA H, 2007, NEUROLOGY
   Oka H, 2007, MOVEMENT DISORD, V22, P1510, DOI 10.1002/mds.21581
   Oka H, 2007, J NEUROL SCI, V254, P72, DOI 10.1016/j.jns.2007.01.002
   Orimo S, 2005, ACTA NEUROPATHOL, V109, P583, DOI 10.1007/s00401-005-0995-7
   PIHA SJ, 1988, CLIN NEUROL NEUROSUR, V90, P221, DOI 10.1016/0303-8467(88)90025-X
   RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303
   ROBERTSON D, 1993, NEW ENGL J MED, V329, P1449, DOI 10.1056/NEJM199311113292003
   ROBERTSON D, 1993, CLIN AUTON RES, V3, P212
   Saiki S, 2004, J NEUROL SCI, V220, P105, DOI 10.1016/j.jns.2004.02.018
   Sandroni P, 1991, Clin Auton Res, V1, P147, DOI 10.1007/BF01826212
   SANDRONI P, 1991, J APPL PHYSIOL, V71, P1563
   SANDYK R, 1992, INT J NEUROSCI, V64, P23, DOI 10.3109/00207459209000532
   Senard JM, 1997, J NEUROL NEUROSUR PS, V63, P584, DOI 10.1136/jnnp.63.5.584
   SENARD JM, 1990, EUR J CLIN INVEST, V20, P613, DOI 10.1111/j.1365-2362.1990.tb01909.x
   Senard JM, 2001, DRUG AGING, V18, P495, DOI 10.2165/00002512-200118070-00003
   SENARD JM, 1993, CLIN NEUROPHARMACOL, V16, P70, DOI 10.1097/00002826-199302000-00008
   Szili-Torok T, 2001, NEUROBIOL AGING, V22, P435, DOI 10.1016/S0197-4580(01)00210-X
   TURKKA JT, 1987, EUR NEUROL, V26, P203, DOI 10.1159/000116337
   Vogel ER, 2005, NEUROLOGY, V65, P1533, DOI 10.1212/01.wnl.0000184504.13173.ef
   Williams DR, 2005, LANCET NEUROL, V4, P605, DOI 10.1016/S1474-4422(05)
NR 61
TC 49
Z9 51
U1 4
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD SEP
PY 2007
VL 130
BP 2425
EP 2432
DI 10.1093/brain/awm174
PN 9
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 218UA
UT WOS:000250039300019
PM 17673498
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Banerjee, S
   Kong, D
   Li, YW
   Sarkar, FH
AF Wang, Zhiwei
   Banerjee, Sanjeev
   Kong, Dejuan
   Li, Yiwei
   Sarkar, Fazlul H.
TI RETRACTED: Down-regulation of Forkhead Box M1 transcription factor leads
   to the inhibition of invasion and angiogenesis of pancreatic cancer
   cells (Retracted article. See vol. 78, pg. 5470, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ENDOTHELIAL GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; LIVER-REGENERATION;
   HEPATOCYTE ENTRY; FACTOR HFH-11B; KAPPA-B; S-PHASE; EXPRESSION; FOXM1;
   MATRIX-METALLOPROTEINASE-9
AB The Forkhead Box M1 (FoxM1) transcription factor has been shown to play important roles in regulating the expression of genes involved in cell proliferation, differentiation, and transformation. Overexpression of FoxM1 has been found in a variety of aggressive human carcinomas including pancreatic cancer. However, the precise role and the molecular mechanism of action of FoxM1 in pancreatic cancer remain unclear. To elucidate the cellular and molecular function of FoxM1, we tested the consequences of down-regulation and up-regulation of FoxM1 in pancreatic cancer cells, respectively. Using multiple cellular and molecular approaches such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, gene transfection, flow cytometry, real-time reverse transcription-PCR, Western blotting, migration, invasion, and angiogenesis assays, we found that down-regulation of FoxM1 inhibited cell growth, decreased cell migration, and decreased invasion of pancreatic cancer cells. FoxM1 down-regulation also decreased cell population in the S phase. Compared with control, FoxM1 small interfering RNA-transfected cells showed decreased expression of cyclin B, cyclin D1, and Cdk2, whereas p21 and p27 expression was increased. We also found that down-regtdation of FoxM1 reduced the expression of matrix metalloproteinase-2 (MMP-2), NIMP-9 and vascular endothelial growth factor, resulting in the inhibition of migration, invasion, and angiogenesis. These findings suggest that FoxM1 down-regulation could be a novel approach for the inhibition of pancreatic tumor progression.
C1 Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Sch Med, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Sch Med, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.
EM sarkarf@karmanos.org
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [5 R01 CA101870-05]
CR APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195
   Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002-9440(10)62337-1
   Duffy MJ, 2004, CLIN BIOCHEM, V37, P541, DOI 10.1016/j.clinbiochem.2004.05.013
   Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323
   Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527
   Harvey SR, 2003, CLIN CANCER RES, V9, P4935
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138
   Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704
   Katoh M, 2004, INT J ONCOL, V25, P1495
   Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003
   Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715
   Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5
   Li YW, 2005, MOL CANCER THER, V4, P389
   Li YW, 2005, BMC CANCER, V5, DOI 10.1186/147-2407-5-7
   Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912
   Minamino T, 2006, J CLIN INVEST, V116, P2316, DOI 10.1172/JCI29637
   Nagakawa Y, 2002, PANCREAS, V24, P169, DOI 10.1097/00006676-200203000-00008
   Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041
   Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393
   RABBANI SA, 2001, SURG ONCOL CLIN N AM, V10, pR10
   Rahman KMW, 2006, CANCER RES, V66, P4952, DOI 10.1158/0008-5472.CAN-05-3918
   SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5
   Teh MT, 2002, CANCER RES, V62, P4773
   Wang XH, 2003, GENE EXPRESSION, V11, P149, DOI 10.3727/000000003108749044
   Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299
   Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200
   Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666
   Wang ZW, 2006, CANCER RES, V66, P7653, DOI 10.1158/0008-5472.CAN-06-1019
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
   Wang ZW, 2006, MOL CANCER THER, V5, P483, DOI 10.1158/1535-7163.MCT-05-0299
   Wey JS, 2005, CANCER, V104, P427, DOI 10.1002/cncr.21145
   Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059
   Ye HG, 1999, MOL CELL BIOL, V19, P8570
   Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626
NR 39
TC 200
Z9 224
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2007
VL 67
IS 17
BP 8293
EP 8300
DI 10.1158/0008-5472.CAN-07-1265
PG 8
WC Oncology
SC Oncology
GA 209RW
UT WOS:000249406700048
PM 17804744
OA Bronze
DA 2018-12-27
ER

PT J
AU Promwikorn, W
   Kifirat, P
   Intasaro, P
   Withyachumnamkul, B
AF Promwikorn, Warapom
   Kifirat, Pornpimol
   Intasaro, Pranom
   Withyachumnamkul, Boonsirm
TI RETRACTED: Changes in integument histology molting cycle of the black
   CBP www.elsevier.com/locate/cbpb and protein expression related to the
   tiger shrimp, Penaeus monodon (Retracted Article. See vol 155, pg 210,
   2010)
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
   BIOLOGY
LA English
DT Article; Retracted Publication
DE histology; integument; Molting cycle; Penaeus monodon; SDS-PAGE
ID CRUSTACEAN ARMADILLIDIUM-VULGARE; ISOPOD PORCELLIO-SCABER; TEGUMENTAL
   GLANDS; DIFFERENTIAL EXPRESSION; ASTACUS-LEPTODACTYLUS;
   GECARCINUS-LATERALIS; CALLINECTES-SAPIDUS; INTERMOLT CYCLE; EPIDERMAL
   DNA; FIDDLER-CRAB
AB We investigated changes in the histology and protein expression in the epidermis and sub-epidermis of the black tiger shrimp (Penaeus monondon) during the molting cycle. The epidermis consists of a cell layer located beneath the cuticle, while the sub-epidermis is mainly composed of sub-epidermal cells and tegumental glands. During the molting cycle, the epidermal cells increase in cell height and number, and the sub-epidermis increases in its storage of carbohydrate, protein, mucus, and other unidentified substances at the time of the active period of cuticular regeneration. At the early premolt (stage D0), the epidermal cells are tidily organized, but short. Storage of carbohydrate and protein in the sub-epidermis is not observed. During the rest of the premolt (D1-4 stages) and the early postmolt A stage, epidermal cell height and subepidermal deposition are increased, and reached a maximum during the D4 to A stages. The period of late postmolt stages B-C3 is the time for a decrease in epidermal cell height and sub-epidermal depositions. Lastly at intermolt stage C4, the epidermal cells become short, and untidily organized. Sub-epidermal deposition is not observed. Protein expression in the epidermis and sub-epidermis was observed by SDS-PAGE. This revealed that the profile of a protein band with a molecular mass of 57 kDa corresponded with the profile observed by histochemistry. All results point to the conclusion that both the epidermis and sub-epidermis play major roles in cuticular regeneration. It may also reflect the level of metbolic activity of the integument during the molting cycle. In addition, for the first time, this work provides direct evidence of the epidermal and sub-epidermal changes that occur during the molting cycle of the black tiger shrimp. (C) 2007 Elsevier Inc. All rights reserved.
C1 Prince Songkla Univ, Fac Sci, Dept Anat, Hat Yai 90112, Songkla, Thailand.
   Mahidol Univ, Fac Sci, Dept Anat, Bangkok 10400, Thailand.
   Mahidol Univ, Fac Sci, Ctr Excellence Shrimp Mol Biol & Biotechnol, Bangkok 10400, Thailand.
RP Promwikorn, W (reprint author), Prince Songkla Univ, Fac Sci, Dept Anat, Hat Yai 90112, Songkla, Thailand.
EM warapom.p@psu.ac.th
CR Ahearn GA, 2004, COMP BIOCHEM PHYS A, V137, P247, DOI 10.1016/j.cbpb.2003.10.012
   BABU DE, 1985, J EXP MAR BIOL ECOL, V88, P129
   Bancroft JD, 2002, THEORY PRACTICE HIST, P153
   BIELEFELD M, 1986, INSECT BIOCHEM, V16, P175, DOI 10.1016/0020-1790(86)90093-4
   Buda ES, 2005, COMP BIOCHEM PHYS B, V140, P521, DOI 10.1016/j.cbpc.2004.11.017
   CARIOLOU MA, 1994, COMP BIOCHEM PHYS B, V108, P367, DOI 10.1016/0305-0491(94)90088-4
   Chan SM, 1998, FEBS LETT, V436, P395, DOI 10.1016/S0014-5793(98)01148-X
   DALL W., 1965, AUSTRALIAN J MAR FRESHWATER RES, V16, P13
   DALL W, 1979, J EXP MAR BIOL ECOL, V36, P103, DOI 10.1016/0022-0981(79)90103-5
   Drach P., 1939, Ann Inst oceanogr Paris, V19, P103
   Endo H, 2000, BIOCHEM BIOPH RES CO, V276, P286, DOI 10.1006/bbrc.2000.3446
   Faircloth LM, 2007, COMP BIOCHEM PHYS B, V146, P370, DOI 10.1016/j.cbpb.2006.11.008
   GREEN JP, 1972, TISSUE CELL, V4, P137, DOI 10.1016/S0040-8166(72)80013-2
   Hagedorn M, 2002, J EXP BIOL, V205, P1935
   HUMPHREYS CR, 1973, COMP BIOCHEM PHYSIOL, V44, P1121, DOI 10.1016/0300-9629(73)90250-8
   Ikeya T, 2001, COMP BIOCHEM PHYS B, V128, P379, DOI 10.1016/S1096-4959(00)00335-3
   Kim HW, 2005, MOL CELL ENDOCRINOL, V242, P80, DOI 10.1016/j.mice.2005.08.001
   Luquet G, 2004, CR PALEVOL, V3, P515, DOI 10.1016/j.crpv.2004.07.015
   MACHADO J, 1990, J EXP BIOL, V150, P159
   MCWHINNI.MA, 1970, COMP BIOCHEM PHYSIOL, V34, P415, DOI 10.1016/0010-406X(70)90182-9
   Pratoomchat B, 2002, COMP BIOCHEM PHYS A, V131, P243, DOI 10.1016/S1095-6433(01)00447-0
   PROMWIKOM W, 2005, J SCI TECHNOL, V27, P499
   PROMWIKORN W, 2004, J SCI TECHNOL, V26, P765
   ROER R, 1984, AM ZOOL, V24, P893
   SCHULTZ TW, 1977, J SUBMICR CYTOL PATH, V9, P37
   SHYAMASUNDARI K, 1978, FOL HISTOCH CYTOCHEM, V16, P247
   SKINNER DM, 1966, AM ZOOL, V6, P235
   SKINNER DM, 1962, BIOL BULL, V123, P635, DOI 10.2307/1539584
   STEVENSON J, 1961, BIOL BULL, V121, P554, DOI 10.2307/1539454
   STEVENSON J R, 1985, P1
   STEVENSON JR, 1962, J EXP ZOOL, V150, P17, DOI 10.1002/jez.1401500104
   STEVENSON JR, 1967, T AM MICROSC SOC, V86, P50, DOI 10.2307/3224424
   Terwilliger NB, 1999, P NATL ACAD SCI USA, V96, P2013, DOI 10.1073/pnas.96.5.2013
   TRAUB M, 1987, GEN COMP ENDOCR, V65, P469, DOI 10.1016/0016-6480(87)90133-X
   TRAVIS DF, 1955, BIOL BULL, V108, P88, DOI 10.2307/1538400
   UENO M, 1992, ACTA HISTOCHEM CYTOC, V25, P505, DOI 10.1267/ahc.25.505
   Varadaraj K, 1996, GENE, V171, P177, DOI 10.1016/0378-1119(96)00018-2
   Watanabe T, 1997, ZOOL SCI, V14, P65, DOI 10.2108/zsj.14.65
   Watanabe T, 2000, COMP BIOCHEM PHYS B, V125, P127, DOI 10.1016/S0305-0491(99)00153-4
   Wheatly MG, 2002, COMP BIOCHEM PHYS B, V132, P163, DOI 10.1016/S1096-4959(01)00520-6
   WITTIG K, 1975, J COMP PHYSIOL, V99, P279, DOI 10.1007/BF00710368
   Ziegler A, 1996, CELL TISSUE RES, V284, P459, DOI 10.1007/s004410050606
   Zou EM, 1999, COMP BIOCHEM PHYS C, V124, P345, DOI 10.1016/S0742-8413(99)00084-5
NR 43
TC 9
Z9 9
U1 5
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1096-4959
EI 1879-1107
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PD SEP
PY 2007
VL 148
IS 1
BP 20
EP 31
DI 10.1016/j.cbpb.2007.04.009
PG 12
WC Biochemistry & Molecular Biology; Zoology
SC Biochemistry & Molecular Biology; Zoology
GA 206OU
UT WOS:000249193600004
PM 17601758
DA 2018-12-27
ER

PT J
AU Prada, PO
   Hirabara, SM
   de Souza, CT
   Schenka, AA
   Zecchin, HG
   Vassallo, J
   Velloso, LA
   Carneiro, E
   Carvalheira, JBC
   Curi, R
   Saad, MJ
AF Prada, P. O.
   Hirabara, S. M.
   de Souza, C. T.
   Schenka, A. A.
   Zecchin, H. G.
   Vassallo, J.
   Velloso, L. A.
   Carneiro, E.
   Carvalheira, J. B. C.
   Curi, R.
   Saad, M. J.
TI RETRACTED: L-glutamine supplementation induces insulin resistance in
   adipose tissue and improves insulin signalling in liver and muscle of
   rats with diet-induced obesity (Retracted article. See vol. 61, pg. 253,
   2018)
SO DIABETOLOGIA
LA English
DT Article; Retracted Publication
DE akt; glutamine; high-fat diet; insulin resistance; insulin signalling;
   phosphatidylinositol 3-kinase; obesity; PI-3K
ID AMINO-ACID-METABOLISM; RECEPTOR SUBSTRATE-1; IN-VIVO; HEXOSAMINE
   PATHWAY; SKELETAL-MUSCLE; PROTEIN-KINASE; SOLEUS MUSCLE; GLUCOSE; MICE;
   PHOSPHORYLATION
AB Aims/hypothesis Diet-induced obesity (DIO) is associated with insulin resistance in liver and muscle, but not in adipose tissue. Mice with fat-specific disruption of the gene encoding the insulin receptor are protected against DIO and glucose intolerance. In cell culture, glutamine induces insulin resistance in adipocytes, but has no effect in muscle cells. We investigated whether supplementation of a high-fat diet with glutamine induces insulin resistance in adipose tissue in the rat, improving insulin sensitivity in the whole animal.
   Materials and methods Male Wistar rats received standard rodent chow or a high-fat diet (HF) or an HF supplemented with alanine or glutamine (HFGln) for 2 months. Light microscopy and morphometry, oxygen consumption, hyperinsulinaemic-euglycaemic clamp and immunoprecipitation/immunoblotting were performed.
   Results HFGln rats showed reductions in adipose mass and adipocyte size, a decrease in the activity of the insulin-induced IRS-phosphatidylinositol 3-kinase (PI3-K)-protein kinase B-forkhead transcription factor box 01 pathway in adipose tissue, and an increase in adiponectin levels. These results were associated with increases in insulin-stimulated glucose uptake in skeletal muscle and insulin-induced suppression of hepatic glucose output, and were accompanied by an increase in the activity of the insulin-induced IRS-PI3-K-Akt pathway in these tissues. In parallel, there were decreases in TNF alpha and IL-6 levels and reductions in c-jun N-terminal kinase (JNK), I kappa B kinase subunit beta (IKK beta) and mammalian target of rapamycin (mTOR) activity in the liver, muscle and adipose tissue. There was also an increase in oxygen consumption and a decrease in the respiratory exchange rate in HFGln rats.
   Conclusions/interpretation Glutamine supplementation induces insulin resistance in adipose tissue, and this is accompanied by an increase in the activity of the hexosamine pathway. It also reduces adipose mass, consequently attenuating insulin resistance and activation of JNK and IKK beta, while improving insulin signalling in liver and muscle.
C1 Univ Estadual Campinas, Dept Clin Med, BR-13083887 Campinas, SP, Brazil.
   Univ Sao Paulo, Inst Ciencias Biomed, Dept Fisiol & Biofis, BR-05508 Sao Paulo, Brazil.
   Univ Estadual Campinas, Dept Patol, Campinas, SP, Brazil.
   Univ Estadual Campinas, Dept Fisiol, Campinas, SP, Brazil.
RP Saad, MJ (reprint author), Univ Estadual Campinas, Dept Clin Med, Rua Tessalia Viera Camargo 126, BR-13083887 Campinas, SP, Brazil.
EM msaad@fcm.unicamp.br
RI Prada, Patricia/R-6269-2018; Hirabara, Sandro/C-4014-2012; Prada,
   Patricia/E-9339-2015; SCHENKA, ANDRE/G-8415-2012; Carvalheira,
   Jose/H-8405-2012
OI Prada, Patricia/0000-0002-4131-4503; Hirabara,
   Sandro/0000-0002-7392-0444; SCHENKA, ANDRE/0000-0002-8162-8996;
   VASSALLO, JOSE/0000-0002-2192-4865
CR Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575
   Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200
   Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047
   Alba-Loureiro TC, 2006, J ENDOCRINOL, V188, P295, DOI 10.1677/joe.1.06438
   Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5
   Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082
   Carvalho E, 2005, AM J PHYSIOL-ENDOC M, V289, pE551, DOI 10.1152/ajpendo.00116.2005
   CHALLISS RAJ, 1986, BIOCHEM J, V233, P377, DOI 10.1042/bj2330377
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   CRETTAZ M, 1980, BIOCHEM J, V186, P525, DOI 10.1042/bj1860525
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   FRAYN KN, 1991, CLIN SCI, V80, P471, DOI 10.1042/cs0800471
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200
   Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862
   Hirata AE, 2003, LIFE SCI, V73, P1369, DOI 10.1016/S0024-3205(03)00477-6
   Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697
   Jeon ES, 2006, J LIPID RES, V47, P653, DOI 10.1194/jlr.M500508-JLR200
   Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050
   Kowalski TJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE613
   Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200
   LEIGHTON B, 1985, BIOCHEM J, V227, P337, DOI 10.1042/bj2270337
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   MARSHALL S, 1991, FASEB J, V5, P3031
   Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X
   Opara EC, 1996, J NUTR, V126, P273
   Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562
   Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813
   Prada PO, 2006, FEBS LETT, V580, P4889, DOI 10.1016/j.febslet.2006.08.004
   Prada PO, 2005, ENDOCRINOLOGY, V146, P1576, DOI 10.1210/en.2004-0767
   Ritchie JWA, 2001, CELL PHYSIOL BIOCHEM, V11, P259, DOI 10.1159/000047812
   ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013
   Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3
   SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Singleton KD, 2005, SHOCK, V24, P583, DOI 10.1097/01.shk.0000185795.96964.71
   Span PN, 2001, CLIN CHEM, V47, P944
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910
   Tremblay F, 2001, J BIOL CHEM, V276, P38052
   Wu GY, 2001, BIOCHEM J, V353, P245, DOI 10.1042/0264-6021:3530245
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   Yatagai T, 2003, METABOLISM, V52, P1274, DOI 10.1016/S0026-0495(03)00195-1
NR 48
TC 42
Z9 46
U1 3
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD SEP
PY 2007
VL 50
IS 9
BP 1949
EP 1959
DI 10.1007/s00125-007-0723-z
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 200OD
UT WOS:000248771800020
PM 17604977
OA Bronze
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Johnson, CS
AF Stapel, Diederik A.
   Johnson, Camille S.
TI RETRACTED: When nothing compares to me: How defensive motivations and
   similarity shape social comparison effects (Retracted article. See vol.
   42, pg. 664, 2012)
SO EUROPEAN JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID SELF-EVALUATION; CONSEQUENCES; VERIFICATION; ENHANCEMENT; IMPLICIT;
   EXPLICIT; THINKING; OTHERS
AB While similarity typically breeds social comparison, all information gained from social comparisons is not equally influential. Three studies illustrate the situations in which individuals defensively interpret social comparison information such that they incorporate information that reflects positively on the self and disregard negative information. Study I extends previous research to show that self-threat broadens the conditions under which defensive interpretations occur to include those in which similarity is ambiguous. Studies 2 and 3 demonstrate that defensive interpretations are less likely to occur when individuals are affirmed or when the comparison information is unimportant. These findings suggest that the impact of social comparisons on self-views is determined by both similarity of comparison targets and the motives of the perceiver Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Tilburg Univ, Tilburg Inst Behav Econ Res, NL-5000 LE Tilburg, Netherlands.
   Stanford Univ, Grad Sch Business, Stanford, CA 94305 USA.
RP Stapel, DA (reprint author), Tilburg Univ, Tilburg Inst Behav Econ Res, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl; camille_johnson@stanford.edu
CR [Anonymous], 2002, AM HERITAGE DICT ENG
   BAUMEISTER RF, 1998, HDB SOCIAL PSYCHOL, V1, P680
   Bayer UC, 2005, EUR J SOC PSYCHOL, V35, P313, DOI 10.1002/ejso.247
   BROWN JD, 1992, J PERS SOC PSYCHOL, V62, P717, DOI 10.1037//0022-3514.62.5.717
   DUNNING D, 2004, MOTIVES UNDERLYING S
   DUNNING D, 2005, SELF INSIGHT ROADLOC
   Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202
   GILBERT DT, 1995, J PERS SOC PSYCHOL, V69, P227, DOI 10.1037/0022-3514.69.2.227
   GOETHALS G, 1977, SOCIAL COMP PROCESSE, P258
   GORDIJN EH, 2006, IN PRESS BRIT J SOCI
   JACCARD J, 1998, INTERACTION EFFECTS
   Markman KD, 2003, PERS SOC PSYCHOL REV, V7, P244, DOI 10.1207/S15327957PSPR0703_04
   MEDNICK SA, 1962, PSYCHOL REV, V69, P220, DOI 10.1037/h0048850
   Miller D. T., 1996, SOCIAL PSYCHOL HDB B, V10, P799
   MORSE S, 1970, J PERS SOC PSYCHOL, V16, P148, DOI 10.1037/h0029862
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   Mussweiler T, 2000, J PERS SOC PSYCHOL, V79, P23, DOI 10.1037/0022-3514.79.1.23
   Sedikides C, 1997, ADV EXP SOC PSYCHOL, V29, P209, DOI 10.1016/S0065-2601(08)60018-0
   SEDIKIDES C, 1993, J PERS SOC PSYCHOL, V65, P317, DOI 10.1037/0022-3514.65.2.317
   Sedikides C., 2004, SELF MEMORY, P161, DOI 10.1037/0022-3514.79.6.906
   Stapel DA, 2006, J EXP SOC PSYCHOL, V42, P397, DOI 10.1016/j.jesp.2005.05.006
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P860, DOI 10.1037/0022-3514.87.6.860
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 2004, SOC COGNITION, V22, P147, DOI 10.1521/soco.22.1.147.30989
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Steele Claude, 1988, ADV EXPT SOCIAL PSYC, P261, DOI DOI 10.1016/S0065-2601(08)60229-4
   SWANN WB, 1989, J PERS SOC PSYCHOL, V57, P782, DOI 10.1037/0022-3514.57.5.782
   TAYLOR SE, 1995, PERS SOC PSYCHOL B, V21, P1278, DOI 10.1177/01461672952112005
   Tesser A., 1988, ADV EXPT SOCIAL PSYC, P181, DOI DOI 10.1016/S0065-2601(08)60227-0
   TROPE Y, 1986, PSYCHOL REV, V93, P239, DOI 10.1037/0033-295X.93.3.239
   TROPE Y, 1994, J PERS SOC PSYCHOL, V66, P646, DOI 10.1037/0022-3514.66.4.646
   Turner J. C., 1987, REDISCOVERING SOCIAL
NR 32
TC 8
Z9 8
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0046-2772
EI 1099-0992
J9 EUR J SOC PSYCHOL
JI Eur. J. Soc. Psychol.
PD SEP-OCT
PY 2007
VL 37
IS 5
BP 824
EP 838
DI 10.1002/ejsp.390
PG 15
WC Psychology, Social
SC Psychology
GA 212XD
UT WOS:000249629400004
DA 2018-12-27
ER

PT J
AU Hoang, TN
AF Hoang, Thienhuong N.
TI RETRACTED: THE RELATIONS BETWEEN PARENTING AND ADOLESCENT MOTIVATION
   (Retracted Article)
SO INTERNATIONAL JOURNAL OF WHOLE SCHOOLING
LA English
DT Article; Retracted Publication
ID INTRINSIC MOTIVATION; ACHIEVEMENT GOALS; CHILDRENS; COMPETENCE;
   AUTHORITARIAN; INVOLVEMENT; ADJUSTMENT; INDULGENT; PATTERNS; TIME
C1 [Hoang, Thienhuong N.] Calif State Polytech Univ Pomona, Coll Educ & Integrat Studies, Dept Educ Grad Pedag Studies, Pomona, CA 91768 USA.
RP Hoang, TN (reprint author), Calif State Polytech Univ Pomona, Coll Educ & Integrat Studies, Dept Educ Grad Pedag Studies, Pomona, CA 91768 USA.
CR AMES C, 1988, J EDUC PSYCHOL, V80, P260, DOI 10.1037/0022-0663.80.3.260
   AMES C, 1992, J EDUC PSYCHOL, V84, P261, DOI 10.1037//0022-0663.84.3.261
   Bandura A., 1986, SOCIAL FOUNDATIONS O
   BARTH JM, 1993, MERRILL PALMER QUART, V39, P173
   BAUMRIND D, 1971, DEV PSYCHOL, V4, P1, DOI 10.1037/h0030372
   BAUMRIND D, 1967, GENET PSYCHOL MONOGR, V75, P43
   BLOOM BL, 1985, FAM PROCESS, V24, P225, DOI 10.1111/j.1545-5300.1985.00225.x
   Deci EL, 1985, INTRINSIC MOTIVATION
   DWECK CS, 1988, PSYCHOL REV, V95, P256, DOI 10.1037//0033-295X.95.2.256
   Eccles J., 1996, FAMILY SCH LINKS DO, P3
   ECCLES JS, 1993, AM PSYCHOL, V48, P90, DOI 10.1037/0003-066X.48.2.90
   Elliot AJ, 1997, J PERS SOC PSYCHOL, V72, P218, DOI 10.1037//0022-3514.72.1.218
   Elliot AJ, 1996, J PERS SOC PSYCHOL, V70, P461, DOI 10.1037//0022-3514.70.3.461
   Epstein J. E., 1999, MARRIAGE FAM REV, V15, P99
   Epstein J. L., 1989, RESEARCH ON MOTIVATI, V3
   GINSBURG GS, 1993, CHILD DEV, V64, P1461, DOI 10.1111/j.1467-8624.1993.tb02964.x
   Gonzalez A., 2005, EDUC PSYCHOL REV, V17, P50
   Gonzalez A. R., 2001, COLL STUDENT J, V35, P182
   Gonzalez AR, 2002, CONTEMP EDUC PSYCHOL, V27, P450, DOI 10.1006/ceps.2001.1104
   GOTTFRIED AE, 1994, J EDUC PSYCHOL, V86, P104, DOI 10.1037//0022-0663.86.1.104
   Grolnick WS, 1999, EDUC PSYCHOL, V34, P3, DOI 10.1207/s15326985ep3401_1
   GROLNICK WS, 1991, J EDUC PSYCHOL, V83, P508, DOI 10.1037/0022-0663.83.4.508
   GROLNICK WS, 1994, CHILD DEV, V65, P237, DOI 10.2307/1131378
   GROLNICK WS, 1989, J EDUC PSYCHOL, V81, P143, DOI 10.1037/0022-0663.81.2.143
   Harackiewicz JM, 2002, J EDUC PSYCHOL, V94, P638, DOI 10.1037//0022-0663.94.3.638
   HOANG T, INTERNATIONAL JOURNA
   KEITH TZ, 1986, J EDUC PSYCHOL, V78, P373, DOI 10.1037/0022-0663.78.5.373
   Lamborn S., 1992, STUDENT ENGAGEMENT A, P153
   LAMBORN SD, 1991, CHILD DEV, V62, P1049, DOI 10.2307/1131151
   Middleton MJ, 1997, J EDUC PSYCHOL, V89, P710, DOI 10.1037/0022-0663.89.4.710
   Midgley C, 1998, CONTEMP EDUC PSYCHOL, V23, P113, DOI 10.1006/ceps.1998.0965
   Pintrich P. R., 1991, ADVANCES IN MOTIVATI, V7
   Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68
   Schunk D, 2002, MOTIVATION IN EDUCAT
   SCHUNK DH, 1995, EDUC PSYCHOL, V30, P213, DOI 10.1207/s15326985ep3004_7
   STEINBERG L, 1994, CHILD DEV, V65, P754, DOI 10.2307/1131416
   STEINBERG L, 1989, CHILD DEV, V60, P1424, DOI 10.2307/1130932
   Steinberg L., 1991, J RES ADOLESCENCE, V1, P19, DOI DOI 10.1111/1532-7795.EP11522650
   Urdan T, 1996, J EDUC PSYCHOL, V88, P422
NR 39
TC 7
Z9 7
U1 0
U2 0
PU WHOLE SCHOOLING CONSORTIUM
PI DETOIT
PA C/O 217 EDUCATION, WAYNE STATE UNIV, DETOIT, MI 48202 USA
SN 1710-2146
J9 INT J WHOLE SCH
JI Int. J. Whole Sch.
PD SEP
PY 2007
VL 3
IS 2
BP 1
EP 21
PG 21
WC Education & Educational Research
SC Education & Educational Research
GA VD7GQ
UT WOS:000437573400001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Takeda, T
   Uzawa, M
AF Iwamoto, J.
   Takeda, T.
   Uzawa, M.
TI RETRACTED: Comparison of effects of alendronate and raloxifene on the
   lumbar bone mineral density, bone turnover, and lipid metabolism in
   elderly women with osteoporosis (Retracted article. See vol. 59, pg.
   167, 2018)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Meeting Abstract; Retracted Publication
CT 29th Annual Meeting of the
   American-Society-for-Bone-and-Mineral-Research
CY SEP 16-19, 2007
CL Honolulu, HI
SP Amer Soc Bone & Mineral Res
C1 [Iwamoto, J.; Takeda, T.] Keio Univ, Dept Sports Med, Tokyo, Japan.
   [Uzawa, M.] Keiyu Orthopaed Hosp, Dept Orthopaed Surg, Gunma, Japan.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2007
VL 22
SU 1
MA T398
BP S331
EP S331
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 225IA
UT WOS:000250509101619
DA 2018-12-27
ER

PT J
AU Xu, CQ
   Lu, YJ
   Pan, ZW
   Chu, WF
   Luo, XB
   Lin, HX
   Xiao, JN
   Shan, HL
   Wang, ZG
   Yang, BF
AF Xu, Chaoqian
   Lu, Yanjie
   Pan, Zhenwei
   Chu, Wenfeng
   Luo, Xiaobin
   Lin, Huixian
   Xiao, Jiening
   Shan, Hongli
   Wang, Zhiguo
   Yang, Baofeng
TI RETRACTED: The muscle-specific microRNAs miR-1 and miR-133 produce
   opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in
   cardiomyocytes (Retracted article. See vol. 124, pg. 3187, 2011)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE miR-1; miR-133; apoptosis; HSP60; HSP70; caspase-9
ID HERG K+ CHANNEL; CARDIAC MYOCYTES; CELL-DEATH; MECHANISMS;
   PROLIFERATION; PROTEIN; DIFFERENTIATION; OVEREXPRESSION; INHIBITION;
   EXPRESSION
AB The microRNAs miR-1 and miR-133 are preferentially expressed in cardiac and skeletal muscles and have been shown to regulate differentiation and proliferation of these cells. We report here a novel aspect of cellular function of miR-1 and miR-133 regulation of cardiomyocyte apoptosis. miR-1 and miR-133 produced opposing effects on apoptosis, induced by oxidative stress in H9c2 rat ventricular cells, with miR-1 being pro-apoptotic and miR-133 being antiapoptotic. miR-1 level was significantly increased in response to oxidative stress. We identified single target sites for miR-1 only, in the 3 '- untranslated regions of the HSP60 and HSP70 genes, and multiple putative target sites for miR-133 throughout the sequence of the caspase-9 gene. miR-1 reduced the levels of HSP60 and HSP70 proteins without changing their transcript levels, whereas miR-133 did not affect HSP60 and HSP70 expression at all. By contrast, miR-133 repressed caspase-9 expression at both the protein and mRNA levels. The post-transcriptional repression of HSP60 and HSP70 and caspase-9 was further confirmed by luciferase reporter experiments. Our results indicate that miR-1 and miR-133 are involved in regulating cell fate with increased miR-1 and/or decreased miR-133 levels favoring apoptosis and decreased miR-1 and/or miR133 levels favoring survival. Post-transcriptional repression of HSP60 and HSP70 by miR-1 and of caspase-9 by miR133 contributes significantly to their opposing actions.
C1 Harbin Med Coll, Dept Pharmacol, State Province Key Lab Biomed Pharmaceut China, Harbin 150086, Peoples R China.
   Harbin Med Coll, Inst Cardiovasc Res, Harbin 150086, Peoples R China.
   Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
   Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
RP Wang, ZG (reprint author), Harbin Med Coll, Dept Pharmacol, State Province Key Lab Biomed Pharmaceut China, Harbin 150086, Peoples R China.
EM wz.email@gmail.com; yangbf@ems.hrbmu.edu.cn
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Gupta S, 2005, J CELL MOL MED, V9, P51, DOI 10.1111/j.1582-4934.2005.tb00336.x
   Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005
   Han H, 2004, AM J PHYSIOL-HEART C, V286, pH2169, DOI 10.1152/ajpheart.00199.2003
   Han H, 2004, CELL PHYSIOL BIOCHEM, V14, P121, DOI 10.1159/000078104
   Han H, 2001, J BIOL CHEM, V276, P26357, DOI 10.1074/jbc.M011136200
   Han YC, 2006, CIRC RES, V99, P415, DOI 10.1161/01.RES.0000237387.05259.a5
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   JACKSON RJ, 2007, SCI STKE, V23, P243
   Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5
   Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kwon C, 2005, P NATL ACAD SCI USA, V102, P18986, DOI 10.1073/pnas.0509535102
   Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787
   Luo XB, 2007, J CELL PHYSIOL, V212, P358, DOI 10.1002/jcp.21030
   MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815
   Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873
   Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103
   Shan YX, 2003, J MOL CELL CARDIOL, V35, P1135, DOI 10.1016/S0022-2828(03)00229-3
   Wang HZ, 2002, CANCER RES, V62, P4843
   Yang BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569
   Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817
NR 31
TC 310
Z9 363
U1 6
U2 43
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD SEP 1
PY 2007
VL 120
IS 17
BP 3045
EP 3052
DI 10.1242/jcs.010728
PG 8
WC Cell Biology
SC Cell Biology
GA 211YC
UT WOS:000249559000007
PM 17715156
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Maringer, M
   Stapel, DA
AF Maringer, Marcus
   Stapel, Diederik A.
TI RETRACTED: Unfinished business: How completeness affects the impact of
   emotional states and emotion concepts on social judgment (Retracted
   article. See vol. 49, pg. 780, 2013)
SO JOURNAL OF EXPERIMENTAL SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE emotional states; emotion concepts; completeness; emotion congruency;
   emotion incongruency
ID IMPRESSION-FORMATION; MOOD; MISATTRIBUTION; ACCESSIBILITY; DETERMINANTS;
   INTERRUPTION; INFORMATION; GOALS
AB In two studies, we compared the impact of cold emotion concept primes with induced hot emotional states on subsequent social judgments. We hypothesized that the completeness of the prime episode is an important determinant of whether accessible information will lead to emotionally congruent or incongruent judgments. We extend previous research on knowledge and emotion accessibility effects by demonstrating that the effects of incomplete versus completed prime episodes are independent of whether we prime emotion states or emotion concepts. That is, our results show that both hot and cold affective information activated by incomplete prime episodes leads to assimilation, whereas information activated by completed prime episodes leads to contrast effects. Implications for accessibility research are discussed. (C) 2006 Elsevier Inc. All rights reserved.
C1 Univ Groningen, Dept Behav & Social Sci, NL-9712 TS Groningen, Netherlands.
RP Maringer, M (reprint author), Tilburg Univ, TIBER, NL-5000 LE Tilburg, Netherlands.
EM m.maringer@rug.nl; d.a.stapel@uvt.nl
RI Cristofaro, Matteo/I-4960-2015
OI Cristofaro, Matteo/0000-0002-3181-8003
CR BUTTERFIELD EC, 1964, PSYCHOL BULL, V62, P309, DOI 10.1037/h0039873
   Chartrand TL, 1996, J PERS SOC PSYCHOL, V71, P464, DOI 10.1037/0022-3514.71.3.464
   Clore GL, 2003, PSYCHOLOGY OF EVALUATION, P335
   Deutsch M., 1968, HDB SOCIAL PSYCHOL, V1, P412
   EICH E, 1989, J EXP PSYCHOL LEARN, V15, P443, DOI 10.1037//0278-7393.15.3.443
   Fiedler K, 2005, J PERS SOC PSYCHOL, V88, P229, DOI 10.1037/0022-3514.88.2.229
   Forgas J. P., 2000, FEELING THINKING ROL, P253
   Forster J, 2005, J EXP SOC PSYCHOL, V41, P220, DOI 10.1016/j.jesp.2004.06.009
   Higgins ET, 1996, SOCIAL PSYCHOL HDB B, P133
   Innes-Ker A, 2002, J PERS SOC PSYCHOL, V83, P804, DOI 10.1037//0022-3514.83.4.804
   KUBOVY M, 1977, J EXP PSYCHOL HUMAN, V3, P359, DOI 10.1037/0096-1523.3.2.359
   Leventhal H, 1987, COGNITION EMOTION, V1, P3, DOI [10.1080/02699938708408361, DOI 10.1080/02699938708408361]
   Lewin K., 1951, FIELD THEORY SOCIAL
   MARINGER M, 2006, ASSIMILATION CONTRAS
   MARTIN LL, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P195
   MARTIN LL, 1986, J PERS SOC PSYCHOL, V51, P493, DOI 10.1037/0022-3514.51.3.493
   MARTIN LL, 1983, J PERS SOC PSYCHOL, V44, P755, DOI 10.1037/0022-3514.44.4.755
   MAYER JD, 1988, J PERS SOC PSYCHOL, V55, P102, DOI 10.1037//0022-3514.55.1.102
   MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   Ottati VC, 1996, J PERS SOC PSYCHOL, V71, P39, DOI 10.1037/0022-3514.71.1.39
   RUSSELL JA, 1978, J PERS SOC PSYCHOL, V36, P1152, DOI 10.1037//0022-3514.36.10.1152
   SCHIFFMAN N, 1992, B PSYCHONOMIC SOC, V30, P9
   SCHWARZ N, 1983, J PERS SOC PSYCHOL, V45, P513, DOI 10.1037/0022-3514.45.3.513
   SCHWARZ N, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P217
   Schwarz N., 1996, SOCIAL PSYCHOL HDB B, P433
   Srull T.K, 1989, MEMORY COGNITION ITS
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   Stapel DA, 2001, COGNITIVE SOCIAL PSYCHOLOGY, P229
   STAPEL DA, 1997, WHAT WE TALK WHEN WE
   STAPEL DA, 2006, ASSIMILATION CONTRAS
   WATSON D, 1985, PSYCHOL BULL, V98, P219, DOI 10.1037/0033-2909.98.2.219
   ZEIGARNIK B, 1927, UNTERSUCHUNGEN HANDL, V9, P1
NR 34
TC 8
Z9 8
U1 2
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-1031
EI 1096-0465
J9 J EXP SOC PSYCHOL
JI J. Exp. Soc. Psychol.
PD SEP
PY 2007
VL 43
IS 5
BP 712
EP 718
DI 10.1016/j.jesp.2006.07.007
PG 7
WC Psychology, Social
SC Psychology
GA 206GZ
UT WOS:000249173200003
DA 2018-12-27
ER

PT J
AU Muthukkumaran, K
   Bokalawela, R
   Mathews, T
   Selladurai, S
AF Muthukkumaran, K.
   Bokalawela, Roshan
   Mathews, Tom
   Selladurai, S.
TI RETRACTED: Determination of dopant of ceria system by density functional
   theory (Retracted article. See vol. 51, pg. 5027, 2016)
SO JOURNAL OF MATERIALS SCIENCE
LA English
DT Article; Retracted Publication
ID AUGMENTED-WAVE METHOD; OXIDE FUEL-CELL; IONIC-CONDUCTIVITY; DOPED CERIA;
   CEO2; TRANSPORT; SOLIDS
AB Oxides with the cubic fluorite structure, e.g., ceria (CeO2), are known to be good solid electrolytes when they are doped with cations of lower valence than the host cations. The high ionic conductivity of doped ceria makes it an attractive electrolyte for solid oxide fuel cells, whose prospects as an environmentally friendly power source are very promising. In these electrolytes, the current is carried by oxygen ions that are transported by oxygen vacancies, present to compensate for the lower charge of the dopant cations. Ionic conductivity in ceria is closely related to oxygen-vacancy formation and migration properties. A clear physical picture of the connection between the choice of a dopant and the improvement of ionic conductivity in ceria is still lacking. Here we present quantum-mechanical first-principles study of the influence of different trivalent impurities on these properties. Our results reveal a remarkable correspondence between vacancy properties at the atomic level and the macroscopic ionic conductivity. The key parameters comprise migration barriers for bulk diffusion and vacancy-dopant interactions, represented by association (binding) energies of vacancy-dopant clusters. The interactions can be divided into repulsive elastic and attractive electronic parts. In the optimal electrolyte, these parts should balance. This finding offers a simple and clear way to narrow the search for superior dopants and combinations of dopants. The ideal dopant should have an effective atomic number between 61 (Pm) and 62 (Sm), and we elaborate that combinations of Nd/Sm and Pr/Gd show enhanced ionic conductivity, as compared with that for each element separately.
C1 Anna Univ, Dept Phys, Madras 600025, Tamil Nadu, India.
   Univ Oklahoma, Homer L Dodge Dept Phys & Astron, Norman, OK 73019 USA.
   Indira Gandhi Ctr Atom Res, Div Mat Sci, Surface Sci Sect, Kalpakkam 603102, Tamil Nadu, India.
RP Selladurai, S (reprint author), Anna Univ, Dept Phys, Madras 600025, Tamil Nadu, India.
EM ssdurai@yahoo.com
CR Andersson DA, 2006, P NATL ACAD SCI USA, V103, P3518, DOI 10.1073/pnas.0509537103
   Balducci G, 2000, CHEM MATER, V12, P677, DOI 10.1021/cm991089e
   BERRY RS, 2000, PHYS CHEM, P512
   BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   BUTLER V, 1983, SOLID STATE IONICS, V8, P109, DOI 10.1016/0167-2738(83)90070-X
   FABER J, 1989, APPL PHYS A-MATER, V49, P225, DOI 10.1007/BF00616848
   GERHARDTANDERSON R, 1981, SOLID STATE IONICS, V5, P547, DOI 10.1016/0167-2738(81)90313-1
   GSCHNEIDNER KA, 1985, J LESS-COMMON MET, V114, P29, DOI 10.1016/0022-5088(85)90387-X
   Hibino T, 2000, SCIENCE, V288, P2031, DOI 10.1126/science.288.5473.2031
   Inaba H, 1996, SOLID STATE IONICS, V83, P1, DOI 10.1016/0167-2738(95)00229-4
   Kharton VV, 2004, SOLID STATE IONICS, V174, P135, DOI 10.1016/j.ssi.2004.06.015
   KILNER JA, 1983, SOLID STATE IONICS, V8, P201, DOI 10.1016/0167-2738(83)90017-6
   KIM DJ, 1989, J AM CERAM SOC, V72, P1415, DOI 10.1111/j.1151-2916.1989.tb07663.x
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758
   Krishnamurthy R, 2004, J AM CERAM SOC, V87, P1821
   Minervini L, 1999, SOLID STATE IONICS, V116, P339, DOI 10.1016/S0167-2738(98)00359-2
   MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188
   Park SD, 2000, NATURE, V404, P265
   PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671
   SCHEWARTZ K, 2006, P NAT AC US, V102, P3497
   Skorodumova NV, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.166601
   Skorodumova NV, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.115108
   Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620
   WANG DY, 1981, SOLID STATE IONICS, V2, P95, DOI 10.1016/0167-2738(81)90005-9
   Yamazaki S, 2000, SOLID STATE IONICS, V136, P913, DOI 10.1016/S0167-2738(00)00569-5
   Yoshida H, 2003, SOLID STATE IONICS, V160, P109, DOI 10.1016/S0167-2738(03)00153-X
NR 27
TC 15
Z9 15
U1 4
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-2461
EI 1573-4803
J9 J MATER SCI
JI J. Mater. Sci.
PD SEP
PY 2007
VL 42
IS 17
BP 7461
EP 7466
DI 10.1007/s10853-006-1486-5
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA 188QQ
UT WOS:000247934800059
DA 2018-12-27
ER

PT J
AU Lu, J
   Wang, XJ
   Yang, X
   Ching, CB
AF Lu, Jie
   Wang, Xiu-Juan
   Yang, Xia
   Ching, Chi-Bun
TI RETRACTED: Characterization and selective crystallization of Famotidine
   polymorphs (Retracted Article. See vol 97, pg 1629, 2008)
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article; Retracted Publication
DE famotidine; polymorph; solid state; characterization; crystallization;
   thermodynamics; solubility; nucleation; polymorphic window
ID POLYMER HETERONUCLEI; CALCIUM-CARBONATE; STABLE POLYMORPH;
   ORGANIC-CRYSTALS; OSTWALDS RULE; IN-SITU; NUCLEATION; SOLVENT; ACID;
   GROWTH
AB Famotidine crystallizes in two different polymorphic forms: the metastable polymorph B and the stable polymorph A. In this work, solid characterization for both polymorphs has been conducted in detail. The solubility, metastable zone width and interfacial energy of both polymorphs in different solvents have been measured. The influence of solvent, cooling rate, initial concentration and the temperature of nucleation on polymorphism has been investigated. Results show that the nature of polymorph that crystallizes from solution depends on the initial concentration of the solution, solvent, cooling rate, and the temperature of nucleation. Polymorph B preferentially crystallizes only at high concentrations. When acetonitrile or methanol is used as solvent, cooling rate can affect the polymorph of product only at high concentrations. While water is used as solvent, cooling rate has no effect on the polymorph of product, and nucleation temperature is found to be the predominant controlling factor. The effect of crystallization conditions on the polymorph of famotidine can be mainly attributed to the conformational polymorphism. Finally the "polymorphic window" for famotidine crystallized from aqueous solution has been described. (c) 2007 Wiley-Liss, Inc.
C1 Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637722, Singapore.
RP Lu, J (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637722, Singapore.
EM lujie@ntu.edu.sg
CR Agarwal P, 2003, CRYST GROWTH DES, V3, P941, DOI 10.1021/cg0256125
   Beach S, 1999, ORG PROCESS RES DEV, V3, P370, DOI 10.1021/op990160z
   Beckmann W, 2000, ORG PROCESS RES DEV, V4, P372, DOI 10.1021/op0000778
   Beckmann W, 2001, ORG PROCESS RES DEV, V5, P387, DOI 10.1021/op010013c
   Bernstein J, 2002, POLYMORPHISM MOL CRY
   BONAFEDE SJ, 1995, J AM CHEM SOC, V117, P7853, DOI 10.1021/ja00135a001
   Childs SL, 2004, CRYST GROWTH DES, V4, P441, DOI 10.1021/cg034243p
   Datta S, 2005, CRYST RES TECHNOL, V40, P233, DOI 10.1002/crat.200410331
   Davey RJ, 2002, CRYSTENGCOMM, V4, P257, DOI 10.1039/b203521a
   Davey RJ, 1997, J AM CHEM SOC, V119, P1767, DOI 10.1021/ja9626345
   Di Martino P, 2002, J CRYST GROWTH, V243, P345, DOI 10.1016/S0022-0248(02)01523-3
   Donnet M, 2005, LANGMUIR, V21, P100, DOI 10.1021/la048525i
   Ferenczy GG, 2000, J MOL STRUC-THEOCHEM, V503, P73, DOI 10.1016/S0166-1280(99)00364-4
   Ferrari ES, 2004, CRYST GROWTH DES, V4, P1061, DOI 10.1021/cg0342112
   GOLIC L, 1989, ACTA CRYSTALLOGR C, V45, P1381, DOI 10.1107/S0108270189001174
   Gracin S, 2004, CRYST GROWTH DES, V4, P1013, DOI 10.1021/cg049954h
   GRANT DJW, 1999, POLYMORPHISM PHARM S, P1
   Groen H, 2001, J PHYS CHEM B, V105, P10723, DOI 10.1021/jp011128l
   Gu CH, 2001, J PHARM SCI, V90, P1878, DOI 10.1002/jps.1137
   Gu CH, 2004, INT J PHARM, V283, P117, DOI 10.1016/j.ijpharm.2004.06.021
   Ha JM, 2004, J AM CHEM SOC, V126, P3382, DOI 10.1021/ja049724r
   HEGEDUS B, 1989, J PHARMACEUT BIOMED, V7, P563, DOI 10.1016/0731-7085(89)80221-3
   Henck JO, 1997, PHARM IND, V59, P165
   Hilden JL, 2003, CRYST GROWTH DES, V3, P921, DOI 10.1021/cg034061v
   Hiremath R, 2004, CHEM COMMUN, P2676, DOI 10.1039/b411649f
   Jones HP, 2005, J PHYS CHEM B, V109, P5273, DOI 10.1021/jp045000q
   KAMLET MJ, 1982, J ORG CHEM, V47, P4971, DOI 10.1021/jo00146a028
   Laird T, 2000, ORG PROCESS RES DEV, V4, P370, DOI 10.1021/op000090s
   Lang MD, 2002, J AM CHEM SOC, V124, P14834, DOI 10.1021/ja0286526
   Lu JJ, 2003, CRYST RES TECHNOL, V38, P63, DOI 10.1002/crat.200310008
   Mirmehrabi M, 2005, J PHARM SCI-US, V94, P1560, DOI 10.1002/jps.20371
   Mitchell CA, 2001, J AM CHEM SOC, V123, P10830, DOI 10.1021/ja004085f
   Morissette Sherry L., 2004, Advanced Drug Delivery Reviews, V56, P275, DOI 10.1016/j.addr.2003.10.020
   Ostwald W., 1897, Z PHYS CHEM, V22, P289, DOI DOI 10.1515/ZPCH-1897-2233
   Overgaard A, 2004, ACTA CRYSTALLOGR A, V60, P480, DOI 10.1107/S0108767304017891
   Price CP, 2005, J AM CHEM SOC, V127, P5512, DOI 10.1021/ja042561m
   SATO K, 1984, J CRYST GROWTH, V66, P441, DOI 10.1016/0022-0248(84)90228-8
   Sohnel O., 1992, PRECIPITATION
   Stoica C, 2005, CRYST GROWTH DES, V5, P975, DOI 10.1021/cg0496641
   Teychene S, 2004, CRYST GROWTH DES, V4, P971, DOI 10.1021/cg0341961
   Threlfall T, 2000, ORG PROCESS RES DEV, V4, P384, DOI 10.1021/op000058y
   Threlfall T, 2003, ORG PROCESS RES DEV, V7, P1017, DOI 10.1021/op030026l
   Tong HHY, 2002, PHARMACEUT RES, V19, P640, DOI 10.1023/A:1015358129817
   Trask AV, 2004, CHEM COMMUN, P890, DOI 10.1039/b400978a
   Vivares D, 2006, CRYST GROWTH DES, V6, P287, DOI 10.1021/cg0500223
   WEISSBUCH I, 1991, SCIENCE, V253, P637, DOI 10.1126/science.253.5020.637
   Weissbuch I, 2003, CRYST GROWTH DES, V3, P125, DOI 10.1021/cg0200560
   WIREKO FC, 1987, J PHYS CHEM-US, V91, P472, DOI 10.1021/j100286a042
   Yu L, 2000, ORG PROCESS RES DEV, V4, P396, DOI 10.1021/op000028v
   Yu L, 2002, J PHARM SCI-US, V91, P2367, DOI 10.1002/jps.10225
   Zaccaro J, 2001, CRYST GROWTH DES, V1, P5, DOI 10.1021/cg0055171
NR 51
TC 11
Z9 15
U1 3
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD SEP
PY 2007
VL 96
IS 9
BP 2457
EP 2468
DI 10.1002/jps.20868
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 206LB
UT WOS:000249183800023
PM 17518361
DA 2018-12-27
ER

PT J
AU He, HB
   Yang, XZ
   Zeng, XW
   Shi, MQ
   Yang, J
   Wu, LM
   Li, LA
AF He, Haibo
   Yang, Xianzhe
   Zeng, Xiaowei
   Shi, Mengqiong
   Yang, Jun
   Wu, Limao
   Li, Lianda
TI RETRACTED: Protective effect of Liuwei Dihuang decoction on early
   diabetic nephropathy induced by streptozotocin via modulating ET-ROS
   axis and matrix metalloproteinase activity in rats (Retracted article.
   See vol. 61, pg. 685, 2009)
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID NITRIC-OXIDE; EXTRACELLULAR-MATRIX; RECEPTOR ANTAGONIST; ENDOTHELIN-ETA;
   EARLY MARKER; MELLITUS; COMPLICATIONS; GLOMERULI; PATHWAY; SYSTEM
AB We aimed to investigate the effects of Liuwei Dihuang decoction (LW) on the endothelin-1-reactive oxidative species (ET-ROS) system and matrix metalloproteinases (MMPs) in the early diabetic nephropathy induced by streptozotocin (STZ) in rats. Rats were divided into six groups as follows: the control group, the untreated model group, the treated groups with the LW (5, 10 and 15 g kg(-1), p.o.) and the aminoguanidine-treated group (100 mg kg(-1), orally). The treatment was performed for 4 weeks, beginning on the fifth week after one intraperitoneal injection of STZ (65 mg kg(-1)). in the untreated model group, increased blood glucose, decreased plasma insulin level and an impaired renal function were observed. There was an altered redox system shown by an increased malondialdehyde and decreased activity of glutathione peroxidase and superoxide dismutase in the renal cortex. An enhanced inducible nitric oxide synthetase, total nitric oxide synthase and constitutive nitric oxide synthase and a declined nitric oxide were found. An increased extracellular matrix was indicated by an abnormality of MMP-2 and MMP-9 activities and an increase in hydroxyproline. An up-regulated ET-1 level and increased mRNA expression of endothelin-converting enzyme, preproET-1 and ETA receptor were presented in the affected renal cortex, but no change in ETB receptor mRNA. The LW was most effective in reversing these changes in diabetic rats and was as effective as aminoguanidine. The benefits of the extracts in relieving the abnormalities in early diabetic nephropathy are likely to be mediated by suppression of the renal ET-ROS system and escalating the activity of MMPs.
C1 Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herb Med, Hangzhou 310058, Zhejiang, Peoples R China.
   Dahe Clique, Ctr Med Sci Anal, Hangzhou 310053, Zhejiang, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herb Med, Hangzhou 310058, Zhejiang, Peoples R China.
EM wulimao@zju.edu.cn
CR Anh NTH, 2003, PHARMAZIE, V58, P593
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   CAMERON NE, 1992, DIABETOLOGIA, V35, P946, DOI 10.1007/BF00401423
   Chen HC, 2000, J LAB CLIN MED, V135, P309, DOI 10.1067/mlc.2000.105616
   Correa RC, 2003, J DIABETES COMPLICAT, V17, P264, DOI 10.1016/S1056-8727(02)00224-6
   Cosenzi A, 2003, J CARDIOVASC PHARM, V42, P752, DOI 10.1097/00005344-200312000-00009
   DAI M, 2002, CHINA J CHIN MAT MED, V25, P625
   Dobretsov M, 2003, BRAIN RES, V960, P174, DOI 10.1016/S0006-8993(02)03828-3
   Dong FQ, 2004, CHINESE MED J-PEKING, V117, P1040
   Han Jing-Chao, 2006, Chinese Journal of Natural Medicines, V4, P125
   He HB, 2006, ACTA PHARMACOL SIN, V27, P1213, DOI 10.1111/j.1745-7254.2006.00373.x
   Hiragushi K, 2001, DIABETES RES CLIN PR, V53, P149, DOI 10.1016/S0168-8227(01)00260-1
   Hu Hong-Yu, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1793
   Kobayashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1197
   Kohan DE, 2000, J LAB CLIN MED, V135, P300, DOI 10.1067/mlc.2000.105972
   Kotajima N, 2000, J DIABETES COMPLICAT, V14, P13, DOI 10.1016/S1056-8727(00)00064-7
   Koya D, 2003, J AM SOC NEPHROL, V14, pS250, DOI 10.1097/01.ASN.0000077412.07578.44
   Lehmann R, 2000, CLIN CHIM ACTA, V297, P135, DOI 10.1016/S0009-8981(00)00240-0
   Llorens S, 2004, EUR J PHARMACOL, V486, P43, DOI 10.1016/j.ejphar.2003.12.003
   McLennan SV, 2002, DIABETOLOGIA, V45, P268, DOI 10.1007/s00125-001-0730-4
   Midwood KS, 2004, INT J BIOCHEM CELL B, V36, P1031, DOI 10.1016/j.biocel.2003.12.003
   Minchenko AG, 2003, FASEB J, V17, P1514, DOI 10.1096/fj.03-0013fje
   Nishikawa T, 2000, NATURE, V404, P787
   Pollock David M., 2005, Current Vascular Pharmacology, V3, P365, DOI 10.2174/157016105774329408
   Rabkin Ralph, 2003, Clin Cornerstone, V5, P1, DOI 10.1016/S1098-3597(03)90014-7
   SCHENA FP, 2005, J AM SOC NEPHROL S1, V18, P16
   Shah SV, 2007, J AM SOC NEPHROL, V18, P16, DOI 10.1681/ASN.2006050500
   Sottile J, 2004, BBA-REV CANCER, V1654, P13, DOI 10.1016/j.bbcan.2003.07.002
   Sugimoto K, 2002, EUR J PHARMACOL, V450, P183, DOI 10.1016/S0014-2999(02)02006-X
   VESTRA MD, 2003, EXCERPTA MED, V1253, P163
   Vural P, 2002, CLIN CHIM ACTA, V320, P43, DOI 10.1016/S0009-8981(02)00024-4
   Wang XiJun, 2004, Chinese Journal of Natural Medicines, V2, P219
   Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x
   [吴晓慧 Wu Xiaohui], 2005, [南京师大学报. 自然科学版, Journal of Nanjing Normal University. Natural Science], V28, P83
   XIANG SL, 2003, CHINA J CHIN MAT MED, V8, P735
   XIE YM, 2005, MOD J INTEGR TRAD CH, V14, P1525
   Xu FP, 2004, CIRCULATION, V110, P1269, DOI 10.1161/01.CIR.0000140766.52771.6D
   YAMANE T, 2004, INT C SER, V1262, P407
   Yokozawa T, 2004, AM J CHINESE MED, V32, P829, DOI 10.1142/S0192415X04002442
   ZHANG JG, 2006, J HAIHAI MED, V24, P294
   Zhang JW, 1997, J NEUROSCI METH, V76, P15, DOI 10.1016/S0165-0270(97)00065-4
NR 41
TC 19
Z9 22
U1 5
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD SEP
PY 2007
VL 59
IS 9
BP 1297
EP 1305
DI 10.1211/jpp.59.9.0015
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 217TQ
UT WOS:000249970600015
PM 17883901
DA 2018-12-27
ER

PT J
AU Mori, T
   Kokubo, H
   Shimizu, H
   Iwamoto, M
   Oiki, S
   Okamoto, Y
AF Mori, Takaharu
   Kokubo, Hironori
   Shimizu, Hirofumi
   Iwamoto, Masayuki
   Oiki, Shigetoshi
   Okamoto, Yuko
TI RETRACTED: Normal mode analysis of polytheonamide B (Retracted article.
   See vol 78, artn 068001, 2009)
SO JOURNAL OF THE PHYSICAL SOCIETY OF JAPAN
LA English
DT Article; Retracted Publication
DE polytheonamides; gramicidin A; ion channel; normal mode analysis;
   elastic rod; peptide libration
ID MOLECULAR-DYNAMICS SIMULATIONS; HIGHLY CYTOTOXIC POLYPEPTIDES; SPONGE
   THEONELLA-SWINHOEI; MARINE SPONGE; GRAMICIDIN CHANNELS; BROWNIAN
   DYNAMICS; TRYPSIN-INHIBITOR; WATER CHANNEL; MONTE-CARLO; SELECTIVITY
AB Polytheonamide B is a linear 48-residue peptide which forms a single beta-helix structure with alternating D- and L-amino acids and contains methylated and hydroxy variants of protemogenic amino acids. To investigate the dynamical properties of polytheonamide B we perform the normal mode analysis. Root-mean-square displacements of all backbone atoms, root-mean-square fluctuations of the backbone dihedral angles (phi, psi), and correlation factors for the C-alpha atom fluctuations and for the dihedral angle fluctuations are calculated. The normal mode analysis reveals that polytheonamide B shows the elastic rod behavior in the very low-frequency regions and that librational motions of backbone amide planes have the modes with relatively low frequencies, which is relevant to the function of polytheonamide B. In addition, these librational motions occur almost independently and weakly anticorrelate with those of the hydrogen-bonded neighboring amide planes. Calculations of the backbone fluctuations show that the flexibility of polytheonamide B is roughly uniform over the entire helix. We compare our results with those of gramicidin A, the analogue of polytheonamide B, to discuss the structures and functions, and obtain some common features in the flexibilities and dynamics of the backbone atoms. These results present important clues for clarifying the function of polytheonamide B at the atomic level.
C1 Nagoya Univ, Sch Sci, Dept Phys, Chikusa Ku, Nagoya, Aichi 4648602, Japan.
   Univ Houston, Dept Chem, Houston, TX 77204 USA.
   Univ Fukui, Fac Med Sci, Dept Mol Physiol & Biophys, Fukui 9101193, Japan.
RP Mori, T (reprint author), Nagoya Univ, Sch Sci, Dept Phys, Chikusa Ku, Nagoya, Aichi 4648602, Japan.
EM tmori@tb.phys.nagoya-u.ac.jp; kokubo@kitten.chem.uh.edu;
   oiki-fki@umin.ac.jp; okamoto@phys.nagoya-u.ac.jp
RI OKAMOTO, Yuko/I-7531-2014
OI OKAMOTO, Yuko/0000-0002-7083-2326
CR ANDERSEN OS, 1984, ANNU REV PHYSIOL, V46, P531
   Boda D, 2000, J PHYS CHEM B, V104, P8903, DOI 10.1021/jp0019658
   BROOKMAN RR, 1983, J ADOLESCENT HEALTH, V4, P187, DOI 10.1002/jcc.540040211
   BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571
   BROOKS BR, 1995, J COMPUT CHEM, V16, P1522, DOI 10.1002/jcc.540161209
   Cheng XL, 2006, J MOL BIOL, V355, P310, DOI 10.1016/j.jmb.2005.10.039
   Chung SH, 2002, BIOPHYS J, V82, P628, DOI 10.1016/S0006-3495(02)75427-1
   de Groot BL, 2003, J MOL BIOL, V333, P279, DOI 10.1016/j.jmb.2003.08.003
   Dorman V, 1996, BIOPHYS J, V70, P121, DOI 10.1016/S0006-3495(96)79554-1
   GO N, 1983, P NATL ACAD SCI-BIOL, V80, P3696, DOI 10.1073/pnas.80.12.3696
   HAMADA T, 1994, TETRAHEDRON LETT, V35, P719, DOI 10.1016/S0040-4039(00)75799-6
   Hamada T, 2005, J AM CHEM SOC, V127, P110, DOI 10.1021/ja045749e
   HAMADA T, 1994, TETRAHEDRON LETT, V35, P609, DOI 10.1016/S0040-4039(00)75851-5
   HAMADA T, UNPUB
   Im W, 2002, J MOL BIOL, V322, P851, DOI 10.1016/S0022-2836(02)00778-7
   Koeppe R E 2nd, 1999, Novartis Found Symp, V225, P44
   LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X
   LEVY RM, 1979, BIOPOLYMERS, V18, P2465, DOI 10.1002/bip.1979.360181008
   MacKerell AD, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P7
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Matsumoto A, 1999, J CHEM PHYS, V110, P11070, DOI 10.1063/1.479043
   Miloshevsky GV, 2006, STRUCTURE, V14, P1241, DOI 10.1016/j.str.2006.006.007
   MONOI H, 1993, BIOPHYS J, V64, P36, DOI 10.1016/S0006-3495(93)81338-9
   NAIK VM, 1986, BIOPHYS J, V49, P1131, DOI 10.1016/S0006-3495(86)83742-0
   NAIK VM, 1992, VIB SPECTROSC, V3, P105, DOI 10.1016/0924-2031(92)80003-K
   NAIK VM, 1993, INT J PEPT PROT RES, V42, P125
   ROUX B, 1994, ANNU REV BIOPH BIOM, V23, P731, DOI 10.1146/annurev.bb.23.060194.003503
   ROUX B, 1988, BIOPHYS J, V53, P297, DOI 10.1016/S0006-3495(88)83107-2
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   STANKOVIC CJ, 1989, SCIENCE, V244, P813, DOI 10.1126/science.2471263
   Strader ML, 2002, J PHYS CHEM A, V106, P1074, DOI 10.1021/jp013658n
   SUEZAKI Y, 1976, BIOPOLYMERS, V15, P2137, DOI 10.1002/bip.1976.360151104
   Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778
   Tama F, 2001, PROTEIN ENG, V14, P1, DOI 10.1093/protein/14.1.1
   URRY DW, 1981, INT J QUANTUM CHEM, P385
   Valadie H, 2003, J MOL BIOL, V332, P657, DOI 10.1016/S0022-2836(03)00851-9
   Varma S, 2006, BIOPHYS J, V90, P112, DOI 10.1529/biophysj.105.059329
   VENKATACHALAM CM, 1984, J COMPUT CHEM, V5, P64, DOI 10.1002/jcc.540050109
   Wallace BA, 1998, J STRUCT BIOL, V121, P123, DOI 10.1006/jsbi.1997.3948
   Yu CH, 2003, BIOPHYS J, V84, P816, DOI 10.1016/S0006-3495(03)74901-7
NR 40
TC 2
Z9 2
U1 4
U2 14
PU PHYSICAL SOC JAPAN
PI TOKYO
PA YUSHIMA URBAN BUILDING 5F, 2-31-22 YUSHIMA, BUNKYO-KU, TOKYO, 113-0034,
   JAPAN
SN 0031-9015
J9 J PHYS SOC JPN
JI J. Phys. Soc. Jpn.
PD SEP
PY 2007
VL 76
IS 9
AR 094801
DI 10.1143/JPSJ.76.094801
PG 10
WC Physics, Multidisciplinary
SC Physics
GA 214GF
UT WOS:000249723300033
DA 2018-12-27
ER

PT J
AU Junquera, C
   Colas, C
   Martinez-Ciriano, C
   Serrano, P
   Castiella, T
   Cebrian-Perez, JA
   Muino-Blanc, T
AF Junquera, Concepcion
   Colas, Carmen
   Martinez-Ciriano, Carmen
   Serrano, Pedro
   Castiella, Tomas
   Cebrian-Perez, Jose Alvaro
   Muino-Blanc, Teresa
TI RETRACTED: A new method for the treatment of sperm samples for
   ultrastructural study based on the use of animal tissues as biological
   containers (Retracted article. See vol. 74, pg. 1209, 2011)
SO MICROSCOPY RESEARCH AND TECHNIQUE
LA English
DT Article; Retracted Publication
DE TEM; spermatozoa; semen samples preparation
ID RAM SPERMATOZOA; ELECTRON-MICROSCOPY; COLD-SHOCK; BULL SPERMATOZOA;
   SEMINAL PLASMA; MEMBRANE; SUSPENSIONS; DAMAGE
AB The study of the ultrastructure of spematozoa by means of transmission electron microscopy often presents with problems of interpretation according to the method employed, depending on whether samples are either centrifuged previously to the fixation or immersed in viscous gels. The major problems of interpretation are: changes in the location of vesicles originated during the maturation process and modifications in the adsorption of seminal plasma proteins to the sperm membrane surface. The aim of our study is to communicate an original new method for the treatment of spermatozoa for ultrastructural study. Our method is based on the use of animal tissues as biological containers, inside which the spermatic suspensions are included. We developed this method using fresh sperm samples taken from mature Rasa aragonesa rams. As biological container, we used 2.5-cm long segments of the intestine of 1-week-old chickens (Gallus gallus) (diameter around 4 mm). To avoid any influence of digestive enzymes of the mucosa on the sperm surface, we put each intestine fragment inside out by means of microdissection forceps under bifocal optical microscope and cold light. One of the edges was tied with thin suture silk. The sperm suspension was injected in the optimal experimental condition and amount. Finally, the still open edge of the intestine segment was tied with silk in the same way as the other segment edge. By using this technique, we can perform a suitable morphological study at an ultrastructural level. In addition, the functional relationship of the ultrastructural components of the target cells is correctly preserved.
C1 Univ Zaragoza, Fac Med, Dept Anat & Histol Humanas, E-50009 Zaragoza, Spain.
   Univ Zaragoza, Fac Vet, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.
   Hosp Clin Univ Lozano Blesa, Zaragoza, Spain.
RP Junquera, C (reprint author), Univ Zaragoza, Fac Med, Dept Anat & Histol Humanas, Domingo Miral SN, E-50009 Zaragoza, Spain.
EM cjunquer@unizar.es
OI /0000-0001-9842-6197
CR AARONSON RP, 1982, J MICROSC-OXFORD, V128, P271, DOI 10.1111/j.1365-2818.1982.tb04629.x
   Barrios B, 2000, BIOL REPROD, V63, P1531, DOI 10.1095/biolreprod63.5.1531
   Blanc-Layrac G, 2000, CELL MOL BIOL, V46, P187
   Francavilla S, 2006, FERTIL STERIL, V85, P940, DOI 10.1016/j.fertnstert.2005.10.027
   GarciaLopez N, 1996, THERIOGENOLOGY, V46, P141, DOI 10.1016/0093-691X(96)00149-5
   Gatti JL, 2005, BIOL REPROD, V72, P1452, DOI 10.1095/biolreprod.104.036426
   HARRISON RAP, 1990, J REPROD FERTIL, V88, P343
   KROGENAES A, 1994, ACTA VET SCAND, V35, P17
   MAUNSBACH AB, 1999, BIOMEDICAL ELECT MIC, P104
   NOGUES C, 1994, J MICROSC-OXFORD, V174, P51, DOI 10.1111/j.1365-2818.1994.tb04324.x
   Ollero M, 1996, INT J ANDROL, V19, P287, DOI 10.1111/j.1365-2605.1996.tb00477.x
   Perez-Pe R, 2001, THERIOGENOLOGY, V56, P425, DOI 10.1016/S0093-691X(01)00574-X
   PFALLER W, 1976, J REPROD FERTIL, V48, P285
   PIHAKASKIMAUNSBACH K, 1990, J ELECTRON MICR TECH, V15, P414, DOI 10.1002/jemt.1060150412
   QUINN PJ, 1969, J REPROD FERTIL, V18, P209
   ROZINEK J, 1977, VET MED-CZECH, V22, P343
   SANTANDER RG, 1970, TECNICAS MICROSCOPIA, P85
   Sullivan R, 2005, BLOOD CELL MOL DIS, V35, P1, DOI 10.1016/j.bcmd.2005.03.005
   WATANABE S, 1988, J ELECTRON MICROSC, V37, P89
NR 19
TC 1
Z9 1
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-910X
EI 1097-0029
J9 MICROSC RES TECHNIQ
JI Microsc. Res. Tech.
PD SEP
PY 2007
VL 70
IS 9
BP 771
EP 775
DI 10.1002/jemt.20466
PG 5
WC Anatomy & Morphology; Biology; Microscopy
SC Anatomy & Morphology; Life Sciences & Biomedicine - Other Topics;
   Microscopy
GA 211UD
UT WOS:000249547900002
PM 17576121
DA 2018-12-27
ER

PT J
AU Gao, XA
   Li, JG
   Wan, BN
   Zhao, JY
   Hu, LQ
   Liu, HQ
   Jie, YX
   Xu, QA
   Wu, ZW
   Yang, Y
   Gong, XZ
   Shen, BA
   Hu, JS
   Shi, YJ
   Ling, BL
   Wang, J
   Sajjad, S
   Zang, Q
   Gao, W
   Zhang, T
   Yu, YW
   Yang, Y
   Han, XF
   Shi, N
   Ming, TF
   Ti, A
   Zhang, WY
   Xu, GS
   Chen, JL
   Luo, GN
   Zhang, XD
   Mao, JS
   Wan, YX
AF Gao, Xiang
   Li, Jiangang
   Wan, Baonian
   Zhao, Junyu
   Hu, Liqun
   Liu, Haiqing
   Jie, Yinxian
   Xu, Qiang
   Wu, Zhenwei
   Yang, Yu
   Gong, Xianzu
   Shen, Biao
   Hu, Jiansheng
   Shi, Yuejiang
   Ling, Bili
   Wang, Jun
   Sajjad, S.
   Zang, Qing
   Gao, Wei
   Zhang, Tao
   Yu, Yaowei
   Yang, Yao
   Han, Xiaofeng
   Shi, Nan
   Ming, Tingfeng
   Ti, Ang
   Zhang, Wenyang
   Xu, Guosheng
   Chen, Junling
   Luo, Guangnan
   Zhang, Xiaodong
   Mao, Jianshan
   Wan, Yuanxi
CA EAST Team
TI RETRACTED: Extension of operational limits on EAST (Retracted article.
   See vol. 50, pg. NIL_0217, 2010)
SO NUCLEAR FUSION
LA English
DT Article; Retracted Publication
ID HIGH-DENSITY OPERATION; SUPERCONDUCTING TOKAMAK; H-MODE; PERFORMANCE;
   HT-7; DISCHARGES; PHYSICS; SYSTEM
AB The first plasma has been achieved successfully in the Experimental Advanced Superconducting Tokamak (EAST). Boronization by the glow discharge (GDC) method was studied in experiments. The plasma performance was obviously improved by GDC boronization. Extension of the operational region and improvement in the plasma performance were obtained. Sawtooth discharges were observed by means of soft x-ray signals, electron cyclotron emission signals and line averaged electron density after boronization. Lower q(a) and more stable operation were also achieved following GDC boronization. The plasma current ramp-up rate was also improved as a result of decreased impurity content and low averaged loop voltage due to boronization.
C1 Chinese Acad Sci, Inst Plasma Phys, Hefei 230031, Anhui, Peoples R China.
RP Gao, XA (reprint author), Chinese Acad Sci, Inst Plasma Phys, POB 1126, Hefei 230031, Anhui, Peoples R China.
EM xgao@ipp.ac.cn
RI Xu, Guosheng/B-4857-2013
CR Asif M, 2005, PHYS PLASMAS, V12, DOI 10.1063/1.1995627
   Frigione D, 1996, NUCL FUSION, V36, P1489, DOI 10.1088/0029-5515/36/11/I04
   Fu P, 2006, NUCL FUSION, V46, pS85, DOI 10.1088/0029-5515/46/3/S11
   Gao X, 2000, NUCL FUSION, V40, P1875, DOI 10.1088/0029-5515/40/11/307
   Goldston RJ, 1996, PLASMA PHYS CONTR F, V38, P1161, DOI 10.1088/0741-3335/38/8/008
   GREENWALD M, 1988, NUCL FUSION, V28, P2199, DOI 10.1088/0029-5515/28/12/009
   Greenwald M, 2002, PLASMA PHYS CONTR F, V44, pR27, DOI 10.1088/0741-3335/44/8/201
   Kadomtsev B., 1976, SOV J PLASMA PHYS, V1, P389
   KAMADA Y, 1991, NUCL FUSION, V31, P1827, DOI 10.1088/0029-5515/31/10/002
   Kaye SM, 2001, PHYS PLASMAS, V8, P1977, DOI 10.1063/1.1343089
   LaBombard B, 2001, PHYS PLASMAS, V8, P2107, DOI 10.1063/1.1352596
   Li JG, 1999, NUCL FUSION, V39, P973, DOI 10.1088/0029-5515/39/8/302
   Li JG, 2001, NUCL FUSION, V41, P1625, DOI 10.1088/0029-5515/41/11/312
   Liu XN, 2006, NUCL FUSION, V46, pS90, DOI 10.1088/0029-5515/46/3/S12
   MURAKAMI M, 1976, NUCL FUSION, V16, P347, DOI 10.1088/0029-5515/16/2/020
   Osborne TH, 2001, PHYS PLASMAS, V8, P2017, DOI 10.1063/1.1345504
   SAMM U, 1995, J NUCL MATER, V220, P25, DOI 10.1016/0022-3115(94)00444-7
   STABLER A, 1992, NUCL FUSION, V32, P1557, DOI 10.1088/0029-5515/32/9/I05
   THOMAS PR, 1990, J NUCL MATER, V176, P3
   Wan BN, 2007, PLASMA SCI TECHNOL, V9, P125, DOI 10.1088/1009-0630/9/2/01
   Wan YX, 2006, PLASMA SCI TECHNOL, V8, P253, DOI 10.1088/1009-0630/8/3/01
   Wan YX, 2000, NUCL FUSION, V40, P1057, DOI 10.1088/0029-5515/40/6/304
   Weng PD, 2005, FUSION ENG DES, V75-79, P143, DOI 10.1016/j.fusengdes.2005.06.263
   Winter J, 1996, PLASMA PHYS CONTR F, V38, P1503, DOI 10.1088/0741-3335/38/9/001
   WINTER J, 1987, J NUCL MATER, V145, P131, DOI 10.1016/0022-3115(87)90318-7
NR 25
TC 22
Z9 25
U1 4
U2 38
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0029-5515
EI 1741-4326
J9 NUCL FUSION
JI Nucl. Fusion
PD SEP
PY 2007
VL 47
IS 9
BP 1353
EP 1357
DI 10.1088/0029-5515/47/9/037
PG 5
WC Physics, Fluids & Plasmas
SC Physics
GA 217SY
UT WOS:000249968800040
DA 2018-12-27
ER

PT J
AU Mullie, P
   Clarys, P
   Deriemaeker, P
   Hebbelinck, M
AF Mullie, P.
   Clarys, P.
   Deriemaeker, P.
   Hebbelinck, M.
TI RETRACTED: Estimation of daily human intake of food flavonoids
   (Retracted article. See vol. 65, pg. 1039, 2014)
SO PLANT FOODS FOR HUMAN NUTRITION
LA English
DT Article; Retracted Publication
DE epidemiology; flavonoid; food frequency questionnaire; food records;
   human intake
ID DIETARY; METABOLISM; CHEMISTRY; RISK
AB The daily intake of food flavonoids was determined using a semiquantitative food frequency questionnaire (FFQ) and a four day non consecutive food diary (4DFR) in a group of 45 female Flemish dietitians. The subjects were asked to report their food intake three times: day 1 using the FFQ (FFQ1); between day 2 and 13 using a four day non consecutive food diary (4DFR); and again the FFQ on day 14 (FFQ2). The total flavonoid intake in mg/day as estimated with the different methods were respectively (mean and SD) for FFQ1 166.0+/-146.6 mg/day; for 4DFR 203.0+/-243.2 mg/day; and for FFQ2 158.3+/-151.8 mg/day. There was a significant different estimate for the amount of flavan-3-ols, flavanones and flavones when comparing the two FFQs with the 4DFR. The two research methods classified 88% of the 45 dietitians in the same or in an adjacent quartile for total flavonoid intake. The findings of this study indicate that the developed FFQ seems to be a simple and reliable method to assign subjects in quartiles of flavonoid intake.
C1 Vrije Univ Brussel VIB, Dept Human Biometry & Biomech, Fac Phys Educ & Physiotherapy, B-1050 Brussels, Belgium.
RP Mullie, P (reprint author), Vrije Univ Brussel VIB, Dept Human Biometry & Biomech, Fac Phys Educ & Physiotherapy, Pleinplaan 2, B-1050 Brussels, Belgium.
EM patrick.mullie@skynet.be
CR Aherne SA, 2002, NUTRITION, V18, P75, DOI 10.1016/S0899-9007(01)00695-5
   Beecher GR, 2003, J NUTR, V133, p3248S
   BEECHER GR, 1999, FLAVONOIDS FOODS ANT
   BLAND JM, 1986, LANCET, V1, P307
   Bravo L, 1998, NUTR REV, V56, P317
   HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267
   HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U
   Knekt P, 2002, AM J CLIN NUTR, V76, P560
   Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478
   Kuhnau J, 1976, World Rev Nutr Diet, V24, P117
   *US DEP AGR, DAT FLAV CONT SEL FO
   Willett WC, 1998, NUTR EPIDEMIOLOGY
NR 12
TC 27
Z9 28
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0921-9668
EI 1573-9104
J9 PLANT FOOD HUM NUTR
JI Plant Food Hum. Nutr.
PD SEP
PY 2007
VL 62
IS 3
BP 93
EP 98
DI 10.1007/s11130-007-0047-7
PG 6
WC Plant Sciences; Chemistry, Applied; Food Science & Technology; Nutrition
   & Dietetics
SC Plant Sciences; Chemistry; Food Science & Technology; Nutrition &
   Dietetics
GA 210ML
UT WOS:000249460200002
PM 17597415
DA 2018-12-27
ER

PT J
AU Kim, KS
   Choi, WH
   Choi, BR
   Oh, S
   Yea, SS
   Yoon, MY
   Kim, DE
AF Kim, Ki-Sun
   Choi, Woo-Hyung
   Choi, Bo-Ra
   Oh, Sangtaek
   Yea, Sung Su
   Yoon, Moon-Young
   Kim, Dong-Eun
TI RETRACTED: Replication of an RNA ligase ribozyme under alternating
   temperature condition (Retracted Article. See vol 581, pg 5733, 2007)
SO FEBS LETTERS
LA English
DT Article; Retracted Publication
DE alternating temperature condition; cross-catalysis; RNA ligase ribozyme;
   self-replication
ID HYDROTHERMAL ECOSYSTEMS; SELF-REPLICATION; PRIMER EXTENSION; TEMPLATE;
   SYSTEMS; PEPTIDE
AB Self-replication process of the RNA ligase ribozyme molecules was investigated by using the modified RNA ligase ribozyme under alternating temperature condition that enhances turnover rate of the RNA ligation reaction. In our experiment, the RNA ligase ribozyme system mainly undergoes a cross-catalytic replication process, in which two ribozymes catalyze each other's synthesis from a total of four RNA substrates under alternating temperature condition, resulting in time-dependent accumulation of additional copies of the starting ribozymes in a reaction mixture. The present study demonstrates that crosscatalytic replication in nucleic acids system can be efficiently devised under the alternating temperature condition. (c) 2007 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
C1 Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea.
   Dong Eui Univ, Dept Biomat Control, Pusan 614714, South Korea.
   Inje Univ Coll Med, Dept Biochem, Pusan 633165, South Korea.
   Hanyang Univ, Dept Chem, Seoul 133791, South Korea.
RP Kim, DE (reprint author), Konkuk Univ, Dept Biosci & Biotechnol, 1 Hwayang Dong, Seoul 143701, South Korea.
EM kimde@konkuk.ac.kr
CR BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155
   DOUDNA JA, 1993, BIOCHEMISTRY-US, V32, P2111, DOI 10.1021/bi00059a032
   DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185
   GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913
   Henley RW, 1996, CIBA F SYMP, V202, P61
   Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786
   JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398
   Joyce GF, 2004, ANNU REV BIOCHEM, V73, P791, DOI 10.1146/annurev.biochem.73.011303.073717
   Kim DE, 2004, CHEM BIOL, V11, P1505, DOI 10.1016/j.chembiol.2004.08.021
   Lee DH, 1997, NATURE, V390, P591
   MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671
   Paul N, 2002, P NATL ACAD SCI USA, V99, P12733, DOI 10.1073/pnas.202471099
   REBEK J, 1991, EXPERIENTIA, V47, P1096, DOI 10.1007/BF01918373
   Reysenbach AL, 2002, SCIENCE, V296, P1077, DOI 10.1126/science.1072483
   Rogers J, 2001, RNA, V7, P395, DOI 10.1017/S135583820100228X
   SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0
   TERFORT A, 1992, ANGEW CHEM INT EDIT, V31, P654, DOI 10.1002/anie.199206541
   TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057
   Yao S, 1997, J AM CHEM SOC, V119, P10559, DOI 10.1021/ja9710619
   ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0
NR 20
TC 1
Z9 1
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD AUG 21
PY 2007
VL 581
IS 21
BP 4065
EP 4072
DI 10.1016/j.febslet.2007.07.048
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 204XS
UT WOS:000249077900028
PM 17674971
OA Bronze
DA 2018-12-27
ER

PT J
AU Guo, JJ
   Zhu, TB
   Xiao, ZXJ
   Chen, CY
AF Guo, Jinjin
   Zhu, Tongbo
   Xiao, Zhi-Xiong J.
   Chen, Chang-Yan
TI RETRACTED: Modulation of intracellular signaling pathways to induce
   apoptosis in prostate cancer cells (Retracted Article. See vol 282, pg
   36132, 2007)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ENDOPLASMIC-RETICULUM STRESS; PHOSPHOINOSITIDE 3-OH KINASE; UNFOLDED
   PROTEIN RESPONSE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR;
   DEPENDENT PHOSPHORYLATION; ENDOTHELIAL-CELLS; SUPPRESSOR GENE;
   RAL-GTPASES; C-MYC
AB An understanding of the molecular pathways defining the susceptibility of prostate cancer, especially refractory prostate cancer, to apoptosis is the key for developing a cure for this disease. We previously demonstrated that up-regulating Ras signaling, together with suppression of protein kinase C (PKC), induces apoptosis. Dysregulation of various intracellular signaling pathways, including those governed by Ras, is the important element in the development of prostate cancer. In this study, we tested whether it is possible to modulate the activities of these pathways and induce an apoptotic crash among them in prostate cancer cells. Our data showed that DU145 cells express a high amount of JNK1 that is phosphorylated after endogenous PKC is suppressed, which initiates caspase 8 cleavage and cytochrome c release, leading to apoptosis. PC3 and LNCaP cells contain an activated Akt. The inhibition of PKC further augments Akt activity, which in turn induces ROS production and the accumulation of unfolded proteins in the endoplasmic reticulum, resulting in cell death. However, the concurrent activation of JNK1 and Akt, under the condition of PKC abrogation, dramatically augment the magnitude of apoptosis in the cells. Thus, our study suggests that Akt, JNK1, and PKC act in concert to signal the intracellular apoptotic machinery for a full execution of apoptosis in prostate cancer cells.
C1 Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
   Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.
RP Chen, CY (reprint author), 21-27 Burlington Ave,Rm 553C, Boston, MA USA.
EM cchen6@bidmc.harvard.edu
FU NCI NIH HHS [R01CA100498]
CR Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128
   Anastasiadis Aristotelis G, 2002, Curr Urol Rep, V3, P222, DOI 10.1007/s11934-002-0068-6
   Anderson KM, 1999, LEUKEMIA RES, V23, P665, DOI 10.1016/S0145-2126(99)00081-8
   Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466
   BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023
   Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487
   Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004
   Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x
   BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0
   BOS JL, 1989, CANCER RES, V49, P4682
   CANTOR SB, 1995, MOL CELL BIOL, V15, P4578
   Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965
   CHEN CY, 1995, ONCOGENE, V11, P1487
   Chen CY, 2001, CELL GROWTH DIFFER, V12, P297
   De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560
   Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471
   Di Cristofano A, 1998, NAT GENET, V19, P348
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0
   Dragovich T, 1998, ONCOGENE, V17, P3207
   Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0
   Federovitch CM, 2005, CURR OPIN CELL BIOL, V17, P409, DOI 10.1016/j.ceb.2005.06.010
   Franzoso G, 2003, CELL DEATH DIFFER, V10, P13, DOI 10.1038/sj.cdd.4401154
   Guo JJ, 2005, J BIOL CHEM, V280, P30422, DOI 10.1074/jbc.M504688200
   Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5
   Izuhara K, 1996, BLOOD, V88, P3910
   Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897
   Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810
   Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690
   KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799
   Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886
   Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817
   Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783
   KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9
   Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236
   Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200
   Lu B, 2006, J IMMUNOL, V176, P6785, DOI 10.4049/jimmunol.176.11.6785
   Ma PH, 2002, MOL CELL BIOL, V22, P2928, DOI 10.1128/MCB.22.9.2928-2938.2002
   Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4
   Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165
   NOBES CD, 1995, J CELL SCI, V108, P225
   Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727
   RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3
   RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0
   RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x
   Ron D, 2006, SCIENCE, V313, P52, DOI 10.1126/science.1130469
   RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439
   Rosner D, 2006, AM J PATHOL, V168, P2054, DOI 10.2353/ajpath.2006.050473
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Schwieger A, 2001, CARCINOGENESIS, V22, P1385, DOI 10.1093/carcin/22.9.1385
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200
   Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5
   Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002
   Woodgett JR, 1996, CANCER SURV, V27, P127
   Yamamoto K, 1999, MOL CELL BIOL, V19, P8469
   Zhang KZ, 2003, NAT CELL BIOL, V5, P769, DOI 10.1038/ncb0903-769
NR 65
TC 8
Z9 11
U1 3
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 17
PY 2007
VL 282
IS 33
BP 24364
EP 24372
DI 10.1074/jbc.M702938200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 199HK
UT WOS:000248686600062
PM 17573344
OA Bronze
DA 2018-12-27
ER

PT J
AU Kiran, K
   Kumar, KS
   Suvardhan, K
   Janardhanam, K
   Chiranjeevi, P
AF Kiran, K.
   Kumar, K. Suresh
   Suvardhan, K.
   Janardhanam, K.
   Chiranjeevi, P.
TI RETRACTED: Preconcentration and solid phase extraction method for the
   determination of Co, Cu, Ni, Zn and Cd in environmental and biological
   samples using activated carbon by FAAS (Retracted article. See vol. 156,
   pg. 624, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE 2-{[1-(2-Hydroxynaphthyl) methylidene] amino} benzoic acid (HNMABA);
   solid phase extraction; activated carbon; environmental and biological
   samples; flame atomic absorption spectrometry
ID ATOMIC-ABSORPTION-SPECTROMETRY; HEAVY-METAL IONS; NATURAL-WATER SAMPLES;
   EMISSION-SPECTROMETRY; TRACE AMOUNTS; SOLVENT-EXTRACTION;
   AQUEOUS-SOLUTION; WASTE-WATER; COLUMN; COPPER
AB 2-{ [1-(2-Hydroxynaphthyl) methylidene] amino} benzoic acid (HNMABA) was synthesized for solid phase extraction (SPE) to the determination of Co, Cu, Ni, Zn and Cd in environmental and biological samples by flame atomic absorption spectrophotometry (FAAS). These metals were sorbed as HNMABA complexes on activated carbon (AC) at the pH range of 5.0 +/- 0.2 and eluted with 6 ml of I M HNO3 in acetone. The effects of sample volume, eluent volume and recovery have been investigated to enhance the sensitivity and selectivity of proposed method. The effect of interferences on the sorption of metal ions was studied. The concentration of the metal ions detected after preconcentration was in agreement with the added amount. The detection limits for the metals studied were in the range of 0.75-3.82 mu g ml(-1). The proposed system produced satisfactory results for the determination of Co, Cu, Ni, Zn and Cd metals in environmental and biological samples. (c) 2007 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Environm Sci, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Chem, Tirupati 517502, Andhra Pradesh, India.
RP Janardhanam, K (reprint author), Sri Venkateswara Univ, Dept Environm Sci, Tirupati 517502, Andhra Pradesh, India.
EM kandukurijanardhanam@gmail.com
CR BAG H, 1999, J ANAL CHEM+, V363, P224
   Balcerzak M, 2002, ANAL SCI, V18, P737, DOI 10.2116/analsci.18.737
   Carasek E, 2000, TALANTA, V51, P173, DOI 10.1016/S0039-9140(99)00274-X
   Cerutti S, 2003, SPECTROCHIM ACTA B, V58, P2015, DOI 10.1016/S0584-8547(03)00179-4
   Dabek L, 2003, J HAZARD MATER, V101, P191, DOI 10.1016/S0304-3894(03)00177-8
   Daorattanachai P, 2005, TALANTA, V67, P59, DOI 10.1016/j.talanta.2005.02.006
   DASILVA JBB, 2001, ANAL BIOANAL CHEM, V369, P657
   Elci L, 1998, TALANTA, V46, P1305, DOI 10.1016/S0039-9140(97)00412-8
   Fritz J. S., 1999, ANAL SOLID PHASE EXT
   Ghiasvand AR, 2005, ASIAN J CHEM, V17, P2143
   Guo Y, 2004, TALANTA, V62, P209, DOI 10.1016/S0039-9140(03)00423-5
   Hanzlik J, 2004, WATER RES, V38, P2178, DOI 10.1016/j.watres.2004.01.037
   Hiraide M, 1999, ANAL SCI, V15, P1055, DOI 10.2116/analsci.15.1055
   Kagaya S, 2000, FRESEN J ANAL CHEM, V366, P842, DOI 10.1007/s002160051582
   Kenawy IMM, 2000, ANAL SCI, V16, P493, DOI 10.2116/analsci.16.493
   Kovacheva P, 2002, ANAL CHIM ACTA, V464, P7, DOI 10.1016/S0003-2670(02)00428-2
   KUBOVA J, 1994, J ANAL ATOM SPECTROM, V9, P241, DOI 10.1039/ja9940900241
   Narin I, 2000, TALANTA, V52, P1041, DOI 10.1016/S0039-9140(00)00468-9
   Pesavento M, 2003, ANAL CHIM ACTA, V480, P171, DOI 10.1016/S0003-2670(02)01597-0
   SANDELL EB, 1959, COLORIMETRIC DETERMI, P409
   SANDELL EB, 1959, COLORIMETRIC DETERMI
   SANTELLI RE, 1989, ANAL CHEM, V61, P1427, DOI 10.1021/ac00188a025
   Shukla R, 2002, TALANTA, V57, P633, DOI 10.1016/S0039-9140(02)00080-2
   Soylak M, 2000, ANAL LETT, V33, P513, DOI 10.1080/00032710008543070
   Soylak M, 1998, FRESEN ENVIRON BULL, V7, P383
   Soylak M, 2003, ASIAN J CHEM, V15, P1735
   Soylak M, 1996, ANAL LETT, V29, P635
   Su XG, 2003, TALANTA, V59, P989, DOI 10.1016/S0039-9140(02)00640-9
   TORAL MI, 1993, TALANTA, V40, P1405, DOI 10.1016/0039-9140(93)80218-G
   Uzun A, 2001, TALANTA, V54, P197, DOI 10.1016/S0039-9140(00)00669-X
   Venkatesh G, 2005, TALANTA, V67, P187, DOI 10.1016/j.talanta.2005.02.017
   Yardim MF, 2003, CHEMOSPHERE, V52, P835, DOI 10.1016/S0045-6535(03)00267-4
   Yunes N, 2003, TALANTA, V59, P943, DOI 10.1016/S0039-9140(02)00639-2
NR 33
TC 19
Z9 23
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD AUG 17
PY 2007
VL 147
IS 1-2
BP 15
EP 20
DI 10.1016/j.jhazmat.2006.12.044
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 205SZ
UT WOS:000249136200003
PM 17316981
DA 2018-12-27
ER

PT J
AU Kim, D
   Jeong, S
   Moona, J
   Han, S
   Chung, J
AF Kim, Dongjo
   Jeong, Sunho
   Moona, Jooho
   Han, Sewoon
   Chung, Jaewon
TI RETRACTED: Organic thin film transistors with ink-jet printed metal
   nanoparticle electrodes of a reduced channel length by laser ablation
   (Retracted article. See vol. 92, pg. Nil_0313, 2008)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTORS; FABRICATION
AB The authors have demonstrated organic thin film transistors (OTFTs) based on the ink-jet printed electrodes in which a reduced channel length is accomplished by laser ablation. Laser ablation on the dried silver nanoparticle electrode formed by ink-jet printing effectively shortened the channel length down to 5 mu m, which is difficult to achieve by ink-jet printing alone. Reducing the channel length using this hybrid technique also allows them to observe the contact resistance effect in the OTFTs, which involves the printed silver nanoparticle electrode of a lower work function with respect to the ionization energy of the organic semiconductor. (c) 2007 American Institute of Physics.
C1 Yonsei Univ, Dept Mat Sci & Engn, Seoul 120749, South Korea.
   Korea Univ, Dept Mech Engn, Seoul 136713, South Korea.
RP Kim, D (reprint author), Yonsei Univ, Dept Mat Sci & Engn, 134 Shinchon Dong, Seoul 120749, South Korea.
EM jmoon@yonsei.ac.kr; jwon@korea.ac.kr
RI Jeong, Sunho/H-4569-2014
OI Jeong, Sunho/0000-0002-5969-1614
CR Austin MD, 2002, APPL PHYS LETT, V81, P4431, DOI 10.1063/1.1526457
   Dimitrakopoulos CD, 2002, ADV MATER, V14, P99, DOI 10.1002/1521-4095(20020116)14:2<99::AID-ADMA99>3.0.CO;2-9
   Facchetti A, 2000, ANGEW CHEM INT EDIT, V39, P4547, DOI 10.1002/1521-3773(20001215)39:24<4547::AID-ANIE4547>3.0.CO;2-J
   KI SH, 2007, SENSOR ACTUAT A-PHYS, V134, P161
   Kim D, 2005, ELECTROCHEM SOLID ST, V8, pJ30, DOI 10.1149/1.2073670
   Kim D, 2007, THIN SOLID FILMS, V515, P7692, DOI 10.1016/j.tsf.2006.11.141
   Kim D, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2424671
   Kim D, 2006, NANOTECHNOLOGY, V17, P4019, DOI 10.1088/0957-4484/17/16/004
   Ko SH, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2360241
   Lee TW, 2005, ADV MATER, V17, P2180, DOI 10.1002/adma.200401672
   Muck T, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1944224
   Muck T, 2004, SYNTHETIC MET, V146, P317, DOI 10.1016/j.synthmet.2004.08.010
   Scheinert S, 2004, PHYS STATUS SOLIDI A, V201, P1263, DOI 10.1002/pssa.200404335
   Sirringhaus H, 2003, MRS BULL, V28, P802, DOI 10.1557/mrs2003.228
   Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123
   Song DH, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2437684
   Stutzmann N, 2003, SCIENCE, V299, P1881, DOI 10.1126/science.1081279
   SZE SM, 2002, SEMICONDUCTOR DEVICE, P199
   Wang JZ, 2004, NAT MATER, V3, P171, DOI 10.1038/nmat1073
   Wu YL, 2005, ADV MATER, V17, P184, DOI 10.1002/adma.200400690
NR 20
TC 17
Z9 18
U1 3
U2 20
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD AUG 13
PY 2007
VL 91
IS 7
AR 071114
DI 10.1063/1.2771059
PG 3
WC Physics, Applied
SC Physics
GA 201XT
UT WOS:000248866600014
DA 2018-12-27
ER

PT J
AU Pan, J
AF Pan, Jin
TI RETRACTED: Direct and rapid monitoring the biochemical reaction of
   interleukin-6 in human using a flow-injection capacitive immunosensor in
   clinical immunoassay (Retracted article. See vol. 129, pg. 991, 2008)
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article; Retracted Publication
DE analytical biochemistry; clinical immunoassay; capacitive inununosensor;
   interleukin-6
ID SELF-ASSEMBLED MONOLAYERS; IMPEDANCE SPECTROSCOPY; GOLD; ANTIBODY;
   ELECTRODES; BIOSENSOR; THIOUREA; DISEASE; SURFACE; ACID
AB An analytical biochemistry system for direct and rapid determination of interleukin-6 (IL-6) in human was developed through a flow-injection capacitive immunosensor in clinical immunoassay. The immunosensor was fabricated by means of covalent coupling IL-6 antibody molecules onto epoxysilane-functionalized biorecognition interface. The presence of epoxysilane provided a congenial microenvironment for the immobilized biomolecules and increased the electron transfer impedance. The formation of the antibody-antigen complex by a simple one-step immunoreaction between the immobilized anti-IL-6 and IL-6 in sample solution introduced a local capacitance change. Under optimum conditions, the proposed inummosensor exhibited a good capacitive response to IL-6 in a linear range from 1.5 x 10(-15) to 8.0 x 10(-13) M with a relatively low detection limit of 2.5 x 10(-16) M at 3 delta. The developed immunosensor shows an acceptable accuracy compared with those obtained from ELISA. The maximum value of the relative standard deviations (RSD) was 7.3% (n = 5) for intra-assay and 6.7% (n = 4) for inter-assay. The storage stability is acceptable in a pH 7.0 PBS at 4 degrees C for 6 days. (C) 2007 Elsevier B.V. All rights reserved.
C1 Chongqing Jiaotong Univ, Sch River & Sea, Chongqing 400074, Peoples R China.
RP Pan, J (reprint author), Chongqing Jiaotong Univ, Sch River & Sea, Chongqing 400074, Peoples R China.
EM jinpan1974@msn.com
CR ATASSI MZ, 1994, MOL IMMUNOLOGY
   BARD AJ, 1980, ELECTRCHEMICAL METHO
   BATAILLARD P, 1988, ANAL CHEM, V60, P2374, DOI 10.1021/ac00172a011
   BECKA AM, 1992, J PHYS CHEM-US, V96, P2657, DOI 10.1021/j100185a049
   Berggren C, 1998, BIOSENS BIOELECTRON, V13, P1061, DOI 10.1016/S0956-5663(98)00058-X
   Berggren C, 2001, ELECTROANAL, V13, P173, DOI 10.1002/1521-4109(200103)13:3<173::AID-ELAN173>3.0.CO;2-B
   Berggren C, 1997, ANAL CHEM, V69, P3651, DOI 10.1021/ac970203e
   Boehm MK, 2000, BIOCHEM J, V346, P519, DOI 10.1042/0264-6021:3460519
   BRAILLY H, 1994, CLIN CHEM, V40, P116
   Cheng ZL, 2001, ELECTROANAL, V13, P68, DOI 10.1002/1521-4109(200101)13:1<68::AID-ELAN68>3.0.CO;2-C
   Fu ZF, 2006, J IMMUNOL METHODS, V312, P61, DOI 10.1016/j.jim.2006.02.006
   GEBBERT A, 1992, ANAL CHEM, V64, P997, DOI 10.1021/ac00033a007
   GLASER R, 1992, PSYCHOSOM MED, V109, P540
   Hosokawa T, 1999, J GASTROEN HEPATOL, V14, P987, DOI 10.1046/j.1440-1746.1999.01989.x
   Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8
   Jiang DC, 2003, BIOSENS BIOELECTRON, V18, P1183, DOI 10.1016/S0956-5663(02)00253-1
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Katz E, 2001, SENSOR ACTUAT B-CHEM, V76, P134, DOI 10.1016/S0925-4005(01)00606-2
   KIM YT, 1993, LANGMUIR, V9, P1941, DOI 10.1021/la00032a001
   KRAKAUER T, 1993, J IMMUNOASSAY, V14, P267, DOI 10.1080/15321819308019854
   LAMBROS LM, 1998, CLIN CHEM, V44, P1351
   Limbut W, 2006, ANAL CHIM ACTA, V561, P55, DOI 10.1016/j.aca.2006.01.021
   Limbut W, 2006, BIOSENS BIOELECTRON, V22, P233, DOI 10.1016/j.bios.2005.12.025
   Luo LQ, 2000, CHINESE J CHEM, V18, P863
   Maupas H, 1997, J ELECTROANAL CHEM, V421, P165, DOI 10.1016/S0022-0728(96)04837-1
   Miller J. C., 1993, STAT ANAL CHEM, P233
   ROSELLE GA, 1982, J CLIN LAB IMMUNOL, V9, P33
   SABATANI E, 1987, J ELECTROANAL CHEM, V219, P365, DOI 10.1016/0022-0728(87)85054-4
   Schoning MJ, 2002, ELECTROANAL, V14, P955, DOI 10.1002/1521-4109(200207)14:13<955::AID-ELAN955>3.0.CO;2-#
   VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253
   Wang MJ, 2004, BIOSENS BIOELECTRON, V19, P575, DOI 10.1016/S0956-5663(03)00252-5
   Weisshaar DE, 2001, ELECTROCHEM COMMUN, V3, P758, DOI 10.1016/S1388-2481(01)00262-4
   WEISSHAAR DE, 1992, J AM CHEM SOC, V114, P5860, DOI 10.1021/ja00040a058
   Wink T, 1997, ANALYST, V122, pR43, DOI 10.1039/a606964i
   Wu ZS, 2005, ANAL CHIM ACTA, V528, P235, DOI 10.1016/j.aca.2004.09.075
   Yang L, 2005, ELECTROANAL, V17, P969, DOI 10.1002/elan.200403195
   YIN R, 2006, SENSOR ACTUAT B-CHEM, V117, P286
NR 37
TC 4
Z9 4
U1 4
U2 16
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD AUG 8
PY 2007
VL 125
IS 2
BP 517
EP 525
DI 10.1016/j.snb.2007.02.046
PG 9
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 203EC
UT WOS:000248956900024
DA 2018-12-27
ER

PT J
AU Chen, JR
   Sui, Y
   Luo, QY
   Jiang, RQ
AF Chen, Jing-Rong
   Sui, Yan
   Luo, Qiu-Yan
   Jiang, Run-Qing
TI RETRACTED: {mu-6,6 '-Diethoxy-2,2 '-[ethane-1,2diylbis(nitri
   lomethylidyne)]diphenolato}trinitratopraseodymium(III)-zinc(II)
   (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn-II-Pr-III complex (systematic name: {6,6'-diethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato-1 kappa O-4(1),O-1',O-6,O-6' :2 kappa O-4(1),N,N',O-1'}tri- nitrato-1 kappa O-6,O'-praseodymium(III)zinc(II)), [PrZn(C20H22N2O4)(NO3)(3)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-ethoxysalicylidene)ethylenediamine (H(2)2L), the Zn-II and Pr-III atoms are doubly bridged by two phenolate O atoms provided by the Schiff base ligand. The coordination of the Zn-II atom is approximately square planar, involving the two imine N atoms and the two phenolate O atoms. The Pr-III centre has a decacoordination environment of O atoms, formed by the phenolate ligands, the two ethoxy O atoms and two O atoms from each of the three nitrates. Some weak C-H center dot center dot center dot O and O center dot center dot center dot Zn [3.159 (4) angstrom] interactions generate a two-dimensional zigzag sheet.
C1 SW Univ, Coll Chem & Chem Engn, Beibei 400715, Peoples R China.
   JingGangShan Univ, Coll Chem & Chem Engn, Key Lab Coordinat Chem, Jian 343009, Peoples R China.
RP Sui, Y (reprint author), SW Univ, Coll Chem & Chem Engn, Beibei 400715, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   BRUKER, 2004, APEX2 VERSION 1 22 S
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PULBCIF
NR 9
TC 1
Z9 1
U1 2
U2 11
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD AUG
PY 2007
VL 63
BP M2091
EP U619
DI 10.1107/S160053680732540
PN 8
PG 13
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200050
DA 2018-12-27
ER

PT J
AU Hu, RH
   Sui, Y
   Fang, XN
   Chen, HM
AF Hu, Rong-Hua
   Sui, Yan
   Fang, Xiao-Niu
   Chen, Hong-Mei
TI RETRACTED: {6,6 '-Diethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato}-trinitratoeuropi
   um(III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB A heteronuclear Zn-II-Eu-III complex (systematic name: {6,6'-diethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)] diphenolato-1K(4)O(1),O-1',O-6,O-6':2K(4)O(1),N,N',O-1'}trinitrato-1K(6)O,O'- europium(III)zinc(II)), [EuZn(C20H22N2O4)(NO3)(3)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-ethoxysalicylidene)ethylenediamine, has been synthesized and structurally characterized. The Zn and Eu atoms are doubly bridged by two phenolate O atoms provided by the Schiff base ligand. The coordination of Zn is square planar with the donor centers of two imine N atoms and two phenolate O atoms. The Eu center has a decacoordination environment formed by the phenolate O atoms, two ethoxy O atoms and two O atoms from each of the three nitrates. No classical intermolecular hydrogen bonds are found. Some weak C-H center dot center dot center dot O and O center dot center dot center dot Zn interactions [O center dot center dot center dot Zn = 3.193 (4) angstrom] generate a two-dimensional zigzag sheet.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jian 343009, JiangXi, Peoples R China.
   JingGangShan Univ, Coll Educ, Jian 343009, JiangXi, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jian 343009, JiangXi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   BRUKER, 2004, APEX2 VERSION 1 22 S
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBICIF
NR 9
TC 1
Z9 1
U1 2
U2 10
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD AUG
PY 2007
VL 63
BP M2039
EP U163
DI 10.1107/S1600536807031121
PN 8
PG 13
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200014
DA 2018-12-27
ER

PT J
AU Liu, T
   Wang, ZW
   Wang, YX
   Xie, ZP
AF Liu, T.
   Wang, Z.-W.
   Wang, Y.-X.
   Xie, Z.-P.
TI RETRACTED: Polymeric KNOF2 (Retracted article. See vol. 66, pg. E13,
   2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL-STRUCTURES
AB The title compound, poly[mu-difluoridooxidonitrato-potassium], [KNOF2](n), crystallizes in the orthorhombic system and adopts the ordered KNO3 structure type. A crystallographic mirror plane passes through N, O and K. In the crystal structure, the polymer chains are linked by weak bonds into an infinite three-dimensional framework.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jinggangshan Univ, Coll Math & Phys, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@163.com
CR BENHAMIDA M, 2005, Z KRISTALLOGR, V22, P165
   Berdonosov PS, 2000, J SOLID STATE CHEM, V149, P236, DOI 10.1006/jssc.1999.8519
   BRUKER, 2005, APEX 2
   Christensen AN, 1996, J APPL CRYSTALLOGR, V29, P265, DOI 10.1107/S0021889895015664
   LIPP C, 2005, Z KRISTALLOGR, V22, P141
   NIMMO JK, 1976, ACTA CRYSTALLOGR B, V32, P1968, DOI 10.1107/S0567740876006894
   Ruck M, 2003, Z ANORG ALLG CHEM, V629, P2133, DOI 10.1002/zaac.200300192
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SAINT SHELXTL
   SOLTZBERG LJ, 1994, ACTA CRYSTALLOGR B, V50, P518, DOI 10.1107/S010876819400073X
   SWAMINATHAN S, 1975, ACTA CRYSTALLOGR A, V31, P628, DOI 10.1107/S0567739475001350
NR 12
TC 0
Z9 0
U1 3
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP I170
EP U20
DI 10.1107/S1600536807027195
PN 8
PG 8
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200002
DA 2018-12-27
ER

PT J
AU Liu, T
   Wang, ZW
   Wang, YX
   Xie, ZP
AF Liu, T.
   Wang, Z.-W.
   Wang, Y.-X.
   Xie, Z.-P.
TI RETRACTED: Tetrakis[mu-(2-pyridyloxy)acetato-kappa O-2 : O
   ']bis{(1,10-phenanthroline-kappa N-2,N ')[(2-pyridyloxy)acetato-kappa
   O]-neodymium(II)} (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The molecule of the title compound, [Nd-2(C7H6NO3)(6)-(C12H8N2)(2)], has an inversion centre midway between the two Nd-III ions, which are bridged by two tridentate and two bidentate carboxylate groups. Each Nd atom is seven-coordinated by two N atoms of a 1,10-phenanthroline ligand and five O atoms of (2-pyridyloxy) acetate ligands. In the crystal structure, intermolecular C-H center dot center dot center dot O hydrogen bonds lead to a supramolecular network.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jinggangshan Univ, Coll Math & Phys, Jian 343009, Peoples R China.
   Univ Sci & Technol, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2080, DOI 10.1107/S1600536807032679
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM2020, DOI 10.1107/S1600536807030917
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
NR 6
TC 0
Z9 0
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2196
EP U1586
DI 10.1107/S1600536807035349
PN 8
PG 14
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200131
DA 2018-12-27
ER

PT J
AU Liu, T
   Wang, ZW
   Wang, YX
   Xie, ZP
AF Liu, T.
   Wang, Z.-W.
   Wang, Y.-X.
   Xie, Z.-P.
TI RETRACTED: (Dihydroxyglyoxime-kappa(2) N,N
   ')bis(1,10-phenanthrofine-kappa N-2,N ')manganese(II) dinitrate
   dihydrate (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the cation of the title compound, [Mn(C12H8N2)(2)- (C2H4N2O4)] (NO3)(2)center dot 2H(2)O, the Mn atom has a distorted octahedral coordination formed by six N atoms from one dihydroxyglyoxime and two 1,10-phenanthroline ligands. In the crystal structure, the components are linked into a three-dimensional framework by O-H center dot center dot center dot O, C-H center dot center dot center dot O, C-H center dot center dot center dot N and O-H center dot center dot center dot N hydrogen bonds and pi-pi stacking interactions, with a centroid-centroid distance of 3.580 (2) angstrom (symmetry code: 1 - x, 2 - y, -z).
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jinggangshan Univ, Coll Math & Phys, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM1887, DOI 10.1107/S1600536807028255
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
NR 6
TC 0
Z9 0
U1 4
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2198
EP U1599
DI 10.1107/S1600536807035076
PN 8
PG 13
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200132
DA 2018-12-27
ER

PT J
AU Sui, Y
   Fang, XN
   Hu, P
   Lin, J
AF Sui, Yan
   Fang, Xiao-Niu
   Hu, Ping
   Lin, Jun
TI RETRACTED: {6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato-1 kappa
   O-4(1),O-1 ',O-6,O-6 ': 2 kappa O-4(1),N,N ',O-1 '}-(methanol-1 kappa
   O)-mu-nitrato-1 : 2 kappa O-2 : O '-dinitrato-1 kappa O-4,O
   '-cerium(III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn-II-Ce-II complex, [CeZn(C18H18- N2O4)(CH4O)(NO3)(3)], with the hexadentate Schiff base compartmental ligand NM-bis(3-methoxysalicylidene)ethylenediamine (H2L), the Zn and Ce atoms are triply bridged by two phenolate O atoms provided by the Schiff base ligand and one nitrate. The five-coordinated Zn is in a square-pyramidal geometry with the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Cell center has a decacoordination environment of O atoms, involving the phenolate O atoms, two methoxy O atoms, one methanol O atom, and two O atoms from two nitrates and one from the bridging nitrate. Strong intermolecular O-H center dot center dot center dot O and some weak C-H center dot center dot center dot O interactions generate a two-dimensional layer structure.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Jiangxi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   BRUKER, 2004, APEX2 VERSIN 1 22
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2007, ACTA CRYSTALLOGR E, V63, pM2013, DOI 10.1107/S1600536807030905
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 2
Z9 2
U1 2
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2135
EP U1003
DI 10.1107/S1600536807033314
PN 8
PG 13
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200082
DA 2018-12-27
ER

PT J
AU Sui, Y
   Li, XF
   Huang, GS
   Wang, GJ
AF Sui, Yan
   Li, Xin-Fa
   Huang, Gan-Sheng
   Wang, Gui-Juan
TI RETRACTED: {mu-6,6 '-diethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolato}-trinitratopraseo
   dymium(III)nickel(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Ni(II)-Pr(III) complex (systematic name: {6,6'-diethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato-1 kappa(4)O(1), O(1)',O(6),O(6'):2 kappa(4)O(1),N,N',O(1)}trinitrato-1 kappa(6)O,O'-praseodymium(III)nickel(II)), [NiPr(C(20)H(22)N(2)O(4))(NO(3))(3)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-ethoxysalicylidene)ethylenediamine (H(2)L), the Ni and Pr atoms are doubly bridged by two phenolate O atoms provided by the Schiff base ligand. The coordination of Ni is square planar with the donor centers of two imine N atoms and two phenolate O atoms. The praseodymium(III) center has a decacoordination environment of O atoms, involving the phenolate O atoms, two ethoxy O atoms and two O atoms each from the three nitrates. Some weak C-H center dot center dot center dot O and O center dot center dot center dot Ni [3.146 (4) angstrom] interactions generate a two-dimensional zigzag sheet.
C1 JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Province Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Province Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   BRUKER, 2004, APEX2 VERSION 1 22 S
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 1
Z9 1
U1 3
U2 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2093
EP U632
DI 10.1107/S1600536807032618
PN 8
PG 13
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200051
DA 2018-12-27
ER

PT J
AU Sui, Y
   Zhang, JH
   Hu, RH
   Yin, LY
AF Sui, Yan
   Zhang, Jin-Hai
   Hu, Rong-Hua
   Yin, Li-Yang
TI RETRACTED: {mu-6,6 '-Diethoxy-2,2
   '-[ethane-1,2-diyl-bis(nitrilomethylidyne)]diphenolatol}trinitratocerium
   (III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn(II)-Ce(II) complex (systematic name: 16,6'-diethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato-l kappa(4) O(1),O(1'),O(6),O(6'):2 kappa(4)O(1),N,N',O(1')}trinitrato-1 kappa (6)O,O'-cerium(III)zinc(II)), [CeZn(C(20)H(22)N(2)O(4))(NO(3))(3)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-ethoxysalicylidene)ethylenediamine, the Zn and Ce atoms are doubly bridged by two phenolate O atoms provided by the Schiff base ligand. The coordination of the Zn atom is square planar with the donor centers of two imine N atoms and two phenolate O atoms. The cerium(III) center has a decacoordination environment of O atoms, involving the phenolate O atoms, two ethoxy O atoms and two O atoms each from the three nitrate ligands. Some weak C-H center dot center dot center dot O and O center dot center dot center dot Zn [O center dot center dot center dot Zn = 3.156 (4) angstrom] interactions generate a two-dimensional zigzag sheet.
C1 JingGangShan Univ, Coll Chem & Chem Engn, Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Inst Food & Drug Control, Jian 343000, Peoples R China.
RP Sui, Y (reprint author), JingGangShan Univ, Coll Chem & Chem Engn, Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   BRUKER, 2004, APEX2 VERSION 1 22
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sui Y, 2006, ACTA CRYSTALLOGR E, V62, pM2230, DOI 10.1107/S1600536806032120
   WESTRIP SP, 2007, UNPUB PUBLCIF
NR 9
TC 2
Z9 2
U1 2
U2 11
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2089
EP U606
DI 10.1107/S1600536807032564
PN 8
PG 13
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200049
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: (1,10-Phenanthroline-kappa(2) N,N
   ')tris(3-phenylpropanoato-kappa O)neodymium(III) (Retracted article. See
   vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The Nd-III atom in the title complex, [Nd(C9H9O2)(3)(C12H8N2)], is coordinated by two N atoms of the 1,10-phenanthroline (phen) ligand and four O atoms of the three 3-phenylpropanoate ligands. This mononuclear complex is further extended into a supramolecular network structure via nonclassical hydrogen bonds between CH groups of 1,10-phenanthroline or 3-phenylpropanoate and O atoms of neighbouring 3-phenylpropanoate molecules.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   [Anonymous], 2005, APEX2
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM1909, DOI 10.1107/S1600536807028693
NR 6
TC 0
Z9 0
U1 4
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2209
EP U1678
DI 10.1107/S1600536807035350
PN 8
PG 14
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200139
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: Bis(2,2 '-bipyridyl-kappa N-2,N ')bis(thiocyanato-kappa
   N)nickel(II) (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, [Ni(NCS)(2)(C10H8N2)(2)], the Ni-II atom is six-coordinated by the four N atoms of two 2,2'-bipyridyl ligands and the two N atoms of two thiocyanate ligands, in a distorted octahedral arrangement. In the crystal structure, intramolecular C-H... N hydrogen bonds and pi-pi stacking interactions, with a centroid-centroid distance of 3.545 (2) angstrom, lead to a supramolecular network structure.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BANGLIN C, 2001, SCIENCE, V291, P102
   Ferey G, 2001, CHEM MATER, V13, P3084, DOI 10.1021/cm011070n
   Hill CL, 1998, CHEM REV, V98, P1, DOI 10.1021/cr960395y
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 11
TC 3
Z9 3
U1 3
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2062
EP U364
DI 10.1107/S1600536807031613
PN 8
PG 10
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200030
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: Bis(2, 2 '-bipyridyl-kappa(2) N,N ')bis(thiocyanato-kappa
   N)zinc(II) (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, [Zn(NCS)(2)(C10H8N2)(2)], the Zn-II atom is six-coordinated by the four N atoms of two 2,2 '-bipyridyl ligands and the two N atoms of two thiocyanate ligands, in a distorted octahedral arrangement. In the crystal structure, intramolecular C-H center dot center dot center dot N and intermolecular C-H center dot center dot center dot S hydrogen bonds and pi-pi stacking interactions, with a centroid-centroid distance of 3.569 (5) angstrom, lead to a supramolecular network structure.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2062, DOI 10.1107/S1600536807031613
   ZHONG H, 2007, ACTA CRYSTALLOGR, V63, pM1241
NR 6
TC 2
Z9 2
U1 4
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2208
EP U1664
DI 10.1107/S1600536807035337
PN 8
PG 10
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200138
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: Bis(2,2 '-bipyridyl-kappa N-2,N ')bis(isothiocyanato-kappa
   N)copper(II) (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, [Cu(NCS)(2)(-)(C10H8N2)(2)], the Cull atom is six-coordinated by the four N atoms of two 2,2'-bipyridyl ligands and the two N atoms of two thiocyanate ligands, in a distorted octahedral arrangement. In the crystal structure, intramolecular C-H center dot center dot center dot N and intermolecular C-H center dot center dot center dot S hydrogen bonds and pi-pi stacking interactions, with a centroid-centroid distance of 3.573 (2) angstrom, lead to a supramolecular network structure.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM2062, DOI 10.1107/S1600536807031613
NR 5
TC 1
Z9 1
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD AUG
PY 2007
VL 63
BP M2141
EP U1036
DI 10.1107/S1600536807033181
PN 8
PG 10
WC Crystallography
SC Crystallography
GA 213UI
UT WOS:000249692200085
DA 2018-12-27
ER

PT J
AU Narulkar, VV
   Prakash, S
   Chandra, K
AF Narulkar, V. V.
   Prakash, S.
   Chandra, K.
TI RETRACTED: Characteristics of porous zirconia coated with hydroxyapatite
   as human bones (Retracted article. See vol. 36, pg. 1347, 2013)
SO BULLETIN OF MATERIALS SCIENCE
LA English
DT Article; Retracted Publication
DE zirconia; porosity; hydroxyapatite; coating; compressive strength
ID PORE-SIZE; COMPOSITE; SCAFFOLDS; CERAMICS; POROSITY
AB Since hydroxyapatite has excellent biocompatibility and bone bonding ability, porous hydroxyapatite ceramics have been intensively studied. However, porous hydroxyapatite bodies are mechanically weak and brittle, which makes shaping and implantation difficult. One way to solve this problem is to introduce a strong porous network onto which hydroxyapatite coating is applied. In this study, porous zirconia and alumina-added zirconia ceramics were prepared by ceramic slurry infiltration of expanded polystyrene bead compacts, followed by firing at 1500 degrees C. Then slurry of hydroxyapatite-borosilicate glass mixed powder was used to coat the porous ceramics, followed by firing at 1200 degrees C. The porous structures without the coating had high porosities of 51-69%, high pore interconnectivity, and sufficiently large pore window sizes (300-500;mu m). The porous ceramics had compressive strengths of 5.3 similar to 36.8 MPa, favourably comparable to the mechanical properties of cancellous bones. In addition, porous hydroxyapatite surface was formed on the top of the composite coating, whereas a borosilicate glass layer was found on the interface. Thus, porous zirconia-based ceramics were modified with a bioactive composite coating for biomedical applications.
C1 [Narulkar, V. V.; Prakash, S.; Chandra, K.] Indian Inst Technol, Metallurgical & Mat Engn Dept, Roorkee 247667, Uttar Pradesh, India.
RP Narulkar, VV (reprint author), Indian Inst Technol, Metallurgical & Mat Engn Dept, Roorkee 247667, Uttar Pradesh, India.
EM vinaynarulkar@gmail.com
CR Bose S, 2003, MAT SCI ENG C-BIO S, V23, P479, DOI 10.1016/S0928-4931(02)00129-7
   Gibson L. J., 1997, CELLULAR SOLIDS STRU
   Hu YF, 2004, CERAM INT, V30, P1787, DOI 10.1016/j.ceramint.2003.12.119
   Kim HW, 2005, J BIOMED MATER RES A, V72A, P258, DOI 10.1002/jbm.a.30219
   Kim HW, 2003, BIOMATERIALS, V24, P3277, DOI 10.1016/S0142-9612(03)00162-5
   Kim HW, 2004, BIOMATERIALS, V25, P4203, DOI 10.1016/j.biomaterials.2003.10.094
   Liu DM, 1997, CERAM INT, V23, P135, DOI 10.1016/S0272-8842(96)00009-0
   Ma PX, 2001, TISSUE ENG, V7, P23, DOI 10.1089/107632701300003269
   NICOLI AN, 2002, BIOMATERIALS, V23, P3833
   Silva VV, 2001, COMPOS SCI TECHNOL, V61, P301, DOI 10.1016/S0266-3538(00)00222-0
   Wen CE, 2004, MATER LETT, V58, P357, DOI 10.1016/S0167-577X(03)004500-7
NR 11
TC 3
Z9 3
U1 2
U2 19
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-4707
EI 0973-7669
J9 B MATER SCI
JI Bull. Mat. Sci.
PD AUG
PY 2007
VL 30
IS 4
BP 309
EP 314
DI 10.1007/s12034-007-0051-4
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA 241TB
UT WOS:000251677600002
DA 2018-12-27
ER

PT J
AU Hong, X
   Lei, L
   Kunert, B
   Naredla, R
   Applequist, SE
   Grandien, A
   Glas, R
AF Hong, Xu
   Lei, Lu
   Kunert, Brita
   Naredla, Rajender
   Applequist, Steven E.
   Grandien, Alf
   Glas, Rickard
TI RETRACTED: Tripeptidyl-peptidase II controls DNA damage responses and in
   vivo gamma-irradiation resistance of tumors (Retracted article. See vol.
   70, pg. 10485, 2010)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID DEPENDENT PROTEIN-KINASE; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA;
   ANTIGEN PRESENTATION; MAMMALIAN TARGET; MTOR INHIBITORS; GIANT PROTEASE;
   ACTIVE-SITE; ATM-KINASE; CELLS
AB Cellular responses to gamma-irradiation exposure are controlled by phosphatidylinositol 3-kinase-related kinases (PIKK) in the nucleus, and in addition, cytosolic PIKKs may have a role in such responses. Here, we show that the expression of tripeptidyl-peptidase II (TPPH), a high molecular weight cytosolic peptidase, required PIKK signaling and that TPPII was rapidly translocated into the nucleus of gamma-irradiated cells. These events were dependent on mammalian target of rapamycin, a cytosolic/mitochondrial PIKK that is activated by gamma-irradiation. Lymphoma cells with inhibited expression of TPPH failed to efficiently stabilize p53 and had reduced ability to arrest proliferation in response to gamma-irradiation. We observed that TPPII contains a BRCA COOH-terminal-like motif, contained within sequences of several proteins involved in DNA damage signaling pathways, and this motif was important for nuclear translocation of TPPH and stabilization of p53. Novel tripeptide-based inhibitors of TPPH caused complete in vivo tumor regression in mice in response to relatively low doses of gamma-irradiation (3-4 Gy/wk). This was observed with established mouse and human tumors of diverse tissue backgrounds, with no tumor regrowth after cancellation of treatment. These TPPH inhibitors had minor effects on tumor growth as single agent and had low cellular toxicity. Our data indicated that TPPH connects signaling by cytosolic/mitochondrial and nuclear PIKK-dependent pathways and that TPPH can be targeted for inhibition of tumor therapy resistance.
C1 Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Mol Med,Dept Med, S-17176 Stockholm, Sweden.
   Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Infect Dis,Dept Med, Stockholm, Sweden.
   Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Dept Med, Stockholm, Sweden.
RP Glas, R (reprint author), Karolinska Univ, Huddinge Hosp, Karolinska Inst, Ctr Mol Med,Dept Med, S-17176 Stockholm, Sweden.
EM rickard.glas@ki.se
CR Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0
   Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455
   Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126
   Bork P, 1997, FASEB J, V11, P68
   Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1570
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Choi EK, 2006, INT J RADIAT BIOL, V82, P277, DOI 10.1080/09553000600702346
   Choudhury A, 2006, SEMIN RADIAT ONCOL, V16, P51, DOI 10.1016/j.semradonc.2005.08.007
   Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029
   Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200
   Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538
   De Winter H, 2005, J MOL GRAPH MODEL, V23, P409, DOI 10.1016/j.jmgm.2004.11.009
   El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949
   Eshleman JS, 2002, CANCER RES, V62, P7291
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200
   Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884
   Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076
   Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978
   Glas R, 1998, NATURE, V392, P618
   Hilbi H, 2000, INFECT IMMUN, V68, P5502, DOI 10.1128/IAI.68.10.5502-5508.2000
   Hong X, 2003, J EXP MED, V197, P1731, DOI 10.1084/jem.20020801
   Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250
   Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877
   McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210
   MUNGER K, 2003, Patent No. 03105835
   Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024
   Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3
   Renn SCP, 1998, J BIOL CHEM, V273, P19173, DOI 10.1074/jbc.273.30.19173
   Rockel B, 2002, EMBO J, V21, P5979, DOI 10.1093/emboj/cdf601
   Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715
   Stavropoulou V, 2006, BIOCHEM BIOPH RES CO, V346, P415, DOI 10.1016/j.bbrc.2006.05.141
   Stavropoulou V, 2005, CANCER RES, V65, P1361, DOI 10.1158/0008-5472.CAN-04-2085
   Tirado OM, 2003, CANCER RES, V63, P6290
   Tomkinson B, 2005, INT J BIOCHEM CELL B, V37, P1933, DOI 10.1016/j.biocel.2005.02.009
   TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508
   Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200
   Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897
   Weppler SA, 2007, RADIOTHER ONCOL, V82, P96, DOI 10.1016/j.radonc.2006.11.004
   Yonekura I, 2006, J CEREBR BLOOD F MET, V26, P1332, DOI 10.1038/sj.jcbfm.9600293
   York IA, 2006, J IMMUNOL, V177, P1434, DOI 10.4049/jimmunol.177.3.1434
   Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753
   Zhang SS, 2007, J CELL BIOCHEM, V101, P451, DOI 10.1002/jcb.21195
   Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275
NR 49
TC 14
Z9 14
U1 2
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2007
VL 67
IS 15
BP 7165
EP 7174
DI 10.1158/0008-5472.CAN-06-4094
PG 10
WC Oncology
SC Oncology
GA 197BW
UT WOS:000248529300017
PM 17671184
OA Bronze
DA 2018-12-27
ER

PT J
AU Deepak, P
   Kumar, S
   Acharya, A
AF Deepak, P.
   Kumar, S.
   Acharya, A.
TI RETRACTED: Interteukin-13-induced type II polarization of inflammatory
   macrophages is mediated through suppression of nuclear factor-kappa B
   and preservation of I kappa B alpha in a T cell lymphoma (retracted
   Article. See vol 158, pg 334, 2009)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE Dalton's lymphoma; IL-13 R alpha 2; IL-13; inflammatory macrophages;
   NF-kappa B; TAM
ID TUMOR-ASSOCIATED MACROPHAGES; HUMAN MONOCYTES; ACTIVATION;
   INTERLEUKIN-13; IL-13; VIVO; PROGRESSION; POPULATION; MODULATION;
   EXPRESSION
AB Spontaneously arising transplantable T cell lymphoma, designated as Dalton's lymphoma (DL), is characterized by a highly invasive and deleterious nature almost completely paralysing the host immune system. The level of interleukin (IL)-13 is elevated in serum and ascitic fluid of the DL-bearing host. IL- 13 is a potent immunosuppressive cytokine and is an alternative activator of macrophages that suppresses the production of nitric oxide (NO) and expression of inducible nitric oxide synthase (iNOS), and proinflammatory cytokines. The expression of iNOS and proinflammatory cytokines are dependent largely upon the activation of nuclear factor-kappa B (NF-kappa B). Activation of NF-kappa B involves the degradation of cytoplasmic inhibitor I kappa B alpha, allowing the nuclear translocation of NF-kappa B and thereby transcription of the iNOS gene. Therefore, in this study we sought to determine whether the alternative activation or type II polarization of macrophages induced by IL-13 is mediated by the suppression of NF-kappa B and cytoplasmic preservation of I kappa B alpha. Western blot analysis and electrophoretic mobility shift assay (EMSA) indicate that tumour-associated macrophages (TAM) or polarized type 11 macrophages are due to preserved protein expression of I kappa B alpha, and therefore suppressed NF-kappa B nuclear translocation. These findings suggest that IL-13 may operate through the suppression of NF-kappa B activation and preservation of I kappa B alpha.
C1 Banaras Hindu Univ, Fac Sci, Dept Zool, Immunol Lab, Varanasi 221005, Uttar Pradesh, India.
RP Acharya, A (reprint author), Banaras Hindu Univ, Fac Sci, Dept Zool, Immunol Lab, Varanasi 221005, Uttar Pradesh, India.
EM acharya@bhu.ac.in
CR Ahn KS, 2005, ANN NY ACAD SCI, V1056, P218, DOI 10.1196/annals.1352.026
   Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Bogdan C, 1997, J IMMUNOL, V159, P4506
   BOTTAZZI B, 1990, J IMMUNOL, V144, P4878
   DOHERTY TM, 1993, J IMMUNOL, V151, P7151
   GHOSH S, 2002, CELL S, V109, P81
   GOLDIE H, 1951, CANCER RES, V1, P173
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0
   KARIN M, 2002, ANN EV IMMUNOL, V8, P621
   KLEIN G, 1951, EXP CELL RES, V2, P518, DOI 10.1016/0014-4827(51)90038-9
   Klimp AH, 2001, CANCER RES, V61, P7305
   Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786
   MALEFYT RD, 1993, J IMMUNOL, V151, P6370
   Manna SK, 1998, J IMMUNOL, V161, P2863
   Mantovani A, 2003, TUMORI, V89, P459
   Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016
   MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735
   MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Parajuli P, 1997, CANCER J, V10, P222
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Sica A, 2000, J IMMUNOL, V164, P762, DOI 10.4049/jimmunol.164.2.762
   Singh MP, 2005, J REPROD IMMUNOL, V65, P17, DOI 10.1016/j.jri.2004.11.001
   Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792
   SOZZANI P, 1995, J BIOL CHEM, V270, P5084, DOI 10.1074/jbc.270.10.5084
   Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4
   TURKSON J, 1998, MOL CELL BIOL, V18, P2445
NR 29
TC 14
Z9 14
U1 3
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD AUG
PY 2007
VL 149
IS 2
BP 378
EP 386
DI 10.1111/j.1365-2249.2007.03427.x
PG 9
WC Immunology
SC Immunology
GA 196KT
UT WOS:000248481000022
PM 17550372
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Tsukumo, DML
   Carvalho, MA
   Carvalheira, JBC
   Prada, PO
   Hirabara, SM
   Schenka, AA
   Araujo, EP
   Vassallo, J
   Curi, R
   Velloso, LA
   Saad, MJA
AF Tsukumo, Daniela M. L.
   Carvalho-Filho, Marco A.
   Carvalheira, Jose B. C.
   Prada, Patricia O.
   Hirabara, Sandro M.
   Schenka, Andre A.
   Araujo, Eliana P.
   Vassallo, Jose
   Curi, Rui
   Velloso, Licio A.
   Saad, Mario J. A.
TI RETRACTED: Loss-of-function mutation in Toll-like receptor 4 prevents
   diet-induced obesity and insulin resistance (Retracted article. See vol.
   65, pg. 1126, 2016)
SO DIABETES
LA English
DT Article; Retracted Publication
ID ADIPOSE-TISSUE; FATTY-ACIDS; IKK-BETA; SERINE PHOSPHORYLATION; TARGETED
   DISRUPTION; INNATE IMMUNITY; KAPPA-B; MICE; SUBSTRATE-1; ACTIVATION
AB Obesity is associated with insulin resistance and a state of abnormal inflammatory response. The Toll-like receptor (TLR)4 has an important role in inflammation and immunity, and its expression has been reported in most tissues of the body, including the insulin-sensitive ones. Because it is activated by lipopolysaccharide and saturated fatty acids, which are inducers of insulin resistance, TLR4 may be a candidate for participation in the cross-talk between inflammatory and metabolic signals. Here, we show that C3H/HeJ mice, which have a loss-of-function mutation in TLR4, are protected against the development of diet-induced obesity. In addition, these mice demonstrate decreased adiposity, increased oxygen consumption, a decreased respiratory exchange ratio, improved insulin sensitivity, and enhanced insulin-signaling capacity in adipose tissue, muscle, and liver compared with control mice daring high-fat feeding. Moreover, in these tissues, control mice fed a high-fat diet show an increase in I kappa B kinase complex and c-Jun NH2-terminal kinase activity, which is prevented in C3H/HeJ mice. In isolated muscles from C3H/ HeJ mice, protection from saturated fatty acid-induced insulin resistance is observed. Thus, TLR4 appears to be an important mediator of obesity and insulin resistance and a potential target for the therapy of these highly prevalent medical conditions.
C1 Univ Estadual Campinas, Dept Internal Med, Campinas, SP, Brazil.
   Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil.
   Univ Estadual Campinas, Dept Pathol, Campinas, SP, Brazil.
RP Saad, MJA (reprint author), Univ Estadual Campinas, FCM, Dept Clin Med, Cidade Univ Zeferino Vaz, BR-13081970 Campinas, SP, Brazil.
EM msaad@fcm.unicamp.br
RI Hirabara, Sandro/C-4014-2012; SCHENKA, ANDRE/G-8415-2012; Prada,
   Patricia/E-9339-2015; Carvalheira, Jose/H-8405-2012; Prada,
   Patricia/R-6269-2018
OI Hirabara, Sandro/0000-0002-7392-0444; SCHENKA,
   ANDRE/0000-0002-8162-8996; Prada, Patricia/0000-0002-4131-4503
CR Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200
   Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047
   Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Arkan MC, 2005, NAT MED, V11, P191, DOI [10.1038/nm1185, 10.1068/nm1185]
   Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084
   Bertelli DF, 2006, ENDOCRINOLOGY, V147, P5385, DOI 10.1210/en.2006-0280
   Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761
   Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3
   Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166
   Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200
   Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200
   Hirabara SM, 2006, BBA-BIOENERGETICS, V1757, P57, DOI 10.1016/j.bbabio.2005.11.007
   Hirabara SM, 2003, FEBS LETT, V541, P109, DOI 10.1016/S0014-5793(03)00316-8
   Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JC126498
   Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342
   Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200
   Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200
   Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   METZE K, 1991, PATHOL RES PRACT, V187, P1031, DOI 10.1016/S0344-0338(11)81078-2
   Murciano C, 2006, MED MYCOL, V44, P149, DOI 10.1080/13693780500294733
   Palliser D, 2004, J IMMUNOL, V172, P2885, DOI 10.4049/jimmunol.172.5.2885
   Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138
   Poggi M, 2007, DIABETOLOGIA, V50, P1267, DOI 10.1007/s00125-007-0654-8
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Schenka AA, 2005, CELL MOL NEUROBIOL, V25, P929, DOI 10.1007/s10571-005-4959-1
   Schreyer SA, 1998, ATHEROSCLEROSIS, V136, P17, DOI 10.1016/S0021-9150(97)00165-2
   Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391
   Senn JJ, 2006, J BIOL CHEM, V281, P26865, DOI 10.1074/jbc.M513304200
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   Song MJ, 2006, BIOCHEM BIOPH RES CO, V346, P739, DOI 10.1016/j.bbrc.2006.05.170
   Suganami T, 2007, BIOCHEM BIOPH RES CO, V354, P45, DOI 10.1016/j.bbrc.2006.12.190
   Suganami T, 2007, ARTERIOSCL THROM VAS, V27, P84, DOI 10.1161/01.ATV.0000251608.09329.9a
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Thirone ACP, 2004, ENDOCRINOLOGY, V145, P281, DOI 10.1210/en.2003-0575
   Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335
   Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620
NR 47
TC 563
Z9 590
U1 5
U2 76
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD AUG
PY 2007
VL 56
IS 8
BP 1986
EP 1998
DI 10.2337/db06-1595
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 196HU
UT WOS:000248473100005
PM 17519423
DA 2018-12-27
ER

PT J
AU Aoki, N
   Jin-No, S
   Nakagawa, Y
   Asai, N
   Arakawa, E
   Tamura, N
   Tamura, T
   Matsuda, T
AF Aoki, Naohito
   Jin-No, Shinji
   Nakagawa, Yoshimi
   Asai, Noriyuki
   Arakawa, Erina
   Tamura, Noriko
   Tamura, Tomohiro
   Matsuda, Tsukasa
TI RETRACTED: Identification and characterization of microvesicles secreted
   by 3T3-L1 adipocytes: redox- and Hormone Dependent induction of milk fat
   globule-epidermal growth factor 8-associated microvesicles (Retracted
   article. See vol. 154, pg. 4437, 2013)
SO ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID CELL-DERIVED EXOSOMES; BREAST-CARCINOMA CELLS; INDUCED
   INSULIN-RESISTANCE; SHED MEMBRANE-VESICLES; DENDRITIC CELLS;
   ADIPOSE-TISSUE; TUMOR-CELLS; MATRIX METALLOPROTEINASES; MULTIVESICULAR
   BODY; MAMMARY-GLANDS
AB Adipocytes are now recognized as endocrine cells secreting adipocytokines, regulating multiple metabolic pathways. In this study, we addressed secretion of microvesicles by 3T3- L1 adipocytes. We found that MFG- E8, one of the exosomal proteins, was present in the microvesicles and was distributed in the sucrose density fractions with 1.13 - 1.20 g/ml, which has been reported for exosomes. Several integral, cytosolic, and nuclear proteins such as caveolin-1, c-Src kinase, and heat shock protein 70 were also found to be microvesicle components. Unexpectedly, adiponectin was also substantially distributed in the microvesicle fractions. Furthermore, proteomic analysis of the microvesicles revealed that many other proteins such as extracellular matrix-related proteins were also present. Microvesicles secreted by 3T3- L1 adipocytes exhibited heterogeneity in size and comprised both smaller exosome-like and larger membrane vesicles as revealed by electron microscopy. Milk fat globule- epidermal growth factor 8 (MFG-E8)-associated adiposomes exhibited binding activity toward phosphatidylserine and apoptotic cells. MFG-E8 in the microvesicles was reduced when cultured in the low-glucose medium or cultured in the high- glucose medium with antioxidant N-acetyl cysteine. Insulin and TNF-alpha also up-regulated MFG-E8 in the microvesicles. Moreover, MFG-E8 was strongly up-regulated in the hypertrophic adipose tissue, predominantly in adipocyte fractions, of diet-induced obese C57BL/6 mice, where increased oxidative stress is induced. Thus, it is suggested that microvesicles, especially MFG-E8-associated ones, modulate adipose functions under redox- and hormone-dependent regulation. Based on the above findings, the adipocyte-derived microvesicles were named adiposomes.
C1 Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.
   Mie Univ, Fac Bioresources, Dept Life Sci, Tsu, Mie 5148507, Japan.
   Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan.
   Natl Inst Adv Ind Sci & Technol, Res Inst Genome Based Biofactory, Sapporo, Hokkaido 0628517, Japan.
   Hokkaido Univ, Grad Sch Agriculture, Lab Mol Environm Microbiol, Sapporo, Hokkaido 0608589, Japan.
RP Aoki, N (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.
EM n-aoki@bio.mie-u.ac.jp
CR Aoki N, 1997, BBA-GEN SUBJECTS, V1334, P182, DOI 10.1016/S0304-4165(96)00091-8
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200
   COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681
   D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200
   DAINIAK N, 1991, BLOOD, V78, P264
   Denzer K, 2000, J CELL SCI, V113, P3365
   Dolo V, 1998, CANCER RES, V58, P4468
   Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9
   DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173
   DOLO V, 1995, J SUBMICR CYTOL PATH, V27, P535
   Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI200421625, 10.1172/JCI20042162S]
   Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216
   Ginestra A, 1998, ANTICANCER RES, V18, P3433
   Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6
   GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1
   Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490
   Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a
   Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102
   HAUSMAN GJ, 1983, J LIPID RES, V24, P522
   Heijnen CJ, 1999, J NEUROIMMUNOL, V100, P197, DOI 10.1016/S0165-5728(99)00194-0
   Heijnen HFG, 1999, BLOOD, V94, P3791
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001
   Kim CW, 2002, CANCER RES, V62, P6312
   Koerner A, 2005, BEST PRACT RES CL EN, V19, P525, DOI 10.1016/j.beem.2005.07.008
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   MATHEW A, 1995, BIOCHEM J, V308, P823, DOI 10.1042/bj3080823
   Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200
   Matsuzawa Y, 2005, BEST PRACT RES CL EN, V19, P637, DOI 10.1016/j.beem.2005.07.001
   Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824
   Nakatani H, 2006, BIOCHEM J, V395, P21, DOI 10.1042/BJ20051459
   Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19
   Okamoto Y, 2000, HORM METAB RES, V32, P47, DOI 10.1055/s-2007-978586
   Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x
   Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200
   POSTE G, 1980, P NATL ACAD SCI-BIOL, V77, P399, DOI 10.1073/pnas.77.1.399
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   SATTA N, 1994, J IMMUNOL, V153, P3245
   Segura E, 2005, BLOOD CELL MOL DIS, V35, P89, DOI 10.1016/j.bcmd.2005.05.003
   Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800
   Shojima N, 2002, DIABETES, V51, P1737, DOI 10.2337/diabetes.51.6.1737
   Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070
   Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233
   Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x
   STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417
   Tang HY, 2005, PROTEOMICS, V5, P3329, DOI 10.1002/pmic.200401275
   Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0
   Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599
   TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5
   Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335
   Veron P, 2005, BLOOD CELL MOL DIS, V35, P81, DOI 10.1016/j.bcmd.2005.05.001
   Vincent JP, 2002, TRENDS CELL BIOL, V12, P57, DOI 10.1016/S0962-8924(01)02227-9
   Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014
   Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200
   Wu XD, 2005, ANTIOXID REDOX SIGN, V7, P526, DOI 10.1089/ars.2005.7.526
   Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200
   Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
   ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2
NR 67
TC 99
Z9 107
U1 7
U2 23
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG
PY 2007
VL 148
IS 8
BP 3850
EP 3862
DI 10.1210/en.2006-1479
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 190UT
UT WOS:000248086800035
PM 17478559
OA Bronze
DA 2018-12-27
ER

PT J
AU El-Remessy, AB
   Al-Shabrawey, M
   Platt, DH
   Bartoli, M
   Behzadian, MA
   Ghaly, N
   Tsai, N
   Motamed, K
   Caldwell, RB
AF El-Remessy, A. B.
   Al-Shabrawey, M.
   Platt, D. H.
   Bartoli, M.
   Behzadian, M. A.
   Ghaly, N.
   Tsai, N.
   Motamed, K.
   Caldwell, R. B.
TI RETRACTED: Peroxynitrite mediates VEGF's angiogenic signal and function
   via a nitration-independent mechanism in endothelial cells (Retracted
   article. See vol. 31, pg. 421, 2017)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE angiogenesis; Src; redox signaling
ID OXYGEN-INDUCED RETINOPATHY; FOCAL ADHESION KINASE; GROWTH-FACTOR;
   NITRIC-OXIDE; TYROSINE NITRATION; NAD(P)H OXIDASE; C-SRC; EXPRESSION;
   RECEPTOR; ACTIVATION
AB The modulation of angiogenic signaling by reactive oxygen species (ROS) is an emerging area of interest in cellular and vascular biology research. We provide evidence here that peroxynitrite, the powerful oxidizing and nitrating free radical, is critically involved in transduction of the VEGF signal. We tested the hypothesis that VEGF induces peroxynitrite formation, which causes tyrosine phosphorylation and mediates endothelial cell migration and tube formation, by studies of vascular endothelial cells in vitro and in a model of hypoxia-induced neovascularization in vivo. The specific peroxynitrite decomposition catalyst FeTPPs blocked VEGF-induced phosphorylation of VEGFR2 and c-Src and inhibited endothelial cell migration and tube formation. Furthermore, exogenous peroxynitrite mimicked VEGF activity in causing phosphorylation of VEGFR2 and stimulating endothelial cell growth and tube formation in vitro and new blood vessel growth in vivo. The selective nitration inhibitor epicatechin enhanced VEGF's angiogenic function in activating VEGFR2, c-Src, and promoting endothelial cell growth, migration, and tube formation in vitro and retinal neovascularization in vivo. Decomposing peroxynitrite with FeTPPs or blocking oxidation using the thiol donor NAC blocked VEGF's angiogenic functions in vitro and in vivo. In conclusion, peroxynitrite is critically involved in transducing VEGF's angiogenic signal via nitration-independent and oxidation-mediated tyrosine phosphorylation.
C1 Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA.
   Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Oral Biol & Maxillofacial Pathol, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
   Univ S Carolina, Dept Ophthalmol, Columbia, SC 29208 USA.
   VA Med Ctr, Augusta, GA USA.
RP El-Remessy, AB (reprint author), Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, CJ-1033,1120 15th St, Augusta, GA 30912 USA.
EM aelremessy@mcg.edu
RI Al-Shabrawey, Mohamed/P-9570-2018
OI Al-Shabrawey, Mohamed/0000-0001-5362-7972
FU NCI NIH HHS [1K01CA89689]; NEI NIH HHS [EY11766, EY04618]
CR Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje
   Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255
   Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089
   Beauchamp MH, 2004, FREE RADICAL BIO MED, V37, P1885, DOI 10.1016/j.freeradbiomed.2004.09.008
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.0.CO;2-1
   Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468
   Brooks SE, 2001, INVEST OPHTH VIS SCI, V42, P222
   Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118
   Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jcb.M107711200
   Deen WM, 2002, FASEB J, V16, P1144
   DENICOLA A, 1995, FREE RADICAL BIO MED, V19, P11, DOI 10.1016/0891-5849(94)00239-G
   Droge W, 2002, PHYSIOL REV, V82, P47
   El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500
   El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612
   El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5
   Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079
   Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Gu WD, 2003, AM J PHYSIOL-HEART C, V285, pH1582, DOI 10.1152/ajpheart.00318.2003
   Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002
   He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130
   Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200
   Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219
   Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200
   Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694
   Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Platt DH, 2005, FREE RADICAL BIO MED, V39, P1353, DOI 10.1016/j.freeradbiomed.2005.06.015
   Pollard SE, 2006, BIOCHEM BIOPH RES CO, V350, P960, DOI 10.1016/j.bbrc.2006.09.131
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   RADI R, 1991, J BIOL CHEM, V266, P4244
   Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7
   Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659
   Schroeder P, 2001, BIOCHEM BIOPH RES CO, V285, P782, DOI 10.1006/bbrc.2001.5210
   Serafini M, 2005, METHOD ENZYMOL, V396, P215, DOI 10.1016/S0076-6879(05)96020-5
   Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8
   van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860
   Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
   Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200
NR 45
TC 76
Z9 79
U1 3
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2007
VL 21
IS 10
BP 2528
EP 2539
DI 10.1096/fj.06-7854com
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 196AS
UT WOS:000248454400027
PM 17384142
DA 2018-12-27
ER

PT J
AU Song, S
   Lee, J
AF Song, Seungkeun
   Lee, Joohyeon
TI RETRACTED: Key factors of heuristic evaluation for game design: Towards
   massively multi-player online role-playing game (Retracted article. See
   vol. 66, pg. 391, 2008)
SO INTERNATIONAL JOURNAL OF HUMAN-COMPUTER STUDIES
LA English
DT Article; Retracted Publication
DE MMORPG game design; usability; heuristics evaluation; design process
AB The computer game industry has become the fastest growing field of the entertainment industry. However, only a very small number of computer game products overcome the costs of production and generate earnings. According to traditional marketing wisdom, customers' preferences must be analyzed correctly to create successful products, and in the gaming industry, such information must be considered during the design process. This research aims to explore key factors of heuristic evaluation for game design. A review of literature pertaining to computer games and HCI was conducted along with an empirical research of a Massively Multi-player Online Role-playing Game (MMORPG). We identified 18 usability issues in MMORPG and presented a recommendation relevant to the issues. Empirical data were applied to a new heuristic evaluation framework. We determined the relationship between key factors and four game categories, such as game interface, game play, game narrative, and game mechanics. Moreover, the results presented 54 key factors for a new heuristic evaluation framework for game design. The conclusion presents key implications of our research in a game design context, particularly related to early design processes. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Yonsei Univ, Cognit Sci Program, Grad Sch, Seoul 120749, South Korea.
RP Lee, J (reprint author), Yonsei Univ, Cognit Sci Program, Grad Sch, 134 Shinchon Dong, Seoul 120749, South Korea.
EM songsk@yonsei.ac.kr; ljhyeon@yonsei.ac.kr
CR ARMSTRONG L, 1997, BUSINESS WEEK
   ARNUM CM, 2002, USABILITY TESTING RE
   Bickford P., 1997, INTERFACE DESIGN ART
   CLANTON C, 1998, P C CHI 98 SUMM HUM, P1
   CORNETT S, 2004, P C CHI 2004, V6, P703
   Crawford C, 1982, ART COMPUTER GAME DE
   DALMU DS, 1999, LEARN FASTER PLAY BE
   Desurvire H., 2004, CHI 04 HUM FACT COMP, P1509, DOI DOI 10.1145/985921.986102
   Dumas J.S., 1999, PRACTICAL GUIDE USAB
   Dumas JS, 2003, HUM FAC ER, P1093
   *ENT SOFTW ASS, 2005, ESS FACTS AB COMP VI
   Ericsson K. A., 1993, PROTOCOL ANAL
   Fabricatore C, 2002, HUM-COMPUT INTERACT, V17, P311, DOI 10.1207/S15327051HCI1704_1
   Federoff M., 2002, THESIS INDIANA U BLO
   FULTON B, 2002, P GAM DEV C
   JENKINS H, 2002, 1 PERSON NEW MEDIA S
   KANTNER L, 1997, P 15 ANN INT C COMP, P153
   KASAVIN G, 2006, HERE ONLINE ROLE PLA
   Kotler P., 1994, MARKETING MANAGEMENT
   Krueger R, 2000, FOCUS GROUPS PRACTIC
   Malone T. W., 1982, HUMAN FACTORS COMPUT
   MALONE TW, 1980, THESIS STANFORD U
   MANNINEN T, 2004, RICH INTERACTION MOD
   MEDLOCK MC, 2002, P US PROF ASS
   MYERS D, 1990, SIMULAT GAMING, V21, P375, DOI 10.1177/104687819002100403
   Nielsen J., 1994, USABILITY INSPECTION
   Nielsen J., 1993, USABILITY ENG
   Norman D. A., 1990, DESIGN EVERYDAY THIN
   Norman M., 1988, POLLS SURVEYS UNDERS
   PAUGLAYAN RJ, 2003, HUMAN COMPUTER INTER, P883
   Shelley B., 2001, GUIDELINES DEV SUCCE
   SHNEIDERMAN B, 1992, DESIGNING HUMAN INTE
   SONG S, 2006, P C HCI2006 MET, V2, P131
   SUDMAN S, 1996, THINKING ABOUT ANSWE
   van Someren MW, 1994, THINK ALOUD METHOD P
   WAGNER JA, 2002, SHOWDOWN CYBERSPACE
   WOODCOCK BS, 2003, ANAL MMOG SUBSCRIPTI
   Yee N., 2003, GENDER AGE DISTRIBUT
NR 38
TC 18
Z9 19
U1 4
U2 24
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1071-5819
EI 1095-9300
J9 INT J HUM-COMPUT ST
JI Int. J. Hum.-Comput. Stud.
PD AUG
PY 2007
VL 65
IS 8
BP 709
EP 723
DI 10.1016/j.ijhcs.2007.01.001
PG 15
WC Computer Science, Cybernetics; Ergonomics; Psychology, Multidisciplinary
SC Computer Science; Engineering; Psychology
GA 181HN
UT WOS:000247427900002
DA 2018-12-27
ER

PT J
AU Xiao, JN
   Yang, BF
   Lin, HX
   Lu, YJ
   Luo, XB
   Wang, ZG
AF Xiao, Jiening
   Yang, Baofeng
   Lin, Huixian
   Lu, Yanjie
   Luo, Xiaobin
   Wang, Zhiguo
TI RETRACTED: Novel approaches for gene-specific interference manipulating
   actions of via microRNAS: Examination on the pacemaker channel genes
   HCN2 and HCN4 (Retracted article. See vol. 227, pg. 877, 2012)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID HYPERPOLARIZATION-ACTIVATED CURRENT; CURRENT I-F; VENTRICULAR MYOCYTES;
   CARDIAC-PACEMAKER; EXPRESSION; MUSCLE; CELLS; HEART; INHIBITION; DISEASE
AB Recent evidence has suggested microRNAs as viable therapeutic targets for a wide range of human disease. However, lack of gene-specificity of microRNA actions may hinder this application. Here we developed two new approaches, the gene-specific microRNA mimic and microRNA-masking antisense approaches, to explore the possibility of using microRNA's principle of actions in a gene-specific manner. We examined the value of these strategies as rational approaches to develop heart rate-reducing agents and "biological pacemakers" by manipulating the expression of the cardiac pacemaker channel genes HCN2 and HCN4. We showed that the gene-specific microRNA mimics, 22-nt RNAs designed to target the 3'untranslated regions (3UTRs) of HCN2 and HCN4, respectively, were efficient in abrogating expression and function of HCN2 and HCN4. The gene-specific microRNA mimics repressed protein levels, accompanied by depressed f-channel conductance and the associated rhythmic activity, without affecting mRNA levels of HCN2 and HCN4. Meanwhile, we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and if conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133. The experimental examination of these techniques and the resultant findings not only indicate feasibility of interfering miRNA action in a gene-specific fashion but also may provide a new research tool for studying function of miRNAs. The new approaches also have the potential of becoming alternative gene therapy strategies.
C1 Montreal Heart Inst, Res Ctr, Montreal, PQ HIT 1C8, Canada.
   Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
   Harbin Med Coll, Dept Pharmacol, State Prov Key Labs Biomed Phamaceut China, Harbin, Peoples R China.
   Harbin Med Coll, Inst Cardiovasc Res, Harbin, Peoples R China.
RP Yang, BF (reprint author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ HIT 1C8, Canada.
EM yangbf@ems.hrbmu.edu.cn; wz.email@gmail.com
CR Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085
   Bucchi A, 2006, CIRCULATION, V114, P992, DOI 10.1161/CIRCULATIONAHA.106.617613
   Cerbai E, 1997, CIRCULATION, V95, P568, DOI 10.1161/01.CIR.95.3.568
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   DiFrancesco D, 2004, DRUGS, V64, P1757, DOI 10.2165/00003495-200464160-00003
   Fernandez-Velasco M, 2003, J PHYSIOL-LONDON, V553, P395, DOI 10.1113/jphysiol.2003.041954
   Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005
   Han W, 2002, CIRC RES, V91, P790, DOI 10.1161/01.RES.0000039534.18114.D9
   Hoppe UC, 1998, CIRCULATION, V97, P55, DOI 10.1161/01.CIR.97.1.55
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Lalevee N, 2005, CARDIOVASC RES, V67, P216, DOI 10.1016/j.cardiores.2005.009
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Pang L, 2003, FEBS LETT, V546, P349, DOI 10.1016/S0014-5793(03)00629-X
   Qu JH, 2003, CIRCULATION, V107, P1106, DOI 10.1161/01.CIR.0000059939.97249.2C
   Qu JH, 2001, CIRC RES, V89, pE8, DOI 10.1161/hh1301.094395
   Rosen MR, 2004, CARDIOVASC RES, V64, P12, DOI 10.1016/j.cardiores.2004.05.012
   Tse HF, 2006, CIRCULATION, V114, P1000, DOI 10.1161/CIRCULATIONHA.106.615385
   Van Bogaert PP, 2003, EUR J PHARMACOL, V478, P161, DOI 10.1016/j.ejphar.2003.08.083
   ZHANG Y, 2006, AM J PHYSIOL, V291, P1446
   Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817
NR 26
TC 142
Z9 161
U1 6
U2 22
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2007
VL 212
IS 2
BP 285
EP 292
DI 10.1002/jcp.21062
PG 8
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 186FF
UT WOS:000247763800003
PM 17516552
OA Bronze
DA 2018-12-27
ER

PT J
AU Luo, XB
   Xiao, JN
   Lin, HX
   Li, BX
   Lu, YJ
   Yang, BF
   Wang, ZG
AF Luo, Xiaobin
   Xiao, Jiening
   Lin, Huixian
   Li, Baoxin
   Lu, Yanjie
   Yang, Baofeng
   Wang, Zhiguo
TI RETRACTED: Transcriptional activation by stimulating protein 1 and
   post-transcriptional repression by muscle-specific microRNAs of
   I-KS-encodina genes and potential implications in regional heterogeneity
   of their expressions (Retracted article. See vol. 227, pg. 877, 2012)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID COMPLETE ATRIOVENTRICULAR-BLOCK; DE-POINTES ARRHYTHMIAS; POTASSIUM
   CHANNEL; ION CHANNELS; INTERVENTRICULAR DISPERSION;
   CELLULAR-DISTRIBUTION; VENTRICULAR-WALL; QT PROLONGATION;
   DOWN-REGULATION; K+ CURRENTS
AB In cardiac cells, KCNQI assembles with KCNEI and forms a channel complex constituting the slow delayed rectifier current I-Ks. Expression of KCNQI and KCNEI are regionally heterogeneous and changes with pathological states of the heart. The aims of this study were to decipher the molecular mechanisms for transcriptional and post-transcriptional regulation expression of KCNQI and KCNEI genes and to shed light on the molecular mechanisms for their spatial heterogeneity of distribution. We cloned the 5'-flanking region and identified the transcription start sites of the KCNQI gene. We characterized the core promoters of KCNQI and KCNEI and revealed the stimulating protein (Sp 1) as a common transactivator of KCNQI and KCNEI by interacting with the Sp I cis-acting elements in the core promoter regions of these genes. We also characterized the 3' untranslated regions (3'UTRs) of the genes and experimentally established KCNQI and KCNEI as targets for repression by the muscle-specific microRNAs miR-133 and miR-1, respectively. We demonstrated spatial heterogeneity of KCNQI and KCNEI distributions at three axes (interventricular, transmural and apical-basal) and disparity between mRNA and protein expressions of these genes. We also found characteristic regional differences of expressions of SpI and miR-l/miR- 133 in the heart. Our study unraveled a novel aspect of the cellular function of miRNAs and suggests that the I-Ks-encoding genes KCNQI and KCNEI expressions are dynamically balanced by transcription factor regulation and miRNA repression. The heterogeneities of SpI and miR-I/miR-133 offer an explanation for the well-recognized regional differences and disparity between mRNA and protein expressions of KCNQI and KCNEI.
C1 Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
   Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
   Harbin Med Coll, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Harbin, Peoples R China.
   Harbin Med Coll, Inst Cardiovasc Res, Harbin, Peoples R China.
RP Wang, ZG (reprint author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.
EM wz.email@gmail.com
CR Akar FG, 2005, ANN MED, V37, P44, DOI 10.1080/07853890510007214
   Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4
   DAY CP, 1990, BRIT HEART J, V63, P342
   GINTANT GA, 1995, AM J PHYSIOL-HEART C, V268, pH604
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Jost N, 2005, CIRCULATION, V112, P1392, DOI 10.1161/CIRCULATIONHA.105.550111
   KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Liu IC, 1999, ISSUES STUD, V35, P1
   Lundquist AL, 2006, GENOMICS, V87, P119, DOI 10.1016/j.ygeno.2005.09.004
   Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873
   Pang L, 2003, FEBS LETT, V546, P349, DOI 10.1016/S0014-5793(03)00629-X
   Pereon Y, 2000, AM J PHYSIOL-HEART C, V278, pH1908
   PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6
   Ramakers C, 2005, J MOL CELL CARDIOL, V38, P153, DOI 10.1016/j.yjmcc.2004.10.011
   Ramakers C, 2003, CARDIOVASC RES, V57, P486, DOI 10.1016/S0008-6363(02)00717-4
   Roden DM, 2005, CIRCULATION, V112, P1376, DOI 10.1061/CIRCULATION.HA.105.562777
   Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0
   Shi H, 2002, CELL PHYSIOL BIOCHEM, V12, P215, DOI 10.1159/000066281
   Szabo G, 2005, PFLUG ARCH EUR J PHY, V450, P307, DOI 10.1007/s00424-005-1445-z
   Szentadrassy N, 2005, CARDIOVASC RES, V65, P851, DOI 10.1016/j.cardiores.2004.11.022
   Tsuji Y, 2006, CIRCULATION, V113, P345, DOI 10.1161/CIRCULATIONAHA.105.552968
   Tsuji Y, 2002, CIRCULATION, V106, P2012, DOI 10.1161/01.CIR.0000031160.86313.24
   Vallon V, 2001, J AM SOC NEPHROL, V12, P2003
   Verduyn SC, 1997, CARDIOVASC RES, V34, P453, DOI 10.1016/S0008-6363(97)00067-9
   Verduyn SC, 1997, J AM COLL CARDIOL, V30, P1575, DOI 10.1016/S0735-1097(97)00333-1
   Volders PGA, 1999, CIRCULATION, V100, P2455, DOI 10.1161/01.CIR.100.24.2455
   Volders PGA, 1999, CIRCULATION, V99, P206, DOI 10.1161/01.CIR.99.2.206
   Wang HZ, 2001, MOL PHARMACOL, V59, P1029
   Zhang BY, 2006, J NETW COMPUT APPL, V29, P1, DOI 10.1016/j.jnca.2004.12.001
   Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817
   Zheng WC, 2007, AM J PHYSIOL-RENAL, V292, pF456, DOI 10.1152/ajprenal.00087.2006
NR 40
TC 77
Z9 85
U1 5
U2 19
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2007
VL 212
IS 2
BP 358
EP 367
DI 10.1002/jcp.21030
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 186FF
UT WOS:000247763800012
PM 17443681
OA Bronze
DA 2018-12-27
ER

PT J
AU Ling, YH
   Li, TH
   Yuan, ZQ
   Haigentz, M
   Weber, TK
   Perez-Soler, R
AF Ling, Yi-He
   Li, Tianhong
   Yuan, Ziqiang
   Haigentz, Missak, Jr.
   Weber, Thomas K.
   Perez-Soler, Roman
TI RETRACTED: Erlotinib, an effective epidermal growth factor receptor
   tyrosine kinase inhibitor, induces p27(KIP1) up-regulation and nuclear
   translocation in association with cell growth inhibition and G1/S phase
   arrest in human non-small-cell lung cancer cell lines (Retracted
   article. See vol. 88, pg. 390, 2015)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID CYCLE PROGRESSION; CDK-INHIBITORS; PHOSPHORYLATION; P27; EXPRESSION;
   COMPLEX; G(1); UBIQUITINATION; LOCALIZATION; MALIGNANCIES
AB Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been shown to have potent antitumor effects against human non-small-cell lung cancer (NSCLC) cell growth; however, the mechanism of such an effect is not elucidated. Here, we demonstrate that erlotinib-induced cell growth inhibition in EGFR high-expressing human H322 NSCLC cells was accompanied by G(1)/S phase arrest, which was largely caused by a decrease in expression of G(1)/S-related cyclins, suppression of activities of cyclin-dependent kinase (CDK) 2 and CDK4, induction of CDK inhibitor p27(KIP1), and retinoblastoma hypophosphorylation. To further understand the role of p27(KIP1) in G(1)/S arrest and cell growth inhibition by erlotinib, we determined its effect on the expression of p27(KIP1) at transcriptional and posttranscriptional levels. Studies using real-time reverse transcription-polymerase chain reaction analysis and p27 promoter-driven luciferase reporter showed that erlotinib treatment resulted in the promotion of p27 gene transcription. In addition, erlotinib treatment led to an increase in p27(KIP1) half-life by inhibiting p27(KIP1) phosphorylation at Thr187 and by down-regulating Skp2 expression. Furthermore, immunofluorescence staining and cell fractionation showed that erlotinib treatment led to p27(KIP1) translocation to the nucleus. Knockdown of p27(KIP1) expression with p27(KIP1) small interfering RNA significantly abrogated erlotinib-induced G(1) phase arrest and cell growth inhibition, suggesting that induction of p27(KIP1) is required for G(1) arrest and cell growth inhibition by erlotinib. It is noteworthy that we found that G(1) arrest and p27(KIP1) up-regulation by erlotinib occurred in the tested sensitive cell lines but to a lesser extent in the resistant cell lines. Taken together, these results suggest that erlotinib inhibits human NSCLC cell growth predominantly by inducing p27(KIP1) expression and by suppressing cell-cycle events involved in the G(1)/S transition.
C1 Montefiore Med Ctr, Dept Oncol, Bronx, NY 10467 USA.
   Montefiore Med Ctr, Dept Mol Genet, Bronx, NY USA.
   Albert Einstein Coll Med, Bronx, NY 10467 USA.
RP Perez-Soler, R (reprint author), Montefiore Med Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.
EM rperezso@montefiore.org
FU NCI NIH HHS [CA91784, CA96515]
CR ADJEJ AA, 2006, CLIN CANC RES, V12
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004
   Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406
   Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343
   Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57
   Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000
   Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245
   Fischer C, 2005, J BIOL CHEM, V280, P37266, DOI 10.1074/jbc.M411580200
   Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200
   HAEDER M, 1988, CANCER RES, V48, P1132
   Herbst RS, 2003, CLIN CANCER RES, V9, P5813
   Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267
   Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309
   Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200
   Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497
   Klapper LN, 2000, ADV CANCER RES, V77, P25
   KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288
   Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200
   Lenferink AEG, 2001, CANCER RES, V61, P6583
   Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4
   Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181
   Moyer JD, 1997, CANCER RES, V57, P4838
   Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900
   Noonberg SB, 2000, DRUGS, V59, P753, DOI 10.2165/00003495-200059040-00003
   Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   SCAGLIOTTI GV, 2004, CLIN CANC RES, V15
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759
   Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1047/jbc.M412367200
   Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.3.CO;2-9
   Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5
   Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762
   Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yaroslavskiy B, 1999, BLOOD, V93, P2907
NR 42
TC 63
Z9 65
U1 3
U2 12
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD AUG
PY 2007
VL 72
IS 2
BP 248
EP 258
DI 10.1124/mol.107.034827
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 193OH
UT WOS:000248282900005
PM 17456787
OA Bronze
DA 2018-12-27
ER

PT J
AU Norajit, K
   Laohakunjit, N
   Kerdchoechuen, O
AF Norajit, Krittika
   Laohakunjit, Natta
   Kerdchoechuen, Orapin
TI RETRACTED: Antibacterial effect of five Zingiberaceae essential oils
   (Retracted Article. See vol 13, pg 488, 2008)
SO MOLECULES
LA English
DT Article; Retracted Publication
DE antibacterial activity; ginger; galangal; turmeric; kaempferia; bastard;
   cardamom
ID ANTIMICROBIAL ACTIVITY; METHANOL EXTRACTS; FOOD SPOILAGE; PLANTS;
   MEDICINE; GINGER
AB Essential oil obtained by hydrodistillation and two different solvent extractions (petroleum ether and ethanol) from five Zingiberaceae species: ginger (Zingiber officinale Roscoe.), galanga (Alpinia galanga Sw.), turmeric (Curcuma longa L.), kaempferia (Boesenbergia pandurata Holtt.) and bastard cardamom (Amomum xanthioides Wall.) was characterized. Volatile components of all extracts were analyzed by gas chromatography-mass spectrometry (GC-MS). The major components of ginger, turmeric, galangal, bastard cardamom and kaempferia were zingiberene, turmerone, methyl chavicol, and gamma-terpinene, respectively. Their antibacterial effects towards Escherichia coli, Staphylococcus aureus, Bacillus cereus and Listeria monocytogenes were tested by a disc diffusion assay. Essential oil of kaempferia and bastard cardamom obtained by hydrodistillation extraction could inhibit growth of all tested bacteria. Essential oil of ginger extracted by hydrodistillation had the highest efficiency against three positive strains of bacteria (S. aureus, B. cereus and L. monocytogenes), with a minimum concentration to inhibit B. cereus and L. monocytogenes of 6.25 mg/mL.
C1 King Mongkuts Univ Technol Thonburi, Sch Bioresources & Technol, Bangkok 10150, Thailand.
RP Kerdchoechuen, O (reprint author), King Mongkuts Univ Technol Thonburi, Sch Bioresources & Technol, Bangkok 10150, Thailand.
EM email_norajit@hotmail.com; orapinkerd@yahoo.com
CR Alzoreky NS, 2003, INT J FOOD MICROBIOL, V80, P223, DOI 10.1016/S0168-1605(02)00169-1
   Baydar H, 2004, FOOD CONTROL, V15, P169, DOI 10.1016/S0956-7135(03)00028-8
   Bendjeddou D, 2003, J ETHNOPHARMACOL, V88, P155, DOI 10.1016/S0378-8741(03)00226-5
   Betts GD, 1999, FOOD CONTROL, V10, P27, DOI 10.1016/S0956-7135(98)00151-0
   BURKILL IH, 1966, DICT EC PRODUCTS MAL, V1, P2402
   Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022
   Cosentino S, 1999, LETT APPL MICROBIOL, V29, P130, DOI 10.1046/j.1472-765X.1999.00605.x
   DEAK T, 1996, HDB FOOD SPOILAGE
   Gulluce M, 2003, J AGR FOOD CHEM, V51, P3958, DOI 10.1021/jf0340308
   Hsieh PC, 2001, FOOD MICROBIOL, V18, P35, DOI 10.1006/fmic.2000.0376
   Jirovetz Leopold, 2003, Acta Pharmaceutica (Zagreb), V53, P73
   Karaman I, 2003, J ETHNOPHARMACOL, V85, P231, DOI 10.1016/S0378-8741(03)00006-0
   Kumar S, 2001, BIOCONJUGATE CHEM, V12, P464, DOI 10.1021/bc0000482
   Kumarasamy Y, 2002, J ETHNOPHARMACOL, V83, P73, DOI 10.1016/S0378-8741(02)00214-3
   Leal PF, 2003, J AGR FOOD CHEM, V51, P2520, DOI 10.1021/jf0260693
   Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502
   Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d
   Nguefack J, 2004, INT J FOOD MICROBIOL, V94, P329, DOI 10.1016/j.ijfoodmicro.2004.02.017
   Sagdic O, 2003, FOOD CONTROL, V14, P141, DOI 10.1016/S0956-7135(02)00057-9
   *SAS, 1991, SAS LANG GUID PERS C, P558
   Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0
   Sekiwa Y, 2000, J AGR FOOD CHEM, V48, P373, DOI 10.1021/jf990674x
   Smid E. J., 1999, HDB FOOD PRESERVATIO, P285
   Srinivasan D, 2001, J ETHNOPHARMACOL, V74, P217, DOI 10.1016/S0378-8741(00)00345-7
   Zancan KC, 2002, J SUPERCRIT FLUID, V24, P57, DOI 10.1016/S0896-8446(02)00013-X
NR 25
TC 35
Z9 37
U1 3
U2 39
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2007
VL 12
IS 8
BP 2047
EP 2060
DI 10.3390/12082047
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 225AA
UT WOS:000250488300036
PM 17960105
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jie, X
   Lang, C
   Jian, Q
   Chaoqun, L
   Dehua, Y
   Yu, S
   Yanping, J
   Luokun, X
   Qiuping, Z
   Hui, W
   Feili, G
   Boquan, J
   Youxin, J
   Jinquan, T
AF Jie, X.
   Lang, C.
   Jian, Q.
   Chaoqun, L.
   Dehua, Y.
   Yu, S.
   Yanping, J.
   Luokun, X.
   Qiuping, Z.
   Hui, W.
   Feili, G.
   Boquan, J.
   Youxin, J.
   Jinquan, T.
TI RETRACTED: Androgen activates PEG10 to promote carcinogenesis in hepatic
   cancer cells (Retracted article. See vol. 30, pg. 2798, 2011)
SO ONCOGENE
LA English
DT Article; Retracted Publication
DE hepatocellular carcinoma; androgen; androgen; receptor; PEG10; apoptosis
ID HEPATOCELLULAR-CARCINOMA; IMPRINTED GENE; APOPTOSIS; EXPRESSION;
   INTERACTS; RECEPTOR; PROTEIN; RETROTRANSPOSON
AB The molecular mechanism of striking higher prevalence of hepatocellular carcinoma (HCC) in male subjects has not yet been fully elucidated. Here, we report that androgen receptor (AR) is differentially expressed in different HCC cell lines. AR agonist dihydrotestosterone (DHT) enhances HCC cell growth and apoptotic resistance. Antagonist flutamide (FLU) blocks the effects of DHT on the HCC cell lines. Paternally expressed gene 10 (PEGI10) is expressed in HCC cell lines at substantial high level. Using small interfering RNAs against AR and PEG10 in AR- and PEG10-expressing BEL-7404 hepatoma cells and HuH7 hepatoma cells (HuH7) cells, and AR-transfection technique in AR-lacking and PEG10-expressing HepG2 cells, we have confirmed that through upregulation and activation of PEG10, DHT enhances HCC cell growth and apoptotic resistance. We have further demonstrated that DHT upregulates expression of human telomerase reverse transcriptase (hTERT) in HCC cell lines in a PEG10-dependent manner. Moreover, AR directly interacts in vivo with androgen-responsive elements in the regions of promoter and exon 2 of PEG10 gene in HCC cell lines. DHT promotes the hepatoma formation in viro nude mice through PEG10 activation. AR antagonists (FLU and valproate) inhibit the hepatoma formation. These findings suggest that PEG10 plays an essential role in hepatocarcinogenesis. The PEG10 inhibition can be a novel approach for therapy of HCC.
C1 Wuhan Univ, Sch Med, Dept Immunol, Wuhan 430071, Hubei, Peoples R China.
   Wuhan Univ, Sch Med, Inst Allergy & Immune Related Dis, Lab Allergy & Clin Immunol, Wuhan 430072, Peoples R China.
   Wuhan Univ, Sch Med, Med Res Ctr, Wuhan 430072, Peoples R China.
   Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China.
   Shanghai Med Univ 2, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China.
   S China Normal Univ, Coll Life Sci, Guangzhou, Peoples R China.
   Wuhan Univ, Sch Med, Dept Pharmacol, Wuhan 430072, Peoples R China.
   Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430074, Peoples R China.
   Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China.
RP Jinquan, T (reprint author), Wuhan Univ, Sch Med, Dept Immunol, Dong Hu Rd 115, Wuhan 430071, Hubei, Peoples R China.
EM jinquan_tan@hotmail.com
CR Death AK, 2005, STEROIDS, V70, P946, DOI 10.1016/j.steroids.2005.07.003
   Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3
   Hu CS, 2006, J IMMUNOL, V177, P6713
   Huang RM, 2003, CANCER RES, V63, P3775
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9
   Li CM, 2006, CANCER RES, V66, P665, DOI 10.1158/0008-5472.CAN-05-1553
   Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200
   Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070
   NAGASUE N, 1995, BRIT J SURG, V82, P542, DOI 10.1002/bjs.1800820435
   Okabe H, 2001, CANCER RES, V61, P2129
   Okabe H, 2003, CANCER RES, V63, P3043
   Ono R, 2006, NAT GENET, V38, P101, DOI 10.1038/ng1699
   Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494
   Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200
   Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833
   Sathya G, 2003, CANCER RES, V63, P8029
   Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24
   Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969
   Steplewski A, 1998, BIOCHEM BIOPH RES CO, V243, P295, DOI 10.1006/bbrc.1997.7821
   Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722
   Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528
   Youssef N, 2001, J PATHOL, V194, P459, DOI 10.1002/path.901
   Yu MW, 2001, J NATL CANCER I, V93, P1644, DOI 10.1093/jnci/93.21.1644
   Zhang DY, 2004, HEPATOLOGY, V39, P954, DOI 10.1002/hep.20135
   Zhang YX, 2005, P NATL ACAD SCI USA, V102, P9890, DOI 10.1073/pnas.0503829102
NR 26
TC 32
Z9 36
U1 5
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG
PY 2007
VL 26
IS 39
BP 5741
EP 5751
DI 10.1038/sj.onc.1210362
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 202EP
UT WOS:000248885100006
PM 17369855
OA Bronze
DA 2018-12-27
ER

PT J
AU Wu, LM
   Qiao, HX
   Li, YK
   Li, LD
AF Wu, Limao
   Qiao, Hongxiang
   Li, Yikui
   Li, Lianda
TI RETRACTED: Cardioprotective effects of the combined use of puerarin and
   Danshensu on acute ischemic myocardial injury in rats (Retracted
   article. See vol. 23, pg. 745, 2009)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE acute myocardial ischemia; Shenge; puerarin; Danshensu
ID SALVIA-MILTIORRHIZA-BUNGE; ANTIOXIDANT PROPERTIES; REPERFUSION INJURY;
   INFARCTION; EXTRACT; HEARTS; HPLC
AB Ischemic heart diseases are the leading cause of death in both developed and developing countries over the past decades. The aim of this study was to investigate the cardioprotective effects of the complex preparation (called Shenge), made of puerarin and Danshensu, on acute ischemic myocardial injury in rats and its underlying mechanisms. The left anterior descending (LAD) coronary artery was occluded to induce myocardial ischemia in hearts of SD rats. Shenge was injected into the tail vein 15 min after occlusion at doses of 0, 30, 60 or 120 mg/kg. Then, the ST elevation was measured at 60, 120 and 240 min after Shenge administration. The infarct size, serum levels of creatine kinase isoenzyme-MB (CK-MB), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (NIDA), and the ST elevation were measured after the rats were killed. Shenge decreased the ST elevation induced by acute myocardial ischemia, reduced infarct size, serum levels of CK-MB, LDH and NIDA and increased the serum activity of SOD in a dose-dependent manner. The combined use of puerarin and Danshensu at a ratio of 1:1 shows the most effective activity. In conclusion, Shenge exerts significant cardioprotective effects against acute ischemic myocardial injury in rats, likely through its antioxidant and antilipid peroxidation properties, and thus may be used as an effective and promising medicine for both prophylaxis and treatment of ischemic heart disease. Copyright (c) 2007 John Wiley & Sons, Ltd.
C1 Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China.
   China Acad Tradit Chinese Med, Xiyuan Hosp, Beijing 100091, Peoples R China.
RP Li, LD (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, Zijingang Campus, Hangzhou 310058, Peoples R China.
EM wulimao@yahoo.com.cn
CR [Anonymous], 1999, ZHONGGUO ZHANG YAO Z
   Bodi V, 2005, INT J CARDIOL, V103, P85, DOI 10.1016/j.ijcard.2004.08.022
   CHANG WS, 1993, ANTICANCER RES, V13, P2165
   Chen EP, 1996, CIRCULATION, V94, P412
   Fan L. L., 1984, ACTA PHARMACOL SINIC, V19, P801
   Gao Q, 2006, LIFE SCI, V79, P217, DOI 10.1016/j.lfs.2005.12.040
   GORDON MH, 1992, FOOD CHEM, V44, P119, DOI 10.1016/0308-8146(92)90322-S
   Grech ED, 1996, AM J CARDIOL, V77, P122, DOI 10.1016/S0002-9149(96)90580-9
   Gu M, 2004, J CHROMATOGR A, V1041, P239, DOI 10.1016/j.chroma.2004.04.030
   Guerra MC, 2000, LIFE SCI, V67, P2997, DOI 10.1016/S0024-3205(00)00885-7
   Haiyun Ling, 2004, J Ethnopharmacol, V94, P101, DOI 10.1016/j.jep.2004.04.016
   Hangaishi M, 2001, BIOCHEM BIOPH RES CO, V285, P1220, DOI 10.1006/bbrc.2001.5319
   He XL, 2004, J CHROMATOGR A, V1022, P77, DOI 10.1016/j.chroma.2003.09.045
   Jin Minghua, 2003, Zhong Yao Cai, V26, P148
   Jin UH, 2006, VASC PHARMACOL, V44, P345, DOI 10.1016/j.vph.2006.01.007
   Liu J, 2001, LIFE SCI, V69, P1833, DOI 10.1016/S0024-3205(01)01267-X
   Liu Q, 2000, J Tongji Med Univ, V20, P43
   Liu Qigong, 1999, Zhongguo Zhongyao Zazhi, V24, P304
   LU XR, 1987, CHINESE MED J-PEKING, V100, P25
   Luo XJ, 2001, BIOMED CHROMATOGR, V15, P493, DOI 10.1002/bmc.105
   Ma Jie, 2002, Zhong Yao Cai, V25, P731
   Overstreet DH, 2002, EUR NEUROPSYCHOPHARM, V12, pS361
   Pan Hong-ping, 2005, Zhongguo Zhongyao Zazhi, V30, P457
   Sieveking DP, 2005, INT J CARDIOL, V105, P40, DOI 10.1016/j.ijcard.2004.10.052
   Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939
   Wang XJ, 2005, J ETHNOPHARMACOL, V97, P441, DOI 10.1016/j.jep.2004.11.036
   Xie Rui-qin, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P895
   Yan B, 2004, PHARMACOL BIOCHEM BE, V78, P319, DOI 10.1016/j.pbb.2004.04.010
   YANAGIHARA K, 1993, CANCER RES, V53, P5815
   Yu BS, 2002, J PHARMACEUT BIOMED, V30, P843, DOI 10.1016/S0731-7085(02)00326-6
   Zhang GQ, 2003, ACTA PHARMACOL SIN, V24, P1212
   Zhao BL, 1996, BIOCHEM MOL BIOL INT, V38, P1171
NR 32
TC 26
Z9 31
U1 4
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD AUG
PY 2007
VL 21
IS 8
BP 751
EP 756
DI 10.1002/ptr.2157
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 197LL
UT WOS:000248556900008
PM 17450507
DA 2018-12-27
ER

PT J
AU Yusoff, ARM
   Syahrul, MN
   Henkel, K
AF Yusoff, A. R. M.
   Syahrul, M. N.
   Henkel, K.
TI RETRACTED: Hydrogenated nanocrystalline silicon germanium thin films
   (Retracted article. See vol. 81, pg. 1071, 2013)
SO PRAMANA-JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
DE silicon; germanium; hot-wire
ID CHEMICAL-VAPOR-DEPOSITION; X-RAY-SCATTERING; AMORPHOUS-SILICON;
   POTENTIAL FLUCTUATIONS; PHOTOMIXING TECHNIQUE; ALLOYS
AB Hydrogenated nanocrystalline silicon germanium thin films (nc-SiGe:H) is an interesting alternative material to replace hydrogenated nanocrystalline silicon (ncSi:H) as the narrow bandgap absorber in an a-Si/a-SiGe/nc-SiGe(nc-Si) triple-junction solar cell due to its higher optical absorption in the wavelength range of interest. In this paper, we present results of optical, structural investigations and electrical characterization of nc-SiGe:H thin films made by hot-wire chemical vapor deposition (HWCVD) with a coil-shaped tungsten filament and with a disilane/germane/hydrogen gas mixture. The optical band gaps of a-SiGe:H and nc-SiGe:H thin-films, which axe deposited with the same disilane/germane/hydrogen gas mixture ratio of 3.4: 1.7: 7, are about 1.58 eV and 2.1 eV, respectively. The nc-SiGe:H thin film exhibits a larger optical absorption coefficient of about 2-4 in the 600-900 nm range when compared to nc-Si:H thin film. Therefore, a thinner nc-SiGe:H layer of similar to 500 nm thickness may be sufficient for the narrow bandgap absorber in an a-Si based multiple-junction solar cell. We enhanced the transport properties as measured by the photoconductivity frequency mixing technique. These improved alloys do not necessarily show an improvement in the degree of structural heterogeneity on the nanometer scale as measured by small-angle X-ray scattering. Decreasing both the filament temperature and substrate temperature produced a film with relatively low structural heterogeneity while photoluminescence showed an order of magnitude increase in defect density for a similar change in the process.
C1 Univ Sci Malaysia, Dept Phys, George Town, Malaysia.
RP Yusoff, ARM (reprint author), Univ Sci Malaysia, Dept Phys, George Town, Malaysia.
EM abdrashid_4@yahoo.com
CR BRAUNSTEIN R, 1958, PHYS REV, V109, P695, DOI 10.1103/PhysRev.109.695
   Cullity B. D., 1978, ELEMENTS XRAY DIFFRA, P281
   Goerigk G, 2001, J APPL PHYS, V90, P5808, DOI 10.1063/1.1413488
   HOWARD JA, 1991, PHYS REV B, V44, P7935, DOI 10.1103/PhysRevB.44.7935
   KLEIN S, 2002, MRS S P, V715
   Lill M, 1999, APPL PHYS LETT, V74, P1284, DOI 10.1063/1.123525
   Meier J., 2004, THIN SOLID FILMS, V518, P451
   Nelson BP, 1998, MATER RES SOC SYMP P, V507, P447, DOI 10.1557/PROC-507-447
   Schropp REI, 2004, THIN SOLID FILMS, V451, P455, DOI 10.1016/j.tsf.2003.10.126
   Sheng SR, 2002, MAT SCI ENG A-STRUCT, V325, P490, DOI 10.1016/S0921-5093(01)01738-5
   SWANEPOEL R, 1983, J PHYS E SCI INSTRUM, V16, P1214, DOI 10.1088/0022-3735/16/12/023
   Tang Y, 1996, J APPL PHYS, V79, P850, DOI 10.1063/1.360904
   Tang Y, 1996, APPL PHYS LETT, V68, P640, DOI 10.1063/1.116494
   WAGNER S, 1988, MATER RES SOC S P, V118, P623
   WANG Q, 2000, TXB CARDIOVASCULAR M, V3, P1
   Williamson D. L., 1995, MATER RES SOC S P, V377, P251
   Williamson DL, 1999, AIP CONF PROC, V462, P272
   Yang J, 1997, APPL PHYS LETT, V70, P2975, DOI 10.1063/1.118761
   YUE GZ, 2000, J NONCRYST SOLIDS B, V266
   YUSOFF ARM, 2002, 2 INT C CAT CVD
NR 20
TC 1
Z9 1
U1 3
U2 17
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0304-4289
EI 0973-7111
J9 PRAMANA-J PHYS
JI Pramana-J. Phys.
PD AUG
PY 2007
VL 69
IS 2
BP 285
EP 300
DI 10.1007/s12043-007-0129-y
PG 16
WC Physics, Multidisciplinary
SC Physics
GA 210JY
UT WOS:000249453700013
DA 2018-12-27
ER

PT J
AU Yang, S
   Laumonier, T
   Menetrey, J
AF Yang Sheng
   Laumonier, Thomas
   Menetrey, Jacques
TI RETRACTED: Heat shock pretreatment enhances porcine myoblasts survival
   after autotransplantation in intact skeletal muscle (Retracted article.
   See vol. 51, pg. 286, 2008)
SO SCIENCE IN CHINA SERIES C-LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE myoblast; heat shock pretreatment; transplantation; skeletal muscle;
   HSP70
ID CELL-DEATH; CYTOCHROME-C; APAF-1 APOPTOSOME; TRANSFER THERAPY; SATELLITE
   CELLS; TRANSPLANTATION; PROTEIN; DYNAMICS; NECROSIS; HSP70
AB Myoblast transplantation (MT) is a cell-based gene therapy treatment, representing a potential treatment for Duchenne muscular dystrophy (DMD), cardiac failure and muscle trauma. The rapid and massive death of transplanted cells after MT is considered as a major hurdle which limits the efficacy of MT treatment. Heat shock proteins (HSPs) are overexpressed when cells undergo various insults. HSPs have been described to protect cells in vivo and in vitro against diverse insults. The aim of our study is to investigate whether HSP overexpression could increase myoblast survival after autotransplantation in pig intact skeletal muscle. HSP expression was induced by warming the cells at 42 degrees C for 1 h. HSP70 expression was quantified by Western blot and flow cytometry 24 h after the treatment. To investigate the myogenic characteristics of myoblasts, desmin and CD56 were analysed by Western blot and flow cytometry; and the fusion index was measured. We also quantified cell survival after autologous transplantation in pig intact skeletal muscle and followed cell integration. Results showed that heat shock treatment of myoblasts induced a significative overexpression of the HSP70 (P < 0.01) without loss of their myogenic characteristics as assessed by FACS and fusion index. In vivo (n=7), the myoblast survival rate was not significantly different at 24 h between heat shock treated and nontreated cells (67.69% +/- 8.35% versus 58.79% +/- 8.35%, P > 0.05). However, the myoblast survival rate in the heat shocked cells increased by twofold at 48 h (53.32 % +/- 8.22 % versus 28.27 +/- % 6.32 %, P < 0.01) and more than threefold at 120 h (26.33% +/- 5.54% versus 8.79% +/- 2.51 %, P < 0.01). Histological analysis showed the presence of non-heat shocked and heat shocked donor myoblasts fused with host myoblasts. These results suggested that heat shock pretreatment increased the HSP70 expression in porcine myoblasts, and improved the survival rate after autologous transplantation. Therefore, heat shock pretreatment of myoblast in vitro is a simple and effective way to enhance cell survival after transplantation in pig. It might represent a potential method to overcome the limitations of IVIT treatment.
C1 Fac Med, Dept Orthoped Surg, CH-1211 Geneva, Switzerland.
   Univ Hosp, CH-1211 Geneva, Switzerland.
   Dalian Univ, Zhongshan Hosp, Dept Orthoped Surg, Dalian 116001, Peoples R China.
RP Menetrey, J (reprint author), Fac Med, Dept Orthoped Surg, CH-1211 Geneva, Switzerland.
CR BAROFFIO A, 1993, MUSCLE NERVE, V16, P498, DOI 10.1002/mus.880160511
   Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113
   Beere HM, 2000, NAT CELL BIOL, V2, P469
   Bouchentouf M, 2004, TRANSPLANTATION, V77, P1349, DOI 10.1097/01.TP.0000121503.01535.F5
   Bruey JM, 2000, NAT CELL BIOL, V2, P645
   el Andalousi RB, 2002, CELL TRANSPLANT, V11, P169
   Fink AL, 1999, PHYSIOL REV, V79, P425
   Holzer N, 2005, NEUROMUSCULAR DISORD, V15, P237, DOI 10.1016/j.nmd.2004.11.001
   Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586
   JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029
   Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W
   Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446
   Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7
   Saleh A, 2000, NAT CELL BIOL, V2, P476
   Sammels LM, 2004, TRANSPLANTATION, V77, P1790, DOI 10.1097/01.tp.0000131150.76841.75
   Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7
   Skuk D, 2003, CURR OPIN RHEUMATOL, V15, P723, DOI 10.1097/00002281-200311000-00007
   Skuk D, 2003, J NEUROPATH EXP NEUR, V62, P951, DOI 10.1093/jnen/62.9.951
   Smythe GM, 2000, MOL THER, V1, P304, DOI 10.1006/mthe.2000.0049
   Suzuki K, 2000, CIRCULATION, V102, P216
   Thompson RB, 2003, CIRCULATION, V108, P264, DOI 10.1161/01.cir.0000087657.29184.9b
   Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643
   Yamashita N, 1997, J MOL CELL CARDIOL, V29, P1805, DOI 10.1006/jmcc.1997.0415
   Yoo KJ, 2000, CIRCULATION, V102, P204
   Zhang M, 2001, J MOL CELL CARDIOL, V33, P907, DOI 10.1006/jmcc.2001.1367
NR 27
TC 8
Z9 8
U1 3
U2 11
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9305
J9 SCI CHINA SER C
JI Sci. China Ser. C-Life Sci.
PD AUG
PY 2007
VL 50
IS 4
BP 438
EP 446
DI 10.1007/s11427-007-0065-6
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 207QU
UT WOS:000249267000002
PM 17653663
DA 2018-12-27
ER

PT J
AU Boldt, J
   Mengistu, A
   Seyfert, UT
   Vogt, A
   Hellstern, P
AF Boldt, J.
   Mengistu, A.
   Seyfert, U. T.
   Vogt, A.
   Hellstern, P.
TI RETRACTED: The impact of a medium molecular weight, low molar
   substitution hydroxyethyl starch dissolved in a physiologically balanced
   electrolyte solution on blood coagulation and platelet function in vitro
   (Retracted article. See vol. 101, pg. 90, 2011)
SO VOX SANGUINIS
LA English
DT Article; Retracted Publication
DE balanced electrolyte solution; blood coagulation; hydroxyethyl starches;
   platelet function.
ID LACTATED RINGERS SOLUTION; WHOLE-BLOOD; AGGREGATION; PLASMA; SALINE;
   THROMBELASTOGRAPHY; AGGREGOMETRY; SURGERY; VOLUME
AB Background and Objectives Hydroxyethyl starches (HES) may have the potential to impact negatively on haemostasis. Recent findings suggest that side-effects on haemostasis stem not only from the physicochemical differences between HES, but also from the composition of the solvent. We compared the effects of a newly developed medium molecular weight (MW) and low molar substitution (MS) HES dissolved in a physiologically balanced electrolyte solution (MW 130, MS 0.42; B-HES) with a commercially available non-balanced HES (MW 130, MS 0.4; NB-HES), and with Ringer's lactate (RL) solution in vitro.
   Materials and Methods Activated partial thromboplastin time (APTT), factor VIII clotting activity (F VIII:C) and von Willebrand factor (vWF) activity were investigated in 48 healthy individuals. Platelet function as measured by turbidimetric platelet aggregometry and whole blood impedance aggregometry induced by adenosine diphosphate (ADP), collagen and thrombin receptor activating peptide (TRAP), and by ADP and TRAP-induced expression of activated platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa was determined in 24 participants. Haemodilution (25% and 50%, v/v for blood coagulation analyses and 20% and 40%, v/v for platelet function studies) was performed using the two HES preparations and RL.
   Results APTT was significantly longer and F VIII and vVVF significantly lower at 25% and 50% dilutions with NB-HES compared to B-HES and RL. At 20% and 40% dilutions, ADP and TRAP-induced expression of activated platelet surface GP IIb/IIIa was significantly increased by B-HES compared to NB-HES and RL. Percentages of platelet GP IIb/IIIa expression were also significantly greater in samples diluted with B-HES than in undiluted blood. Neither the diluent (B-HES, NB-HES and RL) nor the degree of dilution (undiluted, 20% and 40% dilution) had any significant influence on ADP, collagen or TRAP-induced turbidimetric platelet aggregation or impedance platelet aggregation.
   Conclusions In contrast to a non-balanced 130 kDa, MS 0.4 HES (NB-HES), a 130 kDa, MS 0.42 HES preparation dissolved in a physiologically balanced electrolyte solution (B-HES) does not affect APTT, F VIII:C and vWF in vitro. Both types of HES do not affect platelet aggregation induced by ADP, collagen or TRAP. B-HES but not NB-HES increases the expression of activated platelet GP IIb/IIIa induced by ADP or TRAP.
C1 Acad City Hosp, Inst Hemostaseol & Transfus Med, D-67063 Ludwigshafen, Germany.
   Acad City Hosp, Clin Anasthesiol & Intens Care Med, Ludwigshafen, Germany.
RP Hellstern, P (reprint author), Acad City Hosp, Inst Hemostaseol & Transfus Med, Bremerstr 79, D-67063 Ludwigshafen, Germany.
EM peterhellstern@medicusnet.de
CR Blaicher AM, 1998, ANESTH ANALG, V86, P1318, DOI 10.1097/00000539-199806000-00035
   Boldt J, 2007, ANESTH ANALG, V104, P425, DOI 10.1213/01.ane.0000253484.19070.87
   Dailey SE, 2005, J CARDIOTHOR VASC AN, V19, P358, DOI 10.1053/j.jvca.2005.03.014
   Deusch E, 2004, ANESTH ANALG, V99, P665, DOI 10.1213/01.ANE.0000130349.99727.58
   Franz A, 2001, ANESTH ANALG, V92, P1402, DOI 10.1097/00000539-200106000-00008
   Haisch G, 2001, ANESTH ANALG, V92, P565, DOI 10.1213/00000539-200103000-00003
   Konrad CJ, 2000, ANESTH ANALG, V90, P274, DOI 10.1097/00000539-200002000-00007
   Kozek-Langenecker SA, 2005, ANESTHESIOLOGY, V103, P654, DOI 10.1097/00000542-200509000-00031
   Langeron O, 2001, ANESTH ANALG, V92, P855, DOI 10.1097/00000539-200104000-00011
   LECCHI A, 2005, J THROMB HAEMOST S1, V3
   Mani H, 2005, J CLIN PATHOL, V58, P747, DOI 10.1136/jcp.2004.022129
   Roche AM, 2006, ANESTH ANALG, V102, P1274, DOI 10.1213/01.ane.0000197694.48429.94
   Roche AM, 2002, ANAESTHESIA, V57, P950, DOI 10.1046/j.1365-2044.2002.02707.x
   SEYFERT UT, 2007, IN PRESS PLATELETS
   Stogermuller B, 2000, ANESTH ANALG, V91, P823
   Thaler U, 2005, ANAESTHESIA, V60, P554, DOI 10.1111/j.1365-2044.2005.04184.x
   Toth O, 2006, THROMB HAEMOSTASIS, V96, P781, DOI 10.1160/TH06-05-0242
   Treib J, 1996, TRANSFUSION, V36, P450, DOI 10.1046/j.1537-2995.1996.36596282590.x
   von Roten I, 2006, BRIT J ANAESTH, V96, P455, DOI 10.1093/bja/ael019
NR 19
TC 14
Z9 15
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD AUG
PY 2007
VL 93
IS 2
BP 139
EP 144
DI 10.1111/j.1423-0410,2007,00946.x
PG 6
WC Hematology
SC Hematology
GA 205PC
UT WOS:000249126100005
PM 17683357
DA 2018-12-27
ER

PT J
AU Strasser, H
   Marksteiner, R
   Margreiter, E
   Mitterberger, M
   Pinggera, GM
   Frauscher, F
   Fussenegger, M
   Kofler, K
   Bartsch, G
AF Strasser, H.
   Marksteiner, R.
   Margreiter, E.
   Mitterberger, M.
   Pinggera, G. M.
   Frauscher, F.
   Fussenegger, M.
   Kofler, K.
   Bartsch, G.
TI RETRACTED: Transurethral ultrasonography-guided injection of adult
   autologous stem cells versus transurethral endoscopic injection of
   collagen in treatment of urinary incontinence (Retracted Article. See
   vol 28, pg 663, 2010)
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE incontinence; stem cells; myoblasts; fibroblasts; rhabdosphincter;
   urethra; transurethral ultrasound; regeneration
ID FEMALE URETHRAL SPHINCTER; AGE-DEPENDENT APOPTOSIS; RHABDOSPHINCTER
   CELLS; MYOBLAST TRANSFER; BLADDER; MUSCLE; THERAPY; COMPLICATIONS;
   ULTRASOUND; ANATOMY
AB \In the last years preclinical studies have paved the way for the use of adult muscle derived stem cells for reconstruction of the lower urinary tract. Between September 2002 and October 2004, 42 women and 21 men suffering from urinary stress incontinence (age 36-84 years) were recruited and subsequently treated with transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts obtained from skeletal muscle biopsies. The fibroblasts were injected into the urethral submucosa, while the myoblasts were implanted into the rhabdosphincter. In parallel, 7 men and 21 women (age 39-83 years) also diagnosed with urinary stress incontinence were treated with standard transurethral endoscopic injections of collagen. Patients were randomly assigned to both groups. After a follow-up of 12 months incontinence was cured in 39 women and 11 men after injection of autologous myoblasts and fibroblasts. Mean quality of life score (51.38 preoperatively, 104.06 postoperatively), thickness of urethra and rhabdosphincter (2.103 mm preoperatively, 3.303 mm postoperatively) as well as contractility of the rhabdosphincter (0.56 mm preoperatively, 1.462 mm postoperatively) were improved postoperatively. Only in two patients treated with injections of collagen incontinence was cured. The present clinical results demonstrate that, in contrast to injections of collagen, urinary incontinence can be treated effectively with ultrasonography-guided injections of autologous myo- and fibroblasts.
C1 Med Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria.
   Med Univ Innsbruck, Inst Biochem Pharmacol, Innsbruck, Austria.
   Med Univ Innsbruck, Dept Radiol 2, Innsbruck, Austria.
   Sisters Charity Hosp, Dept Otolaryngol, Wels, Austria.
RP Strasser, H (reprint author), Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.
EM hannes.strasser@uibk.ac.at
RI Mitterberger, Michael/C-6113-2009
CR Arcila ME, 1997, J NEUROBIOL, V33, P185, DOI 10.1002/(SICI)1097-4695(199708)33:2<185::AID-NEU7>3.0.CO;2-Z
   BATISTA J, 2002, INCONTINENCE
   Berjukow S, 2004, PROSTATE, V58, P238, DOI 10.1002/pros.10334
   Chancellor MB, 2000, NEUROUROL URODYNAM, V19, P279, DOI 10.1002/(SICI)1520-6777(2000)19:3<279::AID-NAU9>3.0.CO;2-M
   Colleselli K, 1998, J UROLOGY, V160, P49, DOI 10.1016/S0022-5347(01)63025-8
   Falconer C, 2001, INT UROGYNECOL J, V12, pS19, DOI 10.1007/s001920170007
   Frauscher F, 1998, EUR RADIOL, V8, P50, DOI 10.1007/s003300050336
   Groutz A, 2000, NEUROUROL URODYNAM, V19, P127, DOI 10.1002/(SICI)1520-6777(2000)19:2<127::AID-NAU3>3.0.CO;2-K
   Guys JM, 2001, J UROLOGY, V165, P2389, DOI 10.1016/S0022-5347(05)66211-8
   HERSCHORN S, 2002, INCONTINENCE
   Hunskaar S, 2002, INCONTINENCE
   Irintchev A, 1997, J PHYSIOL-LONDON, V500, P775, DOI 10.1113/jphysiol.1997.sp022057
   KIILHOLMA PJ, 1993, NEUROUROL URODYNAM, V12, P131, DOI 10.1002/nau.1930120206
   Klutke C, 2001, UROLOGY, V58, P697, DOI 10.1016/S0090-4295(01)01366-8
   KOELBL H, 2002, INCONTINENCE
   Law PK, 1997, CELL TRANSPLANT, V6, P95, DOI 10.1016/S0963-6897(96)00138-8
   MCKINNEY CD, 1995, J UROLOGY, V153, P149, DOI 10.1097/00005392-199501000-00053
   NOE HN, 1994, UROLOGY, V43, P852, DOI 10.1016/0090-4295(94)90149-X
   Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149
   Pannek J, 2001, J UROLOGY, V166, P1350, DOI 10.1016/S0022-5347(05)65767-9
   Patrick DL, 1999, UROLOGY, V53, P1072
   Patrick DL, 1999, UROLOGY, V53, P71, DOI 10.1016/S0090-4295(98)00454-3
   Perucchini D, 2002, AM J OBSTET GYNECOL, V186, P351, DOI 10.1067/mob.2002.121089
   PETROS PEP, 1994, AM J OBSTET GYNECOL, V171, P1159, DOI 10.1016/0002-9378(94)90056-6
   Smith DP, 1996, UROLOGY, V48, P119, DOI 10.1016/S0090-4295(96)00098-2
   SMITH T, 2002, INCONTINENCE
   Strasser H, 1998, J UROLOGY, V159, P100, DOI 10.1016/S0022-5347(01)64025-4
   Strasser H, 2000, J UROLOGY, V164, P1781, DOI 10.1016/S0022-5347(05)67106-6
   Strasser H, 2004, EXP GERONTOL, V39, P1259, DOI 10.1016/j.exger.2004.07.003
   Strasser H, 2004, UROLOGE A, V43, P1237, DOI 10.1007/s00120-004-0700-9
   Strasser H, 1999, LANCET, V354, P918, DOI 10.1016/S0140-6736(99)02588-X
   Strasser H, 1996, PROSTATE, V28, P24, DOI 10.1002/(SICI)1097-0045(199601)28:1<24::AID-PROS4>3.0.CO;2-O
   Strasser H, 2000, WORLD J UROL, V18, P324, DOI 10.1007/s003450000145
   STRASSER H, 2003, J UROL S, V169, P37
   Sweat SD, 1999, J UROLOGY, V161, P93, DOI 10.1016/S0022-5347(01)62074-3
   Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929
   Watson D, 1999, Arch Facial Plast Surg, V1, P165, DOI 10.1001/archfaci.1.3.165
   Yokoyama T, 2000, WORLD J UROL, V18, P56, DOI 10.1007/s003450050010
   Yokoyama T, 2001, J UROLOGY, V165, P271, DOI 10.1097/00005392-200101000-00077
   Yonneau L, 2000, PROG UROL, V10, P1238
NR 40
TC 52
Z9 63
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
PD AUG
PY 2007
VL 25
IS 4
BP 385
EP 392
DI 10.1007/s00345-007-0190-7
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 202PC
UT WOS:000248914500008
PM 17701044
DA 2018-12-27
ER

PT J
AU Southgate, RJ
   Neill, B
   Prelovsek, O
   El-Osta, A
   Kamei, Y
   Miura, S
   Ezaki, O
   McLoughlin, TJ
   Zhang, W
   Unterman, TG
   Febbraio, MA
AF Southgate, Robert J.
   Neill, Bronwyn
   Prelovsek, Oja
   El-Osta, Assam
   Kamei, Yasutomi
   Miura, Shinji
   Ezaki, Osamu
   McLoughlin, Thomas J.
   Zhang, Wenwei
   Unterman, Terry G.
   Febbraio, Mark A.
TI RETRACTED: FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR
   signaling in mammalian skeletal muscle (Retracted Article. See vol 284,
   pg 20440, 2009)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID PROTEIN-KINASE B; FORKHEAD TRANSCRIPTION FACTOR; FACTOR 4E-BINDING
   PROTEIN-1; INSULIN-RESPONSE SEQUENCE; P70 S6 KINASE; GENE-EXPRESSION;
   TRANSLATION INITIATION; MEDIATED PHOSPHORYLATION; NUCLEAR EXCLUSION;
   UBIQUITIN LIGASE
AB The mammalian target of rapamycin ( mTOR) is regulated by growth factors to promote protein synthesis. In mammalian skeletal muscle, the Forkhead-O1 transcription factor (FOXO1) promotes catabolism by activating ubiquitin-protein ligases. Using C2C12 mouse myoblasts that stably express inducible FOXO1-ER fusion proteins and transgenic mice that specifically overexpress constitutively active FOXO1 in skeletal muscle (FOXO(++/+)), we show that FOXO1 inhibits mTOR signaling and protein synthesis. Activation of constitutively active FOXO1 induced the expression of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) mRNA via binding to the promoter. This resulted in an increased total 4E-BP1 abundance and a reduced 4E-BP1 (Thr-37/46) phosphorylation. The reduction in 4E-BP1 phosphorylation was associated with a reduction in the abundance of Raptor and mTOR proteins, Raptor-associated mTOR, reduced phosphorylation of the downstream protein p70S6 kinase, and attenuated incorporation of [(14)C] phenylalanine into protein. The FOXO(++/+) mice, characterized by severe skeletal muscle atrophy, displayed similar patterns of mRNA expression and protein abundance to those observed in the constitutively active FOXO1 C2C12 myotubes. These data suggest that FOXO1 may be an important therapeutic target for human diseases where anabolism is impaired.
C1 Univ Illinois, Coll Med, Dept Med, Chicago, IL 60607 USA.
   Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60607 USA.
   Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA.
   Baker Heart Res Inst, Cellular & Mol Metab Lab, Melbourne, Vic 3004, Australia.
   Baker Heart Res Inst, Epigenet Human Hlth & Dis Lab, Melbourne, Vic 3004, Australia.
   Natl Inst Hlth & Nutr, Div Clin Nutr, Tokyo 162836, Japan.
   Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1010062, Japan.
   Univ Toledo, Dept Kinesiol, Toledo, OH 43608 USA.
RP Unterman, TG (reprint author), Univ Illinois, Coll Med, Dept Med, Chicago, IL 60607 USA.
EM unterman@uic.edu; mark.febbraio@baker.edu.au
FU NIDDK NIH HHS [DK41430]
CR Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010
   Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200
   Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cao Y, 2006, J BIOL CHEM, V281, P40242, DOI 10.1074/jbc.M608116200
   Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482
   Cooney RN, 1997, SHOCK, V7, P1, DOI 10.1097/00024382-199701000-00001
   DUNCAN R, 1987, J BIOL CHEM, V262, P380
   Fadden P, 1997, J BIOL CHEM, V272, P10240
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Franch HA, 2004, AM J PHYSIOL-RENAL, V287, pF700, DOI 10.1152/ajprenal.00440.2003
   Gingras AC, 2001, PROG MOLEC, V27, P143
   Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039
   Hoffman EP, 2004, NAT MED, V10, P584, DOI 10.1038/nm0604-584
   Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200
   Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107
   Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102
   Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253
   Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255
   Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20
   Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200
   Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686
   Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8
   MATHEWS MB, 2000, TRANSLATIONAL CONTRO, P1
   Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047
   Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100
   Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231
   Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x
   Pearson R B, 1995, Prog Cell Cycle Res, V1, P21
   Price SR, 2003, INT J BIOCHEM CELL B, V35, P617, DOI 10.1016/S1357-2725(02)00385-0
   Proud CG, 1997, BIOCHEM J, V328, P329
   Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179
   Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605
   Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337
   Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4
   Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x
   SHAH OJ, 2000, AM J PHYSIOL-ENDOC M, V279, P715
   Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200
   SONNENBERG N, 1998, CURR OPIN CELL BIOL, V10, P268
   Southgate RJ, 2005, FASEB J, V19, P2072, DOI 10.1096/fj-05-3933fje
   Stephenson AH, 2004, BIOCHEM BIOPH RES CO, V323, P204, DOI 10.1016/j.bbrc.2004.08.076
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836
   Teleman AA, 2005, DEV CELL, V9, P271, DOI 10.1016/j.devcel.2005.07.004
   Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200
   Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004-0777
   Tremblay F, 2001, J BIOL CHEM, V276, P38052
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866
   Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000
   Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200
NR 60
TC 76
Z9 79
U1 2
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 20
PY 2007
VL 282
IS 29
BP 21176
EP 21186
DI 10.1074/jbc.M702039200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 190GP
UT WOS:000248047500044
PM 17510058
OA Bronze
DA 2018-12-27
ER

PT J
AU Zore, GB
   Awad, V
   Thakre, AD
   Halde, UK
   Meshram, NS
   Surwase, BS
   Karuppayil, SM
AF Zore, G. B.
   Awad, V.
   Thakre, A. D.
   Halde, U. K.
   Meshram, N. S.
   Surwase, B. S.
   Karuppayil, S. Mohan
TI RETRACTED: Activity-directed-fractionation and isolation of four
   antibacterial compounds from Abrus precatorius L. roots (Retracted
   article. See vol 23, pg 1161, 2009)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE Abrus precatorius L; Fabaceae; Indian licorice; bioautography;
   antibacterial; antibiotics
ID RESISTANT STAPHYLOCOCCUS-AUREUS; UNITED-STATES; ABRIN; FLAVONOIDS
AB Root extracts of the plant Abrus precatorius L., was tested for antibacterial activity. Various solvent fractions exhibited inhibitory activity against 13 gram-positive and gram-negative bacteria. Root extracts were analyzed by thin layer chromatography (TLC). The antibacterial activity was localized to specific chromatophores in the chloroform fraction through a bioautography assay. It was found localized to four chromatophores out of seven. The chromatophores were isolated from the TLC plates and rechecked for activity against Slaphvlococcus aureus A, using a disc diffusion assay. Among the four active principles isolated, AP 3 (Rf 0.87) exhibited maximum activity i.e. 56% inhibition of growth of S. aureus A, in disc diffusion assay compared to the standard antibiotic Ampicillin. Results of this study suggest that chloroform extractable phytochemicals in A. precatorius L. may yield promising molecules with antibiotic activity.
C1 SRTM Univ, Sch Life Sci, Nanded, Maharashtra, India.
   Govt Ayurved Coll, Nanded, Maharashtra, India.
   Govt Maharashtra, Bombay, Maharashtra, India.
RP Karuppayil, SM (reprint author), SRTM Univ, Sch Life Sci, Nanded, Maharashtra, India.
EM karuppayil@yahoo.com
CR Acharya D., 2004, POSITIVE HLTH, V102, P28
   Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211
   Bagaria A, 2006, J BIOL CHEM, V281, P34465, DOI 10.1074/jbc.M601777200
   Cohen ML, 2000, NATURE, V406, P762, DOI 10.1038/35021206
   Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564
   DAVIS JH, 1978, FLORIDA MED ASS, V65, P189
   DWIVEDI RS, 2006, UNNURTURED UNTAPPED
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Fukai T, 2002, FITOTERAPIA, V73, P536, DOI 10.1016/S0367-326X(02)00168-5
   Fukai T, 2002, LIFE SCI, V71, P1449, DOI 10.1016/S0024-3205(02)01864-7
   Gagneux S, 2006, PLOS PATHOG, V2, P603, DOI 10.1371/journal.ppat.0020061
   KHANNA P, 1989, Proceedings of the National Academy of Sciences India Section B (Biological Sciences), V59, P83
   Krausse R, 2004, J ANTIMICROB CHEMOTH, V54, P243, DOI 10.1093/jac/dkh287
   LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0
   MARTINELLI F, 1987, RIV NUOVO CIMENTO, V10, P1, DOI 10.1007/BF02740933
   Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356
   Naik V.N, 1998, FLORA MARATHWADA RAN
   NATH D, 1992, J ETHNOPHARMACOL, V36, P147, DOI 10.1016/0378-8741(92)90015-J
   OGLE PB, 1949, CIKITSAPROBHAKAR, V1
   OLSNES S, 1974, J BIOL CHEM, V249, P803
   Olukoga A, 2000, J R SOC PROMO HEALTH, V120, P83, DOI 10.1177/146642400012000203
   PHILLIPSON JD, 1989, ACTA PHARM NORDICA, V1, P131
   RASOANAIVO P, 1993, BIOL EVALUATION PLAN, P72
   SEXENA AP, 1986, J EC TAX BOT, V8, P291
   SHARMA PV, 1994, CARAKA SAMHITA, V1
   Shih SF, 2001, J BIOL CHEM, V276, P21870, DOI 10.1074/jbc.M100571200
   Tsuchiya H, 1996, J ETHNOPHARMACOL, V50, P27, DOI 10.1016/0378-8741(96)85514-0
   Valiathan M.S., 2003, LEGACY CARAKA
   VARMA HK, 1989, FORENSIC, V1, P363
   Wagner H, 1996, PLANT DRUG ANAL THIN
   Windholz M., 1983, MERCK INDEX ENCY CHE
   World Health Organization, 2001, WHO GLOB STRAT CONT
   Ya C., 1988, CHEM SIGNIFICANCE CO, P553
   Zhang Y, 1997, FEMS MICROBIOL LETT, V149, P59, DOI 10.1016/S0378-1097(97)00054-2
   1976, WEALTH INDIA RAW MAT, V1
NR 35
TC 6
Z9 8
U1 4
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD JUL 20
PY 2007
VL 21
IS 9
BP 838
EP 845
DI 10.1080/14786410701474928
PN A
PG 8
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 202VL
UT WOS:000248932000013
PM 17763102
DA 2018-12-27
ER

PT J
AU Subrahmanyam, P
   Krishnapriya, B
   Suvardhan, K
   Rekha, D
   Suneeta, Y
   Jayaraj, B
   Chiranjeevi, P
AF Subrahmanyam, P.
   Krishnapriya, B.
   Suvardhan, K.
   Rekha, D.
   Suneeta, Y.
   Jayaraj, B.
   Chiranjeevi, P.
TI RETRACTED: Simple, selective and sensitive spectrophotometric
   determination of fenitrothion using novel chromogenic reagent (Retracted
   Article. See vol 154, pg 1210, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE fenitrothion; 4,4 '-methylene-bis-(p-amino-3 '-hydroxybenzanilide);
   diazotization method; spectrophotometry; water; food grain and
   agriculture soil samples
ID RESIDUES; PARATHION
AB A facile, rapid and sensitive spectrophotometric method was developed for the determination of fenitrothion in its formulations, water, food grain and agriculture soil samples with newly synthesised reagent. The method was based on the alkaline hydrolysis of fenitrothion pesticide and resultant hydrolysed product of fenitrothion was coupled with diazotised 4,4'-methylene-bis-(p-amino-3'-hydroxybenzanilide) in basic medium to give orange coloured product having lambda(max) 480 nm. The formation of coloured derivatives with the coupling agent is instantaneous and stable for 48 h. Beer's law was obeyed in the concentration range of 0. 1-19.0 mu g ml(-1). The proposed method is sensitive, easy to operate and permitted the determination of fenitrothion with a detection limits of 0.085 mu g ml(-1). The experimental results indicate that the procedure can eliminate the fundamental interferences caused by other pesticides and non-target ions, which made these methods more sensitive and selective. The method was applicable to the determination of fenitrothion residue in water, food grain and soil samples up to ng level. (C) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Labs, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Labs, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevipattium@gmail.com
CR ABBOTT DC, 1967, ANALYST, V92, P170, DOI 10.1039/an9679200170
   AOKI Y, 1975, J ASSOC OFF ANA CHEM, V58, P1286
   ATTRI BS, 1976, ABSTRACT ENT NEWS LE, V6, P37
   BURT P. E., 1970, Pesticide Science, V1, P88, DOI 10.1002/ps.2780010303
   DAS DK, 1970, J FOOD SCI TECHNOL, V7, P62
   Deshmukh S. N., 1974, Journal of Food Science and Technology, India, V11, P81
   DRABEK J, 1956, J CHEM PROM, V6, P293
   IVIC GW, 1971, J AGR FOOD CHEM, V19, P405
   KURUNSHKIN VL, 1982, J CHROMATOGR, V58, P10
   LURINI M, 1980, TALANTA, V27, P45
   MORLTHOFF E, 1968, PHANZENSCHUTZ NACHR, V21, P331
   MURTHY P, 1984, B ENVIRON CONTAM TOX, V32, P59
   NARAHASHI J, 1964, ADV INSECT PHYSL, V1, P175
   NISHIZAWA Y, 1960, B AGR CHEM SOC JAPAN, V24, P744, DOI 10.1080/03758397.1960.10857746
   NISHIZAWA Y, 1961, J AGR BIOL CHEM, V25, P605
   NORRIS MV, 1958, J AGR FOOD CHEM, V6, P111, DOI 10.1021/jf60084a003
   RAMAKRISHNA N, 1976, ANALYST, V101, P528, DOI 10.1039/an9760100528
   SASTRY CSP, 1987, TALANTA, V34, P372, DOI 10.1016/0039-9140(87)80051-6
   SASTRY CSP, 1986, J FOOD SCI TECH MYS, V23, P336
   SCHMITT JB, 1962, ANN REV ENTOMOL, V7
   STAN HJ, 1983, J CHROMATOGR, V268, P55, DOI 10.1016/S0021-9673(01)95387-7
   UMEDA M, 1963, J PHARM SOC JPN, V83, P951
NR 22
TC 5
Z9 5
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JUL 19
PY 2007
VL 146
IS 1-2
BP 51
EP 57
DI 10.1016/j.jhazmat.2006.11.047
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 191VI
UT WOS:000248159700006
PM 17188809
DA 2018-12-27
ER

PT J
AU Rekha, D
   Suvardhan, K
   Kumar, JD
   Subramanyam, P
   Prasad, PR
   Lingappa, Y
   Chiranjeevi, P
AF Rekha, D.
   Suvardhan, K.
   Kumar, J. Dilip
   Subramanyam, P.
   Prasad, P. Reddy
   Lingappa, Y.
   Chiranjeevi, P.
TI RETRACTED: Solid phase extraction method for the determination of lead,
   nickel, copper and manganese by flame atomic absorption spectrometry
   using sodium bispiperdine-1,1 '-carbotetrathioate (Na-BPCTT) in water
   samples (Retracted article. See vol 155, pg 393, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE preconcentration; solid phase extraction (SPE); sodium bispiperdine-1,1
   '-carbotetrathioate (Na-BPCTT); amberlite XAD-7; flame atomic absorption
   spectrometry (FAAS); water samples
ID CLOUD-POINT PRECONCENTRATION; ONLINE PRECONCENTRATION; METAL-IONS;
   SPECTROPHOTOMETRIC DETERMINATION; ENVIRONMENTAL-SAMPLES; CHROMOSORB-102
   RESIN; ACTIVATED CARBON; WASTE-WATER; COPRECIPITATION; SEAWATER
AB A novel column solid phase extraction procedure was developed for the determination of lead, nickel, copper and manganese in various water samples by flame atomic absorption spectrometry (FAAS) after preconcentration on sodium bispiperdine-1,1'-carbotetrathioate (Na-BPCTT) supported by Amberlite XAD-7. The sorbed element was subsequently eluted with I M nitric acid and the acid eluates are analysed by Flame atomic absorption spectrometry (FAAS). Various parameters such as pH, amount of adsorbent, eluent type and volume, flow-rate of the sample solution, volume of the sample solution and matrix interference effect on the retention of the metal ions have been studied. The optimum pH for the sorption of above mentioned metal ions was about 6.0 +/- 0.2. The loading capacity of adsorbent for Pb, Cu, Ni and Mn were found to 28, 26, 22 and 20 x 10(-6) g/mL, respectively. The recoveries of lead, copper, nickel and manganese under optimum conditions were found to be 96.7-99.2 at the 95% confident level. The limit of detection was 3.0, 3.2, 2.8 and 3.6 x 10(-6) g/mL for lead, copper, nickel and manganese, respectively by applying a preconcentration factor 50. The proposed enrichment method was applied for metal ions in various water samples. The results were obtained are good agreement with reported method. (C) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Yogivemana Univ, Dept Chem, Kadapa, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR Akama Y, 2003, ANAL CHIM ACTA, V485, P19, DOI 10.1016/S0003-2670(03)00399-4
   Akman S, 2003, TALANTA, V60, P199, DOI 10.1016/S0039-9140(03)00124-3
   ALEXANDROVA A, 1993, ANALYST, V118, P309
   AZIZALRAHMAN AM, 1985, J ENV ANAL CHEM, V22, P251
   Bag H, 1998, TALANTA, V47, P689, DOI 10.1016/S0039-9140(98)00104-0
   Bakircioglu Y, 2004, ANAL LETT, V37, P1937, DOI 10.1081/AL-120039437
   Bakircioglu Y, 2003, ANAL CHIM ACTA, V485, P9, DOI 10.1016/S0003-2670(03)00348-9
   BALAJI T, 1993, THESIS SV U, P80
   Cerutti S, 2003, SPECTROCHIM ACTA B, V58, P2015, DOI 10.1016/S0584-8547(03)00179-4
   Cesur H, 2003, J TRACE MICROPROBE T, V21, P627, DOI 10.1081/TMA-120025814
   Cesur H, 2003, TURK J CHEM, V27, P307
   de Moraes FV, 2003, ECLET QUIM, V28, P9
   Elci L, 2003, ANAL LETT, V36, P987, DOI 10.1081/AL-120019257
   Ensafi AA, 2003, ANAL SCI, V19, P953, DOI 10.2116/analsci.19.953
   Garg BS, 1996, TALANTA, V43, P2093, DOI 10.1016/S0039-9140(96)01994-7
   GOCER O, 2003, J TRACE MICRORPROBE, V21, P249
   Kucukbay FZ, 2003, TURK J CHEM, V27, P375
   Li J, 2003, ATOM SPECTROSC, V24, P169
   Manzoori JL, 2003, ANAL SCI, V19, P579, DOI 10.2116/analsci.19.579
   Manzoori JL, 2002, ANAL CHIM ACTA, V470, P215, DOI 10.1016/S0003-2670(02)00765-1
   Matos GD, 2003, PROCESS BIOCHEM, V39, P81, DOI 10.1016/S0032-9592(02)00315-1
   Nakajima J, 2003, ANAL SCI, V19, P585, DOI 10.2116/analsci.19.585
   RAMADEVI P, 1993, THESIS S V U, P119
   RAMESH A, 2001, THESIS SV U, P79
   Saracoglu S, 2003, ACTA CHIM SLOV, V50, P807
   Saracoglu S, 2003, ANAL SCI, V19, P259, DOI 10.2116/analsci.19.259
   Soylak M, 2004, ANAL LETT, V37, P767, DOI 10.1081/AL-120029751
   Soylak M, 2003, TURK J CHEM, V27, P235
   Tuzen M, 2004, ANAL LETT, V37, P473, DOI 10.1081/AL-120028620
   WASEY A, 1984, TALANTA, V31, P205, DOI 10.1016/0039-9140(84)80051-X
NR 30
TC 31
Z9 32
U1 2
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JUL 19
PY 2007
VL 146
IS 1-2
BP 131
EP 136
DI 10.1016/j.jhazmat.2006.11.059
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 191VI
UT WOS:000248159700016
PM 17208372
DA 2018-12-27
ER

PT J
AU Sivani, C
   Naidu, GR
   Narasimhulu, J
   Rekha, D
   Kumar, JD
   Chiranjeevi, P
AF Sivani, C.
   Naidu, G. Ramakrishna
   Narasimhulu, J.
   Rekha, D.
   Kumar, J. Dilip
   Chiranjeevi, P.
TI RETRACTED: Determination of Co(II) in water and soil samples using
   spectrophotometry coupled with preconcentration on 4-amino methyl
   pyridine anchored silica gel column (Retracted Article. See vol 155, pg
   610, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE 4-aminomethyl pyridine-silica gel (4-AMPSG); preconcentration;
   piperazine dithiocarbamate; cobalt(II); spectrophotometer; water and
   soil samples
ID COBALT; THIOSEMICARBAZONES; CYTOTOXICITY; ADSORPTION; COMPLEXES; COPPER;
   ACID
AB 4-Amino methyl pyridine anchored silica gel (4-AMPS) was used as a sorbent in a simple sensitive spectrophotometry determination of Co(II) in various samples using piperazine dithiocarbamate as a color developing agent (lambda(max) = 390 nm) at pH 5.0 0.2. Beer's law was obeyed over the range of 0.1-5.0 mu g ml(-1). The molar absorptivity and Sandell's sensitivity were 1.257 x 10(5) 1mol(-1) cm(-1) and 0.006145 mu g cm(-2), respectively. Under these conditions, the preconcentration factor obtained was 80, and the detection limit achieved was 5.0 ng ml(-1). The detailed study of various interfering ions made the method more sensitive and selective. The recovery of Co(II) from various samples range from 97.50 to 99.66%. The present method was successfully applied for the determination of Co(II) in various water and soil samples. The proposed method was compared with reported methods in terms of Student's 't'-test and variance ratio 'f'-test which indicates that there is no significant difference between proposed and literature method at 95% confidence level. (C) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Environm Sci, Tirupati 517502, Andhra Pradesh, India.
   JNTU, Dept Chem, Anantapur, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevipattium@gmail.com
CR AAMHIEH A, 1988, SPECTROSC LETT, V21, P411
   BUUHOI PN, 1955, B SOC CHIM FR, V1, P647
   CASOS JS, 1981, COORDIN CHEM REV, V209, P197
   GARG BS, 1988, MICROCHEM J, V38, P144, DOI 10.1016/0026-265X(88)90017-3
   Hall IH, 2000, PHARMAZIE, V55, P937
   IM KS, 1999, J KORIAN CHEM SOC, V43, P644
   Miller MC, 1998, ANTICANCER RES, V18, P4131
   PAVON JMC, 1981, MICROCHEM J, V26, P155, DOI 10.1016/0026-265X(81)90085-0
   Prado AGS, 2002, GREEN CHEM, V4, P42, DOI 10.1039/b108749e
   Prado AGS, 2001, J COLLOID INTERF SCI, V236, P161, DOI 10.1006/jcis.2000.7401
   Reddy BK, 1997, ASIAN J CHEM, V9, P487
   SALINAS F, 1986, ANN CHIM-ROME, V76, P301
   SALINAS F, 1986, MICROCHEM J, V33, P194, DOI 10.1016/0026-265X(86)90054-8
   Sarma LS, 2003, ANAL LETT, V36, P605, DOI 10.1081/AL-120018251
   Soylak M, 2003, ASIAN J CHEM, V15, P1780
   Soylak M, 2003, TRACE ELEM ELECTROLY, V20, P16
   Soylak M, 1997, ANAL LETT, V30, P623, DOI 10.1080/00032719708001806
   Tewari PK, 1999, ANALYST, V124, P1847
NR 18
TC 8
Z9 8
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JUL 19
PY 2007
VL 146
IS 1-2
BP 137
EP 141
DI 10.1016/j.jhazmat.2006.11.060
PG 5
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 191VI
UT WOS:000248159700017
PM 17222507
DA 2018-12-27
ER

PT J
AU Dhaneshwar, SS
   Gairola, N
   Kandpal, M
   Vadnerkar, G
   Bhatt, L
AF Dhaneshwar, Suneela S.
   Gairola, Neha
   Kandpal, Mini
   Vadnerkar, Gaurav
   Bhatt, Lokesh
TI RETRACTED: Colon-specific, mutual azo prodrug of 5-aminosalicylic acid
   with L-tryptophan: Synthesis, kinetic studies and evaluation of its
   mitigating effect in trinitrobenzenesulfonic acid-induced colitis in
   rats (Retracted article. See vol. 17, pg. 930, 2009)
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE mutual azo prodrug; 5-aminosalicylic acid; inflammatory bowel disease;
   L-tryptophan; colon-specific delivery
ID INFLAMMATORY BOWEL-DISEASE; ULCERATIVE-COLITIS; DRUG-DELIVERY;
   OLSALAZINE; INHIBITOR
AB Mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan was synthesized by coupling L-tryptophan with salicylic acid, for targeted drug delivery to the inflamed gut tissue in inflammatory bowel disease. The structure of synthesized prodrug was confirmed by elemental analysis, IR and NMR spectroscopy. In vitro kinetic studies in HCl buffer (pH 1.2) showed negligible release of 5-aminosalicylic acid., whereas in phosphate buffer (pH 7.4) 18% release was observed over a period of 7 h. In rat fecal matter, 87.9% of 5-aminosalicylic acid was released with a half-life of 143.6 min, following first order kinetics. The azo, conjugate was evaluated for its ulcerogenic potential by Rainsford's cold stress method. The ameliorating effect of the azo conjugate and therapeutic efficacy of the carrier system was evaluated in trinitrobenzenesulfonic acid-induced experimental colitis model. The synthesized prodrug was found to be equally effective in mitigating the colitis in rats as that of sulfasalazine without the ulcerogenicity of 5-aminosalicylic acid. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Bharati Vidyapeeth Univ, Poona Coll Pharm, Dept Pharmaceut Chem, Pune 411038, Maharashtra, India.
   Bharati Vidyapeeth Univ, Poona Coll Pharm, Dept Pharmacol, Pune 411038, Maharashtra, India.
RP Dhaneshwar, SS (reprint author), Bharati Vidyapeeth Univ, Poona Coll Pharm, Dept Pharmaceut Chem, Pune 411038, Maharashtra, India.
EM suneeladhaneshwar@rediffmail.com
OI Bhatt, Lokesh/0000-0002-4302-9300
CR Bonner GB, 1993, INFLAMMOPHARMACOLOGY, P247
   Bonner GF, 1996, SOUTHERN MED J, V89, P556, DOI 10.1097/00007611-199606000-00002
   BRZEZINSKI A, 1995, CLEV CLIN J MED, V62, P317
   Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33
   DHANESHWAR SS, 1994, INDIAN DRUGS, V31, P374
   FURNISS BS, 2004, VOGELS TXB PRACTICAL, P835
   Hartmann G, 2000, J PHARMACOL EXP THER, V292, P22
   LI T, 2003, J GASTEROENTEROL, V9, P1028
   Mahmud N, 2001, GUT, V49, P552, DOI 10.1136/gut.49.4.552
   MARCH J, 1992, ADV ORG CHEM, P635
   MEYERS D, 1995, MED THERAPHY INFLAMM, P695
   MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9
   RAINSFORD KD, 1975, AGENTS ACTIONS, V5, P553, DOI 10.1007/BF01972694
   RAINSFORD KD, 1980, BRIT PHARM SOC, P226
   RAO SSC, 1987, GUT, V28, P1474, DOI 10.1136/gut.28.11.1474
   RUBINSTEIN A, 1992, PHARMACEUT RES, V9, P276, DOI 10.1023/A:1018910128452
   SANDS BE, 2000, GASTROENTEROLOGY, V118, P68
   Sutherland LR, 1997, INFLAMM BOWEL DIS, V3, P65, DOI 10.1002/ibd.3780030202
   TAKAGI K, 1976, Patent No. 988466
   YAMADA T, 1992, GASTROENTEROLOGY, V102, P1524, DOI 10.1016/0016-5085(92)91710-L
   ZINGARELLI B, 1993, AGENTS ACTIONS, V39, P150, DOI 10.1007/BF01998968
NR 21
TC 14
Z9 14
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUL 15
PY 2007
VL 15
IS 14
BP 4903
EP 4909
DI 10.1016/j.bmc.2007.04.045
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 183OY
UT WOS:000247583300021
PM 17499512
DA 2018-12-27
ER

PT J
AU Pulukuri, SMK
   Rao, JS
AF Pulukuri, Sai Murali Krishna
   Rao, Jasti S.
TI RETRACTED: Small interfering RNA-directed reversal of urokinase
   plasminogen activator demethylation inhibits prostate tumor growth and
   metastasis (Retracted article. See vol. 78, pg. 3398, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID DOUBLE-STRANDED-RNA; CANCER CELL-LINES; GENE-EXPRESSION; DNA
   METHYLATION; IN-VIVO; MEDIATED INHIBITION; HISTONE DEACETYLASE;
   MAMMALIAN-CELLS; CATHEPSIN-B; RECEPTOR
AB Recent studies have shown that small interfering RNA (siRNA) silences genes at the transcriptional level in human cells. However, the therapeutic potential of siRNA-mediated transcriptional gene silencing remains unclear. Here, we show that siRNA targeted to the urokinase plasminogen activator (uPA) promoter induced epigenetic transcriptional silencing in human prostate cancer cells. This silencing resulted in a dramatic reduction of tumor cell invasion and angiogenesis in vitro. Furthermore, the results from a bioluminescence tumor/metastasis model showed that the silencing of uPA significantly inhibits prostate tumor growth and the incidence of lung metastasis. Our findings represent a potentially powerful new approach to not only epigenetic silencing of metastasis or growth-promoting genes as a cancer therapy, but also as a means to shed light on how aberrant de novo methylation during cancer progression might be targeted to specific sequences.
C1 Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61656 USA.
   Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA.
RP Rao, JS (reprint author), Univ Illinois, Coll Med, Program Canc Biol, One Illini Dr, Peoria, IL 61605 USA.
EM jsrao@uic.edu
FU NINDS NIH HHS [R01 NS057529-01, NS 47699, R01 NS047699, NS 057529, R01
   NS047699-03, R01 NS057529]; NCI NIH HHS [R01 CA116708-02, CA 92393, R01
   CA092393, R01 CA095058-04, CA 75557, R01 CA092393-04, R01 CA075557-09,
   CA 95058, R01 CA075557, R01 CA095058, R01 CA116708, CA 116708]
CR BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Castanotto D, 2005, MOL THER, V12, P179, DOI 10.1016/j.ymthe.2005.03.003
   CELANO P, 1989, BIOTECHNIQUES, V7, P942
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2001, CANCER RES, V61, P3225
   Filleur S, 2003, CANCER RES, V63, P3919
   GAYLIS FD, 1989, J UROLOGY, V142, P193, DOI 10.1016/S0022-5347(17)38709-8
   Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879
   Gondi CS, 2004, CANCER RES, V64, P4069, DOI 10.1158/0008-5472.CAN-04-1243
   Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   HSU DW, 1995, AM J PATHOL, V147, P114
   Janowski BA, 2005, NAT CHEM BIOL, V1, P216, DOI 10.1038/nchembio725
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313
   Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200
   Lakka SS, 2001, INT J ONCOL, V18, P71
   LEUNIG M, 1992, CANCER RES, V52, P6553
   Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742
   Look MP, 1999, APMIS, V107, P150, DOI 10.1111/j.1699-0463.1999.tb01538.x
   MERSCHER S, 1994, BIOTECHNIQUES, V16, P1024
   Miyake H, 1999, INT J ONCOL, V14, P535
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399
   Park CW, 2004, BIOCHEM BIOPH RES CO, V323, P275, DOI 10.1016/j.bbrc.2004.08.096
   Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462
   Pulukuri SMK, 2007, CANCER RES, V67, P930, DOI 10.1158/0008-5472.CAN-06-2892
   Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200
   PYKE C, 1991, AM J PATHOL, V138, P1059
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   Siddique K, 2003, INT J ONCOL, V22, P289
   SKRIVER L, 1984, J CELL BIOL, V99, P753, DOI 10.1083/jcb.99.2.753
   Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682
   Ting AH, 2005, NAT GENET, V37, P906, DOI 10.1038/ng1611
   Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446
   VanVeldhuizen PJ, 1996, AM J MED SCI, V312, P8, DOI 10.1097/00000441-199607000-00002
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   YAMAMOTO M, 1994, CANCER RES, V54, P3656
   Yang JL, 2000, INT J CANCER, V89, P431, DOI 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V
NR 48
TC 53
Z9 57
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2007
VL 67
IS 14
BP 6637
EP 6646
DI 10.1158/0008-5472.CAN-07-0751
PG 10
WC Oncology
SC Oncology
GA 194BN
UT WOS:000248319000016
PM 17638874
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Dasmahapatra, G
   Nitin, Y
   Dai, Y
   Dent, P
   Grant, S
AF Dasmahapatra, Girija
   Yerram, Nitin
   Dai, Yun
   Dent, Paul
   Grant, Steven
TI RETRACTED: Synergistic interactions between vorinostat and sorafenib in
   chronic myelogenous leukemia cells involve mcl-1 and p21(CIP1)
   down-regulation(Retracted article. See vol.22, pg.4959,2016)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID HISTONE DEACETYLASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; ABL-MEDIATED
   RESISTANCE; HYDROXAMIC ACID SAHA; BCR-ABL; IMATINIB MESYLATE;
   DOWN-REGULATION; TYROSINE-KINASE; BLAST CRISIS; PHOSPHATIDYLINOSITOL
   3-KINASE
AB Purpose: Interactions between the multikinase inhibitor sorafenib (Bay 43-9006) and the histone deacetylase inhibitor vorinostat were examined in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate.
   Experimental Design: K562, LAMA 84, and primary CML patient-derived CD34(+) mononuclear cells were exposed to vorinostat followed by sorafenib, after which effects on cell viability and various survival signaling pathways were monitored by flow cytometry, clonogenic assays, and Western blotting. Real-time reverse transcription-PCR was used to monitor gene expression, and the functional contribution of p21(CIP1) and Mcl-1 down-regulation were determined in cells transfected with corresponding constructs.
   Results: Pretreatment (24 h) with vorinostat followed by sorafenib optimally induced mitochondrial injury and cell death in Bcr/Abl(+) cells (e.g., K562 and LAMA 84). Similar results were obtained in imatinib mesylate-resistant cells expressing activated Lyn as well as in primary CD34(+) bone marrow cells obtained from CIVIL patients. This regimen also markedly inhibited CIVIL cell colony formation. Combined but not individual treatment of CIVIL cells with vorinostat and sorafenib triggered pronounced mitochondrial dysfunction (i.e., cytochrome c, Smac, and AIF release), caspase activation, poly (ADP-ribose) polymerase cleavage, and down-regulation of Mcl-1. Sorafenib also blocked vorinostat-mediated induction of p21(CIP1). Down-regulation of Mcl-1 was caspase and transcription independent, whereas p21(CIP1) down-regulation was partially caspase and transcription dependent. Enforced expression of p21(CIP1) and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality.
   Conclusions: These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CIVIL cells through a process that involves Mcl-1 down-regulation and inhibition of p21(CIP1) induction.
C1 Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Goodwin Res Lab 234,Dept Med, Richmond, VA 23298 USA.
   Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Biochem, Richmond, VA 23298 USA.
   Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Pharmacol, Richmond, VA 23298 USA.
RP Grant, S (reprint author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Goodwin Res Lab 234,Dept Med, 401 Coll St, Richmond, VA 23298 USA.
EM sgrant@mcvh-vcu.edu
FU NCI NIH HHS [CA 93738, CA 100866, CA 63753]
CR Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749
   Almenara J, 2002, LEUKEMIA, V16, P1331, DOI 10.1038/sj.leu.2402535
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899
   Bueno-da-Silva AEB, 2003, CELL DEATH DIFFER, V10, P592, DOI 10.1038/sj.cdd.4401210
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Ciccarelli C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-41
   Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189
   Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200
   Donato NJ, 2004, CANCER RES, V64, P672, DOI 10.1158/0008-5472.CAN-03-1484
   Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561
   Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306
   Fiskus W, 2006, CLIN CANCER RES, V12, P5869, DOI 10.1158/1078-0432.CCR-06-0980
   GARCIAMANERO G, 2004, P AN M AM SOC CLIN, V23, P201
   Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538
   Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041
   Hamilton A, 2006, LEUKEMIA, V20, P1035, DOI 10.1038/sj.leu.2404189
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Jin A, 2006, ONCOGENE, V25, P4332, DOI 10.1038/sj.onc.1209459
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9
   La Rosee P, 2002, CANCER RES, V62, P7149
   Lierman E, 2006, BLOOD, V108, P1374, DOI 10.1182/blood-2006-02-004457
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233
   MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558
   Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873
   Moulding DA, 2000, BLOOD, V96, P1756
   Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000
   Nimmanapalli R, 2003, CANCER RES, V63, P5126
   O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259
   Philpott NJ, 1996, BLOOD, V87, P2244
   Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647
   Quintas-Cardama A, 2007, BLOOD, V109, P497, DOI 10.1182/blood-2006-07-035493
   Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Rosato RR, 2007, MOL CANCER THER, V6, P692, DOI 10.1158/1535-7163.MCT-06-0562
   Rosato RR, 2003, MOL CANCER THER, V2, P1273
   Rosato RR, 2006, MOL PHARMACOL, V69, P216, DOI 10.1124/mol.105.017145
   Rosato RR, 2005, MOL CANCER THER, V4, P1772, DOI 10.1158/1535-7163.MCT-05-0157
   Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598
   Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530
   Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X
   Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200
   Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124
   Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Yu C, 2005, LEUKEMIA, V19, P1579, DOI 10.1038/sj.leu.2403868
   Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841
   Yu CR, 2003, CANCER RES, V63, P2118
NR 58
TC 59
Z9 62
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2007
VL 13
IS 14
BP 4280
EP 4290
DI 10.1158/1078-0432.CCR-07-0835
PG 11
WC Oncology
SC Oncology
GA 191DO
UT WOS:000248110500034
PM 17634558
OA Bronze
DA 2018-12-27
ER

PT J
AU Ma, XS
   Bruning, J
   Ashcroft, FM
AF Ma, Xiaosong
   Bruning, Jens
   Ashcroft, Frances M.
TI RETRACTED: Glucagon-like peptide 1 stimulates hypothalamic
   proopiomelanocortin neurons (Retracted article. See vol. 31, pg. 8698,
   2011)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE GLP-1; POMC neurons; L-type Ca(2+) channel; PKA; appetite; obesity
ID CENTRAL-NERVOUS-SYSTEM; NEUROENDOCRINE NEURONS; RAT HYPOTHALAMUS; POMC
   NEURONS; FOOD-INTAKE; RECEPTOR; OBESITY; WEIGHT; EXPRESSION; INSULIN
AB Glucagon-like peptide 1 (GLP-1) is a potent inhibitor of food intake. GLP-1 receptor mRNA is densely expressed in hypothalamic arcuate nucleus ( ARC) and precisely overlaps the area occupied by proopiomelanocortin ( POMC) neurons. Activation of POMC neurons suppresses appetite, and lack of POMC-derived peptides or inhibition of POMC neuronal firing causes obesity. Here, we identify living POMC cells in mouse ARC brain slices by targeted expression of green fluorescent protein. Using whole-cell patch-clamp recordings, we show that GLP-1 increases the spontaneous action-potential firing of POMC neurons. The stimulatory effect of GLP-1 was mimicked by GLP-1 receptor agonist exendin-4 and abolished by the receptor antagonist exendin 9-39. The effect of GLP-1 was unchanged in the presence of the synaptic blockers DAP5 (D(-)-2-amino-5-phosphonopentanoic acid)/CNQX (6-cyano-7-nitroquinoxaline-2,3-dione disodium salt) and picrotoxin. These results suggest that GLP-1 excites POMC neurons postsynaptically, via interaction with GLP-1 receptors on POMC cells. Whole-cell Ca(2+) currents increased similar to 70% in the presence of GLP-1, and this effect was abolished by L-type Ca(2+) channel antagonist nifedipine. Forskolin (which activates cAMP) mimicked the effects of GLP-1 and the PKA inhibitor Rp-8-Bromo-cAMPS (8-bromoadenosine- 3 ',5 '-cyclic monophosphorothioate, Rp-isomer) blocked GLP-1 action. These data indicate that GLP-1 stimulates the electrical activity of hypothalamic POMC neurons by activation of PKA and a subsequent increase in L-type Ca(2+) current. This effect may contribute to the anorectic action of GLP-1, because excitation of POMC cells is well established to reduce food intake.
C1 Univ Oxford, Physiol Lab, Oxford OX1 3PT, England.
   Genet Inst Inc, Dept Mouse Genet & Metab, D-50674 Cologne, Germany.
RP Ashcroft, FM (reprint author), Univ Oxford, Physiol Lab, S Parks Rd, Oxford OX1 3PT, England.
EM frances.ashcroft@physiol.ox.ac.uk
FU Wellcome Trust
CR Acuna-Goycolea C, 2004, J NEUROSCI, V24, P8141, DOI 10.1523/JNEUROSCI.1607-04.2004
   Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004
   Burdakov D, 2002, J NEUROSCI, V22, P6380
   CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156
   DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434
   Gromada J, 1997, PFLUG ARCH EUR J PHY, V434, P515, DOI 10.1007/s004240050431
   HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0
   Huda MSB, 2006, OBES REV, V7, P163, DOI 10.1111/j.1467-789X.2006.00245.x
   Jobst EE, 2004, TRENDS ENDOCRIN MET, V15, P488, DOI 10.1016/j.tem.2004.10.007
   Kakei M, 2002, AUTON NEUROSCI-BASIC, V102, P39, DOI 10.1016/S1566-0702(02)00182-0
   Larsen PJ, 1997, NEUROSCIENCE, V77, P257, DOI 10.1016/S0306-4522(96)00434-4
   Larsen PJ, 1997, ENDOCRINOLOGY, V138, P4445, DOI 10.1210/en.138.10.4445
   Ma XS, 2007, J NEUROSCI, V27, P1529, DOI 10.1523/JNEUROSCI.3583-06.2007
   Ma XS, 2005, MOL ENDOCRINOL, V19, P198, DOI 10.1210/me.2004-0059
   Meeran K, 1999, ENDOCRINOLOGY, V140, P244, DOI 10.1210/en.140.1.244
   Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
   MERCHENTHALER I, 1991, NEUROSCIENCE, V44, P655, DOI 10.1016/0306-4522(91)90085-3
   Naslund E, 2004, BRIT J NUTR, V91, P439, DOI 10.1079/BJN20031064
   Neary NM, 2005, ENDOCRINOLOGY, V146, P5120, DOI 10.1210/en.2005-0237
   Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481
   Plum L, 2006, J CLIN INVEST, V116, P1886, DOI 10.1172/JCI27123
   Schwartz MW, 2000, NATURE, V404, P661
   SCROCCHI LA, 1996, NORMAL WEIGHT GAIN F
   Shughrue PJ, 1996, ENDOCRINOLOGY, V137, P5159, DOI 10.1210/en.137.11.5159
   Tang-Christensen M, 1998, DIABETES, V47, P530, DOI 10.2337/diabetes.47.4.530
   TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848
   THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641
   Tomasik PJ, 2004, J PEDIATR ENDOCR MET, V17, P1623
   Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0
   van den Pol AN, 1998, J NEUROSCI, V18, P7962
   Verdich C, 2001, INT J OBESITY, V25, P1206, DOI 10.1038/sj.ijo.0801655
   Xu AW, 2005, PLOS BIOL, V3, P2168, DOI 10.1371/journal.pbio.0030415
   Yaswen L, 1999, NAT MED, V5, P1066
NR 33
TC 44
Z9 46
U1 4
U2 14
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 4
PY 2007
VL 27
IS 27
BP 7125
EP 7129
DI 10.1523/JNEUROSCI.1025-07.2007
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 186BP
UT WOS:000247754400006
PM 17611265
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Liu, T
   Wang, ZW
   Wang, YX
   Xie, ZP
AF Liu, T.
   Wang, Z.-W.
   Wang, Y.-X.
   Xie, Z.-P.
TI RETRACTED:
   Tetrakis(mu-2-pyridyloxyacetato)bis[(1,10-phenanthroline)(2-pyridyloxyac
   etato)lanthanum(III)] (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID INTERMOLECULAR INTERACTIONS; LANTHANIDE(III) COMPLEXES; ACID
AB The molecule of the title compound, [ La-2( C7H6NO3)(6)( C12H8N2)(2)], has an inversion centre midway between the two La-III ions, which are bridged by two terdentate and two bidentate carboxylate groups. Each La atom is seven-coordinated by two N atoms of a 1,10-phenanthroline ligand and five O atoms of 2-pyridyloxyacetate ligands. In the crystal structure, intermolecular C-H center dot center dot center dot O hydrogen bonds lead to a supramolecular network.
C1 Jinggangshan Univ, Coll Engn, Jinan 343009, Peoples R China.
   Jinggangshan Univ, Coll Math & Phys, Jinan 343009, Peoples R China.
   Jiangxi Univ Sci Tech, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jinan 343009, Peoples R China.
EM taoliu07@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Braga D, 2000, ACCOUNTS CHEM RES, V33, P601, DOI 10.1021/ar990143u
   Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b
   Desiraju GR, 1997, CHEM COMMUN, P1475, DOI 10.1039/a607149j
   Hof F, 2002, ANGEW CHEM INT EDIT, V41, P1488, DOI 10.1002/1521-3773(20020503)41:9<1488::AID-ANIE1488>3.0.CO;2-G
   Johnson DW, 2001, SUPRAMOL CHEM, V13, P639, DOI 10.1080/10610270108027494
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Swiegers GF, 2002, COORDIN CHEM REV, V225, P91, DOI 10.1016/S0010-8545(01)00407-6
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zaworotko MJ, 1997, NATURE, V386, P220, DOI 10.1038/386220a0
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
NR 16
TC 2
Z9 2
U1 3
U2 13
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M2020
EP U2084
DI 10.1107/S1600536807030917
PN 7
PG 14
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900195
DA 2018-12-27
ER

PT J
AU Liu, T
   Xie, ZP
AF Liu, T.
   Xie, Z.-P.
TI RETRACTED: Tetrakis(pyrazine-kappa N)bis(thiocyanato-kappa N) zinc(II)
   (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB In the molecule of the title complex, [Zn(NCS)(2)(C4H4N2)(4)], the Zn-II atom is bonded in a distorted octahedral arrangement composed of two N atoms of two thiocyanate and four N atoms of four pyrazine ligands. A crystallographic twofold rotation axis passes through the Zn atom and the N atoms of two trans-pyrazine rings. In the crystal structure, nonclassical hydrogen bonds and weak pi-pi stacking interactions, with a centroid - centroid distance of 3.3119 ( 6) angstrom ( symmetry code: 1 - x; 2 - y; 1 - z), result in the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   *BRUK AXS INC, 2004, APEX2 BRUK
   Liu T, 2007, ACTA CRYSTALLOGR E, V63, pM1820, DOI 10.1107/S1600536807026852
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELXS 97 SHELXL97
   *SIEM AN X RAY INS, 1996, SAINT SHELXTL
NR 6
TC 2
Z9 2
U1 3
U2 10
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M1908
EP U1106
DI 10.1107/S1600536807028735
PN 7
PG 9
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900108
DA 2018-12-27
ER

PT J
AU Liu, T
   Wang, ZW
   Wang, YX
   Xie, ZP
AF Liu, T.
   Wang, Z.-W.
   Wang, Y.-X.
   Xie, Z.-P.
TI RETRACTED: (Dihydroxyglyoxime-kappa(2) N,N
   ')bis(1,10-phenanthroline-kappa(2) N,N ')copper(II) dinitrate dihydrate
   (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID COMPLEX
AB In the molecule of the title compound, [Cu(C12H8N2)(2)(C2H4N2O4)](NO3)(2)center dot 2H(2)O, the Cu atom has a distorted octahedral coordination formed by six N atoms from one dihydroxyglyoxime and two 1,10-phenanthroline ligands. In the crystal structure, molecules are linked into a three-dimensional framework by O - H center dot center dot center dot O and C - H center dot center dot center dot O hydrogen bonds and by pi-pi stacking interactions, with a centroid-centroid distance of 3.5692 (5) angstrom (symmetry code: 1 - x, 2 - y, 1 - z).
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jingganshan Univ, Coll Math & Phys, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@163.com
CR ALLEN TH, 1987, J CHEM SOC P2, pS1
   BRUKER, 2005, APEX2
   Cervera B, 1997, J CHEM SOC DALTON, P395, DOI 10.1039/a604420d
   CHAUDHURI P, 1991, INORG CHEM, V30, P4777, DOI 10.1021/ic00025a019
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   LI H, 2005, ACTA CRYSTALLOGR C, V61, pM91
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Pope M. T., 1983, HETEROPOLY ISOPOLY O
   Pope M. T., 2001, POLYOXOMETALATE CHEM
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 15
TC 2
Z9 2
U1 5
U2 14
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M1887
EP U936
DI 10.1107/S1600536807028255
PN 7
PG 13
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900093
DA 2018-12-27
ER

PT J
AU Liu, T
   Xie, ZP
AF Liu, T.
   Xie, Z.-P.
TI RETRACTED: Tetrakis(pyrazine-kappa N)bis(thiocyanato-kappa
   N)manganese(II) (Retracted article. See vol. 66, pg. E13, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB In the molecule of the title complex, [Mn(NCS)(2)(C4H4N2)(4)], the Mn-II atom is coordinated in a distorted octahedral arrangement by two N atoms of two SCN- and four N atoms of four pyrazine ligands. A crystallographic twofold rotation axis passes through the Mn atom, and the N and para-N atoms of two trans pyrazine rings. In the crystal structure, the non-classical hydrogen bonds and the weak pi-pi stacking interactions, involving the pyrazine rings of adjacent pyrazine ligands with a centroid-centroid distance of 3.3205 (4) angstrom, contribute to the formation of a supramolecular network structure.
C1 Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Sci & Technol, Dept Chem, Ganzhou 341000, Peoples R China.
RP Liu, T (reprint author), Jinggangshan Univ, Coll Engn, Jian 343009, Peoples R China.
EM taoliu07@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Law NA, 1999, ADV INORG CHEM, V46, P305
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   LIU H, 2004, ACTA CRYSTALLOGR C, V60, pM183
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   PECORARO VL, 1986, ACTA CRYSTALLOGR C, V42, P1151, DOI 10.1107/S0108270186093071
   *SEIM ANAL XRAY IN, 1996, APEX2 SAINT SHELXTL
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 10
TC 4
Z9 4
U1 2
U2 9
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M1820
EP U483
DI 10.1107/S1600536807026852
PN 7
PG 9
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900048
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: (1,10-Phenanthroline-kappa N-2,N ')
   tris(phenoxyacetato)-kappa O;kappa O;kappa O,O '-neodymium(III)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, [ Nd( C8H7O3)(3)( C12H8N2)], the Nd-III atom is six-coordinated by two N atoms of the 1,10-phenanthroline ( phen) ligand and four O atoms of the three phenoxyacetate ligands. In the crystal structure, intermolecular C-H center dot center dot center dot O hydrogen bonds lead to a supramolecular network.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jinan 343009, Peoples R China.
   Jiangxi Univ Finance & Eco, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jinan 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM1885, DOI 10.1107/S1600536807028061
NR 5
TC 0
Z9 0
U1 4
U2 10
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M2019
EP U2070
DI 10.1107/S1600536807030371
PN 7
PG 13
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900194
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: (1,10-Phenanthroline)tri(3-phenyl-propanoato)lanthanum(III)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID LANTHANIDE(III) COMPLEXES; HEXAHYDRATE; ACID
AB The La-III atom in the title complex, [ La(C9H9O2)(3)(C12H8N2)], is coordinated by two N atoms of a 1,10-phenanthroline ( phen) ligand and four O atoms of three phenylpropanoate ligands. This mononuclear complex is further extended into a supramolecular network structure via nonclassical hydrogen bonds between CH groups of 1,10-phenanthroline or phenylpropanoate and O atoms of neighbouring phenylpropanoate ligands.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Daiguebonne C, 2000, INORG CHIM ACTA, V304, P161, DOI 10.1016/S0020-1693(00)00079-7
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN X RAY INS, 1996, SMART SAINT SHELXTL
   STARYNOWICZ P, 1993, ACTA CRYSTALLOGR C, V49, P1895, DOI 10.1107/S0108270193004603
   STARYNOWICZ P, 1991, ACTA CRYSTALLOGR C, V47, P294, DOI 10.1107/S0108270190007892
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zeng XR, 2000, ACTA CRYSTALLOGR C, V56, pE325, DOI 10.1107/S0108270100009604
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
NR 14
TC 1
Z9 1
U1 5
U2 16
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M1909
EP U1119
DI 10.1107/S1600536807028693
PN 7
PG 13
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900109
DA 2018-12-27
ER

PT J
AU Zhong, H
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: (1,10-Phenanthroline)tris(phenoxyacetato) cerium(III)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID LANTHANIDE(III) COMPLEXES; HEXAHYDRATE; ACID
AB In the molecule of the title compound, [Ce(C8H7O3)(3)(C12H8N2)], the Ce-III atom is six-coordinated by two N atoms of the 1,10-phenanthroline ( phen) ligand and four O atoms of the three phenoxyacetate ligands. In the crystal structure, intermolecular C - H center dot center dot center dot O hydrogen bonds lead to a supramolecular network.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Daiguebonne C, 2000, INORG CHIM ACTA, V304, P161, DOI 10.1016/S0020-1693(00)00079-7
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
   STARYNOWICZ P, 1993, ACTA CRYSTALLOGR C, V49, P1895, DOI 10.1107/S0108270193004603
   STARYNOWICZ P, 1991, ACTA CRYSTALLOGR C, V47, P294, DOI 10.1107/S0108270190007892
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zeng XR, 2000, ACTA CRYSTALLOGR C, V56, pE325, DOI 10.1107/S0108270100009604
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
NR 14
TC 1
Z9 1
U1 5
U2 9
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M1885
EP U923
DI 10.1107/S1600536807028061
PN 7
PG 14
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900092
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
   Xu, YP
AF Zhong, H.
   Zeng, X.-R.
   Yang, X.-M.
   Luo, Q.-Y.
   Xu, Y.-P.
TI RETRACTED: (1,10-phenanthroline)tris(phenoxyacetato)lanthanum(III)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID LANTHANIDE(III) COMPLEXES; HEXAHYDRATE; ACID
AB The La-III atom in the title complex, [La(C8H7O3)(3)(C12H8N2)], is coordinated by two N atoms of the 1,10-phenanthroline ligand and four O atoms of three phenoxyacetate ligands. This mononuclear complex is further extended into a supramolecular network structure via nonclassical hydrogen bonds between CH groups of 1,10-phenanthroline and phenoxyacetate and O atoms of neighbouring phenoxyacetate ligands.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BRUKER, 2004, APEX2
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   KAY J, 1972, INORG CHEM, V11, P2818, DOI 10.1021/ic50117a047
   Ma L, 1999, INORG CHEM, V38, P5837, DOI 10.1021/ic990429v
   Mao JG, 1998, POLYHEDRON, V17, P3999, DOI 10.1016/S0277-5387(98)00198-3
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SAINT SHELXTL
   STARYNOWICZ P, 1993, ACTA CRYSTALLOGR C, V49, P1895, DOI 10.1107/S0108270193004603
   STARYNOWICZ P, 1991, ACTA CRYSTALLOGR C, V47, P294, DOI 10.1107/S0108270190007892
   Tsukube H, 2002, CHEM REV, V102, P2389, DOI 10.1021/cr010450p
   Zeng XR, 2000, ACTA CRYSTALLOGR C, V56, pE325, DOI 10.1107/S0108270100009604
   Zhang ZH, 2005, CRYST GROWTH DES, V5, P1191, DOI 10.1021/cg049600q
NR 14
TC 0
Z9 0
U1 4
U2 7
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUL
PY 2007
VL 63
BP M1868
EP U758
DI 10.1107/S1600536807027171
PN 7
PG 14
WC Crystallography
SC Crystallography
GA 191RP
UT WOS:000248149900078
DA 2018-12-27
ER

PT J
AU Blanco, G
   Lemus, JA
   Grande, J
   Gangoso, L
   Grande, JM
   Donazar, JA
   Arroyo, B
   Frias, O
   Hiraldo, F
AF Blanco, Guillermo
   Lemus, Jesus A.
   Grande, Javier
   Gangoso, Laura
   Grande, Juan M.
   Donazar, Jose A.
   Arroyo, Bernardo
   Frias, Oscar
   Hiraldo, Fernando
TI RETRACTED: Geographical variation in cloacal microflora and bacterial
   antibiotic resistance in a threatened avian scavenger in relation to
   diet and livestock farming practices (Retracted article. See vol. 14,
   pg. 3289, 2012)
SO ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID ANTIMICROBIAL RESISTANCE; FOOD ANIMALS; BIRDS; PATHOGENS; SPREAD; FECES;
   SUSCEPTIBILITY; ENTEROCOCCI; POPULATION; EMERGENCE
AB The impact on wildlife health of the increase in the use of antimicrobial agents with the intensification of livestock production remains unknown. The composition, richness and prevalence of cloacal microflora as well as bacterial resistance to antibiotics in nestlings and full-grown Egyptian vultures Neophron percnopterus were assessed in four areas of Spain in which the degree of farming intensification differs. Differences in diet composition, especially the role of stabled livestock carrion, appear to govern the similarities of bacterial flora composition among continental populations, while the insular vulture population (Fuerteventura, Canary Islands) showed differences attributed to isolation. Evidence of a positive relationship between the consumption of stabled livestock carrion and bacterial resistance to multiple antibiotics was found. Bacterial resistance was high for semisynthetic penicillins and enrofloxacin, especially in the area with the most intensive stabled livestock production. The pattern of antibiotic resistance was similar for the different bacterial species within each area. Bacterial resistance to antibiotics may be determined by resistance of bacteria present in the livestock meat remains that constituted the food of this species, as indicated by the fact that resistance to each antibiotic was correlated in Escherichia coli isolated from swine carrion and Egyptian vulture nestlings. In addition, resistance in normal faecal bacteria (present in the microflora of both livestock and vultures) was higher than in Staphylococcus epidermidis, a species indicator of the transient flora acquired presumably through the consumption of wild rabbits. Potential negative effects of the use of antimicrobials in livestock farming included the direct ingestion of these drug residues and the effects of bacterial antibiotic resistance on the health of scavengers.
C1 CSIC, IREC, UCLM, JCCM, Ciudad Real 13005, Spain.
   CSIC, Dept Appl Biol, Estac Biol Donana, Seville 41013, Spain.
   Ministerio Medio Ambiente, Oficina Especies Migratorias, Madrid 28005, Spain.
RP Blanco, G (reprint author), CSIC, IREC, UCLM, JCCM, Ronda Toledo S-N, Ciudad Real 13005, Spain.
EM gublanco2@yahoo.es
RI Gangoso, Laura/C-6575-2015; Blanco, Guillermo/L-3170-2014
OI Gangoso, Laura/0000-0002-6205-6769; Blanco,
   Guillermo/0000-0001-5742-4929; Donazar, Jose Antonio/0000-0002-9433-9755
CR Aarestrup FM, 2001, ANTIMICROB AGENTS CH, V45, P2054, DOI 10.1128/AAC.45.7.2054-2059.2001
   Agustin AI, 2005, LETT APPL MICROBIOL, V41, P39, DOI 10.1111/j.1472-765X.2005.01710.x
   ANGULO FJ, 2004, REV SCI TECH OIE, V23, P467
   BANGERT RL, 1988, AVIAN DIS, V32, P53, DOI 10.2307/1590948
   Barza M, 2002, CLIN INFECT DIS, V34, pS123, DOI 10.1086/340249
   Bengis RH, 2004, REV SCI TECH OIE, V23, P497
   BENITEZ JR, 2003, REV SOC GADITANA HIS, V4, P215
   Blanco G, 2006, J APPL ECOL, V43, P990, DOI 10.1111/j.1365-2664.2006.01200.x
   Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443
   de Carvalho LR, 2003, BRAZ J MICROBIOL, V34, P218, DOI 10.1590/S1517-83822003000300007
   DeBoer LR, 2001, LETT APPL MICROBIOL, V33, P382, DOI 10.1046/j.1472-765X.2001.01015.x
   Dobbin G, 2005, COMP IMMUNOL MICROB, V28, P71, DOI 10.1016/j.cimid.2004.08.001
   Donazar J. A., 2004, LIBRO ROJO AVES ESPA, P129
   Donazar J. A., 1993, LOS BUITRES IBERICOS
   Donazar JA, 2002, BIOL CONSERV, V107, P89, DOI 10.1016/S0006-3207(02)00049-6
   Donazar Jose A., 1997, P117
   Donazar Jose Antonio, 1992, Ardeola, V39, P29
   Fallacara DM, 2001, AVIAN DIS, V45, P128, DOI 10.2307/1593019
   Friend M, 2001, AUK, V118, P290, DOI 10.1642/0004-8038(2001)118[0290:DEIBCF]2.0.CO;2
   Friend M., 1999, FIELD MANUAL WILDLIF, P349
   FRIEND M, 1999, FIELD MANUAL WILDLIF
   Greko C, 1999, ACTA VET SCAND, P87
   Holt J.G, 1994, BERGEYS MANUAL SYSTE, V1-2
   HOLT JG, 1994, BERGEYS MANUAL SYSTE, V2
   Hubalek Zdenek, 1994, Acta Scientiarum Naturalium Academiae Scientiarum Bohemicae Brno, V28, P1
   LANGAN GP, 2000, LAB MED AVIAN EXOTIC, P325
   Langelier K.M., 1993, P231
   Livermore DM, 2001, ENVIRON MICROBIOL, V3, P658, DOI 10.1046/j.1462-2920.2001.00239.x
   MAGURRAN A.E., 1988, ECOLOGICAL DIVERSITY
   MARTI CD, 1987, RAPTOR MANAGEMENT TE, P67
   MARTINEZ F, 2004, QUERCUS, V227, P69
   Mateu E, 2001, J VET MED B, V48, P569, DOI 10.1046/j.1439-0450.2001.00475.x
   McEwen SA, 2002, CLIN INFECT DIS, V34, pS93, DOI 10.1086/340246
   Medina Felix Manuel, 1999, Vieraea, V27, P77
   Molbak K, 2004, J VET MED B, V51, P364, DOI 10.1111/j.1439-0450.2004.00788.x
   Nascimento AMA, 2003, CONDOR, V105, P358, DOI 10.1650/0010-5422(2003)105[0358:AGBIBF]2.0.CO;2
   Negro JJ, 2002, NATURE, V416, P807, DOI 10.1038/416807a
   Normark BH, 2002, J INTERN MED, V252, P91, DOI 10.1046/j.1365-2796.2002.01026.x
   O'Brien TF, 2002, CLIN INFECT DIS, V34, pS78, DOI 10.1086/340244
   Pantosti A, 1999, LANCET, V354, P741, DOI 10.1016/S0140-6736(99)02395-8
   Reche MP, 2003, J VET MED B, V50, P42, DOI 10.1046/j.1439-0450.2003.00623.x
   Refsum T, 2003, J WILDLIFE DIS, V39, P64, DOI 10.7589/0090-3558-39.1.64
   Schneitz C, 2005, FOOD CONTROL, V16, P657, DOI 10.1016/j.foodcont.2004.06.002
   Shultz S, 2004, P ROY SOC B-BIOL SCI, V271, pS458, DOI 10.1098/rsbl.2004.0223
   Sorensen TL, 2002, NEW ENGL J MED, V346, P779
   Swartz MN, 2002, CLIN INFECT DIS, V34, pS111, DOI 10.1086/340248
   Tella JL, 2001, NATURE, V410, P408, DOI 10.1038/35068717
   Travers K, 2002, CLIN INFECT DIS, V34, pS131, DOI 10.1086/340251
   TSUBOKURA M, 1995, J WILDLIFE DIS, V31, P352, DOI 10.7589/0090-3558-31.3.352
   Waldenstrom J, 2002, APPL ENVIRON MICROB, V68, P5911, DOI 10.1128/AEM.68.12.5911-5917.2002
   *WHO, 1999, REV LIT REP WHO WORK
   WINSOR DK, 1981, APPL ENVIRON MICROB, V42, P1123
   Woolhouse MEJ, 2002, TRENDS MICROBIOL, V10, pS3, DOI 10.1016/S0966-842X(02)02428-9
   ZAR JH, 1984, BIOSTAT ANAL
NR 54
TC 36
Z9 39
U1 6
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-2912
EI 1462-2920
J9 ENVIRON MICROBIOL
JI Environ. Microbiol.
PD JUL
PY 2007
VL 9
IS 7
BP 1738
EP 1749
DI 10.1111/j.1462-2920.2007.01291.x
PG 12
WC Microbiology
SC Microbiology
GA 176ZU
UT WOS:000247124200011
PM 17564607
DA 2018-12-27
ER

PT J
AU Fouhy, Y
   Scanlon, K
   Schouest, K
   Spillane, C
   Crossman, L
   Avison, MB
   Ryan, RP
   Dow, JM
AF Fouhy, Yvonne
   Scanlon, Karl
   Schouest, Katherine
   Spillane, Charles
   Crossman, Lisa
   Avison, Matthew B.
   Ryan, Robert P.
   Dow, J. Maxwell
TI RETRACTED: Diffusible signal factor-dependent cell-cell signaling and
   virulence in the nosocomial pathogen Stenotrophomonas maltophilia
   (Retracted article. See vol. 200, 2018)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID CAMPESTRIS PV. CAMPESTRIS; XANTHOMONAS-CAMPESTRIS;
   PSEUDOMONAS-AERUGINOSA; CAENORHABDITIS-ELEGANS; BIOFILM FORMATION;
   DNA-SEQUENCES; GENES; COMMUNICATION; RESISTANCE; SYSTEM
AB The genome of Stenotrophomonas maltophilia encodes a cell-cell signaling system that is highly related to the diffusible signal factor (DSF)-dependent system of the phytopathogen Xanthomonas campestris. Here we show that in S. maltophilia, DSF signaling controls factors contributing to the virulence and antibiotic resistance of this important nosocomial pathogen.
C1 Natl Univ Ireland Univ Coll Cork, BIOMERIT Res Ctr, Dept Microbiol, Biosci Inst, Cork, Ireland.
   Natl Univ Ireland Univ Coll Cork, Dept Biochem, Biosci Inst, Cork, Ireland.
   Wellcome Trust Sanger Inst, Pathogen Sequencing Unit, Cambridge CB10 1SA, England.
   Univ Bristol, Dept Cellular & Mol Med, Sch Med Sci, Bristol BS8 1TD, Avon, England.
RP Dow, JM (reprint author), Natl Univ Ireland Univ Coll Cork, BIOMERIT Res Ctr, Dept Microbiol, Biosci Inst, Cork, Ireland.
EM m.dow@ucc.ie
OI Ryan, Rober/0000-0002-7353-0913; Avison, Matthew/0000-0003-1454-8440;
   Spillane, Charles/0000-0003-3318-323X; Scanlon, Karl/0000-0003-0119-5738
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Avison MB, 2000, J ANTIMICROB CHEMOTH, V46, P879, DOI 10.1093/jac/46.6.879
   Barber CE, 1997, MOL MICROBIOL, V24, P555, DOI 10.1046/j.1365-2958.1997.3721736.x
   Chatterjee S, 2002, MOL PLANT MICROBE IN, V15, P463, DOI 10.1094/MPMI.2002.15.5.463
   Chhabra SR, 2005, TOP CURR CHEM, V240, P279, DOI 10.1007/b98319
   Simionato AVC, 2007, J MASS SPECTROM, V42, P490, DOI 10.1002/jms.1181
   Crossman L, 2004, MICROBES INFECT, V6, P623, DOI 10.1016/j.micinf.2004.01.013
   Darby C, 1999, P NATL ACAD SCI USA, V96, P15202, DOI 10.1073/pnas.96.26.15202
   de Oliveira-Garcia D, 2003, CELL MICROBIOL, V5, P625, DOI 10.1046/j.1462-5822.2003.00306.x
   Denton M, 1998, CLIN MICROBIOL REV, V11, P57, DOI 10.1128/CMR.11.1.57
   Dow JM, 2003, P NATL ACAD SCI USA, V100, P10995, DOI 10.1073/pnas.1833360100
   Dunne C, 2000, MICROBIOL-SGM, V146, P2069, DOI 10.1099/00221287-146-8-2069
   Garcia DO, 2002, BRAZ J MICROBIOL, V33, P157, DOI 10.1590/S1517-83822002000200012
   Gould VC, 2006, J ANTIMICROB CHEMOTH, V57, P199, DOI 10.1093/jac/dki453
   He YW, 2006, MOL MICROBIOL, V59, P610, DOI 10.1111/j.1365-2958.2005.04961.x
   Hentzer M, 2003, EMBO J, V22, P3803, DOI 10.1093/emboj/cdg366
   Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9
   HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73
   Huang TP, 2006, J BACTERIOL, V188, P3116, DOI 10.1128/JB.188.8.3116-3120.2006
   Hugouvieux V, 1998, MOL PLANT MICROBE IN, V11, P537, DOI 10.1094/MPMI.1998.11.6.537
   Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1016/S0378-1097(99)00150-0
   Kurz CL, 2000, TRENDS MICROBIOL, V8, P142, DOI 10.1016/S0966-842X(99)01691-1
   Looney WJ, 2005, BRIT J BIOMED SCI, V62, P145, DOI 10.1080/09674845.2005.11732702
   Mahajan-Miklos S, 2000, MOL MICROBIOL, V37, P981, DOI 10.1046/j.1365-2958.2000.02056.x
   McKay GA, 2003, INFECT IMMUN, V71, P3068, DOI 10.1128/IAI.71.6.3068-3075.2003
   Minkwitz A, 2001, J CLIN MICROBIOL, V39, P139, DOI 10.1128/JCM.39.1.139-145.2001
   Newman KL, 2004, P NATL ACAD SCI USA, V101, P1737, DOI 10.1073/pnas.0308399100
   NEWMAN MA, 1994, MOL PLANT MICROBE IN, V7, P553, DOI 10.1094/MPMI-7-0553
   Okazaki A, 2007, ANTIMICROB AGENTS CH, V51, P359, DOI 10.1128/AAC.00795-06
   PALLERONI NJ, 1993, INT J SYST BACTERIOL, V43, P606, DOI 10.1099/00207713-43-3-606
   Poole K, 2004, CLIN MICROBIOL INFEC, V10, P12, DOI 10.1111/j.1469-0691.2004.00763.x
   RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262
   Sambrook J, 1989, MOL CLONING LAB MANU
   Sanchez P, 2002, ANTIMICROB AGENTS CH, V46, P3386, DOI 10.1128/AAC.46.11.3386-3393.2002
   Scarpari LM, 2003, FEMS MICROBIOL LETT, V222, P83, DOI 10.1016/S0378-1097(03)00251-9
   Senol E, 2004, J HOSP INFECT, V57, P1, DOI 10.1016/j.jhin.2004.01.033
   Slater H, 2000, MOL MICROBIOL, V38, P986, DOI 10.1046/j.1365-2958.2000.02196.x
   Sriramulu DD, 2005, J MED MICROBIOL, V54, P667, DOI 10.1099/jmm.0.45969-0
   STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987
   Tang JL, 1996, MOL PLANT MICROBE IN, V9, P664, DOI 10.1094/MPMI-9-0664
   TANG JL, 1991, MOL GEN GENET, V226, P409
   TURNER P, 1984, MOL GEN GENET, V195, P101, DOI 10.1007/BF00332731
   Visick KL, 2005, J BACTERIOL, V187, P5507, DOI 10.1128/JB.187.16.5507-5519.2005
   Wang LH, 2004, MOL MICROBIOL, V51, P903, DOI 10.1046/j.1365-2958.2003.03883.x
   Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x
   Windhorst S, 2002, J BIOL CHEM, V277, P11042, DOI 10.1074/jbc.M109525200
   Wolf A, 2002, INT J SYST EVOL MICR, V52, P1937, DOI 10.1099/ijs.0.02135-0
   Zhang L, 2001, ANTIMICROB AGENTS CH, V45, P3497, DOI 10.1128/AAC.45.12.3497-3503.2001
NR 48
TC 90
Z9 96
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
EI 1098-5530
J9 J BACTERIOL
JI J. Bacteriol.
PD JUL
PY 2007
VL 189
IS 13
BP 4964
EP 4968
DI 10.1128/JB.00310-07
PG 5
WC Microbiology
SC Microbiology
GA 183ZY
UT WOS:000247612100045
PM 17468254
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Cronin, KJ
   Messina, A
   Thompson, EW
   Morrison, WA
   Stevens, GW
   Knight, KR
AF Cronin, Kevin J.
   Messina, Aurora
   Thompson, Erik W.
   Morrison, Wayne A.
   Stevens, Geoffrey W.
   Knight, Kenneth R.
TI RETRACTED: The role of biological extracellular matrix scaffolds in
   vascularized three-dimensional tissue growth in vivo (Retracted article.
   See vol. 89B, pg. 575, 2009)
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
LA English
DT Article; Retracted Publication
DE extracellular matrix; tissue engineering; vascularized grafts;
   three-dimensional scaffolds; laminin; sea sponge
ID DE-NOVO ADIPOGENESIS; ARTIFICIAL SKIN; ENGINEERED CARTILAGE;
   BASEMENT-MEMBRANE; ADIPOSE-TISSUE; VITRO; GENERATION; MICROSPHERES;
   DEGRADATION; INTEGRA(TM)
AB An in vivo murine vascularized chamber model has been shown to generate spontaneous angiogenesis and new tissue formation. This experiment aimed to assess the effects of common biological scaffolds on tissue growth in this model. Either laminin-1, type I collagen, fibrin glue, hyaluronan, or sea sponge was inserted into silicone chambers containing the epigastric artery and vein, one end was sealed with adipose tissue and the other with bone wax, then incubated subcutaneously. After 2,4, or 6 weeks, tissue from chambers containing collagen 1, fibrin glue, hyaluronan, or no added scaffold (control) had small amounts of vascularized connective tissue. Chambers containing sea sponge had moderate connective tissue growth together with a mild "foreign body" inflammatory response. Chambers containing laminin-1, at a concentration 10-fold lower than its concentration in Matrigel (TM), resulted in a moderate adipogenic response. In summary, (1) biological hydrogels are resorbed and gradually replaced by vascularized connective tissue; (2) sponge-like matrices with large pores support connective tissue growth within the pores and become encapsulated with granulation tissue; (3) laminin-containing scaffolds facilitate adipogenesis. It is concluded that the nature and chemical composition of the scaffold exerts a significant influence on the amount and type of tissue generated in this in vivo chamber model. (c) 2006 Wiley Periodicals, Inc.
C1 Bernard O Brien Inst Microsurg, Melbourne, Vic 3065, Australia.
   Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic 3065, Australia.
   Mater Misericordiae Univ Hosp, Dept Plast & Reconstruct Surg, Dublin 7, Ireland.
RP Knight, KR (reprint author), Bernard O Brien Inst Microsurg, 42 Fitzroy St, Melbourne, Vic 3065, Australia.
EM krknight@unimelb.edu.au
RI Thompson, Erik/A-1425-2009
OI Thompson, Erik/0000-0002-9723-4924; Stevens,
   Geoffrey/0000-0002-5788-4682
CR Beahm EK, 2003, CLIN PLAST SURG, V30, P547, DOI 10.1016/S0094-1298(03)00072-5
   Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429
   Chu TMG, 2002, ANN NY ACAD SCI, V961, P114, DOI 10.1111/j.1749-6632.2002.tb03061.x
   Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D
   Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J
   Fitton AR, 2001, BRIT J PLAST SURG, V54, P208, DOI 10.1054/bjps.2000.3525
   Green D, 2003, TISSUE ENG, V9, P1159, DOI 10.1089/10763270360728062
   Holy CE, 2000, J BIOMED MATER RES, V51, P376, DOI 10.1002/1097-4636(20000905)51:3<376::AID-JBM11>3.0.CO;2-G
   Hutmacher DW, 2001, J BIOMED MATER RES, V55, P203, DOI 10.1002/1097-4636(200105)55:2<203::AID-JBM1007>3.0.CO;2-7
   Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062
   Kedeshian P, 1998, CANCER LETT, V123, P215, DOI 10.1016/S0304-3835(97)00429-1
   Kelly JL, 2006, TISSUE ENG, V12, P2041, DOI 10.1089/ten.2006.12.2041
   Kimura Y, 2002, TISSUE ENG, V8, P603, DOI 10.1089/107632702760240526
   KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005
   Kremer M, 2000, BRIT J PLAST SURG, V53, P459, DOI 10.1054/bjps.2000.3368
   Liao SS, 2004, TISSUE ENG, V10, P73, DOI 10.1089/107632704322791718
   Lindenhayn K, 1999, J BIOMED MATER RES, V44, P149, DOI 10.1002/(SICI)1097-4636(199902)44:2<149::AID-JBM4>3.0.CO;2-C
   Liu YC, 2002, TISSUE ENG, V8, P709, DOI 10.1089/107632702760240616
   Lu LC, 2000, BIOMATERIALS, V21, P1595, DOI 10.1016/S0142-9612(00)00048-X
   Marler JJ, 2000, PLAST RECONSTR SURG, V105, P2049, DOI 10.1097/00006534-200005000-00020
   MEIKLE MC, 1994, BIOMATERIALS, V15, P513, DOI 10.1016/0142-9612(94)90017-5
   Minuth WW, 1998, CELL TISSUE RES, V291, P1
   Nagata N, 2002, J BIOMAT SCI-POLYM E, V13, P579, DOI 10.1163/15685620260178418
   Silverman RP, 1999, PLAST RECONSTR SURG, V103, P1809, DOI 10.1097/00006534-199906000-00001
   Sims CD, 1998, PLAST RECONSTR SURG, V101, P1580, DOI 10.1097/00006534-199805000-00022
   Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186
   Yuksel E, 2000, PLAST RECONSTR SURG, V105, P1712, DOI 10.1097/00006534-200004050-00017
NR 27
TC 18
Z9 19
U1 3
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4973
EI 1552-4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JUL
PY 2007
VL 82B
IS 1
BP 122
EP 128
DI 10.1002/jbm.b.30713
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 184AD
UT WOS:000247612600017
PM 17106890
DA 2018-12-27
ER

PT J
AU Das, M
   Das, S
   Das, DK
AF Das, Manika
   Das, Samarjit
   Das, Dipak K.
TI RETRACTED: Caveolin and MAP kinase interaction in angiotensin II
   preconditioning of the myocardium (Retracted article. See vol. 16, pg.
   2547, 2012)
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE heart; ischaemia; reperfusion; caveolin; MAP kinases; angiotensin II;
   ROS
ID SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; REACTIVE OXYGEN;
   RAT-HEART; SYSTEM; ISCHEMIA/REPERFUSION; HYPERTROPHY; REPERFUSION;
   INHIBITOR; MECHANISM
AB Angiotensin II (Ang II) has been found to exert preconditioning (PC)- like effect in mammalian hearts. The present investigation reported for the first time a unique mitogen activated protein (MAP) kinase signalling in Ang II PC of the heart involving lipid rafts, which generated a survival signal by differentially associating MAP kinases with caveolin. A group of rat hearts was treated with Ang II in the absence or presence of NADPH oxidase inhibitor, apocynin or a cell permeable reactive oxygen species (ROS) scavenger, N-acetyl-cysteine (NAC). Ang II pre-treatment improved post-ischaemic ventricular recovery, myocardial infraction and decreased the number of cardiomyocyte apoptosis indicating PC effect of Ang II. Both apocynin and NAC abolished the PC ability of Ang II. In Ang II treated heart, there was a decreased association of p38MAPK beta & extracellular-signal regulated kinase (ERK) 1/2 (anti-death signalling component) with caveolin while there was an increased association of p38MAPK beta & Jun N-terminal kinase (JNK) (death signalling component) indicating reduced amount of death signal components and increased amount of anti-death signalling components being available to the Ang II treated heart to generate a survival signal, which was reversed with NAC or apocynin. The survival signal was also demonstrated by increased phosphorylation of serine/threonine-protein kinase B (AKT) and enhanced induction of expression of Bcl-2 during Ang II PC and its reversal with NAC & apocynin treated heart.
C1 Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06032 USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06032 USA.
EM ddas@neuron.uchc.edu
FU NHLBI NIH HHS [R01 HL022559, HL 34360, HL 22559, R01 HL034360, HL 33889]
CR BERESEWICZ A, 2004, CARDIOVASC RES, V172, P201
   Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076
   BURKE TM, 1987, AM J PHYSIOL, V252, pH721
   CHEN W, 1995, CIRC RES, V77, P424, DOI 10.1161/01.RES.77.2.424
   Das DK, 2004, J CELL MOL MED, V8, P144, DOI 10.1111/j.1582-4934.2004.tb00270.x
   Das M, 2007, J MOL CELL CARDIOL, V42, P206, DOI 10.1016/j.yjmcc.2006.08.118
   Das S, 2006, CELL BIOCHEM BIOPHYS, V44, P103, DOI 10.1385/CBB:44:1:103
   Das S, 2006, J MOL CELL CARDIOL, V41, P248, DOI 10.1016/j.yjmcc.2006.03.009
   Diaz RJ, 1997, J MOL CELL CARDIOL, V29, P129, DOI 10.1006/jmcc.1996.0258
   Ferreira AJ, 2001, HYPERTENSION, V38, P665, DOI 10.1161/01.HYP.38.3.665
   Golino P, 1996, NAT MED, V2, P35, DOI 10.1038/nm0196-35
   Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614
   GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141
   Izawa Y, 2005, EXP CELL RES, V308, P291, DOI 10.1016/j.yexcr.2005.04.028
   Kyaw M, 2001, HYPERTENS RES, V24, P251, DOI 10.1291/hypres.24.251
   Li JM, 2004, CIRCULATION, V109, P1307, DOI 10.1161/01.CIR.0000118463.23388.B9
   Maulik N, 1999, CIRCULATION, V100, P369
   Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857
   Maulik N, 2000, FEBS LETT, V485, P7, DOI 10.1016/S0014-5793(00)02174-8
   MURRY CE, 1998, CIRCULATION, V78, P77
   Nakano A, 1997, CORONARY ARTERY DIS, V8, P343, DOI 10.1097/00019501-199706000-00003
   OSAKA M, 1994, JPN CIRC J, V58, P259
   PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274
   Pinzar E, 2005, FEBS LETT, V579, P5100, DOI 10.1016/j.febslet.2005.08.019
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   REEVES JP, 1986, J BIOL CHEM, V261, P4948
   Sharma A, 2000, EUR J PHARMACOL, V406, P85, DOI 10.1016/S0014-2999(00)00582-3
   Sharma A, 2000, MOL CELL BIOCHEM, V214, P31, DOI 10.1023/A:1007167519596
   Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690
   Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021
   Suzuki YJ, 2004, J MOL CELL CARDIOL, V37, P1195, DOI 10.1016/j.yjmcc.2004.09.009
   UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317
   VINTENJOHANSEN J, 1999, HEART STRESS, P412
   Wrobleski ST, 2005, CURR TOP MED CHEM, V5, P1005, DOI 10.2174/1568026054985894
   Xie ZL, 2001, J CELL PHYSIOL, V188, P132, DOI 10.1002/jcp.1104
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
NR 36
TC 10
Z9 11
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL-AUG
PY 2007
VL 11
IS 4
BP 788
EP 797
DI 10.1111/j.1582-4934.2007.00067
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 205DM
UT WOS:000249093500013
PM 17760840
DA 2018-12-27
ER

PT J
AU Lin, HX
   Xiao, JN
   Luo, XB
   Wang, HZ
   Gao, HH
   Yang, BF
   Wang, ZG
AF Lin, Huixian
   Xiao, Jiening
   Luo, Xiaobin
   Wang, Huizhen
   Gao, Huanhuan
   Yang, Baofeng
   Wang, Zhiguo
TI RETRACTED: Overexpression HERG K+ channel gene mediates cell-growth
   sianals on activation of oncoproteins SP1 and NF-kappa B and
   inactivation of tumor suppressor Nkx3.1 (Retracted article. See vol.
   227, pg. 877, 2012)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID CANCER-CELLS; TRANSCRIPTION FACTORS; POTASSIUM-CURRENT; EXPRESSION;
   PROLIFERATION; APOPTOSIS; CURRENTS; MOUSE; METHYLATION; PROGRESSION
AB The long QT syndrome gene human ether-a-go-go related gene (HERG) encodes a K+ channel critical to cardiac repolarization. It peculiarly overexpresses in cancer cells of different histogenesis and promotes tumorigenesis. To decipher the molecular mechanisms for HERG overexpression, we identified and characterized the promoter region of the HERG gene, which contains cis-elements for multiple oncoproteins and tumor suppressors. Oncoprotein SpI was found to be essential to driving the HERG promoter thereby transcription. Another oncoprotein NF-kappa B transactivated, while tumor suppressor Nkx3.1 repressed HERG promoter activity and endogenous HERG transcription. Loss-of-function mutations in the corresponding cis-elements rendered a loss of the ability of the oncoproteins Sp1 and NF-kappa B to transactivate, and of the tumor repressor Nkx3.1 to repress, HERG transcription. Either activation of Sp1 and NF-kappa B or silencing of Nkx3.1 promoted tumor cell growth, and the effects were abrogated by HERG inhibition or knockdown, but facilitated by overexpression of HERG, indicating that HERG mediates the cell growth signals generated by activation of oncoproteins or inactivation of tumor suppressors. Binding of Sp1, NF-kappa B, and Nkx3.1 to their respective cis-elements in the HERG promoter in vitro and their presence on the HERG promoter in vivo were confirmed. Therefore, the HERG promoter region is characterized by multiple SpI binding sites that are responsible for transcription initiation of the HERG gene and by binding sites for multiple other oncogenes and tumor suppressor genes being important for regulating HERG expression. The HERG K+ channel is likely a mediator of growth promoting processes induced by oncoproteins and/or by silencing of tumor suppressors.
C1 Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1CB, Canada.
   Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
   Harbin Med Univ, Dept Pharmacol, State Prov Key Lab China, Harbin, Heilongjiang, Peoples R China.
   Harbin Med Univ, Inst Cardiovasc Res, Harbin, Heilongjiang, Peoples R China.
RP Wang, ZG (reprint author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1CB, Canada.
EM wz.email@gmail.com
CR Akbarali HI, 1999, AM J PHYSIOL-CELL PH, V277, pC1284, DOI 10.1152/ajpcell.1999.277.6.C1284
   Arcangeli A, 1997, EUR J NEUROSCI, V9, P2596, DOI 10.1111/j.1460-9568.1997.tb01689.x
   Arcangeli Annarosa, 2005, V266, P225
   Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688
   Bauer CK, 2003, PFLUG ARCH EUR J PHY, V445, P589, DOI 10.1007/s00424-002-0980-0
   Bianchi L, 1998, CANCER RES, V58, P815
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Bowen C, 2000, CANCER RES, V60, P6111
   Cheney P, 2005, SHAKESPEARE QUART, V56, P220
   Cherubini A, 2000, BRIT J CANCER, V83, P1722, DOI 10.1054/bjoc.2000.1497
   Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979
   CONTI M, 2004, J EXP THER ONCOL, V41, P161
   COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4
   Crociani O, 2003, J BIOL CHEM, V278, P2947, DOI 10.1074/jbc.M210789200
   Crociani O, 2000, MECH DEVELOP, V95, P239, DOI 10.1016/S0925-4773(00)00335-X
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   Dupont J, 2004, GYNECOL ONCOL, V94, P449, DOI 10.1016/j.ygyno.2004.05.014
   Gelmann EP, 2003, PROSTATE, V55, P111, DOI 10.1002/pros.10210
   Herbrand H, 2002, MECH DEVELOP, V117, P217, DOI 10.1016/S0925-4773(02)00207-1
   Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200
   LANG F, 1992, PFLUGERS ARCH, V421, P415
   Lastraioli E, 2004, CANCER RES, V64, P606, DOI 10.1158/0008-5472.CAN-03-2360
   Lindholm PF, 2001, CLIN EXP METASTAS, V18, P471, DOI 10.1023/A:1011845725394
   Meyer R, 1998, J PHYSIOL-LONDON, V508, P49, DOI 10.1111/j.1469-7793.1998.049br.x
   Miranda P, 2005, J PHYSIOL-LONDON, V566, P717, DOI 10.1113/jphysiol.2005.085803
   Miyake JH, 1997, GENE, V202, P177, DOI 10.1016/S0378-1119(97)00491-5
   Overholt JL, 2000, ADV EXP MED BIOL, V475, P241
   Pang L, 2003, FEBS LETT, V546, P349, DOI 10.1016/S0014-5793(03)00629-X
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Skotheim RI, 2003, AM J PATHOL, V163, P2149, DOI 10.1016/S0002-9440(10)63571-7
   Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200
   Tamatani T, 2001, CANCER LETT, V171, P165, DOI 10.1016/S0304-3835(01)00611-5
   Tanaka M, 1999, MECH DEVELOP, V85, P179, DOI 10.1016/S0925-4773(99)00084-2
   Voz ML, 2004, ONCOGENE, V23, P179, DOI 10.1038/sj.onc.1207013
   Wang HZ, 2002, CANCER RES, V62, P4843
   Wang L, 1996, CIRC RES, V79, P79, DOI 10.1161/01.RES.79.1.79
   Wang L, 1996, AM J PHYSIOL-HEART C, V270, pH2088
   Wang L, 1997, AM J PHYSIOL-CELL PH, V273, pC1657, DOI 10.1152/ajpcell.1997.273.5.C1657
   Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5
   Yang T, 1997, CIRC RES, V80, P782
   Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114
   YUE L, 2001, J PHYSL, V527, P467
   Zannetti A, 2005, BIOCHEM PHARMACOL, V70, P1277, DOI 10.1016/j.bcp.2005.07.024
   Zhou W, 1998, J GEN PHYSIOL, V111, P781, DOI 10.1085/jgp.111.6.781
NR 45
TC 29
Z9 30
U1 5
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2007
VL 212
IS 1
BP 137
EP 147
DI 10.1002/jcp.21015
PG 11
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 172FK
UT WOS:000246789300015
PM 17311278
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Semin, GR
AF Stapel, Diederik A.
   Semin, Gun R.
TI RETRACTED: The magic spell of language: Linguistic categories and their
   perceptual consequences (Retracted article. See vol. 104, pg. 197, 2013)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE linguistic relativity; language; perception; priming; linguistic
   categorization model
ID DIFFERENT CULTURES; SOCIAL COGNITION; INFORMATION; REPRESENTATION;
   ACCESSIBILITY; IMPLICIT; BEHAVIOR; IMPACT
AB Language is a tool that directs attention to different aspects of reality. Using participants from the same linguistic community, the authors demonstrate in 4 studies that metasemantic features of linguistic categories influence basic perceptual processes. More specifically, the hypothesis that abstract versus concrete language leads to a more global versus local perceptual focus was supported across 4 experiments, in which participants used (Experiment 1) or were primed either supraliminally (Experiments 2 and 3) or subliminally (Experiment 4) with abstract (adjectives) or concrete (verbs) terms. Participants were shown to display a global versus specific perceptual focus (Experiments I and 4), more versus less inclusiveness of categorization (Experiments 2 and 3), and incorporation of more rather than less contextual information (Experiment 3). The implications of this new perspective toward the language-perception interface are discussed in the context of the general linguistic relativity debate.
C1 Tilburg Univ, TIBER, NL-5000 LE Tilburg, Netherlands.
   Free Univ Amsterdam, Dept Social Psychol, Amsterdam, Netherlands.
RP Stapel, DA (reprint author), Tilburg Univ, TIBER, Warandelaan 2,POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl
OI Semin, Gun/0000-0002-5304-5566
CR *AM PSYCH ASS, 2001, PUBL MAN ASS
   Bargh J. A, 2000, HDB RES METHODS SOCI, P253
   Bargh JA, 2006, EUR J SOC PSYCHOL, V36, P147, DOI 10.1002/ejsp.336
   BERLIN B, 1969, BASIC COLOR TERMS U
   BOAS F, 1949, RACE LANGUAGE CULTUR
   Boroditsky L, 2001, COGNITIVE PSYCHOL, V43, P1, DOI 10.1006/cogp.2001.0748
   Boroditsky L., 2003, ENCY COGNITIVE SCI, P917
   BROWN R, 1958, WORDS THINGS
   BROWN R, 1986, SOCIAL PSYCHOL
   Gasper K, 2002, PSYCHOL SCI, V13, P34, DOI 10.1111/1467-9280.00406
   GENTNER D, 2003, ADV STUDY LANGUAGE T
   GREENWALD AG, 1995, PSYCHOL REV, V102, P4, DOI 10.1037//0033-295X.102.1.4
   Griffin D. W., 1992, ADV EXP SOC PSYCHOL, V24, P319
   GUMPERTZ JJ, 1996, RETHINKING LINGUISTI
   Heider F, 1944, AM J PSYCHOL, V57, P243, DOI 10.2307/1416950
   Higgins ET, 1996, SOCIAL PSYCHOL HDB B, P133
   HOFFMAN C, 1986, J PERS SOC PSYCHOL, V51, P1097, DOI 10.1037/0022-3514.51.6.1097
   ISEN AM, 1984, J PERS SOC PSYCHOL, V47, P1206, DOI 10.1037//0022-3514.47.6.1206
   Ji LJ, 2004, J PERS SOC PSYCHOL, V87, P57, DOI 10.1037/0022-3514.87.1.57
   Kay P, 1996, RETHINKING LINGUISTI, P97
   KIMCHI R, 1982, J EXP PSYCHOL HUMAN, V8, P521, DOI 10.1037//0096-1523.8.4.521
   Kitayama S, 2003, PSYCHOL SCI, V14, P201, DOI 10.1111/1467-9280.02432
   Maass A, 2006, J PERS SOC PSYCHOL, V90, P734, DOI 10.1037/0022-3514.90.5.734
   Majid A, 2004, TRENDS COGN SCI, V8, P108, DOI 10.1016/j.tics.2004.01.003
   Norenzayan A, 1999, EUR J SOC PSYCHOL, V29, P1011, DOI 10.1002/(SICI)1099-0992(199912)29:8<1011::AID-EJSP974>3.0.CO;2-A
   Ozgen E, 2004, CURR DIR PSYCHOL SCI, V13, P95, DOI 10.1111/j.0963-7214.2004.00282.x
   Pinker S., 1994, LANGUAGE INSTINCT MI
   Ricoeur P., 1955, SOC RES, V38, P530
   ROSCH E, 1975, J EXP PSYCHOL GEN, V104, P192, DOI 10.1037/0096-3445.104.3.192
   Sapir E., 1951, SELECTED WRITINGS E
   Semin G. F., 1991, EUROPEAN REV SOCIAL, V2, P1, DOI DOI 10.1080/14792779143000006
   Semin GR, 2000, EUR J SOC PSYCHOL, V30, P595, DOI 10.1002/1099-0992(200009/10)30:5<595::AID-EJSP23>3.3.CO;2-1
   SEMIN GR, 1988, J PERS SOC PSYCHOL, V54, P558, DOI 10.1037/0022-3514.54.4.558
   Semin GR, 2002, COGNITION EMOTION, V16, P11, DOI 10.1080/02699930143000112
   SEMIN GR, 2001, HDB SOCIAL PSYCHOL, V1, P159
   SEMIN GR, 2000, EUROPEAN REV SOCIAL, V10, P75
   Smith PK, 2006, J PERS SOC PSYCHOL, V90, P578, DOI 10.1037/0022-3514.90.4.578
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stahlberg D, 2001, J LANG SOC PSYCHOL, V20, P464, DOI 10.1177/0261927X01020004004
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 1996, EUR J SOC PSYCHOL, V26, P827, DOI 10.1002/(SICI)1099-0992(199609)26:5<827::AID-EJSP800>3.0.CO;2-X
   Stapel DA, 2006, J PERS SOC PSYCHOL, V90, P258, DOI 10.1037/0022-3514.90.2.258
   Stapel DA, 2006, J EXP SOC PSYCHOL, V42, P112, DOI 10.1016/j.jesp.2005.02.002
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   STAPEL DA, 1996, POLITICAL BEHAV, V18, P289
   STAPEL DA, IN PRESS EUROPEAN J
   VONHUMBOLDT W, 1843, GESAMMELTE WERKE, V3, P269
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   WHORF BL, 1957, LANGUAGE THOUGHT REA
NR 50
TC 47
Z9 48
U1 2
U2 36
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD JUL
PY 2007
VL 93
IS 1
BP 23
EP 33
DI 10.1037/0022-3514.93.1.23
PG 11
WC Psychology, Social
SC Psychology
GA 185YN
UT WOS:000247746400003
PM 17605586
DA 2018-12-27
ER

PT J
AU Prakash
   Singh, G
   Singh, SM
AF Prakash
   Singh, Gajendra
   Singh, Sukh Mahendra
TI RETRACTED: Cyclophosphamide-induced agenesis of cerebral aqueduct
   resulting in hydrocephalus in mice (Retracted Article. See vol 32, pg
   253, 2009)
SO NEUROSURGICAL REVIEW
LA English
DT Article; Retracted Publication
DE apoptosis; cerebral aqueduct; cerebrospinal fluid; cyclophosphamide;
   ependymal cells; hydrocephalus
ID CORTICAL DEVELOPMENT; CEREBROSPINAL-FLUID; CHICK-EMBRYOS; RAT; BRAIN;
   CSF
AB The present work was undertaken to reveal the mechanism of cerebral aqueduct agenesis found to result in hydrocephalus following intrauterine exposure to model teratogen, cyclophosphamide, in murine fetuses. A single dose of 10-mg/kg body weight cyclophosphamide was injected intaperitoneally to pregnant mice on day 10, 11 or 12 of gestation. Fetuses were collected through abdominal incision on day 18 and studied for various malformations of brain and cranium including hydrocephalus. Incomplete development and failure of canalization of the cerebral aqueduct were detected when serial sections of brain in coronal and transverse planes were studied under the microscope. Biotechnological investigations such as % DNA fragmentation, % viable cell count and cell proliferation assay were carried out on brain cells for further studies. Agenesis and non-canalization of the cerebral aqueduct resulted in increased pressure of CSF, which led to rupture of the aqueduct complicated by leakage and accumulation of CSF in brain substance forming a cavity containing CSF parallel and lateral to the unopened part of the cerebral aqueduct. Incomplete development along with non-canalization of the cerebral aqueduct resulted in blockage of CSF flow through the ventricles that manifest as internal hydrocephalus. External hydrocephalus on the other hand was detected where the CSF accumulated in the cavity formed inside the brain substance and established communication with the CSF in the subarachnoid space. Cyclophosphamide induced inhibition of mitosis and cell differentiation of ependymal cells reflecting a decreased % viable cell count and cell proliferation assay along with augmentation of apoptosis of brain cells quantified as increased % DNA fragmentation count, which were identified as the contributing factors underlying the agenesis and incomplete development of the cerebral aqueduct. The study also suggests that cell survival, proliferation, migration or differentiation of ependymal cells might have been affected, and we speculate that CSF may have an inducing role in the development and canalization of the cerebral aqueduct.
C1 Kasturba Med Coll & Hosp, Dept Anat, Ctr Basic Sci, Mangalore 575004, India.
   Banaras Hindu Univ, Dept Anat, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India.
   Banaras Hindu Univ, Sch Biotechnol, Varanasi 221005, Uttar Pradesh, India.
RP Prakash (reprint author), Kasturba Med Coll & Hosp, Dept Anat, Ctr Basic Sci, Mangalore 575004, India.
EM prakashrinku@rediffmail.com
CR Beni-Adani L, 2006, CHILD NERV SYST, V22, P1543, DOI 10.1007/s00381-006-0193-5
   KAR AK, 1974, INDIAN J MED RES, V62, P905
   Koike M, 2004, CANCER SCI, V95, P541, DOI 10.1111/j.1349-7006.2004.tb03246.x
   MALIK MR, 1976, THESIS BANARAS HINDU
   Mashayekhi F, 2002, BRAIN, V125, P1859, DOI 10.1093/brain/awf182
   Mazur L, 2002, ANTI-CANCER DRUG, V13, P751, DOI 10.1097/00001813-200208000-00010
   Meiniel A, 2007, INT J BIOCHEM CELL B, V39, P463, DOI 10.1016/j.biocel.2006.10.021
   Miyan JA, 1998, EUR J PEDIATR SURG, V8, P43, DOI 10.1055/s-2008-1071253
   Miyan JA, 2003, CAN J PHYSIOL PHARM, V81, P317, DOI 10.1139/Y03-027
   Oi S, 2006, CHILD NERV SYST, V22, P662, DOI 10.1007/s00381-005-0020-4
   Owen-Lynch PJ, 2003, BRAIN, V126, P623, DOI 10.1093/brain/awg058
   PILLANS PI, 1988, ARCH TOXICOL, V62, P230, DOI 10.1007/BF00570147
   PILLANS PI, 1989, CARCINOGENESIS, V10, P83, DOI 10.1093/carcin/10.1.83
   Pourghasem M, 2001, EUR J PEDIATR SURG, V11, pS10, DOI 10.1055/s-2001-19741
   Savion S, 2003, AM J REPROD IMMUNOL, V49, P30, DOI 10.1034/j.1600-0897.2003.01140.x
   SELLINS KS, 1987, J IMMUNOL, V139, P3199
   Singh N, 2003, ORIENT PHARM EXP MED, V3, P72
   SINGH ND, 2006, J APPL TOXICOL  1222
   SINGH SN, 1990, NEUROSURGERY, V27, P103, DOI 10.1227/00006123-199007000-00014
   Wagner C, 2003, J NEUROPATH EXP NEUR, V62, P1019, DOI 10.1093/jnen/62.10.1019
NR 20
TC 0
Z9 2
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5607
EI 1437-2320
J9 NEUROSURG REV
JI Neurosurg. Rev.
PD JUL
PY 2007
VL 30
IS 3
BP 245
EP 251
DI 10.1007/s10143-007-0077-5
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 177XF
UT WOS:000247185100021
PM 17457626
DA 2018-12-27
ER

PT J
AU Mussen, F
   Salek, S
   Walker, S
AF Mussen, Filip
   Salek, Sam
   Walker, Stuart
TI RETRACTED: A quantitative approach to benefit-risk assessment of
   medicines - part 2: The practical application of a new model (Retracted
   Article. See vol 16, pg 1180, 2007)
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article; Retracted Publication
DE benefit-risk; new model; assessment; application
AB Purpose Decisions leading to drug approval demand careful attention with respect to balancing benefits and risks. The new benefit-risk assessment model provides reassembling of the pieces of decision-making information using computer software to present a coherent overall picture for decision-makers. The aims of the study were to evaluate content validity of the new model and examine its practical application.
   Methods The expert panel (Annex 1) drawn from regulatory agencies in USA and Europe, academia and pharmaceutical industry, were encouraged to frank and open discussions about the way in which important, far-reaching decisions are taken within both companies and regulatory agencies and the potential shortcomings of such processes. The main component of the meeting was an interactive demonstration of the application of the technical model MCDA. The model was discussed using a hypothetical scenario based on safety and efficacy data relating to an atypical antipsychotic agent that was clinically tested against placebo and a comparator compound.
   Results The expert panel unanimously agreed that the methodology had great potential and it was recommended that it should be explored further as an adjunct to the decision-making process for both companies and regulatory agencies. An important part of this would be to undertake retrospective testing using actual case studies.
   Conclusions The outcome of the workshop underpins practical utility of the new benefit-risk assessment MCDA model and provides evidence of its content validity. It is hoped that this encourages acceptability by regulatory agencies and the industry for its use in real scenarios. Copyright (C) 2007 John Wiley & Sons, Ltd.
C1 Cardiff Univ, Welsh Sch Pharm, Ctr Socioecon Res, Cardiff CF10 3XF, Wales.
   Merck Sharp & Dohme Ltd, Regulatory Affairs Europe, B-1200 Brussels, Belgium.
   CMR Int, Epsom KT18 7PX, Surrey, England.
RP Salek, S (reprint author), Cardiff Univ, Welsh Sch Pharm, Ctr Socioecon Res, King Edward VII Ave, Cardiff CF10 3XF, Wales.
CR Dodgson J, 2000, MULTICRITERIA ANAL M
   Keeney R., 1976, DECISIONS MULTIPLE O
   MUSSEN F, 2002, DILEMMAS SOLUTIONS G
   PHILLIPS LD, 1989, KNOWLEDGE BASED MANA
NR 4
TC 9
Z9 9
U1 3
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD JUL
PY 2007
VL 16
SU 1
BP S16
EP S41
DI 10.1002/pds.1434
PG 26
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 198JZ
UT WOS:000248625700003
PM 17546574
DA 2018-12-27
ER

PT J
AU Granzow, JW
   Levine, JL
   Chiu, ES
   LoTempio, MM
   Allen, RJ
AF Granzow, Jay W.
   Levine, Joshua L.
   Chiu, Ernest S.
   LoTempio, Maria M.
   Allen, Robert J.
TI RETRACTED: Breast reconstruction with perforator flaps (Retracted
   Article. See vol 121, pg 1873, 2008)
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Retracted Publication
ID DIEP FLAPS; FREE TRAM; MUSCLE
AB Background: Perforator flaps represent the latest in the evolution of soft-tissue flaps. They allow the transfer of the patient's own skin and fat in a reliable manner, with minimal donor-site morbidity. The powerful perforator flap concept allows transfer of tissue from numerous, well-described donor sites to almost any distant site with suitable recipient vessels. Large-volume flaps can be supported reliably with perforators from areas such as the abdomen, buttock, or flank and transferred microsurgically for breast reconstruction.
   Indications: The ideal tissue for breast reconstruction is fat with or without skin, not implants or muscle. Absolute contraindications specific to perforator flaps in the authors' practice include history of previous liposuction of the donor site some previous donor-site surgery, or active smoking (within 1 month before surgery).
   Technique: Perforator flaps are supplied by blood vessels that arise from named, axial vessels and perforate through or around overlying muscles and septa to vascularize the overlying skin and fat. During flap harvest, these perforators are meticulously dissected free from the surrounding muscle, which is spread in the direction of the muscle fibers and preserved intact. The pedicle is anastomosed to recipient vessels in the chest, and the donor site is closed without the use of mesh.
   Conclusion: Perforator flaps allow for safe, reliable tissue transfer from a variety of sites and provide ideal tissue for breast reconstruction, with minimal donorsite morbidity.
C1 Louisiana State Univ, Hlth Sci Ctr, Sect Plast Surg, Baton Rouge, LA 70803 USA.
RP Allen, RJ (reprint author), Suite 180,1300 Hosp Dr, Mt Pleasant, SC 29464 USA.
CR Allen RJ, 2003, PLAST RECONSTR SURG, V112, P91, DOI 10.1097/01.PRS.0000066006.07602.86
   ALLEN RJ, 1994, ANN PLAS SURG, V32, P32, DOI 10.1097/00000637-199401000-00007
   ALLEN RJ, 1995, PLAST RECONSTR SURG, V95, P1207, DOI 10.1097/00006534-199506000-00010
   ALLEN RJ, 1990, P ANN M SE SOC PLAST
   Allen RJ, 2006, PLAST RECONSTR SURG, V118, P333, DOI 10.1097/01.prs.0000227665.56703.a8
   BABINEAUX K, 2005, PLAST RECONSTR SURG, V116, P174
   Futter CM, 2000, BRIT J PLAST SURG, V53, P578, DOI 10.1054/bjps.2000.3427
   Gill PS, 2004, PLAST RECONSTR SURG, V113, P1153, DOI 10.1097/01.PRS.0000110328.47206.50
   GRANZOW JW, UNPUB BREAST RECONST
   Guerra AB, 2004, ANN PLAS SURG, V52, P118, DOI 10.1097/01.sap.0000095437.43805.d1
   Kaplan JL, 2000, PLAST RECONSTR SURG, V105, P943, DOI 10.1097/00006534-200003000-00017
   KOSHIMA I, 1989, BRIT J PLAST SURG, V42, P645, DOI 10.1016/0007-1226(89)90075-1
   Kroll SS, 2001, PLAST RECONSTR SURG, V107, P338, DOI 10.1097/00006534-200102000-00006
   Reardon CM, 2004, BRIT J PLAST SURG, V57, P515, DOI 10.1016/j.bjps.2004.04.019
   Rogers NE, 2002, PLAST RECONSTR SURG, V109, P1919, DOI 10.1097/00006534-200205000-00022
   TAYLOR GI, 1975, PLAST RECONSTR SURG, V56, P243, DOI 10.1097/00006534-197509000-00001
NR 16
TC 21
Z9 22
U1 4
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0032-1052
EI 1529-4242
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUL
PY 2007
VL 120
IS 1
BP 1
EP 12
DI 10.1097/01.prs.0000256044.66107.a6
PG 12
WC Surgery
SC Surgery
GA 180TD
UT WOS:000247388000001
PM 17572536
DA 2018-12-27
ER

PT J
AU Strasser, H
   Marksteiner, R
   Margreiter, E
   Pinggera, GM
   Mitterberger, M
   Frauscher, F
   Ulmer, H
   Fussenegger, M
   Kofler, K
   Bartsch, G
AF Strasser, Hannes
   Marksteiner, Rainer
   Margreiter, Eva
   Pinggera, Germar Michael
   Mitterberger, Michael
   Frauscher, Ferdinand
   Ulmer, Hanno
   Fussenegger, Martin
   Kofler, Kurt
   Bartsch, Georg
TI RETRACTED: Autologous myoblasts and fibroblasts versus collagen for
   treatment of stress urinary incontinence in women: a randomised
   controlled trial (Retracted Article. See vol 372, pg 789, 2008)
SO LANCET
LA English
DT Article; Retracted Publication
ID AGE-DEPENDENT APOPTOSIS; RHABDOSPHINCTER CELLS; URETHRAL SPHINCTER;
   FEMALE URETHRA; MUSCLE; COMPLICATIONS; MANAGEMENT; INJECTION
AB Background Preclinical studies have suggested that transurethral injections of autologous myoblasts can aid in regeneration of the rhabdosphincter, and fibroblasts in reconstruction of the urethral submucosa. We aimed to compare the effectiveness and tolerability of ultrasonography-guided injections of aultologous cells with those of endoscopic injections of Collagen for stress incontinence.
   Methods Between 2002 and 2004, we recruited 63 eligible women with urinary stress incontinence. 42 of these women were randomly assigned to receive transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts, and 21 to receive conventional endoscopic injections of collagen. The first primary outcome measure was an incontinence score (range 0-6) based on a 24-hour voiding diary, a 24-hour pad test, and a patient questionnaire. The other primary outcome measures were contractility of the rhabdosphincter and thickness of both the urethra and rhabdosphincter. Analysis was by intention to treat. This trial is registered with Controlled-Trials.com, number CCTNAPN-16630.
   Findings At 12-months' follow-tip, 38 of the 42 women injected with autologous cells were completely continent, compared with two of the 21 patients given conventional treatment with Collagen. The median incontinence score decreased from a baseline of 6.0 (IQR 6.0-6.0; where 6 represents complete incontinence), to 0 (0-0) for patients treated with autologous cells, and 6.0 (3.5-6.0) for patients treated with Collagen (p < 0.0001). Ultrasonographic measurements showed that the mean thickness of the rhabdosphincter increased from a baseline of 2.13 mm (SD 0.39) for all patients to 3.38 mm (0.26) for patients treated with autologous cells and 2.32 mm (0.44) for patients treated with Collagen (p < 0.0001). Contractility of the rhabdosphincter increased from a baseline of 0.58 mm (SD 0.32) to 1.56 mm (0.28) for patients treated with autologous cells and 0.67 min (0.51) for controls (p < 0.0001). The change in the thickness of the urethra after treatment was not significantly different between treatment groups. No adverse effects were recorded in any of the 63 patients.
   Interpretation Long-term postoperative results and data from multicentre trials with larger numbers of patients are needed to assess whether injection of autologous cells into the rhabdosphincter and the urethra could become a standard treatment for urinary incontinence.
C1 Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria.
   Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria.
   Univ Innsbruck, Dept Radiol 2, A-6020 Innsbruck, Austria.
   Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, A-6020 Innsbruck, Austria.
   Sisters Charity Hosp, Dept Otolaryngol, Wels, Austria.
RP Strasser, H (reprint author), Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.
EM hannes.strasser@uibk.ac.at
RI Ulmer, Hanno/C-3488-2011; Mitterberger, Michael/C-6113-2009
OI Ulmer, Hanno/0000-0001-5911-1002; 
CR Arcila ME, 1997, J NEUROBIOL, V33, P185, DOI 10.1002/(SICI)1097-4695(199708)33:2<185::AID-NEU7>3.0.CO;2-Z
   Berjukow S, 2004, PROSTATE, V58, P238, DOI 10.1002/pros.10334
   Chancellor MB, 2000, NEUROUROL URODYNAM, V19, P279, DOI 10.1002/(SICI)1520-6777(2000)19:3<279::AID-NAU9>3.0.CO;2-M
   Chou ECL, 2003, J UROLOGY, V170, P494, DOI 10.1097/01.ju.0000069432.60521.6f
   Colleselli K, 1998, J UROLOGY, V160, P49, DOI 10.1016/S0022-5347(01)63025-8
   Deng DY, 2007, NEUROUROL URODYNAM, V26, P46, DOI 10.1002/nau.20357
   FALCONER C, 2001, INT UROGYNECOL J S2, V12, P19
   Frauscher F, 1998, EUR RADIOL, V8, P50, DOI 10.1007/s003300050336
   Fritsch H, 2006, NEUROUROL URODYNAM, V25, P128, DOI 10.1002/nau.20133
   Griffiths D, 2005, INCONTINENCE, VOLS 1 AND 2, P585
   Guys JM, 2001, J UROLOGY, V165, P2389, DOI 10.1016/S0022-5347(05)66211-8
   Hunskaar S, 2005, INCONTINENCE, VOLS 1 AND 2, P255
   Irintchev A, 1997, J PHYSIOL-LONDON, V500, P775, DOI 10.1113/jphysiol.1997.sp022057
   Klutke C, 2001, UROLOGY, V58, P697, DOI 10.1016/S0090-4295(01)01366-8
   Law PK, 1997, CELL TRANSPLANT, V6, P95, DOI 10.1016/S0963-6897(96)00138-8
   Leach GE, 1997, J UROLOGY, V158, P875, DOI 10.1016/S0022-5347(01)64346-5
   Liu JB, 2002, J ULTRAS MED, V21, P323, DOI 10.7863/jum.2002.21.3.323
   MCKINNEY CD, 1995, J UROLOGY, V153, P149, DOI 10.1097/00005392-199501000-00053
   MITTERBERGER M, 2007, EUR UROL        0522
   Mostwin J, 2005, INCONTINENCE, VOLS 1 AND 2, P423
   NOE HN, 1994, UROLOGY, V43, P852, DOI 10.1016/0090-4295(94)90149-X
   Pannek J, 2001, J UROLOGY, V166, P1350, DOI 10.1016/S0022-5347(05)65767-9
   Patrick DL, 1999, UROLOGY, V53, P71, DOI 10.1016/S0090-4295(98)00454-3
   PETROS PEP, 1994, AM J OBSTET GYNECOL, V171, P1198
   Prasad SR, 2005, RADIOGRAPHICS, V25, P749, DOI 10.1148/rg.253045067
   Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406
   Smith ARB, 2005, INCONTINENCE, VOLS 1 AND 2, P1297
   Strasser H, 2000, J UROLOGY, V164, P1781, DOI 10.1016/S0022-5347(05)67106-6
   Strasser H, 1999, LANCET, V354, P918, DOI 10.1016/S0140-6736(99)02588-X
   Sweat SD, 1999, J UROLOGY, V161, P93, DOI 10.1016/S0022-5347(01)62074-3
   Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929
   von Heimburg D, 2004, CELLS TISSUES ORGANS, V178, P87, DOI 10.1159/000081719
   Watson D, 1999, Arch Facial Plast Surg, V1, P165, DOI 10.1001/archfaci.1.3.165
   Yiou R, 2003, TRANSPLANTATION, V76, P1053, DOI 10.1097/01.TP.0000090396.71097.C2
   Yokoyama T, 2001, J UROLOGY, V165, P271, DOI 10.1097/00005392-200101000-00077
   Yonneau L, 2000, PROG UROL, V10, P1238
NR 36
TC 102
Z9 111
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 30
PY 2007
VL 369
IS 9580
BP 2179
EP 2186
DI 10.1016/S0140-6736(07)61014-9
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 184LX
UT WOS:000247644200029
PM 17604800
DA 2018-12-27
ER

PT J
AU Lu, LQ
   Yu, L
   Kwang, J
AF Lu, Liqun
   Yu, Li
   Kwang, Jimmy
TI RETRACTED: Baculovirus surface-displayed hemagglutinin of H5N1 influenza
   virus sustains its authentic cleavage, hemagglutination activity, and
   antigenicity (Retracted article. See vol. 388, pg. 620, 2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE hemagglutinin; influenza virus; ie1; baculovirus; transduction; display
ID VESICULAR STOMATITIS-VIRUS; MAMMALIAN-CELLS; IN-VIVO; RECOMBINANT
   BACULOVIRUS; EFFICIENT TRANSDUCTION; GENE DELIVERY; G-PROTEIN; VECTORS;
   MICE; GLYCOPROTEIN
AB Baculovirus-mediated transductions of viral glycoprotein genes into mice were shown to elicit protective immune response in several reports. Here we reported that, under the control of iel promoter from white spot syndrome virus, hemagglutinin (HA) gene of H5N1 influenza virus could be efficiently expressed in both insect and mammalian cells mediated by recombinant baculovirus vectors. The HA protein, partially cleaved as in H5N1 virus, was significantly displayed on the surface of baculovirus and conferred the viral particle hemagglutination activity. Intramuscular injection of the purified HA-dispalying baculovirus into mice stimulated the production of antibodies with Hemagglutination inhibition and neutralization activities against tested influenza virus. These data suggested an alternative way to apply baculovirus as an immunizing reagent against influenza virus infection. (C) 2007 Elsevier Inc. All rights reserved.
C1 Natl Univ Singapore, Anim Hlth Biotechnol Unit, Temasek Life Sci Lab, Singapore 117604, Singapore.
   Chinese Acad Agr Sci, Natl Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin 150001, Peoples R China.
RP Lu, LQ (reprint author), Natl Univ Singapore, Anim Hlth Biotechnol Unit, Temasek Life Sci Lab, 1 Res Link, Singapore 117604, Singapore.
EM luliqun@gmail.com; yuli1962@gmail.com
CR Abe T, 2003, J IMMUNOL, V171, P1133, DOI 10.4049/jimmunol.171.3.1133
   Aoki H, 1999, VET MICROBIOL, V68, P197, DOI 10.1016/S0378-1135(99)00110-8
   BAILEY MJ, 1989, VIROLOGY, V169, P323, DOI 10.1016/0042-6822(89)90157-8
   Barsoum J, 1997, HUM GENE THER, V8, P2011, DOI 10.1089/hum.1997.8.17-2011
   BOSCH FX, 1979, VIROLOGY, V95, P197, DOI 10.1016/0042-6822(79)90414-8
   Boyce FM, 1996, P NATL ACAD SCI USA, V93, P2348, DOI 10.1073/pnas.93.6.2348
   Facciabene A, 2004, J VIROL, V78, P8663, DOI 10.1128/JVI.78.16.8663-8672.2004
   He QG, 2005, J VIROL METHODS, V127, P46, DOI 10.1016/j.jviromet.2005.03.004
   Hsu CS, 2004, BIOTECHNOL BIOENG, V88, P42, DOI 10.1002/bit.20213
   Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095
   Liu WJ, 2005, VIROLOGY, V334, P327, DOI 10.1016/j.virol.2005.01.047
   LU L, 2006, BIOPHYS RES COMMUN, V340, P178
   Lu LQ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-71
   Lu LQ, 2003, J VIROL, V77, P535, DOI 10.1128/JVI.77.1.535-545.2003
   Mangor JT, 2001, J VIROL, V75, P2544, DOI 10.1128/JVI.75.6.2544-2556.2001
   NEW N, 2006, BMC MICROBIOL, V6
   Pieroni L, 2001, HUM GENE THER, V12, P871, DOI 10.1089/104303401750195845
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937
   Sarkis C, 2000, P NATL ACAD SCI USA, V97, P14638, DOI 10.1073/pnas.260472897
   Takada A, 1999, J VIROL, V73, P8303
   Tani H, 2003, J VIROL, V77, P9799, DOI 10.1128/JVI.77.18.9799-9808.2003
   WOOD JM, 1985, AVIAN DIS, V29, P867, DOI 10.2307/1590681
NR 22
TC 31
Z9 41
U1 3
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 29
PY 2007
VL 358
IS 2
BP 404
EP 409
DI 10.1016/j.bbrc.2007.04.148
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 174FM
UT WOS:000246927300005
PM 17499217
DA 2018-12-27
ER

PT J
AU Herschkovitz, A
   Liu, YF
   Ilan, E
   Ronen, D
   Boura-Halfon, S
   Zick, Y
AF Herschkovitz, Avia
   Liu, Yan-Fang
   Ilan, Erez
   Ronen, Denise
   Boura-Halfon, Sigalit
   Zick, Yehiel
TI RETRACTED: Common inhibitory serine sites phosphorylated by IRS-1
   kinases, triggered by insulin and inducers of insulin resistance
   (Retracted article. See vol. 293, pg. 7266, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID RECEPTOR SUBSTRATE-1 IRS-1; KAPPA-B KINASE; INDUCED TYROSINE
   PHOSPHORYLATION; SKELETAL-MUSCLE; SERINE/THREONINE PHOSPHORYLATION;
   JUXTAMEMBRANE REGION; SIGNALING PATHWAYS; PROTEIN; ACTIVATION; CERAMIDE
AB The Insulin Receptor Substrate (IRS) proteins are key players in insulin signal transduction and are the best studied targets of the insulin receptor. Ser/Thr phosphorylation of IRS proteins negatively modulates insulin signaling; therefore, the identification of IRS kinases and their target Ser phosphorylation sites is of physiological importance. Here we show that in Fao rat hepatoma cells, the I kappa B kinase beta (IKK beta) is an IRS-1 kinase activated by selected inducers of insulin resistance, including sphingomyelinase, ceramide, and free fatty acids. Moreover, IKK beta shares a repertoire of seven potential target sites on IRS-1 with protein kinase C zeta( PKC zeta), an IRS-1 kinase activated both by insulin and by inducers of insulin resistance. We further show that mutation of these seven sites (Ser-265, Ser-302, Ser-325, Ser-336, Ser-358, Ser-407, and Ser-408) confers protection from the action of IKK beta and PKC beta when they are overexpressed in Fao cells or primary hepatocytes. This enables the mutated IRS proteins to better propagate insulin signaling. These findings suggest that insulin-stimulated IRS kinases such as PKC zeta overlap with IRS kinases triggered by inducers of insulin resistance, such as IKK beta, to phosphorylate IRS-1 on common Ser sites.
C1 Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel.
   Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem, IL-76100 Rehovot, Israel.
RP Zick, Y (reprint author), Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel.
EM yehiel.zick@weizmann.ac.il
CR Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200
   Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047
   Berry MN, 2000, BIOCHEM SOC T, V28, P131, DOI 10.1042/bst0280131
   Cousin SP, 2001, ENDOCRINOLOGY, V142, P229, DOI 10.1210/en.142.1.229
   de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200
   DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f
   Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911
   Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2
   Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383
   Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200
   Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200
   Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895
   Kim JA, 2005, J BIOL CHEM, V280, P23173, DOI 10.1074/jbc.M501439200
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lallena MJ, 1999, MOL CELL BIOL, V19, P2180
   Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588
   Liu YF, 2004, MOL CELL BIOL, V24, P9668, DOI 10.1128/MCB.24.21.9668-9681.2004
   Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200
   Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200
   Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200
   Nakamori Y, 2006, J CELL BIOL, V173, P665, DOI 10.1083/jcb.200601065
   Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298
   Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911
   Powell DJ, 2004, BIOCHEM J, V382, P619, DOI 10.1042/BJ20040139
   Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934
   Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3
   Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8
   Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200
   SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083
   Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200
   Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620
   Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)81297-6
   Zick Y, 2004, BIOCHEM SOC T, V32, P812, DOI 10.1042/BST0320812
NR 35
TC 74
Z9 76
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 22
PY 2007
VL 282
IS 25
BP 18018
EP 18027
DI 10.1074/jbc.M610949200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 179PK
UT WOS:000247302000008
PM 17446166
OA Bronze
DA 2018-12-27
ER

PT J
AU Fletcher, G
   Rorth, P
AF Fletcher, Georgina
   Rorth, Pernille
TI RETRACTED: Drosophila stathmin is required to maintain tubulin pools
   (Retracted article. See vol. 19, pg. 1682, 2009)
SO CURRENT BIOLOGY
LA English
DT Article; Retracted Publication
ID FOLLICULAR EPITHELIUM; CELLS; PHOSPHOPROTEIN; POLARIZATION;
   MICROTUBULES; INCREASES; PAR-1
AB Stathmin, or Oncoprotein 18 (Op18), is the founding member of a phosphoprotein family that can regulate the microtubule cytoskeleton by sequestering tubulin and promoting microtubule catastrophe [1-3]. Stathmin is subject to spatially and temporally controlled regulatory phosphorylation, which inhibits its interaction with tubulin [4-6]. Drosophila Stathmin has similar properties to the mammalian proteins [7]. We find that Drosophila Stathmin is required for specific microtubule-dependent processes: maintenance of oocyte identity within a germline cyst and localization of polarity. determinants. Unexpectedly, microtubules are less abundant in stathmin mutant cells compared to normal cells, showing that a key function of Stathmin in vivo is the long-term maintenance of the microtubule cytoskeleton. The microtubule network re-forms more slowly after coldshock in stathmin mutant follicle cells. Surprisingly, stathmin mutant animals and tissues show a marked decrease in total tubulin-protein levels, and this might explain the effect on the microtubule cytoskeleton. Stathmin overexpression also increases tubulin protein. Free alpha- and beta-tubulin have been shown to negatively autoregulate their own synthesis [8-10]. We suggest that Stathmin serves to maintain a noninhibitory, soluble, and releasable tubulin pool.
C1 European Mol Biol Lab, D-69117 Heidelberg, Germany.
RP Rorth, P (reprint author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.
EM rorth@embl.de
CR Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5
   Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3
   Borghese L, 2006, DEV CELL, V10, P497, DOI 10.1016/j.devcel.2006.02.004
   CARON JM, 1985, J CELL BIOL, V101, P1763, DOI 10.1083/jcb.101.5.1763
   Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7
   Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P10, DOI 10.1016/S0955-0674(89)80030-4
   Doerflinger H, 2003, DEVELOPMENT, V130, P3965, DOI 10.1242/dev.00616
   GonzalezGaray ML, 1996, J CELL BIOL, V135, P1525, DOI 10.1083/jcb.135.6.1525
   Howell B, 1999, J CELL SCI, V112, P3713
   Huynh JR, 2004, CURR BIOL, V14, pR438, DOI 10.1016/j.cub.2004.05.040
   Iancu C, 2001, J CELL SCI, V114, P909
   Jankovics F, 2006, DEV CELL, V11, P375, DOI 10.1016/j.devcel.2006.07.014
   Jin KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com
   Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289
   Liedtke W, 2002, AM J PATHOL, V160, P469, DOI 10.1016/S0002-9440(10)64866-3
   Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x
   Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108
   Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362
   Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393
   Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062
   Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038
   SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D
   Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891
NR 23
TC 8
Z9 9
U1 3
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD JUN 19
PY 2007
VL 17
IS 12
BP 1067
EP 1071
DI 10.1016/j.cub.2007.05.034
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 181AL
UT WOS:000247409000030
PM 17555966
OA Bronze
DA 2018-12-27
ER

PT J
AU Yu, LW
   Chen, KJ
   Song, J
   Xu, J
   Li, W
   Li, HM
   Wang, M
   Li, XF
   Huang, XF
AF Yu, Lin Wei
   Chen, Kun Ji
   Song, Jie
   Xu, Jun
   Li, Wei
   Li, Hong Min
   Wang, Mu
   Li, Xue Fei
   Huang, Xin Fan
TI RETRACTED: Self-assembled Si quantum-ring structures on a Si substrate
   by plasma-enhanced chemical vapor deposition based on a growth-etching
   competition mechanism (Retracted article, see vol 19, pg 2412, 2007)
SO ADVANCED MATERIALS
LA English
DT Article; Retracted Publication
ID THIN-FILMS; ARRAYS; DOTS; COALESCENCE; NUCLEATION; STRESSES; SURFACES;
   SI(001)
AB Self-assembled Si quantum-ring structures on a Si(100) substrate are fabricated by using a PECVD technique based on a growth-etching competition mechanism. The as-grown Si ring structures have superior morphology, excellent rotational symmetry, and ultrathin edge width (down to 10 nm, see figure). This growth model also represents a general scheme for controlling and tailoring the shape, size, and complexity of self-assembled nanostructures.
C1 Nanjing Univ, Dept Phys, Natl Lab Solid State Microstruct, Nanjing 210093, Peoples R China.
RP Chen, KJ (reprint author), Nanjing Univ, Dept Phys, Natl Lab Solid State Microstruct, Nanjing 210093, Peoples R China.
EM kjchen@nju.edu.cn
CR Banin U, 1999, NATURE, V400, P542
   BOLAND JJ, 1992, SCIENCE, V256, P1304, DOI 10.1126/science.256.5061.1304
   Cammarata RC, 2000, J MATER RES, V15, P2468, DOI 10.1557/JMR.2000.0354
   CHAKRABORTY T, 1994, PHYS REV B, V50, P8460, DOI 10.1103/PhysRevB.50.8460
   COPEL M, 1994, PHYS REV LETT, V72, P1236, DOI 10.1103/PhysRevLett.72.1236
   Cui J, 2003, APPL PHYS LETT, V83, P2907, DOI 10.1063/1.1616992
   Floro JA, 2001, J APPL PHYS, V89, P4886, DOI 10.1063/1.1352563
   Foldi P, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.155325
   Gammon D, 2002, PHYS TODAY, V55, P36, DOI 10.1063/1.1522165
   Garcia JM, 1997, APPL PHYS LETT, V71, P2014, DOI 10.1063/1.119772
   Gill SPA, 2002, J APPL MECH-T ASME, V69, P425, DOI 10.1115/1.1469001
   Ji R, 2006, ADV MATER, V18, P2593, DOI 10.1002/adma.200601136
   Kastner M. A., 2002, International Journal of High Speed Electronics and Systems, V12, P1101, DOI 10.1142/S0129156402001940
   KERN W, 1983, RCA ENG, V28, P99
   Lorke A, 2000, PHYS REV LETT, V84, P2223, DOI 10.1103/PhysRevLett.84.2223
   Mano T, 2005, NANO LETT, V5, P425, DOI 10.1021/nl048192+
   Matos-Abiague A, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.166801
   Pearson DH, 1999, ADV MATER, V11, P769
   Pettersson H, 2000, PHYSICA E, V6, P510, DOI 10.1016/S1386-9477(99)00096-X
   Schroeder TW, 2004, J VAC SCI TECHNOL A, V22, P578, DOI 10.1116/1.1699336
   Shchukin V. A., 2004, EPITAXY NANOSTRUCTUR
   Stangl J, 2004, REV MOD PHYS, V76, P725, DOI 10.1103/RevModPhys.76.725
   Wang ZK, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.137208
   Warburton RJ, 2000, NATURE, V405, P926, DOI 10.1038/35016030
   Yan F, 2004, NANO LETT, V4, P1193, DOI 10.1021/nl0497169
   Zhu FQ, 2004, ADV MATER, V16, P2155, DOI 10.1002/adma.200400675
   Zinke-Allmang M, 1999, THIN SOLID FILMS, V346, P1, DOI 10.1016/S0040-6090(98)01479-5
NR 27
TC 10
Z9 10
U1 8
U2 34
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD JUN 18
PY 2007
VL 19
IS 12
BP 1577
EP +
DI 10.1002/adma.200602804
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 186EL
UT WOS:000247761800004
DA 2018-12-27
ER

PT J
AU Sahoo, NK
   Thakur, S
   Tokas, RB
   Kamble, NM
AF Sahoo, N. K.
   Thakur, S.
   Tokas, R. B.
   Kamble, N. M.
TI RETRACTED: Relative performances of effective medium formulations in
   interpreting specific composite thin films optical properties (Retracted
   article. See vol. 420, pg. 992, 2017)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 4th International Workshop on Basic Aspects of Non-Equilibrium Plasmas
   Interacting with Surface
CY JAN 30-FEB 01, 2006
CL Mt Fuji, JAPAN
SP 21st Century Ctr Excellence, Keio Univ, Open Univ, Ctr Atomic & Mole Engn, Japan Soc Appl Phys
DE effective medium approximation; optical coatings; codeposition; oxide
   thin films; binary composites; ellipsometry; scanning probe microscopy;
   thin film morphology; band gap
ID STRUCTURE ZONE MODEL; SPECTROSCOPIC ELLIPSOMETRY; SPECTRAL
   REPRESENTATION; LIGHT-SCATTERING; EVOLUTION; COEVAPORATION; DEPOSITION;
   SILICON; STRESS
AB Several powerful effective medium formulations/approximation (EMA) and associated theories with different origins and concepts have been discussed and utilized here in order to model the experimental refractive index evolutions of ZrO2-SiO2 and Gd2O3-SiO2 composite films with respect to their compositional mixings. Amongst these formulations, the Bottcher's generalized theory has been noticed to have more versatility and can simulate varieties of experimental observations incorporating a form factor parameter to account for the grain structure and morphology to a great extent. The refractive index modeling results of most of the available theories were compared with respect to their functional evolutions and limitations. It was noticed that at higher silica fractions (>20%) in our composite films, the effective experimental refractive index parameters have remained close to the most modeling results and Bbttcher's expression has shown to fit the observable parameters very accurately. However, under low silica compositions (<20%) the refractive index values of the composite films depicted different functional evolutions. Such deviations have been attributed to the various morphological, grain structure and band gap supremacies observed in these specific composite films which are not accounted by the effective medium formulations and approximations. These observations are well supported by the atomic force microscopy results. (c) 2007 Elsevier B.V. All rights reserved.
C1 Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
RP Sahoo, NK (reprint author), Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
EM nksahoo@barc.gov.in
CR Adamik M, 1999, PHYS STATUS SOLIDI A, V175, P637, DOI 10.1002/(SICI)1521-396X(199910)175:2<637::AID-PSSA637>3.0.CO;2-7
   Armelao L, 2005, J MATER CHEM, V15, P1838, DOI 10.1039/b500521c
   Barabash S, 1999, J PHYS-CONDENS MAT, V11, P10323, DOI 10.1088/0953-8984/11/50/324
   BERGMAN DJ, 1978, PHYS REP, V43, P378, DOI 10.1016/0370-1573(78)90009-1
   Blanckenhagen B., 2002, APPL OPTICS, V41, P3137
   Bosch S, 2001, SOLID STATE ELECTRON, V45, P703, DOI 10.1016/S0038-1101(01)00092-2
   BOTTCHER CJF, 1973, THEORY ELECT POLARIZ, V1
   Boyd R. W., 1996, Pure and Applied Optics, V5, P505, DOI 10.1088/0963-9659/5/5/005
   BRAGG WL, 1953, ACTA CRYSTALLOGR, V6, P865, DOI 10.1107/S0365110X53002519
   Braun MM, 2006, THIN SOLID FILMS, V496, P505, DOI 10.1016/j.tsf.2005.08.173
   Chen JS, 1996, APPL OPTICS, V35, P90, DOI 10.1364/AO.35.000090
   Cho YJ, 2002, APPL PHYS LETT, V80, P1249, DOI 10.1063/1.1448384
   Cox SJ, 1998, J PHYS D APPL PHYS, V31, P1611, DOI 10.1088/0022-3727/31/14/002
   Dakka A, 2000, APPL OPTICS, V39, P2745, DOI 10.1364/AO.39.002745
   FELDMAN A, 1989, APPL OPTICS, V28, P5229, DOI 10.1364/AO.28.005229
   FELDMAN A, 1986, J VAC SCI TECHNOL A, V4, P2969, DOI 10.1116/1.573610
   Gao L, 2003, J PHYS-CONDENS MAT, V15, P4397, DOI 10.1088/0953-8984/15/25/310
   GUNNING WJ, 1989, APPL OPTICS, V28, P2945, DOI 10.1364/AO.28.002945
   HAGGANS CW, 1993, J OPT SOC AM A, V10, P2217, DOI 10.1364/JOSAA.10.002217
   Henda R, 2002, J VAC SCI TECHNOL A, V20, P1369, DOI 10.1116/1.1486005
   Jackson J. D., 1975, CLASSICAL ELECTRODYN
   Jacobsson R., 1975, PHYS THIN FILMS, V8, P51
   Karkkainen K, 2001, IEEE T GEOSCI REMOTE, V39, P1013, DOI 10.1109/36.921419
   KOBAYASHI M, 1983, APPL OPTICS, V22, P3121, DOI 10.1364/AO.22.003121
   Koo WH, 2004, J VAC SCI TECHNOL A, V22, P2048, DOI 10.1116/1.1782638
   Lai FD, 2001, J VAC SCI TECHNOL B, V19, P2617, DOI 10.1116/1.1408951
   LANDAU LD, 1984, ELECTRODYNAMICS CONT, P42
   Lee H, 2001, J APPL PHYS, V90, P813, DOI 10.1063/1.1378337
   LOOYENGA H, 1965, PHYSICA, V31, P401, DOI 10.1016/0031-8914(65)90045-5
   Min M, 2003, ASTRON ASTROPHYS, V404, P35, DOI 10.1051/0004-6361:20030456
   Mirica E, 2004, CRYST GROWTH DES, V4, P157, DOI 10.1021/cg025596b
   MONECKE J, 1994, J PHYS-CONDENS MAT, V6, P907, DOI 10.1088/0953-8984/6/4/010
   Osipov AV, 2005, THIN SOLID FILMS, V472, P31, DOI 10.1016/j.tsf.2004.06.102
   OUELLETTE MF, 1991, J VAC SCI TECHNOL A, V9, P1188, DOI 10.1116/1.577600
   RAVINDRA NM, 1986, J APPL PHYS, V60, P1139, DOI 10.1063/1.337358
   Sahoo NK, 1998, APPL OPTICS, V37, P698, DOI 10.1364/AO.37.000698
   SANKUR H, 1989, J APPL PHYS, V66, P807, DOI 10.1063/1.343501
   SANKUR HO, 1991, APPL OPTICS, V30, P495, DOI 10.1364/AO.30.000495
   Savaloni H, 2004, NANOTECHNOLOGY, V15, P311, DOI 10.1088/0957-4484/15/3/014
   Spanier JE, 2000, PHYS REV B, V61, P10437, DOI 10.1103/PhysRevB.61.10437
   Wang JG, 2005, OPT COMMUN, V247, P107, DOI 10.1016/j.optcom.2004.11.039
   Wurm G, 2003, ASTROPHYS J, V595, P891, DOI 10.1086/377437
   Yoon JG, 1998, J KOREAN PHYS SOC, V33, P699
NR 43
TC 15
Z9 15
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD JUN 15
PY 2007
VL 253
IS 16
BP 6787
EP 6799
DI 10.1016/j.apsusc.2007.01.131
PG 13
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 177MB
UT WOS:000247156100019
DA 2018-12-27
ER

PT J
AU Leman, ES
   Schoen, RE
   Weissfeld, JL
   Cannon, GW
   Sokoll, LJ
   Chan, DW
   Getzenberg, RH
AF Leman, Eddy S.
   Schoen, Robert E.
   Weissfeld, Joel L.
   Cannon, Grant W.
   Sokoll, Lori J.
   Chan, Daniel W.
   Getzenberg, Robert H.
TI RETRACTED: Initial analyses of colon cancer-specific antigen (CCSA)-3
   and CCSA-4 as colorectal cancer-associated serum markers (Retracted
   article. See vol. 73, pg. 1034, 2013)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID MATRIX PROTEIN ALTERATIONS; FECAL-OCCULT-BLOOD
AB Colon cancer-specific antigen (CCSA)-3 and CCSA-4 are novel colon cancer markers identified by focused proteomic analysis of nuclear structural proteins. The goal of these studies was to evaluate serum-based CCSA-3 and CCSA-4 in the detection of individuals with preneoplastic and neoplastic lesions using ELISAs. Serum samples from 107 subjects undergoing colonoscopy, 28 subjects with colorectal cancer, and 125 subjects with benign disease or other types of cancer were evaluated. Individuals who underwent colonoscopy were classified into mutually exclusive categories, including normal colon, hyperplastic polyp, nonadvanced adenoma, and advanced adenoma. Sensitivity and specificity for both CCSA-3 and CCSA-4 were evaluated using receiver operating characteristic (ROC) curves. At a cutoff of 2 mu g/mL for CCSA-3 and 0.3 mu g/mL for CCSA-4, each marker detected all 28 colorectal cancers, for a sensitivity of 100% (lower 95% confidence bound, 89.8%). The sensitivity for detection of the combined end point of colorectal. cancer and advanced adenoma for CCSA-3 was 89.1% [95% confidence interval (95% CI), 76.4-96.4%] and for CCSA-4 was 84.8% (95% CI, 71.1-93.7%) and 91.3% (95% CI, 79.2-97.6%) for either marker positive. The specificity in individuals with normal, hyperplastic polyps, or nonadvanced adenomas was 82.0% (95% CI, 72.4-89.4%) and 91.0% (95% CI, 83.0-96.0%) for CCSA-3 and CCSA-4, respectively. ROC curves for CCSA-3 and CCSA-4 reveal an area under the curve of 0.94 (95% CI, 0.90-0.98%). In these initial analyses, CCSA-3 and CCSA-4 show promise as potential serum markers for detection of colorectal cancer and advanced adenomas.
C1 Johns Hopkins Univ, Sch Med, Brady Urol Inst, Baltimore, MD USA.
   Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA.
   Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
   Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
RP Getzenberg, RH (reprint author), Johns Hopkins Univ Hosp, Brady Urol Inst, Marburg 121,600 N Wolfe St, Baltimore, MD 21287 USA.
EM rgetzen1@jhmi.edu
FU NCI NIH HHS [U01 CA084968]
CR Bond J H, 2000, Semin Gastrointest Dis, V11, P176
   Brunagel G, 2004, J CELL BIOCHEM, V91, P365, DOI 10.1002/jcb.10695
   Brunagel G, 2002, CANCER RES, V62, P2437
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7
   Konety BR, 1999, J CELL BIOCHEM, P183
   Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434
   MILLER TE, 1992, CANCER RES, V52, P422
   Pepe MS, 2003, STAT EVALUATION MED
   Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015
   2001, MMMWR MORBIDITY MORT, P162
NR 11
TC 39
Z9 40
U1 2
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2007
VL 67
IS 12
BP 5600
EP 5605
DI 10.1158/0008-5472.CAN-07-0649
PG 6
WC Oncology
SC Oncology
GA 180JV
UT WOS:000247360100005
PM 17575123
OA Bronze
DA 2018-12-27
ER

PT J
AU Hagiwara, S
   Iwasaka, H
   Matsumoto, S
   Noguchi, T
AF Hagiwara, Satoshi
   Iwasaka, Hideo
   Matsumoto, Shigekiyo
   Noguchi, Takayuki
TI RETRACTED: Introduction of antisense oligonucleotides to heat shock
   protein 47 prevents pulmonary fibrosis in lipopolysaccharide-induced
   pneumopathy of the rat (Retracted article. See vol. 792, pg. 80, 2016)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE antisense; pulmonary fibrosis; heat shock protein 47; ARDS
ID STRESS-PROTEIN HSP47; GROWTH-FACTOR; MOLECULAR CHAPERONE; COLLAGEN;
   EXPRESSION; MICE; ACCUMULATION; PROCOLLAGEN; TISSUE; MOUSE
AB Acute respiratory distress syndrome (ARDS) confers high morbidity, and in part due to pulmonary fibrosis. The 47-kDa heat shock protein 47 (HSP 47) is a collagen-specific molecular chaperone that has been shown to play a major role in the processing and secretion of procollagen. We examined the effect of antisense oligonucleotides against HSP 47 in Wistar rats with lipopolysaccharide (LPS)-induced pulmonary fibrosis. These rats expressed heat shock protein (HSP) 47 and collagen in response to LPS. The distribution of HSP 47 was similar to that of collagen, and all control rats displayed pulmonary fibrosis after intratracheal administration of 20 mg/kg LPS alone. Antisense oligonucleotides (100 nmol/kg dissolved in saline) were administered with the LPS among experimental subjects. Subsequent immunoblot analysis confirmed the inhibition of HSP 47 by the administration of antisense oligonucleotides. The oligonucleotides significantly improved pulmonary fibrosis among those rats administered LPS, but the oligonucletides themselves did not produce any significant changes in the behavior or histology of the lungs among control rats. These findings suggest that HSP 47 antisense oligonucleotides improve lung fibrosis among rats with LPS-induced pneumopathy. (c) 2007 Elsevier B.V. All rights reserved.
C1 Oita Univ, Fac Med, Dept Brain & Nerve Sci, Yufu City, Oita 8795593, Japan.
RP Hagiwara, S (reprint author), Oita Univ, Fac Med, Dept Brain & Nerve Sci, 1-1 Idaigaoka Hasamamachi, Yufu City, Oita 8795593, Japan.
EM saku@med.oita-u.ac.jp
CR Abdollahi A, 2005, J EXP MED, V201, P925, DOI 10.1084/jem.20041393
   AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595
   ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467
   Bonniaud P, 2005, J IMMUNOL, V175, P5390, DOI 10.4049/jimmunol.175.8.5390
   Bonniaud P, 2004, AM J RESP CELL MOL, V31, P510, DOI 10.1165/rcmb.2004-0158OC
   Bouros D, 2005, EUR RESPIR J, V26, P693, DOI 10.1183/09031936.05.00145004
   Chen Y, 2005, TOXICOL LETT, V155, P353, DOI 10.1016/j.toxlet.2004.10.011
   Christensen PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL487
   GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959
   Hetzel M, 2005, LUNG, V183, P225, DOI 10.1007/s00408-004-2534-z
   Hocher B, 2000, AM J RESP CELL MOL, V23, P19, DOI 10.1165/ajrcmb.23.1.4030
   Kakugawa T, 2004, EUR RESPIR J, V24, P57, DOI 10.1183/09031936.04.00120803
   Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809
   MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617
   Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4
   Nagata K, 2003, SEMIN CELL DEV BIOL, V14, P275, DOI 10.1016/j.semcdb.2003.09.020
   NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903
   NAKAMURA K, 1989, EUR J PHARMACOL, V169, P259, DOI 10.1016/0014-2999(89)90023-X
   Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094
   NATSUME T, 1994, J BIOL CHEM, V269, P31224
   Razzaque MS, 1999, HISTOL HISTOPATHOL, V14, P1199, DOI 10.14670/HH-14.1199
   Razzaque MS, 1997, J PATHOL, V183, P24
   SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517
   Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469
   SAUK JJ, 1994, J BIOL CHEM, V269, P3941
   SCHINS RP, 1994, EUR RESPIR J, V7, P515
   Selman M, 1996, BRAZ J MED BIOL RES, V29, P1117
   Sharma SK, 1996, AM J RESP CRIT CARE, V154, P193, DOI 10.1164/ajrccm.154.1.8680680
   Shimabukuro DW, 2003, CRIT CARE MED, V31, pS524, DOI 10.1097/01.CCM.0000081437.06466.B3
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x
   Sunamoto M, 1998, LAB INVEST, V78, P967
   TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x
   Tran PL, 1997, J CLIN INVEST, V99, P608, DOI 10.1172/JCI119203
   WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0
   Xu YD, 2003, AM J PHYSIOL-LUNG C, V285, pL527, DOI 10.1152/ajplung.00298.2002
   Zhang XY, 2000, AM J RESP CRIT CARE, V162, P1561, DOI 10.1164/ajrccm.162.4.9908093
   Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412
   Zisman DA, 2005, METH MOLEC MED, V117, P3
NR 39
TC 16
Z9 18
U1 3
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUN 14
PY 2007
VL 564
IS 1-3
BP 174
EP 180
DI 10.1016/j.ejphar.2007.02.057
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 175FP
UT WOS:000246998800023
PM 17400207
DA 2018-12-27
ER

PT J
AU Santpere, G
   Puig, B
   Ferrer, I
AF Santpere, G.
   Puig, B.
   Ferrer, I.
TI RETRACTED: Oxidative damage of 14-3-3 zeta and gamma isoforms in
   Alzheimer's disease and cerebral amyloid angiopathy (Retracted article.
   See vol. 161, pg. 663, 2009)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; cerebral amyloid angiopathy; 14-3-3; A beta;
   oxidative stress; lipoxidation
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; ACTIVATED PROTEIN-KINASE; TAU-PROTEIN;
   NEURODEGENERATIVE DISORDERS; NEUROFIBRILLARY TANGLES; OXIDIZED PROTEINS;
   REDOX PROTEOMICS; SAPK/JNK-P; STRESS; BRAIN
AB Previous studies have shown oxidative damage resulting from amyloid A beta exposure to cultured cells and in murine models. A target of oxidation is 14-3-3 which comprises a group of proteins involved in kinase activation and chaperone activity. The present study shows glycoxidative damage, as revealed with mono and bi-dimensional gel electrophoresis and Western blotting, followed by in-gel digestion and mass spectrometry, in the frontal cortex in Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA), a neurodegenerative disease with deposition of A beta in cerebral blood vessels and in diffuse plaques unaccompanied by intraneuronal hyper-phosphorylated tau deposition. malondialdehyde-lysine (MDA-Lys)-, but not 4-hydroxy-2-nonenal (HNE)-immunoreactive adducts, and N-carboxyethyl-lysine (CEL), but not N-carboxymethyl-lysine (CML)-products, were present in 14-3-3 involving zeta and gamma isoforms in both AD and CAA. These findings demonstrate that 14-3-3 glyco- and lipoxidation occurs in AD and CAA, probably as a direct consequence of A beta deposition. (C) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 Univ Barcelona, Hosp Llobregat, Hosp Univ Llobregat, Fac Med,IDIBELL,Inst Neuropatol,Serv Anat Patol, E-08907 Lhospitalet De Llobregat, Spain.
RP Ferrer, I (reprint author), Univ Barcelona, Hosp Llobregat, Hosp Univ Llobregat, Fac Med,IDIBELL,Inst Neuropatol,Serv Anat Patol, Carrer Feixa Llarga SN, E-08907 Lhospitalet De Llobregat, Spain.
EM 8082ifa@comb.es
CR Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200
   Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005
   Atzori C, 2001, J NEUROPATH EXP NEUR, V60, P1190, DOI 10.1093/jnen/60.12.1190
   Avila J, 2002, MOL NEUROBIOL, V25, P213, DOI 10.1385/MN:25:3:213
   Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197
   Boyd-Kimball D, 2005, NEUROSCIENCE, V132, P313, DOI 10.1016/j.neuroscience.2004.12.022
   Braak H., 1999, CEREB CORTEX, V14, P475, DOI DOI 10.1007/978-1-4615-4885-014
   BRIDGES D, 2005, SCI STKE, pRE10, DOI DOI 10.1126/STKE.2962005RE10
   Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9
   Butterfield DA, 2006, EUR J PHARMACOL, V545, P39, DOI 10.1016/j.ejphar.2006.06.026
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6
   Butterfield DA, 2003, CURR MED CHEM, V10, P2651, DOI 10.2174/0929867033456422
   Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3
   Cecchi C, 2002, FREE RADICAL BIO MED, V33, P1372, DOI 10.1016/S0891-5849(02)01049-3
   CHAUHAN V, 2006, PATHOPHYSIOLOGY, V3, P195
   Coblitz B, 2006, FEBS LETT, V580, P1531, DOI 10.1016/j.febslet.2006.02.014
   Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6
   DAVIES KJA, 1987, J BIOL CHEM, V262, P9895
   Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0
   Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171
   Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7
   Duyckaerts C., 2003, NEURODEGENERATION MO, P47
   Ferl RJ, 1996, ANNU REV PLANT PHYS, V47, P49, DOI 10.1146/annurev.arplant.47.1.49
   Ferrer I., 2005, Current Alzheimer Research, V2, P3, DOI 10.2174/1567205052772713
   Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016
   Fountoulakis M, 1999, J NEURAL TRANSM-SUPP, P323
   FU RR, 2000, ANN REV PHARM TOXICO, V40, P617
   GARRISON WM, 1962, RADIAT RES, V16, P483, DOI 10.2307/3571084
   Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200
   Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002
   Hernandez F, 2004, NEUROSCI LETT, V357, P143, DOI 10.1016/j.neulet.2003.12.049
   Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2
   Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121
   Masters C.L., 2003, NEURODEGENERATION MO, P69
   Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291
   Munoz FJ, 2005, SUB CELL BIOCHEM, V38, P147
   Muslin AJ, 2005, CURR TOP DEV BIOL, V65, P211
   Nicopolitidis P, 2001, INT J COMMUN SYST, V14, P1, DOI 10.1002/dac.481
   Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2
   Nunomura A, 2006, J NEUROPATH EXP NEUR, V65, P631, DOI 10.1097/01.jnen.0000228136.58062.bf
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200
   Pei Jin-Jing, 2001, Journal of Alzheimer's Disease, V3, P41
   Puig B, 2004, NEUROPATH APPL NEURO, V30, P491, DOI 10.1111/j.1365-2990.2004.00569.x
   Richard M, 2003, ACTA NEUROPATHOL, V105, P296, DOI 10.1007/s00401-002-0642-5
   Sergeant N, 2005, BBA-MOL BASIS DIS, V1739, P179, DOI 10.1016/j.bbadis.2004.06.020
   Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X
   Sultana R, 2006, J NEUROSCI RES, V84, P409, DOI 10.1002/jnr.20876
   Takahashi Y, 2003, NEUROCHEM RES, V28, P1265, DOI 10.1023/A:1024296932670
   Umahara T, 2004, ACTA NEUROPATHOL, V108, P279, DOI 10.1007/s00401-004-0885-4
   van Heusden GPH, 2005, IUBMB LIFE, V57, P623, DOI 10.1080/15216540500252666
   Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274
   Yuan ZF, 2004, J BIOL CHEM, V279, P26105, DOI 10.1074/jbc.M308298200
   Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880
   Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x
NR 55
TC 13
Z9 13
U1 3
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD JUN 8
PY 2007
VL 146
IS 4
BP 1640
EP 1651
DI 10.1016/j.neuroscience.2007.03.013
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 176RB
UT WOS:000247101500021
PM 17445990
DA 2018-12-27
ER

PT J
AU Qadeer, G
   Rama, NH
   Chen, WT
AF Qadeer, Ghulam
   Rama, Nasim Hasan
   Chen, Wen-Tong
TI RETRACTED: 2-(2,4-Dichlorophenylsulfanyl)acetohydrazide (Retracted
   article. See vol 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB The title compound, C8H8Cl2N2OS, is an important intermediate for the synthesis of biologically active heterocyclic compounds. The planar hydrazide group is oriented with respect to the benzene ring at a dihedral angle of 88.93 (3)degrees.
C1 Quidi I Azam Univ, Dept Chem, Islamabad 45320, Pakistan.
   JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Prov Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Rama, NH (reprint author), Quidi I Azam Univ, Dept Chem, Islamabad 45320, Pakistan.
EM nasimhrama@yahoo.com
CR Ahmad R, 2001, NUCLEOS NUCLEOT NUCL, V20, P1671, DOI 10.1081/NCN-100105903
   ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   ALTALIB M, 1990, SYNTHETIC COMMUN, V20, P1811, DOI 10.1080/00397919008053105
   [Anonymous], 1998, SMART
   *BRUK AXS INC, 1999, SAINT SHELXTL
   El-Emam AA, 2004, BIOORGAN MED CHEM, V12, P5107, DOI 10.1016/j.bmc.2004.07.033
   FURNISS BS, 1978, VOGELS TXB PRACTICAL, P1125
   Nardelli M, 1995, J APPL CRYSTALLOGR, V28, P659, DOI [10.1107/S0021889895007138, DOI 10.1107/S0021889895007138]
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELX97 SHELXL97
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
   Wang LH, 2004, CHINESE J INORG CHEM, V20, P775
   YOUSIF MY, 1986, J CHEM SOC PAKISTAN, V8, P183
   Zheng XM, 2003, J FLUORINE CHEM, V123, P163, DOI 10.1016/S0022-1139(03)00168-4
NR 14
TC 2
Z9 2
U1 7
U2 14
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUN
PY 2007
VL 63
BP O2932
EP U2692
DI 10.1107/S1600536807011891
PN 6
PG 10
WC Crystallography
SC Crystallography
GA 191GD
UT WOS:000248118400278
DA 2018-12-27
ER

PT J
AU Qadeer, G
   Rama, NH
   Chen, WT
AF Qadeer, Ghulam
   Rama, Nasim Hasan
   Chen, Wen-Tong
TI RETRACTED: 2,6-Dimethoxybenzohydrazide (Retracted article. See vol 66,
   pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB The title compound, C9H12N2O3, is an important intermediate for the synthesis of biologically active heterocyclic compounds. The planar hydrazide group is oriented with respect to the benzene ring at a dihedral angle of 82.93 (3)degrees.
C1 Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan.
   JingGangShan Univ, JiangXi Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jinan 343009, Jiangxi, Peoples R China.
RP Rama, NH (reprint author), Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan.
EM nasimhrama@yahoo.com
CR Ahmad R, 2001, NUCLEOS NUCLEOT NUCL, V20, P1671, DOI 10.1081/NCN-100105903
   ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   ALTALIB M, 1990, SYNTHETIC COMMUN, V20, P1811, DOI 10.1080/00397919008053105
   [Anonymous], 1998, SMART
   *BRUK AXS INC, 1999, SAINT SHELXTL
   ELEMAM AA, 2004, BIOORGAN MED CHEM, V12, P5017
   FURNISS BS, 1978, VOGELS TXB PRACTICAL, P1125
   Nardelli M, 1995, J APPL CRYSTALLOGR, V28, P659, DOI [10.1107/S0021889895007138, DOI 10.1107/S0021889895007138]
   Sheldrick G.M, 1996, SADABS
   Sheldrick G.M., 1997, SHELXS 97 SHELXL 97
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
   Wang LH, 2004, CHINESE J INORG CHEM, V20, P775
   YOUSIF MY, 1986, J CHEM SOC PAKISTAN, V8, P183
   Zheng XM, 2003, J FLUORINE CHEM, V123, P163, DOI 10.1016/S0022-1139(03)00168-4
NR 14
TC 3
Z9 3
U1 2
U2 8
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD JUN
PY 2007
VL 63
BP O2892
EP U2342
DI 10.1107/S1600536807022593
PN 6
PG 8
WC Crystallography
SC Crystallography
GA 191GD
UT WOS:000248118400243
DA 2018-12-27
ER

PT J
AU Yang, YM
   Lu, PC
   Zhu, TT
   Liu, CH
AF Yang, Yu-Min
   Lu, Peng-Cheng
   Zhu, Tao-Tao
   Liu, Chang-Hong
TI RETRACTED: Bis(2-formylphenolato-kappa O-2,O ')iron(II) (Retracted
   article. See vol 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title complex, [ Fe( C7H5O2)(2)], is a mononuclear iron(II) complex with a distorted square planar coordination geometry and has the central Fe2+ ion located on an inversion centre, with four O atoms from two 2-formylphenolate ligands.
C1 Nantong Univ, Jiangsu Prov Key Lab Neuroregenerat, Nantong 226001, Peoples R China.
   Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China.
RP Liu, CH (reprint author), Nantong Univ, Jiangsu Prov Key Lab Neuroregenerat, Nantong 226001, Peoples R China.
EM changhong_liu2223@yahoo.com.cn
CR Sheldrick G.M, 1996, SADABS
   SHELFO SW, 1997, ATLAS UROL CLIN N AM, V5, P1
   SIEMENS, 1996, SMART SAINT
NR 3
TC 17
Z9 17
U1 3
U2 23
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUN
PY 2007
VL 63
BP M1613
EP U442
DI 10.1107/S1600536807021721
PN 6
PG 7
WC Crystallography
SC Crystallography
GA 191GD
UT WOS:000248118400049
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
AF Zhong, H.
   Zeng, X.-R.
   Yang, X.-M.
   Luo, Q.-Y.
TI RETRACTED: Bis(4,4 '-bipyridine-kappa N-2,N ')tetrakis(nitrato-kappa
   O-2,O ')cerium(IV) (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The asymmetric unit of the title compound, [ Ce( NO3)(4)-( C10H8N2)(2)], contains one half-molecule. The Ce-IV atom, lying on a crystallographic twofold rotation axis, is ten-coordinated by two N atoms of 4,4'-bipyridine and eight O atoms of four NO3(-) ligands. In the crystal structure, intra- and inter-molecular C-H center dot center dot center dot O hydrogen bonds link the molecules into a supramolecular network.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BENELLI C, 1992, MATER CHEM PHYS, V31, P137, DOI 10.1016/0254-0584(92)90166-6
   DEBORAH LB, 2000, INORG CHIM ACTA, V304, P161
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   Miller J. S., 2001, MAGNETISM MOL MAT
   MILLER JS, 2001, MAGNETISM MOL MAT, V1
   MILLER JS, 2002, MAGNETISM MOL MAT, V3
   Modolo G, 1998, J ALLOY COMPD, V271, P248, DOI 10.1016/S0925-8388(98)00064-4
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
NR 11
TC 1
Z9 1
U1 3
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUN
PY 2007
VL 63
BP M1592
EP U337
DI 10.1107/S1600536807021502
PN 6
PG 11
WC Crystallography
SC Crystallography
GA 191GD
UT WOS:000248118400036
DA 2018-12-27
ER

PT J
AU Spargo, FJ
   McGee, SL
   Dzamko, N
   Watt, MJ
   Kemp, BE
   Britton, SL
   Koch, LG
   Hargreaves, M
   Hawley, JA
AF Spargo, Fiona J.
   McGee, Sean L.
   Dzamko, Nick
   Watt, Matthew J.
   Kemp, Bruce E.
   Britton, Steven L.
   Koch, Lauren G.
   Hargreaves, Mark
   Hawley, John A.
TI RETRACTED: Dysregulation of muscle lipid metabolism in rats selectively
   bred for low aerobic running capacity (Retracted article. see vol 293,
   E1845, 2007)
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article; Retracted Publication
DE exercise capacity; insulin resistance; mitochondrial biogenesis; lipids
ID HORMONE-SENSITIVE LIPASE; TYPE-2 DIABETES-MELLITUS; ACTIVATED
   PROTEIN-KINASE; HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE;
   ADIPOSE-TISSUE; ARTIFICIAL SELECTION; ACCUMULATION; EXPRESSION;
   PHOSPHORYLATION
AB As substrate for evaluation of metabolic diseases, we developed novel rat models that contrast for endurance exercise capacity. Through two-way artificial selection, we created rodent phenotypes of intrinsically low- capacity runners ( LCR) and high- capacity runners ( HCR) that also differed markedly for cardiovascular and metabolic disease risk factors. Here, we determined skeletal muscle proteins with putative roles in lipid and carbohydrate metabolism to better understand the mechanisms underlying differences in whole body substrate handling between phenotypes. Animals ( generation 16) differed for endurance running capacity by 295%. LCR animals had higher resting plasma glucose ( 6.58 +/- 0.45 vs. 6.09 +/- 0.45 mmol/ l), insulin ( 0.48 +/- 0.03 vs. 0.32 +/- 0.02 ng/ ml), nonesterified fatty acid ( 0.57 +/- 0.14 v 0.35 +/- 0.05 mM), and triglyceride ( TG; 0.47 +/- 0.11 vs. 0.25 +/- 0.08 mmol/ l) concentrations ( all P < 0.05). Muscle TG ( 72.3 +/- 14.7 vs. 38.9 +/- 6.2 mmol/ kg dry muscle wt; P < 0.05) and diacylglycerol ( 96 +/- 28 vs. 42 +/- 8 pmol/ mg dry muscle wt; P < 0.05) contents were elevated in LCR vs. HCR rats. Accompanying the greater lipid accretion in LCR was increased fatty acid translocase/ CD36 content ( 1,014 +/- 80 vs. 781 +/- 70 arbitrary units; P < 0.05) and reduced TG lipase activity ( 0.158 +/- 0.0125 vs. 0.274 +/- 0.018 mmol . min(-1) . kg dry muscle wt(-1); P < 0.05). Muscle glycogen, GLUT4 protein, and basal phosphorylation states of AMP- activated protein kinase-alpha(1), AMP- activated protein kinase-alpha 2, and acetyl- CoA carboxylase were similar in LCR and HCR. In conclusion, rats with low intrinsic aerobic capacity demonstrate abnormalities in lipid- handling capacity. These disruptions may, in part, be responsible for the increased risk of metabolic disorders observed in this phenotype.
C1 RMIT Univ, Sch Med Sci, Exercise Metab Grp, Bundoora, Vic 3083, Australia.
   Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia.
   St Vincents Inst Med Res, Dept Med, Fitzroy, Vic 3065, Australia.
   Univ Michigan, Ann Arbor, MI 48109 USA.
RP Hawley, JA (reprint author), RMIT Univ, Sch Med Sci, Exercise Metab Grp, POB 71,Plenty Rd, Bundoora, Vic 3083, Australia.
EM john.hawley@rmit.edu.au
RI Kemp, Bruce/L-2633-2014; Koch, Lauren/D-1258-2010; Hawley,
   John/U-3814-2018
OI Kemp, Bruce/0000-0001-6735-5082; Hawley, John/0000-0002-0886-9881;
   McGee, Sean/0000-0001-6953-106X; Dzamko, Nicolas/0000-0002-9121-0294
FU NCRR NIH HHS [RR-17718]; NHLBI NIH HHS [HL-64270]
CR Beaudet AL, 1995, METABOLIC MOL BASES, V1, P79
   Benton CR, 2006, J APPL PHYSIOL, V100, P377, DOI 10.1152/japplphysiol.00781.2005
   Blaak EE, 2005, BEST PRACT RES CL EN, V19, P391, DOI 10.1016/j.beem.2005.04.001
   Blanck H. M., 2006, Morbidity and Mortality Weekly Report, V55, P985
   Booth FW, 2000, J APPL PHYSIOL, V88, P774
   Chabowski A, 2006, AM J PHYSIOL-ENDOC M, V291, pE675, DOI 10.1152/ajpendo.00096.2006
   Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202
   Duncan Glen E, 2006, Curr Diab Rep, V6, P29, DOI 10.1007/s11892-006-0048-1
   FRAYN KN, 1980, J LIPID RES, V21, P139
   Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755
   Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200
   HANSEN C, 1984, ALCOHOL CLIN EXP RES, V8, P477, DOI 10.1111/j.1530-0277.1984.tb05706.x
   Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005
   Hawley JA, 2006, J APPL PHYSIOL, V100, P1751, DOI 10.1152/japplphysiol.00150.2006
   Howlett RA, 2003, J APPL PHYSIOL, V94, P1682, DOI 10.1152/japplphysiol.00556.2002
   Kavanagh T, 2003, J AM COLL CARDIOL, V42, P2139, DOI 10.1016/j.jacc.2003.07.028
   Kelley DE, 2002, ANNU REV NUTR, V22, P325, DOI 10.1146/annurev.nutr.22.010402.102912
   Koch LG, 2001, PHYSIOL GENOMICS, V5, P45
   Krssak M, 2004, REV ENDOCR METAB DIS, V5, P127, DOI 10.1023/B:REMD.0000021434.98627.dc
   Langfort J, 1998, ADV EXP MED BIOL, V441, P219
   Lessard SJ, 2004, ENDOCRINOLOGY, V145, P5665, DOI 10.1210/en.2004-0659
   Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983
   PASSONEAU LA, 1993, ENZYMATIC ANAL PRACT
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Perseghin G, 2005, CURR OPIN LIPIDOL, V16, P416, DOI 10.1097/01.mol.0000174401.07056.56
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   PREISS J, 1986, J BIOL CHEM, V261, P8597
   Reznick RM, 2006, J PHYSIOL-LONDON, V574, P33, DOI 10.1113/jphysiol.2006.109512
   SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169
   Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583
   SLEIN M, 1963, METHODS ENZYMATIC AN
   Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913
   TURINSKY J, 1990, J BIOL CHEM, V265, P733
   WALSH B, 2006, J APPL PHYSIOL, V100, P1751
   Watt MJ, 2006, ENDOCRINOLOGY, V147, P2077, DOI 10.1210/en.2005-1074
   Watt MJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE500, DOI 10.1152/ajpendo.00361.2005
   Watt MJ, 2005, DIABETOLOGIA, V48, P105, DOI 10.1007/s00125-004-1598-x
   Watt MJ, 2003, J PHYSIOL-LONDON, V550, P325, DOI 10.1113/jphysiol.2003.043133
   Wisloff U, 2005, SCIENCE, V307, P418, DOI 10.1126/science.1108177
   Yang X, 2002, DIABETOLOGIA, V45, P1584, DOI 10.1007/s00125-002-0905-7
NR 44
TC 13
Z9 13
U1 3
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JUN
PY 2007
VL 292
IS 6
BP E1631
EP E1636
DI 10.1152/ajpendo.00702.2006
PG 6
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 188SH
UT WOS:000247939100016
PM 17284571
DA 2018-12-27
ER

PT J
AU Carlisle, MA
AF Carlisle, Maxine Alexis
TI RETRACTED: Did we make a mistake? (Retracted article. See vol. 53, pg.
   2105, 2007)
SO CANADIAN FAMILY PHYSICIAN
LA English
DT Editorial Material; Retracted Publication
C1 No Ontario Sch Med, Toronto, ON, Canada.
RP Carlisle, MA (reprint author), No Ontario Sch Med, Toronto, ON, Canada.
NR 0
TC 1
Z9 1
U1 1
U2 8
PU COLL FAMILY PHYSICIANS CANADA
PI MISSISSAUGA
PA 2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA
SN 0008-350X
EI 1715-5258
J9 CAN FAM PHYSICIAN
JI Can. Fam. Phys.
PD JUN
PY 2007
VL 53
BP 1062
EP 1063
PG 2
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 179MM
UT WOS:000247293900031
PM 17882767
DA 2018-12-27
ER

PT J
AU Chen, CS
   Wang, YC
   Yang, HC
   Huang, PH
   Kulp, SK
   Yang, CC
   Lu, YS
   Matsuyama, S
   Chen, CY
   Chen, CS
AF Chen, Chang-Shi
   Wang, Yu-Chieh
   Yang, Hsiao-Ching
   Huang, Po-Hsien
   Kulp, Samuel K.
   Yang, Chih-Cheng
   Lu, Yen-Shen
   Matsuyama, Shigemi
   Chen, Ching-Yu
   Chen, Ching-Shih
TI RETRACTED: Histone deacetylase inhibitors sensitize prostate cancer
   cells to agents that produce DNA double-strand breaks by targeting Ku70
   acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID PHASE-II; FATTY-ACIDS; WILD-TYPE; BINDING; ESTRAMUSTINE; PROTEIN;
   PHENYLBUTYRATE; DOXORUBICIN; PREDNISONE; ETOPOSIDE
AB This study reports a historic deacetylation- independent mechanism whereby historic deacetylase (HDAC) inhibitors sensitize prostate cancer cells to DNA-damaging agents by targeting Ku70 acetylation. Ku70 represents a crucial component of the nonhomologous end joining repair machinery for DNA double-strand breaks (DSB). Our data indicate that pretreatment of prostate cancer cells with HDAC inhibitors (trichostatin A, suberoylanilide hydroxamic acid, MS-275, and OSU-HDAC42) led to increased Ku70 acetylation accompanied by reduced DNA-binding affinity without disrupting the Ku70/ KuSO heterodimer formation. As evidenced by increased Ser 139 -phosphorylated histone H2AX (gamma H2AX), impaired Ku70 function diminished cellular capability to repair DNA DSBs induced by bleomycin, doxorubicin, and etoposide, thereby enhancing their cell-killing effect. This sensitizing effect was most prominent when cells were treated with HDAC inhibitors and DNA-damaging agents sequentially. Mimicking acetylation was done by replacing K282, K317, K331, K338, K539, or K542 with glutamine via site-directed mutagenesis, which combined with computer docking analysis was used to analyze the role of these lysine residues in the interactions of Ku70 with DNA broken ends. Mutagenesis of K282, K338, K539, or K542 suppressed the activity of Ku70 to bind DNA, whereas mutagenesis of K317 or K331 with glutamine had no significant effect. Moreover, overexpression of K282Q or K338Q rendered DU-145 cells more susceptible to the effect of DNA-damaging agents on gamma H2AX formation and cell killing. Overall, the ability of HDAC inhibitors to regulate cellular ability to repair DNA damage by targeting Ku70 acetylation underlies the viability of their combination with DNA-damaging agents as a therapeutic strategy for prostate cancer.
C1 [Chen, Chang-Shi; Wang, Yu-Chieh; Yang, Hsiao-Ching; Huang, Po-Hsien; Kulp, Samuel K.; Yang, Chih-Cheng; Lu, Yen-Shen; Chen, Ching-Shih] Ohio State Univ, Coll Pharm, Div Med Chem, Parks Hall,500 W 12Th Ave, Columbus, OH 43210 USA.
   [Chen, Ching-Yu] Natl Taiwan Univ, Coll Med, Dept Family Med, Taipei, Taiwan.
   [Chen, Ching-Yu] Natl Hlth Res Inst, Gerontol Res Div, Taipei, Taiwan.
   [Matsuyama, Shigemi] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
RP Chen, CS (reprint author), Ohio State Univ, Coll Pharm, Div Med Chem, Parks Hall,500 W 12Th Ave, Columbus, OH 43210 USA.
EM chen.844@osu.edu
RI Chen, Chang-Shi/B-9251-2009
OI Chen, Chang-Shi/0000-0002-8201-3635; CHEN, CHING-YU/0000-0002-4095-4197
FU NCI NIH HHS [CA112250]
CR Banath JP, 2003, CANCER RES, V63, P4347
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Borden LS, 2006, CANCER, V107, P1093, DOI 10.1002/cncr.22078
   Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2
   Fiedler W, 2006, EUR J CANCER, V42, P200, DOI 10.1016/j.ejca.2005.07.030
   Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753
   Haas NB, 2000, AM J CLIN ONCOL-CANC, V23, P589, DOI 10.1097/00000421-200012000-00012
   Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6
   ISAACS WB, 1991, CANCER RES, V51, P4716
   Kim JH, 2004, INT J RADIAT ONCOL, V59, P1174, DOI 10.1016/j.ijrobp.2004.03.001
   Kim MS, 2003, CANCER RES, V63, P7291
   Kulp SK, 2006, CLIN CANCER RES, V12, P5199, DOI 10.1158/1078-0432.CCR-06-0429
   Kurz EU, 2001, MOL CANCER THER, V1, P121
   Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056
   Lu Q, 2005, J MED CHEM, V48, P5530, DOI 10.1021/jm0503749
   Lu Q, 2004, J MED CHEM, V47, P467, DOI 10.1021/jm0303655
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088
   Nothwehr SF, 2003, NAT CELL BIOL, V5, P281, DOI 10.1038/ncb0403-281
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   PIENTA KJ, 1994, J CLIN ONCOL, V12, P2005, DOI 10.1200/JCO.1994.12.10.2005
   Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt
   Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229
   Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955
   Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950
   Shack S, 1996, CLIN CANCER RES, V2, P865
   SINGH UC, 1984, J COMPUT CHEM, V5, P129, DOI 10.1002/jcc.540050204
   Small EJ, 1996, J CLIN ONCOL, V14, P1617, DOI 10.1200/JCO.1996.14.5.1617
   Smith DC, 2003, CANCER, V98, P269, DOI 10.1002/cncr.11494
   Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000
   Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842
   Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068
   Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003
   Wu XT, 1996, MOL CELL BIOL, V16, P5186
   YIN MB, 1991, CANCER COMMUN, V3, P45
   Zhang Y, 2006, INT J RADIAT ONCOL, V65, P859, DOI 10.1016/j.ijrobp.2006.03.019
NR 42
TC 135
Z9 139
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2007
VL 67
IS 11
BP 5318
EP 5327
DI 10.1158/0008-5472.CAN-06-3996
PG 10
WC Oncology
SC Oncology
GA 175NS
UT WOS:000247020900035
PM 17545612
OA Bronze
DA 2018-12-27
ER

PT J
AU Gong, X
   Kole, L
   Iskander, K
   Jaiswal, AK
AF Gong, Xing
   Kole, Labanyamoy
   Iskander, Karim
   Jaiswal, Anil K.
TI RETRACTED: NRH : Quinone oxidoreductase 2 and NAD(P)H : quinone
   oxidoreductase 1 protect tumor suppressor p53 against 20S proteasomal
   degradation leading to stabilization and activation of p53 (Retracted
   article. See vol. 75, pg. 615, 2015)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID SKIN CARCINOGENESIS; INCREASES SUSCEPTIBILITY; MENADIONE TOXICITY;
   DT-DIAPHORASE; MOUSE SKIN; IN-VIVO; GENE; NQO1; DISRUPTION; DEFICIENCY
AB Tumor suppressor p53 is either lost or mutated in several types of cancer. MDM2 interaction with p53 results in ubiquitination and 26S proteasomal degradation of p53 Chronic DNA damage leads to inactivation of MDM2 stabilization of p53, and apoptotic cell death. Here, we presen; a novel MDM2/ubiquitination-independent mechanism of stabilization and transient activation of p53. The present studies show that 20S proteasomes degrade p53. The 20S degradation of p53 was observed in ubiquitin-efficient and -deficient cells, indicating that this pathway of degradation did not require ubiquitination of p53. The cytosolic quinone oxidoreductases [NRH:quinone oxidoreductase 2 (NQ02) and NAD(P)H:quinone oxidoreductase I (NQ01)] interacted with p53 and protected p53 against 20S proteasomal degradation. Further studies revealed that acute exposure to radiation or chemical leads to induction of NQ01 and NQ02 that stabilizes and transiently activates p53 and downstream genes. These results suggest that stress-induced NQ01 and NQ02 transiently stabilize p53, which leads to protection against adverse effects of stressors.
C1 Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
RP Jaiswal, AK (reprint author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ajaiswal@bcm.tmc.edu
FU NIEHS NIH HHS [R01 ES07943]
CR Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200
   Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200
   Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052726799
   Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898
   Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499
   Dai MS, 2006, NEOPLASIA, V8, P630, DOI 10.1593/neo.06334
   Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200
   Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157
   Iskander K, 2004, CANCER RES, V64, P5925, DOI 10.1158/0008-5472.CAN-04-0763
   Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074
   KOLE L, 1994, BIOCHEM BIOPH RES CO, V200, P351, DOI 10.1006/bbrc.1994.1455
   Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009
   Long DJ, 2000, CANCER RES, V60, P5913
   Long DJ, 2002, CANCER RES, V62, P3030
   Long DJ, 2002, J BIOL CHEM, V277, P46131, DOI 10.1074/jbc.M208675200
   Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166
   Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3
   Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367
   Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382
   Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X
   Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x
   SEGURAAGUILAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P33, DOI 10.1016/0167-4838(92)90421-9
   Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231
NR 23
TC 78
Z9 80
U1 3
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2007
VL 67
IS 11
BP 5380
EP 5388
DI 10.1158/0008-5472.CAN-07-0323
PG 9
WC Oncology
SC Oncology
GA 175NS
UT WOS:000247020900042
PM 17545619
OA Bronze
DA 2018-12-27
ER

PT J
AU Lozano, SC
   Hard, BM
   Tversky, B
AF Lozano, Sandra C.
   Hard, Bridgette Martin
   Tversky, Barbara
TI RETRACTED: Putting action in perspective (Retracted article. See vol.
   110, pg. 123, 2009)
SO COGNITION
LA English
DT Article; Retracted Publication
DE perspective-taking; embodied cognition; action understanding; language;
   spatial reasoning
ID MOTOR; FMRI
AB Embodied approaches to cognition propose that our own actions influence our understanding of the world. Do other people's actions also have this influence? The present studies show that perceiving another person's actions changes the way people think about objects in a scene. In Study 1, participants viewed a photograph and answered a question about the location of one object relative to another. The question either did or did not call attention to an action being performed in the scene. Studies 2 and 3 focused on whether depicting an action in a scene influenced perspective choice. Across all studies, drawing attention to action, whether verbally or pictorially, led observers to encode object locations from the actor's spatial perspective. Study 4 demonstrated that the tendency to adopt the actor's perspective might be mediated by motor experience. (c) 2006 Elsevier B.V. All rights reserved.
C1 Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.
RP Lozano, SC (reprint author), Stanford Univ, Dept Psychol, Jordan Hall,Bldg 01-420, Stanford, CA 94305 USA.
EM scl@psych.stanford.edu
CR Barsalou LW, 1999, BEHAV BRAIN SCI, V22, P577
   Barsalou LW, 2003, PSYCHOL LEARN MOTIV, V43, P43, DOI 10.1016/S0079-7421(03)01011-9
   Blakemore SJ, 2005, NEUROPSYCHOLOGIA, V43, P260, DOI 10.1016/j.neuropsychologia.2004.11.012
   Borghi AM, 2004, MEM COGNITION, V32, P863, DOI 10.3758/BF03196865
   Buccino G, 2005, COGNITIVE BRAIN RES, V24, P355, DOI 10.1016/j.cogbrainres.2005.02.020
   Calvo-Merino B, 2005, CEREB CORTEX, V15, P1243, DOI 10.1093/cercor/bhi007
   CARLSON LA, 2005, GROUNDING COGNITION, P35
   Chao LL, 2000, NEUROIMAGE, V12, P478, DOI 10.1006/nimg.2000.0635
   Glenberg A. M., 1997, BEHAV BRAIN SCI, V2, P1
   HARD BM, IN PRESS J EXPT PSYC
   Hart R. A., 1973, IMAGE ENV COGNITIVE, P246
   INHELDER B, 1956, CHILDS CONCEPTION SP
   Kan IP, 2003, COGN NEUROPSYCHOL, V20, P525, DOI 10.1080/02643290244000257
   Martin M, 1998, MEM COGNITION, V26, P193, DOI 10.3758/BF03201132
   RUBIN DC, 1983, MEM COGNITION, V11, P335, DOI 10.3758/BF03202446
   Wilson M, 2002, PSYCHON B REV, V9, P625, DOI 10.3758/BF03196322
   Wilson M, 2005, PSYCHOL BULL, V131, P460, DOI 10.1037/0033-2909.131.3.460
NR 17
TC 14
Z9 15
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0010-0277
J9 COGNITION
JI Cognition
PD JUN
PY 2007
VL 103
IS 3
BP 480
EP 490
DI 10.1016/j.cognition.2006.04.010
PG 11
WC Psychology, Experimental
SC Psychology
GA 163BQ
UT WOS:000246133900007
PM 16765339
DA 2018-12-27
ER

PT J
AU Mengistu, AM
   Wolf, MW
   Boldt, J
   Rohm, KD
   Suttner, SW
   Piper, SN
AF Mengistu, A. M.
   Wolf, M. W.
   Boldt, J.
   Roehm, K. D.
   Suttner, S. W.
   Piper, S. N.
TI RETRACTED: Influence of controlled hypotension using esmolol and sodium
   nitroprusside on natriuretic peptides in patients undergoing endonasal
   sinus surgery (Retracted article. See vol. 28, pg. 468, 2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE atrial natriuretic factor; natriuretic peptide; brain; hypotension;
   controlled; esmolol; nitroprusside; surgery, nasal
ID HEART-FAILURE; HIP-ARTHROPLASTY; HEALTHY-SUBJECTS; ATRIAL; METOPROLOL;
   SECRETION; RESPONSES; RELEASE; DISEASE; PROTEIN
AB Background and objective: Atrial and brain natriuretic peptide, synthesized by cardiac myocytes, are mediators secreted secondary to cardiac volume expansion and increased filling pressure. The study was designed to assess serum concentration of atrial and brain natriuretic peptide in patients undergoing endonasal sinus surgery receiving controlled hypotension. Methods: We studied 45 patients without cardiovascular history, scheduled for elective endonasal sinus surgery. Patients were allocated to one of three groups: controlled hypotension was induced either by using esmolol (n = 15) or sodium nitroprusside (n = 15) with a mean arterial pressure of 50-55 mmHg. In the control group (n = 15), mean arterial pressure was adjusted to 70-80 mmHg. Atrial and brain natriuretic peptides were measured preoperatively (TI), at the end of surgery (T2), 2 h (T3), 24 h (T4) and 48 h (T5) postoperatively. Results: Preoperative atrial and brain natriuretic peptide plasma levels were within normal ranges and similar between all groups. Patients treated with esmolol (atrial natriuretic peptide: 2.46 +/- 0.7 5 mu g mL(-1); brain natriuretic peptide: 4.34 +/- 3.06 mu g mL(-1)) and sodium nitropusside (atrial natriuretic peptide: 2.48 +/- 0.92 mu g mL(-1); brain natriuretic peptide: 4.49 +/- 3.21 mu g mL(-1)) showed significantly lower concentrations of atrial and brain natriuretic peptide at T2 and T3 compared with controls (atrial natriuretic peptide: 5.31 +/- 2.3 2 mu g mL(-1); brain natriuretic peptide: 13.26 +/- 8.98 mu g mL(-1), P < 0.01) as well as a reduction in blood loss and duration of surgery. Conclusions: Controlled hypotension decreases the release of natriuretic peptides in cardiovascular healthy patients. This effect may be contributed to by changes in cardiac filling pressure due to lower systemic resistance and diminished perfusion pressure.
C1 Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Mengistu, AM (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM a.mengistu@gmx.de
CR BERLIN I, 1993, EUR J CLIN PHARMACOL, V44, P127, DOI 10.1007/BF00315469
   Davis ME, 2006, CIRCULATION, V113, P977, DOI 10.1161/CIRCULATIONAHA.105.567727
   DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797
   Doust JA, 2005, BRIT MED J, V330, P625, DOI 10.1136/bmj.330.7492.625
   FERRI C, 1989, MED-RIV ENC MED ITAL, V9, P172
   Freitas Joao, 2005, Rev Port Cardiol, V24, P81
   Habler O, 2000, ANAESTHESIST, V49, P687
   Hryniewicz K, 2003, CIRCULATION, V108, P971, DOI 10.1161/01.CIR.0000085070.39873.B1
   KELLER N, 1991, SCAND J CLIN LAB INV, V51, P73
   KOHNO M, 1987, AM HEART J, V113, P1160, DOI 10.1016/0002-8703(87)90929-X
   Kragelund C, 2005, NEW ENGL J MED, V352, P666, DOI 10.1056/NEJMoa042330
   LEGAULT L, 1992, CAN J PHYSIOL PHARM, V70, P1549, DOI 10.1139/y92-222
   Levin ER, 1998, NEW ENGL J MED, V339, P321
   Maeda K, 1998, AM HEART J, V135, P825, DOI 10.1016/S0002-8703(98)70041-9
   Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233
   Melo LG, 1996, AM J PHYSIOL-HEART C, V270, pH306
   Piper SN, 2003, ANASTH INTENSIV NOTF, V38, P781
   Piper SN, 2002, EUR J ANAESTH, V19, P609, DOI 10.1017/S0265021502000996
   Richards AM, 2004, TRENDS ENDOCRIN MET, V15, P170
   Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093
   SHARROCK NE, 1993, ANESTH ANALG, V76, P580
   Silver MA, 2006, CURR OPIN NEPHROL HY, V15, P14
   SKOVRAK JP, 1997, AM J PHYSIOL, V273, pR301
   SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0
   ten Wolde M, 2003, CIRCULATION, V107, P2082, DOI 10.1161/01.CIR.0000070020.79932.DB
   Terasako K, 2002, ANAESTH INTENS CARE, V30, P588
   Tsubo T, 1993, Masui, V42, P66
   van den Meiracker AH, 2003, J CARDIOVASC PHARM, V42, P462, DOI 10.1097/00005344-200310000-00002
   YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195
   Yeh HM, 2005, BRIT J SURG, V92, P1041, DOI 10.1002/bjs.4947
NR 30
TC 10
Z9 11
U1 4
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD JUN
PY 2007
VL 24
IS 6
BP 529
EP 534
DI 10.1017/S0265021506002286
PG 6
WC Anesthesiology
SC Anesthesiology
GA 175US
UT WOS:000247040100010
PM 17241506
DA 2018-12-27
ER

PT J
AU An, Y
   Xiao, YB
   Zhong, QJ
AF An, Yong
   Xiao, Ying-Bin
   Zhong, Qian-Jin
TI RETRACTED: Open-heart surgery in patients with liver cirrhosis
   (Retracted article. See vol. 41, pg. 1412, 2012)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Article; Retracted Publication
DE open-heart surgery; cardiopulmonary bypass; liver cirrhosis; Child-Pugh
   classification; postoperative complications; postoperative mortality
ID CARDIOPULMONARY BYPASS; CARDIAC OPERATIONS; SURGICAL-TREATMENT;
   MORTALITY; JAUNDICE
AB Background: This retrospective study was designed to examine morbidity and mortality rates and to find predictors of outcome in patients with liver cirrhosis (LC) undergoing open-heart surgery. Methods: Between May 1996 and June 2005, 24 patients with LC underwent an open-heart surgery in our institution. Results: There were 14 females and 10 mates. Their age ranged from 36 to 72 (average 53 +/- 13) years. Seventeen cases were classified as having Child-Pugh class A cirrhosis, six as having class B cirrhosis, and one as having class C cirrhosis. The mean cardiopulmonary bypass (CPB) time and the cross-clamp time were 160 +/- 53 and 90 +/- 42 min, respectively. In the first 24 h after operation, the mean chest tube output was 1080 +/- 320 ml. Mean duration of mechanical ventilation was 32 +/- 22 h and mean intensive care unit stay time was 11 +/- 8 days. Sixty-six percent of the patients experienced significant morbidity. Fifty-three percent of patients with class A cirrhosis and 100% of those with class B and C cirrhosis suffered postoperative complications. The overall mortality rate was 25%. Postoperative mortality of patients with Child-Pugh class A cirrhosis, class B cirrhosis, and C cirrhosis were 6, 67, and 100%, respectively. Preoperative serum total bilirubin (TB), cholinesterase (ChE), and CPB time were defined as predictors to differentiate survivors and nonsurvivors. Conclusion: Child-Pugh class is related to morbidity and mortality after open-heart surgery in patients with LC. But CPB surgery is associated with higher morbidity and mortality in patients with advanced LC. The increased serum level of TB and the tow serum concentration of ChE preoperativety, and the prolonged CPB time were found to be predictors of outcome in patients with LC undergoing open heart surgery. (C) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
C1 Third Mil Med Univ, Xin Qiao Hosp, Dept Cardiovasc Surg, Chongqing 400037, Peoples R China.
RP An, Y (reprint author), Third Mil Med Univ, Xin Qiao Hosp, Dept Cardiovasc Surg, Chongqing 400037, Peoples R China.
EM anyongsmcvs@163.com
CR Aggarwal A, 2001, CHEST, V119, P1489, DOI 10.1378/chest.119.5.1489
   Bizouarn P, 1999, ANN THORAC SURG, V67, P1334, DOI 10.1016/S0003-4975(99)00226-X
   CHU CM, 1984, THORAX, V39, P52, DOI 10.1136/thx.39.1.52
   COLLINS JD, 1983, LANCET, V1, P1119
   DOBERNECK RC, 1983, AM J SURG, V146, P306, DOI 10.1016/0002-9610(83)90402-6
   Hayashida N, 2004, ANN THORAC SURG, V77, P500, DOI 10.1016/j.athoracsur.2003.06.021
   HILL DM, 1980, SOUTHERN MED J, V73, P906, DOI 10.1097/00007611-198007000-00023
   Hirata N, 1999, J CARDIAC SURG, V14, P172, DOI 10.1111/j.1540-8191.1999.tb00973.x
   JOCHANAN EN, 2000, AM HEART J, V140, P111
   Kaplan M, 2002, HEART SURG FORUM, V5, P60
   KAY JH, 1992, ANN THORAC SURG, V53, P1132, DOI 10.1016/0003-4975(92)90411-V
   Klemperer JD, 1998, ANN THORAC SURG, V65, P85, DOI 10.1016/S0003-4975(97)00931-4
   MATHIE RT, 1993, CRIT CARE MED, V21, pS72, DOI 10.1097/00003246-199302001-00013
   MATSUDA H, 1989, JPN CIRC J, V53, P175, DOI 10.1253/jcj.53.175
   McCaughan GW, 2000, J GASTROEN HEPATOL, V15, pG90, DOI 10.1046/j.1440-1746.2000.02273.x
   Michalopoulos A, 1997, HEPATO-GASTROENTEROL, V44, P779
   Ninomiya M, 2001, Jpn J Thorac Cardiovasc Surg, V49, P391, DOI 10.1007/BF02913158
   Nollert G, 2001, THORAC CARDIOV SURG, V49, P226, DOI 10.1055/s-2001-16115
   Ota T, 1996, Kyobu Geka, V49, P916
   Paparella D, 2002, EUR J CARDIO-THORAC, V21, P232, DOI 10.1016/S1010-7940(01)01099-5
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Reinhartz O, 1998, J THORAC CARDIOV SUR, V116, P633, DOI 10.1016/S0022-5223(98)70171-0
   Toyoda Y, 1996, J CARDIOVASC SURG, V37, P305
   Yaku H, 2000, AUST NZ J SURG, V70, P77, DOI 10.1046/j.1440-1622.2000.01753.x
   Yamamoto Taira, 2002, Jpn J Thorac Cardiovasc Surg, V50, P526
NR 25
TC 25
Z9 26
U1 4
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD JUN
PY 2007
VL 31
IS 6
BP 1094
EP 1098
DI 10.1016/j.ejcts.2007.01.042
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 179LE
UT WOS:000247290300024
PM 17314050
OA Bronze
DA 2018-12-27
ER

PT J
AU Dhaneshwar, SS
   Kandpal, M
   Vadnerkar, G
   Rathi, B
   Kadam, SS
AF Dhaneshwar, Suneela S.
   Kandpal, Mini
   Vadnerkar, Gaurav
   Rathi, Badal
   Kadam, S. S.
TI RETRACTED: Synthesis, kinetic studies and pharmacological evaluation of
   mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug
   delivery in inflammatory bowel disease (Retracted article. See vol. 43,
   pg. 2909, 2008)
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE mutual azo prodrug; 5-aminosalicylic acid; inflammatory bowel disease;
   L-tyrosine
ID ULCERATIVE-COLITIS; RATS; OLSALAZINE; INHIBITOR; MODELS
AB Mutual azo prodrug of 5-aminosalicylic acid with L-tyrosine was synthesized by coupling L-tyrosine with salicylic acid, for targeted drug delivery to the inflamed gut tissue in inflammatory bowel disease. The structure was confirmed by elemental analysis, IR and NMR spectroscopy. In vitro kinetic studies in rat fecal matter showed 87.18% release of 5-aminosalicylic acid with a half-life of 140.28 min, following first order kinetics. Therapeutic efficacy of the carrier system and the mitigating effect of the azo conjugate were evaluated in trinitrobenzenesulfonic acid-induced experimental colitis model. Myeloperoxidase activity was determined by the method of Krawisz et al. The synthesized prodrug was found to produce comparable mitigating effect as that of sulfasalazine on colitis in rats. (c) 2006 Elsevier Masson SAS. All rights reserved.
C1 Bharati Vidyapeeth Deemed Univ, Poona Coll Pharm, Dept Pharmaceut Chem, Pune 411038, Maharashtra, India.
   Bharati Vidyapeeth Deemed Univ, Poona Coll Pharm, Dept Pharmacol, Pune 411038, Maharashtra, India.
RP Dhaneshwar, SS (reprint author), Bharati Vidyapeeth Deemed Univ, Poona Coll Pharm, Dept Pharmaceut Chem, Pune 411038, Maharashtra, India.
EM suneeladhaneshwar@rediffmail.com
CR Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33
   Furniss B. S., 1978, VOGELS TXB PRACTICAL, P688
   Hartmann G, 2000, J PHARMACOL EXP THER, V292, P22
   HUNJRA AS, 2006, INDIAN J PHARM ED RE, V40, P40
   KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344
   LI T, 2003, GASTROENTEROLOGY, V9, P1028
   Mahmud N, 2001, GUT, V49, P552, DOI 10.1136/gut.49.4.552
   MARCH J, 1986, ADV ORGANIC CHEM REA, P355
   MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9
   RAINSFORD KD, 1975, AGENTS ACTIONS, V5, P553, DOI 10.1007/BF01972694
   RAINSFORD KD, 1980, P BR PHARM SOC, pP226
   RAO SSC, 1987, GUT, V28, P1474, DOI 10.1136/gut.28.11.1474
   RUBINSTEIN A, 1992, PHARMACEUT RES, V9, P276, DOI 10.1023/A:1018910128452
   SANDS BE, 2000, GASTROENTEROLOGY, V118, P68
   SUNEELA D, 1994, INDIAN DRUGS, V31, P374
   Sutherland LR, 1997, INFLAMM BOWEL DIS, V3, P65, DOI 10.1002/ibd.3780030202
   TAKAGI K, 1976, Patent No. 3988
   YAMADA T, 1992, GASTROENTEROLOGY, V102, P1524, DOI 10.1016/0016-5085(92)91710-L
   ZINGARELLI B, 1993, AGENTS ACTIONS, V39, P150, DOI 10.1007/BF01998968
NR 19
TC 8
Z9 8
U1 3
U2 21
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN
PY 2007
VL 42
IS 6
BP 885
EP 890
DI 10.1016/j.ejmech.2006.11.017
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 182ZG
UT WOS:000247541900015
PM 17258353
DA 2018-12-27
ER

PT J
AU Gilani, MM
   Zarchi, MK
   Ghaemmaghami, F
   Behtash, N
   Mousavi, AS
   Ansaripoor, S
AF Gilani, Mitra Modares
   Zarchi, Mojgan Karimi
   Ghaemmaghami, Fatemeh
   Behtash, Naderch
   Mousavi, Azam Sadat
   Ansaripoor, Sohella
TI RETRACTED: A study to evaluate the utility of presurgical CA125 to
   predict optimal tumor cytoreduction of epithelial ovarian cancer
   (Retracted article. See vol. 111, pg. 516, 2008)
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article; Retracted Publication
DE ovarian cancer; CA125; optimal cytoreduction
ID COMPUTED-TOMOGRAPHY; PROGNOSTIC FACTOR; CARCINOMA; SURGERY; SURVIVAL;
   CHEMOTHERAPY; MANAGEMENT; DEBULKING; CA-125; IMPACT
AB Objective. To determine the ability of a preoperative serum CA125 to predict optimal primary tumor cytoreduction in patients with stage III and IV epithelial ovarian cancer (EOC).
   Materials and methods. The records of patients with advanced stage who underwent primary surgery for EOC at Tehran University, Vali-Asr Hospital between 2000 and 2002 were reviewed. Inclusion criteria included FIGO stage III/IV disease, surgery by gynecologic oncology faculty, preoperative CA125, and an operative note clearly defining volume of residual disease. Without optimal cytoreduction was determined using the receiver operator curve (ROC).
   Results. One hundred and twenty cases of advanced stage EOC were identified, of which 90 cases of stage III/IV met our inclusion criteria. Serum CA 125 <= 400 was identified with OD >= 75% of the time. Conversely, optimal cytoreduction was performed in <= 40% of patients with CA 125 >= 4000. The area under the ROC curve for CA125 was 0.680. The optimal cytoreduction rate for those with and without ascites was 38% and 77%, respectively (P < 0.001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.696.
   Conclusion. We conclude that CA125 level did not reliably predict optimal cytoreduction in patients with stage III-IV EOC. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Teheran Med Sci, Vali Asr Hosp, Dept Gynecol Oncol, Tehran, Iran.
RP Zarchi, MK (reprint author), Univ Teheran Med Sci, Vali Asr Hosp, Dept Gynecol Oncol, Keshavarz Blvd, Tehran, Iran.
EM drkarimi2001@yahoo.com
RI Karimi- Zarchi, Mojgan/I-6568-2017
OI Karimi- Zarchi, Mojgan/0000-0002-8734-9971
CR Barlow TS, 2006, INT J GYNECOL CANCER, V16, P496, DOI 10.1111/j.1525-1438.2006.00573.x
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Bristow RE, 2000, CANCER, V89, P1532, DOI 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A
   Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248
   Brockbank EC, 2004, INT J GYNECOL CANCER, V14, P42, DOI 10.1111/j.1048-891x.2004.14065.x
   Byrom J, 2002, BJOG-INT J OBSTET GY, V109, P369, DOI 10.1111/j.1471-0528.2002.01216.x
   Chi DS, 2000, GYNECOL ONCOL, V77, P227, DOI 10.1006/gyno.2000.5749
   Cooper BC, 2002, OBSTET GYNECOL, V100, P59, DOI 10.1016/S0029-7844(02)02057-4
   Curtin JP, 1997, GYNECOL ONCOL, V64, P9, DOI 10.1006/gyno.1996.4550
   EISENKOP SM, 1992, GYNECOL ONCOL, V47, P203, DOI 10.1016/0090-8258(92)90107-T
   GRIFFITHS CT, 1979, CANCER TREAT REP, V63, P235
   HACKER NF, 1983, OBSTET GYNECOL, V61, P413
   HOSKINS WJ, 1994, AM J OBSTET GYNECOL, V170, P974, DOI 10.1016/S0002-9378(94)70090-7
   MAYER AR, 1992, GYNECOL ONCOL, V47, P223, DOI 10.1016/0090-8258(92)90110-5
   MCGUIRE WP, 1999, NEW ENGL J MED, V334, P1
   Memarzadeh S, 2003, INT J GYNECOL CANCER, V13, P120, DOI 10.1046/j.1525-1438.2003.13019.x
   OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138
   RUBIN SC, 1993, OBSTET GYNECOL, V82, P143
   Vergote I, 1998, GYNECOL ONCOL, V71, P431, DOI 10.1006/gyno.1998.5213
NR 19
TC 13
Z9 14
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN
PY 2007
VL 105
IS 3
BP 780
EP 783
DI 10.1016/j.ygyno.2007.02.027
PG 4
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 172PG
UT WOS:000246815700036
PM 17433423
DA 2018-12-27
ER

PT J
AU Suvardhan, K
   Rekha, D
   Kumar, KS
   Prasad, PR
   Kumar, JD
   Jayaraj, B
   Chiranjeevi, P
AF Suvardhan, K.
   Rekha, D.
   Kumar, K. Suresh
   Prasad, P. Reddy
   Kumar, J. Dilip
   Jayaraj, B.
   Chiranjeevi, P.
TI RETRACTED: Novel analytical reagent for the application of cloud-point
   preconcentration and flame atomic absorption spectrometric determination
   of nickel in natural water samples (Retracted article. See vol. 153, pg.
   899, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE nickel;
   N-quino[8,7-b]azin-5-yl-2,3,5,6,8,9,11,12octahydrobenzo[b][1,4,7,10,13]p
   entaoxacyclopentadecin-15-yl-methanimine; cloud-point extraction
   preconcentration (CPE-P); triton X-114; flame atomic absorption
   spectrometry (FAAS); water samples
ID FLOW-INJECTION-ANALYSIS; MICELLE-MEDIATED METHODOLOGY; PLASMA-MASS
   SPECTROMETRY; EXTRACTION PRECONCENTRATION; SPECTROPHOTOMETRIC
   DETERMINATION; EMISSION-SPECTROMETRY; TRACE-ELEMENTS; REAL SAMPLES;
   COBALT; SPECIATION
AB Cloud-point extraction was applied as a preconcentration of nickel after formation of complex with newly synthesized N-quino[8,7-b]azin-5-yl-2,3,5,6,8,9,11,12octahydrobenzo[b][1,4,7,10,13]pentaoxacyclopentadecin-15-yl-methanimine, and later determined by flame atomic absorption spectrometry (FAAS) using octyl phenoxy polyethoxy ethanol (Triton X-114) as surfactant. Nickel was complexed with N-quino[8,7-b]azin-5-yl-2,3,5,6,8,9,11,12octahydrobenzo[b][1,4,7,10,13]pentaoxacyclopentadecin-15-yl-methanimine in an aqueous phase and was kept for 15 min in a thermo-stated bath at 40 degrees C. Separation of the two phases was accomplished by centrifugation for 15 min at 4000 rpm. The chemical variables affecting the cloud-point extraction were evaluated, optimized and successfully applied to the nickel determination in various water samples. Under the optimized conditions, the preconcentration system of 100 ml sample permitted an enhancement factor of 50-fold. The detailed study of various interferences made the method more selective. The detection limits obtained under optimal condition was 0.042 ng ml(-1). The extraction efficiency was investigated at different nickel concentrations (20-80 ng ml(-1)) and good recoveries (99.05-99.93%) were obtained using present method. The proposed method has been applied successfully for the determination of nickel in various water samples and compared with reported method in terms of Student's t-test and variance ratio f-test which indicate the significance of present method over reported and spectrophotometric methods at 95% confidence level. (c) 2006 Elsevier B. V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevipattium@gmail.com
CR Ali A, 1999, ANAL CHIM ACTA, V392, P283, DOI 10.1016/S0003-2670(99)00223-8
   Chen JR, 2001, ANAL CHIM ACTA, V450, P215, DOI 10.1016/S0003-2670(01)01367-8
   Chen JR, 2001, ANAL CHIM ACTA, V434, P325, DOI 10.1016/S0003-2670(01)00849-2
   da Silva MAM, 1998, J ANAL ATOM SPECTROM, V13, P1369, DOI 10.1039/a806309e
   da Silva MAM, 2001, SPECTROCHIM ACTA B, V56, P1941
   da Silva MAM, 2000, SPECTROCHIM ACTA B, V55, P803
   de Wuilloud JCA, 2002, SPECTROCHIM ACTA B, V57, P365, DOI 10.1016/S0584-8547(01)00393-7
   FAN ZF, 2003, MICROCHIM ACTA, V152, P29
   Ferreira SLC, 2001, ANAL CHIM ACTA, V445, P145, DOI 10.1016/S0003-2670(01)01262-4
   Giokas DL, 2001, J ANAL ATOM SPECTROM, V16, P521, DOI 10.1039/b010055m
   Giokas DL, 2002, TALANTA, V56, P415, DOI 10.1016/S0039-9140(01)00564-1
   Kristiansen J, 2000, ANAL CHIM ACTA, V403, P265, DOI 10.1016/S0003-2670(99)00568-1
   Liang P, 2005, MICROCHIM ACTA, V152, P47, DOI 10.1007/s00604-005-0415-7
   Luconi MO, 2000, TALANTA, V51, P123, DOI 10.1016/S0039-9140(99)00252-0
   Manzoori JL, 2002, MICROCHEM J, V72, P1, DOI 10.1016/S0026-265X(01)00113-8
   Manzoori JL, 2003, ANAL SCI, V19, P579, DOI 10.2116/analsci.19.579
   Manzoori JL, 2002, ANAL CHIM ACTA, V470, P215, DOI 10.1016/S0003-2670(02)00765-1
   Manzoori JL, 2003, MICROCHIM ACTA, V141, P201, DOI 10.1007/s00604-002-0945-1
   Oliveros MCC, 1998, J ANAL ATOM SPECTROM, V13, P547, DOI 10.1039/a801635f
   Paleologos EK, 2001, ANAL CHIM ACTA, V436, P49, DOI 10.1016/S0003-2670(01)00884-4
   Paleologos EK, 2001, ANALYST, V126, P389, DOI 10.1039/b009521b
   Paleologos EK, 2000, J ANAL ATOM SPECTROM, V15, P287, DOI 10.1039/a908974h
   Sanz-Medel A, 1999, SPECTROCHIM ACTA B, V54, P251, DOI 10.1016/S0584-8547(98)00241-9
   Saracoglu S, 2002, ANAL CHIM ACTA, V452, P77, DOI 10.1016/S0003-2670(01)01425-8
   Shuyu Chen, 2002, Analytica Chimica Acta, V451, P305, DOI 10.1016/S0003-2670(01)01401-5
   Silva MF, 1998, ANALYST, V123, P1803, DOI 10.1039/a804789h
   Sombra L, 2001, ANALYST, V126, P1172, DOI 10.1039/b009251g
   Stalikas CD, 2002, TRAC-TREND ANAL CHEM, V21, P343, DOI 10.1016/S0165-9936(02)00502-2
   Suvardhan K, 2004, J HAZARD MATER, V112, P233, DOI 10.1016/j.jhazmat.2004.05.003
   TEMPLETON D, 1990, BIOL MONITORING CHEM
   Teo KC, 2001, ANALYST, V126, P534, DOI 10.1039/b008717n
   Underwood EJ, 1977, TRACE ELEMENTS HUMAN
   Uzun A, 2001, TALANTA, V54, P197, DOI 10.1016/S0039-9140(00)00669-X
   YAN ZY, 1989, J ANAL ATOM SPECTROM, V4, P797, DOI 10.1039/ja9890400797
   Ye YX, 2002, TALANTA, V57, P945, DOI 10.1016/S0039-9140(02)00141-8
   YUZEFOVSKY AI, 1994, J ANAL ATOM SPECTROM, V9, P1195, DOI 10.1039/ja9940901195
NR 36
TC 16
Z9 17
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JUN 1
PY 2007
VL 144
IS 1-2
BP 126
EP 131
DI 10.1016/j.jhazmat.2006.10.001
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 178BV
UT WOS:000247197100016
PM 17110022
DA 2018-12-27
ER

PT J
AU Priya, BK
   Subrahmanayam, P
   Suvardhan, K
   Kumar, KS
   Rekha, D
   Rao, AV
   Rao, GC
   Chiranjeevi, P
AF Priya, B. Krishna
   Subrahmanayam, P.
   Suvardhan, K.
   Kumar, K. Suresh
   Rekha, D.
   Rao, A. Venkata
   Rao, G. C.
   Chiranjeevi, P.
TI RETRACTED: Cloud point extraction of palladium in water samples and
   alloy mixtures using new synthesized reagent with flame atomic
   absorption spectrometry (FAAS) (Retracted Article. See vol 153, pg 1320,
   2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE palladium; preconcentration; 4-(2-naphthalenyl)thiozol-2yl azo
   chromotropic acid (NTACA); cloud point extraction; flame atomic
   absorption spectrometry; water samples and alloys
ID SPECTROPHOTOMETRIC DETERMINATION; TRACE CADMIUM; ONLINE
   PRECONCENTRATION; ACTIVATED CARBON; COBALT; COPPER;
   1-(2-PYRIDYLAZO)-2-NAPHTHOL; 8-HYDROXYQUINOLINE; SURFACTANT; ENRICHMENT
AB The present paper outlines novel, simple and sensitive method for the determination of palladium by flame atomic absorption spectrometry (FAAS) after separation and preconcentration by cloud point extraction (CPE). The cloud point methodology was successfully applied for palladium determination by using new reagent 4-(2-naphthalenyl)thiozol-2yl azo chromotropic acid (NTACA) and hydrophobic ligand Triton X-114 as chelating agent and nonionic surfactant respectively in the water samples and alloys. The following parameters such as pH, concentration of the reagent and Triton X-114, equilibrating temperature and centrifuging time were evaluated and optimized to enhance the sensitivity and extraction efficiency of the proposed method. The preconcentration factor was found to be (50-fold) for 250 ml of water sample. Under optimum condition the detection limit was found as 0.067 ng ml(-1) for palladium in various environmental matrices. The present method was applied for the determination of palladium in various water samples, alloys and the result shows good agreement with reported method and the recoveries are in the range of 96.7-99.4%. (c) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevipattium@gmail.com
CR AbuBakr MS, 1996, INDIAN J CHEM A, V35, P69
   AKWAN S, 1992, J ANAL ATOM SPECTROM, V7, P187
   ANEGKI K, 1998, ANAL SCI, V14, P523
   Bakircioglu Y, 2000, SPECTROCHIM ACTA B, V55, P1129, DOI 10.1016/S0584-8547(00)00226-3
   Bruzzoniti MC, 2003, J CHROMATOGR A, V1007, P93, DOI 10.1016/S0021-9673(03)00931-2
   Cervera ML, 2003, ANAL BIOANAL CHEM, V375, P820, DOI 10.1007/s00216-003-1796-2
   Chen JR, 2005, TALANTA, V67, P992, DOI 10.1016/j.talanta.2005.04.029
   Chen JR, 2001, ANAL CHIM ACTA, V434, P325, DOI 10.1016/S0003-2670(01)00849-2
   Chen JR, 2001, ANAL LETT, V34, P2169, DOI 10.1081/AL-100106848
   CHHAKKAR AK, 1994, FRESEN J ANAL CHEM, V350, P127, DOI 10.1007/BF00323173
   Choi HS, 1996, B KOR CHEM SOC, V17, P338
   DAKSHINAMOORTHY A, 1994, J RADIOAN NUCL CH AR, V177, P327, DOI 10.1007/BF02061129
   Ferrer R, 1996, ANAL CHIM ACTA, V330, P199, DOI 10.1016/0003-2670(96)00176-6
   FULI Z, 1993, MICROCHEM J, V48, P104
   HIRAIDE M, 1994, ANAL SCI, V10, P505, DOI 10.2116/analsci.10.505
   Howard M, 1999, J ANAL ATOM SPECTROM, V14, P1209, DOI 10.1039/a903337h
   IVANOV VM, 1982, GETEROCIKLICESKIE AZ
   JHA A, 1993, J CHIN CHEM SOC-TAIP, V40, P351, DOI 10.1002/jccs.199300054
   KONAR B, 1994, FRESEN J ANAL CHEM, V348, P281, DOI 10.1007/BF00324034
   LAZARO F, 1988, ANAL CHIM ACTA, V214, P217, DOI 10.1016/S0003-2670(00)80443-2
   Liang P, 2005, MICROCHIM ACTA, V152, P47, DOI 10.1007/s00604-005-0415-7
   MALVANKAR PL, 1991, ANALYST, V116, P1081, DOI 10.1039/an9911601081
   Manzoori JL, 2003, ANAL SCI, V19, P579, DOI 10.2116/analsci.19.579
   Manzoori JL, 2003, MICROCHIM ACTA, V141, P201, DOI 10.1007/s00604-002-0945-1
   Mathew VJ, 1997, TALANTA, V44, P1699, DOI 10.1016/S0039-9140(97)00013-1
   MORE PS, 1994, ANAL LETT, V27, P1737, DOI 10.1080/00032719408007432
   Morozko S.A., 1995, ZH ANAL KHIM, V50, P629
   MOROZKO SA, 1996, ZH ANAL KHIM, V51, P631
   Ozcan M, 2002, ANAL LETT, V35, P1075, DOI 10.1081/AL-120004556
   PINTO CG, 1995, ANAL CHEM, V67, P2606
   SAKURABA S, 1994, FRESEN J ANAL CHEM, V349, P523, DOI 10.1007/BF00323986
   Sato K, 1999, BUNSEKI KAGAKU, V48, P261
   Savvin S.B., 2000, RUSS CHEM REV, V69, P187
   Shemirani F, 2005, INDIAN J CHEM A, V44, P1211
   Shemirani F, 2001, ANAL LETT, V34, P2179, DOI 10.1081/AL-100106849
   Sohrin Y, 2001, BUNSEKI KAGAKU, V50, P369, DOI 10.2116/bunsekikagaku.50.369
   Soylak M, 1998, FRESEN ENVIRON BULL, V7, P383
   Soylak M, 2004, KUWAIT J SCI ENG, V31, P47
   Soylak M, 2004, ASIAN J CHEM, V16, P1625
   Tang AN, 2005, TALANTA, V67, P942, DOI 10.1016/j.talanta.2005.04.016
   TERADA K, 1977, B CHEM SOC JPN, V50, P1060, DOI 10.1246/bcsj.50.1060
   Tokalioglu S, 2000, ANAL SCI, V16, P1169, DOI 10.2116/analsci.16.1169
   TRIPATHY H, 1975, J INDIAN CHEM SOC, V52, P168
   Warnken KW, 1999, J ANAL ATOM SPECTROM, V14, P247, DOI 10.1039/a806822d
   Yaman M, 1999, J ANAL ATOM SPECTROM, V14, P275, DOI 10.1039/a807432a
   Yuan CG, 2005, MICROCHIM ACTA, V150, P329, DOI 10.1007/s00604-005-0360-5
   ZHEFENG F, 2003, MICROCHIM ACTA, V152, P29
   ZHU YY, 1993, ANAL LETT, V26, P309, DOI 10.1080/00032719308017387
NR 48
TC 18
Z9 19
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JUN 1
PY 2007
VL 144
IS 1-2
BP 152
EP 158
DI 10.1016/j.jhazmat.2006.10.002
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 178BV
UT WOS:000247197100020
PM 17097229
DA 2018-12-27
ER

PT J
AU Johnson, CS
   Stapel, DA
AF Johnson, Camille S.
   Stapel, Diederik A.
TI RETRACTED: No pain, no gain: The conditions under which upward
   comparisons lead to better performance (Retracted article. See vol. 103,
   pg. 415, 2012)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE social comparison; self-affirmation; performance; motivation;
   self-evaluations
ID SOCIAL COMPARISONS; SELF-ESTEEM; ROLE-MODELS; IMPACT; MECHANISMS;
   CONTRAST; OTHERS; CREATIVITY; IDENTITY; BEHAVIOR
AB In 3 studies, the authors explored the relation between threatening upward social comparisons and performance. In an initial study, participants were exposed to comparison targets who either threatened or boosted self-evaluations and then completed a performance task. Participants exposed to the threatening target performed better than those in a control group, whereas those exposed to the nonthreatening target performed worse. In Study 2, self-affirmation prior to comparison with threatening targets eliminated performance improvements. In Study 3, performance improvements were found only when the performance domain was different from the domain of success of the comparison target. These boundary conditions suggest that increases in performance following social comparison arise from individuals' motivations to maintain and repair self-evaluations. Implications for the study of the behavioral consequences of social comparison are discussed.
C1 Stanford Univ, Grad Sch Business Behav Res, Stanford, CA 94305 USA.
   Tilburg Univ, Tilburg Inst Behav Econ Res, NL-5000 LE Tilburg, Netherlands.
RP Johnson, CS (reprint author), Stanford Univ, Grad Sch Business Behav Res, 518 Mem Way, Stanford, CA 94305 USA.
EM johnson.1967@osu.edu; d.a.stapel@uvt.ni
FU NIMH NIH HHS [T32 MH19728, F31 MH64238-01]
CR AKINOLA M, 2007, DARK SIDE CREATIVITY
   ALICKE MD, 1995, J PERS SOC PSYCHOL, V68, P804, DOI 10.1037//0022-3514.68.5.804
   Baumeister RF, 2003, PSYCHOL SCI, P1, DOI 10.1111/1529-1006.01431
   Beauregard KS, 2001, MOTIV EMOTION, V25, P135, DOI 10.1023/A:1010665926045
   Blanton H, 1999, J PERS SOC PSYCHOL, V76, P420, DOI 10.1037//0022-3514.76.3.420
   Collins RL, 1996, PSYCHOL BULL, V119, P51, DOI 10.1037//0033-2909.119.1.51
   CROCKER J, 1989, PSYCHOL REV, V96, P608, DOI 10.1037//0033-295X.96.4.608
   Dijksterhuis A, 1998, J PERS SOC PSYCHOL, V75, P862, DOI 10.1037//0022-3514.75.4.862
   DUNNING D, 2004, MOTIVES UNDERLYING S
   Finlay WML, 2001, EUR J SOC PSYCHOL, V31, P579, DOI 10.1002/ejsp.88
   FITZSIMONS GM, 2005, GOALS LABORS FRIENDS
   Friedman RS, 2001, J PERS SOC PSYCHOL, V81, P1001, DOI 10.1037//0022-3514.81.6.1001
   Jackson LA, 1996, J PERS SOC PSYCHOL, V70, P241, DOI 10.1037/0022-3514.70.2.241
   Johnson CS, 2007, EUR J SOC PSYCHOL, V37, P258, DOI 10.1002/ejsp.361
   JOHNSON CS, SELF IDENITY
   JOHNSON CS, 2007, UNPUB NOT ALL POSITI
   Lockwood P, 1997, J PERS SOC PSYCHOL, V73, P91, DOI 10.1037//0022-3514.73.1.91
   Lockwood P, 2002, J PERS SOC PSYCHOL, V82, P343, DOI 10.1037//0022-3514.82.3.343
   Lockwood P, 2002, J PERS SOC PSYCHOL, V83, P854, DOI 10.1037//0022-3514.83.4.854
   Major B., 1991, SOCIAL COMP CONT THE, P237
   Marx DM, 2002, PERS SOC PSYCHOL B, V28, P1183, DOI 10.1177/01461672022812004
   MCFARLIN DB, 1984, BASIC APPL SOC PSYCH, V5, P223, DOI 10.1207/s15324834basp0503_5
   MEDNICK SA, 1962, PSYCHOL REV, V69, P220, DOI 10.1037/h0048850
   Moskowitz GB, 1999, J PERS SOC PSYCHOL, V76, P911, DOI 10.1037/0022-3514.76.6.911
   Mussweiler T, 2004, J PERS SOC PSYCHOL, V87, P832, DOI 10.1037/0022-3514.87.6.832
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553
   SETA JJ, 1982, J PERS SOC PSYCHOL, V42, P281, DOI 10.1037/0022-3514.42.2.281
   SETA JJ, 1991, PERS SOC PSYCHOL B, V17, P560, DOI 10.1177/0146167291175011
   Sherman DK, 2002, CURR DIR PSYCHOL SCI, V11, P119, DOI 10.1111/1467-8721.00182
   Sigall H, 1998, Pers Soc Psychol Rev, V2, P218, DOI 10.1207/s15327957pspr0203_5
   Spencer SJ, 2005, J PERS SOC PSYCHOL, V89, P845, DOI 10.1037/0022-3514.89.6.845
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P860, DOI 10.1037/0022-3514.87.6.860
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Stapel DA, 2000, J PERS SOC PSYCHOL, V79, P1068, DOI 10.1037//0022-3514.79.6.1068
   STAPEL DA, IN PRESS EUROPEAN J
   Steele Claude, 1988, ADV EXPT SOCIAL PSYC, P261, DOI DOI 10.1016/S0065-2601(08)60229-4
   Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037//0003-066X.52.6.613
   Tesser A, 2000, PERS SOC PSYCHOL REV, V4, P290, DOI 10.1207/S15327957PSPR0404_1
   Tesser A., 1988, ADV EXPT SOCIAL PSYC, P181, DOI DOI 10.1016/S0065-2601(08)60227-0
   Turner J. C, 1979, SOCIAL PSYCHOL INTER, P33, DOI DOI 10.1016/S0065-2601(05)37005-5
   Wheeler L, 1997, Pers Soc Psychol Rev, V1, P54, DOI 10.1207/s15327957pspr0101_4
   WOOD JV, 1989, PSYCHOL BULL, V106, P231, DOI 10.1037//0033-2909.106.2.231
NR 43
TC 27
Z9 29
U1 2
U2 22
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD JUN
PY 2007
VL 92
IS 6
BP 1051
EP 1067
DI 10.1037/0022-3514.92.6.1051
PG 17
WC Psychology, Social
SC Psychology
GA 175CV
UT WOS:000246991100007
PM 17547488
DA 2018-12-27
ER

PT J
AU Chen, L
   Thung, SN
   Woo, SLC
AF Chen, Li
   Thung, Swan N.
   Woo, Savio L. C.
TI RETRACTED: Metabolic basis of sexual dimorphism in PKU mice after
   genome-targeted PAH gene therapy (Retracted article. See vol. 18, pg.
   2190, 2010)
SO MOLECULAR THERAPY
LA English
DT Article; Retracted Publication
ID SITE-SPECIFIC RECOMBINATION; PHAGE PHI-C31 INTEGRASE; MOUSE MODEL;
   PHENOTYPIC CORRECTION; PHENYLALANINE-HYDROXYLASE; HUMAN-CELLS;
   PHENYLKETONURIA; EXPRESSION; HYPERPHENYLALANINEMIA; VECTORS
AB We have previously reported a transgene delivery system based on phiBT1 bacteriophage integrase that results in targeted insertion of transgenes into mammalian genomes, and its use in the delivery of murine phenylalanine hydroxylase (PAH) complementary DNA (cDNA) into the hepatocytes of male phenylketonuria (PKU) mice, leading to a complete and permanent correction of their hyperphenylalaninemic phenotype. In this study, we report only partial phenotypic correction in female PKU mice, even though hepatic PAH activities in both sexes after gene treatment were similar. Daily injections of tetrahydrobiopterin (BH(4)), an essential co-factor for phenylalanine hydroxylation, in the gene-treated females led to complete correction of their PKU phenotype. After gonadectomy, serum phenylalanine levels in the gene-treated females were reduced to normal, whereas those in the gene-treated males remained unchanged. The sterile gene-treated PKU mice were subjected to daily sex hormone injections. Whereas the estradiol-treated sterile males developed hyperphenylalaninemia, the dihydrotestosterone-treated sterile females remained normal phenylalaninemic. The results indicate that it is estrogen that suppresses the steady-state levels of BH 4 in mouse hepatocytes that became limiting, which is the underlying mechanism for the observed sexual dimorphism in PKU mice after PAH gene treatment. Livers of the PAH gene-corrected PKU mice also appeared normal and without apparent pathologies.
C1 Mt Sinai Sch Med, Carl C Icahn Ctr Gene Therapy & Mol Med, Dept Gene & Cell Med, New York, NY 10029 USA.
   Mt Sinai Sch Med, Dept Pathol, New York, NY USA.
RP Woo, SLC (reprint author), Mt Sinai Sch Med, Carl C Icahn Ctr Gene Therapy & Mol Med, Dept Gene & Cell Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.
EM savio.woo@mssm.edu
CR Allen BG, 2005, NAT METHODS, V2, P975, DOI 10.1038/NMETH814
   Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787
   Chalberg TW, 2005, INVEST OPHTH VIS SCI, V46, P2140, DOI 10.1167/iovs.04-1252
   Chalberg TW, 2006, J MOL BIOL, V357, P28, DOI 10.1016/j.jmb.2005.11.098
   Chen L, 2005, P NATL ACAD SCI USA, V102, P15581, DOI 10.1073/pnas.0503877102
   Dafhnis-Calas F, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni192
   Dale Y, 2003, J CHROMATOGR B, V788, P1, DOI 10.1016/S1570-0232(02)01005-X
   Davidoff AM, 2003, BLOOD, V102, P480, DOI 10.1182/blood-2002-09-2889
   Ding Z, 2006, GENE THER, V13, P587, DOI 10.1038/sj.gt.3302684
   Ehrhardt A, 2005, MOL THER, V11, P695, DOI 10.1016/j.ymthe.2005.01.010
   EISENSMITH RC, 1995, ADV GENET, V32, P199
   FANG B, 1994, GENE THER, V1, P247
   Ginsburg DS, 2005, ADV GENET, V54, P179, DOI 10.1016/S0065-2660(05)54008-2
   Gregory MA, 2003, J BACTERIOL, V185, P5320, DOI 10.1128/JB.185.17.5320-5323.2003
   Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775
   Harding CO, 2006, GENE THER, V13, P457, DOI 10.1038/sj.gt.3302678
   Held PK, 2005, MOL THER, V11, P399, DOI 10.1016/j.ymthe.2004.11.001
   Ishikawa Y, 2006, J GENE MED, V8, P646, DOI 10.1002/jgm.891
   Khan MS, 2005, TRENDS PLANT SCI, V10, P1, DOI 10.1016/j.tplants.2004.11.001
   Koch R, 2005, MOL GENET METAB, V86, pS139, DOI 10.1016/j.ymgme.2005.09.004
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   LORIJN RHW, 1981, EUR J OBSTET GYN R B, V12, P281, DOI 10.1016/0028-2243(81)90050-2
   Lutz KA, 2004, PLANT J, V37, P906, DOI 10.1111/j.1365-313X.2004.02015.x
   Malla S, 2005, NUCLEIC ACIDS RES, V33, P6101, DOI 10.1093/nar/gki922
   Mochizuki S, 2004, GENE THER, V11, P1081, DOI 10.1038/sj.gt.3302262
   Nakayama G, 2006, MOL GENET GENOMICS, V275, P1, DOI 10.1007/s00438-005-0026-3
   Oh HJ, 2004, PEDIATR RES, V56, P278, DOI 10.1203/01.PDR.0000132873.29067.0E
   Olivares EC, 2001, GENE, V278, P167, DOI 10.1016/S0378-1119(01)00711-9
   Ortiz-Urda S, 2003, HUM GENE THER, V14, P923, DOI 10.1089/104303403765701204
   PENG H, 1988, P NATL ACAD SCI USA, V85, P8146, DOI 10.1073/pnas.85.21.8146
   Quenneville SP, 2004, MOL THER, V10, P679, DOI 10.1016/j.ymthe.2004.05.034
   Sarkissian CN, 2000, MOL GENET METAB, V69, P188, DOI 10.1006/mgme.2000.2974
   Smith MCA, 2004, NUCLEIC ACIDS RES, V32, P2607, DOI 10.1093/nar/gkh538
   Stoll SM, 2002, J BACTERIOL, V184, P3657, DOI 10.1128/JB.184.13.3657-3663.2002
   Thomason LC, 2001, MOL GENET GENOMICS, V265, P1031, DOI 10.1007/s004380100498
   Thorpe HM, 1998, P NATL ACAD SCI USA, V95, P5505, DOI 10.1073/pnas.95.10.5505
   Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001
   Yang HY, 2002, J BACTERIOL, V184, P1859, DOI 10.1128/JB.184.7.1859-1864.2002
   Zheng JS, 2003, CIRCULATION, V108, P1238, DOI 10.1161/01.CIR.0000089082.40285.C3
NR 39
TC 14
Z9 14
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JUN
PY 2007
VL 15
IS 6
BP 1079
EP 1085
DI 10.1038/sj.mt.6300137
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 168WX
UT WOS:000246555800007
PM 17406346
OA Other Gold
DA 2018-12-27
ER

PT J
AU Barnett, RL
AF Barnett, Richard-Laurent
TI RETRACTED: Of difference contrived: The semiotics of sameness in J.-K.
   Huysmans' A 'Rebours' (Retracted article. See vol. 42, pg. 359, 2015)
SO NEOHELICON
LA English
DT Article; Retracted Publication
ID REBOURS
AB To postulate a poetic of desire is to invoke the comportments of difference. The call for difference breeds inevitably a radical encounter with failure. The multiplex problematic of text as posture sires repercussions in Huysmans's A rebours. The novel is Sustained by a series of tropes rescinded as the non-figurability of otherness calls for inscription by proxy. The pleasure of the text resides in the de-signifying power of representation.
C1 Univ Libre Bruxelles, B-1050 Brussels, Belgium.
RP Barnett, RL (reprint author), Univ Libre Bruxelles, 67 Rue Buye, B-1050 Brussels, Belgium.
EM RL_Barnett@msn.com
CR ANTOSH RB, 1986, REALITY ILLUSION NOV
   AUDOIN PH, 1985, HUYSMANS
   BARNETT RL, 1987, ESPRIT CREATEUR, V27, P39
   BARNETT RL, 1998, EUROPEAN STUDIES, P137
   BARNETT RL, 2005, ANALECTA MALACITANA, V18, P74
   BARNETT RL, 1997, DEGRES REV SYNTHESE, V36, P178
   BARNETT RL, 1999, RIVISTA LETT MODERN, V58, P212
   BARNETT RL, 1998, TEXTUALITIES, P84
   Barthes Roland, 1973, PLAISIR TEXTE
   BERNHEIMER C, 1984, ROMANTISME, V14, P105, DOI 10.3406/roman.1984.4704
   BRUNEL P, 1985, HUYSMANS
   CIRILLO VD, 1983, ANN I UNIVERSITARIO, V25, P651
   COGNY P, 1987, ECRITURE ECRITURE
   DE MAN P., 1979, ALLEGORIES READING
   FUMAROLI M, 1977, REBOURS, P17
   GAILLARD F, 1980, ESPRIT DECADENCE, V1
   GASHCE R, 1988, YALE FRENCH STUDIES, V74, P183
   GAVIRIA RC, 1980, QUIMERA, V2, P53
   GENTTE G, 1987, SEUILS
   Huysmans Joris-Karl, 1977, A REBOURS
   KINGCAID RA, 1987, ESPRIT CREATEUR, V27, P68
   KRISTEVA J, 1966, TEL QUEL, P51
   LEVIN MS, 1996, HUYSMANS VOID
   LLOYD C, 1998, DURHAM U J, V81, P111
   LOOMIS JB, 1984, NINETEEN CENT FR ST, V12, P147
   MILLER JH, 1986, TEXTUAL ANAL SOME RE, P167
   PORTER LM, 1987, AM IMAGO, V44, P51
   PRZYBOS J, 1985, ESPRIT CREATEUR, V25, P105
   RIFFATERRE M, 1979, PRODUTION TEXTE
   Riffaterre Michael, 1978, SEMIOTICS POETRY
   VILCOT JP, 1980, ESPRIT DECADENCE, V1
   ZIEGLER RE, 1986, FORUM MOD LANG STUD, V22, P365, DOI 10.1093/fmls/22.4.365
   1976, PENSEES
NR 33
TC 1
Z9 1
U1 2
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD JUN
PY 2007
VL 34
IS 1
BP 137
EP 143
DI 10.1007/s11059-007-1013-y
PG 7
WC Literature
SC Literature
GA 176JM
UT WOS:000247081000012
DA 2018-12-27
ER

PT J
AU Ma, JF
   Peng, LW
   Guo, JK
   Lu, QT
   Lu, CM
   Zhang, LX
AF Ma, Jinfang
   Peng, Lianwei
   Guo, Jinkui
   Lu, Qingtao
   Lu, Congming
   Zhang, Lixin
TI RETRACTED: LPA2 is required for efficient assembly of photosystem II in
   Arabidopsis thaliana (Retracted article. See vol.28, pg. 3061, 2016)
SO PLANT CELL
LA English
DT Article; Retracted Publication
ID CHLOROPLAST GENE-EXPRESSION; OXYGEN-EVOLVING CENTER; ENCODED D1 PROTEIN;
   CHLAMYDOMONAS-REINHARDTII; SPLIT-UBIQUITIN; CHLOROPHYLL-A; IN-VIVO;
   MEMBRANE; COMPLEXES; NUCLEAR
AB To elucidate the molecular mechanism of photosystem II ( PSII) assembly, we characterized the low psii accumulation2 (lpa2) mutant of Arabidopsis thaliana, which is defective in the accumulation of PSII supercomplexes. The levels and processing patterns of the RNAs encoding the PSII subunits are unaltered in the mutant. In vivo protein-labeling experiments showed that the synthesis of CP43 ( for chlorophyll a binding protein) was greatly reduced, but CP47, D1, and D2 were synthesized at normal rates in the lpa2-1 mutant. The newly synthesized CP43 was rapidly degraded in lpa2-1, and the turnover rates of D1 and D2 were higher in lpa2-1 than in wild-type plants. The newly synthesized PSII proteins were assembled into PSII complexes, but the assembly of PSII was less efficient in the mutant than in wild-type plants. LPA2 encodes an intrinsic thylakoid membrane protein, which is not an integral subunit of PSII. Yeast two-hybrid assays indicated that LPA2 interacts with the PSII core protein CP43 but not with the PSII reaction center proteins D1 and D2. Moreover, direct interactions of LPA2 with Albino3 (Alb3), which is involved in thylakoid membrane biogenesis and cell division, were also detected. Thus, the results suggest that LPA2, which appears to form a complex with Alb3, is involved in assisting CP43 assembly within PSII.
C1 Chinese Acad Sci, Photosynth Res Ctr, Key Lab Photosynth & Environm Mol Physiol, Inst Bot, Beijing 100093, Peoples R China.
   Natl Plant Gene Res Ctr, Beijing 100093, Peoples R China.
RP Zhang, LX (reprint author), Chinese Acad Sci, Photosynth Res Ctr, Key Lab Photosynth & Environm Mol Physiol, Inst Bot, Beijing 100093, Peoples R China.
EM zhanglixin@ibcas.ac.cn
CR ADIR N, 1990, J BIOL CHEM, V265, P12563
   Barkan A, 2000, BIOCHIMIE, V82, P559, DOI 10.1016/S0300-9084(00)00602-7
   BARKAN A, 1988, EMBO J, V7, P2637, DOI 10.1002/j.1460-2075.1988.tb03116.x
   Bellafiore S, 2002, PLANT CELL, V14, P2303, DOI 10.1105/tpc.003442
   BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175
   BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, V4, P113
   Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x
   DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991
   Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087
   Gohre V, 2006, PLANT CELL, V18, P1454, DOI 10.1105/tpc.105.038695
   GoldschmidtClermont M, 1998, INT REV CYTOL, V177, P115
   Guo JK, 2005, FEBS LETT, V579, P3619, DOI 10.1016/j.febslet.2005.05.049
   Hager M, 2002, J BIOL CHEM, V277, P14031, DOI 10.1074/jbc.M112053200
   Hankamer B, 1999, NAT STRUCT BIOL, V6, P560, DOI 10.1038/9341
   Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x
   Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X
   Iwata S, 2004, CURR OPIN STRUC BIOL, V14, P447, DOI 10.1016/j.sbi.2004.07.002
   JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315
   Jensen ON, 1999, METH MOL B, V112, P513
   Klostermann E, 2002, BIOCHEM J, V368, P777, DOI 10.1042/BJ20021291
   Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leister D, 2003, TRENDS GENET, V19, P47, DOI 10.1016/S0168-9525(02)00003-3
   Lennartz K, 2001, PLANT CELL, V13, P2539, DOI 10.1105/tpc.13.11.2539
   Lima A, 2006, P NATL ACAD SCI USA, V103, P12631, DOI 10.1073/pnas.0605452103
   LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x
   Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224
   Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055
   Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286
   Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529
   Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365
   NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109
   Nelson N, 2006, ANNU REV PLANT BIOL, V57, P521, DOI 10.1146/annurev.arplant.57.032905.105350
   Ossenbuhl F, 2006, PLANT CELL, V18, P2236, DOI 10.1105/tpc.106.043646
   Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226
   Pasch JC, 2005, APPL MICROBIOL BIOT, V69, P440, DOI 10.1007/s00253-005-0029-3
   Peltier JB, 2004, J BIOL CHEM, V279, P49367, DOI 10.1074/jbc.M406763200
   Peng LW, 2006, PLANT CELL, V18, P955, DOI 10.1105/tpc.105.037689
   Plucken H, 2002, FEBS LETT, V532, P85, DOI 10.1016/S0014-5793(02)03634-7
   PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0
   Rochaix JD, 2001, PLANT PHYSIOL, V127, P1394, DOI 10.1104/pp.127.4.1394
   ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x
   Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098
   SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Spence E, 2004, J BIOL CHEM, V279, P55792, DOI 10.1074/jbc.M411041200
   Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187
   Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717
   Suorsa M, 2004, EUR J BIOCHEM, V271, P96, DOI 10.1046/j.1432-1033.2003.03906.x
   Swiatek M, 2001, PLANT CELL, V13, P1347, DOI 10.1105/tpc.13.6.1347
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504
   vanWijk KJ, 1997, BIOCHEMISTRY-US, V36, P6178, DOI 10.1021/bi962921l
   Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003
   Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2
   YU JJ, 1990, PLANT CELL, V2, P315
   YU JJ, 1993, J BIOL CHEM, V268, P7407
   Zhang LX, 1999, J BIOL CHEM, V274, P16062, DOI 10.1074/jbc.274.23.16062
   Zhang LX, 2002, FEBS LETT, V512, P13, DOI 10.1016/S0014-5793(02)02218-4
   Zhang LX, 2000, PLANT CELL, V12, P1769, DOI 10.1105/tpc.12.9.1769
   Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589
NR 62
TC 59
Z9 69
U1 5
U2 22
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
EI 1532-298X
J9 PLANT CELL
JI Plant Cell
PD JUN
PY 2007
VL 19
IS 6
BP 1980
EP 1993
DI 10.1105/tpc.107.050526
PG 14
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA 195ZV
UT WOS:000248451900019
PM 17601825
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Yusoff, ARM
   Syahrul, MN
   Henkel, K
AF Yusoff, A. R. M.
   Syahrul, M. N.
   Henkel, K.
TI RETRACTED: High resolution transmission electron microscope studies of
   a-Si : H solar cells (Retracted article. See vol. 81, pg. 1069, 2013)
SO PRAMANA-JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
DE hydrogenated amorphous silicon; hydrogen dilution; low substrate
   temperature
ID OPEN-CIRCUIT VOLTAGE
AB Hydrogenated amorphous silicon (a-Si:H) single junction solar cells with high open circuit voltage (V-oc) are fabricated using a wide bandgap boron-doped Si:H p-layer deposited at high hydrogen dilution, low substrate temperature and with H-2-plasma treatment that promotes nanocrystalline silicon (nc-Si:H) formation. This paper presents the structure of this p-type material characterized by high resolution transmission electron microscope (HRTEM). It is found that the p-layer that leads to high Voc a-Si:H solar cells is a mixed-phase material that contains fine-grained nc-Si:H embedded in a-Si:H matrix.
C1 Univ Sci Malaysia, Dept Phys, George Town, Malaysia.
RP Yusoff, ARM (reprint author), Univ Sci Malaysia, Dept Phys, George Town, Malaysia.
EM abdrashid_4@yahoo.com
CR GUHA S, 1986, APPL PHYS LETT, V49, P218, DOI 10.1063/1.97176
   Koval RJ, 2002, APPL PHYS LETT, V81, P1258, DOI 10.1063/1.1499735
   LIAO X, 2002, P 29 IEEE PVSC, P1234
   WANG W, 2002, P 29 IEEE PVSC, P1082
NR 4
TC 1
Z9 1
U1 3
U2 10
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0304-4289
EI 0973-7111
J9 PRAMANA-J PHYS
JI Pramana-J. Phys.
PD JUN
PY 2007
VL 68
IS 6
BP 995
EP 999
DI 10.1007/s12043-007-0098-1
PG 5
WC Physics, Multidisciplinary
SC Physics
GA 218HZ
UT WOS:000250007900011
DA 2018-12-27
ER

PT J
AU Basic-Jukic, N
   Hrsak-Puljic, I
   Kes, P
   Bubic-Filipi, L
   Pasini, J
   Hudolin, T
   Kastelan, Z
   Reiner, Z
   Kordic, M
   Brunetta, B
   Juric, I
AF Basic-Jukic, N.
   Hrsak-Puljic, I.
   Kes, P.
   Bubic-Filipi, L.
   Pasini, J.
   Hudolin, T.
   Kastelan, Z.
   Reiner, Z.
   Kordic, M.
   Brunetta, B.
   Juric, I.
TI RETRACTED: Renal transplantation in patients with Balkan endemic
   nephropathy (Retracted article. See vol. 43, pg. 1365, 2011)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Retracted Publication
ID DISEASE
AB Background. Balkan endemic nephropathy (BEN) is a chronic tubulointerstitial disease prevalent in Croatia, Romania, Bulgaria, Bosnia and Herzegovina, and Serbia. In addition to renal disease, an increased incidence of upper urothelial carcinomas (UUCs) has been observed in the foci of BEN. Carcinoma may occur alone or in combination with BEN. Immunosuppression is associated with an increased risk for development of different malignancies. There are no data in the literature about the outcome of patients with BEN after transplantation.
   Methods. We performed a retrospective evaluation of the database and review of the charts and pathology reports of 601 renal transplant recipients treated at our institution. Results. From January 1995 to December 2004, kidney transplantations were performed in nine patients with BEN. One-year graft survival was 100%. A man, who was transplanted in 1997 died 2 years after transplantation with a functioning graft due to disseminated cancer from the pelvis of his own kidney. A female patient developed UCC 2 years after transplantation. They were both treated with a bolus of methylprednisolone before transplantation, because of four HLA-mismatches. A male patient developed UCC in the native and transplanted kidneys. He underwent a native nephroureterectomy with partial nephroureterectomy of transplanted kidney. His graft function was preserved with decreased immunosuppression. Three years later a urinary bladder carcinoma was discovered on a regularly performed multislice computed tomography. One patient developed a skin malignancy. Other patients have had uneventful posttransplantation courses with excellent graft function. Thus, 33.3% of patients with BEN developed UUC, compared with a 0.67% prevalence of urinary tract tumors among transplanted patients with other causes of end-stage renal disease.
   Conclusion. Patients with BEN are at increased risk for the development of UCC after transplantation. Regular screening for early detection of malignancy is mandatory. Longer follow-up and results from other transplant centers are needed to further investigate the relationship between BEN and UCC after renal transplantation.
C1 UHC Zagreb, Dept Dialysis, Zagreb 10000, Croatia.
RP Basic-Jukic, N (reprint author), UHC Zagreb, Dept Dialysis, Kispaticeva 12, Zagreb 10000, Croatia.
CR Boskovic S, 1977, Med Arh, V31, P375
   Briggs JD, 2001, NEPHROL DIAL TRANSPL, V16, P1545, DOI 10.1093/ndt/16.8.1545
   Ceovic S, 1976, Lijec Vjesn, V98, P301
   Cvoriscec D, 1998, CLIN CHEM LAB MED, V36, P271, DOI 10.1515/CCLM.1998.046
   Djukanovic L, 2002, INT J ARTIF ORGANS, V25, P852
   FERLUGA D, 1996, ZAGREBI ACAD CROAT S, P17
   Fuchs R., 1996, ENDEMIC NEPHROPATHY, P31
   Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1
   NIKOLOV I G, 1990, Journal of Environmental Pathology Toxicology and Oncology, V10, P317
   PENN I, 1977, Urology, V10, P57
   PENN I, 1986, CANC TRANSPLANTATION, P3
   PETRINSKAVENKOV.S, 1969, INT S END NEPHR SOF, P95
   Petronic V., 2002, FACTA U, V9, P98
   Petronic V.J., 1991, KIDNEY INT S34, V34, P77
   PICHLER O, 1959, LIJEC VJESN, V81, P295
   Radovanovic Z, 1991, KIDNEY INT S34, V34, P75
   YANG TC, 1998, CHUNG HUA I HSUEH TS, V61, P281
   2003, CROATIAN REGISTRY RE
NR 18
TC 11
Z9 12
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2007
VL 39
IS 5
BP 1432
EP 1435
DI 10.1016/j.transproceed.2006.11.019
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 185LJ
UT WOS:000247712200030
PM 17580155
DA 2018-12-27
ER

PT J
AU Lagaud, GJ
   Young, A
   Acena, A
   Morton, MF
   Barrett, TD
   Shankley, NP
AF Lagaud, Guy J.
   Young, Andy
   Acena, Auzon
   Morton, Magda F.
   Barrett, Terrance D.
   Shankley, Nigel P.
TI RETRACTED: Obestatin reduces food intake and suppresses body weight gain
   in rodents (Retracted article. See vol. 388, pg. 619, 2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE obestatin; ghrelin; feeding; body weight; obesity; endocrine
ID GROWTH-HORMONE-SECRETION; COUPLED RECEPTOR GPR39; GHRELIN; RATS;
   PYY3-36; MODIFY
AB Obestatin was recently described as a bioactive peptide encoded for by the same gene as ghrelin but with opposite actions on food intake. Although some groups have confirmed these findings others find no effect. We investigated the effect of obestatin on feeding in rodents over a wide range of doses. Acute administration of obestatin inhibited feeding at doses of 10-100 nmol/kg i.p. in mice and 100-300 nmol/kg i.p. in lean and Zucker fatty rats. Interestingly, the dose-response relationship was U-shaped such that both low and high doses were without effect in either species. Treatment of mice with obestatin over a 7-day period decreased body weight gain and food consumption. Overall, obestatin suppressed food intake and body weight gain in rodent and an unusual dose-response relationship was found. These findings may explain the difficulties in reproducing the effects of obestatin on feeding reported by some groups. (c) 2007 Elsevier Inc. All rights reserved.
C1 Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA.
RP Lagaud, GJ (reprint author), Johnson & Johnson Pharmaceut Res & Dev LLC, 3210 Merryfield Row, San Diego, CA 92121 USA.
EM Glagaud@prdus.jnj.com
CR Abbott CR, 2006, INT J OBESITY, V30, P288, DOI 10.1038/sj.ijo.0803137
   Bassil AK, 2007, BRIT J PHARMACOL, V150, P58, DOI 10.1038/sj.bjp.0706969
   Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887
   Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204
   Boggiano MM, 2005, OBES REV, V6, P307, DOI 10.1111/j.1467-789X.2005.00218.x
   Bresciani E, 2006, J ENDOCRINOL INVEST, V29, pRC16, DOI 10.1007/BF03344175
   Camina JP, 2007, J CELL PHYSIOL, V211, P1, DOI 10.1002/icp.20925
   Carlini VP, 2007, BIOCHEM BIOPH RES CO, V352, P907, DOI 10.1016/j.bbrc.2006.11.112
   CHARTREL N, 2007, SCIENCE, V315, pC766, DOI DOI 10.1126/SCIENCE.1135047
   Choi SJ, 2002, BRAIN RES, V928, P30, DOI 10.1016/S0006-8993(01)03330-3
   Dun SL, 2006, J ENDOCRINOL, V191, P481, DOI 10.1677/joe.1.06944
   Gourcerol G, 2006, PEPTIDES, V27, P2811, DOI 10.1016/j.peptides.2006.07.012
   HOLST B, 2007, ENDOCRINOLOGY, V148, P13, DOI DOI 10.1210/EN.2006-0933
   Lauwers E, 2006, BIOCHEM BIOPH RES CO, V351, P21, DOI 10.1016/j.bbrc.2006.09.141
   Nogueiras R, 2007, ENDOCRINOLOGY, V148, P21, DOI 10.1210/en.2006.0915
   Samson WK, 2007, AM J PHYSIOL-REG I, V292, pR637, DOI 10.1152/ajpregu.00395.2006
   Seoane LM, 2006, J ENDOCRINOL INVEST, V29, pRC13, DOI 10.1007/BF03344174
   STALLONE DD, 1994, INT J OBESITY, V18, P679
   Stenstrom B, 2006, J GASTROINTEST SURG, V10, P1384, DOI 10.1016/j.gassur.2006.07.005
   Szentirmai E, 2006, NEUROSCI LETT, V404, P222, DOI 10.1016/j.neulet.2006.05.053
   Tremblay F, 2007, ENDOCRINOLOGY, V148, P501, DOI 10.1210/en.2006-1275
   Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090
   Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325
   Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255
   ZHANG JV, 2007, SCIENCE, V315, pC766
   Zizzari P, 2007, ENDOCRINOLOGY, V148, P1648, DOI 10.1210/en.2006-1231
NR 26
TC 102
Z9 109
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 25
PY 2007
VL 357
IS 1
BP 264
EP 269
DI 10.1016/j.bbrc.2007.03.138
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 161PW
UT WOS:000246028800043
PM 17418097
DA 2018-12-27
ER

PT J
AU Thati, B
   Noble, A
   Creaven, BS
   Walsh, M
   McCann, M
   Kavanagh, K
   Devereux, M
   Egan, DA
AF Thati, Bhumika
   Noble, Andy
   Creaven, Bernadette S.
   Walsh, Maureen
   McCann, Malachy
   Kavanagh, Kevin
   Devereux, Michael
   Egan, Denise A.
TI RETRACTED: A study of the role of apoptotic cell death and cell cycle
   events mediating the mechanism of action of
   6-hydroxycoumarin-3-carboxylatosilver in human malignant hepatic cells
   (Retracted article. See vol. 337, pg. 146, 2013)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE coumarin-3-carboxylic acid; silver complex; apoptotic cell death;
   chemotherapeutic potential; cyto-selectivity
ID ACTIVATED PROTEIN-KINASE; IN-VITRO; COUMARIN DERIVATIVES;
   MELANOMA-CELLS; COMPLEXES; CYTOTOXICITY; PATHWAYS; SERIES
AB Previously our research group has studied the anti-proliferative effects of a series of hydroxylated derivatives and silver (1) complexes of coumarin-3-carboxylic acid (C-3-COOH) using two human-derived carcinoma cell lines (A-498 and Hep-G2). Results obtained suggested that both hydroxylation and complexation with silver served to significantly augment the cytotoxic properties of C-3-COOH, to yield a compound, namely 6-hydroxycoumarin-3-carboxylatosilver (6-OH-C-COO-Ag) which could act as a potent and cyto-selective agent, capable of killing cancer cells, and with limited toxicity to cells derived from normal tissue. Here we seek to expand on these findings by probing the molecular mechanism underlying this effect. Results from cytological staining clearly illustrated cellular changes consistent with the induction of apoptotic cell death and which occurred 24 h post-drug-treatment. Additionally, electrophoretic analysis of genomic DNA showed the presence of a ladder pattern, characteristic of apoptotic cell death. This result was subsequently confirmed using a selection of biochemical assays, where increased activity of pro-apoptotic caspases 3 and 9, and increased cleavage of poly(ADP-ribose)-polymerase protein (PARP) were observed. This result was further underpinned by the appearance of a sub-G(1) peak, representing hypo-diploid cells, using flow cytometric analysis. Furthermore, 6-OH-C-COO-Ag was seen to function through an alteration in the percentage of cells entering the G(0)/G(1) phase of cell cycle. Consequently, 6-OH-C-COO-Ag has been shown to a more potent and selective anti-cancer agent than cisplatin, capable of altering key biochemical events leading to the execution of apoptotic cell death as early as 24 h post-treatment, suggesting that it may represent a novel therapeutic agent for the safe and effective treatment of cancer in man. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Ctr Pharmaceut Res & Dev, Inst Technol, Dublin 24, Ireland.
   Inst Technol, Dept Sci, Dublin, Ireland.
   Natl Univ Ireland, Dept Chem, Maynooth, Kildare, Ireland.
   Natl Univ Ireland, Dept Biol, Maynooth, Kildare, Ireland.
   Dublin Inst Technol, Dublin 1, Ireland.
RP Egan, DA (reprint author), Ctr Pharmaceut Res & Dev, Inst Technol, Dublin 24, Ireland.
EM denise.egan@ittdublin.ie
OI Kavanagh, Kevin/0000-0003-3186-0292
CR Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4
   COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058
   Creaven BS, 2006, INORG CHIM ACTA, V359, P3976, DOI 10.1016/j.ica.2006.04.006
   EGAN D, 1990, DRUG METAB REV, V22, P503, DOI 10.3109/03602539008991449
   Egan D, 1997, CANCER LETT, V118, P201, DOI 10.1016/S0304-3835(97)00331-5
   Finn GJ, 2005, EUR J PHARM SCI, V26, P16, DOI 10.1016/j.ejps.2005.04.016
   Finn GJ, 2004, CANCER LETT, V214, P43, DOI 10.1016/j.canlet.2004.04.022
   Finn GJ, 2004, BIOCHEM PHARMACOL, V67, P1779, DOI 10.1016/j.bcp.2004.01.014
   Finn GJ, 2001, MELANOMA RES, V11, P461, DOI 10.1097/00008390-200110000-00004
   FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P382
   FRICKER PS, 1994, METAL COMPOUNDS CANC, P10
   Hayes JD, 1998, CHEM-BIOL INTERACT, V112, P51, DOI 10.1016/S0009-2797(97)00151-8
   Hofmanova J, 1998, EUR J PHARMACOL, V350, P273, DOI 10.1016/S0014-2999(98)00264-7
   Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200
   Hoult JRS, 1996, GEN PHARMACOL-VASC S, V27, P713, DOI 10.1016/0306-3623(95)02112-4
   Jimenez-Orozco FA, 1999, MELANOMA RES, V9, P243, DOI 10.1097/00008390-199906000-00005
   KARTNER N, 1993, CANCER RES, V53, P3976
   KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P224
   Kokotos G, 1997, BIOORG MED CHEM LETT, V7, P2165, DOI 10.1016/S0960-894X(97)00384-3
   Kolodziej H, 1997, Z NATURFORSCH C, V52, P240
   Kostova I, 2001, ARCH PHARM, V334, P157, DOI 10.1002/1521-4184(200105)334:5<157::AID-ARDP157>3.0.CO;2-S
   Laurin P, 1999, BIOORG MED CHEM LETT, V9, P2079, DOI 10.1016/S0960-894X(99)00329-7
   MANALOV I, 2002, ARCH PHARM MED CHEM, V333, P93
   MARSHALL ME, 1986, AM SOC ONCOL, V5, P186
   MARSHALL ME, 1994, J CANCER RES CLIN, V120, P535
   Marzano C, 2002, TOXICOL IN VITRO, V16, P413, DOI 10.1016/S0887-2333(02)00022-X
   MAUCHER A, 1993, J CANCER RES CLIN, V119, P150, DOI 10.1007/BF01229529
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Murray R.D., 1982, NATURAL COUMARINS OC, P1
   Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834
   Nunez R, 2001, Curr Issues Mol Biol, V3, P67
   Pillai SP, 1999, J NAT PROD, V62, P1358, DOI 10.1021/np990048u
   SHARMA S, 1994, CANCER RES, V54, P5848
   THATI B, 2006, IN PRESS CANC LETT
NR 34
TC 19
Z9 19
U1 3
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 18
PY 2007
VL 250
IS 1
BP 128
EP 139
DI 10.1016/j.canlet.2006.10.015
PG 12
WC Oncology
SC Oncology
GA 164UM
UT WOS:000246260100015
PM 17126993
DA 2018-12-27
ER

PT J
AU Okudaira, T
   Hirashima, M
   Ishikawa, C
   Makishi, S
   Tomita, M
   Matsuda, T
   Kawakami, H
   Taira, N
   Ohshiro, K
   Masuda, M
   Takasu, N
   Mori, N
AF Okudaira, Taeko
   Hirashima, Mitsuomi
   Ishikawa, Chie
   Makishi, Shoko
   Tomita, Mariko
   Matsuda, Takehiro
   Kawakami, Hirochika
   Taira, Naoya
   Ohshiro, Kazuiku
   Masuda, Masato
   Takasu, Nobuyuki
   Mori, Naoki
TI RETRACTED: A modified version of galectin-9 suppresses cell growth and
   induces apoptosis of human T-cell leukemia virus type I-infected T-cell
   lines (Retracted article. See vol. 129, pg. 2762, 2011)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE galectin-9; HTLV-I; ATL; NF-kappa B; apoptosis
ID NF-KAPPA-B; ONCOGENE PRODUCT TAX; CONSTITUTIVE ACTIVATION; HTLV-I;
   MONOCLONAL-ANTIBODY; GENE-EXPRESSION; PROTEIN; TRANSFORMATION;
   RETROVIRUS; INHIBITOR
AB ATL is a fatal malignancy of T lymphocytes caused by HTLV-I infection and remains incurable. Galectins are a family of animal lectins that function both extracellularly (by interacting with cell surface and extracellular matrix glycoproteins and glycolipids) and intracellularly (by interacting with cytoplasmic and nuclear proteins) to modulate signaling pathways. We found that protease-resistant galectin-9 by modification of its linker peptide, hG9NC(null), prevented cell growth of HTLV-I-infected T-cell lines and primary ATL cells. The suppression of cell growth was inhibited by lactose, but not by sucrose, indicating that beta-galactoside binding is essential for hG9NC(null) -induced cell growth suppression. hG9NC(null) induced cell cycle arrest by reducing the expression of cyclin D1, cyclin D2, cyclin B1, Cdk1, Cdk4, CA6, Cdc25C and c-Myc, and apoptosis by reducing the expression of XIAP, c-IAP2 and survivin. Most of these genes are regulated by NF-kappa B, which plays a critical role in oncogenesis by HTLV-I. hG9NC(null) suppressed 1 kappa B alpha phosphorylation, resulting in suppression of NF-kappa B. Most importantly, treatment with hG9NC(null) (6.7 mg/kg injected intraperitoneally every day) reduced tumor formation from an HTLV-I-infected T-cell line when these cells were inoculated subcutaneously into SCID mice. Our results suggest that hG9NC(null) could be a suitable agent for the management of ATL. (c) 2007 Wiley-Liss, Inc.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 90301, Japan.
   Kagawa Univ, Fac Med, Dept Immunol & Immunopathol, Miki, Kagawa, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 90301, Japan.
   Univ Ryukyus, Fac Med, Div Oral & Maxillofacial Funct Rehabil, Nishihara, Okinawa 90301, Japan.
   Heartlife Hosp, Dept Hematol, Okinawa, Japan.
   Okinawa Prefectural Nanbu Med Ctr, Dept Hematol, Okinawa, Japan.
   Childrens Med Ctr, Okinawa, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-morie@med.u-ryukyu.ac.jp
CR Arbel-Goren R, 2005, J BIOL CHEM, V280, P19105, DOI 10.1074/jbc.M502060200
   Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8
   Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057
   Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979
   Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Hinz M, 1999, MOL CELL BIOL, V19, P2690
   Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198
   Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304
   Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912
   Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976
   Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   Nishi N, 2005, FEBS LETT, V579, P2058, DOI 10.1016/j.febslet.2005.02.054
   Okudaira T, 2006, MOL CANCER THER, V5, P704, DOI 10.1158/1535-7163.MCT-05-0434
   PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519
   Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535
   Salvatore P, 2000, INT J ONCOL, V17, P1015
   Seth A, 1997, AIDS, V11, P1059
   Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595
   Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q
   Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211
   Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969
   Taylor GP, 2005, ONCOGENE, V24, P6047, DOI 10.1038/sj.onc.1208979
   Tomita M, 2006, LEUKEMIA RES, V30, P313, DOI 10.1016/j.leukres.2005.08.004
   Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416
   Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731
   Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429
   Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646
   YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Zhang CH, 1996, J IMMUNOL, V157, P3980
   Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271
NR 48
TC 21
Z9 22
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 15
PY 2007
VL 120
IS 10
BP 2251
EP 2261
DI 10.1002/ijc.22534
PG 11
WC Oncology
SC Oncology
GA 155GE
UT WOS:000245565100025
PM 17278100
OA Bronze
DA 2018-12-27
ER

PT J
AU Davis, AJ
   Im, YJ
   Dubin, JS
   Tomer, KB
   Boss, WF
AF Davis, Amanda J.
   Im, Yang Ju
   Dubin, Joshua S.
   Tomer, Kenneth B.
   Boss, Wendy F.
TI RETRACTED: Arabidopsis phosphatidylinositol phosphate kinase 1 binds
   F-actin and recruits phosphatidylinositol 4-kinase beta 1 to the actin
   cytoskeleton (Retracted article. See vol. 284, pg. 16060, 2009)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID PLECKSTRIN HOMOLOGY DOMAIN; POLLEN-TUBE GROWTH; ROOT HAIR-CELLS;
   PHOSPHOINOSITIDE METABOLISM; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; 5-KINASE;
   PROTEIN; ORGANIZATION; CYCLODEXTRINS
AB The actin cytoskeleton can be influenced by phospholipids and lipid-modifying enzymes. In animals the phosphatidylinositol phosphate kinases (PIPKs) are associated with the cytoskeleton through a scaffold of proteins; however, in plants such an interaction was not clear. Our approach was to determine which of the plant PIPKs interact with actin and determine whether the PIPK-actin interaction is direct. Our results indicate that AtPIPK1 interacts directly with actin and that the binding is mediated through a predicted linker region in the lipid kinase. AtPIPK1 also recruits AtPI4K beta 1 to the cytoskeleton. Recruitment of AtPI4K beta 1 to F-actin was dependent on the C-terminal catalytic domain of phosphatidylinositol-4-phosphate 5-kinase but did not require the presence of the N-terminal 251 amino acids, which includes 7 putative membrane occupation and recognition nexus motifs. In vivo studies confirm the interaction of plant lipid kinases with the cytoskeleton and suggest a role for actin in targeting PIPKs to the membrane.
C1 N Carolina State Univ, Raleigh, NC 27695 USA.
   NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
RP Boss, WF (reprint author), N Carolina State Univ, Box 7649, Raleigh, NC 27695 USA.
EM wendy_boss@ncsu.edu
CR ABE S, 1992, J EXP BOT, V43, P941, DOI 10.1093/jxb/43.7.941
   Boss Wendy E., 2006, V39, P181
   CARRAWAY KL, 1992, CYTOSKELETON PRACTIC, P47
   Davis AJ, 2004, J LIPID RES, V45, P1783, DOI 10.1194/jlr.D400005-JLR200
   Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787
   Dowd PE, 2006, PLANT CELL, V18, P1438, DOI 10.1105/tpc.106.041582
   Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008
   Fauvelle F, 1997, J PHARM SCI, V86, P935, DOI 10.1021/js9602453
   Gubbels MJ, 2006, J CELL SCI, V119, P2236, DOI 10.1242/jcs.02949
   Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C
   Heilmann I, 1999, PLANT PHYSIOL, V119, P1331, DOI 10.1104/pp.119.4.1331
   Helling D, 2006, PLANT CELL, V18, P3519, DOI 10.1105/tpc.106.047373
   Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4
   Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779
   Im YJ, 2007, J BIOL CHEM, V282, P5443, DOI 10.1074/jbc.M611342200
   Javierre I, 2002, J COLLOID INTERF SCI, V254, P120, DOI 10.1006/jcis.2002.8545
   Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200
   KARUPPIAH N, 1995, BIOCHEM BIOPH RES CO, V211, P60, DOI 10.1006/bbrc.1995.1778
   Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317
   Kovar DR, 2000, PLANT CELL, V12, P583, DOI 10.1105/tpc.12.4.583
   Kusner DJ, 2003, ARCH BIOCHEM BIOPHYS, V412, P231, DOI 10.1016/S0003-9861(03)00052-3
   Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624
   Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770
   OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B
   Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200
   Perera IY, 2005, FEBS LETT, V579, P3427, DOI 10.1016/j.febslet.2005.05.018
   Preuss ML, 2006, J CELL BIOL, V172, P991, DOI 10.1083/jcb.200508116
   Preuss ML, 2004, PLANT CELL, V16, P1589, DOI 10.1105/tpc.021634
   Shimada H, 2004, PLANT CELL PHYSIOL, V45, P960, DOI 10.1093/pcp/pch130
   Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4
   SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3
   Staiger CJ, 2006, CURR OPIN PLANT BIOL, V9, P554, DOI 10.1016/j.pbi.2006.09.013
   Staiger CJ, 1997, TRENDS PLANT SCI, V2, P275, DOI 10.1016/S1360-1385(97)86350-9
   Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761
   Stevenson-Paulik J, 2003, PLANT PHYSIOL, V132, P1053, DOI 10.1104/pp.103.021758
   Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2
   Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4
   TAN Z, 1992, PLANT PHYSIOL, V100, P2116, DOI 10.1104/pp.100.4.2116
   Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8
   Van Gestel K, 2002, J EXP BOT, V53, P659, DOI 10.1093/jexbot/53.369.659
   Vincent P, 2005, J CELL BIOL, V168, P801, DOI 10.1083/jcb.200412074
   Westergren T, 2001, BIOCHEM J, V359, P583, DOI 10.1042/0264-6021:3590583
   XU P, 1992, PLANT CELL, V4, P941
   Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867
   Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200
   Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517
   Zhong RQ, 2004, PLANT CELL, V16, P3242, DOI 10.1105/tpc.104.027466
NR 47
TC 14
Z9 14
U1 2
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 11
PY 2007
VL 282
IS 19
BP 14121
EP 14131
DI 10.1074/jbc.M611728200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 164PJ
UT WOS:000246245800022
PM 17379598
OA Bronze
DA 2018-12-27
ER

PT J
AU Stanca, I
AF Stanca, Ioan
TI RETRACTED: Intermodulation in microwave resonators on the basis of
   high-temperature superconductors (Retracted Article)
SO MODERN PHYSICS LETTERS B
LA English
DT Article; Retracted Publication
DE microwave resonators; intermodulation; HTSC; thin films
ID YBA2CU3O7-X THIN-FILMS; SURFACE-RESISTANCE; MICROSTRIP RESONATOR; FIELD;
   MICROSCOPY; DISTORTION; SAPPHIRE; LINES; GHZ
AB Generation of mixed frequency (intermodulation) in superconducting microwave resonators caused by HTSC-nonlinearity is theoretically investigated. The general ratio of the power of an intermodulation signal relative to the dynamic characteristics of the resonator, the physical parameters of HTSC, and the power of pumping waves are obtained. On the basis of the data available in the literature, the parameter describing nonlinearity of HTSC is estimated. The prospects of use of various types of resonators for diagnostics of HTSC-nonlinearity are analyzed.
C1 [Stanca, Ioan] Univ Oradea, Dept Phys, RO-410087 Oradea, Romania.
RP Stanca, I (reprint author), Univ Oradea, Dept Phys, RO-410087 Oradea, Romania.
EM istanca@uoradea.ro
CR Abu Bakar M, 2002, PHYSICA C, V372, P692, DOI 10.1016/S0921-4534(02)00833-X
   Andreone A, 2000, PHYSICA C, V341, P2687, DOI 10.1016/S0921-4534(00)01474-X
   Anlage SM, 1997, IEEE T APPL SUPERCON, V7, P3686, DOI 10.1109/77.622218
   COOKE DW, 1990, J SUPERCOND, V3, P261, DOI 10.1007/BF00625266
   Cruickshank D, 2003, J EUR CERAM SOC, V23, P2721, DOI 10.1016/S0955-2219(03)00145-6
   Dahm T, 1997, J APPL PHYS, V81, P2002, DOI 10.1063/1.364056
   Diete W, 1997, IEEE T APPL SUPERCON, V7, P1236, DOI 10.1109/77.620737
   DIETE W, 1995, APPL SUPERCOND, V2, P1107
   Golosovsky M, 1996, APPL PHYS LETT, V68, P1579, DOI 10.1063/1.116685
   Hein M, 1997, IEEE T APPL SUPERCON, V7, P1264, DOI 10.1109/77.620746
   Jacob MV, 2003, SUPERCOND SCI TECH, V16, P412, DOI 10.1088/0953-2048/16/3/315
   Lahl P, 2002, PHYSICA C, V372, P486, DOI 10.1016/S0921-4534(02)00728-1
   OATES DE, 1990, J SUPERCOND, V3, P251, DOI 10.1007/BF00625265
   OATES DE, 1991, IEEE T MICROW THEORY, V39, P1522, DOI 10.1109/22.83827
   Sheen DM, 1991, IEEE T APPL SUPERCON, V1, P108, DOI 10.1109/77.84617
   SHEN ZY, 1992, IEEE T MICROW THEORY, V40, P2424, DOI 10.1109/22.179912
   Takeuchi I, 1997, APPL PHYS LETT, V71, P2026, DOI 10.1063/1.119776
   Vendik OG, 1997, IEEE T MICROW THEORY, V45, P173, DOI 10.1109/22.557597
   WILKER C, 1995, IEEE T APPL SUPERCON, V5, P1665, DOI 10.1109/77.402896
   Willemsen BA, 1997, APPL PHYS LETT, V71, P3898, DOI 10.1063/1.120537
   Wunsch S, 2002, PHYSICA C, V372, P478, DOI 10.1016/S0921-4534(02)00726-8
NR 21
TC 0
Z9 0
U1 4
U2 9
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0217-9849
EI 1793-6640
J9 MOD PHYS LETT B
JI Mod. Phys. Lett. B
PD MAY 10
PY 2007
VL 21
IS 11
BP 679
EP 692
DI 10.1142/S0217984907012876
PG 14
WC Physics, Applied; Physics, Condensed Matter; Physics, Mathematical
SC Physics
GA 243LP
UT WOS:000251798700006
DA 2018-12-27
ER

PT J
AU Bulanova, E
   Budagian, V
   Duitman, E
   Orinska, Z
   Krause, H
   Ruckert, R
   Reiling, N
   Bulfone-Paus, S
AF Bulanova, Elena
   Budagian, Vadim
   Duitman, Erwin
   Orinska, Zane
   Krause, Hans
   Rueckert, Rene
   Reiling, Norbert
   Bulfone-Paus, Silvia
TI RETRACTED: Soluble interleukin (IL)-15R alpha is generated by
   alternative splicing or proteolytic cleavage and forms functional
   complexes with IL-15 (Retracted Article. See vol 286, pg 5934, 2011)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID RECEPTOR-ALPHA-CHAIN; T-CELLS; IN-VIVO; IDENTIFICATION; INFLAMMATION;
   ACTIVATION; EXPRESSION; PREVENTS; ISOFORMS; CLONING
AB Interleukin 15 (IL-15) is a pleiotropic cytokine that is hardly detectable in biological fluids. Here, we show that IL-15 forms functional heterocomplexes with soluble high affinity IL-15 receptor alpha (IL-15R alpha) chain in mouse serum and cell-conditioned medium, which prevents IL-15 detection by ELISA. We also demonstrate that two soluble IL-15R alpha (sIL-15R alpha) sushi domain isoforms are generated through a novel alternative splicing mechanism within the IL-15R alpha gene. These isoforms potentiate IL-15 action by promoting the IL-15-mediated proliferation of the CTLL cell line and interferon gamma production by murine NK cells, which suggests a role in IL-15 transpresentation. Conversely, a full-length sIL-15R alpha ectodomain released by tumor necrosis factor-alpha-converting enzyme (TACE)-dependent proteolysis inhibits IL-15 activity. Thus, a dual mechanism of sIL-15R alpha generation exists in mice, giving rise to polypeptides with distinct properties, which regulate IL-15 function.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Res Ctr Borstel, Dept Immunochem & Biochem Microbiol, D-23845 Borstel, Germany.
   Charite, Dept Urol, D-12200 Berlin, Germany.
RP Bulanova, E (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
EM ebulanova@fz-borstel.de
CR ANDERSON DM, 1995, J BIOL CHEM, V270, P29862
   Becknell B, 2005, ADV IMMUNOL, V86, P209, DOI 10.1016/S0065-2776(04)86006-1
   Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200
   Blum H, 1996, J IMMUNOL, V157, P1846
   Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669
   Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874
   Budagian V, 2006, CYTOKINE GROWTH F R, V17, P259, DOI 10.1016/j.cytogfr.2006.05.001
   Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045
   Bulfone-Paus S, 1999, FASEB J, V13, P1575
   Burkett PR, 2004, J EXP MED, V200, P825, DOI 10.1084/jem.20041389
   DOHERTY TM, 1993, J IMMUNOL, V151, P7151
   Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978
   Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6
   Fernandez-Botran R, 2000, EXPERT OPIN INV DRUG, V9, P497, DOI 10.1517/13543784.9.3.497
   GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x
   GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x
   Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343
   Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727
   Mortier E, 2006, J BIOL CHEM, V281, P1612, DOI 10.1074/jbc.M508624200
   Mortier E, 2004, J IMMUNOL, V173, P1681, DOI 10.4049/jimmunol.173.3.1681
   MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X
   Nishimura H, 2005, FASEB J, V19, P19, DOI 10.1096/fj.04-2633com
   Onu A, 1997, J IMMUNOL, V158, P255
   Ruchatz H, 1998, J IMMUNOL, V160, P5654
   Ruckert R, 2005, J IMMUNOL, V174, P5507, DOI 10.4049/jimmunol.174.9.5507
   Vamosi G, 2004, P NATL ACAD SCI USA, V101, P11082, DOI 10.1073/pnas.0403916101
   van Heel DA, 2006, GUT, V55, P444, DOI 10.1136/gut.2005.079335
   Waldmann TA, 2004, ARTHRITIS RES THER, V6, P174, DOI 10.1186/ar1202
   Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200
   Wei XQ, 2001, J IMMUNOL, V167, P277, DOI 10.4049/jimmunol.167.1.277
NR 30
TC 50
Z9 51
U1 5
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 4
PY 2007
VL 282
IS 18
BP 13167
EP 13179
DI 10.1074/jbc.M610036200
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 162BC
UT WOS:000246060300005
PM 17327231
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
AF Zhong, H.
   Zeng, X.-R.
   Yang, X.-M.
   Luo, Q.-Y.
TI RETRACTED: Tetrakis(nitrato-kappa O-2,O ')bis(4-phenyl-pyridine-kappa
   N)cerium(IV) (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BENELLI C, 1992, MATER CHEM PHYS, V31, P137, DOI 10.1016/0254-0584(92)90166-6
   DEBORAH LB, 2000, INORG CHIM ACTA, V304, P161
   FARRUGIA LJ, 2000, ACTA CRYSTALLOGR C, V56, P435
   Miller J. S., 2001, MAGNETISM MOL MAT
   MILLER JS, 2001, MAGNETISM MOL MAT, V1
   MILLER JS, 2002, MAGNETISM MOL MAT, V3
   Modolo G, 1998, J ALLOY COMPD, V271, P248, DOI 10.1016/S0925-8388(98)00064-4
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
NR 11
TC 0
Z9 0
U1 3
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD MAY
PY 2007
VL 63
BP M1455
EP U271
DI 10.1107/S1600536807018831
PN 5
PG 10
WC Crystallography
SC Crystallography
GA 190SN
UT WOS:000248080100134
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
AF Zhong, H.
   Zeng, X.-R.
   Yang, X.-M.
   Luo, Q.-Y.
TI RETRACTED: Tetrakis(pyridine-kappa N)bis(thiocyanato-kappa N)copper(II)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELX97 SHELX97
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM1379, DOI 10.1107/S1600536807017461
NR 4
TC 1
Z9 1
U1 3
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD MAY
PY 2007
VL 63
BP M1445
EP U262
DI 10.1107/S160053680701879X
PN 5
PG 9
WC Crystallography
SC Crystallography
GA 190SN
UT WOS:000248080100129
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
AF Zhong, H.
   Zeng, X.-R.
   Yang, X.-M.
   Luo, Q.-Y.
TI RETRACTED: Tetrakis(pyridine-kappa N)bis(thiocyan-ato kappa N)cobalt(II)
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   POPE MT, 2001, POLYOXOMETALATE CHEM, P319
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1996, SMART SAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 11
TC 2
Z9 2
U1 2
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD MAY
PY 2007
VL 63
BP M1379
EP U120
DI 10.1107/S1600536807017461
PN 5
PG 9
WC Crystallography
SC Crystallography
GA 190SN
UT WOS:000248080100095
DA 2018-12-27
ER

PT J
AU Taira, T
   Matsuyama, W
   Mitsuyama, H
   Kawahara, KI
   Higashimoto, I
   Maruyama, I
   Osame, M
   Arimura, K
AF Taira, T.
   Matsuyama, W.
   Mitsuyama, H.
   Kawahara, K. -I.
   Higashimoto, I.
   Maruyama, I.
   Osame, M.
   Arimura, K.
TI RETRACTED: Increased serum high mobility group box-1 level in
   Churg-Strauss syndrome (Retracted article. See vol. 154, pg. 433, 2008)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE eosinophil; inflammation; vasculitis
ID TERM-FOLLOW-UP; NONHISTONE CHROMOSOMAL-PROTEINS; DOMAIN RECEPTOR-1
   CONTRIBUTES; IDIOPATHIC PULMONARY-FIBROSIS; ANTIBODIES P-ANCA; SYSTEMIC
   VASCULITIS; CHROMATIN PROTEIN; CUTTING EDGE; CYTOKINE; CELLS
AB Churg-Strauss syndrome (CSS) is a rare form of systemic vasculitis occurring in patients with asthma and hypereosinophilia; however, its mechanisms involved in the severe tissue inflammation with vasculitis are poorly understood. High mobility group box 1 (HMGB1) protein, originally identified as a DNA binding protein, also has potent pro-inflammatory and proangiogenic properties. In this study, we hypothesized that HMGB1 might be associated with CSS, and examined serum HMGB1 levels and compared those of asthma patients and healthy volunteers. We also investigated HMGB1 expression in the lesion, and eosinophil HMGB1 amount in CSS patients. We found that the serum HMGB1 levels in CSS patients were significantly higher than those of asthma patients and healthy volunteers. Eosinophils in the CSS lesion expressed HMGB1 and HMGB1 level in eosinophils from CSS patients was significantly higher than that of asthma patients, while there was no significant difference in HMGB1 levels in peripheral mononuclear cells. The serum HMGB1 level in CSS patients decreased after the steroid therapy, and showed significant positive correlations with several molecules, including soluble interleukin-2 receptor, soluble thrombomodulin, and eosinophil cationic protein in sera. We propose that HMGB1 might contribute to the pathogenesis of CSS.
C1 Kagoshima Univ Hosp, Resp & Stress Care Ctr, Div Resp Med, Kagoshima 8908520, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Lab & Vasc Med Cardiovasc & Resp Disorders A, Kagoshima 890, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Resp & Stress Care Ctr, Div Resp Med, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950
   Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565
   Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338
   Conron M, 2000, THORAX, V55, P870, DOI 10.1136/thorax.55.10.870
   Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197
   Franco J, 1999, THORAX, V54, P558, DOI 10.1136/thx.54.6.558
   Gayraud M, 2001, ARTHRITIS RHEUM, V44, P666, DOI 10.1002/1529-0131(200103)44:3<666::AID-ANR116>3.3.CO;2-1
   GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1
   Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003
   Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916
   Haugeberg G, 1998, CLIN RHEUMATOL, V17, P364, DOI 10.1007/BF01450893
   JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206
   Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0
   LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001
   Lotfi R, 2007, J IMMUNOTHER, V30, P16, DOI 10.1097/01.cji.0000211324.53396.f6
   Marrugo J, 1996, MOL IMMUNOL, V33, P1119, DOI 10.1016/S0161-5890(96)00073-9
   MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806
   Matsuyama W, 2006, AM J PATHOL, V168, P866, DOI 10.2353/ajpath.2006.050801
   Matsuyama W, 2005, AM J RESP CELL MOL, V33, P565, DOI 10.1165/rcmb.2005-0236OC
   Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490
   Matsuyama W, 2004, BLOOD, V104, P184, DOI 10.1182/blood-2003-12-4274
   Matsuyama W, 2007, BLOOD, V109, P22, DOI 10.1182/blood-2006-04-015206
   Mitola S, 2006, J IMMUNOL, V176, P12, DOI 10.4049/jimmunol.176.1.12
   Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337
   Noth I, 2003, LANCET, V361, P587, DOI 10.1016/S0140-6736(03)12518-4
   Pullerits R, 2003, ARTHRITIS RHEUM, V48, P1693, DOI 10.1002/art.11028
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schmitt WH, 1998, ARTHRITIS RHEUM, V41, P445, DOI 10.1002/1529-0131(199803)41:3<445::AID-ART10>3.3.CO;2-V
   Schnabel A, 1999, THORAX, V54, P771, DOI 10.1136/thx.54.9.771
   Sobajima J, 1998, CLIN EXP IMMUNOL, V111, P402
   Sobajima J, 1997, CLIN EXP IMMUNOL, V107, P135, DOI 10.1046/j.1365-2249.1997.d01-907.x
   Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763
   Taguchi A, 2000, NATURE, V405, P354
   Tatsis E, 1998, ANN INTERN MED, V129, P370, DOI 10.7326/0003-4819-129-5-199809010-00004
   Telusma G, 2006, INT IMMUNOL, V18, P1563, DOI 10.1093/intimm/dxl089
   Uesugi H, 1998, J RHEUMATOL, V25, P703
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Wang HC, 1999, SURGERY, V126, P389, DOI 10.1067/msy.1999.99167
   WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8
   Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455
   Weller Peter F., 2001, Journal of Allergy and Clinical Immunology, V108, P175, DOI 10.1067/mai.2001.117176
   Yamada S, 2003, CLIN CHEM, V49, P1535, DOI 10.1373/49.9.1535
   Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648
   Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100
NR 44
TC 18
Z9 23
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAY
PY 2007
VL 148
IS 2
BP 241
EP 247
DI 10.1111/j.1365-2249.2007.03347.x
PG 7
WC Immunology
SC Immunology
GA 155UL
UT WOS:000245603800006
PM 17437420
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Nakayama, M
AF Fujii, Yoshitaka
   Nakayama, Masahiro
TI RETRACTED: Prevention of pain due to injection of propofol with IV
   administration of lidocaine 40 mg plus metoclopramide 2.5, 5, or 10 mg
   or saline: A randomized, double-blind study in Japanese adult surgical
   patients (Retracted article. See vol. 40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE intravenous anesthetic; propofol; pain; lidocaine; metoclopramide
ID PRETREATMENT; FORMULATION; LIGNOCAINE
AB Background: Pain on Injection is a recognized adverse event (AE) with propofol, an agent used to induce general anesthesia in surgical patients. Lidocaine (LID) has been found efficacious in reducing pain on injection of propofol; however, this type of pain may not be completely eliminated with LID. Metoclopramide (MET) is a dopamine receptor agonist with antiemetic and prokinetic properties used for the treatment of nausea and facilitation of gastric emptying in patients with gastroparesis. MET also has local anesthetic properties similar to those of LID.
   Objective: The aim of this study was to examine the effects of LID administered with 3 different doses of MET or saline on pain on injection of propofol in Japanese adults undergoing elective surgery.
   Methods: This randomized, double-blind study was conducted at the Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan. Japanese patients aged 20 to 67 years who were scheduled to undergo elective surgery were eligible for participation. Patients were randomized to receive IV administration of LID 40 mg + MET 2.5, 5, or 10 mg or saline. A rubber tourniquet was used to perform I minute of venous occlusion before administration of the study and control drugs, and then 25% of the total calculated dose of propofol (2 mg/kg) was injected into the dorsal vein of the hand through a 20-G IV cannula at a rate of 1 mL/s. During a 10-second pause before the induction of anesthesia, patients were questioned by a blinded investigator about the pain intensity on injection. Pain intensity was assessed through the use of a 4-point verbal rating scale, with scores ranging from 0 (no pain) to 3 (severe pain). Incidence and intensity of pain (as assessed by mean pain scores) were determined in each of the 4 study groups. Extrapyramidal reactions and injection-site AEs, including pain, edema, wheals, and inflammation occurring up to 24 hours after surgery were recorded by a blinded investigator.
   Results: The study enrolled 240 patients (126 men, 114 women; mean [SD] age, 43 [13] years [range, 20-67 years]; mean [SD] height, 160 [8] cm [133-181 cm]; mean [SD] body weight, 57 [10] kg [range, 33-85 kg]). There were 60 patients randomized to each of the 4 study groups, which were comparable in distribution of demographic characteristics. Incidence of propofol-induced pain was significantly lower, but the intensity of pain was not less, in the groups that received LID/MET 40/5 or 40/10 (both, 5%) compared with those who received LID/MET 40/2.5 or LID/saline (18% and 20%, respectively) (all, P < 0.05). There were no reports of injection-site AEs or extrapyramidal reactions after injection of the control or study drugs in any of the study groups.
   Conclusion: Among these 240 Japanese patients undergoing elective surgery, IV administration of LID/MET 40/5 or 40/10 was associated with lower incidence, but not lower mean pain intensity scores, of pain on injection of propofol than LID/MET 40/2.5 or LID/saline before induction of anesthesia.
C1 Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, Tokyo 1438541, Japan.
   Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, 6-11-1,Ohmori Nishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR Agarwal A, 2004, ANESTH ANALG, V98, P683, DOI 10.1213/01.ANE.0000103266.73568.18
   ALBIBI R, 1983, ANN INTERN MED, V98, P86, DOI 10.7326/0003-4819-98-1-86
   BROWN EM, 1989, CAN J ANAESTH, V36, P307, DOI 10.1007/BF03010770
   DESMOND PV, 1986, MED J AUSTRALIA, V144, P366
   FLEISHER LA, 1996, CLIN ANESTH, P443
   GANTA R, 1992, BRIT J ANAESTH, V69, P316, DOI 10.1093/bja/69.3.316
   HYNYNEN M, 1985, ACTA ANAESTH SCAND, V29, P651, DOI 10.1111/j.1399-6576.1985.tb02274.x
   KING SY, 1992, ANESTH ANALG, V74, P246, DOI 10.1213/00000539-199202000-00013
   Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005
   Lai Y Y, 1993, Ma Zui Xue Za Zhi, V31, P31
   Larsen B, 2001, ANAESTHESIST, V50, P842, DOI 10.1007/s00101-001-0234-0
   Liaw WJ, 1999, ACTA ANAESTH SCAND, V43, P24, DOI 10.1034/j.1399-6576.1999.430106.x
   Liljeroth E, 2001, ACTA ANAESTH SCAND, V45, P839, DOI 10.1034/j.1399-6576.2001.045007839.x
   Lin S S, 1994, Acta Anaesthesiol Sin, V32, P73
   Macario A, 1999, ANESTH ANALG, V88, P1085, DOI 10.1097/00000539-199905000-00023
   MAROOF M, 1995, BRIT J ANAESTH, V74, P8
   MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x
   MECKLEM DWJ, 1994, ANAESTH INTENS CARE, V22, P568
   Memis D, 2002, ANESTH ANALG, V95, P606, DOI 10.1213/01.ANE.0000023204.79877.7A
   Picard P, 2000, ANESTH ANALG, V90, P963
   SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x
   STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202
NR 22
TC 13
Z9 17
U1 2
U2 4
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD MAY
PY 2007
VL 29
IS 5
BP 856
EP 861
DI 10.1016/j.clinthera.2007.05.019
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 180BT
UT WOS:000247335600007
PM 17697904
DA 2018-12-27
ER

PT J
AU Chu, KHW
AF Chu, Kwang-Hua W.
TI RETRACTED: A pedagogical look at Jeans' density scale (Retracted
   article. See vol. 32, pg. 1439, 2011)
SO EUROPEAN JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
AB We illustrate the derivations of Jeans' criteria for the gravitational instabilities in a static homogeneous Newtonian system for pedagogical objectives. The critical Jeans density surface is presented in terms of dimensionless sound speeds and (characteristic) length scales.
C1 Xinjiang Univ, Dept Phys, Urumqi 830046, Peoples R China.
RP Chu, KHW (reprint author), Xinjiang Univ, Dept Phys, Urumqi 830046, Peoples R China.
CR Binney J., 1987, GALACTIC DYNAMICS
   BOERNER G, 1992, EARLY UNIVERSE FACTS
   CHANDRASEKHAR S, 1961, YDRODYNAMIC HYDROMAG
   Einstein A, 1917, SITZBER K PREUSS AKA, P142
   Fridman A. M., 1984, PHYS GRAVITATING SYS, VI
   Fridman A. M, 1984, PHYS GRAVITATING SYS, VII
   Jeans JH, 1902, PHILOS T R SOC LOND, V199, P1, DOI 10.1098/rsta.1902.0012
   KIESSLING MKH, 1989, J STAT PHYS, V55, P203, DOI 10.1007/BF01042598
   Kiessling MKH, 2003, ADV APPL MATH, V31, P132, DOI 10.1016/S0196-8858(02)00556-0
   Peebles P. J. E, 1980, LARGE SCALE STRUCTUR
NR 10
TC 1
Z9 1
U1 5
U2 14
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0143-0807
EI 1361-6404
J9 EUR J PHYS
JI Eur. J. Phys.
PD MAY
PY 2007
VL 28
IS 3
BP 501
EP 507
DI 10.1088/0143-0807/28/3/011
PG 7
WC Education, Scientific Disciplines; Physics, Multidisciplinary
SC Education & Educational Research; Physics
GA 167PU
UT WOS:000246464400024
DA 2018-12-27
ER

PT J
AU Kokko, H
   Wong, BBM
AF Kokko, Hanna
   Wong, Bob B. M.
TI RETRACTED: What determines sex roles in mate searching ?(Retracted
   article. See vol. 70, pg. 742, 2016)
SO EVOLUTION
LA English
DT Article; Retracted Publication
DE mate search; multiple mating; pheromone; sex roles; sperm competition
ID POTENTIAL REPRODUCTIVE RATES; BIASED PREDATION; EVOLUTIONARY GAME;
   LOCATING BEHAVIOR; CRINIA-GEORGIANA; MATING SYSTEMS; SEARCH COSTS;
   FIDDLER-CRAB; SELECTION; FEMALE
AB In a seminal paper, Hammerstein and Parker (1987) described how sex roles in mate searching can be frequency dependent: the need for one sex to perform mate searching is diminished when the opposite sex takes on the greater searching effort. Intriguingly, this predicts that females are just as likely to search as males, despite a higher potential reproductive rate by the latter sex. This prediction, however, is not supported by data: male mate searching prevails in nature. Counterexamples also exist in the empirical literature. Depending on the taxon studied, female mate searching can arise in either low-or high-density conditions, and suggested explanations differ accordingly. We examine these puzzling observations by building two models (with and without sperm competition). When sperm competition is explicitly included, male mate searching becomes the dominant pattern; when it is excluded, male mate searching predominates only if we assume that costs of searching are higher for females. Consequently, two hypotheses emerge from our models. The multiple-mating hypothesis explains male searching on the basis of the ubiquity of sperm competition, and predicts that female searching can arise in low-density situations in which sperm can become limiting. It can also explain cases of female pheromone production, where males pay the majority of search costs. The sex-specific cost hypothesis predicts the opposite pattern of female searching in high-density conditions, and it potentially applies to some species in which sperm limitation is unlikely.
C1 Univ Helsinki, Dept Biol & Environm Sci, Lab Ecol & Evolutionary Dynam, FIN-00014 Helsinki, Finland.
   Australian Natl Univ, Sch Bot & Zool, Canberra, ACT 0200, Australia.
   Monash Univ, Sch Biol Sci, Clayton, Vic 3800, Australia.
RP Kokko, H (reprint author), Univ Helsinki, Dept Biol & Environm Sci, Lab Ecol & Evolutionary Dynam, FIN-00014 Helsinki, Finland.
EM hanna.kokko@helsinki.fi; bob.wong@sci.monash.edu.au
RI Kokko, Hanna/C-7861-2009
CR ACHARYA L, 1995, ANIM BEHAV, V49, P1461, DOI 10.1016/0003-3472(95)90067-5
   ALCOCK J, 1994, ETHOLOGY, V97, P103
   ALCOCK J, 1981, J KANSAS ENTOMOL SOC, V54, P681
   Alexander R.D., 1975, P35
   Angioy AM, 2003, CHEM SENSES, V28, P279, DOI 10.1093/chemse/28.4.279
   Arnqvist G, 2004, EVOLUTION, V58, P1383
   Badyaev AV, 2002, AUK, V119, P301, DOI 10.1642/0004-8038(2002)119[0301:PSTITC]2.0.CO;2
   BATEMAN AJ, 1948, HEREDITY, V2, P349, DOI 10.1038/hdy.1948.21
   Blows MW, 2002, P ROY SOC B-BIOL SCI, V269, P1113, DOI 10.1098/rspb.2002.2002
   Byers JA, 2005, AM NAT, V166, P661, DOI 10.1086/497401
   Byrne PG, 2004, BEHAV ECOL, V15, P872, DOI 10.1093/beheco/arh100
   Byrne PG, 2000, EVOLUTION, V54, P968
   CARDE RT, 1984, J CHEM ECOL, V10, P25, DOI 10.1007/BF00987640
   CLUTTONBROCK TH, 1992, Q REV BIOL, V67, P437, DOI 10.1086/417793
   CLUTTONBROCK TH, 1991, NATURE, V351, P58
   DAVIES NB, 1979, ANIM BEHAV, V27, P1253, DOI 10.1016/0003-3472(79)90070-8
   DeRivera CE, 2003, BEHAV ECOL SOCIOBIOL, V53, P72, DOI 10.1007/s00265-002-0555-2
   Derivera CE, 2005, ANIM BEHAV, V70, P289, DOI 10.1016/j.anbehav.2004.10.027
   Dunn PO, 2007, BEHAV ECOL SOCIOBIOL, V61, P449, DOI 10.1007/s00265-006-0272-3
   GOTMARK F, 1993, P ROY SOC B-BIOL SCI, V253, P143, DOI 10.1098/rspb.1993.0094
   Gotthard K, 1999, BEHAV ECOL SOCIOBIOL, V45, P424, DOI 10.1007/s002650050580
   Grafe TU, 1997, ANIM BEHAV, V53, P1103, DOI 10.1006/anbe.1996.0427
   GREENFIELD MD, 1981, FLA ENTOMOL, V64, P4, DOI 10.2307/3494597
   Groddeck J, 2004, J INSECT BEHAV, V17, P397, DOI 10.1023/B:JOIR.0000031539.52983.89
   GWYNNE DT, 1987, ANIM BEHAV, V35, P571, DOI 10.1016/S0003-3472(87)80283-X
   Hammerstein P., 1987, Life Sciences Research Report, V39, P119
   Hardling R, 2005, J EVOLUTION BIOL, V18, P106, DOI 10.1111/j.1420-9101.2004.00795.x
   Hardling R, 2003, AM NAT, V161, P395, DOI 10.1086/367587
   Houston AI, 2005, BIOL PHILOS, V20, P933, DOI 10.1007/s10539-005-9016-4
   Houston AI, 2005, TRENDS ECOL EVOL, V20, P33, DOI 10.1016/j.tree.2004.10.008
   Houston AI, 2002, PHILOS T ROY SOC B, V357, P351, DOI 10.1098/rstb.2001.0925
   Hunt J, 2004, NATURE, V432, P1024, DOI 10.1038/nature03084
   Husak JF, 2006, ETHOLOGY, V112, P572, DOI 10.1111/j.1439-0310.2005.01189.x
   Ide J, 2000, ECOL LETT, V3, P433, DOI 10.1046/j.1461-0248.2000.00169.x
   Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423
   JUMPER GY, 1991, AM NAT, V138, P1431, DOI 10.1086/285295
   Kasumovic MM, 2007, BEHAV ECOL, V18, P189, DOI 10.1093/beheco/arl072
   KIRSCHFELD K, 1976, Z NATURFORSCH C, V31, P764, DOI 10.1515/znc-1976-11-1231
   Koga T, 2001, ANIM BEHAV, V62, P201, DOI 10.1006/anbe.2001.1740
   Kokko H, 2001, ECOL LETT, V4, P159, DOI 10.1046/j.1461-0248.2001.00212.x
   Kokko H, 2005, EVOLUTION, V59, P1876
   Kokko H, 2006, EVOLUTION, V60, P467, DOI 10.1554/05-613.1
   Kokko H, 2003, TRENDS ECOL EVOL, V18, P103, DOI 10.1016/S0169-5347(03)00009-0
   Kokko H, 2006, PHILOS T R SOC B, V361, P319, DOI 10.1098/rstb.2005.1784
   Kokko H, 2006, ANNU REV ECOL EVOL S, V37, P43, DOI 10.1146/annurev.ecolsys.37.091305.110259
   Kuussaari M, 1998, OIKOS, V82, P384, DOI 10.2307/3546980
   Levitan DR, 2004, AM NAT, V164, P298, DOI 10.1086/423150
   LUCAS JR, 1995, AM NAT, V146, P365, DOI 10.1086/285805
   MCDONALD DB, 1993, BEHAV ECOL, V4, P297, DOI 10.1093/beheco/4.4.297
   MCNAMARA JM, 1986, AM NAT, V127, P358, DOI 10.1086/284489
   McNamara JM, 1996, NATURE, V380, P215, DOI 10.1038/380215a0
   Melville JM, 2003, J INSECT BEHAV, V16, P97, DOI 10.1023/A:1022853413104
   METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K
   Nahrung HF, 2004, J INSECT BEHAV, V17, P353, DOI 10.1023/B:JOIR.0000031536.59988.0d
   Okuda N, 1999, ANIM BEHAV, V58, P273, DOI 10.1006/anbe.1999.1148
   OWENSMITH N, 1993, BEHAV ECOL SOCIOBIOL, V32, P177
   Parker GA, 1996, P ROY SOC B-BIOL SCI, V263, P315, DOI 10.1098/rspb.1996.0048
   PARKER GA, 1978, BEHAV ECOLOGY EVOLUT, P214
   Pen I, 1999, AM NAT, V153, P384, DOI 10.1086/303183
   POCKLINGTON R, 1995, ANIM BEHAV, V49, P1122, DOI 10.1006/anbe.1995.0141
   Queller DC, 1997, P ROY SOC B-BIOL SCI, V264, P1555, DOI 10.1098/rspb.1997.0216
   Rhainds M, 1999, ENTOMOL EXP APPL, V91, P375, DOI 10.1046/j.1570-7458.1999.00505.x
   Rowe L., 2005, SEXUAL CONFLICT
   Stuart-Fox DM, 2003, ANIM BEHAV, V66, P541, DOI 10.1006/anbe.2003.2235
   Svensson M, 1996, BIOL REV, V71, P113, DOI 10.1111/j.1469-185X.1996.tb00743.x
   Takacs S, 2002, NATURWISSENSCHAFTEN, V89, P57, DOI 10.1007/s00114-001-0282-y
   TAYLOR PD, 1990, AM NAT, V135, P95, DOI 10.1086/285034
   Trivers RL, 1972, SEXUAL SELECTION DES, P139
   Webb JN, 1999, ANIM BEHAV, V58, P983, DOI 10.1006/anbe.1999.1215
   WELLS KD, 1977, ANIM BEHAV, V25, P666, DOI 10.1016/0003-3472(77)90118-X
   Wickman PO, 1997, BEHAV ECOL SOCIOBIOL, V40, P321, DOI 10.1007/s002650050348
   Wickman PO, 1999, OIKOS, V84, P463, DOI 10.2307/3546425
   Wiklund C, 1998, BEHAV ECOL, V9, P20, DOI 10.1093/beheco/9.1.20
   ZEIL J, 1983, J COMP PHYSIOL, V150, P379, DOI 10.1007/BF00605027
NR 74
TC 59
Z9 60
U1 3
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-3820
EI 1558-5646
J9 EVOLUTION
JI Evolution
PD MAY
PY 2007
VL 61
IS 5
BP 1162
EP 1175
DI 10.1111/j.1558-5646.2007.00090.x
PG 14
WC Ecology; Evolutionary Biology; Genetics & Heredity
SC Environmental Sciences & Ecology; Evolutionary Biology; Genetics &
   Heredity
GA 163ZB
UT WOS:000246200800014
PM 17492969
OA Bronze
DA 2018-12-27
ER

PT J
AU Rangarajan, M
   Palanivelu, C
   Madankumar, MV
   Senthilkumar, R
AF Rangarajan, Muthukumaran
   Palanivelu, Chinnusamy
   Madankumar, Madhupalayam Velusamy
   Senthilkumar, Rangaswamy
TI RETRACTED: Emergency laparoscopic cholecystectomy for acute empyema of
   the gallbladder in pregnancy (Retracted article. See vol 19, pg 398,
   2009)
SO JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
LA English
DT Article; Retracted Publication
DE mucocele; safety precautions; laparoscopic cholecystectomy; pregnancy;
   empyema gallbladder
AB This report describes a pregnant patient on whom emergency laparoscopic cholecystectomy was performed for empyema gallbladder. The patient was in her second trimester of pregnancy. The distended gallbladder was decompressed before dissection was commenced. There was no mortality, morbidity or conversion. There were no complications for either mother or child related to general anesthesia.
C1 [Rangarajan, Muthukumaran; Palanivelu, Chinnusamy; Madankumar, Madhupalayam Velusamy; Senthilkumar, Rangaswamy] GEM Hosp, Dept Surg Gastroenterol, Coimbatore 641045, Tamil Nadu, India.
RP Rangarajan, M (reprint author), GEM Hosp, Dept Surg Gastroenterol, 45-A,Pankaja Mill Rd, Coimbatore 641045, Tamil Nadu, India.
EM rangy68@gmail.com
CR Al-Fozan H, 2002, CURR OPIN OBSTET GYN, V14, P375, DOI 10.1097/00001703-200208000-00003
   Conron RW, 1999, AM SURGEON, V65, P259
   Grigoriu M, 2003, Chirurgia (Bucur), V98, P453
   Lachman E, 1999, J AM ASSOC GYN LAP, V6, P347, DOI 10.1016/S1074-3804(99)80075-9
   Lu EJ, 2004, AM J SURG, V188, P755, DOI 10.1016/j.amsjurg.2004.09.002
   PUCCI RO, 1991, AM J OBSTET GYNECOL, V165, P401, DOI 10.1016/0002-9378(91)90102-W
   SINGH K, 2005, LAPAROSCOPIC CHOLECY, V67, P131
   Stepp K, 2004, OBSTET GYN CLIN N AM, V31, P485, DOI 10.1016/j.ogc.2004.05.002
NR 8
TC 1
Z9 1
U1 1
U2 10
PU COLL PHYSICIANS & SURGEONS PAKISTAN
PI KARACHI
PA SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN
SN 1022-386X
EI 1681-7168
J9 JCPSP-J COLL PHYSICI
JI JCPSP-J. Coll. Physicians Surg.
PD MAY
PY 2007
VL 17
IS 5
BP 275
EP 276
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 319UO
UT WOS:000257190000009
PM 17553325
DA 2018-12-27
ER

PT J
AU Watanabe, M
   Matsuyama, W
   Shirahama, Y
   Mitsuyama, H
   Oonakahara, K
   Noma, S
   Higashimoto, I
   Osame, M
   Arimura, K
AF Watanabe, Masaki
   Matsuyama, Wataru
   Shirahama, Yuko
   Mitsuyama, Hideo
   Oonakahara, Ken-ichi
   Noma, Satoshi
   Higashimoto, Ikkou
   Osame, Mitsuhiro
   Arimura, Kimiyoshi
TI RETRACTED: Dual effect of AMD3100, a CXCR4 antagonist, on
   bleomycin-induced lung inflammation (Retracted Article. See vol 181, pg
   6670, 2008)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID INDUCED PULMONARY-FIBROSIS; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   CHEMOKINE RECEPTOR CXCR4; COLONY-STIMULATING FACTOR; FACTOR-I; HIV-1
   ENTRY; LYMPHOCYTE CHEMOATTRACTANT; COUPLED RECEPTOR; DEFICIENT MICE; P38
   MAPK
AB The chemokine receptor CXCR4, which binds the chemokine stromal cell-derived factor 1, has been reported to be involved in the chemotaxis of inflammatory cells. In addition, AMD3100, an antagonist of CXCR4, has been reported to be an attractive drug candidate for therapeutic intervention in several disorders in which CXCR4 is critically involved. However, little is known about the therapeutic value of AMD3100 in the treatment of pulmonary fibrosis. In this study, we examined the effects of AMD3100 on a murine bleomycin-induced pulmonary fibrosis model. Concurrent administration of AMD3100 and bleomycin apparently attenuated bleomycin-induced pulmonary inflammation. In this process, an inhibition of neutrophil recruitment at early stage followed by the decrease of other inflammatory cell recruitment in the lung were observed. In addition, it also inhibited the expression of cytokines, including MCP-1, MIP-2, MIP-1 alpha, and TGF-beta. In contrast, when AMD3100 was administered following bleomycin treatment, the bleomycin-induced lung inflammation progressed and resulted in severe pulmonary fibrosis. In this process, an increase of inflammatory cell recruitment, an up-regulation of lung MCP-1 and TGF-beta, and a remarkable activation of p44/42 MAPK in neutrophils were observed. U0126, an inhibitor of p44/42 MAPK, significantly abolished these effects. Thus, AMD3100 has dual effect on bleomycin-induced pulmonary fibrosis. Difference of inflammatory cell recruitment and activation might be associated with the dual effect of AMD3100 on bleomycin-induced pulmonary fibrosis.
C1 Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima 8908520, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111
   ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371
   ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467
   Azoulay E, 2003, CRIT CARE MED, V31, P1442, DOI 10.1097/01.CCM.0000050453.28177.33
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Charnaux N, 2005, FEBS J, V272, P1937, DOI 10.1111/j.1742-4658.2005.04624.x
   COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639
   Day RM, 2001, AM J RESP CELL MOL, V25, P613, DOI 10.1165/ajrcmb.25.5.4521
   De Klerck B, 2005, ARTHRITIS RES THER, V7, pR1208, DOI 10.1186/ar1806
   DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313
   Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000
   Inoshima I, 2004, AM J PHYSIOL-LUNG C, V286, pL1038, DOI 10.1152/ajplung.00167.2003
   IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1
   Jozsef L, 2002, BRIT J PHARMACOL, V135, P1167, DOI 10.1038/sj.bjp.0704561
   Keane MP, 1999, J IMMUNOL, V162, P5511
   KHALIL N, 1993, J CLIN INVEST, V92, P1812, DOI 10.1172/JCI116771
   KHALIL N, 1991, CIBA F SYMP, V157, P194
   Kim KH, 2005, AM J RESP CELL MOL, V33, P271, DOI 10.1165/rcmb.2005-0111OC
   Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286
   Lawson WE, 2005, AM J PATHOL, V167, P1267, DOI 10.1016/S0002-9440(10)61214-X
   Lee DY, 2000, MAT SCI ENG A-STRUCT, V289, P1, DOI 10.1016/S0921-5093(00)00937-0
   Lee HS, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-23
   Lenoir M, 2004, J IMMUNOL, V172, P7136, DOI 10.4049/jimmunol.172.11.7136
   Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6
   Link DC, 2005, IMMUNOL RES, V32, P169, DOI 10.1385/IR:32:1-3:169
   Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X
   Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004
   Matsuoka H, 2002, AM J PHYSIOL-LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001
   Matsuyama W, 2006, J IMMUNOL, V176, P1928, DOI 10.4049/jimmunol.176.3.1928
   Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490
   Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686
   McColl SR, 1999, J IMMUNOL, V163, P2829
   Mizuno K, 2005, CLIN EXP IMMUNOL, V139, P490, DOI 10.1111/j.1365-2249.2005.02721.x
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935
   Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151
   Okuma T, 2004, J PATHOL, V204, P594, DOI 10.1002/path.1667
   Oonakahara K, 2004, AM J RESP CELL MOL, V30, P671, DOI 10.1165/rcmb.2003-0340OC
   Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997
   Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963
   Rollins BJ, 1997, BLOOD, V90, P909
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Smith RE, 1998, J LEUKOCYTE BIOL, V64, P528
   SMITH RE, 1995, J LEUKOCYTE BIOL, V57, P782
   Suga M, 1999, EUR RESPIR J, V14, P376, DOI 10.1034/j.1399-3003.1999.14b23.x
   Sun WM, 2001, GASTROENTEROL CLIN N, V30, P15, DOI 10.1016/S0889-8553(05)70165-5
   Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022
   Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143
   Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7
   Yousefi S, 2001, J LEUKOCYTE BIOL, V69, P1045
   ZHANG K, 1995, AM J PATHOL, V147, P352
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 62
TC 10
Z9 11
U1 3
U2 15
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2007
VL 178
IS 9
BP 5888
EP 5898
DI 10.4049/jimmunol.178.9.5888
PG 11
WC Immunology
SC Immunology
GA 161YZ
UT WOS:000246054400055
PM 17442973
OA Bronze
DA 2018-12-27
ER

PT J
AU Kim, JD
   Lee, CG
AF Kim, Jeong-Dong
   Lee, Choul-Gyun
TI RETRACTED: Purification and characterization of extracellular
   beta-glucosidase from Sinorhiziobium kostiense AFK-13 and its algal
   lytic effect on Anabaena flos-aquae (Retracted article. See vol 17, pg
   1908, 2007)
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE beta-Glucosidase; Sinorhizobium kostiense; extracellular; algal lytic
ID ALGICIDAL ACTIVITY; CYANOBACTERIA; STRAIN; WATER; GENE; AERUGINOSA;
   CHLORELLA; BACTERIUM; CELLULASE; COMPLEX
AB A beta-glucosidase from the algal lytic bacterium Sinorhizobium kostiense AFK-13, grown in complex media containing cellobiose, was purified to homogeneity by successive ammonium sulfate precipitation, and anion-exchange and gelfiltration chromatographies. The enzyme was shown to be a monomeric protein with an apparent molecular mass of 52 kDa and isoelectric point of approximately 5.4. It was optimally active at pH 6.0 and 40 degrees C and possessed a specific activity of 260.4 U/mg of protein against 4-nitrophenyl-beta-D-glucopyranoside (pNPG). A temperature-stability analysis demonstrated that the enzyme was unstable at 50 degrees C and above. The enzyme did not require divalent cations for activity, and its activity was significantly suppressed by Hg2+ and Ag-+,Ag- whereas sodium dodecyl sulfate (SDS) and Triton X-100 moderately inhibited the enzyme to under 70% of its initial activity. In an algal lytic activity analysis, the growth of cyanobacteria, such as Anabaena flos-aquae, A. cylindrica, A. macrospora, Oscillatoria sancta, and Microcystis aeruginosa, was strongly inhibited by a treatment of 20 ppm/disc or 30 ppm/disc concentration of the enzyme.
C1 Inha Univ, Dept Biol Engn, Inst Ind Biotechnol, Inchon 402751, South Korea.
RP Lee, CG (reprint author), Inha Univ, Dept Biol Engn, Inst Ind Biotechnol, Inchon 402751, South Korea.
EM leecg@inha.ac.kr
OI Lee, Choul-Gyun/0000-0002-4684-7990
CR BERGER PS, 1979, WATER RES, V13, P267, DOI 10.1016/0043-1354(79)90205-7
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CASTENHOLZ RW, 1988, METHOD ENZYMOL, V167, P68
   Choi HJ, 2005, BIOL CONTROL, V33, P335, DOI 10.1016/j.biocontrol.2005.03.007
   Colombo V, 2004, BRAZ J MICROBIOL, V35, P110, DOI 10.1590/S1517-83822004000100018
   Elisashvili VI, 1999, BIOCHEMISTRY-MOSCOW+, V64, P718
   Gonzalez JM, 1996, APPL ENVIRON MICROB, V62, P4433
   Harchand RK, 1997, J BASIC MICROB, V37, P93, DOI 10.1002/jobm.3620370204
   HYUN HH, 1985, J BACTERIOL, V164, P1162
   Jung HK, 2006, J MICROBIOL BIOTECHN, V16, P952
   Kim J, 2006, ANN SURG ONCOL, V13, P16
   Kim JD, 2006, J MICROBIOL BIOTECHN, V16, P52
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee SO, 2000, APPL ENVIRON MICROB, V66, P4334, DOI 10.1128/AEM.66.10.4334-4339.2000
   Lucas R, 2000, J AGR FOOD CHEM, V48, P3698, DOI 10.1021/jf0002591
   MERRIL CR, 1984, ELECTROPHORESIS, V5, P289, DOI 10.1002/elps.1150050509
   Nakkharat P, 2006, J BIOTECHNOL, V123, P304, DOI 10.1016/j.jbiotec.2005.12.015
   NELSON NJ, 1957, METHOD ENZYMOL, V3, P85
   Riccio P, 1999, ENZYME MICROB TECH, V24, P123, DOI 10.1016/S0141-0229(98)00066-0
   SAKATA T, 1991, NIPPON SUISAN GAKK, V57, P1147
   Sestelo ABF, 2004, WORLD J MICROB BIOT, V20, P633, DOI 10.1023/B:WIBI.0000043195.80695.17
   Skory CD, 1996, APPL MICROBIOL BIOT, V46, P353, DOI 10.1007/s002530050829
   SOMOGYI M, 1952, J BIOL CHEM, V195, P19
   SOMVILLE M, 1984, APPL ENVIRON MICROB, V48, P1181
   Unanue M, 1999, MICROB ECOL, V37, P36, DOI 10.1007/s002489900128
   Villena MA, 2006, ENZYME MICROB TECH, V39, P229, DOI 10.1016/j.enzmictec.2005.10.018
   Villena MA, 2005, J APPL MICROBIOL, V99, P558, DOI 10.1111/j.1365-2672.2005.02627.x
   Wang XL, 2005, HARMFUL ALGAE, V4, P433, DOI 10.1016/j.hal.2004.06.001
   Yamamoto Y, 1998, J APPL PHYCOL, V10, P391, DOI 10.1023/A:1008077414808
   Yang L, 2004, J AGR FOOD CHEM, V52, P1940, DOI 10.1021/jf030476c
   Zuniga M, 2002, APPL ENVIRON MICROB, V68, P6051, DOI 10.1128/AEM.68.12.6051-6058.2002
NR 31
TC 7
Z9 7
U1 2
U2 16
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
EI 1738-8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD MAY
PY 2007
VL 17
IS 5
BP 745
EP 752
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 173FT
UT WOS:000246859600007
PM 18051295
DA 2018-12-27
ER

PT J
AU Nagy, N
   Shiroto, K
   Malik, G
   Huang, CK
   Gaestel, M
   Abdellatif, M
   Tosaki, A
   Maulik, N
   Das, DK
AF Nagy, Norbert
   Shiroto, Keisuke
   Malik, Gautam
   Huang, Chi-Kuang
   Gaestel, Mathias
   Abdellatif, Maha
   Tosaki, Arpad
   Maulik, Nilanjana
   Das, Dipak K.
TI RETRACTED: Ischemic preconditioning involves dual cardio-protective axes
   with p38MAPK as upstream target (Retracted article. See vol. 53, pg.
   743, 2012)
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article; Retracted Publication
DE p38MAP kinase; MAPKAP kinase 2; MSK-1; CREB; ischemia/reperfusion
ID HUMAN SKELETAL-MUSCLE; SIGNAL-TRANSDUCTION; MAP KINASES; TRANSCRIPTION
   FACTOR; SURVIVAL; CREB; ACTIVATION; HEART; REPERFUSION; APOPTOSIS
AB The existing literature indicates a crucial role of p38 MAP (mitogen-activated protein) kinase (p38MAPK) and its downstream target MAPKAP kinase 2 (MK2) in ischemic preconditioning (IPC). Accordingly, deletion of MK:2 gene should abolish the cardioprotective ability of IPC. Interestingly, we were able to partially precondition the hearts from MK2(-/-) knockout mice suggesting the existence of an as yet unknown altemative downstream target of p38MAPK. A recent study from our laboratory also determined a crucial role of CREB (cyclic AMP response element binding protein) in IPC. Since CREB is a downstream target of MSK-I (mitogen- and stress-activated protein kinase-1) situated at the crossroad of ERK (extracellular receptor kinase) and p38MAPK signaling pathways, we reasoned that MSK-1 could be a downstream molecular target for p38MAPK and ERK signaling in the IPC hearts. To test this hypothesis, the rat hearts were subjected to IPC by four cyclic episodes of 5 min ischemia and 10 min reperfusion. As expected, IPC induced the activation of ERK1/2, p38MAPK, MK2 and HSP (heat shock protein) 27 as evidenced by their increased phosphorylation; and the inhibition of p38MAPK with SB203580 almost completely, and the inhibition of ERK1/2 with PD098059 partially, abolished cardioprotective effects of IPC. Inhibition of MSK-1 with short hairpin RNA (shRNA) also abolished the IPC-induced cardioprotection: SB203580 partially blocked the effects of MSK-1 suggesting that MSK-1 sits downstream of p38MAPK. shRNA-MSK-1 blocked the contribution of both p38MAPK and ERK1/2 as it is uniquely situated at the downstream crossroad of both of these MAP kinases. Although MSK-I sits downstream of both ERK1/2 and p38MAPK, ERK1/2 activation appears to play less significant role compared to p38MAPK, since its inhibition blocked MSK activation only partially. Consistent with these results, shRNA-MSK-1 blocked the partial PC in MK2-/- hearts, and in combination with SB203580, completely abolished the PC effects in the wild-type hearts. The IPC-induced survival signaling was almost completely inhibited with SB203580, and only partially with PD 098059 as evidenced from the inhibition patterns of IPC induced activation of CREB, Akt and Bcl-2. Again SB203580 alone or in combination with shRNA-MSK-1 inhibited IPC induced survival signal comparatively, suggesting that MSK-I exists downstream of p38MAPK. Taken together, these results indicate for the first time MSK-I as an alternative (other than MK2) downstream target for p38MAPK, which also transmits survival signal through the activation of CREB. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Connecticut, Sch Med, FAHA Cardiovasc Res Ctr, Inst Cardiovasc Res, Farmington, CT 06030 USA.
   Univ Med & Dent New Jersey, Newark, NJ 07103 USA.
   Univ Halle Wittenberg, Hallem, Germany.
   Univ Debrecen, H-4012 Debrecen, Hungary.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, FAHA Cardiovasc Res Ctr, Inst Cardiovasc Res, Farmington, CT 06030 USA.
EM ddas@neuron.uchc.edu
OI Gaestel, Matthias/0000-0002-4944-4652
FU NHLBI NIH HHS [HL 33889, HL 22559, HL 56803]
CR BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889
   Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358
   Chevalier D, 2000, BIOCHEMISTRY-US, V39, P6145, DOI 10.1021/bi9928389
   Das DK, 2006, CARDIOVASC RES, V70, P254, DOI 10.1016/j.cardiores.2006.02.023
   Das S, 2006, CELL BIOCHEM BIOPHYS, V44, P103, DOI 10.1385/CBB:44:1:103
   Das S, 2005, J PHARMACOL EXP THER, V314, P762, DOI 10.1124/jpet.105.084285
   Das S, 2006, J MOL CELL CARDIOL, V41, P248, DOI 10.1016/j.yjmcc.2006.03.009
   Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   Halestrap AP, 2006, CIRC RES, V99, P10, DOI 10.1161/01.RES.0000233145.94073.b8
   Krook A, 2000, AM J PHYSIOL-REG I, V279, pR1716
   Maulik N, 1999, CIRCULATION, V100, P369
   Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2
   Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857
   Maulik N, 1996, FEBS LETT, V396, P233, DOI 10.1016/0014-5793(96)01109-X
   Nakamura Y, 2004, CARDIOVASC RES, V64, P322, DOI 10.1016/j.cardiores.2004.07.013
   Otani H, 2004, ANTIOXID REDOX SIGN, V6, P449, DOI 10.1089/152308604322899521
   Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358
   Sato M, 2000, AM J PHYSIOL-HEART C, V279, pH901
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shintani-Ishida K, 2006, BIOCHEM BIOPH RES CO, V345, P1600, DOI 10.1016/j.bbrc.2006.05.077
   Shiroto K, 2005, J MOL CELL CARDIOL, V38, P93, DOI 10.1016/j.yjmcc.2004.10.018
   Suzuki YJ, 2004, J MOL CELL CARDIOL, V37, P1195, DOI 10.1016/j.yjmcc.2004.09.009
   Takeishi Y, 2001, J MOL CELL CARDIOL, V33, P1989, DOI 10.1006/jmcc.2001.1463
   Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90
   Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002
   Yu M, 2001, J PHYSIOL-LONDON, V536, P273, DOI 10.1111/j.1469-7793.2001.00273.x
NR 29
TC 38
Z9 43
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD MAY
PY 2007
VL 42
IS 5
BP 981
EP 990
DI 10.1016/j.yjmcc.2007.02.010
PG 10
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA 173YS
UT WOS:000246909000010
PM 17397860
DA 2018-12-27
ER

PT J
AU Al-Sweiti, Y
   Soffker, D
AF Al-Sweiti, Yousef
   Soeffker, Dirk
TI RETRACTED: Modeling and control of an elastic ship-mounted crane using
   variable gain model-based controller (Retracted article. See vol. 20,
   pg. 1920, 2014)
SO JOURNAL OF VIBRATION AND CONTROL
LA English
DT Article; Retracted Publication
DE elastic cranes; multi-model problem; variable-gain controller;
   variable-gain PI observer; disturbance estimation; disturbance
   compensation
AB This paper deals with mathematical modeling and control of elastic ship cranes which have the Maryland Rigging. The model contains three inputs to control the vibrations in the plane of the boom; the luff angle is proposed to control the elastic vibration in the boom, and the total length of the upper cable in conjunction with the position of its lower suspension point are proposed to control the pendulation of the payload. The disturbance acting on the ship due to sea motions is represented by the rolling displacement of the ship about its center of gravity. The dynamics of the crane is described by a variable model problem. Accordingly, a variable gain observer and a variable gain controller are designed to cover the operation of the crane for all possible equilibrium points in the working space. The switching action between these gains takes place automatically according to the output of a region finder, which uses the measurements of the luff angle and the length of the upper cable to detect the current operating region. PI-Observer is used to estimate the states and the unknown disturbance force acting directly on the payload; the observer guarantees that the estimated states converge to their real values even though a nonzero disturbance force acts on the payload. The controller uses the estimated states and the measured roll angle to create the required active damping and therefore to compensate for the rolling effects. Stability and performance robustness are ensured for the total working space and also for the expected range of the payload mass. Simulation results show that the observer can estimate the states and the unknown disturbance acting on the payload very well and that the controller can reduce the payload pendulations significantly.
C1 Univ Duisburg Essen, Fac Engn, Duisburg, Germany.
RP Al-Sweiti, Y (reprint author), Univ Duisburg Essen, Fac Engn, Duisburg, Germany.
CR Abdel-Rahman EM, 2003, J VIB CONTROL, V9, P1327, DOI 10.1177/107754603031164
   ALSWEITI Y, 2005, DETC 2005 ASME 20 BI
   DADONE P, 1999, INTELLIGENT ENG SYST, V9, P751
   INMAN DJ, 1989, VIBRATION CONTROL ME, P141
   Kimiaghalam B., 1999, Proceedings of the 1999 American Control Conference (Cat. No. 99CH36251), P586, DOI 10.1109/ACC.1999.782895
   Kimiaghalam B., 2000, P AM CONTR C CHIC IL, V2, P1047
   KRAJCIN I, 2005, DETC 2005 ASME 20 BI
   MEIROVITCH L, 1986, ELEMENTS VIBRATION A, P300
   MULLER PC, 1998, P IEE INT C CONTROL, P734
   SOFFKER D, 1995, INT J SYST SCI, V26, P1571, DOI 10.1080/00207729508929120
   SOFFKER D, 1993, ASME J DYNAMIC SYSTE, V3, P518
   YUAN GH, 1997, DETC 97 P ASME DES E
NR 12
TC 13
Z9 13
U1 4
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1077-5463
EI 1741-2986
J9 J VIB CONTROL
JI J. Vib. Control
PD MAY
PY 2007
VL 13
IS 5
BP 657
EP 685
DI 10.1177/107754630704246
PG 29
WC Acoustics; Engineering, Mechanical; Mechanics
SC Acoustics; Engineering; Mechanics
GA 173QD
UT WOS:000246886700012
DA 2018-12-27
ER

PT J
AU Yin, B
   Tsai, ML
   Hasz, DE
   Rathe, SK
   Le Beau, MM
   Largaespada, DA
AF Yin, B.
   Tsai, M. L.
   Hasz, D. E.
   Rathe, S. K.
   Le Beau, M. M.
   Largaespada, D. A.
TI RETRACTED: A microarray study of altered gene expression after
   cytarabine resistance in acute myeloid leukemia (Retracted article. See
   vol. 24, pg. 1543, 2010)
SO LEUKEMIA
LA English
DT Letter; Retracted Publication
C1 Univ Minnesota, Ctr Canc, Dept Genet Cel Biol & Dev, Minneapolis, MN 55455 USA.
   Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA.
   Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA.
RP Yin, B (reprint author), Univ Minnesota, Ctr Canc, Dept Genet Cel Biol & Dev, Minneapolis, MN 55455 USA.
EM larga002@umn.edu
CR Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101
   Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046
   Galmarini CM, 2002, BRIT J HAEMATOL, V117, P860, DOI 10.1046/j.1365-2141.2002.03538.x
   LARGAESPADA DA, 1995, J VIROL, V69, P5095
   Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985
   Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465
   Yin B, 2006, EXP HEMATOL, V34, P631, DOI 10.1016/j.exphem.2006.01.015
   Zhou Y, 2006, LEUKEMIA RES, V30, P469, DOI 10.1016/j.leukres.2005.08.024
NR 8
TC 13
Z9 13
U1 5
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAY
PY 2007
VL 21
IS 5
BP 1093
EP 1097
DI 10.1038/sj.leu.2404595
PG 6
WC Oncology; Hematology
SC Oncology; Hematology
GA 161FM
UT WOS:000245999900031
PM 17301810
OA Bronze
DA 2018-12-27
ER

PT J
AU Kumar, G
   Ho, CC
   Co, CC
AF Kumar, Girish
   Ho, Chia-Chi
   Co, Carlos C.
TI RETRACTED: Guiding cell migration using one-way micropattern arrays
   (Retracted article. See vol. 30, 2018)
SO ADVANCED MATERIALS
LA English
DT Article; Retracted Publication
ID ENDOTHELIAL-CELLS; GEOMETRIC CONTROL; ADHESION; SURFACES; ACTIN;
   ATTACHMENT; MOTILITY; CULTURE; MICROFILAMENT; BIOMATERIALS
C1 Univ Cincinnati, Dept Chem & Mat Engn, Cincinnati, OH 45221 USA.
RP Co, CC (reprint author), Univ Cincinnati, Dept Chem & Mat Engn, 497 Rhodes Hall, Cincinnati, OH 45221 USA.
EM cco@alpha.che.uc.edu
CR Barry JJA, 2006, ADV MATER, V18, P1406, DOI 10.1002/adma.200502719
   Berg MC, 2004, LANGMUIR, V20, P1362, DOI 10.1021/la0355489
   Bhat RR, 2005, ADV MATER, V17, P2802, DOI 10.1002/adma.200500858
   Bhatia SN, 1999, FASEB J, V13, P1883
   Bhatia SN, 1997, J BIOMED MATER RES, V34, P189, DOI 10.1002/(SICI)1097-4636(199702)34:2<189::AID-JBM8>3.0.CO;2-M
   Bhatt KH, 2005, LANGMUIR, V21, P6603, DOI 10.1021/la050658w
   BOOCOCK CA, 1989, DEVELOPMENT, V107, P881
   BOWERSOX JC, 1982, CANCER RES, V42, P2547
   Brock A, 2003, LANGMUIR, V19, P1611, DOI 10.1021/la026394k
   Bryant SJ, 2006, MACROMOLECULES, V39, P4395, DOI 10.1021/ma060145b
   CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677
   Castner DG, 2002, SURF SCI, V500, P28, DOI 10.1016/S0039-6028(01)01587-4
   Cavalcanti-Adam EA, 2006, EUR J CELL BIOL, V85, P219, DOI 10.1016/j.ejcb.2005.09.011
   Charest JL, 2004, BIOMATERIALS, V25, P4767, DOI 10.1016/j.biomaterials.2003.12.011
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Cheng XH, 2004, J BIOMED MATER RES A, V70A, P159, DOI 10.1002/jbm.a.30053
   Co CC, 2005, J AM CHEM SOC, V127, P1598, DOI 10.1021/ja044382a
   CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211
   Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441
   FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1
   FUHR G, 1992, BIOCHIM BIOPHYS ACTA, V1108, P215, DOI 10.1016/0005-2736(92)90028-K
   Fukuda J, 2006, BIOMATERIALS, V27, P1479, DOI 10.1016/j.biomaterials.2005.09.015
   Geissler M, 2004, ADV MATER, V16, P1249, DOI 10.1002/adma.200400835
   HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365
   Hubbell JA, 1999, CURR OPIN BIOTECH, V10, P123, DOI 10.1016/S0958-1669(99)80021-4
   HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X
   Jiang XY, 2005, P NATL ACAD SCI USA, V102, P975, DOI 10.1073/pnas.0408954102
   Kim H, 2004, BIOMACROMOLECULES, V5, P822, DOI 10.1021/bm034341r
   KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400
   Kumar G, 2005, LANGMUIR, V21, P9267, DOI 10.1021/la050332n
   Kumar G, 2003, LANGMUIR, V19, P10550, DOI 10.1021/la035309l
   Lahann J, 2005, MRS BULL, V30, P185, DOI 10.1557/mrs2005.50
   Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5
   LEE JH, 1995, PROG POLYM SCI, V20, P1043, DOI 10.1016/0079-6700(95)00011-4
   Li S, 2002, P NATL ACAD SCI USA, V99, P3546, DOI 10.1073/pnas.052018099
   Li S, 2001, BIORHEOLOGY, V38, P101
   Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359
   Luo N, 2003, MACROMOLECULES, V36, P6739, DOI 10.1021/ma0344341
   Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7
   Mrksich M, 2005, MRS BULL, V30, P180, DOI 10.1557/mrs2005.49
   Nakanishi J, 2004, J AM CHEM SOC, V126, P16314, DOI 10.1021/ja044684c
   Odde DJ, 2000, BIOTECHNOL BIOENG, V67, P312, DOI 10.1002/(SICI)1097-0290(20000205)67:3<312::AID-BIT7>3.3.CO;2-6
   Okajima S, 2005, LANGMUIR, V21, P4043, DOI 10.1021/la046994e
   Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com
   Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320
   STOKES CL, 1990, LAB INVEST, V63, P657
   STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552
   SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335
   Tanase M, 2005, LAB CHIP, V5, P598, DOI 10.1039/b500243e
   THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0
   Wedlich-Soldner R, 2004, EXP CELL RES, V301, P8, DOI 10.1016/j.yexcr.2004.08.011
   Wilson WC, 2003, ANAT REC PART A, V272A, P491, DOI 10.1002/ar.a.10057
   YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571
   Yang IH, 2005, BIOMATERIALS, V26, P6599, DOI 10.1016/j.biomaterials.2005.04.024
   Yang J, 2005, MRS BULL, V30, P189, DOI 10.1557/mrs2005.51
   Yousaf MN, 2001, P NATL ACAD SCI USA, V98, P5992, DOI 10.1073/pnas.101112898
   Zheng HP, 2004, LANGMUIR, V20, P7215, DOI 10.1021/la049856y
NR 60
TC 84
Z9 85
U1 5
U2 50
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD APR 20
PY 2007
VL 19
IS 8
BP 1084
EP 1090
DI 10.1002/adma.200601629
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 167EB
UT WOS:000246432800009
DA 2018-12-27
ER

PT J
AU Thati, B
   Noble, A
   Creaven, BS
   Walsh, M
   McCann, M
   Kavanagh, K
   Devereux, M
   Egan, DA
AF Thati, Bhumika
   Noble, Andy
   Creaven, Bernadette S.
   Walsh, Maureen
   McCann, Malachy
   Kavanagh, Kevin
   Devereux, Michael
   Egan, Denise A.
TI RETRACTED: In vitro anti-tumour and cyto-selective effects of
   coumarin-3-carboxylic acid and three of its hydroxylated derivatives,
   along with their silver-based complexes, using human epithelial
   carcinoma cell lines (Retracted article. See vol. 338, pg. 330, 2013)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE coumarin-3-carboxylic acid; hydroxylated coumarin-3-carboxylic acid
   derivatives; silver complexes; chemotherapeutic potential;
   cyto-selectivity
ID ACTIVATED PROTEIN-KINASE; MALIGNANT MELANOMA-CELLS; COUMARIN
   DERIVATIVES; ANTICANCER ACTIVITY; CYTOTOXICITY; SERIES; AGENTS
AB The chemotherapeutic potential of coumarin-3-carboxylic acid (C-3-COOH) and a series of three hydroxylated coumarin-3-carboxylic acid ligands, namely 6-hydroxy-coumarin-3-carboxylic acid (6-OH-C-3-COOH), 7-hydroxycoumarin-3-carboxylic acid (7-OH-C-3-COOH) and 8-hydroxy-coumarin-3-carboxylic acid (8-OH-C-3-COOH), along with their corresponding silver-based complexes, namely 6-hydroxycoumarin-3-carboxylatosilver (6-OH-C-COO-Ag), 7-hydroxycoumarin-3-carboxylatosilver (7-OH-C-COO-Ag) and 8-hydroxycoumarin-3-carboxylatosilver (8-OH-C-COO-Ag), was determined using two human-derived carcinoma (A-498 and Hep-G2), along with two non-carcinoma human-derived cell lines (CHANG and HK-2). All of the ligands and their silver complexes induced a concentration-dependent cytotoxic effect. Furthermore, hydroxylation of C-3-COOH and its subsequent complexation with silver led to the production of a series of compounds with dramatically enhanced cytotoxicity, with 6-OH-C-3-COO-Ag having the greatest activity. Additionally, all of the metal-based complexes were selectively cytotoxic to both carcinoma-derived cell lines, relative to normal renal and hepatic cells. In comparative studies with cisplatin, and based on the IC50 values obtained with Hep-G2 cells, it appeared that the coumarin-silver complexes were between 2 and 5.5 times more cytotoxic than cisplatin. All of the coumarin-silver complexes inhibited DNA synthesis, which did not appear to be mediated through intercalation. Furthermore, results obtained from Ames tests showed that all of the test agents and their phase I metabolites were non-mutagenic. Taken together, these findings suggest that both hydroxylation particularly in the 6th position and complexation with silver, served to significantly augment the cytotoxic properties of C-3-COOH, to yield a compound which acts as a cyto-selective agent, as it is a significant killer of cancer, relative to normal cells. We suggest that this group of compounds may have a therapeutic role to play in the successful treatment and management of cancer in man. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Ctr Pharmaceut R&D, Sch Sci, Inst Technol, Dublin 24, Ireland.
   Sch Sci, Inst Technol, Dept Sci, Dublin 24, Ireland.
   Natl Univ Ireland, Dept Chem, Maynooth, Kildare, Ireland.
   Natl Univ Ireland, Dept Biol, Maynooth, Kildare, Ireland.
   Dublin Inst Technol, Dublin 1, Ireland.
RP Egan, DA (reprint author), Ctr Pharmaceut R&D, Sch Sci, Inst Technol, Dublin 24, Ireland.
EM denise.egan@ittdublin.ie
OI Kavanagh, Kevin/0000-0003-3186-0292
CR Baul TSB, 2004, J ORGANOMET CHEM, V689, P4691, DOI 10.1016/j.jorganchem.2004.07.050
   Creaven BS, 2006, INORG CHIM ACTA, V359, P3976, DOI 10.1016/j.ica.2006.04.006
   Cross HJ, 1996, INT J CANCER, V66, P404
   DEEGAN C, IN PRESS CHEM BIOL
   DOUGHERTY G, 1983, BIOSCIENCE REP, V3, P453, DOI 10.1007/BF01121956
   EGAN D, 1990, DRUG METAB REV, V22, P503, DOI 10.3109/03602539008991449
   Egan D, 1997, CANCER LETT, V118, P201, DOI 10.1016/S0304-3835(97)00331-5
   Finn GJ, 2005, EUR J PHARM SCI, V26, P16, DOI 10.1016/j.ejps.2005.04.016
   Finn GJ, 2004, CANCER LETT, V214, P43, DOI 10.1016/j.canlet.2004.04.022
   Finn GJ, 2004, BIOCHEM PHARMACOL, V67, P1779, DOI 10.1016/j.bcp.2004.01.014
   Finn GJ, 2001, MELANOMA RES, V11, P461, DOI 10.1097/00008390-200110000-00004
   FRICKER PS, 1994, ROLE METALS CANC THE, P10
   Han I, 2003, BIOORGAN MED CHEM, V11, P5443, DOI 10.1016/j.bmc.2003.09.023
   Hayes JD, 1998, CHEM-BIOL INTERACT, V112, P51, DOI 10.1016/S0009-2797(97)00151-8
   Heffeter P, 2006, BIOCHEM PHARMACOL, V71, P426, DOI 10.1016/j.bcp.2005.11.009
   Hidalgo E, 1998, TOXICOL LETT, V98, P169, DOI 10.1016/S0378-4274(98)00114-3
   Hofmanova J, 1998, EUR J PHARMACOL, V350, P273, DOI 10.1016/S0014-2999(98)00264-7
   Hoult JRS, 1996, GEN PHARMACOL-VASC S, V27, P713, DOI 10.1016/0306-3623(95)02112-4
   Jimenez-Orozco FA, 1999, MELANOMA RES, V9, P243, DOI 10.1097/00008390-199906000-00005
   KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P224
   Kokotos G, 1997, BIOORG MED CHEM LETT, V7, P2165, DOI 10.1016/S0960-894X(97)00384-3
   Kolodziej H, 1997, Z NATURFORSCH C, V52, P240
   Kostova I, 2001, ARCH PHARM, V334, P157, DOI 10.1002/1521-4184(200105)334:5<157::AID-ARDP157>3.0.CO;2-S
   Laurin P, 1999, BIOORG MED CHEM LETT, V9, P2079, DOI 10.1016/S0960-894X(99)00329-7
   LORCOZIO A, 1993, EUR J CANCER, V29, P1985
   MANALOV I, 2002, ARCH PHARM MED CHEM, V333, P93
   MARSHALL ME, 1986, AM SOC ONCOL, V5, P186
   MARSHALL ME, 1994, J CANCER RES CLIN, V120, P535
   Marzano C, 2002, TOXICOL IN VITRO, V16, P413, DOI 10.1016/S0887-2333(02)00022-X
   MAUCHER A, 1993, J CANCER RES CLIN, V119, P150, DOI 10.1007/BF01229529
   MORAN DM, 1983, MUTAT RES, V113, P173
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Murray R.D., 1982, NATURAL COUMARINS OC, P1
   Pillai SP, 1999, J NAT PROD, V62, P1358, DOI 10.1021/np990048u
   PORTEOUS JD, 1985, J ARCHIT PLAN RES, V2, P169
   SHARMA S, 1994, CANCER RES, V54, P5848
   WARING M, 1970, Journal of Molecular Biology, V54, P247, DOI 10.1016/0022-2836(70)90429-8
NR 37
TC 93
Z9 97
U1 4
U2 42
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 18
PY 2007
VL 248
IS 2
BP 321
EP 331
DI 10.1016/j.canlet.2006.08.009
PG 11
WC Oncology
SC Oncology
GA 154SV
UT WOS:000245528800018
PM 16996681
DA 2018-12-27
ER

PT J
AU Roman-Gomez, J
   Cordeu, L
   Agirre, X
   Jimenez-Velasco, A
   Jose-Eneriz, ES
   Garate, L
   Calasanz, MJ
   Heiniger, A
   Torres, A
   Prosper, F
AF Roman-Gomez, Jose
   Cordeu, Lucia
   Agirre, Xabier
   Jimenez-Velasco, Antonio
   Jose-Eneriz, Edurne San
   Garate, Leire
   Calasanz, Maria Jose
   Heiniger, Anabel
   Torres, Antonio
   Prosper, Felipe
TI RETRACTED: Epigenetic regulation of Wnt-signaling pathway in acute
   lymphoblastic leukemia (Retracted article. See vol. 120, pg. 3625, 2012)
SO BLOOD
LA English
DT Article; Retracted Publication
ID INHIBITORY FACTOR-I; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE
   MYELOID-LEUKEMIA; STEM-CELLS; PROMOTER HYPERMETHYLATION; CANCER-CELLS;
   HEPATOCELLULAR-CARCINOMA; INTESTINAL EPITHELIUM; COLORECTAL-CANCER;
   PROGNOSTIC-FACTOR
AB Activation of the Wnt/beta-catenin signaling pathway is a hallmark of a number of solid tumors. We analyzed the regulation of the Wnt/beta-catenin pathway in acute lymphoblastic leukemia (ALL) and its role in the pathogenesis of the disease. We found that expression of the Wnt inhibitors sFRP1, sFRP2, sFRP4, sFRP5, WIF1, Dkk3, and Hdpr1 was down-regulated due to abnormal promoter methylation in ALL. cell lines and samples from patients with ALL. Methylation of Wnt inhibitors was associated with activation of the Wnt-signaling pathway as demonstrated by the up-regulation of the Wnt target genes WNT16, FZ3, TCF1, LEF1, and cyclin 131 in cell lines and samples and the nuclear localization of p-catenin in cell lines. Treatment of ALL cells with the Wnt inhibitor quercetin or with the demethylating agent 5-aza-2'-deoxycytidine induced an inactivation of the Wnt pathway and induced apoptosis of ALL cells. Finally, in a group of 261 patients with newly diagnosed ALL, abnormal methylation of Writ inhibitors was associated with decreased 10-year disease-free survival (25% versus 66% respectively, P < .001) and overall survival (28% versus 61% respectively, P = .001). Our results indicate a role of abnormal Wnt signaling in ALL and establish a group of patients with a significantly worse prognosis (methylated group).
C1 Reina Sofia Hosp, Dept Hematol, Cordoba 14004, Spain.
   Univ Navarra, Fdn Appl Med Res, Div Canc, Clin Univ, Navarra, Spain.
   Univ Navarra, Area Cell Therapy & Hematol Serv, Clin Univ, Navarra, Spain.
   Univ Navarra, Dept Genet, Sch Sci, E-31080 Pamplona, Spain.
   Hosp Carlos Haya, Dept Hematol, Malaga, Spain.
RP Roman-Gomez, J (reprint author), Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.
EM peperosa@teleline.es
RI Calasanz, MJ/R-5813-2016; Prosper, Felipe/H-6859-2017
OI Calasanz, MJ/0000-0002-0374-3008; Prosper, Felipe/0000-0001-6115-8790
CR Agirre X, 2006, ONCOGENE, V25, P1862, DOI 10.1038/sj.onc.1209236
   Batra S, 2006, BIOCHEM BIOPH RES CO, V342, P1228, DOI 10.1016/j.bbrc.2006.02.084
   Caricasole A, 2003, J BIOL CHEM, V278, P37024, DOI 10.1074/jbc.M300191200
   Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873
   Chim CS, 2006, LEUKEMIA, V20, P907, DOI 10.1038/sj.leu.2404176
   de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Jiang C, 2004, MOL CANCER THER, V3, P877
   Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974
   Khan NI, 2006, HISTOL HISTOPATHOL, V21, P761, DOI 10.14670/HH-21.761
   Koinuma K, 2006, ONCOGENE, V25, P139, DOI 10.1038/sj.onc.1209009
   Lee HC, 2006, FRONT BIOSCI, V11, P1901, DOI 10.2741/1933
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X
   Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/j.onc.1208568
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464
   Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9
   Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004
   NAUX P, 2005, NAT CLIN PRACT ON S1, V2, pS36
   Ortega JJ, 2001, HAEMATOLOGICA, V86, P586
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Pinto D, 2005, EXP CELL RES, V306, P357, DOI 10.1016/j.yexcr.2005.02.022
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Ribera JM, 2002, HAEMATOLOGICA, V87, P154
   Ribera JM, 1998, HAEMATOLOGICA, V83, P222
   Roman-Gomez J, 2005, J CLIN ONCOL, V23, P7043, DOI 10.1200/JCO.2005.01.4944
   Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   Roman-Gomez J, 2006, CLIN CANCER RES, V12, P4845, DOI 10.1158/1078-0432.CCR-05-2592
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18
   Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Timm A, 2005, CURR TOP MICROBIOL, V290, P225
   Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255
   Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746
   Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340
NR 51
TC 130
Z9 138
U1 4
U2 26
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD APR 15
PY 2007
VL 109
IS 8
BP 3462
EP 3469
DI 10.1182/blood-2006-09-047043
PG 8
WC Hematology
SC Hematology
GA 156OJ
UT WOS:000245658500055
PM 17148581
OA Bronze
DA 2018-12-27
ER

PT J
AU Meeran, SM
   Katiyar, S
   Elmets, CA
   Katiyar, SK
AF Meeran, Syed M.
   Katiyar, Suchitra
   Elmets, Craig A.
   Katiyar, Santosh K.
TI RETRACTED: Interleukin-12 deficiency is permissive for angiogenesis in
   UV radiation-induced skin tumors (Retracted article. See vol. 78, pg.
   6708, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ENDOTHELIAL GROWTH-FACTOR; GREEN TEA POLYPHENOLS; INDUCED
   IMMUNOSUPPRESSION; MATRIX METALLOPROTEINASES; IL-12; CANCER; MICE;
   INHIBITION; CELL; REGRESSION
AB We have shown previously that endogenous deficiency of interleukin (IL)-12 promotes photocarcinogenesis in mice. To characterize the role of IL-12 deficiency in tumor angiogenesis, we developed IL-12p35 knockout (IL-12 KO) mice on a C3H/HeN background. IL-12 KO mice and their wild-type (WT) counterparts were subjected to a photocarcinogenesis protocol. When tumor yield was stabilized, samples of tumor and tumor-uninvolved UVB-exposed skin were collected and subjected to immunohistochemistry, gelatinolytic zymography, real-time PCR, and Western blot analysis of angiogenic factors. We found that the protein, mRNA expression and/or activity of the matrix metalloproteinases (MMP)-2, MMP-3, MNIP-7, and MMP-9, and basic fibroblast growth factor, which play crucial roles in tumor growth, were significantly higher in UVB-exposed skin and tumors of IL-12 KO mice compared with WT mice. With respect to the tumor vasculature, the expression of CD31-positive cells and the expression of vascular endothelial growth factor were higher in the tumors of IL-12 KO mice than WTs. The proliferative capacity of tumor cells of the IL-12 KO mice was significantly higher than their WT counterparts when determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and by analyzing the expression of cyclin D1. The level of the proinflammatory cytokine IL-6 and the expression of IL-23 in tumors of IL-12 KO mice were markedly higher than in the tumors of WT mice. IL-23 has been shown to promote tumor growth. Together, these data indicate for the first time that IL-12 deficiency promotes proangiogenic stimuli in UVB-induced skin tumors and suggest that endogenous enhancement of IL-12 levels maybe effective in the prevention and treatment of UV-induced skin cancers.
C1 Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL 35294 USA.
   Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU NIAMS NIH HHS [P30 AR050948, P30 AR050948-030001, AR 050948-01]; NCCIH
   NIH HHS [AT 002536, R01 AT002536, R01 AT002536-01A2]
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   BRUNDA MJ, 1994, J LEUKOCYTE BIOL, V55, P280
   BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Chen L, 1997, J IMMUNOL, V159, P351
   Colombo MP, 1996, CANCER RES, V56, P2531
   Conti CJ, 2002, ONCOLOGIST, V7, P4, DOI 10.1634/theoncologist.7-suppl_3-4
   Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555
   Dias S, 1998, INT J CANCER, V78, P361, DOI 10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Katiyar SK, 2006, OXIDATIVE STRESS, DISEASE AND CANCER, P933, DOI 10.1142/9781860948046_0033
   Katiyar Santosh K., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P17
   Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117
   Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556
   Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448
   Mantena SK, 2005, J NUTR, V135, P2871
   Meeran SM, 2006, MOL CANCER THER, V5, P825, DOI 10.1158/1535-7163.MCT-06-0003
   Meeran SM, 2006, CLIN CANCER RES, V12, P2272, DOI 10.1158/1078-0432.CCR-05-2672
   Meunier L, 1998, REV MED INTERNE, V19, P247, DOI 10.1016/S0248-8663(97)89326-5
   Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095
   MULLER G, 1995, J IMMUNOL, V155, P4661
   NASTALA CL, 1994, J IMMUNOL, V153, P1697
   Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4
   RISAU W, 1995, FASEB J, V9, P926
   Robertson MJ, 1996, ONCOLOGIST, V1, P88
   Schlaeppi JM, 1999, CANCER METAST REV, V18, P473, DOI 10.1023/A:1006358220123
   Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717
   Schwarz A, 1996, J INVEST DERMATOL, V106, P1187, DOI 10.1111/1523-1747.ep12347944
   Siders WM, 1998, J IMMUNOL, V160, P5465
   Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429
   Sundelin K, 2005, ACTA OTO-LARYNGOL, V125, P765, DOI 10.1080/00016480510027484
   Vayalil PK, 2003, CARCINOGENESIS, V24, P927, DOI 10.1093/carcin/bgg025
   YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877
   Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006
   ZOU JP, 1995, INT IMMUNOL, V7, P1135, DOI 10.1093/intimm/7.7.1135
NR 40
TC 21
Z9 22
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2007
VL 67
IS 8
BP 3785
EP 3793
DI 10.1158/0008-5472.CAN-06-3134
PG 9
WC Oncology
SC Oncology
GA 158GL
UT WOS:000245779600041
PM 17440092
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Kawakami, H
   Tomita, M
   Okudaira, T
   Ishikawa, C
   Matsuda, T
   Tanaka, Y
   Nakazato, T
   Taira, N
   Ohshiro, K
   Mori, N
AF Kawakami, Hirochika
   Tomita, Mariko
   Okudaira, Taeko
   Ishikawa, Chie
   Matsuda, Takehiro
   Tanaka, Yuetsu
   Nakazato, Tetsuro
   Taira, Naoya
   Ohshiro, Kazuiku
   Mori, Naoki
TI RETRACTED: Inhibition of heat shock protein-90 modulates multiple
   functions required for survival of human T-cell leukemia virus type
   1-infected T-cell lines and adult T-cell leukemia cells (Retracted
   article. See vol. 129, pg. 2762, 2011)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE ATL; HTLV-1; 17-AAG; Hsp90; client protein
ID NF-KAPPA-B; I TAX; CONSTITUTIVE ACTIVATION; KINASE-ACTIVITY;
   GROWTH-CONTROL; CYCLIN D1; HTLV-I; HSP90; TRANSFORMATION; EXPRESSION
AB The molecular chaperone Hsp90 is involved in the stabilization and conformational maturation of many signaling proteins that are deregulated in cancers. The geldanamycin derivative 17-AAG is currently tested in clinical trials and known to inhibit the function of Hsp90 and promote the proteasomal degradation of its misfolded client proteins. ATL is a fatal malignancy of T lymphocytes caused by HTLV-I infection and remains incurable. Since Hsp90 is overexpressed in HTLV-I-infected T-cell lines and primary ATL cells, we analyzed the effects of 17-AAG on cell survival, apoptosis and expression of signal transduction proteins. HTLV-I-infected T-cell lines and primary ATL cells were significantly more sensitive to 17-AAG in cell survival assays than normal PBMCs. 17-AAG induced the inhibition of cell cycle and apoptosis. These effects could be mediated by inactivation of NF-kappa B, API and PI3K/Akt pathways, as well as reduction of expression of proteins involved in the G(1)-S cell cycle transition and apoptosis. Proteasome inhibition interfered with 17-AAG-mediated signaling proteins depletion. Collectively, our results indicate that 17-AAG suppresses ATL cell survival through, at least in part, destabilization of several client proteins and suggest that 17-AAG is a potentially useful chemotherapeutic agent for ATL. (c) 2007 Wiley-Liss, Inc.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Immunol, Nishihara, Okinawa 9030215, Japan.
   Naha City Hosp, Dept Internal Med, Naha, Japan.
   Heart Life Hosp, Dept Internal Med, Nakagsuku, Japan.
   Okinawa Prefectural Nanbu Med Ctr, Dept Hematol, Haebaru, Japan.
   Childrens Med Ctr, Haebaru, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200
   Fukuda R, 2005, P NATL ACAD SCI USA, V102, P15213, DOI 10.1073/pnas.0507184102
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   Hall WW, 2005, ONCOGENE, V24, P5965, DOI 10.1038/sj.onc.1208975
   Higuchi M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-29
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Hinz M, 1999, MOL CELL BIOL, V19, P2690
   Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304
   Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825
   Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006
   Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913
   Kawakami A, 1999, BLOOD, V94, P3847
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864
   Peloponese JM, 2006, J BIOL CHEM, V281, P8927, DOI 10.1074/jbc.M510598200
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Sanda T, 2006, LEUKEMIA, V20, P590, DOI 10.1038/sj.leu.2404129
   Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797
   Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211
   Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   Tomita M, 2006, LEUKEMIA RES, V30, P313, DOI 10.1016/j.leukres.2005.08.004
   Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475
   Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9
NR 45
TC 18
Z9 21
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2007
VL 120
IS 8
BP 1811
EP 1820
DI 10.1002/ijc.22403
PG 10
WC Oncology
SC Oncology
GA 143DM
UT WOS:000244700200029
PM 17230513
DA 2018-12-27
ER

PT J
AU Subrahmanyam, P
   Krishnapriya, B
   Reddy, LR
   Jayaraj, B
   Chiranjeevi, P
AF Subrahmanyam, P.
   Krishnapriya, B.
   Reddy, L. Ravindra
   Jayaraj, B.
   Chiranjeevi, P.
TI RETRACTED: Spectrophotometric determination of Fenitrothion in
   formulations and environmental samples (Retracted Article. See vol 75,
   pg 1149, 2008)
SO TALANTA
LA English
DT Article; Retracted Publication
DE Fenitrothion; 4,4 '-methylene-bis-(p-amino-2 '-carboxybenzanilide);
   diazotization method (DM); spectrophotometry; water; foodgrain and
   agriculture soil samples
ID RESIDUES; PARATHION
AB A facile, rapid and sensitive spectrophotometric method was developed for the determination of Fenitrothion in its formulations, water, food grain and agriculture soil samples with newly synthesised reagent. The method was based on the alkaline hydrolysis of Fenitrothion pesticide and resultant hydrolysed product of Fenitrothion was coupled with diazotised 4,4'-methylene bis-(p-amino-2'-carboxybenzanilide) in basic medium to give yellow coloured product having lambda(max) 482 nm. The formation of coloured derivatives with the coupling agent is instantaneous and stable for 30 h. Beer's law was obeyed in the concentration range of 0.2-13.0 mu g mL(-1). The proposed method is sensitive, easy to operate and permitted the determination of Fenitrothion with a detection limits of 0.077 mu g mL(-1). The experimental results indicate that the procedure can eliminate the fundamental interferences caused by other pesticides and non-target ions, which made these methods more sensitive and selective. The method was applicable to the determination of Fenitrothion residue in water, food grain and soil samples up to ng level. (C) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Labs, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Labs, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevipattium@gmail.com
CR ABBOTT DC, 1967, ANALYST, V92, P170, DOI 10.1039/an9679200170
   AOKI Y, 1975, J ASSOC OFF ANA CHEM, V58, P1286
   ATTRI BS, 1976, J ENT ABSTR ENT NEWS, V6, P37
   DAS DK, 1970, J FOOD SCI TECHNOL, V7, P62
   Deshmukh S. N., 1974, Journal of Food Science and Technology, India, V11, P81
   IVIC GW, 1971, J AGR FOOD CHEM, V19, P405
   KURUNSHKIN VL, 1982, J CHROMATOGR, V58, P10
   LURINI M, 1980, TALANTA, V27, P45
   MORLTHOFF E, 1968, PHANZENSCHUTZ NACHR, V21, P331
   MURTHY P, 1984, B ENVIRON CONTAM TOX, V32, P59
   NISHIZAWA Y, 1960, B AGR CHEM SOC JAPAN, V24, P744, DOI 10.1080/03758397.1960.10857746
   NISHIZAWA Y, 1961, J AGR BIOL CHEM, V25, P605
   NORRIS MV, 1958, J AGR FOOD CHEM, V6, P111, DOI 10.1021/jf60084a003
   RAMAKRISHNA N, 1976, ANALYST, V101, P528, DOI 10.1039/an9760100528
   SASTRY CSP, 1987, TALANTA, V34, P372, DOI 10.1016/0039-9140(87)80051-6
   SASTRY CSP, 1986, J FOOD SCI TECH MYS, V23, P336
   STAN HJ, 1983, J CHROMATOGR, V268, P55, DOI 10.1016/S0021-9673(01)95387-7
   UMEDA M, 1963, J PHARM SOC JPN, V83, P951
NR 18
TC 1
Z9 2
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD APR 15
PY 2007
VL 72
IS 1
BP 106
EP 112
DI 10.1016/j.talanta.2006.10.003
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 164IB
UT WOS:000246225900014
PM 19071589
DA 2018-12-27
ER

PT J
AU Treharne, KJ
   Crawford, RM
   Xu, Z
   Chen, JH
   Best, OG
   Schulte, EA
   Gruenert, DC
   Wilson, SM
   Sheppard, DN
   Kunzelmann, K
   Mehta, A
AF Treharne, Kate J.
   Crawford, Russell M.
   Xu, Zhe
   Chen, Jeng-Haur
   Best, O. Giles
   Schulte, Eva A.
   Gruenert, Dieter C.
   Wilson, Stuart M.
   Sheppard, David N.
   Kunzelmann, Karl
   Mehta, Anil
TI RETRACTED: Protein kinase CK2, cystic fibrosis transmembrane conductance
   regulator, and the Delta F508 mutation (Retracted Article. See vol 283,
   pg 25103, 2008)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NUCLEOSIDE DIPHOSPHATE KINASE; POLYAMINE METABOLISM; CHAPERONE CALNEXIN;
   MOLECULAR-BASIS; WILD-TYPE; CFTR; PHOSPHORYLATION; CELLS; CHANNEL;
   INHIBITION
AB Deletion of phenylalanine 508 ( Delta F508) from the first nucleotide-binding domain ( NBD1) of the cystic fibrosis transmembrane conductance regulator ( CFTR) is the most common mutation in cystic fibrosis. The F508 region lies within a surface-exposed loop that has not been assigned any interaction with associated proteins. Here we demonstrate that the pleiotropic protein kinase CK2 that controls protein trafficking, cell proliferation, and development binds wild-type CFTR near F508 and phosphorylates NBD1 at Ser-511 in vivo and that mutation of Ser-511 disrupts CFTR channel gating. Importantly, the interaction of CK2 with NBD1 is selectively abrogated by the Delta F508 mutation without disrupting four established CFTR-associated kinases and two phosphatases. Loss of CK2 association is functionally corroborated by the insensitivity of Delta F508-CFTR to CK2 inhibition, the absence of CK2 activity in Delta F508 CFTR-expressing cell membranes, and inhibition of CFTR channel activity by a peptide that mimics the F508 region of CFTR ( but not the equivalent Delta F508 peptide). Disruption of this CK2-CFTR association is the first described Delta F508-dependent protein-protein interaction that provides a new molecular paradigm in the most frequent form of cystic fibrosis.
C1 Univ Dundee, Ninewells Hosp, Dept Maternal & Child Hlth, Dundee DD1 9SY, Scotland.
   Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England.
   Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA.
   Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany.
RP Mehta, A (reprint author), Univ Dundee, Ninewells Hosp, Dept Maternal & Child Hlth, Dundee DD1 9SY, Scotland.
EM a.mehta@dundee.ac.uk
RI Best, Oliver/E-9060-2010
OI Best, Oliver/0000-0003-2685-3880; Kunzelmann, Karl/0000-0002-4583-7037
FU Wellcome Trust [069150/Z/02/Z]
CR Amaral MD, 2004, J MOL NEUROSCI, V23, P41, DOI 10.1385/JMN:23:1-2:041
   Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9
   CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8
   COLLETT A, 2002, AM J PHYSIOL, V28, pL261
   Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269
   Crawford RM, 2007, FASEB J, V21, P88, DOI 10.1096/fj.06-6804com
   Crawford RM, 2006, MOL CELL BIOL, V26, P5921, DOI 10.1128/MCB.00315-06
   Russell M, 2006, CELL SIGNAL, V18, P1595, DOI 10.1016/j.cellsig.2006.01.001
   DAHAN D, 2001, PFLUEGERS ARCH S1, V443, P92
   DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0
   DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0
   Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200
   Gadsby D.C., 1999, PHYSIOL REV, V79, pS77
   Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176
   Gruenert D C, 2004, J Cyst Fibros, V3 Suppl 2, P191, DOI 10.1016/j.jcf.2004.05.040
   Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200
   Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622
   Ishihara K, 2003, BIOCHEM J, V371, P917, DOI 10.1042/BJ20021331
   Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731
   KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460
   Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x
   Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200
   Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040
   Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469
   LUKACS GL, 1993, J BIOL CHEM, V268, P21592
   Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8
   Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev
   MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401
   Mehta A, 2005, PEDIATR PULM, V39, P292, DOI 10.1002/ppul.20147
   Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200
   MURAO S, 1989, J BIOL CHEM, V264, P8356
   OU WJ, 1992, J BIOL CHEM, V267, P23789
   Penque D, 2000, LAB INVEST, V80, P857, DOI 10.1038/labinvest.3780090
   PIND S, 1994, J BIOL CHEM, V269, P12784
   RENNERT OM, 1976, TEX REP BIOL MED, V34, P187
   Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107
   Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088
   RUSSELL DH, 1979, PEDIATR RES, V13, P1137, DOI 10.1203/00006450-197910000-00011
   RUSSELL DH, 1983, CRC CR REV CL LAB SC, V18, P261
   Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8
   Scott-ward TS, 2004, MOL MEMBR BIOL, V21, P27, DOI 10.1080/09687680310001597758
   Sheppard D. N., 1999, PHYSIOL REV, V79, pS23
   Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797
   STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698
   Tabary O, 2000, J IMMUNOL, V164, P3377, DOI 10.4049/jimmunol.164.6.3377
   Thiagarajah JR, 2003, CURR OPIN PHARMACOL, V3, P594, DOI 10.1016/j.coph.2003.06.012
   Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881
   Tirouvanziam R, 2000, AM J RESP CELL MOL, V23, P121, DOI 10.1165/ajrcmb.23.2.4214
   Tirouvanziam R, 2002, AM J PHYSIOL-LUNG C, V283, pL445, DOI 10.1152/ajplung.00419.2001
   Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912
   TREHARNE KJ, 2001, PEDIATR PULM, V22, P240
   Tugizov S, 2005, J VIROL, V79, P1099, DOI 10.1128/JVI.79.2.1099-1112.2005
   Wang HM, 2001, MOL CELL BIOCHEM, V227, P167, DOI 10.1023/A:1013112908734
   Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5
   Welsh MJ, 2001, METABOLIC MOL BASES, VIII, P5121
   Zhu Tang, 2002, Methods Mol Med, V70, P99
NR 56
TC 11
Z9 12
U1 2
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 6
PY 2007
VL 282
IS 14
BP 10804
EP 10813
DI 10.1074/jbc.M610956200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 160LB
UT WOS:000245941000074
PM 17289674
OA Bronze
DA 2018-12-27
ER

PT J
AU Chiappini, B
   Absil, B
   Rubay, J
   Noirhomme, P
   Funken, JC
   Verhelst, R
   Poncelet, A
   El Khoury, G
AF Chiappini, Bruno
   Absil, Bruno
   Rubay, Jean
   Noirhomme, Philippe
   Funken, Jean-Christophe
   Verhelst, Robert
   Poncelet, Alain
   El Khoury, Gebrine
TI RETRACTED: The Ross procedure: Clinical and echocardiographic follow-up
   in 219 consecutive patients (Retracted Article. See vol 84, pg 712,
   2007)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID AORTIC-VALVE DISEASE; PULMONARY AUTOGRAFT; SYSTEMIC CIRCULATION; ROOT
   REPLACEMENT; OPERATION; POSITION; CHILDREN; DILATATION; REOPERATION;
   EXPERIENCE
AB Background. The replacement of the diseased aortic valve with a pulmonary autograft has been shown to provide excellent hemodynamic results and to be associated with low morbidity and mortality rates.
   Methods. From 1991 to 2005, 219 patients undergoing the Ross operation were identified. All patients underwent transthoracic echocardiography at discharge and were scheduled for a yearly study thereafter. The echocardiographic study consisted of a morphologic analysis of the pulmonary autograft with measurement of end-systolic diameters at three levels: annulus, sinuses of Valsalva, and origin of the ascending aorta 2 cm above the sinotubular junction. The dynamic analysis evaluated the function of the aortic autograft and the pulmonary homograft. Maximal and mean aortic and pulmonary transvalvular pressure gradients were investigated.
   Results. The 30-day mortality was 1.8% (n = 4). Cardiac deaths were not related to the autograft. The 10-year actuarial survival was 95.7% +/- 2.1%. Six patients (2.8%) had grade 2 autograft valve regurgitation. No grade 3 or 4 pulmonary regurgitation was identified. At their most recent follow-up, 28 patients (13.1%) had grade 1 insufficiency of the pulmonary homograft, and 10 patients (4.6%) had a peak transvalvular gradient of 17.9 +/- 10.2 mm Hg.
   Conclusions. Our current experience suggests that replacement of the aortic root with a pulmonary autograft can be safely performed in infants, children, and adults and is associated with low mortality and morbidity rates. It constitutes an elegant alternative to the use of prosthetic valves in the treatment of aortic valve diseases.
C1 Catholic Univ Louvain, St Luc Hosp, Dept Thorac & Cardiovasc Surg, B-1200 Brussels, Belgium.
RP Chiappini, B (reprint author), Catholic Univ Louvain, St Luc Hosp, Dept Thorac & Cardiovasc Surg, Ave Hippocrate 10, B-1200 Brussels, Belgium.
EM bruno_chiappini@hotmail.com
CR ALLEN MD, 1991, CIRCULATION, V84, P94
   BAUDET EM, 1995, J THORAC CARDIOV SUR, V109, P858, DOI 10.1016/S0022-5223(95)70309-8
   Carr-White GS, 2000, CIRCULATION, V102, P15
   Chambers JC, 1997, CIRCULATION, V96, P2206
   Daenen W, 1998, EUR J CARDIO-THORAC, V13, P673, DOI 10.1016/S1010-7940(98)00090-6
   David TE, 2000, J THORAC CARDIOV SUR, V119, P210, DOI 10.1016/S0022-5223(00)70175-9
   Elkins R C, 1996, Semin Thorac Cardiovasc Surg, V8, P345
   Elkins RC, 1999, ANN THORAC SURG, V68, pS14, DOI 10.1016/S0003-4975(99)00841-3
   Elkins RC, 1999, J HEART VALVE DIS, V8, P499
   Elkins RC, 1998, ANN THORAC SURG, V65, P496, DOI 10.1016/S0003-4975(97)01373-8
   Elkins RC, 1996, ANN THORAC SURG, V62, P450, DOI 10.1016/0003-4975(96)00278-0
   Elkins RC, 1996, ANN THORAC SURG, V61, P1141, DOI 10.1016/0003-4975(96)00072-0
   ELKINS RC, 1992, ANN SURG, V216, P363, DOI 10.1097/00000658-199209000-00016
   HOKKEN RB, 1995, EUR J CARDIO-THORAC, V9, P378, DOI 10.1016/S1010-7940(05)80170-8
   Hokken RB, 1997, J THORAC CARDIOV SUR, V113, P667, DOI 10.1016/S0022-5223(97)70223-X
   JAFFE WM, 1990, J THORAC CARDIOV SUR, V100, P167
   JENKINS KJ, 1991, CIRCULATION, V84, P173
   KOUCHOUKOS NT, 1994, NEW ENGL J MED, V330, P1, DOI 10.1056/NEJM199401063300101
   LASKE A, 1996, ANN THORAC SURG, V10, P1097
   Leyh RG, 2002, J THORAC CARDIOV SUR, V124, P1048, DOI 10.1067/mtc.2002.124882
   Moidl R, 2000, J HEART VALVE DIS, V9, P190
   Oury JH, 1998, ANN THORAC SURG, V66, pS162, DOI 10.1016/S0003-4975(98)01028-5
   PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1
   ROSS D, 1992, EUR J CARDIO-THORAC, V6, P113, DOI 10.1016/1010-7940(92)90115-E
   ROSS DN, 1967, LANCET, V2, P956
   SANDERS SP, 1980, AM J CARDIOL, V46, P429, DOI 10.1016/0002-9149(80)90012-0
   Savoye C, 2000, AM J CARDIOL, V85, P854, DOI 10.1016/S0002-9149(99)00880-2
   Schoof PH, 1998, J THORAC CARDIOV SUR, V115, P1264, DOI 10.1016/S0022-5223(98)70208-9
   SIEVERS HH, 1993, J THORAC CARDIOV SUR, V105, P775
   Simon P, 2001, EUR J CARDIO-THORAC, V19, P118, DOI 10.1016/S1010-7940(00)00638-2
   Simon-Kupilik N, 2002, EUR J CARDIO-THORAC, V21, P470, DOI 10.1016/S1010-7940(02)00016-7
   Sonnenberg Brian H., 1999, Journal of the American College of Cardiology, V33, p554A
   Sundt TM, 2001, J THORAC CARDIOV SUR, V122, P1249, DOI 10.1067/mtc.2001.116320
   Takkenberg JJM, 2002, EUR J CARDIO-THORAC, V22, P70, DOI 10.1016/S1010-7940(02)00202-6
   Takkenberg JJM, 1999, ANN THORAC SURG, V67, P551, DOI 10.1016/S0003-4975(98)01274-0
   Tantengco MVT, 1999, AM J CARDIOL, V83, P915, DOI 10.1016/S0002-9149(98)01062-5
NR 36
TC 12
Z9 14
U1 3
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD APR
PY 2007
VL 83
IS 4
BP 1285
EP 1289
DI 10.1016/j.athoracsur.2006.11.072
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 149WZ
UT WOS:000245178900009
PM 17383328
DA 2018-12-27
ER

PT J
AU Pan, FM
   Ye, DQ
   Zhang, KC
   Li, XP
   Xu, JH
   Chen, H
AF Pan, Faming
   Ye, Dongqing
   Zhang, Kechun
   Li, Xiangpei
   Xu, Jianhua
   Chen, Hong
TI RETRACTED: Gln50Ter Polymorphism of Fc gamma receptor IIB gene
   associated with genetic susceptibility to human systemic lupus
   erythematosus in Chinese populations (Retracted Article. See vol 303, pg
   67, 2011)
SO ARCHIVES OF DERMATOLOGICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Fc gamma RIIB; polymorphism; single nucleotide; Lupus erythematosus;
   systemic; susceptibility; Chinese; family-based association test (FBAT)
ID FOLLICULAR DENDRITIC CELLS; IIIB POLYMORPHISMS; DEFICIENT MICE;
   JAPANESE; DISEASE; AUTOIMMUNITY; FCGR2B
AB The aim of this study was to investigate the role of Fc gamma RIIB gene in susceptibility to systemic lupus erythematosus (SLE) using family-based association methods. In total, 119 patients with SLE from 95 nuclear families, aged from 14 to 78 years, who met the American College of Rheumatology (ACR) 1997 criteria, were recruited, as were 316 family members of these patients. A family-based association analysis was used to explore the relationship between gene polymorphism and SLE. We studied three single-nucleotide polymorphisms (SNPs, rs10917661, rs5017567, and rs1050499) encoding non-synonymous substitution in the Fc gamma RIIB gene with respect to genetic susceptibility to SLE in collection of 435 subjects from 95 nuclear families. We performed the genotyping using PCR-restriction fragment length polymorphism method. Among 119 SLE patients, the frequencies of Fc gamma RIIB Gln/Gln,Gln/Ter and Ter/Ter genotypes were 12.7, 60.7 and 26.6%. Univariate (single-marker) family-based association tests (FBATs) demonstrated that variant alleles at a SNP, rs10917661, in exon 2 of Fc gamma RIIB gene were significantly associated with genetic susceptibility to SLE in additive model (exon 2, Z = 3.444, P = 0.00057). transmission/disequilibrium test (TDT) and sibship disequilibuium test (SDT) analysis showed an excess of the alleles of 50Ter from heterozygous parents to affected offspring (chi(2) = 10.88, P = 0.0013). However, the rs5017567 and rs1050499 SNPs were not found in Chinese population. Our findings provide strong evidence suggesting that a Fc gamma RIIB-Gln50Ter loci might be the susceptible factor of SLE in Chinese population.
C1 Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei 230032, Anhui, Peoples R China.
   Anhui Provincial Hosp, Dept Rheumatol, Hefei 230000, Peoples R China.
   Anhui Med Univ, Affiliated Hosp 1, Dept Rheumatol, Hefei 230032, Anhui, Peoples R China.
RP Ye, DQ (reprint author), Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei 230032, Anhui, Peoples R China.
EM ydq@ahmu.edu.cn
CR Amoura Z, 2000, ARTHRITIS RHEUM-US, V43, P76, DOI 10.1002/1529-0131(200001)43:1<76::AID-ANR10>3.0.CO;2-I
   Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3
   Chu ZT, 2004, TISSUE ANTIGENS, V63, P21, DOI 10.1111/j.1399-0039.2004.00142.x
   Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179
   Dijstelbloem HM, 2001, TRENDS IMMUNOL, V22, P510, DOI 10.1016/S1471-4906(01)02014-2
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Haberman AM, 2003, NAT REV IMMUNOL, V3, P757, DOI 10.1038/nri1178
   Hatta Y, 1999, GENES IMMUN, V1, P53, DOI 10.1038/sj.gene.6363639
   Jiang Y, 2000, IMMUNOGENETICS, V51, P429, DOI 10.1007/s002510050641
   Kosco-Vilbois MH, 2003, NAT REV IMMUNOL, V3, P764, DOI 10.1038/nri1179
   Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257
   Kyogoku C, 2002, GENES IMMUN, V3, P488, DOI 10.1038/sj.gene.6363921
   Li XL, 2003, ARTHRITIS RHEUM, V48, P3242, DOI 10.1002/art.11313
   Magnusson V, 2004, ARTHRITIS RHEUM, V50, P1348, DOI 10.1002/art.20151
   Qin DH, 2000, J IMMUNOL, V164, P6268, DOI 10.4049/jimmunol.164.12.6268
   Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   Salmon JE, 2001, ARTHRITIS RHEUM, V44, P739
   Siriboonrit U, 2003, TISSUE ANTIGENS, V61, P374, DOI 10.1034/j.1399-0039.2003.00047.x
   SLIGNSBY JH, 1997, IMMUNOGENETICS, V46, P361
   Su KH, 2004, J IMMUNOL, V172, P7186, DOI 10.4049/jimmunol.172.11.7186
   Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0
   Tew JG, 2001, TRENDS IMMUNOL, V22, P361, DOI 10.1016/S1471-4906(01)01942-1
   van der Pol WL, 1998, IMMUNOGENETICS, V48, P222, DOI 10.1007/s002510050426
NR 24
TC 5
Z9 6
U1 5
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-3696
EI 1432-069X
J9 ARCH DERMATOL RES
JI Arch. Dermatol. Res.
PD APR
PY 2007
VL 299
IS 1
BP 47
EP 51
DI 10.1007/s00403-006-0732-7
PG 5
WC Dermatology
SC Dermatology
GA 151LT
UT WOS:000245292500007
PM 17393178
DA 2018-12-27
ER

PT J
AU Aggarwal, BB
   Banerjee, S
   Bharadwaj, U
   Sung, B
   Shishodia, S
   Sethi, G
AF Aggarwal, Bharat B.
   Banerjee, Sanjeev
   Bharadwaj, Uddalak
   Sung, Bokyung
   Shishodia, Shishir
   Sethi, Gautam
TI RETRACTED: Curcumin induces the degradation of cyclin E expression
   through ubiquitin-dependent pathway and up-regulates cyclin-dependent
   kinase inhibitors p21 and p27 in multiple human tumor cell lines
   (Retracted article. See vol. 102, pg. 147, 2016)
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE curcurnin; cyclin E; proteasome; p21; p27; p53
ID FACTOR-KAPPA-B; BREAST-CANCER; DOWN-REGULATION; COP9 SIGNALOSOME; E
   OVEREXPRESSION; PROTEIN-KINASE; MELANOMA-CELLS; APOPTOSIS;
   PROLIFERATION; ACTIVATION
AB Curcumin, a well-known chemopreventive agent, has been shown to suppress the proliferation of a wide variety of tumor cells through a mechanism that is not fully understood. Cyclin E, a proto-oncogene that is overexpressed in many human cancers, mediates the G, to S transition, is a potential target of curcumin. We demonstrate in this report a dose- and time-dependent down-regulation of expression of cyclin E by curcumin that correlates with the decrease in the proliferation of human prostate and breast cancer cells. The suppression of cyclin E expression was not cell type dependent as down-regulation occurred in estrogen-positive and -negative breast cancer cells, androgen-dependent and -independent prostate cancer cells, leukemia and lymphoma cells, head and neck carcinoma cells, and lung cancer cells. Curcumin-induced down-regulation of cyclin E was reversed by proteasome inhibitors, lactacystin and N-acetyl-L-leuCyl-L-leucyl-L-norleucinal, suggesting the role of ubiquitin-dependent proteasomal pathway. We found that curcumin enhanced the expression of tumor cyclin-dependent kinase (CDK) inhibitofs p21 and p27 as well as tumor suppressor protein p53 but suppressed the expression of retinoblastoma protein. Curcumin also induced the accumulation of the cells in G1 phase of the cell cycle. Overall, our results suggest that proteasome-mediated down-regulation of cyclin E and up-regulation of CDK inhibitors may contribute to the antiproliferative effects of curcumin against various tumors. (c) 2006 Elsevier Inc. All rights reserved.
C1 [Aggarwal, Bharat B.] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.
RP Aggarwal, BB (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Aggarwal, Bharat/G-3388-2013
OI Sethi, Gautam/0000-0002-8677-8475
FU NCI NIH HHS [P01 CA 91844, P50 CA 97007]
CR Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400
   AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x
   Akli S, 2003, CANCER BIOL THER, V2, pS38
   Ali RE, 2006, ANN NY ACAD SCI, V1067, P394, DOI 10.1196/annals.1354.056
   Balasubramanian S, 2004, J BIOL CHEM, V279, P24007, DOI 10.1074/jbc.M314331200
   Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630
   Berglund P, 2005, CANCER RES, V65, P9727, DOI 10.1158/0008-5472.CAN-04-3984
   Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043
   Chen AP, 2005, AM J PHYSIOL-GASTR L, V288, pG447, DOI 10.1152/ajpgi.00209.2004
   Chen H, 1999, ANTICANCER RES, V19, P3675
   Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914
   Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200
   Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199
   DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201
   GONG JP, 1994, CANCER RES, V54, P4285
   Guttridge DC, 1999, MOL CELL BIOL, V19, P5785
   Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434
   Hong RL, 1999, CLIN CANCER RES, V5, P1884
   Iida H, 1997, BLOOD, V90, P3707
   Jana NR, 2004, J BIOL CHEM, V279, P11680, DOI 10.1074/jbc.M310369200
   KEYOMARSI K, 1994, CANCER RES, V54, P380
   Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153
   KEYOMARSI K, 1995, ONCOGENE, V11, P941
   KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107
   Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203
   KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y
   KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288
   Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4
   Li JQ, 2001, HUM PATHOL, V32, P945, DOI 10.1053/hupa.2001.27116
   Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605
   Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133
   Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010
   Moragoda L, 2001, ANTICANCER RES, V21, P873
   Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048
   Muller-Tidow C, 2001, CANCER RES, V61, P647
   Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612
   Park MJ, 2002, INT J ONCOL, V21, P379
   Pollmann C, 2001, CANCER RES, V61, P8416
   Qin JC, 2004, ANTICANCER RES, V24, P2991
   Rosen DG, 2006, CANCER-AM CANCER SOC, V106, P1925, DOI 10.1002/cncr.21767
   Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B
   Scuderi R, 1996, BLOOD, V87, P3360
   Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043
   Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Siwak DR, 2005, CANCER, V104, P879, DOI 10.1002/cncr.21216
   Spruck CH, 1999, NATURE, V401, P297
   Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076
   Tikhomirov O, 2003, CANCER RES, V63, P39
   Tomita M, 2006, CANCER SCI, V97, P322, DOI 10.1111/j.1349-7006.2006.00175.x
   Tomita M, 2006, LEUKEMIA RES, V30, P313, DOI 10.1016/j.leukres.2005.08.004
   Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127
   Zheng MZ, 2004, MELANOMA RES, V14, P165, DOI 10.1097/01.cmr.0000129374.76399.19
NR 56
TC 113
Z9 120
U1 4
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR 1
PY 2007
VL 73
IS 7
BP 1024
EP 1032
DI 10.1016/j.bcp.2006.12.010
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 152ZO
UT WOS:000245401300012
PM 17240359
DA 2018-12-27
ER

PT J
AU Dhaneshwar, SS
   Gairola, N
   Kandpal, M
   Bhatt, L
   Vadnerkar, G
   Kadam, SS
AF Dhaneshwar, Suneela S.
   Gairola, Neha
   Kandpal, Mini
   Bhatt, Lokesh
   Vadnerkar, Gaurav
   Kadam, S. S.
TI RETRACTED: Synthesis, kinetic studies and pharmacological evaluation of
   mutual azo prodrug of 5-aminosalicylic acid with D-phenylaianine for
   colon specific drug delivery in inflammatory bowel disease (Retracted
   article. See vol. 19, pg. 1035, 2009)
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article; Retracted Publication
DE mutual azo prodrug; 5-aminosalicylic acid; Inflammatory bowel disease;
   D-phenylalanine
ID ULCERATIVE-COLITIS; RATS; OLSALAZINE; INHIBITOR; MICE
AB Mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine was synthesized by coupling D-phenylalanine with salicylic acid, for targeted drug delivery to the inflamed gut tissue in inflammatory bowel disease. The structure of synthesized prodrug was confirmed by elemental analysis, IR and NMR spectroscopy. In vitro kinetic studies in HCl buffer (pH 1.2) showed negligible release of 5-amino salicylic acid, whereas in phosphate buffer (pH 7.4) only 15% release was observed over a period of 7 h. In rat fecal matter the release of 5-aminosalicylic acid was almost complete (85%), with a half-life of 160.1 min, following first order kinetics. The azo conjugate was evaluated for its ulcerogenic potential by Rainsford's cold stress method. Therapeutic efficacy of the carrier system and the mitigating effect of the azo conjugate were evaluated in trinitrobenzenesulfonic acid-induced experimental colitis model. The synthesized prodrug was found to be equally effective in mitigating the colitis in rats as that of sulfasalazine without the ulcerogenicity of 5-aminosalicylic acid. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Bharati Vidyapeeth Univ, Poona Coll Pharm, Dept Pharmaceut Chem, Pune 411038, Maharashtra, India.
   Poona Coll Pharm, Bharati Vidyapeeth Univ, Dept Pharmacol, Pune 411038, Maharashtra, India.
RP Dhaneshwar, SS (reprint author), Bharati Vidyapeeth Univ, Poona Coll Pharm, Dept Pharmaceut Chem, Pune 411038, Maharashtra, India.
EM suneeladhaneshwar@rediffmail.com
OI Bhatt, Lokesh/0000-0002-4302-9300
CR Bonner GB, 1993, INFLAMMOPHARMACOLOGY, P247
   Bonner GF, 1996, SOUTHERN MED J, V89, P556, DOI 10.1097/00007611-199606000-00002
   BRZEZINSKI A, 1995, CLEV CLIN J MED, V62, P317
   Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33
   DHANESHWAR SS, 1994, INDIAN DRUGS, V31, P374
   Furniss B. S., 1978, VOGELS TXB PRACTICAL, P688
   Hartmann G, 2000, J PHARMACOL EXP THER, V292, P22
   Li T., 2003, WORLD J GASTEROENTER, V9, P1028
   Mahmud N, 2001, GUT, V49, P552, DOI 10.1136/gut.49.4.552
   MARCH J, 1986, ADV ORGANIC CHEM REA, P688
   MEYERS BE, 1979, INFLAMMATION, V3, P225, DOI 10.1007/BF00914179
   MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9
   NIELSEN NM, 1988, J PHARM SCI, V77, P285, DOI 10.1002/jps.2600770402
   RAINSFORD KD, 1975, AGENTS ACTIONS, V5, P553, DOI 10.1007/BF01972694
   RAINSFORD KD, 1980, P BR PHARM SOC, P226
   RAO SSC, 1987, GUT, V28, P1474, DOI 10.1136/gut.28.11.1474
   RUBINSTEIN A, 1992, PHARMACEUT RES, V9, P276, DOI 10.1023/A:1018910128452
   SANDS BE, 2000, GASTROENTEROLOGY, V118, P68
   Sutherland LR, 1997, INFLAMM BOWEL DIS, V3, P65, DOI 10.1002/ibd.3780030202
   Uekama K, 1997, J MED CHEM, V40, P2755, DOI 10.1021/jm970130r
   YAMADA T, 1992, GASTROENTEROLOGY, V102, P1524, DOI 10.1016/0016-5085(92)91710-L
   ZINGARELLI B, 1993, AGENTS ACTIONS, V39, P150, DOI 10.1007/BF01998968
NR 22
TC 10
Z9 11
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 1
PY 2007
VL 17
IS 7
BP 1897
EP 1902
DI 10.1016/j.bmcl.2007.01.031
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 158XE
UT WOS:000245827900013
PM 17280832
DA 2018-12-27
ER

PT J
AU Hoffmann, D
   Grunwald, T
   Kuate, S
   Wildner, O
AF Hoffmann, Dennis
   Grunwald, Thomas
   Kuate, Seraphin
   Wildner, Oliver
TI RETRACTED: Mechanistic analysis and comparison of viral fusogenic
   membrane proteins for their synergistic effects on chemotherapy
   (Retracted article. See vol. 8, pg. 1787, 2009)
SO CANCER BIOLOGY & THERAPY
LA English
DT Article; Retracted Publication
DE viral fusogenic membrane proteins; apoptosis; Bcl-2; p53; oncolytic
   adenovirus vector; chemotherapy
ID VESICULAR STOMATITIS-VIRUS; MEASLES-VIRUS; ADENOVIRAL VECTORS;
   CELL-FUSION; REPLICATING ADENOVIRUS; COLORECTAL-CANCER; RECOMBINANT
   ADENOVIRUSES; ENVELOPED VIRUSES; CONTROLLED-TRIAL; GENE-THERAPY
AB Previously we demonstrated that the expression of fusogenic membrane proteins (FMG) of measles virus (MV-H/F) can synergistically enhance chemotherapy. In this study, we used median - effect analysis to evaluate whether the expression of respiratory syncytial virus (RSV-F), as well as vesicular stomatitis virus (VSV-G) can also synergistically enhance chemotherapy. Furthermore we elucidated by western blot analysis some molecular pathways that might be responsible for this effect. We showed in colorectal cancer cell lines that the expression of MV-H/F, but also of RSV-F, as well as VSV-G can synergistically enhance p53-independent clinically relevant chemotherapy (FOLFOX) over most of the cytotoxic dose range. In a subcutaneous HT-29 colorectal xenograft model, we demonstrated that the administration of replication-deficient adenovirus vectors encoding MV-H/F, RSV-F or VSV-G in combination with FOLFOX significantly enhanced treatment outcome when compared to the treatment with each compound individually. The anti-neoplastic efficacy of RSV-F was somewhat better than that of MV-H/F and both were statistically significantly more efficacious than VSV-G alone or in combination with chemotherapy. Treatment efficacy was further significantly improved when the replication-deficient FMG encoding vectors were trans-complemented for replication with a replication-restricted oncolytic adenovirus to improve tumor transduction efficiency. The combination of FMG expression, chemotherapy and trans-complementing oncolytic vectors resulted in a significantly better treatment efficacy than treatment with its components as single-or double-agent therapy. Our data indicates that FMG expression (i.e., RSV-F and MV-H/ F) in combination with chemotherapy and viral oncolysis warrants further investigations.
C1 Ruhr Univ Bochum, Inst Microbiol & Hyg, Dept Mol & Med Virol, D-44801 Bochum, Germany.
RP Wildner, O (reprint author), Ruhr Univ Bochum, Inst Microbiol & Hyg, Dept Mol & Med Virol, Bldg MA,Rm 6-40, D-44801 Bochum, Germany.
EM Wildner@ruhr-uni-bochum.de
RI Grunwald, Thomas/J-7728-2015
CR Ahmed A, 2003, GENE THER, V10, P1663, DOI 10.1038/sj.gt.3302064
   Alemany R, 1999, CANCER GENE THER, V6, P21, DOI 10.1038/sj.cgt.7700001
   Bateman A, 2000, CANCER RES, V60, P1492
   Bateman AR, 2002, CANCER RES, V62, P6566
   BETT AJ, 1993, J VIROL, V67, P5911
   Caballero M, 1998, J VIROL, V72, P8198
   CHOU J, 1991, QUANTITATION SYNERGI, P223
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   CHOU TC, 1996, WINDOWS SOFTWARE DOS
   CHOU TC, 1991, MEDIAN EFFECT PRINCI, P61
   DANIEL PT, 2003, ESSAYS BIOCHEM, P3973
   Dion LD, 1996, GENE THER, V3, P1021
   DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L
   Erlenhoefer C, 2001, J VIROL, V75, P4499, DOI 10.1128/JVI.75.10.4499-4505.2001
   Esimone CO, 2005, J APPL MICROBIOL, V99, P1346, DOI 10.1111/j.1365-2672.2005.02732.x
   FERNANDEZ E, 1994, INT J CANCER, V57, P786, DOI 10.1002/ijc.2910570605
   FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454
   FREDERICKSEN BL, 1995, J VIROL, V69, P1435
   Fu XP, 2003, MOL THER, V7, P748, DOI 10.1016/S1525-0016(03)00092-3
   Galanis E, 2001, HUM GENE THER, V12, P811, DOI 10.1089/104303401750148766
   GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627
   Hitt DC, 2000, MOL BIOTECHNOL, V14, P197, DOI 10.1385/MB:14:3:197
   Hoffmann D, 2006, GENE THER, V13, P1534, DOI 10.1038/sj.gt.3302806
   Hoffmann D, 2006, MOL CANCER THER, V5, P2013, DOI 10.1158/1535-7163.MCT-06-0128
   Horn GP, 2005, J VIROL, V79, P1911, DOI 10.1128/JVI.79.3.1911-1917.2005
   Inoue H, 2000, J BIOL CHEM, V275, P28028
   JAIN RK, 1990, CANCER RES, V50, pS814
   JAROSZESKI MJ, 1995, MEHTODS MOL BIOL, P48355
   Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23
   Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638
   Kuate S, 2004, J GENE MED, V6, P1197, DOI 10.1002/jgm.623
   Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0
   Landers JE, 1997, CANCER RES, V57, P3562
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3
   LANZREIN M, 1994, BIOCHEM J, V302, P313, DOI 10.1042/bj3020313
   Lee CT, 2004, CANCER RES, V64, P6660, DOI 10.1158/0008-5472.CAN-04-1200
   Li H, 2001, HUM GENE THER, V12, P2155, DOI 10.1089/10430340152710504
   Mittereder N, 1996, J VIROL, V70, P7498
   Momand J, 1997, J CELL BIOCHEM, V64, P343
   Nakamura T, 2004, NAT BIOTECHNOL, V22, P331, DOI 10.1038/nbt942
   Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354
   Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102
   RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3
   RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   SUPERTI F, 1987, J GEN VIROL, V68, P387, DOI 10.1099/0022-1317-68-2-387
   Techaarpornkul S, 2002, VIROLOGY, V294, P296, DOI 10.1006/viro.2001.1340
   UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706
   WILD TF, 1994, J VIROL, V68, P7546
   Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810
   Wolkersdorfer GW, 2004, J GENE MED, V6, P652, DOI 10.1002/jgm.551
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939
   Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01
NR 61
TC 7
Z9 7
U1 2
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD APR
PY 2007
VL 6
IS 4
BP 510
EP 518
DI 10.4161/cbt.6.4.3815
PG 9
WC Oncology
SC Oncology
GA 191AR
UT WOS:000248102700012
PM 17374986
OA Bronze
DA 2018-12-27
ER

PT J
AU Kong, DJ
   Li, YW
   Wang, ZW
   Banerjee, S
   Sarkar, FH
AF Kong, Dejuan
   Li, Yiwei
   Wang, Zhiwei
   Banerjee, Sanjeev
   Sarkar, Fazlul H.
TI RETRACTED: Inhibition of angiogenesis and invasion by 3,3
   '-diindolylmethane is mediated by the NF-kappa B downstream target genes
   MMP-9 and uPA that regulated bioavailability of VEGF in prostate cancer
   (Retracted article. See vol. 78, pg. 5471, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ENDOTHELIAL GROWTH-FACTOR; SPLICE VARIANTS; DOWN-REGULATION;
   TUMOR-GROWTH; CELLS; MATRIX-METALLOPROTEINASE-9; RECEPTORS; EXPRESSION;
   BIOLOGY; TUMORIGENICITY
AB Progression of prostate cancer is believed to be dependent on angiogenesis induced by tumor cells. 3,3'-Diindolylmethane (DIM) has been shown to repress neovascularization in a Matrigel plug assay and inhibit cell proliferation, migration, invasion, and capillary tube formation of cultured human umbilical vein endothelial cells. However, the molecular mechanism, by which DIM inhibits angiogenesis and invasion, has not been fully elucidated. Therefore, we sought to explore the molecular mechanism by which DIM inhibits angiogenesis and invasion specifically by investigating the role of angiogenic factors secreted by prostate cancer cells which control all steps of angiogenesis. We found that BioResponse DIM (B-DIM), a formulated DIM with higher bioavailability, inhibited angiogenesis and invasion by reducing the bioavailability of vascular endothelial growth factor (VEGF) via repressing extracellular matrix-degrading proteases, such as matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), in human prostate cancer cells and reduced vascularity (angiogenesis) in vivo using Matrigel plug assay. We also found that B-DIM treatment inhibited DNA binding activity of nuclear factor-kappa B (NF-kappa B), which is known to mediate the expression of many NF-kappa B downstream target genes, including VEGF, IL-8, uPA, and MMP-9, all of which are involved in angiogenesis, invasion, and metastasis. Our data suggest that inhibition of NF-kappa B DNA binding activity by B-DIM contributes to the regulated bioavailability of VEGF by MMP-9 and uPA and, in turn, inhibits invasion and angiogenesis, which could be mechanistically linked with the antitumor activity of B-DIM as observed previously by our laboratory in a prostate cancer animal model.
C1 Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, 740 Hudson Webber Canc Res Ctr,4160 John R Detroi, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [5R01CA108535-03]
CR Bergers G, 2000, NAT CELL BIOL, V2, P737
   Bhuiyan MMR, 2006, CANCER RES, V66, P10064, DOI 10.1158/0008-5472.CAN-06-2011
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chang XF, 2006, CARCINOGENESIS, V27, P541, DOI 10.1093/carcin/bgi230
   Chang XF, 2005, CARCINOGENESIS, V26, P771, DOI 10.1093/carcin/bgi018
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Garikapaty VPS, 2006, BIOCHEM BIOPH RES CO, V340, P718, DOI 10.1016/j.bbrc.2005.12.059
   Gustafsson T, 2005, J APPL PHYSIOL, V98, P2137, DOI 10.1152/japplphysiol.01402.2004
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Huang S, 2000, CANCER RES, V60, P5334
   Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535
   Keller MJ, 2003, J VIROL, V77, P6666, DOI 10.1128/JVI.77.12.6666-6675.2003
   Kristal AR, 2002, NUTR CANCER, V42, P1, DOI 10.1207/S15327914NC421_1
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Li YW, 2005, FRONT BIOSCI, V10, P236, DOI 10.2741/1523
   Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561
   Mira E, 2004, J CELL SCI, V117, P1847, DOI 10.1242/jcs.01035
   Miyamoto H, 2005, MOL CARCINOGEN, V44, P1, DOI 10.1002/mc.20121
   Neufeld G, 1999, FASEB J, V13, P9
   Ortega N, 1998, BIOL CELL, V90, P381, DOI 10.1016/S0248-4900(98)80087-7
   Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390
   Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200
   Rahman KMW, 2005, CANCER RES, V65, P364
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498
   Rosenbaum-Dekel Y, 2005, BIOCHEM BIOPH RES CO, V332, P271, DOI 10.1016/j.bbrc.2005.04.123
   SAH J, 2004, J CELL BIOCHEM, V91, P100
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
   Xie KP, 2004, CYTOKINE GROWTH F R, V15, P297, DOI 10.1016/j.cytogfr.2004.04.003
NR 34
TC 161
Z9 167
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2007
VL 67
IS 7
BP 3310
EP 3319
DI 10.1158/0008-5472.CAN-06-4277
PG 10
WC Oncology
SC Oncology
GA 156BM
UT WOS:000245622900050
PM 17409440
OA Bronze
DA 2018-12-27
ER

PT J
AU Heng, BC
AF Heng, Boon Chin
TI RETRACTED: Disparity in medical fees for donor and self freeze-thaw
   embryo transfer cycle - A covert form of embryo commercialization?
   (Retracted Article. See vol 7, pg 118, 2007)
SO DEVELOPING WORLD BIOETHICS
LA English
DT Letter; Retracted Publication
ID DONATION
C1 Natl Univ Singapore, Singapore 119074, Singapore.
RP Heng, BC (reprint author), Natl Univ Singapore, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
EM denhenga@nus.edu.sg
CR Bankowski BJ, 2005, FERTIL STERIL, V84, P823, DOI 10.1016/j.fertnstert.2005.02.057
   Edwards RG, 1997, HUM REPROD, V12, P3, DOI 10.1093/humrep/12.1.3
   Guerin JF, 1998, HUM REPROD, V13, P1129, DOI 10.1093/humrep/13.5.1129
   Sauer M, 2006, REPROD BIOMED ONLINE, V12, P153, DOI 10.1016/S1472-6483(10)60855-3
   SERHAL P, 1993, FERTIL STERIL, V59, P936
NR 5
TC 1
Z9 1
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1471-8731
EI 1471-8847
J9 DEV WORLD BIOETH
JI Dev. World Bioeth.
PD APR
PY 2007
VL 7
IS 1
BP 49
EP 50
DI 10.1111/j.1471-8847.2006.00156.x
PG 2
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA 219ZK
UT WOS:000250126500011
PM 17355335
DA 2018-12-27
ER

PT J
AU Hashizume, K
   Suzuki, S
   Komatsu, A
   Hiramatsu, K
   Mori, J
   Yamazaki, M
   Takeda, T
   Kakizawa, T
   Miyamoto, T
   Koizumi, Y
   Ichikawa, K
AF Hashizume, Kiyoshi
   Suzuki, Satoru
   Komatsu, Ai
   Hiramatsu, Kunihide
   Mori, Jun-ichiro
   Yamazaki, Masanori
   Takeda, Teiji
   Kakizawa, Tomoko
   Miyamoto, Takahide
   Koizumi, Yoichi
   Ichikawa, Kazuo
TI RETRACTED: Administration of recombinant human growth hormone normalizes
   GH-IGF1 axis and improves malnutrition-related disorders in patients
   with anorexia nervosa (Retracted Article. See vol 56, pg 726, 2009)
SO ENDOCRINE JOURNAL
LA English
DT Article; Retracted Publication
DE anorexia nervosa; growth hormone (GH); insulin-like growth factor-I
   (IGF-I); malnutrition
ID EATING-DISORDERS; FACTOR-I; FEEDBACK-REGULATION; WEIGHT-LOSS;
   HYPOPITUITARISM; LIPOPROTEINS; SECRETION; MORTALITY; LIPIDS; WOMEN
AB High serum level of GH in the presence of low plasma level of insulin-like growth factor-I (IGF-I) is one of the endocrinological features of anorexia nervosa (AN). Whether the amount of endogenous GH is not enough to increase IGF-I is not certain. We studied the effect of recombinant human growth hormone (rhGH) on the GH-IGF-I axis and oil malrultrition-related disorders in this syndrome. Twenty patients with AN were divided into two groups; one (N = 13) was given rhGH (0.33 mg/day), and the other (N = 7) was given placebo for 6 or 12 months, respectively. During each treatment, levels of serum GH, plasma IGF-I, serum thyroid hormones, serum cholesterol, fasting plasma glucose and cardiac function were monitored. Changes in body mass index (BMI) and calorie taken were also evaluated. Plasma IGF-I level increased from 74.4 +/- 41.9 to 269.0 +/- 31.2 mu g/L (P < 0.001) during administration of rhGH, which associated with a decrease in serum GH level from 17.0 +/- 15.0 to 1.6 +/- 0.8 mu g/L (P < 0.001). Administration of rhGH increased BMI, body temperature, fasting plasma glucose level, and food intake. Serum level of triiodothyronine, but not thyroxine, increased during treatment with rhGH. The treatment decreased serum levels of both total and HDL-cholesterol. Studies with echocardiography showed an increase in cardiac Output during the treatment with rhGH. These improvements were not observed in patients treated with placebo. Administration of rhGH is recommended as one of the methods of managing the patients with AN.
C1 [Hashizume, Kiyoshi; Suzuki, Satoru; Komatsu, Ai; Hiramatsu, Kunihide; Mori, Jun-ichiro; Yamazaki, Masanori; Takeda, Teiji; Kakizawa, Tomoko; Miyamoto, Takahide; Koizumi, Yoichi; Ichikawa, Kazuo] Shinshu Univ, Grad Sch Med, Dept Aging Med & Geriatr, Inst Aging & Adaptat, Matsumoto, Nagano 3908621, Japan.
RP Hashizume, K (reprint author), Shinshu Univ, Grad Sch Med, Dept Aging Med & Geriatr, Inst Aging & Adaptat, Matsumoto, Nagano 3908621, Japan.
CR ABE H, 1983, ENDOCRINOLOGY, V113, P1319, DOI 10.1210/endo-113-4-1319
   *AM PSYCH ASS, 1999, DIAGN STAT MAN MENT, P539
   Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169
   BERMANN M, 1994, J CLIN INVEST, V94, P138, DOI 10.1172/JCI117299
   Case T, 1999, INT J EAT DISORDER, V25, P187, DOI 10.1002/(SICI)1098-108X(199903)25:2<187::AID-EAT8>3.0.CO;2-9
   DESIMONE GD, 1994, BRIT HEART J, V71, P287
   Diekmann T, 1998, J CLIN ENDOCR METAB, V83, P1752, DOI 10.1210/jc.83.5.1752
   GARNER DM, 1982, PSYCHOL MED, V12, P871, DOI 10.1017/S0033291700049163
   GROTHAUS KL, 1998, J CLIN ADOLESC PSYCH, V4, P146
   Mehler PS, 1998, INT J EAT DISORDER, V24, P217, DOI 10.1002/(SICI)1098-108X(199809)24:2<217::AID-EAT11>3.0.CO;2-W
   MEHLER PS, 1996, NUTR CLIN PRACT, V19, P347
   Melmed S, 1996, J PEDIATR ENDOCR MET, V9, P369
   Nakai Y, 1999, J CLIN ENDOCR METAB, V84, P1226, DOI 10.1210/jc.84.4.1226
   Pollock G, 1996, ACAD EMERG MED, V3, P700, DOI 10.1111/j.1553-2712.1996.tb03495.x
   Portes ES, 2000, CLIN ENDOCRINOL, V53, P183, DOI 10.1046/j.1365-2265.2000.01071.x
   Ramsay R, 1999, BRIT J PSYCHIAT, V175, P147, DOI 10.1192/bjp.175.2.147
   ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O
   RUBIN RT, 2001, ENDOCRINOLOGY, P631
   SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072
   Stoving RK, 1999, J CLIN ENDOCR METAB, V84, P2056, DOI 10.1210/jc.84.6.2056
   Stoving RK, 1999, J CLIN ENDOCR METAB, V84, P1346, DOI 10.1210/jc.84.4.1346
   Stoving RK, 1999, J PSYCHIATR RES, V33, P139, DOI 10.1016/S0022-3956(98)00049-1
   Swenne I, 1999, ACTA PAEDIATR, V88, P304, DOI 10.1080/08035259950170079
   Swenne I, 2000, ACTA PAEDIATR, V89, P447, DOI 10.1080/080352500750028177
   TANNENBAUM GS, 1983, SCIENCE, V220, P77, DOI 10.1126/science.6338593
   Vitiello B, 2000, BIOL PSYCHIAT, V47, P777, DOI 10.1016/S0006-3223(99)00319-4
   Wolthers T, 1996, METABOLISM, V45, P1016, DOI 10.1016/S0026-0495(96)90273-5
   YAMASHITA H, 1986, ENDOCRINOLOGY, V128, P857
   YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832
NR 29
TC 11
Z9 12
U1 3
U2 16
PU JAPAN ENDOCRINE SOC
PI KYOTO
PA 75  YANAGINOBANBA NISHIIRU-MASUYA-CHO, SANJOU-DORI, NAKAGYOU-KU, KYOTO,
   604-8111, JAPAN
SN 0918-8959
EI 1348-4540
J9 ENDOCR J
JI Endocr. J.
PD APR
PY 2007
VL 54
IS 2
BP 319
EP 327
DI 10.1507/endocrj.K05-178
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 261MK
UT WOS:000253083100018
PM 17339748
OA Bronze
DA 2018-12-27
ER

PT J
AU Sahnoun, L
   Belghith, M
   Jouini, R
   Jallouli, M
   Maazoun, K
   Krichene, I
   Mekki, M
   Ben Brahim, M
   Nouri, A
AF Sahnoun, L.
   Belghith, M.
   Jouini, R.
   Jallouli, M.
   Maazoun, K.
   Krichene, I.
   Mekki, M.
   Ben Brahim, M.
   Nouri, A.
TI RETRACTED: Spontaneous perforation of the extrahepatic bile duct in
   infancy: Report of two cases and literature review (Retracted article.
   See vol 19, pg. 40, 2009)
SO EUROPEAN JOURNAL OF PEDIATRIC SURGERY
LA English
DT Review; Retracted Publication
DE bile duct perforation; spontaneous; bile peritonitis
ID SPONTANEOUS BILIARY PERFORATION; CHOLEDOCHAL CYST; IDIOPATHIC
   PERFORATION; COMMON BILE; DIAGNOSIS; CHILDREN; TRACT
AB Background: Spontaneous perforation of the bile duct (SPBD) is a rare disease in infancy. The pathogenesis, diagnostic modalities and treatment options for this condition are reviewed and discussed. Methods: The authors report 2 new observations of SPBD in 2 male newborns aged respectively 27 and 21 days. Results: The 2 newborns presented with cholestatic jaundice. Abdominal sonography showed an extrahepatic mass. Exploratory laparotomy revealed that the perforation was located in the cystic duct in the first case and in the common bile duct (CBD) in the second. The site of perforation was repaired and both patients underwent simple external biliary drainage. The postoperative course was uneventful for both patients with follow-up ranging from 2 to 4 years. Conclusions: SPBD is a rare, but important cause of surgical jaundice in infants. The pathogenesis of SPBD is unknown and multifactorial and diagnosis is often problematic. Surgical management is always required and a conservative approach is usually recommended. The prognosis is good with early surgical management.
C1 Hosp Fattouma Bourguiba, Serv Chirurg Pediat, Dept Paediat Surg, Monastir 5000, Tunisia.
RP Sahnoun, L (reprint author), Hosp Fattouma Bourguiba, Serv Chirurg Pediat, Dept Paediat Surg, Monastir 5000, Tunisia.
EM lassaad.sahnoun@rns.tn
OI Jallouli, Mohamed/0000-0002-6137-6787
CR ANDERSSON D, 1982, PEDIATRICS, V70, P601
   ANDO H, 1995, J AM COLL SURGEONS, V181, P125
   Ando K, 1998, EUR J PEDIATR SURG, V8, P23, DOI 10.1055/s-2008-1071113
   Balsarkar D J, 2001, Indian J Gastroenterol, V20, P198
   BANANI SA, 1993, J PEDIATR SURG, V28, P950
   Cameron RB, 1986, PEDIAT SURG INT, V1, P206
   Chardot C, 1996, EUR J PEDIATR SURG, V6, P341, DOI 10.1055/s-2008-1071011
   CHILUKURI S, 1990, AM J OBSTET GYNECOL, V163, P1201, DOI 10.1016/0002-9378(90)90690-9
   DAVENPORT M, 1991, BRIT J SURG, V78, P1068, DOI 10.1002/bjs.1800780912
   GAUTHIER F, 1986, CHIR PEDIATR, V27, P148
   Goldberg D, 2000, J PEDIATR GASTR NUTR, V31, P201, DOI 10.1097/00005176-200008000-00024
   HALLER JO, 1989, RADIOLOGY, V172, P621, DOI 10.1148/radiology.172.3.2672089
   HAMMOUDI SM, 1988, J PEDIATR SURG, V23, P185, DOI 10.1016/S0022-3468(88)80155-6
   Hasegawa T, 2000, PEDIATR SURG INT, V16, P550, DOI 10.1007/s003830000433
   Hirigoyen MB, 1995, EUR J PEDIATR SURG, V5, P375, DOI 10.1055/s-2008-1066248
   Holland R M, 1992, Semin Pediatr Surg, V1, P125
   Karnak I, 1997, J PEDIATR SURG, V32, P736
   Kasat LS, 2001, PEDIATR SURG INT, V17, P463, DOI 10.1007/s003830000477
   KOLBE A, 1986, J PEDIATR SURG, V21, P1139, DOI 10.1016/0022-3468(86)90027-8
   LACHAUX A, 1994, ARCH PEDIATRIE, V1, P38
   LILLY JR, 1974, SURGERY, V75, P664
   LLOYD DA, 1980, BRIT J SURG, V67, P621, DOI 10.1002/bjs.1800670905
   MELTEM BK, 2000, J PEDIAT GASTAROENTE, V31, P83
   Prabakaran S, 2000, PEDIATR SURG INT, V16, P109, DOI 10.1007/s003830050032
   Pradas DVI, 1999, PEDIATR SURG INT, V15, P401
   Rhoads K, 2002, J PEDIATR SURG, V37, P1374, DOI 10.1053/jpsu.2002.35029
   SO SKS, 1983, PEDIATRICS, V71, P402
   SONNENBERG E, 1991, RADIOLOGY, V178, P687
   Spigland N, 1996, J PEDIATR SURG, V31, P782, DOI 10.1016/S0022-3468(96)90132-3
   Suresh-Babu MV, 1998, J PEDIATR GASTR NUTR, V26, P461, DOI 10.1097/00005176-199804000-00019
   Xanthakos SA, 2003, J PEDIATR GASTR NUTR, V36, P287, DOI 10.1097/00005176-200302000-00024
NR 31
TC 7
Z9 9
U1 3
U2 9
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0939-7248
EI 1439-359X
J9 EUR J PEDIATR SURG
JI Eur. J. Pediatr. Surg.
PD APR
PY 2007
VL 17
IS 2
BP 132
EP 135
DI 10.1055/s-2007-965123
PG 4
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA 166UY
UT WOS:000246407300012
PM 17503309
DA 2018-12-27
ER

PT J
AU Ma, LM
   Jiang, XQ
   Wang, JX
   Xu, ZG
   Li, Z
AF Ma, Limin
   Jiang, Xiangqian
   Wang, Jinxing
   Xu, Zhengao
   Li, Zhu
TI RETRACTED: Study on the expression specifications of geometrical
   products for function, design, manufacture and verification based on the
   improved GPS language (Retracted article. See vol. 57, pg. 1259, 2011)
SO INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY
LA English
DT Article; Retracted Publication
DE GPS; geometrical specification model; surface model; operation;
   geometrical feature; specification
AB For the design, manufacture and verification, a consistent geometrical model for the product functional geometry is required. In this paper, we analyze the relation of the geometrical model with the design, manufacture, and verification of the geometrical product. Based on the improved GPS language, the new concepts and mathematical tools for the geometrical specifications are defined. A surface model defined in the new GPS can be divided into three models: nominal, specification and verification surface model. Expanded geometrical features exist in three "worlds": nominal, specification and verification worlds. Operations are specific mathematical tools to obtain ideal or non-ideal features, or values of characteristics, their nominal value and their limit(s). The operations used to define the specifications can be divided into seven classes: partition, extraction, filtration, association, collection, construction, and evaluation. With a simple mechanism as an example, the geometrical expression specifications for the functions, design, manufacture and verification of a product are illustrated.
C1 Huazhong Univ Sci & Technol, Sch Mech Engn, Wuhan 430074, Peoples R China.
   Univ Huddersfield, Ctr Precis Technol, Huddersfield HD1 3DH, W Yorkshire, England.
RP Ma, LM (reprint author), Huazhong Univ Sci & Technol, Sch Mech Engn, Wuhan 430074, Peoples R China.
EM ly_mlm@163.com
CR [Anonymous], 1999, 146601 ISO
   BALLU M, 1995, 4 CIRP SEM TOK JAP, P31
   BENNICH P, 1993, P 1993 INT FOR DIM T, V27, P269
   *ISO, 2002, ISOTS174502
   *ISO, 2002, BUS PLAN ISO TC 213
   *ISO, 2003, ISOTR16610
   *ISO, 2001, ISOTS174501
   *ISO, 1995, ISOTR4638
   JIANG X, 2002, 2 INT S INSTR SCI TE, V3, P9
   MA Li-min, 2004, J SHANGHAI U, V8, P7
NR 10
TC 4
Z9 4
U1 4
U2 19
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-3768
EI 1433-3015
J9 INT J ADV MANUF TECH
JI Int. J. Adv. Manuf. Technol.
PD APR
PY 2007
VL 32
IS 9-10
BP 990
EP 998
DI 10.1007/s00170-005-0395-0
PG 9
WC Automation & Control Systems; Engineering, Manufacturing
SC Automation & Control Systems; Engineering
GA 152KW
UT WOS:000245361900017
DA 2018-12-27
ER

PT J
AU Wang, YJ
   Chen, KP
   Yao, Q
   Han, X
AF Wang, Yong-Jie
   Chen, Ke-Ping
   Yao, Qin
   Han, Xu
TI RETRACTED: Transcriptional analysis of the DNA polymerase gene of Bombyx
   mori parvo-like virus (China isolate) (Retracted Article. See vol 45, pg
   478, 2007)
SO JOURNAL OF MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE Bombyx mori parvo-like virus; DNA polymerase gene; conserved motif;
   transcription analysis
ID LINEAR MITOCHONDRIAL PLASMID; SPOT SYNDROME VIRUS; STRUCTURAL FEATURES;
   NUCLEOTIDE-SEQUENCE; RNA-POLYMERASES; PROTEIN; IDENTIFICATION;
   NEUROSPORA; EXPRESSION; INVERTRON
AB The Bombyx mori parvo-like virus (China isolate) DNA polymerase (BmDNV-3 dnapol) gene has been tentatively identified based on the presence of conserved motifs. In the present study, we perform a transcriptional analysis of the BmDNV-3 dnapol gene using the total RNA isolated from BmDNV-3 infected silkworm at different times. Northern blot analysis with a BmDNV-3 dnapol-specific riboprobe showed a major transcript of 3.3 kb. 5'-RACE revealed that the major transcription start point was located 20 nucleotides downstream of the TATA box. In a temporal expression analysis using differentia) RT-PCR, BmDNV-3 dnapol transcript was detected at low levels at 6 h.p.i., increased from 6 to 36 h.p.i., and remained fairly constant thereafter. Analysis of the predicted DNA polymerase sequence using neighbor-joining and protein parsimony algorithms indicated that the predicted 1115-residue polypeptide contained five motifs associated with DNA polymerases synthetic activities and three additional motifs associated with polymerases possessing 3' to 5' exonuclease activity. The molecular phylogenetic analysis of this gene supported the placement of Bombyx mori parvo-like virus in a separate virus family.
C1 Anhui Acad Agr Sci, Inst Fisheries, Hefei 230031, Peoples R China.
   Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Peoples R China.
RP Wang, YJ (reprint author), Anhui Acad Agr Sci, Inst Fisheries, Hefei 230031, Peoples R China.
EM hfwangyongjie@163.com
CR BENSIMHON M, 1983, NUCLEIC ACIDS RES, V11, P4521, DOI 10.1093/nar/11.13.4521
   BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610
   Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509
   Bois F, 1999, MOL GEN GENET, V261, P508, DOI 10.1007/s004380050994
   Bulach DM, 1999, J INVERTEBR PATHOL, V73, P59, DOI 10.1006/jipa.1998.4797
   CHAN BSS, 1991, CURR GENET, V20, P225
   Chen LL, 2002, VIROLOGY, V293, P44, DOI 10.1006/viro.2001.1273
   COURT DA, 1992, CURR GENET, V22, P385, DOI 10.1007/BF00352440
   GRABHERR R, 1992, VIROLOGY, V188, P721, DOI 10.1016/0042-6822(92)90527-V
   Handa H, 2002, MOL GENET GENOMICS, V267, P797, DOI 10.1007/s00438-002-0711-4
   HERMANNS J, 1992, CURR GENET, V22, P491, DOI 10.1007/BF00326415
   Hess M, 1997, VIROLOGY, V238, P145, DOI 10.1006/viro.1997.8815
   ISHINO M, 1987, VIROLOGY, V156, P414, DOI 10.1016/0042-6822(87)90421-1
   Kim EK, 2000, CURR GENET, V38, P283, DOI 10.1007/s002940000157
   Klassen R, 2003, MOL GENET GENOMICS, V270, P190, DOI 10.1007/s00438-003-0920-5
   KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2
   Lee AM, 1998, VIROLOGY, V248, P35, DOI 10.1006/viro.1998.9245
   LIU JJ, 1995, VIROLOGY, V209, P538, DOI 10.1006/viro.1995.1286
   Lo CF, 1999, DIS AQUAT ORGAN, V35, P175, DOI 10.3354/dao035175
   LU A, 1997, BACULOVIRUSES, P171
   LU HS, 1998, MOL BIOL INSECT VIRU, P382
   MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473
   Nakai R, 2000, FEMS MICROBIOL LETT, V190, P99, DOI 10.1016/S0378-1097(00)00328-1
   Swofford D. L., 1998, PAUP PHYLOGENETIC AN
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TOMALSKI MD, 1988, VIROLOGY, V167, P591, DOI 10.1016/S0042-6822(88)90122-5
   Verheust C, 2005, J BACTERIOL, V187, P1966, DOI 10.1128/JB.187.6.1966-1973.2005
   VLADIMIR V, 2006, PNAS, V103, P4540
   WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.bi.60.070191.002501
   WANG YJ, 2006, CHINESE J BIOTECHNOL, V22, P706
NR 30
TC 2
Z9 4
U1 3
U2 11
PU MICROBIOLOGICAL  SOCIETY KOREA
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER 803, 635-4 YEOGSAM-DONG, KANGNAM-KU,
   SEOUL 135-703, SOUTH KOREA
SN 1225-8873
J9 J MICROBIOL
JI J. Microbiol.
PD APR
PY 2007
VL 45
IS 2
BP 139
EP 145
PG 7
WC Microbiology
SC Microbiology
GA 163CP
UT WOS:000246136600008
PM 17483799
DA 2018-12-27
ER

PT J
AU Riahi, S
   Moghaddam, AB
   Ganjali, MR
   Norouzi, P
   Latifi, M
AF Riahi, Siavash
   Moghaddam, Abdolmajid Bayandori
   Ganjali, Mohamad Reza
   Norouzi, Parviz
   Latifi, Maryam
TI RETRACTED: Calculation of electrode potentials of
   5-(1,3-dioxo-2-phenyl-indan-2-yl)-2,3-dihydroxy-benzoic acid, molecular
   structure and vibrational spectra: A combined experimental and
   computational study (Retracted article. See vol. 964, pg. 332, 2011)
SO JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
LA English
DT Article; Retracted Publication
DE redox reaction; cyclic voltammetry; ab initio calculation; anticoagulant
   compound; IR spectrum
ID K 2,3-EPOXIDE REDUCTASE; AQUEOUS-SOLUTION; VITAMIN-K; ELECTROCHEMICAL
   SYNTHESIS; THEORETICAL CALCULATIONS; REDOX POTENTIALS; ANTICOAGULANT;
   WARFARIN; QUINONES; 4-HYDROXY-1-METHYL-2(1H)-QUINOLONE
AB Geometric parameters and the vibrational frequencies values of 5-(1,3-dioxo-2-phenyl-indan-2-yl)-2,3-dihydroxy-benzoic acid (DPID) and 3-(1,3-dioxo-2-phenyl-indan-2-yl)-5,6-dioxo-eyelohexa-1,3-dienecarboxylic acid (DPIDC) were computed using ab initio molecular orbital calculations (HF) and density function theory (B3LYP) methods with the 6-31G(d) basis set, respectively. The calculated IR spectrum of DPID used for the assignment of IR frequencies, is observed in the experimental FT-IR spectrum. Correlations between theoretical and experimental vibrational frequencies of the MID molecule were 0.999. Furthermore, the electrode potentials of DPID in acetonitrile have been calculated. It was also obtained experimentally with the aid of an electrochemical technique (cyclic voltammetry) which was 236 mV. The theoretical and experimental values for the electrode potential of this compound are in excellent agreement and there are only a 0.021 and 0.018 V for B3LYP and HF methods, respectively, discrepancy between experimental and theoretical results. The agreement mutually verifies the accuracy of the experimental method and the validity of the applied mathematical model. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Yasuj, Dept Chem, Yasuj, Iran.
   Univ Tehran, Fac Chem, Ctr Excellence Electrochem, Tehran, Iran.
   Univ Tehran Med Sci, Endocrine & Metab Res Ctr, Tehran, Iran.
RP Riahi, S (reprint author), Univ Yasuj, Dept Chem, POB 75914-353, Yasuj, Iran.
EM riahisv@khayam.ut.ac.ir
RI norouzi, parviz/B-4647-2009; Riahi, Siavash/E-6826-2010; Ganjali,
   Mohammad Reza/C-7640-2009
OI Ganjali, Mohammad Reza/0000-0002-2968-0981
CR Alanko J, 1999, FREE RADICAL BIO MED, V26, P193, DOI 10.1016/S0891-5849(98)00179-8
   BEAUREGARD JR, 1955, J AGR FOOD CHEM, V3, P124, DOI 10.1021/jf60048a002
   COMPTON RG, 1989, J ELECTROANAL CHEM, V258, P79, DOI 10.1016/0022-0728(89)85163-0
   Dolmella A, 1999, J MOL STRUCT, V513, P177, DOI 10.1016/S0022-2860(99)00119-2
   DRIEBERGEN RJ, 1990, ANAL CHIM ACTA, V234, P285, DOI 10.1016/S0003-2670(00)83570-9
   FASCO MJ, 1982, J BIOL CHEM, V257, P1210
   FASCO MJ, 1982, J BIOL CHEM, V257, P4894
   FIELD JB, 1955, CIRCULATION, V11, P576, DOI 10.1161/01.CIR.11.4.576
   LINK KP, 1959, CIRCULATION, V19, P97, DOI 10.1161/01.CIR.19.1.97
   LISTER SG, 1992, INT J QUANTUM CHEM, V41, P293, DOI 10.1002/qua.560410206
   MARTIN GR, 1994, WILDLIFE RES, V21, P85, DOI 10.1071/WR9940085
   Miertus S, 1981, CHEM PHYS, V55, P17
   Moghaddam AB, 2006, J ELECTROANAL CHEM, V586, P161, DOI 10.1016/j.jelechem.2005.10.012
   Moghaddam AB, 2005, ELECTROCHIM ACTA, V51, P739, DOI 10.1016/j.electacta.2005.05.050
   Moghaddam AB, 2006, CHEM PHARM BULL, V54, P1391, DOI 10.1248/cpb.54.1391
   Namazian M, 2004, J ELECTROANAL CHEM, V573, P49, DOI 10.1016/j.jelechem.2004.06.020
   Namazian M, 2004, CHEM PHYS LETT, V396, P424, DOI 10.1016/j.cplett.2004.08.089
   PULAY P, 1979, J AM CHEM SOC, V101, P2550, DOI 10.1021/ja00504a009
   REYNOLDS CA, 1990, J AM CHEM SOC, V112, P7545, DOI 10.1021/ja00177a015
   REYNOLDS CA, 1988, J CHEM SOC CHEM COMM, P1434, DOI 10.1039/c39880001434
   REYNOLDS CA, 1988, NATURE, V334, P80, DOI 10.1038/334080a0
   Riahi S, 2006, J MOL STRUC-THEOCHEM, V774, P107, DOI 10.1016/j.theochem.2006.06.035
   Scott AP, 1996, J PHYS CHEM-US, V100, P16502, DOI 10.1021/jp960976r
   SHAPIRO SL, 1960, J ORG CHEM, V25, P1860, DOI 10.1021/jo01081a008
   Silva CO, 2000, J PHYS CHEM A, V104, P2402, DOI 10.1021/jp992103d
   THIJSSEN HHW, 1989, BIOCHEM PHARMACOL, V38, P1115, DOI 10.1016/0006-2952(89)90257-8
   THIJSSEN HHW, 1988, BRIT J PHARMACOL, V95, P675, DOI 10.1111/j.1476-5381.1988.tb11692.x
   THIJSSEN HHW, 1987, J PHARMACOL EXP THER, V243, P1082
   THIJSSEN HHW, 1995, PESTIC SCI, V43, P73, DOI 10.1002/ps.2780430112
   YAMAUCHI Y, 1986, J CHEM PHYS, V84, P2278
   Yao JQ, 2003, CHEM RES TOXICOL, V16, P668, DOI 10.1021/tx0340549
   Young D, 2001, COMPUTATIONAL CHEM
NR 32
TC 22
Z9 22
U1 2
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-1280
J9 J MOL STRUC-THEOCHEM
JI Theochem-J. Mol. Struct.
PD APR 1
PY 2007
VL 807
IS 1-3
BP 137
EP 145
DI 10.1016/j.theochem.2006.12.026
PG 9
WC Chemistry, Physical
SC Chemistry
GA 157DK
UT WOS:000245698600018
DA 2018-12-27
ER

PT J
AU Li, RX
   Luo, XP
   Archer, DF
   Chegini, N
AF Li, Rongxiu
   Luo, Xiaoping
   Archer, David F.
   Chegini, Nasser
TI RETRACTED: Doxycycline alters the expression of matrix metalloproteases
   in the endometrial cells exposed to ovarian steroids and
   pro-inflammatory cytokine (Retracted article. See vol. 125, pg. 106,
   2018)
SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 51st Annual Meeting of the Society-for-Gynecologic-Investigation
CY MAR 24-27, 2004
CL Houston, TX
SP Soc Gynecol Invest
DE uterine bleeding; endometrium; doxycycline; proteases; cytokine
ID CHEMICALLY-MODIFIED TETRACYCLINES; TISSUE INHIBITOR; STROMAL CELLS;
   CHRONIC PERIODONTITIS; EPITHELIAL-CELLS; IN-VITRO; DIFFERENTIAL
   REGULATION; GELATINASE-A; TGF-BETA; THERAPY
AB Evidence suggests that doxycycline (Dox), acting through an anti-inflammatory mechanism, inhibits expression of matrix metalloproteinases (MMPs). Since the endometrial environment in contraceptive users experiencing breakthrough bleeding is characterized by elevated production of MMPs, we examined the effect of Dox on endometrial expression of MMPs using an in vitro model consisting of endometrial glandular epithelial cells (GEC), stromal (ESC) cells, and an endometrial surface epithelial cell line (HES). GEC, ESC and RES maintained under defined culture conditions expressed variable levels of MMP-2 and MMP-9, and Dox in a dose-dependent manner (1-50 mu g/ml) reduced the production of proMMP-2 after 24 h treatment (P < 0.05). Dox (25 mu g/ml), alone or in combination with 17 beta estradiol (E2), medroxyprogesterone acetate (MPA) and E2 + MPA (10(-8) M), as well as TNF-alpha (25 ng/ml) in cell- and time-dependent manners, moderately altered the expression of MMP-2 and MMP-9 mRNA in GEC, ESC and HES compared to untreated controls (P < 0.05). Dox, either alone or in combination with ovarian steroids and TNF-alpha, reduced production of pro-MMP-2 and proMMP9, as well as TIMP-1 and TIMP-2, without affecting the level of active MMPs produced by these cells (P < 0.05). In conclusion, the results indicate that Dox only moderately and in a cell-specific manner reduces expression of MMPs without influencing their activity, suggesting that Dox's therapeutic benefits in controlling irregular breakthrough bleeding in contraceptive users occurs site specifically and possibly through a mechanism involving MMPs and TIMPs expression. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Florida, Dept OBGYN, Gainesville, FL 32610 USA.
   Eastern Virginia Med Sch, Norfolk, VA 23501 USA.
RP Chegini, N (reprint author), Univ Florida, Dept OBGYN, Box 100294, Gainesville, FL 32610 USA.
EM cheginin@obgyn.ufl.edu
FU NICHD NIH HHS [HD43175, HD37432]
CR Acharya MR, 2004, DRUG RESIST UPDATE, V7, P195, DOI 10.1016/j.drup.2004.04.002
   Axisa B, 2002, STROKE, V33, P2858, DOI 10.1161/01.STR.0000038098.04291.F6
   Bruner-Tran KL, 2006, J CLIN ENDOCR METAB, V91, P1554, DOI 10.1210/jc.2005-2024
   Chegini N, 2003, FERTIL STERIL, V80, P564, DOI 10.1016/S0015-0282(03)00797-0
   CHEGINI N, 1992, ENDOCRINOLOGY, V130, P2373, DOI 10.1210/en.130.4.2373
   Choi DH, 2004, J PERIODONTAL RES, V39, P20, DOI 10.1111/j.1600-0765.2004.00696.x
   Cornet PB, 2005, J CLIN ENDOCR METAB, V90, P1001, DOI 10.1210/jc.2004-1277
   Curry TE, 2003, ENDOCR REV, V24, P428, DOI 10.1210/er.2002-0005
   D'Agostino P, 1998, J INFECT DIS, V177, P489, DOI 10.1086/517383
   Di Nezza LA, 2003, GYNECOL ONCOL, V89, P325, DOI 10.1016/S0090-8258(03)00089-1
   Emingil G, 2004, J PERIODONTOL, V75, P106, DOI 10.1902/jop.2004.75.1.106
   Goffin F, 2002, GYNECOL OBSTET INVES, V53, P105, DOI 10.1159/000053003
   Golub LM, 2001, J CLIN PERIODONTOL, V28, P146, DOI 10.1034/j.1600-051x.2001.028002146.x
   Hanemaaijer R, 1998, Adv Dent Res, V12, P114
   Heinonen Pentti K., 2003, Archives of Gynecology and Obstetrics, V268, P284, DOI 10.1007/s00404-002-0376-6
   Hickey M, 2001, FERTIL STERIL, V75, P288, DOI 10.1016/S0015-0282(00)01690-3
   Hoyt JC, 2006, J IMMUNOL, V176, P567, DOI 10.4049/jimmunol.176.1.567
   Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021
   Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj/onc/1205291
   Kaitu'u TJ, 2005, BIOL REPROD, V73, P672, DOI 10.1095/biolreprod.105.042473
   Lee HM, 2004, J PERIODONTOL, V75, P453, DOI 10.1902/jop.2004.75.3.453
   Lee KS, 2004, J ALLERGY CLIN IMMUN, V113, P902, DOI 10.1016/j.jaci.2004.03.008
   Li DQ, 2001, EXP EYE RES, V73, P449, DOI 10.1006/exer.2001.1054
   LI R, 2006, HUM REPROD
   Liu J, 2003, J VASC SURG, V38, P1376, DOI 10.1016/S0741-5214(03)01022-X
   Luo XP, 2004, AM J PHYSIOL-ENDOC M, V287, pE991, DOI 10.1152/ajpendo.00200.2004
   MALIK S, 2006, HUM REPROD
   Marbaix E, 2000, HUM REPROD, V15, P120, DOI 10.1093/humrep/15.suppl_3.120
   Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010
   Onoda T, 2004, J LAB CLIN MED, V143, P207, DOI 10.1016/j.lab.2003.12.012
   OVERALL CM, 1991, J BIOL CHEM, V266, P14064
   Prifti S, 2004, GYNECOL ENDOCRINOL, V18, P23, DOI 10.1080/09513590310001651740
   Quinton ND, 2003, AM J REPROD IMMUNOL, V50, P224, DOI 10.1034/j.1600-0897.2003.00071.x
   Ramamurthy NS, 2002, J PERIODONTOL, V73, P726, DOI 10.1902/jop.2002.73.7.726
   RAWDANOWICZ TJ, 1994, J CLIN ENDOCR METAB, V79, P530, DOI 10.1210/jc.79.2.530
   Rhoton-Vlasak A, 2005, FERTIL STERIL, V83, P659, DOI 10.1016/j.fertnstert.2004.11.009
   Roberts M, 2005, MOL HUM REPROD, V11, P751, DOI 10.1093/molehr/gah233
   Salvi GE, 2005, J CLIN PERIODONTOL, V32, P108, DOI 10.1111/j.1600-051X.2005.00785.x
   Siemonsma MA, 2003, SURGERY, V133, P268, DOI 10.1067/msy.2003.27
   Singer C F, 2000, Ceska Gynekol, V65, P211
   Smith VA, 2004, BRIT J OPHTHALMOL, V88, P619, DOI 10.1136/bjo.2003.025551
   Solomon A, 2000, INVEST OPHTH VIS SCI, V41, P2544
   TOTH A, 1988, J INT MED RES, V16, P270, DOI 10.1177/030006058801600404
   Vincent AJ, 2002, HUM REPROD, V17, P1189, DOI 10.1093/humrep/17.5.1189
   WALTERS MD, 1990, OBSTET GYNECOL, V75, P867
   Weisberg E, 2006, HUM REPROD, V21, P295, DOI 10.1093/humrep/dei273
   Zhang J, 2000, BIOL REPROD, V62, P85, DOI 10.1095/biolreprod62.1.85
   Zhang X, 2005, FRONT BIOSCI-LANDMRK, V10, P353, DOI 10.2741/1533
NR 48
TC 16
Z9 19
U1 2
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-0378
J9 J REPROD IMMUNOL
JI J. Reprod. Immunol.
PD APR
PY 2007
VL 73
IS 2
BP 118
EP 129
DI 10.1016/j.jri.2006.08.082
PG 12
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA 157AK
UT WOS:000245690800003
PM 17010446
DA 2018-12-27
ER

PT J
AU Calnan, M
   Wainwright, D
   O'Neill, C
   Winterbottom, A
   Watkins, C
AF Calnan, M.
   Wainwright, D.
   O'Neill, C.
   Winterbottom, A.
   Watkins, C.
TI RETRACTED: Illness action rediscovered: a case study of upper limb pain
   (Retracted article. see vol 29, pg 955, 2007)
SO SOCIOLOGY OF HEALTH & ILLNESS
LA English
DT Article; Retracted Publication
DE illness action; behaviour; clinical uncertainty; pain
ID HEALTH-CARE; BACK-PAIN; HELP; EXPERIENCES; DISORDERS; DYNAMICS;
   SERVICES; BEHAVIOR; PATIENT; SEARCH
AB Theoretical frameworks provide generalised accounts of illness action although empirical studies of the process are still in short supply. This study of upper limb pain provided a case study of illness action; as it is a common condition, there is uncertainty about its treatment and management, orthodox and non-orthodox care are seen as legitimate sources of help and it is linked with a range of causes.
   Face-to-face informal interviews were carried out with 47 informants with upper limb pain and their practitioners (n=19). The data were analysed in two different ways. The general stages of the illness action process were identified through a descriptive analysis of the upper limb pain sufferers' accounts and the policies and practices reported by their practitioners. Then, case studies were constructed to depict individual pathways through healthcare and consequences for sufferers. The illness action process was characterised by the normalisation and accommodation of pain informed by a discourse that predominantly invoked ageing and the wear and tear of the body. Practitioners also preferred to adopt a biomechanical approach and were reluctant to attribute psychosocial labels. The case studies illustrated the divergent, negotiated and opportunistic nature of the process and showed that the use of both orthodox and non-orthodox care formed only part of strategies used to manage upper limb pain. Sufferers evaluated the care they received in terms of pain alleviation, and were resigned to searching for the best way of living with their pain.
C1 Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.
RP Calnan, M (reprint author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.
EM m.w.calnan@bristol.ac.uk
OI O'Neill, Claire/0000-0003-3497-0235
CR Adamson C, 1997, SOCIOL HEALTH ILL, V19, P133, DOI 10.1111/1467-9566.ep10934391
   Aldrich S, 2000, BEHAV RES THER, V38, P457, DOI 10.1016/S0005-7967(99)00062-5
   ALONZO AA, 1984, SOC SCI MED, V19, P499, DOI 10.1016/0277-9536(84)90045-5
   ARSKEY H, 1998, RSI EXPERTS
   BLAXTER M, 2004, HLTH KEY CONCEPTS
   Bongers PM, 2001, BMJ-BRIT MED J, V322, P64, DOI 10.1136/bmj.322.7278.64
   BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251
   Calnan M, 1983, Sociol Health Illn, V5, P149, DOI 10.1111/1467-9566.ep10491503
   Calnan M, 2005, SOC SCI MED, V60, P1937, DOI 10.1016/j.socscimed.2004.08.058
   CALNAN M, 1987, HLTH ILLNESS LAY PER
   CANAAN J, 1999, HLTH WORK CRITICAL P
   Carpentier N, 2005, QUAL HEALTH RES, V15, P289, DOI 10.1177/1049732304270813
   CHARMAZ K, 2000, HDB SOCIAL STUDIES H
   Coggon D, 2000, RHEUMATOLOGY, V39, P1057, DOI 10.1093/rheumatology/39.10.1057
   CORNWELL J, 1984, HARD EARNED LIVES
   COWIE B, 1976, SOC SCI MED, V10, P87, DOI 10.1016/0037-7856(76)90059-7
   Dingwall R., 1976, ASPECTS OF ILLNESS
   Fabrega H., 1974, DIS SOCIAL BEHAV
   Gerhardt Utah, 1989, IDEAS ILLNESS INTELL
   Hellstrom C, 2001, TIME SOC, V10, P77, DOI 10.1177/0961463X01010001005
   Lawton J, 2003, SOCIOL HEALTH ILL, V25, P23
   Macfarlane GJ, 2000, BRIT MED J, V321, P676, DOI 10.1136/bmj.321.7262.676
   May C, 1999, SOC SCI MED, V48, P523, DOI 10.1016/S0277-9536(98)00372-4
   MCKINLAY JB, 1972, J HEALTH SOC BEHAV, V13, P115, DOI 10.2307/2136896
   MECHANIC D, 1987, J HEALTH SOC BEHAV, V28, P131, DOI 10.2307/2137127
   Mechanic D, 1968, MED SOCIOLOGY
   Nettleton S., 2004, SOCIAL THEORY HLTH, V2, P47, DOI DOI 10.1057/PALGRAVE.STH.8700013
   NIOSH, 1997, MUSC DIS WORKPL FACT
   Palmer K, 2000, ANN RHEUM DIS, V59, P5, DOI 10.1136/ard.59.1.5
   PALMER K, 2000, HUNTERS DIS OCCUPATI
   *PAN MUSC DIS, 2001, MUSC DIS WORKPL
   Paterson C, 1999, BRIT J GEN PRACT, V49, P626
   Pescosolido B., 1996, SOCIOLOGY MENTAL ILL
   Pescosolido B. A., 1991, ADV MED SOCIOLOGY, P161
   Pescosolido BA, 2004, SOC SCI MED, V58, P1795, DOI 10.1016/S0277-9536(03)00398-8
   PESCOSOLIDO BA, 1992, AM J SOCIOL, V97, P1096, DOI 10.1086/229863
   Pescosolido BA, 1998, SOC SCI MED, V46, P275, DOI 10.1016/S0277-9536(97)00160-3
   PESCOSOLIDO BA, 1996, RES SOCIOL HEA A & B, V13, P171
   REID J, 1991, SOC SCI MED, V32, P601, DOI 10.1016/0277-9536(91)90295-N
   Rhodes LA, 1999, SOC SCI MED, V48, P1189, DOI 10.1016/S0277-9536(98)00418-3
   ROBINSON D, 1971, PROCESS BECOMING ILL
   ROGERS A, 1997, NPCRCD SERIES
   Ruston A, 1998, BRIT MED J, V316, P1060
   Sanders C, 2002, SOCIOL HEALTH ILL, V24, P227, DOI 10.1111/1467-9566.00292
   SHARMA U, 1995, MODERN MED LAY PERSP
   Strauss A. L., 1998, BASICS QUALITATIVE R
   Summerfield D, 2001, BRIT MED J, V322, P95, DOI 10.1136/bmj.322.7278.95
   THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207
   Uehara ES, 2001, SOC SCI MED, V52, P519, DOI 10.1016/S0277-9536(00)00157-X
   Young JT, 2004, SOCIOL HEALTH ILL, V26, P1, DOI 10.1111/j.1467-9566.2004.00376.x
   ZOLA IK, 1973, SOC SCI MED, V7, P677, DOI 10.1016/0037-7856(73)90002-4
NR 51
TC 13
Z9 13
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9889
EI 1467-9566
J9 SOCIOL HEALTH ILL
JI Sociol. Health Ill.
PD APR
PY 2007
VL 29
IS 3
BP 321
EP 346
DI 10.1111/j.1467-9566.2007.00543.x
PG 26
WC Public, Environmental & Occupational Health; Social Sciences,
   Biomedical; Sociology
SC Public, Environmental & Occupational Health; Biomedical Social Sciences;
   Sociology
GA 161UA
UT WOS:000246040400001
PM 17470215
OA Bronze
DA 2018-12-27
ER

PT J
AU Xue, SR
   Xue, Y
   Xue, R
AF Xue, Shu-ren
   Xue, Yu
   Xue, Rong
TI RETRACTED: Carvedilol restore cardiac calcium release channel structure
   and function in heart failure (Retracted article. See vol. 125, Pg. 293,
   2008)
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article; Retracted Publication
DE carvedilol; heart failure; calcium; sarcoplasmic reticulum; ion channels
ID RYANODINE RECEPTOR FUNCTION; FKBP12.6-MEDIATED STABILIZATION; FAILING
   HEART; CA2+ RELEASE; MUSCLE; EXPRESSION; BLOCKADE; FKBP12.6; PROTEIN
AB Background: The ryanodine receptor (RyR2) on cardiac sarcoplasmic reticulum is the key calcium release channel required for excitation-contraction coupling. In failing hearts, the stoichiometry and function of the RyR2 macromolecular complex is altered.
   Aims: In the present study, we used a well-characterized canine model of pacing-induced HF to show that Carvedilol both restores the normal stoichiometry of the RyR2 macromolecular complex and normalizes the function of the channel.
   Methods: A rapid cardiac pacing regimen that results in severe HF was used. Animals were assigned to I of 4 groups: (1) normal without heart instrumentation (n=6), (2) HF (n=6), (3) HF treated with Carvedilol (n=6), and (4) normal without heart instrumentation plus Carvedilol (n=6). In groups 2 and 3, after baseline measurements had been obtained, rapid left ventricular (LV) pacing was initiated at 2 10 bpm for 3 weeks, followed by an additional week of pacing at 240 bpm with an external pacemaker. Carvedilol was begun 2 weeks after initiation of pacing and continued for 2 weeks. Carvedilol was begun 2 weeks after baseline measurement for the control dogs with heart instrumentation. SR membranes were prepared from canine ventricular tissue, protein concentration was measured by Bradford assay.
   Results: Here, we show that systemic oral administration of Carvedilol reverses protein kinase A hyperphosphorylation of RyR2, restores the stoichiometry of the RyR2 macromolecular complex, and normalizes single-channel function in a canine model of heart failure.
   Conclusions: These results may, in part, explain the improved cardiac function observed in heart failure patients treated with Carvedilol. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Teachers Coll Hang Zhou, Clin Med Coll, Cardiovasc Inst Hang Zhou, Dept Cardiol, Hangzhou, Zhe Jiang Prov, Peoples R China.
   Shang Hai Fu Xing Med & Pharmacol Co, Shanghai, Peoples R China.
RP Xue, SR (reprint author), Teachers Coll Hang Zhou, Clin Med Coll, Cardiovasc Inst Hang Zhou, Dept Cardiol, 126 Weng Zhou Rd, Hangzhou, Zhe Jiang Prov, Peoples R China.
EM xueshuren@yahoo.co.uk
CR Braunwald E, 2000, CIRCULATION, V102, P14
   BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3
   Dawn B, 2001, J MOL CELL CARDIOL, V33, P161, DOI 10.1006/jmcc.2000.1291
   Doi M, 2002, CIRCULATION, V105, P1374, DOI 10.1161/hc1102.105270
   Eisner DA, 2000, CIRC RES, V87, P1087, DOI 10.1161/01.RES.87.12.1087
   Freedman NJ, 2004, J CLIN INVEST, V113, P1379, DOI 10.1172/JCI200421748
   Gilbert EM, 1996, CIRCULATION, V94, P2817, DOI 10.1161/01.CIR.94.11.2817
   Hasenfuss G, 2003, CIRCULATION, V107, P378, DOI 10.1161/01.CIR.0000046342.46135.CB
   Houser SR, 2003, CIRC RES, V92, P350, DOI 10.1161/01.RES.0000060027.40275.A6
   Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990
   KIUCHI K, 1993, J CLIN INVEST, V91, P907, DOI 10.1172/JCI116312
   Lehnart SE, 2004, ANN NY ACAD SCI, V1015, P144, DOI 10.1196/annals.1302.012
   Lehnart SE, 2004, CIRCULATION, V109, P3208, DOI 10.1161/01.CIR.0000132472.98675.EC
   Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8
   Marks AR, 2002, CIRCULATION, V105, P272, DOI 10.1161/circ.105.3.272
   Marks AR, 2003, CIRCULATION, V107, P1456, DOI 10.1161/01.CIR.0000059745.95643.83
   Marks AR, 1996, PHYSIOL REV, V76, P631
   Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8
   Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818
   Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268
   Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699
   *MERIT HF STUD GRO, 1999, LANCET, V353, P2001, DOI DOI 10.1016/S0140-6736(99)04444-2
   Nagatsu M, 2000, CIRCULATION, V101, P653, DOI 10.1161/01.CIR.101.6.653
   Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271
   Okuda S, 2004, CIRCULATION, V109, P911, DOI 10.1161/01.CIR.0000115526.92541.D2
   Ono K, 2000, CARDIOVASC RES, V48, P323, DOI 10.1016/S0008-6363(00)00191-7
   Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101
   Plank DM, 2003, AM J PHYSIOL-HEART C, V285, pH305, DOI 10.1152/ajpheart.00425.2002
   Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49
   Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578
   Scoote M, 2003, HEART, V89, P371, DOI 10.1136/heart.89.4.371
   Wang J, 1997, CIRCULATION, V96, P2683, DOI 10.1161/01.CIR.96.8.2683
   XUE SR, 2000, CHIN J CARDIOL, V28, P200
   Yano M, 2003, CIRCULATION, V107, P477, DOI 10.1161/01.CIR.0000044917.74408.BE
NR 34
TC 6
Z9 7
U1 3
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAR 20
PY 2007
VL 116
IS 2
BP 231
EP 235
DI 10.1016/j.ijcard.2006.03.051
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 148PS
UT WOS:000245087700015
PM 16824631
DA 2018-12-27
ER

PT J
AU Sato, Y
   Honda, Y
   Iwamoto, J
AF Sato, Yoshihiro
   Honda, Yoshiaki
   Iwamoto, Jun
TI RETRACTED: Risedronate and ergocalciferol prevent hip fracture in
   elderly men with Parkinson disease(Retracted article.See
   vol.87,pg.239,2016)
SO NEUROLOGY
LA English
DT Article; Retracted Publication
ID RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL OSTEOPOROSIS; BONE MASS;
   WOMEN; ABSORPTIOMETRY; METACARPAL; DENSITY
AB Background: There is a high incidence of hip fractures in patients with Parkinson disease ( PD). Bone mineral density ( BMD) is decreased in patients with PD, correlating with the immobilization- induced bone resorption and hypovitaminosis D with compensatory hyperparathyroidism. Objective: To evaluate the effectiveness of risedronate, an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in elderly men with PD. Methods: This was a 2- year, randomized, double- blind, placebo- controlled trial. In a prospective study of patients with PD, 121 patients received a daily dose of 2.5 mg risedronate and vitamin D2 1,000 IU for 2 years, and the remaining 121 received placebo and vitamin D2 1,000 IU. Incidence of hip fractures was compared between the two groups. Results: Nine patients sustained hip fractures in the placebo group, and three hip fractures occurred in the risedronate group. The relative risk of a hip fracture in the risedronate group vs the placebo group was 0.33 ( 95% CI, 0.09 to 1.20). BMD increased by 2.2% in the risedronate group and decreased by 2.9% in the placebo group ( p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 46.7% in the risedronate group and by 33.0% in the placebo group. Conclusion: Treatment with risedronate and vitamin D2 increases bone mineral density in elderly men with Parkinson disease and reduces the risk of hip fractures.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   Hagino H, 1999, BONE, V24, P265, DOI 10.1016/S8756-3282(98)00175-6
   Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   KAO CH, 1994, NUCL MED COMMUN, V15, P173, DOI 10.1097/00006231-199403000-00010
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Sato Y, 1999, J NEUROL NEUROSUR PS, V66, P64, DOI 10.1136/jnnp.66.1.64
   Sato Y, 1997, NEUROLOGY, V49, P1273, DOI 10.1212/WNL.49.5.1273
   Sato Y, 2004, AM J PHYS MED REHAB, V83, P298, DOI 10.1097/01.PHM.0000122877.28631.23
   Sato Y, 2001, J NEUROL SCI, V182, P89, DOI 10.1016/S0022-510X(00)00458-5
   Sato Y, 1999, BONE, V24, P271, DOI 10.1016/S8756-3282(98)00185-9
   Sato Y, 2006, MOVEMENT DISORD, V21, P924, DOI 10.1002/mds.20825
   Shiraki M, 2003, OSTEOPOROSIS INT, V14, P225, DOI 10.1007/s00198-002-1369-9
   TAGGART H, 1995, AGE AGEING, V24, P326, DOI 10.1093/ageing/24.4.326
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
NR 19
TC 60
Z9 63
U1 4
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 20
PY 2007
VL 68
IS 12
BP 911
EP 915
DI 10.1212/01.wnl.0000257089.50476.92
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 147WL
UT WOS:000245034400008
PM 17372126
DA 2018-12-27
ER

PT J
AU Zhao, BW
   Chen, XM
   Zhu, K
   Zhu, LZ
AF Zhao, Baowei
   Chen, Xuemin
   Zhu, Kun
   Zhu, Lizhong
TI RETRACTED: Micellar solubilization of TCE and PCE by mixed surfactant:
   Effects of surfactant partitioning and DNAPL mixing (Retracted article.
   See vol. 327, pg. 144, 2008)
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article; Retracted Publication
DE DNAPLs; mixed surfactant; solubilization; partitioning
ID OIL-WATER SYSTEMS; ETHOXYLATED NONIONIC SURFACTANTS;
   CHLORINATED-HYDROCARBON MICROEMULSIONS; EMULSION PHASE INVERSION;
   POLYETHOXYLATED SURFACTANTS; RETROGRADE TRANSITION; MIXTURES; BEHAVIOR;
   REMEDIATION; DODECANE
AB Efforts to remove the dense nonaqueous phase liquids (DNAPLs) in subsurface by mobilizing them face with risks of driving the contaminants deeper into aquifer zones. This spurs research for modifying the approach for in situ remediation. In this paper, micellar solubilization of trichloroethene (TCE), tetrachloroethene (PCE) and their mixture (TCE-PCE) by mixed nonionic and anionic surfactant, Triton X-100 (TV00) and sodium dodecylbenzene suffonate (SDBS) in DNAPL/water systems was presented. Given 1:40 phase ratio of DNAPL/water (v/v) and the total surfactant concentration from 200 to 10,000mg/L, mixed TXIOO-SDBS at the total mass ratios of 3:1, 1:1 and 1:3 exhibited significant solubilization for TCE, PCE and TCE-PCE mixture (1: 1, v/v). The solubilization extent of sole TCE by TX I OO-SDBS was much larger than by single TX100 and even largerthan by single SD13S at the ratios of 1:1 and 1:3. The solubilization extent of sole PCE by TXIOO-SDBS was between those by single TX100 and single SDBS. In mixed TCE-PCE system, the solubilization extent of TCE or PCE by TXIOO-SDBS was larger than by single SDBS at the ratios of 1:1 and 1:3 while less than by single TX100 at large surfactant concentration. TX100 partitioning into the organic phase dictated the solubilization extent. The TX100 losses into TCE and TCE-PCE phases were great when single TX100 was used, while those into PCE phase were much less. No partitioning of SDBS into DNAPLs was observed. In mixed surfactant systems, SDBS decreased greatly the partition loss of TX100 into DNAPLs. The extent of TX100 partition decreased with the amount of SDBS increasing and the polarity of DNAPL decreasing. The mechanism for reduction of TX100 partition was discussed. TX100 and SDBS formed mixed micelles in the solution phase. The inability of SDBS to partition into DNAPLs and the mutual affinity of SDBS and TX100 in the mixed micelle controlled the partitioning of TX100 into DNAPL phase. The work presented here demonstrates that mixed nonionic-anionic surfactants may be probably potentially better systems than the corresponding single ones for remediation of polar DNAPLs, which could decrease risks of driving the contaminants deeper into aquifers. (c) 2006 Elsevier B.V. All rights reserved.
C1 Lanzhou Jiaotong Univ, Sch Environm & Municipal Engn, Lanzhou 730070, Peoples R China.
   Zhejiang Univ, Dept Environm Sci, Hangzhou 310028, Peoples R China.
RP Zhao, BW (reprint author), Lanzhou Jiaotong Univ, Sch Environm & Municipal Engn, Lanzhou 730070, Peoples R China.
EM baoweizhao@mail.lzjtu.cn; zhbw2001@sina.com
RI x, z/A-9144-2010
CR Acosta E, 2002, ENVIRON SCI TECHNOL, V36, P4618, DOI 10.1021/es0158859
   *AGWSE, 1992, GROUND WATER, V30, P781
   Boving TB, 2000, J CONTAM HYDROL, V42, P51, DOI 10.1016/S0169-7722(99)00077-7
   BROOKS BW, 1994, J COLLOID INTERF SCI, V162, P67, DOI 10.1006/jcis.1994.1009
   BROOKS BW, 1994, J COLLOID INTERF SCI, V162, P59, DOI 10.1006/jcis.1994.1008
   Butler EC, 1998, WATER RES, V32, P1345, DOI 10.1016/S0043-1354(97)00360-6
   Cowell MA, 2000, ENVIRON SCI TECHNOL, V34, P1583, DOI 10.1021/es9908826
   FOUNTAIN JC, 1991, J HAZARD MATER, V28, P295, DOI 10.1016/0304-3894(91)87081-C
   GRACIAA A, 1983, J COLLOID INTERF SCI, V93, P474, DOI 10.1016/0021-9797(83)90431-9
   GRACIAA A, 1984, SPE RESERVOIR ENG, V2, P305
   HARUSAWA F, 1980, J COLLOID INTERF SCI, V74, P435, DOI 10.1016/0021-9797(80)90212-X
   HARUSAWA F, 1981, J PHYS CHEM-US, V85, P882, DOI 10.1021/j150607a029
   Harwell JH, 1999, COLLOID SURFACE A, V151, P255, DOI 10.1016/S0927-7757(98)00785-7
   HOLLAND PM, 1983, J PHYS CHEM-US, V87, P1984, DOI 10.1021/j100234a030
   Jawitz JW, 2003, ENVIRON SCI TECHNOL, V37, P1983, DOI 10.1021/es0256921
   KILE DE, 1989, ENVIRON SCI TECHNOL, V23, P832, DOI 10.1021/es00065a012
   Marquez N, 2002, ANAL CHIM ACTA, V452, P129, DOI 10.1016/S0003-2670(01)01439-8
   Marquez N, 2000, ANAL CHIM ACTA, V405, P267, DOI 10.1016/S0003-2670(99)00759-X
   MARQUEZ N, 1995, COLLOID SURFACE A, V100, P225, DOI 10.1016/0927-7757(95)03184-F
   Marquez N, 2003, ANAL CHIM ACTA, V477, P293, DOI 10.1016/S0003-2670(02)01407-1
   PENNELL KD, 1993, ENVIRON SCI TECHNOL, V27, P2332, DOI 10.1021/es00048a005
   Pennell KD, 1997, ENVIRON SCI TECHNOL, V31, P1382, DOI 10.1021/es960604w
   POPE GA, 1996, ACS S SERIES, V594
   Prak DJL, 2002, WATER RES, V36, P3463, DOI 10.1016/S0043-1354(02)00070-2
   Ravera F, 1997, LANGMUIR, V13, P4817, DOI 10.1021/la962096+
   Rosen Milton J., 1989, SURFACTANTS INTERFAC
   ROSEN MJ, 1982, J COLLOID INTERF SCI, V86, P164, DOI 10.1016/0021-9797(82)90052-2
   Rubingh D. N., 1979, SOLUTION CHEM SURFAC, P337
   SAITO H, 1967, J COLLOID INTERF SCI, V24, P10, DOI 10.1016/0021-9797(67)90271-8
   SALAGER JL, 1995, LANGMUIR, V11, P37, DOI 10.1021/la00001a010
   Uchiyama H, 2000, IND ENG CHEM RES, V39, P2704, DOI 10.1021/ie990819p
   *USEPA, 1993, 15401R93073 EPA
   WARR GG, 1983, J PHYS CHEM-US, V87, P4520, DOI 10.1021/j100245a036
   WEST CC, 1992, ENVIRON SCI TECHNOL, V26, P2324, DOI 10.1021/es00036a002
   YAWS CL, 1999, CHEM PROPERTIES HDB
   Ysambertt F, 1997, COLLOID SURFACE A, V125, P131, DOI 10.1016/S0927-7757(96)03841-1
   Zhao BW, 2006, J HAZARD MATER, V136, P513, DOI 10.1016/j.jhazmat.2005.08.036
   Zhao BW, 2005, CHEMOSPHERE, V58, P33, DOI 10.1016/j.chemosphere.2004.08.067
   Zhong LR, 2003, J CONTAM HYDROL, V60, P55, DOI 10.1016/S0169-7722(02)00063-3
   Zhou MF, 2000, ENVIRON SCI TECHNOL, V34, P1985, DOI 10.1021/es9811546
   Zhu LZ, 2003, CHEMOSPHERE, V53, P459, DOI 10.1016/S0045-6535(03)00541-1
   Zimmerman JB, 1999, ENVIRON SCI TECHNOL, V33, P169, DOI 10.1021/es9802910
NR 42
TC 10
Z9 10
U1 4
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
EI 1873-4359
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD MAR 15
PY 2007
VL 296
IS 1-3
BP 167
EP 173
DI 10.1016/j.colsurfa.2006.09.041
PG 7
WC Chemistry, Physical
SC Chemistry
GA 152DZ
UT WOS:000245342400024
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Wiehagen, KR
   Pulko, V
   Van Keulen, VP
   Faubion, WA
   Knutson, KL
   Pease, LR
AF Radhakrishnan, Suresh
   Wiehagen, Karla R.
   Pulko, Vesna
   Van Keulen, Virginia P.
   Faubion, William A.
   Knutson, Keith L.
   Pease, Larry R.
TI RETRACTED: Induction of a Th1 response from Th2-polarized T cells by
   activated dendritic cells: Dependence on TCR : peptide-MHC interaction,
   ICAM-1, IL-12, and IFN-gamma (Retracted article. See vol. 184, pg. 6555,
   2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID CROSS-LINKING; IMMUNE-RESPONSES; LEISHMANIA-MAJOR; DEFICIENT MICE;
   CUTTING EDGE; HELPER; B7-DC; LYMPHOCYTES; MOLECULE; RECEPTOR
AB Dendritic cells (DC) are important regulators of T cell immunity. The degree of stimulation, the pattern of costimulatory molecules expressed, and the cytokines secreted by DC dictate the nature of the effector and memory cells generated, particularly with respect to their Th1 or Th2 phenotypes. In this study, we demonstrate that the addition of activated DC to spleen cultures containing established Th2-polarized CD4(+) T cells was sufficient to suppress Th2 and induce Th1 cytokines in a recall response, a phenomenon referred to as phenotype reversal. The ability of activated DC to induce phenotype reversal displayed exquisite Ag specificity. The DC activator B7-DC cross-linking Ab (XAb) was > 10,000-fold more efficient at inducing phenotype reversal than the TLR agonists CpG-oligodeoxynucleotide and Gardiquimod. Characterization of the mechanisms governing phenotype reversal revealed the requirement for cognate interaction between the TCR:peptide-MHC complex, the expression of the costimulation/adhesion molecule ICAM-1, and secretion of IL-12 and IFN-gamma by the activated DC. The requirement for the costimulation/adhesion molecule SLAM (signaling lymphocytic activation molecule) was found to be quantitative. Thus, activation of DC, particularly by crosslinking B7-DC, can modulate well-established Th2 T cell responses in an Ag-specific manner. Because the regulation of mouse and human DC by B7-DC XAb overlaps in several significant ways, immune modulation with B7-DC XAb is a potential strategy for treating Th2-mediated diseases. The Journal of Immunology, 2007, 178: 3583-3592.
C1 Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
   Mayo Clin, Coll Med, Div Gastroenterol, Dept Internal Med, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
FU NCI NIH HHS [CA 194996, CA 96859]; NHLBI NIH HHS [HL 077296]; NIDDK NIH
   HHS [DK 64194]
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Ahmadzadeh M, 2002, P NATL ACAD SCI USA, V99, P11802, DOI 10.1073/pnas.192263099
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815
   Blocki FA, 2006, FASEB J, V20, P2408, DOI 10.1096/fj.06-6171fje
   Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7
   Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102
   Castro AG, 1999, J IMMUNOL, V163, P5860
   Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297
   Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647
   FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362
   Graham DB, 2006, J IMMUNOL, V176, P291, DOI 10.4049/jimmunol.176.1.291
   Greenspan D.C., 1994, BIOCERAMICS, V7, P28
   HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23
   Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2
   Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   MANETTI R, 1995, EUR J IMMUNOL, V25, P2656, DOI 10.1002/eji.1830250938
   Mattner F, 1996, EUR J IMMUNOL, V26, P1553, DOI 10.1002/eji.1830260722
   McCarter M, 2005, SURGERY, V138, P321, DOI 10.1016/j.surg.2005.06.011
   MCKEAN DJ, 1985, J IMMUNOL, V135, P3205
   Mondino A, 1996, P NATL ACAD SCI USA, V93, P2245, DOI 10.1073/pnas.93.6.2245
   Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x
   Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807
   Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8
   Ozenci V, 2005, PROSTATE, V65, P20, DOI 10.1002/pros.20229
   Parronchi P, 1999, J IMMUNOL, V163, P5946
   Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038
   Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102
   Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   ROMAGNANI S, 1991, INT J CLIN LAB RES, V21, P152
   Salomon B, 1998, J IMMUNOL, V161, P5138
   Schweitzer AN, 1997, J IMMUNOL, V158, P2713
   SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223
   Smits HH, 2002, J IMMUNOL, V168, P1710, DOI 10.4049/jimmunol.168.4.1710
   Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942
   Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Wang NH, 2004, J EXP MED, V199, P1255, DOI 10.1084/jem.20031835
   WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367
   XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95
   Zanussi S, 2003, CANCER IMMUNOL IMMUN, V52, P28, DOI 10.1007/s00262-002-0333-z
NR 49
TC 26
Z9 30
U1 3
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 15
PY 2007
VL 178
IS 6
BP 3583
EP 3592
DI 10.4049/jimmunol.178.6.3583
PG 10
WC Immunology
SC Immunology
GA 146NX
UT WOS:000244942400030
PM 17339455
OA Bronze
DA 2018-12-27
ER

PT J
AU Schwamborn, JC
   Muller, M
   Becker, AHM
   Puschel, AW
AF Schwamborn, Jens C.
   Mueller, Myriam
   Becker, Annemarie H. M.
   Pueschel, Andreas W.
TI RETRACTED: Ubiquitination of the GTPase Rap1B by the ubiquitin ligase
   Smurf2 is required for the establishment of neuronal polarity (Retracted
   article. See vol. 33, pg. 3012, 2014)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE GTPase; neuronal polarity; ubiquitin
ID CULTURED HIPPOCAMPAL-NEURONS; RETINAL GROWTH CONES; INDEPENDENT
   REGULATION; CHEMOTROPIC RESPONSES; MAMMALIAN-CELLS; DEGRADATION;
   PATHWAY; AXON; GSK-3-BETA; ACTIVATION
AB The development of a polarised morphology with multiple dendrites and a single axon is an essential step in the differentiation of neurons. The establishment of neuronal polarity is directed by the sequential activity of the GTPases Rap1B and Cdc42. Rap1B is initially present in all neurites of unpolarised neurons, but becomes restricted to the tip of a single process during the establishment of neuronal polarity where it specifies axonal identity. Here, we show that the ubiquitin ligases Smad ubiquitination regulatory factor-1 (Smurf1) and Smurf2 are essential for neurite growth and neuronal polarity, respectively, and regulate the GTPases Rho and Rap1B in hippocampal neurons. Smurf2 is required for the restriction of Rap1B to a single neurite. Smurf2 ubiquitinates inactive Rap1B and initiates its degradation through the ubiquitin/proteasome pathway (UPS). Degradation of Rap1B restricts it to a single neurite and thereby ensures that neurons extend a single axon.
C1 Univ Munster, Abt Mol Biol, Inst Allgemeine Zool & Genet, D-48149 Munster, Germany.
RP Puschel, AW (reprint author), Univ Munster, Abt Mol Biol, Inst Allgemeine Zool & Genet, Schlosspl 5, D-48149 Munster, Germany.
EM apuschel@uni-muenster.de
RI Schwamborn, Jens/F-9395-2011
CR Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073
   Bradke F, 1997, NEURON, V19, P1175, DOI 10.1016/S0896-6273(00)80410-9
   Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0
   Campbell DS, 2003, NEURON, V37, P939, DOI 10.1016/S0896-6273(03)00158-2
   Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7
   Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808
   Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442
   Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918
   de Anda FC, 2005, NATURE, V436, P704, DOI 10.1038/nature03811
   de Rooij J, 1998, NATURE, V396, P474
   DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317
   DOTTI CG, 1988, J NEUROSCI, V8, P1454
   Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874
   Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017
   Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476
   Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9
   Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712
   Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021
   Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236
   Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200
   Nakata K, 2005, CELL, V120, P407, DOI 10.1016/j.cell.2004.12.017
   Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944
   Schwamborn JC, 2006, METHOD ENZYMOL, V406, P715, DOI 10.1016/S0076-6879(06)06056-3
   Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295
   Schwamborn JC, 2004, J BIOL CHEM, V279, P30923, DOI 10.1074/jbc.C400082200
   Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7
   Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009
   Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650
   TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9
   van Roessel P, 2004, CELL, V119, P707, DOI 10.1016/j.cell.2004.11.028
   Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772
   Wiggin GR, 2005, DEV CELL, V8, P803, DOI 10.1016/j.devcel.2005.05.007
   Yamada T, 2005, J BIOL CHEM, V280, P33026, DOI 10.1074/jbc.M50487200
   Yan D, 2006, J CELL BIOL, V174, P415, DOI 10.1083/jcb.200511028
   Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012
   Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011
   Zhu HT, 1999, NATURE, V400, P687
NR 43
TC 75
Z9 78
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD MAR 7
PY 2007
VL 26
IS 5
BP 1410
EP 1422
DI 10.1038/sj.emboj.7601580
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 143JE
UT WOS:000244716000019
PM 17318188
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
   Xiao, SZ
AF Zhong, H.
   Zeng, X. -R.
   Yang, X. -M.
   Luo, Q. -Y.
   Xiao, S. -Z.
TI RETRACTED: Chloridobis(1,10-phenanthroline-kappa N-2,N ')copper(I)
   hexahydrate (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS
LA English
DT Article; Retracted Publication
AB The Cu-I atom in the title complex, [CuCl(C12H8N2)(2)](.)6H(2)O, exists in a distorted trigonal-bipyramidal coordination geometry defined by one Cl atom and four N atoms of two 1,10-phenanthroline ligands. In the crystal structure, molecules are linked into a three- dimensional framework by O-H (...) O hydrogen bonds and pi-pi stacking interactions. Four water molecules lie on crystallographic twofold rotation axes.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 323009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 323009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   POPE MT, 1983, HETEROPOLY ISOPOLY O, P125
   POPE MT, 2001, POLYOXOMETALATE CHEM, P319
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART JSAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 12
TC 1
Z9 1
U1 5
U2 10
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2056-9890
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Crystallogr. Commun.
PD MAR
PY 2007
VL 63
BP m826
EP m828
DI 10.1107/S160053680700791X
PN 3
PG 3
WC Crystallography
SC Crystallography
GA 153KY
UT WOS:000245434500084
DA 2018-12-27
ER

PT J
AU Tanskanen, M
   Paetau, A
   Salonen, O
   Salmi, T
   Lamminen, A
   Lindsberg, P
   Somer, H
   Kiuru-Enari, S
AF Tanskanen, Maarit
   Paetau, Anders
   Salonen, Oili
   Salmi, Tapani
   Lamminen, Antti
   Lindsberg, Perttu
   Somer, Hannu
   Kiuru-Enari, Sari
TI RETRACTED: Severe ataxia with neuropathy in hereditary gelsolin
   amyloidosis: A case report (Retracted Article. See vol 16, pg 246, 2009)
SO AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
LA English
DT Article; Retracted Publication
DE AGel amyloidosis; amyloid; ataxia; complement; gelsolin; peripheral
   neuropathy; posterior column degeneration
ID FAMILIAL AMYLOIDOSIS; FINNISH TYPE; COMPLEMENT ACTIVATION; MYOPATHY;
   AMYLOIDOGENESIS; POLYNEUROPATHY; ANGIOPATHY; ALZHEIMERS; MUTATION;
   REVEALS
AB Hereditary gelsolin amyloidosis (AGel amyloidosis) is a systemic disorder caused by a G654A or G654T gelsolin mutation, reported from Europe, North America, and Japan. Principal clinical signs are corneal lattice dystrophy, cutis laxa. and cranial neuropathy, often deleterious at advanced age. Peripheral neuropathy, if present, is usually mild. We report a 78-year-old male Finnish patient who presented with ataxia and mainly sensory peripheral polyneuropathy (PNP) signs, causing severe disability and ambulation loss. Electrophysiological studies showed severe generalized chronic mainly axonal sensorimotor PNP with facial paralysis. In magnetic resonance imaging proximal lower limb and axial muscle atrophy with fatty degeneration as well as moderate spinal cord atrophy were seen. A G654A gelsolin mutation was demonstrated but no other possible causes of his disability were found. At age 79 years he became bedridden and died of pulmonary embolism. Neuropathological examination revealed marked gelsolin amyloid deposition at vascular and connective tissue sites along the entire length of the peripheral nerves extending to the spinal nerve roots, associated with severe degeneration of nerve fibers and posterior columns. Our report shows that advanced AGel amyloidosis due to degeneration of central and distal sensory nerve projections results in deleterious ataxia with fatal outcome. Severe posterior column atrophy may reflect radicular AGel deposition, although even altered gelsolin-actin interactions in neural cells possibly contribute to neurodegeneration with successive ataxia in carriers of a G654A gelsolin mutation.
C1 Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Radiol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurophysiol, FIN-00014 Helsinki, Finland.
   Biomedicum, Neurosci Program, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
RP Tanskanen, M (reprint author), Univ Helsinki, Dept Pathol, Haartmaninkatu 3,POB 21, FIN-00014 Helsinki, Finland.
EM maarit.tanskanen@helsinki.fi
RI Lindsberg, Perttu/F-1271-2010
CR Akiya S, 1996, OPHTHALMOLOGY, V103, P1106, DOI 10.1016/S0161-6420(96)30560-5
   BRADY ST, 1984, NATURE, V310, P56, DOI 10.1038/310056a0
   Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277
   Conceicao I, 2003, MUSCLE NERVE, V28, P715, DOI 10.1002/mus.10474
   DELACHAPELLE A, 1992, NAT GENET, V2, P157, DOI 10.1038/ng1092-157
   Delcey V, 2002, REV MED INTERNE, V23, P144, DOI 10.1016/S0248-8663(01)00530-6
   Kangas H, 1996, HUM MOL GENET, V5, P1237, DOI 10.1093/hmg/5.9.1237
   Kiuru S, 2000, THROMB HAEMOSTASIS, V83, P491
   Kiuru S, 1998, AMYLOID, V5, P55, DOI 10.3109/13506129809007291
   Kiuru S, 1999, ANN NEUROL, V45, P305, DOI 10.1002/1531-8249(199903)45:3<305::AID-ANA5>3.0.CO;2-E
   Kiuru-Enari S, 2005, BRIT J DERMATOL, V152, P250, DOI 10.1111/J.1365-2133.2004.06276.X
   Kiuru-Enari S, 2002, J NEUROPATH EXP NEUR, V61, P565, DOI 10.1093/jnen/61.6.565
   KLAUS EDMUND, 1959, PSYCHIAT ET NEUROL, V138, P79
   Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X
   Lauria G, 2000, ANN NEUROL, V47, P104, DOI 10.1002/1531-8249(200001)47:1<104::AID-ANA17>3.3.CO;2-O
   LEVY E, 1990, J EXP MED, V172, P1865, DOI 10.1084/jem.172.6.1865
   Makishita H, 1996, AMYLOID, V3, P134, DOI 10.3109/13506129609014366
   MERETOJA J, 1969, ANN CLIN RES, V14, P314
   METZLER JP, 1992, SKELETAL RADIOL, V21, P463
   NYLANDER PO, 1990, HUM HERED, V40, P272, DOI 10.1159/000153944
   Page LJ, 2005, EMBO J, V24, P4124, DOI 10.1038/sj.emboj.7600872
   Paunio T, 1998, J BIOL CHEM, V273, P16319, DOI 10.1074/jbc.273.26.16319
   PAUNIO T, 1992, GENOMICS, V13, P237, DOI 10.1016/0888-7543(92)90235-K
   PAUNIO T, 1994, HUM MOL GENET, V3, P2223, DOI 10.1093/hmg/3.12.2223
   RINTALA AE, 1988, SCAND J PLAST RECONS, V22, P141, DOI 10.3109/02844318809072386
   Robinson RC, 2001, P NATL ACAD SCI USA, V98, P2117, DOI 10.1073/pnas.051635098
   Rosenberg ME, 2001, INVEST OPHTH VIS SCI, V42, P634
   Rostagno A, 2002, J BIOL CHEM, V277, P49782, DOI 10.1074/jbc.M206448200
   SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5
   Spuler S, 1998, ANN NEUROL, V43, P719, DOI 10.1002/ana.410430606
   Stewart HS, 2000, BRIT J OPHTHALMOL, V84, P390, DOI 10.1136/bjo.84.4.390
   Suk JY, 2006, BIOCHEMISTRY-US, V45, P2234, DOI 10.1021/bi0519295
   Tanskanen M, 2005, NEUROPATH APPL NEURO, V31, P589, DOI 10.1111/j.1365-2990.2005.00652.x
   WEEDS AG, 1993, FEBS LETT, V335, P119, DOI 10.1016/0014-5793(93)80452-Z
   Westberg JA, 1999, FASEB J, V13, P1621
NR 35
TC 16
Z9 16
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1350-6129
EI 1744-2818
J9 AMYLOID
JI Amyloid-J. Protein Fold. Disord.
PD MAR
PY 2007
VL 14
IS 1
BP 89
EP 95
DI 10.1080/13506120601116393
PG 7
WC Biochemistry & Molecular Biology; Medicine, General & Internal;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; General & Internal Medicine; Research
   & Experimental Medicine
GA 163WS
UT WOS:000246194500009
PM 17453628
DA 2018-12-27
ER

PT J
AU Sen, P
   Chakraborty, PK
   Raha, S
AF Sen, Prosenjit
   Chakraborty, Prabir Kumar
   Raha, Sanghamitra
TI RETRACTED: Activation of p38MAPK by repetitive low-grade oxidative
   stress leads to pro-survival effects (Retracted Article. See vol 1783,
   pg 345, 2008)
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article; Retracted Publication
DE p38MAPK; Akt; NF kappa B; IKK; p65; repetitive stress; apoptosis
ID NF-KAPPA-B; PROTEIN-KINASE-C; HYDROGEN-PEROXIDE; CATALASE ACTIVITY;
   GENE-EXPRESSION; P38; APOPTOSIS; CELLS; AKT; INFLAMMATION
AB V79 lung fibroblasts were subjected to repetitive oxidative stress in culture through exposures to 30 mu M H2O2 for 4 weeks. Within the first week of treatment p38MAPK became dually phosphorylated and became increasingly phosphorylated during the 4-week stress period. Akt also became phosphorylated on Ser(473) and Thr(308) after the second week of treatment and remained phosphorylated throughout the study. NF kappa B p65 and I kappa B kinase (IKK) became phosphorylated and NF kappa B transcriptional activity became augmented during repetitive stress. Treatment of the cells concurrently with SB203580, a specific p38MAPK inhibitor, robustly blocked activation of NF kappa B transcriptional activity, phosphorylation of p65, and IKK but only partially blocked Akt phosphorylation. Similar simultaneous treatment with PI-3 kinase inhibitor LY294002 prominently blocked Akt phosphorylation. Pre-exposure to short interfering RNA (si RNA) to p38MAPK resulted in a complete blockage of the NF kappa B p65 and IKK phosphorylations as well as the anti-apoptotic influence induced by a single low dose of H2O2 but produced a partial obstruction of Akt phosphorylation. Repetitively stressed cells were found to be significantly resistant to apoptosis-inducing agents such as ultraviolet radiation (UVR) and mM H2O2. Concurrent treatment with SB203580 almost completely restored the normal apoptotic response such as DNA fragmentation after UVR and mM H2O2. LY294002, a PI-3 kinase inhibitor and SN-50, an inhibitor of NF kappa B, produced partial restorations of the apoptotic response. We conclude that activation of p38MAPK by repetitive oxidative stress is the key event which through its command over down-stream survival elements such as Akt and NF kappa B controls the anti-apoptotic environment of the repetitively H2O2-stressed cells. (c) 2006 Elsevier B.V. All rights reserved.
C1 Saha Inst Nucl Phys, Crystallog & Mol Biol Div, Kolkata 700064, W Bengal, India.
RP Raha, S (reprint author), Saha Inst Nucl Phys, Crystallog & Mol Biol Div, 1-AF Bidhan Nagar, Kolkata 700064, W Bengal, India.
EM sanghamitra.raha@saha.ac.in
CR Baines CP, 1998, J MOL CELL CARDIOL, V30, P383, DOI 10.1006/jmcc.1997.0601
   Carper D, 2001, FREE RADICAL BIO MED, V31, P90, DOI 10.1016/S0891-5849(01)00561-5
   Chen ZH, 2005, NEUROSCI LETT, V383, P256, DOI 10.1016/j.neulet.2005.04.022
   Choi H, 2006, EXP BIOL MED, V231, P463, DOI 10.1177/153537020623100412
   Cornejo P, 2005, NITRIC OXIDE-BIOL CH, V13, P54, DOI 10.1016/j.niox.2005.04.009
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Das DK, 2006, CARDIOVASC RES, V70, P254, DOI 10.1016/j.cardiores.2006.02.023
   Das DK, 2006, MOL INTERV, V6, P36, DOI 10.1124/mi.6.1.7
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Dejean LM, 2006, CELL DEATH DIFFER, V13, P1387, DOI 10.1038/sj.cdd.4401949
   Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y
   Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003
   Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507
   Han H, 2001, J BIOL CHEM, V276, P26357, DOI 10.1074/jbc.M011136200
   Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017
   Keightley JA, 2004, MOL CELL PROTEOMICS, V3, P167, DOI 10.1074/mcp.M300119-MCP200
   Kim DK, 2001, FREE RADICAL BIO MED, V30, P563, DOI 10.1016/S0891-5849(00)00504-9
   LAI C, 1996, J MOL CELL CARDIOL, V106, P157
   Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5
   Li JF, 2005, BRAIN RES, V1060, P62, DOI 10.1016/j.brainres.2005.08.047
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Manna SK, 2006, BIOCHEM PHARMACOL, V71, P1602, DOI 10.1016/j.bcp.2006.02.014
   McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ2001501
   Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725
   Ozes ON, 1999, NATURE, V401, P82
   Poswig A, 1999, J INVEST DERMATOL, V112, P13, DOI 10.1046/j.1523-1747.1999.00465.x
   Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200
   Schulz R, 2002, CARDIOVASC RES, V55, P690, DOI 10.1016/S0008-6363(02)00319-X
   Sen P, 2006, FEBS LETT, V580, P278, DOI 10.1016/j.febslet.2005.12.013
   Sen P, 2005, FEBS LETT, V579, P4402, DOI 10.1016/j.febslet.2005.06.081
   Sen P, 2003, MOL CELL BIOCHEM, V253, P241, DOI 10.1023/A:1026020101379
   Sen P, 2003, MUTAT RES-FUND MOL M, V529, P87, DOI 10.1016/S0027-5107(03)00106-4
   SPITZ DR, 1992, ARCH BIOCHEM BIOPHYS, V292, P221, DOI 10.1016/0003-9861(92)90071-4
   Tang XQ, 2005, BRAIN RES, V1057, P57, DOI 10.1016/j.brainres.2005.07.072
   van der Woude CJ, 2004, APOPTOSIS, V9, P123, DOI 10.1023/B:APPT.0000018794.26438.22
   Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336
   Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tiba.2004.11.009
   Zmijewski JW, 2005, BIOCHEM SOC T, V33, P1385, DOI 10.1042/BST0331385
NR 39
TC 14
Z9 14
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 0006-3002
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD MAR
PY 2007
VL 1773
IS 3
BP 367
EP 374
DI 10.1016/j.bbamcr.2006.11.012
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 147LS
UT WOS:000245005100008
PM 17196679
OA Bronze
DA 2018-12-27
ER

PT J
AU Thanomsub, B
   Pumeechockchai, W
   Limtrakul, A
   Arunrattiyakorn, P
   Petchleelaha, W
   Nitoda, T
   Kanzaki, H
AF Thanomsub, Benjamas
   Pumeechockchai, Wanna
   Limtrakul, Anirut
   Arunrattiyakorn, Panarat
   Petchleelaha, Wipawan
   Nitoda, Teruhiko
   Kanzaki, Hiroshi
TI RETRACTED: Chemical structures and biological activities of rhamnolipids
   produced by Pseudomonas aeruginosa B189 isolated from milk factory waste
   (Retracted Article. See vol 100, pg 6141, 2009)
SO BIORESOURCE TECHNOLOGY
LA English
DT Article; Retracted Publication
DE rhamnolipid; glycolipid; Pseudomonas; biosurfactant; anticancer;
   biological activity
ID LEUKEMIA-CELL LINE; GLYCOLIPID BIOSURFACTANTS; MICROBIAL-PRODUCTION;
   LIPIDS; DIFFERENTIATION; LIPOPEPTIDE; SURFACTIN; STRAIN; GENE
AB The aim of this work was to study chemical structures and biological activities of rhamnolipids produced by Pseudomonas aeruginosa B189 isolated from milk factory waste. The culture produced two biosurfactants, a and b, which showed strong activity and were identified as L-rhamnopyranosyl-(L)-rhamnopyranosyl-beta-hydroxydecanoyl-beta-hydroxydecanoate or Rha-Rha-C-10-C-10 and (L)-rhamnopyranosyl-(L)-rhamnopyranosyl-beta-hydroxydecanoyl-beta-hydroxydodecanoate or Rha-Rha-C-10-C-12, respectively. Both compounds exhibited higher surfactant activities tested by the drop collapse test than several artificial surfactants such as SDS and Tween 80. Rhamnolipid a showed significant antiproliferative activity against human breast cancer cell line (MCF-7) at minimum inhibitory concentration (MIC) at 6.25 mu g/mL while rhamnolipid b showed MIC against insect cell line C6/36 at 50 mu g/mL. (c) 2006 Published by Elsevier Ltd.
C1 Srinakharinwirot Univ, Fac Med, Dept Microbiol, Bangkok 10110, Thailand.
   Srinakharinwirot Univ, Fac Sci, Dept Chem, Bangkok 10110, Thailand.
   Okayama Univ, Fac Agr, Dept Bioresources Chem, Okayama 7008530, Japan.
RP Thanomsub, B (reprint author), Srinakharinwirot Univ, Fac Med, Dept Microbiol, Bangkok 10110, Thailand.
EM benjamat@swu.ac.th
CR Benincasa M, 2004, ANTON LEEUW INT J G, V85, P1, DOI 10.1023/B:ANTO.0000020148.45523.41
   Desai JD, 1997, MICROBIOL MOL BIOL R, V61, P47
   Haba E, 2003, BIOTECHNOL BIOENG, V81, P316, DOI 10.1002/bit.10474
   HATCHISON ML, 1997, MOL PLANT MICROBE IN, V10, P347
   Haussler S, 2003, INFECT IMMUN, V71, P2970, DOI 10.1128/IAI.71.5.2970-2975.2003
   HILL EL, 1991, AM SOC MICROBIOLOGY, P1184
   Isoda H, 1997, CYTOTECHNOLOGY, V25, P191, DOI 10.1023/A:1007982909932
   Kitamoto D, 2002, J BIOSCI BIOENG, V94, P187, DOI 10.1263/jbb.94.187
   KITAMOTO D, 1990, AGR BIOL CHEM TOKYO, V54, P31, DOI 10.1080/00021369.1990.10869918
   Lang S, 1999, APPL MICROBIOL BIOT, V51, P22, DOI 10.1007/s002530051358
   Mikkola R, 2000, EUR J BIOCHEM, V267, P4068, DOI 10.1046/j.1432-1033.2000.01467.x
   MORIKAWA M, 1993, J BACTERIOL, V175, P6459, DOI 10.1128/jb.175.20.6459-6466.1993
   Peypoux F, 1999, APPL MICROBIOL BIOT, V51, P553, DOI 10.1007/s002530051432
   Rahman KSM, 2003, BIORESOURCE TECHNOL, V90, P159, DOI 10.1016/S0960-8524(03)00114-7
   Sandrin TR, 2000, APPL ENVIRON MICROB, V66, P4585, DOI 10.1128/AEM.66.10.4585-4588.2000
   Sudo T, 2000, CYTOTECHNOLOGY, V33, P259, DOI 10.1023/A:1008137817944
   Thanomsub B, 2004, J APPL MICROBIOL, V96, P588, DOI 10.1111/j.1365-2672.2004.02202.x
   Vollenbroich D, 1997, BIOLOGICALS, V25, P289, DOI 10.1006/biol.1997.0099
   WOHLFARTH S, 1988, J GEN MICROBIOL, V134, P433
NR 19
TC 31
Z9 33
U1 2
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD MAR
PY 2007
VL 98
IS 5
BP 1149
EP 1153
DI 10.1016/j.biortech.2005.10.045
PG 5
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 126UR
UT WOS:000243541500027
PM 16781144
DA 2018-12-27
ER

PT J
AU L'taief, B
   Sifi, B
   Gtari, M
   Zaman-Allah, M
   Lachaal, M
AF L'taief, Boulbaba
   Sifi, Bouaziz
   Gtari, Maher
   Zaman-Allah, Mainassara
   Lachaal, Mokhtar
TI RETRACTED: Phenotypic and molecular characterization of chickpea
   rhizobia isolated from different areas of Tunisia (Retracted article.
   See vol. 59, pg. 587, 2013)
SO CANADIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE Cicer arietinum; Mesorhizobium ciceri; Mesorhizobium mediterraneum;
   genetic diversity; polymerase chain reaction; restriction fragment
   length polymorphism
ID CICER-ARIETINUM-L; LENGTH-POLYMORPHISM ANALYSIS; GENETIC DIVERSITY;
   WOODY LEGUMES; BRADYRHIZOBIUM; NOV; SOIL
AB Several phenotypic markers were used in this study to determine the biodiversity of rhizobial strains nodulating Cicer arietinum L. in various areas of Tunisia. They include symbiotic traits, the use of 21 biochemical substrates, and tolerance to salinity and pH. In addition, restriction fragment length polymorphisms (RFLPs) of PCR-amplified 16S rDNA were compared with those of reference strains. Numeric analysis of the phenotypic characteristics showed that the 48 strains studied fell into three distinct groups. This heterogeneity was highly supported by the RFLP analysis of 16S rRNA genes, and two ribotypes were identified. Chickpea rhizobia isolated from Tunisian soils are both phenotypically and genetically diverse. Results showed that 40 and 8 isolates were assigned, respectively, to Mesorhizobium ciceri and Mesorhizobium mediterraneum.
C1 Fac Sci Tunis, Dept Biol, Tunis 1060, Tunisia.
   INRAT, Lab Grandes Cultures, Atiana 2080, Tunisia.
   Fac Sci Tunis, Lab Microorganismes & Biomol Act, Tunis 1060, Tunisia.
   Fac Sci Tunis, Dept Biol, Tunis 1060, Tunisia.
RP L'taief, B (reprint author), Fac Sci Tunis, Dept Biol, Campus Univ 1060, Tunis 1060, Tunisia.
EM lboulaba@yahoo.com
RI Zaman-Allah, Mainassara/J-7364-2018
OI Zaman-Allah, Mainassara/0000-0002-8120-5125
CR BERINGER JE, 1974, J GEN MICROBIOL, V84, P188
   BROUGHTON WJ, 1971, BIOCHEM J, V125, P1075, DOI 10.1042/bj1251075
   CADAHIA E, 1986, ARCH MICROBIOL, V146, P239, DOI 10.1007/BF00403223
   Carelli M, 2000, APPL ENVIRON MICROB, V66, P4785, DOI 10.1128/AEM.66.11.4785-4789.2000
   CHAKRABARTI SK, 1986, CAN J MICROBIOL, V32, P524, DOI 10.1139/m86-096
   EXCOFFIER L, 1992, GENETICS, V131, P479
   GAO JL, 1994, INT J SYST BACTERIOL, V44, P151, DOI 10.1099/00207713-44-1-151
   GAUR YD, 1979, NEW PHYTOL, V83, P745, DOI 10.1111/j.1469-8137.1979.tb02305.x
   GRAHAM PH, 1992, CAN J MICROBIOL, V38, P475, DOI 10.1139/m92-079
   Graham PH, 1964, PLANT SOIL, V20, P283
   Herrera-Cervera JA, 1999, FEMS MICROBIOL ECOL, V30, P87, DOI 10.1016/S0168-6496(99)00044-6
   Jarvis BDW, 1997, INT J SYST BACTERIOL, V47, P895, DOI 10.1099/00207713-47-3-895
   Jarvis BDW, 1982, INT J SYST BACTERIOL, V32, P371
   Jordan D. C., 1984, BERGEYS MANUAL SYSTE, P234
   JORDAN DC, 1982, INT J SYST BACTERIOL, V32, P136, DOI 10.1099/00207713-32-1-136
   KERSTERS K, 1984, INT J SYST BACTERIOL, V34, P56, DOI 10.1099/00207713-34-1-56
   KINGSLEY MT, 1983, CAN J MICROBIOL, V29, P518, DOI 10.1139/m83-081
   Laguerre G, 1997, APPL ENVIRON MICROB, V63, P4748
   LAGUERRE G, 1994, APPL ENVIRON MICROB, V60, P56
   NOUR SM, 1994, CAN J MICROBIOL, V40, P345, DOI 10.1139/m94-057
   Odee DW, 1997, PLANT SOIL, V188, P65, DOI 10.1023/A:1004204413140
   Paffetti D, 1996, APPL ENVIRON MICROB, V62, P2279
   RUPELA OP, 1990, P 2 INT WORKSH CHICK, P13
   VANROSSUM D, 1995, APPL ENVIRON MICROB, V61, P1599
   VINCENT JM, 1970, IBP HDB, V15, P44
   Vinuesa P, 1998, APPL ENVIRON MICROB, V64, P2096
NR 26
TC 14
Z9 15
U1 3
U2 9
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA
SN 0008-4166
J9 CAN J MICROBIOL
JI Can. J. Microbiol.
PD MAR
PY 2007
VL 53
IS 3
BP 427
EP 434
DI 10.1139/W06-127
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology; Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology; Microbiology
GA 181GZ
UT WOS:000247426500012
PM 17538653
DA 2018-12-27
ER

PT J
AU Raffoul, JJ
   Banerjee, S
   Singh-Gupta, V
   Knoll, ZE
   Fite, A
   Zhang, H
   Abrams, J
   Sarkar, FH
   Hillman, GG
AF Raffoul, Julian J.
   Banerjee, Sanjeev
   Singh-Gupta, Vinita
   Knoll, Zvi E.
   Fite, Alemu
   Zhang, Hao
   Abrams, Judith
   Sarkar, Fazlul H.
   Hillman, Gilda G.
TI RETRACTED: Down-regulation of apurinic/apyrimidinic endonuclease 1/redox
   factor-1 expression by soy isoflavones enhances prostate cancer
   radiotherapy in vitro and in vivo (Retracted article. See vol. 78, pg.
   6028, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; DNA-REPAIR ENZYME; BASE EXCISION-REPAIR; ALTERED EXPRESSION;
   ORTHOTOPIC MODEL; BINDING ACTIVITY; DAMAGING AGENTS; TUMOR-MODEL;
   GENISTEIN; CELLS
AB We previously showed that genistein, the major bioactive component of soy isoflavones, acts as a radiosensitizer and potentiates prostate tumor cell killing by radiation in vitro and in animal tumor models in vivo. However, when given alone in vivo, pure genistein promoted increased lymph node metastasis, which was not observed with a soy isoflavone mixture consisting of genistein, daidzein, and glycitein. In this study, we show that soy inhibits tumor cell growth and potentiates radiation-induced cell killing in vitro like pure genistein. In an orthotopic model, combining soy isoflavones with tumor irradiation inhibited prostate tumor growth. To determine the molecular mechanisms by which soy isoflavones potentiate radiotherapy, we investigated apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) and nuclear factor kappa B (NF-kappa B), two signaling molecules involved in survival pathways. Soy isoflavones decreased APEI/Ref-1 expression in vitro, whereas radiation up-regulated it. Pretreatment with soy isoflavones followed by radiation inhibited APEI/Ref-1 expression. APEI/Ref-1 decrease correlated with decreased DNA-binding activity of NF-kappa B mediated by soy isoflavones and radiation, thus promoting cell killing. In vivo treatment of prostate tumors with soy isoflavones and radiation down-regulated APEI/Ref-1 protein expression and NF-kappa B activity, confirming the molecular alterations observed in vitro. The down-regulation of APEI/Ref-1 and NF-kappa B by isoflavones, in vitro and in vivo, supports our hypothesis that these markers represent biological targets of isoflavones. Indeed, a 2-fold increase in APEI/Ref-1 expression, obtained by cDNA transfection, resulted in a 2-fold increase in NF-kappa B DNA-binding activity, and both of which were down-regulated by soy isoflavones, confirming the cross-talk between these molecules and, in turn, causing radiosensitization.
C1 Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Radiat Oncol, Detroit, MI 48201 USA.
   Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.
   Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Integrated Biostat Unit, Detroit, MI 48201 USA.
RP Hillman, GG (reprint author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Radiat Oncol, 515 Hudson Webber Canc Res Ctr,4100 John R Rd, Detroit, MI 48201 USA.
EM hillmang@karmanos.org
CR Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330
   Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585
   Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11
   Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X
   Freitas S, 2003, CLIN CANCER RES, V9, P4689
   Guan ZJ, 2005, ARTERIOSCL THROM VAS, V25, P96, DOI 10.1161/01.ATV.0000150418.14698.75
   Hall JL, 2001, CIRC RES, V88, P1247, DOI 10.1161/hh1201.091796
   Herring CJ, 1998, BRIT J CANCER, V78, P1128, DOI 10.1038/bjc.1998.641
   Hillman GG, 2004, MOL CANCER THER, V3, P1271
   Hillman GG, 2001, CLIN CANCER RES, V7, P382
   Hillman GG, 2001, CLIN CANCER RES, V7, P136
   Holzbeierlein JM, 2005, CURR OPIN UROL, V15, P17, DOI 10.1097/00042307-200501000-00005
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Kelley MR, 2001, CLIN CANCER RES, V7, P824
   Li YW, 2002, CLIN CANCER RES, V8, P2369
   Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1
   Madhusudan S, 2005, TRENDS MOL MED, V11, P503, DOI 10.1016/j.molmed.2005.09.004
   Moore DH, 2000, CLIN CANCER RES, V6, P602
   Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200
   Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200
   RAFFOUL JJ, 2007, IN PRESS INT J CANC
   Raffoul JJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-107
   Robertson KA, 2001, CANCER RES, V61, P2220
   ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519
   Sarkar FH, 2002, CANCER METAST REV, V21, P265, DOI 10.1023/A:1021210910821
   Sarkar FH, 2006, CANCER RES, V66, P3347, DOI 10.1158/0008-5472.CAN-05-4526
   Sarkar FH, 2004, FRONT BIOSCI-LANDMRK, V9, P2714, DOI 10.2741/1430
   Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496
   Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112
   Sonn GA, 2005, PROSTATE CANCER P D, V8, P304, DOI 10.1038/sj.pcan.4500825
   Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03
   Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367
   Triest JA, 1998, CLIN CANCER RES, V4, P2009
   WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884
   Wang D, 2004, MOL CANCER THER, V3, P679
   Wang Y, 2006, RADIAT RES, V166, P73, DOI 10.1667/RR3590.1
   XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x
   XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x
   Xu Y, 1997, ANTICANCER RES, V17, P3713
   Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287
   Yang S, 2005, MOL CANCER THER, V4, P1923, DOI 10.1158/1535-7163.MCT-05-0229
   ZIETMAN AL, 1993, CANCER, V71, P959, DOI 10.1002/1097-0142(19930201)71:3+<959::AID-CNCR2820711411>3.0.CO;2-L
NR 43
TC 82
Z9 88
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2007
VL 67
IS 5
BP 2141
EP 2149
DI 10.1158/0008-5472.CAN-06-2147
PG 9
WC Oncology
SC Oncology
GA 143QQ
UT WOS:000244738100034
PM 17332344
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, JY
   Zhang, YF
AF Li, Jinyong
   Zhang, Yafei
TI RETRACTED: Langmuir-Blodgett films of single-walled carbon nanotubes
   (Retracted article. See vol. 50, pg. 2376, 2012)
SO CARBON
LA English
DT Article; Retracted Publication
ID PURIFICATION; POLYMERS
AB Large arrays of well-aligned carbon nanotubes on glass, silicon, quartz, etc. have been successfully prepared by Langmuir-Blodgett deposition. The overall direction of the carbon nanotubes alignment can be controlled both by compression and dipping process. Several factors involved in the deposition process were investigated in an attempt to understand the deposition technique and to optimize the quality of the films. Deposition can be performed in a layer-by-layer fashion up to several hundreds layers, allowing to readily control the film thickness. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Shanghai Jiao Tong Univ, Natl Key Lab Nano Micro Fabricat Technol, Key Lab Thin Film & Microfabricat, Minist Educ,Inst Micro & Nano Sci & Technol, Shanghai 200030, Peoples R China.
RP Li, JY (reprint author), Shanghai Jiao Tong Univ, Natl Key Lab Nano Micro Fabricat Technol, Key Lab Thin Film & Microfabricat, Minist Educ,Inst Micro & Nano Sci & Technol, Shanghai 200030, Peoples R China.
EM ljy@sjtu.edu.cn
CR Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340
   Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928
   Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95
   Chiang IW, 2001, J PHYS CHEM B, V105, P8297, DOI 10.1021/jp0114891
   Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0
   Dai LM, 2003, NANOTECHNOLOGY, V14, P1081, DOI 10.1088/0957-4484/14/10/305
   DUDA G, 1988, THIN SOLID FILMS, V159, P221, DOI 10.1016/0040-6090(88)90633-5
   Fischer JE, 2003, J APPL PHYS, V93, P2157, DOI 10.1063/1.1536733
   Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744
   Hamon MA, 2001, CHEM PHYS LETT, V347, P8, DOI 10.1016/S0009-2614(01)01035-1
   Huang SM, 2004, NANO LETT, V4, P1025, DOI 10.1021/nl049691d
   KONG J, 2000, SCIENCE, V287, P5453
   Kshama B., 1997, SCIENCE, V278, P655
   Li JY, 2005, PHYSICA E, V28, P309, DOI 10.1016/j.physe.2005.03.022
   Li YL, 2004, SCIENCE, V304, P276, DOI 10.1126/science.1094982
   LUCCIO TD, 2004, CARBON, V42, P1119
   Nakayama Y, 2001, SYNTHETIC MET, V117, P207, DOI 10.1016/S0379-6779(00)00365-9
   Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791
   PHILIP K, 1999, SCIENCE, V286, P2148
   Rao SG, 2003, NATURE, V425, P36, DOI 10.1038/425036a
   Saito R, 1998, PHYS REV B, V57, P4145, DOI 10.1103/PhysRevB.57.4145
   Shimoda H, 2002, PHYSICA B, V323, P135, DOI 10.1016/S0921-4526(02)00877-3
   Strong KL, 2003, CARBON, V41, P1477, DOI 10.1016/S0008-6223(03)00014-9
   Sun X, 2004, CHEM PHYS LETT, V394, P266, DOI 10.1016/j.cplett.2004.07.014
NR 24
TC 17
Z9 18
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0008-6223
J9 CARBON
JI Carbon
PD MAR
PY 2007
VL 45
IS 3
BP 493
EP 498
DI 10.1016/j.carbon.2006.10.027
PG 6
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 145PY
UT WOS:000244878200004
DA 2018-12-27
ER

PT J
AU Sohrab, S
   Mathur, PN
AF Sohrab, Sadaf
   Mathur, Praveen N.
TI RETRACTED: Management of central airway obstruction (Retracted Article.
   See vol 9, pg 308, 2008)
SO CLINICAL LUNG CANCER
LA English
DT Review; Retracted Publication
DE airway stents; argon plasma coagulation; Brachytherapy; cryotherapy;
   endobronchial therapy; laser therapy; photodynamic therapy
ID ND-YAG LASER; DOSE-RATE BRACHYTHERAPY; OCCULT LUNG-CANCER; BRONCHOSCOPIC
   PHOTODYNAMIC THERAPY; REMOTE AFTERLOADING BRACHYTHERAPY; EXTERNAL-BEAM
   RADIOTHERAPY; ARGON PLASMA COAGULATION; ENDOBRONCHIAL CARCINOMA;
   TRACHEOBRONCHIAL STENOSIS; BRONCHOGENIC-CARCINOMA
AB The efficacy of interventional pulmonology for palliation of patients with central airway obstruction has been established, and its curative potential for early cancer has raised great interest in current screening programs. The success of endoscopic strategies for palliation and treatment with curative intent strongly depends on the diligent identification of the various factors in lung cancer management, including full comprehension of the limits and potential of each particular technique. In the palliative setting of alleviating central airway obstruction, laser resection, electrocautery, argon plasma coagulation, and stenting are techniques that can provide immediate relief, in contrast with cryotherapy, brachytherapy, and photodynamic therapy, which have delayed effects. With curative intent, intraluminal techniques that easily coagulate early-stage cancer lesions will increase the implementation of interventional pulmonology for benign and relatively benign diseases, as well as early cancer lesions and its precursors at their earliest stage of disease.
C1 Indiana Univ, Sch Med, Div Pulm & Crit Care Allergy & Occupat Med, Indiana Univ Hosp, Indianapolis, IN 46202 USA.
RP Mathur, PN (reprint author), Indiana Univ, Sch Med, Div Pulm & Crit Care Allergy & Occupat Med, Indiana Univ Hosp, 550 N Univ Blvd,Suite 4903, Indianapolis, IN 46202 USA.
EM pmathur@iupui.edu
CR AYGUN C, 1992, INT J RADIAT ONCOL, V23, P127, DOI 10.1016/0360-3016(92)90551-R
   BARLOW DE, 1982, GASTROINTEST ENDOSC, V28, P73, DOI 10.1016/S0016-5107(82)73002-0
   Bolliger CT, 2002, EUR RESPIR J, V19, P356, DOI 10.1183/09031936.02.00204602
   BOLLIGER CT, 1993, CHEST, V104, P1653, DOI 10.1378/chest.104.6.1653
   Bolliger CT, 1997, SEM RESP CRIT CARE M, V18, P563, DOI 10.1055/s-2007-1009372
   Bolliger CT, 1996, THORAX, V51, P1127, DOI 10.1136/thx.51.11.1127
   CAVALIERE S, 1988, CHEST, V94, P15, DOI 10.1378/chest.94.1.15
   CAVALIERE S, 2000, INTERVENTIONAL BRONC, V30, P108
   COLT HG, 1992, GASTROINTEST ENDOSC, V38, P485, DOI 10.1016/S0016-5107(92)70482-9
   Coulter TD, 2000, CHEST, V118, P516, DOI 10.1378/chest.118.2.516
   DOUGHERTY TJ, 1975, J NATL CANCER I, V55, P115, DOI 10.1093/jnci/55.1.115
   DOUGHERTY TJ, 1979, J NATL CANCER I, V62, P231
   DOUGHERTY TJ, 1978, CANCER RES, V38, P2628
   DUMON JF, 1982, CHEST, V81, P278, DOI 10.1378/chest.81.3.278
   DUMON JF, 1990, CHEST, V97, P328, DOI 10.1378/chest.97.2.328
   Edel ES, 1987, MAYO CLIN P, V14, P62
   Ernst A, 2004, AM J RESP CRIT CARE, V169, P1278, DOI 10.1164/rccm.200210-118150
   Forest V, 2005, CRYOBIOLOGY, V50, P29, DOI 10.1016/j.cryobiol.2004.09.007
   Forest V, 2006, LUNG CANCER, V54, P79, DOI 10.1016/j.lungcan.2006.05.026
   Freitag L, 1997, THORAC CARDIOV SURG, V45, P6, DOI 10.1055/s-2007-1013675
   Freitag L, 2000, PROG RESPIR RES, V30, P171
   FREITAG L, 2001, EUR RESP MONOGR, V6, P272
   Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U
   Grund K E, 1994, Endosc Surg Allied Technol, V2, P42
   Hayata Y, 1996, LASER MED SCI, V11, P255, DOI 10.1007/BF02134916
   HAYATA Y, 1982, CHEST, V82, P10, DOI 10.1378/chest.82.1.10
   HENSCHKE UK, 1964, RADIOLOGY, V83, P344, DOI 10.1148/83.2.344
   Hernandez P, 1996, THORAX, V51, P354, DOI 10.1136/thx.51.4.354
   HILARIS BS, 1988, ATLAS BRACHYTHERAPY, P184
   HOMASSON JP, 1986, CHEST, V90, P159, DOI 10.1378/chest.90.2.159
   Huber RM, 1997, INT J RADIAT ONCOL, V38, P533, DOI 10.1016/S0360-3016(97)00008-4
   Kato H, 1998, J PHOTOCH PHOTOBIO B, V42, P96, DOI 10.1016/S1011-1344(97)00128-0
   KATO H, 1985, J THORAC CARDIOV SUR, V90, P420
   Kelly JF, 2000, INT J RADIAT ONCOL, V48, P697, DOI 10.1016/S0360-3016(00)00693-3
   Kunst PWA, 2002, J CLIN ONCOL, V20, P2745, DOI 10.1200/JCO.2002.20.11.2745
   LAFORET EG, 1976, NEW ENGL J MED, V294, P941, DOI 10.1056/NEJM197604222941710
   Lee P, 2002, CLIN CHEST MED, V23, P241, DOI 10.1016/S0272-5231(03)00075-3
   LIPSON RL, 1966, P 9 INT CANC C TOK
   Mathur PN, 1996, CHEST, V110, P718, DOI 10.1378/chest.110.3.718
   McCaughan JS, 1997, J THORAC CARDIOV SUR, V114, P940, DOI 10.1016/S0022-5223(97)70008-4
   MEHTA AC, 1993, CHEST, V104, P673, DOI 10.1378/chest.104.3.673
   Miyazawa T, 2000, CHEST, V118, P959, DOI 10.1378/chest.118.4.959
   Miyazawa T, 2004, AM J RESP CRIT CARE, V169, P1096, DOI 10.1164/rccm.200311-1784OC
   Moghissi K, 1999, EUR J CARDIO-THORAC, V15, P1, DOI 10.1016/S1010-7940(98)00295-4
   Moghissi K, 2003, EUR RESPIR J, V22, P535, DOI 10.1183/09031936.03.00005203
   Monnier P, 1996, CHEST, V110, P1161, DOI 10.1378/chest.110.5.1161
   MONTGOMERY WW, 1965, ARCHIV OTOLARYNGOL, V82, P320
   Morice RC, 2001, CHEST, V119, P781, DOI 10.1378/chest.119.3.781
   Noppen M, 1999, CHEST, V115, P532, DOI 10.1378/chest.115.2.532
   Reichle G, 2000, Pneumologie, V54, P508, DOI 10.1055/s-2000-8254
   Saad CP, 2003, CHEST, V124, P1993, DOI 10.1378/chest.124.5.1993
   Saito M, 1996, INT J RADIAT ONCOL, V34, P1029, DOI 10.1016/0360-3016(95)02390-9
   SANDERSON DR, 1981, ANN OTO RHINOL LARYN, V90, P354, DOI 10.1177/000348948109000414
   SANDERSON DR, 1975, MAYO CLIN PROC, V50, P435
   Schuurman B, 2004, RESPIRATION, V71, P410, DOI 10.1159/000079648
   SHAH H, 1995, CHEST, V107, P1744, DOI 10.1378/chest.107.6.1744
   SPEISER B, 1990, INT J RADIAT ONCOL, V18, P1443, DOI 10.1016/0360-3016(90)90320-J
   SPEISER B, 1991, INT J RADIAT ONCOL, V20, P1133, DOI 10.1016/0360-3016(91)90216-Q
   SPEISER BL, 1993, INT J RADIAT ONCOL, V25, P579, DOI 10.1016/0360-3016(93)90002-D
   SUTEDJA G, 1994, THORAX, V49, P1243, DOI 10.1136/thx.49.12.1243
   SUTEDJA G, 1995, RESPIRATION, V62, P148
   SUTEDJA TG, 1995, CHEST, V107, P556, DOI 10.1378/chest.107.2.556
   TOTY L, 1981, THORAX, V36, P175, DOI 10.1136/thx.36.3.175
   UNGER M, 1984, SURG CLIN N AM, V64, P931
   van Boxem T, 1999, CHEST, V116, P1108, DOI 10.1378/chest.116.4.1108
   van Boxem TJ, 1998, EUR RESPIR J, V11, P169, DOI 10.1183/09031936.98.11010169
   van Boxem TJM, 2000, CHEST, V117, P887, DOI 10.1378/chest.117.3.887
   VERGNON JM, 1995, CHEST, V107, P741, DOI 10.1378/chest.107.3.741
   Vonk-Noordegraaf A, 2001, CHEST, V120, P1811, DOI 10.1378/chest.120.6.1811
   Vonk-Noordegraaf A, 2003, LUNG CANCER-J IASLC, V39, P49, DOI 10.1016/S0169-5002(02)00309-4
   Wood DE, 2003, ANN THORAC SURG, V76, P167, DOI 10.1016/S0003-4975(03)00033-X
   Yokomise H, 1998, RESPIRATION, V65, P489, DOI 10.1159/000029321
NR 72
TC 6
Z9 10
U1 1
U2 8
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1525-7304
EI 1938-0690
J9 CLIN LUNG CANCER
JI Clin. Lung Cancer
PD MAR
PY 2007
VL 8
IS 5
BP 305
EP 312
PG 8
WC Oncology
SC Oncology
GA 160BK
UT WOS:000245911600001
PM 17562229
DA 2018-12-27
ER

PT J
AU Munro, PT
   Howie, N
   Gerstenmaier, JF
AF Munro, Philip T.
   Howie, Neil
   Gerstenmaier, Jan F.
TI RETRACTED: Do peripheral blood cultures taken in the emergency
   department influence clinical management? (Retracted Article. See vol
   24, pg 373, 2007)
SO EMERGENCY MEDICINE JOURNAL
LA English
DT Editorial Material; Retracted Publication
ID PNEUMONIA
AB Background: Blood cultures are routinely used to investigate suspected sepsis in the emergency department despite several studies showing their limited influence on patient management.
   Objectives: To quantify the use and clinical relevance of blood cultures obtained in the emergency department.
   Methods: A retrospective study of blood cultures taken in the emergency department between 1 January 2003 and 31 December 2004. Microbiology results and patients' records were reviewed to determine the influence of positive cultures on subsequent patient management.
   Results: 2213 blood cultures were taken in the emergency department over the study period. 132 (6%) yielded a positive result. Three positive cultures had incomplete information. Of the remaining 129 positive cultures, 30 (1.4% of all cultures) were "true positives'' and 4 (0.18%) influenced subsequent patient management.
   Conclusions: Blood cultures taken in our emergency department (Southern General Hospital, Glasgow, UK) rarely yield bacterial growth, and over 2 years only four cultures seemed to directly influence patient management. Better guidelines are required for targeted use of blood cultures in the emergency department.
C1 So Gen Hosp, Emergency Dept, Glasgow G51 4TF, Lanark, Scotland.
RP Munro, PT (reprint author), So Gen Hosp, Dept Emergency Med, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.
EM phil.munro@sgh.scot.nhs.uk
CR Cisneros-Herreros JM, 2005, ENFERM INFEC MICR CL, V23, P135, DOI 10.1157/13072162
   Corbo J, 2004, EMERG MED J, V21, P446, DOI 10.1136/emj.2003.005306
   Kelly AM, 1998, J ACCID EMERG MED, V15, P254
   Kennedy M, 2005, ANN EMERG MED, V46, P393, DOI 10.1016/j.annemergmed.2005.05.025
   Leonard P, 2003, EMERG MED J, V20, P347, DOI 10.1136/emj.20.4.347
   Mills AM, 2005, ANN EMERG MED, V46, P285, DOI 10.1016/j.annemergmed.2005.03.003
   Stuart PJ, 2002, MED J AUSTRALIA, V177, P131
   Sturmann KM, 1996, ACAD EMERG MED, V3, P768, DOI 10.1111/j.1553-2712.1996.tb03513.x
NR 8
TC 7
Z9 7
U1 2
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1472-0205
EI 1472-0213
J9 EMERG MED J
JI Emerg. Med. J.
PD MAR
PY 2007
VL 24
IS 3
BP 211
EP 212
DI 10.1136/emj.2006.043307
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA 145AO
UT WOS:000244837900024
PM 17351230
OA Green Published
DA 2018-12-27
ER

PT J
AU Gourgiotis, S
   Baratsis, S
AF Gourgiotis, Stavros
   Baratsis, Sotirios
TI RETRACTED: Rectal prolapse (Retracted Article. See vol 22, pg 1561,
   2007)
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Review; Retracted Publication
DE rectal prolapse; aetiology; symptoms; surgery
ID LAPAROSCOPIC SUTURE RECTOPEXY; HIGH-RISK PATIENTS; ABDOMINAL RECTOPEXY;
   PERINEAL RECTOSIGMOIDECTOMY; OUTLET OBSTRUCTION; SURGICAL-TREATMENT;
   RESECTION-RECTOPEXY; FECAL INCONTINENCE; DELORMES PROCEDURE;
   IVALON-SPONGE
AB Introduction Rectal prolapse, or procidentia, is defined as a protrusion of the rectum beyond the anus. It commonly occurs at the extremes of age. Rectal prolapse frequently coexists with other pelvic floor disorders, and patients have symptoms associated with combined rectal and genital prolapse. Few patients, a lack of randomized trials and difficulties in the interpretation of studies of anorectal physiology have made the understanding of this disorder difficult.
   Methods of treatment Surgical management is aimed at restoring physiology by correcting the prolapse and improving continence and constipation, whereas in patients with concurrent genital and rectal prolapse, an interdisciplinary surgical approach is required. Operation should be reserved for those patients in whom medical treatment has failed, and it may be expected to relieve symptoms. Numerous surgical procedures have been suggested to treat rectal prolapse. They are generally classified as abdominal or perineal according to the route of access. However, the controversy as to which operation is appropriate cannot be answered definitively, as the extent of a standardized diagnostic assessment and the types of surgical procedures have not been identified in published series.
   Literature review This review encompasses rectal prolapse, including aetiology, symptoms and treatment. The English-language literature about rectal prolapse was identified using Medline, and additional cited works not detected in the initial search were obtained. Articles reporting on prospective and retrospective comparisons and case reports were included.
C1 Royal Liverpool Univ Hosp, Div Gen Surg & Oncol, Liverpool L18 5HG, Merseyside, England.
   Evangelismos Gen Hosp Athens, Dept Surg 1, Athens, Greece.
RP Gourgiotis, S (reprint author), Royal Liverpool Univ Hosp, Div Gen Surg & Oncol, 21 Millersdale Rd,Mossley Hill, Liverpool L18 5HG, Merseyside, England.
EM drsgourgiotis@tiscali.co.uk
CR Agachan F, 1997, SOUTH MED J, V90, P925, DOI 10.1097/00007611-199709000-00013
   Aitola PT, 1999, DIS COLON RECTUM, V42, P655, DOI 10.1007/BF02234145
   ALTEMEIE.WA, 1971, ANN SURG, V173, P993, DOI 10.1097/00000658-197106010-00018
   Altman D, 2006, DIS COLON RECTUM, V49, P28, DOI 10.1007/s10350-005-0217-3
   Araki Y, 1999, SURG TODAY, V29, P970, DOI 10.1007/BF02482800
   ARNDT M, 1988, INT J COLORECTAL DIS, V3, P141, DOI 10.1007/BF01648355
   Athanasiadis S, 1996, INT J COLORECTAL DIS, V11, P42, DOI 10.1007/s003840050017
   Ayav A, 2005, INT J COLORECTAL DIS, V20, P173, DOI 10.1007/s00384-004-0647-8
   Azimuddin K, 2001, AM SURGEON, V67, P622
   BAKER R, 1995, DIS COLON RECTUM, V38, P199, DOI 10.1007/BF02052451
   Benoist S, 2001, AM J SURG, V182, P168, DOI 10.1016/S0002-9610(01)00672-9
   BLATCHFORD GJ, 1989, NETH J SURG, V41, P126
   Boccasanta P, 2004, DIS COLON RECTUM, V47, P1285, DOI 10.1007/s10350-004-0582-3
   Boccasanta P, 2004, INT J COLORECTAL DIS, V19, P359, DOI 10.1007/s00384-003-0572-2
   Boccasanta P, 1999, DIGEST SURG, V16, P415, DOI 10.1159/000018758
   BOUTSIS C, 1974, DIS COLON RECTUM, V17, P21, DOI 10.1007/BF02587532
   BRAZZELLI M, 2000, COCHRANE DB SYST REV, V2
   Briel JW, 1997, DIS COLON RECTUM, V40, P1228, DOI 10.1007/BF02055169
   BRODEN B, 1968, DIS COLON RECTUM, V11, P330, DOI 10.1007/BF02616986
   Bruch HP, 1999, DIS COLON RECTUM, V42, P1189, DOI 10.1007/BF02238572
   CARTER AE, 1983, BRIT J SURG, V70, P522, DOI 10.1002/bjs.1800700906
   CIROCCO WC, 1993, AM SURGEON, V59, P265
   Cutait D, 1959, P R SOC MED S, V52, P105
   DARZI A, 1995, SURG ENDOSC-ULTRAS, V9, P301
   DEEN KI, 1994, BRIT J SURG, V81, P302, DOI 10.1002/bjs.1800810253
   Dekel A, 2000, BRIT J OBSTET GYNAEC, V107, P125, DOI 10.1111/j.1471-0528.2000.tb11589.x
   Delorme R, 1900, B MEM SOC CHIR PARIS, V266, P499
   DEVADHAR DS, 1965, DIS COLON RECTUM, V8, P75, DOI 10.1007/BF02617054
   DIETZEN CD, 1989, NETH J SURG, V41, P140
   Felt-Bersma RJF, 2001, GASTROENTEROL CLIN N, V30, P199, DOI 10.1016/S0889-8553(05)70174-6
   FINLAY IG, 1991, BRIT J SURG, V78, P687, DOI 10.1002/bjs.1800780618
   FRYKMAN HM, 1955, AM J SURG, V90, P780, DOI 10.1016/0002-9610(55)90700-5
   FRYKMAN HM, 1969, SURG GYNECOL OBSTETR, V129, P1225
   GABRIEL WB, 1963, PRINCIPLES PRACTICES
   GABRIEL WB, 1948, PRINCIPLES PRACTICES
   Galili Y, 1997, EUR J SURG, V163, P445
   Gonzalez-Argente FX, 2001, DIS COLON RECTUM, V44, P920
   Graf W, 1996, EUR J SURG, V162, P905
   Hamalainen KPJ, 1996, DIS COLON RECTUM, V39, P262, DOI 10.1007/BF02049465
   Heah SM, 2000, DIS COLON RECTUM, V43, P638, DOI 10.1007/BF02235579
   HILTUNEN KM, 1986, AM J SURG, V151, P489, DOI 10.1016/0002-9610(86)90110-8
   Himpens J, 1999, SURG ENDOSC, V13, P139, DOI 10.1007/s004649900923
   Hovey MA, 1997, DIS COLON RECTUM, V40, P1254, DOI 10.1007/BF02055174
   HUBER FT, 1995, WORLD J SURG, V19, P138, DOI 10.1007/BF00316999
   HUGHES ESR, 1957, SURG ANUS ANAL CANAL
   IHRE T, 1975, DIS COLON RECTUM, V18, P391, DOI 10.1007/BF02587429
   Jacobs LK, 1997, SURG CLIN N AM, V77, P49, DOI 10.1016/S0039-6109(05)70532-6
   JOHANSEN OB, 1993, DIS COLON RECTUM, V36, P767, DOI 10.1007/BF02048369
   JOHNSON T, 1634, WORKS FAMOUS CHIRURG
   Karasick S, 1999, EUR RADIOL, V9, P450, DOI 10.1007/s003300050690
   KEIGHLEY MRB, 1984, BRIT J SURG, V71, P892, DOI 10.1002/bjs.1800711129
   KEIGHLEY MRB, 1983, BRIT J SURG, V70, P229, DOI 10.1002/bjs.1800700415
   Kellokumpu IH, 2000, SURG ENDOSC-ULTRAS, V14, P634, DOI 10.1007/s004640000017
   Kessler H, 1999, SURG ENDOSC, V13, P858, DOI 10.1007/s004649901119
   Khanna AK, 1996, EUR J SURG, V162, P143
   Kim DS, 1999, DIS COLON RECTUM, V42, P460, DOI 10.1007/BF02234167
   Kling KM, 1996, AM SURGEON, V62, P857
   KRAM HB, 1989, SURGERY, V105, P790
   KUIJPERS HC, 1992, WORLD J SURG, V16, P826, DOI 10.1007/BF02066977
   LAKE SP, 1984, DIS COLON RECTUM, V27, P589, DOI 10.1007/BF02553844
   LECHAUX JP, 1995, DIS COLON RECTUM, V38, P301, DOI 10.1007/BF02055608
   LEIGHTON JA, 1993, DIS COLON RECTUM, V36, P182, DOI 10.1007/BF02051176
   Liberman H, 2000, DIS COLON RECTUM, V43, P188, DOI 10.1007/BF02236980
   LOCKHARTMUMMERY JP, 1910, LANCET, V1, P641
   Longo A, 1998, P 6 WORLD C END SURG, P777
   LOYGUE J, 1984, DIS COLON RECTUM, V27, P356, DOI 10.1007/BF02552998
   LUUKKONEN P, 1992, INT J COLORECTAL DIS, V7, P219, DOI 10.1007/BF00341225
   Malik N, 1997, DIS COLON RECTUM, V40, P1382, DOI 10.1007/BF02050827
   MANN CV, 1988, BRIT J SURG, V75, P34, DOI 10.1002/bjs.1800750113
   MANN CV, 1969, DIS COLON RECTUM, P238
   MCKEE RF, 1992, SURG GYNECOL OBSTET, V174, P145
   MCMAHAN JD, 1987, AM SURGEON, V53, P37
   Mellgren A, 1997, DIS COLON RECTUM, V40, P817, DOI 10.1007/BF02055439
   MIKULICZ J, 1889, ARCH KLIN CHIR, V38, P74
   Miles W E, 1933, Proc R Soc Med, V26, P1445
   Mollen RMHG, 2000, DIS COLON RECTUM, V43, P1283, DOI 10.1007/BF02237437
   MONRO A, 1811, MORBID ANATOMY HUMAN, P363
   MOODY RL, 1969, DIS COLON RECTUM ANU, P238
   MORGAN CN, 1972, BRIT J SURG, V59, P840
   Moschcowitz AV, 1912, SURG GYNECOL OBSTET, V15, P7
   MUIR EG, 1955, P ROY SOC MED, V48, P33
   MYERS JO, 1991, DIS COLON RECTUM, V34, P416, DOI 10.1007/BF02053694
   Nicholls R. J., 1994, Annali Italiani di Chirurgia, V65, P157
   NOVELL JR, 1994, BRIT J SURG, V81, P904, DOI 10.1002/bjs.1800810638
   OLIVER GC, 1994, DIS COLON RECTUM, V37, P461, DOI 10.1007/BF02076192
   Ommer A, 2006, LANGENBECK ARCH SURG, V391, P32, DOI 10.1007/s00423-005-0004-6
   Pantanowitz D, 1975, S Afr J Surg, V13, P53
   PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656
   PENFOLD JCB, 1972, BRIT J SURG, V59, P846, DOI 10.1002/bjs.1800591103
   Pescatori M, 1998, INT J COLORECTAL DIS, V13, P223, DOI 10.1007/s003840050165
   Peters WA, 2001, AM J OBSTET GYNECOL, V184, P1488, DOI 10.1067/mob.2001.114853
   PORTER N, 1961, ANN R COLL SURG ENGL, V31, P379
   PRASAD ML, 1986, DIS COLON RECTUM, V29, P547
   RAMANUJAM PS, 1994, DIS COLON RECTUM, V37, P1027, DOI 10.1007/BF02049318
   RIOLANUS I, 1598, METHODUS MEDENDI TAM, P142
   RIPSTEIN CB, 1952, AM J SURG, V83, P68, DOI 10.1016/0002-9610(52)90161-X
   ROBERTS PL, 1988, ARCH SURG-CHICAGO, V123, P554
   Roig JV, 1998, REV ESP ENFERM DIG, V90, P800
   ROSS AHM, 1989, BRIT J SURG, V76, P610, DOI 10.1002/bjs.1800760629
   SALMON F, 1831, PRACTICAL OBSERVATIO, P1
   SAYFAN J, 1990, BRIT J SURG, V77, P143, DOI 10.1002/bjs.1800770209
   SCAGLIA M, 1994, DIS COLON RECTUM, V37, P805, DOI 10.1007/BF02050146
   SCHLINKERT RT, 1985, DIS COLON RECTUM, V28, P409, DOI 10.1007/BF02560226
   Schultz I, 2000, DIS COLON RECTUM, V43, P35, DOI 10.1007/BF02237241
   SENAPATI A, 1994, DIS COLON RECTUM, V37, P456, DOI 10.1007/BF02076191
   Sielezneff I, 1999, DIS COLON RECTUM, V42, P367, DOI 10.1007/BF02236355
   Siproudhis L, 1998, BRIT J SURG, V85, P1527
   SOLLA JA, 1989, NETH J SURG, V41, P132
   Solomon MJ, 2002, BRIT J SURG, V89, P35, DOI 10.1046/j.0007-1323.2001.01957.x
   SPEAKMAN CTM, 1991, BRIT J SURG, V78, P1431, DOI 10.1002/bjs.1800781207
   Stevenson ARL, 1998, DIS COLON RECTUM, V41, P46, DOI 10.1007/BF02236895
   SUN WM, 1989, BRIT J SURG, V76, P290, DOI 10.1002/bjs.1800760323
   Takesue Y, 1999, SURG TODAY, V29, P290, DOI 10.1007/BF02483026
   TANCER ML, 1987, OBSTET GYNECOL, V70, P951
   THEUERKAUF FJ, 1970, ANN SURG, V171, P819, DOI 10.1097/00000658-197006010-00002
   TJANDRA JJ, 1993, DIS COLON RECTUM, V36, P501, DOI 10.1007/BF02050018
   TOBIN SA, 1994, BRIT J SURG, V81, P1681, DOI 10.1002/bjs.1800811141
   WASSEF R, 1986, CURR PROB SURG, V23, P402, DOI 10.1016/0011-3840(86)90011-0
   Watts AMI, 2000, BRIT J SURG, V87, P218, DOI 10.1046/j.1365-2168.2000.01342.x
   WATTS JD, 1985, DIS COLON RECTUM, V28, P96, DOI 10.1007/BF02552654
   WEDELL J, 1987, CHIRURG, V58, P423
   WELLS C, 1959, P ROY SOC MED, V52, P602
   Whitlow C B, 1997, J La State Med Soc, V149, P22
   WILLIAMS JG, 1992, DIS COLON RECTUM, V35, P830, DOI 10.1007/BF02047867
   WINDE G, 1993, EUR J SURG, V159, P301
   WOMACK NR, 1987, GUT, V28, P1228, DOI 10.1136/gut.28.10.1228
   Woodall J., 1617, SURG MATE
   WROBLESKI DE, 1979, DIS COLON RECTUM, V22, P569, DOI 10.1007/BF02587009
   Xynos E, 1999, SURG ENDOSC-ULTRAS, V13, P862, DOI 10.1007/s004649901120
   Yakut M, 1998, INT SURG, V83, P53
   Zhioua F, 1993, Rev Fr Gynecol Obstet, V88, P277
NR 131
TC 30
Z9 32
U1 1
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-1958
EI 1432-1262
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD MAR
PY 2007
VL 22
IS 3
BP 231
EP 243
DI 10.1007/s00384-006-0198-2
PG 13
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 140CV
UT WOS:000244481500001
PM 17021747
DA 2018-12-27
ER

PT J
AU Pierantoni, GM
   Rinaldo, C
   Mottolese, M
   Di Benedetto, A
   Esposito, F
   Soddu, S
   Fusco, A
AF Pierantoni, Giovanna Maria
   Rinaldo, Cinzia
   Mottolese, Marcella
   Di Benedetto, Anna
   Esposito, Francesco
   Soddu, Silvia
   Fusco, Alfredo
TI RETRACTED: High-mobility group A1 inhibits p53 by cytoplasmic
   relocalization of its proapoptotic activator HIPK2 (Retracted article.
   See vol. 123, pg. 4979, 2013)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID INTERACTING PROTEIN KINASE-2; HMGI(Y) PROTEIN; HMGA1 PROTEINS;
   DNA-DAMAGE; IN-VIVO; EXPRESSION; APOPTOSIS; PHOSPHORYLATION; CARCINOMAS;
   NEOPLASIAS
AB High-mobility group A1 (HMGA1) overexpression and gene rearrangement are frequent events in human cancer, but the molecular basis of HMGA1 oncogenic activity remains unclear. Here we describe a mechanism through which HMGA1 inhibits p53-mediated apoptosis by counteracting the p53 proapoptotic activator homeodomain-interacting protein kinase 2 (HIPK2). We found that HMGA1 overexpression promoted HIPK2 relocalization in the cytoplasm and inhibition of p53 apoptotic function, while HIPK2 overexpression reestablished HIPK2 nuclear localization and sensitivity to apoptosis. HIPK2 depletion by RNA interference suppressed the antiapoptotic effect of HMGA1, which indicates that HIPK2 is the target required for HMGA1 to repress the apoptotic activity of p53. Consistent with this process, a strong correlation among HMGA1 overexpression, HIPK2 cytoplasmic localization, and low spontaneous apoptosis index (comparable to that observed in mutant p53-carrying tumors) was observed in WT p53-expressing human breast carcinomas. Hence, cytoplasmic relocalization of HIPK2 induced by HMGA1 overexpression is a mechanism of inactivation of p53 apoptotic function that we believe to be novel.
C1 Ist Nazl Tumori Regina Elena, Dipartimento Oncol Sperimentale, I-00158 Rome, Italy.
   Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy.
   Ist Nazl Tumori Regina Elena, Serv Anat Patol, Rome, Italy.
   Naples Oncogenomic Ctr, Ctr Ingn Genet, Biotecnol Avanzate, Naples, Italy.
   Scuola Europea Med Mol, Naples, Italy.
RP Soddu, S (reprint author), Ist Nazl Tumori Regina Elena, Dipartimento Oncol Sperimentale, Via Messi Oro,156, I-00158 Rome, Italy.
EM soddu@ifo.it
RI Soddu, Silvia/K-2467-2018
OI Soddu, Silvia/0000-0001-8526-0044
CR Abe N, 1999, CANCER RES, V59, P1169
   Abe N, 2002, PANCREAS, V25, P198, DOI 10.1097/01.MPA.0000018635.15184.82
   Appella E, 2000, PATHOL BIOL, V48, P227
   BACCHETTI S, 1993, INT J ONCOL, V3, P781
   Bandiera A, 1998, CANCER RES, V58, P426
   BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545
   Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj/onc/1205368
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Cecchinelli B, 2006, CELL DEATH DIFFER, V13, P1994, DOI 10.1038/sj.cdd.4401933
   Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05
   Chiappetta G, 1998, CANCER RES, V58, P4193
   Chiappetta G, 1996, ONCOGENE, V13, P2439
   Chiappetta G, 2004, CLIN CANCER RES, V10, P7637, DOI 10.1158/1078-0432.CCR-04-0291
   Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M
   CHIAPPETTA G, 1995, ONCOGENE, V10, P1307
   D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714
   Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717
   Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032
   Fedele M, 1996, CANCER RES, V56, P1896
   Frasca F, 2006, CANCER RES, V66, P2980, DOI 10.1158/0008-5472.CAN-05-2637
   Frontini M, 2004, CELL CYCLE, V3, P217
   Fukuda M, 1997, NATURE, V390, P308
   Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3
   GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1
   Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715
   Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200
   Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262
   Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075
   Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200
   Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027
   Moller A, 2003, CANCER RES, V63, P4310
   MOTTOLESE M, 2007, IN PRESS AM J SURG P
   Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8
   Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190
   Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839
   Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635
   REEVES R, 1990, J BIOL CHEM, V265, P8573
   Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310
   Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475
   Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997
   Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   Sobin L, 2002, TNM CLASSIFICATION M
   TAMIMI Y, 1993, CANCER RES, V53, P5512
   Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9
   Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8
   Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X
   ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0
NR 50
TC 71
Z9 75
U1 3
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 2007
VL 117
IS 3
BP 693
EP 702
DI 10.1172/JC129852
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 142PR
UT WOS:000244662500028
PM 17290307
DA 2018-12-27
ER

PT J
AU Gulati, BR
   Deepa, R
   Singh, BK
   Rao, CD
AF Gulati, B. R.
   Deepa, R.
   Singh, B. K.
   Rao, C. Durga
TI RETRACTED: Diversity in Indian equine rotaviruses: Identification of
   genotype G10,P6[1] and G1 strains and a new VP7 genotype (G16) strain in
   specimens from diarrheic foals in India (Retracted Article. See vol 45,
   pg 2354, 2007)
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID SEROTYPE-SPECIFIC NEUTRALIZATION; LONG RNA ELECTROPHEROTYPE; SUBGROUP-I
   SPECIFICITY; BOVINE ROTAVIRUS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI;
   GENOMIC CHARACTERIZATION; MONOCLONAL-ANTIBODIES; SURFACE-PROTEINS;
   UNITED-STATES
AB Rotaviruses causing severe diarrhea in foals in two organized farms in northern India, during the period from 2003 to 2005, were characterized by electropherotyping, serotyping, and sequence analysis of the genes encoding the outer capsid proteins. Of 137 specimens, 47 (34.31%) were positive for rotavirus and exhibited at least five different electropherotypes (E), E1 to E5. Strains belonging to different electropherotypes exhibited either a different serotype/genotype specificity or a lack of reactivity to typing monoclonal antibodies (Nubs) used in this study. Strains belonging to E1, E2, and E5 exhibited genotype G10,P6[1], G3, and G1 specificities and accounted for 19.0, 42.9, and 9.5% of the isolates, respectively. Though they possessed GIO-type VP7, the El strains exhibited high reactivity with the G6-specific NUb, suggesting that the uncommon combination of the outer capsid proteins altered the specificity of the conformation-dependent antigenic epitopes on VP7. E3 and E4 strains accounted for 28.6% of the isolates and were untypeable. Sequence analysis of VP7 from E4 strains (Erv92 and Erv99) revealed that they represent a new VP7 genotype, G16. The detection of unexpected bovine rotavirus-derived G10,P6[1] reassortants, G1 serotype strains, and a new genotype (G16) strain in two distant farms reveals an interesting epidemiological situation and diversity of equine rotaviruses in India.
C1 Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.
   Natl Res Ctr Equines, Hisar, Haryana, India.
RP Rao, CD (reprint author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.
EM cdr@mcbl.iisc.ernet.in
CR Aijaz S, 1996, ARCH VIROL, V141, P715, DOI 10.1007/BF01718329
   ARIAS CF, 1986, GENE, V47, P211, DOI 10.1016/0378-1119(86)90065-X
   BEARDS G, 1992, J CLIN MICROBIOL, V30, P1432
   BROWNING GF, 1992, ARCH VIROL, V125, P121, DOI 10.1007/BF01309632
   Browning GF, 1996, ARCH VIROL, V141, P1077, DOI 10.1007/BF01718611
   BROWNING GF, 1991, J GEN VIROL, V72, P1059, DOI 10.1099/0022-1317-72-5-1059
   BROWNING GF, 1992, J CLIN MICROBIOL, V30, P59
   BROWNING GF, 1991, J CLIN MICROBIOL, V29, P2043
   CHEN DY, 1992, J VIROL, V66, P432
   CHEN DY, 1992, VIROLOGY, V186, P228, DOI 10.1016/0042-6822(92)90077-3
   CHEN DY, 1989, P NATL ACAD SCI USA, V86, P3743, DOI 10.1073/pnas.86.10.3743
   Ciarlet M, 2001, VIRUS GENES, V22, P5, DOI 10.1023/A:1008175716816
   CIARLET M, 1994, J CLIN MICROBIOL, V32, P2609
   Cunliffe NA, 1999, J MED VIROL, V57, P308, DOI 10.1002/(SICI)1096-9071(199903)57:3<308::AID-JMV15>3.3.CO;2-2
   DAS M, 1993, VIROLOGY, V194, P374, DOI 10.1006/viro.1993.1271
   DORMITZER PR, 1992, VIROLOGY, V187, P18
   DUNN SJ, 1993, VIROLOGY, V197, P397, DOI 10.1006/viro.1993.1601
   Dunn SV, 2000, J ADV NURS, V31, P165, DOI 10.1046/j.1365-2648.2000.01248.x
   DYALLSMITH ML, 1986, P NATL ACAD SCI USA, V83, P3465, DOI 10.1073/pnas.83.10.3465
   ESTES MK, 1989, MICROBIOL REV, V53, P410
   ESTES MK, 2001, FIELDS VIROLOGY, V2, P1747
   FLEWETT TH, 1975, VET REC, V96, P477
   GENTSCH JR, 1993, VIROLOGY, V194, P424, DOI 10.1006/viro.1993.1280
   GERNA G, 1992, J CLIN MICROBIOL, V30, P9
   Gomara MI, 2004, J CLIN MICROBIOL, V42, P2541, DOI 10.1128/JCM.42.6.2541-2547.2004
   GREENBERG H, 1983, INFECT IMMUN, V39, P91
   GREENBERG HB, 1983, J GEN VIROL, V64, P313, DOI 10.1099/0022-1317-64-2-313
   HARDY ME, 1992, VIROLOGY, V191, P291, DOI 10.1016/0042-6822(92)90191-Q
   HARDY ME, 1991, J CLIN MICROBIOL, V29, P889
   HERRING AJ, 1982, J CLIN MICROBIOL, V16, P473
   Holmes JL, 1999, ARCH VIROL, V144, P1381, DOI 10.1007/s007050050594
   HOSHINO Y, 1985, P NATL ACAD SCI USA, V82, P8701, DOI 10.1073/pnas.82.24.8701
   HOSHINO Y, 1983, J CLIN MICROBIOL, V18, P585
   HOSHINO Y, 1983, INFECT IMMUN, V41, P1031
   HUM CP, 1989, VIROLOGY, V170, P55, DOI 10.1016/0042-6822(89)90351-6
   IMAGAWA H, 1993, ARCH VIROL, V131, P169, DOI 10.1007/BF01379088
   IMAGAWA H, 1994, J CLIN MICROBIOL, V32, P2009
   IMAGAWA H, 1991, J VET MED SCI, V53, P1079, DOI 10.1292/jvms.53.1079
   IMAGAWA H, 1998, EQUINE INFECT DIS, V8, P201
   Isa P, 1996, ARCH VIROL, V141, P1601, DOI 10.1007/BF01718285
   Jagannath MR, 2000, ARCH VIROL, V145, P1339, DOI 10.1007/s007050070094
   JOHNSON MA, 1989, GENE, V84, P73, DOI 10.1016/0378-1119(89)90141-8
   KAPIKIAN AZ, 1996, FIELDS VIROLOGY, P1657
   KOBAYASHI N, 1991, J GEN VIROL, V72, P117, DOI 10.1099/0022-1317-72-1-117
   Li B, 1996, ARCH VIROL, V141, P155, DOI 10.1007/BF01718596
   LI BG, 1993, J CLIN MICROBIOL, V31, P3075
   MACKOW ER, 1988, VIROLOGY, V165, P511, DOI 10.1016/0042-6822(88)90595-8
   MCCRAE MA, 1987, GENE, V55, P9, DOI 10.1016/0378-1119(87)90243-5
   Mendez E, 1996, J VIROL, V70, P1218
   Nakagomi T, 2003, ARCH VIROL, V148, P925, DOI 10.1007/s00705-002-0967-3
   PADILLANORIEGA L, 1990, J CLIN MICROBIOL, V28, P1114
   Pesavento JB, 2003, J VIROL, V77, P3291, DOI 10.1128/JVI.77.5.3291-3296.2003
   Rao CD, 2000, VIROLOGY, V276, P104, DOI 10.1006/viro.2000.0472
   Roberts L, 2004, SCIENCE, V305, P1890, DOI 10.1126/science.305.5692.1890
   RODGER SM, 1980, VET MICROBIOL, V5, P243, DOI 10.1016/0378-1135(80)90011-5
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Santos N, 1998, J CLIN MICROBIOL, V36, P2727
   Sato M, 1997, J CLIN MICROBIOL, V35, P1266
   SMITH M, 1979, AUST J EXP BIOL MED, V57, P583, DOI 10.1038/icb.1979.61
   SUKUMARAN M, 1992, ARCH VIROL, V126, P239, DOI 10.1007/BF01309698
   TANIGUCHI K, 1988, J VIROL, V62, P1870
   TANIGUCHI K, 1991, J GEN VIROL, V72, P2929, DOI 10.1099/0022-1317-72-12-2929
   TANIGUCHI K, 1994, VIROLOGY, V198, P325, DOI 10.1006/viro.1994.1035
   Tsunemitsu H, 2001, ARCH VIROL, V146, P1949, DOI 10.1007/s007050170044
   Varghese V, 2006, VIRUS GENES, V32, P241, DOI 10.1007/s11262-005-6908-y
   Varshney B, 2002, ARCH VIROL, V147, P143, DOI 10.1007/s705-002-8308-z
   WARD RL, 1984, J CLIN MICROBIOL, V19, P748
NR 67
TC 26
Z9 27
U1 3
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAR
PY 2007
VL 45
IS 3
BP 972
EP 978
DI 10.1128/JCM.01696-06
PG 7
WC Microbiology
SC Microbiology
GA 148JU
UT WOS:000245071500042
PM 17135436
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Bruns, MB
   Miller, MW
AF Bruns, Marla B.
   Miller, Michael W.
TI RETRACTED: Functional nerve growth factor and trkA autocrine/paracrine
   circuits in adult rat cortex are revealed by episodic ethanol exposure
   and withdrawal (Retracted article. See vol. 120, pg. 1141, 2012)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE alcohol; anterograde; dementia; neurotrophin; pyramidal neurons;
   receptor; somatosensory cortex; translation
ID AFFINITY NEUROTROPHIN RECEPTORS; CHRONIC ALCOHOL-CONSUMPTION;
   MESSENGER-RNA EXPRESSION; BASAL FOREBRAIN NEURONS; PRIMARY
   VISUAL-CORTEX; NGF GENE-TRANSFER; MATURE RAT; SOMATOSENSORY CORTEX;
   CHOLINERGIC NEURONS; AGED RATS
AB The hypothesis tested is that cortical neurotrophins communicate through an inducible autocrine/paracrine mechanism. As ethanol (Et) can induce cortical nerve growth factor (NGF) expression, adult rats were challenged with Et on three consecutive days per week for 6 weeks. The focus of the study was layer V, the chief repository of receptor-expressing neuronal cell bodies. Brains were collected immediately after the sixth Et exposure or 72 h later [i.e., following withdrawal (WD)]. Double-label in situ hybridization-immunohistochemistry studies showed that many neuronal somata co-expressed NGF mRNA with NGF, trkA, or phosphorylated trk (p-trk), essential components of an inducible autocrine system. The frequencies of co-labeling were affected by neither Et nor WD. On the contrary, Et increased the number of NGF mRNA-expressing neurons and the amount of NGF mRNA expressed per cell. Et also increased total cortical concentration of NGF protein, the number of layer V neurons expressing trkA transcript, the amount of trkA mRNA expressed per neuron, and trkA phosphorylation. Following WD, the frequency of NGF-mRNA-expressing cells increased, although transcript and protein content fell. WD induced an increase in trkA mRNA and protein expression, however, p-trk expression was unaffected. Thus, Et treatment reveals that layer V has inducible autocrine/paracrine and anterograde neurotrophin systems. WD unveils the dynamism and recruitability of these systems.
C1 SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
   Vet Affairs Med Ctr, Res Serv, Syracuse, NY USA.
   Dev Alcohol Exposure Alcohol Res Ctr, Syracuse, NY USA.
RP Miller, MW (reprint author), SUNY Upstate Med Univ, Dept Neurosci & Physiol, 750 E Adams St, Syracuse, NY 13210 USA.
EM millermw@mail.upstate.edu
FU NIAAA NIH HHS [AA07568, AA15245, AA06916]
CR Acheson A, 1996, PHILOS T ROY SOC B, V351, P417, DOI 10.1098/rstb.1996.0037
   Allen SJ, 2006, CLIN SCI, V110, P175, DOI 10.1042/CS20050161
   ALOE L, 1993, DRUG ALCOHOL DEPEN, V31, P159, DOI 10.1016/0376-8716(93)90068-2
   ARENDT T, 1988, NATURE, V332, P448, DOI 10.1038/332448a0
   Arendt T, 1994, J Neural Transm Suppl, V44, P173
   ARENDT T, 1995, NEUROSCIENCE, V65, P647, DOI 10.1016/0306-4522(94)00523-8
   ARENDT T, 1989, NEUROSCIENCE, V33, P435, DOI 10.1016/0306-4522(89)90397-7
   Barde Y A, 1994, Prog Clin Biol Res, V390, P45
   Blesch A, 2005, MOL THER, V11, P916, DOI 10.1016/j.ymthe.2005.01.007
   Brooks AI, 2000, HUM GENE THER, V11, P2341, DOI 10.1089/104303400750038453
   Cadete-Leite A, 2003, NEUROSCIENCE, V119, P1055, DOI 10.1016/S0306-4522(03)00205-7
   Carmignoto G, 1997, J PHYSIOL-LONDON, V498, P153, DOI 10.1113/jphysiol.1997.sp021848
   Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163
   Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.0.CO;2-S
   CHARNESS ME, 1993, ALCOHOL CLIN EXP RES, V17, P2, DOI 10.1111/j.1530-0277.1993.tb00718.x
   Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157
   Conner JM, 1997, J NEUROSCI, V17, P2295
   CUELLO AC, 1992, MOL NEUROBIOL, V6, P451, DOI 10.1007/BF02757946
   De Simone R, 1993, Ann Ist Super Sanita, V29, P179
   De Witte P, 2003, NEUROSCI BIOBEHAV R, V27, P189, DOI 10.1016/S0149-7634(03)00030-7
   ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3
   ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x
   FISCHER W, 1994, NEUROCHEM INT, V25, P47, DOI 10.1016/0197-0186(94)90052-3
   Franke B, 2000, EXP NEUROL, V165, P125, DOI 10.1006/exnr.2000.7453
   Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P
   GAROFALO L, 1994, EXP NEUROL, V125, P195, DOI 10.1006/exnr.1994.1024
   Gericke CA, 2006, J NEURAL TRANSM, V113, P813, DOI 10.1007/s00702-005-0361-x
   Givens B, 2000, HIPPOCAMPUS, V10, P111, DOI 10.1002/(SICI)1098-1063(2000)10:1<111::AID-HIPO12>3.0.CO;2-1
   HALLMAN LE, 1988, J COMP NEUROL, V272, P149, DOI 10.1002/cne.902720111
   Hamelink C, 2005, J PHARMACOL EXP THER, V314, P780, DOI 10.1124/jpet.105.085779
   Hashimoto T, 2003, J NEUROSCI, V23, P6315
   HICKS SP, 1977, EXP NEUROL, V56, P410, DOI 10.1016/0014-4886(77)90357-0
   Howe CL, 2005, CURR OPIN NEUROBIOL, V15, P40, DOI 10.1016/j.conb.2005.01.010
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Huerta M.F., 1984, P687
   Humpel C, 2002, J NEURAL TRANSM-SUPP, P253
   Jacobs JS, 1999, J NEUROCYTOL, V28, P571, DOI 10.1023/A:1007019422675
   Jakubowska-Dogru E, 2005, NEUROSCI LETT, V382, P45, DOI 10.1016/j.neulet.2005.02.059
   Jiang B, 2003, J NEUROSCI, V23, P3761
   Jiang XY, 2005, J NEUROCHEM, V94, P713, DOI 10.1111/j.1471-4159.2005.03200.x
   Klein RL, 2000, BRAIN RES, V875, P144, DOI 10.1016/S0006-8993(00)02634-2
   KOH S, 1989, EXP NEUROL, V106, P209, DOI 10.1016/0014-4886(89)90154-4
   KORSCHING S, 1985, EMBO J, V4, P1389, DOI 10.1002/j.1460-2075.1985.tb03791.x
   LARKFORS L, 1987, MOL BRAIN RES, V3, P55, DOI 10.1016/0169-328X(87)90044-1
   LEONG SK, 1983, EXP NEUROL, V56, P410
   Lessmann V, 1998, GEN PHARMACOL-VASC S, V31, P667
   LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916
   Luo J, 1999, J NEUROSCI, V19, P10014
   Luo J, 1996, BRAIN RES, V737, P34, DOI 10.1016/0006-8993(96)00657-9
   MACLENNAN AJ, 1995, NEUROSCI LETT, V197, P105
   Mallei A, 2004, J NEUROCHEM, V90, P1085, DOI 10.1111/j.1471-4159.2004.02568.x
   Melis F, 1996, NEUROSCIENCE, V74, P155, DOI 10.1016/0306-4522(96)00109-1
   MILLER MW, 1992, BRAIN RES, V595, P17, DOI 10.1016/0006-8993(92)91447-M
   MILLER MW, 1987, EXP BRAIN RES, V67, P339
   Miller MW, 2006, J NEUROCHEM, V97, P1182, DOI 10.1111/j.1471-4159.2006.03858.x
   MILLER MW, 1993, BRAIN RES, V627, P104, DOI 10.1016/0006-8993(93)90753-A
   Miller MW, 2004, J NEUROBIOL, V60, P490, DOI 10.1002/neu.20059
   Miller MW, 2004, EXP NEUROL, V189, P173, DOI 10.1016/j.expneurol.2004.05.026
   Miller MW, 2000, J NEUROCYTOL, V29, P453, DOI 10.1023/A:1007207527842
   Miller MW, 2000, BRAIN RES, V852, P355, DOI 10.1016/S0006-8993(99)02176-9
   Miller R, 2002, BRAIN RES, V950, P137, DOI 10.1016/S0006-8993(02)03014-7
   Mooney SM, 2001, BRAIN RES, V911, P71, DOI 10.1016/S0006-8993(01)02718-4
   Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8
   Nagy J, 2001, DRUG ALCOHOL DEPEN, V61, P155, DOI 10.1016/S0376-8716(00)00132-0
   Niewiadomska G, 2002, NEUROBIOL AGING, V23, P601, DOI 10.1016/S0197-4580(01)00345-1
   OLTON D, 1991, ADV EXP MED BIOL, V295, P353
   PETERS A, 1980, J NEUROCYTOL, V9, P163, DOI 10.1007/BF01205156
   Pitts AF, 1995, SOMATOSENS MOT RES, V12, P329, DOI 10.3109/08990229509093666
   Pitts AF, 2000, J COMP NEUROL, V418, P241, DOI 10.1002/(SICI)1096-9861(20000313)418:3<241::AID-CNE1>3.0.CO;2-M
   Reichardt LF, 2004, CELL, V118, P141, DOI 10.1016/j.cell.2004.07.008
   RESNICOFF M, 1994, LAB INVEST, V71, P657
   Rubin R, 2004, BIOCHEM PHARMACOL, V68, P2009, DOI 10.1016/j.bcp.2004.06.032
   Santin LJ, 2000, ALCOHOL, V20, P149, DOI 10.1016/S0741-8329(99)00070-1
   SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E
   SCHOFIELD BR, 1987, J COMP NEUROL, V261, P85, DOI 10.1002/cne.902610107
   Seabold GK, 1998, DEV BRAIN RES, V108, P139, DOI 10.1016/S0165-3806(98)00043-1
   Steigerwald ES, 1997, ALCOHOL CLIN EXP RES, V21, P1553, DOI 10.1097/00000374-199712000-00001
   Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02
   Tang NF, 2006, J NEUROCHEM, V96, P1480, DOI 10.1111/j.1471-4159.2006.03649.x
   Tapia-Arancibia L, 2001, J NEUROSCI RES, V63, P200, DOI 10.1002/1097-4547(20010115)63:2<200::AID-JNR1012>3.0.CO;2-Q
   THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593
   Thomas MP, 1998, ALCOHOL CLIN EXP RES, V22, P51, DOI 10.1111/j.1530-0277.1998.tb03616.x
   Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667
   Tonra JR, 1999, MICROSC RES TECHNIQ, V45, P225, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<225::AID-JEMT6>3.3.CO;2-T
   Victor M, 1971, Contemp Neurol Ser, V7, P1
   VICTOR M, 1994, CAN J NEUROL SCI, V21, P88, DOI 10.1017/S031716710004899X
   WALKER DW, 1978, NEUROPSYCHOLOGIA, V16, P545, DOI 10.1016/0028-3932(78)90082-9
   WALKER DW, 1971, PHYSIOL BEHAV, V7, P773, DOI 10.1016/0031-9384(71)90147-8
   White AM, 2000, HIPPOCAMPUS, V10, P88, DOI 10.1002/(SICI)1098-1063(2000)10:1<88::AID-HIPO10>3.0.CO;2-L
   WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231
   WISE SP, 1977, J COMP NEUROL, V175, P129, DOI 10.1002/cne.901750202
   Zou LL, 2002, HUM GENE THER, V13, P2173, DOI 10.1089/104303402320987860
NR 92
TC 10
Z9 11
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD MAR
PY 2007
VL 100
IS 5
BP 1155
EP 1168
DI 10.1111/j.1471-4159.2006.04301.x
PG 14
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 134WN
UT WOS:000244115200002
PM 17316397
OA Bronze
DA 2018-12-27
ER

PT J
AU Maestro, M
   Gomez-Reino, C
   Nicoletti, D
   Sigueiro, R
   Fraga, R
   Ghini, A
   Torneiro, M
   Mourino, A
AF Maestro, Miguel
   Gomez-Reino, Clara
   Nicoletti, Daniel
   Sigueiro, Rita
   Fraga, Ramon
   Ghini, Alberto
   Torneiro, Mercedes
   Mourino, Antonio
TI RETRACTED: Novel synthetic approach to 1 alpha,25-dihydroxyvitamin D-3
   and analogues (Retracted article. See vol. 108, pg. 178, 2008)
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th Workshop on Vitamin D
CY APR 07-12, 2006
CL Victoria, CANADA
SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd
DE 1 alpha,25-dihydroxyvitamin D-3; new synthetic approach; vitamin D
   analogues; Negishi coupling; palladium-catalyzed-cascades; conjugate
   polyenes
ID VITAMIN-D CALCIFEROL; D-3; METABOLITES; EFFICIENT; ISOMERS
AB A mild and stereoconvergent synthesis of 1 alpha,25-dihydroxyvitamin D-3 (calcitriol, 1a) is described. The key step is a cascade process consisting of two consecutive transformations: An initial palladium-catalyzed 6-exo-cyclocarbopalladation of vinyl triflate 4 followed by a Negishi cross-coupling reaction with alkenyl zinc 3. This approach is of interest for the rapid synthesis of a variety of new vitamin D-3 analogues of therapeutic potential, especially those modified at the triene and ring-A. The mildness of the method also allows the preparation of thermal sensitive vitamin D-3 analogues. (c) 2006 Elsevier Ltd. All Fights reserved.
C1 Univ Santiago Compostela, Dept Quim Organ, CSIC, E-15706 Santiago, Spain.
   Univ Santiago Compostela, Unidad Asociada, CSIC, E-15706 Santiago, Spain.
   Univ A Coruna, Dept Quim Fundamental, E-15071 La Coruna, Spain.
RP Mourino, A (reprint author), Univ Santiago Compostela, Dept Quim Organ, CSIC, E-15706 Santiago, Spain.
EM qomourin@usc.es
OI Maestro, Miguel/0000-0001-8922-8033
CR Addo JK, 1999, STEROIDS, V64, P273, DOI 10.1016/S0039-128X(99)00009-4
   BAGGIOLINI EG, 1986, J ORG CHEM, V51, P3098, DOI 10.1021/jo00366a004
   BINDERUP L, 1992, REV CONTEMP PHARMACO, V3, P357
   BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200
   DAI HY, 1994, SYNTHESIS-STUTTGART, P1383
   FELDMAN D, 1997, VITAMIN D
   Garcia AM, 1997, J ORG CHEM, V62, P6353, DOI 10.1021/jo970605m
   Hanazawa T, 2003, ORG LETT, V5, P523, DOI 10.1021/ol0274007
   Kabat M M, 2001, Curr Opin Drug Discov Devel, V4, P808
   LYTHGOE B, 1980, CHEM SOC REV, V9, P449, DOI 10.1039/cs9800900449
   MASCARENAS JL, 1991, TETRAHEDRON, V47, P3485, DOI 10.1016/S0040-4020(01)86410-3
   MELLO R, 1989, J AM CHEM SOC, V111, P6749, DOI 10.1021/ja00199a039
   Mourino A, 1997, TETRAHEDRON LETT, V38, P4713, DOI 10.1016/S0040-4039(97)01005-8
   Palmieri GMA, 1997, J CLIN ENDOCR METAB, V82, P3516
   SARDINA FJ, 1986, J ORG CHEM, V51, P1264, DOI 10.1021/jo00358a018
   SESTELO JP, 1993, J ORG CHEM, V58, P118
   SHEVES M, 1977, J CHEM SOC CHEM COMM, P21, DOI 10.1039/c39770000021
   TROST BM, 1992, J AM CHEM SOC, V114, P9836, DOI 10.1021/ja00051a016
   VANALSTYNE EM, 1994, J AM CHEM SOC, V116, P6207, DOI 10.1021/ja00093a021
   ZHU GD, 1995, CHEM REV, V95, P1877, DOI 10.1021/cr00038a007
NR 20
TC 1
Z9 1
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAR
PY 2007
VL 103
IS 3-5
SI SI
BP 231
EP 234
DI 10.1016/j.jsbmb.2006.12.026
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 158WU
UT WOS:000245826800007
PM 17254774
DA 2018-12-27
ER

PT J
AU Kato, S
   Fujiki, R
   Kim, MS
   Kitagawa, H
AF Kato, Shigeaki
   Fujiki, Ryoji
   Kim, Mi-Sun
   Kitagawa, Hirochika
TI RETRACTED: Ligand-induced transrepressive function of VDR requires a
   chromatin remodeling complex, WINAC (Retracted article. See vol. 126,
   pg. 56, 2011)
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th Workshop on Vitamin D
CY APR 07-12, 2006
CL Victoria, CANADA
SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd
DE acetylated histone; transrepression; VDIR; VDR; WSTF
ID NUCLEAR RECEPTORS; TRANSCRIPTION; BROMODOMAIN; PROMOTER; SUPERFAMILY;
   SELECTIVITY; MODULE; GENES
AB We have previously shown that the novel ATP-dependent chromatin remodeling complex WINAC is required for the ligand-bound Vitamin D receptor (VDR)-mediated transrepression of the 25(OH)D-3 1 alpha-hydroxylase [1 alpha(OH)ase] gene. However, the molecular basis for VDR promoter association, which does not involve its binding to specific DNA sequences, remains unclear. To address this issue, we investigated the function of WSTF in terms of the association between WINAC and chromatin for ligand-induced transrepression by VDR. Results of in vitro experiments using chromatin templates showed that the association of unliganded VDR with the promoter required physical interactions between WSTF and both VDR and acetylated histones prior to VDR association with chromatin. The acetylated histone-interacting region of WSTF was mapped to the bromodomain, and a WSTF mutant lacking the bromodomain served as a dominant-negative mutant in terms of ligand-induced transrepression of the lot(OH)ase gene. Thus, our findings indicate that WINAC associates with chromatin through a physical interaction between the WSTF bromodomain and acetylated histones, that appears to be indispensable for VDR/promoter association for ligand-induced transrepression of 1 alpha(OH)ase gene expression. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Dhalluin C, 1999, NATURE, V399, P491
   Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7
   Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0
   Glass CK, 2000, GENE DEV, V14, P121
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9
   Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422
   Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kato S, 2004, J STEROID BIOCHEM, V89-90, P173, DOI 10.1016/j.jsbmb.2004.03.100
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   ONATE SA, 1995, SCIENCE, V270, P1354
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
NR 27
TC 19
Z9 20
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAR
PY 2007
VL 103
IS 3-5
SI SI
BP 372
EP 380
DI 10.1016/j.jsbmb.2006.12.038
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 158WU
UT WOS:000245826800031
PM 17368181
DA 2018-12-27
ER

PT J
AU Cohen-Lahav, M
   Douvdevani, A
   Chaimovitz, C
   Shany, S
AF Cohen-Lahav, Merav
   Douvdevani, Amos
   Chaimovitz, Cidio
   Shany, Shraga
TI RETRACTED: The anti-inflammatory activity of 1,25-dihydroxyvitamin D-3
   in macrophages (Retracted article. See vol. 127, pg. 444, 2011)
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th Workshop on Vitamin D
CY APR 07-12, 2006
CL Victoria, CANADA
SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd
DE vitamin D analog; I kappa B alpha; NF kappa B; macrophages; TNF alpha;
   anti-inflammatory
ID NF-KAPPA-B; CAPD PATIENTS; TNF-ALPHA; EXPRESSION
AB In a previous study we demonstrated a down-regulatory effect of vitamin D active metabolite (1,25(OH)(2)D-3) and its vitamin D, analog (1,24(OH)(2)D-2) on TNF alpha expression in macrophages. We also found an inhibitory effect in the physiological concentration (10(-10) M) of 1,25(OH)(2)D-3 which was dose-dependent. This down-regulation, caused by the decrease in NF kappa B activity by 1,25(OH)(2)D-3 and 1,24(OH)(2)D-2, was demonstrated in P388D1 cells transfected with NF kappa B reporter gene (p NF kappa B-Luc) and by EMSA.
   In our present study we investigated the processes leading to reduced NF kappa B activity on P388D1 cells.
   A decrease in nuclei NF kappa B-p65 and an increase in cytosolic NF kappa B-p65, were measured, while no changes in total NF kappa B-p65 mRNA and protein levels were observed. Simultaneously, a significant increase in both mRNA and protein levels of the NF kappa B-cytosolic inhibitor, I kappa B alpha, were determined. The half-life of I kappa B alpha-mRNA increased, with a parallel decrease in the phosphorylation of its protein, as the first step of ubiquitinization and degradation. The present results demonstrate that 1,25(OH)(2)D-3 and 1,24(OH)(2)D-2 inhibit TNF alpha expression in macrophages, by increasing I kappa B alpha and decreasing NF kappa B activity. Since NF kappa B is a major transcription factor for TNF alpha and other inflammatory mediators, these findings suggest that 1,25(OH)(2)D-3 and 1,24(OH)(2)D-2 may be used therapeutically as anti-inflammatory agents. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Clin Biochem, IL-84101 Beer Sheva, Israel.
   Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Nephrol, IL-84101 Beer Sheva, Israel.
RP Shany, S (reprint author), Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Clin Biochem, POB 151, IL-84101 Beer Sheva, Israel.
EM shany@bgu.ac.il
RI Daleprane, Julio/H-2597-2012
OI Daleprane, Julio/0000-0002-3493-1386; Douvdevani,
   Amos/0000-0002-0197-6481
CR BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689
   BRANISTEANU DD, 1993, CLIN EXP IMMUNOL, V94, P412
   Cohen ML, 2001, KIDNEY INT, V59, P69, DOI 10.1046/j.1523-1755.2001.00467.x
   Cohen-Lahav M, 2006, NEPHROL DIAL TRANSPL, V21, P889, DOI 10.1093/ndt/gfi254
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Jiang Y, 2002, J IMMUNOL, V168, P3323, DOI 10.4049/jimmunol.168.7.3323
   LEMIRE JM, 1992, AUTOIMMUNITY, V12, P143, DOI 10.3109/08916939209150321
   Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277
   May Ekkehard, 2004, Current Drug Targets - Inflammation and Allergy, V3, P377, DOI 10.2174/1568010042634596
   May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3
   Schottelius AJG, 2004, EXP DERMATOL, V13, P193, DOI 10.1111/j.0906-6705.2004.00205.x
   Shany S, 2001, STEROIDS, V66, P319, DOI 10.1016/S0039-128X(00)00154-9
   SHANY S, 1991, KIDNEY INT, V39, P1005, DOI 10.1038/ki.1991.127
   Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178
NR 14
TC 92
Z9 94
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAR
PY 2007
VL 103
IS 3-5
SI SI
BP 558
EP 562
DI 10.1016/j.jsbmb.2006.12.093
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 158WU
UT WOS:000245826800066
PM 17267205
DA 2018-12-27
ER

PT J
AU Tseng, JD
   Chen, PS
AF Tseng, J. -D.
   Chen, P. -S.
TI RETRACTED: Reduced-sized single coupled-line low-pass filter (Retracted
   article. See vol. 57, pg. 2228, 2015)
SO MICROWAVE AND OPTICAL TECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE coupled line; transmission line; low-pass filter
AB A low-pass filter consisted of one inner-connected coupled-line and two open-stub transmission lines possessed quasi-elliptic frequency response and wide rejection bandwidth is proposed. The analysis is based on transmission line and coupled-line circuit model. Two-port impedance matrices and a T-type equivalent circuit were derived. On the basis of this equivalent circuit, a circuit with 3 dB cutoff frequency at 2.45 GHz were designed, simulated, and measured. The simulated and measured results are in good agreement within 0-12 GHz. (c) 2007 Wiley Periodicals, Inc.
RP Tseng, JD (reprint author), 35 Chung Shan Rd,Lane 215,Sector 1, Taiping City 411, Taichung County, Taiwan.
CR CHIOU YC, 2005, MICROW C P APMC, V3, P1
   Hsieh LH, 2003, IEEE T MICROW THEORY, V51, P193, DOI 10.1109/TMTT.2002.806901
   KUO JT, 2001, MICR C P APMC, V1, P330
   LEE MQ, 2002, MICR S IEEE MTT S IN, V3, P1797
   LEVY R, 2005, MICR S DIG IEEE MTT, P12
   LI R, 2005, MICR C P APMC, P1
   LIN ZS, IN PRESS J TECHNOL
   Manchec A, 2006, IEEE MICROW WIREL CO, V16, P4, DOI [10.1109/LMWC.2005.861361, 10.1109/LMWC.2005.961361]
   TSENG JD, 2004, 2004 INT C EL APPL C
   TSENG JD, 2005, INT S COMM NOV 20 22
   Tu WH, 2005, IEEE MICROW WIREL CO, V15, P404, DOI 10.1109/LMWC.2005.850479
   WENZEL RJ, 1970, MICROWAVE THEORY TEC, V18, P1150
   XU YG, IN PRESS J TECHNOL
   ZYSMAN GI, 1969, IEEE T MICROW THEORY, VMT17, P753, DOI 10.1109/TMTT.1969.1127055
NR 14
TC 3
Z9 4
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0895-2477
EI 1098-2760
J9 MICROW OPT TECHN LET
JI Microw. Opt. Technol. Lett.
PD MAR
PY 2007
VL 49
IS 3
BP 612
EP 615
DI 10.1002/mop.22199
PG 4
WC Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA 134RV
UT WOS:000244102500038
DA 2018-12-27
ER

PT J
AU Greger, JG
   Fursov, N
   Cooch, N
   McLarney, S
   Freedman, LP
   Edwards, DP
   Cheskis, BJ
AF Greger, James G.
   Fursov, Natalie
   Cooch, Neil
   McLarney, Sean
   Freedman, Leonard P.
   Edwards, Dean P.
   Cheskis, Boris J.
TI RETRACTED: Phosphorylation of MNAR promotes estrogen activation of
   phosphatidylinositol 3-kinase (Retracted Article. See vol 30, pg 1568,
   2010)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID MCF-7 CELLS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; STEROID-HORMONES;
   NUCLEAR RECEPTOR; CANCER CELLS; SRC; PROTEIN; BREAST; ALPHA
AB Estrogen actions are mediated by a complex interface of direct control of gene expression (the so-called "genomic action") and by regulation of cell signaling/phosphorylation cascades, referred to as the "nongenomic," or extranuclear, action. We have previously described the identification of MNAR (modulator of nongenomic action of estrogen receptor) as a novel scaffold protein that regulates estrogen receptor alpha (ER alpha) activation of cSrc. In this study, we have investigated the role of MNAR in 17 beta-estradiol (E2)-induced activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Consistent with our previous results, a direct correlation was established between MNAR expression levels and E2-induced activation of PI3 and Akt kinases. Endogenous MNAR, ER alpha, cSrc, and p85, the regulatory subunit of PI3 kinase, interacted in MCF7 cells treated with E2. The interaction between p85 and MNAR required activation of cSrc and MNAR phosphorylation on Tyr 920. Consequently, the mutation of this tyrosine to alanine (Y920A) abrogated the interaction between MNAR and p85 and the E2-induced activation of the PI3K/Akt pathway, which was required for the E2-induced protection of MCF7 cells from apoptosis. Nonetheless, the Y920A mutant potentiated the E2-induced activation of the Src/MAPK pathway and MCF7 cell proliferation, as observed with the wild-type MNAR. These results provide new and important insights into the molecular mechanisms of E2-induced regulation of cell proliferation and apoptosis.
C1 Wyeth Res, Womens Hlth & Musculoskeletal Biol, Nucl Receptors, Collegeville, PA 19426 USA.
   Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA.
RP Cheskis, BJ (reprint author), Wyeth Res, Womens Hlth & Musculoskeletal Biol, Nucl Receptors, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM cheskib@wyeth.com
CR Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200
   Barletta F, 2004, MOL ENDOCRINOL, V18, P1096, DOI 10.1210/me.2003-0335
   Boonyaratanakornkit V, 2004, ESSAYS BIOCHEM, V40, P105, DOI 10.1042/bse0400105
   Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5
   Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Cato AC, 2002, SCI STKE
   Cheskis BJ, 2004, J CELL BIOCHEM, V93, P20, DOI 10.1002/jcb.20180
   Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151
   Falkenstein E, 2000, PHARMACOL REV, V52, P513
   Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365-2362.2000.0300s3051.x
   Greger JG, 2006, STEROIDS, V71, P317, DOI 10.1016/j.steroids.2005.09.016
   Haas D, 2005, MOL ENDOCRINOL, V19, P2035, DOI 10.1210/me.2004-0531
   Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991
   Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239
   Koga M, 2004, BIOCHEM BIOPH RES CO, V324, P321, DOI 10.1016/j.bbrc.2004.09.060
   Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5
   Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491
   Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912
   Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x
   Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283
   Santen RJ, 2005, J STEROID BIOCHEM, V95, P155, DOI 10.1016/j.jsbmb.2005.04.025
   Shupnik MA, 2004, ONCOGENE, V23, P7979, DOI 10.1038/sj.onc.1208076
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121
   Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   Watson CS, 2003, EXP BIOL MED, V228, P1272
   Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699
NR 35
TC 45
Z9 47
U1 3
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAR
PY 2007
VL 27
IS 5
BP 1904
EP 1913
DI 10.1128/MCB.01732-06
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 137PW
UT WOS:000244305500029
PM 17194752
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Sorek, N
   Poraty, L
   Sternberg, H
   Bar, E
   Lewinsohn, E
   Yalovsky, S
AF Sorek, Nadav
   Poraty, Limor
   Sternberg, Hasana
   Bar, Enat
   Lewinsohn, Efraim
   Yalovsky, Shaul
TI RETRACTED: Activation status-coupled transient S acylation determines
   membrane partitioning of a plant Rho-related GTPase(Retracted article.
   See vol 37, Artn e00321-17, 2017)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID DETERGENT-RESISTANT MEMBRANES; PLASMA-MEMBRANE; ARABIDOPSIS-THALIANA;
   LIPID RAFTS; POLYBASIC DOMAIN; CAAX MOTIF; LIVE CELLS; H-RAS; GTPASES;
   LOCALIZATION
AB ROPs or RACs are plant Rho-related GTPases implicated in the regulation of a multitude of signaling pathways that function at the plasma membrane by virtue of posttranslationall lipid modifications. The relationship between ROP activation status and membrane localization has not been established. Here we demonstrate that endogenous ROPs, as well as a transgenic HiS(6)-green fluorescent protein (GFP)-AtROP6 fusion protein, were partitioned between Triton X-100-solluble and -insoluble membranes. In contrast, an activated HiS(6)-GFP-Atrop6(CA) mutant protein accumulated exclusively in detergent-resistant membranes. GDP induced accumulation of ROPs in Triton-soluble membranes, whereas GTP gamma S induced accumulation of ROPs in detergent-resistant membranes. Recombinant wild-type and constitutively active AtROP6 isoforms were purified from Arabidopsis plants, and their lipids were cleaved and analyzed by gas chromatography-coupled mass spectrometry. In Triton-soluble membranes, wild-type AtROP6 was only prenylated, primarily by geranylgeranyl. The activated AtROP6 that accumulated in detergent-resistant membranes was modified by prenyl and acyl lipids. The acyl lipids were identified as palmitic and stearic acids. In agreement, activated HiS(6)(_) GFP-Atrop6(CA)mS(156) in which cysteine 116 Was mutated into serine accumulated in Triton-soluble membranes. These findings show that upon GTP binding and activation, AtROP6 and possibly other ROPs are transiently S acyllated, which induces their partitioning into detergent-resistant membranes.
C1 Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel.
   New Yaar Res Ctr, Agr Res Org, Dept Field & Vegetable Crops, IL-30095 Ramat Yishay, Israel.
RP Yalovsky, S (reprint author), Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel.
EM Shauly@tauex.tau.ac.il
CR AUSUBEL FM, 1995, CURRENT PROTOCOLS MO
   Bagnat M, 2002, P NATL ACAD SCI USA, V99, P14183, DOI 10.1073/pnas.172517799
   Bloch D, 2005, MOL BIOL CELL, V16, P1913, DOI 10.1091/mbc.E04-07-0562
   Borner GHH, 2005, PLANT PHYSIOL, V137, P104, DOI 10.1104/pp.104.053041
   Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145
   Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796
   Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200
   Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8
   CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x
   del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571
   FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6
   Fischer U, 2004, CURR OPIN PLANT BIOL, V7, P670, DOI 10.1016/j.ppi.2004.09.007
   Golub T, 2005, J CELL BIOL, V169, P151, DOI 10.1083/jcb.200407058
   HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O
   Ivanchenko M, 2000, PLANT J, V24, P79, DOI 10.1046/j.1365-313x.2000.00855.x
   Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x
   Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317
   Lavy M, 2006, PLANT J, V46, P934, DOI 10.1111/j.1365-313X.2006.02749.x
   Lavy M, 2002, PLANT CELL, V14, P2431, DOI 10.1105/tpc.005561
   Lemichez E, 2001, GENE DEV, V15, P1808, DOI 10.1101/gad.900401
   Lin YK, 1996, PLANT CELL, V8, P293, DOI 10.1105/tpc.8.2.293
   London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1
   Maurer-Stroh S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-212
   Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910
   Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111
   Molendijk AJ, 2001, EMBO J, V20, P2779, DOI 10.1093/emboj/20.11.2779
   Morel J, 2006, MOL CELL PROTEOMICS, V5, P1396, DOI 10.1074/mcp.M600044-MCP200
   Nibau C, 2006, TRENDS PLANT SCI, V11, P309, DOI 10.1016/j.tplants.2006.04.003
   Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009
   Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091
   Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050
   Proszynski TJ, 2006, J CELL BIOL, V173, P861, DOI 10.1083/jcb.200602007
   Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654
   Rodriguez-Concepcion M, 1999, EMBO J, V18, P1996, DOI 10.1093/emboj/18.7.1996
   Schrick K, 2000, GENE DEV, V14, P1471
   Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954
   Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311
   Winge P, 2000, GENETICS, V156, P1959
   Winge P, 1997, PLANT MOL BIOL, V35, P483, DOI 10.1023/A:1005804508902
NR 40
TC 87
Z9 91
U1 3
U2 20
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAR
PY 2007
VL 27
IS 6
BP 2144
EP 2154
DI 10.1128/MCB.02347-06
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 147LD
UT WOS:000245003600014
PM 17242203
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Li, MD
   Zheng, YG
   Ji, M
AF Li, Ming Dong
   Zheng, You Guang
   Ji, Min
TI RETRACTED: Synthesis of gefitinib from methyl
   3-hydroxy-4-methoxy-benzoate (Retracted Article. See vol 12, pg 2160,
   2007)
SO MOLECULES
LA English
DT Article; Retracted Publication
DE gefitinib; tyrosine kinase inhibitors; methyl
   3-hydroxy-4-methoxybenzoate
ID RECEPTOR TYROSINE KINASES; DRUG DISCOVERY; CANCER
AB This paper reports a novel synthesis Of gefitinib starting from methyl 3-hydroxy-4-methoxybenzoate. The process starts with alkylation of the starting material, followed by nitration, reduction, cyclization, chlorination and two successive amination reactions. The intermediates and target molecule were characterized by H-1-NMR, C-13-NMR, MS and the purities of all these compounds were determined by HPLC. This novel synthetic route produced overall yields as high as 37.4%.
C1 Southeast Univ, Lab Pharmaceut Engn, Sch Chem & Chem Engn, Jiangsu Lab Biomat & Devices, Nanjing 210096, Peoples R China.
RP Ji, M (reprint author), Southeast Univ, Lab Pharmaceut Engn, Sch Chem & Chem Engn, Jiangsu Lab Biomat & Devices, Nanjing 210096, Peoples R China.
EM seu301@126.com; jimin@seu.edu.cn
CR Barker AJ, 2001, BIOORG MED CHEM LETT, V11, P1911, DOI 10.1016/S0960-894X(01)00344-4
   Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951
   GIBSON KH, 1998, Patent No. 5770599
   Gilday J.P., 2006, WO, Patent No. 2004024703
   Grosios K, 2003, DRUG FUTURE, V28, P679, DOI 10.1358/dof.2003.028.07.857184
   Kamath S, 2006, MED RES REV, V26, P569, DOI 10.1002/med.20070
   Knesl P, 2006, MOLECULES, V11, P286, DOI 10.3390/11040286
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Wang JQ, 2006, BIOORG MED CHEM LETT, V16, P4102, DOI 10.1016/j.bmcl.2006.04.080
NR 9
TC 5
Z9 8
U1 5
U2 30
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD MAR
PY 2007
VL 12
IS 3
BP 673
EP 678
DI 10.3390/12030673
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 153LQ
UT WOS:000245437400035
PM 17851420
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Ramani, P
   Chandrasekar, T
   Anuja, N
   Muthusekar, MR
   Sherlin, HJ
   Kulkarni, A
AF Ramani, Pratibha
   Chandrasekar, T.
   Anuja, N.
   Muthusekar, M. R.
   Sherlin, Herald J.
   Kulkarni, Amol
TI RETRACTED: A swelling in the buccal mucosa with intracranial involvement
   (Retracted article. See vol. 106, pg. 463, 2008)
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Editorial Material; Retracted Publication
ID NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; ORAL-CAVITY; MAXILLOFACIAL
   REGION; CLASSIFICATION; CHEMOTHERAPY; SALIVARY; REGIMEN; HEAD; NECK
C1 Saveetha Dent Coll & Hosp, Dept Oral & Maxillofacial Pathol, Madras 77, Tamil Nadu, India.
RP Ramani, P (reprint author), Saveetha Dent Coll & Hosp, Dept Oral & Maxillofacial Pathol, 162 Poonamallee High Rd, Madras 77, Tamil Nadu, India.
EM dr_pratibha@rediffmail.com
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Allen CM, 1997, ORAL SURG ORAL MED O, V84, P595, DOI 10.1016/S1079-2104(97)90357-7
   ASFER JC, 2004, PATHOLOGIC BASIS DIS, P676
   CABANILLAS F, 1987, J CLIN ONCOL, V5, P407, DOI 10.1200/JCO.1987.5.3.407
   CHEN SY, 1995, ORAL SURG ORAL MED O, V80, P192, DOI 10.1016/S1079-2104(05)80202-1
   Colomo L, 2003, BLOOD, V101, P78, DOI 10.1182/bllod-2002-04-1286
   COLTMAN CA, 1988, CANC CHEMOTHERAPY CH, P194
   CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25
   Daley Tom, 2003, J Can Dent Assoc, V69, P577
   ENZINGER FM, 1995, SOFT TISSUE TUMORS, P355
   FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404
   Friedrich RE, 2003, ANTICANCER RES, V23, P931
   Haddad A J, 2001, J Can Dent Assoc, V67, P664
   Kolokotronis A, 2005, ORAL SURG ORAL MED O, V99, P303, DOI 10.1016/j.tripleo.2004.03.028
   MARK RJ, 1991, ARCH OTOLARYNGOL, V117, P396
   NEVILLE B, 2002, ORAL MAXILLOFACIAL P, P371
   Nikitakis NG, 2002, ORAL ONCOL, V38, P201, DOI 10.1016/S1368-8375(01)00047-1
   Noguchi M, 2000, Rinsho Ketsueki, V41, P591
   Rees TD, 1999, PERIODONTOL 2000, V21, P145, DOI 10.1111/j.1600-0757.1999.tb00173.x
   Shindoh M, 1997, J ORAL PATHOL MED, V26, P283, DOI 10.1111/j.1600-0714.1997.tb01238.x
   SODERHOLM AL, 1990, INT J ORAL MAX SURG, V19, P131, DOI 10.1016/S0901-5027(05)80126-2
   Solomides CC, 2002, HUM PATHOL, V33, P153, DOI 10.1053/hupa.2002.30721
   Speight PM, 2002, ORAL DIS, V8, P229, DOI 10.1034/j.1601-0825.2002.02870.x
   TEMPLE HT, 2000, CLIN ORTHOP RELAT R, V373, P208
   Thompson LDR, 2000, AM J SURG PATHOL, V24, P640, DOI 10.1097/00000478-200005000-00002
   TOMICH CE, 1991, SURG PATHOLOGY SALIV, P347
   VALLY IM, 1990, ORAL SURG ORAL MED O, V69, P191, DOI 10.1016/0030-4220(90)90327-O
   van der Waal RIF, 2005, INT J ORAL MAX SURG, V34, P391, DOI 10.1016/j.ijom.2004.08.009
   Vega Francisco, 2005, Ann Diagn Pathol, V9, P340, DOI 10.1016/j.anndiagpath.2005.09.020
   Vose UM, 1998, SEMIN ONCOL, V25, P483
   ZANAKIS SN, 1992, ORAL SURG ORAL MED O, V74, P340, DOI 10.1016/0030-4220(92)90072-X
   Zucca E, 1999, ANN ONCOL, V10, P1023, DOI 10.1023/A:1008313229892
NR 32
TC 4
Z9 4
U1 3
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1079-2104
EI 1528-395X
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD MAR
PY 2007
VL 103
IS 3
BP 308
EP 313
DI 10.1016/j.tripleo.2006.09.010
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 153NH
UT WOS:000245441700006
PM 17197205
DA 2018-12-27
ER

PT J
AU Kain, ZN
   MacLaren, J
AF Kain, Zeev N.
   MacLaren, Jill
TI RETRACTED: P less than .05: What does it really mean? (Retracted
   Article. See vol 120, pg 698, 2007)
SO PEDIATRICS
LA English
DT Editorial Material; Retracted Publication
ID CONFIDENCE-INTERVALS; VALUES; PAIN
C1 Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Dept Child Psychiat, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Ctr Adv Perioperat Hlth, New Haven, CT 06510 USA.
RP MacLaren, J (reprint author), Yale Univ, Sch Med, Dept Anesthesiol, 333 Cedar St, New Haven, CT 06510 USA.
EM zeev.kain@yale.edu
OI Chorney, Jill/0000-0002-6137-049X
FU NICHD NIH HHS [R01HD37007-02]
CR Cohen J, 1988, STAT POWER ANAL BEHA
   COLVIN DF, 1980, SOUTHERN MED J, V73, P1020, DOI 10.1097/00007611-198008000-00019
   Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P355, DOI 10.1016/S0895-4356(97)00295-3
   Fisher R. A., 1935, DESIGN EXPT
   Fisher R. A., 1925, STAT METHODS RES WOR
   FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2
   GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746
   JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12
   Kirk RE, 1996, EDUC PSYCHOL MEAS, V56, P746, DOI 10.1177/0013164496056005002
   SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429
   SNYDER P, 1993, J EXP EDUC, V61, P334, DOI 10.1080/00220973.1993.10806594
NR 11
TC 7
Z9 7
U1 3
U2 13
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2007
VL 119
IS 3
BP 608
EP 610
DI 10.1542/peds.2006-3030
PG 3
WC Pediatrics
SC Pediatrics
GA 141LK
UT WOS:000244579800020
PM 17332213
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Marx, DM
AF Stapel, Diederik A.
   Marx, David M.
TI RETRACTED: Distinctiveness is key: How different types of self-other
   similarity moderate social comparison effects (Retracted article. See
   vol. 39, pg. 264, 2013)
SO PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN
LA English
DT Article; Retracted Publication
DE social comparison; similarity; distinctiveness; self-evaluation;
   contrast; assimilation
ID CONTRAST; JUDGMENT; ME; CATEGORIZATION; ASSIMILATION; CONTEXT; IMPACT
AB In relevant research to date, the impact of self-other similarity on the outcome of social comparison effects is not well understood. The authors argue that the extent to which this similarity is distinctive is a key to understanding such effects. In two experiments, they demonstrate that when self-other similarity is distinctive (unique), assimilation is more likely, whereas when self-other similarity is nondistinctive (common), contrast is more likely. These results suggest that what matters is the type rather than the quantity of similarity: Similarity on one distinctive dimension more readily leads to assimilation than similarity on numerous nondistinctive dimensions. Importantly, these assimilation effects are especially likely to occur when the comparison dimension is unimportant. Contrast is more likely to occur when the comparison dimension is important. Thus, these findings both replicate and extend Tesser's (1988) Self-Evaluation Maintenance Model.
C1 Tilburg Univ, TIBER, NL-5000 LE Tilburg, Netherlands.
   San Diego State Univ, San Diego, CA 92182 USA.
RP Stapel, DA (reprint author), Tilburg Univ, TIBER, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl
CR Biernat M., 2002, EUROPEAN REV SOCIAL, V12, P103
   Blanton H, 2002, J EXP SOC PSYCHOL, V38, P253, DOI 10.1006/jesp.2001.1510
   Blanton H, 2001, COGNITIVE SOCIAL PSYCHOLOGY, P75
   BREWER MB, 1994, J PERS SOC PSYCHOL, V66, P268, DOI 10.1037/0022-3514.66.2.268
   BROWN JD, 1992, J PERS SOC PSYCHOL, V62, P717, DOI 10.1037//0022-3514.62.5.717
   CASH TF, 1983, PERS SOC PSYCHOL B, V9, P351, DOI 10.1177/0146167283093004
   CIALDINI RB, 1976, J PERS SOC PSYCHOL, V34, P366, DOI 10.1037//0022-3514.34.3.366
   Eiser JR, 1972, CATEGORIZATION SOCIA
   Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202
   GERARD HB, 1974, J PERS SOC PSYCHOL, V29, P836, DOI 10.1037/h0036204
   JELLISON JM, 1969, J PERS SOC PSYCHOL, V11, P115, DOI 10.1037/h0027042
   Jetten J, 1998, J PERS SOC PSYCHOL, V74, P1481, DOI 10.1037/0022-3514.74.6.1481
   Lockwood P, 1997, J PERS SOC PSYCHOL, V73, P91, DOI 10.1037//0022-3514.73.1.91
   MANIS M, 1991, J PERS SOC PSYCHOL, V61, P203, DOI 10.1037//0022-3514.61.2.203
   McFarland C, 2001, SOC COGNITION, V19, P547, DOI 10.1521/soco.19.5.547.19911
   MILLER DT, 1988, J PERS SOC PSYCHOL, V55, P908, DOI 10.1037/0022-3514.55.6.908
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   Nabokov Vladimir, 1962, PALE FIRE
   NEWMAN SE, 1989, J PERS SOC PSYCHOL, V56, P876, DOI 10.1037/0022-3514.56.6.876
   PELHAM BW, 1995, J PERS SOC PSYCHOL, V69, P825, DOI 10.1037//0022-3514.69.5.825
   Stapel DA, 2006, J EXP SOC PSYCHOL, V42, P397, DOI 10.1016/j.jesp.2005.05.006
   Stapel DA, 2005, J PERS SOC PSYCHOL, V88, P1029, DOI 10.1037/0022-3514.88.6.1029
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P860, DOI 10.1037/0022-3514.87.6.860
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Stapel DA, 2000, J PERS SOC PSYCHOL, V79, P1068, DOI 10.1037//0022-3514.79.6.1068
   Stapel DA, 1997, J PERS SOC PSYCHOL, V73, P1177, DOI 10.1037//0022-3514.73.6.1177
   Suls J. M., 2000, HDB SOCIAL COMP THEO
   TAYLOR SE, 1989, PSYCHOL REV, V96, P569, DOI 10.1037//0033-295X.96.4.569
   Tesser A., 1988, ADV EXPT SOCIAL PSYC, P181, DOI DOI 10.1016/S0065-2601(08)60227-0
   Tiedens LZ, 2003, J PERS SOC PSYCHOL, V85, P1049, DOI 10.1037/0022-3514.85.6.1049
   Turner J. C, 1979, SOCIAL PSYCHOL INTER, P33, DOI DOI 10.1016/S0065-2601(05)37005-5
   TVERSKY A, 1977, PSYCHOL REV, V84, P327, DOI 10.1037/0033-295X.84.4.327
   WOOD JV, 1989, PSYCHOL BULL, V106, P231, DOI 10.1037//0033-2909.106.2.231
NR 33
TC 11
Z9 11
U1 2
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0146-1672
EI 1552-7433
J9 PERS SOC PSYCHOL B
JI Pers. Soc. Psychol. Bull.
PD MAR
PY 2007
VL 33
IS 3
BP 439
EP 448
DI 10.1177/0146167206296105
PG 10
WC Psychology, Social
SC Psychology
GA 142JQ
UT WOS:000244646000011
PM 17312323
DA 2018-12-27
ER

PT J
AU Pandya, NM
   Jain, SM
   Santani, DD
AF Pandya, N. M.
   Jain, S. M.
   Santani, D. D.
TI RETRACTED: Pathophysiological actions of protease activated receptors
   (PARs) (Retracted Article. See vol 62, pg 880, 2007)
SO PHARMAZIE
LA English
DT Review; Retracted Publication
ID SMOOTH-MUSCLE-CELL; VASCULAR ENDOTHELIAL-CELLS; HUMAN MESANGIAL CELLS;
   THROMBIN-RECEPTOR; PLASMINOGEN-ACTIVATOR; MOLECULAR-CLONING;
   EPITHELIAL-CELLS; NERVOUS-SYSTEM; GROWTH-FACTOR; TISSUE-TYPE
AB Serine proteases such as thrombin, mast cell tryptase, trypsin, or cathepsin G, for example, are highly active mediators with diverse biological activities. So far, proteases have been considered to act primarily as degradative enzymes in the extracellular space. However, their biological actions in tissues and cells suggest important roles as a part of the body's hormonal communication system during inflammation and immune response. These effects can be attributed to the activation of a new subfamily of G protein-coupled receptors, termed protease-activated receptors (PARs). Four members of the PAR family have been cloned so far. Thus, certain proteases act as signaling molecules that specifically regulate cells by activating PARs. After stimulation, PARs couple to various G proteins and activate signal transduction pathways resulting in the rapid transcription of genes that are involved in inflammation. For example, PARs are widely expressed by cells involved in immune responses and inflammation, regulate endothelial-leukocyte interactions, and modulate the secretion of inflammatory mediators or neuropeptides. Together, the PAR family necessitates a paradigm shift in thinking about hormone action, to include proteases as key modulators of biological function. Novel compounds that can modulate PAR function may be potent candidates for the treatment of inflammatory or immune diseases.
C1 CU Shah Coll Pharm & Res, Dept Pharmacol, Wadhwan City 363030, Dist Surendrana, India.
   LM Coll Pharm, Dept Pharmacol, Ahmadabad, Gujarat, India.
RP Pandya, NM (reprint author), CU Shah Coll Pharm & Res, Dept Pharmacol, Wadhwan City 363030, Dist Surendrana, India.
EM pandyapharmacist@rediffmail.com
CR Andersen H, 1999, P NATL ACAD SCI USA, V96, P11189, DOI 10.1073/pnas.96.20.11189
   Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257
   Bono F, 2000, ARTERIOSCL THROM VAS, V20, pE107, DOI 10.1161/01.ATV.20.11.e107
   Bono F, 1997, BIOCHEM BIOPH RES CO, V241, P762, DOI 10.1006/bbrc.1997.7847
   Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255
   Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200
   Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225
   Carmeliet P, 2001, SCIENCE, V293, P1602, DOI 10.1126/science.1064981
   Cheung WM, 1998, CAN J PHYSIOL PHARM, V76, P16, DOI 10.1139/cjpp-76-1-16
   Chi LQ, 2001, J INTERF CYTOK RES, V21, P231, DOI 10.1089/107999001750169871
   COLOTTA F, 1994, AM J PATHOL, V144, P975
   Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658
   Coughlin SR, 2001, THROMB HAEMOSTASIS, V86, P298
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078
   Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405
   Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429
   Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0
   Donovan FM, 1997, J NEUROSCI, V17, P5316
   Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396
   Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233
   Festoff BW, 1996, SEMIN THROMB HEMOST, V22, P267, DOI 10.1055/s-2007-999018
   Forteza RM, 2001, PULM PHARMACOL THER, V14, P107, DOI 10.1006/pupt.2000.0276
   Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645
   GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419
   Graff J, 2002, J PHARMACOL EXP THER, V300, P952, DOI 10.1124/jpet.300.3.952
   Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353
   Grandaliano G, 2000, AM J KIDNEY DIS, V35, P726, DOI 10.1016/S0272-6386(00)70022-9
   GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440
   Hamilton JR, 2001, J CARDIOVASC PHARM, V38, P108, DOI 10.1097/00005344-200107000-00012
   HAYAKAWA Y, 1995, THROMB HAEMOSTASIS, V74, P704
   HE CJ, 1991, J CELL PHYSIOL, V146, P131, DOI 10.1002/jcp.1041460117
   Heidland A, 1997, KIDNEY INT, V52, pS32
   Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393
   Hirano F, 2002, ANN RHEUM DIS, V61, P834, DOI 10.1136/ard.61.9.834
   Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203
   HUNG DT, 1992, J BIOL CHEM, V267, P20831
   Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581
   Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0
   Jeziorska M, 1997, J PATHOL, V182, P115, DOI 10.1002/(SICI)1096-9896(199705)182:1<115::AID-PATH806>3.0.CO;2-9
   KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966
   Kahn ML, 1998, NATURE, V394, P690
   Kameda H, 1997, BRIT J HAEMATOL, V97, P348, DOI 10.1046/j.1365-2141.1997.522700.x
   Kaplanski G, 1998, BLOOD, V92, P1259
   Kaplanski G, 1997, J IMMUNOL, V158, P5435
   Kaufmann R, 1999, CANCER LETT, V139, P109, DOI 10.1016/S0304-3835(99)00025-7
   Kawabata A, 2001, BIOCHEM BIOPH RES CO, V282, P432, DOI 10.1006/bbrc.2001.4597
   King C, 1998, J IMMUNOL, V161, P3645
   Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938
   Koo BH, 2002, FEBS LETT, V523, P85, DOI 10.1016/S0014-5793(02)02948-4
   KOTANI I, 1995, THROMB RES, V77, P493, DOI 10.1016/0049-3848(95)00025-9
   KU DD, 1986, J CARDIOVASC PHARM, V8, P29, DOI 10.1097/00005344-198601000-00005
   Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007
   Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073
   Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048
   Lourbakos A, 1998, FEBS LETT, V435, P45, DOI 10.1016/S0014-5793(98)01036-9
   Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001
   Luthi A, 1997, J NEUROSCI, V17, P4688
   Ma L, 2001, BRIT J PHARMACOL, V134, P701, DOI 10.1038/sj.bjp.0704312
   Macey MG, 1998, CLIN EXP RHEUMATOL, V16, P108
   Macfarlane SR, 2001, PHARMACOL REV, V53, P245
   McLean K, 2001, THROMB RES, V103, P281, DOI 10.1016/S0049-3848(01)00330-9
   Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D
   Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597
   Mirza H, 1997, BLOOD, V90, P3914
   Mizutani A, 1997, BRAIN RES, V761, P93, DOI 10.1016/S0006-8993(97)00338-7
   Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043
   Monno R, 2001, J AM SOC NEPHROL, V12, P891
   Muehlenweg B, 2000, J BIOL CHEM, V275, P33562, DOI 10.1074/jbc.C000383200
   MURAMATSU I, 1992, CAN J PHYSIOL PHARM, V70, P996, DOI 10.1139/y92-137
   Naldini A, 2000, GEN PHARMACOL-VASC S, V35, P255, DOI 10.1016/S0306-3623(01)00113-6
   Naldini A, 1998, J CELL PHYSIOL, V177, P76, DOI 10.1002/(SICI)1097-4652(199810)177:1<76::AID-JCP8>3.0.CO;2-B
   NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031
   Noorbakhsh F, 2003, NAT REV NEUROSCI, V4, P981, DOI 10.1038/nrn1255
   Norman JT, 1996, KIDNEY INT, V49, pS61
   NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950
   NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x
   Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910
   Ohmori T, 1999, THROMB RES, V93, P291, DOI 10.1016/S0049-3848(98)00188-1
   Raza SL, 2000, J BIOL CHEM, V275, P41243, DOI 10.1074/jbc.M005788200
   Rerolle JP, 2000, KIDNEY INT, V58, P1841, DOI 10.1046/j.1523-1755.2000.00355.x
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   RUEF C, 1993, EUR RESPIR J, V6, P1429
   Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x
   Schaeffer P, 1997, BIOCHEM PHARMACOL, V53, P487, DOI 10.1016/S0006-2952(96)00735-6
   Schultheiss M, 1997, CELL MOL LIFE SCI, V53, P842, DOI 10.1007/s000180050104
   Seeliger S, 2003, FASEB J, V17, P1871, DOI 10.1096/fj.02-1112com
   Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200
   Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.3.CO;2-4
   SMITH CCT, 1986, CLIN SCI, V70, P495, DOI 10.1042/cs0700495
   Smith R, 2000, FEBS LETT, V484, P285, DOI 10.1016/S0014-5793(00)02146-3
   Steinhoff M, 1999, EXP DERMATOL, V8, P282
   Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x
   Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897
   Suidan HS, 1996, SEMIN THROMB HEMOST, V22, P125, DOI 10.1055/s-2007-998999
   SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T
   Szaba FM, 2002, BLOOD, V99, P1053, DOI 10.1182/blood.V99.3.1053
   Takada M, 1998, CIRC RES, V82, P980, DOI 10.1161/01.RES.82.9.980
   THOMAS CA, 1977, NATURE, V269, P521, DOI 10.1038/269521a0
   TORDAI A, 1993, J IMMUNOL, V150, P4876
   VASSALLO RR, 1992, J BIOL CHEM, V267, P6081
   VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389
   Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898
   VILLAMEDIANA LM, 1990, KIDNEY INT, V38, P956, DOI 10.1038/ki.1990.297
   VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V
   Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021
   Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012
   Wang YM, 1997, KIDNEY INT, V52, P371, DOI 10.1038/ki.1997.343
   WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220
   Whetsell WO, 1996, J NEUROPATH EXP NEUR, V55, P1, DOI 10.1097/00005072-199601000-00001
   WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527
   WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469
   Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247
   Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642
   Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65
   ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589
NR 116
TC 4
Z9 5
U1 4
U2 9
PU GOVI-VERLAG  PHARMAZEUTISCHER VERLAG GMBH
PI ESCHBORN
PA PHARMAZEUTISCCARL MANNICH STR 26, D-65760 ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD MAR
PY 2007
VL 62
IS 3
BP 163
EP 169
DI 10.1691/ph.2007.3.6722
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 145OU
UT WOS:000244875200001
PM 17416190
DA 2018-12-27
ER

PT J
AU Hall, BG
   Salipante, SJ
AF Hall, Barry G.
   Salipante, Stephen J.
TI RETRACTED: Measures of clade confidence do not correlate with accuracy
   of phylogenetic trees (Retracted article, see vol 3, pg 1403, 2007)
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article; Retracted Publication
ID MULTIPLE SEQUENCE ALIGNMENT; NUCLEOTIDE-SEQUENCES; MAXIMUM-LIKELIHOOD;
   BAYESIAN-INFERENCE; BOOTSTRAP MEASURES; MRBAYES; PROTEIN; SUPPORT
AB Metrics of phylogenetic tree reliability, such as parametric bootstrap percentages or Bayesian posterior probabilities, represent internal measures of the topological reproducibility of a phylogenetic tree, while the recently introduced aLRT (approximate likelihood ratio test) assesses the likelihood that a branch exists on a maximum-likelihood tree. Although those values are often equated with phylogenetic tree accuracy, they do not necessarily estimate how well a reconstructed phylogeny represents cladistic relationships that actually exist in nature. The authors have therefore attempted to quantify how well bootstrap percentages, posterior probabilities, and aLRT measures reflect the probability that a deduced phylogenetic clade is present in a known phylogeny. The authors simulated the evolution of bacterial genes of varying lengths under biologically realistic conditions, and reconstructed those known phylogenies using both maximum likelihood and Bayesian methods. Then, they measured how frequently clades in the reconstructed trees exhibiting particular bootstrap percentages, aLRT values, or posterior probabilities were found in the true trees. The authors have observed that none of these values correlate with the probability that a given clade is present in the known phylogeny. The major conclusion is that none of the measures provide any information about the likelihood that an individual clade actually exists. It is also found that the mean of all clade support values on a tree closely reflects the average proportion of all clades that have been assigned correctly, and is thus a good representation of the overall accuracy of a phylogenetic tree.
C1 Bellingham Res Inst, Bellingham, WA USA.
   Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
RP Hall, BG (reprint author), Bellingham Res Inst, Bellingham, WA USA.
EM barryhall@zeninternet.com
CR Alfaro ME, 2003, MOL BIOL EVOL, V20, P255, DOI 10.1093/molbev/msg028
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687
   Douady CJ, 2003, MOL BIOL EVOL, V20, P248, DOI 10.1093/molbev/msg042
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hall B. G., 2004, PHYLOGENETIC TREES M
   Hall BG, 2006, P NATL ACAD SCI USA, V103, P5431, DOI 10.1073/pnas.0508991103
   Hall BG, 2005, MOL BIOL EVOL, V22, P792, DOI 10.1093/molbev/msi066
   HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540
   Huelsenbeck JP, 2002, SYST BIOL, V51, P673, DOI 10.1080/10635150290102366
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   JUKES T H, 1969, P21
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Mau B, 1999, BIOMETRICS, V55, P1, DOI 10.1111/j.0006-341X.1999.00001.x
   Nei M., 2000, MOL EVOLUTION PHYLOG
   Rannala B, 1996, J MOL EVOL, V43, P304, DOI 10.1007/BF02338839
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Suzuki Y, 2002, P NATL ACAD SCI USA, V99, P16138, DOI 10.1073/pnas.212646199
   Taylor DJ, 2004, MOL BIOL EVOL, V21, P1534, DOI 10.1093/molbev/msh156
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Thompson JD, 1999, NUCLEIC ACIDS RES, V27, P2682, DOI 10.1093/nar/27.13.2682
   Wilcox TP, 2002, MOL PHYLOGENET EVOL, V25, P361, DOI 10.1016/S1055-7903(02)00244-0
   ZHARKIKH A, 1992, MOL BIOL EVOL, V9, P1119
NR 25
TC 9
Z9 9
U1 3
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD MAR
PY 2007
VL 3
IS 3
BP 473
EP 481
AR e51
DI 10.1371/journal.pcbi.0030051
PG 9
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 163VJ
UT WOS:000246191000013
PM 17367204
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hu, XY
   Xu, YM
   Qiao, Y
   Wu, DL
   Sa, YL
   Fu, Q
   Yu, JJ
   Zhang, XR
   Zhang, J
   Gu, BJ
   Chen, R
   Xie, H
AF Hu, X. Y.
   Xu, Y. M.
   Qiao, Y.
   Wu, D. L.
   Sa, Y. L.
   Fu, Q.
   Yu, J. J.
   Zhang, X. R.
   Zhang, J.
   Gu, B. J.
   Chen, R.
   Xie, H.
TI RETRACTED: Reduced semen quality in chronic prostatitis patients that
   induce the release of apoptotic protein Omi/HtrA2 from spermatozoa
   (Retracted article. see vol 104, pg 398, 2007)
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article; Retracted Publication
DE chronic prostatitis; cytokines; male infertility; Omi/HtrA2; semen
   quality
ID PELVIC PAIN SYNDROME; ACCESSORY-GLAND INFECTION; MALE-INFERTILITY;
   CELL-DEATH; PARAMETERS; IMPACT; MOTIF
AB The relationship between chronic prostatitis and fertility has been disputed for many years. Several groups have shown infection and autoimmune response against prostate antigens could have a deleterious effect on semen quality and fertility. This study was conducted to test the hypothesis that Omi/HtrA2-induced apoptosis in chronic prostatitis could be a mechanism underlying the observed clinical benefit. The Omi/HtrA2 serine protease is a nuclear-encoded mitochondrial protein, which can be released from mitochondria into the cytosol after apoptosis stimuli, inducing apoptosis in caspase-dependent and independent manners. Forty-one patients diagnosed as suffering from chronic prostatitis were included. Healthy normal individuals were included as controls. Human spermatozoa in the semen were purified by Percoll-gradient technique to separate the seminal plasma and other round cells. Measurements for sperm concentration, motility, morphology, proinflammatory cytokines, Omi/HtrA2 mRNA and protein levels in spermatozoa of chronic protatitis patients, were performed accordingly. Significantly increased levels of proinflammatory cytokines were detected in seminal plasma from these prostatitis patients. Omi/HtrA2 mRNA and protein levels were significantly higher in prostatitis men than in normal men. This study shows that chronic prostatitis patients present important alterations in their semen quality parameters, Omi/HtrA2 mRNA and protein levels of spermatozoa. We speculate that the inflammatory process involved may affect male fertility by release of proapoptotic protein Omi/HtrA2.
C1 Shanghai Jiao Tong Univ, Dept Urol, Peoples Hosp 6, Shanghai 200233, Peoples R China.
RP Xu, YM (reprint author), Shanghai Jiao Tong Univ, Dept Urol, Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM urologist2010@yahoo.com.cn
CR Batstone GRD, 2002, CLIN EXP IMMUNOL, V128, P302, DOI 10.1046/j.1365-2249.2002.01853.x
   BIERKLUNDT JTE, 2002, CURR OPIN UROL, V12, P63
   Blink E, 2004, CELL DEATH DIFFER, V11, P937, DOI 10.1038/sj.cdd.4401409
   Collins MM, 2000, ANN INTERN MED, V133, P367, DOI 10.7326/0003-4819-133-5-200009050-00013
   Engeler DS, 2003, EUR UROL, V44, P546, DOI 10.1016/S0302-2838(03)00370-1
   Estrada LS, 1997, INT J ANDROL, V20, P237, DOI 10.1046/j.1365-2605.1997.00062.x
   Everaert K, 2003, ANDROLOGIA, V35, P325, DOI 10.1046/j.1439-0272.2003.00569.x
   Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052
   Krieger JN, 2003, INFECT DIS CLIN N AM, V17, P395, DOI 10.1016/S0891-5520(03)00003-5
   Ludwig M, 2003, ANDROLOGIA, V35, P152, DOI 10.1046/j.1439-0272.2003.00553.x
   Menkveld R, 2003, ANDROLOGIA, V35, P288, DOI 10.1046/j.1439-0272.2003.00574.x
   Motrich RD, 2005, HUM REPROD, V20, P2567, DOI 10.1093/humrep/dei073
   Pasqualotto FF, 2000, UROLOGY, V55, P881, DOI 10.1016/S0090-4295(99)00613-5
   Ponniah S, 2000, PROSTATE, V44, P49
   Schoor Richard A, 2002, Curr Urol Rep, V3, P324, DOI 10.1007/s11934-002-0058-8
   Sekine K, 2005, BIOCHEM BIOPH RES CO, V330, P279, DOI 10.1016/j.bbrc.2005.02.165
   Sharma RK, 1996, UROLOGY, V48, P835, DOI 10.1016/S0090-4295(96)00313-5
   Sikka SC, 2001, CURR MED CHEM, V8, P851, DOI 10.2174/0929867013373039
   Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125
   Weidner W, 1999, HUM REPROD UPDATE, V5, P421, DOI 10.1093/humupd/5.5.421
   Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903
NR 21
TC 6
Z9 8
U1 3
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
EI 1476-5608
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD MAR
PY 2007
VL 10
IS 1
BP 104
EP 108
DI 10.1038/sj.pcan.4500919
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 141UR
UT WOS:000244604800017
PM 17043678
OA Bronze
DA 2018-12-27
ER

PT J
AU Hosseinkhani, H
   Hosseinkhani, M
   Khademhosseini, A
   Kobayashi, H
AF Hosseinkhani, Hossein
   Hosseinkhani, Mohsen
   Khademhosseini, Ali
   Kobayashi, Hisatoshi
TI RETRACTED: Bone regeneration through controlled release of bone
   morphogenetic protein-2 from 3-D tissue engineered nano-scaffold
   (Retracted article. See vol. 232, pg. 271, 2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE nano-scaffold; peptide amphiphile; nanofibers; self-assembly; bone
   regeneration
ID FIBROBLAST-GROWTH-FACTOR; IN-VIVO; ECTOPIC OSTEOINDUCTION; HYDROGELS;
   COLLAGEN; DEFECTS; RHBMP-2; CARRIER; MATRIX; VITRO
AB The objective of the present study was to enhance ectopic bone formation through the controlled release of bone morphogenetic protein-2 (BMP-2) from an injectable three dimensional (3-D) tissue engineered nano-scaffold. We demonstrate that a 3-D scaffold can be formed by mixing of peptide-amphiphile (PA) aqueous solution with BMP-2 suspension. A 3-D network of nanofibers was formed by mixing BMP-2 suspensions with dilute aqueous solutions of PA. Scanning electron microscopy (SEM) observation revealed the formation of fibrous assemblies with an extremely high aspect ratio and high surface areas. In vivo release profile of BMP-2 from 3-D network of nanofibers was investigated. In addition, ectopic bone formation induced by the released BMP-2 was assessed in a rat model using histological and biochemical examinations. It was demonstrated that the injection of an aqueous solution of PA together with BMP-2 into the back subcutis of rats, resulted in the formation of a transparent 3-D hydrogel at the injected site and induced significant homogeneous ectopic bone formation around the injected site, in marked contrast to BMP-2 injection alone or PA injection alone. The combination of BMP-2-induced bone formation is a promising procedure to improve tissue regeneration. (c) 2006 Elsevier B.V. All rights reserved.
C1 NIMS, ICYS, Tsukuba, Ibaraki 3050044, Japan.
   Kyoto Univ Hosp, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan.
   MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Ctr Biomed Engn, Cambridge, MA 02139 USA.
   NIMS, Ctr Biomat, Tsukuba, Ibaraki 3050044, Japan.
   Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Tokyo 1138549, Japan.
RP Hosseinkhani, H (reprint author), NIMS, ICYS, Tsukuba, Ibaraki 3050044, Japan.
EM hossein.hosseinkhani@nims.go.jp
RI Xu, Qingguo/C-1962-2014; Khademhosseini, Ali/A-9435-2010; kobayashi,
   hisatoshi/H-2720-2011
OI Xu, Qingguo/0000-0003-3191-0771; Khademhosseini,
   Ali/0000-0002-2692-1524; kobayashi, hisatoshi/0000-0001-9487-0725
CR Bostrom M, 1996, CLIN ORTHOP RELAT R, P272, DOI 10.1097/00003086-199606000-00034
   Cai SS, 2005, BIOMATERIALS, V26, P6054, DOI 10.1016/j.biomaterials.2005.03.012
   Dogan AK, 2005, J BIOMED MATER RES B, V74B, P504
   DOWNS EC, 1992, J CELL PHYSIOL, V152, P422, DOI 10.1002/jcp.1041520225
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x
   FUJIMURA K, 1995, BIOCHEM BIOPH RES CO, V208, P316, DOI 10.1006/bbrc.1995.1340
   GOMBOTZ WR, 1993, J BIOMAT SCI-POLYM E, V5, P49
   GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187
   IWAKURA A, 2001, CIRCULATION, V104, P1325
   Kusumoto K, 1998, BRIT J PLAST SURG, V51, P275, DOI 10.1054/bjps.1998.0008
   Ma ZW, 2005, TISSUE ENG, V11, P101, DOI 10.1089/ten.2005.11.101
   MIYAMOTO S, 1993, CLIN ORTHOP RELAT R, P333
   NAGAI H, 1995, BONE, V16, P367, DOI 10.1016/8756-3282(94)00049-2
   Okubo Y, 2000, INT J ORAL MAX SURG, V29, P62, DOI 10.1016/S0901-5027(00)80127-7
   Ozeki M, 2001, J DRUG TARGET, V9, P461, DOI 10.3109/10611860108998780
   Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4
   REDDI AH, 1993, J BONE MINER RES, V8, pS499
   Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142-9612(03)00339-9
   Ueda H, 2002, BIOMATERIALS, V23, P1003, DOI 10.1016/S0142-9612(01)00211-3
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Woo KM, 2003, J BIOMED MATER RES A, V67A, P531, DOI 10.1002/jbm.a.10098
   Yamagiwa H, 2001, J BONE MINER METAB, V19, P20, DOI 10.1007/s007740170056
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005
NR 24
TC 139
Z9 143
U1 3
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 26
PY 2007
VL 117
IS 3
BP 380
EP 386
DI 10.1016/j.jconrel.2006.11.018
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 146IQ
UT WOS:000244928100010
PM 17207881
DA 2018-12-27
ER

PT J
AU Adibhatla, RM
   Hatcher, JF
AF Adibhatla, Rao Muralikrishna
   Hatcher, J. F.
TI RETRACTED: Secretory phospholipase A(2) IIA is up-regulated by TNF-alpha
   and IL-1 alpha/beta after transient focal cerebral ischemia in rat
   (Retracted article. See vol. 1507, pg. 154, 2013)
SO BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE phospholipase A(2); cytokines; TNF-alpha; interleukin-1;
   phosphatidylcholine; stroke; focal cerebral ischemia
ID TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; NEURONAL CELL-DEATH;
   BRAIN-INJURY; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; LIPID-PEROXIDATION;
   CDP-CHOLINE; EXPRESSION; STROKE; INTERLEUKIN-1
AB Cerebral ischemia initiates an inflammatory response in the brain that is associated with the induction of a variety of cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 alpha/beta (IL-1 alpha/beta) that contributes to stroke injury. Transient middle cerebral artery occlusion (tMCAO) in spontaneously hypertensive rat (SHR) resulted in significant increases in TNF-alpha and IL-1 beta levels. We have previously demonstrated up-regulation of secretory phospholipase A(2) IIA (sPLA(2) IIA) mRNA and protein expression, increased PLA(2) activity, and loss of phosphatidylcholine after 1-h tMCAO and 24-h reperfusion in SHR. Treatment with TNF-a antibody or IL-1 receptor antagonist significantly attenuated infarction volume, sPLA(2) IIA protein expression, PLA(2) activity and significantly restored phosphatidylcholine levels after tMCAO. This suggests that cytokine induction up-regulates sPLA(2) IIA protein expression, resulting in altered lipid metabolism that contributes to stroke injury. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, Madison, WI 53792 USA.
   Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA.
   Univ Wisconsin, Neurosci Training Program, Madison, WI 53792 USA.
   Vet Adm Hosp, Madison, WI 53705 USA.
RP Adibhatla, RM (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, H4-330,600 Highland Ave, Madison, WI 53792 USA.
EM adibhatl@neurosurg.wisc.edu
FU NINDS NIH HHS [NS42008, R01 NS042008]
CR Adibhatla RM, 2006, AAPS J, V8, pE314
   Adibhatla RM, 2006, J BIOL CHEM, V281, P6718, DOI 10.1074/jbc.M512112200
   Adibhatla RM, 2006, FREE RADICAL BIO MED, V40, P376, DOI 10.1016/j.freeradbiomed.2005.08.044
   Adibhatla RM, 2005, BRAIN RES, V1058, P193, DOI 10.1016/j.brainres.2005.07.067
   Adibhatla RM, 2003, ANTIOXID REDOX SIGN, V5, P647, DOI 10.1089/152308603770310329
   Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672
   Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583
   Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664
   Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200
   Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233
   Boutin H, 2001, J NEUROSCI, V21, P5528
   Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715
   Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1
   Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363
   HEMELRIJCK AV, 2003, J NEUROCHEM, V87, P66
   Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086
   Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028
   Iadecola C, 2005, STROKE, V36, P182, DOI 10.1161/01.STR.0000153797.33611.d8
   Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051
   Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014
   Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005
   Lin TN, 2004, J NEUROCHEM, V90, P637, DOI 10.1111/j.1471-4159.2004.02540.x
   LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481
   Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017
   Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400
   Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699
   Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P676
   Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28
   Paxinos G, 1998, RAT BRAIN STEREOTAXI
   PAXINOS G, 1995, RAT NERVOUS SYSTEM
   Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229
   Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x
   ROTHWELL NJ, 2001, INFLAMMATION STROKE, P173
   Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5
   SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533
   Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8
   Spangelo BL, 2000, ANN NY ACAD SCI, V917, P597
   Sun GY, 2005, MOL NEUROBIOL, V31, P27, DOI 10.1385/MN:31:1-3:027
   Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
   Sun GY, 1995, PROG BRAIN RES, V105, P231
   Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7
   Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002
   Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2
   WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404
   Yagami T, 2002, J NEUROCHEM, V81, P449, DOI 10.1046/j.1471-4159.2002.00800.x
   Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114
   Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x
   Yoshikawa T, 2001, J HISTOCHEM CYTOCHEM, V49, P777, DOI 10.1177/002215540104900611
NR 48
TC 51
Z9 56
U1 4
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD FEB 23
PY 2007
VL 1134
IS 1
BP 199
EP 205
DI 10.1016/j.brainres.2006.11.080
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 142GZ
UT WOS:000244638700023
PM 17204250
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Allert, M
   Dwyer, MA
   Hellinga, HW
AF Allert, Malin
   Dwyer, Mary A.
   Hellinga, Homme W.
TI RETRACTED: Local encoding of computationally designed enzyme activity
   (Retracted article. See vol 378, pg 759, 2008)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE protein design; enzyme design; triose phosphate; isomerase; periplasmic
   binding proteins
ID LIGAND-BINDING SITES; TRIOSEPHOSPHATE ISOMERASE; ESCHERICHIA-COLI;
   DIHYDROXYACETONE PHOSPHATE; CATALYTIC ANTIBODIES; TRANSITION-STATE;
   PROTEINS; CONSTRUCTION; EVOLUTION; RECEPTOR
AB One aim of computational protein design is to introduce novel enzyme activity into proteins of known structure by predicting mutations that stabilize transition states. Previously, we showed that it is possible to introduce triose phosphate isomerase activity into the ribose-binding protein of Escherichia coli by constructing 17 mutations in the first two layers of residues that surround the wild-type ligand-binding site. Here, we report that these mutations can be "transplanted" into a homologous ribose-binding protein, isolated from the hyperthermophilic bacterium Thermoanaerobacter tengcongensis, with retention of catalytic activity, substrate affinity, and reaction pH dependence. The observed 10(5)-10(6)-fold rate enhancement corresponds to 70% of the maximally known transition-state binding energy. The wild-type sequences in these two homologues are almost perfectly conserved in the vicinity of their ribose-binding sites, but diverge significantly at increasing distance from these sites. The results demonstrate that the computationally designed mutations are sufficient to encode the observed enzyme activity, that all the observed activity is encoded locally within the layer of residues directly in contact with the substrate and that, in this case, at least 70% of transition state stabilization energy can be achieved using straightforward considerations of stereochemical complementarity between enzyme and reactants. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Pharmacol & Mol Canc Biol, Durham, NC 27710 USA.
RP Hellinga, HW (reprint author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.
EM hwh@biochem.duke.edu
FU NIH HHS [5 DP1 OD 000122-02, DP1 OD000122]
CR Allert M, 2004, P NATL ACAD SCI USA, V101, P7907, DOI 10.1073/pnas.0401309101
   Ashworth J, 2006, NATURE, V441, P656, DOI 10.1038/nature04818
   Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302
   Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515
   Boehr DD, 2006, SCIENCE, V313, P1638, DOI 10.1126/science.1130258
   Bolon DN, 2001, P NATL ACAD SCI USA, V98, P14274, DOI 10.1073/pnas.251555398
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   COLLINS KD, 1974, J BIOL CHEM, V249, P136
   Cui Q, 2001, J AM CHEM SOC, V123, P2284, DOI 10.1021/ja002886c
   Daniel RM, 2003, ANNU REV BIOPH BIOM, V32, P69, DOI 10.1146/annurev.biophys.32.110601.142445
   De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860
   Dwyer MA, 2004, CURR OPIN STRUC BIOL, V14, P495, DOI 10.1016/j.sbi.2004.07.004
   Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432
   Dwyer MA, 2003, P NATL ACAD SCI USA, V100, P11255, DOI 10.1073/pnas.2032284100
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105
   Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0
   Fersht A., 1999, STRUCTURE MECH PROTE, P103
   FRAENKEL DG, 1986, ANNU REV BIOCHEM, V55, P317, DOI 10.1146/annurev.biochem.55.1.317
   Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172
   Guallar V, 2004, J MOL BIOL, V337, P227, DOI 10.1016/j.jmb.2003.11.016
   Gutteridge A, 2005, TRENDS BIOCHEM SCI, V30, P622, DOI 10.1016/j.tibs.2005.09.006
   HALL A, 1975, BIOCHEMISTRY-US, V14, P4348, DOI 10.1021/bi00690a032
   Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839
   Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/10399710290038972
   HELLINGA HW, 1991, J MOL BIOL, V222, P763, DOI 10.1016/0022-2836(91)90510-D
   HELLINGA HW, 1991, J MOL BIOL, V222, P787, DOI 10.1016/0022-2836(91)90511-4
   Hilvert D, 2000, ANNU REV BIOCHEM, V69, P751, DOI 10.1146/annurev.biochem.69.1.751
   JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021
   Jogl G, 2003, P NATL ACAD SCI USA, V100, P50, DOI 10.1073/pnas.0233793100
   JOSEPHMCCARTHY D, 1994, BIOCHEMISTRY-US, V33, P2824, DOI 10.1021/bi00176a011
   KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0
   KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005
   KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903
   LODI PJ, 1994, BIOCHEMISTRY-US, V33, P2809, DOI 10.1021/bi00176a009
   LOEWENTHAL R, 1993, J MOL BIOL, V232, P574, DOI 10.1006/jmbi.1993.1412
   Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556
   Mader MM, 1997, CHEM REV, V97, P1281, DOI 10.1021/cr960435y
   Marvin JS, 2001, NAT STRUCT BIOL, V8, P795, DOI 10.1038/nsb0901-795
   Midelfort KS, 2004, J MOL BIOL, V343, P685, DOI 10.1016/j.jmb.2004.08.019
   Millet O, 2003, P NATL ACAD SCI USA, V100, P12700, DOI 10.1073/pnas.2134311100
   MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L
   NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5939, DOI 10.1021/bi00416a018
   Park HS, 2006, SCIENCE, V311, P535, DOI 10.1126/science.1118953
   Pinto AL, 1997, P NATL ACAD SCI USA, V94, P5562, DOI 10.1073/pnas.94.11.5562
   PLAUT B, 1972, BIOCHEM J, V129, P311, DOI 10.1042/bj1290311
   RICHARD JP, 1985, BIOCHEMISTRY-US, V24, P949, DOI 10.1021/bi00325a021
   RIEDER SV, 1959, J BIOL CHEM, V234, P1007
   Segel I. H., 1975, ENZYME KINETICS, P18
   Stevenson JD, 2000, NAT PROD REP, V17, P535, DOI 10.1039/b006389o
   Torrance JW, 2005, J MOL BIOL, V347, P565, DOI 10.1016/j.jmb.2005.01.044
   Wang L, 2006, BIOCHEMISTRY-US, V45, P1383, DOI 10.1021/bi0518242
   Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i
NR 53
TC 10
Z9 11
U1 3
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD FEB 23
PY 2007
VL 366
IS 3
BP 945
EP 953
DI 10.1016/j.jmb.2006.12.002
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 137LS
UT WOS:000244294700021
PM 17196220
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Banerjee, S
   Zhang, YX
   Wang, ZW
   Che, MX
   Chiao, PJ
   Abbruzzese, JL
   Sarkar, FH
AF Banerjee, Sanjeev
   Zhang, Yuxiang
   Wang, Zhiwei
   Che, Mingxin
   Chiao, Paul J.
   Abbruzzese, James L.
   Sarkar, Fazlul H.
TI RETRACTED: In vitro and in vivo molecular evidence of genistein action
   in augmenting the efficacy of cisplatin in pancreatic cancer (Retracted
   article.See vol.139, pg.2145,2016)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE pancreatic cancer cells; orthotopic model; cisplatin; genistein
ID FACTOR-KAPPA-B; SOY ISOFLAVONE GENISTEIN; CARCINOMA-CELLS;
   CHEMOTHERAPEUTIC-AGENTS; CHEMOPREVENTIVE AGENTS; TRANSCRIPTION FACTOR;
   INCREASED APOPTOSIS; ORTHOTOPIC MODEL; DOWN-REGULATION; INHIBITION
AB We recently reported the potential of genistein in augmenting gemcitabine-induced killing of pancreatic cancer (Banerjee, S. et al., Cancer Research 2005;65:9064-72). Since cis-diaminedi-chloroplatinum (11) (cisplatin) is widely used against solid tumors, we further investigated whether genistein pretreatment could be used as a novel strategy for cisplatin-induced killing of pancreatic cancer cells in vitro and enhanced antitumor activity in vivo. Our in vitro results showed that pretreatment of cells with genistein followed by cisplatin resulted in significant loss of cell viability and potentiated apoptosis irrespective of the metastatic ability of cells. Mechanistically, genistein augmented cisplatin induced killing by down regulating transcription factor- NF-kappa B and anti-apoptotic Akt expression. NF-kappa B was found upregulated when pancreatic cancer cells were exposed to cisplatin, suggesting the potential mechanism of acquired chemo-resistance. In addition, we also showed, for the first time, that genistein in combination with cisplatin is more effective antitumor agent in our orthotopic tumor model. But most importantly, our data also showed that a specific target, such as NF-kappa B, was inactivated in animal tumors treated with genistein and cisplatin. Immunohistochemical data showed reduced staining for phospho-p65, Bcl-xL and MMP-9 in treated tumors compared to control tumors, but the lowest activity was seen in the combination group. These results provide strong molecular in vivo evidence in support of our hypothesis that inactivation of the NF-kappa B signaling pathway by genistein results in the chemo-sensitization of pancreatic tumors to cisplatin, which is likely to be an important and novel strategy for the treatment of pancreatic cancer. (c) 2006 Wiley-Liss, Inc.
C1 Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, 110 E Warren, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [1R01CA101870-03]
CR ADLERCREUTZ CHT, 1995, J NUTR, V125, pS757, DOI 10.1093/jn/125.3_Suppl.757S
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Alhasan SA, 1999, NUTR CANCER, V34, P12, DOI 10.1207/S15327914NC340102
   Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168
   Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330
   Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949
   BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S
   Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020
   Bharti AC, 2002, ANN NY ACAD SCI, V973, P392, DOI 10.1111/j.1749-6632.2002.tb04671.x
   Bondar VM, 2002, MOL CANCER THER, V1, P989
   Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005
   Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585
   Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0
   Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914
   Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730
   El-Rayes BF, 2003, CANCER INVEST, V21, P73, DOI 10.1081/CNV-120016406
   Fahy BN, 2004, J AM COLL SURGEONS, V198, P591, DOI 10.1016/j.jamcollsurg.2003.12.005
   Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037
   Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323
   Fujioka S, 2003, CLIN CANCER RES, V9, P346
   Gatti L, 2005, METH MOLEC MED, V111, P127
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hillman GG, 2004, MOL CANCER THER, V3, P1271
   HUANG JM, 1992, J BIOL CHEM, V267, P15511
   Khoshyomn S, 2000, PEDIATR NEUROSURG, V33, P123, DOI 10.1159/000028993
   Kim D, 2005, FRONT BIOSCI-LANDMRK, V10, P975, DOI 10.2741/1592
   Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650
   Li YW, 1999, INT J ONCOL, V15, P525
   Li YW, 2004, PANCREAS, V28, pE90, DOI 10.1097/00006676-200405000-00020
   Li YW, 2004, NEOPLASIA, V6, P354, DOI 10.1593/neo.03478
   Li YW, 2002, CLIN CANCER RES, V8, P2369
   Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X
   Lockhart AC, 2005, GASTROENTEROLOGY, V128, P1642, DOI 10.1053/j.gastro.2005.03.039
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   Marverti G, 1996, CLIN CANCER RES, V2, P991
   Mohammad RM, 2003, MOL CANCER THER, V2, P1361
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Ng SSW, 2000, CANCER RES, V60, P5451
   NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R
   OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5
   Papazisis KT, 2006, CANCER LETT, V233, P255, DOI 10.1016/j.canlet.2005.03.022
   Perego P, 1997, APOPTOSIS, V2, P540, DOI 10.1023/A:1026442716000
   Ravindranath MH, 2004, ADV EXP MED BIOL, V546, P121
   Sarkar FH, 2004, MUTAT RES-FUND MOL M, V555, P53, DOI 10.1016/j.mrfmmm.2004.04.015
   Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396
   Tamura S, 2003, PIGM CELL RES, V16, P470, DOI 10.1034/j.1600-0749.2003.00068.x
   Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998
   Wang CY, 1999, NAT MED, V5, P412
   Wang WX, 1999, CLIN CANCER RES, V5, P119
   West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6
NR 53
TC 68
Z9 73
U1 3
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 15
PY 2007
VL 120
IS 4
BP 906
EP 917
DI 10.1002/ijc.22332
PG 12
WC Oncology
SC Oncology
GA 129BT
UT WOS:000243704100025
PM 17131310
DA 2018-12-27
ER

PT J
AU Kumar, KS
   Suvardhan, K
   Krishnaiah, L
   Rekha, D
   Kiran, K
   Janardhanam, K
   Jayaraj, B
   Chiranjeevi, P
AF Kumar, K. Suresh
   Suvardhan, K.
   Krishnaiah, L.
   Rekha, D.
   Kiran, K.
   Janardhanam, K.
   Jayaraj, B.
   Chiranjeevi, P.
TI RETRACTED: Development of novel reactions for the simple and sensitive
   spectrophotometric determination of vanadium in various samples
   (Retracted Article. See vol 75, pg 1146, 2008)
SO TALANTA
LA English
DT Article; Retracted Publication
DE vanadium(V); 4-aminoantipyrine; dopamine hydrochloride; NEDA;
   spectrophotometry; pharmaceutical; synthetic; environmental and
   biological samples
ID FLOW-INJECTION DETERMINATION; CATALYTIC DETERMINATION; TRACE VANADIUM;
   BROMATE; OXIDATION; PRECONCENTRATION; COMPLEX; WATER; ACID
AB Development of novel reactions for rapid, sensitive and selective spectrophotometric determination of trace amounts of vanadium(V) was studied. The methods are based on either the oxidation of 4-aminoantipyrine (4-AAP) by vanadium in acidic medium (pH 3) and coupling with N-(1-naphthyl)ethylenediamine dihydrochloride (NEDA) to give violet color derivative or on the oxidation of dopamine hydrochloride (DPH) by vanadium in acidic medium and coupling with 4-AAP to yield red color derivative. The violet color derivative having an absorbance maximum at 565 nm is stable for 2 days and the red color derivative with gimel(max) 494 nm for 9 days. Beer's law is obeyed for vanadium in the concentration range 0.025-4.5 mu g ml(-1) (violet color derivative) and 0.045-5.0 mu g ml(-1) (red color derivative), respectively. The optimum reaction conditions and other important analytical parameters were established. Interference due to various non-target ions was also investigated. The proposed methods were applied to the analysis of vanadium(V) in pharmaceutical, synthetic, environmental and biological samples. The performance of proposed method was evaluated in terms of Student's t-test and variance ratio F-test, which indicates the significance of proposed method over reported method. (c) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Environm Sci, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR ABBASI SA, 1987, ANAL LETT, V20, P1347
   Agnihotri N, 1999, ANAL SCI, V15, P1261, DOI 10.2116/analsci.15.1261
   Ahmed MJ, 1999, TALANTA, V48, P1085, DOI 10.1016/S0039-9140(98)00329-4
   *APHA, 1995, STAND METH EX WAT WA, P3
   Coetzee PP, 2002, WATER SA, V28, P37
   Ensafi AA, 1997, FRESEN J ANAL CHEM, V358, P480, DOI 10.1007/s002160050450
   GLICK D, 1973, METHOD BIOCHEM ANAL, V21, P39
   HELMUT H, 1976, METAL IONS BIOL SYST, V6
   HIRAYAMA K, 1981, NIPPON KAGAKU KAISHI, P98, DOI 10.1246/nikkashi.1981.98
   HWANG JM, 1985, J CHIN CHEM SOC-TAIP, V32, P405, DOI 10.1002/jccs.198500063
   Itoh A, 1998, BUNSEKI KAGAKU, V47, P109
   JACKSON ML, 1987, SOIL CHEM ANAL, P326
   KOLTHOFF IM, 1971, TREATISE ANAL CHEM 3, V2, P89
   Kumar TNK, 2005, J IRAN CHEM SOC, V2, P161
   MARCZENKO Z, 1986, SEPARATION SPECTROPH, P627
   Mohamed AA, 2000, ANAL SCI, V16, P151, DOI 10.2116/analsci.16.151
   Mohamed AA, 2001, ANAL SCI, V17, P769, DOI 10.2116/analsci.17.769
   MOTTOLA HA, 1989, ANAL CHEM, V66, pR131
   Nakano S, 2003, TALANTA, V61, P203, DOI 10.1016/S0039-9140(03)00241-8
   PATEL B, 1990, ANALYST, V115, P1063, DOI 10.1039/an9901501063
   PATTY FA, 1963, IND HYGIENE TOXICOLO, V2, P1171
   PAUL KKR, 1982, AM IND HYG ASSOC J, V43, P529, DOI 10.1080/15298668291410152
   QIUFEN H, 2004, B KOREAN CHEM SOC, V25, P263
   Seaborn Carol D., 1991, Magnesium and Trace Elements, V10, P327
   Shiobara T, 1999, TALANTA, V49, P1083, DOI 10.1016/S0039-9140(99)00020-X
   Sikalos TS, 2000, MIKROCHIM ACTA, V135, P197, DOI 10.1007/s006040070011
   TAYLOR MJC, 1994, ANALYST, V119, P1263, DOI 10.1039/an9941901263
   Varma RL, 2000, CHEM ANAL-WARSAW, V45, P745
   Wuilloud RG, 2000, SPECTROCHIM ACTA B, V55, P671, DOI 10.1016/S0584-8547(00)00215-9
   YAMANE T, 1980, ANAL CHIM ACTA, V119, P389, DOI 10.1016/S0003-2670(01)93642-6
   YAMASHIGE T, 1989, ANALYST, V114, P1071, DOI 10.1039/an9891401071
NR 31
TC 6
Z9 6
U1 3
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD FEB 15
PY 2007
VL 71
IS 2
BP 588
EP 595
DI 10.1016/j.talanta.2006.04.037
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 138NO
UT WOS:000244369600012
PM 19071345
DA 2018-12-27
ER

PT J
AU Dressman, HK
   Berchuck, A
   Chan, G
   Zhai, J
   Bild, A
   Sayer, R
   Cragun, J
   Clarke, J
   Whitaker, RS
   Li, LH
   Gray, J
   Marks, J
   Ginsburg, GS
   Potti, A
   West, M
   Nevins, JR
   Lancaster, JM
AF Dressman, Holly K.
   Berchuck, Andrew
   Chan, Gina
   Zhai, Jun
   Bild, Andrea
   Sayer, Robyn
   Cragun, Janiel
   Clarke, Jennifer
   Whitaker, Regina S.
   Li, LiHua
   Gray, Jonathan
   Marks, Jeffrey
   Ginsburg, Geoffrey S.
   Potti, Anil
   West, Mike
   Nevins, Joseph R.
   Lancaster, Johnathan M.
TI RETRACTED: An integrated genomic-based approach to individualized
   treatment of patients with advanced-stage ovarian cancer (Retracted
   article. See vol. 30, pg. 678, 2012)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION PROFILES; GYNECOLOGIC-ONCOLOGY-GROUP; TUMOR-SUPPRESSOR
   GENE; CDNA MICROARRAY; P53 MUTATIONS; CHEMOTHERAPY; SURVIVAL; ARRAY;
   CARCINOMA; PATTERNS
AB Purpose
   The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease.
   Patients and Methods
   A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample external validation set. In parallel, expression signatures that define the status of oncogenic signaling pathways were evaluated in 119 primary ovarian cancers and 12 ovarian cancer cell lines. In an effort to increase chemotherapy sensitivity, pathways shown to be activated in platinum-resistant cancers were subject to targeted therapy in ovarian cancer cell lines.
   Results
   Gene expression profiles identified patients with ovarian cancer likely to be resistant to primary platinum-based chemotherapy with greater than 80% accuracy. In patients with platinum-resistant disease, we identified expression signatures consistent with activation of Src and Rb/E2F pathways, components of which were successfully targeted to increase response in ovarian cancer cell lines.
   Conclusion
   We have defined a strategy for treatment of patients with advanced-stage ovarian cancer that uses therapeutic stratification based on predictions of response to chemotherapy, coupled with prediction of oncogenic pathway deregulation, as a method to direct the use of targeted agents.
C1 H Lee Moffitt Canc Ctr & Res Inst, Div Gynecol Surg Oncol, Tampa, FL 33612 USA.
   H Lee Moffitt Canc Ctr & Res Inst, Div Canc Prevent & Control, Tampa, FL 33612 USA.
   Duke Univ, Med Ctr, Inst Genome Sci & Policy, Dept Mol Genet & Microbiol, Durham, NC USA.
   Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC USA.
   Duke Univ, Med Ctr, Dept Surg, Durham, NC USA.
   Duke Univ, Med Ctr, Dept Med, Durham, NC USA.
   Duke Univ, Inst Stat & Decis Sci, Durham, NC 27706 USA.
   Univ Wales Hosp, Inst Med Genet, Cardiff CF4 4XW, S Glam, Wales.
RP Lancaster, JM (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Div Gynecol Surg Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM lancasjm@moffitt.usf.edu
OI Clarke, Jennifer/0000-0002-2723-7249
CR BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246
   Berchuck A, 2004, AM J OBSTET GYNECOL, V190, P910, DOI 10.1016/j.ajog.2004.02.005
   Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Havrilesky LJ, 2001, GYNECOL ONCOL, V83, P491, DOI 10.1006/gyno.2001.6464
   Helleman J, 2006, INT J CANCER, V118, P1963, DOI 10.1002/ijc.21599
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990
   Jazaeri AA, 2005, CLIN CANCER RES, V11, P6300, DOI 10.1158/1072-0432.CCR-04-2682
   JODRELL DI, 1992, J CLIN ONCOL, V10, P520, DOI 10.1200/JCO.1992.10.4.520
   KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513
   Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004
   LEVIN L, 1993, J NATL CANCER I, V85, P1732, DOI 10.1093/jnci/85.21.1732
   LUCUS J, 2006, SPARSE STAT MODELING
   McGuire WP, 1999, ANN ONCOL, V10, P29, DOI 10.1023/A:1008303300675
   MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589
   McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   Ono K, 2000, CANCER RES, V60, P5007
   Piccart MJ, 2003, INT J GYNECOL CANCER, V13, P144, DOI 10.1111/j.1525-1438.2003.13357.x
   Reles A, 2001, CLIN CANCER RES, V7, P2984
   Rustin GJS, 1996, J CLIN ONCOL, V14, P1545, DOI 10.1200/JCO.1996.14.5.1545
   Rustin GJS, 1999, ANN ONCOL, V10, P21, DOI 10.1023/A:1008351216605
   Sawiris GP, 2002, CANCER RES, V62, P2923
   Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279
   Schmider A, 2000, GYNECOL ONCOL, V77, P237, DOI 10.1006/gyno.2000.5748
   Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X
   Shridhar V, 2001, CANCER RES, V61, P5895
   Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070
   Spentzos D, 2005, J CLIN ONCOL, V23, P7911, DOI 10.1200/JCO.2005.02.9363
   Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176
   Wenham RM, 2002, BEST PRACT RES CL OB, V16, P483, DOI 10.1053/beog.2002.0298
   Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05
NR 34
TC 198
Z9 201
U1 5
U2 25
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 10
PY 2007
VL 25
IS 5
BP 517
EP 525
DI 10.1200/JCO.2006.06.3743
PG 9
WC Oncology
SC Oncology
GA 135TI
UT WOS:000244176000010
PM 17290060
DA 2018-12-27
ER

PT J
AU Fukuba, H
   Yamashita, H
   Nagano, Y
   Jin, HG
   Hiji, M
   Ohtsuki, T
   Takahashi, T
   Kohriyama, T
   Matsumoto, M
AF Fukuba, Hiromasa
   Yamashita, Hiroshi
   Nagano, Yoshito
   Jin, Hong Guo
   Hiji, Masanori
   Ohtsuki, Toshiho
   Takahashi, Tetsuya
   Kohriyama, Tatsuo
   Matsumoto, Masayasu
TI RETRACTED: Siah-1 facilitates lubiquitination and degradation of factor
   inhibiting HIF-1 alpha (FIH) (Retracted article. See vol. 388, pg. 618,
   2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Siah-1; factor inhibiting HIF-1 alpha (FIH); hypoxia-inducible factor
   (HIF)-1 alpha; ubiquitin ligase; ubiquitin-proteasome system; hypoxia
ID HYPOXIA-INDUCIBLE FACTOR; TRANSCRIPTIONAL ACTIVITY; FACTOR HIF;
   HYDROXYLATION; ALPHA; PROTEIN; O-2; VHL
AB Hypoxia-inducible factor-1 alpha (HIF-1 alpha) has a central role in neuroprotective responses to hypoxia in the brain. Hydroxylation of HIF-1 alpha by prolyl-hydroxylase PHD and aspargynyl-hydroxylase FIH (factor inhibiting HIF-1 alpha) causes proteasomal degradation and transcriptional inhibition of HIF-1 alpha. Siah ubiquitin ligases regulate the abundance of PHD via targeting for proteasomal degradation. The present study identified Siah-1 as a binding partner for another hydroxylase FIH. Siah-1 and FIH coimmunoprecipitated each other in mammalian cells. Siah-1 was found both to interact with the JmjC domain of FIH through its substrate-binding domain and to specifically ubiquitinate FIH via its RING finger domain. Siah-1 facilitated FIH degradation via the ubiquitin-proteasome pathway under hypoxic conditions. Such findings suggest that Siah ubiquitin ligases might play a role as up-stream regulators of both hydroxylases for HIF-1 alpha, i.e., PHD and FIH, by targeting them for proteasomal degradation, leading to increased HIF-1 alpha abundance, and transcriptional activity in hypoxia. (c) 2006 Elsevier Inc. All rights reserved.
C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosc & Therapeut, Hiroshima 7348551, Japan.
RP Yamashita, H (reprint author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosc & Therapeut, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM t-yamashiht@hpli.pref.hiroshima.jp
OI NAGANO, YOSHITO/0000-0002-7974-4824
CR Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jin HG, 2006, NEUROSCI LETT, V408, P62, DOI 10.1016/j.neulet.2006.08.038
   Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200
   Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253
   Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001
   Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9
   Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408
   Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200
   Yamashita H, 2006, J NEUROCHEM, V98, P45, DOI 10.1111/j.1471-4159.2006.03815.x
NR 14
TC 24
Z9 29
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 9
PY 2007
VL 353
IS 2
BP 324
EP 329
DI 10.1016/j.bbrc.12.051
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 126VH
UT WOS:000243543100017
PM 17188242
DA 2018-12-27
ER

PT J
AU Rekha, D
   Suvardhan, K
   Kumar, KS
   Subrahmanyam, P
   Jayaraj, B
   Naidu, GR
   Chiranjeevi, P
AF Rekha, D.
   Suvardhan, K.
   Kumar, K. Suresh
   Subrahmanyam, P.
   Jayaraj, B.
   Naidu, G. Ramakrishna
   Chiranjeevi, P.
TI RETRACTED: Spectrophotometric determination of V(V) in environmental,
   biological, pharmaceutical and alloy samples by novel oxidative coupling
   reactions (Retracted Article. See vol 152, pg 1340, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE vanadium (V); 4-bromophenyl hydrazine (4-BPH); N-(1-naphthyl
   ethylenediamine dihydrochloride (NEDA); chromotropic acid (CA);
   spectrophotometry; environmental; biological; pharmaceutical and steel
   samples
ID NATURAL-WATERS; TRACE AMOUNTS; VANADIUM; EXTRACTION; CHROMATOGRAPHY;
   SPECTROMETRY; SEPARATION; SPECIATION; BROMATE
AB A Novel, rapid, sensitive and selective reactions are developed for spectrophotometric determination of trace amounts of vanadium (V) in environmental, biological, pharmaceutical and alloy samples was studied. The methods were based on interactions of 4-bromophenyl hydrazine (4-BPH) with N-(1-naphthyl ethylenediamine dihydrochloride (NEDA) in the presence of vanadium in acidic medium (acetate buffer of pH 3.0) to give violet colored derivative or on the oxidation of 4-bromophenyl hydrazine by vanadium in basic medium and coupling with chromotropic acid (CA) to yield red color derivative. The violet color derivative having an absorbance maximum at 570 nm which is stable for 7 days and the red derivative with lambda(max) 495 nm for 5 days. Beer's law was obeyed for vanadium in the concentration range of 0.5-6.0 mu g ml(-1) (violet derivative) and 0.6-7.0 mu g ml(-1) (red derivative), respectively. The optimum reaction conditions and other important analytical parameters were established to enhance the sensitivity of the proposed methods. Interference due to various non-target ions was also investigated. The proposed methods were applied to the analysis of vanadium (V) in environmental, biological, pharmaceutical and steel samples. The performance of proposed methods were evaluated in terms of Student's t-test and Variance ratio F-test that indicates the significance of proposed methods over reported method. (c) 2006 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Environm Sci, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevipattium@gmail.com
CR Bosque-Sendra JM, 1998, FRESEN J ANAL CHEM, V360, P31, DOI 10.1007/s002160050637
   CHAKRABORTY R, 1994, FRESEN J ANAL CHEM, V349, P774, DOI 10.1007/BF00325657
   CHAUHAN RS, 1992, B CHEM SOC JPN, V65, P1033, DOI 10.1246/bcsj.65.1033
   Coetzee PP, 2002, WATER SA, V28, P37
   DEBEER H, 1994, FRESEN J ANAL CHEM, V348, P806, DOI 10.1007/BF01780981
   DUPONT V, 1991, ANAL CHEM, V63, P520, DOI 10.1021/ac00005a026
   Ensafi AA, 1997, FRESEN J ANAL CHEM, V358, P480, DOI 10.1007/s002160050450
   GLICK D, 1973, METHOD BIOCHEM ANAL, V21, P39
   Hu QF, 2004, B KOR CHEM SOC, V25, P263
   IRANPOOR N, 1992, TALANTA, V39, P281, DOI 10.1016/0039-9140(92)80033-A
   KAWAKUBO S, 1995, ANALYST, V120, P2719, DOI 10.1039/an9952002719
   Kumar TNK, 2005, J IRAN CHEM SOC, V2, P161
   MIURA J, 1990, ANAL CHEM, V62, P1424, DOI 10.1021/ac00213a015
   MURTHY GVR, 1989, ANALYST, V114, P493, DOI 10.1039/an9891400493
   Nakano S, 2003, TALANTA, V61, P203, DOI 10.1016/S0039-9140(03)00241-8
   SERRAT FB, 1996, FRESENIUS J ANAL CHI, V349, P717
   Taylor MJC, 1996, ANAL CHIM ACTA, V329, P275, DOI 10.1016/0003-2670(96)00123-7
   UNDERWOOD JE, 1977, TRACE ELEMENTS HUMAN, P314
   YAMAN M, 1994, FRESEN J ANAL CHEM, V350, P504, DOI 10.1007/BF00321796
   Zucchi C, 1998, FRESEN J ANAL CHEM, V360, P128, DOI 10.1007/s002160050658
NR 20
TC 4
Z9 4
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD FEB 9
PY 2007
VL 140
IS 1-2
BP 180
EP 186
DI 10.1016/j.jhazmat.2006.06.061
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 138KW
UT WOS:000244362500020
PM 16872742
DA 2018-12-27
ER

PT J
AU Johnston, CA
   Siderovski, DP
AF Johnston, Christopher A.
   Siderovski, David P.
TI RETRACTED: Structural basis for nucleotide exchange on G alpha(i)
   subunits and receptor coupling specificity (Retracted article. See vol.
   109, pg. 1808, 2012)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE G protein-coupled receptors; guanine nucleotide exchange; heterotrimeric
   G proteins
ID G PROTEIN INTERACTIONS; HETEROTRIMERIC G-PROTEINS; DOPAMINE-RECEPTOR;
   ALPHA-SUBUNIT; CONFORMATIONAL-CHANGES; CARBOXYL-TERMINUS;
   CRYSTAL-STRUCTURE; ACTIVATION; RHODOPSIN; BINDING
AB Heterotrimeric G proteins are molecular switches that relay information intracellularly in response to various extracellular signals. How ligand-activated G protein-coupled receptors act at a distance to exert exchange activity on the Ga nucleotide binding pocket is poorly understood. Here we describe the synergistic action of two peptides: one from the third intracellular loop of the D2 dopamine receptor (NN), and a second, Ga-GDP-binding peptide (KB-752) that mimics the proposed role of G beta gamma in receptor-promoted nucleotide exchange. The structure of both peptides in complex with G(alpha i1) suggests that conformational changes in the beta 3/alpha 2 loop and 136 strand act in concert for efficient nucleotide exchange. Two key residues in the alpha 4 helix were found to define a receptor/G(alpha i) coupling specificity determinant.
C1 Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Ctr Neurosci, Chapel Hill, NC 27599 USA.
RP Siderovski, DP (reprint author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 ME Jones Bldg,Manning Dr, Chapel Hill, NC 27599 USA.
EM dsiderov@med.unc.edu
FU NIGMS NIH HHS [R01 GM074268, F32 GM076944]
CR Afshar K, 2004, CELL, V119, P219, DOI 10.1016/j.cell.2004.09.026
   Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963
   Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071
   Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3
   Chung DA, 2002, BIOCHEMISTRY-US, V41, P3596, DOI 10.1021/bi015811+
   Damian M, 2006, EMBO J, V25, P5693, DOI 10.1038/sj.emboj.7601449
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921
   Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798
   Holler C, 1999, CELL MOL LIFE SCI, V55, P257, DOI 10.1007/s000180050288
   IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0
   Johnston CA, 2005, STRUCTURE, V13, P1069, DOI 10.1016/j.str.2005.04.007
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kazmi MA, 2000, BIOCHEMISTRY-US, V39, P3734, DOI 10.1021/bi992354c
   Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200
   LIRI T, 1998, NATURE, V394, P35
   McCudden CR, 2005, CELL MOL LIFE SCI, V62, P551, DOI 10.1007/s00018-004-4462-3
   Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+
   Mukhopadhyay S, 2002, METHOD ENZYMOL, V344, P350
   Nanoff C, 2006, MOL PHARMACOL, V69, P397, DOI 10.1124/mol.105.016725
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   Neve KA, 2004, J RECEPT SIG TRANSD, V24, P165, DOI 10.1081/LRST-200029981
   Newman-Tancredi A, 1999, MOL PHARMACOL, V55, P564
   Oldham WM, 2006, NAT STRUCT MOL BIOL, V13, P772, DOI 10.1038/nsmb1129
   Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752
   Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p
   Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103
   SENOGLES SE, 1990, J BIOL CHEM, V265, P4507
   Slessareva JE, 2003, J BIOL CHEM, V278, P50530, DOI 10.1074/jbc.M304417200
   Ulfers AL, 2002, PROTEIN SCI, V11, P2526, DOI 10.1110/ps.0218402
   Van Eps N, 2006, P NATL ACAD SCI USA, V103, P16194, DOI 10.1073/pnas.0607972103
   VOSS T, 1993, J BIOL CHEM, V268, P4637
   Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379
   Zhang Y, 2006, PLOS COMPUT BIOL, V2, P88, DOI 10.1371/journal.pcbi.0020013
NR 39
TC 30
Z9 35
U1 2
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 6
PY 2007
VL 104
IS 6
BP 2001
EP 2006
DI 10.1073/pnas.0608599104
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 135BD
UT WOS:000244127900049
PM 17264214
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU An, Z
   Wu, YL
   Lin, F
   Zhu, L
AF An, Zhe
   Wu, Yan-Li
   Lin, Feng
   Zhu, Ling
TI RETRACTED: Triaqua(1,10-phenanthroline) sulfatocopper(II) monohydrate
   (Retracted article. See vol. 67, pg. E16, 2011)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title compound, [Cu(SO(4))(C(12)H(8)N(2))(H(2)O)(3)]center dot H(2)O, the Cu(II) centre exhibits a slightly distorted cis-CuN(2)O(4) octahedral coordination defined by two N atoms from a 1,10-phenanthroline molecule, one O atom from a sulfato dianion and three O atoms from coordinated water molecules.
C1 Harbin Med Coll, Sch Pharmaceut Sci, Harbin 150086, Peoples R China.
RP Zhu, L (reprint author), Harbin Med Coll, Sch Pharmaceut Sci, Harbin 150086, Peoples R China.
EM zhuling0321@sohu.com
CR *BRUK, 1998, SMART SAINT SHELXTL
   Chen XM, 2002, CHEM-EUR J, V8, P4811, DOI 10.1002/1521-3765(20021018)8:20<4811::AID-CHEM4811>3.0.CO;2-R
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   Wang HY, 2007, ACTA CRYSTALLOGR E, V63, pM7, DOI 10.1107/S1600536806051087
   Xu L, 2003, INORG CHEM COMMUN, V6, P740, DOI 10.1016/S1387-7003(03)00055-8
   Yu CH, 2006, ACTA CRYSTALLOGR E, V62, pM1758, DOI 10.1107/S1600536806025840
NR 7
TC 3
Z9 3
U1 5
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2007
VL 63
BP M477
EP M478
DI 10.1107/S160053680700591
PN 2
PG 2
WC Crystallography
SC Crystallography
GA 150AF
UT WOS:000245187300089
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
   Li, ML
AF Zhong, H.
   Zeng, X. -R.
   Yang, X. -M.
   Luo, Q. -Y.
   Li, M. -L.
TI RETRACTED: (Dimethylglyoxime-kappa N-2,N ')
   bis(1,10-phenanthroline-kappa N-2,N ')nickel(II) dinitrate dihydrate
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID COMPLEX
AB In the molecule of the title compound, [Ni(Cl2H8N2)(2)(C4H8-N2O2)](NO3)(2)center dot 2H(2)O, the Ni atom has a distorted octahedral coordination formed by six N atoms from one dimethylglyoxime and two 1,10-phenanthroline ligands. In the crystal structure, molecules are linked into a three-dimensional framework by O-H center dot center dot center dot O hydrogen bonds and pi-pi stacking interactions.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Cervera B, 1997, J CHEM SOC DALTON, P395, DOI 10.1039/a604420d
   CHAUDHURI P, 1991, INORG CHEM, V30, P4777, DOI 10.1021/ic00025a019
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Pope M. T., 1983, HETEROPOLY ISOPOLY O
   Pope M. T., 2001, POLYOXOMETALATE CHEM
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELSX97 SHELXL97
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 14
TC 3
Z9 3
U1 4
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2007
VL 63
BP M639
EP M641
DI 10.1107/S1600536807004102
PN 2
PG 3
WC Crystallography
SC Crystallography
GA 150AF
UT WOS:000245187300152
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Yang, XM
   Luo, QY
   Li, ML
AF Zhong, H.
   Zeng, X. -R.
   Yang, X. -M.
   Luo, Q. -Y.
   Li, M. -L.
TI RETRACTED: Dimethylglyoxime-kappa(2) N,N ')
   bis(1,10-phenanthroline-kappa(2) N,N ') zinc(II) dinitrate dihydrate
   (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, [Zn(Cl2H8N2)(2)-(C4H8N2O2)](NO3)(2)center dot 2H(2)O, the Zn atom has a distorted octahedral coordination formed by six N atoms from one dimethylglyoxime and two 1,10-phenanthroline ligands. In the crystal structure, molecules are linked into a three-dimensional framework by O-H center dot center dot center dot O hydrogen bonds and pi-pi stacking interactions.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
   Jiangxi Univ Finance & Econ, Inst Appl Mat, Nanchang 330032, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SIANT SHELXTL
   Zhong H, 2007, ACTA CRYSTALLOGR E, V63, pM639, DOI 10.1107/S1600536807004102
NR 5
TC 5
Z9 5
U1 6
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2007
VL 63
BP M642
EP M644
DI 10.1107/S1600536807004096
PN 2
PG 3
WC Crystallography
SC Crystallography
GA 150AF
UT WOS:000245187300153
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Luo, QY
   Li, ML
   Xiao, SZ
AF Zhong, H.
   Zeng, X. -R.
   Luo, Q. -Y.
   Li, M. -L.
   Xiao, S. -Z.
TI RETRACTED: (8-Quinolinol-kappa N-2,O)bis(8-quinolinolato-kappa(2)
   N,O)-zinc(II) glyoxal hemisolvate monohydrate (Retracted article. See
   vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The Zn-II atom in the title complex, [Zn(C9H6NO)(2)-(C9H7NO)]center dot 0.5C(2)H(2)O(2)center dot H2O, exists in an octahedral coordination geometry defined by three O and three N atoms from three 8-hydroxyquinoline ligands. The glyoxal molecule lies on a centre of inversion. In the crystal structure, molecules are linked into a three-dimensional framework by O-H center dot center dot center dot O hydrogen bonds and pi-pi stacking interactions.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Prov Key Lab Coordinat, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   NAING K, 1995, INORG CHEM, V34, P350, DOI 10.1021/ic00105a054
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   POPE MT, 1983, HETEROPOLY ISOPOLY O, P125
   POPE MT, 2001, POLYOXOMETALATE CHEM, P319
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM, 1996, SMART SAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 13
TC 1
Z9 1
U1 6
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2007
VL 63
BP M492
EP M494
DI 10.1107/S1600536807001171
PN 2
PG 3
WC Crystallography
SC Crystallography
GA 150AF
UT WOS:000245187300095
DA 2018-12-27
ER

PT J
AU Gao, XJ
   Pang, PF
   Wu, SH
   Yang, WY
   Huang, SJ
   Cai, QY
   Grimes, CA
AF Gao, Xianjuan
   Pang, Pengfei
   Wu, Shihui
   Yang, Wenyue
   Huang, Sijing
   Cai, Qingyun
   Grimes, Craig A.
TI RETRACTED: Acid phosphatase assay with a wireless magnetoelastic
   biosensor (Retracted article. See vol. 40, pg. 3472, 2007)
SO ANALYTICAL LETTERS
LA English
DT Article; Retracted Publication
DE phosphatase; wireless; magnetoelastic; biosensor
ID ALKALINE-PHOSPHATASE; PROSTATE-CANCER; SERUM; IMMUNOASSAY; MEMBRANE;
   SENSORS
AB A wireless remote-query disposable magnetoelastic biosensor is developed for the assay of acid phosphatase (ACP). The sensor was fabricated by applying a layer of pH-sensitive polymer to a magnetoelastic ribbon and, on top of it, a sensing film containing bovine serum albumin and adenosine-5'-monophosphate (5'-AMP), the substrate of ACP. In response to an externally applied time-varying magnetic field, the magnetoelastic sensor mechanically vibrates at a characteristic frequency that is inversely dependent on the mass of the attached film. Because the magnetoelastic sensor is magnetostrictive, the mechanical vibrations of the sensor launch magnetic flux that can be detected remotely from the sensor using a pick-up coil. The ACP-catalyzed hydrolysis of 5'-AMP decreases the solution pH, resulting in the polymer shrinking and, consequently, the resonance frequency of the magnetoelastic sensor increasing. The experimental condition was optimized to be 37 degrees C, in 2.5 mM sodium citrate buffer solution (pH 6.5). Using citrate as buffer can enhance the ACP activity, partly offsetting the effect of the buffer capacity on the sensitivity. The kinetic parameter were measured to be: 1.64 x 10(-3) M ( Michaelis constant) and 130 Hz/min ( maximum initial rate). This work provides a remote enzymatic assay of ACP. The relative standard deviation in the measurements of six sensors in parallel is 3.4%. The proposed sensor can determine 0.2 similar to 1.2 U/ml of ACP.
C1 Hunan Univ, Dept Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China.
RP Cai, QY (reprint author), Hunan Univ, Dept Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China.
EM qycai0001@hnu.cn
CR BRONSTEIN I, 1989, CLIN CHEM, V35, P1441
   Cai QY, 2000, SENSOR ACTUAT B-CHEM, V71, P112, DOI 10.1016/S0925-4005(00)00599-2
   Cai QY, 1995, ANALYST, V120, P2833, DOI 10.1039/an9952002833
   Cai QY, 2004, ANAL CHEM, V76, P4038, DOI 10.1021/ac0498516
   Castanon-Fernandez J, 2000, ANAL CHIM ACTA, V406, P225, DOI 10.1016/S0003-2670(99)00772-2
   CHEUNG CK, 1995, CLIN CHEM, V41, P679
   Dulinska J, 2002, ACTA BIOCHIM POL, V49, P357
   EWA LW, 1996, ANAL BIOCHEM, V241, P167
   Gonnety JT, 2006, AFR J BIOTECHNOL, V5, P35
   Katsu T, 1996, ELECTROANAL, V8, P1101, DOI 10.1002/elan.1140081205
   Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066
   MATSUKURA H, 1988, J CHROMATOGR-BIOMED, V434, P196, DOI 10.1016/0378-4347(88)80075-6
   OSTROWSKI WS, 1994, CLIN CHIM ACTA, V226, P121, DOI 10.1016/0009-8981(94)90209-7
   Puckett LG, 2003, BIOSENS BIOELECTRON, V18, P675, DOI 10.1016/S0956-5663(03)00033-2
   Ruan CM, 2004, BIOSENS BIOELECTRON, V20, P585, DOI 10.1016/j.bios.2004.03.003
   Ruan CM, 2003, ANAL CHEM, V75, P6494, DOI 10.1021/ac034562n
   Schmidt S, 2001, SENSOR ACTUAT A-PHYS, V94, P189, DOI 10.1016/S0924-4247(01)00708-7
   Shankar K, 2005, SENSOR ACTUAT B-CHEM, V107, P640, DOI 10.1016/j.snb.2004.11.038
   Valimaki MJ, 2005, CLIN CHEM, V51, P2382, DOI 10.1373/clinchem.2005.055749
   VAUGHAN A, 1971, ANAL CHEM, V43, P721
   Veeramani S, 2005, ENDOCR-RELAT CANCER, V12, P805, DOI 10.1677/erc.1.00950
   WATANABE F, 1979, CLIN CHIM ACTA, V91, P273, DOI 10.1016/0009-8981(79)90483-2
   Yu F., 2001, TSINGHUA SCI TECHNOL, V6, P421
NR 23
TC 2
Z9 2
U1 5
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0003-2719
EI 1532-236X
J9 ANAL LETT
JI Anal. Lett.
PD FEB
PY 2007
VL 40
IS 3
BP 471
EP 482
DI 10.1080/00032710601017649
PG 12
WC Chemistry, Analytical
SC Chemistry
GA 120XR
UT WOS:000243120600006
DA 2018-12-27
ER

PT J
AU Raghavendra, PB
   Sreenivasan, Y
   Ramesh, GT
   Manna, SK
AF Raghavendra, Pongali B.
   Sreenivasan, Yashin
   Ramesh, Govindarajan T.
   Manna, Sunil K.
TI RETRACTED: Cardiac glycoside induces cell death via FasL by activating
   calcineurin and NF-AT, but apoptosis initially proceeds through
   activation of caspases (Retracted article. See vol. 18, pg. 910, 2013)
SO APOPTOSIS
LA English
DT Article; Retracted Publication
DE NF-AT; FasL; calcineurin; Bcl-xL; apoptosis
ID FACTOR-KAPPA-B; OLEANDRIN SUPPRESSES ACTIVATION; T-CELLS; NUCLEAR
   FACTOR; CYCLOSPORINE-A; POTENTIATES APOPTOSIS; SIGNALING PATHWAYS;
   LIGAND EXPRESSION; TRANSCRIPTION; RESISTANCE
AB Decrease in caspase activity is a common phenomenon in drug resistance. For effective therapeutic intervention, detection of such agents, which affects other pathway independent of caspases to promote cell death, might be important. Oleandrin, a polyphenolic glycoside induced cell death through activation of caspases in a variety of human tumour cells. In this report we provide evidence that besides caspases activation, oleandrin interacts with plasma membrane, changes fluidity of the membrane, disrupts Na+/K+-ATPase pump, enhances intracellular free Ca2+ and thereby activates calcineurin. Calcineurin, in turns, activates nuclear transcription factor NF-AT and its dependent genes such as FasL, which induces cell death as a late response of oleandrin. Cell death at early stages is mediated by caspases where inhibitors partially protected oleandrin-mediated cell death in vector-transfected cells, but almost completely in Bcl-xL-overexpressed cells. Overall, our data suggest that oleandrin might be important therapeutic molecule in case of tumors where cell death pathway occurs due to deregulation of caspase-mediated pathway
C1 Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.
   Texas So Univ, Dept Biol, Houston, TX 77004 USA.
RP Manna, SK (reprint author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.
EM manna@cdfd.org.in
FU NCRR NIH HHS [G12 RR003045-180001]
CR Abbasi S, 2005, J BIOL CHEM, V280, P36737, DOI 10.1074/jbc.M506493200
   Beltowski J, 2002, ACTA BIOCHIM POL, V49, P515
   Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102
   Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017
   Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100
   CHENG HO, 1998, IMMUNOLOGY, V95, P15537
   Contini P, 2005, J IMMUNOL, V175, P7244, DOI 10.4049/jimmunol.175.11.7244
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2
   EVELOFF J, 1979, J CELL BIOL, V83, P16, DOI 10.1083/jcb.83.1.16
   Goel A, 2005, EXP HEMATOL, V33, P784, DOI 10.1016/j.exphem.2005.04.005
   Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2
   GUPTA RS, 1986, J CELL PHYSIOL, V127, P197, DOI 10.1002/jcp.1041270202
   GUPTA RS, 1985, J BIOL CHEM, V260, P6843
   IYU D, 2004, CELL COMMUN SIGNAL, V2, P1, DOI DOI 10.1186/1478-811X-2-1
   Kingsbury TJ, 2000, GENE DEV, V14, P1595
   Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367
   Kondoh M, 2001, J HEALTH SCI, V47, P78, DOI 10.1248/jhs.47.78
   Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066
   Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003
   LIMA JE, 2003, HYPERTENSION, V41, P1386
   Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143
   Manna SK, 1997, J IMMUNOL, V159, P5042
   Manna SK, 2006, J CELL PHYSIOL, V207, P195, DOI 10.1002/jcp.20555
   Manna SK, 2000, CANCER RES, V60, P3838
   Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1
   Mueller T, 2003, CANCER RES, V63, P513
   Nakajima H, 1997, TRANSPLANT P, V29, P1096, DOI 10.1016/S0041-1345(96)00427-7
   Padilla LA, 2002, GYNECOL ONCOL, V85, P59, DOI 10.1006/gyno.2002.6604
   Padma S, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-7
   Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988
   Rusnak F, 2000, PHYSIOL REV, V80, P1483
   Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200
   Sata M, 1999, BIOCHEM BIOPH RES CO, V263, P430, DOI 10.1006/bbrc.1999.1392
   Sennesael JJ, 2005, TRANSPLANTATION, V80, P1578, DOI 10.1097/01.tp.0000184623.35773.6a
   Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6
   Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486
   Sreenivasan Y, 2003, BIOCHEM PHARMACOL, V66, P2223, DOI 10.1016/j.bcp.2003.07.010
   Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253
   WATTENBERG LW, 1990, ANTIMUTAGENESIS ANTI, V2, P155
   Williams D, 2006, ADV CHRONIC KIDNEY D, V13, P47, DOI 10.1053/j.ackd.2005.11.001
   Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963
   YASEEN NR, 1993, J BIOL CHEM, V268, P14285
   Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949
   Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2
NR 44
TC 37
Z9 39
U1 3
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
J9 APOPTOSIS
JI Apoptosis
PD FEB
PY 2007
VL 12
IS 2
BP 307
EP 318
DI 10.1007/s10495-006-0626-3
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 129YL
UT WOS:000243765900004
PM 17203245
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Yousef, GM
   Naghibi, B
AF Yousef, George M.
   Naghibi, Bibi
TI RETRACTED: Malakoplakia outside the urinary tract (Retracted article.
   See vol. 133, pg. 850, 2009)
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Review; Retracted Publication
ID MALAKOPLAKIA; INFECTION; PATIENT; ADENOCARCINOMA; MORPHOGENESIS;
   TUBERCULOSIS; NECK
AB Context.-Malakoplakia is a rare granulomatous disease that occurs commonly in the urinary tract. Histologically, it is defined by sheets of histiocytes (Hansemann cells) with accumulation of granular basophilic periodic acid-Schiff-positive, diastase-resistant inclusions and calcified Michaelis-Gutmann bodies, which are pathognomonic but not necessary for diagnosis. In addition to the urinary tract, malakoplakia has been reported in other organs, including the gastrointestinal tract, central nervous system, female genital tract, and the tongue.
   Objectives.-To review the literature of reported sites of malakoplakia outside the urinary tract and their variable clinical presentations, and to discuss the main diagnostic features and differential diagnoses of malakoplakia. The pathogenesis and possible etiologic factors are also presented.
   Data Sources.-Data for this work were collected from the published literature, textbooks, and the Internet.
   Conclusions.-It is important to be aware of the existence of this entity in abnormal locations. In many situations, malignancy can be mimicked, especially when the lesion is ulcerated and is accompanied by lymph node involvement. Misinterpreting large, rapidly growing nodules of malakoplakia as tumor might lead to overstaging. Pathologists should be also aware of the possibility of malakoplakia coexisting with other lesions, such as tuberculosis and carcinoma, in the same specimen.
C1 Eastern Hlth Discipline Pathol, St John, NF A1B 3V6, Canada.
RP Yousef, GM (reprint author), Eastern Hlth Discipline Pathol, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.
EM gyousef@mtsinai.on.ca
CR ABDOU NI, 1977, NEW ENGL J MED, V297, P1413, DOI 10.1056/NEJM197712292972601
   Agnarsdottir M, 2004, UPSALA J MED SCI, V109, P255, DOI 10.3109/2000-1967-089
   Agnarsdottir M, 2004, ACTA OBSTET GYN SCAN, V83, P214, DOI 10.1111/j.0001-6349.2004.077c.x
   AUGUST C, 1994, ULTRASTRUCT PATHOL, V18, P483, DOI 10.3109/01913129409023223
   Bates AW, 1997, POSTGRAD MED J, V73, P171, DOI 10.1136/pgmj.73.857.171
   Carbone M, 2002, PANMINERVA MED, V44, P159
   ESPARZA AR, 1989, AM J SURG PATHOL, V13, P225, DOI 10.1097/00000478-198903000-00008
   Govender D, 1999, PATHOLOGY, V31, P280, DOI 10.1080/003130299105160
   Gustavo LC, 2004, ARCH PATHOL LAB MED, V128, P153
   Jeffrey PB, 1996, ACTA CYTOL, V40, P970
   Kumar V, 2005, PLAST RECONSTR SURG, V116, p125E, DOI 10.1097/01.prs.0000186541.38070.26
   LOPEZ GP, 1995, ACTA OTORRINOLARINGO, V46, P315
   LOU TY, 1974, HUM PATHOL, V5, P191, DOI 10.1016/S0046-8177(74)80066-3
   Matter MJC, 2001, DIS COLON RECTUM, V44, P1371, DOI 10.1007/BF02234800
   MCCLURE J, 1981, POSTGRAD MED J, V57, P95, DOI 10.1136/pgmj.57.664.95
   Michaelis L, 1902, Z KLIN MED, V47, P208
   Minor L, 2003, J UROLOGY, V170, P568, DOI 10.1097/01.ju.0000071475.79104.98
   Pang LC, 2005, RESPIRATION, V72, P95, DOI 10.1159/000083409
   Pang Leou-Chuan, 2003, Ear Nose Throat J, V82, P876
   Pillay K, 2002, PATHOLOGY, V34, P332, DOI 10.1080/00313020220149459
   Repassy Denes L., 2002, Pathology & Oncology Research, V8, P202
   Rickert CH, 2000, ACTA NEUROPATHOL, V99, P595, DOI 10.1007/s004010051167
   Schmerber S, 2003, ARCH OTOLARYNGOL, V129, P1240, DOI 10.1001/archotol.129.11.1240
   SCOTT EVZ, 1958, J UROLOGY, V79, P52
   Shin MS, 1999, CHEST, V115, P889, DOI 10.1378/chest.115.3.889
   Sinha Saroj Kant, 2003, Indian J Gastroenterol, V22, P234
   van Crevel R, 1998, AM J MED, V105, P74, DOI 10.1016/S0002-9343(98)00130-2
   VOLK E, 1992, ANN CLIN LAB SCI, V22, P300
   Wielenberg AJ, 2004, AM J ROENTGENOL, V183, P1703, DOI 10.2214/ajr.183.6.01831703
   ZUK RJ, 1990, VIRCHOWS ARCH A, V417, P181, DOI 10.1007/BF02190538
NR 30
TC 61
Z9 67
U1 3
U2 12
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD FEB
PY 2007
VL 131
IS 2
BP 297
EP 300
PG 4
WC Medical Laboratory Technology; Medicine, Research & Experimental;
   Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
   Pathology
GA 137UL
UT WOS:000244317700019
PM 17284117
DA 2018-12-27
ER

EF